PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fadloun, A; Kobi, D; Delacroix, L; Dembele, D; Michel, I; Lardenois, A; Tisserand, J; Losson, R; Mengus, G; Davidson, I				Fadloun, A.; Kobi, D.; Delacroix, L.; Dembele, D.; Michel, I.; Lardenois, A.; Tisserand, J.; Losson, R.; Mengus, G.; Davidson, I.			Retinoic acid induces TGF beta-dependent autocrine fibroblast growth	ONCOGENE			English	Article						TAF4; transcription regulation; CTGF; MBD1; ENPP1/PC-1	LIVER STELLATE CELLS; TREATED HL-60 CELLS; TFIID COMPLEX; INCREASES SUSCEPTIBILITY; EMBRYONAL CARCINOMA; TARGET GENES; EXPRESSION; DIFFERENTIATION; PROTEIN; TRANSCRIPTION	To evaluate the role of murine TFIID subunit TAF4 in activation of cellular genes by all-trans retinoic acid (T-RA), we have characterized the T-RA response of taf4(lox/-) and taf4(-/-) embryonic fibroblasts. T-RA regulates almost 1000 genes in taf4(lox/-) cells, but less than 300 in taf4(-/-) cells showing that TAF4 is required for T-RA regulation of most, but not all cellular genes. We further show that T-RA-treated taf4(lox/-) cells exhibit transforming growth factor (TGF) beta-dependent autocrine growth and identify a set of genes regulated by loss of TAF4 and by T-RA corresponding to key mediators of the TGF beta signalling pathway. T-RA rapidly and potently induces expression of connective tissue growth factor (CTGF) via a conserved DR2 type response element in its proximal promoter leading to serum-free autocrine growth. These results highlight the role of TAF4 as a cofactor in the cellular response to T-RA and identify the genetic programme of a novel cross talk between the T-RA and TGFb pathways that leads to deregulated cell growth.	[Fadloun, A.; Kobi, D.; Delacroix, L.; Dembele, D.; Michel, I.; Lardenois, A.; Tisserand, J.; Losson, R.; Mengus, G.; Davidson, I.] Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP,UMR7104, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP,UMR7104, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	irwin@titus.u-strasbg.fr	Dembélé, Doulaye/O-6513-2017; Lardenois, Aurélie/AAA-8961-2020	Dembélé, Doulaye/0000-0003-3879-6940; Delacroix, Laurence/0000-0003-3440-5359; Davidson, Irwin/0000-0001-5533-1171; MENGUS, Gabrielle/0000-0002-2844-1778				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bohnsack BL, 2004, GENE DEV, V18, P1345, DOI 10.1101/gad.1184904; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Cerignoli F, 2002, CANCER RES, V62, P1196; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Eifert C, 2006, MOL REPROD DEV, V73, P796, DOI 10.1002/mrd.20444; Falender AE, 2005, GENE DEV, V19, P794, DOI 10.1101/gad.1290105; FALK LA, 1991, BLOOD, V77, P1248; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; GLICK AB, 1991, DEVELOPMENT, V111, P1081; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Grob P, 2006, STRUCTURE, V14, P511, DOI 10.1016/j.str.2005.11.020; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Harris Thomas M, 2002, Funct Integr Genomics, V2, P105, DOI 10.1007/s10142-002-0062-6; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Koda H, 1996, BIOCHEM BIOPH RES CO, V221, P565, DOI 10.1006/bbrc.1996.0636; Krig SR, 2002, TOXICOL SCI, V68, P102, DOI 10.1093/toxsci/68.1.102; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069; Lee YJ, 2000, FEBS LETT, V472, P230, DOI 10.1016/S0014-5793(00)01461-7; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Matangkasombut O, 2004, ADV PROTEIN CHEM, V67, P67; Mengus G, 2005, EMBO J, V24, P2753, DOI 10.1038/sj.emboj.7600748; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Meyre D, 2005, NAT GENET, V37, P863, DOI 10.1038/ng1604; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Nugent P, 1998, J CELL PHYSIOL, V177, P36, DOI 10.1002/(SICI)1097-4652(199810)177:1<36::AID-JCP4>3.0.CO;2-F; Nunes I, 1996, CANCER RES, V56, P495; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1053/jhep.1997.v26.pm0009328313; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913; ROBERTS AB, 1992, CANCER SURV, V14, P205; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Thuault S, 2002, J BIOL CHEM, V277, P45510, DOI 10.1074/jbc.M206556200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; Yu Q, 2000, GENE DEV, V14, P163	53	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					477	489		10.1038/sj.onc.1210657	http://dx.doi.org/10.1038/sj.onc.1210657			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637747				2022-12-25	WOS:000252426100008
J	Clark, N; Keeble, J; Fernandes, ES; Starr, A; Liang, L; Sugden, D; de Winter, P; Brain, SD				Clark, Natalie; Keeble, Julie; Fernandes, Elizabeth S.; Starr, Anna; Liang, Lihuan; Sugden, David; de Winter, Patricia; Brain, Susan D.			The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin	FASEB JOURNAL			English	Article						mouse sensory nerves; knockout; substance P; capsaicin	GENE-RELATED PEPTIDE; NITRIC-OXIDE SYNTHASE; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; MICE LACKING; MECHANISM; INJURY; PAIN; PHARMACOLOGY; ACTIVATION	Transient potential vanilloid 1 (TRPV1) receptor is an ion channel receptor primarily localized on sensory nerves and activated by specific stimuli to initiate and amplify pain and inflammation, as typified by murine models of scald and arthritis. Little is known of the role of TRPV1 in sepsis, an infective disease associated with inflammation. Through use of a sublethal murine model of lipopolysaccharide-induced peritoneal sepsis, we provide novel evidence that genetic deletion of TRPV1 leads to an enhanced onset of various pathological components of systemic endotoxemia. Paired studies of TRPV1 knockout (KO) and wild-type mice demonstrate significantly enhanced hypotension (56 +/- 2% vs. 38 +/- 6% decrease in blood pressure, n = 12), hypothermia (13 +/- 3% vs. 7 +/- 1% decrease in core temperature, n = 6), and peritoneal exudate mediator levels (TNF-alpha, 0.78 +/- 0.2 vs. 0.38 +/- 0.1 ng/ ml; nitrite, for NO, 35 +/- 10 vs. 15 +/- 3 mu M; n = 8) in TRPV1 KO mice, indicating loss of protective effect. Findings correlated with liver edema and raised plasma levels of aspartate aminotransferase in TRPV1 KO mice. These data suggest that TRPV1 may play an important regulatory role in sepsis independent of the major sensory neuropeptide substance P. The findings are relevant to developing strategies that increase the beneficial, and reduce the harmful, components of sepsis to prevent and treat this often fatal condition.	Kings Coll London, Div Cardiovasc, London SE1 9NH, England; Kings Coll London, Reprod & Endocrinol Div, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	Brain, SD (corresponding author), Kings Coll London, Div Cardiovasc, Franklin Wilkins Bldg,Waterloo Campus,150 Stamfor, London SE1 9NH, England.	sue.brain@kcl.ac.uk	Fernandes, Elizabeth S/J-9397-2012; Brain, Susan/L-3681-2013; Fernandes, Elizabeth S./Q-7276-2019	Fernandes, Elizabeth S./0000-0002-0567-2514; Brain, Susan/0000-0002-9684-8342; Keeble, Julie/0000-0002-8891-1129				Arnalich F, 1996, REGUL PEPTIDES, V65, P115, DOI 10.1016/0167-0115(96)00080-8; Beer S, 2002, CRIT CARE MED, V30, P1794, DOI 10.1097/00003246-200208000-00020; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL393; Bryant P, 2003, J SURG RES, V112, P152, DOI 10.1016/S0022-4804(03)00154-9; Cao T, 1999, AM J PHYSIOL-REG I, V277, pR476, DOI 10.1152/ajpregu.1999.277.2.R476; Cao T, 2000, J IMMUNOL, V164, P5424, DOI 10.4049/jimmunol.164.10.5424; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1999, P NATL ACAD SCI USA, V96, P7658, DOI 10.1073/pnas.96.14.7658; Chen CW, 2003, BRIT J PHARMACOL, V140, P1077, DOI 10.1038/sj.bjp.0705533; Chu CJ, 2003, J BIOL CHEM, V278, P13633, DOI 10.1074/jbc.M211231200; CUNHA FQ, 1994, IMMUNOLOGY, V81, P211; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Demirbilek S, 2004, ANESTH ANALG, V99, P1501, DOI 10.1213/01.ANE.0000132975.02854.65; Dogan MD, 2004, BRIT J PHARMACOL, V143, P1023, DOI 10.1038/sj.bjp.0705977; Franco-Penteado CF, 2005, J PHARMACOL EXP THER, V313, P440, DOI 10.1124/jpet.104.078147; Gilroy DW, 2005, CIRCULATION, V111, P2, DOI 10.1161/01.CIR.0000152696.25879.CE; Gomes RN, 2005, SHOCK, V24, P590, DOI 10.1097/01.shk.0000183395.29014.7c; Grant AD, 2002, J PHYSIOL-LONDON, V543, P1007, DOI 10.1113/jphysiol.2002.018846; Harada N, 2006, THROMB HAEMOSTASIS, V95, P788, DOI 10.1160/TH05-09-0636; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Iida T, 2005, NEUROSCI LETT, V378, P28, DOI 10.1016/j.neulet.2004.12.007; Joe B, 1997, LIPIDS, V32, P1173, DOI 10.1007/s11745-997-0151-8; JOYCE CD, 1990, SURGERY, V108, P1097; Keeble J, 2005, ARTHRITIS RHEUM, V52, P3248, DOI 10.1002/art.21297; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGI CA, 1991, J AUTON PHARMACOL, V11, P173, DOI 10.1111/j.1474-8673.1991.tb00317.x; Mailman D, 2002, SHOCK, V18, P177, DOI 10.1097/00024382-200208000-00015; Moriyama T, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-3; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Puneet P, 2006, J IMMUNOL, V176, P3813, DOI 10.4049/jimmunol.176.6.3813; Ralevic V, 2002, LIFE SCI, V71, P2577, DOI 10.1016/S0024-3205(02)02086-6; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; ROGER GH, 1990, COMPTES RENDUS SOC B, V2, P646; Rousseau E, 2005, AM J PHYSIOL-LUNG C, V288, pL460, DOI 10.1152/ajplung.00252.2004; Scotland RS, 2004, CIRC RES, V95, P1027, DOI 10.1161/01.RES.0000148633.93110.24; Shimozawa N, 2006, GASTROENTEROLOGY, V131, P1826, DOI 10.1053/j.gastro.2006.09.005; Szallasi A, 1999, PHARMACOL REV, V51, P159; Szolcsanyi J, 2004, NEUROPEPTIDES, V38, P377, DOI 10.1016/j.npep.2004.07.005; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Vlach KD, 2000, COMPARATIVE MED, V50, P160; Wadachi R, 2006, J DENT RES, V85, P49, DOI 10.1177/154405910608500108	43	80	84	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3747	3755		10.1096/fj.06-7460com	http://dx.doi.org/10.1096/fj.06-7460com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17601984				2022-12-25	WOS:000250517800036
J	Kim, JS; Ryoo, ZY; Chun, JS				Kim, Jae-Sung; Ryoo, Zae Young; Chun, Jang-Soo			Cytokine-like 1 (CYTL1) regulates the chondrogenesis of mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CHONDROCYTES; GENE; P38; DIFFERENTIATION; IDENTIFICATION; MECHANISMS; APOPTOSIS; SOX9	To identify novel molecules regulating chondrogenesis and cartilage development, we screened a cartilage-specific expressed sequence tag data base. Cytokine-like 1 (Cytl1), a possible cytokine candidate with unknown function that was originally identified in bone marrow-derived CD34-positive cells, was selected for functional characterization. In view of the initial observation that Cytl1 is predominantly expressed in chondrocytes and cartilage, we investigated its possible role in chondrogenesis and hypertrophic maturation of chondrocytes. Cytl1 expression was very low in mesenchymal cells, dramatically increased during chondrogenesis, and decreased during hypertrophic maturation, both in vivo and in vitro. The role of Cytl1 in chondrogenesis and hypertrophic maturation was examined by treating chondrifying mesenchymal cells with exogenous Cytl1 or ectopic expression of Cytl1. Notably, exogenous Cytl1 caused chondrogenic differentiation of mouse limb bud mesenchymal cells during micromass culture. Lentivirus-mediated overexpression of Cytl1 additionally induced chondrogenic differentiation of mesenchymal cells. However, Cytl1 did not affect the hypertrophic maturation of chondrocytes. Cytl1 exerted its chondrogenic effect via stimulation of Sox9 transcriptional activity. In addition, Cytl1 caused expression of insulin-like growth factor 1, which has a capacity to induce chondrogenesis. Thus, our results collectively suggest that chondrocyte-specific Cytl1 regulates chondrogenesis as a novel autocrine factor, but not hypertrophic maturation of chondrocytes during cartilage development.	Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea; Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Taegu 702701, South Korea	Gwangju Institute of Science & Technology (GIST); Kyungpook National University	Kim, JS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea.	jschun@gist.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Ficker M, 2004, DEV BIOL, V268, P7, DOI 10.1016/j.ydbio.2003.11.023; Furumatsu T, 2005, J BIOL CHEM, V280, P8343, DOI 10.1074/jbc.M413913200; Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652; Hearn MTW, 2000, J MOL RECOGNIT, V13, P223, DOI 10.1002/1099-1352(200009/10)13:5<223::AID-JMR501>3.3.CO;2-C; Hermansson M, 2004, J BIOL CHEM, V279, P43514, DOI 10.1074/jbc.M407041200; Hong S, 2005, J BIOL CHEM, V280, P7685, DOI 10.1074/jbc.M412444200; Hwang SG, 2005, J BIOL CHEM, V280, P29780, DOI 10.1074/jbc.M411793200; Kawakami Y, 2005, P NATL ACAD SCI USA, V102, P2414, DOI 10.1073/pnas.0407510102; Kim JS, 2005, CELL DEATH DIFFER, V12, P201, DOI 10.1038/sj.cdd.4401511; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kumar S, 2001, OSTEOARTHR CARTILAGE, V9, P641, DOI 10.1053/joca.2001.0421; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Liu X, 2000, GENOMICS, V65, P283, DOI 10.1006/geno.2000.6170; Mariani FV, 2003, NATURE, V423, P319, DOI 10.1038/nature01655; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Oh CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200; Oh J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-314; Ohno S., 1970, EVOLUTION GENE DUPLI, DOI [10.1005667/978-3-642-86659-3.567, 10.1007/978-3-642-86659-3, DOI 10.1007/978-3-642-86659-3, 10. 1007/978-3-642-86659-3]; Peale FV, 2001, J PATHOL, V195, P7, DOI 10.1002/path.888; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Ryu JH, 2006, J BIOL CHEM, V281, P22039, DOI 10.1074/jbc.M601804200; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; Tickle C, 2002, AM J MED GENET, V112, P250, DOI 10.1002/ajmg.10774; Zhang XP, 2004, BONE, V34, P809, DOI 10.1016/j.bone.2003.12.026; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	32	59	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29359	29367		10.1074/jbc.M700965200	http://dx.doi.org/10.1074/jbc.M700965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17644814	hybrid			2022-12-25	WOS:000249788000032
J	de Almeida, SF; Picarote, G; Fleming, JV; Carmo-Fonseca, M; Azevedo, JE; de Sousa, M				de Almeida, Srgio F.; Picarote, Goncalo; Fleming, John V.; Carmo-Fonseca, Maria; Azevedo, Jorge E.; de Sousa, Maria			Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; CELL-SURFACE EXPRESSION; ER STRESS; HEREDITARY HEMOCHROMATOSIS; MOLECULAR CHAPERONES; TRANSCRIPTION FACTOR; ATF6; BETA(2)-MICROGLOBULIN; 4-PHENYLBUTYRATE; BINDING	HFE C282Y, the mutant protein associated with hereditary hemochromatosis (HH), fails to acquire the correct conformation in the endoplasmic reticulum (ER) and is targeted for degradation. We have recently shown that an active unfolded protein response (UPR) is present in the cells of patients with HH. Now, by using HE K 293T cells, we demonstrate that the stability of HFE C282Y is influenced by the UPR signaling pathway that promotes its degradation. Treatment of HFE C282Y-expressing cells with tauroursodeoxycholic acid (TUDCA), a bile acid derivative with chaperone properties, or with the chemical chaperone sodium 4-phenylbutyrate (4PBA) impeded the UPR activation. However, although TUDCA led to an increased stability of the mutant protein, 4PBA contributed to a more efficient disposal of HFE C282Y to the degradation route. Fluorescence microscopy and biochemical analysis of the subcellular localization of HFE revealed that a major portion of the C282Y mutant protein forms intracellular aggregates. Although neither TUDCA nor 4PBA restored the correct folding and intracellular trafficking of HFE C282Y, 4PBA prevented its aggregation. These data suggest that TUDCA hampers the UPR activation by acting directly on its signal transduction pathway, whereas 4PBA suppresses ER stress by chemically enhancing the ER capacity to cope with the expression of misfolded HFE, facilitating its degradation. Together, these data shed light on the molecular mechanisms involved in HFE C282Y-related HH and open new perspectives on the use of orally active chemical chaperones as a therapeutic approach for HH.	Univ Porto, Inst Ciencias Biomed Abel Salazar, Inst Biol Mol & Celular, Iron Genes & Imune Syst Lab, P-4150 Oporto, Portugal; Univ Lisbon, Fac Med, Inst Mol Med, P-1649 Lisbon, Portugal; Inst Ciencias Biomed Abel Salazar, Inst Biol Mol & Celular, P-4150 Oporto, Portugal	Universidade do Porto; Universidade de Lisboa; Universidade do Porto	de Sousa, M (corresponding author), Inst Biol Mol & Celular, Rua Campo Alegre 823, Oporto, Portugal.	mdesousa@ibmc.up.pt	de Almeida, Sergio/H-3002-2019; de Almeida, Sergio F/F-9197-2010; Azevedo, Jorge E/A-4113-2008	de Almeida, Sergio/0000-0002-7774-1355; de Almeida, Sergio F/0000-0002-7774-1355; Azevedo, Jorge E/0000-0001-7714-5302; Carmo-Fonseca, Maria/0000-0002-3402-7143; de sousa, maria/0000-0002-4552-185X				Ben-Arieh SV, 2001, J VIROL, V75, P10557, DOI 10.1128/JVI.75.21.10557-10562.2001; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; de Almeida SF, 2007, J IMMUNOL, V178, P3612, DOI 10.4049/jimmunol.178.6.3612; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fleming JV, 2004, BIOCHEM J, V379, P253, DOI 10.1042/BJ20031525; Fleming JV, 2003, J BIOL CHEM, V278, P686, DOI 10.1074/jbc.M210718200; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kubota K, 2006, J NEUROCHEM, V97, P1259, DOI 10.1111/j.1471-4159.2006.03782.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	30	136	140	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27905	27912		10.1074/jbc.M702672200	http://dx.doi.org/10.1074/jbc.M702672200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17626021	hybrid			2022-12-25	WOS:000249455600039
J	Ott, M; Norberg, E; Walter, KM; Schreiner, P; Kemper, C; Rapaport, D; Zhivotovsky, B; Orrenius, S				Ott, Martin; Norberg, Erik; Walter, Katharina M.; Schreiner, Patrick; Kemper, Christian; Rapaport, Doron; Zhivotovsky, Boris; Orrenius, Sten			The mitochondrial TOM complex is required for tBid/Bax-induced cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; CONFORMATIONAL-CHANGE; INTERMEMBRANE SPACE; IMPORT PORE; BAX; PROTEINS; INSERTION; CARDIOLIPIN; ACTIVATION; PATHWAY	Cytochrome c release from mitochondria is a key event in apoptosis signaling that is regulated by Bcl-2 family proteins. Cleavage of the BH3-only protein Bid by multiple proteases leads to the formation of truncated Bid (tBid), which, in turn, promotes the oligomerization/insertion of Bax into the mitochondrial outer membrane and the resultant release of proteins residing in the intermembrane space. Bax, a monomeric protein in the cytosol, is targeted by a yet unknown mechanism to the mitochondria. Several hypotheses have been put forward to explain this targeting specificity. Using mitochondria isolated from different mutants of the yeast Saccharomyces cerevisiae and recombinant proteins, we have now investigated components of the mitochondrial outer membrane that might be required for tBid/Bax-induced cytochrome c release. Here, we show that the protein translocase of the outer mitochondrial membrane is required for Bax insertion and cytochrome c release.	Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm, Div Toxicol, S-17177 Stockholm, Sweden; Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; Univ Tubingen, Interfacultry Inst Biochem, D-72076 Tubingen, Germany	Karolinska Institutet; Karolinska Institutet; University of Munich; Eberhard Karls University of Tubingen	Orrenius, S (corresponding author), Karolinska Inst, Inst Environm Med, Box 210, S-17177 Stockholm, Sweden.	Sten.Orrenius@ki.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; Schreiner, Patrick/0000-0002-3141-9133; Ott, Martin/0000-0001-6367-3091				Ahting U, 2005, J BIOL CHEM, V280, P48, DOI 10.1074/jbc.M410905200; Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bellot G, 2007, CELL DEATH DIFFER, V14, P785, DOI 10.1038/sj.cdd.4402055; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Choi SY, 2007, CELL DEATH DIFFER, V14, P597, DOI 10.1038/sj.cdd.4402020; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DAUM G, 1982, J BIOL CHEM, V257, P3028; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Nakamura Y, 2004, J BIOL CHEM, V279, P21223, DOI 10.1074/jbc.M314156200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Rapaport D, 2005, J CELL BIOL, V171, P419, DOI 10.1083/jcb.200507147; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Szklarz LKS, 2007, J MOL BIOL, V368, P44, DOI 10.1016/j.jmb.2007.01.016; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200	28	63	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27633	27639		10.1074/jbc.M703155200	http://dx.doi.org/10.1074/jbc.M703155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635912	hybrid			2022-12-25	WOS:000249455600010
J	Wise, EL; Duchesnes, C; da Fonseca, PCA; Allen, RA; Williams, TJ; Pease, JE				Wise, Emma L.; Duchesnes, Cecile; da Fonseca, Paula C. A.; Allen, Rodger A.; Williams, Timothy J.; Pease, James E.			Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL EOTAXIN RECEPTOR; BACKBONE DYNAMICS; IDENTIFICATION; EXPRESSION; BINDING; DETERMINANTS; INFLAMMATION; DOMAINS; CLONING; POTENT	Chemokine receptor CCR3 is highly expressed by eosinophils and signals in response to binding of the eotaxin family of chemokines, which are up-regulated in allergic disorders. Consequently, CCR3 blockade is of interest as a possible therapeutic approach for the treatment of allergic disease. We have described previously a bispecific antagonist of CCR1 and CCR3 named UCB35625 that was proposed to interact with the transmembrane residues Tyr-41, Tyr-113, and Glu-287 of CCR1, all of which are conserved in CCR3. Here, we show that cells expressing the CCR3 constructs Y113A and E287Q are insensitive to antagonism by UCB35625 and also exhibit impaired chemotaxis in response to CCL11/eotaxin, suggesting that these residues are important for antagonist binding and also receptor activation. Furthermore, mutation of the residue Tyr-113 to alanine was found to turn the antagonist UCB35625 into a CCR3 agonist. Screens of small molecule libraries identified a novel specific agonist of CCR3 named CH0076989. This was able to activate eosinophils and transfectants expressing both wild-type CCR3 and a CCR1-CCR3 chimeric receptor lacking the CCR3 amino terminus, indicating that this region of CCR3 is not required for CH0076989 binding. A direct interaction with the transmembrane helices of CCR3 was supported by mutation of the residues Tyr-41, Tyr-113, and Glu-287 that resulted in complete loss of CH0076989 activity, suggesting that the compound mimics activation by CCL11. We conclude that both agonists and antagonists of CCR3 appear to occupy overlapping sites within the transmembrane helical bundle, suggesting a fine line between agonism and antagonism of chemokine receptors.	Imperial Coll London, Fac Med, Natl Heart & Lung Inst Div, Leukocyte Biol Sect, London SW7 2AZ, England; Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, Struct Elect Microscopy Team, London SW3 6JB, England; UCB Celltech, Slough SL1 3WE, Berks, England	Imperial College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Celltech Group Ltd	Pease, JE (corresponding author), Imperial Coll London, Fac Med, Natl Heart & Lung Inst Div, Leukocyte Biol Sect, S Kensington Campus, London SW7 2AZ, England.	j.pease@imperial.ac.uk	Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341; da Fonseca, Paula/0000-0001-8656-5747	Medical Research Council [G0400503B] Funding Source: researchfish; Wellcome Trust [076036/Z/04/Z, 076036] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; Anderskewitz R, 2005, BIOORG MED CHEM LETT, V15, P669, DOI 10.1016/j.bmcl.2004.11.039; Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Crump MP, 1999, PROTEIN SCI, V8, P2041, DOI 10.1110/ps.8.10.2041; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200; Duchesnes UE, 2006, MOL IMMUNOL, V43, P1221, DOI 10.1016/j.molimm.2005.07.015; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; Haskell CA, 2006, MOL PHARMACOL, V69, P309, DOI 10.1124/mol.105.014779; HASLETT C, 1985, AM J PATHOL, V119, P101; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; Mayer MR, 2001, J BIOL CHEM, V276, P13911, DOI 10.1074/jbc.M011202200; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Phillips RM, 2003, J IMMUNOL, V170, P6190, DOI 10.4049/jimmunol.170.12.6190; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 2005, EUR J IMMUNOL, V35, P1301, DOI 10.1002/eji.200425171; Sabroe I, 1999, J IMMUNOL, V162, P2946; Saita Y, 2006, J IMMUNOL, V177, P3116, DOI 10.4049/jimmunol.177.5.3116; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Stroke IL, 2006, BIOCHEM BIOPH RES CO, V349, P221, DOI 10.1016/j.bbrc.2006.08.019; Struyf S, 1999, J IMMUNOL, V162, P4903; Tang CM, 2005, EXPERT OPIN THER TAR, V9, P1247, DOI 10.1517/14728222.9.6.1247; Ting PC, 2005, BIOORG MED CHEM LETT, V15, P1375, DOI 10.1016/j.bmcl.2005.01.016; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Vaidehi N, 2006, J BIOL CHEM, V281, P27613, DOI 10.1074/jbc.M601389200; Xanthou G, 2003, EUR J IMMUNOL, V33, P2241, DOI 10.1002/eji.200323787; Ye JP, 2000, J BIOL CHEM, V275, P27250; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947; Ye JQ, 2001, BIOCHEMISTRY-US, V40, P7820, DOI 10.1021/bi010252s	44	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27935	27943		10.1074/jbc.M703255200	http://dx.doi.org/10.1074/jbc.M703255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635911	Green Accepted, hybrid			2022-12-25	WOS:000249455600042
J	Ageichik, AV; Samejima, K; Kaufmann, SH; Earnshaw, WC				Ageichik, Alexander V.; Samejima, Kumiko; Kaufmann, Scott H.; Earnshaw, William C.			Genetic analysis of the short splice variant of the inhibitor of caspase-activated DNase (ICAD-S) in chicken DT40 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENTATION FACTOR; CHROMATIN CONDENSATION; ENDONUCLEASE-G; APOPTOSIS; CLEAVAGE; NUCLEASE; CAD; EXPRESSION; PHOSPHATIDYLSERINE; NUCLEOPHOSMIN/B23	We have studied the regulation of the caspase-Activated DNase ( CAD) by its inhibitor, ICAD. To study the role of ICAD short and long splice forms ICAD-S and ICAD-L, respectively, in vivo, we constructed chicken DT40 cell lines in which the entire coding regions of ICAD alone or ICAD plus CAD were deleted. ICAD and ICAD/CAD double knockouts lacked both DNA fragmentation and nuclear fragmentation after the induction of apoptosis. We constructed a model humanized system in which human ICAD-L and CAD proteins expressed in DT40 ICAD/CAD double knock-out cells could rescue both DNA fragmentation and stage II chromatin condensation. ICAD-S could not replace ICAD-L as a chaperone for folding active CAD in these cells. However, a modified version of ICAD-S, in which the two caspase-3 cleavage sites were replaced with two tobacco etch virus (TEV) protease cleavage sites (ICAD- S-2TEV) and which was therefore resistant to caspase cleavage, did inhibit CAD activation upon induction of apoptosis in vivo. Moreover, ICAD-L-2TEV was functional as a chaperone for the production of active CAD in DT40 cells. In extracts prepared from these cells, we were able to activate CAD by cleavage of ICAD-L2TEV with TEV protease under non-apoptotic conditions. Thus, ICAD appears to be the only functional inhibitor of CAD activation in these cell- free extracts. Taken together, these observations indicate that ICAD-S may function together with ICAD-L as a buffer to prevent inappropriate CAD activation, particularly in cells where ICAD-S is the dominant form of ICAD protein.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Mayo Clin, Coll Med, Dept Mol Pharmacol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Div Oncol Res, Rochester, MN 55905 USA	University of Edinburgh; Mayo Clinic; Mayo Clinic	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Swann Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	Bill.Earnshaw@ed.ac.uk	Earnshaw, William/AAY-7438-2020	Kaufmann, Scott/0000-0002-4900-7145; Earnshaw, William/0000-0002-7191-0621	NCI NIH HHS [R01 CA069008] Funding Source: Medline; Wellcome Trust [043189, 073915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Arakawa H, 2001, BMC Biotechnol, V1, P7, DOI 10.1186/1472-6750-1-7; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Boulares AH, 2001, J BIOL CHEM, V276, P38185; Cannon JS, 1999, J VIROL, V73, P4786, DOI 10.1128/JVI.73.6.4786-4793.1999; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; Chen DX, 2000, J BIOL CHEM, V275, P38508, DOI 10.1074/jbc.M003906200; Cho SG, 2003, J CELL BIOL, V163, P71, DOI 10.1083/jcb.200303003; Chou CC, 2001, MOL PHARMACOL, V59, P38, DOI 10.1124/mol.59.1.38; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FADOK VA, 1992, J IMMUNOL, V148, P2207; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Irvine RA, 2005, MOL CELL BIOL, V25, P294, DOI 10.1128/MCB.25.1.294-302.2005; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kawane K, 1999, CELL DEATH DIFFER, V6, P745, DOI 10.1038/sj.cdd.4400547; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Korfali N, 2004, J BIOL CHEM, V279, P1030, DOI 10.1074/jbc.M306277200; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li XL, 2005, GENE DEV, V19, P2705, DOI 10.1101/gad.1359305; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Masuoka F, 2001, JPN J CANCER RES, V92, P806, DOI 10.1111/j.1349-7006.2001.tb01165.x; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Nagase H, 2003, CELL DEATH DIFFER, V10, P142, DOI 10.1038/sj.cdd.4401139; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vagnarelli P, 2006, NAT CELL BIOL, V8, P1133, DOI 10.1038/ncb1475; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; Woo EJ, 2004, MOL CELL, V14, P531, DOI 10.1016/S1097-2765(04)00258-8; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	41	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27374	27382		10.1074/jbc.M704307200	http://dx.doi.org/10.1074/jbc.M704307200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17616520	Green Accepted, hybrid			2022-12-25	WOS:000249304900079
J	Nikolaev, VO; Boettcher, C; Dees, C; Bunemann, M; Lohse, MJ; Zenk, MH				Nikolaev, Viacheslav O.; Boettcher, Chotima; Dees, Christian; Buenemann, Moritz; Lohse, Martin J.; Zenk, Meinhart H.			Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BASIS; BINDING; RETICULINE; DISSOCIATION; METABOLITES; MODULATION; AGONISTS; RATS; MICE	G-protein activation by receptors is generally measured using S-35-GTP gamma S binding assays in cell membranes and cannot be well assessed in intact cells. We have recently developed a fluorescence resonance energy transfer (FRET)-based approach to monitor G(i)-protein activation in living cells. Here we report that this technique can be used to determine structure-activity relationships of receptor agonists in intact cells. We have recently shown that morphine is biosynthesized de novo by mammals via a multistep pathway different from that in plants. However, the pharmacological properties of morphine precursors are poorly understood. Here, we directly monitored mu-opioid receptor (MOR)-mediated G(i)-protein activation in living cells by FRET and validated this method with classical GTP gamma S binding assays. Receptor binding studies and FRET measurements demonstrated that several (R)-configurated morphine precursors such as (R)-reticuline, salutaridine, salutaridinol, thebaine, and codeine were partial MOR agonists. Some closer precursors such as oripavine, codeinone, and morphinone activated G(i)-proteins as strongly as morphine, but with slightly lower potencies. The more distant the precursors were positioned in the pathway with respect to morphine, the less efficient and potent they were at MOR. Comparison of pharmacological properties of close morphine precursors and concentrations in which they occur in animal tissues suggests that they might activate MOR signaling under physiological conditions. Taken together, our data indicate that FRET-based assays of G-protein activation can serve to determine the abilities of compounds to activate G-protein signaling directly and in living cells.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Wurzburg, Bio Imaging Ctr, D-97078 Wurzburg, Germany; Univ Halle Wittenberg, Bioctr, D-06120 Halle, Germany	University of Wurzburg; University of Wurzburg; Martin Luther University Halle Wittenberg	Nikolaev, VO (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacherstr 9, D-97078 Wurzburg, Germany.	nikolaev@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Nikolaev, Vyacheslav/AAT-7746-2020	Lohse, Martin J/0000-0002-0599-3510; Bottcher, Chotima/0000-0002-6226-586X				ACETO MD, 1990, NIDA RES MG, V95, P578; Aceto MD, 1999, EUR J PHARMACOL, V365, P143, DOI 10.1016/S0014-2999(98)00862-0; Allen RS, 2004, NAT BIOTECHNOL, V22, P1559, DOI 10.1038/nbt1033; Boettcher C, 2005, P NATL ACAD SCI USA, V102, P8495, DOI 10.1073/pnas.0503244102; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Bunemann M, 2001, J BIOL CHEM, V276, P47512, DOI 10.1074/jbc.M108652200; Chen JJ, 2000, PLANTA MED, V66, P251, DOI 10.1055/s-2000-8562; CHEN ZR, 1991, LIFE SCI, V48, P2165, DOI 10.1016/0024-3205(91)90150-A; Corbett AD, 2006, BRIT J PHARMACOL, V147, pS153, DOI 10.1038/sj.bjp.0706435; Cowan A, 2003, INT J CLIN PRACT, P3; Dias KLG, 2004, PLANTA MED, V70, P328, DOI 10.1055/s-2004-818944; FANG S, 1984, J MED CHEM, V27, P1361, DOI 10.1021/jm00376a026; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Gibson SK, 2006, P NATL ACAD SCI USA, V103, P212, DOI 10.1073/pnas.0509763102; Jordan B, 1998, BRIT J ANAESTH, V81, P12, DOI 10.1093/bja/81.1.12; KARDOS J, 1984, ARZNEIMITTEL-FORSCH, V34-2, P1758; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; KODAIRA H, 1989, P NATL ACAD SCI USA, V86, P716, DOI 10.1073/pnas.86.2.716; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P69; Morais LCSL, 1998, J ETHNOPHARMACOL, V62, P57, DOI 10.1016/S0378-8741(98)00044-0; Nikolaev VO, 2006, J BIOL CHEM, V281, P24506, DOI 10.1074/jbc.M603266200; Poeaknapo C, 2004, P NATL ACAD SCI USA, V101, P14091, DOI 10.1073/pnas.0405430101; Raehal KM, 2005, AAPS J, V7, pE587, DOI 10.1208/aapsj070360; Saidak Z, 2006, BRIT J PHARMACOL, V147, P671, DOI 10.1038/sj.bjp.0706661; Thompson CM, 2004, J PHARMACOL EXP THER, V308, P547, DOI 10.1124/jpet.103.058602; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; YEH SY, 1981, ARCH INT PHARMACOD T, V254, P223; Zhu W, 2003, MOL BRAIN RES, V117, P83, DOI 10.1016/S0169-328X(03)00323-1; Zhu W, 2005, J IMMUNOL, V175, P7357, DOI 10.4049/jimmunol.175.11.7357	32	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27126	27132		10.1074/jbc.M703272200	http://dx.doi.org/10.1074/jbc.M703272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17616524	hybrid			2022-12-25	WOS:000249304900053
J	Dentelli, P; Rosso, A; Zeoli, A; Gambino, R; Pegoraro, L; Pagano, G; Falcioni, R; Brizzi, MF				Dentelli, Patrizia; Rosso, Arturo; Zeoli, Annarita; Gambino, Roberto; Pegoraro, Luigi; Pagano, Gianfranco; Falcioni, Rita; Brizzi, Maria Felice			Oxidative stress-mediated mesangial cell proliferation requires RAC-1/Reactive oxygen species production and beta 4 integrin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; LOW-DENSITY LIPOPROTEINS; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; EGF-RECEPTOR; CYCLE PROGRESSION; OXIDIZED LDL; ACTIVATION; DIFFERENTIATION; INVOLVEMENT	Lipid abnormalities and oxidative stress, by stimulating mesangial cell ( MC) proliferation, can contribute to the development of diabetes-associated renal disease. In this study we investigated the molecular events elicited by oxidized low density lipoproteins ( ox- LDL) in MC. We demonstrate that in MC cultured in the presence of ox- LDL, survival and mitogenic signals on Akt and Erk1/2 MAPK pathways are induced, respectively. Moreover, as shown by the expression of the dominant negative Rac-1 construct, we first report that ox- LDL-mediated cell survival and cell cycle progression depend on Rac-1 GTPase-mediated reactive oxygen species production and on epidermal growth factor receptor transactivation. By silencing Akt and blocking Erk1/2 MAPK pathways, we also demonstrate that these signals are downstream to Rac-1/reactive oxygen species production and epidermal growth factor receptor activation. Finally, by endogenous depletion of beta 4 integrin, expressed in MC, we provide evidence that the expression of this adhesion molecule is essential for ox-LDL-mediated MC dysfunction. Our data identify a novel signaling pathway involved in oxidative stress-induced diabetes-associated renal disease and provide the rationale for therapeutically targeting beta 4 integrin.	Univ Turin, Dept Internal Med, Turin, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	University of Turin; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, Turin, Italy.	mariafelice.brizzi@unito.it	Brizzi, Maria Felice/J-7882-2016; GAMBINO, Roberto/AAC-7517-2022; Falcioni, Rita/H-8869-2017	GAMBINO, Roberto/0000-0003-1902-3627; Falcioni, Rita/0000-0002-3745-4327				Auge N, 2002, ARTERIOSCL THROM VAS, V22, P1990, DOI 10.1161/01.ATV.0000043453.21629.3B; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beisswenger PJ, 2005, DIABETES, V54, P3274, DOI 10.2337/diabetes.54.11.3274; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bokemeyer D, 2000, J AM SOC NEPHROL, V11, P232, DOI 10.1681/ASN.V112232; Bon G, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1651; Bon G, 2006, CLIN CANCER RES, V12, P3280, DOI 10.1158/1078-0432.CCR-05-2223; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Brizzi MF, 2004, FASEB J, V18, P1249, DOI 10.1096/fj.03-1053fje; Brizzi MF, 2002, DIABETES, V51, P3311, DOI 10.2337/diabetes.51.11.3311; Brizzi MF, 2002, J CLIN INVEST, V109, P111, DOI 10.1172/JCI13617; Bussolati B, 1999, AM J PATHOL, V154, P623, DOI 10.1016/S0002-9440(10)65307-2; Chettab K, 2002, THROMB HAEMOSTASIS, V87, P141; Chiarugi Paola, 2003, Ital J Biochem, V52, P28; CORITSIDIS G, 1991, KIDNEY INT, V39, P858, DOI 10.1038/ki.1991.108; Dentelli P, 2005, ONCOGENE, V24, P6394, DOI 10.1038/sj.onc.1208786; Ebrahimian TG, 2006, AM J PATHOL, V169, P719, DOI 10.2353/ajpath.2006.060042; FALCIONI R, 1988, CANCER RES, V48, P816; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Folgiero V, 2007, CANCER RES, V67, P1645, DOI 10.1158/0008-5472.CAN-06-2980; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Gulati P, 2001, IUBMB LIFE, V52, P25, DOI 10.1080/15216540252774720; Hiran TS, 2003, J CELL SCI, V116, P3771, DOI 10.1242/jcs.00681; Hordijk PL, 2006, CIRC RES, V98, P453, DOI 10.1161/01.RES.0000204727.46710.5e; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kamanna VS, 2002, HISTOL HISTOPATHOL, V17, P497, DOI 10.14670/HH-17.497; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; ODONNELL MP, 1991, CONTEMP ISS NEPHROL, P37; Previtali SC, 2003, J NEUROSCI, V23, P5520; REDGRAVE TG, 1979, J LIPID RES, V20, P217; Shankland SJ, 1997, KIDNEY INT, V52, P294, DOI 10.1038/ki.1997.335; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Song QH, 2003, CELL TISSUE RES, V312, P203, DOI 10.1007/s00441-002-0693-x; Song QH, 2001, J CELL BIOCHEM, V80, P397, DOI 10.1002/1097-4644(20010301)80:3<397::AID-JCB140>3.0.CO;2-W; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; VEDIE B, 1991, J LIPID RES, V32, P1359; Wanner C, 1997, KIDNEY INT, pS102; YEH H, 1999, AM J PHYSIOL, V276, pC838; Yi XY, 1998, CELL ADHES COMMUN, V5, P237, DOI 10.3109/15419069809040294; Yoon SO, 2006, CANCER RES, V66, P2732, DOI 10.1158/0008-5472.CAN-05-2941	50	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26101	26110		10.1074/jbc.M703132200	http://dx.doi.org/10.1074/jbc.M703132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17604276	hybrid			2022-12-25	WOS:000249239600013
J	Hilditch, S; Berghall, S; Kalkkinen, N; Penttila, M; Richard, P				Hilditch, Satu; Berghall, Suvi; Kalkkinen, Nisse; Penttilae, Merja; Richard, Peter			The missing link in the fungal D-galacturonate pathway - Identification of the L-threo-3-deoxy-hexulosonate aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URONIC ACID METABOLISM; MOLD HYPOCREA-JECORINA; D-ALTRONIC ACID; ASPERGILLUS-NIDULANS; ESCHERICHIA-COLI; PURIFICATION; DEGRADATION; BACTERIA; CATABOLISM; MUTANTS	The fungal path for the catabolism of D-galacturonate is only partially known. It is however distinctly different to the well-known bacterial path. The known elements of the fungal path are D-galacturonate reductase converting D-galacturonate to L-galactonate and L-galactonate dehydratase converting L-galactonate to L-threo-3-deoxy-hexulosonate (2-keto-3-deoxy-L-galactonate). Here we describe the missing link in this pathway, an aldolase converting L-threo-3-deoxy-hexulosonate to pyruvate and L-glyceraldehyde. Fungal enzymes converting L-glyceraldehyde to glycerol have been described previously. The L-threo-3deoxy-hexulosonate aldolase activity was induced in the mold Hypocrea jecorina ( Trichoderma reesei) during growth on D-galacturonate. The enzyme was purified from this mold and a partial amino acid sequence obtained. This sequence was then used to identify the corresponding gene from the H. jecorina genome. The deletion of the gene resulted in a strain unable to grow on D-galacturonate and accumulating L-threo-3-deoxy-hexulosonate. The open reading frame was cloned from cDNA and functionally expressed in the yeast Saccharomyces cerevisiae. A histidine-tagged protein was expressed, purified, and characterized. The enzyme catalyzed reaction was reversible. With L-threo-3-deoxy-hexulosonate as substrate the K-m was 3.5 mM and with pyruvate and L- glyceraldehyde the K-m were 0.5 and 1.2 mM, respectively.	VTT Tech Res Ctr, Espoo 02044, Finland; Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland	VTT Technical Research Center Finland; University of Helsinki	Richard, P (corresponding author), VTT Tech Res Ctr, POB 1000,Tietotie 2, Espoo 02044, Finland.	Peter.Richard@vtt.fi	Richard, Peter/A-4229-2009; Penttilä, Merja E/A-4710-2013; Kalkkinen, Nisse EJ/B-3923-2010	Richard, Peter/0000-0003-0922-6092; Hilditch, Satu/0000-0002-6141-224X; Penttila, Merja/0000-0002-6929-1032				ASHWELL J, 1960, J BIOL CHEM, V235, P1559; Buchanan CL, 1999, BIOCHEM J, V343, P563, DOI 10.1042/0264-6021:3430563; CYNKIN MA, 1960, J BIOL CHEM, V235, P1576; DAHMS AS, 1974, BIOCHEM BIOPH RES CO, V60, P1433; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; Elshafei AM, 2001, ENZYME MICROB TECH, V29, P76, DOI 10.1016/S0141-0229(01)00346-5; ELZAINY TA, 1973, J BACTERIOL, V114, P457, DOI 10.1128/JB.114.1.457-459.1973; HICKMAN J, 1960, J BIOL CHEM, V235, P1566; HONDMANN DHA, 1991, J GEN MICROBIOL, V137, P629, DOI 10.1099/00221287-137-3-629; HUBSCHWERLEN C, 1986, SYNTHETIC COMMUN, V11, P962; Kuorelahti S, 2005, BIOCHEMISTRY-US, V44, P11234, DOI 10.1021/bi050792f; Kuorelahti S, 2006, MOL MICROBIOL, V61, P1060, DOI 10.1111/j.1365-2958.2006.05294.x; Lamble HJ, 2005, CHEM COMMUN, P124, DOI 10.1039/b413255f; Liepins J, 2006, FEBS J, V273, P4229, DOI 10.1111/j.1742-4658.2006.05423.x; Mandel M, 1969, ADV CHEM SER, V95, P391, DOI [10.1021/ba-1969-0095.ch023, DOI 10.1021/BA-1969-0095.CH023]; MARTENSUZONOVA E, 2005, 23 FUNG GEN C, V52, P93; MELOCHE HP, 1964, J BIOL CHEM, V239, P2515; PENTTILA M, 1987, GENE, V61, P155, DOI 10.1016/0378-1119(87)90110-7; Poutanen M, 2001, RAPID COMMUN MASS SP, V15, P1685, DOI 10.1002/rcm.424; SMILEY JD, 1960, J BIOL CHEM, V235, P1571; Tenkanen M, 2000, J BIOTECHNOL, V78, P149, DOI 10.1016/S0168-1656(99)00240-0; TWERDOCHLIB AL, 1994, CAN J MICROBIOL, V40, P896, DOI 10.1139/m94-144; UITZETTER JHAA, 1986, J GEN MICROBIOL, V132, P1167; VISSER J, 1988, J GEN MICROBIOL, V134, P655	24	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26195	26201		10.1074/jbc.M704401200	http://dx.doi.org/10.1074/jbc.M704401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17609199	hybrid			2022-12-25	WOS:000249239600023
J	Wu, F; Vij, N; Roberts, L; Lopez-Briones, S; Joyce, S; Chakravarti, S				Wu, Feng; Vij, Neeraj; Roberts, Luke; Lopez-Briones, S.; Joyce, Sarah; Chakravarti, Shukti			A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; KERATAN SULFATE PROTEOGLYCAN; CRYSTAL-STRUCTURE; CORNEAL OPACITY; FIBROMODULIN; CD14; LPS; TOLL-LIKE-RECEPTOR-4; DECORIN; RECOGNITION	Lumican is an extracellular matrix protein modified as a proteoglycan in some tissues. The core protein with leucinerich repeats, characteristic of the leucine-rich-repeat superfamily, binds collagen fibrils and regulates its structure. In addition, we believe that lumican sequestered in the pericellular matrix interacts with cell surface proteins for specific cellular functions. Here we show that bacterial lipopolysaccharide sensing by the Toll-like receptor 4 signaling pathway and innate immune response is regulated by lumican. Primary cultures of lumican-deficient ( Lum (-/-)) macrophages show impaired innate immune response to lipopolysaccharides with lower induction of tumor necrosis factor alpha(TNF alpha) and interleukin-6. Macrophage response to other pathogen-associated molecular patterns is not adversely affected by lumican deficiency, suggesting a specific role for the lumican core protein in the Toll-like receptor 4 pathway. An exogenous recombinant lumican core protein increases lipopolysaccharide-mediated TNF alpha induction and partially rescues innate immune response in Lum (-/-) macrophages. We further show that the core protein binds lipopolysaccharide. Immunoprecipitation of lumican from peritoneal lavage coprecipitates CD14, a cell surface lipopolysaccharide-binding protein that is involved in its presentation to Toll-like receptor 4. The Lum (-/-) mice are hypo-responsive to lipopolysaccharide-induced septic shock, with poor induction of proinflammatory cytokines, TNF alpha, and interleukins 1 beta and 6 in the serum. Taken together, the data indicates a novel role for lumican in the presentation of bacterial lipopolysaccharide to CD14 and host response to this bacterial endotoxin.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Chakravarti, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	schakra1@jhmi.edu	lopez, sergio/AAE-5784-2021	Lopez-Briones, Sergio/0000-0003-0273-0958	NEI NIH HHS [EY11654, R01 EY011654] Funding Source: Medline; NATIONAL EYE INSTITUTE [R56EY011654, R01EY011654] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Beutler B, 2001, J ENDOTOXIN RES, V7, P277, DOI 10.1177/09680519010070040901; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Chakravarti S, 2002, GLYCOCONJUGATE J, V19, P287, DOI 10.1023/A:1025348417078; Chakravarti S, 2003, INVEST OPHTH VIS SCI, V44, P2422, DOI 10.1167/iovs.02-0783; CHAKRAVARTI S, 1995, GENOMICS, V27, P481, DOI 10.1006/geno.1995.1080; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; DURIEUX JJ, 1994, EUR J IMMUNOL, V24, P2006, DOI 10.1002/eji.1830240911; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; Funderburgh JL, 1997, INVEST OPHTH VIS SCI, V38, P1159; He YW, 2004, NAT IMMUNOL, V5, P88, DOI 10.1038/ni1021; Hocking AM, 1998, MATRIX BIOL, V17, P1; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kim JI, 2005, J BIOL CHEM, V280, P11347, DOI 10.1074/jbc.M414607200; Knapp S, 2006, AM J RESP CRIT CARE, V173, P122, DOI 10.1164/rccm.200505-730OC; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lash GE, 2006, J IMMUNOL METHODS, V309, P205, DOI 10.1016/j.jim.2005.12.007; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; O'Neill LAJ, 2005, NAT MED, V11, P1161, DOI 10.1038/nm1105-1161; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Triantafilou M, 2004, BIOCHEM SOC T, V32, P636, DOI 10.1042/BST0320636; Vij N, 2005, INVEST OPHTH VIS SCI, V46, P88, DOI 10.1167/iovs.04-0833; Vij N, 2004, EXP EYE RES, V78, P957, DOI 10.1016/j.exer.2003.12.006; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Waterer GW, 2003, CRIT CARE, V7, P308, DOI 10.1186/cc2164; Waterer GW, 2003, CRIT CARE MED, V31, P1367, DOI 10.1097/01.CCM.0000063088.86079.03; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Werling D, 2003, VET IMMUNOL IMMUNOP, V91, P1, DOI 10.1016/S0165-2427(02)00228-3; Wunderink Richard G, 2003, Curr Opin Crit Care, V9, P384, DOI 10.1097/00075198-200310000-00008	47	99	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26409	26417		10.1074/jbc.M702402200	http://dx.doi.org/10.1074/jbc.M702402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616530	hybrid			2022-12-25	WOS:000249239600046
J	Matsuo, Y; Oshima, T; Loh, PC; Morimoto, T; Ogasawara, N				Matsuo, Yoshitaka; Oshima, Taku; Loh, Pek Chin; Morimoto, Takuya; Ogasawara, Naotake			Isolation and characterization of a dominant negative mutant of Bacillus subtilis GTP-binding protein, YlqF, essential for biogenesis and maintenance of the 50 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-LOOP GTPASES; ESCHERICHIA-COLI; MOLECULAR MECHANISM; TRANSLATION FACTORS; RNA; ERA; OBG; OVEREXPRESSION; SUPPRESSION; STABILITY	The circularly permuted GTPase YlqF is essential for cell viability and is broadly conserved from Gram-positive bacteria to eukaryotes. We previously reported that YlqF participates in the late step of 50 S ribosomal subunit assembly in Bacillus subtilis. Here, we demonstrate that an N-terminal deletion mutant of YlqF (YlqF Delta N10) inhibits cell growth even in the presence of wild-type YlqF. In contrast to the wild-type protein, the GTPase activity of this mutant was not stimulated by the 50 S subunit and did not dissociate from the premature 50 S subunit. Thus, YlqF Delta N10 acts as a competitive inhibitor of wild-type YlqF. Premature 50 S subunit lacking ribosomal protein L27 and with a reduced amount of L16 accumulated in YlqF Delta N10-overexpressing cells and in YlqF-depleted cells, suggesting that YlqF Delta N10 binds to the premature 50 S subunit. Moreover, premature 50 S subunit from both YlqF Delta N10-overexpressing and YlqF-depleted cells more strongly enhanced the GTPase activity of YlqF than the mature 50 S subunit of the 70 S ribosome. Collectively, our results indicate that YlqF is targeted to the premature 50 S subunit lacking ribosomal proteins L16 and L27 to assemble functional 50 S subunit through a GTPase activity-dependent conformational change of 23 S rRNA.	Nara Inst Sci & Technol, Grad Sch Informat Sci, Dept Bioinformat & Genom, Nara 6300101, Japan	Nara Institute of Science & Technology	Ogasawara, N (corresponding author), Nara Inst Sci & Technol, Grad Sch Informat Sci, Dept Bioinformat & Genom, 8916-5 Takayama, Nara 6300101, Japan.	nogasawa@bs.naist.jp	Ogasawara, Naotake/B-7971-2011; Loh, Pek Chin/S-9048-2017	Loh, Pek Chin/0000-0003-4865-0523				ALLEN SH, 1986, ARCH BIOCHEM BIOPHYS, V249, P137, DOI 10.1016/0003-9861(86)90568-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brown ED, 2005, BIOCHEM CELL BIOL, V83, P738, DOI 10.1139/O05-162; Comartin DJ, 2006, CURR OPIN PHARMACOL, V6, P453, DOI 10.1016/j.coph.2006.05.005; Czyz A, 2005, ACTA BIOCHIM POL, V52, P35; Daigle DM, 2004, J BACTERIOL, V186, P1381, DOI 10.1128/JB.186.5.1381-1387.2004; DAMMEL CS, 1995, GENE DEV, V9, P626, DOI 10.1101/gad.9.5.626; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Hage Aziz El, 2004, RNA Biol, V1, P10; Hang JQ, 2003, EUR J BIOCHEM, V270, P4164, DOI 10.1046/j.1432-1033.2003.03813.x; Himeno H, 2004, NUCLEIC ACIDS RES, V32, P5303, DOI 10.1093/nar/gkh861; Hwang J, 2006, MOL MICROBIOL, V61, P1660, DOI 10.1111/j.1365-2958.2006.05348.x; Inoue K, 2003, MOL MICROBIOL, V48, P1005, DOI 10.1046/j.1365-2958.2003.03475.x; Jiang MX, 2006, J BACTERIOL, V188, P6757, DOI 10.1128/JB.00444-06; Kawai Y, 2006, MICROBIOL-SGM, V152, P1129, DOI 10.1099/mic.0.28497-0; Klein DJ, 2004, RNA, V10, P1366, DOI 10.1261/rna.7390804; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; LAALAMI S, 1994, MOL MICROBIOL, V11, P293, DOI 10.1111/j.1365-2958.1994.tb00309.x; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Lin B, 2004, J BACTERIOL, V186, P481, DOI 10.1128/JB.186.2.481-489.2004; Matsuo Y, 2006, J BIOL CHEM, V281, P8110, DOI 10.1074/jbc.M512556200; Morimoto T, 2002, MICROBIOL-SGM, V148, P3539, DOI 10.1099/00221287-148-11-3539; Moriya S, 1998, MOL MICROBIOL, V29, P179, DOI 10.1046/j.1365-2958.1998.00919.x; Muench SP, 2006, P NATL ACAD SCI USA, V103, P12359, DOI 10.1073/pnas.0602585103; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; Rodnina MV, 2000, BIOL CHEM, V381, P377, DOI 10.1515/BC.2000.050; Sato A, 2005, GENES CELLS, V10, P393, DOI 10.1111/j.1365-2443.2005.00851.x; Sayed A, 1999, BIOCHEM BIOPH RES CO, V264, P51, DOI 10.1006/bbrc.1999.1471; Schaefer L, 2006, J BACTERIOL, V188, P8252, DOI 10.1128/JB.01213-06; Scott JM, 1999, J BACTERIOL, V181, P4653, DOI 10.1128/JB.181.15.4653-4660.1999; Sharma MR, 2005, MOL CELL, V18, P319, DOI 10.1016/j.molcel.2005.03.028; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; Takahashi N, 2003, MASS SPECTROM REV, V22, P287, DOI 10.1002/mas.10057; Uicker WC, 2006, MOL MICROBIOL, V59, P528, DOI 10.1111/j.1365-2958.2005.04948.x; Uicker WC, 2007, J BACTERIOL, V189, P2926, DOI 10.1128/JB.01654-06; Wout P, 2004, J BACTERIOL, V186, P5249, DOI 10.1128/JB.186.16.5249-5257.2004; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1	38	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25270	25277		10.1074/jbc.M703894200	http://dx.doi.org/10.1074/jbc.M703894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17613524	hybrid			2022-12-25	WOS:000249014100012
J	Oatley, JM; Avarbock, MR; Brinster, RL				Oatley, Jon M.; Avarbock, Mary R.; Brinster, Ralph L.			Glial cell line-derived neurotrophic factor regulation of genes essential for self-renewal of mouse spermatogonial stem cells is dependent on src family kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; GDNF; ACTIVATION; PATHWAYS; PHOSPHORYLATION; TRANSPLANTATION; SURVIVAL; FATE; PCR	Self-renewal and differentiation by spermatogonial stem cells (SSCs) is the foundation for continual spermatogenesis. SSC self-renewal is dependent on glial cell line-derived neurotrophic factor ( GDNF); however, intracellular mechanisms stimulated by GDNF in SSCs are unknown. To investigate these mechanisms we utilized a culture system that maintains a mouse undifferentiated germ cell population enriched for self-renewing SSCs. In these cultures mRNA for the transcription factors Bcl6b, Erm, and Lhx1 are up-regulated by GDNF and decreased in its absence. The expression of all three molecules was further identified in undifferentiated spermatogonia in vivo. Using small interfering RNA to reduce expression and transplantation to quantify stem cell numbers, Bcl6b, Erm, and Lhx1 were shown to be important for SSC maintenance in vitro. Next, GDNF was shown to activate both Akt and Src family kinase (SFK) signaling in SSCs, and culture of SSCs with inhibitors to Akt or SFKs followed by transplantation analysis showed significant impairment of SSC maintenance in vitro. Apoptosis analysis revealed a significant increase in the percentage of apoptotic cells when Akt, but not SFK, signaling was impaired, indicating that multiple signaling pathways are responsible for SSC self-renewal and survival. Biochemical and gene expression experiments revealed that GDNF up-regulated expression of Bcl6b, Erm, and Lhx1 transcripts is dependent on SFK signaling. Overall, these data demonstrate that GDNF up-regulation of Bcl6b, Erm, and Lhx1 expression through SFK signaling is a key component of the intracellular mechanism for SSC self-renewal.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Brinster, RL (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	cpope@vet.upenn.edu		Brinster, Ralph/0000-0003-1408-7656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044445, R01HD052728] Funding Source: NIH RePORTER; NICHD NIH HHS [HD044445, R01 HD052728, R01 HD044445, HD052728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anneren C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Braydich-Stolle L, 2007, DEV BIOL, V304, P34, DOI 10.1016/j.ydbio.2006.12.013; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; Chen C, 2005, NATURE, V436, P1030, DOI 10.1038/nature03894; De Rooij DG, 2000, J ANDROL, V21, P776; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Lee J, 2007, DEVELOPMENT, V134, P1853, DOI 10.1242/dev.003004; Melillo RM, 1999, CANCER RES, V59, P1120; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; Nagano M, 1999, BIOL REPROD, V60, P1429, DOI 10.1095/biolreprod60.6.1429; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Naughton CK, 2006, BIOL REPROD, V74, P314, DOI 10.1095/biolreprod.105.047365; Oatley JM, 2006, P NATL ACAD SCI USA, V103, P9524, DOI 10.1073/pnas.0603332103; Oatley JM, 2006, METHOD ENZYMOL, V419, P259, DOI 10.1016/S0076-6879(06)19011-4; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P6415, DOI 10.1074/jbc.M608952200; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; Ryu BY, 2005, P NATL ACAD SCI USA, V102, P14302, DOI 10.1073/pnas.0506970102; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; TEGELENBOSCH RAJ, 1993, MUTAT RES, V290, P193; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513	29	233	256	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25842	25851		10.1074/jbc.M703474200	http://dx.doi.org/10.1074/jbc.M703474200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17597063	hybrid, Green Accepted			2022-12-25	WOS:000249014100070
J	Shetterly, S; Jost, F; Watson, SR; Knegtel, R; Macher, BA; Holmes, EH				Shetterly, Susan; Jost, Franziska; Watson, Susan R.; Knegtel, Ronald; Macher, Bruce A.; Holmes, Eric H.			Site-specific fucosylation of sialylated polylactosamines by alpha 1,3/4-fucosyltransferases-V and -VI is defined by amino acids near the N terminus of the catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MOLECULAR-CLONING; HELICOBACTER-PYLORI; TRANSFERASE GENES; FUCT-III; LEWIS-X; DIRECTED MUTAGENESIS; SUBSTRATE-BINDING; MYELOID CELLS; PC9 CELLS	Fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor NeuAc alpha 2-3Gal beta 1-4Glc-NAc beta 1-3Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc beta 1-ceramide leads to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex. Human alpha 1,3/4-fucosyltransferase (FucT)-V catalyzes primarily the synthesis of VIM2, whereas human FucT-VI catalyzes primarily the synthesis of sialyl-Le(x). Thus, these two enzymes have distinct "site-specific fucosylation" properties. Amino acid sequence alignment of these enzymes showed that there are 24 amino acid differences in their catalytic domains. Studies were conducted to determine which of the amino acid differences are responsible for the site-specific fucosylation properties of each enzyme. Domain swapping (replacing a portion of the catalytic domain from one enzyme with an analogous portion from the other enzyme) demonstrated that site-specific fucosylation was defined within a 40-amino acid segment containing 8 amino acid differences between the two enzymes. Site-directed mutagenesis studies demonstrated that the site-specific fucosylation properties of these enzymes could be reversed by substituting 4 amino acids from one sequence with the other. These results were observed in both in vitro enzyme assays and flow cytometric analyses of Chinese hamster ovary cells transfected with plasmids containing the various enzyme constructs. Modeling studies of human FucT using a structure of a bacterial fucosyltransferase as a template demonstrated that the amino acids responsible for site-specific fucosylation map near the GDP-fucose-binding site. Additional enzyme studies demonstrated that FucT-VI has similar to 12-fold higher activity compared with FucT-V and that the Trp(124)/Arg(110) site in these enzymes is responsible primarily for this activity difference.	San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Vertex Pharmaceut Europle Ltd, Abingdon OX14 4RY, Oxon, England	California State University System; San Francisco State University; University of California System; University of California San Francisco; Vertex Pharmaceuticals	Holmes, EH (corresponding author), San Francisco State Univ, Dept Chem & Biochem, 1600 Holloway Ave, San Francisco, CA 94132 USA.	eholmes@sfsu.edu			NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD000262] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA70740] Funding Source: Medline; NIMHD NIH HHS [P20 MD000262] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		ALHADEFF JA, 1989, CRIT REV ONCOL HEMAT, V9, P37, DOI 10.1016/S1040-8428(89)80014-9; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Chester MA, 1998, EUR J BIOCHEM, V257, P293; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; Coullin P, 2003, CYTOGENET GENOME RES, V103, P111, DOI 10.1159/000076298; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Dupuy F, 2004, GLYCOBIOLOGY, V14, P347, DOI 10.1093/glycob/cwh053; FUKUSHI Y, 1984, J EXP MED, V160, P506, DOI 10.1084/jem.160.2.506; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; Holmes EH, 2000, J BIOL CHEM, V275, P24237, DOI 10.1074/jbc.M000888200; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; Javaud C, 2003, GENETICA, V118, P157, DOI 10.1023/A:1024101625214; Jost F, 2005, GLYCOBIOLOGY, V15, P165, DOI 10.1093/glycob/cwh157; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kaneko M, 1999, CYTOGENET CELL GENET, V86, P329, DOI 10.1159/000015329; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LEPENDU J, 1989, J IMMUNOGENET, V16, P53; MACHER BA, 1988, J BIOL CHEM, V263, P10186; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Pykari M, 2000, J BIOL CHEM, V275, P40057, DOI 10.1074/jbc.M007922200; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; ReguigneArnould I, 1996, CR ACAD SCI III-VIE, V319, P783; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Sherwood AL, 2000, BIOCHEM BIOPH RES CO, V273, P870, DOI 10.1006/bbrc.2000.3018; Sherwood AL, 1999, GLYCOBIOLOGY, V9, P637, DOI 10.1093/glycob/9.7.637; Sun HY, 2007, J BIOL CHEM, V282, P9973, DOI 10.1074/jbc.M610285200; Toppila S, 1999, EUR J BIOCHEM, V261, P208, DOI 10.1046/j.1432-1327.1999.00257.x; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; Watkins WM, 2001, ADV EXP MED BIOL, V491, P231; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	45	3	3	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24882	24892		10.1074/jbc.M702395200	http://dx.doi.org/10.1074/jbc.M702395200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604274	hybrid			2022-12-25	WOS:000248933000045
J	Waltari, E; Hijmans, RJ; Peterson, AT; Nyari, AS; Perkins, SL; Guralnick, RP				Waltari, Eric; Hijmans, Robert J.; Peterson, A. Townsend; Nyari, Arpad S.; Perkins, Susan L.; Guralnick, Robert P.			Locating Pleistocene Refugia: Comparing Phylogeographic and Ecological Niche Model Predictions	PLOS ONE			English	Article							MITOCHONDRIAL-DNA PHYLOGEOGRAPHY; CLIMATE-CHANGE; SPECIES DISTRIBUTIONS; MOLECULAR PHYLOGEOGRAPHY; BIODIVERSITY INFORMATION; GENETIC CONSEQUENCES; EXTINCTION RISK; SPECIATION; CONSERVATISM; RANGE	Ecological niche models (ENMs) provide a means of characterizing the spatial distribution of suitable conditions for species, and have recently been applied to the challenge of locating potential distributional areas at the Last Glacial Maximum (LGM) when unfavorable climate conditions led to range contractions and fragmentation. Here, we compare and contrast ENM-based reconstructions of LGM refugial locations with those resulting from the more traditional molecular genetic and phylogeographic predictions. We examined 20 North American terrestrial vertebrate species from different regions and with different range sizes for which refugia have been identified based on phylogeographic analyses, using ENM tools to make parallel predictions. We then assessed the correspondence between the two approaches based on spatial overlap and areal extent of the predicted refugia. In 14 of the 20 species, the predictions from ENM and predictions based on phylogeographic studies were significantly spatially correlated, suggesting that the two approaches to development of refugial maps are converging on a similar result. Our results confirm that ENM scenario exploration can provide a useful complement to molecular studies, offering a less subjective, spatially explicit hypothesis of past geographic patterns of distribution.	[Waltari, Eric; Perkins, Susan L.] Amer Museum Nat Hist, Div Invertebrate Zool, New York, NY 10024 USA; [Hijmans, Robert J.] Int Rice Res Inst, Los Banos, Laguna, Philippines; [Peterson, A. Townsend; Nyari, Arpad S.] Univ Kansas, Museum Nat Hist, Lawrence, KS 66045 USA; [Peterson, A. Townsend; Nyari, Arpad S.] Univ Kansas, Biodivers Res Ctr, Lawrence, KS 66045 USA; [Guralnick, Robert P.] Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; [Guralnick, Robert P.] Univ Colorado, Univ Colorado Museum, Boulder, CO 80309 USA	American Museum of Natural History (AMNH); CGIAR; International Rice Research Institute (IRRI); University of Kansas; University of Kansas; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Waltari, E (corresponding author), Amer Museum Nat Hist, Div Invertebrate Zool, New York, NY 10024 USA.	ewaltari@amnh.org	Guralnick, Rob/E-7767-2010; Hijmans, Robert/N-3299-2016; Peterson, A. Townsend/I-5697-2013; Perkins, Susan/D-3408-2018	Peterson, A. Townsend/0000-0003-0243-2379; Hijmans, Robert/0000-0001-5872-2872; Waltari, Eric/0000-0001-6930-9645; Perkins, Susan/0000-0002-5400-5662	U.S. Army Research Laboratory; U.S. Army Research Office [W911NF-05-1-0271.]	U.S. Army Research Laboratory(United States Department of DefenseUS Army Research Laboratory (ARL)); U.S. Army Research Office	This research is based upon work supported by, or in part by, the U.S. Army Research Laboratory and the U.S. Army Research Office under grant number W911NF-05-1-0271.	Anderson RP, 2003, ECOL MODEL, V162, P211, DOI 10.1016/S0304-3800(02)00349-6; Araujo MB, 2006, J BIOGEOGR, V33, P1712, DOI 10.1111/j.1365-2699.2006.01482.x; Araujo MB, 2005, GLOBAL ECOL BIOGEOGR, V14, P529, DOI 10.1111/j.1466-822x.2005.00182.x; Araujo MB, 2005, ECOGRAPHY, V28, P693, DOI 10.1111/j.2005.0906-7590.04253.x; Araujo MB, 2006, J BIOGEOGR, V33, P1677, DOI 10.1111/j.1365-2699.2006.01584.x; Arbogast BS, 1999, J MAMMAL, V80, P142, DOI 10.2307/1383215; Avise JC, 1998, P ROY SOC B-BIOL SCI, V265, P1707, DOI 10.1098/rspb.1998.0492; Barrowclough GF, 2004, MOL ECOL, V13, P1911, DOI 10.1111/j.1365-294X.2004.02215.x; Brant SV, 2003, MOL ECOL, V12, P1435, DOI 10.1046/j.1365-294X.2003.01789.x; Brant SV, 2002, MOL PHYLOGENET EVOL, V22, P163, DOI 10.1006/mpev.2001.1057; Burbrink FT, 2000, EVOLUTION, V54, P2107, DOI 10.1554/0014-3820(2000)054[2107:MDPOTP]2.0.CO;2; Burns KJ, 2006, MOL PHYLOGENET EVOL, V38, P117, DOI 10.1016/j.ympev.2005.07.008; Canhos V.P., 2004, Biodiversity Informatics, V1, P1; Carstens BC, 2004, SYST BIOL, V53, P781, DOI 10.1080/10635150490522296; Carstens BC, 2007, EVOLUTION, V61, P1439, DOI 10.1111/j.1558-5646.2007.00117.x; Castoe TA, 2007, MOL PHYLOGENET EVOL, V42, P193, DOI 10.1016/j.ympev.2006.07.002; Collins WD, 2006, J CLIMATE, V19, P2122, DOI 10.1175/JCLI3761.1; Cook JA, 2004, MOL PHYLOGENET EVOL, V30, P767, DOI 10.1016/S1055-7903(03)00248-3; Crespi EJ, 2003, MOL ECOL, V12, P969, DOI 10.1046/j.1365-294X.2003.01797.x; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DUTILLEUL P, 1993, BIOMETRICS, V49, P305, DOI 10.2307/2532625; Dynesius M, 2000, P NATL ACAD SCI USA, V97, P9115, DOI 10.1073/pnas.97.16.9115; Edwards JL, 2000, SCIENCE, V289, P2312, DOI 10.1126/science.289.5488.2312; Edwards SV, 2000, EVOLUTION, V54, P1839; Fedorov VB, 2002, P ROY SOC B-BIOL SCI, V269, P2071, DOI 10.1098/rspb.2002.2126; Fink S, 2004, MOL ECOL, V13, P3501, DOI 10.1111/j.1365-294X.2004.02351.x; Graham CH, 2004, EVOLUTION, V58, P1781, DOI 10.1554/03-274; Graham RW, 1996, SCIENCE, V272, P1601; Guisan A, 2000, ECOL MODEL, V135, P147, DOI 10.1016/S0304-3800(00)00354-9; Guralnick RP, 2006, PLOS BIOL, V4, P1908, DOI 10.1371/journal.pbio.0040381; Hasumi H., 2004, K 1 COUPLED MODEL MI, P34; Hewitt GM, 2004, PHILOS T R SOC B, V359, P183, DOI 10.1098/rstb.2003.1388; Hewitt GM, 1996, BIOL J LINN SOC, V58, P247, DOI 10.1111/j.1095-8312.1996.tb01434.x; Hewitt GM, 2001, MOL ECOL, V10, P537, DOI 10.1046/j.1365-294x.2001.01202.x; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; Hijmans RJ, 2006, GLOBAL CHANGE BIOL, V12, P2272, DOI 10.1111/j.1365-2486.2006.01256.x; Hoffman R.S., 1981, P25; Holt RD, 1996, EVOL ECOL, V10, P1, DOI 10.1007/BF01239342; Hopkins D. M., 1982, PALEOECOLOGY BERINGI; Howes BJ, 2006, MOL PHYLOGENET EVOL, V40, P183, DOI 10.1016/j.ympev.2006.03.008; Hugall A, 2002, P NATL ACAD SCI USA, V99, P6112, DOI 10.1073/pnas.092538699; Jackson ST, 2000, QUATERNARY SCI REV, V19, P489, DOI 10.1016/S0277-3791(99)00093-1; Jakob SS, 2007, MOL ECOL, V16, P1713, DOI 10.1111/j.1365-294X.2007.03228.x; Kidd DM, 2006, J BIOGEOGR, V33, P1851, DOI 10.1111/j.1365-2699.2006.01574.x; Knouft JH, 2006, ECOLOGY, V87, pS29, DOI 10.1890/0012-9658(2006)87[29:PAOTEO]2.0.CO;2; Marsh DM, 2004, ECOLOGY, V85, P3396, DOI 10.1890/03-0713; Martinez-Meyer E, 2006, J BIOGEOGR, V33, P1779, DOI [10.1111/j.1365-2699.2006.01612.x, 10.1111/j.1365-2699.2006.01482_33_10.x]; Martinez-Meyer E, 2004, GLOBAL ECOL BIOGEOGR, V13, P305, DOI 10.1111/j.1466-822X.2004.00107.x; MARTINEZMEYER E, 2002, THESIS U KANSAS LAWR; Miller GH, 2002, QUATERNARY SCI REV, V21, P33, DOI 10.1016/S0277-3791(01)00085-3; Miller MP, 2006, MOL ECOL, V15, P145, DOI 10.1111/j.1365-294X.2005.02765.x; Pearson RG, 2003, GLOBAL ECOL BIOGEOGR, V12, P361, DOI 10.1046/j.1466-822X.2003.00042.x; Pearson RG, 2007, J BIOGEOGR, V34, P102, DOI 10.1111/j.1365-2699.2006.01594.x; Pearson RG, 2006, J BIOGEOGR, V33, P1704, DOI 10.1111/j.1365-2699.2006.01460.x; Peterson AT, 1999, SCIENCE, V285, P1265, DOI 10.1126/science.285.5431.1265; Peterson AT, 2004, DIVERS DISTRIB, V10, P237, DOI 10.1111/j.1366-9516.2004.00097.x; Peterson AT, 2003, Q REV BIOL, V78, P419, DOI 10.1086/378926; PETERSON AT, 2005, CLIMATE CHANGE BIODI, P211; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; PIELOU EC, 1991, ICE AGE RETURN LIFE; Rangel TFLVB, 2006, GLOBAL ECOL BIOGEOGR, V15, P321, DOI 10.1111/j.1466-822x.2006.00237.x; Ray N, 2001, INTERNET ARCHAEOLOGY, V11; Rodriguez-Robles JA, 1999, MOL ECOL, V8, P1923, DOI 10.1046/j.1365-294x.1999.00793.x; Ruegg KC, 2006, J BIOGEOGR, V33, P1172, DOI 10.1111/j.1365-2699.2006.01517.x; Runck AM, 2005, MOL ECOL, V14, P1445, DOI 10.1111/j.1365-294X.2005.02501.x; Soberon J, 1999, TRENDS ECOL EVOL, V14, P291, DOI 10.1016/S0169-5347(99)01617-1; Soberon Jorge, 2005, Biodiversity Informatics, V2, P1; Sommer RS, 2006, MAMMAL REV, V36, P251, DOI 10.1111/j.1365-2907.2006.00093.x; Spellman GM, 2007, MOL ECOL, V16, P1055, DOI 10.1111/j.1365-294X.2007.03199.x; Steele CA, 2006, MOL ECOL, V15, P2477, DOI 10.1111/j.1365-294X.2006.02950.x; Stein Barbara R., 2004, Biodiversity Informatics, V1, P14; Stockwell D, 1999, INT J GEOGR INF SCI, V13, P143, DOI 10.1080/136588199241391; Stone KD, 2002, MOL ECOL, V11, P2049, DOI 10.1046/j.1365-294X.2002.01596.x; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Thuiller W, 2005, GLOBAL CHANGE BIOL, V11, P2234, DOI 10.1111/j.1365-2486.2005.001018.x; WAKELEY J, 2006, COALESCENT THEORY, P220; Waltari E, 2005, MOL ECOL, V14, P3005, DOI 10.1111/j.1365-294X.2005.02625.x; Weisrock DW, 2000, MOL PHYLOGENET EVOL, V14, P152, DOI 10.1006/mpev.1999.0689; WELLS PV, 1983, ECOL MONOGR, V53, P341, DOI 10.2307/1942644; Wieczorek J, 2004, INT J GEOGR INF SCI, V18, P745, DOI 10.1080/13658810412331280211; Wiens JJ, 2004, EVOLUTION, V58, P193, DOI 10.1111/j.0014-3820.2004.tb01586.x; Wiens JJ, 2005, ANNU REV ECOL EVOL S, V36, P519, DOI 10.1146/annurev.ecolsys.36.102803.095431; Yesson C, 2006, SYST BIOL, V55, P785, DOI 10.1080/1063515060081570; Zamudio KR, 2003, EVOLUTION, V57, P1631; Zink RM, 2000, CONSERV BIOL, V14, P1394, DOI 10.1046/j.1523-1739.2000.99082.x	85	418	430	2	88	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e563	10.1371/journal.pone.0000563	http://dx.doi.org/10.1371/journal.pone.0000563			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622339	Green Published, gold			2022-12-25	WOS:000207452000001
J	Badr, CE; Hewett, JW; Breakefield, XO; Tannous, BA				Badr, Christian E.; Hewett, Jeffrey W.; Breakefield, Xandra O.; Tannous, Bakhos A.			A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSGENIC MOUSE MODEL; QUANTITATIVE MEASUREMENT; ALKALINE-PHOSPHATASE; GENE-EXPRESSION; QUALITY-CONTROL; PROTEIN; LUCIFERASE; GOLGI; CELLS	Background. The secretory pathway is a critical index of the capacity of cells to incorporate proteins into cellular membranes and secrete proteins into the extracellular space. Importantly it is disrupted in response to stress to the endoplasmic reticulum that can be induced by a variety of factors, including expression of mutant proteins and physiologic stress. Activation of the ER stress response is critical in the etiology of a number of diseases, such as diabetes and neurodegeneration, as well as cancer. We have developed a highly sensitive assay to monitor processing of proteins through the secretory pathway and endoplasmic reticulum ( ER) stress in real-time based on the naturally secreted Gaussia luciferase ( Gluc). Methodology/Principle Findings. An expression cassette for Gluc was delivered to cells, and its secretion was monitored by measuring luciferase activity in the conditioned medium. Gluc secretion was decreased down to 90% when these cells were treated with drugs that interfere with the secretory pathway at different steps. Fusing Gluc to a fluorescent protein allowed quantitation and visualization of the secretory pathway in real-time. Expression of this reporter protein did not itself elicit an ER stress response in cells; however, Gluc proved very sensitive at sensing this type of stress, which is associated with a temporary decrease in processing of proteins through the secretory pathway. The Gluc secretion assay was over 20,000-fold more sensitive as compared to the secreted alkaline phosphatase (SEAP), a well established assay for monitoring of protein processing and ER stress in mammalian cells. Conclusions/Significance. The Gluc assay provides a fast, quantitative and sensitive technique to monitor the secretory pathway and ER stress and its compatibility with high throughput screening will allow discovery of drugs for treatment of conditions in which the ER stress is generally induced.	[Badr, Christian E.; Hewett, Jeffrey W.; Breakefield, Xandra O.; Tannous, Bakhos A.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA; [Breakefield, Xandra O.; Tannous, Bakhos A.] Massachusetts Gen Hosp, Dept Radiol, Ctr Mol Imaging Res, Boston, MA 02114 USA; [Badr, Christian E.; Breakefield, Xandra O.; Tannous, Bakhos A.] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Tannous, BA (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.	btannous@hms.harvard.edu	badr, christian/AAX-1192-2020		NARSAD; Bachmann-Strauss Foundation; NINDS [5P01 NS037409, P30NS4577-05]; NIH [P50 CA86355-04, NS45776]; Brain Tumor Society; NATIONAL CANCER INSTITUTE [P50CA086355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045776, P01NS037409] Funding Source: NIH RePORTER	NARSAD(NARSAD); Bachmann-Strauss Foundation; NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brain Tumor Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from NARSAD, Bachmann-Strauss Foundation, NINDS (5P01 NS037409 and P30NS4577-05), NIH (P50 CA86355-04 and NS45776) and Brain Tumor Society.	BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERTRAND F, 1994, AM J PHYSIOL, V266, pC611, DOI 10.1152/ajpcell.1994.266.3.C611; BREAKEFIELD XO, 1981, J NEUROSCI RES, V6, P349, DOI 10.1002/jnr.490060310; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FORER A, 1972, SCIENCE, V175, P774, DOI 10.1126/science.175.4023.774; HEWETT JW, P NATL ACAD IN PRESS; Hiramatsu N, 2005, ANAL BIOCHEM, V339, P249, DOI 10.1016/j.ab.2005.01.023; Hiramatsu N, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl515; Hirota Morihiko, 2006, Journal of Toxicological Sciences, V31, P149, DOI 10.2131/jts.31.149; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Li F, 2005, BRAIN RES, V1048, P59, DOI 10.1016/j.brainres.2005.04.058; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mao CH, 2004, NAT MED, V10, P1013, DOI 10.1038/nm1004-1013; Markova SV, 2004, J BIOL CHEM, V279, P3212, DOI 10.1074/jbc.M309639200; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; Sena-Esteves M, 2004, J VIROL METHODS, V122, P131, DOI 10.1016/j.jviromet.2004.08.017; Shang J, 2005, METHODS, V35, P390, DOI 10.1016/j.ymeth.2004.10.012; Stevens FJ, 1999, IMMUNOL TODAY, V20, P451, DOI 10.1016/S0167-5699(99)01502-9; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; TARTAKOFF A, 1978, J CELL BIOL, V79, P694, DOI 10.1083/jcb.79.3.694; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	30	102	108	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e571	10.1371/journal.pone.0000571	http://dx.doi.org/10.1371/journal.pone.0000571			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593970	gold, Green Submitted, Green Published			2022-12-25	WOS:000207451800015
J	Gosden, TP; Svensson, EI				Gosden, Thomas P.; Svensson, Erik I.			Female Sexual Polymorphism and Fecundity Consequences of Male Mating Harassment in the Wild	PLOS ONE			English	Article								Genetic and phenotypic variation in female response towards male mating attempts has been found in several laboratory studies, demonstrating sexually antagonistic co-evolution driven by mating costs on female fitness. Theoretical models suggest that the type and degree of genetic variation in female resistance could affect the evolutionary outcome of sexually antagonistic mating interactions, resulting in either rapid development of reproductive isolation and speciation or genetic clustering and female sexual polymorphisms. However, evidence for genetic variation of this kind in natural populations of non-model organisms is very limited. Likewise, we lack knowledge on female fecundity-consequences of matings and the degree of male mating harassment in natural settings. Here we present such data from natural populations of a colour polymorphic damselfly. Using a novel experimental technique of colour dusting males in the field, we show that heritable female colour morphs differ in their propensity to accept male mating attempts. These morphs also differ in their degree of resistance towards male mating attempts, the number of realized matings and in their fecundity-tolerance to matings and mating attempts. These results show that there may be genetic variation in both resistance and tolerance to male mating attempts ( fitness consequences of matings) in natural populations, similar to the situation in plant-pathogen resistance systems. Male mating harassment could promote the maintenance of a sexual mating polymorphism in females, one of few empirical examples of sympatric genetic clusters maintained by sexual conflict.	[Gosden, Thomas P.; Svensson, Erik I.] Lund Univ, Dept Anim Ecol, S-22362 Lund, Sweden	Lund University	Gosden, TP (corresponding author), Lund Univ, Dept Anim Ecol, S-22362 Lund, Sweden.	Thomas.Gosden@zooekol.lu.se	Gosden, Thomas/F-2154-2010; Svensson, Erik/E-8324-2010	Gosden, Thomas/0000-0002-5175-0405; Svensson, Erik/0000-0001-9006-016X	Swedish Research Council; The Swedish council for Environment, Agriculture and Spatial Planning (FORMAS); Oscar & Lilli Lamm Stiftelse	Swedish Research Council(Swedish Research CouncilEuropean Commission); The Swedish council for Environment, Agriculture and Spatial Planning (FORMAS)(Swedish Research Council Formas); Oscar & Lilli Lamm Stiftelse	This study was financially supported by grants from the Swedish Research Council (VR), The Swedish council for Environment, Agriculture and Spatial Planning (FORMAS) and Oscar & Lilli Lamm Stiftelse awarded to E. I. S.	Arnqvist G, 2000, P NATL ACAD SCI USA, V97, P10460, DOI 10.1073/pnas.97.19.10460; Arnqvist G, 2002, NATURE, V415, P787, DOI 10.1038/415787a; ARNQVIST G, 1992, ANIM BEHAV, V43, P559, DOI 10.1016/S0003-3472(05)81016-4; Arnqvist G, 2000, ANIM BEHAV, V60, P145, DOI 10.1006/anbe.2000.1446; Cooper G, 1996, P ROY SOC B-BIOL SCI, V263, P1343, DOI 10.1098/rspb.1996.0197; Corbet P. S., 1999, DRAGONFLIES BEHAV EC; Crudgington HS, 2005, AM NAT, V165, pS72, DOI 10.1086/429353; Crudgington HS, 2000, NATURE, V407, P855, DOI 10.1038/35038154; Eberhard WG, 2004, EVOLUTION, V58, P1947; Fincke OM, 2004, ANIM BEHAV, V67, P833, DOI 10.1016/j.anbehav.2003.04.017; Gavrilets S, 2000, NATURE, V407, P150, DOI 10.1038/35025140; Gavrilets S, 2000, NATURE, V403, P886, DOI 10.1038/35002564; Gavrilets S, 2002, P NATL ACAD SCI USA, V99, P10533, DOI 10.1073/pnas.152011499; Hardling R, 2006, AM NAT, V167, P401, DOI 10.1086/498946; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.1111/j.1558-5646.1998.tb05132.x; Holland B, 1999, P NATL ACAD SCI USA, V96, P5083, DOI 10.1073/pnas.96.9.5083; Joron M, 2003, NATURE, V424, P191, DOI 10.1038/nature01713; Lew TA, 2006, EVOLUTION, V60, P97; Linder JE, 2005, J EVOLUTION BIOL, V18, P568, DOI 10.1111/j.1420-9101.2004.00872.x; Martin OY, 2003, NATURE, V423, P979, DOI 10.1038/nature01752; Parker GA, 1998, PHILOS T R SOC B, V353, P261, DOI 10.1098/rstb.1998.0208; Reinhardt K, 2003, P ROY SOC B-BIOL SCI, V270, P2371, DOI 10.1098/rspb.2003.2515; Restif O, 2004, AM NAT, V164, pE90, DOI 10.1086/423713; Rice WR, 2006, PHILOS T R SOC B, V361, P287, DOI 10.1098/rstb.2005.1787; Rice WR, 1997, BEHAV ECOL SOCIOBIOL, V41, P1, DOI 10.1007/s002650050357; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; ROBERTSON HM, 1985, ANIM BEHAV, V33, P805, DOI 10.1016/S0003-3472(85)80013-0; Sakaluk SK, 2006, AM NAT, V167, P94, DOI 10.1086/498279; Sanchez-Guillen RA, 2005, BIOL J LINN SOC, V85, P471, DOI 10.1111/j.1095-8312.2005.00506.x; SCHLUTER D, 1988, EVOLUTION, V42, P849, DOI [10.2307/2408904, 10.1111/j.1558-5646.1988.tb02507.x]; *STATS, 2003, STATISTICA DAT AN SO; Stutt AD, 2001, P NATL ACAD SCI USA, V98, P5683, DOI 10.1073/pnas.101440698; Svensson EI, 2005, J EVOLUTION BIOL, V18, P1503, DOI 10.1111/j.1420-9101.2005.00946.x; Svensson EI, 2005, AM NAT, V165, P567, DOI 10.1086/429278; Wigby S, 2004, EVOLUTION, V58, P1028	35	70	71	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e580	10.1371/journal.pone.0000580	http://dx.doi.org/10.1371/journal.pone.0000580			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593979	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451800024
J	Rosa, GT; Gillet, L; Smith, CM; de Lima, BD; Stevenson, PG				Rosa, Gustavo T.; Gillet, Laurent; Smith, Christopher M.; de Lima, Brigitte D.; Stevenson, Philip G.			IgG Fc Receptors Provide an Alternative Infection Route for Murine Gamma-Herpesvirus-68	PLOS ONE			English	Article								Background. Herpesviruses can be neutralized in vitro but remain infectious in immune hosts. One difference between these settings is the availability of immunoglobulin Fc receptors. The question therefore arises whether a herpesvirus exposed to apparently neutralizing antibody can still infect Fc receptor(+) cells. Principal Findings. Immune sera blocked murine gamma-herpesvirus-68 (MHV-68) infection of fibroblasts, but failed to block and even enhanced its infection of macrophages and dendritic cells. Viral glycoprotein-specific monoclonal antibodies also enhanced infection. MHV-68 appeared to be predominantly latent in macrophages regardless of whether Fc receptors were engaged, but the infection was not abortive and new virus production soon overwhelmed infected cultures. Lytically infected macrophages down-regulated MHC class I-restricted antigen presentation, endocytosis and their response to LPS. Conclusions. IgG Fc receptors limit the neutralization of gamma-herpesviruses such as MHV-68.	[Rosa, Gustavo T.; Gillet, Laurent; Smith, Christopher M.; de Lima, Brigitte D.; Stevenson, Philip G.] Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England	University of Cambridge	Stevenson, PG (corresponding author), Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England.	pgs27@cam.ac.uk	Stevenson, Philip/F-6651-2011; Stevenson, Philip g/F-9688-2014	Stevenson, Philip g/0000-0002-3520-5060; Gillet, Laurent/0000-0002-1047-2525	Portuguese Foundation for Science and Technology; Wellcome Trust [GR076956MA]; Medical Research Council [G0400427, G9800903]; Cancer Research UK [C19612/A6189]; MRC [G9800943, G0400427] Funding Source: UKRI; Medical Research Council [G9800943] Funding Source: researchfish	Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	GTR and BdL were supported by a Portuguese Foundation for Science and Technology studentships. This work was supported by a Wellcome Trust ( Senior Clinical Fellow GR076956MA to PGS) and grants from the Medical Research Council (G0400427, G9800903) and Cancer Research UK (C19612/A6189). LG is a Postdoctoral Researcher of the Fonds National Belge de la Recherche Scientifique (FNRS).	Adler H, 2000, J VIROL, V74, P6964, DOI 10.1128/JVI.74.15.6964-6974.2000; Bennett NJ, 2005, PLOS BIOL, V3, P638, DOI 10.1371/journal.pbio.0030120; BLASKOVIC D, 1980, ACTA VIROL, V24, P468; Boname JM, 2004, IMMUNITY, V20, P305, DOI 10.1016/S1074-7613(04)00047-0; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Christensen JP, 1999, P NATL ACAD SCI USA, V96, P5135, DOI 10.1073/pnas.96.9.5135; Coleman HM, 2005, J GEN VIROL, V86, P561, DOI 10.1099/vir.0.80565-0; Dal Conto AJ, 2000, J VIROL, V74, P11304, DOI 10.1128/JVI.74.23.11304-11310.2000; De Lima BD, 2004, J VIROL, V78, P5103, DOI 10.1128/JVI.78.10.5103-5112.2004; Dialyna IA, 2004, AIDS, V18, P1263, DOI 10.1097/00002030-200406180-00004; EHTISHAM S, 1993, J VIROL, V67, P5247, DOI 10.1128/JVI.67.9.5247-5252.1993; Flano E, 2000, J IMMUNOL, V165, P1074, DOI 10.4049/jimmunol.165.2.1074; Flano E, 2002, IMMUNOL RES, V25, P201, DOI 10.1385/IR:25:3:201; Galfre G, 1981, Methods Enzymol, V73, P3; Gangappa S, 2002, J VIROL, V76, P11460, DOI 10.1128/JVI.76.22.11460-11468.2002; Gill MB, 2006, J GEN VIROL, V87, P1465, DOI 10.1099/vir.0.81760-0; Gillet L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000347; Gillet L, 2007, J VIROL, V81, P280, DOI 10.1128/JVI.01616-06; Gillet L, 2006, J GEN VIROL, V87, P3515, DOI 10.1099/vir.0.82313-0; Iankov ID, 2006, J VIROL, V80, P8530, DOI 10.1128/JVI.00593-06; Kim IJ, 2002, J IMMUNOL, V168, P3958, DOI 10.4049/jimmunol.168.8.3958; Knossow M, 2006, IMMUNOLOGY, V119, P1, DOI 10.1111/j.1365-2567.2006.02421.x; KOHL S, 1982, J IMMUNOL, V129, P370; Kraehenbuhl JP, 2000, ANNU REV CELL DEV BI, V16, P301, DOI 10.1146/annurev.cellbio.16.1.301; Lee Y, 2004, EUR J BIOCHEM, V271, P1094, DOI 10.1111/j.1432-1033.2004.04011.x; Liu LZ, 1999, J IMMUNOL, V163, P868; Lopes FB, 2004, J VIROL, V78, P13370, DOI 10.1128/JVI.78.23.13370-13375.2004; Lubinski JM, 2002, J VIROL, V76, P9232, DOI 10.1128/JVI.76.18.9232-9241.2002; Maidji E, 2006, AM J PATHOL, V168, P1210, DOI 10.2353/ajpath.2006.050482; MARTOS LM, 1970, J GEN VIROL, V7, P169, DOI 10.1099/0022-1317-7-2-169; May JS, 2005, TRAFFIC, V6, P780, DOI 10.1111/j.1600-0854.2005.00316.x; May JS, 2005, J VIROL, V79, P5059, DOI 10.1128/JVI.79.8.5059-5068.2005; May JS, 2005, J VIROL, V79, P3459, DOI 10.1128/JVI.79.6.3459-3467.2005; Mbopi-Keou FX, 2004, AIDS, V18, P338, DOI 10.1097/00002030-200401230-00030; MILLER G, 1972, J INFECT DIS, V125, P403, DOI 10.1093/infdis/125.4.403; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; PANTOPHLET R, ANN REV IMMUNOL, V24, P739; PEIRIS JSM, 1979, NATURE, V282, P509, DOI 10.1038/282509a0; Qiao SW, 2007, IMMUNOLOGY, V120, P145, DOI 10.1111/j.1365-2567.2006.02507.x; Sangster MY, 2000, J IMMUNOL, V164, P1820, DOI 10.4049/jimmunol.164.4.1820; SISSONS JGP, 1980, J INFECT DIS, V142, P442, DOI 10.1093/infdis/142.3.442; Speck SH, 1999, CURR OPIN MICROBIOL, V2, P403; Stevenson PG, 2004, CURR OPIN IMMUNOL, V16, P456, DOI 10.1016/j.coi.2004.05.002; Stevenson PG, 1999, J GEN VIROL, V80, P477, DOI 10.1099/0022-1317-80-2-477; Stevenson PG, 2002, MICROBES INFECT, V4, P1177, DOI 10.1016/S1286-4579(02)01643-X; Stevenson PG, 2002, NAT IMMUNOL, V3, P733, DOI 10.1038/ni818; Stevenson PG, 1999, P NATL ACAD SCI USA, V96, P9281, DOI 10.1073/pnas.96.16.9281; Stevenson PG, 1999, J VIROL, V73, P1075, DOI 10.1128/JVI.73.2.1075-1079.1999; Stevenson PG, 1998, J VIROL, V72, P943, DOI 10.1128/JVI.72.2.943-949.1998; Stevenson PG, 1999, EUR J IMMUNOL, V29, P1059, DOI 10.1002/(SICI)1521-4141(199904)29:04<1059::AID-IMMU1059>3.0.CO;2-L; Stewart JP, 1998, J EXP MED, V187, P1941, DOI 10.1084/jem.187.12.1941; SUNILCHANDRA NP, 1992, J GEN VIROL, V73, P2347, DOI 10.1099/0022-1317-73-9-2347; van Montfort T, 2007, J IMMUNOL, V178, P3177, DOI 10.4049/jimmunol.178.5.3177; Weck KE, 1999, J VIROL, V73, P3273, DOI 10.1128/JVI.73.4.3273-3283.1999; YAO QY, 1991, INT J CANCER, V48, P45; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; YOSHINO K, 1965, VIROLOGY, V26, P44, DOI 10.1016/0042-6822(65)90024-3; Zinkernagel RM, 2006, IMMUNOL REV, V211, P310, DOI 10.1111/j.0105-2896.2006.00402.x	58	39	40	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e560	10.1371/journal.pone.0000560	http://dx.doi.org/10.1371/journal.pone.0000560			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593961	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451800006
J	Zhang, SP; McCormack, FX; Levesque, RC; O'Toole, GA; Lau, GW				Zhang, Shiping; McCormack, Francis X.; Levesque, Roger C.; O'Toole, George A.; Lau, Gee W.			The Flagellum of Pseudomonas aeruginosa Is Required for Resistance to Clearance by Surfactant Protein A	PLOS ONE			English	Article								Surfactant protein A (SP-A) is an important lung innate immune protein that kills microbial pathogens by opsonization and membrane permeabilization. We investigated the basis of SP-A-mediated pulmonary clearance of Pseudomonas aeruginosa using genetically-engineered SP-A mice and a library of signature-tagged P. aeruginosa mutants. A mutant with an insertion into flgE, the gene that encodes flagellar hook protein, was preferentially cleared by the SP-A(+/+) mice, but survived in the SP-A(-/-) mice. Opsonization by SP-A did not play a role in flgE clearance. However, exposure to SP-A directly permeabilized and killed the flgE mutant, but not the wild-type parental strain. P. aeruginosa strains with mutation in other flagellar genes, as well as mucoid, nonmotile isolates from cystic fibrosis patients, were also permeabilized by SP-A. Provision of the wild-type fliC gene restored the resistance to SP-A-mediated membrane permeabilization in the fliC-deficient bacteria. In addition, non-mucoid, motile revertants of CF isolates reacquired resistance to SP-A-mediated membrane permeability. Resistance to SP-A was dependent on the presence of an intact flagellar structure, and independent of flagellar-dependent motility. We provide evidence that flagellar-deficient mutants harbor inadequate amounts of LPS required to resist membrane permeabilization by SP-A and cellular lysis by detergent targeting bacterial outer membranes. Thus, the flagellum of P. aeruginosa plays an indirect but important role resisting SP-A-mediated clearance and membrane permeabilization.	[Lau, Gee W.] Univ Illinois, Dept Pathobiol, Urbana, IL 61801 USA; [Zhang, Shiping; McCormack, Francis X.] Univ Cincinnati, Coll Med, Div Pulm & Crit Care Med, Cincinnati, OH USA; [Levesque, Roger C.] Univ Laval, Ctr Rech Fonct Struct & Ingn Prot, Ste Foy, PQ, Canada; [Levesque, Roger C.] Univ Laval, Fac Med, Ste Foy, PQ, Canada; [O'Toole, George A.] Dartmouth Med Sch, Dept Microbiol & Immunol, Hanover, NH USA	University of Illinois System; University of Illinois Urbana-Champaign; University System of Ohio; University of Cincinnati; Laval University; Laval University; Dartmouth College	Lau, GW (corresponding author), Univ Illinois, Dept Pathobiol, Urbana, IL 61801 USA.	geelau@uiuc.edu	McCormack, Francis X./ABE-8398-2020; Levesque, Roger C./ABD-8407-2021; Lau, Gee W/H-4073-2018	McCormack, Francis X./0000-0001-7168-9464; Levesque, Roger/0000-0001-8315-5937	NIH [AI057915, HL-68861]; American Lung Association [RG-131-N]; Department of Veterans Affairs (Merit Award); National Center for Research Resources [C06 RR 16515-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR001615] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI057915] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association; Department of Veterans Affairs (Merit Award)(US Department of Veterans Affairs); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the NIH (AI057915) and American Lung Association (RG-131-N) to GWL; and the NIH (HL-68861) and the Department of Veterans Affairs (Merit Award) to FXM. This investigation was partially conducted at the University of Illinois at Urbana-Champaign in a facility constructed with the support from Research Facilities Improvement Program Grant Number C06 RR 16515-01 from the National Center for Research Resources, National Institutes of Health.	Arora SK, 2005, INFECT IMMUN, V73, P4395, DOI 10.1128/IAI.73.7.4395-4398.2005; Arora SK, 1998, INFECT IMMUN, V66, P1000, DOI 10.1128/IAI.66.3.1000-1007.1998; BAUGHMAN RP, 1993, AM REV RESPIR DIS, V147, P653, DOI 10.1164/ajrccm/147.3.653; BOYCE JR, 1982, INFECT IMMUN, V37, P840, DOI 10.1128/IAI.37.2.840-844.1982; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Crowther JE, 2004, J IMMUNOL, V172, P6866, DOI 10.4049/jimmunol.172.11.6866; Dasgupta N, 2003, MOL MICROBIOL, V50, P809, DOI 10.1046/j.1365-2958.2003.03740.x; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Fleiszig SMJ, 2001, INFECT IMMUN, V69, P4931, DOI 10.1128/IAI.69.8.4931-4937.2001; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; Griese M, 1997, EUR RESPIR J, V10, P1983, DOI 10.1183/09031936.97.10091983; Gunther A, 1996, AM J RESP CRIT CARE, V153, P176; Harshey RM, 2003, ANNU REV MICROBIOL, V57, P249, DOI 10.1146/annurev.micro.57.030502.091014; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73, DOI 10.1128/MMBR.43.1.73-102.1979; Kim W, 2003, J BACTERIOL, V185, P3111, DOI 10.1128/JB.185.10.3111-3117.2003; Kojima S, 2001, BIOCHEMISTRY-US, V40, P13041, DOI 10.1021/bi011263o; Kong FS, 2006, CELL MICROBIOL, V8, P1121, DOI 10.1111/j.1462-5822.2006.00696.x; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KRATOCHVIL B, 1965, ANAL CHEM, V37, P111, DOI 10.1021/ac60220a028; Kuzmenko AI, 2006, BIOCHEMISTRY-US, V45, P2679, DOI 10.1021/bi0522652; Lau GW, 2005, TRENDS MICROBIOL, V13, P389, DOI 10.1016/j.tim.2005.05.011; Lau GW, 2004, INFECT IMMUN, V72, P4275, DOI 10.1128/IAI.72.7.4275-4278.2004; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2; MAHENTHIRALINGAM E, 1995, INFECT IMMUN, V63, P4519, DOI 10.1128/IAI.63.11.4519-4523.1995; MAHENTHIRALINGAM E, 1994, INFECT IMMUN, V62, P596, DOI 10.1128/IAI.62.2.596-605.1994; Malloy JL, 2005, AM J PHYSIOL-LUNG C, V288, pL409, DOI 10.1152/ajplung.00322.2004; Mariencheck WI, 2003, AM J RESP CELL MOL, V28, P528, DOI 10.1165/rcmb.2002-0141OC; Mariencheck WI, 1999, AM J PHYSIOL-LUNG C, V277, pL777, DOI 10.1152/ajplung.1999.277.4.L777; McCormack FX, 2003, J BIOL CHEM, V278, P36250, DOI 10.1074/jbc.M303086200; NEWMAN SL, 1993, J CLIN INVEST, V92, P624, DOI 10.1172/JCI116630; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; Potvin E, 2003, ENVIRON MICROBIOL, V5, P1294, DOI 10.1046/j.1462-2920.2003.00542.x; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Rubio F, 2004, THORAX, V59, P318, DOI 10.1136/thx.2003.014902; Schaeffer LM, 2004, J IMMUNOL, V173, P1959, DOI 10.4049/jimmunol.173.3.1959; Singh PK, 2000, AM J PHYSIOL-LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799; Soutourina OA, 2003, FEMS MICROBIOL REV, V27, P505, DOI 10.1016/S0168-6445(03)00064-0; Suwabe A, 1996, ARCH BIOCHEM BIOPHYS, V327, P285, DOI 10.1006/abbi.1996.0123; Tart AH, 2006, J BACTERIOL, V188, P6483, DOI 10.1128/JB.00636-06; Toutain CM, 2005, J BACTERIOL, V187, P771, DOI 10.1128/JB.187.2.771-777.2005; Wolfgang MC, 2004, P NATL ACAD SCI USA, V101, P6664, DOI 10.1073/pnas.0307553101; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668; Zhang SP, 2005, PLOS PATHOG, V1, P259, DOI 10.1371/journal.ppat.0010031	54	32	34	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e564	10.1371/journal.pone.0000564	http://dx.doi.org/10.1371/journal.pone.0000564			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593964	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451800009
J	Delys, L; Detours, V; Franc, B; Thomas, G; Bogdanova, T; Tronko, M; Libert, F; Dumont, JE; Maenhaut, C				Delys, L.; Detours, V.; Franc, B.; Thomas, G.; Bogdanova, T.; Tronko, M.; Libert, F.; Dumont, J. E.; Maenhaut, C.			Gene expression and the biological phenotype of papillary thyroid carcinomas	ONCOGENE			English	Article						cancer; thyroid; microarrays; molecular phenotype	GROWTH-FACTOR RECEPTOR; CANCER; INVASION; MECHANISMS; PROFILES; REVEALS; BRAF; OVEREXPRESSION; METASTASIS; MIGRATION	The purpose of this paper is to correlate the molecular phenotype of papillary thyroid carcinoma (PTC) to their biological pathology. We hybridized 26 PTC on microarrays and showed that nearly 44% of the transcriptome was regulated in these tumors. We then combined our data set with two published PTC microarray studies to produce a platform- and study-independent list of PTC-associated genes. We further confirmed the mRNA regulation of 15 genes from this list by quantitative reverse transcription PCR. Analysis of this list with statistical tools led to several conclusions: (1) there is a change in cell population with an increased expression of genes involved in the immune response, reflecting lymphocyte infiltration in the tumor compared to the normal tissue. (2) The c-jun N-terminal kinase pathway is activated by overexpression of its components. ( 3) The activation of ERKK1/2 by genetic alterations is supplemented by activation of the epidermal growth factor but not of the insulin-like growth factor signaling pathway. (4) There is a downregulation of immediate early genes. (5) We observed an overexpression of many proteases in accordance with tumor remodeling, and suggested a probable role of S100 proteins and annexin A2 in this process. (6) Numerous overexpressed genes favor the hypothesis of a collective migration mode of tumor cells.	[Delys, L.; Detours, V.; Libert, F.; Dumont, J. E.; Maenhaut, C.] Univ Libre Bruxelles, Inst Interdisciplinary Res, Sch Med, Brussels, Belgium; [Franc, B.] Univ Versailles St Quentin Yvelines, Serv Anat & Cytol Pathol, Fac Med Paris Ile France Ouest, Hop Ambroise Pare APHP, Boulogne, France; [Thomas, G.] Singleton Hosp, S W Wales Canc Inst, Swansea Clin Sch, Swansea SA2 8QA, W Glam, Wales; [Bogdanova, T.; Tronko, M.] Kiev Endocrinol & Metab Res Inst, Kiev, Ukraine	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Singleton Hospital; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine	Delys, L (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, Sch Med, Campus Erasme,Route Lennik 808, B-1070 Brussels, Belgium.	laurent.delys@ulb.ac.be; cmaenhau@ulb.ac.be	Tronko, Mykola/AAQ-3327-2021	Tronko, Mykola/0000-0001-7421-0981; Bogdanova, Tetiana/0000-0001-5119-0236				Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Baris O, 2005, ONCOGENE, V24, P4155, DOI 10.1038/sj.onc.1208578; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Ciampi R, 2005, ENDOCR PATHOL, V16, P163, DOI 10.1385/EP:16:3:163; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Detours V, 2005, BRIT J CANCER, V92, P1545, DOI 10.1038/sj.bjc.6602521; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Fluge O, 2006, THYROID, V16, P161; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Haugen DRF, 1996, CANCER RES, V56, P1184; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; HOELTING T, 1994, J CLIN ENDOCR METAB, V79, P401, DOI 10.1210/jc.79.2.401; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; LiVolsi VA, 2004, WHO CLASSIFICATION T, P57; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mitsiades CS, 2006, J CLIN ENDOCR METAB, V91, P3662, DOI 10.1210/jc.2006-0055; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Pavlidis P, 2003, BIOINFORMATICS, V19, P1620, DOI 10.1093/bioinformatics/btg227; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235; Semov A, 2005, J BIOL CHEM, V280, P20833, DOI 10.1074/jbc.M412653200; Shin E, 2004, YONSEI MED J, V45, P306, DOI 10.3349/ymj.2004.45.2.306; Sid B, 2006, INT J BIOCHEM CELL B, V38, P1729, DOI 10.1016/j.biocel.2006.04.005; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Wattel S, 2005, ONCOGENE, V24, P6902, DOI 10.1038/sj.onc.1208849; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856	42	62	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7894	7903		10.1038/sj.onc.1210588	http://dx.doi.org/10.1038/sj.onc.1210588			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17621275				2022-12-25	WOS:000252163500007
J	Rigas, AC; Robson, CN; Curtin, NJ				Rigas, A. C.; Robson, C. N.; Curtin, N. J.			Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer	ONCOGENE			English	Article						androgen-independent prostate cancer; bicalutamide; cyclin-dependent kinase inhibitor; LNCaP	GROWTH-INHIBITION; CYCLIN; RECEPTOR; CELLS; BICALUTAMIDE; EXPRESSION; P27(KIP1); PHOSPHORYLATION; PROGRESSION; ANTAGONIST	Antiandrogens are initially effective in controlling prostate cancer (CaP), the second most common cancer in men, but resistance, associated with the loss of androgen-regulated cell cycle control, is a major problem. At present there is no effective treatment for androgen-independent prostate cancer ( AIPC). Cellular proliferation is driven by cyclin-dependent kinases (CDKs) with kinase inhibitors (for example, p27) applying the breaks. We present the first investigation of the therapeutic potential of CDK inhibitors, using the guanine-based CDK inhibitor NU2058 (CDK2 IC50=17 mu M, CDK1 IC50 26 mu M), in comparison with the antiandrogen bicalutamide ( Casodex) in AIPC cells. A panel of AIPC cells was found to be resistant to Casodex-induced growth inhibition, but with the exception of PC3 (GI(50)=38 mu M) and CWR22Rv1 (GI(50)=46 mu M) showed similar sensitivity to NU2058 (GI(50)=10-17 mu M) compared to androgen-sensitive LNCaP cells (GI(50)=15 mu M). In LNCaP cells and their Casodex-resistant derivative, LNCaP-cdxR, growth inhibition by NU2058 was accompanied by a concentration-dependent increase in p27 levels, reduced CDK2 activity and pRb phosphorylation, a decrease in early gene expression and G1 cell cycle phase arrest in both cell lines. In response to Casodex, there were similar observations in LNCaP cells ( GI(50)=6 +/- 3 mu M Casodex) but not in LNCaP-cdxR cells (GI(50)=24 +/- 5 lM Casodex).	[Rigas, A. C.; Robson, C. N.; Curtin, N. J.] Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Curtin, NJ (corresponding author), Newcastle Univ, No Inst Canc Res, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.curtin@ncl.ac.uk		Curtin, Nicola/0000-0003-1369-1843	MRC [G0500966] Funding Source: UKRI; Medical Research Council [G0500966] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Arris CE, 2000, J MED CHEM, V43, P2797, DOI 10.1021/jm990628o; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Drees M, 1997, CLIN CANCER RES, V3, P273; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ferrando AA, 1996, HUM GENET, V97, P91; Gregory CW, 2001, J ANDROL, V22, P537; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hara T, 2003, CANCER RES, V63, P149; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hardcastle IR, 2004, J MED CHEM, V47, P3710, DOI 10.1021/jm0311442; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; KAWAMATA N, 1995, CANCER RES, V55, P2266; Knillova J, 2004, NEOPLASMA, V51, P358; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Kokontis JM, 2005, PROSTATE, V65, P287, DOI 10.1002/pros.20285; Li YW, 2000, INT J ONCOL, V17, P755; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Tepper CG, 2002, CANCER RES, V62, P6606; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9	29	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7611	7619		10.1038/sj.onc.1210586	http://dx.doi.org/10.1038/sj.onc.1210586			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599054				2022-12-25	WOS:000251537800002
J	Gingis-Velitski, S; Ishai-Michaeli, R; Vlodavsky, I; Ilan, N				Gingis-Velitski, Svetlana; Ishai-Michaeli, Rivka; Vlodavsky, Israel; Ilan, Neta			Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing	FASEB JOURNAL			English	Article						heparan sulfate; cell invasion; cell migration; stimulatory antibody	EPIDERMAL-GROWTH-FACTOR; SULFATE PROTEOGLYCANS; CANCER METASTASIS; FACTOR EXPRESSION; CELL-MIGRATION; KEY ENZYME; TUMOR; ANGIOGENESIS; INHIBITION; IDENTIFICATION	Heparanase is a mammalian endo-beta-D-glucuronidase capable of cleaving HS side chains at a limited number of sites, activity that is strongly implicated in tumor metastasis, neovascularization, inflammation, and autoimmunity. Clinically, up- regulation of heparanase mRNA and protein expression has been documented in a variety of primary human tumors, correlating with reduced postoperative survival and increased lymph node and distant metastasis, thus providing strong clinical support for the prometastatic feature of the enzyme and making it an attractive target for the development of anticancer and anti- inflammatory drugs. Screening a panel of monoclonal antibodies for their ability to inhibit heparanase enzymatic activity, we noted that one hybridoma, 6F8, exhibited the opposite effect and significantly enhanced heparanase activity. Here, we provide evidence that antibody 6F8 enhances the activity of recombinant and cellular heparanase, facilitates invasion of tumor- derived cells in vitro, and improves wound healing in a mouse punch model in vivo. These results support a role of heparanase in the course of wound healing and, moreover, suggest that monoclonal antibodies can be applied clinically for the enhancement, rather than inhibition, of certain enzymes.	Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hebrew Univ Jerusalem, Med Ctr, Dept Oncol, IL-91905 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01-CA106456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; BARNER M, 1987, BLOOD, V70, P551; Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x; Edovitsky E, 2006, BLOOD, V107, P3609, DOI 10.1182/blood-2005-08-3301; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Ferro V, 2004, MINI-REV MED CHEM, V4, P693, DOI 10.2174/1389557043403729; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Goldschmidt O, 2003, FASEB J, V17, P1015, DOI 10.1096/fj.02-0773com; Goldshmidt O, 2004, J PATHOL, V203, P594, DOI 10.1002/path.1554; He XT, 2004, CANCER RES, V64, P3928, DOI 10.1158/0008-5472.CAN-03-2718; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Kram V, 2006, J CELL PHYSIOL, V207, P784, DOI 10.1002/jcp.20625; Levidiotis V, 2005, NEPHROLOGY, V10, P167, DOI 10.1111/j.1440-1797.2005.00388.x; Levidiotis V, 2001, KIDNEY INT, V60, P1287, DOI 10.1046/j.1523-1755.2001.00934.x; Levy-Adam F, 2005, J BIOL CHEM, V280, P20457, DOI 10.1074/jbc.M414546200; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182; Miao HQ, 2006, CURR MED CHEM, V13, P2101, DOI 10.2174/092986706777935230; Myler HA, 2006, J BIOCHEM, V139, P339, DOI 10.1093/jb/mvj061; Nadir Y, 2006, J THROMB HAEMOST, V4, P2443, DOI 10.1111/j.1538-7836.2006.02212.x; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; Oliveira S, 2006, EXPERT OPIN BIOL TH, V6, P605, DOI 10.1517/14712598.6.6.605; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Saijo M, 2003, HISTOCHEM CELL BIOL, V120, P493, DOI 10.1007/s00418-003-0589-1; Sanderson RD, 2005, J CELL BIOCHEM, V96, P897, DOI 10.1002/jcb.20602; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Sandler A, 2006, CLIN CANCER RES, V12, p4421S, DOI 10.1158/1078-0432.CCR-06-0796; Shafat I, 2006, BIOCHEM BIOPH RES CO, V341, P958, DOI 10.1016/j.bbrc.2006.01.048; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I., 1999, PROTOCOLS CELL BIOL, V1; Vlodavsky I, 2006, PATHOPHYSIOL HAEMO T, V35, P116, DOI 10.1159/000093553; Waterman M, 2007, MODERN PATHOL, V20, P8, DOI 10.1038/modpathol.3800710; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	42	15	17	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3986	3993		10.1096/fj.07-8866com	http://dx.doi.org/10.1096/fj.07-8866com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17628014				2022-12-25	WOS:000251283500023
J	Wallace, JL; Dicay, M; McKnight, W; Martin, GR				Wallace, John L.; Dicay, Michael; McKnight, Webb; Martin, Gary R.			Hydrogen sulfide enhances ulcer healing in rats	FASEB JOURNAL			English	Article						resolution; nonsteroidal antiinflammatory drugs; nitric oxide; mucosal defense	K-ATP CHANNELS; NITRIC-OXIDE; GASTROINTESTINAL-TRACT; MUCOSAL LESIONS; GROWTH-FACTOR; STIMULATION; INHIBITION; INJURY; DRUGS; CELLS	Hydrogen sulfide is an endogenous mediator that relaxes vascular smooth muscle, exhibits several antiinflammatory activities, and contributes to gastric mucosal defense. This study was performed to examine the role of hydrogen sulfide in the resolution of injury; specifically, the healing of gastric ulcers. Ulcers were induced in rats by serosal application of acetic acid. This elicited a marked increase in gastric expression of the two key enzymes in hydrogen sulfide synthesis (cystathionine- beta-synthase and cystathionine-gamma- lyase) and in hydrogen sulfide synthesis. Twice-daily treatment for a week with hydrogen sulfide donors significantly increased the extent of healing of gastric ulcers as compared to vehicle-treatment. Similar treatment with L-cysteine, a precursor for hydrogen sulfide, also accelerated healing of the ulcers, and the effect was abolished by cotreatment with an inhibitor of cystathionine-gamma- lyase. The beneficial effects of hydrogen sulfide on ulcer healing were not dependent on nitric oxide synthesis, nor did they appear to occur through activation of ATP-sensitive K+ channels. These results suggest that hydrogen sulfide is produced in the gastric mucosa in response to injury and acts to promote healing. The results further suggest that drugs releasing hydrogen sulfide could be employed to accelerate healing of gastric ulcers, and possibly of other wounds. -Wallace, J. L., Dicay, M., McKnight, W., Martin, G. R. Hydrogen sulfide enhances ulcer healing in rats.	Univ Calgary, Inflammat Res Network, Calgary, AB, Canada	University of Calgary	Wallace, JL (corresponding author), Univ Calgary, Dept Pharm & Therapeut, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wallacej@ucalgary.ca	Wallace, John/AAL-3763-2021					Abe K, 1996, J NEUROSCI, V16, P1066; Blackstone E, 2005, SCIENCE, V308, P518, DOI 10.1126/science.1108581; BOYD SC, 1981, LIFE SCI, V28, P2987, DOI 10.1016/0024-3205(81)90276-9; BRZOZWSKI T, 1995, DIGESTION, V56, P463, DOI 10.1159/000201277; Distrutti E, 2006, J PHARMACOL EXP THER, V316, P325, DOI 10.1124/jpet.105.091595; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; FERREIRA SH, 1991, EUR J PHARMACOL, V201, P121, DOI 10.1016/0014-2999(91)90333-L; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Fiorucci S, 2006, GASTROENTEROLOGY, V131, P259, DOI 10.1053/j.gastro.2006.02.033; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; KONTUREK SJ, 1988, GASTROENTEROLOGY, V94, P1300, DOI 10.1016/0016-5085(88)90667-1; Ma L, 1999, AM J PHYSIOL-GASTR L, V276, pG238, DOI 10.1152/ajpgi.1999.276.1.G238; Ma L, 2000, AM J PHYSIOL-GASTR L, V279, pG341, DOI 10.1152/ajpgi.2000.279.2.G341; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; OKABE S, 1971, AM J DIG DIS, V16, P277, DOI 10.1007/BF02235252; Peura DA, 2004, AM J MED, V117, p63S, DOI 10.1016/j.amjmed.2004.07.010; Qu K, 2006, STROKE, V37, P889, DOI 10.1161/01.STR.0000204184.34946.41; SANDOR Z, 1995, SCAND J GASTROENTERO, V30, P19, DOI 10.3109/00365529509090263; Satoh H, 1997, JPN J PHARMACOL, V73, P59, DOI 10.1254/jjp.73.59; STADLER P, 1991, DIGEST DIS SCI, V36, P594, DOI 10.1007/BF01297025; Tang GH, 2005, MOL PHARMACOL, V68, P1757, DOI 10.1124/mol.105.017467; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1994, EUR J PHARMACOL, V271, P525, DOI 10.1016/0014-2999(94)90814-1; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje	26	176	188	3	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4070	4076		10.1096/fj.07-8669com	http://dx.doi.org/10.1096/fj.07-8669com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17634391				2022-12-25	WOS:000251283500031
J	Reddi, AL; Ying, GG; Duan, L; Chen, GS; Dimri, M; Douillard, P; Druker, BJ; Naramura, M; Band, V; Band, H				Reddi, Alagarsamy Lakku; Ying, GuoGuang; Duan, Lei; Chen, Gengsheng; Dimri, Manjari; Douillard, Patrice; Druker, Brian J.; Naramura, Mayumi; Band, Vimla; Band, Hamid			Binding of Cbl to a phospholipase C gamma 1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE; DOWN-REGULATION; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; CSF-1 RECEPTOR; DOMAIN BINDING; BREAST-CANCER; SH2 DOMAIN; B-CELLS	Ubiquitin conjugation to receptor tyrosine kinases is a critical biochemical step in attenuating their signaling through lysosomal degradation. Our previous studies have established Cbl as an E3 ubiquitin ligase for ubiquitinylation and degradation of platelet-derived growth factor receptor (PDGFR) alpha and PDGFR beta. However, the role of endogenous Cbl in PDGFR regulation and the molecular mechanisms of this regulation remain unclear. Here, we demonstrate that endogenous Cbl is essential for ligand-induced ubiquitinylation and degradation of PDGFR beta; this involves the Cbl TKB domain binding to PDGFR beta phosphotyrosine 1021, a known phospholipase C (PLC) gamma 1 SH2 domain-binding site. Lack of Cbl or ablation of the Cbl-binding site on PDGFR beta impedes receptor sorting to the lysosome. Cbl-deficient cells also show more PDGF-induced PLC gamma 1 association with PDGFR beta and enhanced PLC-mediated cell migration. Thus, Cbl-dependent negative regulation of PDGFR beta involves a dual mechanism that concurrently promotes ubiquitin-dependent lysosomal sorting of the receptor and competitively reduces the recruitment of a positive mediator of receptor signaling.	ENH Res Inst, Div Mol Oncol, Evanston, IL 60201 USA; ENH Res Inst, Div Canc Biol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Weinberg Coll Arts & Sci, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60201 USA; Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA; Eucodis GmbH, A-1230 Vienna, Austria	Northwestern University; Feinberg School of Medicine; Northwestern University; Oregon Health & Science University	Band, H (corresponding author), ENH Res Inst, Div Mol Oncol, 1001 Univ Pl, Evanston, IL 60201 USA.	h-band@northwestern.edu		Naramura, Mayumi/0000-0003-3658-0767; Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA 87986, CA94143, CA81076, CA99163, CA96844, CA76118, 1U54 CA119341-01, CA 99900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA119341, R01CA094143, R01CA096844, R01CA099163, R01CA076118, R01CA081076, R01CA087986, R01CA099900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amyere M, 2000, MOL BIOL CELL, V11, P3453, DOI 10.1091/mbc.11.10.3453; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Betsholtz C, 2004, CURR OPIN NEPHROL HY, V13, P45, DOI 10.1097/00041552-200401000-00007; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304; Cho SD, 2006, INT J ONCOL, V28, P1361; Choi JH, 2003, MOL CELLS, V15, P245; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; Ding H, 2004, NAT GENET, V36, P1111, DOI 10.1038/ng1415; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Finerty PJ, 2005, BIOCHEMISTRY-US, V44, P694, DOI 10.1021/bi048641k; Firth JD, 2001, WOUND REPAIR REGEN, V9, P86, DOI 10.1046/j.1524-475x.2001.00086.x; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hamilton TG, 2003, MOL CELL BIOL, V23, P4013, DOI 10.1128/MCB.23.11.4013-4025.2003; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Hu JJ, 2005, J BIOL CHEM, V280, P18943, DOI 10.1074/jbc.M414157200; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jeon MS, 2004, IMMUNITY, V21, P167, DOI 10.1016/j.immuni.2004.07.013; Kitadai Y, 2006, INT J CANCER, V119, P2567, DOI 10.1002/ijc.22229; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lev DC, 2005, CLIN CANCER RES, V11, P306; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MORI S, 1993, J BIOL CHEM, V268, P577; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ohrt T, 2004, CELL SIGNAL, V16, P1291, DOI 10.1016/j.cellsig.2004.03.017; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; PLATE KH, 1992, LAB INVEST, V67, P529; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rohde CM, 2004, J BIOL CHEM, V279, P43448, DOI 10.1074/jbc.M314170200; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Schmahl J, 2007, NAT GENET, V39, P52, DOI 10.1038/ng1922; Schmidt MHH, 2006, ONCOGENE, V25, P3071, DOI 10.1038/sj.onc.1209329; Slagsvold T, 2006, TRENDS CELL BIOL, V16, P317, DOI 10.1016/j.tcb.2006.04.004; SMALLRIDGE RC, 1992, ENDOCRINOLOGY, V131, P1883, DOI 10.1210/en.131.4.1883; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yu H, 1998, EXP CELL RES, V243, P113, DOI 10.1006/excr.1998.4132; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49; Zeng S, 2005, BLOOD, V105, P226, DOI 10.1182/blood-2004-05-1768	71	32	38	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29336	29347		10.1074/jbc.M701797200	http://dx.doi.org/10.1074/jbc.M701797200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17620338	hybrid			2022-12-25	WOS:000249788000030
J	Marco, E; Foucaud, M; Langer, I; Escrieut, C; Tikhonova, IG; Fourmy, D				Marco, Esther; Foucaud, Magali; Langer, Ingrid; Escrieut, Chantal; Tikhonova, Irina G.; Fourmy, Daniel			Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED MOLECULAR-DYNAMICS; TOGGLE SWITCH MODEL; B/GASTRIN RECEPTOR; LIGAND-BINDING; TRANSMEMBRANE DOMAINS; RHODOPSIN STRUCTURE; CRYSTAL-STRUCTURE; GASTRIN RECEPTOR; INVERSE AGONISM; B RECEPTOR	Gprotein-coupled receptors (GPCRs) represent a major focus in functional genomics programs and drug development research, but their important potential as drug targets contrasts with the still limited data available concerning their activation mechanism. Here, we investigated the activation mechanism of the cholecystokinin-2 receptor (CCK2R). The three-dimensional structure of inactive CCK2R was homology-modeled on the basis of crystal coordinates of inactive rhodopsin. Starting from the inactive CCK2R modeled structure, active CCK2R (namely cholecystokinin-occupied CCK2R) was modeled by means of steered molecular dynamics in a lipid bilayer and by using available data from other GPCRs, including rhodopsin. By comparing the modeled structures of the inactive and active CCK2R, we identified changes in the relative position of helices and networks of interacting residues, which were expected to stabilize either the active or inactive states of CCK2R. Using targeted molecular dynamics simulations capable of converting CCK2R from the inactive to the active state, we delineated structural changes at the atomic level. The activation mechanism involved significant movements of helices VI and V, a slight movement of helices IV and VII, and changes in the position of critical residues within or near the binding site. The mutation of key amino acids yielded inactive or constitutively active CCK2R mutants, supporting this proposed mechanism. Such progress in the refinement of the CCK2R binding site structure and in knowledge of CCK2R activation mechanisms will enable target-based optimization of nonpeptide ligands.	Inst Fed Rech, INSERM, U858, F-31432 Toulouse, France; Univ Toulouse 3, F-31062 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Fourmy, D (corresponding author), Inst Louis Bugnard, IFR 31, U858, BP 84225, F-31432 Toulouse 4, France.	fourmyd@toulouse.inserm.fr	Fourmy, Daniel/AAE-3703-2019	Fourmy, Daniel/0000-0001-9910-4827				Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Beinborn M, 2004, MOL PHARMACOL, V65, P753, DOI 10.1124/mol.65.3.753; Blaker M, 2000, MOL PHARMACOL, V58, P399, DOI 10.1124/mol.58.2.399; BLEVINS GT, 1994, J PHARMACOL EXP THER, V269, P911; Bond RA, 2006, TRENDS PHARMACOL SCI, V27, P92, DOI 10.1016/j.tips.2005.12.007; Boucard AA, 2003, BIOCHEM J, V370, P829, DOI 10.1042/BJ20021566; Compoint M, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1869413; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; Crocker E, 2006, J MOL BIOL, V357, P163, DOI 10.1016/j.jmb.2005.12.046; Ding WQ, 2002, CANCER RES, V62, P947; Dufresne M, 2006, PHYSIOL REV, V86, P805, DOI 10.1152/physrev.00014.2005; Elling CE, 2006, J BIOL CHEM, V281, P17337, DOI 10.1074/jbc.M512510200; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Foucaud M, 2006, MOL PHARMACOL, V69, P680, DOI 10.1124/mol.105.019992; Gales C, 2003, ONCOGENE, V22, P6081, DOI 10.1038/sj.onc.1206823; Gales C, 2003, MOL PHARMACOL, V63, P973, DOI 10.1124/mol.63.5.973; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Haskell-Luevano C, 2001, BIOCHEMISTRY-US, V40, P6164, DOI 10.1021/bi010025q; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Herranz R, 2003, MED RES REV, V23, P559, DOI 10.1002/med.10042; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Jongejan A, 2005, NAT CHEM BIOL, V1, P98, DOI 10.1038/nchembio714; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; Kopin AS, 2000, TRENDS PHARMACOL SCI, V21, P346, DOI 10.1016/S0165-6147(00)01526-1; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Langer I, 2005, J BIOL CHEM, V280, P22198, DOI 10.1074/jbc.M501786200; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Ludeke S, 2005, J MOL BIOL, V353, P345, DOI 10.1016/j.jmb.2005.08.039; Matrai J, 2004, PROTEIN SCI, V13, P3139, DOI 10.1110/ps.04825004; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Noble F, 1999, PHARMACOL REV, V51, P745; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Reubi JC, 2003, ENDOCR REV, V24, P389, DOI 10.1210/er.2002-0007; Rodriguez-Barrios F, 2005, J AM CHEM SOC, V127, P7570, DOI 10.1021/ja042289g; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; SCHMASSMANN A, 1994, GUT, V35, P270, DOI 10.1136/gut.35.2.270; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Silvente-Poirot S, 1999, J BIOL CHEM, V274, P23191, DOI 10.1074/jbc.274.33.23191; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691	49	29	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28779	28790		10.1074/jbc.M700349200	http://dx.doi.org/10.1074/jbc.M700349200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17599907	Green Published, hybrid			2022-12-25	WOS:000249642100052
J	Bengrine, A; Li, JQ; Hamm, LL; Awayda, MS				Bengrine, Abderrahmane; Li, Jinqing; Hamm, L. Lee; Awayda, Mouhamed S.			Indirect activation of the epithelial Na+ channel by trypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; XENOPUS OOCYTES; INHIBITION; EXPRESSION; SUBUNIT; PROTEASES; CLEAVAGE; ENAC	We tested the hypothesis that the serine protease trypsin can indirectly activate the epithelial Na+ channel (ENaC). Experiments were carried out in Xenopus oocytes and examined the effects on the channel formed by all three human ENaC subunits and that formed by Xenopus epsilon and human beta and gamma subunits ( epsilon beta gamma ENaC). Low levels of trypsin (1- 10 ng/ml) were without effects on the oocyte endogenous conductances and were specifically used to test the effects on ENaC. Addition of 1 ng/ml trypsin for 60 min stimulated the amiloride-sensitive human ENaC conductance (gNa) by similar to 6-fold. This effect on the gNa was [Na+]-independent, thereby ruling out an interaction with channel feedback inhibition by Na+. The indirect nature of this activation was confirmed in cell-attached patch clamp experiments with trypsin added to the outside of the pipette. Trypsin was comparatively ineffective at activating epsilon beta gamma ENaC, a channel that exhibited a high spontaneous open probability. These observations, in combination with surface binding experiments, indicated that trypsin indirectly activated membrane-resident channels. Activation by trypsin was also dependent on catalytic activity of this protease but was not accompanied by channel subunit proteolysis. Channel activation was dependent on downstream activation of G-proteins and was blocked by G-protein inhibition by injection of guanyl-5 '-yl thiophosphate and by pre-stimulation of phospholipase C. These data indicate a receptor-mediated activation of ENaC by trypsin. This trypsin-activated receptor is distinct from that of protease-activated receptor-2, because the response to trypsin was unaffected by protease-activated receptor-2 overexpression or knockdown.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; Tulane Univ, Ctr Hlth Sci, Dept Med, New Orleans, LA 70112 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Tulane University	Awayda, MS (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall,3435 Main St, Buffalo, NY 14214 USA.	awayda@buffalo.edu			NIDDK NIH HHS [DK 55626] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055626] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreasen D, 2006, J AM SOC NEPHROL, V17, P968, DOI 10.1681/ASN.2005060637; Awayda Mouhamed S., 2006, V337, P101; Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; Awayda MS, 2000, J GEN PHYSIOL, V115, P559, DOI 10.1085/jgp.115.5.559; Awayda MS, 1999, AM J PHYSIOL-CELL PH, V277, pC216, DOI 10.1152/ajpcell.1999.277.2.C216; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Bachhuber T, 2005, J BIOL CHEM, V280, P31587, DOI 10.1074/jbc.M504347200; Bengrine A, 2007, FASEB J, V21, P1189, DOI 10.1096/fj.06-6046com; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC761, DOI 10.1152/ajpcell.1997.272.3.C761; Bueno OF, 1998, MOL BRAIN RES, V59, P165, DOI 10.1016/S0169-328X(98)00129-6; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Carattino MD, 2006, J BIOL CHEM, V281, P18901, DOI 10.1074/jbc.M604109200; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; DURIEUX ME, 1994, FEBS LETT, V337, P235, DOI 10.1016/0014-5793(94)80198-3; ELS WJ, 1991, J GEN PHYSIOL, V98, P1197, DOI 10.1085/jgp.98.6.1197; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; Harris M, 2007, J BIOL CHEM, V282, P58, DOI 10.1074/jbc.M605125200; Helms MN, 2005, J BIOL CHEM, V280, P40885, DOI 10.1074/jbc.M509646200; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Horowitz LF, 2005, J GEN PHYSIOL, V126, P243, DOI 10.1085/jgp.200509309; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Jovov B, 2002, J BIOL CHEM, V277, P4134, DOI 10.1074/jbc.M108354200; Kamatchi GL, 2003, BRAIN RES, V968, P227, DOI 10.1016/S0006-8993(03)02245-5; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; LEWIS SA, 1986, P NATL ACAD SCI USA, V83, P5345, DOI 10.1073/pnas.83.14.5345; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu L, 2002, HYPERTENSION, V39, P860, DOI 10.1161/01.HYP.0000013055.48885.8D; Ma HP, 2005, J AM SOC NEPHROL, V16, P3182, DOI 10.1681/ASN.2005040434; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McSorley T, 2006, EUR J CELL BIOL, V85, P673, DOI 10.1016/j.ejcb.2006.01.005; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OGrady SM, 1996, J BIOL CHEM, V271, P29080, DOI 10.1074/jbc.271.46.29080; ORCE GG, 1980, AM J PHYSIOL, V239, pF459, DOI 10.1152/ajprenal.1980.239.5.F459; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Schultheiss M, 1997, CELL MOL LIFE SCI, V53, P842, DOI 10.1007/s000180050104; Shapira H, 1998, J BIOL CHEM, V273, P19431, DOI 10.1074/jbc.273.31.19431; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Tong QS, 2004, J BIOL CHEM, V279, P22654, DOI 10.1074/jbc.M401004200; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vallet VR, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133588; Verghese GM, 2006, AM J PHYSIOL-CELL PH, V291, pC1258, DOI 10.1152/ajpcell.00637.2005; Vesey DA, 2007, NEPHROLOGY, V12, P36, DOI 10.1111/j.1440-1797.2006.00746.x; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828	52	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26884	26896		10.1074/jbc.M611829200	http://dx.doi.org/10.1074/jbc.M611829200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627947	hybrid			2022-12-25	WOS:000249304900028
J	Leipold, MD; Vinogradov, E; Whitfield, C				Leipold, Michael D.; Vinogradov, Evgeny; Whitfield, Chris			Glycosyltransferases involved in biosynthesis of the outer core region of Escherichia coli lipopolysaccharides exhibit broader substrate Specificities than is predicted from lipopolysaccharide structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-ENTERICA; POLYACRYLAMIDE GELS; ASSEMBLY SYSTEM; OLIGOSACCHARIDE; ENZYMES; LIPOOLIGOSACCHARIDE; ENTEROBACTERIACEAE; DIVERSITY; PORTION; GENES	The waaJ, waaT, and waaR genes encode alpha- 1,2-glycosyltransferases involved in synthesis of the outer core region of the lipopolysaccharide of Escherichia coli. They belong to the glycosyltransferase CAZy family 8, characterized by the GT-A fold, DXD motifs, and by retention of configuration at the anomeric carbon of the donor sugar. Each enzyme adds a hexose residue at the same stage of core oligosaccharide backbone extension. However, they differ in the epimers for their donor nucleotide sugars, and in their acceptor residues. WaaJ is a UDP-glucose: ( galactosyl) LPS alpha- 1,2-glucosyltransferase, whereas WaaR and WaaT have UDP-glucose:( glucosyl) LPS alpha- 1,2-glucosyltransferase and UDP-galactose:( glucosyl) LPS alpha- 1,2-galactosyltransferase activities, respectively. The objective of this work was to examine their ability to utilize alternate donors and acceptors. When expressed in the heterologous host, each enzyme was able to extend the alternate LPS acceptor in vivo but they retained their natural donor specificity. In vitro assays were then performed to test the effect of substituting the epimeric donor sugar on incorporation efficiency with the natural LPS acceptor of the enzyme. Although each enzyme could utilize the alternate donor epimer, activity was compromised because of significant decreases in k(cat) and corresponding increases in K-m( donor). Finally, in vitro assays were performed to probe acceptor preference in the absence of the cellular machinery. The results were enzyme-dependent: while an alternate acceptor had no significant effect on the kinetic behavior of His(6)-WaaT, His(6)-WaaJ showed a significantly decreased k(cat) and increased K-m( acceptor). These results illustrate the differences in behavior between closely related glycosyltransferase enzymes involved in the synthesis of similar glycoconjugates and have implications for glycoengineering applications.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca	Leipold, Michael/A-9452-2013	Leipold, Michael/0000-0001-5389-0906; Vinogradov, Evgeny/0000-0002-5364-1376				Aharoni A, 2006, NAT METHODS, V3, P609, DOI 10.1038/NMETH899; Amor K, 2000, INFECT IMMUN, V68, P1116, DOI 10.1128/IAI.68.3.1116-1124.2000; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; Kaniuk NA, 2004, J BIOL CHEM, V279, P31237, DOI 10.1074/jbc.M401879200; Kaniuk NA, 2002, MOL MICROBIOL, V46, P1305, DOI 10.1046/j.1365-2958.2002.03243.x; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; Leipold MD, 2007, J BIOL CHEM, V282, P1257, DOI 10.1074/jbc.M608164200; Muller-Loennies S, 2002, EUR J BIOCHEM, V269, P5982, DOI 10.1046/j.1432-1033.2002.03322.x; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; SCHMIDT G, 1970, EUR J BIOCHEM, V14, P357, DOI 10.1111/j.1432-1033.1970.tb00297.x; Seeberger PH, 2005, NAT REV DRUG DISCOV, V4, P751, DOI 10.1038/nrd1823; Thibodeaux CJ, 2007, NATURE, V446, P1008, DOI 10.1038/nature05814; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; WILSON DB, 1964, J BIOL CHEM, V239, P2469; Yang QL, 1996, J EXP MED, V183, P323, DOI 10.1084/jem.183.1.323	25	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26786	26792		10.1074/jbc.M704131200	http://dx.doi.org/10.1074/jbc.M704131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631498	hybrid			2022-12-25	WOS:000249304900018
J	Arora, V; Cheung, HH; Plenchette, S; Micali, OC; Liston, P; Korneluk, RG				Arora, Vinay; Cheung, Herman H.; Plenchette, Stephanie; Micali, O. Cristina; Liston, Peter; Korneluk, Robert G.			Degradation of survivin by the x-linked inhibitor of apoptosis (XIAP)-XAF1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIAP-ASSOCIATED FACTOR-1; TRAIL-INDUCED APOPTOSIS; UBIQUITIN-PROTEASOME PATHWAY; DOWN-REGULATION; CANCER-CELLS; MAMMALIAN-CELLS; XAF1 EXPRESSION; HYPERMETHYLATION; SMAC/DIABLO; PROTEIN	X-linked inhibitor of apoptosis ( XIAP)-associated factor 1 ( XAF1) is a putative tumor suppressor in which expression is significantly reduced in human cancer cell lines and primary tumors. The proapoptotic effects of XAF1 have been attributed to both caspase-dependent and - independent means. In particular, XAF1 reverses the anti-caspase activity of XIAP, a physiological inhibitor of apoptosis. We further investigated the function of XAF1 by examining its relationship with other IAPs. Immunoprecipitation studies indicate that XAF1 binds to XIAP, cIAP1, cIAP2, Livin, TsIAP, and NAIP but not Survivin, an IAP that prevents mitotic catastrophe and in which antiapoptotic activity is exerted through direct XIAP interaction and stabilization. We found that overexpressed XAF1 down-regulates the protein expression of Survivin. Under these conditions, Survivin expression was restored in the presence of the proteasome inhibitor MG132 or a XIAP RING mutant that is defective in ubiquitin-protein isopeptide ligase ( E3) activity, suggesting that XAF1 interaction activates E3 activity of XIAP and targets Survivin by direct ubiquitination. In addition, RNAinterference targeting endogenous XIAP protected Survivin degradation by XAF1. Furthermore, interferon-beta-mediated XAF1 induction promoted formation of an endogenous XIAP-XAF1-Survivin complex. This complex facilitated Survivin degradation, which was prevented in XAF1 (-/-) stable clones. Altogether, our study demonstrates that XAF1 mediates Survivin down-regulation through a complex containing XIAP, supporting dual roles for XAF1 in apoptosis and mitotic catastrophe.	Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Children's Hospital of Eastern Ontario	Korneluk, RG (corresponding author), Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada.	bob@mgcheo.med.uottawa.ca	高, 雨莉/HGU-8187-2022; Plenchette, Stéphanie/AAA-5155-2021	Plenchette, Stéphanie/0000-0003-4483-9206				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Borden EC, 2005, J INTERF CYTOK RES, V25, P511, DOI 10.1089/jir.2005.25.511; Byun DS, 2003, CANCER RES, V63, P7068; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Cheung HH, 2006, CLIN CANCER RES, V12, P3238, DOI 10.1158/1078-0432.CCR-06-0817; Cheung HH, 2001, J NEUROCHEM, V78, P524, DOI 10.1046/j.1471-4159.2001.00433.x; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Fang XL, 2006, INT J CANCER, V118, P2485, DOI 10.1002/ijc.21636; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lee MG, 2006, ONCOGENE, V25, P5807, DOI 10.1038/sj.onc.1209867; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Ma L, 2006, CELL DEATH DIFFER, V13, P2079, DOI 10.1038/sj.cdd.4401959; Ma Tian Le, 2005, Chin J Dig Dis, V6, P10, DOI 10.1111/j.1443-9573.2005.00180.x; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Micali OC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-52; Nakao K, 2006, ONCOL REP, V16, P389; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Perrelet D, 2004, J NEUROSCI, V24, P3777, DOI 10.1523/JNEUROSCI.0413-04.2004; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; Qi R, 2007, CANCER GENE THER, V14, P82, DOI 10.1038/sj.cgt.7700992; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074; Schultze K, 2006, APOPTOSIS, V11, P1503, DOI 10.1007/s10495-006-8896-3; Sharief MK, 2002, ARCH NEUROL-CHICAGO, V59, P1115, DOI 10.1001/archneur.59.7.1115; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Wheatley SP, 2005, INT REV CYTOL, V247, P35, DOI 10.1016/S0074-7696(05)47002-3; Wilkinson JC, 2004, J BIOL CHEM, V279, P51082, DOI 10.1074/jbc.M408655200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhao J, 2000, J CELL SCI, V113, P4363	36	128	137	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26202	26209		10.1074/jbc.M700776200	http://dx.doi.org/10.1074/jbc.M700776200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17613533	hybrid			2022-12-25	WOS:000249239600024
J	Xu, Y; Farmer, SR; Smith, BD				Xu, Yong; Farmer, Stephen R.; Smith, Barbara D.			Peroxisome proliferator-activated receptor gamma interacts with CIITA center dot RFX5 complex to repress type I collagen gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN SKIN FIBROBLASTS; REGULATORY FACTOR-X; PPAR-GAMMA; TGF-BETA; NUCLEAR RECEPTORS; INTERFERON-GAMMA; TRANSCRIPTION FACTOR; COL1A2 TRANSCRIPTION; TRANSACTIVATOR CIITA	Recent reports demonstrate that peroxisome proliferator-activated receptor gamma ( PPAR gamma), a member of the nuclear receptor superfamily, acts as a repressor of type I collagen synthesis. Our data demonstrate that exogenously expressed PPAR gamma down-regulates collagen expression in a dose-responsive manner in human lung fibroblast cells. Silencing PPAR gamma using lentiviruses expressing short hairpin RNAs partially reverses interferon-gamma ( IFN-gamma)- induced repression and activates collagen mRNA levels. Previous studies indicate that IFN-gamma represses collagen gene expression and induces major histocompatibility complex II (MHC II) expression by activating the formation of a regulatory factor for X-box 5 ( RFX5) complex with class II transactivator ( CIITA). This report demonstrates that PPAR gamma is within the RFX5 center dot CIITA complex as judged by co-immunoprecipitation and DNA affinity precipitation studies. Most importantly, occupancy of PPAR gamma on the collagen transcription start site and MHC II promoter increases with IFN-gamma treatment. The PPAR gamma agonist, troglitazone, sensitizes the cells to IFN-gamma treatment by increasing recruitment of PPAR gamma to collagen gene while repressing collagen expression, and these effects are blocked by the PPAR gamma antagonist T0070907. PPAR gamma may mediate IFN-gamma-stimulated collagen transcription down-regulation and MHC II up-regulation by interacting with CIITA as well as regulating CIITA expression. Therefore, PPAR gamma is a critical target for investigations into therapeutics of diseases involving extracellular matrix remodeling and the immune response.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Smith, BD (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627; Farmer, Stephen/0000-0003-2483-2795	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, R01HL068094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051586, R56DK058825, R56DK051586, R01DK058825] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL013262-31, HL68094] Funding Source: Medline; NIDDK NIH HHS [DK58825, DK51586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Belvisi MG, 2006, EUR J PHARMACOL, V533, P101, DOI 10.1016/j.ejphar.2005.12.048; Blaschke F, 2006, ARTERIOSCL THROM VAS, V26, P28, DOI 10.1161/01.ATV.0000191663.12164.77; Burgess HA, 2005, AM J PHYSIOL-LUNG C, V288, pL1146, DOI 10.1152/ajplung.00383.2004; Buttice G, 2006, CIRC RES, V98, P472, DOI 10.1161/01.RES.0000204725.46332.97; Chen J, 2006, AM J PHYSIOL-HEART C, V291, pH1738, DOI 10.1152/ajpheart.00341.2006; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Collin M, 2006, CRIT CARE MED, V34, P1131, DOI 10.1097/01.CCM.0000206472.63040.6D; Coustry F, 2001, J BIOL CHEM, V276, P40621, DOI 10.1074/jbc.M106918200; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; Gelman L, 2005, CURR OPIN CELL BIOL, V17, P216, DOI 10.1016/j.ceb.2005.02.002; Genovese T, 2005, EUR RESPIR J, V25, P225, DOI 10.1183/09031936.05.00049704; Ghosh AK, 2004, ARTHRITIS RHEUM-US, V50, P1305, DOI 10.1002/art.20104; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Giri SN, 2002, BIOPHARM DRUG DISPOS, V23, P203, DOI 10.1002/bdd.311; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; Higashi K, 2003, J BIOL CHEM, V278, P5156, DOI 10.1074/jbc.M208724200; Huang THW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-102; Ide T, 2003, THROMB RES, V110, P311, DOI 10.1016/S0049-3848(03)00418-3; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Jabrane-Ferrat N, 2002, MOL CELL BIOL, V22, P5616, DOI 10.1128/MCB.22.15.5616-5625.2002; Jaster R, 2005, J CELL MOL MED, V9, P670, DOI 10.1111/j.1582-4934.2005.tb00497.x; JHONDARES E, 2007, BIOCHEM BIOPH RES CO, V354, P1021; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; Kohno S, 2006, BIOMED PHARMACOTHER, V60, P18, DOI 10.1016/j.biopha.2005.04.004; Kon K, 2002, BIOCHEM BIOPH RES CO, V291, P55, DOI 10.1006/bbrc.2002.6385; Kwak BR, 2002, CIRC RES, V90, P356, DOI 10.1161/hh0302.104924; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Lee YJ, 1997, J IMMUNOL, V158, P2065; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441-06; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Moreno CS, 1997, J IMMUNOL, V158, P5841; Nandan D, 1997, J IMMUNOL, V158, P1095; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Ogata T, 2004, J AM COLL CARDIOL, V43, P1481, DOI 10.1016/j.jacc.2003.11.043; Ollero M, 2004, J CELL PHYSIOL, V200, P235, DOI 10.1002/jcp.20020; Panchapakesan U, 2005, AM J PHYSIOL-RENAL, V289, pF1153, DOI 10.1152/ajprenal.00097.2005; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Pascual G, 2006, TRENDS ENDOCRIN MET, V17, P321, DOI 10.1016/j.tem.2006.08.005; Ramirez F, 2006, MATRIX BIOL, V25, P365, DOI 10.1016/j.matbio.2006.05.002; Rizzo G, 2006, CURR OPIN PHARMACOL, V6, P421, DOI 10.1016/j.coph.2006.03.012; Schaefer KL, 2005, CANCER RES, V65, P2251, DOI 10.1158/0008-5472.CAN-04-3037; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Standiford Theodore J, 2005, Proc Am Thorac Soc, V2, P226, DOI 10.1513/pats.200501-010AC; Sun K, 2006, ACTA PHARMACOL SIN, V27, P715, DOI 10.1111/j.1745-7254.2006.00299.x; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100; Xu JY, 2003, AM J PHYSIOL-GASTR L, V285, pG20, DOI 10.1152/ajpgi.00474.2002; Xu Y, 2006, J BIOL CHEM, V281, P9260, DOI 10.1074/jbc.M511724200; Xu Y, 2004, J BIOL CHEM, V279, P41319, DOI 10.1074/jbc.M404174200; Xu Y, 2003, J BIOL CHEM, V278, P49134, DOI 10.1074/jbc.M309003200; Xu Y, 2007, MOL IMMUNOL, V44, P1709, DOI 10.1016/j.molimm.2006.07.294; Yang L, 2006, AM J PHYSIOL-GASTR L, V291, pG902, DOI 10.1152/ajpgi.00124.2006; Yavrom S, 2005, J BIOL CHEM, V280, P40650, DOI 10.1074/jbc.M510094200; Ye P, 2006, GERONTOLOGY, V52, P69, DOI 10.1159/000090951; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zafiriou S, 2005, J AM SOC NEPHROL, V16, P638, DOI 10.1681/ASN.2004040278; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	78	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26046	26056		10.1074/jbc.M703652200	http://dx.doi.org/10.1074/jbc.M703652200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17611194	hybrid			2022-12-25	WOS:000249239600008
J	Meenan, NAG; Visai, L; Valtulina, V; Schwarz-Linek, U; Norris, NC; Gurusiddappa, S; Hook, M; Speziale, P; Potts, JR				Meenan, Nicola A. G.; Visai, Livia; Valtulina, Viviana; Schwarz-Linek, Ulrich; Norris, Nicole C.; Gurusiddappa, Sivashankarappa; Hoeoek, Magnus; Speziale, Pietro; Potts, Jennifer R.			The tandem beta-zipper model defines high affinity fibronectin-binding repeats within staphylococcus aureus FnBPA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-A; STREPTOCOCCUS-DYSGALACTIAE; MEDIATE ADHERENCE; ANTIBODY-RESPONSE; LIGAND-BINDING; INVASION; ADHESIN; INTERNALIZATION; IDENTIFICATION; DOMAIN	Binding of the fibronectin-binding protein FnBPA from Staphylococcus aureus to the human protein fibronectin has previously been implicated in the development of infective endocarditis, specifically in the processes of platelet activation and invasion of the endothelium. We recently proposed a model for binding of fibronectin to FnBPA in which the bacterial protein contains 11 potential binding sites (FnBPA-1 to FnBPA11), each composed of motifs that bind to consecutive fibronectin type 1 modules in the N-terminal domain of fibronectin. Here we show that six of the 11 sites bind with dissociation constants in the nanomolar range; other sites bind more weakly. The high affinity binding sites include FnBPA-1, the sequence of which had previously been thought to be encompassed by the fibrinogen-binding A domain of FnBPA. Both the number and sequence conservation of the type-1 module binding motifs appears to be important for high affinity binding. The in vivo relevance of the in vitro binding studies is confirmed by the presence of antibodies in patients with S. aureus infections that specifically recognize complexes of these six high affinity repeats with fibronectin.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Univ Pavia, Ctr Ingn Tissutale, I-27100 Pavia, Italy; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Texas Syst Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ York, Dept Chem, York YO10 5DD, N Yorkshire, England	University of Pavia; University of York - UK; University of Pavia; University of St Andrews; University of Texas System; University of Texas Health Science Center Houston; University of York - UK	Speziale, P (corresponding author), Univ Pavia, Dept Biochem, Viale Taramelli 3-B, I-27100 Pavia, Italy.	pspeziale@unipv.it	Visai, Livia/R-7397-2017; Meenan, Nicola/A-4884-2010	Visai, Livia/0000-0003-1181-3632; Meenan, Nicola/0000-0002-0294-4983; Schwarz-Linek, Ulrich/0000-0003-0526-223X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI020624] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed S, 2001, INFECT IMMUN, V69, P2872, DOI 10.1128/IAI.69.5.2872-2877.2001; Arrecubieta C, 2006, J INFECT DIS, V193, P1109, DOI 10.1086/501366; Casolini F, 1998, INFECT IMMUN, V66, P5433, DOI 10.1128/IAI.66.11.5433-5442.1998; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Davis JS, 2005, INTERN MED J, V35, pS79, DOI 10.1111/j.1444-0903.2005.00982.x; Fitzgerald JR, 2006, MOL MICROBIOL, V59, P212, DOI 10.1111/j.1365-2958.2005.04922.x; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Fowler T, 2000, EUR J CELL BIOL, V79, P672, DOI 10.1078/0171-9335-00104; FROMAN G, 1987, J BIOL CHEM, V262, P6564; Grundmeier M, 2004, INFECT IMMUN, V72, P7155, DOI 10.1128/IAI.72.12.7155-7163.2004; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; HUFF S, 1994, J BIOL CHEM, V269, P15563; Ing M, 1997, STAPHYLOCOCCI HUMAN, P331; Ingham KC, 2004, J BIOL CHEM, V279, P42945, DOI 10.1074/jbc.M406984200; Jett BD, 2002, INFECT IMMUN, V70, P4697, DOI 10.1128/IAI.70.8.4697-4700.2002; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; Keane FM, 2007, BIOCHEMISTRY-US, V46, P7226, DOI 10.1021/bi700454x; Kintarak S, 2004, INFECT IMMUN, V72, P5668, DOI 10.1128/IAI.72.10.5668-5675.2004; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LINDGREN PE, 1993, EUR J BIOCHEM, V214, P819, DOI 10.1111/j.1432-1033.1993.tb17985.x; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; Lowy FD, 2003, J CLIN INVEST, V111, P1265, DOI 10.1172/JC1200318535; Mandal S, 2002, J INFECTION, V44, P143, DOI 10.1053/jinf.2001.0952; Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462-5822.2001.00157.x; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; Murakawa GJ, 2004, CUTIS, V73, P7; Nashev D, 2004, FEMS MICROBIOL LETT, V233, P45, DOI 10.1016/j.femsle.2004.01.032; Peacock SJ, 2000, J INFECTION, V41, P23, DOI 10.1053/jinf.2000.0657; Peacock SJ, 1999, MICROBIOL-SGM, V145, P3477, DOI 10.1099/00221287-145-12-3477; Penkett CJ, 1998, BIOCHEMISTRY-US, V37, P17054, DOI 10.1021/bi9814080; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Que YA, 2005, J EXP MED, V201, P1627, DOI 10.1084/jem.20050125; Raibaud S, 2005, J BIOL CHEM, V280, P18803, DOI 10.1074/jbc.M501731200; Rice K, 2001, INFECT IMMUN, V69, P3791, DOI 10.1128/IAI.69.6.3791-3799.2001; Rindi S, 2006, EUR J CLIN INVEST, V36, P536, DOI 10.1111/j.1365-2362.2006.01675.x; Roche FM, 2004, J BIOL CHEM, V279, P38433, DOI 10.1074/jbc.M402122200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwarz-Linek U, 2004, J BIOL CHEM, V279, P39017, DOI 10.1074/jbc.M405083200; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Schwarz-Linek U, 2006, MICROBES INFECT, V8, P2291, DOI 10.1016/j.micinf.2006.03.011; Sherwood M, 2006, AM J MED SCI, V331, P84, DOI 10.1097/00000441-200602000-00014; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; Sinha B, 2005, THROMB HAEMOSTASIS, V94, P266, DOI 10.1160/TH05-04-0235; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; Speziale P, 1996, J BIOL CHEM, V271, P1371, DOI 10.1074/jbc.271.3.1371; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; TALAY SR, 1992, INFECT IMMUN, V60, P3837, DOI 10.1128/IAI.60.9.3837-3844.1992; Visai L, 2003, BBA-PROTEINS PROTEOM, V1646, P173, DOI 10.1016/S1570-9639(03)00020-7; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; Williams RJ, 2002, CALCIFIED TISSUE INT, V70, P416, DOI 10.1007/s00223-001-2073-z; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; ZARDI L, 1985, EUR J BIOCHEM, V146, P571, DOI 10.1111/j.1432-1033.1985.tb08690.x	56	78	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25893	25902		10.1074/jbc.M703063200	http://dx.doi.org/10.1074/jbc.M703063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606607	hybrid			2022-12-25	WOS:000249014100075
J	Sommer, ME; Farrens, DL; McDowell, JH; Weber, LA; Smith, WC				Sommer, Martha E.; Farrens, David L.; McDowell, J. Hugh; Weber, Lauren A.; Smith, W. Clay			Dynamics of arrestin-rhodopsin interactions - Loop movement is involved in arrestin activation and receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; VISUAL ARRESTIN; CRYSTAL-STRUCTURE; PHOSPHORYLATED RHODOPSIN; SPLICE VARIANT; BETA-ARRESTIN; MECHANISM; MEMBRANES; SITE; PHOSPHORHODOPSIN	In this study we investigate conformational changes in Loop V-VI of visual arrestin during binding to light-activated, phosphorylated rhodopsin ( Rho*-P) using a combination of site-specific cysteine mutagenesis and intramolecular fluorescence quenching. Introduction of cysteines at positions in the N-domain at residues predicted to be in close proximity to Ile-72 in Loop V-VI of arrestin ( i.e. Glu-148 and Lys-298) appear to form an intramolecular disulfide bond with I72C, significantly diminishing the binding of arrestin to Rho*-P. Using a fluorescence approach, we show that the steady-state emission from a monobromobimane fluorophore in Loop V-VI is quenched by tryptophan residues placed at 148 or 298. This quenching is relieved upon binding of arrestin to Rho*-P. These results suggest that arrestin Loop V-VI moves during binding to Rho*-P and that conformational flexibility of this loop is essential for arrestin to adopt a high affinity binding state.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	Oregon Health & Science University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Smith, WC (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	csmith@eye.ufl.edu	Smith, W. Clay/AAQ-1589-2021	Sommer, Martha E./0000-0003-0493-8584	NATIONAL EYE INSTITUTE [P30EY008571, R01EY015436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA018169] Funding Source: NIH RePORTER; NEI NIH HHS [EY08571, EY015436, EY06225] Funding Source: Medline; NIDA NIH HHS [DA018169] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Ascano M, 2006, MOL VIS, V12, P1516; CRAFT CM, 1995, FEBS LETT, V362, P247, DOI 10.1016/0014-5793(95)00213-S; Dinculescu A, 2002, J BIOL CHEM, V277, P11703, DOI 10.1074/jbc.M111833200; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hanson SM, 2006, J BIOL CHEM, V281, P3458, DOI 10.1074/jbc.M512148200; Hanson SM, 2006, P NATL ACAD SCI USA, V103, P4900, DOI 10.1073/pnas.0600733103; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Mansoor SE, 2006, P NATL ACAD SCI USA, V103, P3060, DOI 10.1073/pnas.0511010103; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Schroder K, 2002, J BIOL CHEM, V277, P43987, DOI 10.1074/jbc.M206211200; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Smith WC, 2004, MOL VIS, V10, P392; Sommer ME, 2006, J BIOL CHEM, V281, P9407, DOI 10.1074/jbc.M510037200; Sommer ME, 2005, J BIOL CHEM, V280, P6861, DOI 10.1074/jbc.M411341200; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200	40	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25560	25568		10.1074/jbc.M702155200	http://dx.doi.org/10.1074/jbc.M702155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606620	hybrid			2022-12-25	WOS:000249014100042
J	Iseli, C; Ambrosini, G; Bucher, P; Jongeneel, CV				Iseli, Christian; Ambrosini, Giovanna; Bucher, Philipp; Jongeneel, C. Victor			Indexing Strategies for Rapid Searches of Short Words in Genome Sequences	PLOS ONE			English	Article								Searching for matches between large collections of short (14-30 nucleotides) words and sequence databases comprising full genomes or transcriptomes is a common task in biological sequence analysis. We investigated the performance of simple indexing strategies for handling such tasks and developed two programs, fetchGWI and tagger, that index either the database or the query set. Either strategy outperforms megablast for searches with more than 10,000 probes. FetchGWI is shown to be a versatile tool for rapidly searching multiple genomes, whose performance is limited in most cases by the speed of access to the filesystem. We have made publicly available a Web interface for searching the human, mouse, and several other genomes and transcriptomes with oligonucleotide queries.	[Iseli, Christian; Jongeneel, C. Victor] Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland; [Iseli, Christian; Ambrosini, Giovanna; Bucher, Philipp; Jongeneel, C. Victor] Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland; [Ambrosini, Giovanna; Bucher, Philipp] Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; Swiss Institute of Bioinformatics; University of Lausanne; Swiss Institute Experimental Cancer Research	Iseli, C (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Batiment Genopode, Lausanne, Switzerland.	Christian.Iseli@licr.org	Iseli, Christian/AAM-3878-2020; Jongeneel, Cornelis V/B-2135-2012	Iseli, Christian/0000-0002-2296-2863; Ambrosini, Giovanna/0000-0003-1294-6541; Jongeneel, Cornelis Victor/0000-0002-3922-1906				Benson DA, 2006, NUCLEIC ACIDS RES, V34, pD16, DOI 10.1093/nar/gkj157; Brenner S, 2000, P NATL ACAD SCI USA, V97, P1665, DOI 10.1073/pnas.97.4.1665; Iseli C, 2002, GENOME RES, V12, P1068, DOI 10.1101/gr.62002; Jongeneel CV, 2005, GENOME RES, V15, P1007, DOI 10.1101/gr.4041005; Knuth D, 1997, SORTING SEARCHING, P409; Kuhn RM, 2007, NUCLEIC ACIDS RES, V35, pD668, DOI 10.1093/nar/gkl928; Lal A, 1999, CURR OPIN MOL THER, V1, P720; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Praz V, 2004, NUCLEIC ACIDS RES, V32, pD542, DOI 10.1093/nar/gkh107; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Schmid CD, 2006, NUCLEIC ACIDS RES, V34, pD82, DOI 10.1093/nar/gkj146; Stalker J, 2004, GENOME RES, V14, P951, DOI 10.1101/gr.1863004; Wei CL, 2004, P NATL ACAD SCI USA, V101, P11701, DOI 10.1073/pnas.0403514101; Wheeler DL, 2007, NUCLEIC ACIDS RES, V35, pD5, DOI 10.1093/nar/gkl1031; Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478	16	56	58	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e579	10.1371/journal.pone.0000579	http://dx.doi.org/10.1371/journal.pone.0000579			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593978	gold, Green Published			2022-12-25	WOS:000207451800023
J	Mizumachi, T; Suzuki, S; Naito, A; Carcel-Trullols, J; Evans, TT; Spring, PM; Oridate, N; Furuta, Y; Fukuda, S; Higuchi, M				Mizumachi, T.; Suzuki, S.; Naito, A.; Carcel-Trullols, J.; Evans, T. T.; Spring, P. M.; Oridate, N.; Furuta, Y.; Fukuda, S.; Higuchi, M.			Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells	ONCOGENE			English	Article						docetaxel; drug resistance; head and neck cancer; mitochondrial DNA; Fo-ATPase	BREAST-CANCER; OXIDATIVE STRESS; REACTIVE OXYGEN; P-GLYCOPROTEIN; APOPTOSIS; EXPRESSION; DEATH; DETERMINES; CARCINOMA; SYNTHASE	Docetaxel is one of the most effective chemotherapeutic agents against cancer; nevertheless, some patients develop resistance. Unfortunately, their causes and mechanisms remain unknown. We created docetaxel-resistant DRHEp2 from human laryngeal cancer HEp2 and investigated the roles of mitochondrial DNA (mtDNA) and reactive oxygen species (ROS) on docetaxel resistance. DRHEp2 had greatly increased mtDNA content. Reduction of mtDNA content in DRHEp2 by ethidium bromide treatment reduced the resistance. These results indicate the possible roles of mtDNA-coded enzymes in mitochondrial respiratory chain (MRC) in resistant mechanisms. Oligomycin A, an Fo-ATPase inhibitor, eliminated docetaxel resistance in DRHEp2; in contrast, inhibitors of other MRC did not. RNA interference targeted to Fo-ATPase d-subunit restored docetaxel-induced cytotoxicity to DRHEp2. These results indicate the roles of Fo-ATPase for resistant mechanisms. Docetaxel induced ROS generation in HEp2 but not in DRHEp2 and antioxidant pyrrolidine dithiocarbamate eliminated docetaxel-induced cytotoxicity, suggesting roles of ROS in docetaxel-induced cell death. Furthermore, inhibition of Fo-ATPase by Oligomycin A induced docetaxel-mediated ROS generation in DRHEp2. Taken together, DRHEp2 acquired docetaxel resistance through increasing Fo-ATPase, which led to diminish docetaxel-induced ROS generation and subsequently inhibited cell death. In conclusion, mtDNA plays an important role in developing docetaxel resistance through the reduction of ROS generation by regulating Fo-ATPase.	[Mizumachi, T.; Suzuki, S.; Naito, A.; Carcel-Trullols, J.; Evans, T. T.; Higuchi, M.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; [Mizumachi, T.; Suzuki, S.; Oridate, N.; Furuta, Y.; Fukuda, S.] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan; [Spring, P. M.] Univ Arkansas Med Sci, Dept Otolaryngol Head & Neck Surg, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Hokkaido University; University of Arkansas System; University of Arkansas Medical Sciences	Higuchi, M (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Slot 516, Little Rock, AR 72205 USA.	mhiguchi@uams.edu	Fukuda, Satoshi/A-8433-2012; Suzuki, Seigo/G-5378-2012; Oridate, Nobuhiko/ABC-4116-2020; Oridate, Nobuhiko/G-5365-2012; Mizumachi, Takatsugu/G-5479-2012	Oridate, Nobuhiko/0000-0002-6968-3028; 	NCI NIH HHS [R01 CA100846, R01 CA100846-04, R01 CA100846-01A1, R01 CA100846-02, R01 CA100846-06, R01 CA100846-05, R01 CA100846-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Alexandre J, 2006, INT J CANCER, V119, P41, DOI 10.1002/ijc.21685; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BISSERY MC, 1995, ANTI-CANCER DRUG, V6, P339, DOI 10.1097/00001813-199506000-00001; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Caporossi D, 2003, FREE RADICAL BIO MED, V35, P1355, DOI 10.1016/j.freeradbiomed.2003.08.008; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Higuchi M, 2006, ONCOGENE, V25, P1437, DOI 10.1038/sj.onc.1209190; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434; Kim SJ, 2005, CLIN CANCER RES, V11, P8425, DOI 10.1158/1078-0432.CCR-05-0449; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kirkland RA, 2007, EXP NEUROL, V204, P458, DOI 10.1016/j.expneurol.2006.09.013; Lee CF, 2005, ANN NY ACAD SCI, V1042, P246, DOI 10.1196/annals.1338.027; Li YC, 2004, CHEMOTHERAPY, V50, P55, DOI 10.1159/000077803; Lievre A, 2005, J CLIN ONCOL, V23, P3517, DOI 10.1200/JCO.2005.07.044; Liu B, 2001, J SURG RES, V99, P179, DOI 10.1006/jsre.2001.6126; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Qian W, 2005, AM J PHYSIOL-CELL PH, V289, pC1466, DOI 10.1152/ajpcell.00265.2005; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Schaaf GJ, 2002, FREE RADICAL RES, V36, P835, DOI 10.1080/1071576021000005267; Schrijvers D, 2005, CURR OPIN ONCOL, V17, P218, DOI 10.1097/01.cco.0000158735.91723.0e; Shalli K, 2005, FASEB J, V19, P1299, DOI 10.1096/fj.04-3178fje; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; WILS P, 1994, BIOCHEM PHARMACOL, V48, P1528, DOI 10.1016/0006-2952(94)90580-0; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3	30	50	54	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					831	838		10.1038/sj.onc.1210681	http://dx.doi.org/10.1038/sj.onc.1210681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17637738	Green Accepted			2022-12-25	WOS:000252884500012
J	Cuenin, S; Tinel, A; Janssens, S; Tschopp, J				Cuenin, S.; Tinel, A.; Janssens, S.; Tschopp, J.			p53-induced protein with a death domain (PIDD) isoforms differentially activate nuclear factor-kappaB and caspase-2 in response to genotoxic stress	ONCOGENE			English	Article						PIDD; DNA repair; NF-kappa B; caspase-2	DNA-DAMAGE; B ACTIVATION; INDUCED APOPTOSIS; MITOCHONDRIA; NEMO; ATM	Cellsres pond to DNA damage in a complex way and the fate of damaged cells depends on the balance between pro-and antiapoptotic signals. This is of crucial importance in cancer as genotoxic stress is implied both in oncogenesis and in classical tumor therapies. p53-induced protein with a death domain (PIDD), initially described as a p53-inducible gene, is one of the molecular switches able to activate a survival or apoptotic program. Two isoforms of PIDD, PIDD ( isoform 1) and LRDD ( isoform 2), have already been reported and we describe here a third isoform. These three isoforms are differentially expressed in tissues and cell lines. Genotoxic stress only affects PIDD isoform 3 mRNA levels, whereas isoforms 1 and 2 mRNA levels remain unchanged. All isoforms are capable of activating nuclear factor-kappaB in response to genotoxic stress, but only isoform 1 interacts with RIP-associated ICH-1/CED-3 homologous protein with a death domain and activates caspase-2. Isoform 2 counteracts the pro-apoptotic function of isoform 1, whereas isoform 3 enhances it. Thus, the differential splicing of PIDD mRNA leads to the formation of at least three proteins with antagonizing/agonizing functions, thereby regulating cell fate in response to DNA damage.	[Cuenin, S.; Tinel, A.; Janssens, S.; Tschopp, J.] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Tschopp, J (corresponding author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	jurg.tschopp@unil.ch	Janssens, Sophie/HHN-1756-2022					Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Campbell KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-101; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hay RT, 2004, NAT CELL BIOL, V6, P89, DOI 10.1038/ncb0204-89; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Katzenberger RJ, 2006, MOL CELL BIOL, V26, P9256, DOI 10.1128/MCB.01125-06; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Pick R, 2006, BIOCHEM BIOPH RES CO, V349, P1329, DOI 10.1016/j.bbrc.2006.08.176; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049	21	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					387	396		10.1038/sj.onc.1210635	http://dx.doi.org/10.1038/sj.onc.1210635			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637755				2022-12-25	WOS:000252256000015
J	Brunelli, R; Papi, M; Arcovito, G; Bompiani, A; Castagnola, M; Parasassi, T; Sampaolese, B; Vincenzoni, F; De Spirito, M				Brunelli, Roberto; Papi, Massimiliano; Arcovito, Giuseppe; Bompiani, Adriano; Castagnola, Massimo; Parasassi, Tiziana; Sampaolese, Beatrice; Vincenzoni, Federica; De Spirito, Marco			Globular structure of human ovulatory cervical mucus	FASEB JOURNAL			English	Article						atomic force microscopy; hydrophobicity; MUC5B; recurrence analysis	SCANNING-ELECTRON-MICROSCOPY; GASTRIC MUCIN; SPERM; CYCLE; PH; MICROSTRUCTURES; ULTRASTRUCTURE; AGGREGATION; LIGHT	Human cervical mucus is a heterogeneous mixture of mucin glycoproteins whose relative concentration changes during the ovulatory phases, thereby producing different mucus aggregation structures that can periodically permit the transit of spermatozoa for fertilization. In preovulatory phase, mucus is arranged in compact fiber- like structures where sperm transit is hindered. Previously, through observations made of fixed and dehydrated samples, a permissive structure in the ovulatory phase was attributed to the larger diameters of pores in the mucus network. Instead, by means of atomic force microscopy, we can show, for the first time, that unfixed ovulatory mucus is composed by floating globules of mucin aggregates. This finding sheds new light on the mechanism that governs spermatozoa transit toward the uterine cavity. In addition, we demonstrate that the switch from globular ovulatory to fibrous preovulatory mucus largely depends on a pH- driven mechanism. Analysis of mucin 5B primary sequence, the main mucin in ovulatory mucus, highlights pH- sensitive domains that are associated to flexible regions prone to drive aggregation. We suggest an involvement of these domains in the fiber- to- globule switch in cervical mucus.	Univ Roma La Sapienza, Dipartimento Sci Ginecol Perinatol Puericultura, Rome, Italy; Univ Cattolica Sacro Cuore, Ist Fis, Rome, Italy; Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Ist Biochim & Biochim Clin, Rome, Italy; Ist Sci Int Paolo IV, Rome, Italy; CNR, Inst Chim Riconsimento Mol, Rome, Italy; CNR, Ist Neurobiol Med Mol, Rome, Italy	Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); Consiglio Nazionale delle Ricerche (CNR)	De Spirito, M (corresponding author), Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Ist Fis, Largo V Vito 1, I-00168 Rome, Italy.	m.despirito@rm.unicatt.it	Sampaolese, Beatrice/H-7704-2013; De Spirito, Marco/U-3817-2019; Castagnola, Massimo/AAB-2825-2019; Castagnola, Massimo/AAM-6355-2021; Papi, Massimiliano/B-3168-2012; De Spirito, Marco/C-5386-2008; Papi, Massimiliano/AAC-3657-2022; SAMPAOLESE, BEATRICE/O-5505-2019	De Spirito, Marco/0000-0003-4260-5107; Castagnola, Massimo/0000-0002-0959-7259; De Spirito, Marco/0000-0003-4260-5107; Papi, Massimiliano/0000-0002-0029-1309; SAMPAOLESE, BEATRICE/0000-0001-7833-1801; Vincenzoni, Federica/0000-0002-0124-2234; Parasassi, Tiziana/0000-0002-9795-0568				Bansil R, 1997, P SOC PHOTO-OPT INS, V2982, P116, DOI 10.1117/12.273605; BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0; Cao XX, 1999, BIOPHYS J, V76, P1250, DOI 10.1016/S0006-3495(99)77288-7; Ceric F, 2005, J ELECTRON MICROSC, V54, P479, DOI 10.1093/jmicro/dfh106; CHRETIEN FC, 1991, HUM REPROD, V6, P1192, DOI 10.1093/oxfordjournals.humrep.a137511; CHRETIEN FC, 1973, FERTIL STERIL, V24, P746; CHRETIEN FC, 1989, HUM REPROD, V4, P359, DOI 10.1093/oxfordjournals.humrep.a136908; EGGERTKRUSE W, 1993, FERTIL STERIL, V59, P617; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gipson IK, 1999, BIOL REPROD, V60, P58, DOI 10.1095/biolreprod60.1.58; Gipson IK, 2001, J CLIN ENDOCR METAB, V86, P594, DOI 10.1210/jc.86.2.594; Giuliani A, 2000, BIOPHYS J, V78, P136, DOI 10.1016/S0006-3495(00)76580-5; HONG Z, 2002, AM PHYS SOC ANN APS; Hong ZN, 2005, BIOMACROMOLECULES, V6, P3458, DOI 10.1021/bm0505843; Lagow E, 1999, HUM REPROD UPDATE, V5, P280, DOI 10.1093/humupd/5.4.280; Menarguez M, 2003, HUM REPROD, V18, P1782, DOI 10.1093/humrep/deg382; MOGHISSI KS, 1972, FERTIL STERIL, V23, P295; ODEBLAD E, 1968, ACTA OBSTET GYN SCAN, VS 47, P57, DOI 10.3109/00016346809156845; ODEBLAD E, 1961, ACTA OBSTET GYNEC S2, V45, P127; PAPANICOLAOU GN, 1946, AM J OBSTET GYNECOL, V51, P316, DOI 10.1016/S0002-9378(16)40012-8; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; RYDBERG E, 1948, ACTA OBSTET GYN SCAN, V28, P172; WEBBER CL, 1994, J APPL PHYSIOL, V76, P965, DOI 10.1152/jappl.1994.76.2.965; WOLF DP, 1978, FERTIL STERIL, V30, P163; YUDIN AI, 1989, BIOL REPROD, V40, P661, DOI 10.1095/biolreprod40.3.661; YUREWICZ EC, 1982, J BIOL CHEM, V257, P2314; ZANEVELD LJD, 1975, OBSTET GYNECOL, V46, P419; Zbilut JP, 2003, BIOPHYS J, V85, P3544, DOI 10.1016/S0006-3495(03)74774-2	28	69	73	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3872	3876		10.1096/fj.07-8189com	http://dx.doi.org/10.1096/fj.07-8189com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17606809				2022-12-25	WOS:000251283500012
J	Battle, DJ; Kasim, M; Wang, J; Dreyfuss, G				Battle, Daniel J.; Kasim, Mumtaz; Wang, Jin; Dreyfuss, Gideon			SMN-independent subunits of the SMN complex - Identification of a small nuclear ribonucleoprotein assembly intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; DEAD-BOX PROTEIN; MOTOR-NEURON COMPLEX; STRESS GRANULES; GENE-PRODUCT; SURVIVAL; COMPONENT; DP103; RNA; TRANSLATION	The survival of motor neurons (SMN) complex is essential for the biogenesis of small nuclear ribonucleoprotein (snRNP) complexes in eukaryotic cells. Reduced levels of SMN cause the motor neutron degenerative disease, spinal muscular atrophy. We identify here stable subunits of the SMN complex that do not contain SMN. Sedimentation and immunoprecipitation experiments using cell extracts reveal at least three complexes composed of Gemin3, -4, and -5; Gemin6, -7, and unrip; and SMN with Gemin2, as well as free Gemin5. Complexes containing Gemin3-Gemin4-Gemin5 and Gemin6-Gemin7-unrip persist at similar levels when SMN is reduced. In cells, immunofluorescence microscopy shows differential localization of Gemin5 after cell stress. We further show that the Gemin5-containing subunits bind small nuclear RNA independently of the SMN complex and without a requirement for exogenous ATP. ATP hydrolysis is, however, required for displacement of small nuclear RNAs from the Gemin5-containing subunits and their assembly into snRNPs. These findings demonstrate a modular nature of the SMN complex and identify a new intermediate in the snRNP assembly process.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Dreyfuss, G (corresponding author), 415 Curie Blvd,328 CRB, Philadelphia, PA 19147 USA.	gdreyfuss@hhmi.upenn.edu	Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				Achsel T, 2001, P NATL ACAD SCI USA, V98, P3685, DOI 10.1073/pnas.071033998; Anderson P, 2002, CELL STRESS CHAPERON, V7, P213, DOI 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2; Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Battle DJ, 2006, MOL CELL, V23, P273, DOI 10.1016/j.molcel.2006.05.036; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Carissimi C, 2005, FEBS LETT, V579, P2348, DOI 10.1016/j.febslet.2005.03.034; Carissimi C, 2006, J BIOL CHEM, V281, P37009, DOI 10.1074/jbc.M607505200; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; Fierro-Monti I, 2006, J PROTEOME RES, V5, P1367, DOI 10.1021/pr0504539; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; Grimmler M, 2005, HUM MOL GENET, V14, P3099, DOI 10.1093/hmg/ddi343; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Hua YM, 2004, FEBS LETT, V572, P69, DOI 10.1016/j.febslet.2004.07.010; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Lee MB, 2005, MOL CELL BIOL, V25, P1879, DOI 10.1128/MCB.25.5.1879-1890.2005; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Otter S, 2007, J BIOL CHEM, V282, P5825, DOI 10.1074/jbc.M608528200; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; Voss MD, 2001, J VIROL, V75, P11781, DOI 10.1128/JVI.75.23.11781-11790.2001; Wan LL, 2005, MOL CELL BIOL, V25, P5543, DOI 10.1128/MCB.25.13.5543-5551.2005; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Xu PL, 2003, ACTA BIOCH BIOPH SIN, V35, P909; Yong J, 2004, MOL CELL BIOL, V24, P2747, DOI 10.1128/MCB.24.7.2747-2756.2004; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188	46	46	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27953	27959		10.1074/jbc.M702317200	http://dx.doi.org/10.1074/jbc.M702317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640873	hybrid			2022-12-25	WOS:000249455600044
J	Moretti, FA; Chauhan, AK; Iaconcig, A; Porro, F; Baralle, FE; Muro, AF				Moretti, Federico A.; Chauhan, Anil K.; Iaconcig, Alessandra; Porro, Fabiola; Baralle, Francisco E.; Muro, Andres F.			A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INJURED ARTERIOLES; THROMBUS GROWTH; MESSENGER-RNA; SECRETION; EXPRESSION; SUBSTRATE; PROTEINS; BINDING; REGION; CELLS	The origin of the fibronectin (FN) found in the extracellular matrix of tissues has not been defined experimentally. Previous studies suggest that there is contribution from both local tissue production and transfer from plasma, but the extent of this phenomenon has not been addressed. We have shown before that engineered mice constitutively expressing extra domain A-containing FN (EDA(+)FN) have a significant decrease of FN levels in plasma and most tissues. We showed that hepatocytes modified to produce EDA(+)FN have normal extracellular matrix-FN levels but secrete less soluble FN. When we performed a liver-specific EDiA-exon deletion in these animals, FN levels were restored both in plasma and tissues. Therefore, an important fraction of tissue FN, approximately an equal amount of that produced by the tissue itself, is actually plasma-derived, suggesting that plasma is an important source of tissue FN. The present results halve potential significance for understanding the contributions of plasma FN, and perhaps other plasma proteins, in the modulation of cellular activities and in the formation of the extracellular matrix of tissues.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Muro, AF (corresponding author), Harvard Univ, Harvard Med Sch, CBR Inst Biomed Res, Dept Pathol, Boston, MA 02115 USA.	muro@icgeb.org	Muro, Andrés F/K-3156-2016	Muro, Andrés F/0000-0002-9628-0494; Moretti, Federico Andrea/0000-0003-3187-3683; Chauhan, Anil/0000-0001-8554-0898				Bae E, 2004, J BIOL CHEM, V279, P35749, DOI 10.1074/jbc.M406283200; Chauhan AK, 2004, GENE, V324, P55, DOI 10.1016/j.gene.2003.09.026; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GUTMAN A, 1987, P NATL ACAD SCI USA, V84, P7179, DOI 10.1073/pnas.84.20.7179; Hynes RO, 1990, FIBRONECTINS; Kellendonk C, 2000, GENESIS, V26, P151, DOI 10.1002/(SICI)1526-968X(200002)26:2<151::AID-GENE17>3.0.CO;2-E; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; KOWALCZYK AP, 1990, BLOOD, V75, P2335; Malarkey DE, 2005, TOXICOL PATHOL, V33, P27, DOI 10.1080/01926230590881826; Matuskova J, 2006, ARTERIOSCL THROM VAS, V26, P1391, DOI 10.1161/01.ATV.0000216282.58291.c6; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Ni HY, 2003, P NATL ACAD SCI USA, V100, P2415, DOI 10.1073/pnas.2628067100; Nyberg P, 2004, EMBO J, V23, P2166, DOI 10.1038/sj.emboj.7600214; OH E, 1981, P NATL ACAD SCI-BIOL, V78, P3218, DOI 10.1073/pnas.78.5.3218; OWENS MR, 1982, BLOOD, V59, P1305; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; PRICE J, 1985, J NEUROSCI, V5, P2205; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sottile J, 1998, J CELL SCI, V111, P2933; TAMKUN JW, 1983, J BIOL CHEM, V258, P4641; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; WANG A, 1991, J BIOL CHEM, V266, P15598; Yang ZS, 2006, J NEUROSCI, V26, P3829, DOI 10.1523/JNEUROSCI.4247-05.2006; Yi M, 2003, P NATL ACAD SCI USA, V100, P11435, DOI 10.1073/pnas.1635112100	33	89	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28057	28062		10.1074/jbc.M611315200	http://dx.doi.org/10.1074/jbc.M611315200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644525	hybrid, Green Published			2022-12-25	WOS:000249455600055
J	Mesika, A; Ben-Dor, S; Laviad, EL; Futerman, AH				Mesika, Adi; Ben-Dor, Shifra; Laviad, Elad L.; Futerman, Anthony H.			New functional motif in Hox domain-containing ceramide Synthases - Identification of a novel region flanking the Hox and TLC domains essential for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONGEVITY ASSURANCE GENES; FAMILY-MEMBERS; LAG1; COA	Ceramide is synthesized in mammals by a family of ceramide synthases (CerS) each of which uses a relatively restricted set of fatty acyl-CoAs for N-acylation of the sphingoid long chain base (Pewzner-Jung, Y., Ben-Dor, S., and Futerman, A. H. ( 2006) J. Biol. Chem. 281, 25001-25005). CerS are characterized by two functional domains, the (T) under bar ram-(L) under bar ag-(C) under bar LN8 (TLC) domain and the homeobox (Hox) domain, which is found in all mammalian CerS except CerS1. We now demonstrate that the majority of the Hox domain is not required for CerS activity since its deletion in CerS5 does not affect activity. Subsequently, we define a highly conserved new motif of 12 amino acid residues that flanks the Hox and TLC domains but is not part of the TLC domain, which is essential for CerS5 and CerS6 activity. Two positively charged residues in this domain, one of which is conserved in all putative CerS in all organisms, are essential for activity since site-directed mutagenesis of either (Lys-134 and Lys-140 in CerS5) results in an similar to 50% loss of activity, whereas mutation of both leads to a complete loss of activity. Because this region is conserved across species, we propose that it plays a previously unidentified and essential role in CerS activity and can be used as a new motif to define Hox domain-containing CerS.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Serv, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il	BEN-DOR, SHIFRA/M-6718-2019	BEN-DOR, SHIFRA/0000-0001-9604-1939; Futerman, Anthony/0000-0003-0013-0115				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; Kageyama-Yahara N, 2006, BIOCHEM J, V398, P585, DOI 10.1042/BJ20060697; Lahiri S, 2005, J BIOL CHEM, V280, P33735, DOI 10.1074/jbc.M506485200; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Mizutani Y, 2006, BIOCHEM J, V398, P531, DOI 10.1042/BJ20060379; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Spassieva S, 2006, J BIOL CHEM, V281, P33931, DOI 10.1074/jbc.M608092200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0; Yu Y, 2006, MICROBIOL RES, V161, P203, DOI 10.1016/j.micres.2005.08.002	21	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27366	27373		10.1074/jbc.M703487200	http://dx.doi.org/10.1074/jbc.M703487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17609214	hybrid			2022-12-25	WOS:000249304900078
J	Chan, EYW; Kir, S; Tooze, SA				Chan, Edmond Y. W.; Kir, Serkan; Tooze, Sharon A.			SiRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PROGRAMMED CELL-DEATH; PROTEIN-KINASE; C-ELEGANS; SACCHAROMYCES-CEREVISIAE; TUMOR-SUPPRESSOR; STARVATION; MACROAUTOPHAGY; INHIBITION; INDUCTION	Autophagy is a vital response to nutrient starvation. Here, we screened a kinase-specific siRNA library using an autophagy assay in human embryonic kidney 293 cells that measures lipidation of the marker protein GFP-LC3 following amino acid starvation. This screen identified ULK1 in addition to other novel candidates that could be confirmed with multiple siRNAs. Knockdown of ULK1, but not the related kinase ULK2, inhibited the autophagic response. Also, ULK1 knockdown inhibited rapamycin-induced autophagy consistent with a role downstream of mTOR. Overexpression of ULK1 inhibited autophagy and this inhibition was independent of its kinase activity. Deletion of the PDZ domain-binding Val-Tyr-Ala motif at the ULK1 C terminus generated a more potent dominant-negative protein. Further deletions revealed that the minimal ULK1 dominant-negative region could be mapped to residues 1-351. Full-length ULK1 localized to cytoplasmic structures, some of which were GFP-LC3-positive, and this localization required the conserved C-terminal domain. In contrast, ULK1-(1-351) was diffuse in the cytoplasm. These experiments reveal at least two domains in ULK1 which likely function via unique sets of effectors to regulate autophagy.	Canc Res UK London Res Inst, Secretory Pathways Lab, London WC2A 3PX, England	Cancer Research UK	Tooze, SA (corresponding author), Canc Res UK London Res Inst, Secretory Pathways Lab, 44 Lincolns Inn Field, London WC2A 3PX, England.	Sharon.Tooze@cancer.org.uk	Chan, Edmond Y.W./A-1940-2013	Chan, Edmond Y.W./0000-0001-9777-0252; Tooze, Sharon/0000-0002-2182-3116				Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Budovskaya YV, 2005, P NATL ACAD SCI USA, V102, P13933, DOI 10.1073/pnas.0501046102; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Kuma A, 2007, AUTOPHAGY, V3, P323, DOI 10.4161/auto.4012; Kuroyanagi H, 1998, GENOMICS, V51, P76, DOI 10.1006/geno.1998.5340; Lee SB, 2007, EMBO REP, V8, P360, DOI 10.1038/sj.embor.7400917; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mavrakis M, 2006, HUM MOL GENET, V15, P2962, DOI 10.1093/hmg/ddl239; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Moffat J, 2007, TRENDS PHARMACOL SCI, V28, P149, DOI 10.1016/j.tips.2007.02.009; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; Okazaki N, 2000, MOL BRAIN RES, V85, P1, DOI 10.1016/S0169-328X(00)00218-7; Otto GP, 2004, J BIOL CHEM, V279, P15621, DOI 10.1074/jbc.M311139200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Rodriguez-Enriquez S, 2004, INT J BIOCHEM CELL B, V36, P2463, DOI 10.1016/j.biocel.2004.04.009; Samari HR, 2005, BIOCHEM J, V386, P237, DOI 10.1042/BJ20040609; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tekinay T, 2006, EUKARYOT CELL, V5, P1797, DOI 10.1128/EC.00342-05; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; Tomoda T, 2004, GENE DEV, V18, P541, DOI 10.1101/gad.1151204; Tomoda T, 1999, NEURON, V24, P833, DOI 10.1016/S0896-6273(00)81031-4; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546; Yan J, 1999, ONCOGENE, V18, P5850, DOI 10.1038/sj.onc.1202988; Young ARJ, 2006, J CELL SCI, V119, P3888, DOI 10.1242/jcs.03172; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhou X, 2007, P NATL ACAD SCI USA, V104, P5842, DOI 10.1073/pnas.0701402104	57	346	358	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25464	25474		10.1074/jbc.M703663200	http://dx.doi.org/10.1074/jbc.M703663200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17595159	hybrid			2022-12-25	WOS:000249014100032
J	Nord, AS; Vranizan, K; Tingley, W; Zambon, AC; Hanspers, K; Fong, LG; Hu, Y; Bacchetti, P; Ferrin, TE; Babbitt, PC; Doniger, SW; Skarnes, WC; Young, SG; Conklin, BR				Nord, Alex S.; Vranizan, Karen; Tingley, Whittemore; Zambon, Alexander C.; Hanspers, Kristina; Fong, Loren G.; Hu, Yan; Bacchetti, Peter; Ferrin, Thomas E.; Babbitt, Patricia C.; Doniger, Scott W.; Skarnes, William C.; Young, Stephen G.; Conklin, Bruce R.			Modeling Insertional Mutagenesis Using Gene Length and Expression in Murine Embryonic Stem Cells	PLOS ONE			English	Article							FUNCTIONAL-ANALYSIS; INTEGRATION; GENOME; TARGETS; SUPPRESSION; DROSOPHILA; RESOURCES; REGIONS; SITES; MICE	Background. High-throughput mutagenesis of the mammalian genome is a powerful means to facilitate analysis of gene function. Gene trapping in embryonic stem cells (ESCs) is the most widely used form of insertional mutagenesis in mammals. However, the rules governing its efficiency are not fully understood, and the effects of vector design on the likelihood of gene-trapping events have not been tested on a genome-wide scale. Methodology/Principal Findings. In this study, we used public gene-trap data to model gene-trap likelihood. Using the association of gene length and gene expression with gene-trap likelihood, we constructed spline-based regression models that characterize which genes are susceptible and which genes are resistant to gene-trapping techniques. We report results for three classes of gene-trap vectors, showing that both length and expression are significant determinants of trap likelihood for all vectors. Using our models, we also quantitatively identified hotspots of gene-trap activity, which represent loci where the high likelihood of vector insertion is controlled by factors other than length and expression. These formalized statistical models describe a high proportion of the variance in the likelihood of a gene being trapped by expression-dependent vectors and a lower, but still significant, proportion of the variance for vectors that are predicted to be independent of endogenous gene expression. Conclusions/Significance. The findings of significant expression and length effects reported here further the understanding of the determinants of vector insertion. Results from this analysis can be applied to help identify other important determinants of this important biological phenomenon and could assist planning of large-scale mutagenesis efforts.	[Nord, Alex S.; Fong, Loren G.; Hu, Yan; Young, Stephen G.] Univ Calif Los Angeles, Dept Med, MacDonald Med Res Labs, Los Angeles, CA 90024 USA; [Nord, Alex S.; Vranizan, Karen; Tingley, Whittemore; Zambon, Alexander C.; Hanspers, Kristina; Doniger, Scott W.; Conklin, Bruce R.] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA; [Nord, Alex S.; Ferrin, Thomas E.; Babbitt, Patricia C.] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; [Nord, Alex S.; Ferrin, Thomas E.; Babbitt, Patricia C.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Tingley, Whittemore; Zambon, Alexander C.; Hanspers, Kristina; Conklin, Bruce R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Vranizan, Karen] Univ Calif Berkeley, Funct Genom Lab, Berkeley, CA 94720 USA; [Bacchetti, Peter] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Doniger, Scott W.] Washington Univ, Sch Med, St Louis, MO USA; [Skarnes, William C.] Sanger Inst Hinxton, Wellcome Trust, Cambridge, England; [Conklin, Bruce R.] Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California Los Angeles; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California San Francisco; Washington University (WUSTL); Wellcome Trust Sanger Institute; University of California System; University of California San Francisco	Nord, AS (corresponding author), Univ Calif Los Angeles, Dept Med, MacDonald Med Res Labs, Los Angeles, CA 90024 USA.	nordalex@u.washing-ton.edu; bconklin@gladstone.ucsf.edu	Conklin, Bruce/E-4738-2019	Nord, Alexander/0000-0003-4259-7514; Young, Stephen/0000-0001-7270-3176; Conklin, Bruce/0000-0003-1463-6061	NIH [HL66621, HG002766]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066621] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	NIH Grants HL66621 and HG002766	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Akaike H., 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921; Baba Tomoya, 2006, Mol Syst Biol, V2; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Birney E, 2006, NUCLEIC ACIDS RES, V34, pD556, DOI 10.1093/nar/gkj133; Boor C., 1978, PRACTICAL GUIDE SPLI; Bushman F, 2005, NAT REV MICROBIOL, V3, P848, DOI 10.1038/nrmicro1263; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De-Zolt S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj026; Donoho G, 1998, MOL CELL BIOL, V18, P4070, DOI 10.1128/MCB.18.7.4070; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Friedel RH, 2005, P NATL ACAD SCI USA, V102, P13188, DOI 10.1073/pnas.0505474102; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; HOLMESSON L, 2001, ADV GENET, V43, P33; Irizarry RA, 2006, BIOINFORMATICS, V22, P789, DOI 10.1093/bioinformatics/btk046; Liu HB, 2006, J VIROL, V80, P7765, DOI 10.1128/JVI.00542-06; Matthews KA, 2005, NAT REV GENET, V6, P179, DOI 10.1038/nrg1554; McCullagh P, 1989, GEN LINEAR MODELS; Miller DG, 2003, MOL CELL BIOL, V23, P3550, DOI 10.1128/MCB.23.10.3550-3557.2003; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Narezkina A, 2004, J VIROL, V78, P11656, DOI 10.1128/JVI.78.21.11656-11663.2004; Nord AS, 2006, NUCLEIC ACIDS RES, V34, pD642, DOI 10.1093/nar/gkj097; Osipovich AB, 2004, NUCLEIC ACIDS RES, V32, P2912, DOI 10.1093/nar/gkh604; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; Schnutgen F, 2005, P NATL ACAD SCI USA, V102, P7221, DOI 10.1073/pnas.0502273102; Shigeoka T, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni022; Skarnes WC, 2004, NAT GENET, V36, P543, DOI 10.1038/ng0604-543; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Taganov KD, 2004, J VIROL, V78, P5848, DOI 10.1128/JVI.78.11.5848-5855.2004; To C, 2004, NUCLEIC ACIDS RES, V32, pD557, DOI 10.1093/nar/gkh106; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100	41	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e617	10.1371/journal.pone.0000617	http://dx.doi.org/10.1371/journal.pone.0000617			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637833	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452100007
J	Mizrachy-Schwartz, S; Kravchenko-Balasha, N; Ben-Bassat, H; Klein, S; Levitzki, A				Mizrachy-Schwartz, Sarit; Kravchenko-Balasha, Nataly; Ben-Bassat, Hannah; Klein, Shoshana; Levitzki, Alexander			Optimization of Energy-Consuming Pathways towards Rapid Growth in HPV-Transformed Cells	PLOS ONE			English	Article								Cancer is a complex, multi-step process characterized by misregulated signal transduction and altered metabolism. Cancer cells divide faster than normal cells and their growth rates have been reported to correlate with increased metabolic flux during cell transformation. Here we report on progressive changes in essential elements of the biochemical network, in an in vitro model of transformation, consisting of primary human keratinocytes, human keratinocytes immortalized by human papillomavirus 16 (HPV16) and passaged repeatedly in vitro, and the extensively-passaged cells subsequently treated with the carcinogen benzo[a]pyrene. We monitored changes in cell growth, cell size and energy metabolism. The more transformed cells were smaller and divided faster, but the cellular energy flux was unchanged. During cell transformation the protein synthesis network contracted, as shown by the reduction in key cap-dependent translation factors. Moreover, there was a progressive shift towards internal ribosome entry site (IRES)-dependent translation. The switch from cap to IRES-dependent translation correlated with progressive activation of c-Src, an activator of AMP-activated protein kinase (AMPK), which controls energy-consuming processes, including protein translation. As cellular protein synthesis is a major energy-consuming process, we propose that the reduction in cell size and protein amount provide energy required for cell survival and proliferation. The cap to IRES-dependent switch seems to be part of a gradual optimization of energy-consuming mechanisms that redirects cellular processes to enhance cell growth, in the course of transformation.	[Mizrachy-Schwartz, Sarit; Kravchenko-Balasha, Nataly; Klein, Shoshana; Levitzki, Alexander] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel; [Ben-Bassat, Hannah] Hadassah Univ Hosp, Expt Surg Lab, IL-91120 Jerusalem, Israel; [Ben-Bassat, Hannah] Hadassah Univ Hosp, Israel Natl Skin Bank, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il	Kravchenko-Balasha, Nataly/D-7683-2016	Kravchenko-Balasha, Nataly/0000-0001-6943-7479				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Carrera AC, 2004, J CELL SCI, V117, P4615, DOI 10.1242/jcs.01311; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Holcik M, 2005, RNA, V11, P1605, DOI 10.1261/rna.2158605; Holcik M, 2004, CURR CANCER DRUG TAR, V4, P299, DOI 10.2174/1568009043333005; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; MITRANIROSENBAUM S, 1992, INTERVIROLOGY, V33, P76, DOI 10.1159/000150234; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; Otto GA, 2004, CELL, V119, P369, DOI 10.1016/j.cell.2004.09.038; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Santin AD, 2005, VIROLOGY, V331, P269, DOI 10.1016/j.virol.2004.09.045; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Vermes I, 2000, J IMMUNOL METHODS, V243, P167, DOI 10.1016/S0022-1759(00)00233-7; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WARBURG O, 1956, SCIENCE, V124, P269; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200	29	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e628	10.1371/journal.pone.0000628	http://dx.doi.org/10.1371/journal.pone.0000628			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622357	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452000019
J	Pfalz, M; Vogel, H; Mitchell-Olds, T; Kroymann, J				Pfalz, Marina; Vogel, Heiko; Mitchell-Olds, Thomas; Kroymann, Juergen			Mapping of QTL for Resistance against the Crucifer Specialist Herbivore Pieris brassicae in a New Arabidopsis Inbred Line Population, Da(1)-12xEi-2	PLOS ONE			English	Article							QUANTITATIVE TRAIT LOCI; INSECT RESISTANCE; SECONDARY METABOLISM; GENETIC-VARIATION; TRICHOME DENSITY; CHAIN ELONGATION; NATURAL ENEMIES; THALIANA; MYROSINASE; EXPRESSION	Background. In Arabidopsis thaliana and other crucifers, the glucosinolate-myrosinase system contributes to resistance against herbivory by generalist insects. As yet, it is unclear how crucifers defend themselves against crucifer-specialist insect herbivores. Methodology/Principal Findings. We analyzed natural variation for resistance against two crucifer specialist lepidopteran herbivores, Pieris brassicae and Plutella xylostella, among Arabidopsis thaliana accessions and in a new Arabidopsis recombinant inbred line (RIL) population generated from the parental accessions Da(1)-12 and Ei-2. This RIL population consists of 201 individual F-8 lines genotyped with 84 PCR-based markers. We identified six QTL for resistance against Pieris herbivory, but found only one weak QTL for Plutella resistance. To elucidate potential factors causing these resistance QTL, we investigated leaf hair ( trichome) density, glucosinolates and myrosinase activity, traits known to influence herbivory by generalist insects. We identified several previously unknown QTL for these traits, some of which display a complex pattern of epistatic interactions. Conclusions/Significance. Although some trichome, glucosinolate or myrosinase QTL colocalize with Pieris QTL, none of these traits explained the resistance QTL convincingly, indicating that resistance against specialist insect herbivores is influenced by other traits than resistance against generalists.	[Pfalz, Marina; Mitchell-Olds, Thomas; Kroymann, Juergen] Max Planck Inst Chem Ecol, Dept Genet & Evolut, Jena, Germany; [Vogel, Heiko] Max Planck Inst Chem Ecol, Dept Entomol, Jena, Germany; [Mitchell-Olds, Thomas] Duke Univ, Dept Biol, Durham, NC USA	Max Planck Society; Max Planck Society; Duke University	Kroymann, J (corresponding author), Max Planck Inst Chem Ecol, Dept Genet & Evolut, Jena, Germany.	kroymann@ice.mpg.de	Kroymann, Juergen/B-4317-2013; Kroymann, Juergen/AAY-8562-2021; Mitchell-Olds, Thomas/K-8121-2012	Kroymann, Juergen/0000-0002-4573-6498; Mitchell-Olds, Thomas/0000-0003-3439-9921	Max Planck Society; Bundesministerium fur Bildung und Forschung [PTJ-BIO/0313063]; Deutsche Forschungsgemeinschaft [KR 2237/2-1, KR 2237/2-2]; European Commission [QLRT-2000-01097]	Max Planck Society(Max Planck SocietyFoundation CELLEX); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by the Max Planck Society, the Bundesministerium fur Bildung und Forschung (PTJ-BIO/0313063), the Deutsche Forschungsgemeinschaft (KR 2237/2-1 and KR 2237/2-2), and the European Commission ( Contract QLRT-2000-01097).	Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; Barth C, 2006, PLANT J, V46, P549, DOI 10.1111/j.1365-313X.2006.02716.x; Benderoth M, 2006, P NATL ACAD SCI USA, V103, P9118, DOI 10.1073/pnas.0601738103; BONNEMAISON L, 1965, ANNU REV ENTOMOL, V10, P233, DOI 10.1146/annurev.en.10.010165.001313; Brown PD, 2003, PHYTOCHEMISTRY, V62, P471, DOI 10.1016/S0031-9422(02)00549-6; Buchner R., 1987, GLUCOSINOLATES RAPES, P50, DOI DOI 10.1007/978-94-009-3615-7; Campos de Quiros H., 2000, Theoretical and Applied Genetics, V101, P429, DOI 10.1007/s001220051500; CHADCHAWAN S, 1993, PLANT PHYSIOL, V103, P671, DOI 10.1104/pp.103.2.671; Field B, 2004, PLANT PHYSIOL, V135, P828, DOI 10.1104/pp.104.039347; Grubb CD, 2006, TRENDS PLANT SCI, V11, P89, DOI 10.1016/j.tplants.2005.12.006; Halkier BA, 2006, ANNU REV PLANT BIOL, V57, P303, DOI 10.1146/annurev.arplant.57.032905.105228; Handley R, 2005, ECOL ENTOMOL, V30, P284, DOI 10.1111/j.0307-6946.2005.00699.x; HILL DS, 1987, AGR INSECT PESTS TEM, P411; HUANG XP, 1994, J CHEM ECOL, V20, P1025, DOI 10.1007/BF02059739; Husebye H, 2002, PLANT PHYSIOL, V128, P1180, DOI 10.1104/pp.010925; Jander G, 2001, PLANT PHYSIOL, V126, P890, DOI 10.1104/pp.126.2.890; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kliebenstein D, 2002, GENETICS, V161, P325; Kliebenstein DJ, 2005, CURR OPIN PLANT BIOL, V8, P264, DOI 10.1016/j.pbi.2005.03.002; Kliebenstein DJ, 2001, GENETICS, V159, P359; Kliebenstein DJ, 2001, PLANT CELL, V13, P681, DOI 10.1105/tpc.13.3.681; Kliebenstein DJ, 2001, PLANT PHYSIOL, V126, P811, DOI 10.1104/pp.126.2.811; Koornneef M, 2004, ANNU REV PLANT BIOL, V55, P141, DOI 10.1146/annurev.arplant.55.031903.141605; Koroleva OA, 2000, PLANT PHYSIOL, V124, P599, DOI 10.1104/pp.124.2.599; Kroymann J, 2005, NATURE, V435, P95, DOI 10.1038/nature03480; Kroymann J, 2003, P NATL ACAD SCI USA, V100, P14587, DOI 10.1073/pnas.1734046100; Kroymann J, 2001, PLANT PHYSIOL, V127, P1077, DOI 10.1104/pp.010416; Lambrix V, 2001, PLANT CELL, V13, P2793, DOI 10.1105/tpc.13.12.2793; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Loudet O, 2002, THEOR APPL GENET, V104, P1173, DOI 10.1007/s00122-001-0825-9; MAGRATH R, 1994, HEREDITY, V72, P290, DOI 10.1038/hdy.1994.39; Mauricio R, 2005, GENETICA, V123, P75, DOI 10.1007/s10709-002-2714-9; Mauricio R, 1998, AM NAT, V151, P20, DOI 10.1086/286099; Mauricio R, 1997, EVOLUTION, V51, P1435, DOI [10.2307/2411196, 10.1111/j.1558-5646.1997.tb01467.x]; Miles CI, 2005, J COMP PHYSIOL A, V191, P147, DOI 10.1007/s00359-004-0580-x; Mitchell-Olds T, 1998, GENETICS, V149, P739; MITHEN R, 1995, HEREDITY, V74, P210, DOI 10.1038/hdy.1995.29; Ratzka A, 2002, P NATL ACAD SCI USA, V99, P11223, DOI 10.1073/pnas.172112899; Raybould AF, 2001, HEREDITY, V87, P383, DOI 10.1046/j.1365-2540.2001.00954.x; Renwick JAA, 1999, ENTOMOL EXP APPL, V91, P51, DOI 10.1023/A:1003693005761; Renwick JAA, 2002, ENTOMOL EXP APPL, V104, P35, DOI 10.1023/A:1021231732022; SAMSON PR, 1983, PROT ECOL, V5, P199; Satagopan JM, 1996, GENETICS, V144, P805; SCHOONHO.LM, 1969, ENTOMOL EXP APPL, V12, P555, DOI 10.1007/BF00297086; SHELTON AM, 1991, J ENTOMOL SCI, V26, P17, DOI 10.18474/0749-8004-26.1.17; STADLER E, 1995, PHYSIOL ENTOMOL, V20, P175, DOI 10.1111/j.1365-3032.1995.tb00814.x; Symonds VV, 2005, GENETICS, V169, P1649, DOI 10.1534/genetics.104.031948; Thangstad OP, 2004, PLANT MOL BIOL, V54, P597, DOI 10.1023/B:PLAN.0000038272.99590.10; Tuinstra MR, 1997, THEOR APPL GENET, V95, P1005, DOI 10.1007/s001220050654; van Loon J.J.A., 1992, Chemoecology, V3, P39, DOI 10.1007/BF01261455; Van Ooijen JW, 1999, HEREDITY, V83, P613, DOI 10.1038/sj.hdy.6886230; Wang S., 2001, WINDOWS QTL CARTOGRA; Wittstock U, 2004, P NATL ACAD SCI USA, V101, P4859, DOI 10.1073/pnas.0308007101; Wittstock U, 2002, TRENDS PLANT SCI, V7, P263, DOI 10.1016/S1360-1385(02)02273-2; XUE JP, 1995, PLANT MOL BIOL, V27, P911, DOI 10.1007/BF00037019; Zhang JM, 2002, PHYSIOL PLANTARUM, V115, P25, DOI 10.1034/j.1399-3054.2002.1150103.x; Zhang ZY, 2006, PLANT CELL, V18, P1524, DOI 10.1105/tpc.105.039602	58	39	39	4	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e578	10.1371/journal.pone.0000578	http://dx.doi.org/10.1371/journal.pone.0000578			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593977	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451800022
J	Vitousek, MN; Mitchell, MA; Woakes, AJ; Niemack, MD; Wikelski, M				Vitousek, Maren N.; Mitchell, Mark A.; Woakes, Anthony J.; Niemack, Michael D.; Wikelski, Martin			High Costs of Female Choice in a Lekking Lizard	PLOS ONE			English	Article							IGUANAS AMBLYRHYNCHUS-CRISTATUS; FALSE DISCOVERY RATE; POPULATION BIOLOGY; BODY-SIZE; MATING SYSTEM; MATE CHOICE; HEART-RATE; MARINE; EVOLUTION; PERFORMANCE	Although the cost of mate choice is an essential component of the evolution and maintenance of sexual selection, the energetic cost of female choice has not previously been assessed directly. Here we report that females can incur high energetic costs as a result of discriminating among potential mates. We used heart rate biologging to quantify energetic expenditure in lek-mating female Galapagos marine iguanas (Amblyrhynchus cristatus). Receptive females spent 78.9 +/- 23.2kJ of energy on mate choice over a 30-day period, which is equivalent to, similar to 3/4 one day's energy budget. Females that spent more time on the territories of high-quality, high-activity males displayed greater energetic expenditure on mate choice, lost more mass, and showed a trend towards producing smaller follicles. Choosy females also appear to face a reduced probability of survival if El Nino conditions occur in the year following breeding. These findings indicate that female choice can carry significant costs, and suggest that the benefits that lek-mating females gain through mating with a preferred male may be higher than previously predicted.	[Vitousek, Maren N.; Wikelski, Martin] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; [Mitchell, Mark A.] Louisiana State Univ, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA; [Woakes, Anthony J.] Univ Birmingham, Ctr Ornithol, Sch Biosci, Edgbaston, England; [Niemack, Michael D.] Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Louisiana State University System; Louisiana State University; University of Birmingham; Princeton University	Vitousek, MN (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	mvitouse@princeton.edu		Vitousek, Maren N./0000-0003-2855-0832	SGER IOB [0118069]; NSF LTREB; Animal Behavior Society, Sigma Xi and Princeton University	SGER IOB; NSF LTREB(National Science Foundation (NSF)); Animal Behavior Society, Sigma Xi and Princeton University	This work was supported by grants SGER IOB 0118069 and NSF LTREB ( to MW) and grants from the Animal Behavior Society, Sigma Xi and Princeton University ( to MV). Our protocol adhered to the Animal Behavior Society Guidelines for the Use of Animals in Research, and was approved by the Princeton University IACUC Committee #1439.	ALATALO RV, 1998, P R SOC B, V353, P2297; Angilletta MJ, 2000, ECOLOGY, V81, P2957, DOI 10.1890/0012-9658(2000)081[2957:TEOTEO]2.0.CO;2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borgia G., 1979, SEXUAL SELECTION REP, P19; Butler PJ, 2004, FUNCT ECOL, V18, P168, DOI 10.1111/j.0269-8463.2004.00821.x; Butler PJ, 2002, J EXP BIOL, V205, P1917; Byers JA, 2005, AM NAT, V166, P661, DOI 10.1086/497401; Gartrell BD, 2002, ZOO BIOL, V21, P253, DOI 10.1002/zoo.10017; GIBSON RM, 1992, BEHAV ECOL, V3, P300, DOI 10.1093/beheco/3.4.300; Gotthard K, 1999, BEHAV ECOL SOCIOBIOL, V45, P424, DOI 10.1007/s002650050580; Hancock TV, 2001, COMP BIOCHEM PHYS A, V130, P67, DOI 10.1016/S1095-6433(01)00365-8; Head ML, 2005, PLOS BIOL, V3, P289, DOI 10.1371/journal.pbio.0030033; in den Bosch HAJ, 1998, J HERPETOL, V32, P410, DOI 10.2307/1565456; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; Kirkpatrick M, 1996, EVOLUTION, V50, P2125, DOI [10.2307/2410684, 10.1111/j.1558-5646.1996.tb03603.x]; Kraak SBM, 1996, BEHAV ECOL, V7, P353, DOI 10.1093/beheco/7.3.353; LAURIE WA, 1990, J ANIM ECOL, V59, P515, DOI 10.2307/4878; LAURIE WA, 1990, J ANIM ECOL, V59, P529, DOI 10.2307/4879; LAURIE WA, 1990, J ANIM ECOL, V59, P545, DOI 10.2307/4880; LICHTENBELT WDV, 1993, ECOLOGY, V74, P1157, DOI 10.2307/1940486; Luttbeg B, 2001, ETHOLOGY, V107, P545, DOI 10.1046/j.1439-0310.2001.00694.x; MILES DB, 1995, OECOLOGIA, V103, P261, DOI 10.1007/BF00329089; MILINSKI M, 1992, P ROY SOC LOND B BIO, V268, P517; Nakagawa S, 2004, BEHAV ECOL, V15, P1044, DOI 10.1093/beheco/arh107; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; Partecke J, 2002, BEHAV ECOL SOCIOBIOL, V51, P579, DOI 10.1007/s00265-002-0469-z; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; POMIANKOWSKI A, 1995, P ROY SOC B-BIOL SCI, V260, P21, DOI 10.1098/rspb.1995.0054; RAUCH N, 1985, BEHAV ECOL SOCIOBIOL, V16, P125, DOI 10.1007/BF00295146; REYNOLDS JD, 1992, P ROY SOC B-BIOL SCI, V250, P57, DOI 10.1098/rspb.1992.0130; REYNOLDS JD, 1990, AM NAT, V136, P230, DOI 10.1086/285093; SHUSTER SM, 2003, MG BEH ECOL, pR7; Tallamy DW, 2003, P ROY SOC B-BIOL SCI, V270, P77, DOI 10.1098/rspb.2002.2198; TRILLMICH KGK, 1983, Z TIERPSYCHOL, V63, P141; Verhoeven KJF, 2005, OIKOS, V108, P643, DOI 10.1111/j.0030-1299.2005.13727.x; Wikelski M, 1997, ECOLOGY, V78, P2204, DOI 10.2307/2265956; Wikelski M, 2005, P ROY SOC B-BIOL SCI, V272, P1985, DOI 10.1098/rspb.2005.3205; Wikelski M, 2003, INTEGR COMP BIOL, V43, P376, DOI 10.1093/icb/43.3.376; Wikelski M, 1995, J BIOL RHYTHM, V10, P335, DOI 10.1177/074873049501000407; Wikelski M, 2001, ETHOLOGY, V107, P623, DOI 10.1046/j.1439-0310.2001.00701.x; Wikelski M, 1996, ANIM BEHAV, V52, P581, DOI 10.1006/anbe.1996.0199; Wong BBM, 2003, P ROY SOC B-BIOL SCI, V270, pS36, DOI 10.1098/rsbl.2003.0003	42	24	24	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e567	10.1371/journal.pone.0000567	http://dx.doi.org/10.1371/journal.pone.0000567			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593966	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451800011
J	Gery, S; Virk, RK; Chumakov, K; Yu, A; Koeffler, HP				Gery, S.; Virk, R. K.; Chumakov, K.; Yu, A.; Koeffler, H. P.			The clock gene Per2 links the circadian system to the estrogen receptor	ONCOGENE			English	Article						circadian rhythms; ER alpha; breast cancer; Per2; transcriptional activation; estrogen	EXPRESSION; CANCER; MOUSE	Circadian rhythms regulate diverse physiological processes including homeostatic functions of steroid hormones and their receptors. Estrogen receptor-alpha (ER alpha) is essential for normal mammary gland physiology and is a prognostic marker for the treatment of breast cancer. We report that Per2, a core clock gene, links the circadian cycle to the ER alpha signaling network. Binding of enhances ER alpha degradation, while suppression of Per2 levels leads to ER alpha stabilization. In turn, Per2 itself is estrogen inducible in these cells, suggesting a feedback mechanism to attenuate stimulation by estrogen. In addition, overexpression of Per2 in breast cancer cells leads to significant growth inhibition, loss of clonogenic ability and apoptosis. Taken together, these results further support a critical role for peripheral circadian regulation in tissue homeostasis and suggest a novel role for clock genes in estrogen receptor-positive breast cancer.	[Gery, S.; Virk, R. K.; Chumakov, K.; Yu, A.; Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, UCLA Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gery, S (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, UCLA Sch Med, Davis Bldg 5066,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org						Chen ST, 2005, CARCINOGENESIS, V26, P1241, DOI 10.1093/carcin/bgi075; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106; Hansen J, 2001, JNCI-J NATL CANCER I, V93, P1513, DOI 10.1093/jnci/93.20.1513; Hua H, 2006, CANCER SCI, V97, P589, DOI 10.1111/j.1349-7006.2006.00225.x; Ishida N, 2007, NEUROSCI RES, V57, P483, DOI 10.1016/j.neures.2006.12.012; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Metz RP, 2006, DEV DYNAM, V235, P263, DOI 10.1002/dvdy.20605; Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104; Nakamura TJ, 2005, J NEUROSCI RES, V82, P622, DOI 10.1002/jnr.20677; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Perrin JS, 2006, P NATL ACAD SCI USA, V103, P5591, DOI 10.1073/pnas.0601310103; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Romagnolo D, 1998, MOL CARCINOGEN, V22, P102, DOI 10.1002/(SICI)1098-2744(199806)22:2<102::AID-MC5>3.0.CO;2-O; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050	26	141	145	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7916	7920		10.1038/sj.onc.1210585	http://dx.doi.org/10.1038/sj.onc.1210585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599055				2022-12-25	WOS:000252163500010
J	Begley, LA; MacDonald, JW; Day, ML; Macoska, JA				Begley, Lesa A.; MacDonald, James W.; Day, Mark L.; Macoska, Jill A.			CXCL12 activates a robust transcriptional response in human prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER CELLS; IN-VITRO; SIGNALING PATHWAYS; TUMOR-GROWTH; METASTASIS; SECRETION; KINASE; MICROENVIRONMENT; ANGIOGENESIS	CXCL12 is a CXC-type chemokine that plays important roles in hematopoiesis, development, and organization of the immune system and supports the survival or growth of a variety of normal or malignant cell types. Our laboratory recently showed that CXCL12 is secreted by aging stromal fibroblast cells and is a major paracrine factor that specifically stimulates the proliferation of prostate epithelial cells. The current study shows that this CXCL12-mediated proliferative response may be either ERK-dependent or ERK-independent. Moreover, CXCL12 initiates a previously undefined and complex global transcriptional response in prostate epithelial cells. This CXCL12-mediated transcriptional response directly stimulates the expression of genes encoding proteins that are involved in the promotion of cellular proliferation and progression through the cell cycle, tumor metastasis, and cellular motility, and directly represses the transcription of genes encoding proteins involved in cell-cell adhesion and resistance to apoptosis. Thus, CXCL12 may play a major role in the etiology of benign proliferative disease in the context of an aging tissue microenvironment.	Univ Michigan, Dept Urol, Canc Ctr & Geriatr Ctr 6217, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Macoska, JA (corresponding author), Univ Michigan, Dept Urol, Canc Ctr & Geriatr Ctr 6217, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	jcoska@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065313] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA 46592] Funding Source: Medline; NIDDK NIH HHS [P50 DK 065313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Begley L, 2006, GENE CHROMOSOME CANC, V45, P136, DOI 10.1002/gcc.20274; Begley L, 2005, AGING CELL, V4, P291, DOI 10.1111/j.1474-9726.2005.00173.x; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Chaib H, 2001, CANCER RES, V61, P2390; Chen YC, 2003, CANCER RES, V63, P4801; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Cunha GR, 1996, ACTA ANAT, V155, P63; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Hayward SW, 1998, DIFFERENTIATION, V63, P131, DOI 10.1046/j.1432-0436.1998.6330131.x; Hoffmann R, 2004, NAT GENET, V36, P664, DOI 10.1038/ng0704-664; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jacobsen SJ, 2001, UROLOGY, V58, P5, DOI 10.1016/S0090-4295(01)01298-5; Jakobsen H, 1988, Scand J Urol Nephrol Suppl, V107, P26; Koch AE, 2005, ARTHRITIS RHEUM, V52, P710, DOI 10.1002/art.20932; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Lapteva N, 2005, CANCER GENE THER, V12, P84, DOI 10.1038/sj.cgt.7700770; Macoska JA, 2004, CANCER GENET CYTOGEN, V154, P36, DOI 10.1016/j.cancergencyto.2004.02.013; Mochizuki H, 2004, BIOCHEM BIOPH RES CO, V320, P656, DOI 10.1016/j.bbrc.2004.06.013; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Olumi AF, 1998, CANCER RES, V58, P4525; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Spano JP, 2004, ANN ONCOL, V15, P613, DOI 10.1093/annonc/mdh136; Sun Q, 2006, GENOME RES, V16, P197, DOI 10.1101/gr.4108706; Taichman RS, 2002, CANCER RES, V62, P1832; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Wang JH, 2005, CELL SIGNAL, V17, P1578, DOI 10.1016/j.cellsig.2005.03.022	36	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26767	26774		10.1074/jbc.M700440200	http://dx.doi.org/10.1074/jbc.M700440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631494	hybrid			2022-12-25	WOS:000249304900016
J	Denisov, IG; Grinkova, YV; McLean, MA; Sligar, SG				Denisov, Ilia G.; Grinkova, Yelena V.; McLean, Mark A.; Sligar, Stephen G.			The one-electron autoxidation of human cytochrome p450 3A4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; PHOSPHOLIPID-BILAYER NANODISCS; NANOSCALE LIPID-BILAYERS; CYANIDE BINDING; ACTIVE-SITE; LIGAND-BINDING; NITRIC-OXIDE; MEMBRANE-PROTEINS; HORSERADISH-PEROXIDASE; GEMINATE RECOMBINATION	Monomeric cytochrome P450 3A4 ( CYP3A4), the most prevalent cytochrome P450 in human liver, can simultaneously bind one, two, or three molecules of substrates and effectors. The difference in the functional properties of such binding intermediates gives rise to homotropic and heterotropic cooperative kinetics of this enzyme. To understand the overall kinetic processes operating in CYP3A4, we documented the kinetics of autoxidation of the oxy-ferrous intermediate of CYP3A4 as a function of testosterone concentration. The rate of autoxidation in the presence of testosterone was significantly lower than that observed with no substrate present. Stability of the oxy-ferrous complex in CYP3A4 and the amplitude of the geminate CO rebinding increased significantly as a result of binding of just one testosterone molecule. In contrast, the slow phase in the kinetics of cyanide binding to the ferric CYP3A4 correlated with a shift of the heme iron spin state, which is only caused by the association of a second molecule of testosterone. Our results show that the first substrate binding event prevents the escape of diatomic ligands from the distal heme binding pocket, stabilizes the oxy-ferrous complex, and thus serves as an important modulator of the uncoupling channel in the cytochromes P450.	Univ Illinois, Ctr Biophys & Computat Biol, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, Dept Biochem, 116 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	s-sligar@uiuc.edu	Denisov, Ilia G/J-6590-2013; Denisov, Gleb/J-6549-2013	Denisov, Ilia G/0000-0002-7878-2626; Denisov, Gleb/0000-0002-1246-0552; McLean, Mark/0000-0001-9125-293X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031756, R01GM033775, R37GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31756, GM 33775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1990, BIOCHEMISTRY-US, V29, P1271, DOI 10.1021/bi00457a024; Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; BANCI L, 1993, BIOPHYS J, V65, P806, DOI 10.1016/S0006-3495(93)81122-6; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; BLANCK J, 1991, XENOBIOTICA, V21, P121, DOI 10.3109/00498259109039456; Cao WX, 2004, BIOCHEMISTRY-US, V43, P7017, DOI 10.1021/bi0497291; Clark JP, 2006, J INORG BIOCHEM, V100, P1075, DOI 10.1016/j.jinorgbio.2005.11.020; Cojocaru V, 2007, BBA-GEN SUBJECTS, V1770, P390, DOI 10.1016/j.bbagen.2006.07.005; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; Denisov IG, 2007, J BIOL CHEM, V282, P7066, DOI 10.1074/jbc.M609589200; Denisov IG, 2006, J BIOL CHEM, V281, P23313, DOI 10.1074/jbc.M605511200; DOLMAN D, 1968, BIOCHEMISTRY-US, V7, P3991, DOI 10.1021/bi00851a028; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Duan H, 2004, ARCH BIOCHEM BIOPHYS, V424, P141, DOI 10.1016/j.abb.2004.02.010; DUNFORD HB, 1978, CAN J CHEM, V56, P2844, DOI 10.1139/v78-468; ERMAN JE, 1974, BIOCHEMISTRY-US, V13, P39, DOI 10.1021/bi00698a007; FISHER MT, 1987, BIOCHEMISTRY-US, V26, P4797, DOI 10.1021/bi00389a029; FISHER MT, 1985, BIOCHEMISTRY-US, V24, P6696, DOI 10.1021/bi00344a059; Gautier C, 2004, J BIOL CHEM, V279, P4358, DOI 10.1074/jbc.M305048200; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; GUENGERICH FP, 1976, BIOCHEM BIOPH RES CO, V70, P951; Gustafsson MCU, 2004, BIOCHEMISTRY-US, V43, P5474, DOI 10.1021/bi035904m; Henry ER, 1997, BIOPHYS J, V72, P652, DOI 10.1016/S0006-3495(97)78703-4; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; Jakopitsch C, 2005, J BIOL CHEM, V280, P42411, DOI 10.1074/jbc.M508009200; KELLIS JT, 1987, J BIOL CHEM, V262, P8840; LAMBEIR AM, 1983, J INORG BIOCHEM, V19, P291, DOI 10.1016/0162-0134(83)80002-6; LAMBEIR AM, 1983, BIOPHYS CHEM, V18, P195, DOI 10.1016/0301-4622(83)80031-3; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MAUREL P, 1979, MICROSOMES DRUG OXID, V1, P359; MCKENNA CE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P109, DOI 10.1016/0304-4165(91)90082-R; McLean MA, 1996, BIOCHIMIE, V78, P700, DOI 10.1016/S0300-9084(97)82527-8; Mouawad L, 2007, PROTEIN SCI, V16, P781, DOI 10.1110/ps.062374707; Nath A, 2007, BIOCHEMISTRY-US, V46, P2059, DOI 10.1021/bi602371n; Negrerie M, 2001, J BIOL CHEM, V276, P46815, DOI 10.1074/jbc.M102224200; Nienhaus K, 2004, J BIOL CHEM, V279, P22944, DOI 10.1074/jbc.M401561200; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; Puntarulo S, 1998, FREE RADICAL BIO MED, V24, P1324, DOI 10.1016/S0891-5849(97)00463-2; ROHLFS RJ, 1988, J BIOL CHEM, V263, P1803; Rydberg P, 2007, J PHYS CHEM B, V111, P5445, DOI 10.1021/jp070390c; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SEGEL IH, 1975, ENZYME KINETICS, P72; Sligar SG, 2003, BIOCHEM BIOPH RES CO, V312, P115, DOI 10.1016/j.bbrc.2003.09.188; SLIGAR SG, 1974, BIOCHEM BIOPH RES CO, V61, P290, DOI 10.1016/0006-291X(74)90565-8; SLIGAR SG, 2007, IN PRESS DRUG METAB; Tetreau C, 2005, BBA-GEN SUBJECTS, V1724, P411, DOI 10.1016/j.bbagen.2005.04.024; TIAN WD, 1995, J BIOL CHEM, V270, P8673, DOI 10.1074/jbc.270.15.8673; TOTANI K, 1983, ARCH BIOCHEM BIOPHYS, V222, P207, DOI 10.1016/0003-9861(83)90518-0; Wade RC, 2004, J INORG BIOCHEM, V98, P1175, DOI 10.1016/j.jinorgbio.2004.02.007; Wang LH, 2001, J BIOL CHEM, V276, P14737, DOI 10.1074/jbc.M009177200; Wienkers LC, 2005, NAT REV DRUG DISCOV, V4, P825, DOI 10.1038/nrd1851; Ye X, 2006, J AM CHEM SOC, V128, P1444, DOI 10.1021/ja057172m; Ye X, 2005, J AM CHEM SOC, V127, P5854, DOI 10.1021/ja042365f; Zangar RC, 2004, TOXICOL APPL PHARM, V199, P316, DOI 10.1016/j.taap.2004.01.018	63	53	53	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26865	26873		10.1074/jbc.M704747200	http://dx.doi.org/10.1074/jbc.M704747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650504	hybrid			2022-12-25	WOS:000249304900026
J	Di Matteo, A; Gianni, S; Schinina, ME; Giorgi, A; Altieri, F; Calosci, N; Brunori, M; Travaglini-Allocatelli, C				Di Matteo, Adele; Gianni, Stefano; Schinina, M. Eugenia; Giorgi, Alessandra; Altieri, Fabio; Calosci, Nicoletta; Brunori, Maurizio; Travaglini-Allocatelli, Carlo			A strategic protein in cytochrome C maturation - Three-dimensional structure of CcmH and binding to apocytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; DISULFIDE BONDS; ACTIVE-SITE; IN-VITRO; HEME; REACTIVITY; PATHWAY; SPECIFICITY; BIOGENESIS; IONIZATION	CcmH ((c) under bar ytochromes (c) under bar (m) under bar aturation protein H) is an essential component of the assembly line necessary for the maturation of c-type cytochromes in the periplasm of Gram-negative bacteria. The protein is a membrane-anchored thiol-oxidoreductase that has been hypothesized to be involved in the recognition and reduction of apocytochrome c, a prerequisite for covalent heme attachment. Here, we present the 1.7 angstrom crystal structure of the soluble periplasmic domain of CcmH from the opportunistic pathogen Pseudomonas aeruginosa (Pa-CcmH*). The protein contains a three-helix bundle, i.e. a fold that is different from that of all other thiol-oxidoreductases reported so far. The catalytic Cys residues of the conserved LRCXXC motif (Cys(25) and Cys(28)), located in a long loop connecting the first two helices, form a disulfide bond in the oxidized enzyme. We have determined the pK(a) values of these 2 Cys residues of Pa-CcmH* ( both > 8) and propose a possible mechanistic role for a conserved Ser(36) and a water molecule in the active site. The interaction between Pa-CcmH* and Pa-apocyt c(551) ( where cyt c(551) represents cytochrome c(551)) was characterized in vitro following the binding kinetics by stopped-flow using a Trp-containing fluorescent variant of Pa-CcmH* and a dansylated peptide, mimicking the apocytochrome c551 heme binding motif. The kinetic results show that the protein has a moderate affinity to its apocyt substrate, consistent with the role of Pa-CcmH as an intermediate component of the assembly line for c-type cytochrome biogenesis.	Univ Rome, Dipartimento Sci Biochim & Ist Biol & Patol Mol C, I-00815 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Brunori, M (corresponding author), Univ Rome, Dipartimento Sci Biochim & Ist Biol & Patol Mol C, Piazzale A Morro 5, I-00815 Rome, Italy.	maurizio.brunori@uniroma1.it	gianni, stefano/C-8536-2009; Altieri, Fabio/D-2790-2009; Di Matteo, Adele/AAC-8338-2019	Altieri, Fabio/0000-0002-6546-2738; Di Matteo, Adele/0000-0002-5921-7365; Gianni, Stefano/0000-0003-1653-1925; Brunori, Maurizio/0000-0002-7795-1635; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126				Ahuja U, 2005, J BIOL CHEM, V280, P236, DOI 10.1074/jbc.M410912200; Bhattacharyya R, 2004, PROTEIN ENG DES SEL, V17, P795, DOI 10.1093/protein/gzh093; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; Colbert CL, 2006, P NATL ACAD SCI USA, V103, P4410, DOI 10.1073/PNAS.0600552103; Crow A, 2004, J BIOL CHEM, V279, P23654, DOI 10.1074/jbc.M402823200; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DALTROP O, 2003, J BIOL CHEM, V278, P23408; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Edeling MA, 2004, J BACTERIOL, V186, P4030, DOI 10.1128/JB.186.12.4030-4033.2004; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Feissner RE, 2006, MOL MICROBIOL, V61, P219, DOI 10.1111/j.1365-2958.2006.05221.x; Fersht A, 1999, STRUCTURE MECH PROTE, P132; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOMGREN A, 1995, STRUCTURE CAMB, V3, P239; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Lamzin VS, 2000, NAT STRUCT BIOL, V7, P978, DOI 10.1038/80763; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewin A, 2006, J BIOL CHEM, V281, P35467, DOI 10.1074/jbc.M607047200; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Menchise V, 2001, BIOCHEM J, V359, P65, DOI 10.1042/0264-6021:3590065; Meyer EH, 2005, P NATL ACAD SCI USA, V102, P16113, DOI 10.1073/pnas.0503473102; Monika EM, 1997, J MOL BIOL, V271, P679, DOI 10.1006/jmbi.1997.1227; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Rios-Velazquez C, 2003, J BACTERIOL, V185, P422, DOI 10.1128/JB.185.2.422-431.2003; Setterdahl AT, 2000, BIOCHEMISTRY-US, V39, P10172, DOI 10.1021/bi000663t; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; Stirnimann CU, 2005, STRUCTURE, V13, P985, DOI 10.1016/j.str.2005.04.014; Tan JT, 2004, CHEMBIOCHEM, V5, P1479, DOI 10.1002/cbic.200400036; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; Turkarslan S, 2006, MOL MICROBIOL, V60, P537, DOI 10.1111/j.1365-2958.2006.05148.x	47	33	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27012	27019		10.1074/jbc.M702702200	http://dx.doi.org/10.1074/jbc.M702702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623665	hybrid			2022-12-25	WOS:000249304900042
J	Pei, XH; Guo, XH; Coppel, R; Mohandas, N; An, XL				Pei, Xinhong; Guo, Xinhua; Coppel, Ross; Mohandas, Narla; An, Xiuli			Plasmodium falciparum erythrocyte membrane protein 3 (PfEMP3) destabilizes erythrocyte membrane skeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH PROTEIN; RED-BLOOD-CELLS; SURFACE-ANTIGEN; FUNCTIONAL-CHARACTERIZATION; MALARIAL INFECTION; GENE DISRUPTION; BETA-SPECTRIN; BINDING-SITES; STABILITY; DOMAINS	Plasmodium falciparum erythrocyte membrane protein 3 (PfEMP3) is a parasite-derived protein that appears on the cytoplasmic surface of the host cell membrane in the later stages of the parasite's development where it associates with membrane skeleton. We have recently demonstrated that a 60-residue fragment (FIa1, residues 38-97) of PfEMP3 bound to spectrin. Here we show that this polypeptide binds specifically to a site near the C terminus of alpha-spectrin at the point that spectrin attaches to actin and protein 4.1R in forming the junctions of the membrane skeletal network. We further show that this polypeptide disrupts formation of the ternary spectrin-actin-4.1R complex in solution. Importantly, when incorporated into the cell, the PfEMP3 fragment causes extensive reduction in shear resistance of the cell. We conjecture that the loss of mechanical cohesion of the membrane may facilitate the exit of the mature merozoites from the cell.	New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10065 USA; Monash Univ, Dept Microbiol, Monash, Vic 3800, Australia	New York Blood Center; Monash University	An, XL (corresponding author), Red Cell Physiol Lab, 310 E 37th St, New York, NY 10021 USA.	xan@nybloodcenter.org	Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, R01DK026263, P01DK032094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 26263, DK 32094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An XL, 2005, BIOCHEMISTRY-US, V44, P10681, DOI 10.1021/bi047331z; An XL, 2004, BIOCHEMISTRY-US, V43, P310, DOI 10.1021/bi035653h; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BECKER PS, 1987, J CLIN INVEST, V80, P557, DOI 10.1172/JCI113104; Bennett BJ, 1997, J BIOL CHEM, V272, P15299, DOI 10.1074/jbc.272.24.15299; COHEN CM, 1980, CELL, V21, P875, DOI 10.1016/0092-8674(80)90451-1; CONBOY JG, 1991, BLOOD, V78, P2438, DOI 10.1182/blood.V78.9.2438.bloodjournal7892438; Cooke BM, 2002, BRIT J HAEMATOL, V117, P203, DOI 10.1046/j.1365-2141.2002.03404.x; Cooke BM, 2001, ADV PARASIT, V50, P1, DOI 10.1016/S0065-308X(01)50029-9; Cowman AF, 2006, SCIENCE, V313, P1245, DOI 10.1126/science.1132940; Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X; DASILVA E, 1994, MOL BIOCHEM PARASIT, V66, P59, DOI 10.1016/0166-6851(94)90036-1; FOLEY M, 1991, MOL BIOCHEM PARASIT, V46, P137, DOI 10.1016/0166-6851(91)90207-M; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Hanspal M, 2002, BLOOD, V100, P1048, DOI 10.1182/blood-2002-01-0101; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; MAGOWAN C, 1995, BLOOD, V86, P3196; MOHANDAS N, 1982, BLOOD, V59, P768; Oh SS, 2000, MOL BIOCHEM PARASIT, V108, P237, DOI 10.1016/S0166-6851(00)00227-9; Pei XH, 2005, J BIOL CHEM, V280, P31166, DOI 10.1074/jbc.M505298200; Pei XH, 2007, BLOOD, V110, P1036, DOI 10.1182/blood-2007-02-076919; Raphael P, 2000, MOL BIOCHEM PARASIT, V110, P259, DOI 10.1016/S0166-6851(00)00283-8; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Silva MD, 2005, MOL MICROBIOL, V56, P990, DOI 10.1111/j.1365-2958.2005.04603.x; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; Ursitti JA, 1996, J BIOL CHEM, V271, P6636, DOI 10.1074/jbc.271.12.6636; Waller KL, 2003, BLOOD, V102, P1911, DOI 10.1182/blood-2002-11-3513; Waller KL, 2002, MOL BIOCHEM PARASIT, V119, P125, DOI 10.1016/S0166-6851(01)00395-4; Wandersee N J, 2000, Hematol J, V1, P235, DOI 10.1038/sj.thj.6200030; Wandersee NJ, 2003, BLOOD, V101, P325, DOI 10.1182/blood-2002-01-0113	31	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26754	26758		10.1074/jbc.M701612200	http://dx.doi.org/10.1074/jbc.M701612200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626011	hybrid			2022-12-25	WOS:000249304900014
J	Thon, M; Al-Abdallah, Q; Hortschansky, P; Brakhage, AA				Thoen, Marcel; Al-Abdallah, Qusai; Hortschansky, Peter; Brakhage, Axel A.			The thioredoxin system of the filamentous fungus Aspergillus nidulans - Impact on development and oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES; PARASITE PLASMODIUM-FALCIPARUM; ESCHERICHIA COLI B; PENICILLIN BIOSYNTHESIS; SEXUAL DEVELOPMENT; GLUTATHIONE-REDUCTASE; DROSOPHILA-MELANOGASTER; ALDEHYDE DEHYDROGENASE; CATALASE GENES; FUMIGATUS	Redox regulation has been shown to be of increasing importance for many cellular processes. Here, redox homeostasis was addressed in Aspergillus nidulans, an important model organism for fundamental biological questions such as development, gene regulation or the regulation of the production of secondary metabolites. We describe the characterization of a thioredoxin system from the filamentous fungus A. nidulans. The A. nidulans thioredoxin A(AnTrxA) is an 11.6-kDa protein with a characteristic thioredoxin active site motif (WCGPC) encoded by the trxA gene. The corresponding thioredoxin reductase (AnTrxR), encoded by the trxR gene, represents a homodimeric flavoprotein with a native molecular mass of 72.2 kDa. When combined in vitro, the in Escherichia coli overproduced recombinant proteins AnTrxA and AnTrxR were able to reduce insulin and oxidized glutathione in an NADPH-dependent manner indicating that this in vitro redox system is functional. Moreover, we have created a thioredoxin A deletion strain that shows decreased growth, an increased catalase activity, and the inability to form reproductive structures like conidiophores or cleistothecia when cultivated under standard conditions. However, addition of GSH at low concentrations led to the development of sexual cleistothecia, whereas high GSH levels resulted in the formation of asexual conidiophores. Furthermore, by applying the principle of thioredoxin-affinity chromatography we identified several novel putative targets of thioredoxin A, including a hypothetical protein with peroxidase activity and an aldehyde dehydrogenase.	Leibniz Inst Nat Prod Res & Infect Bio HKI, Dept Mol & Apll Microbiol, D-07745 Jena, Germany; Univ Jena, D-07745 Jena, Germany	Hans Knoll Institute (HKI); Friedrich Schiller University of Jena	Brakhage, AA (corresponding author), Leibniz Inst Nat Prod Res & Infect Bio HKI, Dept Mol & Apll Microbiol, D-07745 Jena, Germany.	Axel.Brakhage@hki-jena.de		Al Abdallah, Qusai/0000-0002-6532-0617				Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Aguirre J, 2005, TRENDS MICROBIOL, V13, P111, DOI 10.1016/j.tim.2005.01.007; Aguirre J, 2006, MED MYCOL, V44, pS101, DOI 10.1080/13693780600900080; AHARONOWITZ Y, 1993, J BACTERIOL, V175, P623, DOI 10.1128/JB.175.3.623-629.1993; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Balmer Y, 2004, P NATL ACAD SCI USA, V101, P2642, DOI 10.1073/pnas.0308583101; Bauer H, 2003, EUR J BIOCHEM, V270, P4272, DOI 10.1046/j.1432-1033.2003.03812.x; Bauer H, 2002, J BIOL CHEM, V277, P17457, DOI 10.1074/jbc.M200636200; BEERS RF, 1952, J BIOL CHEM, V195, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brakhage AA, 2005, PHYTOCHEMISTRY, V66, P1200, DOI 10.1016/j.phytochem.2005.02.030; BRAKHAGE AA, 1995, J BACTERIOL, V177, P2781, DOI 10.1128/jb.177.10.2781-2788.1995; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; COHEN G, 1994, J BACTERIOL, V176, P973, DOI 10.1128/JB.176.4.973-984.1994; DIAMOND RD, 1982, INFECT IMMUN, V38, P487, DOI 10.1128/IAI.38.2.487-495.1982; Dubuisson M, 2004, FEBS LETT, V571, P161, DOI 10.1016/j.febslet.2004.06.080; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Flipphi M, 2001, J BIOL CHEM, V276, P6950, DOI 10.1074/jbc.M005769200; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GOLDBERG I, 1989, BIOCHIM BIOPHYS ACTA, V991, P330, DOI 10.1016/0304-4165(89)90124-4; Hisabori T, 2005, J EXP BOT, V56, P1463, DOI 10.1093/jxb/eri170; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann B, 2001, GENETICS, V157, P141; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hortschansky P, 2007, EMBO J, V26, P3157, DOI 10.1038/sj.emboj.7601752; Ito JI, 2006, INFECT IMMUN, V74, P5075, DOI 10.1128/IAI.00815-06; Jeon SJ, 2002, EUR J BIOCHEM, V269, P5423, DOI 10.1046/j.1432-1033.2002.03231.x; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kawasaki L, 2002, MOL MICROBIOL, V45, P1153, DOI 10.1046/j.1365-2958.2002.03087.x; Kawasaki L, 1997, J BACTERIOL, V179, P3284, DOI 10.1128/jb.179.10.3284-3292.1997; Kawasaki L, 2001, J BACTERIOL, V183, P1434, DOI 10.1128/JB.183.4.1434-1440.2001; Kim HS, 2002, FUNGAL GENET BIOL, V37, P72, DOI 10.1016/S1087-1845(02)00029-4; Kniemeyer O, 2006, CURR GENET, V49, P178, DOI 10.1007/s00294-005-0047-9; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; Lara-Ortiz T, 2003, MOL MICROBIOL, V50, P1241, DOI 10.1046/j.1365-2958.2003.03800.x; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LEMARECHAL P, 1992, EUR J BIOCHEM, V210, P421; Litzka O, 1995, MOL GEN GENET, V249, P557, DOI 10.1007/BF00290581; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATHIEU I, 1992, BIOCHEM J, V285, P255, DOI 10.1042/bj2850255; MOONEY JL, 1990, GENE DEV, V4, P1473, DOI 10.1101/gad.4.9.1473; MOORE EC, 1964, J BIOL CHEM, V239, P3453; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nayak T, 2006, GENETICS, V172, P1557, DOI 10.1534/genetics.105.052563; Philippe B, 2003, INFECT IMMUN, V71, P3034, DOI 10.1128/IAI.71.6.3034-3042.2003; Rahlfs S, 2001, EUR J BIOCHEM, V268, P1404, DOI 10.1046/j.1432-1327.2001.02005.x; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scherer M, 2002, EUKARYOT CELL, V1, P725, DOI 10.1128/EC.1.5.725-735.2002; Serrato AJ, 2002, BIOCHEM J, V367, P491, DOI 10.1042/BJ20020103; Shen ML, 2000, BIOCHEM PHARMACOL, V60, P947, DOI 10.1016/S0006-2952(00)00435-4; Sprote P, 2007, ARCH MICROBIOL, V188, P69, DOI 10.1007/s00203-007-0224-y; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Toone WM, 2001, ONCOGENE, V20, P2336, DOI 10.1038/sj.onc.1204384; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; Weidner G, 1998, CURR GENET, V33, P378, DOI 10.1007/s002940050350; WICKES B, 2004, EPICENTRE FORUM, V11, P7; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; WILLIAMS CH, 1967, J BIOL CHEM, V242, P5226; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; XU XM, 1991, J BIOCHEM-TOKYO, V109, P678, DOI 10.1093/oxfordjournals.jbchem.a123440; Yager L N, 1992, Biotechnology, V23, P19	69	82	90	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27259	27269		10.1074/jbc.M704298200	http://dx.doi.org/10.1074/jbc.M704298200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631497	hybrid			2022-12-25	WOS:000249304900067
J	Zhu, J; Jia, X; Xiao, G; Kang, Y; Partridge, NC; Qin, L				Zhu, Ji; Jia, Xun; Xiao, Guozhi; Kang, Yibin; Partridge, Nicola C.; Qin, Ling			EGF-like Ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by Osteoblasts - Implications for osteolytic bone metastases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; KAPPA-B-LIGAND; RECEPTOR ACTIVATOR; CANCER METASTASIS; CELLS; RESORPTION; MICE; DIFFERENTIATION; OSTEOPROTEGERIN; MC3T3-E1	Epidermal growth factor ( EGF)-like ligands and their receptors constitute one of the most important signaling networks functioning in normal tissue development and cancer biology. Recent in vivo mouse models suggest this signaling network plays an essential role in bone metabolism. Using a coculture system containing bone marrow macrophage and osteoblastic cells, here we report that EGF-like ligands stimulate osteoclastogenesis by acting on osteoblastic cells. This stimulation is not a direct effect because osteoclasts do not express functional EGF receptors ( EGFRs). Further studies reveal that EGF-like ligands strongly regulate the expression of two secreted osteoclast regulatory factors in osteoblasts by decreasing osteoprotegerin ( OPG) expression and increasing monocyte chemoattractant protein 1 ( MCP1) expression in an EGFR-dependent manner and consequently stimulate TRAP-positive osteoclast formation. Addition of exogenous OPG completely inhibited osteoclast formation stimulated by EGF-like ligands, while addition of a neutralizing antibody against MCP-1 exhibited partial inhibition. Coculture with bone metastatic breast cancer MDA-MB-231 cells had similar effects on the expression of OPG and MCP1 in the osteoblastic cells, and those effects could be partially abolished by the EGFR inhibitor PD153035. Because a high percentage of human carcinomas express EGF-like ligands, our findings suggest a novel mechanism for osteolytic lesions caused by cancer cells metastasizing to bone.	UMDNJ, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Princeton University	Qin, L (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	qinl1@umdnj.edu		Partridge, Nicola/0000-0002-5406-4814; Kang, Yibin/0000-0002-1626-6730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK071988] Funding Source: NIH RePORTER; NIDDK NIH HHS [K01 DK 071988] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angelucci A, 2006, ENDOCR-RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100; Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028; Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008-5472.CAN-05-2630; Chan SY, 2000, J BIOL CHEM, V275, P38693, DOI 10.1074/jbc.M004189200; Davideau JL, 1995, CONNECT TISSUE RES, V32, P47, DOI 10.3109/03008209509013705; HATA RI, 1984, ENDOCRINOLOGY, V115, P867, DOI 10.1210/endo-115-3-867; Hirata A, 2002, CANCER RES, V62, P2554; IBBOTSON KJ, 1986, P NATL ACAD SCI USA, V83, P2228, DOI 10.1073/pnas.83.7.2228; Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200; Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood-2004-09-3645; KUMEGAWA M, 1983, CALCIFIED TISSUE INT, V35, P542, DOI 10.1007/BF02405091; LORENZO JA, 1986, J CLIN INVEST, V77, P1897, DOI 10.1172/JCI112517; Miettinen PJ, 1999, NAT GENET, V22, P69, DOI 10.1038/8773; NG KW, 1983, CALCIFIED TISSUE INT, V35, P298, DOI 10.1007/BF02405050; NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P471, DOI 10.1677/erc.1.00956; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078-0432.CCR-05-1806; Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200; RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo-107-1-270; Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Schneider MR, 2005, ENDOCRINOLOGY, V146, P5237, DOI 10.1210/en.2005-0418; Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STERN PH, 1985, J CLIN INVEST, V76, P2016, DOI 10.1172/JCI112202; TAKAHASHI N, 1986, J CLIN INVEST, V78, P894, DOI 10.1172/JCI112677; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOKOTA K, 1986, J BIOL CHEM, V261, P5410; Younes MN, 2005, CANCER RES, V65, P4716, DOI 10.1158/0008-5472.CAN-04-4196	40	88	94	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26656	26665		10.1074/jbc.M705064200	http://dx.doi.org/10.1074/jbc.M705064200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636266	hybrid			2022-12-25	WOS:000249304900004
J	Han, S; Liu, Y; Chang, A				Han, Sumin; Liu, Yu; Chang, Amy			Cytoplasmic hsp70 promotes ubiquitination for endoplasmic reticulum-associated degradation of a misfolded mutant of the yeast plasma membrane ATPase, PMA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; ER-ASSOCIATED DEGRADATION; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNFOLDED PROTEIN RESPONSE; SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; MOLECULAR CHAPERONES; QUALITY-CONTROL; H+-ATPASE; STRESS-RESPONSE	Cells have a variety of strategies for dealing with misfolded proteins. Heat shock response involves transcriptional induction of chaperones to promote and/or correct folding, and also activation of the ubiquitin/proteasome system to degrade defective proteins. In the secretory pathway, it is primarily luminal misfolded or unassembled proteins that trigger the unfolded protein response which, like heat shock, induces chaperones and components of the endoplasmic reticulum (ER)-associated degradation ( ERAD) pathway. To understand cellular response to a misfolded polytopic membrane protein of the secretory pathway, we studied Pma1-D378S, a model ERAD substrate. Expression of misfolded Pma1 induces heat shock response in the absence of increased temperature. Overexpression of HSF1, the transcription factor that mediates heat shock response, increases degradation of Pma1-D378S without temperature upshift. Nevertheless, efficient Pma1-D378S degradation occurs in an hsf1 mutant that maintains basal transcription levels but cannot mediate transcriptional activation. Thus, heat shock protein induction enhances but is not necessary for ERAD. The Ssa group of cytoplasmic Hsp70 chaperones is required for ERAD of both Pma1-D378S and another transmembrane ERAD substrate, Ste6*. In the absence of Ssa chaperones, ubiquitination of both substrates is impaired, resulting in stabilization. We suggest a role for Hsp70 cytoplasmic chaperones in recognition by the endoplasmic reticulum-associated ubiquitination machinery.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chang, A (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	amychang@umich.edu	Chang, Amy/AAS-5491-2020; Liu, Yu/X-5864-2019	Chang, Amy/0000-0003-3682-6456; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058212, R01GM058212] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Cashikar AG, 2005, J BIOL CHEM, V280, P23869, DOI 10.1074/jbc.M502854200; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Friant S, 2003, EMBO J, V22, P3783, DOI 10.1093/emboj/cdg375; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; Haslbeck M, 2005, J BIOL CHEM, V280, P23861, DOI 10.1074/jbc.M502697200; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; Huyer G, 2004, J BIOL CHEM, V279, P38369, DOI 10.1074/jbc.M402468200; Huyer G, 2004, MOL BIOL CELL, V15, P908, DOI 10.1091/mbc.E03-07-0546; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; Nishikawa S, 2005, J BIOCHEM, V137, P551, DOI 10.1093/jb/mvi068; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; PARK HO, 1991, GENE DEV, V5, P1299, DOI 10.1101/gad.5.7.1299; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; Ravid T, 2006, EMBO J, V25, P533, DOI 10.1038/sj.emboj.7600946; Rose MD., 1990, METHODS YEAST GENETI; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; SHERMAN F, 1986, METHODS YEAT GENETIC; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Trotter EW, 2002, J BIOL CHEM, V277, P44817, DOI 10.1074/jbc.M204686200; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	50	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26140	26149		10.1074/jbc.M701969200	http://dx.doi.org/10.1074/jbc.M701969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17631501	hybrid			2022-12-25	WOS:000249239600017
J	Wan, DC; Pomerantz, JH; Brunet, LJ; Kim, JB; Chou, YF; Wu, BM; Harland, R; Blau, HM; Longaker, MT				Wan, Derrick C.; Pomerantz, Jason H.; Brunet, Lisa J.; Kim, Jae-Beom; Chou, Yu-Fen; Wu, Benjamin M.; Harland, Richard; Blau, Helen M.; Longaker, Michael T.			Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHOGENETIC PROTEIN; GENE-EXPRESSION; OSTEOBLASTIC DIFFERENTIATION; SKELETAL OVEREXPRESSION; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; STROMAL CELLS; STEM-CELLS; ANTAGONIST; XENOPUS	Several investigations have demonstrated a precise balance to exist between bone morphogenetic protein (BMP) agonists and antagonists, dictating BMP signaling and osteogenesis. We report a novel approach to manipulate BMP activity through a down-regulation of the potent BMP antagonist Noggin, and examined the effects on the bone forming capacity of osteoblasts. Reduction of noggin enhanced BMP signaling and in vitro osteoblast bone formation, as demonstrated by both gene expression profiles and histological staining. The effects of noggin suppression on in vivo bone formation were also investigated using critical-sized calvarial defects in mice repaired with noggin-suppressed osteoblasts. Radiographic and histological analyses revealed significantly more bone regeneration at 2 and 4 weeks post-injury. These findings strongly support the concept of enhanced osteogenesis through a down-regulation in Noggin and suggest a novel approach to clinically accelerate bone formation, potentially allowing for earlier mobilization of patients following skeletal injury or surgical resection.	Stanford Univ, Dept Surg, Stanford, CA 94305 USA; Stanford Univ, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA	Stanford University; Stanford University; University of California System; University of California Berkeley; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Longaker, MT (corresponding author), 257 Campus Dr, Stanford, CA 94305 USA.	longaker@stanford.edu		Wu, Benjamin/0000-0001-5236-8534; Wan, Derrick/0000-0003-4666-1683	NIDCR NIH HHS [R01 DE14526, R01 DE13194] Funding Source: Medline; NIGMS NIH HHS [R01 GM49346] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014526, R01DE013194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049346] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aalami OO, 2004, PLAST RECONSTR SURG, V114, P713, DOI 10.1097/01.PRS.0000131016.12754.30; Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Ahn J, 2003, J BONE JOINT SURG AM, V85A, P667, DOI 10.2106/00004623-200304000-00013; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Carlisle Elliot, 2005, Spine J, V5, p240S, DOI 10.1016/j.spinee.2005.02.014; Chou YF, 2005, J BIOMED MATER RES B, V75B, P81, DOI 10.1002/jbm.b.30261; Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958; DELMAS PD, 1990, J BONE MINER RES, V5, P5, DOI 10.1002/jbmr.5650050104; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem-67-4-741; Frick KK, 1998, AM J PHYSIOL-RENAL, V275, pF840, DOI 10.1152/ajprenal.1998.275.5.F840; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004-0766; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Hager-Theodorides AL, 2002, J IMMUNOL, V169, P5496, DOI 10.4049/jimmunol.169.10.5496; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jamali M, 2001, FEBS LETT, V509, P126, DOI 10.1016/S0014-5793(01)03151-9; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Kleeman TJ, 2001, SPINE, V26, P2751, DOI 10.1097/00007632-200112150-00026; Klug CA, 2000, BLOOD, V96, P894, DOI 10.1182/blood.V96.3.894.015k35_894_901; Lee AJ, 2000, ANN CLIN BIOCHEM, V37, P432, DOI 10.1258/0004563001899573; Margolis RN, 1996, J CLIN ENDOCR METAB, V81, P872, DOI 10.1210/jc.81.3.872; Mathy JA, 2003, PLAST RECONSTR SURG, V112, P528, DOI 10.1097/01.PRS.0000070729.05978.BB; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pereira RC, 2000, J CELL PHYSIOL, V182, P239, DOI 10.1002/(SICI)1097-4652(200002)182:2<239::AID-JCP13>3.0.CO;2-W; Petryk A, 2005, BONE, V36, P617, DOI 10.1016/j.bone.2005.01.018; Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Steiner Claudia, 2002, Eff Clin Pract, V5, P143; Tataria M, 2006, J PEDIATR SURG, V41, P624, DOI 10.1016/j.jpedsurg.2005.12.001; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VALENZUELA DM, 1995, J NEUROSCI, V15, P607; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	45	121	125	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26450	26459		10.1074/jbc.M703282200	http://dx.doi.org/10.1074/jbc.M703282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17609215	hybrid			2022-12-25	WOS:000249239600050
J	Kuei, C; Sutton, S; Bonaventure, P; Pudiak, C; Shelton, J; Zhu, J; Nepomuceno, D; Wu, JJ; Chen, JC; Kamme, F; Seierstad, M; Hack, MD; Bathgate, RAD; Hossain, MA; Wade, JD; Atack, J; Lovenberg, TW; Liu, CL				Kuei, Chester; Sutton, Steven; Bonaventure, Pascal; Pudiak, Cindy; Shelton, Jonathan; Zhu, Jessica; Nepomuceno, Diane; Wu, Jiejun; Chen, Jingcai; Kamme, Fredrik; Seierstad, Mark; Hack, Michael D.; Bathgate, Ross A. D.; Hossain, Mohammed Akhter; Wade, John D.; Atack, John; Lovenberg, Timothy W.; Liu, Changlu			R3(B Delta 23-27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7 - In vitro and in vivo characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEUS INCERTUS; BINDING-SITES; MESSENGER-RNA; MOUSE-BRAIN; RAT-BRAIN; IDENTIFICATION; INSULIN; LIGAND; EXPRESSION; GENE	Both relaxin-3 and its receptor ( GPCR135) are expressed predominantly in brain regions known to play important roles in processing sensory signals. Recent studies have shown that relaxin-3 is involved in the regulation of stress and feeding behaviors. The mechanisms underlying the involvement of relaxin-3/GPCR135 in the regulation of stress, feeding, and other potential functions remain to be studied. Because relaxin-3 also activates the relaxin receptor ( LGR7), which is also expressed in the brain, selective GPCR135 agonists and antagonists are crucial to the study of the physiological functions of relaxin-3 and GPCR135 in vivo. Previously, we reported the creation of a selective GPCR135 agonist ( a chimeric relaxin-3/INSL5 peptide designated R3/I5). In this report, we describe the creation of a high affinity antagonist for GPCR135 and GPCR142 over LGR7. This GPCR135 antagonist, R3(B Delta 23-27) R/I5, consists of the relaxin-3 B-chain with a replacement of Gly(23) to Arg, a truncation at the C terminus ( Gly(24)-Trp(27) deleted), and the A-chain of INSL5. In vitro pharmacological studies showed that R3( B Delta 23-27) R/I5 binds to human GPCR135 ( IC50 = 0.67 nM) and GPCR142 ( IC50 = 2.29 nM) with high affinity and is a potent functional GPCR135 antagonist ( pA2 = 9.15) but is not a human LGR7 ligand. Furthermore, R3( B Delta 23-27) R/I5 had a similar binding profile at the rat GPCR135 receptor ( IC50 = 0.25 nM, pA2 = 9.6) and lacked affinity for the rat LGR7 receptor. When administered to rats intracerebroventricularly, R3( B Delta 23-27) R/I5 blocked food intake induced by the GPCR135 selective agonist R3/I5. Thus, R3( B Delta 23-27) R/I5 should prove a useful tool for the further delineation of the functions of the relaxin-3/GPCR135 system.	Johnson & Johnson Pharmaceut Res & Dev, LLC, San Diego, CA 92121 USA; Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia	Johnson & Johnson; Johnson & Johnson USA; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Liu, CL (corresponding author), Johnson & Johnson Pharmaceut Res & Dev, LLC, 3210 Merryfield Row, San Diego, CA 92121 USA.	cliu9@prdus.jnj.com	Bathgate, Ross/ABE-6471-2020; Bonaventure, Pascal/K-3052-2015	Bathgate, Ross/0000-0001-6301-861X; Bonaventure, Pascal/0000-0003-2971-6152; Hossain, Mohammed/0000-0002-9961-0006; Wade, John/0000-0002-1352-6568; Atack, John/0000-0002-3410-791X				ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; Bathgate RAD, 2006, BIOCHEMISTRY-US, V45, P1043, DOI 10.1021/bi052233e; Boels K, 2004, DEV BRAIN RES, V152, P265, DOI 10.1016/j.devbrainres.2004.06.002; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; Burazin TCD, 2002, J NEUROCHEM, V82, P1553, DOI 10.1046/j.1471-4159.2002.01114.x; Chen JC, 2005, J PHARMACOL EXP THER, V312, P83, DOI 10.1124/jpet.104.073486; Conklin D, 1999, GENOMICS, V60, P50, DOI 10.1006/geno.1999.5899; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Goto M, 2001, J COMP NEUROL, V438, P86, DOI 10.1002/cne.1303; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; Hida T, 2006, J RECEPT SIG TRANSD, V26, P147, DOI 10.1080/10799890600623373; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; Koman A, 1996, J BIOL CHEM, V271, P20238, DOI 10.1074/jbc.271.34.20238; Krajnc-Franken MAM, 2004, MOL CELL BIOL, V24, P687, DOI 10.1128/MCB.24.2.687-696.2004; Liu CL, 2005, J BIOL CHEM, V280, P292, DOI 10.1074/jbc.M409916200; Liu CL, 2005, MOL PHARMACOL, V67, P231, DOI 10.1124/mol.104.006700; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; Ma S, 2007, NEUROSCIENCE, V144, P165, DOI 10.1016/j.neuroscience.2006.08.072; McGowan BMC, 2005, ENDOCRINOLOGY, V146, P3295, DOI 10.1210/en.2004-1532; Nistri S, 2005, CURR NEUROVASC RES, V2, P225, DOI 10.2174/1567202054368362; POTTER E, 1994, P NATL ACAD SCI USA, V91, P8777, DOI 10.1073/pnas.91.19.8777; Rosengren KJ, 2006, J BIOL CHEM, V281, P5845, DOI 10.1074/jbc.M511210200; Scott DJ, 2005, ANN NY ACAD SCI, V1041, P8, DOI 10.1196/annals.1282.002; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Sutton SW, 2005, NEUROENDOCRINOLOGY, V82, P139, DOI 10.1159/000091267; Sutton SW, 2004, NEUROENDOCRINOLOGY, V80, P298, DOI 10.1159/000083656; Tanaka M, 2005, EUR J NEUROSCI, V21, P1659, DOI 10.1111/j.1460-9568.2005.03980.x; THORNTON SM, 1995, J NEUROENDOCRINOL, V3, P165; Tregear G., 1981, PEPTIDES SYNTHESIS S, P249; Whittingham JL, 1998, BIOCHEMISTRY-US, V37, P11516, DOI 10.1021/bi980807s; Wilson BC, 2006, NEUROSCI LETT, V393, P160, DOI 10.1016/j.neulet.2005.09.059; Zhao L, 1999, ENDOCRINOLOGY, V140, P445, DOI 10.1210/en.140.1.445	40	113	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25425	25435		10.1074/jbc.M701416200	http://dx.doi.org/10.1074/jbc.M701416200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606621	hybrid			2022-12-25	WOS:000249014100028
J	Newell, JL; Fay, PJ				Newell, Jennifer L.; Fay, Philip J.			Proteolysis at Arg(740) facilitates subsequent bond cleavages during thrombin-catalyzed activation of factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; PORCINE FACTOR-VIII; PROTEIN-C; LIGHT-CHAIN; FACTOR XA; HEAVY-CHAIN; A2 SUBUNIT; FACTOR-V; FACTOR-IXA; INACTIVATION	Thrombin activates factor VIII by proteolysis at three P1 residues: Arg(372), Arg(740), and Arg(1689). Cleavage at Arg372 and Arg1689 are essential for procofactor activation; however cleavage at Arg740 has not been rigorously studied. To evaluate the role for cleavage at Arg740, we prepared and stably expressed two recombinant B-domainless factor VIII mutants, R740H and R740Q to slow and eliminate, respectively, cleavage at this site. Specific activity values for the variants were similar to 50 and 20%, respectively, that of wild-type factor VIII. Activation of factor VIII R740H by thrombin showed an similar to 40-fold reduction in the rate of A2 subunit generation, which reflected an similar to 20-fold reduction in cleavage rate at Arg372. Similarly, a similar to 40-fold rate reduction in cleavage at Arg1689 and consequent generation of the A3-C1-C2 subunit were observed. Rate values for A2 and A3-C1-C2 subunit generation were reduced by > 700-fold and similar to 140-fold, respectively, in the R740Q variant. These results suggest that initial cleavage at Arg740 affects cleavage at both Arg372 and Arg1689 sites. Results obtained evaluating proteolysis of the factor VIII mutants by factor Xa revealed more modest rate reductions (< 10-fold) in generating A2 and A3-C1-C2 subunits from either variant, suggesting that factor Xa-catalyzed activation of factor VIII was significantly less dependent upon prior cleavage at residue 740 than thrombin. Overall, these results support a model whereby cleavage of factor VIII by thrombin is an ordered pathway with cleavage at Arg740 facilitating cleavages at Arg372 and Arg1689, which result in procofactor activation.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	philip_fay@urmc.rochester.edu			NHLBI NIH HHS [HL38199, HL76213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076213, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansong C, 2006, J THROMB HAEMOST, V4, P842, DOI 10.1111/j.1538-7836.2006.01831.x; Bianchini EP, 2005, P NATL ACAD SCI USA, V102, P10099, DOI 10.1073/pnas.0504704102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; Donath MJSH, 1996, EUR J BIOCHEM, V240, P365, DOI 10.1111/j.1432-1033.1996.0365h.x; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; Jenkins PV, 2002, BLOOD, V100, P501, DOI 10.1182/blood-2001-12-0361; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KALAFATIS M, 1995, ARTERIOSCL THROM VAS, V15, P2181, DOI 10.1161/01.ATV.15.12.2181; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; Manithody C, 2003, BLOOD, V101, P4802, DOI 10.1182/blood-2003-01-0126; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Nogami K, 2005, BLOOD, V105, P4362, DOI 10.1182/blood-2004-10-3939; Nogami K, 2005, J BIOL CHEM, V280, P18476, DOI 10.1074/jbc.M412778200; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; PIETERS J, 1989, BLOOD, V74, P1021; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; Varfaj F, 2006, BIOCHEM J, V396, P355, DOI 10.1042/BJ20060117; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wakabayashi H, 2004, J BIOL CHEM, V279, P12677, DOI 10.1074/jbc.M311042200; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	35	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25367	25375		10.1074/jbc.M703433200	http://dx.doi.org/10.1074/jbc.M703433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17595160	hybrid			2022-12-25	WOS:000249014100022
J	Liu, Q; Kriksunov, IA; Moreau, C; Graeff, R; Potter, BVL; Lee, HC; Hao, Q				Liu, Qun; Kriksunov, Irina A.; Moreau, Christelle; Graeff, Richard; Potter, Barry V. L.; Lee, Hon Cheung; Hao, Quan			Catalysis-associated conformational changes revealed by human CD38 complexed with a non-hydrolyzable substrate analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE PHOSPHATE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CALCIUM-RELEASE; ACTIVE-SITE; CYCLASE; HYDROLYSIS; IDENTIFICATION; DERIVATIVES	Cyclic ADP-ribose (cADPR) is a calcium mobilization messenger important for mediating a wide range of physiological functions. The endogenous levels of cADPR in mammalian tissues are primarily controlled by CD38, a multifunctional enzyme capable of both synthesizing and hydrolyzing cADPR. In this study, a novel non-hydrolyzable analog of cADPR, N1-cIDPR (N1-cyclic inosine diphosphate ribose), was utilized to elucidate the structural determinants involved in the hydrolysis of cADPR. N1-cIDPR inhibits CD38-catalyzed cADPR hydrolysis with an IC50 of 0.26 mM. N1-cIDPR forms a complex with CD38 or its inactive mutant in which the catalytic residue Glu-226 is mutated. Both complexes have been determined by x-ray crystallography at 1.7 and 1.76 A resolution, respectively. The results show that N1-cIDPR forms two hydrogen bonds (2.61 and 2.64 angstrom) with Glu-226, confirming our previously proposed model for cADPR catalysis. Structural analyses reveal that both the enzyme and substrate cADPR undergo catalysis-associated conformational changes. From the enzyme side, residues Glu-146, Asp-147, and Trp-125 work collaboratively to facilitate the formation of the Michaelis complex. From the substrate side, cADPR is found to change its conformation to fit into the active site until it reaches the catalytic residue. The binary CD38-cADPR model described here represents the most detailed description of the CD38-catalyzed hydrolysis of cADPR at atomic resolution. Our structural model should provide insights into the design of effective cADPR analogs.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China; Cornell Univ, MacCHESS, Cornell High Energy Synchroton Source, Ithaca, NY 14853 USA; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England	University of Minnesota System; University of Minnesota Twin Cities; University of Hong Kong; Cornell University; University of Bath	Hao, Q (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	qh22@cornell.edu	Lee, Hon Cheung/C-4329-2009; Liu, Qun/A-8757-2011; Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012; Hao, Quan/C-4304-2009; Graeff, Richard Milton/B-3425-2011	Liu, Qun/0000-0002-1179-290X; Hao, Quan/0000-0002-9642-0514	NCRR NIH HHS [RR01646] Funding Source: Medline; NIGMS NIH HHS [GM061568] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061568] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cakir-Kiefer I, 2001, BIOCHEM J, V358, P399, DOI 10.1042/bj3580399; Deaglio S, 2006, BLOOD, V108, P1135, DOI 10.1182/blood-2006-01-013003; Ferrero E, 1997, J IMMUNOL, V159, P3858; Fukushi Y, 2001, J BIOL CHEM, V276, P649, DOI 10.1074/jbc.M004469200; Graeff R, 2002, BIOCHEM J, V367, P163, DOI 10.1042/BJ20020644; Graeff R, 2001, J BIOL CHEM, V276, P12169, DOI 10.1074/jbc.M011299200; Graeff R, 2006, J BIOL CHEM, V281, P28951, DOI 10.1074/jbc.M604370200; Graham SM, 2001, NUCLEOS NUCLEOT NUCL, V20, P169, DOI 10.1081/NCN-100002079; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526; Johnson JD, 2006, DIABETES, V55, P2737, DOI 10.2337/db05-1455; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Khoo KM, 2000, J BIOL CHEM, V275, P24807, DOI 10.1074/jbc.M908231199; Kirchberger T, 2006, BRIT J PHARMACOL, V149, P337, DOI 10.1038/sj.bjp.0706869; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Lee HC, 2000, CHEM IMMUNOL, V75, P39; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LEE HC, 2002, CYCLIC ADP RIBOSE NA, P1; Liu Q, 2005, STRUCTURE, V13, P1331, DOI 10.1016/j.str.2005.05.012; Liu Q, 2007, J BIOL CHEM, V282, P5853, DOI 10.1074/jbc.M609093200; Liu Q, 2006, J BIOL CHEM, V281, P32861, DOI 10.1074/jbc.M606365200; Moreau C, 2006, J MED CHEM, V49, P5162, DOI 10.1021/jm060275a; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Munshi C, 2000, J BIOL CHEM, V275, P21566, DOI 10.1074/jbc.M909365199; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Partida-Sanchez S, 2004, IMMUNITY, V20, P279, DOI 10.1016/S1074-7613(04)00048-2; Takahashi J, 2003, BIOCHEM BIOPH RES CO, V312, P434, DOI 10.1016/j.bbrc.2003.10.143; Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083; Wagner GK, 2005, J ORG CHEM, V70, P4810, DOI 10.1021/jo050085s; Yamamoto-Katayama S, 2002, J MOL BIOL, V316, P711, DOI 10.1006/jmbi.2001.5386	41	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24825	24832		10.1074/jbc.M701653200	http://dx.doi.org/10.1074/jbc.M701653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591784	hybrid			2022-12-25	WOS:000248933000038
J	Buceta, J; Herranz, H; Canela-Xandri, O; Reigada, R; Sagues, F; Milan, M				Buceta, Javier; Herranz, Hector; Canela-Xandri, Oriol; Reigada, Ramon; Sagues, Francesc; Milan, Marco			Robustness and Stability of the Gene Regulatory Network Involved in DV Boundary Formation in the Drosophila Wing	PLOS ONE			English	Article							DORSAL-VENTRAL BOUNDARY; INDUCIBLE ANTAGONIST; PATTERN-FORMATION; NOTCH ACTIVATION; FRINGE; EXPRESSION; SERRATE; PROTEIN; SIGNAL; CELLS	Gene regulatory networks have been conserved during evolution. The Drosophila wing and the vertebrate hindbrain share the gene network involved in the establishment of the boundary between dorsal and ventral compartments in the wing and adjacent rhombomeres in the hindbrain. A positive feedback-loop between boundary and non-boundary cells and mediated by the activities of Notch and Wingless/Wnt-1 leads to the establishment of a Notch dependent organizer at the boundary. By means of a Systems Biology approach that combines mathematical modeling and both in silico and in vivo experiments in the Drosophila wing primordium, we modeled and tested this regulatory network and present evidence that a novel property, namely refractoriness to the Wingless signaling molecule, is required in boundary cells for the formation of a stable dorsal-ventral boundary. This new property has been validated in vivo, promotes mutually exclusive domains of Notch and Wingless activities and confers stability to the dorsal-ventral boundary. A robustness analysis of the regulatory network complements our results and ensures its biological plausibility.	[Buceta, Javier; Canela-Xandri, Oriol] CeRQT, Barcelona, Spain; [Herranz, Hector; Milan, Marco] ICREA, Barcelona, Spain; [Herranz, Hector; Milan, Marco] IRB, Barcelona, Spain; [Reigada, Ramon; Sagues, Francesc] Univ Barcelona, Dept Quim Fis, E-08028 Barcelona, Spain	ICREA; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona	Buceta, J (corresponding author), CeRQT, Parc Cient Barcelona, Barcelona, Spain.	jbuceta@pcb.ub.es; mmilan@pcb.ub.es	Sagues, Francesc/K-6414-2015; Milan, Marco/H-1450-2015; Buceta, Javier/ABB-1696-2021; Reigada, Ramon/A-2450-2012; Buceta, Javier/E-3705-2010	Sagues, Francesc/0000-0002-2956-5676; Milan, Marco/0000-0002-7111-6444; Buceta, Javier/0000-0003-1791-0011; Buceta, Javier/0000-0003-1791-0011; Reigada, Ramon/0000-0003-2177-7014	Ramon y Cajal; Juan de la Cierva; MEC [FIS2005-457, FIS2006-01197, BQU2003-05042-C02-01, BFU2004-00167/BMC]; DURSI [2005-SGR/00653, 2005-SGR/00118]; EU [LSHM-CP-2003-503330]; IRB Barcelona; ICREA Funding Source: Custom	Ramon y Cajal(Spanish Government); Juan de la Cierva(Instituto de Salud Carlos III); MEC(European Commission); DURSI; EU(European Commission); IRB Barcelona; ICREA(ICREA)	J.B. and H.H. acknowledge the Ramon y Cajal and the Juan de la Cierva programs, which provide their researcher contracts, respectively. Partial support was provided by MEC under grants FIS2005-457 and FIS2006-01197 (O.C-X. and J.B.), BQU2003-05042-C02-01 (R. R. and F. S), and BFU2004-00167/BMC (H. H and M. M.), and by DURSI through projects 2005-SGR/00653 (O.C-X., J.B., R. R., and F. S.) and 2005-SGR/00118 (H. H. and M. M.). M. M.'s laboratory also acknowledges support from an EU research contract LSHM-CP-2003-503330 (APOPIS) and IRB Barcelona intramural funds.	Amoyel M, 2005, DEVELOPMENT, V132, P775, DOI 10.1242/dev.01616; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Buceta J, 2005, BIOPHYS J, V89, P2199, DOI 10.1529/biophysj.105.063743; Cheng YC, 2004, DEV CELL, V6, P539, DOI 10.1016/S1534-5807(04)00097-8; CROSS MC, 1993, REV MOD PHYS, V65, P851, DOI 10.1103/RevModPhys.65.851; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; Di Ventura B, 2006, NATURE, V443, P527, DOI 10.1038/nature05127; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Fong SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/ng1432; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Gerlitz O, 2002, GENE DEV, V16, P1055, DOI 10.1101/gad.991802; Giraldez AJ, 2003, DEVELOPMENT, V130, P6533, DOI 10.1242/dev.00904; Giraldez AJ, 2002, DEV CELL, V2, P667, DOI 10.1016/S1534-5807(02)00180-6; Gonzalez A, 2006, GENETICS, V174, P1625, DOI 10.1534/genetics.106.061218; Grueber WB, 2003, CELL, V112, P805, DOI 10.1016/S0092-8674(03)00160-0; Herranz H, 2006, EMBO REP, V7, P297, DOI 10.1038/sj.embor.7400617; Ibanes M, 2006, MOL SYST BIOL, V2, DOI 10.1038/mbs4100098; Irvine KD, 2001, ANNU REV CELL DEV BI, V17, P189, DOI 10.1146/annurev.cellbio.17.1.189; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KOCH AJ, 1994, REV MOD PHYS, V66, P1481, DOI 10.1103/RevModPhys.66.1481; Kruse K, 2004, DEVELOPMENT, V131, P4843, DOI 10.1242/dev.01335; Kyoda K, 1999, Pac Symp Biocomput, P77; LUMSDEN A, 1991, PHILOS T R SOC B, V331, P281, DOI 10.1098/rstb.1991.0017; Micchelli CA, 1999, NATURE, V401, P473, DOI 10.1038/46779; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Milan M, 2000, DEVELOPMENT, V127, P3069; Nolo R, 2000, CELL, V102, P349, DOI 10.1016/S0092-8674(00)00040-4; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rauskolb C, 1999, NATURE, V401, P476, DOI 10.1038/46786; Raya A, 2004, NATURE, V427, P121, DOI 10.1038/nature02190; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; SCHLOOSER G, 2004, MODULARITY DEV EVOLU; Shoresh M, 1998, GENETICS, V150, P283; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615; Zeng YA, 2004, DEVELOPMENT, V131, P2911, DOI 10.1242/dev.01177	45	27	27	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e602	10.1371/journal.pone.0000602	http://dx.doi.org/10.1371/journal.pone.0000602			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622347	gold, Green Submitted, Green Published			2022-12-25	WOS:000207452000009
J	Geiger, T; Levitzki, A				Geiger, Tamar; Levitzki, Alexander			Loss of Robustness and Addiction to IGF1 during Early Keratinocyte Transformation by Human Papilloma Virus 16	PLOS ONE			English	Article								Infection of keratinocytes with high risk human Papilloma virus causes immortalization, and when followed by further mutations, leads to cervical cancer and other anogenital tumors. Here we monitor the progressive loss of robustness in an in vitro model of the early stages of transformation that comprises normal keratinocytes and progressive passages of HPV16 immortalized cells. As transformation progresses, the cells acquire higher proliferation rates and gain the ability to grow in soft agar. Concurrently, the cells lose robustness, becoming more sensitive to serum starvation and DNA damage by Cisplatin. Loss of robustness in the course of transformation correlates with significant reductions in the activities of the anti-apoptotic proteins PKB/Akt, Erk, Jnk and p38 both under normal growth conditions and upon stress. In parallel, loss of robustness is manifested by the shrinkage of the number of growth factors that can rescue starving cells from apoptosis, with the emergence of dependence solely on IGF1. Treatment with IGF1 activates PKB/Akt and Jnk and through them inhibits p53, rescuing the cells from starvation. We conclude that transformation in this model induces higher susceptibility of cells to stress due to reduced anti-apoptotic signaling and hyper-activation of p53 upon stress.	[Geiger, Tamar; Levitzki, Alexander] Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silverman Inst Life Sci, Unit Cellular Signaling, Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silverman Inst Life Sci, Unit Cellular Signaling, Jerusalem, Israel.	levitzki@vms.huji.ac.il	Geiger, Tamar/C-2349-2014	Geiger, Tamar/0000-0002-9526-197X	Hebrew University; Algen Biopharmaceuticals Ltd	Hebrew University; Algen Biopharmaceuticals Ltd	Funds from the Hebrew University and Algen Biopharmaceuticals Ltd.	Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BenBassat H, 1997, CANCER RES, V57, P3741; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Billecke CA, 2002, ONCOGENE, V21, P4481, DOI 10.1038/sj.onc.1205546; Boyer SN, 1996, CANCER RES, V56, P4620; BRAUN L, 1990, CANCER RES, V50, P7324; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; Chen CL, 2007, BRIT J CANCER, V96, P591, DOI 10.1038/sj.bjc.6603597; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; De Potter IY, 2001, EXP CELL RES, V271, P315, DOI 10.1006/excr.2001.5390; DURST M, 1991, J VIROL, V65, P796; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Edmondson SR, 2003, ENDOCR REV, V24, P737, DOI 10.1210/er.2002-0021; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Galvan V, 2003, J BIOL CHEM, V278, P13325, DOI 10.1074/jbc.M211398200; GIRINSKY T, 1995, CANCER RES, V55, P3726; HEMBREE JR, 1994, CANCER RES, V54, P3160; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Lembo D, 2006, VIRUS RES, V122, P189, DOI 10.1016/j.virusres.2006.06.011; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; MITRANIROSENBAUM S, 1992, INTERVIROLOGY, V33, P76, DOI 10.1159/000150234; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Nishino T, 2002, J BIOL CHEM, V277, P33943, DOI 10.1074/jbc.M201338200; Niu GL, 2005, MOL CELL BIOL, V25, P7432, DOI 10.1128/MCB.25.17.7432-7440.2005; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Reinmuth N, 2002, CLIN CANCER RES, V8, P3259; Rey O, 1999, ONCOGENE, V18, P6997, DOI 10.1038/sj.onc.1203180; Rodeck U, 1997, J CELL SCI, V110, P113; Salcedo M, 2002, INT J EXP PATHOL, V83, P275, DOI 10.1046/j.1365-2613.2002.00198.x; Sanclemente G, 2002, J EUR ACAD DERMATOL, V16, P231, DOI 10.1046/j.1473-2165.2002.00419.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Shen MR, 2006, CARCINOGENESIS, V27, P962, DOI 10.1093/carcin/bgi336; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang YZ, 1998, PROSTATE, V35, P165; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wu YP, 2004, GROWTH HORM IGF RES, V14, P52, DOI 10.1016/j.ghir.2003.08.003; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	50	7	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e605	10.1371/journal.pone.0000605	http://dx.doi.org/10.1371/journal.pone.0000605			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622350	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452000012
J	Le Roux, JJ; Wieczorek, AM; Wright, MG; Tran, CT				Le Roux, Johannes J.; Wieczorek, Ania M.; Wright, Mark G.; Tran, Carol T.			Super-Genotype: Global Monoclonality Defies the Odds of Nature	PLOS ONE			English	Article								The ability to respond to natural selection under novel conditions is critical for the establishment and persistence of introduced alien species and their ability to become invasive. Here we correlated neutral and quantitative genetic diversity of the weed Pennisetum setaceum Forsk. Chiov. (Poaceae) with differing global (North American and African) patterns of invasiveness and compared this diversity to native range populations. Numerous molecular markers indicate complete monoclonality within and among all of these areas (F-ST=0.0) and is supported by extreme low quantitative trait variance (Q(ST)=0.00065-0.00952). The results support the general-purpose-genotype hypothesis that can tolerate all environmental variation. However, a single global genotype and widespread invasiveness under numerous environmental conditions suggests a super-genotype. The super-genotype described here likely evolved high levels of plasticity in response to fluctuating environmental conditions during the Early to Mid Holocene. During the Late Holocene, when environmental conditions were predominantly constant but extremely inclement, strong selection resulted in only a few surviving genotypes.	[Le Roux, Johannes J.; Wieczorek, Ania M.; Tran, Carol T.] Univ Hawaii Manoa, Dept Trop Plant & Soil Sci, Honolulu, HI 96822 USA; [Wright, Mark G.] Univ Hawaii Manoa, Dept Plant & Environm Sci, Honolulu, HI 96822 USA	University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa	Le Roux, JJ (corresponding author), Univ Hawaii Manoa, Dept Trop Plant & Soil Sci, Honolulu, HI 96822 USA.	roux@hawaii.edu	Wright, Mark G/A-7349-2009	Le Roux, Johannes/0000-0001-7911-9810; Wright, Mark/0000-0002-1643-7560	USDATSTAR	USDATSTAR(United States Department of Agriculture (USDA))	The research conducted in this study was financially supported by a USDATSTAR grant to Dr. Ania Wieczorek.	Agrawal AA, 2001, SCIENCE, V294, P321, DOI 10.1126/science.1060701; Asker S. E., 1992, APOMIXIS PLANTS; ASSIENAN B, 1995, THEOR APPL GENET, V91, P672, DOI 10.1007/BF00223296; BAKER H. G., 1965, The genetics of colonizing species: Proc. 1st Internat, Union biol Sci., Asilomar, California., P147; BAKER HG, 1967, EVOLUTION, V21, P853, DOI 10.1111/j.1558-5646.1967.tb03440.x; Barcaccia G, 2006, HEREDITY, V96, P322, DOI 10.1038/sj.hdy.6800808; BORNKAMM R, 1989, J ARID ENVIRON, V17, P271, DOI 10.1016/S0140-1963(18)30915-7; BROUGHTON WJ, 1971, BIOCHEM J, V125, P1075, DOI 10.1042/bj1251075; Carino DA, 1999, MOL ECOL, V8, P2127, DOI 10.1046/j.1365-294x.1999.00786.x; CHABOUDEZ P, 1994, AUST J BOT, V42, P283, DOI 10.1071/BT9940283; Cox GW, 2004, ALIEN SPECIES EVOLUT; DeWitt TJ, 1998, TRENDS ECOL EVOL, V13, P77, DOI 10.1016/S0169-5347(97)01274-3; ELLSTRAND NC, 1987, AM J BOT, V74, P123, DOI 10.2307/2444338; Fleitmann D, 2003, SCIENCE, V300, P1737, DOI 10.1126/science.1083130; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; Hamilton MB, 1999, BIOTECHNIQUES, V27, P500, DOI 10.2144/99273st03; Joubert D. F., 2002, Dinteria, P37; KALENDAR R, 2004, FASTPCR PCR PRIMER D; LAVERGNE S, P NATL ACAD SCI US, V104, P3883; Lee CE, 2002, TRENDS ECOL EVOL, V17, P386, DOI 10.1016/S0169-5347(02)02554-5; Martel E, 2004, PLANT SYST EVOL, V249, P139, DOI 10.1007/s00606-004-0191-6; Merila J, 2001, J EVOLUTION BIOL, V14, P892, DOI 10.1046/j.1420-9101.2001.00348.x; Milton SJ, 1998, S AFR J SCI, V94, P57; Neumann K., 1989, AFR ARCHAEOL REV, V7, P97, DOI DOI 10.1007/BF01116839; Nicoll K, 2004, QUATERNARY SCI REV, V23, P561, DOI 10.1016/j.quascirev.2003.10.004; Novak SJ, 2000, CAN J BOT, V78, P1469, DOI 10.1139/cjb-78-11-1469; Palenchar PM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r91; Parker IM, 2003, CONSERV BIOL, V17, P59, DOI 10.1046/j.1523-1739.2003.02019.x; Pigliucci M, 2005, TRENDS ECOL EVOL, V20, P481, DOI 10.1016/j.tree.2005.06.001; Pigliucci M, 2006, J EXP BIOL, V209, P2362, DOI 10.1242/jeb.02070; Poulin J, 2005, DIVERS DISTRIB, V11, P241, DOI 10.1111/j.1366-9516.2005.00136.x; Prentice IC, 2000, J BIOGEOGR, V27, P507, DOI 10.1046/j.1365-2699.2000.00425.x; Price JP, 2002, P ROY SOC B-BIOL SCI, V269, P2429, DOI 10.1098/rspb.2002.2175; Price TD, 2003, P ROY SOC B-BIOL SCI, V270, P1433, DOI 10.1098/rspb.2003.2372; Rambuda TD, 2004, DIVERS DISTRIB, V10, P409, DOI 10.1111/j.1366-9516.2004.00100.x; Reed DH, 2003, EVOLUTION, V57, P1822; Sakai AK, 2001, ANNU REV ECOL SYST, V32, P305, DOI 10.1146/annurev.ecolsys.32.081501.114037; Saltonstall K, 2003, MOL ECOL, V12, P1689, DOI 10.1046/j.1365-294X.2003.01849.x; *SAS I, 2001, P REG SAS I; *SAS I, 2001, P NEST SAS I; Schmelzer GH, 1997, EUPHYTICA, V96, P23, DOI 10.1023/A:1002974304592; Schwilk DW, 1997, PLANT ECOL, V132, P77, DOI 10.1023/A:1009755320731; Stenoien HK, 2005, MOL ECOL, V14, P137, DOI 10.1111/j.1365-294X.2004.02359.x; van Kleunen M, 2005, NEW PHYTOL, V166, P49, DOI 10.1111/j.1469-8137.2004.01296.x; Wang RC, 2003, PLANT PHYSIOL, V132, P556, DOI 10.1104/pp.103.021253; WILLIAMS DG, 1993, FUNCT ECOL, V7, P623, DOI 10.2307/2390140; WILLIAMS DG, 1995, ECOLOGY, V76, P1569, DOI 10.2307/1938158	47	49	49	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e590	10.1371/journal.pone.0000590	http://dx.doi.org/10.1371/journal.pone.0000590			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611622	gold, Green Published			2022-12-25	WOS:000207451900007
J	Lee, HR; Helquist, SA; Kool, ET; Johnson, KA				Lee, Harold R.; Helquist, Sandra A.; Kool, Eric T.; Johnson, Kenneth A.			Importance of hydrogen bonding for efficiency and specificity of the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR-GROOVE; NONPOLAR ISOSTERE; ACTIVE-SITE; FIDELITY; REPLICATION; DIFLUOROTOLUENE; SELECTIVITY; MECHANISM	To assess the contribution to discrimination afforded by base pair hydrogen bonding during DNA replication by the human mitochondrial DNA polymerase, we examined nucleoside mimics lacking hydrogen bond forming capability but retaining the overall steric shape of the natural nucleotide. We employed oligonucleotide templates containing either a deoxyadenosine shape mimic (dQ) or a deoxythymidine shape mimic (dF). Additionally, the nucleoside triphosphate analogs difluorotoluene deoxynucleoside triphosphate, 9-methyl-1-H-imidazo[(4,5)-b] pyridine deoxyribose triphosphate, and 4-methylbenzimidazole deoxyribose triphosphate (dZTP; another dATP shape mimic) were assayed. We used pre-steady state methods to determine the kinetic parameters governing nucleotide incorporation, k(pol) and K-d. In general, the loss of hydrogen bonding potential led to 2 -3 kcal/mol reduction in ground state binding free energy, whereas effects on the maximum rate of polymerization were quite variable, ranging from negligible (dATP: dF) to nearly 4 kcal/mol (dZTP: dT). Although we observed only a 46-fold reduction in discrimination when dF was present in the template, there was a complete elimination of discrimination when dQ was present in the template. Our data with dF indicate that hydrogen bonding contributes 2.2 kcal/mol toward the efficiency of incorporation, whereas data with dQ (which may overestimate the effect due to poor steric mimicry) suggest a contribution of up to 6.8 kcal/mol. Taken together, the data suggest that sterics are necessary but not sufficient to achieve optimal efficiency and fidelity for DNA polymerase. Base pair hydrogen bonding contributes at least a third of the energy underlying nucleoside incorporation efficiency and specificity.	[Lee, Harold R.; Helquist, Sandra A.; Kool, Eric T.; Johnson, Kenneth A.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	University of Texas System; University of Texas Austin; Stanford University	Johnson, KA (corresponding author), Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, 2500 Speedway, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu		Kool, Eric/0000-0002-7310-2935	NIGMS NIH HHS [R01 GM044613-17A1, R01 GM044613, GM 044613, GM 072705] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613, R01GM072705] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2005, STRUCTURE, V13, P1653, DOI 10.1016/j.str.2005.07.020; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GAO JL, 1994, BIOPHYS CHEM, V51, P253, DOI 10.1016/0301-4622(94)00046-8; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Guckian KM, 1997, ANGEW CHEM INT EDIT, V36, P2825, DOI 10.1002/anie.199728251; Guckian KM, 1998, J ORG CHEM, V63, P9652, DOI 10.1021/jo9805100; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim TW, 2006, J BIOL CHEM, V281, P2289, DOI 10.1074/jbc.M510744200; Kim TW, 2005, P NATL ACAD SCI USA, V102, P15803, DOI 10.1073/pnas.0505113102; Kool ET, 2006, CHEM COMMUN, P3665, DOI 10.1039/b605414e; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s; Lee HR, 2008, J BIOL CHEM, V283, P14411, DOI 10.1074/jbc.M705006200; Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200; Morales JC, 2000, BIOCHEMISTRY-US, V39, P12979, DOI 10.1021/bi001578o; Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Potapova O, 2006, BIOCHEMISTRY-US, V45, P890, DOI 10.1021/bi051792i; SCHWEITZER BA, 1994, J ORG CHEM, V59, P7238, DOI 10.1021/jo00103a013; SCHWEITZER BA, 1995, J AM CHEM SOC, V117, P1863, DOI 10.1021/ja00112a001; Spratt TE, 2001, BIOCHEMISTRY-US, V40, P2647, DOI 10.1021/bi002641c; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14402	14410		10.1074/jbc.M705007200	http://dx.doi.org/10.1074/jbc.M705007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	17650502	hybrid, Green Published			2022-12-25	WOS:000255941400027
J	Attard, G; Clark, J; Ambroisine, L; Fisher, G; Kovacs, G; Flohr, P; Berney, D; Foster, CS; Fletcher, A; Gerald, WL; Moller, H; Reuter, V; De Bono, JS; Scardino, P; Cuzick, J; Cooper, CS				Attard, G.; Clark, J.; Ambroisine, L.; Fisher, G.; Kovacs, G.; Flohr, P.; Berney, D.; Foster, C. S.; Fletcher, A.; Gerald, W. L.; Moller, H.; Reuter, V.; De Bono, J. S.; Scardino, P.; Cuzick, J.; Cooper, C. S.		Transatlantic Prostate Grp	Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer	ONCOGENE			English	Article						prostate cancer; ERG gene; ERG gene break point; Gleason score; prognosis	INTEROBSERVER REPRODUCIBILITY; RADICAL PROSTATECTOMY; GLEASON; CARCINOMA; PATHOLOGISTS; GENE; MEN	New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of diagnosis, Gleason score provides the gold standard for assessing the aggressiveness of prostate cancer. However, the recent discovery of TMPRSS2 fusions to the ERG gene in prostate cancer raises the possibility of using alterations at the ERG locus as additional mechanism-based prognostic indicators. Fluorescence in situ hybridization (FISH) assays were used to assess ERG gene status in a cohort of 445 prostate cancers from patients who had been conservatively managed. The FISH assays detected separation of 50 (labelled green) and 30 ( labelled red) ERG sequences, which is a consequence of the TMPRSS2-ERG fusion, and additionally identify interstitial deletion of genomic sequences between the tandemly located TMPRSS2 and ERG gene sequences on chromosome 21. Cancers lacking ERG alterations exhibited favourable cause-specific survival (90% survival at 8 years). We identify a novel category of prostate cancers, characterized by duplication of the fusion of TMPRSS2 to ERG sequences together with interstitial deletion of sequences 50 to ERG (called '2 + Edel'), which by comparison exhibited extremely poor cause-specific survival (hazard ratio 6.10, 95% confidence ratio = 3.33-11.15, P < 0.001, 25% survival at 8 years). In multivariate analysis, '2 + Edel' provided significant prognostic information (P = 0.003) in addition to that provided by Gleason score and prostate-specific antigen level at diagnosis. Other individual categories of ERG alteration were associated with intermediate or good prognosis. We conclude that determination of ERG gene status, including duplication of the fusion of TMPRSS2 to ERG sequences in 2 + Edel, allows strati. cation of prostate cancer into distinct survival categories.	[Attard, G.; Flohr, P.; Fletcher, A.; Cooper, C. S.] Inst Canc Res, Male Urolog Canc Res Ctr, Sutton SM2 5NG, Surrey, England; [Attard, G.; De Bono, J. S.] Royal Marsden NHS Trust Fdn Hosp, Surrey, England; [Ambroisine, L.; Cuzick, J.] Univ London, Wolfson Inst Prevent Med, London, England; [Kovacs, G.] Heidelberg Univ, Fac Med, Mol Oncol Lab, Heidelberg, Germany; [Foster, C. S.] Royal Liverpool Hosp, Dept Pathol, London, England; [Gerald, W. L.; Reuter, V.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Moller, H.] Kings Coll London, Canc Registry, London, England; [Scardino, P.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY USA	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Queen Mary University London; Ruprecht Karls University Heidelberg; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Memorial Sloan Kettering Cancer Center; University of London; King's College London; Memorial Sloan Kettering Cancer Center	Cooper, CS (corresponding author), Inst Canc Res, Male Urolog Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	Colin.Cooper@icr.ac.uk		Attard, Gerhardt/0000-0002-4811-7983; de Bono, Johann S/0000-0002-2034-595X; Berney, Daniel/0000-0001-5474-8696; Moller, Henrik/0000-0001-8200-5929	NATIONAL CANCER INSTITUTE [P50CA092629] Funding Source: NIH RePORTER; MRC [G0501019] Funding Source: UKRI; Medical Research Council [G0501019] Funding Source: Medline; NCI NIH HHS [P50 CA092629-07, P50 CA092629] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adolfsson J, 1997, UROLOGY, V50, P722, DOI 10.1016/S0090-4295(97)00320-8; Albertsen PC, 2005, J NATL CANCER I, V97, P1248, DOI 10.1093/jnci/dji248; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Allsbrook WC, 2001, HUM PATHOL, V32, P74, DOI 10.1053/hupa.2001.21134; Allsbrook WC, 2001, HUM PATHOL, V32, P81, DOI 10.1053/hupa.2001.21135; Bill-Axelson A, 2005, NEW ENGL J MED, V352, P1977, DOI 10.1056/NEJMoa043739; Bostwick D G, 1999, Semin Urol Oncol, V17, P222; Chism DB, 2003, INT J RADIAT ONCOL, V56, P1241, DOI 10.1016/S0360-3016(03)00268-2; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Cox D. R., 1984, ANAL SURVIVAL DATA; Cuzick J, 2006, BRIT J CANCER, V95, P1186, DOI 10.1038/sj.bjc.6603411; DEMICHELIS F, 2007, ONCOGENE; Foster CS, 2000, PROSTATE, P4; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Lambros MBK, 2006, LAB INVEST, V86, P398, DOI 10.1038/labinvest.3700390; Melia J, 2006, HISTOPATHOLOGY, V48, P644, DOI 10.1111/j.1365-2559.2006.02393.x; NAM RK, 2007, CANC BIOL THER; Oyama T, 2005, ARCH PATHOL LAB MED, V129, P1004; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Smith EB, 2002, CANCER-AM CANCER SOC, V94, P2282, DOI 10.1002/cncr.10457; Soller MJ, 2006, GENE CHROMOSOME CANC, V45, P717, DOI 10.1002/gcc.20329; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; van der Kwast TH, 2006, INT J CANCER, V118, P2538, DOI 10.1002/ijc.21667; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Yao SL, 2002, J NATL CANCER I, V94, P958; Yoshimoto M, 2006, NEOPLASIA, V8, P465, DOI 10.1593/neo.06283	33	348	370	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					253	263		10.1038/sj.onc.1210640	http://dx.doi.org/10.1038/sj.onc.1210640			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637754	Green Accepted			2022-12-25	WOS:000252256000001
J	Morimoto, K; Satoh-Yamaguchi, K; Hamaguchi, A; Inoue, Y; Takeuchi, M; Okada, M; Ikeda, W; Takai, Y; Imai, T				Morimoto, K.; Satoh-Yamaguchi, K.; Hamaguchi, A.; Inoue, Y.; Takeuchi, M.; Okada, M.; Ikeda, W.; Takai, Y.; Imai, T.			Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs	ONCOGENE			English	Article						Necl-5; poliovirus receptor; CD226; cancer cell; platelet; metastasis	IMMUNOGLOBULIN SUPERFAMILY; ADHESION; POLIOVIRUS; MIGRATION; DNAM-1; MEMBER; CD155; IDENTIFICATION; PROLIFERATION; INHIBITION	Necl-5 is an immunoglobulin (Ig)-like molecule that was originally identified as a poliovirus receptor and is often upregulated in cancer cells. We recently found that it colocalizes with integrin alpha(v)beta(3) at the leading edges of moving cells and enhances growth factor-induced cell movement and proliferation. Upon cell-cell contact, Necl-5 is removed from the cell surface by its trans-interaction with the cell adhesion molecule nectin-3, resulting in reduced cell movement and proliferation. Here, we investigated the role of Necl-5 in the interaction of cancer cells with platelets. Necl-5 was upregulated in CT26 cells, a colon adenocarcinoma cell line. When CT26 cells were injected into the tail vein of mice, they were arrested in the pulmonary vessels by adhering to platelets and subsequently metastasized to the lungs. Overexpression of Necl-5 in CT26 cells enhanced this metastasis, while inhibition of the trans-interaction of Necl-5 with CD226 by an anti-Necl-5 monoclonal antibody reduced the metastasis. Depletion of platelets by treatment with a rabbit anti-mouse platelet serum reduced the Necl-5-enhanced metastasis in mice. Thus, the trans-interaction of upregulated Necl-5 in cancer cells with its counter-receptor in platelets, probably CD226, is critical for efficient metastasis of cancer cells to the lungs.	[Morimoto, K.; Satoh-Yamaguchi, K.; Hamaguchi, A.; Inoue, Y.; Takeuchi, M.; Okada, M.; Imai, T.] KAN Res Inst Ic, Kobe MI R&D Ctr, Kobe, Hyogo 6500047, Japan; [Ikeda, W.; Takai, Y.] Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka, Japan	KAN Research Institute; Osaka University	Imai, T (corresponding author), KAN Res Inst Ic, Kobe MI R&D Ctr, 6-7-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	imai@kan.eisai.co.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; CRISSMAN JD, 1988, CANCER RES, V48, P4065; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; Fujito T, 2005, J CELL BIOL, V171, P165, DOI 10.1083/jcb.200501090; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hirota T, 2005, ONCOGENE, V24, P2229, DOI 10.1038/sj.onc.1208409; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Kojima H, 2003, J BIOL CHEM, V278, P36748, DOI 10.1074/jbc.M300702200; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nash GF, 2002, LANCET ONCOL, V3, P425, DOI 10.1016/S1470-2045(02)00789-1; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Sherrington PD, 1997, J BIOL CHEM, V272, P21735, DOI 10.1074/jbc.272.35.21735; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Sloan KE, 2005, CANCER RES, V65, P10930, DOI 10.1158/0008-5472.CAN-05-1890; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	31	53	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					264	273		10.1038/sj.onc.1210645	http://dx.doi.org/10.1038/sj.onc.1210645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637752				2022-12-25	WOS:000252256000002
J	Moussa, O; Riker, J; Klein, J; Fraig, M; Halushka, P; Watson, D				Moussa, O.; Riker, Jm; Klein, J.; Fraig, M.; Halushka, Pv; Watson, Dk			Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents	ONCOGENE			English	Article						bladder cancer; thromboxane synthase; chemosensitivity	INTRACELLULAR ACCUMULATION; LINES; CIS-DIAMMINEDICHLOROPLATINUM(II); CARCINOMA; CISPLATIN; APOPTOSIS; A(2); PACLITAXEL; RESISTANCE; MIGRATION	Recently, we reported prognostic significance of thromboxane synthase (TXAS) gene expression in invasive bladder cancer. The positive correlation between elevated TXAS expression and shorter patient survival supports a potential role for TXAS-regulated pathways in tumor metastases. In this study, using immunohistochemical analysis, we found an increased expression of TXAS protein in bladder cancer. Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells with the TXAS inhibitors furegrelate or ozagrel induced an apoptotic effect measured as an increase in caspase-3 activation and cell death, and decreased survivin expression. Pharmacological inhibition of TXAS using the TXAS inhibitor furegrelate increased sensitivity to the chemotherapeutic agents cisplatin and paclitaxel. Molecular inhibition of TXAS expression by siRNA significantly decreased cell growth and migration. In concordance with the pharmacological data, siRNA-mediated reduction of TXAS expression increased sensitivity to cisplatin and paclitaxel in T24 and TCC-SUP cells. In summary, the data support a role for the thromboxane A(2) pathway in the pathogenesis of bladder cancer and the potential utility of modulation of this signaling pathway for cancer chemotherapy.	[Moussa, O.; Riker, Jm; Klein, J.; Watson, Dk] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Moussa, O.; Riker, Jm; Klein, J.; Fraig, M.; Watson, Dk] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Watson, Dk] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Moussa, O (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Room 313,86 Jonathan Lucas St, Charleston, SC 29425 USA.	moussa@musc.edu	Fraig, Mostafa M/I-1670-2016	Fraig, Mostafa M/0000-0003-1119-3672				Bando T, 1997, ANTICANCER RES, V17, P3345; Bando T, 1998, ANTICANCER RES, V18, P1079; Bando T, 1998, ANTICANCER RES, V18, P1085; Bokemeyer C, 1998, WORLD J UROL, V16, P155, DOI 10.1007/s003450050044; Calabro Fabio, 2002, Curr Opin Urol, V12, P441, DOI 10.1097/00042307-200209000-00013; Giese A, 1999, Neuro Oncol, V1, P3, DOI 10.1093/neuonc/1.1.3; Hour TC, 2000, ANTICANCER RES, V20, P3221; Jantke J, 2004, ACTA NEUROCHIR, V146, P483, DOI 10.1007/s00701-004-0238-z; Jariyawat S, 1997, BIOCHEM MOL BIOL INT, V42, P113; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kamath K, 2005, J BIOL CHEM, V280, P12902, DOI 10.1074/jbc.M414477200; Kasahara K, 1996, BRIT J CANCER, V74, P1553, DOI 10.1038/bjc.1996.588; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Moussa O, 2005, CANCER RES, V65, P11581, DOI 10.1158/0008-5472.CAN-05-1622; MURPHY S, 1990, GLIA, V3, P205, DOI 10.1002/glia.440030307; Nie DT, 2004, AM J PATHOL, V164, P429, DOI 10.1016/S0002-9440(10)63133-1; PASCUAL J, 1988, PROSTAG LEUKOTR ESS, V33, P53, DOI 10.1016/0952-3278(88)90123-8; Pradono P, 2002, CANCER RES, V62, P63; Safirstein R, 1985, AM J PHYSIOL, V249, P490; Sakai H, 2006, FEBS LETT, V580, P3368, DOI 10.1016/j.febslet.2006.05.007; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; WALD M, 1989, BIOCHEM PHARMACOL, V38, P3347, DOI 10.1016/0006-2952(89)90633-3; Watkins Gareth, 2005, Int Semin Surg Oncol, V2, P23, DOI 10.1186/1477-7800-2-23; Yoshizato K, 2002, NEUROSURGERY, V50, P343, DOI 10.1097/00006123-200202000-00021	25	34	34	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					55	62		10.1038/sj.onc.1210629	http://dx.doi.org/10.1038/sj.onc.1210629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17603559				2022-12-25	WOS:000252118700006
J	Wells, V; Downward, J; Mallucci, L				Wells, V.; Downward, J.; Mallucci, L.			Functional inhibition of PI3K by the beta GBP molecule suppresses Ras-MAPK signalling to block cell proliferation	ONCOGENE			English	Article						beta GBP; beta-galactoside binding protein; PI3K; Ras; MAPK	GALACTOSIDE-BINDING-PROTEIN; NEGATIVE GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; KINASE; CANCER; ACTIVATION; CHROMOSOME-22; ABNORMALITIES; EXPRESSION; SARCOMA	The mechanisms of signal transduction from cell surface receptors to the interior of the cell are fundamental to the understanding of the role that positive and negative growth factors play in cell physiology and in human diseases. Here, we show that a functional link between phosphatidylinositol-3-OH kinase (PI3K) and Ras is suppressed by the beta-galactoside binding protein (bGBP) molecule, a cytokine and a negative cell-cycle regulator. Ras-mitogen-activated protein kinase (MAPK) signalling is blocked by bGBP owing to its ability to inhibit the p110 catalytic subunit of PI3K, whose basal activity is required for Ras activation. Functional inhibition of p110 by bGBP results in downregulation of PI3K activity, suppression of Ras-GTP loading, consequent loss of MAPK activation and block of cell proliferation. This study sheds light on the molecular mechanisms whereby bGBP can control cell proliferation and, by extension, may potentially control tumorigenesis by controlling PI3K.	[Wells, V.; Mallucci, L.] Kings Coll London, Pharmaceut Sci Res Div, Cell Signalling & Growth Lab, London SE1 9NH, England; [Downward, J.] Canc Res UK, Lincolns Inn Fields Labs, London Res Inst, Signal Transduct Lab, London, England	University of London; King's College London; Cancer Research UK	Mallucci, L (corresponding author), Kings Coll London, Pharmaceut Sci Res Div, Cell Signalling & Growth Lab, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	livio.mallucci@kcl.ac.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; BRIDGE JA, 1990, AM J CLIN PATHOL, V93, P26, DOI 10.1093/ajcp/93.1.26; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Mallucci L, 2003, BIOCHEM PHARMACOL, V66, P1563, DOI 10.1016/S0006-2952(03)00512-4; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; POWIS G, 1994, CANCER RES, V54, P2419; Ravatn R, 2005, CANCER RES, V65, P1631, DOI 10.1158/0008-5472.CAN-04-1970; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; WELLS V, 1992, BIOCHIM BIOPHYS ACTA, V1121, P239, DOI 10.1016/0167-4838(92)90152-4; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	33	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7709	7714		10.1038/sj.onc.1210580	http://dx.doi.org/10.1038/sj.onc.1210580			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17603562				2022-12-25	WOS:000251537800013
J	Lopez, CI; Belmonte, SA; De Blas, GA; Mayorga, LS				Lopez, Cecilia I.; Belmonte, Silvia A.; De Blas, Gerardo A.; Mayorga, Luis S.			Membrane-permeant Rab3A triggers acrosomal exocytosis in living human sperm	FASEB JOURNAL			English	Article						membrane-permeant proteins; arginine-rich peptides; Rab3A; acrosome reaction	ARGININE-RICH PEPTIDES; CELL-PENETRATING PEPTIDES; GTP-BINDING PROTEIN; HUMAN SPERMATOZOA; PLASMA-MEMBRANE; MOUSE SPERM; KINASE-A; TRANSLOCATION; TRANSDUCTION; INVOLVEMENT	The acrosome reaction is a regulated Ca2+-dependent secretion event required for sperm-egg interaction. Previous studies indicate that the process requires Rab3-dependent tethering of membranes, SNARE complex assembly, and Ca2+-mediated activation of synaptotagmin. Sperm are transcriptionally and translationally inactive; hence, most studies of the exocytosis mechanism are limited to membrane-permeant reagents. The effect of proteins involved in exocytosis has been assessed only in permeabilized cells. Polyarginine peptides are a powerful tool for delivering macromolecules to cells. Most reports indicate that membrane translocation of arginine-containing proteins requires endocytosis; therefore, this strategy might not be useful in sperm. However, our results indicate that GST and Rab3A, when fused with an arginine-rich peptide, were able to translocate into sperm. Moreover, membrane-permeant Rab3A initiated exocytosis when prenylated and activated with GTP. We show here that a key event after the cytoplasmic Ca2+ increase caused by progesterone is the activation of Rab3A. When active Rab3A is introduced into sperm, Ca2+ in the extracellular medium and in the cytoplasm is dispensable. However, a Ca2+ efflux from inside the acrosome is still required to achieve exocytosis. In conclusion, arginine-containing proteins can penetrate the sperm plasma membrane and thus are valuable tools to study sperm physiology in intact cells.-Lopez, C. I., Belmonte, S. A., De Blas, G. A., Mayorga, L. S. Membrane-permeant Rab3A triggers acrosomal exocytosis in living human sperm.	Univ Nacl Cuyo, Fac Ciencias Med, Inst Histol & Embriol, Biol Cellulaire & Mol Lab, Mendoza, Argentina	University Nacional Cuyo Mendoza	Mayorga, LS (corresponding author), Casilla Correo 56, RA-5500 Mendoza, Argentina.	lmayorga@fcm.uncu.edu.ar	Belmonte, Silvia Alejandra Alejandra/AAW-5131-2021	Mayorga, Luis S/0000-0002-5995-0671				BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barclay JW, 2005, CELL CALCIUM, V38, P343, DOI 10.1016/j.ceca.2005.06.012; Belmonte SA, 2005, DEV BIOL, V285, P393, DOI 10.1016/j.ydbio.2005.07.001; Branham MAT, 2006, J BIOL CHEM, V281, P8656, DOI 10.1074/jbc.M508854200; Breitbart H, 2003, CELL MOL BIOL, V49, P321; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Cross NL, 1999, MOL REPROD DEV, V53, P92, DOI 10.1002/(SICI)1098-2795(199905)53:1<92::AID-MRD11>3.3.CO;2-H; Darszon A, 2001, DEV BIOL, V240, P1, DOI 10.1006/dbio.2001.0387; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; De Blas GA, 2005, PLOS BIOL, V3, P1801, DOI 10.1371/journal.pbio.0030323; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0; DOWNING MA, 2005, J MORPHOL, V263, P179; Fawcett D. W., 1970, Biol Reprod, V2, P90, DOI 10.1095/biolreprod2.Supplement_2.90; FICHARD JP, 2003, J BIOL CHEM, V278, P585; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Garde J, 1996, FEBS LETT, V391, P263, DOI 10.1016/0014-5793(96)00749-1; Harrison DA, 2000, BIOL REPROD, V62, P811, DOI 10.1095/biolreprod62.3.811; Herrick SB, 2005, J CELL PHYSIOL, V202, P663, DOI 10.1002/jcp.20172; Iida H, 1999, DEV BIOL, V211, P144, DOI 10.1006/dbio.1999.9302; Jimenez-Gonzalez C, 2006, HUM REPROD UPDATE, V12, P253, DOI 10.1093/humupd/dmi050; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Katterle Y, 2004, BRIT J CANCER, V90, P230, DOI 10.1038/sj.bjc.6601506; Kirkman-Brown JC, 2003, DEV BIOL, V259, P71, DOI 10.1016/S0012-1606(03)00137-4; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; MENDOZA C, 1992, J REPROD FERTIL, V95, P755; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Michod D, 2004, ONCOGENE, V23, P8971, DOI 10.1038/sj.onc.1207999; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Narita K, 2005, FASEB J, V19, P1558, DOI 10.1096/fj.04-2714fje; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje; Roggero CM, 2005, DEV BIOL, V285, P422, DOI 10.1016/j.ydbio.2005.07.007; Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; TOMES C, 2006, MOL MECH EXOCYTOSIS, P117; Tomes CN, 2005, MOL HUM REPROD, V11, P43, DOI 10.1093/molehr/gah126; Travis AJ, 2002, J CLIN INVEST, V110, P731, DOI [10.1172/JCI200216392, 10.1172/JCI0216392]; Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Ward CR, 1999, MOL REPROD DEV, V53, P413, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;413::AID-MRD7&gt;3.0.CO;2-W; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084	46	39	40	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4121	4130		10.1096/fj.06-7716com	http://dx.doi.org/10.1096/fj.06-7716com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625073				2022-12-25	WOS:000251283500037
J	Paruch, S; Heinis, M; Lemay, J; Hoeffel, G; Maranon, C; Hosmalin, A; Perianin, A				Paruch, Sylvain; Heinis, Mylene; Lemay, Julie; Hoeffel, Guillaume; Maranon, Conception; Hosmalin, Anne; Perianin, Axel			CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression	FASEB JOURNAL			English	Article						HIV-1 coreceptors; signal transducers; infection	HUMAN-IMMUNODEFICIENCY-VIRUS; PHORBOL-MYRISTATE ACETATE; ACTIVATED PROTEIN-KINASE; CHEMOKINE RECEPTOR CCR5; NF-KAPPA-B; HUMAN-NEUTROPHILS; HTLV-III; T-CELLS; TRANSACTIVATOR GENE; D DEFINES	The chemokine receptor CCR5 plays an important role as an entry gate for the human immunodeficiency virus-1 (HIV-1) and for viral postentry events. Among signal transducers used by chemoattractant receptors, the phosphatidylcholine-specific phospholipase D (PLD) produces large amounts of second messengers in most cell types. However, the relevance of PLD isoforms to CCR5 signaling and HIV-1 infection process remains unexplored. We show here that CCR5 activation by MIP-1 beta in HeLa-MAGI cells triggered a rapid and substantial PLD activity, as assessed by mass choline production. This activity required the activation of ERK1/2-MAP kinases and involved both PLD1 and PLD2. MIP-1 beta also promoted the activation of an HIV-1 long terminal repeat (LTR) by the transactivator Tat in HeLa P4.2 cells through a process involving ERK1/2. Expression of wild-type and catalytically inactive PLDs dramatically boosted and inhibited the LTR activation, respectively, without altering Tat expression. Wild-type and inactive PLDs also respectively potentiated and inhibited HIV-1(BAL) replication in MAGI cells. Finally, in monocytic THP-1 cells, antisense oligo-nucleotides to both PLDs dramatically inhibited the HIV-1 replication. Thus, PLD is activated downstream of ERK1/2 upon CCR5 activation and plays a major role in promoting HIV-1 LTR transactivation and virus replication, which may open novel perspectives to anti-HIV-1 strategies.-Paruch, S., Heinis, M., Lemay, J., Hoeffel, G., Maranon, C., Hosmalin, A., Perianin, A. CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression.	Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Perianin, A (corresponding author), Inst Cochin, Dept Biol Cellulaire, Pavillon G Roussy 5eme Etage, P502, 27, rue du Faubourg, St Jacques, F-75014 Paris, France.	perianin@cochin.inserm.fr	Hoeffel, Guillaume/ABG-4881-2021; Hosmalin, Anne/AAF-8561-2019; C, maranon/E-1484-2013	Hoeffel, Guillaume/0000-0002-2534-4972; Hosmalin, Anne/0000-0001-9021-3488; C, maranon/0000-0002-7827-6301; Lemay, Julie/0000-0002-4029-9911				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arthos J, 2000, J VIROL, V74, P6418, DOI 10.1128/JVI.74.14.6418-6424.2000; Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; Benelli R, 2000, J INFECT DIS, V182, P1643, DOI 10.1086/317597; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BRUNET A, 1994, ONCOGENE, V9, P3379; Bukrinskaya A, 1998, J EXP MED, V188, P2113, DOI 10.1084/jem.188.11.2113; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Djerdjouri B, 1999, BIOCHEM BIOPH RES CO, V264, P371, DOI 10.1006/bbrc.1999.1533; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Gutkind J.S, 2000, SCI STKE; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; Hu QH, 2002, BIOCHEM BIOPH RES CO, V292, P325, DOI 10.1006/bbrc.2002.6675; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; Klebanoff SJ, 1999, BLOOD, V93, P350, DOI 10.1182/blood.V93.1.350.401k18_350_356; Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856; Kutsch O, 2002, J VIROL, V76, P8776, DOI 10.1128/JVI.76.17.8776-8786.2002; Kwan WH, 2005, J VIROL, V79, P7291, DOI 10.1128/JVI.79.12.7291-7299.2005; Kwun HJ, 2003, FEBS LETT, V544, P38, DOI 10.1016/S0014-5793(03)00446-0; LEUNG DW, 1995, P NATL ACAD SCI USA, V92, P4813, DOI 10.1073/pnas.92.11.4813; Lin YL, 2006, AIDS, V20, P1369, DOI 10.1097/01.aids.0000233570.51899.e2; Lin YL, 2002, P NATL ACAD SCI USA, V99, P15590, DOI 10.1073/pnas.242134499; LISCOVITCH M, 1993, J LIPID MEDIATOR, V8, P177; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; Mueller A, 2004, FEBS LETT, V570, P126, DOI 10.1016/j.febslet.2004.04.100; Muthalif MM, 2000, J PHARMACOL EXP THER, V293, P268; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Paruch S, 2005, FASEB J, V19, P142, DOI 10.1096/fj.05-3881fje; Pedruzzi E, 1998, CELL SIGNAL, V10, P481, DOI 10.1016/S0898-6568(97)00174-5; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Pirounaki M, 2000, J VIROL METHODS, V85, P151, DOI 10.1016/S0166-0934(99)00163-9; Powner DJ, 2005, J CELL SCI, V118, P2975, DOI 10.1242/jcs.02432; Rizzi C, 2006, J IMMUNOL, V176, P999, DOI 10.4049/jimmunol.176.2.999; Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180; Su SB, 1999, BLOOD, V93, P3885, DOI 10.1182/blood.V93.11.3885.411k19_3885_3892; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; West MJ, 2001, J VIROL, V75, P8524, DOI 10.1128/JVI.75.18.8524-8537.2001; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	53	13	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4038	4046		10.1096/fj.06-7325com	http://dx.doi.org/10.1096/fj.06-7325com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17627030				2022-12-25	WOS:000251283500028
J	Payne, HL; Connelly, WM; Ives, JH; Lehner, R; Furtmuller, B; Sieghart, W; Tiwari, P; Lucocq, JM; Lees, G; Thompson, CL				Payne, Helen L.; Connelly, William M.; Ives, Jane H.; Lehner, Reinhard; Furtmuller, Birgit; Sieghart, Werner; Tiwari, Priyanka; Lucocq, John M.; Lees, George; Thompson, Christopher L.			GABA(A) alpha 6-containing receptors are selectively compromised in cerebellar granule cells of the ataxic mouse, stargazer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPORAL-LOBE EPILEPSY; SUBUNIT MESSENGER-RNAS; NEUROTROPHIC FACTOR; DELTA-SUBUNIT; A RECEPTOR; MUTANT MOUSE; QUANTITATIVE IMPORTANCE; POSTNATAL-DEVELOPMENT; SYNAPTIC INHIBITION; BETA-3 SUBUNITS	Stargazer mice fail to express the gamma 2 isoform of transmembrane alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate ( AMPA) receptor regulatory proteins that has been shown to be absolutely required for the trafficking and synaptic targeting of excitatory AMPA receptors in adult murine cerebellar granule cells. Here we show that 30 +/- 6% fewer inhibitory gamma-aminobutyric acid, type A (GABA(A)), receptors were expressed in adult stargazer cerebellum compared with controls because of a specific loss of GABAA receptor expression in the cerebellar granule cell layer. Radioligand binding assays allied to in situ immunogold-EM analysis and furosemide-sensitive tonic current estimates revealed that expression of the extrasynaptic (alpha 6 beta x delta) alpha 6-containing GABA(A) receptor were markedly and selectively reduced in stargazer. These observations were compatible with a marked reduction in expression of GABAA receptor alpha 6,delta (mature cerebellar granule cell-specific proteins), and beta 3 subunit expression in stargazer. The subunit composition of the residual alpha 6-containing GABA(A) receptors was unaffected by the stargazer mutation. However, we did find evidence of an similar to 4-fold up-regulation of alpha 1 beta delta receptors that may compensate for the loss of alpha 6-containing GABA(A) receptors. PCR analysis identified a dramatic reduction in the steady-state level of alpha 6 mRNA, compatible with alpha 6 being the primary target of the stargazer mutation-mediated GABAA receptor abnormalities. We propose that some aspects of assembly, trafficking, targeting, and/or expression of extrasynaptic alpha 6-containing GABA(A) receptors in cerebellar granule cells are selectively regulated by AMPA receptor-mediated signaling.	Univ Durham, Sch Biol & Biomed Sci, Sci Res Labs, Durham DH1 3LE, England; Med Univ Vienna, Ctr Brain Res, Vienna, Austria; Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, A-1090 Vienna, Austria; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Otago, Sch Med Sci, Dept Pharmacol & Toxicol, Dunedin, New Zealand	Durham University; Medical University of Vienna; University of Vienna; University of Dundee; University of Otago	Payne, HL (corresponding author), Univ Durham, Sch Biol & Biomed Sci, Sci Res Labs, South Rd, Durham DH1 3LE, England.	H.L.Payne@durham.ac.uk	Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302; Connelly, William/0000-0002-0986-6260; lucocq, john/0000-0002-5191-0093	Austrian Science Fund FWF [P 17203] Funding Source: Medline; Medical Research Council [G0401395] Funding Source: Medline; Wellcome Trust [066204, 0543478, 059767/Z99/Z] Funding Source: Medline; MRC [G0401395] Funding Source: UKRI	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Brickley SG, 1999, J NEUROSCI, V19, P2960; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Bulleit RF, 2000, DEV BRAIN RES, V119, P1, DOI 10.1016/S0165-3806(99)00119-4; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen L, 1999, P NATL ACAD SCI USA, V96, P12132, DOI 10.1073/pnas.96.21.12132; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; DRESCHER DG, 1993, J NEUROCHEM, V61, P1167, DOI 10.1111/j.1471-4159.1993.tb03638.x; Elmariah SB, 2004, J NEUROSCI, V24, P2380, DOI 10.1523/JNEUROSCI.4112-03.2004; Gault LM, 1997, J NEUROSCI, V17, P2391; Gault LM, 1998, J NEUROCHEM, V70, P1907; Hamann M, 2002, NEURON, V33, P625, DOI 10.1016/S0896-6273(02)00593-7; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Heynen AJ, 2000, NEURON, V28, P527, DOI 10.1016/S0896-6273(00)00130-6; Ives JH, 2004, J BIOL CHEM, V279, P31002, DOI 10.1074/jbc.M402214200; Ives JH, 2002, NEUROPHARMACOLOGY, V43, P715, DOI 10.1016/S0028-3908(02)00164-8; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jones A, 1997, J NEUROSCI, V17, P1350; Jovanovic JN, 2004, J NEUROSCI, V24, P522, DOI 10.1523/JNEUROSCI.3606-03.2004; KORPI ER, 1995, MOL PHARMACOL, V47, P283; KORPI ER, 1993, NEUROSCIENCE, V53, P483, DOI 10.1016/0306-4522(93)90212-X; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; Leroy C, 2004, J PHYSIOL-LONDON, V557, P473, DOI 10.1113/jphysiol.2003.059246; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCOCQ J, 1994, J ANAT, V184, P1; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Nusser Z, 1998, J NEUROSCI, V18, P1693; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Poltl A, 2003, J NEUROCHEM, V87, P1444, DOI 10.1046/j.1471-4159.2003.02135.x; QIAO X, 1998, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Rouach N, 2005, NAT NEUROSCI, V8, P1525, DOI 10.1038/nn1551; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; SLANY A, 1995, MOL PHARMACOL, V48, P385; Suzuki K, 2005, J NEUROSCI, V25, P9535, DOI 10.1523/JNEUROSCI.2191-05.2005; Thompson CL, 1996, NEUROPHARMACOLOGY, V35, P1337, DOI 10.1016/S0028-3908(96)00114-1; Thompson CL, 2000, NEUROSCI LETT, V283, P85, DOI 10.1016/S0304-3940(00)00930-7; Thompson CL, 1998, MOL BRAIN RES, V60, P282, DOI 10.1016/S0169-328X(98)00205-8; THOMPSON CL, 1994, J NEUROCHEM, V62, P2037; Tia S, 1996, J NEUROSCI, V16, P3630; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Tretter V, 1997, J NEUROSCI, V17, P2728; Wafford KA, 1996, MOL PHARMACOL, V50, P670; Yamada MK, 2002, J NEUROSCI, V22, P7580; ZHENG T, 1993, DEV BRAIN RES, V75, P91, DOI 10.1016/0165-3806(93)90068-L	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29130	29143		10.1074/jbc.M700111200	http://dx.doi.org/10.1074/jbc.M700111200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17646167	hybrid, Green Accepted			2022-12-25	WOS:000249788000008
J	Hong, BS; Senisterra, G; Rabeh, WM; Vedadi, M; Leonardi, R; Zhang, YM; Rock, CO; Jackowski, S; Park, HW				Hong, Bum Soo; Senisterra, Guillermo; Rabeh, Wael M.; Vedadi, Masoud; Leonardi, Roberta; Zhang, Yong-Mei; Rock, Charles O.; Jackowski, Suzanne; Park, Hee-Won			Crystal structures of human pantothenate kinases - Insights into allosteric regulation and mutations linked to a neurodegeneration disordew	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN IRON ACCUMULATION; HALLERVORDEN-SPATZ-SYNDROME; SURFACE SALT BRIDGES; COENZYME-A; PROTEIN STABILITY; FEEDBACK-REGULATION; ESCHERICHIA-COLI; BINDING; PANK2; FOLD	Pantothenate kinase (PanK) catalyzes the first step in CoA biosynthesis and there are three human genes that express four isoforms with highly conserved catalytic core domains. Here we report the homodimeric structures of the catalytic cores of PanK1 alpha and PanK3 in complex with acetyl-CoA, a feedback inhibitor. Each monomer adopts a fold of the actin kinase superfamily and the inhibitor-bound structures explain the basis for the allosteric regulation by CoA thiciesters. These structures also provide an opportunity to investigate the structural effects of the PanK2 mutations that have been implicated in neurodegeneration. Biochemical and thermodynamic analyses of the PanK3 mutant proteins corresponding to PanK2 mutations show that mutant proteins with compromised activities and/or stabilities correlate with a higher incidence of the early onset of disease.	Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5G 1L5, Canada; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	University of Toronto; Structural Genomics Consortium; University of Toronto; St Jude Children's Research Hospital	Park, HW (corresponding author), Univ Toronto, Struct Genom Consortium, 100 Coll St, Toronto, ON M5G 1L5, Canada.	heewon.park@utoronto.ca	Rabeh, Wael/AAO-4647-2020; Jackowski, Suzanne/N-8168-2018	Rabeh, Wael/0000-0001-6071-8581; Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM062896, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM62896, GM34496] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Das S, 2006, ACTA CRYSTALLOGR D, V62, P628, DOI 10.1107/S0907444906012728; Gregory A, 2005, FOLIA NEUROPATHOL, V43, P286, DOI 10.1016/B978-0-444-63233-3.00019-1; Hartig MB, 2006, ANN NEUROL, V59, P248, DOI 10.1002/ana.20771; Hayflick SJ, 2003, NEW ENGL J MED, V348, P33, DOI 10.1056/NEJMoa020817; Hong BS, 2006, STRUCTURE, V14, P1251, DOI 10.1016/j.str.2006.06.008; Hortnagel K, 2003, HUM MOL GENET, V12, P321, DOI 10.1093/hmg/ddg026; Ivey RA, 2004, J BIOL CHEM, V279, P35622, DOI 10.1074/jbc.M403152200; Johnson MA, 2004, ANN NY ACAD SCI, V1012, P282, DOI 10.1196/annals.1306.023; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Kotzbauer PT, 2005, J NEUROSCI, V25, P689, DOI 10.1523/JNEUROSCI.4265-04.2005; Lee CF, 2005, BIOCHEMISTRY-US, V44, P16817, DOI 10.1021/bi0519654; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Leonardi R, 2005, J BIOL CHEM, V280, P3314, DOI 10.1074/jbc.M411608200; Leonardi R, 2007, P NATL ACAD SCI USA, V104, P1494, DOI 10.1073/pnas.0607621104; Lindman S, 2006, BIOPHYS J, V90, P2911, DOI 10.1529/biophysj.105.071050; Makhatadze GI, 2003, J MOL BIOL, V327, P1135, DOI 10.1016/S0022-2836(03)00233-X; Matulis D, 2005, BIOCHEMISTRY-US, V44, P5258, DOI 10.1021/bi048135v; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pokkuluri PR, 2002, BIOPHYS J, V82, P391, DOI 10.1016/S0006-3495(02)75403-9; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sarver RW, 2002, J BIOMOL SCREEN, V7, P21, DOI 10.1177/108705710200700104; Schwehm JM, 1998, BIOPHYS J, V74, pA234; Senisterra GA, 1997, BIOCHEMISTRY-US, V36, P11002, DOI 10.1021/bi9711590; Senisterra GA, 2006, J BIOMOL SCREEN, V11, P940, DOI 10.1177/1087057106294699; SONG WJ, 1994, J BIOL CHEM, V269, P27051; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; Stadtman ER, 2003, ANTIOXID REDOX SIGN, V5, P577, DOI 10.1089/152308603770310239; Strop P, 2000, BIOCHEMISTRY-US, V39, P1251, DOI 10.1021/bi992257j; Takano K, 1999, BIOCHEMISTRY-US, V38, P6623, DOI 10.1021/bi9901228; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thomas M, 2004, MOVEMENT DISORD, V19, P36, DOI 10.1002/mds.10650; Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang K, 2006, J BACTERIOL, V188, P5532, DOI 10.1128/JB.00469-06; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhang YM, 2006, J BIOL CHEM, V281, P107, DOI 10.1074/jbc.M508825200; Zhang YM, 2005, J BIOL CHEM, V280, P32594, DOI 10.1074/jbc.M506275200; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572	46	63	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27984	27993		10.1074/jbc.M701915200	http://dx.doi.org/10.1074/jbc.M701915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17631502	hybrid			2022-12-25	WOS:000249455600048
J	Davies, JQ; Chang, GW; Yona, S; Gordon, S; Stacey, M; Lin, HH				Davies, John Q.; Chang, Gin-Wen; Yona, Simon; Gordon, Siamon; Stacey, Martin; Lin, Hsi-Hsien			The role of receptor oligomerization in modulating the expression and function of leukocyte adhesion-G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; EGF-TM7 FAMILY; SURFACE EXPRESSION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PLANAR POLARITY; CELLULAR LIGAND; SECRETIN FAMILY; HUMAN EMR2; GROWTH	The human leukocyte adhesion-G protein-coupled receptors (GPCRs), the epidermal growth factor (EGF)-TM7 proteins, are shown here to function as homo- and hetero-oligomers. Using cell surface cross-linking, co-immunoprecipitation, and fluorescence resonance energy transfer analysis of EMR2, an EGF-TM7 receptor predominantly expressed in myeloid cells, we demonstrate that it forms dimers in a reaction mediated exclusively by the TM7 moiety. We have also identified a naturally occurring but structurally unstable EMR2 splice variant that acts as a dominant negative modulator by dimerizing with the wild type receptor and down-regulating its expression. Additionally, heterodimerization between closely related EGF-TM7 members is shown to result in the modulation of expression and ligand binding properties of the receptors. These findings suggest that receptor homo- and hetero-oligomerization play a regulatory role in modulating the expression and function of leukocyte adhesion-GPCRs.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Chang Gung Univ, Coll Med, Dept Microbiol & Immunol, Tao Yuan, Taiwan	University of Oxford; Chang Gung University	Stacey, M (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	martin.stacey@path.ox.ac.uk; hhlin@mail.cgu.edu.tw	LIN, Hsi-Hsien/N-1488-2015; Yona, Simon/ABE-6572-2020	Yona, Simon/0000-0002-3984-2008	MRC [G0500623] Funding Source: UKRI; Medical Research Council [G0500623] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Boanca G, 2007, J BIOL CHEM, V282, P534, DOI 10.1074/jbc.M607694200; Chang GW, 2007, BIOCHEM BIOPH RES CO, V353, P133, DOI 10.1016/j.bbrc.2006.11.148; Chang GW, 2003, FEBS LETT, V547, P145, DOI 10.1016/S0014-5793(03)00695-1; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Davies B, 2004, MOL CELL BIOL, V24, P8642, DOI 10.1128/MCB.24.19.8642-8648.2004; FRASER CM, 1982, BIOCHEM BIOPH RES CO, V109, P21, DOI 10.1016/0006-291X(82)91560-1; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Kwakkenbos MJ, 2006, FASEB J, V20, P2582, DOI 10.1096/fj.06-6500fje; Kwakkenbos MJ, 2004, IMMUNOGENETICS, V55, P655, DOI 10.1007/s00251-003-0625-2; Kwakkenbos MJ, 2002, J LEUKOCYTE BIOL, V71, P854; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; Lippiat JD, 2002, DIABETES, V51, pS377, DOI 10.2337/diabetes.51.2007.S377; Lu BW, 1999, CURR BIOL, V9, P1247, DOI 10.1016/S0960-9822(99)80505-3; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Michalska K, 2006, J MOL BIOL, V360, P105, DOI 10.1016/j.jmb.2006.04.066; Milligan G, 2004, SEMIN CELL DEV BIOL, V15, P263, DOI 10.1016/j.semcdb.2003.12.012; Milligan G, 2003, LIFE SCI, V74, P181, DOI 10.1016/j.lfs.2003.09.005; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Okada T, 2006, P NATL ACAD SCI USA, V103, P6471, DOI 10.1073/pnas.0511020103; Okada T, 2007, J BIOL CHEM, V282, P2433, DOI 10.1074/jbc.M607490200; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Sarmiento JM, 2004, J BIOL CHEM, V279, P47017, DOI 10.1074/jbc.M410011200; Seck T, 2003, J BIOL CHEM, V278, P23085, DOI 10.1074/jbc.M211280200; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Shima Y, 2004, DEV CELL, V7, P205, DOI 10.1016/j.devcel.2004.07.007; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Volynski KE, 2004, EMBO J, V23, P4423, DOI 10.1038/sj.emboj.7600443; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Wang YM, 2003, J BIOL CHEM, V278, P3210, DOI 10.1074/jbc.M210431200; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; Zal T, 2002, IMMUNITY, V16, P521, DOI 10.1016/S1074-7613(02)00301-1	56	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27343	27353		10.1074/jbc.M704096200	http://dx.doi.org/10.1074/jbc.M704096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17620333	hybrid			2022-12-25	WOS:000249304900076
J	Koropatkin, N; Randich, AM; Bhattacharyya-Pakrasi, M; Pakrasi, HB; Smith, TJ				Koropatkin, Nicole; Randich, Amelia M.; Bhattacharyya-Pakrasi, Maitrayee; Pakrasi, Himadri B.; Smith, Thomas J.			The structure of the iron-binding protein, FutA1, from Synechocystis 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC TRANSPORT PROTEIN; CRYSTAL-STRUCTURE; FERRIC REDUCTASE; METAL-BINDING; ANION; NEISSERIA; MANGANESE; SYSTEM	Cyanobacteria account for a significant percentage of aquatic primary productivity even in areas where the concentrations of essential micronutrients are extremely low. To better understand the mechanism of iron selectivity and transport, the structure of the solute binding domain of an ATP binding cassette iron transporter, FutA1, was determined in the presence and absence of iron. The iron ion is bound within the "C-clamp" structure via four tyrosine and one histidine residues. There are extensive interactions between these ligating residues and the rest of the protein such that the conformations of the side chains remain relatively unchanged as the iron is released by the opening of the metal binding cleft. This is in stark contrast to the zinc-binding protein, ZnuA, where the domains of the metalbinding protein remain relatively fixed, whereas the ligating residues rotate out of the binding pocket upon metal release. The rotation of the domains in FutA1 is facilitated by two flexible beta-strands running along the back of the protein that act like a hinge during domain motion. This motion may require relatively little energy since total contact area between the domains is the same whether the protein is in the open or closed conformation. Consistent with the pH dependence of iron binding, the main trigger for iron release is likely the histidine in the iron-binding site. Finally, neither FutA1 nor FutA2 binds iron as a siderophore complex or in the presence of anions, and both preferentially bind ferrous over ferric ions.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA	Donald Danforth Plant Science Center; Washington University (WUSTL)	Smith, TJ (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	tsmith@danforthcenter.org	Randich, Amelia/AAY-8606-2020; Smith, Thomas J/K-9086-2013	Randich, Amelia/0000-0002-5172-7280; Smith, Thomas J/0000-0003-3528-6793	NIGMS NIH HHS [GM 078800] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM078800] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee S, 2003, J MOL BIOL, V333, P1061, DOI 10.1016/j.jmb.2003.09.008; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Borer PM, 2005, MAR CHEM, V93, P179, DOI 10.1016/j.marchem.2004.08.006; Bouige P, 2002, CURR PROTEIN PEPT SC, V3, P541, DOI 10.2174/1389203023380486; Bruker, 1997, SMART SAINT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Crichton R R, 1990, Adv Protein Chem, V40, P281, DOI 10.1016/S0065-3233(08)60288-0; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Gould S. J., 2001, BOOK LIFE ILLUSTRATE; Guo ML, 2003, J BIOL CHEM, V278, P2490, DOI 10.1074/jbc.M208776200; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Hantke K, 2001, BIOMETALS, V14, P239, DOI 10.1023/A:1012984713391; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katoh H, 2001, PLANT CELL PHYSIOL, V42, P823, DOI 10.1093/pcp/pce106; Khan AG, 2007, BIOCHEM J, V403, P43, DOI 10.1042/BJ20061589; King GM, 1999, APPL ENVIRON MICROB, V65, P4393; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rukhman V, 2005, J MOL BIOL, V348, P961, DOI 10.1016/j.jmb.2005.03.006; SHERIFF S, 1985, P NATL ACAD SCI USA, V82, P1104, DOI 10.1073/pnas.82.4.1104; Shouldice SR, 2004, J BACTERIOL, V186, P3903, DOI 10.1128/JB.186.12.3903-3910.2004; Smith TJ, 2004, J APPL CRYSTALLOGR, V37, P654, DOI 10.1107/S0021889804009859; Takeda K, 2007, FEBS J, V274, P1318, DOI 10.1111/j.1742-4658.2007.05680.x; Tom-Yew SAL, 2005, J BIOL CHEM, V280, P9283, DOI 10.1074/jbc.M412479200; VOGEL AI, 1963, TXB QUANTITATIVE INO, P3899; Waldron KJ, 2007, J BIOL CHEM, V282, P3837, DOI 10.1074/jbc.M609916200; Wei BX, 2007, BIOCHEMISTRY-US, V46, P8734, DOI 10.1021/bi700763w; Zarnowski R, 2005, MICROBIOL-SGM, V151, P2233, DOI 10.1099/mic.0.27918-0	35	28	30	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27468	27477		10.1074/jbc.M704136200	http://dx.doi.org/10.1074/jbc.M704136200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626019	hybrid			2022-12-25	WOS:000249304900088
J	Li, JQ; Poulikakos, PI; Dai, ZP; Testa, JR; Callaway, DJE; Bu, ZM				Li, Jianquan; Poulikakos, Poulikos I.; Dai, Zhongping; Testa, Joseph R.; Callaway, David J. E.; Bu, Zimei			Protein kinase c phosphorylation disrupts Na+/H+ exchanger regulatory factor 1 autoinhibition and promotes cystic fibrosis transmembrane conductance regulator macromolecular assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; PDZ DOMAINS; BETA(2)-ADRENERGIC RECEPTOR; BIOLOGICAL MACROMOLECULES; FUNCTIONAL EXPRESSION; COUPLED RECEPTORS; ADAPTER PROTEINS; STRUCTURAL BASIS; MOLECULAR-BASIS; P2Y1 RECEPTOR	An emerging theme in cell signaling is that membrane-bound channels and receptors are organized into supramolecular signaling complexes for optimum function and cross-talk. In this study, we determined how protein kinase C (PKC) phosphorylation influences the scaffolding protein Na+/H+ exchanger regulatory factor 1 (NHERF) to assemble protein complexes of cystic fibrosis transmembrane conductance regulator ( CFTR), a chloride ion channel that controls fluid and electrolyte transport across cell membranes. NHERF directs polarized expression of receptors and ion transport proteins in epithelial cells, as well as organizes the homo- and hetero-association of these cell surface proteins. NHERF contains two modular PDZ domains that are modular protein-protein interaction motifs, and a C-terminal domain. Previous studies have shown that NHERF is a phosphoprotein, but how phosphorylation affects NHERF to assemble macromolecular complexes is unknown. We show that PKC phosphorylates two amino acid residues Ser-339 and Ser-340 in the C-terminal domain of NHERF, but a serine 162 of PDZ2 is specifically protected from being phosphorylated by the intact C-terminal domain. PKC phosphorylation-mimicking mutant S339D/S340D of NHERF has increased affinity and stoichiometry when binding to C-CFTR. Moreover, solution small angle x-ray scattering indicates that the PDZ2 and C-terminal domains contact each other in NHERF, but such intramolecular domain-domain interactions are released in the PKC phosphorylation-mimicking mutant indicating that PKC phosphorylation disrupts the autoinhibition interactions in NHERF. The results demonstrate that the C-terminal domain of NHERF functions as an intramolecular switch that regulates the binding capability of PDZ2, and thus controls the stoichiometry of NHERF to assemble protein complexes.	Fox Chase Canc Ctr, Div Populat Sci, Div Basic Sci, Philadelphia, PA 19111 USA; NYU, Sch Med, New York, NY 10016 USA	Fox Chase Cancer Center; New York University	Bu, ZM (corresponding author), Fox Chase Canc Ctr, Div Populat Sci, Div Basic Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Zimei.bu@fccc.edu			NCI NIH HHS [CA 06927, CA 114047] Funding Source: Medline; NHLBI NIH HHS [R01 HL 086496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA114047, P30CA006927] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Biemans-Oldehinkel E, 2006, FEBS LETT, V580, P1023, DOI 10.1016/j.febslet.2005.11.079; Bossard F, 2007, AM J PHYSIOL-LUNG C, V292, pL1085, DOI 10.1152/ajplung.00445.2005; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bu ZM, 1999, BIOPHYS J, V77, P1064, DOI 10.1016/S0006-3495(99)76956-0; Bu ZM, 1998, J APPL CRYSTALLOGR, V31, P533, DOI 10.1107/S0021889897015422; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Chappe V, 2004, P NATL ACAD SCI USA, V101, P390, DOI 10.1073/pnas.0303411101; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Deliot N, 2005, AM J PHYSIOL-CELL PH, V289, pC159, DOI 10.1152/ajpcell.00456.2004; Donowitz M, 2005, J PHYSIOL-LONDON, V567, P3, DOI 10.1113/jphysiol.2005.090399; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Duan DY, 2005, ACTA PHARMACOL SIN, V26, P265, DOI 10.1111/j.1745-7254.2005.00061.x; Engelman DM, 2005, NATURE, V438, P578, DOI 10.1038/nature04394; ENGELMAN DM, 1975, ANNU REV BIOPHYS BIO, V4, P219, DOI 10.1146/annurev.bb.04.060175.001251; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fouassier L, 2005, EXP CELL RES, V306, P264, DOI 10.1016/j.yexcr.2005.02.011; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Glatter von O., 1982, SMALL ANGLE XRAY SCA, P167; Guerra L, 2005, J BIOL CHEM, V280, P40925, DOI 10.1074/jbc.M505103200; Guerra L, 2004, PFLUG ARCH EUR J PHY, V449, P66, DOI 10.1007/s00424-004-1293-2; Guggino WB, 2004, AM J RESP CRIT CARE, V170, P815, DOI 10.1164/rccm.200403-381WS; GUGIGNO WB, 2006, NAT REV MOL CELL BIO, V7, P426; Haggie PM, 2004, J BIOL CHEM, V279, P5494, DOI 10.1074/jbc.M312445200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harris BZ, 2001, J CELL SCI, V114, P3219; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Ho DL, 2004, J BIOL CHEM, V279, P39146, DOI 10.1074/jbc.M404565200; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Karthikeyan S, 2002, J BIOL CHEM, V277, P18973, DOI 10.1074/jbc.M201507200; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Lamprecht G, 2006, AM J PHYSIOL-GASTR L, V291, pG766, DOI 10.1152/ajpgi.00135.2006; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lederer ED, 2003, J AM SOC NEPHROL, V14, P1711, DOI 10.1097/01.ASN.0000072744.67971.21; Li CY, 2004, J BIOL CHEM, V279, P24673, DOI 10.1074/jbc.M400688200; Li JQ, 2005, J BIOL CHEM, V280, P37634, DOI 10.1074/jbc.M502305200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mazzochi C, 2006, AM J PHYSIOL-RENAL, V291, pF1113, DOI 10.1152/ajprenal.00195.2006; Middleton LM, 1998, AM J PHYSIOL-CELL PH, V275, pC293, DOI 10.1152/ajpcell.1998.275.1.C293; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Riordan JR, 2005, ANNU REV PHYSIOL, V67, P701, DOI 10.1146/annurev.physiol.67.032003.154107; RIORDAN JR, 1989, SCIENCE, V245, P1066; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Terawaki S, 2006, STRUCTURE, V14, P777, DOI 10.1016/j.str.2006.01.015; Thelin WR, 2005, J PHYSIOL-LONDON, V567, P13, DOI 10.1113/jphysiol.2005.091041; VANHOLDE KE, 1998, PRINCIPLES PHYS BIOC, P328; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Walther D, 2000, J APPL CRYSTALLOGR, V33, P350, DOI 10.1107/S0021889899015976; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; WESLH MJ, 1995, SCI AM, V273, P52; Wiehe K, 2005, PROTEINS, V60, P207, DOI 10.1002/prot.20559; Wriggers W, 2001, J STRUCT BIOL, V133, P193, DOI 10.1006/jsbi.2000.4350; Yamazaki J, 1999, BIOPHYS J, V76, P1972, DOI 10.1016/S0006-3495(99)77356-X; Yoo D, 2004, J BIOL CHEM, V279, P6863, DOI 10.1074/jbc.M311599200	85	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27086	27099		10.1074/jbc.M702019200	http://dx.doi.org/10.1074/jbc.M702019200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17613530	hybrid			2022-12-25	WOS:000249304900050
J	Treede, I; Braun, A; Sparla, R; Kuhnel, M; Giese, T; Turner, JR; Anes, E; Kulaksiz, H; Fullekrug, J; Stremmel, W; Griffiths, G; Ehehalt, R				Treede, Irina; Braun, Annika; Sparla, Richard; Kuehnel, Mark; Giese, Thomas; Turner, Jerrold R.; Anes, Elsa; Kulaksiz, Hasan; Fuellekrug, Joachim; Stremmel, Wolfgang; Griffiths, Gareth; Ehehalt, Robert			Anti-inflammatory effects of phosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INFLAMMATORY-BOWEL-DISEASE; FACTOR-ALPHA; KAPPA-B; ULCERATIVE-COLITIS; EPITHELIAL-CELLS; MUCOSAL BARRIER; GASTRIC-MUCOSA; FATTY-ACIDS; TNF-ALPHA	We recently showed that mucus from patients with ulcerative colitis, a chronic inflammatory disorder of the colon, is characterized by a low level of phosphatidylcholine (PC) while clinical studies reveal that therapeutic addition of PC using slow release preparations is beneficial. The positive role of PC in this disease is still elusive. Here we tested the hypothesis that exogenous application of PC has anti-inflammatory properties using three model systems. First, human Caco-2 cells were treated with tumor necrosis factor-alpha (TNF-alpha) to induce a pro-inflammatory response via activation of NF-kappa B. Second, latex bead phagosomes were analyzed for their ability to assemble actin in vitro, a process linked to pro-inflammatory signaling and correlating with the growth versus killing of mycobacteria in macrophages. The third system used was the rapid assembly of plasma membrane actin in macrophages in response to sphingosine 1-phosphate. TNF-alpha induced a pro-inflammatory response in Caco-2 cells, including 1) assembly of plasma membrane actin; 2) activation of both MAPKs ERK and p38; 3) transport of NF-kappa B subunits to the nucleus; and 4) subsequent up-regulation of the synthesis of pro-inflammatory gene products. Exogenous addition of most PCs tested significantly inhibited these processes. Other phospholipids like sphingomyelin or phosphatidylethanolamine showed no effects in these assays . PC also inhibited latex bead phagosome actin assembly, the killing of Mycobacterium tuberculosis in macrophages, and the sphingosine 1-phosphate-induced actin assembly in macrophages. TNF-alpha induces the activation of signaling molecules and the reorganization of the actin cytoskeleton in human intestinal cells. Exogenous application of PC blocks pro-inflammatory signaling in Caco-2 cells, in phagosomes in vitro and facilitates intracellular survival of mycobacteria. We provide further evidence that actin assembly by membranes is part of the pro-inflammatory response. Collectively, these results provide a molecular foundation for the clinical studies showing a beneficial effect of PC therapy in ulcerative colitis.	Univ Hosp Heidelberg, Dept Gastroenterol, D-69120 Heidelberg, Germany; European Mol Biol Lab, Cell Biol Program, D-69117 Heidelberg, Germany; Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany; Univ Lisbon, Fac Pharm, URIA, Mol Pathogenesis Ctr, P-1600083 Lisbon, Portugal; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; Universidade de Lisboa; University of Chicago	Ehehalt, R (corresponding author), Univ Hosp Heidelberg, Dept Gastroenterol, INF 345, D-69120 Heidelberg, Germany.	robert_ehehalt@med.uni-heidelberg.de	Anes, Elsa/K-3124-2013; Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009; iMed.ULisboa, HPI/B-4239-2014; Füllekrug, Joachim/A-6581-2008	Anes, Elsa/0000-0001-5934-0198; Turner, Jerrold R/0000-0003-0627-9455; iMed.ULisboa, HPI/0000-0001-5934-0198; Ehehalt, Robert/0000-0003-4252-5801; Stremmel, Wolfgang/0000-0002-8545-1753	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061931, R01DK068271] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061931-07, R01 DK068271-03, R01 DK061931, R01 DK068271] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Anes E, 2006, CELL MICROBIOL, V8, P939, DOI 10.1111/j.1462-5822.2005.00675.x; Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036; ASLAN A, 1992, AM J GASTROENTEROL, V87, P432; Barrios JM, 2000, GASTROENTEROLOGY, V118, P1179, DOI 10.1016/S0016-5085(00)70371-4; Belluzzi A, 2002, P NUTR SOC, V61, P391, DOI 10.1079/PNS2002171; Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; BENGMARK S, 1995, JPEN-PARENTER ENTER, V19, P410, DOI 10.1177/0148607195019005410; BERNHARD W, 1995, BBA-LIPID LIPID MET, V1255, P99, DOI 10.1016/0005-2760(94)00221-J; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; BUTLER BD, 1983, AM J PHYSIOL, V244, pG645, DOI 10.1152/ajpgi.1983.244.6.G645; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; DESCHRYVERKECSKEMETI K, 1989, J CLIN INVEST, V84, P1355, DOI 10.1172/JCI114306; DIAL EJ, 1984, GASTROENTEROLOGY, V87, P379; DUNJIC BS, 1993, SCAND J GASTROENTERO, V28, P89, DOI 10.3109/00365529309096051; Ehehalt R, 2004, SCAND J GASTROENTERO, V39, P737, DOI 10.1080/00365520410006233; ELHARIRI LM, 1992, J PHARM PHARMACOL, V44, P651, DOI 10.1111/j.2042-7158.1992.tb05487.x; FABIA R, 1992, DIGESTION, V53, P35, DOI 10.1159/000200969; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fish SM, 1999, GUT, V45, P191, DOI 10.1136/gut.45.2.191; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hanauer Stephen B, 2003, Rev Gastroenterol Disord, V3, P81; HILLS BA, 1989, GASTROENTEROLOGY, V97, P294, DOI 10.1016/0016-5085(89)90064-4; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kaiser GC, 1997, GASTROENTEROLOGY, V112, P1231, DOI 10.1016/S0016-5085(97)70135-5; KAO YCJ, 1991, GASTROENTEROLOGY, V101, P7, DOI 10.1016/0016-5085(91)90454-S; KIVILUOTO T, 1991, GASTROENTEROLOGY, V100, P38, DOI 10.1016/0016-5085(91)90580-E; Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218; Koukouritaki SB, 1999, MOL MED, V5, P382, DOI 10.1007/BF03402127; LICHTENBERGER LM, 1983, SCIENCE, V219, P1327, DOI 10.1126/science.6828859; LICHTENBERGER LM, 1995, ANNU REV PHYSIOL, V57, P565, DOI 10.1146/annurev.ph.57.030195.003025; Lichtenstein GR, 2006, CLIN GASTROENTEROL H, V4, P621, DOI 10.1016/j.cgh.2006.03.002; Lichtenstein GR, 2006, GASTROENTEROLOGY, V130, P940, DOI 10.1053/j.gastro.2006.01.048; LUGEA A, 1994, GASTROENTEROLOGY, V107, P720, DOI 10.1016/0016-5085(94)90119-8; Maaser C, 2002, Z GASTROENTEROL, V40, P525, DOI 10.1055/s-2002-32808; Manjari V, 2000, PROSTAG LEUKOTR ESS, V62, P85, DOI 10.1054/plef.1999.0125; Marano CW, 1998, J MEMBRANE BIOL, V161, P263, DOI 10.1007/s002329900333; MARTIN GP, 1981, J PHARM PHARMACOL, V33, P754, DOI 10.1111/j.2042-7158.1981.tb13926.x; Mehran M, 1995, AM J PHYSIOL-GASTR L, V269, pG953, DOI 10.1152/ajpgi.1995.269.6.G953; Mourelle M, 1996, GASTROENTEROLOGY, V110, P1093, DOI 10.1053/gast.1996.v110.pm8612998; Nakamura K, 2006, WORLD J GASTROENTERO, V12, P4628, DOI 10.3748/wjg.v12.i29.4628; Nervi F, 2000, GASTROENTEROLOGY, V118, P1265, DOI 10.1016/S0016-5085(00)70380-5; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PACHECO S, 1987, CLIN SCI, V73, P361, DOI 10.1042/cs0730361; Patel B, 2002, INFLAMM BOWEL DIS, V8, P340, DOI 10.1097/00054725-200209000-00005; Pedron T, 2003, J BIOL CHEM, V278, P33878, DOI 10.1074/jbc.M303749200; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; PUGLIELLI L, 1994, GASTROENTEROLOGY, V107, P244, DOI 10.1016/0016-5085(94)90083-3; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Stremmel W, 2005, GUT, V54, P966, DOI 10.1136/gut.2004.052316; SWARM RA, 1987, AM J SURG, V153, P48, DOI 10.1016/0002-9610(87)90200-5; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Vallee S, 2004, EXP CELL RES, V297, P165, DOI 10.1016/j.yexcr.2004.03.007; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VanDeventer SJH, 1997, GUT, V40, P443, DOI 10.1136/gut.40.4.443; Wallace JL, 1996, FASEB J, V10, P731, DOI 10.1096/fasebj.10.7.8635690; Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516	63	183	193	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27155	27164		10.1074/jbc.M704408200	http://dx.doi.org/10.1074/jbc.M704408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636253	Green Accepted, hybrid			2022-12-25	WOS:000249304900056
J	Tan, KR; Gonthier, A; Baur, R; Ernst, M; Goeldner, M; Sigel, E				Tan, Kelly R.; Gonthier, Anne; Baur, Roland; Ernst, Margot; Goeldner, Maurice; Sigel, Erwin			Proximity-accelerated chemical coupling reaction in the benzodiazepine-binding site of gamma-aminobutyric acid type a receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT GABA(A) RECEPTOR; ALPHA-SUBUNIT; COVALENT MODIFICATION; XENOPUS OOCYTES; SUBTYPES; STOICHIOMETRY; EXPRESSION; CHANNELS; LIGANDS; MUTAGENESIS	Benzodiazepines are widely used drugs. They exert sedative/hypnotic, anxiolytic, muscle relaxant, and anticonvulsant effects and act through a specific high affinity binding site on the major inhibitory neurotransmitter receptor, the gamma-aminobutyric acid type A (GABA(A)) receptor. Ligands of the benzodiazepine-binding site are classified into three groups depending on their mode of action: positive and negative allosteric modulators and antagonists. To rationally design ligands of the benzodiazepine site in different isoforms of the GABAA receptor, we need to understand the relative positioning and overlap of modulators of different allosteric properties. To solve these questions, we used a proximity-accelerated irreversible chemical coupling reaction. GABAA receptor residues thought to reside in the benzodiazepine-binding site were individually mutated to cysteine and combined with a cysteine-reactive benzodiazepine site ligand. Direct apposition of reaction partners is expected to lead to a covalent reaction. We describe here such a reaction of predominantly alpha(1)H101C and also three other mutants (alpha(1)G157C, alpha (1)V202C, and alpha (1)V211C) with an Imid-NCS derivative in which a reactive isothiocyanate group (-NCS) replaces the azide group ( -N-3) in the partial negative allosteric modulator Ro15-4513. Our results show four contact points of imidazobenzodiazepines with the receptor, alpha(1)H101C being shared by classical benzodiazepines. Taken together with previous data, a similar orientation of these ligands within the benzodiazepine-binding pocket may be proposed.	Univ Bern, Inst Biochem & Mol Med, CH-3012 Bern, Switzerland; Univ Louis Pasteur Strasbourg 1, Fac Pharm, CNRS, Lab Chim Bioorgan,Unite Mixte Rech 7175LC1, F-67401 Illkirch Graffenstaden, France; Med Univ Vienna, Ctr Brain Res, Div Biochem & Mol Biol, A-1090 Vienna, Austria	University of Bern; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Medical University of Vienna	Sigel, E (corresponding author), Univ Bern, Inst Biochem & Mol Med, Buhlstr 28, CH-3012 Bern, Switzerland.	Erwin.sigel@mci.unibe.ch	Sigel, Erwin/F-7736-2015	Ernst, Margot/0000-0002-9809-2649				Barnard EA, 1998, PHARMACOL REV, V50, P291; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Baur R, 2006, FEBS LETT, V580, P1616, DOI 10.1016/j.febslet.2006.02.002; Berezhnoy D, 2004, J BIOL CHEM, V279, P3160, DOI 10.1074/jbc.M311371200; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; Boileau AJ, 2002, NEUROPHARMACOLOGY, V43, P695, DOI 10.1016/S0028-3908(02)00036-9; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Davies M, 1998, J NEUROCHEM, V70, P2188; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Dunn SMJ, 1999, MOL PHARMACOL, V56, P768; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; Foucaud B, 2001, TRENDS PHARMACOL SCI, V22, P170, DOI 10.1016/S0165-6147(00)01674-6; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; He XH, 2001, MED CHEM RES, V10, P269; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Huang Q, 1998, J MED CHEM, V41, P4130, DOI 10.1021/jm980317y; Huang Q, 2000, J MED CHEM, V43, P71, DOI 10.1021/jm990341r; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kotzyba-Hibert F, 1999, MOL NEUROBIOL, V20, P45, DOI 10.1007/BF02741364; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Rizk MS, 2006, BIOCHEMISTRY-US, V45, P543, DOI 10.1021/bi0516632; Sawyer GW, 2002, J BIOL CHEM, V277, P50036, DOI 10.1074/jbc.M209281200; Sigel E, 2005, MOL NUTR FOOD RES, V49, P228, DOI 10.1002/mnfr.200400104; Sigel E, 1998, MOL PHARMACOL, V54, P1097, DOI 10.1124/mol.54.6.1097; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; Strakhova MI, 2000, MOL PHARMACOL, V58, P1434, DOI 10.1124/mol.58.6.1434; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728	40	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26316	26325		10.1074/jbc.M702153200	http://dx.doi.org/10.1074/jbc.M702153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626010	hybrid			2022-12-25	WOS:000249239600036
J	Gao, S; Zhao, YZ; Kong, LF; Toselli, P; Chou, IN; Stone, P; Li, W				Gao, Song; Zhao, Yinzhi; Kong, Lingfa; Toselli, Paul; Chou, Iih-Nan; Stone, Phillip; Li, Wande			Cloning and characterization of the rat lysyl oxidase gene promoter - Identification of core promoter elements and functional nuclear factor I-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CIGARETTE-SMOKE CONDENSATE; FETAL LUNG FIBROBLASTS; TRANSCRIPTIONAL ACTIVATION; DOWN-REGULATION; MESSENGER-RNA; GROWTH-FACTOR; EXPRESSION; SEQUENCE; FAMILY	Lysyl oxidase (LO) stabilizes the extracellular matrix by crosslinking collagen and elastin. To assess the transcriptional regulation of LO, we cloned the 5'-flanking region with 3,979 bp of the rat LO gene. LO transcription started at multiple sites clustered at the region from -78 to -51 upstream of ATG. The downstream core promoter element functionally independent of the initiator predominantly activated the TATA-less LO gene. 5' Deletion assays illustrated a sequence of 804 bp upstream of ATG sufficient for eliciting the maximal promoter activity and the region -709/-598 exhibiting strongly enhancing effects on the reporter gene expression in transiently transfected RFL6 cells. DNase I footprinting assays showed a protected pattern existing in the fragment -612/-580, which contains a nuclear factor I ( NFI)-binding site at the region -594/-580 confirmed by electrophoretic mobility supershift assays. Mutations on this acting site decreased both NFI binding affinity in gel shift assays and stimulation of SV40 promoter activities in cells transfected with the NFI-binding site-SV40 promoter chimeric construct. Furthermore, at least two functional NFI-binding sites, including another one located at -147/-133, were identified in the LO promoter region -804/-1. Only NFI-A and NFI-B were expressed in rat lung fibroblasts, and their interaction with the LO gene was sensitively modulated by exogenous stimuli such as cigarette smoke condensate. In conclusion, the isolated rat LO gene promoter contains functionally independent initiator and downstream core promoter elements, and the conserved NFI-binding sites play a critical role in the LO gene activation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA	Boston University; Boston University	Li, W (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K121, Boston, MA 02118 USA.	wandeli@bu.edu		Li, Wande/0000-0002-2515-0799; Stone, Phillip/0000-0001-6220-690X	NIEHS NIH HHS [R01-ES 11340] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011340] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; BOAK AM, 1994, AM J RESP CELL MOL, V11, P751, DOI 10.1165/ajrcmb.11.6.7946403; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Chen LJ, 2005, TOXICOL SCI, V83, P372, DOI 10.1093/toxsci/kfi019; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; Csiszar K, 1996, MOL BIOL REP, V23, P97, DOI 10.1007/BF00424435; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; Gao B, 1998, MOL CELL BIOCHEM, V178, P187, DOI 10.1023/A:1006843514666; Gao S, 2005, TOXICOL SCI, V87, P197, DOI 10.1093/toxsci/kfi212; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giampuzzi M, 2003, BBA-PROTEINS PROTEOM, V1647, P245, DOI 10.1016/S1570-9639(03)00059-1; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; HARRIS ED, 1993, NUTR REV, V51, P235, DOI 10.1111/j.1753-4887.1993.tb03111.x; Hong HH, 2002, J PERIODONTOL, V73, P145, DOI 10.1902/jop.2002.73.2.145; Husain A, 2007, DRUG METAB DISPOS, V35, P721, DOI 10.1124/dmd.106.014621; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; Li WD, 2000, J CELL BIOCHEM, V78, P550, DOI 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.3.CO;2-#; Li WD, 2003, J CELL BIOCHEM, V88, P152, DOI 10.1002/jcb.10304; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; Majumder S, 2001, GENE EXPRESSION, V9, P203, DOI 10.3727/000000001783992588; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; Moore DD, 1995, GLOB MOB SURV; Morel Y, 1999, MOL CELL BIOL, V19, P6825; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Norquay LD, 2001, BIOCHEM J, V354, P387, DOI 10.1042/0264-6021:3540387; Reynaud C, 1999, CELL MOL BIOL, V45, P1237; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Roy R, 1996, J CELL BIOCHEM, V62, P411, DOI 10.1002/(SICI)1097-4644(199609)62:3<411::AID-JCB11>3.0.CO;2-L; Saux CJ, 1997, J CELL BIOCHEM, V64, P328, DOI 10.1002/(SICI)1097-4644(199702)64:2<328::AID-JCB14>3.0.CO;2-E; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; SNIDER GL, 1986, AM REV RESPIR DIS, V133, P149, DOI 10.1164/arrd.1986.133.1.149; SONG YL, 1999, ARTERIOSCL THROM VAS, V20, P982; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; Zhou TY, 2001, J BIOL CHEM, V276, P25503, DOI 10.1074/jbc.M102875200	48	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25322	25337		10.1074/jbc.M610108200	http://dx.doi.org/10.1074/jbc.M610108200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17597074	hybrid			2022-12-25	WOS:000249014100018
J	McInerney, P; O'Donnell, M				McInerney, Peter; O'Donnell, Mike			Replisome fate upon encountering a leading strand block and clearance from DNA by recombination proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; STALLED REPLICATION FORKS; IRRADIATED ESCHERICHIA-COLI; BETA-SLIDING CLAMP; LAGGING-STRAND; RECA PROTEIN; PYRIMIDINE DIMER; IN-VITRO; REPAIR; MECHANISM	Replication forks that collapse upon encountering a leading strand lesion are reactivated by a recombinative repair process called replication restart. Using rolling circle DNA substrates to model replication forks, we examine the fate of the helicase and both DNA polymerases when the leading strand polymerase is blocked. We find that the helicase continues over 0.5 kb but less than 3 kb and that the lagging strand DNA polymerase remains active despite its connection to a stalled leading strand enzyme. Furthermore, the blocked leading strand polymerase remains stably bound to the replication fork, implying that it must be dismantled from DNA in order for replication restart to initiate. Genetic studies have identified at least four gene products required for replication restart, RecF, RecO, RecR, and RecA. We find here that these proteins displace a stalled polymerase at a DNA template lesion. Implications of these results for replication fork collapse and recovery are discussed.	Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Howard Hughes Med Inst, Lab DNA Replicat, 1230 York Ave, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839, R01GM062540] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62540, GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Burnouf DY, 2004, J MOL BIOL, V335, P1187, DOI 10.1016/j.jmb.2003.11.049; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Courcelle J, 2003, ANNU REV GENET, V37, P611, DOI 10.1146/annurev.genet.37.110801.142616; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Courcelle J, 1999, J BACTERIOL, V181, P916, DOI 10.1128/JB.181.3.916-922.1999; Courcelle J, 2001, P NATL ACAD SCI USA, V98, P8196, DOI 10.1073/pnas.121008898; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Galletto R, 2004, J MOL BIOL, V343, P83, DOI 10.1016/j.jmb.2004.07.055; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Hegde SP, 1996, P NATL ACAD SCI USA, V93, P14468, DOI 10.1073/pnas.93.25.14468; Heller RC, 2006, NATURE, V439, P557, DOI 10.1038/nature04329; Heller RC, 2005, J BIOL CHEM, V280, P34143, DOI 10.1074/jbc.M507224200; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022; Jergic S, 2007, NUCLEIC ACIDS RES, V35, P2813, DOI 10.1093/nar/gkm079; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KHIDHIR MA, 1985, MOL GEN GENET, V199, P133, DOI 10.1007/BF00327522; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Langston LD, 2006, MOL CELL, V23, P155, DOI 10.1016/j.molcel.2006.05.034; Leu FP, 2003, MOL CELL, V11, P315, DOI 10.1016/S1097-2765(03)00042-X; Leu FP, 2001, J BIOL CHEM, V276, P47185, DOI 10.1074/jbc.M106780200; Li XJ, 2000, J BIOL CHEM, V275, P34757, DOI 10.1074/jbc.M006556200; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; Lopes M, 2006, MOL CELL, V21, P15, DOI 10.1016/j.molcel.2005.11.015; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McInerney P, 2004, J BIOL CHEM, V279, P21543, DOI 10.1074/jbc.M401649200; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mizukoshi T, 2003, J BIOL CHEM, V278, P42234, DOI 10.1074/jbc.C300285200; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; O'Donnell M, 2006, J BIOL CHEM, V281, P10653, DOI 10.1074/jbc.R500028200; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Schlacher K, 2005, MOL CELL, V17, P561, DOI 10.1016/j.molcel.2005.01.006; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; Turner J, 1995, METHOD ENZYMOL, V262, P442; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WHITBY MC, 1995, MOL GEN GENET, V246, P174, DOI 10.1007/BF00294680; WITKIN EM, 1987, P NATL ACAD SCI USA, V84, P6805, DOI 10.1073/pnas.84.19.6805; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; WU CA, 1992, J BIOL CHEM, V267, P4030; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	67	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25903	25916		10.1074/jbc.M703777200	http://dx.doi.org/10.1074/jbc.M703777200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17609212	hybrid			2022-12-25	WOS:000249014100076
J	Shimoda, M; Hashimoto, G; Mochizuki, S; Ikeda, E; Nagai, N; Ishida, S; Okada, Y				Shimoda, Masayuki; Hashimoto, Gakuji; Mochizuki, Satsuki; Ikeda, Eiji; Nagai, Norihiro; Ishida, Susumu; Okada, Yasunori			Binding of ADAM28 to p-selectin glycoprotein ligand-1 enhances p-selectin-mediated leukocyte adhesion to endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; MDC-L; METALLOPROTEASE-DISINTEGRIN; CATALYTIC-ACTIVITY; CLEAVAGE; SURFACE; FAMILY; DOMAIN; PSGL-1	ADAMs ( a disintegrin and metalloproteinases) are a recently discovered gene family of multifunctional proteins with the disintegrin-like and metalloproteinase domains. To analyze the biological functions of ADAM28, we screened binding molecules to secreted-type ADAM28 (ADAM28s) by the yeast two-hybrid system and identified P-selectin glycoprotein ligand-1 (PSGL-1). Binding between the disintegrin-like domain of ADAM28s and the extracellular portion of PSGL-1 was determined by yeast two-hybrid assays, binding assays of the domain-specific recombinant ADAM28s species using PSGL-1 stable transfectants and leukocyte cell lines expressing native PSGL-1 (HL-60 cells and Jurkat cells), and co-immunolocalization and co-immunoprecipitation of the molecules in these cells. Incubation of HL-60 cells with recombinant ADAM28s enhanced the binding to P-selectin-coated wells and P-selectin-expressing endothelial cells. In addition, intravenous injection of ADAM28s-treated HL-60 cells increased their accumulation in the pulmonary microcirculation and alveolar spaces in a mouse model of endotoxin-induced inflammation. These data suggest a novel function that ADAM28s promotes PSGL-1/P-selectinmediated leukocyte rolling adhesion to endothelial cells and subsequent infiltration into tissue spaces through interaction with PSGL- 1 on leukocytes under inflammatory conditions.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, Tokyo 1600016, Japan	Keio University; Keio University	Okada, Y (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan.	okada@sc.itc.keio.ac.jp	Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755				Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bridges LC, 2005, BIOCHEM J, V387, P101, DOI 10.1042/BJ20041444; Bridges LC, 2003, BIOCHEMISTRY-US, V42, P3734, DOI 10.1021/bi026871y; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Friederichs J, 2000, CANCER RES, V60, P6714; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; Hashimoto G, 2004, J BIOL CHEM, V279, P32483, DOI 10.1074/jbc.M314216200; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hirose M, 1998, INT IMMUNOL, V10, P639, DOI 10.1093/intimm/10.5.639; Howard L, 2001, FEBS LETT, V498, P82, DOI 10.1016/S0014-5793(01)02506-6; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kameda H, 1997, BRIT J HAEMATOL, V97, P348, DOI 10.1046/j.1365-2141.1997.522700.x; Kunkel EJ, 1997, AM J PHYSIOL-HEART C, V272, pH1391, DOI 10.1152/ajpheart.1997.272.3.H1391; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; Mazzocca A, 2005, CANCER RES, V65, P4728, DOI 10.1158/0008-5472.CAN-04-4449; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; Mitsui Y, 2006, CANCER RES, V66, P9913, DOI 10.1158/0008-5472.CAN-06-0377; Mochizuki S, 2004, BIOCHEM BIOPH RES CO, V315, P79, DOI 10.1016/j.bbrc.2004.01.022; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476; Ohtsuka T, 2006, INT J CANCER, V118, P263, DOI 10.1002/ijc.21324; OKADA Y, 2005, KELLEYS TXB RHEUMATO, P63; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; Reiss K, 2006, PHARMACOL THERAPEUT, V111, P985, DOI 10.1016/j.pharmthera.2006.02.009; Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004; Roberts CM, 1999, J BIOL CHEM, V274, P29251, DOI 10.1074/jbc.274.41.29251; Shao JY, 1998, P NATL ACAD SCI USA, V95, P6797, DOI 10.1073/pnas.95.12.6797; Shiomi T, 2005, LAB INVEST, V85, P1489, DOI 10.1038/labinvest.3700351; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Stefanidakis M, 2006, BLOOD, V108, P1441, DOI 10.1182/blood-2006-02-005363; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; Thodeti CK, 2003, J BIOL CHEM, V278, P9576, DOI 10.1074/jbc.M208937200; Villard E, 1998, J BIOL CHEM, V273, P25191, DOI 10.1074/jbc.273.39.25191; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275	53	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25864	25874		10.1074/jbc.M702414200	http://dx.doi.org/10.1074/jbc.M702414200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17597069	hybrid			2022-12-25	WOS:000249014100072
J	Woo, SY; Kim, DH; Jun, CB; Kim, YM; Haar, EV; Lee, SI; Hegg, JW; Bandhakavi, S; Griffin, TJ; Kim, DH				Woo, So-Yon; Kim, Dong-Hwan; Jun, Chang-Bong; Kim, Young-Mi; Haar, Emilie Vander; Lee, Seong-il; Hegg, James W.; Bandhakavi, Sricharan; Griffin, Timothy J.; Kim, Do-Hyung			PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; MAMMALIAN TARGET; BINDING PARTNER; C-MYC; RAPAMYCIN; TOR; PHOSPHORYLATION; RAPTOR; IDENTIFICATION; RICTOR	The protein kinase mammalian target of rapamycin ( mTOR) plays an important role in the coordinate regulation of cellular responses to nutritional and growth factor conditions. mTOR achieves these roles through interacting with raptor and rictor to form two distinct protein complexes, mTORC1 and mTORC2. Previous studies have been focused onmTORC1to elucidate the central roles of the complex in mediating nutritional and growth factor signals to the protein synthesis machinery. Functions of mTORC2, relative to mTORC1, have remained little understood. Here we report identification of a novel component of mTORC2 named PRR5 ( PRoline-Rich protein 5), a protein encoded by a gene located on a chromosomal region frequently deleted during breast and colorectal carcinogenesis ( Johnstone, C. N., Castellvi-Bel, S., Chang, L. M., Sung, R. K., Bowser, M. J., Pique, J. M., Castells, A., and Rustgi, A. K. ( 2005) Genomics 85, 338-351). PRR5 interacts with rictor, but not raptor, and the interaction is independent of mTOR and not disturbed under conditions that disrupt the mTOR-rictor interaction. PRR5, unlike Sin1, another component of mTORC2, is not important for the mTOR-rictor interaction and mTOR activity toward Akt phosphorylation. Despite no significant effect of PRR5 on mTORC2-mediated Akt phosphorylation, PRR5 silencing inhibits Akt and S6K1 phosphorylation and reduces cell proliferation rates, a result consistent with PRR5 roles in cell growth and tumorigenesis. The inhibition of Akt and S6K1 phosphorylation by PRR5 knock down correlates with reduction in the expression level of platelet-derived growth factor receptor beta ( PDGFR beta). PRR5 silencing impairs PDGF-stimulated phosphorylation of S6K1 and Akt but moderately reduces epidermal growth factor- and insulin-stimulated phosphorylation. These findings propose a potential role of mTORC2 in the cross-talk with the cellular machinery that regulates PDGFR beta expression and signaling.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kim, DH (corresponding author), 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	dhkim@umn.edu		Griffin, Timothy/0000-0001-6801-2559; Kim, Do-Hyung/0000-0002-2924-4370	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072004, R56DK072004] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK072004] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gatherar IM, 2004, FUNGAL GENET BIOL, V41, P463, DOI 10.1016/j.fgb.2003.12.004; Hackzell A, 2002, J BIOL CHEM, V277, P39769, DOI 10.1074/jbc.M204483200; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Izumi H, 2001, J CELL SCI, V114, P1533; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Johnstone CN, 2005, GENOMICS, V85, P338, DOI 10.1016/j.ygeno.2004.11.002; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Molander C, 2001, MOL BIOL REP, V28, P223, DOI 10.1023/A:1015701232589; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shih AH, 2006, CANCER LETT, V232, P139, DOI 10.1016/j.canlet.2005.02.002; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	43	152	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25604	25612		10.1074/jbc.M704343200	http://dx.doi.org/10.1074/jbc.M704343200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17599906	hybrid			2022-12-25	WOS:000249014100047
J	Zhang, F; Li, PL				Zhang, Fan; Li, Pin-Lan			Reconstitution and characterization of a nicotinic acid adenine dinucleotide phosphate (NAADP)-sensitive Ca2+ release channel from liver Lysosomes of rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; MUCOLIPIDOSIS TYPE-IV; ARTERIAL SMOOTH-MUSCLE; SEA-URCHIN EGG; SARCOPLASMIC-RETICULUM; CATION CHANNEL; BETA-CELLS; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTORS; PYRIDINE-NUCLEOTIDE	Nicotinic acid adenine dinucleotide phosphate ( NAADP) is capable of inducing global Ca2+ increases via a lysosome-associated mechanism, but the mechanism mediating NAADP-induced intracellular Ca2+ release remains unclear. The present study reconstituted and characterized a lysosomal NAADP-sensitive Ca2+ release channel using purified lysosomes from rat liver. Furthermore, the identity of lysosomal NAADP-sensitive Ca2+ release channels was also investigated. It was found that NAADP activates lysosomal Ca2+ release channels at concentrations of 1 nM to 1 mu M, but this activating effect of NAADP was significantly reduced when the concentrations used increased to 10 or 100 mu M. Either activators or blockers of Ca2+ release channels on the sarcoplasmic reticulum (SR) had no effect on the activity of these NAADP-activated Ca2+ release channels. Interestingly, the activity of this lysosomal NAADP-sensitive Ca2+ release channel increased when the pH in cis solution decreased, but it could not be inhibited by a lysosomal H+-ATPase antagonist, bafilomycin A1. However, the activity of this channel was significantly inhibited by plasma membrane L-type Ca2+ channel blockers such as verapamil, diltiazem, and nifedipine, or the nonselective Ca2+, Na+ channel blocker, amiloride. In addition, blockade of TRP-ML1 ( transient receptor potential-mucolipin 1) protein by anti-TRP-ML1 antibody markedly attenuated NAADP-induced activation of these lysosomal Ca2+ channels. These results for the first time provide direct evidence that a NAADP-sensitive Ca2+ release channel is present in the lysosome of native liver cells and that this channel is associated with TRP-ML1, which is different from ER/SR Ca2+ release channels.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Li, PL (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, 410 N 12th St,POB 980613, Richmond, VA 23298 USA.	pli@vcu.edu			NHLBI NIH HHS [R01 HL091464, R01 HL075316, HL075316-01, HL057244-09] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057244, R01HL075316, R01HL091464, R29HL057244] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Anyatonwu GI, 2003, J BIOL CHEM, V278, P45528, DOI 10.1074/jbc.M307863200; BACHORIK PS, 1978, BIOCHEMISTRY-US, V17, P5287, DOI 10.1021/bi00617a032; BAINTON D, 1981, J CELL BIOL, V91, P66; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Brailoiu E, 2005, J BIOL CHEM, V280, P5646, DOI 10.1074/jbc.M408746200; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cantiello HF, 2005, PFLUG ARCH EUR J PHY, V451, P304, DOI 10.1007/s00424-005-1448-9; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; Churamani D, 2004, BIOCHEM J, V380, P449, DOI 10.1042/BJ20031754; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2001, EMBO J, V20, P2666, DOI 10.1093/emboj/20.11.2666; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Dammermann W, 2005, J BIOL CHEM, V280, P21394, DOI 10.1074/jbc.M413085200; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; EVANS WH, 1969, FEBS LETT, V3, P237, DOI 10.1016/0014-5793(69)80146-8; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Kawashima A, 1998, KIDNEY INT, V54, P275, DOI 10.1046/j.1523-1755.1998.00958.x; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lee KW, 2003, INT J DEV BIOL, V47, P411; Li PL, 2001, AM J PHYSIOL-HEART C, V280, pH208, DOI 10.1152/ajpheart.2001.280.1.H208; Mandi M, 2006, BIOCHEM J, V395, P233, DOI 10.1042/BJ20051002; Manzoni M, 2004, FEBS LETT, V567, P219, DOI 10.1016/j.febslet.2004.04.080; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Miedel MT, 2006, J BIOL CHEM, V281, P12751, DOI 10.1074/jbc.M511104200; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Nusco GA, 2002, BIOCHEM BIOPH RES CO, V290, P1015, DOI 10.1006/bbrc.2001.6286; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; PLATTNER H, 1975, EXP CELL RES, V91, P333, DOI 10.1016/0014-4827(75)90112-3; Pryor PR, 2006, TRAFFIC, V7, P1388, DOI 10.1111/j.1600-0854.2006.00475.x; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Saxena SK, 2007, INT J BIOL SCI, V3, P47; Soyombo AA, 2006, J BIOL CHEM, V281, P7294, DOI 10.1074/jbc.M508211200; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; Tang WX, 2002, AM J PHYSIOL-HEART C, V282, pH1304, DOI 10.1152/ajpheart.00843.2001; Teiwes J, 2007, AM J HYPERTENS, V20, P109, DOI 10.1016/j.amjhyper.2006.05.022; TINKER A, 1992, J GEN PHYSIOL, V100, P495, DOI 10.1085/jgp.100.3.495; TINKER A, 1993, J GEN PHYSIOL, V102, P1107, DOI 10.1085/jgp.102.6.1107; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; WISHER MH, 1975, BIOCHEM J, V146, P375, DOI 10.1042/bj1460375; YAMADA H, 1984, J BIOCHEM, V95, P1155, DOI 10.1093/oxfordjournals.jbchem.a134704; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200; Yi XY, 2006, AM J PHYSIOL-HEART C, V290, pH1136, DOI 10.1152/ajpheart.00296.2005; Yusufi ANK, 2001, BIOCHEM J, V353, P531, DOI 10.1042/0264-6021:3530531; ZEEVI DA, 2007, IN PRESS BIOCH BIOPH; Zhang F, 2006, AM J PHYSIOL-HEART C, V291, pH274, DOI 10.1152/ajpheart.01064.2005	60	104	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25259	25269		10.1074/jbc.M701614200	http://dx.doi.org/10.1074/jbc.M701614200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17613490	hybrid			2022-12-25	WOS:000249014100011
J	Bendetz-Nezer, S; Seger, R				Bendetz-Nezer, Sarit; Seger, Rony			Role of non-phosphorylated activation loop residues in determining ERK2 dephosphorylation, activity, and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; EXCHANGE MASS-SPECTROMETRY; MAP KINASE; PROTEIN-KINASE; DOCKING INTERACTIONS; GROWTH-FACTOR; PHOSPHORYLATION; IDENTIFICATION; SPECIFICITY; PHOSPHATASE	Extracellular signal- regulated kinases ( ERKs) activity is regulated by MAPK/ ERK kinases ( MEKs), which phosphorylate the regulatory Tyr and Thr residues in ERKs activation loop, and by various phosphatases that remove the incorporated phosphates. Although the role of the phosphorylated residues in the activation loop of ERKs is well studied, much less is known about the role of other residues within this loop. Here we substituted several residues within amino acids 173 - 177 of ERK2 and studied their role in ERK2 phosphorylation, substrate recognition, and subcellular localization. We found that substitution of residues 173 - 175 and particularly Pro(174) to alanines reduces the EGFinduced ERK2 phosphorylation, without modifying its in vitro phosphorylation by MEK1. Examining the ability of these mutants to be dephosphorylated revealed that 173- 5A mutants are hypersensitive to phosphatases, indicating that these residues are important for setting the phosphorylation/ dephosphorylation balance of ERKs. In addition, 173- 5A mutants reduced ERK2 activity toward Elk-1, without affecting the activity of ERK2 toward MBP, while substitution of residues 176-8 decreased ERK2 activity toward both substrates. Substitution of Asp(177) to alanine increased nuclear localization of the construct in MEK1-overexpressing cells, suggesting that this residue together with His(176) is involved in the dissociation of ERK2 from MEKs. Combining CRS/ CD motif and the activation loop mutations revealed that these two regions cooperate in determining the net phosphorylation of ERK2, but the role of the CRS/ CD motif predominates that of the activation loop residues. Thus, we show here that residues 173 - 177 of ERK2 join other regulatory regions of ERKs in governing ERK activity.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	rony.seger@weizmann.ac.il						Aebersold DM, 2004, MOL CELL BIOL, V24, P10000, DOI 10.1128/MCB.24.22.10000-10015.2004; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bardwell L, 2006, BIOCHEM SOC T, V34, P837, DOI 10.1042/BST0340837; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chuderland D, 2005, MOL BIOTECHNOL, V29, P57, DOI 10.1385/MB:29:1:57; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; Imajo M, 2006, IUBMB LIFE, V58, P312, DOI 10.1080/15216540600746393; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Liu SJ, 2006, P NATL ACAD SCI USA, V103, P5326, DOI 10.1073/pnas.0510506103; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023; Perlson E, 2006, J MOL BIOL, V364, P938, DOI 10.1016/j.jmb.2006.09.056; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHAUL YD, 2006, BIOCH BIOPHYS ACTA; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; Yao Z, 2001, ONCOGENE, V20, P7588, DOI 10.1038/sj.onc.1204963; Yao Zhong, 2004, Current Genomics, V5, P385, DOI 10.2174/1389202043349309; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2006, J BIOL CHEM, V281, P38834, DOI 10.1074/jbc.M608916200; Zhou TJ, 2006, STRUCTURE, V14, P1011, DOI 10.1016/j.str.2006.04.006	44	6	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25114	25122		10.1074/jbc.M703120200	http://dx.doi.org/10.1074/jbc.M703120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17597065	hybrid			2022-12-25	WOS:000248933000066
J	Cabral, LMP; Wengert, M; da Ressurreicao, AAA; Feres-Elias, PHP; Almeida, FG; Vieyra, A; Caruso-Neves, C; Einicker-Lamas, M				Cabral, Lindsey M. P.; Wengert, Mira; da Ressurreicao, Alexandre A. A.; Feres-Elias, Pedro H. P.; Almeida, Fernando G.; Vieyra, Adalberto; Caruso-Neves, Celso; Einicker-Lamas, Marcelo			Ceramide is a potent activator of plasma membrane Ca2+-ATPase from kidney proximal tubule cells with protein kinase a as an intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-ATPASE ACTIVITY; BASOLATERAL MEMBRANES; HUMAN ERYTHROCYTES; INDUCED APOPTOSIS; CALCIUM-PUMP; PHOSPHORYLATION; SPHINGOSINE; SPHINGOMYELINASE; SPHINGOLIPIDS; STIMULATION	The kidney proximal tubules are involved in reabsorbing two-thirds of the glomerular ultrafiltrate, a key Ca2+-modulated process that is essential for maintaining homeostasis in body fluid compartments. The basolateral membranes of these cells have a Ca2+-ATPase, which is thought to be responsible for the fine regulation of intracellular Ca2+ levels. In this paper we show that nanomolar concentrations of ceramide (Cer(50) = 3.5 nM), a natural product derived from sphingomyelinase activity in biological membranes, promotes a 50% increase of Ca2+-ATPase activity in purified basolateral membranes. The stimulatory effect of ceramide occurs through specific and direct (cAMP-independent) activation of a protein kinase A (blocked by 10 nM of the specific inhibitor of protein kinase A (PKA), the 5-22 peptide). The activation of PKA by ceramide results in phosphorylation of the Ca2+-ATPase, as detected by an anti-Ser/Thr specific PKA substrate antibody. It is observed a straight correlation between increase of Ca2+-ATPase activity and PKA-mediated phosphorylation of the Ca2+ pump molecule. Ceramide also stimulates phosphorylation of renal Ca2+-ATPaseviaproteinkinaseC, but stimulation of this pathway, which inhibits the Ca2+ pump in kidney cells, is counteracted by the ceramide-triggered PKA-mediated phosphorylation. The potent effect of ceramide reveals a new physiological activator of the plasma membrane Ca2+-ATPase, which integrates the regulatory network of glycerolipids and sphingolipids present in the basolateral membranes of kidney cells.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Fisicoquim Biol Aida Hasson Voloch, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Bioquim Renal, BR-21949900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Einicker-Lamas, M (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Fisicoquim Biol Aida Hasson Voloch, BR-21949900 Rio De Janeiro, Brazil.	einicker@biof.ufrj.br	Caruso-Neves, Celso/C-4014-2013	Caruso-Neves, Celso/0000-0002-2415-7753				Assuncao-Miranda I, 2005, REGUL PEPTIDES, V127, P151, DOI 10.1016/j.regpep.2004.11.004; Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.imlet.2004.09.001; Bollinger CR, 2005, BBA-MOL CELL RES, V1746, P284, DOI 10.1016/j.bbamcr.2005.09.001; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUMENDILPODEVIN EF, 1983, BIOCHIM BIOPHYS ACTA, V735, P86, DOI 10.1016/0005-2736(83)90263-8; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Caride AJ, 1998, J LAB CLIN MED, V132, P149, DOI 10.1016/S0022-2143(98)90010-5; Caruso-Neves C, 2000, BBA-BIOMEMBRANES, V1468, P107, DOI 10.1016/S0005-2736(00)00248-0; COELHOSAMPAIO T, 1991, J BIOL CHEM, V266, P10249; Coka-Guevara S, 1999, EUR J BIOCHEM, V263, P71, DOI 10.1046/j.1432-1327.1999.00456.x; Colina C, 2002, BIOCHEM J, V362, P247, DOI 10.1042/0264-6021:3620247; Colombaioni L, 2004, BRAIN RES REV, V46, P328, DOI 10.1016/j.brainresrev.2004.07.014; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; Einicker-Lamas M, 2003, J BIOCHEM, V134, P529, DOI 10.1093/jb/mvg170; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gomez-Munoz A, 2004, FEBS LETT, V562, P5, DOI 10.1016/S0014-5793(04)00211-X; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hoekstra D, 2003, J LIPID RES, V44, P869, DOI 10.1194/jlr.R300003-JLR200; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; IWATA M, 1995, P NATL ACAD SCI USA, V92, P8970, DOI 10.1073/pnas.92.19.8970; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; Jayadev S, 2000, AM J PHYSIOL-CELL PH, V279, pC1640; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P19, DOI 10.1016/0005-2736(92)90158-I; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P3772, DOI 10.1021/bi00467a025; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maia J.C.C., 1983, GENES ANTIGENES PARA, P146; Nogaroli L, 2005, INT J BIOCHEM CELL B, V37, P79, DOI 10.1016/j.biocel.2004.05.020; Nurminen TA, 2002, J AM CHEM SOC, V124, P12129, DOI 10.1021/ja017807r; RANGEL LB, 2001, BIOCHIM BIOPHYS ACTA, V1564, P310; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; TAO JG, 1992, BIOCHIM BIOPHYS ACTA, V1107, P213, DOI 10.1016/0005-2736(92)90407-D; TAUSSKY HM, 1952, J BIOL CHEM, V202, P675; Tornquist K, 2004, BIOCHEM J, V380, P661, DOI 10.1042/BJ20031637; Tortelote GG, 2004, FEBS LETT, V576, P31, DOI 10.1016/j.febslet.2004.08.055; Valverde RHF, 2005, J BIOL CHEM, V280, P30611, DOI 10.1074/jbc.M501880200; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; VIEYRA A, 1986, J BIOL CHEM, V261, P4247; Weerth SH, 2007, CELL CALCIUM, V41, P155, DOI 10.1016/j.ceca.2006.06.006; Wengert M, 2005, INT J BIOCHEM CELL B, V37, P155, DOI 10.1016/j.biocel.2004.06.006; WRIGHT LC, 1993, ARCH BIOCHEM BIOPHYS, V306, P277, DOI 10.1006/abbi.1993.1512; Zager RA, 2000, J AM SOC NEPHROL, V11, P894, DOI 10.1681/ASN.V115894	54	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24599	24606		10.1074/jbc.M701669200	http://dx.doi.org/10.1074/jbc.M701669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17606608	hybrid			2022-12-25	WOS:000248933000014
J	Wang, WP; Kwok, AM; Chan, JY				Wang, Weiping; Kwok, Annie M.; Chan, Jefferson Y.			The p65 isoform of Nrf1 is a dominant negative inhibitor of ARE-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; EMBRYONIC LETHALITY; STRESS-RESPONSE; MAF; FAMILY; KEAP1; ACTIVATION; INDUCTION	Oxidative stress-responsive transcription is regulated in part through cis-active sequences known as antioxidant response elements (ARE). Activation through the ARE involves members of the CNC-subfamily of basic leucine zipper proteins including Nrf1 and Nrf2. In particular, Nrf2 has been shown to coordinate induction of genes encoding antioxidant and phase 2 metabolizing enzymes in response to stimulation with electrophilic compounds and exposure to xenobiotics. Here we show that the 65-kDa isoform of the Nrf1 gene functions as a repressor of Nrf2. Transient expression of p65Nrf1 suppressed Nrf2-mediated activation of ARE-dependent reporter genes in cells. Induction of endogenous ARE-genes is blocked in Hepa1c1c7 cells stably expressing p65Nrf1 leading to increased cell death. Consistent with these findings, electrophilic activation of ARE-gene expression is augmented by loss of p65Nrf1 function in Nrf1(-/-) fibroblasts, and the protective effects of oxidative preconditioning and ARE-gene expression are blocked in Nrf1(-/-) cells stably expressing p65Nrf1. Gel shift experiments demonstrated that p65Nrf1 binds the antioxidant response element as a heterodimer with small-Maf protein. Immunoprecipitation studies demonstrated that p65Nrf1 competes with Nrf2 for interaction with small-Maf protein and binding to the antioxidant response element in vivo. Together, these results demonstrate that p65Nrf1 has the potential to play an important role in modulating the response to oxidative stress by functioning as a transdominant repressor of Nrf2-mediated activation of ARE-dependent gene transcription.	Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Chan, JY (corresponding author), Univ Calif Irvine, Dept Pathol, D440 Med Sci 1, Irvine, CA 92697 USA.	jchan@uci.edu			NATIONAL CANCER INSTITUTE [R01CA091907, R56CA091907] Funding Source: NIH RePORTER; NCI NIH HHS [CA91907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; CHAN JY, 1995, HUM GENET, V95, P265; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Igarashi K, 2006, ANTIOXID REDOX SIGN, V8, P107, DOI 10.1089/ars.2006.8.107; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; LUNA L, 1995, GENOMICS, V27, P237, DOI 10.1006/geno.1995.1037; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Motohashi H, 2007, CANCER SCI, V98, P135, DOI 10.1111/j.1349-7006.2006.00358.x; Myhrstad MCW, 2001, BBA-GENE STRUCT EXPR, V1517, P212, DOI 10.1016/S0167-4781(00)00276-1; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wang WP, 2006, J BIOL CHEM, V281, P19676, DOI 10.1074/jbc.M602802200; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Xu ZR, 2005, P NATL ACAD SCI USA, V102, P4120, DOI 10.1073/pnas.0500660102; Yamamoto T, 2006, GENES CELLS, V11, P575, DOI 10.1111/j.1365-2443.2006.00965.x; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003	39	53	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24670	24678		10.1074/jbc.M700159200	http://dx.doi.org/10.1074/jbc.M700159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17609210	hybrid			2022-12-25	WOS:000248933000022
J	Wu, F; Yang, F; Vinnakota, KC; Beard, DA				Wu, Fan; Yang, Feng; Vinnakota, Kalyan C.; Beard, Daniel A.			Computer modeling of mitochondrial tricarboxylic acid cycle, oxidative phosphorylation, metabolite transport, and electrophysiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; LIVER-MITOCHONDRIA; BOVINE HEART; OXOGLUTARATE CARRIER; REACTION-MECHANISM; ENERGY-METABOLISM; CITRATE SYNTHASE; CALCIUM-IONS; SIMULATION; DEHYDROGENASE	A computational model of mitochondrial metabolism and electrophysiology is introduced and applied to analysis of data from isolated cardiac mitochondria and data on phosphate metabolites in striated muscle in vivo. This model is constructed based on detailed kinetics and thermodynamically balanced reaction mechanisms and a strict accounting of rapidly equilibrating biochemical species. Since building such a model requires introducing a large number of adjustable kinetic parameters, a correspondingly large amount of independent data from isolated mitochondria respiring on different substrates and subject to a variety of protocols is used to parameterize the model and ensure that it is challenged by a wide range of data corresponding to diverse conditions. The developed model is further validated by both in vitro data on isolated cardiac mitochondria and in vivo experimental measurements on human skeletal muscle. The validated model is used to predict the roles of NAD and ADP in regulating the tricarboxylic acid cycle dehydrogenase fluxes, demonstrating that NAD is the more important regulator. Further model predictions reveal that a decrease of cytosolic pH value results in decreases in mitochondrial membrane potential and a corresponding drop in the ability of the mitochondria to synthesize ATP at the hydrolysis potential required for cellular function.	Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Biotechnol & Bioengn Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Beard, DA (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	dbeard@mcw.edu	Vinnakota, Kalyan/G-4706-2010	Vinnakota, Kalyan/0000-0003-2185-2213; Wu, Fan/0000-0001-8339-4049	NHLBI NIH HHS [HL070011] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL070011, R01HL070011] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHS MJ, 1979, AM J PHYSIOL, V237, pR174, DOI 10.1152/ajpregu.1979.237.3.R174; Alberty R. A., 2003, THERMODYNAMICS BIOCH; Anderson CM, 2002, J NEUROSCI, V22, P9203; BARMAN TE, 1969, ENZYME HDB, P764; Beard DA, 2005, PLOS COMPUT BIOL, V1, P252, DOI 10.1371/journal.pcbi.0010036; Beard DA, 2003, AM J PHYSIOL-HEART C, V285, pH1826, DOI 10.1152/ajpheart.00380.2003; Beard DA, 2001, ANN BIOMED ENG, V29, P298, DOI 10.1114/1.1359450; Beard DA, 2006, PLOS COMPUT BIOL, V2, P1093, DOI 10.1371/journal.pcbi.0020107; Bose S, 2003, J BIOL CHEM, V278, P39155, DOI 10.1074/jbc.M306409200; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; Cortassa S, 2003, BIOPHYS J, V84, P2734, DOI 10.1016/S0006-3495(03)75079-6; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; FALL CP, 2002, COMPUTATIONAL CELL B, P171; GARFINKEL D, 1979, AM J PHYSIOL, V237, pR181, DOI 10.1152/ajpregu.1979.237.3.R181; GUTMAN M, 1977, BIOCHEMISTRY-US, V16, P3067, DOI 10.1021/bi00633a004; Hatefi Y, 1976, ENZYMES, P175; HENSON CP, 1964, BIOCHEMISTRY-US, V3, P338, DOI 10.1021/bi00891a007; INDIVERI C, 1991, EUR J BIOCHEM, V198, P339, DOI 10.1111/j.1432-1033.1991.tb16021.x; JENESON JA, 1992, THESIS U UTRECHT UTR; Kantor PF, 2000, CIRC RES, V86, P580, DOI 10.1161/01.RES.86.5.580; Kaplan RS, 2001, J MEMBRANE BIOL, V179, P165, DOI 10.1007/s002320010046; KOHN MC, 1979, AM J PHYSIOL, V237, pR153, DOI 10.1152/ajpregu.1979.237.3.R153; KOHN MC, 1983, ANN BIOMED ENG, V11, P511, DOI 10.1007/BF02364082; KOHN MC, 1983, ANN BIOMED ENG, V11, P361, DOI 10.1007/BF02584214; KOHN MC, 1979, AM J PHYSIOL, V237, pR167, DOI 10.1152/ajpregu.1979.237.3.R167; KOHN MC, 1979, AM J PHYSIOL, V237, pR159, DOI 10.1152/ajpregu.1979.237.3.R159; LAKSHMINARAYANA.N, 1969, TRANSPORT PHENOMENA, P58; LANOUE K, 1970, J BIOL CHEM, V245, P102; LANOUE KF, 1974, J BIOL CHEM, V249, P7514; LANOUE KF, 1972, J BIOL CHEM, V247, P667; LANOUE KF, 1973, J BIOL CHEM, V248, P7171; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1979, BIOCHEM J, V180, P533, DOI 10.1042/bj1800533; MENTEN LE, 1981, COMPUT BIOMED RES, V14, P91, DOI 10.1016/0010-4809(81)90043-4; Nelson D.L.C., 2005, LEHNINGER PRINCIPLES, V4th ed., P601; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PENNER PE, 1969, J BIOL CHEM, V244, P1070; PLAUT GWE, 1979, BIOCHEMISTRY-US, V18, P3430, DOI 10.1021/bi00582a034; SHEPHERD D, 1969, BIOCHEM J, V114, P597, DOI 10.1042/bj1140597; SMITH CM, 1971, FEBS LETT, V18, P35, DOI 10.1016/0014-5793(71)80400-3; SMITH CM, 1974, J BIOL CHEM, V249, P1497; Vinnakota K, 2006, BIOPHYS J, V91, P1264, DOI 10.1529/biophysj.105.073296; Voet D, 2006, FUNDAMENTALS BIOCH; Williamson J R, 1973, Symp Soc Exp Biol, V27, P241; Williamson J R, 1980, Ann N Y Acad Sci, V341, P593, DOI 10.1111/j.1749-6632.1980.tb47201.x; Williamson J. R., 1976, GLUCONEOGENESIS ITS, P165; WILLIAMSON JR, 1979, ANNU REV PHYSIOL, V41, P485, DOI 10.1146/annurev.ph.41.030179.002413; Wu F, 2007, AM J PHYSIOL-CELL PH, V292, pC115, DOI 10.1152/ajpcell.00237.2006	49	147	149	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24525	24537		10.1074/jbc.M701024200	http://dx.doi.org/10.1074/jbc.M701024200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591785	hybrid			2022-12-25	WOS:000248933000006
J	Krarup, A; Wallis, R; Presanis, JS; Gal, P; Sim, RB				Krarup, Anders; Wallis, Russell; Presanis, Julia S.; Gal, Peter; Sim, Robert B.			Simultaneous Activation of Complement and Coagulation by MBL-Associated Serine Protease 2	PLOS ONE			English	Article								The complement system is an important immune mechanism mediating both recognition and elimination of foreign bodies. The lectin pathway is one pathway of three by which the complement system is activated. The characteristic protease of this pathway is Mannan-binding lectin (MBL)-associated serine protease 2 (MASP2), which cleaves complement proteins C2 and C4. We present a novel and alternative role of MASP2 in the innate immune system. We have shown that MASP2 is capable of promoting fibrinogen turnover by cleavage of prothrombin, generating thrombin. By using a truncated active form of MASP2 as well as full-length MASP2 in complex with MBL, we have shown that the thrombin generated is active and can cleave both factor XIII and fibrinogen, forming cross-linked fibrin. To explore the biological significance of these findings we showed that fibrin was covalently bound on a bacterial surface to which MBL/MASP2 complexes were bound. These findings suggest that, as has been proposed for invertebrates, limited clotting may contribute to the innate immune response.	[Krarup, Anders; Wallis, Russell; Presanis, Julia S.; Sim, Robert B.] Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; [Wallis, Russell] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Gal, Peter] Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, Budapest, Hungary	University of Oxford; University of Leicester; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Krarup, A (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England.	anders.krarup@bioch.ox.ac.uk	Sim, Bob/A-1354-2008; Gal, Peter/B-5886-2011	Sim, Bob/0000-0002-2855-7455; Wallis, Russell/0000-0002-8705-5295	Medical Research Council UK; Hungarian National Science Foundation [OTKA T046444]; British-Hungarian Bilateral ST Project [GB4/03]; MRC [G0501425] Funding Source: UKRI; Medical Research Council [G0501425] Funding Source: researchfish	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Hungarian National Science Foundation; British-Hungarian Bilateral ST Project; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded by the Medical Research Council UK, the Hungarian National Science Foundation Grant OTKA T046444, and the British-Hungarian Bilateral S&T Project GB4/03. AK is the recipient of an MRC doctoral training award. JSP held an MRC doctoral training award. The funding sources were not involved in the design, analysis, or interpretation of the results obtained in this study.	Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Bereczky Z, 2003, PATHOPHYSIOL HAEMO T, V33, P430, DOI 10.1159/000083841; Chen CB, 2004, J BIOL CHEM, V279, P26058, DOI 10.1074/jbc.M401318200; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Flick MJ, 2004, J CLIN INVEST, V113, P1596, DOI 10.1172/JCI200420741; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Hajela K, 2002, IMMUNOBIOLOGY, V205, P467, DOI 10.1078/0171-2985-00147; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAY AB, 1974, BRIT J HAEMATOL, V27, P669, DOI 10.1111/j.1365-2141.1974.tb06633.x; Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005; Krarup A, 2004, J BIOL CHEM, V279, P47513, DOI 10.1074/jbc.M407161200; Krem MM, 2000, TRENDS CARDIOVAS MED, V10, P171, DOI 10.1016/S1050-1738(00)00068-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda Y, 2001, PEPTIDES, V22, P1511, DOI 10.1016/S0196-9781(01)00473-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; Mullarky IK, 2005, INFECT IMMUN, V73, P3888, DOI 10.1128/IAI.73.7.3888-3895.2005; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Pike RN, 2005, FEBS J, V272, P4842, DOI 10.1111/j.1742-4658.2005.04880.x; PILATTE Y, 1989, J IMMUNOL METHODS, V120, P37, DOI 10.1016/0022-1759(89)90286-X; Presanis JS, 2004, MOL IMMUNOL, V40, P921, DOI 10.1016/j.molimm.2003.10.013; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; SIM RB, 1981, METHOD ENZYMOL, V80, P26; SIM RB, 1981, METHOD ENZYMOL, V80, P43; SKOGEN WF, 1988, BLOOD, V71, P1475; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Travis J, 1983, Behring Inst Mitt, P56	35	185	207	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e623	10.1371/journal.pone.0000623	http://dx.doi.org/10.1371/journal.pone.0000623			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637839	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452100013
J	Molnar-Szakacs, I; Wu, AD; Robles, FJ; Iacoboni, M				Molnar-Szakacs, Istvan; Wu, Allan D.; Robles, Francisco J.; Iacoboni, Marco			Do You See What I Mean? Corticospinal Excitability During Observation of Culture-Specific Gestures	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX EXCITABILITY; LEFT-HEMISPHERE; SOCIAL CATEGORIZATION; PREMOTOR CORTEX; MIRROR NEURONS; SELF; RECOGNITION; MODULATION; FACILITATION	People all over the world use their hands to communicate expressively. Autonomous gestures, also known as emblems, are highly social in nature, and convey conventionalized meaning without accompanying speech. To study the neural bases of cross-cultural social communication, we used single pulse transcranial magnetic stimulation (TMS) to measure corticospinal excitability (CSE) during observation of culture-specific emblems. Foreign Nicaraguan and familiar American emblems as well as meaningless control gestures were performed by both a Euro-American and a Nicaraguan actor. Euro-American participants demonstrated higher CSE during observation of the American compared to the Nicaraguan actor. This motor resonance phenomenon may reflect ethnic and cultural ingroup familiarity effects. However, participants also demonstrated a nearly significant (p = 0.053) actor by emblem interaction whereby both Nicaraguan and American emblems performed by the American actor elicited similar CSE, whereas Nicaraguan emblems performed by the Nicaraguan actor yielded higher CSE than American emblems. The latter result cannot be interpreted simply as an effect of ethnic ingroup familiarity. Thus, a likely explanation of these findings is that motor resonance is modulated by interacting biological and cultural factors.	[Molnar-Szakacs, Istvan] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Ctr Biol Creat, Los Angeles, CA 90095 USA; [Molnar-Szakacs, Istvan; Wu, Allan D.; Robles, Francisco J.; Iacoboni, Marco] Univ Calif Los Angeles, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA USA; [Molnar-Szakacs, Istvan; Iacoboni, Marco] Univ Calif Los Angeles, FPR UCLA Ctr Culture Brain & Dev, Los Angeles, CA USA; [Molnar-Szakacs, Istvan; Iacoboni, Marco] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Wu, Allan D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Iacoboni, Marco] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Molnar-Szakacs, I (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Ctr Biol Creat, Los Angeles, CA 90095 USA.	imolnar@ucla.edu			FPR-UCLA Center for Culture, Brain and Development, Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation; Northstar Fund; National Center for Research Resources [RR12169, RR13642, RR08655, NINDS K23-NS045764]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR013642, C06RR012169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS045764] Funding Source: NIH RePORTER	FPR-UCLA Center for Culture, Brain and Development, Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation; Northstar Fund; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This project was supported by the FPR-UCLA Center for Culture, Brain and Development, Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Northstar Fund and the National Center for Research Resources grants RR12169, RR13642 and RR08655 and NINDS K23-NS045764 (ADW).	Aziz-Zadeh L, 2006, J NEUROSCI, V26, P2964, DOI 10.1523/JNEUROSCI.2921-05.2006; Aziz-Zadeh L, 2004, EUR J NEUROSCI, V19, P2609, DOI 10.1111/j.0953-816X.2004.03348.x; Aziz-Zadeh L, 2002, EXP BRAIN RES, V144, P127, DOI 10.1007/s00221-002-1037-5; Baldissera F, 2001, EUR J NEUROSCI, V13, P190, DOI 10.1046/j.0953-816x.2000.01368.x; Bigler RS, 2006, ADV CHILD DEV BEHAV, V34, P39, DOI 10.1016/S0065-2407(06)80004-2; Birdwhistell R., 1970, KINESICS CONTEXT; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Buccino G, 2004, BRAIN LANG, V89, P370, DOI 10.1016/S0093-934X(03)00356-0; Buccino G, 2004, J COGNITIVE NEUROSCI, V16, P114, DOI 10.1162/089892904322755601; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Clark S, 2004, NEUROPSYCHOLOGIA, V42, P105, DOI 10.1016/S0028-3932(03)00144-1; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; EKMAN P, 1972, J COMMUN, V22, P353, DOI 10.1111/j.1460-2466.1972.tb00163.x; EKMAN P., 1969, SEMIOTICA, V1, P49, DOI DOI 10.1515/SEMI.1969.1.1.49; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608, DOI 10.1152/jn.1995.73.6.2608; Fecteau S, 2005, NEUROREPORT, V16, P1591, DOI 10.1097/01.wnr.0000179079.54906.1b; Ferrari PF, 2003, EUR J NEUROSCI, V17, P1703, DOI 10.1046/j.1460-9568.2003.02601.x; Fogassi L, 2005, SCIENCE, V308, P662, DOI 10.1126/science.1106138; Gaertner SL., 1999, CULTURAL DIVIDES UND, P173; Gallagher HL, 2004, NEUROPSYCHOLOGIA, V42, P1725, DOI 10.1016/j.neuropsychologia.2004.05.006; Gallese V, 2004, TRENDS COGN SCI, V8, P396, DOI 10.1016/j.tics.2004.07.002; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; GALLESE V, 2002, ATTENTION PERFORM, P247; Goldin-Meadow S, 2005, TRENDS COGN SCI, V9, P234, DOI 10.1016/j.tics.2005.03.006; Goldin-Meadow S., 2003, HEARING GESTURE OUR; Heiser M, 2003, EUR J NEUROSCI, V17, P1123, DOI 10.1046/j.1460-9568.2003.02530.x; Hewstone M, 2002, ANNU REV PSYCHOL, V53, P575, DOI 10.1146/annurev.psych.53.100901.135109; HORNSTEIN H, 1976, CRUELTY KINDNESS NEW; Iacoboni M, 1999, SCIENCE, V286, P2526, DOI 10.1126/science.286.5449.2526; Iacoboni M, 2005, PLOS BIOL, V3, P529, DOI 10.1371/journal.pbio.0030079; Iverson JM, 2005, PSYCHOL SCI, V16, P367, DOI 10.1111/j.0956-7976.2005.01542.x; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; Johnson-Frey SH, 2005, CEREB CORTEX, V15, P681, DOI 10.1093/cercor/bhh169; KENDON A, 1981, SEMIOTICA, V37, P129; Kendon A., 1972, STUDIES DYADIC COMMU, P177, DOI DOI 10.1016/B978-0-08-015867-9.50013-7; Kendon A., 1983, NONVERBAL INTERACTIO, V11, P13, DOI [10.1016/j.specom.2013.09.008, DOI 10.1016/J.SPECOM.2013.09.008]; Koski L, 2005, CLIN NEUROPHYSIOL, V116, P2099, DOI 10.1016/j.clinph.2005.06.006; MAASS A, 1989, J PERS SOC PSYCHOL, V57, P981, DOI 10.1037/0022-3514.57.6.981; McNeill D., 1992, HAND MIND WHAT HANDS; Molnar-Szakacs I, 2005, CEREB CORTEX, V15, P986, DOI 10.1093/cercor/bhh199; Molnar-Szakacs I, 2005, EUR J NEUROSCI, V21, P2000, DOI 10.1111/j.1460-9568.2005.04019.x; Molnar-Szakacs I, 2006, SOC COGN AFFECT NEUR, V1, P235, DOI 10.1093/scan/nsl029; Molnar-Szakacs I, 2006, NEUROIMAGE, V33, P923, DOI 10.1016/j.neuroimage.2006.07.035; Morris D., 1979, GESTURES THEIR ORIGI; Nakamura A, 2004, NEUROIMAGE, V23, P25, DOI 10.1016/j.neuroimage.2004.04.034; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PARK B, 1982, J PERS SOC PSYCHOL, V42, P1051, DOI 10.1037/0022-3514.42.6.1051; Patuzzo S, 2003, NEUROPSYCHOLOGIA, V41, P1272, DOI 10.1016/S0028-3932(02)00293-2; PAYRATO L, 1993, J PRAGMATICS, V20, P193, DOI 10.1016/0378-2166(93)90046-R; Perani D, 2001, NEUROIMAGE, V14, P749, DOI 10.1006/nimg.2001.0872; RABBIE JM, 1982, COOPERATION HELPING, P128; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Robbins JM, 2005, PERS SOC PSYCHOL REV, V9, P32, DOI 10.1207/s15327957pspr0901_3; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Stevens JA, 2000, NEUROREPORT, V11, P109, DOI 10.1097/00001756-200001170-00022; Tai YF, 2004, CURR BIOL, V14, P117, DOI 10.1016/j.cub.2004.01.005; TAJFEL H, 1971, EUR J SOC PSYCHOL, V1, P149, DOI 10.1002/ejsp.2420010202; Theoret H, 2004, COGNITIVE BRAIN RES, V20, P54, DOI 10.1016/j.cogbrainres.2004.01.003; Uddin LQ, 2005, NEUROIMAGE, V25, P926, DOI 10.1016/j.neuroimage.2004.12.018; Uddin LQ, 2007, TRENDS COGN SCI, V11, P153, DOI 10.1016/j.tics.2007.01.001; Uddin LQ, 2006, SOC COGN AFFECT NEUR, V1, P65, DOI 10.1093/scan/nsl003; Umilta MA, 2001, NEURON, V31, P155, DOI 10.1016/S0896-6273(01)00337-3; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; ZAIDEL E, 1978, CEREBRAL CORRELATES, P263	66	80	80	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e626	10.1371/journal.pone.0000626	http://dx.doi.org/10.1371/journal.pone.0000626			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637842	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452100016
J	Mzilahowa, T; McCall, PJ; Hastings, IM				Mzilahowa, Themba; McCall, Philip J.; Hastings, Ian M.			"Sexual" Population Structure and Genetics of the Malaria Agent P. falciparum	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM; LINKAGE DISEQUILIBRIUM; INOCULATION RATES; DRUG-RESISTANCE; PARASITES; TRANSMISSION; MARKERS; INFECTIONS; INTENSITY; EVOLUTION	The population genetics and structure of P. falciparum determine the rate at which malaria evolves in response to interventions such as drugs and vaccines. This has been the source of considerable recent controversy, but here we demonstrate the organism to be essentially sexual, in an area of moderately high transmission in the Lower Shire Valley, Malawi. Seven thousand mosquitoes were collected and dissected, and genetic data were obtained on 190 oocysts from 56 infected midguts. The oocysts were genotyped at three microsatellite loci and the MSP1 locus. Selfing rate was estimated as 50% and there was significant genotypic linkage disequilibrium (LD) in the pooled oocysts. A more appropriate analysis searching for genotypic LD in outcrossed oocysts and/or haplotypic LD in the selfed oocysts found no evidence for LD, indicating that the population was effectively sexual. Inbreeding estimates at MSP1 were higher than at the microsatellites, possibly indicative of immune action against MSP1, but the effect was confounded by the probable presence of null mutations. Mating appeared to occur at random in mosquitoes and evidence regarding whether malaria clones in the same host were related ( presumably through simultaneous inoculation in the same mosquito bite) was ambiguous. This is the most detailed genetic analysis yet of P. falciparum sexual stages, and shows P. falciparum to be a sexual organism whose genomes are in linkage equilibrium, which acts to slow the emergence of drug resistance and vaccine insensitivity, extending the likely useful therapeutic lifespan of drugs and vaccines.	[Mzilahowa, Themba; McCall, Philip J.; Hastings, Ian M.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Mzilahowa, Themba] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi	Liverpool School of Tropical Medicine; University of Liverpool; University of Malawi	Hastings, IM (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.	hastings@liverpool.ac.uk		McCall, Philip J/0000-0002-0007-3985; Hastings, Ian/0000-0002-1332-742X	UNICEF/UNDP/World Bank/WHO; Gates Malaria Partnership (GMP)	UNICEF/UNDP/World Bank/WHO(World Health Organization); Gates Malaria Partnership (GMP)	Financial support from the UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) and the Gates Malaria Partnership (GMP) is gratefully acknowledged.	Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467, DOI 10.1093/oxfordjournals.molbev.a026247; Anderson TJC, 2000, GENET RES, V75, P285, DOI 10.1017/S0016672300004481; [Anonymous], 1987, PUBLICATIONS S AFRIC; [Anonymous], 1993, MOSQUITO ECOLOGY FIE; Anthony TG, 2000, PARASITOLOGY, V121, P121, DOI 10.1017/S003118209900623X; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P3346, DOI 10.1073/pnas.95.7.3346; BENNETT J. H., 1956, HEREDITY, V10, P51, DOI 10.1038/hdy.1956.3; BURKOT TR, 1988, AM J TROP MED HYG, V39, P135, DOI 10.4269/ajtmh.1988.39.135; Carter R, 2000, NAT MED, V6, P241, DOI 10.1038/73062; CONWAY DJ, 1991, PARASITOLOGY, V103, P1, DOI 10.1017/S0031182000059217; Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506; CURTIS CF, 1986, T ROY SOC TROP MED H, V80, P889, DOI 10.1016/0035-9203(86)90248-8; Durand P, 2003, AM J TROP MED HYG, V68, P345, DOI 10.4269/ajtmh.2003.68.345; DYE C, 1991, PARASITOL TODAY, V7, P236, DOI 10.1016/0169-4758(91)90236-H; Dye C, 1997, P ROY SOC B-BIOL SCI, V264, P61, DOI 10.1098/rspb.1997.0009; DYE C, 1990, NATURE, V348, P120, DOI 10.1038/348120b0; Goudet J, 1995, J HERED, V86, P485, DOI 10.1093/oxfordjournals.jhered.a111627; Goudet J., 2001, FSTAT PROGRAM ESTIMA; GREEN RF, 1995, J THEOR BIOL, V174, P87, DOI 10.1006/jtbi.1995.0081; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; Hastings IM, 2006, PARASITOLOGY, V132, P615, DOI 10.1017/S0031182005009790; Hastings IM, 1996, PARASITOLOGY, V112, P155, DOI 10.1017/S0031182000084717; Hastings IM, 1997, PARASITOL TODAY, V13, P375, DOI 10.1016/S0169-4758(97)01110-1; Hastings IM, 1997, PARASITOLOGY, V115, P133, DOI 10.1017/S0031182097001261; Hastings IM, 2003, TRENDS PARASITOL, V19, P70, DOI 10.1016/S1471-4922(02)00017-X; Hastings IM, 2005, ACTA TROP, V94, P218, DOI 10.1016/j.actatropica.2005.04.003; HASTINGS IM, 2003, J PARASITOL, V89, pS62; Haubold B, 2000, BIOINFORMATICS, V16, P847, DOI 10.1093/bioinformatics/16.9.847; Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3; HILL WG, 1995, GENET RES, V65, P53, DOI 10.1017/S0016672300033000; Hill William G., 1995, Proceedings of the Royal Society of London Series B Biological Sciences, V262, P249, DOI 10.1098/rspb.1995.0203; HUDSON RR, 1994, J EVOLUTION BIOL, V7, P535, DOI 10.1046/j.1420-9101.1994.7050535.x; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335; MZILAHOWA T, 2005, THESIS LIVERPOOL SCH; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; Paul REL, 1999, T ROY SOC TROP MED H, V93, P587, DOI 10.1016/S0035-9203(99)90057-3; PONNUDURAI T, 1991, T ROY SOC TROP MED H, V85, P175, DOI 10.1016/0035-9203(91)90012-N; PROVINE EWB, 1986, SELECTED PAPERS S WR; RANFORDCARTWRIGHT LC, 1991, MOL BIOCHEM PARASIT, V49, P239, DOI 10.1016/0166-6851(91)90067-G; Razakandrainibe FG, 2005, P NATL ACAD SCI USA, V102, P17388, DOI 10.1073/pnas.0508871102; READ AF, 1992, PARASITOL TODAY, V8, P239, DOI 10.1016/0169-4758(92)90125-L; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; Schneider S., 2000, ARLEQUIN VER 2 000 S; SMITH T, 1993, ACTA TROP, V54, P55, DOI 10.1016/0001-706X(93)90068-M; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B; Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; Talisuna AO, 2002, T ROY SOC TROP MED H, V96, P310, DOI 10.1016/S0035-9203(02)90108-2; Tibayrenc M., 1995, Advances in Parasitology, V36, P47, DOI 10.1016/S0065-308X(08)60490-X; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; WALLIKER D, 1991, PARASITOL TODAY, V7, P232, DOI 10.1016/0169-4758(91)90235-G; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WALLIKER D, 1990, NATURE, V348, P120, DOI 10.1038/348120a0; WHO, 1975, MAN PRACT ENT 2	55	41	41	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e613	10.1371/journal.pone.0000613	http://dx.doi.org/10.1371/journal.pone.0000613			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637829	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452100003
J	Eddleston, M; Udayakumara, N; Adhikari, S; de Silva, D; Sheriff, MHR; Waidyaratne, DL				Eddleston, Michael; Udayakumara, Nilantha; Adhikari, Sriyantha; de Silva, Dhamika; Sheriff, M. H. Rezvi; Waidyaratne, Dhananjaya L.			The Importance of Poisoning vs. Road Traffic Injuries as a Cause of Death in Rural Sri Lanka	PLOS ONE			English	Article								Background. Road traffic crashes are considered by the WHO to be the most important global cause of death from injury. However, this may not be true for large areas of rural Asia where road vehicles are uncommon. The issue is important, since emphasising the importance of road traffic crashes risks switching resources to urban areas, away from already underfunded rural regions. In this study, we compared the importance of road traffic crashes with other forms of injury in a poor rural region of South Asia. Methodology/Principal Findings. We collected data on all deaths from injury in the North Central Province of Sri Lanka (NCP; population 1,105,198 at 2001 census) over 18 months using coronial, hospital, and police data. We calculated the incidence of death from all forms of intentional and unintentional injury in the province. The annual incidence of death from injury in the province was high: 84.2 per 100,000 population. Half of the deaths were from self-harm (41.3/100,000). Poisoning (35.7/100,000)-in particular, pesticide self-poisoning (23.7/100,000)-was the most common cause of death, being 3.9-fold more common than road traffic crashes (9.1/100,000). Conclusions/Significance. In poor rural regions of South Asia, fatal self-harm and pesticide self-poisoning in particular are significantly more important than road traffic injuries as a cause of death. It is possible that the data used by the WHO to calculate global injury estimates are biased towards urban areas with better data collection but little pesticide poisoning. More studies are required to inform a debate about the importance of different forms of injury and how avoidable deaths from any cause can be prevented. In the meantime, marked improvements in the effectiveness of therapy for pesticide poisoning, safer storage, reduced pesticide use, or reductions in pesticide toxicity are required urgently to reduce the number of deaths from self-poisoning in rural Asia.	[Eddleston, Michael] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England; [Eddleston, Michael; Sheriff, M. H. Rezvi] Univ Colombo, Dept Clin Med, Ox Col Collaborat, Colombo, Sri Lanka; [de Silva, Dhamika] Off Prov Director Hlth Serv, Anuradhapura, North Central P, Sri Lanka; [Waidyaratne, Dhananjaya L.] Anuradhapura Gen Hosp, Anuradhapura, North Central P, Sri Lanka	University of Oxford; University of Colombo	Eddleston, M (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England.	eddlestonm@yahoo.com			Wellcome's Tropical Interest Group [GR063560MA]; Wellcome Trust/National Health; Medical Research Council International Collaborative Research [071669MA]	Wellcome's Tropical Interest Group; Wellcome Trust/National Health(Wellcome Trust); Medical Research Council International Collaborative Research	ME is a Wellcome Trust Career Development Fellow; this work was funded by grant GR063560MA from the Wellcome's Tropical Interest Group to ME. The South Asian Clinical Toxicology Research Collaboration (SACTRC) is funded by the Wellcome Trust/National Health and Medical Research Council International Collaborative Research Grant 071669MA.	Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; Bertolote JM, 2006, BRIT J PSYCHIAT, V189, P201, DOI 10.1192/bjp.bp.105.020834; Bose A, 2006, TROP MED INT HEALTH, V11, P1553, DOI 10.1111/j.1365-3156.2006.01707.x; *DEP CENS STAT GOS, 2007, MIDY POP VIT STAT DI; Eddleston M, 2006, CLIN TOXICOL, V44, P283, DOI 10.1080/15563650600584444; Eddleston M, 2005, BRIT J PSYCHIAT, V187, P583, DOI 10.1192/bjp.187.6.583; Eddleston M, 2005, LANCET, V366, P1452, DOI 10.1016/S0140-6736(05)67598-8; Eddleston M, 2004, BMJ-BRIT MED J, V328, P42, DOI 10.1136/bmj.328.7430.42; Eddleston M, 2007, INT J EPIDEMIOL, V36, P208, DOI 10.1093/ije/dyl240; FERNANDO R, 1998, MANAGEMENT POISONING, P192; Gajalakshmi V, 2007, INT J EPIDEMIOL, V36, P203, DOI 10.1093/ije/dyl308; Gawarammana IB, 2004, MED J AUSTRALIA, V180, P20, DOI 10.5694/j.1326-5377.2004.tb05768.x; Gutierrez JM, 2006, PLOS MED, V3, P727, DOI 10.1371/journal.pmed.0030150; International Fund for Agricultural Development, 2002, ASS RUR POV AS PAC; Joseph A, 2003, BRIT MED J, V326, P1121, DOI 10.1136/bmj.326.7399.1121; Krug EG, 2004, LANCET, V364, P1563, DOI 10.1016/S0140-6736(04)17328-5; Kularatne SAM, 2002, POSTGRAD MED J, V78, P276, DOI 10.1136/pmj.78.919.276; [李献云 Li Xianyun], 2002, [中国心理卫生杂志, Chinese Mental Health Journal], V16, P681; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Pearson V, 2002, SUICIDE LIFE-THREAT, V32, P359, DOI 10.1521/suli.32.4.359.22345; Peden M., 2004, WORLD REPORT ROAD TR; Phillips MR, 2002, LANCET, V360, P1728, DOI 10.1016/S0140-6736(02)11681-3; Sharma SK, 2004, AM J TROP MED HYG, V71, P234, DOI 10.4269/ajtmh.2004.71.234; THEAKSTON RDG, 1990, T ROY SOC TROP MED H, V84, P301, DOI 10.1016/0035-9203(90)90297-R; WHO, 2001, WORLD HLTH REPORT 20; *WHO REG OFF W PAC, 2005, FACT SHEET HLTH POV; World Health Organization, 2002, WORLD REPORT VIOLENC; World Health Organization, 2004, WORLD HLTH REP 2004; Yang GH, 2005, BIOMED ENVIRON SCI, V18, P379	29	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e599	10.1371/journal.pone.0000599	http://dx.doi.org/10.1371/journal.pone.0000599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622344	gold, Green Published			2022-12-25	WOS:000207452000006
J	Abel, U; Deichmann, A; Bartholomae, C; Schwarzwaelder, K; Glimm, H; Howe, S; Thrasher, A; Garrigue, A; Hacein-Bey-Abina, S; Cavazzana-Calvo, M; Fischer, A; Jaeger, D; von Kalle, C; Schmidt, M				Abel, Ulrich; Deichmann, Annette; Bartholomae, Cynthia; Schwarzwaelder, Kerstin; Glimm, Hanno; Howe, Steven; Thrasher, Adrian; Garrigue, Alexandrine; Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina; Fischer, Alain; Jaeger, Dirk; von Kalle, Christof; Schmidt, Manfred			Real-Time Definition of Non-Randomness in the Distribution of Genomic Events	PLOS ONE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; RETROVIRAL VECTOR INTEGRATION; GENE-THERAPY; SEQUENCE; ASSOCIATION; REPEATS; TARGETS; CANCER	Features such as mutations or structural characteristics can be non-randomly or non-uniformly distributed within a genome. So far, computer simulations were required for statistical inferences on the distribution of sequence motifs. Here, we show that these analyses are possible using an analytical, mathematical approach. For the assessment of non-randomness, our calculations only require information including genome size, number of ( sampled) sequence motifs and distance parameters. We have developed computer programs evaluating our analytical formulas for the real-time determination of expected values and p-values. This approach permits a flexible cluster definition that can be applied to most effectively identify non-random or non-uniform sequence motif distribution. As an example, we show the effectivity and reliability of our mathematical approach in clinical retroviral vector integration site distribution.	[Abel, Ulrich; Deichmann, Annette; Bartholomae, Cynthia; Schwarzwaelder, Kerstin; Glimm, Hanno; Jaeger, Dirk; von Kalle, Christof; Schmidt, Manfred] Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany; [Abel, Ulrich; Howe, Steven] Tumor Ctr Heidelberg Mannheim, Dept Med Biostat, Heidelberg, Germany; [Thrasher, Adrian] UCL, Mol Immunol Unit, Inst Child Hlth, London, England; [Thrasher, Adrian] Great Ormond St Hosp NHS Trust, Dept Clin Immunol, London, England; [Garrigue, Alexandrine; Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina; Fischer, Alain] Univ Paris 05, INSERM Unit 768, Hop Necker, Paris, France; [Garrigue, Alexandrine; Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina; Fischer, Alain] Univ Paris 05, Fac Med, Paris, France; [Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina] Hop Necker Enfants Malad, Dept Biotherapies, Paris, France; [Fischer, Alain] Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, Paris, France; [von Kalle, Christof] Cincinnati Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH USA	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	von Kalle, C (corresponding author), Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany.	christof.kalle@nct-heidelberg.de; manfred.schmidt@nct-heidelberg.de	Howe, Steven J/C-4801-2008	Howe, Steven J/0000-0003-2940-2874; Garrigue, Alexandrine/0000-0002-2660-3681	Deutsche Forschungsgemeinschaft [SPP1230]; German Ministry of Education and Research; EU; Great Ormond Street Hospital Childrens Charity [V1223] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); EU(European Commission); Great Ormond Street Hospital Childrens Charity	This work was supported by the Deutsche Forschungsgemeinschaft ( Grant SPP1230), the German Ministry of Education and Research ( Grant TREATID) and the EU ( VIth Framework Program, CONSERT and CLINIGENE).	Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bakker EG, 2006, PLANT CELL, V18, P1803, DOI 10.1105/tpc.106.042614; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Calmels B, 2005, BLOOD, V106, P2530, DOI 10.1182/blood-2005-03-1115; Camargo AA, 2001, P NATL ACAD SCI USA, V98, P12103, DOI 10.1073/pnas.201182798; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; DUDEWICZ EJ, 1988, MODERN MATH STAT; Garrigan D, 2006, NAT REV GENET, V7, P669, DOI 10.1038/nrg1941; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Gerhard DS, 2004, GENOME RES, V14, P2121, DOI 10.1101/gr.2596504; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HARTUNG J, 1987, STATISTIK; Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laufs S, 2003, BLOOD, V101, P2191, DOI 10.1182/blood-2002-02-0627; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Modlich U, 2005, BLOOD, V105, P4235, DOI 10.1182/blood-2004-11-4535; Montini E, 2006, NAT BIOTECHNOL, V24, P687, DOI 10.1038/nbt1216; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Riva A, 2004, COMPUT BIOL CHEM, V28, P109, DOI 10.1016/j.compbiolchem.2003.12.004; Subramanian S, 2003, BIOINFORMATICS, V19, P681, DOI 10.1093/bioinformatics/btg067; Subramanian S, 2003, BIOINFORMATICS, V19, P549, DOI 10.1093/bioinformatics/btg029; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Wang JX, 2006, GENE, V365, P11, DOI 10.1016/j.gene.2005.09.031; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wu XL, 2006, VIROLOGY, V344, P292, DOI 10.1016/j.virol.2005.08.047; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413	37	28	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e570	10.1371/journal.pone.0000570	http://dx.doi.org/10.1371/journal.pone.0000570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593969	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451800014
J	Fowler, MA; Sidiropoulou, K; Ozkan, ED; Phillips, CW; Cooper, DC				Fowler, Melissa A.; Sidiropoulou, Kyriaki; Ozkan, Emin D.; Phillips, Christopher W.; Cooper, Donald C.			Corticolimbic Expression of TRPC4 and TRPC5 Channels in the Rodent Brain	PLOS ONE			English	Article							LONG-TERM POTENTIATION; METABOTROPIC GLUTAMATE-RECEPTOR-5; SYNAPTIC PLASTICITY; SURFACE EXPRESSION; PREFRONTAL CORTEX; SUBSTANTIA-NIGRA; CALCIUM CURRENTS; RECEPTOR; ACTIVATION; MODULATION	The canonical transient receptor potential ( TRPC) channels are a family of non-selective cation channels that are activated by increases in intracellular Ca2+ and G(q)/phospholipase C-coupled receptors. We used quantitative real-time PCR, in situ hybridization, immunoblots and patch-clamp recording from several brain regions to examine the expression of the predominant TRPC channels in the rodent brain. Quantitative real-time PCR of the seven TRPC channels in the rodent brain revealed that TRPC4 and TRPC5 channels were the predominant TRPC subtypes in the adult rat brain. In situ hybridization histochemistry and immunoblotting further resolved a dense corticolimbic expression of the TRPC4 and TRPC5 channels. Total protein expression of HIP TRPC4 and 5 proteins increased throughout development and peaked late in adulthood (6-9 weeks). In adults, TRPC4 expression was high throughout the frontal cortex, lateral septum (LS), pyramidal cell layer of the hippocampus ( HIP), dentate gyrus (DG), and ventral subiculum (vSUB). TRPC5 was highly expressed in the frontal cortex, pyramidal cell layer of the HIP, DG, and hypothalamus. Detailed examination of frontal cortical layer mRNA expression indicated TRPC4 mRNA is distributed throughout layers 2-6 of the prefrontal cortex (PFC), motor cortex (MCx), and somatosensory cortex (SCx). TRPC5 mRNA expression was concentrated specifically in the deep layers 5/6 and superficial layers 2/3 of the PFC and anterior cingulate. Patch-clamp recording indicated a strong metabotropic glutamate-activated cation current-mediated depolarization that was dependent on intracellular Ca2+ and inhibited by protein kinase C in brain regions associated with dense TRPC4 or 5 expression and absent in regions lacking TRPC4 and 5 expression. Overall, the dense corticolimbic expression pattern suggests that these Gq/PLC coupled nonselective cation channels may be involved in learning, memory, and goal-directed behaviors.	[Fowler, Melissa A.; Ozkan, Emin D.; Phillips, Christopher W.; Cooper, Donald C.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Sidiropoulou, Kyriaki] FORTH, Computat Biol Lab, IMBB, Vassilika Vouton, Heraklio, Greece	University of Texas System; University of Texas Southwestern Medical Center Dallas; Foundation for Research & Technology - Hellas (FORTH)	Cooper, DC (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.	Don.Cooper@utsouthwestern.edu	Ozkan, Emin Deniz/A-5752-2009; Sidiropoulou, Kyriaki/AAA-2126-2021	Ozkan, Emin Deniz/0000-0002-1073-6703; Sidiropoulou, Kyriaki/0000-0001-7400-4678	NIDA K [K-01 DA017750-01]; NARSAD Young Investigator; NIDA institutional training [T32-DA7290]; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA017750, T32DA007290] Funding Source: NIH RePORTER	NIDA K(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NARSAD Young Investigator(NARSAD); NIDA institutional training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by a NIDA K award (K-01 DA017750-01) to DCC, a NARSAD Young Investigator award to DCC, and a NIDA institutional training grant (T32-DA7290) to MAF.	Ajay SM, 2006, PHYSIOLOGY, V21, P289, DOI 10.1152/physiol.00009.2006; BERENDSE HW, 1992, J COMP NEUROL, V316, P314, DOI 10.1002/cne.903160305; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005; BROG JS, 1993, J COMP NEUROL, V338, P255, DOI 10.1002/cne.903380209; Carr DB, 2002, J NEUROSCI, V22, P6846; Chung YH, 2006, BRAIN RES, V1085, P132, DOI 10.1016/j.brainres.2006.02.087; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cooper DC, 2005, PLOS BIOL, V3, P1123, DOI 10.1371/journal.pbio.0030175; Cooper DC, 2002, NEUROCHEM INT, V41, P333, DOI 10.1016/S0197-0186(02)00068-2; De March Z, 2006, NEUROSCI LETT, V402, P35, DOI 10.1016/j.neulet.2006.03.061; Glazebrook PA, 2005, PFLUG ARCH EUR J PHY, V451, P125, DOI 10.1007/s00424-005-1468-5; Gold SJ, 2004, METHOD ENZYMOL, V389, P205; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Gruenbaum LM, 1999, LEARN MEMORY, V6, P292; Gubellini P, 2004, NEUROPHARMACOLOGY, V46, P761, DOI 10.1016/j.neuropharm.2003.11.021; HARDIE RC, 2006, J PHYSL; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kampfer H, 1999, J INVEST DERMATOL, V113, P369, DOI 10.1046/j.1523-1747.1999.00704.x; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kanki H, 2001, MOL PHARMACOL, V60, P989, DOI 10.1124/mol.60.5.989; Kim SJ, 2003, NATURE, V426, P285, DOI 10.1038/nature02162; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Kreitzer AC, 2005, J NEUROSCI, V25, P10537, DOI 10.1523/JNEUROSCI.2959-05.2005; Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; Martorana A, 2006, EUR J NEUROSCI, V24, P732, DOI 10.1111/j.1460-9568.2006.04932.x; Miura M, 2002, J NEUROSCI, V22, P8379; Nasif FJ, 2005, J PHARMACOL EXP THER, V312, P1305, DOI 10.1124/jpet.104.075184; Nasif FJ, 2005, J NEUROSCI, V25, P3674, DOI 10.1523/JNEUROSCI.0010-05.2005; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Otsuka Y, 1998, TOHOKU J EXP MED, V185, P139, DOI 10.1620/tjem.185.139; Putney James W Jr, 2004, Novartis Found Symp, V258, P123; Putney JW, 2005, PFLUG ARCH EUR J PHY, V451, P29, DOI 10.1007/s00424-005-1416-4; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SCHIEGG A, 1995, J NEUROPHYSIOL, V74, P1046, DOI 10.1152/jn.1995.74.3.1046; Shinoe T, 2005, J NEUROSCI, V25, P11194, DOI 10.1523/JNEUROSCI.2338-05.2005; Simonyi A, 2005, DRUG NEWS PERSPECT, V18, P353, DOI 10.1358/dnp.2005.18.6.927927; Sosa R, 2002, J NEUROCHEM, V81, P973, DOI 10.1046/j.1471-4159.2002.00883.x; STEFANI A, 1994, J NEUROSCI, V14, P6734; Tichopad A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng122; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; VENKATACHALAM K, 2004, NOV FDN S, P172; Vertes RP, 2004, SYNAPSE, V51, P32, DOI 10.1002/syn.10279; von Bohlen und Halbach O, 2005, CELL TISSUE RES, V322, P201, DOI 10.1007/s00441-005-0004-4; Xie Q, 2005, EXP EYE RES, V81, P5, DOI 10.1016/j.exer.2005.01.003; Zhang F, 1997, SCIENCE, V275, P1318, DOI 10.1126/science.275.5304.1318; Zhu HF, 2005, CRYST GROWTH DES, V5, P289, DOI 10.1021/cg0498857; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	54	118	118	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e573	10.1371/journal.pone.0000573	http://dx.doi.org/10.1371/journal.pone.0000573			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593972	Green Submitted, gold, Green Published			2022-12-25	WOS:000207451800017
J	Yang, F; Strand, DW; Rowley, DR				Yang, F.; Strand, D. W.; Rowley, D. R.			Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma	ONCOGENE			English	Article						transforming growth factor-beta; fibroblast growth factor; prostate cancer; stroma; angiogenesis	MOUSE MODEL; EXPRESSION; ANGIOGENESIS; RECEPTOR; INDUCTION; FGF; GROWTH-FACTOR-BETA-1; SECRETION; PHENOTYPE; FIBROSIS	Transforming growth factor-beta (TGF-beta) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-beta regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-beta action in cancer-associated reactive stroma, we developed prostate stromal cells null for TGF-beta receptor II (T beta RII) or engineered to express a dominant-negative Smad3 to attenuate TGF-beta signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-beta signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TbRII null or dominant-negative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-beta signaling in stroma. In vitro, TGF-b stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-b signaling were refractory to TGF-beta-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-beta signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TbRII/Smad3-dependent upregulation of FGF-2 expression and release.	[Yang, F.; Strand, D. W.; Rowley, D. R.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Rowley, DR (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,325D, Houston, TX 77030 USA.	drowley@bcm.tmc.edu	Strand, Douglas/A-1702-2011; Strand, Douglas/K-4003-2019	Strand, Douglas/0000-0002-0746-927X	NCI NIH HHS [P50-CA58204, U54-CA126568, UO1-CA84296, R01-CA058093] Funding Source: Medline; NIDDK NIH HHS [R01-DK045909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA126568, R01CA058093, P50CA058204, U01CA084296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Backhaus R, 2004, J CELL SCI, V117, P1727, DOI 10.1242/jcs.01027; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Butter S, 2001, EUR J PHARMACOL, V422, P47, DOI 10.1016/S0014-2999(01)01072-X; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; COFFEY RJ, 1986, CANCER RES, V46, P1164; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dow JK, 2000, UROLOGY, V55, P800, DOI 10.1016/S0090-4295(00)00457-X; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EASTHAM JA, 1995, LAB INVEST, V73, P628; Fukabori Y, 1997, Int J Urol, V4, P597, DOI 10.1111/j.1442-2042.1997.tb00316.x; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078-0432.CCR-04-0632; Huss WJ, 2003, PROSTATE, V54, P8, DOI 10.1002/pros.10163; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Peehl DM, 1998, PROSTATE, V35, P125, DOI 10.1002/(SICI)1097-0045(19980501)35:2<125::AID-PROS6>3.0.CO;2-I; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Polnaszek N, 2003, CANCER RES, V63, P5754; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; ROWLEY DR, 2007, TRANSFORMING GROWTH; Sakko AJ, 2001, CANCER RES, V61, P926; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Story MT, 1996, PROSTATE, V28, P219; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Uchiyama-Tanaka Y, 2002, KIDNEY INT, V62, P799, DOI 10.1046/j.1523-1755.2002.00537.x; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702	37	67	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					450	459		10.1038/sj.onc.1210663	http://dx.doi.org/10.1038/sj.onc.1210663			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637743				2022-12-25	WOS:000252426100005
J	Milgram, NW; Araujo, JA; Hagen, TM; Treadwell, BV; Ames, BN				Milgram, N. W.; Araujo, J. A.; Hagen, T. M.; Treadwell, B. V.; Ames, B. N.			Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests	FASEB JOURNAL			English	Article						LA; ALC; cognitive aging; mitochondria; visuo-spatial working memory	SHORT-TERM-MEMORY; OLD RATS; MITOCHONDRIAL DECAY; OXIDATIVE DAMAGE; DIABETIC POLYNEUROPATHY; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; MODEL; BRAIN; DYSFUNCTION	Beagle dogs between 7.6 and 8.8 years of age administered a twice daily supplement of alpha-lipoic acid (LA) and acetyl-L-carnitine (ALC) over similar to 2 months made significantly fewer errors in reaching the learning criterion on two landmark discrimination tasks compared to controls administered a methylcellulose placebo. Testing started after a 5 day wash-in. The dogs were also tested on a variable delay version of a previously acquired spatial memory task; results were not significant. The improved performance on the landmark task of dogs supplemented with LA + ALC provides evidence of the effectiveness of this supplement in improving discrimination and allocentric spatial learning. We suggest that long-term maintenance on LA and ALC may be effective in attenuating age-associated cognitive decline by slowing the rate of mitochondrial decay and cellular aging.	CanCog Technol, Toronto, ON M5A 4K2, Canada; Univ Toronto, Div Life Sci, Scarborough, ON M1C 1A4, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; Oregon State Univ, Linus Pauling Inst Sci & Med, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Juvenon Inc, Incline Village, NV USA; Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of Toronto; University Toronto Scarborough; University of Toronto; Oregon State University; University of California System; University of California Berkeley; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Milgram, NW (corresponding author), CanCog Technol, 120 Carlton St,Suite 204, Toronto, ON M5A 4K2, Canada.	milgram@psych.utoronto.ca						Adams B, 2000, BEHAV BRAIN RES, V108, P47, DOI 10.1016/S0166-4328(99)00132-1; Adams B, 2000, PROG NEURO-PSYCHOPH, V24, P675, DOI 10.1016/S0278-5846(00)00101-9; Ametov AS, 2003, DIABETES CARE, V26, P770, DOI 10.2337/diacare.26.3.770; Ando S, 2001, J NEUROSCI RES, V66, P266, DOI 10.1002/jnr.1220; BACHEVALIER J, 1991, NEUROBIOL AGING, V12, P99, DOI 10.1016/0197-4580(91)90048-O; BARTUS RT, 1978, J GERONTOL, V33, P858, DOI 10.1093/geronj/33.6.858; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; CAPRIOLI A, 1995, J GERONTOL A-BIOL, V50, pB232, DOI 10.1093/gerona/50A.4.B232; Chan ADF, 2002, BEHAV NEUROSCI, V116, P443, DOI 10.1037//0735-7044.116.3.443; Christie LA, 2005, PROG NEURO-PSYCHOPH, V29, P361, DOI 10.1016/j.pnpbp.2004.12.002; COGAN DG, 1979, AM J OPHTHALMOL, V88, P361, DOI 10.1016/0002-9394(79)90634-2; Cummings BJ, 1996, NEUROBIOL AGING, V17, P259, DOI 10.1016/0197-4580(95)02060-8; GIACCONE G, 1990, NEUROSCI LETT, V114, P178, DOI 10.1016/0304-3940(90)90068-K; Hagen TM, 1998, ANN NY ACAD SCI, V854, P214, DOI 10.1111/j.1749-6632.1998.tb09904.x; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P1870, DOI 10.1073/pnas.261708898; Hagen TM, 2000, ANTIOXID REDOX SIGN, V2, P473, DOI 10.1089/15230860050192251; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Head E, 2000, NEUROBIOL AGING, V21, P89, DOI 10.1016/S0197-4580(00)00093-2; HEAD E, 1995, BEHAV NEUROSCI, V109, P851, DOI 10.1037/0735-7044.109.5.851; Head E, 2002, J NEUROCHEM, V82, P375, DOI 10.1046/j.1471-4159.2002.00969.x; Head E, 2001, FUNCT NEUROBIOL AGIN, V2001, P457; IMPERATO A, 1991, ANN N Y ACAD SCI, V621, P90; Konrad T, 1999, DIABETES CARE, V22, P280, DOI 10.2337/diacare.22.2.280; Lieberman HR, 2006, NUTR REV, V64, pS10, DOI 10.1111/j.1753-4887.2006.tb00252.x; Liu JK, 2002, P NATL ACAD SCI USA, V99, P1876, DOI 10.1073/pnas.261709098; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; MARRIOTT JG, 1980, AGE, V3, P7, DOI 10.1007/BF02434999; Milgram NW, 1999, LEARN MEMORY, V6, P54; Milgram NW, 2002, NEUROBIOL AGING, V23, P737, DOI 10.1016/S0197-4580(02)00020-9; Milgram NW, 2002, NEUROSCI BIOBEHAV R, V26, P679, DOI 10.1016/S0149-7634(02)00039-8; MILGRAM NW, 1994, BEHAV NEUROSCI, V108, P57, DOI 10.1037/0735-7044.108.1.57; Montgomery SA, 2003, INT CLIN PSYCHOPHARM, V18, P61, DOI 10.1097/00004850-200303000-00001; Rapp PR, 1997, NEUROREPORT, V8, P1923, DOI 10.1097/00001756-199705260-00026; RAPP PR, 1989, J NEUROSCI, V9, P3568; Schulz R, 2006, ENCY AGING; Sharma M, 2003, EUR NEUROPSYCHOPHARM, V13, P241, DOI 10.1016/S0924-977X(03)00008-7; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sima AAF, 2005, DIABETES CARE, V28, P89, DOI 10.2337/diacare.28.1.89; Studzinski CM, 2006, NEUROBIOL LEARN MEM, V86, P197, DOI 10.1016/j.nlm.2006.02.005; Tapp P. D, 2006, HDB MODELS HUMAN AGI, P415, DOI DOI 10.1016/B978-012369391-4/50036-9; Tapp PD, 2003, LEARN MEMORY, V10, P64, DOI 10.1101/lm.54403; Tetewsky SJ, 1999, NEUROLOGY, V52, P958, DOI 10.1212/WNL.52.5.958; WHITE HL, 1990, NEUROCHEM RES, V15, P597, DOI 10.1007/BF00973749; Yasui F, 2002, NEUROSCI LETT, V334, P177, DOI 10.1016/S0304-3940(02)01127-8; Ziegler D, 2004, DIABETIC MED, V21, P114, DOI 10.1111/j.1464-5491.2004.01109.x	48	38	40	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3756	3762		10.1096/fj.07-8531com	http://dx.doi.org/10.1096/fj.07-8531com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17622567				2022-12-25	WOS:000250517800037
J	Gutternigg, M; Kretschmer-Lubich, D; Paschinger, K; Rendic, D; Hader, J; Geier, P; Ranftl, R; Jantsch, V; Lochnit, G; Wilson, IBH				Gutternigg, Martin; Kretschmer-Lubich, Dorothea; Paschinger, Katharina; Rendic, Dubravko; Hader, Josef; Geier, Petra; Ranftl, Ramona; Jantsch, Verena; Lochnit, Guenter; Wilson, Iain B. H.			Biosynthesis of truncated N-linked oligosaccharides results from non-orthologous hexosaminidase-mediated mechanisms in nematodes, plants, and insects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MANNOSIDASE-II; CORE ALPHA-1,3-LINKED FUCOSE; CARBOHYDRATE-ACTIVE ENZYMES; CAENORHABDITIS-ELEGANS; ARABIDOPSIS-THALIANA; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; ACETYLGLUCOSAMINYLTRANSFERASE-I; STREPTOCOCCUS-PNEUMONIAE; BETA-HEXOSAMINIDASE	In many invertebrates and plants, the N-glycosylation profile is dominated by truncated paucimannosidic N-glycans, i.e. glycans consisting of a simple trimannosylchitobiosyl core often modified by core fucose residues. Even though they lack antennal N-acetylglucosamine residues, the biosynthesis of these glycans requires the sequential action of GlcNAc transferase I, Golgi mannosidase II, and, finally, beta-N-acetylglucosaminidases. In Drosophila, the recently characterized enzyme encoded by the fused lobes (fdl) gene specifically removes the non-reducing N-acetylglucosamine residue from the alpha 1,3-antenna of N-glycans. In the present study, we examined the products of five beta-N-acetylhexosaminidase genes from Caenorhabditis elegans (hex-1 to hex-5, corresponding to reading frames T14F9.3, C14C11.3, Y39A1C.4, Y51F10.5, and Y70D2A.2) in addition to three from Arabidopsis thaliana (AtHEX1, AtHEX2, and AtHEX3, corresponding to reading frames At1g65590, At3g55260, and At1g05590). Based on homology, the Caenorhabditis HEX-1 and all three Arabidopsis enzymes are members of the same sub-family as the aforementioned Drosophila fused lobes enzyme but either act as chitotriosidases or non-specifically remove N-acetylglucosamine from both N-glycan antennae. The other four Caenorhabditis enzymes are members of a distinct sub-family; nevertheless, two of these enzymes displayed the same alpha 1,3-antennal specificity as the fused lobes enzyme. Furthermore, a deletion of part of the Caenorhabditis hex-2 gene drastically reduces the native N-glycan-specific hexosaminidase activity in mutant worm extracts and results in a shift in the N-glycan profile, which is a demonstration of its in vivo enzymatic relevance. Based on these data, it is hypothesized that the genetic origin of pauci-mannosidic glycans in nematodes, plants, and insects involves highly divergent members of the same hexosaminidase gene family.	Univ Nat Resources & Appl Life Sci, Dept Chem, BOKU, A-1190 Vienna, Austria; Vienna Bioctr 2, Abt Chromosomenbiol, A-1030 Vienna, Austria; Univ Giessen, Inst Biochem, D-35292 Giessen, Germany	University of Natural Resources & Life Sciences, Vienna; Vienna Biocenter (VBC); Justus Liebig University Giessen	Wilson, IBH (corresponding author), Univ Nat Resources & Appl Life Sci, Dept Chem, BOKU, Muthgasse 18, A-1190 Vienna, Austria.	iain.wilson@boku.ac.at	Rendic, Dubravko/A-9368-2010; Wilson, Iain/B-3326-2009; Jantsch, Verena/A-3910-2017	Wilson, Iain/0000-0001-8996-1518; Jantsch, Verena/0000-0002-1978-682X; Paschinger, Katharina/0000-0002-3594-7136	Austrian Science Fund FWF [P 18447] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; Aoki K, 2007, J BIOL CHEM, V282, P9127, DOI 10.1074/jbc.M606711200; Aumiller JJ, 2006, PROTEIN EXPRES PURIF, V47, P571, DOI 10.1016/j.pep.2005.11.026; Bakker H, 1999, BIOCHEM BIOPH RES CO, V261, P829, DOI 10.1006/bbrc.1999.1117; Bencurova M, 2003, BIOCHIMIE, V85, P413, DOI 10.1016/S0300-9084(03)00072-5; Betenbaugh MJ, 2004, CURR OPIN STRUC BIOL, V14, P601, DOI 10.1016/j.sbi.2004.09.001; BOLANOWSKI MA, 1983, MECH AGEING DEV, V21, P295, DOI 10.1016/0047-6374(83)90048-9; Carter C, 2004, PLANT CELL, V16, P3285, DOI 10.1105/tpc.104.027078; Chen SH, 2002, BBA-GEN SUBJECTS, V1573, P271, DOI 10.1016/S0304-4165(02)00393-8; CLARKE VA, 1995, J BIOL CHEM, V270, P8805, DOI 10.1074/jbc.270.15.8805; Coutinho PM, 1999, ROY SOC CH, P3; Diez B, 2005, FEMS MICROBIOL LETT, V242, P257, DOI 10.1016/j.femsle.2004.11.017; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Fan XL, 2005, GLYCOBIOLOGY, V15, P952, DOI 10.1093/glycob/cwi075; Faveeuw C, 2003, EUR J IMMUNOL, V33, P1271, DOI 10.1002/eji.200323717; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; Gao BL, 2002, INT J PARASITOL, V32, P1293, DOI 10.1016/S0020-7519(02)00110-8; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Gradnig G, 1996, CARBOHYD RES, V287, P49, DOI 10.1016/0008-6215(96)00065-1; Griffitts JS, 2005, SCIENCE, V307, P922, DOI 10.1126/science.1104444; Gutternigg M, 2004, EUR J BIOCHEM, V271, P1348, DOI 10.1111/j.1432-1033.2004.04045.x; Hanneman AJ, 2006, GLYCOBIOLOGY, V16, P874, DOI 10.1093/glycob/cwl011; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Haslam SM, 1999, J BIOL CHEM, V274, P20953, DOI 10.1074/jbc.274.30.20953; Henrissat B, 2001, PLANT MOL BIOL, V47, P55, DOI 10.1023/A:1010667012056; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; HORI H, 1983, ARCH BIOCHEM BIOPHYS, V220, P415, DOI 10.1016/0003-9861(83)90431-9; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; Hou YM, 2001, BIOCHEMISTRY-US, V40, P2201, DOI 10.1021/bi002018s; Iseli B, 1996, FEBS LETT, V382, P186, DOI 10.1016/0014-5793(96)00174-3; Kaji H, 2003, NAT BIOTECHNOL, V21, P667, DOI 10.1038/nbt829; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; Leonard R, 2006, J BIOL CHEM, V281, P4867, DOI 10.1074/jbc.M511023200; LI SC, 1970, J BIOL CHEM, V245, P5153; LIU PS, 1991, TETRAHEDRON LETT, V32, P719, DOI 10.1016/S0040-4039(00)74866-0; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; Morelle W, 2000, GLYCOBIOLOGY, V10, P941, DOI 10.1093/glycob/10.9.941; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; Mucha J, 2004, BIOCHEM J, V382, P67, DOI 10.1042/BJ20040535; MULDER H, 1995, EUR J BIOCHEM, V232, P272, DOI 10.1111/j.1432-1033.1995.tb20809.x; PARKER GF, 1991, FEBS LETT, V290, P58, DOI 10.1016/0014-5793(91)81225-W; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Paschinger K, 2006, J BIOL CHEM, V281, P28265, DOI 10.1074/jbc.M602878200; Poltl G, 2007, FEBS J, V274, P714, DOI 10.1111/j.1742-4658.2006.05615.x; Rendic D, 2006, J BIOL CHEM, V281, P3343, DOI 10.1074/jbc.M508334200; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; Sarkar M, 2006, J BIOL CHEM, V281, P12776, DOI 10.1074/jbc.M512769200; Shi H, 2006, METHOD ENZYMOL, V417, P359, DOI 10.1016/S0076-6879(06)17022-6; Strasser R, 1999, GLYCOCONJUGATE J, V16, P787, DOI 10.1023/A:1007127815012; Strasser R, 2006, PLANT J, V45, P789, DOI 10.1111/j.1365-313X.2005.02648.x; Strasser R, 2004, GLYCOCONJUGATE J, V21, P275, DOI 10.1023/B:GLYC.0000045099.29038.04; Strasser R, 2000, FEBS LETT, V472, P105, DOI 10.1016/S0014-5793(00)01443-5; Takahashi N, 2003, EUR J BIOCHEM, V270, P2627, DOI 10.1046/j.1432-1033.2003.03636.x; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; Tomiya N, 2006, J BIOL CHEM, V281, P19545, DOI 10.1074/jbc.M603312200; Van Patten SM, 2007, GLYCOBIOLOGY, V17, P467, DOI 10.1093/glycob/cwm008; van Remoortere A, 2003, GLYCOBIOLOGY, V13, P217, DOI 10.1093/glycob/cwg025; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133; VONSCHAEWEN A, 1993, PLANT PHYSIOL, V102, P1109, DOI 10.1104/pp.102.4.1109; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 2002, CURR OPIN STRUC BIOL, V12, P569, DOI 10.1016/S0959-440X(02)00367-6; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Wilson IBH, 2001, BBA-GEN SUBJECTS, V1527, P88, DOI 10.1016/S0304-4165(01)00151-9; Wu Y, 2001, J BIOL CHEM, V276, P42557, DOI 10.1074/jbc.M103479200; Wuhrer M, 2004, BIOCHEM J, V378, P625, DOI 10.1042/BJ20031380; Zeleny R, 1997, ANAL BIOCHEM, V246, P96, DOI 10.1006/abio.1996.9973; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; Zhang YH, 2005, DEV BIOL, V285, P330, DOI 10.1016/j.ydbio.2005.06.037; Zhu SX, 2004, BIOCHEM J, V382, P995, DOI 10.1042/BJ20040793	76	73	85	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27825	27840		10.1074/jbc.M704235200	http://dx.doi.org/10.1074/jbc.M704235200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17636254	hybrid, Green Accepted			2022-12-25	WOS:000249455600031
J	Moker, N; Reihlen, P; Kramer, R; Morbach, S				Moeker, Nina; Reihlen, Philipp; Kraemer, Reinhard; Morbach, Susanne			Osmosensing properties of the histidine protein kinase MtrB from Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI K-12; BETAINE CARRIER BETP; OSMOTIC-STRESS; IN-VITRO; MYCOBACTERIUM-TUBERCULOSIS; RESPONSE REGULATOR; BACILLUS-SUBTILIS; GLYCINE BETAINE; SYSTEM	The MtrB-MtrA two component system of Corynebacterium glutamicum was recently shown to be in involved in the osmostress response as well as cell wall metabolism. To address the question of whether the histidine protein kinase MtrB is an osmosensor, the kinase was purified and reconstituted into liposomes in a functionally active form. The activity regulation was investigated by varying systematically physicochemical parameters, which are putative stimuli that could be used by the bacterial cell to detect osmotic conditions. Membrane shrinkage was ruled out as a stimulus for activation of MtrB. Instead, MtrB was shown to be activated upon the addition of various chemical compounds, like sugars, amino acids, and polyethylene glycols. Because of the different chemical nature of the solutes, it seems unlikely that they bind to a specific binding site. Instead, they are proposed to act via a change of the hydration state of the protein shifting MtrB into the active state. For MtrB activation it was essential that these solutes were added at the same side as the cytoplasmic domains of the kinase were located, indicating that hypertonicity is sensed by MtrB via cytoplasmatically located protein domains. This was confirmed by the analysis of two MtrB mutants in which either the large periplasmic loop or the HAMP domain was deleted. These mutants were regulated similar to wild type MtrB. Thus, we postulate that MtrB belongs to a class of histidine protein kinases that sense environmental changes at cytoplasmatic protein domains independently of the periplasmic loop and the cytoplasmic HAMP domain.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	University of Cologne	Morbach, S (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	s.morbach@uni-koeln.de						Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; BHAT R, 1992, PROTEIN SCI, V1, P1133, DOI 10.1002/pro.5560010907; Brocker M, 2006, FEMS MICROBIOL LETT, V264, P205, DOI 10.1111/j.1574-6968.2006.00456.x; Cangelosi GA, 2006, ANTIMICROB AGENTS CH, V50, P461, DOI 10.1128/AAC.50.2.461-468.2006; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; Fleischer R, 2007, J BIOL CHEM, V282, P8583, DOI 10.1074/jbc.M605785200; Fol M, 2006, MOL MICROBIOL, V60, P643, DOI 10.1111/j.1365-2958.2006.05137.x; Gerharz T, 2003, BIOCHEMISTRY-US, V42, P5917, DOI 10.1021/bi0340595; GOLBY P, 1999, J BACTERIOL, V181, P1248; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Guillouet S, 1995, APPL MICROBIOL BIOT, V44, P496, DOI 10.1007/s002530050588; Heermann R, 2003, MOL MICROBIOL, V47, P839, DOI 10.1046/j.1365-2958.2003.03348.x; Hoskisson PA, 2006, TRENDS MICROBIOL, V14, P444, DOI 10.1016/j.tim.2006.08.005; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Hulko M, 2006, CELL, V126, P929, DOI 10.1016/j.cell.2006.06.058; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; Inaba M, 2003, J BIOL CHEM, V278, P12191, DOI 10.1074/jbc.M212204200; Janausch IG, 2002, J BIOL CHEM, V277, P39809, DOI 10.1074/jbc.M204482200; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; Jung K, 2000, J BIOL CHEM, V275, P40142, DOI 10.1074/jbc.M008917200; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Kneuper H, 2005, J BIOL CHEM, V280, P20596, DOI 10.1074/jbc.M502015200; Mascher T, 2004, ANTIMICROB AGENTS CH, V48, P2888, DOI 10.1128/AAC.48.8.2888-2896.2004; Mascher T, 2006, FEMS MICROBIOL LETT, V264, P133, DOI 10.1111/j.1574-6968.2006.00444.x; Moker N, 2004, MOL MICROBIOL, V54, P420, DOI 10.1111/j.1365-2958.2004.04249.x; Moker N, 2007, J BACTERIOL, V189, P3645, DOI 10.1128/JB.01920-06; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; Nottebrock D, 2003, FEMS MICROBIOL LETT, V218, P305, DOI 10.1111/j.1574-6968.2003.tb11533.x; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Ronsch H, 2003, J BIOTECHNOL, V104, P87, DOI 10.1016/S0168-1656(03)00166-4; Rothenbucher MC, 2006, J BACTERIOL, V188, P1950, DOI 10.1128/JB.188.5.1950-1958.2006; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Sanowar S, 2005, BIOCHEM J, V390, P769, DOI 10.1042/BJ20050060; Schiller D, 2004, FEBS LETT, V563, P108, DOI 10.1016/S0014-5793(04)00279-0; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; Tropis M, 2005, J BIOL CHEM, V280, P26573, DOI 10.1074/jbc.M502104200; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Weiss V, 2002, J MOL MICROB BIOTECH, V4, P229; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200; Zahrt TC, 2000, J BACTERIOL, V182, P3832, DOI 10.1128/JB.182.13.3832-3838.2000	50	20	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27666	27677		10.1074/jbc.M701749200	http://dx.doi.org/10.1074/jbc.M701749200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650500	hybrid			2022-12-25	WOS:000249455600014
J	Baker, BM; Tortorella, D				Baker, Brooke M.; Tortorella, Domenico			Dislocation of an endoplasmic reticulum membrane glycoprotein involves the formation of partially dislocated ubiquitinated polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; I HEAVY-CHAINS; INTRACELLULAR DEGRADATION; RECEPTOR SUBUNITS; ER; COMPLEX; RETROTRANSLOCATION; PROTEASOME; RECOGNITION; DOMAIN	Accumulation of improperly folded polypeptides in the endoplasmic reticulum ( ER) can trigger a stress response that leads to the export of aberrant proteins into the cytosol and their ultimate proteasomal degradation. Human cytomegalovirus encodes a type I glycoprotein, US11, that binds to nascent MHC class I heavy chain molecules and causes their dislocation from the ER to the cytosol where they are degraded by the proteasome. Examination of US11-mediated class I degradation has identified a host of cellular proteins involved in the dislocation reaction, including the cytosolic AAA ATPase p97, the membrane protein Derlin-1, and the E3 ubiquitin ligase Sel1L. However, the intermediate steps occurring between the initiation of dislocation and full extraction of the misfolded substrate into the cytosol are not known. We demonstrate that US11 itself undergoes ER export and proteasomal degradation and utilize this system to define multiple steps of US11 dislocation. Treatment of US11-expressing cells with proteasome inhibitor resulted in the accumulation of glycosylated and ubiquitinated species as well as a deglycosylated US11 intermediate. Subcellular fractionation of proteasome-inhibited US11 cells demonstrated that deglycosylated intermediates continued to be integrated within the ER membrane, suggesting that the proteasome functions in the latter steps of dislocation. The data supports a model in which US11 is modified with ubiquitin, whereas the transmembrane region is integrated in the ER membrane, and deglycosylation occurs before complete dislocation.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tortorella, D (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl,Box 1124, New York, NY 10029 USA.	domenico.tortorella@mssm.edu		Tortorella, Domenico/0000-0003-0961-3535	NIAID NIH HHS [AI 060905, AI 07647] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060905] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Ben-Saadon R, 2004, J BIOL CHEM, V279, P41414, DOI 10.1074/jbc.M407201200; Cadwell K, 2005, SCIENCE, V309, P127, DOI 10.1126/science.1110340; Carlson EJ, 2006, EMBO J, V25, P4557, DOI 10.1038/sj.emboj.7601307; Chen XC, 1998, J BACTERIOL, V180, P527, DOI 10.1128/JB.180.3.527-537.1998; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Faitova J, 2006, CELL MOL BIOL LETT, V11, P488, DOI 10.2478/s11658-006-0040-4; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; Furman MH, 2002, J BIOL CHEM, V277, P3258, DOI 10.1074/jbc.M109765200; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Jessop CE, 2007, EMBO J, V26, P28, DOI 10.1038/sj.emboj.7601505; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; JONES TR, 1991, J VIROL, V65, P2024, DOI 10.1128/JVI.65.4.2024-2036.1991; Kalies KU, 2005, EMBO J, V24, P2284, DOI 10.1038/sj.emboj.7600731; KOIDE N, 1974, J BIOL CHEM, V249, P4897; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; LE A, 1990, J BIOL CHEM, V265, P14001; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lilley BN, 2003, MOL BIOL CELL, V14, P3690, DOI 10.1091/mbc.E03-03-0192; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Meusser B, 2004, MOL CELL, V14, P247, DOI 10.1016/S1097-2765(04)00212-6; Mueller B, 2006, J CELL BIOL, V175, P261, DOI 10.1083/jcb.200605196; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Oresic K, 2006, J BIOL CHEM, V281, P19395, DOI 10.1074/jbc.M601026200; PARHAM P, 1979, J IMMUNOL, V123, P342; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; SCHLESINGER DH, 1975, BIOCHEMISTRY-US, V14, P2214, DOI 10.1021/bi00681a026; Schmidt M, 2005, BIOL CHEM, V386, P725, DOI 10.1515/BC.2005.085; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schulze A, 2005, J MOL BIOL, V354, P1021, DOI 10.1016/j.jmb.2005.10.020; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Tirosh B, 2005, J VIROL, V79, P2768, DOI 10.1128/JVI.79.5.2768-2779.2005; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wahlman J, 2007, CELL, V129, P943, DOI 10.1016/j.cell.2007.03.046; Wang QY, 2006, J CELL BIOL, V174, P963, DOI 10.1083/jcb.200605100; Wang XL, 2007, J CELL BIOL, V177, P613, DOI 10.1083/jcb.200611063; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zhong XY, 2006, HUM MOL GENET, V15, P2409, DOI 10.1093/hmg/ddl164	67	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26845	26856		10.1074/jbc.M704315200	http://dx.doi.org/10.1074/jbc.M704315200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650499	hybrid			2022-12-25	WOS:000249304900024
J	Kurosu, H; Choi, M; Ogawa, Y; Dickson, AS; Goetz, R; Eliseenkova, AV; Mohammadi, M; Rosenblatt, KP; Kliewer, SA; Kuro-o, M				Kurosu, Hiroshi; Choi, Mihwa; Ogawa, Yasushi; Dickson, Addie S.; Goetz, Regina; Eliseenkova, Anna V.; Mohammadi, Moosa; Rosenblatt, Kevin P.; Kliewer, Steven A.; Kuro-o, Makoto			Tissue-specific expression of beta Klotho and fibroblast growth factor (FGF) receptor Isoforms determines metabolic activity of FGF19 and FGF21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; DOMINANT HYPOPHOSPHATEMIC RICKETS; NEGATIVE FEEDBACK-REGULATION; PHOSPHATE HOMEOSTASIS; STRUCTURAL BASIS; FACTOR FAMILY; PPAR-ALPHA; MICE; FIBROBLAST-GROWTH-FACTOR-21; SUPPRESSION	The fibroblast growth factor (FGF) 19 subfamily of ligands, FGF19, FGF21, and FGF23, function as hormones that regulate bile acid, fatty acid, glucose, and phosphate metabolism in target organs through activating FGF receptors ( FGFR1-4). We demonstrated that Klotho and beta Klotho, homologous single-pass transmembrane proteins that bind to FGFRs, are required for metabolic activity of FGF23 and FGF21, respectively. Here we show that, like FGF21, FGF19 also requires beta Klotho. Both FGF19 and FGF21 can signal through FGFR1-3 bound by beta Klotho and increase glucose uptake in adipocytes expressing FGFR1. Additionally, both FGF19 and FGF21 bind to the beta Klotho-FGFR4 complex; however, only FGF19 signals efficiently through FGFR4. Accordingly, FGF19, but not FGF21, activates FGF signaling in hepatocytes that primarily express FGFR4 and reduces transcription of CYP7A1 that encodes the rate-limiting enzyme for bile acid synthesis. We conclude that the expression of beta Klotho, in combination with particular FGFR isoforms,determines the tissue-specific metabolic activities of FGF19 and FGF21.	Univ Texas, SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University	Kuro-o, M (corresponding author), 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Makoto.Kuro-o@UTSouthwestern.edu	Mohammadi, Moosa/ABA-6745-2020; Ogawa, Yasushi/I-1140-2012; Goetz, Regina/M-2411-2019; Ogawa, Yasushi/M-8900-2014; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Goetz, Regina/0000-0003-3681-4703; Ogawa, Yasushi/0000-0003-3553-9607; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025326, R01AG015326, R01AG019712] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG025326, R01 AG 15326, R01 AG 19712, R01 AG019712, R01 AG025326-04, R01 AG019712-06] Funding Source: Medline; NIDCR NIH HHS [R01 DE 13686, R01 DE013686] Funding Source: Medline; NIDDK NIH HHS [DK 067158, R01 DK067158] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Bauer I, 2005, ARCH BIOCHEM BIOPHYS, V438, P36, DOI 10.1016/j.abb.2005.03.016; Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501; Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2005, J CLIN INVEST, V115, P2202, DOI 10.1172/JCI23076; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Ogawa Y, 2007, P NATL ACAD SCI USA, V104, P7432, DOI 10.1073/pnas.0701600104; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Schiavi SC, 2004, KIDNEY INT, V65, P1, DOI 10.1111/j.1523-1755.2004.00355.x; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	32	567	652	0	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26687	26695		10.1074/jbc.M704165200	http://dx.doi.org/10.1074/jbc.M704165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623664	hybrid, Green Accepted			2022-12-25	WOS:000249304900007
J	Lee, J; Michael, AJ; Martynowski, D; Goldsmith, EJ; Phillips, MA				Lee, Jeongmi; Michael, Anthony J.; Martynowski, Dariusz; Goldsmith, Elizabeth J.; Phillips, Margaret A.			Phylogenetic diversity and the structural basis of substrate specificity in the beta/alpha-barrel fold basic amino acid decarboxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC ORNITHINE DECARBOXYLASES; BIOSYNTHETIC ARGININE DECARBOXYLASE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; DIAMINOPIMELATE DECARBOXYLASE; POLYAMINE BIOSYNTHESIS; IRREVERSIBLE INHIBITORS; MOLECULAR REPLACEMENT; ANGSTROM RESOLUTION; TRYPANOSOMA-BRUCEI	The beta/alpha-barrel fold type basic amino acid decarboxylases include eukaryotic ornithine decarboxylases (ODC) and bacterial and plant enzymes with activity on L-arginine and meso-diaminopimelate. These enzymes catalyze essential steps in polyamine and lysine biosynthesis. Phylogenetic analysis suggests that diverse bacterial species also contain ODC-like enzymes from this fold type. However, in comparison with the eukaryotic ODCs, amino acid differences were identified in the sequence of the 3(10)-helix that forms a key specificity element in the active site, suggesting they might function on novel substrates. Putative decarboxylases from a phylogenetically diverse range of bacteria were characterized to determine their substrate preference. Enzymes from species within Methanosarcina, Pseudomonas, Bartonella, Nitrosomonas, Thermotoga, and Aquifex showed a strong preference for L-ornithine, whereas the enzyme from Vibrio vulnificus (VvL/ODC) had dual specificity functioning well on both L-ornithine and L-lysine. The x-ray structure of VvL/ODC was solved in the presence of the reaction products putrescine and cadaverine to 1.7 and 2.15 A, respectively. The overall structure is similar to eukaryotic ODC; however, reorientation of the 310-helix enlarging the substrate binding pocket allows L-lysine to be accommodated. The structure of the putrescine-bound enzyme suggests that a bridging water molecule between the shorter L-ornithine and key active site residues provides the structural basis for VvL/ODC to also function on this substrate. Our data demonstrate that there is greater structural and functional diversity in bacterial polyamine biosynthetic decarboxylases than previously suspected.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	margaret.phillips@UTSouthwestern.edu	Lee, Jeongmi/AAJ-7720-2020; Martynowski, Dariusz/AAU-6083-2020	Lee, Jeongmi/0000-0002-9948-7554; Martynowski, Dariusz/0000-0001-7617-7716	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 34432, R01 AI034432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; Cavalier-Smith T, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-19; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fries D.S., 2003, BURGERS MED CHEM DRU, P1033; GILLIN FD, 1984, J PROTOZOOL, V31, P161, DOI 10.1111/j.1550-7408.1984.tb04308.x; Gokulan K, 2003, J BIOL CHEM, V278, P18588, DOI 10.1074/jbc.M301549200; Graham DE, 2002, J BIOL CHEM, V277, P23500, DOI 10.1074/jbc.M203467200; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Heby O, 1995, INT J DEV BIOL, V39, P737; HIATT AC, 1986, J BIOL CHEM, V261, P1293; Hurt DE, 2006, ACTA CRYSTALLOGR D, V62, P312, DOI 10.1107/S0907444905042642; Jackson LK, 2004, BIOCHEMISTRY-US, V43, P12990, DOI 10.1021/bi048933l; KALLIO A, 1981, BIOCHEM J, V200, P69, DOI 10.1042/bj2000069; Karatan E, 2005, J BACTERIOL, V187, P7434, DOI 10.1128/JB.187.21.7434-7443.2005; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Kidron H, 2007, MOL BIOL EVOL, V24, P79, DOI 10.1093/molbev/msl133; KITZ R, 1962, J BIOL CHEM, V237, P3245; KOSSIAKOFF A, 1987, BIOL MACROMOLECULES; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Momany C, 2002, ACTA CRYSTALLOGR D, V58, P549, DOI 10.1107/S0907444902000148; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patel CN, 2006, J BACTERIOL, V188, P2355, DOI 10.1128/JB.188.7.2355-2363.2006; PEGG AE, 1979, BIOCHIM BIOPHYS ACTA, V568, P416, DOI 10.1016/0005-2744(79)90310-3; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; Qu N, 2003, BIOCHEM J, V375, P465, DOI 10.1042/BJ20030382; Ray SS, 2002, STRUCTURE, V10, P1499, DOI 10.1016/S0969-2126(02)00880-8; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Seiler N, 1998, INT J ONCOL, V13, P993; Shah R, 2004, J BIOL CHEM, V279, P35760, DOI 10.1074/jbc.M405366200; Shah R, 2007, BIOCHEMISTRY-US, V46, P2831, DOI 10.1021/bi6023447; Sturgill G, 2004, MOL MICROBIOL, V51, P437, DOI 10.1046/j.1365-2958.2003.03835.x; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Takatsuka Y, 2000, J BACTERIOL, V182, P6732, DOI 10.1128/JB.182.23.6732-6741.2000; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WU WH, 1973, J BIOL CHEM, V248, P1687; YAMAMOTO S, 1994, MICROBIOL-UK, V140, P3117, DOI 10.1099/13500872-140-11-3117	50	45	66	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27115	27125		10.1074/jbc.M704066200	http://dx.doi.org/10.1074/jbc.M704066200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626020	hybrid			2022-12-25	WOS:000249304900052
J	Shikata, K; Fukui, T; Atomi, H; Imanaka, T				Shikata, Kenichi; Fukui, Toshiaki; Atomi, Haruyuki; Imanaka, Tadayuki			A novel ADP-forming Succinyl-CoA synthetase in Thermococcus kodakaraensis structurally related to the archaeal nucleoside diphosphate-forming Acetyl-CoA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON; PYROCOCCUS-FURIOSUS; FERREDOXIN OXIDOREDUCTASE; ESCHERICHIA-COLI; HALOARCULA-MARISMORTUI; PEPTIDE FERMENTATION; ACETATE FORMATION; ATP SYNTHESIS; ENZYME; COENZYME	We have identified and characterized a structurally novel succinyl-CoA synthetase (SCS) from the hyperthermophilic Archaea Thermococcus kodakaraensis. The presence of an SCS completes the metabolic pathway from glutamate to succinate in Thermococcales, which had not been clarified because of the absence of classical SCS homologs on their genomes. The SCS from T. kodakaraensis (SCSTk) is a heteromeric enzyme(alpha(2)beta(2)) encoded by TK1880 (alpha-subunit) and TK0943 (beta-subunit). Although both SCSTk and classical SCSs harbor the five domains present in enzymes of the acyl-CoA synthetase ( nucleoside diphosphate-forming) superfamily, the domain order and distribution among subunits in SCSTk (alpha-subunit domains 1-2-5; beta- subunit, domains 3-4) are distinct from those of classical SCSs (alpha-subunit, domains 1-2; beta- subunit, domains 3-4-5) and instead resemble the acetyl-CoA synthetases from Pyrococcus furiosus (ACSs I-Pf and IIPf). Comparison of the four Thermococcales genomes revealed that each strain harbors five alpha- and two beta-subunit homologs. Sequence similarity suggests that the beta-subunit of SCSTk is also a component of the presumed ACS II from T. kodakaraensis (ACS IITk). We coexpressed the alpha/beta-genes of SCSTk (TK1880/TK0943) and of ACS IITk (TK0139/ TK0943). ACS IITk recognizes a broad range of hydrophobic/aromatic acid compounds, as is the case with ACS IIPf, whereas SCSTk displays a distinct and relatively strict substrate specificity for several acids, including succinate. This indicates that the alpha-subunits are responsible for the distinct substrate specificities of SCSTk and ACS IITk.	Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan	Kyoto University	Imanaka, T (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan.	imanaka@sbchem.kyoto-u.ac.jp	福居, 俊昭/K-5056-2012; Fukui, Toshiaki/S-6882-2019	福居, 俊昭/0000-0003-4557-6284; Fukui, Toshiaki/0000-0003-4557-6284; Atomi, Haruyuki/0000-0001-9687-6426				ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; Atomi Haruyuki, 2004, Archaea, V1, P263, DOI 10.1155/2004/204953; Brasen C, 2004, FEMS MICROBIOL LETT, V241, P21, DOI 10.1016/j.femsle.2004.09.033; Brasen C, 2004, ARCH MICROBIOL, V182, P277, DOI 10.1007/s00203-004-0702-4; Cohen GN, 2003, MOL MICROBIOL, V47, P1495, DOI 10.1046/j.1365-2958.2003.03381.x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Field J, 2000, MOL MICROBIOL, V38, P446, DOI 10.1046/j.1365-2958.2000.02143.x; Fraser ME, 2006, J BIOL CHEM, V281, P11058, DOI 10.1074/jbc.M511785200; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Fraser ME, 2002, BIOCHEMISTRY-US, V41, P537, DOI 10.1021/bi011518y; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Fukui T, 2005, GENOME RES, V15, P352, DOI 10.1101/gr.3003105; Heider J, 1996, J BACTERIOL, V178, P780, DOI 10.1128/jb.178.3.780-787.1996; Itoh T, 2003, J BIOSCI BIOENG, V96, P203, DOI 10.1263/jbb.96.203; Johnson JD, 1998, J BIOL CHEM, V273, P27573, DOI 10.1074/jbc.273.42.27573; Joyce MA, 2000, BIOCHEMISTRY-US, V39, P17, DOI 10.1021/bi991696f; Kanai T, 2005, J BIOTECHNOL, V116, P271, DOI 10.1016/j.jbiotec.2004.11.002; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Krahe M, 1996, FEMS MICROBIOL REV, V18, P271, DOI 10.1111/j.1574-6976.1996.tb00243.x; Labes A, 2001, ARCH MICROBIOL, V176, P329, DOI 10.1007/s002030100330; Ma K, 1997, P NATL ACAD SCI USA, V94, P9608, DOI 10.1073/pnas.94.18.9608; Mai XH, 1996, J BACTERIOL, V178, P5897, DOI 10.1128/jb.178.20.5897-5903.1996; MAI XH, 1994, J BIOL CHEM, V269, P16726; Mai XH, 1996, J BACTERIOL, V178, P5890, DOI 10.1128/jb.178.20.5890-5896.1996; Musfeldt M, 2002, J BACTERIOL, V184, P636, DOI 10.1128/JB.184.3.636-644.2002; Musfeldt M, 1999, J BACTERIOL, V181, P5885, DOI 10.1128/JB.181.18.5885-5888.1999; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; Robb FT, 2001, METHOD ENZYMOL, V330, P134; Sanchez LB, 2000, J BIOL CHEM, V275, P5794, DOI 10.1074/jbc.275.8.5794; SCHAFER T, 1991, ARCH MICROBIOL, V155, P366; SCHAFER T, 1993, ARCH MICROBIOL, V159, P72, DOI 10.1007/BF00244267; Takeda Y., 1969, METHOD ENZYMOL, V13, P153, DOI [DOI 10.1016/0076-6879(69)13032-3, 10.1016/0076-6879(69)13032-3]; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	33	31	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26963	26970		10.1074/jbc.M702694200	http://dx.doi.org/10.1074/jbc.M702694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640871	hybrid			2022-12-25	WOS:000249304900036
J	Ashish; Paine, MS; Perryman, PB; Yang, L; Yin, HL; Krueger, JK				Ashish; Paine, Matthew S.; Perryman, Paul B.; Yang, Lin; Yin, Helen L.; Krueger, Joanna K.			Global structure changes associated with Ca2+ activation of full-length human plasma gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-REGULATORY PROTEIN; RAY SOLUTION SCATTERING; HELIX LATCH HYPOTHESIS; TERMINAL HALF; CALCIUM; BINDING; DOMAIN; BIOSYNTHESIS; CONFORMATION; APOPTOSIS	Gelsolin regulates the dynamic assembly and disassembly of the actin-based cytoskeleton in non-muscle cells and clears the circulation of filaments released following cell death. Gelsolin is a six-domain ( G1 -G6) protein activated by calcium via a multi-step process that involves unfolding from a compact form to a more open form in which the three actin-binding sites ( on the G1, G2, and G4 subdomains) become exposed. To follow the global structural changes that accompany calcium activation of gelsolin, small-angle x-ray scattering (SAXS) data were collected for full-length human plasma gelsolin at nanomolar to millimolar concentrations of free Ca-2(+). Analysis of these data showed that, upon increasing free Ca2 (+) levels, the radius of gyration (Rg) increased nearly 12 A, from 31.1 +/- 0.3 to 43 +/- 2A, and the maximum linear dimension ( Dmax) of the gelsolin molecule increased 55 A, from 100 to 155 A. Structural reconstruction of gelsolin from these data provided a striking visual tracking of the gradual Ca2(+)- induced opening of the gelsolin molecule and highlighted the critical role played by the flexible linkers between homologous domains. The tightly packed architecture of calcium-free gelsolin, seen from both SAXS and x-ray crystallographic models, is already partially opened up in as low as 0.5 nm Ca-2(+) . Our data confirm that, although the molecule springs open from 0 to 1 mu M free Ca2 (+), even higher calcium concentrations help to stabilize a more open structure, with increases in Rg and Dmax of similar to 2 and similar to 15 A, respectively. At these higher calcium levels, the SAXS-based models provide a molecular shape that is compatible with that of the crystal structures solved for Ca2(+)/gelsolin C-terminal and N-terminal halves +/- monomeric G-actin. Placement of these crystal structures within the boundaries of the SAXS-based model suggests a movement of the G1/G2 subunits that would be required upon binding to actin.	Univ N Carolina, Dept Chem, Charlotte, NC 28223 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of North Carolina; University of North Carolina Charlotte; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Krueger, JK (corresponding author), Univ N Carolina, Dept Chem, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	jkkruege@uncc.edu	Krueger, Joanna/A-3110-2011; Yang, Lin/D-5872-2013	Yang, Lin/0000-0003-1057-9194				Arai M, 1999, DEV DYNAM, V215, P297, DOI 10.1002/(SICI)1097-0177(199908)215:4<297::AID-AJA2>3.3.CO;2-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burtnick LD, 2004, EMBO J, V23, P2713, DOI 10.1038/sj.emboj.7600280; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Cheng F, 2002, BIOPHYS J, V83, P753, DOI 10.1016/S0006-3495(02)75206-5; Choe H, 2002, J MOL BIOL, V324, P691, DOI 10.1016/S0022-2836(02)01131-2; Chumnarnsilpa S, 2006, J MOL BIOL, V357, P773, DOI 10.1016/j.jmb.2006.01.026; Kiselar JG, 2003, MOL CELL PROTEOMICS, V2, P1120, DOI 10.1074/mcp.M300068-MCP200; Kiselar JG, 2003, P NATL ACAD SCI USA, V100, P3942, DOI 10.1073/pnas.0736004100; Kolappan SL, 2003, J MOL BIOL, V329, P85, DOI 10.1016/S0022-2836(03)00383-8; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; KRIGBAUM WR, 1970, BIOCHEMISTRY-US, V9, P1216, DOI 10.1021/bi00807a024; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1987, BIORHEOLOGY, V24, P643; Lagarrigue E, 2003, EUR J BIOCHEM, V270, P4105, DOI 10.1046/j.1432-1033.2003.03803.x; Lagarrigue E, 2003, EUR J BIOCHEM, V270, P2236, DOI 10.1046/j.1432-1033.2003.03591.x; Lin KM, 2000, J BIOL CHEM, V275, P27746; Lueck A, 2000, BIOCHEMISTRY-US, V39, P5274, DOI 10.1021/bi992871v; MISHRA VS, 1994, GENOMICS, V23, P560, DOI 10.1006/geno.1994.1543; Narayan K, 2003, FEBS LETT, V552, P82, DOI 10.1016/S0014-5793(03)00933-5; PATKOWSKI A, 1990, BIOPOLYMERS, V30, P427, DOI 10.1002/bip.360300320; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; YIN HL, 1984, J BIOL CHEM, V259, P5271; YU FX, 1991, J BIOL CHEM, V266, P19269; Zhang Y, 2006, EMBO J, V25, P4458, DOI 10.1038/sj.emboj.7601323	34	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25884	25892		10.1074/jbc.M702446200	http://dx.doi.org/10.1074/jbc.M702446200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17604278	hybrid			2022-12-25	WOS:000249014100074
J	Ito, A; Suganami, T; Miyamot, Y; Yoshimasa, Y; Takeya, M; Kamei, Y; Ogawa, Y				Ito, Ayaka; Suganami, Takayoshi; Miyamot, Yoshihiro; Yoshimasa, Yasunao; Takeya, Motohiro; Kamei, Yasutomi; Ogawa, Yoshihiro			Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL ENDOTHELIAL-CELLS; ADIPOSE-TISSUE; INSULIN-RESISTANCE; 3T3-L1 CELLS; ADENOVIRUS TRANSDUCTION; MACROPHAGE INFILTRATION; SUSTAINED ACTIVATION; INFLAMMATORY CHANGES; GENE-EXPRESSION; PPAR-GAMMA	Monocyte chemoattractant protein-1 ( MCP-1), an important chemokine whose expression is increased during the course of obesity, plays a role in macrophage infiltration into obese adipose tissue. This study was designed to elucidate the role of mitogen-activated protein kinase ( MAPK) phosphatase-1 ( MKP-1) in the induction of MCP-1 during the course of adipocyte hypertrophy. We examined the time course of MKP-1 and MCP-1 mRNA expression and extracellular signal-regulated kinase ( ERK) phosphorylation in the adipose tissue from mice rendered mildly obese by a short term high fat diet. We also studied the role of MKP-1 in the induction of MCP-1 in 3T3-L1 adipocytes during the course of adipocyte hypertrophy. MCP-1 mRNA expression was increased, followed by ERK activation and down-regulation of MKP-1, an inducible dual specificity phosphatase to inactivate ERK, in the adipose tissue at the early stage of obesity induced by a short term high fat diet, when macrophages are not infiltrated. Down-regulation of MKP-1 preceded ERK activation and increased production of MCP-1 in 3T3-L1 adipocytes in vitro during the course of adipocyte hypertrophy. Adenovirus-mediated restoration of MKP-1 in hypertrophied 3T3-L1 adipocytes reduced the otherwise increased ERK phosphorylation, thereby leading to the significant reduction of MCP-1 mRNA expression. This study provides evidence that the down-regulation of MKP-1 is critical for increased production of MCP-1 during the course of adipocyte hypertrophy.	Tokyo Med & Dent Univ, Med Res Inst, Chiyoda Ku, Dept Mol Med & Metab, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Med Res Inst, Chiyoda Ku, Ctr Excellence Program Frontier Res Mol Destruct, Tokyo 1010062, Japan; Natl Cardiovasc Ctr Hosp & Res Inst, Dept Med, Div Atherosclerosis & Diabet, Osaka 5600005, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto 8608556, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Cerebral & Cardiovascular Center - Japan; Kumamoto University	Ogawa, Y (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Chiyoda Ku, Dept Mol Med & Metab, 2-3-10 Kanda Surugadai, Tokyo 1010062, Japan.	ogawa.mmm@mri.tmd.ac.jp	SUGANAMI, Takayoshi/A-9475-2016; Miyamoto, Yoshihiro/L-8583-2013	Miyamoto, Yoshihiro/0000-0002-1337-0508				Barry OP, 2001, J BIOL CHEM, V276, P15537, DOI 10.1074/jbc.M010847200; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Cancello R, 2005, DIABETES, V54, P2277, DOI 10.2337/diabetes.54.8.2277; Chen AR, 2005, OBES RES, V13, P1311, DOI 10.1038/oby.2005.159; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Fain JN, 2005, INT J OBESITY, V29, P1299, DOI 10.1038/sj.ijo.0803032; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; Hosono T, 2005, GENE, V348, P157, DOI 10.1016/j.gene.2005.01.005; Jinnouchi K, 2003, J PATHOL, V200, P406, DOI 10.1002/path.1362; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kamei N, 2006, J BIOL CHEM, V281, P26602, DOI 10.1074/jbc.M601284200; Kamon J, 2001, CELL SIGNAL, V13, P105, DOI 10.1016/S0898-6568(00)00137-6; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kouyama R, 2005, ENDOCRINOLOGY, V146, P3481, DOI 10.1210/en.2005-0003; Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200; Lin YW, 2003, J BIOL CHEM, V278, P21534, DOI 10.1074/jbc.M301854200; Manzano RG, 2002, ONCOGENE, V21, P4435, DOI 10.1038/sj.onc.1205542; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Orlicky DJ, 2001, J LIPID RES, V42, P460; Orlicky DJ, 2001, J LIPID RES, V42, P910; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Ross SA, 2003, BIOCHEM BIOPH RES CO, V302, P354, DOI 10.1016/S0006-291X(03)00180-3; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sakaue H, 2004, J BIOL CHEM, V279, P39951, DOI 10.1074/jbc.M407353200; SKURK T, 2006, J CLIN ENDOCR METAB, V92, P1023; Suganami E, 2004, DIABETES, V53, P2443, DOI 10.2337/diabetes.53.9.2443; Suganami T, 2005, ARTERIOSCL THROM VAS, V25, P2062, DOI 10.1161/01.ATV.0000183883.72263.13; Suganami T, 2007, BIOCHEM BIOPH RES CO, V354, P45, DOI 10.1016/j.bbrc.2006.12.190; Suganami T, 2007, ARTERIOSCL THROM VAS, V27, P84, DOI 10.1161/01.ATV.0000251608.09329.9a; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tong ZM, 2002, CANCER RES, V62, P5528; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yoshimura H, 2006, INFLAMM RES, V55, P543, DOI 10.1007/s00011-006-5144-9	44	77	80	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25445	25452		10.1074/jbc.M701549200	http://dx.doi.org/10.1074/jbc.M701549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17611196	hybrid			2022-12-25	WOS:000249014100030
J	Meng, X; Xiao, BL; Cai, ST; Huang, XJ; Li, F; Bolstad, J; Trujillo, R; Airey, J; Chen, SRW; Wagenknecht, T; Liu, Z				Meng, Xing; Xiao, Bailong; Cai, Shitian; Huang, Xiaojun; Li, Fei; Bolstad, Jeff; Trujillo, Ramon; Airey, Judith; Chen, S. R. Wayne; Wagenknecht, Terence; Liu, Zheng			Three-dimensional localization of serine 2808, a phosphorylation site in cardiac ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; KINASE-A PHOSPHORYLATION; CA2+ RELEASE; VENTRICULAR-TACHYCARDIA; CRYOELECTRON MICROSCOPY; MALIGNANT HYPERTHERMIA; FK506-BINDING PROTEIN; SUDDEN-DEATH; MUTATIONS; BINDING	Type 2 ryanodine receptor (RyR2) is the major calcium release channel in cardiac muscle. Phosphorylation of RyR2 by cAMP-dependent protein kinase A and by calmodulin-dependent protein kinase II modulates channel activity. Hyperphosphorylation at a single amino acid residue, Ser- 2808, has been proposed to directly disrupt the binding of a 12.6-kDa FK506- binding protein (FKBP12.6) to RyR2, causing a RyR2 malfunction that triggers cardiac arrhythmias in human heart failure. To determine the structural basis of the interaction between Ser-2808 and FKBP12.6, we have employed two independent approaches to map this phosphorylation site in RyR2 by three- dimensional cryo-electron microscopy. In one approach, we inserted a green fluorescent protein (GFP) after amino acid Tyr-2801, and mapped the GFP three- dimensional location in the RyR2 structure. In another approach, the binding site of monoclonal antibody 34C was mapped in the three- dimensional structure of skeletal muscle RyR1. The epitope of antibody 34C has been mapped to amino acid residues 2,756 through 2,803 of the RyR1 sequence, corresponding to residues 2,722 through 2,769 of the RyR2 sequence. These locations of GFP insertion and antibody binding are adjacent to one another in domain 6 of the cytoplasmic clamp region. Importantly, the three-dimensional location of the Ser-2808 phosphorylation site is 105-120 angstrom distance from the FKBP12.6 binding site mapped previously, indicating that Ser-2808 is unlikely to be directly involved in the binding of FKBP12.6 to RyR2, as had been proposed previously.	Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Mol Biol & Biochem, Calgary, AB T2N 4N1, Canada; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA; Univ Nevada, Dept Pharmacol, Reno, NV 89557 USA	State University of New York (SUNY) System; Wadsworth Center; University of Calgary; University of Calgary; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Nevada System of Higher Education (NSHE); University of Nevada Reno	Liu, Z (corresponding author), Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA.		Xiao, Bailong/B-6187-2012	Liu, Zheng/0000-0001-6952-3406	NCRR NIH HHS [P41 RR001219-21, RR01219, P41 RR001219] Funding Source: Medline; NIAMS NIH HHS [AR40615, R01 AR040615, R01 AR040615-16] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM HEART ASS, 2007, HEART DIS STROK STAT; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Choi G, 2004, CIRCULATION, V110, P2119, DOI 10.1161/01.CIR.0000144471.98080.CA; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 2006, 3 DIMENSIONAL ELECT, P145; George CH, 2006, CIRC RES, V98, P88, DOI 10.1161/01.RES.0000199296.70534.7c; George CH, 2003, CIRC RES, V93, P531, DOI 10.1161/01.RES.0000091335.07574.86; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JEKAKUMAR LH, 2001, BIOCHEM BIOPH RES CO, V281, P979; Jiang DW, 2004, P NATL ACAD SCI USA, V101, P13062, DOI 10.1073/pnas.0402388101; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Laitinen PJ, 2001, CIRCULATION, V103, P485, DOI 10.1161/01.CIR.103.4.485; Lehnart SE, 2004, CIRCULATION, V109, P3208, DOI 10.1161/01.CIR.0000132472.98675.EC; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Liu Z, 2005, J BIOL CHEM, V280, P37941, DOI 10.1074/jbc.M505714200; Liu Z, 2002, J BIOL CHEM, V277, P46712, DOI 10.1074/jbc.M208124200; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; Paolini C, 2004, J MOL BIOL, V342, P145, DOI 10.1016/j.jmb.2004.07.035; Priori SG, 2002, CIRCULATION, V106, P69, DOI 10.1161/01.CIR.0000020013.73106.D8; Priori SG, 2001, CIRCULATION, V103, P196; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Samso M, 2005, NAT STRUCT MOL BIOL, V12, P539, DOI 10.1038/nsmb938; Sharma MR, 2006, BIOPHYS J, V90, P164, DOI 10.1529/biophysj.105.063503; Stange M, 2003, J BIOL CHEM, V278, P51693, DOI 10.1074/jbc.M310406200; Tester DJ, 2004, MAYO CLIN PROC, V79, P1380, DOI 10.4065/79.11.1380; Thomas NL, 2005, BIOCHEM BIOPH RES CO, V331, P231, DOI 10.1016/j.bbrc.2005.02.194; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wang RW, 2007, J BIOL CHEM, V282, P17785, DOI 10.1074/jbc.M700660200; Wang RW, 2004, J BIOL CHEM, V279, P3635, DOI 10.1074/jbc.M311367200; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; Xiao BL, 2004, CIRC RES, V94, P487, DOI 10.1161/01.RES.0000115945.89741.22; Zhang J, 2003, J BIOL CHEM, V278, P14211, DOI 10.1074/jbc.M213164200	41	46	48	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25929	25939		10.1074/jbc.M704474200	http://dx.doi.org/10.1074/jbc.M704474200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606610	hybrid, Green Accepted			2022-12-25	WOS:000249014100078
J	Pooler, AM; McIlhinney, RAJ				Pooler, Amy M.; McIlhinney, R. A. Jeffrey			Lateral diffusion of the GABA(B) receptor is regulated by the GABA(B2) C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE DYNAMICS; AMPA RECEPTOR; GLYCINE RECEPTORS; SUBUNIT; EXPRESSION; MOBILITY; NMDA; GB2; HETERODIMERIZATION; CYTOSKELETON	GABA(B) (gamma-aminobutyric acid, type B) is a heterodimeric G-protein-coupled receptor. The GABA(B1) subunit, which contains an endoplasmic reticulum retention sequence, is only transported to the cell surface when it is associated with the GABA(B2) subunit. Fluorescence recovery after photobleaching studies in transfected COS-7 cells and hippocampal neurons revealed that GABAB2 diffuses slowly within the plasma membrane whether expressed alone or with the GABAB1 subunit. Treatment of cells with brefeldin A revealed that GABAB2 moves freely within the endoplasmic reticulum, suggesting that slow movement of GABAB2 is a result of its plasma membrane insertion. Disruption of the cytoskeleton did not affect the mobility of GABAB2, indicating that its restricted diffusion is not due to direct interactions with actin or tubulin. To determine whether the C terminus of GABAB2 regulates its diffusion, this region of the subunit was attached to the lymphocyte membrane protein, CD2, which then exhibited a slower rate of lateral diffusion. Furthermore, co-expression of a cytoplasmically expressed soluble form of the GABAB2 C terminus increased movement of the GABAB2 subunit. We constructed forms of GABAB2 with various C-terminal truncations. Truncation of GABAB2 after residue 862, but not residue 886, caused a dramatic increase in its mobility, suggesting that the region between these two residues is critical for restricting GABAB2 diffusion. Finally, we investigated whether activation of GABAB might modulate its movement. Treatment of COS-7 cells with the GABAB receptor agonist baclofen significantly increased its mobile fraction. These data show that the restricted movement of GABAB at the cell surface is regulated by a region within its C terminus.	MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England		McIlhinney, RAJ (corresponding author), MRC, Anat Neuropharmacol Unit, Mansfield Rd, Oxford OX1 3TH, England.	jeff.mcilhinney@pharm.ox.ac.uk	Pooler, Amy/C-5146-2008		Medical Research Council [MC_U138162357] Funding Source: Medline; MRC [MC_U138162357] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allison DW, 1998, J NEUROSCI, V18, P2423; Andrasfalvy BK, 2004, J PHYSIOL-LONDON, V559, P543, DOI 10.1113/jphysiol.2004.065219; Ashby MC, 2006, J NEUROSCI, V26, P7046, DOI 10.1523/JNEUROSCI.1235-06.2006; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Balasubramanian S, 2007, J BIOL CHEM, V282, P4162, DOI 10.1074/jbc.M607695200; Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Calver AR, 2001, J NEUROSCI, V21, P1203; Chan WY, 2001, MOL CELL NEUROSCI, V17, P577, DOI 10.1006/mcne.2001.0965; Charrier C, 2006, J NEUROSCI, V26, P8502, DOI 10.1523/JNEUROSCI.1758-06.2006; Coleman SK, 2003, J NEUROSCI, V23, P798; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Fairfax BP, 2004, J BIOL CHEM, V279, P12565, DOI 10.1074/jbc.M311389200; Grunewald S, 2002, MOL PHARMACOL, V61, P1070, DOI 10.1124/mol.61.5.1070; Jacob TC, 2005, J NEUROSCI, V25, P10469, DOI 10.1523/JNEUROSCI.2267-05.2005; Kammerer RA, 1999, BIOCHEMISTRY-US, V38, P13263, DOI 10.1021/bi991018t; Knight AR, 1996, NEUROPHARMACOLOGY, V35, P703, DOI 10.1016/0028-3908(96)84642-9; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Pagano A, 2001, J NEUROSCI, V21, P1189; Peran M, 2006, CELL MOTIL CYTOSKEL, V63, P747, DOI 10.1002/cm.20156; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Poncer JC, 1997, NEURON, V18, P463, DOI 10.1016/S0896-6273(00)81246-5; Pucadyil TJ, 2007, GLYCOCONJUGATE J, V24, P25, DOI 10.1007/s10719-006-9008-x; Pucadyil TJ, 2004, BIOCHEMISTRY-US, V43, P15852, DOI 10.1021/bi0480887; Scott L, 2006, P NATL ACAD SCI USA, V103, P762, DOI 10.1073/pnas.0505557103; Sharma K, 2006, MOL CELL NEUROSCI, V31, P702, DOI 10.1016/j.mcn.2006.01.010; Shen L, 2000, J NEUROSCI, V20, P7932; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Tovar KR, 2002, NEURON, V34, P253; Uezono Y, 2006, AM J PHYSIOL-CELL PH, V290, pC200, DOI 10.1152/ajpcell.00269.2005; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yang G, 2006, J NEUROSCI, V26, P9082, DOI 10.1523/JNEUROSCI.3018-06.2006; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798	35	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25349	25356		10.1074/jbc.M702358200	http://dx.doi.org/10.1074/jbc.M702358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17597070	hybrid			2022-12-25	WOS:000249014100020
J	Gilham, D; Labonte, ED; Rojas, JC; Jandacek, RJ; Howles, PN; Hui, DY				Gilham, Dean; Labonte, Eric D.; Rojas, Juan C.; Jandacek, Ronald J.; Howles, Philip N.; Hui, David Y.			Carboxyl ester lipase deficiency exacerbates dietary lipid absorption abnormalities and resistance to diet-induced obesity in pancreatic triglyceride lipase knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; CHOLESTEROL ABSORPTION; RETINYL ESTERS; FAT-ABSORPTION; HYDROLYSIS; TETRAHYDROLIPSTATIN; INHIBITOR; ORLISTAT	This study evaluated the contributions of carboxyl ester lipase (CEL) and pancreatic triglyceride lipase (PTL) in lipid nutrient absorption. Results showed PTL deficiency has minimal effect on triacylglycerol (TAG) absorption under low fat dietary conditions. Interestingly, PTL-/- mice displayed significantly reduced TAG absorption compared with wild type mice under high fat/high cholesterol dietary conditions (80.1 +/- 3.7 versus 91.5 +/- 0.7%, p < 0.05). Net TAG absorption was reduced further to 61.1 +/- 3.8% in mice lacking both PTL and CEL. Cholesterol absorption was 41% lower in PTL-/- mice compared with control mice (p < 0.05), but this difference was not exaggerated in PTL-/-, CEL-/- mice. Retinyl palmitate absorption was reduced by 45 and 60% in PTL-/- mice (p < 0.05) and PTL-/-, CEL-/- mice (p < 0.01), respectively. After 15 weeks of feeding, the high fat/high cholesterol diet, wild type, and CEL-/- mice gained similar to 24 g of body weight. However, body weight gain was 6.2 and 8.6 g less (p < 0.01) in PTL-/- and PTL-/-, CEL-/- mice, respectively, despite their consumption of comparable amounts of the high fat/ high cholesterol diet. The decrease body weight gain in PTL-/- and PTL-/-, CEL-/- mice was attributed to their absorption of fewer calories from the high fat/ high cholesterol diet, thereby resulting in less fat mass accumulation than that observed in wild type and CEL-/- mice. Thus, this study documents that PTL and CEL serve complementary functions, working together to mediate the absorption of a major portion of dietary fat and fat-soluble vitamin esters. The reduced lipid absorption efficiency due to PTL and CEL inactivation also resulted in protection against diet-induced obesity.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 2120 E Galbraith Rd ML 0507, Cincinnati, OH 45237 USA.	huidy@email.uc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067416, U24DK059630] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK067416, R01 DK067416-03, DK067416, U24 DK059630, U24 DK59630] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Armand M, 2007, CURR OPIN CLIN NUTR, V10, P156, DOI 10.1097/MCO.0b013e3280177687; BORGSTROM B, 1960, J CLIN INVEST, V39, P809, DOI 10.1172/JCI104100; BORGSTROM B, 1988, BIOCHIM BIOPHYS ACTA, V962, P308, DOI 10.1016/0005-2760(88)90260-3; COHN JS, 1993, J LIPID RES, V34, P2033; D'Agostino D, 2002, J BIOL CHEM, V277, P7170, DOI 10.1074/jbc.M108328200; FERNANDEZ E, 1989, BIOCHIM BIOPHYS ACTA, V1001, P249, DOI 10.1016/0005-2760(89)90107-0; Fox M, 2004, ALIMENT PHARM THER, V19, P311, DOI 10.1111/j.1365-2036.2004.01848.x; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; Huggins KW, 2003, J BIOL CHEM, V278, P42899, DOI 10.1074/jbc.M303422200; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Le NA, 1997, METABOLISM, V46, P584, DOI 10.1016/S0026-0495(97)90198-0; Lowe ME, 2000, BIOCHIMIE, V82, P997, DOI 10.1016/S0300-9084(00)01184-6; Lowe ME, 2002, J LIPID RES, V43, P2007, DOI 10.1194/jlr.R200012-JLR200; Lowe ME, 1998, J BIOL CHEM, V273, P31215, DOI 10.1074/jbc.273.47.31215; Padwal RS, 2007, LANCET, V369, P71, DOI 10.1016/S0140-6736(07)60033-6; Palmer WK, 1998, ATHEROSCLEROSIS, V136, P115, DOI 10.1016/S0021-9150(97)00193-7; PAYNE RM, 1994, AM J PHYSIOL, V266, P914; RIGTRUP KM, 1994, BIOCHEMISTRY-US, V33, P2661, DOI 10.1021/bi00175a039; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216-003-2224-3; van Bennekum AM, 2000, BIOCHEMISTRY-US, V39, P4900, DOI 10.1021/bi9927235; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a	25	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24642	24649		10.1074/jbc.M702530200	http://dx.doi.org/10.1074/jbc.M702530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604277	Green Accepted, hybrid			2022-12-25	WOS:000248933000019
J	Yang, XY; Zhou, J; Sun, L; Wei, ZY; Gao, JY; Gong, WM; Xu, RM; Rao, ZH; Liu, YF				Yang, Xiaoyu; Zhou, Jie; Sun, Lei; Wei, Zhiyi; Gao, Jianying; Gong, Weimin; Xu, Rui-Ming; Rao, Zihe; Liu, Yingfang			Structural basis for the function of DCN-1 in protein neddylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIGASE; NEDD8; CULLIN; SCF	Covalent modification by Nedd8 (neddylation) stimulates the ubiquitin-protein isopeptide ligase (E3) activities of Cullins. DCN-1, an evolutionarily conserved protein, promotes neddylation of Cullins in vivo, binds directly to Nedd8, and associates with Cdc53 in the budding yeast Saccharomyces cerevisiae. The 1.9 angstrom resolution structure of yeast DCN-1 shows that the region encompassing residues 66-269 has a rectangular parallelepiped-like all alpha-helical structures, consisting of an EF-hand motif N-terminal domain and a closely juxtaposed C-terminal domain with six alpha-helices. The EF-hand motif structure is highly similar to that of the c-Cbl ubiquitin E3 ligase. We also demonstrate that DCN-1 directly binds to Rbx-1, a factor important for protein neddylation. The structural and biochemical results are consistent with the role of DCN-1 as a scaffold protein in a multisubunit neddylation E3 ligase complex.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; NYU, Sch Med, Helen L & Martin S Kimmel Ctr Biol & Med, Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Tsinghua Univ, Struct Biol Lab, Beijing 100084, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; New York University; New York University; Tsinghua University	Liu, YF (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	liuy@ibp.ac.cn	Rao, Zihe/HCH-6944-2022; Wei, Zhiyi/N-9995-2019; xu, rui/GRX-5734-2022; Wei, Zhiyi/B-5001-2010; Sun, Lei/F-5167-2012; Wei, Zhiyi/C-4315-2014	Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kurz T, 2005, NATURE, V435, P1257, DOI 10.1038/nature03662; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu XH, 2003, CELL CYCLE, V2, P59, DOI 10.4161/cc.2.1.273; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Parry G, 2004, SEMIN CELL DEV BIOL, V15, P221, DOI 10.1016/j.semcdb.2003.12.003; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Sarkaria I, 2006, CANCER RES, V66, P9437, DOI 10.1158/0008-5472.CAN-06-2074; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	21	35	37	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24490	24494		10.1074/jbc.C700038200	http://dx.doi.org/10.1074/jbc.C700038200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17597076	hybrid			2022-12-25	WOS:000248933000002
J	Barquero-Calvo, E; Chaves-Olarte, E; Weiss, DS; Guzman-Verri, C; Chacon-Diaz, C; Rucavado, A; Moriyon, I; Moreno, E				Barquero-Calvo, Elias; Chaves-Olarte, Esteban; Weiss, David S.; Guzman-Verri, Caterina; Chacon-Diaz, Carlos; Rucavado, Alexandra; Moriyon, Ignacio; Moreno, Edgardo			Brucella abortus Uses a Stealthy Strategy to Avoid Activation of the Innate Immune System during the Onset of Infection	PLOS ONE			English	Article								Background. To unravel the strategy by which Brucella abortus establishes chronic infections, we explored its early interaction with innate immunity. Methodology/Principal Findings. Brucella did not induce proinflammatory responses as demonstrated by the absence of leukocyte recruitment, humoral or cellular blood changes in mice. Brucella hampered neutrophil (PMN) function and PMN depletion did not influence the course of infection. Brucella barely induced proinflammatory cytokines and consumed complement, and was strongly resistant to bactericidal peptides, PMN extracts and serum. Brucella LPS (BrLPS), NH-polysaccharides, cyclic glucans, outer membrane fragments or disrupted bacterial cells displayed low biological activity in mice and cells. The lack of proinflammatory responses was not due to conspicuous inhibitory mechanisms mediated by the invading Brucella or its products. When activated 24 h post-infection macrophages did not kill Brucella, indicating that the replication niche was not fusiogenic with lysosomes. Brucella intracellular replication did not interrupt the cell cycle or caused cytotoxicity in WT, TLR4 and TLR2 knockout cells. TNF-alpha-induction was TLR4- and TLR2-dependent for live but not for killed B. abortus. However, intracellular replication in TLR4, TLR2 and TLR4/2 knockout cells was not altered and the infection course and anti-Brucella immunity development upon BrLPS injection was unaffected in TLR4 mutant mice. Conclusion/Significance. We propose that Brucella has developed a stealth strategy through PAMPs reduction, modification and hiding, ensuring by this manner low stimulatory activity and toxicity for cells. This strategy allows Brucella to reach its replication niche before activation of antimicrobial mechanisms by adaptive immunity. This model is consistent with clinical profiles observed in humans and natural hosts at the onset of infection and could be valid for those intracellular pathogens phylogenetically related to Brucella that also cause long lasting infections.	[Barquero-Calvo, Elias; Chaves-Olarte, Esteban; Guzman-Verri, Caterina; Chacon-Diaz, Carlos; Moreno, Edgardo] Univ Nacl, Escuela Med Vet, Programa Invest Enfermedades Trop, Heredia, Costa Rica; [Chaves-Olarte, Esteban; Chacon-Diaz, Carlos] Univ Costa Rica, Fac Microbiol, Ctr Invest Enfermedades Trop, San Jose, Costa Rica; [Weiss, David S.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; [Weiss, David S.] NYU, Sch Med, Skirball Inst, New York, NY USA; [Rucavado, Alexandra] Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose, Costa Rica; [Moriyon, Ignacio] Univ Navarra, Dept Microbiol, Navarra, Spain	Universidad Nacional Costa Rica; Universidad Costa Rica; New York University; New York University; Universidad Costa Rica; University of Navarra	Moreno, E (corresponding author), Univ Nacl, Escuela Med Vet, Programa Invest Enfermedades Trop, Heredia, Costa Rica.	emoreno@medvet.una.ac.cr	Rucavado, Alexandra/AGY-1867-2022; Guzman-Verri, Caterina/AAP-3074-2020; Moriyon, Ignacio/N-4764-2016	Guzman-Verri, Caterina/0000-0003-1036-920X; Moriyon, Ignacio/0000-0002-4288-0195; BARQUERO-CALVO, ELIAS/0000-0003-4428-3340	Universidad Nacional [FIDA-2006]; FS-CONARE UNA/UCR, Costa Rica [NeTropica 8-N-2005]; IFS [B/3456-1, B/3456-2]; Ministerio de Ciencia y Tecnologia of Spain [AGL2004-01162/GAN]	Universidad Nacional; FS-CONARE UNA/UCR, Costa Rica; IFS(International Foundation for Science); Ministerio de Ciencia y Tecnologia of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was funded by grants from FIDA-2006, from the Universidad Nacional, FS-CONARE UNA/UCR, Costa Rica, NeTropica 8-N-2005, grant B/3456-1 and B/3456-2, from IFS and AGL2004-01162/GAN from Ministerio de Ciencia y Tecnologia of Spain.	ACKERMANN MR, 1988, VET PATHOL, V25, P28, DOI 10.1177/030098588802500104; Andersen-Nissen E, 2005, P NATL ACAD SCI USA, V102, P9247, DOI 10.1073/pnas.0502040102; Aragon V, 1996, J BACTERIOL, V178, P1070, DOI 10.1128/jb.178.4.1070-1079.1996; Arellano-Reynoso B, 2005, NAT IMMUNOL, V6, P618, DOI 10.1038/ni1202; Ariza J, 1999, REV MED MICROBIOL, V10, P125; Babu MM, 2006, J BACTERIOL, V188, P2761, DOI 10.1128/JB.188.8.2761-2773.2006; Baldwin C. L., 2004, Brucella: molecular and cellular biology, P341; Billard E, 2005, INFECT IMMUN, V73, P8418, DOI 10.1128/IAI.73.12.8418-8424.2005; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; BOHME DH, 1959, J EXP MED, V110, P9, DOI 10.1084/jem.110.1.9; Buwitt-Beckmann U, 2005, FEBS J, V272, P6354, DOI 10.1111/j.1742-4658.2005.05029.x; Campos MA, 2004, INFECT IMMUN, V72, P176, DOI 10.1128/IAI.72.1.176-186.2004; CANNAT A, 1981, ANN INST PASTEUR IMM, VD132, P15; Celli J, 2003, J EXP MED, V198, P545, DOI 10.1084/jem.20030088; Chaves-Olarte E, 2002, CELL MICROBIOL, V4, P663, DOI 10.1046/j.1462-5822.2002.00221.x; Cheminay U, 2004, INFECT IMMUN, V72, P468, DOI 10.1128/IAI.72.1.468-477.2004; Chen DX, 2004, BLOOD, V104, P1344, DOI 10.1182/blood-2003-12-4365; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COATES TD, 1992, MANUAL CLIN LAB IMMU, P409; Copin R, 2007, J IMMUNOL, V178, P5182, DOI 10.4049/jimmunol.178.8.5182; DETEJADA GM, 1995, INFECT IMMUN, V63, P3054; Duenas AI, 2004, INT IMMUNOL, V16, P1467, DOI 10.1093/intimm/dxh148; ELBERG SS, 1957, J EXP MED, V106, P545, DOI 10.1084/jem.106.4.545; ENRIGHT FM, 1990, VET IMMUNOL IMMUNOP, V26, P171, DOI 10.1016/0165-2427(90)90065-Z; FERNANDES DM, 1995, INFECT IMMUN, V63, P1130, DOI 10.1128/IAI.63.3.1130-1133.1995; Freer E, 1996, J BACTERIOL, V178, P5867, DOI 10.1128/jb.178.20.5867-5876.1996; Fretin D, 2005, CELL MICROBIOL, V7, P687, DOI 10.1111/j.1462-5822.2005.00502.x; FUKUHARA M, 1969, BIOCHEM PHARMACOL, V18, P475; GAMAZO C, 1989, INFECT IMMUN, V57, P1419, DOI 10.1128/IAI.57.5.1419-1426.1989; Garcia-Ramallo E, 2002, J IMMUNOL, V169, P6467, DOI 10.4049/jimmunol.169.11.6467; Giambartolomei GH, 2004, J IMMUNOL, V173, P4635, DOI 10.4049/jimmunol.173.7.4635; GOMEZMIGUEL MJ, 1986, INFECT IMMUN, V53, P678; Gross A, 2000, INFECT IMMUN, V68, P342, DOI 10.1128/IAI.68.1.342-351.2000; Guzman-Verri C, 2002, P NATL ACAD SCI USA, V99, P12375, DOI 10.1073/pnas.192439399; Guzman-Verri C, 2001, J BIOL CHEM, V276, P44435, DOI 10.1074/jbc.M105606200; Huang LY, 2003, J IMMUNOL, V171, P1441, DOI 10.4049/jimmunol.171.3.1441; HUDSON L, 1976, P298; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; JIANG XS, 1993, INFECT IMMUN, V61, P124, DOI 10.1128/IAI.61.1.124-134.1993; Kawai Y, 2000, FEMS IMMUNOL MED MIC, V28, P197, DOI 10.1016/S0928-8244(00)00156-5; KILLION JW, 1986, INFECT IMMUN, V54, P1; Kim S, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-22; KOSSACK RE, 1981, INFECT IMMUN, V31, P674, DOI 10.1128/IAI.31.2.674-678.1981; Kwak SH, 2006, THROMB HAEMOSTASIS, V95, P829, DOI 10.1160/TH05-12-0782; Lamontagne J, 2007, J PROTEOME RES, V6, P1519, DOI 10.1021/pr060636a; Lapaque N, 2006, CELL MICROBIOL, V8, P401, DOI 10.1111/j.1462-5822.2005.00629.x; Lapaque N, 2005, CURR OPIN MICROBIOL, V8, P60, DOI 10.1016/j.mib.2004.12.003; Lembo A, 2003, INFECT IMMUN, V71, P6058, DOI 10.1128/IAI.71.10.6058-6062.2003; Manterola L, 2005, J BACTERIOL, V187, P5631, DOI 10.1128/JB.187.16.5631-5639.2005; Marchesini MI, 2004, MICROB PATHOGENESIS, V37, P95, DOI 10.1016/j.micpath.2004.06.001; Mastroeni P, 2004, MICROBES INFECT, V6, P398, DOI 10.1016/j.micinf.2003.12.009; MORENO E, 1984, INFECT IMMUN, V46, P74, DOI 10.1128/IAI.46.1.74-80.1984; Moreno E., 2004, Brucella: molecular and cellular biology, P287; MORENO E, 1981, INFECT IMMUN, V31, P362, DOI 10.1128/IAI.31.1.362-370.1981; Moreno E, 2002, P NATL ACAD SCI USA, V99, P1, DOI 10.1073/pnas.022622699; MORENO E, 2001, PROKARYOTES 1, V5, P315; MORIYON I, 2004, INTRACELLULAR PATHOG, P204; Murphy EA, 2001, FEMS IMMUNOL MED MIC, V32, P85, DOI 10.1111/j.1574-695X.2001.tb00536.x; Pappas G, 2005, NEW ENGL J MED, V352, P2325, DOI 10.1056/NEJMra050570; PHILLIPS M, 1989, AM J VET RES, V50, P318; Pizarro-Cerda J, 1999, J IMMUNOL, V162, P3519; PUGH GW, 1989, AM J VET RES, V50, P323; Rafiei A, 2006, J INFECTION, V53, P315, DOI 10.1016/j.jinf.2005.11.024; Rajashekara G, 2005, CELL MICROBIOL, V7, P1459, DOI 10.1111/j.1462-5822.2005.00570.x; RASOOL O, 1992, INFECT IMMUN, V60, P1699, DOI 10.1128/IAI.60.4.1699-1702.1992; RILEY LK, 1984, INFECT IMMUN, V46, P224, DOI 10.1128/IAI.46.1.224-230.1984; Rittig MG, 2003, J LEUKOCYTE BIOL, V74, P1045, DOI 10.1189/jlb.0103015; Sander A, 1997, J CLIN MICROBIOL, V35, P584, DOI 10.1128/JCM.35.3.584-587.1997; Santamaria C, 2005, ANTIMICROB AGENTS CH, V49, P1340, DOI [10.1128/AAC.49.4.1340-1345.2005, 10.1128/AAc.49.4.1340-1345.2005]; Sha J, 2004, INFECT IMMUN, V72, P3987, DOI 10.1128/IAI.72.7.3987-4003.2004; SPINK WW, 1956, NATURE BRUCELLOSIS, P464; Sun YH, 2002, INFECT IMMUN, V70, P4826, DOI 10.1128/IAI.70.9.4826-4832.2002; THIELE OW, 1969, EUR J BIOCHEM, V7, P393, DOI 10.1111/j.1432-1033.1969.tb19621.x; Weiss DS, 2005, INFECT IMMUN, V73, P5137, DOI 10.1128/IAI.73.8.5137-5143.2005; Weiss DS, 2004, J IMMUNOL, V172, P4463, DOI 10.4049/jimmunol.172.7.4463; WEISS DS, 2002, MOL CELLULAR MICROBI, P439; YOUNG EJ, 1985, J INFECT DIS, V151, P682, DOI 10.1093/infdis/151.4.682; Zahringer U, 2004, J BIOL CHEM, V279, P21046, DOI 10.1074/jbc.M313370200; Zhan YF, 1996, INFECT IMMUN, V64, P2782, DOI 10.1128/IAI.64.7.2782-2786.1996	79	224	242	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e631	10.1371/journal.pone.0000631	http://dx.doi.org/10.1371/journal.pone.0000631			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637846	Green Submitted, gold, Green Published			2022-12-25	WOS:000207452100020
J	Boggio, EM; Putignano, E; Sassoe-Pognetto, M; Pizzorusso, T; Giustetto, M				Boggio, Elena M.; Putignano, Elena; Sassoe-Pognetto, Marco; Pizzorusso, Tommaso; Giustetto, Maurizio			Visual Stimulation Activates ERK in Synaptic and Somatic Compartments of Rat Cortical Neurons with Parallel Kinetics	PLOS ONE			English	Article								Background. Extracellular signal-regulated kinase (ERK) signalling pathway plays a crucial role in regulating diverse neuronal processes, such as cell proliferation and differentiation, and long-term synaptic plasticity. However, a detailed understanding of the action of ERK in neurons is made difficult by the lack of knowledge about its subcellular localization in response to physiological stimuli. To address this issue, we have studied the effect of visual stimulation in vivo of dark-reared rats on the spatial-temporal dynamics of ERK activation in pyramidal neurons of the visual cortex. Methodology/Principal Findings. Using immunogold electron microscopy, we show that phosphorylated ERK (pERK) is present in dendritic spines, both at synaptic and non-synaptic plasma membrane domains. Moreover, pERK is also detected in presynaptic axonal boutons forming connections with dendritic spines. Visual stimulation after dark rearing during the critical period causes a rapid increase in the number of pERK-labelled synapses in cortical layers I-II/III. This visually-induced activation of ERK at synaptic sites occurs in pre- and post-synaptic compartments and its temporal profile is identical to that of ERK activation in neuronal cell bodies. Conclusions/Significance. Visual stimulation in vivo increases pERK expression at pre- and post-synaptic sites of axo-spinous junctions, suggesting that ERK plays an important role in the local modulation of synaptic function. The data presented here support a model in which pERK can have early and late actions both centrally in the cell nucleus and peripherally at synaptic contacts.	[Boggio, Elena M.; Sassoe-Pognetto, Marco; Giustetto, Maurizio] Univ Turin, Dipartimento Anat Farmacol & Med Legale, Turin, Italy; [Boggio, Elena M.; Sassoe-Pognetto, Marco; Giustetto, Maurizio] Univ Turin, Ist Nazl Neurosci, Turin, Italy; [Putignano, Elena; Pizzorusso, Tommaso] Scuola Normale Super Pisa, Pisa, Italy; [Putignano, Elena; Pizzorusso, Tommaso] CNR, Inst Neurosci, I-56100 Pisa, Italy; [Pizzorusso, Tommaso] Univ Florence, Dipartimento Psicol, Florence, Italy	University of Turin; University of Turin; Scuola Normale Superiore di Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Florence	Giustetto, M (corresponding author), Univ Turin, Dipartimento Anat Farmacol & Med Legale, Turin, Italy.	maurizio.giustetto@unito.it	giustetto, maurizio/D-6606-2011; Sassoe-Pognetto, Marco/AAE-3536-2022; Pizzorusso, Tommaso/D-1399-2013	giustetto, maurizio/0000-0003-1323-4060; Sassoe-Pognetto, Marco/0000-0001-8906-0613; Putignano, Elena/0000-0002-4313-408X; Pizzorusso, Tommaso/0000-0001-5614-0668	MIUR [PRIN 2005053844, PRIN 2005059123]; FIRB [RBNE019J7C]; Regione Piemonte [142]	MIUR(Ministry of Education, Universities and Research (MIUR)); FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Regione Piemonte(Regione Piemonte)	This work was supported by MIUR (PRIN #2005053844 to MG; PRIN #2005059123 to MSP; FIRB project #RBNE019J7C), Regione Piemonte (Grant #142 to MG).	Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; Berardi N, 2004, NEURON, V44, P905, DOI 10.1016/S0896-6273(04)00796-2; Berardi N, 2003, TRENDS NEUROSCI, V26, P369, DOI 10.1016/S0166-2236(03)00168-1; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Burkhalter A, 2006, J NEUROSCI, V26, P12274, DOI 10.1523/JNEUROSCI.2599-06.2006; Cancedda L, 2003, J NEUROSCI, V23, P7012, DOI 10.1523/JNEUROSCI.23-18-07012.2003; Coogan AN, 1999, J NEUROPHYSIOL, V81, P103, DOI 10.1152/jn.1999.81.1.103; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; Derkach VA, 2007, NAT REV NEUROSCI, V8, P101, DOI 10.1038/nrn2055; Di Cristo G, 2001, SCIENCE, V292, P2337, DOI 10.1126/science.1059075; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Futter M, 2005, P NATL ACAD SCI USA, V102, P3489, DOI 10.1073/pnas.0409802102; Galvan A, 2006, NEUROSCIENCE, V143, P351, DOI 10.1016/j.neuroscience.2006.09.019; Giovannini MG, 2001, J NEUROSCI, V21, P7053, DOI 10.1523/JNEUROSCI.21-18-07053.2001; Goldin M, 2003, EUR J NEUROSCI, V17, P2529, DOI 10.1046/j.1460-9568.2003.02694.x; Gong RM, 2006, NEUROREPORT, V17, P1575, DOI 10.1097/01.wnr.0000234742.42818.ff; Govindarajan A, 2006, NAT REV NEUROSCI, V7, P575, DOI 10.1038/nrn1937; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Holzer M, 2001, NEUROSCIENCE, V105, P1031, DOI 10.1016/S0306-4522(01)00245-7; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Lisman J., 2006, SCI STKE, V2006, pr; Majdan M, 2006, NAT NEUROSCI, V9, P650, DOI 10.1038/nn1674; Mataga N, 2004, NEURON, V44, P1031, DOI 10.1016/j.neuron.2004.11.028; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; Oray S, 2004, NEURON, V44, P1021, DOI 10.1016/j.neuron.2004.12.001; Otis KO, 2006, CURR OPIN NEUROBIOL, V16, P329, DOI 10.1016/j.conb.2006.05.001; Putignano E, 2007, NEURON, V53, P747, DOI 10.1016/j.neuron.2007.02.007; Racz B, 2004, NAT NEUROSCI, V7, P917, DOI 10.1038/nn1303; Ratto GM, 2006, ADV EXP MED BIOL, V557, P122; Rosenblum K, 2000, J NEUROSCI, V20, P977, DOI 10.1523/JNEUROSCI.20-03-00977.2000; SASSOEPOGNETTO M, 1994, J NEUROSCI, V14, P5131; Schafe GE, 2000, J NEUROSCI, V20, P8177; Schroder FH, 2006, EAU EBU UPDATE SERIE, V4, P2; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Sgambato V, 1998, J NEUROSCI, V18, P8814; Sindreu CB, 2007, NEURON, V53, P79, DOI 10.1016/j.neuron.2006.11.024; Sutton MA, 2006, CELL, V127, P49, DOI 10.1016/j.cell.2006.09.014; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; Thompson KR, 2004, NEURON, V44, P997, DOI 10.1016/j.neuron.2004.11.025; Wallace W, 2004, J NEUROSCI, V24, P6928, DOI 10.1523/JNEUROSCI.1110-04.2004; Wang LJ, 2002, CIRC RES, V91, P821, DOI 10.1161/01.RES.0000041029.97988.E9; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Yasuda R, 2006, NAT NEUROSCI, V9, P283, DOI 10.1038/nn1635; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	59	35	36	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e604	10.1371/journal.pone.0000604	http://dx.doi.org/10.1371/journal.pone.0000604			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622349	gold, Green Published, Green Submitted			2022-12-25	WOS:000207452000011
J	Anginot, A; Dacquin, R; Mazzorana, M; Jurdic, P				Anginot, Adrienne; Dacquin, Romain; Mazzorana, Marlene; Jurdic, Pierre			Lymphocytes and the Dap12 Adaptor Are Key Regulators of Osteoclast Activation Associated with Gonadal Failure	PLOS ONE			English	Article								Bone resorption by osteoclasts is necessary to maintain bone homeostasis. Osteoclast differentiation from hematopoietic progenitors and their activation depend on M-CSF and RANKL, but also requires co-stimulatory signals acting through receptors associated with DAP12 and FcR gamma adaptors. Dap12 mutant mice (K Delta 75) are osteopetrotic due to inactive osteoclasts but, surprisingly, these mice are more sensitive than WT mice to bone loss following an ovariectomy. Because estrogen withdrawal is known to disturb bone mass, at least in part, through lymphocyte interaction, we looked at the role of mature lymphocytes on osteoclastogenesis and bone mass in the absence of functional DAP12. Lymphocytes were found to stimulate an early osteoclast differentiation response from Dap12-deficient progenitors in vitro. In vivo, Rag1-/- mice lacking mature lymphocytes did not exhibit any bone phenotype, but lost their bone mass after ovariectomy like K Delta 75 mice. K Delta 75; Rag1-/ double mutant female mice exhibited a more severe osteopetrosis than Dap12-deficient animals but lost their bone mass after ovariectomy, like single mutants. These results suggest that both DAP12 and mature lymphocytes act synergistically to maintain bone mass under physiological conditions, while playing similar but not synergistic co-stimulatory roles in protecting bone loss after gonadal failure. Thus, our data support a role for lymphocytes during osteoclast differentiation and suggest that they may function as accessory cells when regular osteoclast function is compromised.	[Anginot, Adrienne; Dacquin, Romain; Mazzorana, Marlene; Jurdic, Pierre] Univ Lyon 1, Ecole Normale Super, Inst Federatif Biosci Gerland Lyon Sud, CNRS,INRA,Inst Genom Fonct Lyon, F-69365 Lyon, France	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Jurdic, P (corresponding author), Univ Lyon 1, Ecole Normale Super, Inst Federatif Biosci Gerland Lyon Sud, CNRS,INRA,Inst Genom Fonct Lyon, F-69365 Lyon, France.	pierre.jurdic@enslyon.fr	Anginot, Adrienne/N-9299-2017	MAZZORANA, Marlene/0000-0002-3956-4319	Agence Nationale pour la Recherche, ANR; Fondation pour la Recherche Medicale (FRM); INSERM; French Ministry of Research; Association pour la Recherche contre le Cancer (ARC)	Agence Nationale pour la Recherche, ANR(French National Research Agency (ANR)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR))	This work was supported by grants from the Agence Nationale pour la Recherche, ANR maladies rares; Fondation pour la Recherche Medicale (FRM), and ProA program from INSERM. A. Anginot was a recipient of a PhD grant from the French Ministry of Research and from the Association pour la Recherche contre le Cancer (ARC); R. Dacquin has been a recipient of an ARC fellowship and is currently recipient of INSERM fellowship.	Baron R, 2004, NAT MED, V10, P458, DOI 10.1038/nm0504-458; Carlsten H, 2005, IMMUNOL REV, V208, P194, DOI 10.1111/j.0105-2896.2005.00326.x; Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Faccio R, 2003, J CELL BIOCHEM, V90, P871, DOI 10.1002/jcb.10694; Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074; Humphrey MB, 2004, J BONE MINER RES, V19, P224, DOI 10.1359/JBMR.0301234; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726; LI Y, 2007, BLOOD; Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775; MASUZAWA T, 1994, J CLIN INVEST, V94, P1090, DOI 10.1172/JCI117424; Miyaura C, 1997, P NATL ACAD SCI USA, V94, P9360, DOI 10.1073/pnas.94.17.9360; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nataf S, 2005, AM J PATHOL, V166, P275, DOI 10.1016/S0002-9440(10)62251-1; Onoe Y, 2000, J BONE MINER RES, V15, P541, DOI 10.1359/jbmr.2000.15.3.541; Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027; Paloneva J, 2000, NAT GENET, V25, P357, DOI 10.1038/77153; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Perry MJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE1159, DOI 10.1152/ajpendo.2000.279.5.E1159; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Shibutani T, 2000, J BIOMED MATER RES, V50, P153, DOI 10.1002/(SICI)1097-4636(200005)50:2<153::AID-JBM9>3.0.CO;2-R; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Thurmond TS, 2000, ENDOCRINOLOGY, V141, P2309, DOI 10.1210/en.141.7.2309; Tomasello E, 2000, IMMUNITY, V13, P355, DOI 10.1016/S1074-7613(00)00035-2; Turnbull IR, 2007, NAT REV IMMUNOL, V7, P155, DOI 10.1038/nri2014; TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275; Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550	35	19	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e585	10.1371/journal.pone.0000585	http://dx.doi.org/10.1371/journal.pone.0000585			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611620	gold, Green Submitted, Green Published			2022-12-25	WOS:000207451900005
J	Wu, YL; Torchia, J; Yao, W; Lane, NE; Lanier, LL; Nakamura, MC; Humphrey, MB				Wu, Yalei; Torchia, James; Yao, Wei; Lane, Nancy E.; Lanier, Lewis L.; Nakamura, Mary C.; Humphrey, Mary Beth			Bone Microenvironment Specific Roles of ITAM Adapter Signaling during Bone Remodeling Induced by Acute Estrogen-Deficiency	PLOS ONE			English	Article								Immunoreceptor tyrosine-based activation motif (ITAM) signaling mediated by DAP12 or Fc epsilon receptor I gamma chain (FcR gamma) have been shown to be critical for osteoclast differentiation and maturation under normal physiological conditions. Their function in pathological conditions is unknown. We studied the role of ITAM signaling during rapid bone remodeling induced by acute estrogen-deficiency in wild-type (WT), DAP12-deficient (DAP12-/-), FcR gamma-deficient (FcR gamma-/-) and double-deficient (DAP12-/- FcR gamma-/-) mice. Six weeks after ovariectomy (OVX), DAP12-/-FcR gamma-/- mice showed resistance to lumbar vertebral body (LVB) trabecular bone loss, while WT, DAP12-/- and FcR gamma-/- mice had significant LVB bone loss. In contrast, all ITAM adapter-deficient mice responded to OVX with bone loss in both femur and tibia of approximately 40%, relative to basal bone volumes. Only WT mice developed significant cortical bone loss after OVX. In vitro studies showed microenvironmental changes induced by OVX are indispensable for enhanced osteoclast formation and function. Cytokine changes, including TGF beta and TNF alpha, were able to induce osteoclastogenesis independent of RANKL in BMMs from WT but not DAP12-/- and DAP12-/-FcR gamma-/- mice. FSH stimulated RANKL-induced osteoclast differentiation from BMMs in WT, but not DAP12-/- and DAP12-/-FcR gamma-/- mice. Our study demonstrates that although ITAM adapter signaling is critical for normal bone remodeling, estrogen-deficiency induces an ITAM adapter-independent bypass mechanism allowing for enhanced osteoclastogenesis and activation in specific bony microenvironments.	[Humphrey, Mary Beth] VA Med Ctr, Dept Med & Microbiol & Immunol, Oklahoma City, OK USA; [Humphrey, Mary Beth] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Wu, Yalei; Torchia, James; Nakamura, Mary C.] Univ Calif San Francisco, Dept Med, VA Med Ctr, San Francisco, CA USA; [Wu, Yalei; Lanier, Lewis L.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Yao, Wei; Lane, Nancy E.] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA; [Lanier, Lewis L.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Davis; University of California System; University of California San Francisco	Humphrey, MB (corresponding author), VA Med Ctr, Dept Med & Microbiol & Immunol, Oklahoma City, OK USA.	marybeth-humphrey@ouhsc.edu	Nakamura, Mary/ABI-2887-2020; Lanier, Lewis L/E-2139-2014; Yao, Wei/O-8187-2019; yao, wei/GVS-3913-2022	Nakamura, Mary/0000-0001-8127-9426; Lanier, Lewis L/0000-0003-1308-3952; Yao, Wei/0000-0002-1198-1161; yao, wei/0000-0002-1198-1161; Torchia, James/0000-0001-5291-8698	Veterans Affairs; National Institutes of Health [RO1 AR050038, R01 AR043052, K24- AR048841, R01 AI068129]; Abbott Scholars in Rheumatology; Rosalind Russell Center for Arthritis Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD051958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR048841, R01AR043052, R01AR050038] Funding Source: NIH RePORTER	Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Abbott Scholars in Rheumatology; Rosalind Russell Center for Arthritis Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the Veterans Affairs (MBH and MCN), National Institutes of Health Grants RO1 AR050038 (MCN), R01 AR043052 (NEL), K24- AR048841 (NEL), and R01 AI068129 (LLL), Abbott Scholars in Rheumatology (MBH), and the Rosalind Russell Center for Arthritis Research (MCN). LLL is an American Cancer Society Research Professor. MCN is an American Cancer Society Research Scholar.	Daci E, 2000, J BONE MINER RES, V15, P1510, DOI 10.1359/jbmr.2000.15.8.1510; Daws MR, 2003, J IMMUNOL, V171, P594, DOI 10.4049/jimmunol.171.2.594; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Hamerman JA, 2006, J IMMUNOL, V177, P2051, DOI 10.4049/jimmunol.177.4.2051; Hankenson KD, 2005, MATRIX BIOL, V24, P362, DOI 10.1016/j.matbio.2005.05.008; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x; Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Lindberg MK, 2006, BONE, V38, P85, DOI 10.1016/j.bone.2005.07.027; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Oshima S, 2006, FEBS LETT, V580, P1251, DOI 10.1016/j.febslet.2006.01.038; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; Philbrick WM, 1998, P NATL ACAD SCI USA, V95, P11846, DOI 10.1073/pnas.95.20.11846; Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468; Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051; Turnbull IR, 2007, NAT REV IMMUNOL, V7, P155, DOI 10.1038/nri2014; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Van Wesenbeeck L, 2002, P NATL ACAD SCI USA, V99, P14303, DOI 10.1073/pnas.202332999; Wise GE, 1998, EUR J ORAL SCI, V106, P397, DOI 10.1111/j.1600-0722.1998.tb02205.x; Zhao HB, 2005, J BONE MINER RES, V20, P2116, DOI 10.1359/JBMR.050724	25	51	51	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e586	10.1371/journal.pone.0000586	http://dx.doi.org/10.1371/journal.pone.0000586			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611621	Green Submitted, gold, Green Published			2022-12-25	WOS:000207451900006
J	Desnoyers, L; Pai, R; Ferrando, R; Hotzel, K; Le, T; Ross, J; Carano, R; D'Souza, A; Qing, J; Mohtashemi, I; Ashkenazi, A; French, D				Desnoyers, Lr; Pai, R.; Ferrando, Re; Hotzel, K.; Le, T.; Ross, J.; Carano, R.; D'Souza, A.; Qing, J.; Mohtashemi, I.; Ashkenazi, A.; French, Dm			Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models	ONCOGENE			English	Article						fibroblast growth factor; hepatocellular carcinoma; FGF19; colon adenocarcinoma; FGFR4; beta-catenin	FACTOR RECEPTOR-3; HUMAN BREAST; ACTIVATING MUTATIONS; INCREASED EXPRESSION; MULTIPLE-MYELOMA; PROSTATE-CANCER; FIBROBLAST; FGFR4; GENE; TRANSLOCATION	Although fibroblast growth factor 19 (FGF19) can promote liver carcinogenesis in mice its involvement in human cancer is not well characterized. Here we report that FGF19 and its cognate receptor FGF receptor 4 (FGFR4) are coexpressed in primary human liver, lung and colon tumors and in a subset of human colon cancer cell lines. To test the importance of FGF19 for tumor growth, we developed an anti-FGF19 monoclonal antibody that selectively blocks the interaction of FGF19 with FGFR4. This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice. The efficacy of the antibody in these models was linked to inhibition of FGF19-dependent activation of FGFR4, FRS2, ERK and beta-catenin. These findings suggest that the inactivation of FGF19 could be beneficial for the treatment of colon cancer, liver cancer and other malignancies involving interaction of FGF19 and FGFR4.	[Desnoyers, Lr; D'Souza, A.; Qing, J.; Ashkenazi, A.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Pai, R.; Ferrando, Re; Hotzel, K.; French, Dm] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Le, T.; Ross, J.; Carano, R.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA; [Mohtashemi, I.] Genentech Inc, Dept Protein Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	French, D (corresponding author), Genentech Inc, Dept Mol Oncol, MS 72B,1 DNA Way, San Francisco, CA 94080 USA.	dfrench@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				ANTHONY PP, 1979, J TOXICOL ENV HEALTH, V5, P301, DOI 10.1080/15287397909529751; Bange J, 2002, CANCER RES, V62, P840; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gowardhan B, 2005, BRIT J CANCER, V92, P320, DOI 10.1038/sj.bjc.6602274; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Huang Yao Qi, 1993, Anticancer Research, V13, P887; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jang JH, 2000, CANCER RES, V60, P4049; Jang JH, 2001, CANCER RES, V61, P3541; Jeffers Michael, 2002, Expert Opin Ther Targets, V6, P469, DOI 10.1517/14728222.6.4.469; Jubb Adrian M, 2006, Methods Mol Biol, V326, P255; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; Kobayashi M, 2006, CANCER-AM CANCER SOC, V106, P636, DOI 10.1002/cncr.21607; Krejci P, 2001, LEUKEMIA, V15, P228, DOI 10.1038/sj.leu.2402012; Lee FT, 1997, RADIOLOGY, V203, P465, DOI 10.1148/radiology.203.2.9114106; LISCIA DS, 1989, ONCOGENE, V4, P1219; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Mattila MMT, 2001, ONCOGENE, V20, P2791, DOI 10.1038/sj.onc.1204430; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Morimoto Y, 2003, CANCER, V98, P2245, DOI 10.1002/cncr.11778; Nicholes K, 2002, AM J PATHOL, V160, P2295, DOI 10.1016/S0002-9440(10)61177-7; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Qian ZR, 2004, J CLIN ENDOCR METAB, V89, P1904, DOI 10.1210/jc.2003-031489; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Ruohola JK, 2001, CANCER RES, V61, P4229; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Shima K, 2003, IEEE T ENERGY CONVER, V18, P63, DOI 10.1109/TEC.2002.808337; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; Spinola M, 2005, J CLIN ONCOL, V23, P7307, DOI 10.1200/JCO.2005.17.350; Streit S, 2004, INT J CANCER, V111, P213, DOI 10.1002/ijc.20204; Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078-0432.CCR-04-0408; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Yamada SM, 2002, NEUROL RES, V24, P244, DOI 10.1179/016164102101199864; Yu CD, 2005, J BIOL CHEM, V280, P17707, DOI 10.1074/jbc.M411771200; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481	46	202	238	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					85	97		10.1038/sj.onc.1210623	http://dx.doi.org/10.1038/sj.onc.1210623			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599042				2022-12-25	WOS:000252118700009
J	Lerner-Marmarosh, N; Miralem, T; Gibbs, PEM; Maines, MD				Lerner-Marmarosh, Nicole; Miralem, Tihomir; Gibbs, Peter E. M.; Maines, Mahin D.			Regulation of TNF-alpha-activated PKC-zeta signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase	FASEB JOURNAL			English	Article						heme oxygenase; protein kinase C-zeta	PROTEIN-KINASE-C; NF-KAPPA-B; HEME OXYGENASE-1; TYROSINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; CELLS; INDUCTION; BILIRUBIN; TRANSCRIPTION; PURIFICATION	Human biliverdin reductase ( hBVR) is a dual function enzyme: a catalyst for bilirubin formation and a S/T/Y kinase that shares activators with protein kinase C (PKC)-zeta, including cytokines, insulin, and reactive oxygen species ( ROS). Presently, we show that hBVR increases PKC-zeta autophosphorylation, stimulation by TNF-alpha, as well as cytokine stimulation of NF-kappa B DNA binding and promoter activity. S-149 in hBVR S/T kinase domain and S-230 in (YLSF)-F-230 in hBVR's docking site for the SH2 domain of signaling proteins are phosphorylation targets of PKC-zeta. Two hBVR- based peptides, (KRNRYLSF)-F-230 (# 1) and KKRILHC281 (# 2), but not their S -> A or C -> A derivatives, respectively, blocked PKC-zeta stimulation by TNF-alpha and its membrane translocation. The C- terminal- based peptide KYCCSRK296 (# 3), enhanced PKC-zeta stimulation by TNF-alpha; for this, Lys(296) was essential. In metabolically P-32-labeled HEK293 cells transfected with hBVR or PKC-zeta, TNF-alpha increased hBVR phosphorylation. TNF-alpha did not stimulate PKC-zeta in cells infected with small interfering RNA for hBVR or transfected with hBVR with a point mutation in the nucleotide-binding loop (G(17)), S149, or S230; this was similar to the response of "kinase-dead" PKC-zeta(K281R). We suggest peptide #1 blocks PKC-zeta-docking site interaction, peptide #2 disrupts function of the PKC-zeta C1 domain, and peptide # 3 alters ATP presentation to the kinase. The findings are of potential significance for development of modulators of PKC-zeta activity and cellular response to cytokines.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Maines, MD (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	mahin_maines@urmc.rochester.edu	Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442	NIEHS NIH HHS [ES-04066, ES-012187] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066, R01ES012187] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; BELL JE, 1988, ARCH BIOCHEM BIOPHYS, V263, P1, DOI 10.1016/0003-9861(88)90607-8; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Cariou B, 2002, MOL CELL BIOL, V22, P6959, DOI 10.1128/MCB.22.20.6959-6970.2002; Choi AMK, 2005, AM J RESP CRIT CARE, V171, P1318, DOI 10.1164/ajrccm.171.11.953; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; Farese RV, 2005, EXP BIOL MED, V230, P593; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Immenschuh S, 2006, HISTOL HISTOPATHOL, V21, P679, DOI 10.14670/HH-21.679; Kamiya A, 2004, HEPATOLOGY, V40, P527, DOI 10.1002/hep.20362; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lerner-Marmarosh N, 2005, P NATL ACAD SCI USA, V102, P7109, DOI 10.1073/pnas.0502173102; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Maines MD, 2007, J BIOL CHEM, V282, P8110, DOI 10.1074/jbc.M513427200; Maines MD, 2005, PHYSIOLOGY, V20, P382, DOI 10.1152/physiol.00029.2005; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1996, EUR J BIOCHEM, V235, P372, DOI 10.1111/j.1432-1033.1996.00372.x; Mancuso C, 2004, ANTIOXID REDOX SIGN, V6, P878, DOI 10.1089/1523086041798097; Miralem T, 2005, J BIOL CHEM, V280, P17084, DOI 10.1074/jbc.M413121200; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2006, CELL DEATH DIFFER, V13, P702, DOI 10.1038/sj.cdd.4401823; Moscat J, 2002, ADV ENZYME REGUL, V42, P173, DOI 10.1016/S0065-2571(01)00029-2; Myers MG, 1996, MOL CELL BIOL, V16, P4147; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sheftel AD, 2007, J BIOL CHEM, V282, P10480, DOI 10.1074/jbc.M700240200; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Szczesna-Skorupa E, 2004, J BIOL CHEM, V279, P13953, DOI 10.1074/jbc.M312170200; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Wyatt TA, 1997, AM J PHYSIOL-LUNG C, V273, pL1007, DOI 10.1152/ajplung.1997.273.5.L1007; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033	58	38	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3949	3962		10.1096/fj.07-8544com	http://dx.doi.org/10.1096/fj.07-8544com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17639074				2022-12-25	WOS:000251283500020
J	Bursy, J; Pierik, AJ; Pica, N; Bremer, E				Bursy, Jan; Pierik, Antonio J.; Pica, Nathalie; Bremer, Erhard			Osmotically induced synthesis of the compatible solute hydroxyectoine is mediated by an evolutionarily conserved ectoine hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HALOMONAS-ELONGATA; TETRAHYDROPYRIMIDINE DERIVATIVES; PROLINE 4-HYDROXYLASE; BACILLUS-SUBTILIS; HIGH OSMOLARITY; AMINO-ACID; BIOSYNTHESIS; GENES; TRANSPORT	By using natural abundance C-13 NMR spectroscopy, we investigated the types of compatible solutes synthesized in a variety of Bacilli under high salinity growth conditions. Glutamate, proline, and ectoine were the dominant compatible solutes synthesized by the various Bacillus species. The majority of the inspected Bacilli produced the tetrahydropyrimidine ectoine in response to high salinity stress, and a subset of these also synthesized a hydroxylation derivative of ectoine, 5-hydroxyectoine. In Salibacillus salexigens, a representative of the ectoine- and 5-hydroxyectoine-producing species, ectoine production was linearly correlated with the salinity of the growth medium and dependent on an ectABC biosynthetic operon. The formation of 5-hydroxyectoine was primarily a stationary growth phase phenomenon. The enzyme responsible for ectoine hydroxylation (EctD) was purified from S. salexigens to apparent homogeneity. The EctD protein was shown in vitro to directly hydroxylate ectoine in a reaction dependent on iron(II), molecular oxygen, and 2-oxoglutarate. We identified the structural gene (ectD) for the ectoine hydroxylase in S. salexigens. Northern blot analysis showed that the transcript levels of the ectABC and ectD genes increased as a function of salinity. Many EctD-related proteins can be found in data base searches in various Bacteria. Each of these bacterial species also contains an ectABC ectoine biosynthetic gene cluster, suggesting that 5-hydroxyectoine biosynthesis strictly depends on the prior synthesis of ectoine. Our data base searches and the biochemical characterization of the EctD protein from S. salexigens suggest that the EctD-related ectoine hydroxylases are members of a new subfamily within the non-heme-containing, iron(II)and 2-oxoglutarate-dependent dioxygenase superfamily (EC 1.14.11).	Univ Marburg, Dept Biol, Microbiol Lab, D-35032 Marburg, Germany	Philipps University Marburg	Bremer, E (corresponding author), Univ Marburg, Dept Biol, Microbiol Lab, Karl-von-Frisch-Str, D-35032 Marburg, Germany.	bremer@staff.uni-marburg.de	Pierik, Antonio J/G-1108-2010	Pierik, Antonio J/0000-0002-1509-6370				Alekshun MN, 1999, TRENDS MICROBIOL, V7, P410, DOI 10.1016/S0966-842X(99)01589-9; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Borges N, 2002, EXTREMOPHILES, V6, P209, DOI 10.1007/s007920100236; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; Canovas D, 1998, SYST APPL MICROBIOL, V21, P487, DOI 10.1016/S0723-2020(98)80060-X; Canovas D, 1997, J BIOL CHEM, V272, P25794, DOI 10.1074/jbc.272.41.25794; Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; da Costa M. S., 1998, V61, P117; DULANEY EUGENE L., 1968, DEVELOP IND MICROBIOL, V9, P260; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; GALINSKI EA, 1994, FEMS MICROBIOL REV, V15, P95, DOI 10.1111/j.1574-6976.1994.tb00128.x; GALINSKI EA, 1985, EUR J BIOCHEM, V149, P135, DOI 10.1111/j.1432-1033.1985.tb08903.x; Garabito MJ, 1997, INT J SYST BACTERIOL, V47, P735, DOI 10.1099/00207713-47-3-735; Garcia-Estepa R, 2006, J BACTERIOL, V188, P3774, DOI 10.1128/JB.00136-06; Goller K, 1998, FEMS MICROBIOL LETT, V161, P293; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; Heyrman J, 2003, INT J SYST EVOL MICR, V53, P501, DOI 10.1099/ijs.0.02371-0; INBAR L, 1988, J BIOL CHEM, V263, P16014; INBAR L, 1993, EUR J BIOCHEM, V214, P897, DOI 10.1111/j.1432-1033.1993.tb17993.x; JEBBAR M, 1992, J BACTERIOL, V174, P5027, DOI 10.1128/JB.174.15.5027-5035.1992; Kappes RM, 1998, MICROBIOL-UK, V144, P83, DOI 10.1099/00221287-144-1-83; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; Kuhlmann AU, 2002, APPL ENVIRON MICROB, V68, P772, DOI 10.1128/AEM.68.2.772-783.2002; KUNTE HJ, 1993, J MICROBIOL METH, V17, P129; Lawrence CC, 1996, BIOCHEM J, V313, P185, DOI 10.1042/bj3130185; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; LIPPERT K, 1992, APPL MICROBIOL BIOT, V37, P61; Louis P, 1997, MICROBIOL-UK, V143, P1141, DOI 10.1099/00221287-143-4-1141; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; Manzanera M, 2004, FEMS MICROBIOL LETT, V233, P347, DOI 10.1016/j.femsle.2004.03.005; Manzanera M, 2002, APPL ENVIRON MICROB, V68, P4328, DOI 10.1128/AEM.68.9.4328-4333.2002; Mori H, 1997, J BACTERIOL, V179, P5677, DOI 10.1128/jb.179.18.5677-5683.1997; Nau-Wagner G, 1999, APPL ENVIRON MICROB, V65, P560; Ono H, 1999, J BACTERIOL, V181, P91, DOI 10.1128/JB.181.1.91-99.1999; PETERS P, 1990, FEMS MICROBIOL LETT, V71, P157; Pflughoeft KJ, 2003, APPL ENVIRON MICROB, V69, P5919, DOI 10.1128/AEM.69.10.5919-5927.2003; Prabhu J, 2004, APPL ENVIRON MICROB, V70, P3130, DOI 10.1128/AEM.70.5.3130-3132.2004; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; Reshetnikov AS, 2006, ARCH MICROBIOL, V184, P286, DOI 10.1007/s00203-005-0042-z; Roberts MF, 2000, FRONT BIOSCI-LANDMRK, V5, pD796, DOI 10.2741/roberts; Roessler M, 2001, ENVIRON MICROBIOL, V3, P743, DOI 10.1046/j.1462-2920.2001.00252.x; Sauer T, 1998, BIOTECHNOL BIOENG, V57, P306, DOI 10.1002/(SICI)1097-0290(19980205)57:3<306::AID-BIT7>3.0.CO;2-L; Schnoor M, 2004, BIOCHEM BIOPH RES CO, V322, P867, DOI 10.1016/j.bbrc.2004.07.200; Shibasaki T, 1999, APPL ENVIRON MICROB, V65, P4028; Solomon EI, 2003, P NATL ACAD SCI USA, V100, P3589, DOI 10.1073/pnas.0336792100; STROM AR, 1993, MOL MICROBIOL, V8, P205, DOI 10.1111/j.1365-2958.1993.tb01564.x; TALIBART R, 1994, J BACTERIOL, V176, P5210, DOI 10.1128/JB.176.17.5210-5217.1994; WHATMORE AM, 1990, J GEN MICROBIOL, V136, P2527, DOI 10.1099/00221287-136-12-2527; Wood JM, 2001, COMP BIOCHEM PHYS A, V130, P437, DOI 10.1016/S1095-6433(01)00442-1; Zhao B, 2006, CURR MICROBIOL, V53, P183, DOI 10.1007/s00284-005-0396-0	54	114	123	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31147	31155		10.1074/jbc.M704023200	http://dx.doi.org/10.1074/jbc.M704023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17636255	hybrid			2022-12-25	WOS:000250309200004
J	Lu, HAJ; Sun, TX; Matsuzaki, T; Yi, XH; Eswara, J; Bouley, R; Mckee, M; Brown, D				Lu, Hua A. J.; Sun, Tian-Xiao; Matsuzaki, Toshiyuki; Yi, Xian-Hua; Eswara, Jairam; Bouley, Richard; Mckee, Mary; Brown, Dennis			Heat shock protein 70 interacts with aquaporin-2 and regulates its trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT; MOLECULAR CHAPERONE; WATER CHANNEL; COATED PITS; INTRACELLULAR VESICLES; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; RAT-KIDNEY; HSC70; CLATHRIN	The trafficking of aquaporin-2 (AQP2) involves multiple complex pathways, including regulated, cAMP-, and cGMP-mediated pathways, as well as a constitutive recycling pathway. Although several accessory proteins have been indirectly implicated in AQP2 recycling, the direct protein-protein interactions that regulate this process remain largely unknown. Using yeast two-hybrid screening of a human kidney cDNA library, we have identified the 70-kDa heat shock proteins as AQP2-interacting proteins. Interaction was confirmed by mass spectrometry of proteins pulled down from rat kidney papilla extract using a GST-AQP2 C-terminal fusion protein (GST-A2C) as a bait, by co-immunoprecipitation (IP) assays, and by direct binding assays using purified hsc70 and the GST-A2C. The direct interaction of AQP2 with hsc70 is partially inhibited by ATP, and the Ser-256 residue in the AQP2 C terminus is important for this direct interaction. Vasopressin stimulation in cells enhances the interaction of hsc70 with AQP2 in IP assays, and vasopressin stimulation in vivo induces an increased co-localization of hsc70 and AQP2 on the apical membrane of principal cells in rat kidney collecting ducts. Functional knockdown of hsc70 activity in AQP2 expressing cells results in membrane accumulation of AQP2 and reduced endocytosis of rhodaminetransferrin. Our data also show that AQP2 interacts with hsp70 in multiple in vitro binding assays. Finally, in addition to hsc70 and hsp70, AQP2 interacts with several other key components of the endocytotic machinery in co-IP assays, including clathrin, dynamin, and AP2. To summarize, we have identified the 70-kDa heat shock proteins as a AQP2 interactors and have shown for hsc70 that this interaction is involved in AQP2 trafficking.	Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Brown, D (corresponding author), Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA.	brown@receptor.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521, P01DK038452, K08DK075940, P30DK043351] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK075940, DK38452, DK43351, DK57521] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bouley R, 2000, J CLIN INVEST, V106, P1115, DOI 10.1172/JCI9594; Briknarova K, 2001, NAT STRUCT BIOL, V8, P349, DOI 10.1038/86236; Brive L, 2001, BIOCHEM BIOPH RES CO, V289, P1099, DOI 10.1006/bbrc.2001.6087; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; BROWN D, 1983, NATURE, V302, P253, DOI 10.1038/302253a0; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Callahan MK, 2002, J BIOL CHEM, V277, P33604, DOI 10.1074/jbc.M202890200; Carrello A, 2004, CELL STRESS CHAPERON, V9, P167, DOI 10.1379/CSC-26R.1; Chang HC, 2002, J CELL BIOL, V159, P477, DOI 10.1083/jcb.200205086; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; Clay JR, 2002, J NEUROSCI RES, V67, P745, DOI 10.1002/jnr.10182; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Inoue T, 1998, AM J PHYSIOL-RENAL, V275, pF752, DOI 10.1152/ajprenal.1998.275.5.F752; Irmer H, 1997, J BIOL CHEM, V272, P2230; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; Klussmann E, 2000, REV PHYSIOL BIOCH P, V141, P33, DOI 10.1007/BFb0119577; Klussmann E, 2001, J BIOL CHEM, V276, P20451, DOI 10.1074/jbc.M010270200; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lu H, 2004, AM J PHYSIOL-RENAL, V286, pF233, DOI 10.1152/ajprenal.00179.2003; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mironova R, 2001, MOL MICROBIOL, V39, P1061, DOI 10.1046/j.1365-2958.2001.02304.x; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; Nielsen S, 1999, J AM SOC NEPHROL, V10, P647; Noda Y, 2004, FEBS LETT, V568, P139, DOI 10.1016/j.febslet.2004.05.021; Procino G, 2003, FASEB J, V17, P1886, DOI 10.1096/fj.02-0870fje; Russo LM, 2006, AM J PHYSIOL-RENAL, V291, pF246, DOI 10.1152/ajprenal.00437.2005; SABOLIC I, 1995, J MEMBRANE BIOL, V143, P165, DOI 10.1007/BF00233445; Sasaki S, 2000, NEPHROL DIAL TRANSPL, V15, P21, DOI 10.1093/ndt/15.suppl_6.21; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Sun TX, 2002, AM J PHYSIOL-RENAL, V282, pF998, DOI 10.1152/ajprenal.00257.2001; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; Tutar Y, 2006, GENETICS, V172, P851, DOI 10.1534/genetics.105.048926; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; Valenti G, 2000, J CELL SCI, V113, P1985; Valenti G, 2005, ENDOCRINOLOGY, V146, P5063, DOI 10.1210/en.2005-0868; van Balkom BWM, 2004, AM J PHYSIOL-RENAL, V286, pF216, DOI 10.1152/ajprenal.00307.2003; van Balkom BWM, 2003, J BIOL CHEM, V278, P1101, DOI 10.1074/jbc.M207339200; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	58	94	99	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28721	28732		10.1074/jbc.M611101200	http://dx.doi.org/10.1074/jbc.M611101200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17636261	hybrid			2022-12-25	WOS:000249642100046
J	Wittrup, A; Sandgren, S; Lilja, J; Bratt, C; Gustavsson, N; Moergelin, M; Belting, M				Wittrup, Anders; Sandgren, Staffan; Lilja, Johanna; Bratt, Charlotte; Gustavsson, Niklas; Moergelin, Matthias; Belting, Mattias			Identification of proteins released by mammalian cells that mediate DNA internalization through proteoglycan-dependent macropinocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; PLASMID DNA; BINDING PROTEIN; HEPATIC-UPTAKE; GENE-TRANSFER; SURFACE PROTEOGLYCANS; INTRAVENOUS-INJECTION; CYCLOPHILIN-B; TARGET-CELLS; ENDOCYTOSIS	Naked DNA plasmid represents the simplest vehicle for gene therapy and DNA-based vaccination purposes; however, the, molecular mechanisms of DNA uptake in mammalian cells are poorly understood. Here, we show that naked DNA uptake occurs via proteoglycan-dependent macropinocytosis, thus challenging the concept of a specific DNA-internalizing receptor. Cells genetically deficient in proteoglycans, which constitute a major source of cell-surface polyanions, exhibited substantially decreased uptake of likewise polyanionic DNA. The apparent paradox was explained by the action of DNA-transporting proteins present in conditioned medium. Complexes between these proteins and DNA require proteoglycans for cellular entry. Mass spectrometry analysis of cell medium components identified several proteins previously shown to associate with DNA and to participate in membrane transport of macromolecular cargo. The major pathway for proteoglycan-dependent DNA uptake was macropinocytosis, whereas caveolae-dependent and clathrin-dependent pathways were not involved, as determined by using caveolin-1 knock-out cells, dominant-negative constructs for dynamin and Eps15, and macropinocytosis- disruptive drugs, as well as confocal fluorescence co-localization studies. Importantly, a significant fraction of internalized DNA was translocated to the nucleus for expression. Our results provide novel insights into the mechanism of DNA uptake by mammalian cells and extend the emerging role of proteoglycans in macromolecular transport.	Lund Univ, Dept Clin Sci, Sect Oncol, S-22185 Lund, Sweden; Lund Univ, Sect Clin & Expt Infect Dis, S-22185 Lund, Sweden; Lund Univ, Dept Biochem, Mass Spectrometry Grp, S-22185 Lund, Sweden	Lund University; Lund University; Lund University	Belting, M (corresponding author), Lund Univ, Dept Clin Sci, Sect Oncol, Barngatan 21, S-22185 Lund, Sweden.	mattias.belting@med.lu.se	Gustavsson, Niklas/D-5712-2011; Welinder, Charlotte/G-1144-2014	Welinder, Charlotte/0000-0001-9626-0576; Belting, Mattias/0000-0003-1585-5434; Wittrup, Anders/0000-0003-4918-0500				Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899; ALLAIN F, 1994, J BIOL CHEM, V269, P16537; Basner-Tschakarjan E, 2004, GENE THER, V11, P765, DOI 10.1038/sj.gt.3302221; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; Benimetskaya L, 1997, NAT MED, V3, P414, DOI 10.1038/nm0497-414; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; EHRLICH M, 1976, BIOCHIM BIOPHYS ACTA, V454, P397, DOI 10.1016/0005-2787(76)90266-5; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Harris EN, 2004, J BIOL CHEM, V279, P36201, DOI 10.1074/jbc.M405322200; Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983; Hisazumi J, 2004, PHARM RES-DORDR, V21, P1223, DOI 10.1023/B:PHAM.0000033009.17594.e5; Joo EJ, 2005, GLYCOBIOLOGY, V15, P1, DOI 10.1093/glycob/cwh132; Kaneda Yasufumi, 2001, Current Molecular Medicine (Hilversum), V1, P493, DOI 10.2174/1566524013363519; KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505; Kobayashi N, 2001, J PHARMACOL EXP THER, V297, P853; Laktionov PP, 1999, NUCLEIC ACIDS RES, V27, P2315, DOI 10.1093/nar/27.11.2315; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nisole S, 2002, J BIOL CHEM, V277, P20877, DOI 10.1074/jbc.M110024200; OLSEN I, 1974, IMMUNOLOGY, V27, P973; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Said EA, 2002, J BIOL CHEM, V277, P37492, DOI 10.1074/jbc.M201194200; Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200; Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200; Satkauskas S, 2001, MOL THER, V4, P317, DOI 10.1006/mthe.2001.0465; Takagi T, 1998, BIOCHEM BIOPH RES CO, V245, P729, DOI 10.1006/bbrc.1998.8521; Takakura Y, 1999, PHARMACEUT RES, V16, P503, DOI 10.1023/A:1018842210588; Vogel JC, 2000, HUM GENE THER, V11, P2253, DOI 10.1089/104303400750035780; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Watson K, 1999, J BIOL CHEM, V274, P21707, DOI 10.1074/jbc.274.31.21707; WOLFF JA, 1992, J CELL SCI, V103, P1249; Yasuda K, 2004, IMMUNOLOGY, V111, P282, DOI 10.1111/j.1365-2567.2004.01814.x	48	39	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27897	27904		10.1074/jbc.M701611200	http://dx.doi.org/10.1074/jbc.M701611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623661	hybrid			2022-12-25	WOS:000249455600038
J	Barreyro, FJ; Kobayashi, S; Bronk, SF; Werneburg, NW; Malhi, H; Gores, GJ				Barreyro, Fernando J.; Kobayashi, Shogo; Bronk, Steven F.; Werneburg, Nathan W.; Malhi, Harmeet; Gores, Gregory J.			Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; FATTY LIVER-DISEASE; PALMITATE-INDUCED APOPTOSIS; BETA-CELL APOPTOSIS; FAMILY-MEMBER BIM; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; INDUCE APOPTOSIS; TYROSINE PHOSPHORYLATION; PROAPOPTOTIC FUNCTION	Hepatocyte lipoapoptosis, a critical feature of nonalcoholic steatohepatitis, can be replicated in vitro by incubating hepatocytes with saturated free fatty acids (FFA). These toxic FFA induce Bim expression, which is requisite for their cytotoxicity. Because the FoxO3a transcription factor has been implicated in Bim expression, our aim was to determine if FFA induce Bim by a FoxO3a-dependent mechanism. In Huh-7 cells, the saturated FFA, palmitic and stearic acid, increased Bim mRNA 16-fold. Treatment of cells with the saturated FFA induced FoxO3a dephosphorylation (activation) and nuclear translocation and stimulated a FoxO luciferase-based reporter assay; direct binding of FoxO3a to the Bim promoter was also confirmed by a chromatin immunoprecipitation assay. A small interfering RNA-targeted knockdown of FoxO3a abrogated FFA-mediated Bim induction and apoptosis. FoxO3a was activated by a phosphatase 2A-dependent mechanism, since okadaic acid- and small interfering RNA-targeted knockdown of this phosphatase blocked FoxO3a dephosphorylation, Bim expression, and apoptosis. Consistent with these data, phosphatase 2A activity was also stimulated 3-fold by saturated FFA. Immunoprecpitation studies revealed an FFA-dependent association between FoxO3a and protein phosphatase 2A. FFA-mediated FoxO3a activation by protein phosphatase 2A was also observed in HepG2 cells and murine hepatocytes. In conclusion, saturated FFA stimulate protein phosphatase 2A activity, which activates FoxO3a, inducing expression of the intracellular death mediator Bim.	Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu						Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alvarado-Kristensson M, 2005, J BIOL CHEM, V280, P6238, DOI 10.1074/jbc.M409718200; Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604; Artwohl M, 2004, FASEB J, V18, P146, DOI 10.1096/fj.03-0301fje; Baskin-Bey ES, 2005, AM J PHYSIOL-GASTR L, V289, pG987, DOI 10.1152/ajpgi.00371.2005; Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Bouillet P, 2000, ANN NY ACAD SCI, V926, P83; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920; Chatfield K, 2004, BIOCHEM BIOPH RES CO, V323, P1313, DOI 10.1016/j.bbrc.2004.09.003; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Feldstein AE, 2003, J HEPATOL, V39, P978, DOI 10.1016/S0168-8278(03)00460-4; Fernandez-Real JM, 2003, DIABETES CARE, V26, P1362, DOI 10.2337/diacare.26.5.1362; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guicciardi ME, 2005, GUT, V54, P1024, DOI 10.1136/gut.2004.053850; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; Harmala-Brasken AS, 2003, ONCOGENE, V22, P7677, DOI 10.1038/sj.onc.1207077; Hickson-Bick DLM, 2002, AM J PHYSIOL-HEART C, V282, pH656, DOI 10.1152/ajpheart.00726.2001; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Kowluru A, 2005, BIOCHEM PHARMACOL, V69, P1681, DOI 10.1016/j.bcp.2005.03.018; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Leskinen MH, 2005, SCAND J CLIN LAB INV, V65, P485, DOI 10.1080/00365510510025836; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lu ZH, 2003, BIOCHEM BIOPH RES CO, V303, P1002, DOI 10.1016/S0006-291X(03)00449-2; Malhi H, 2006, J BIOL CHEM, V281, P12093, DOI 10.1074/jbc.M510660200; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Mu YM, 2001, ENDOCRINOLOGY, V142, P3590, DOI 10.1210/en.142.8.3590; Nehra V, 2001, DIGEST DIS SCI, V46, P2347, DOI 10.1023/A:1012338828418; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Pagano G, 2002, HEPATOLOGY, V35, P367, DOI 10.1053/jhep.2002.30690; Patil S, 2005, NEUROSCI LETT, V384, P288, DOI 10.1016/j.neulet.2005.05.003; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ray RM, 2005, J BIOL CHEM, V280, P31091, DOI 10.1074/jbc.M503041200; RICHIERI GV, 1995, J LIPID RES, V36, P229; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Summers LKM, 2002, DIABETOLOGIA, V45, P369, DOI 10.1007/s00125-001-0768-3; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wieckowska A, 2006, HEPATOLOGY, V44, P27, DOI 10.1002/hep.21223; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010; Yin KJ, 2006, J NEUROSCI, V26, P2290, DOI 10.1523/JNEUROSCI.5103-05.2006; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353	65	154	161	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27141	27154		10.1074/jbc.M704391200	http://dx.doi.org/10.1074/jbc.M704391200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626006	hybrid			2022-12-25	WOS:000249304900055
J	Bernacchi, S; Henriet, S; Dumas, P; Paillart, JC; Marquet, R				Bernacchi, Serena; Henriet, Simon; Dumas, Philippe; Paillart, Jean-Christophe; Marquet, Roland			RNA and DNA binding properties of HIV-1 vif protein - A fluorescence study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOCAPSID PROTEIN; GENOMIC RNA; REVERSE TRANSCRIPTION; CYTIDINE DEAMINATION; VIRION INCORPORATION; ANTIVIRAL ACTIVITY; INFECTED-CELLS; VIRAL-RNA; 5' REGION	The HIV-1 viral infectivity factor (Vif) is a small basic protein essential for viral fitness and pathogenicity. Some "non-permissive" cell lines cannot sustain replication of Vif(-) HIV-1 virions. In these cells, Vif counteracts the natural antiretroviral activity of the DNA-editing enzymes APOBEC3G/3F. Moreover, Vif is packaged into viral particles through a strong interaction with genomic RNA in viral nucleoprotein complexes. To gain insights into determinants of this binding process, we performed the first characterization of Vif/nucleic acid interactions using Vif intrinsic fluorescence. We determined the affinity of Vif for RNA fragments corresponding to various regions of the HIV-1 genome. Our results demonstrated preferential and moderately cooperative binding for RNAs corresponding to the 5 '-untranslated region of HIV-1 ( 5 '-untranslated region) and gag (cooperativity parameter omega similar to 65 - 80, and K-d = 45 - 55 nM). In addition, fluorescence spectroscopy allowed us to point out the TAR apical loop and a short region in gag as primary strong affinity binding sites ( Kd = 9.5 - 14 nM). Interestingly, beside its RNA binding properties, the Vif protein can also bind the corresponding DNA oligonucleotides and their complementary counterparts with an affinity similar to the one observed for the RNA sequences, while other DNA sequences displayed reduced affinity. Taken together, our results suggest that Vif binding to RNA and DNA offers several nonexclusive ways to counteract APOBEC3G/3F factors, in addition to the well documented Vif-induced degradation by the proteasome and to the Vif-mediated repression of translation of these antiviral factors.	CNRS, UPR 9002, F-67084 Strasbourg, France; Univ Strasbourg, CNRS, IBMC, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Marquet, R (corresponding author), CNRS, UPR 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	r.marquet@ibmc.u-strasbg.fr	Paillart, Jean-Christophe/A-4171-2010	Paillart, Jean-Christophe/0000-0003-1647-8917; Henriet, Simon/0000-0001-8792-6639; bernacchi, serena/0000-0003-2824-8326; Marquet, Roland/0000-0002-4209-3976				Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2000.5182; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; Cancio R, 2004, BIOCHEM J, V383, P475, DOI 10.1042/BJ20040914; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Cruceanu M, 2006, NUCLEIC ACIDS RES, V34, P593, DOI 10.1093/nar/gkj458; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; Douaisi M, 2004, BIOCHEM BIOPH RES CO, V321, P566, DOI 10.1016/j.bbrc.2004.07.005; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Henriet S, 2005, J MOL BIOL, V354, P55, DOI 10.1016/j.jmb.2005.09.025; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; Holmes RK, 2007, J BIOL CHEM, V282, P2587, DOI 10.1074/jbc.M607298200; Kao Sandra, 2004, Retrovirology, V1, P27, DOI 10.1186/1742-4690-1-27; Karczewski MK, 1996, J VIROL, V70, P494, DOI 10.1128/JVI.70.1.494-507.1996; Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Kobayashi M, 2005, J BIOL CHEM, V280, P18573, DOI 10.1074/jbc.C500082200; LAKOWICZJR, 1999, PRINCIPLES FLUORESCE; Lee N, 2003, NUCLEIC ACIDS RES, V31, P4847, DOI 10.1093/nar/gkg679; LEE TH, 1986, SCIENCE, V231, P1546, DOI 10.1126/science.3006243; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Ohagen A, 2000, J VIROL, V74, P11055, DOI 10.1128/JVI.74.23.11055-11066.2000; Paillart JC, 2004, J BIOL CHEM, V279, P48397, DOI 10.1074/jbc.M408294200; Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200; Paoletti AC, 2002, BIOCHEMISTRY-US, V41, P15423, DOI 10.1021/bi026307n; Santa-Marta M, 2005, J BIOL CHEM, V280, P8765, DOI 10.1074/jbc.M409309200; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+; Simon JHM, 1999, J VIROL, V73, P2667, DOI 10.1128/JVI.73.4.2667-2674.1999; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Takeuchi H, 2005, J BIOL CHEM, V280, P375, DOI 10.1074/jbc.M408987200; Tsodikov OV, 2001, BIOPHYS J, V81, P1960, DOI 10.1016/S0006-3495(01)75847-X; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	53	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26361	26368		10.1074/jbc.M703122200	http://dx.doi.org/10.1074/jbc.M703122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17609216	hybrid			2022-12-25	WOS:000249239600041
J	Greenwood, SM; Mizielinska, SM; Frenguelli, BG; Harvey, J; Connolly, CN				Greenwood, Sam M.; Mizielinska, Sarah M.; Frenguelli, Bruno G.; Harvey, Jenni; Connolly, Christopher N.			Mitochondrial dysfunction and dendritic beading during neuronal toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; RECEPTOR ACTIVATION; REVERSIBLE CHANGES; FOREBRAIN NEURONS; OXIDATIVE STRESS; DISTINCT ROLES; IN-VITRO; CALCIUM; EXCITOTOXICITY; ABNORMALITIES	Mitochondrial dysfunction ( depolarization and structural collapse), cytosolic ATP depletion, and neuritic beading are early hallmarks of neuronal toxicity induced in a variety of pathological conditions. We show that, following global exposure to glutamate, mitochondrial changes are spatially and temporally coincident with dendritic bead formation. During oxygen-glucose deprivation, mitochondrial depolarization precedes mitochondrial collapse, which in turn is followed by dendritic beading. These events travel as a wave of activity from distal dendrites toward the neuronal cell body. Despite the spatiotemporal relationship between dysfunctional mitochondria and dendritic beads, mitochondrial depolarization and cytoplasmic ATP depletion do not trigger these events. However, mitochondrial dysfunction increases neuronal vulnerability to these morphological changes during normal physiological activity. Our findings support a mechanism whereby, during glutamate excitotoxicity, Ca2+ influx leads to mitochondrial depolarization, whereas Na+ influx leads to an unsustainable increase in ATP demand (Na+, K+ -ATPase activity). This leads to a drop in ATP levels, an accumulation of intracellular Na+ ions, and the subsequent influx of water, leading to microtubule depolymerization, mitochondrial collapse, and dendritic beading. Following the removal of a glutamate challenge, dendritic recovery is dependent upon the integrity of the mitochondrial membrane potential, but not on a resumption of ATP synthesis or Na+, K+ -ATPase activity. Thus, dendritic recovery is not a passive reversal of the events that induce dendritic beading. These findings suggest that the degree of calcium influx and mitochondrial depolarization inflicted by a neurotoxic challenge, determines the ability of the neuron to recover its normal morphology.	Univ Dundee, Ninewells Med Sch, Inst Neurosci, Dundee DD1 9SY, Scotland	University of Dundee	Connolly, CN (corresponding author), Univ Dundee, Ninewells Med Sch, Inst Neurosci, Dundee DD1 9SY, Scotland.	n.connolly@dundee.ac.uk	Frenguelli, Bruno/C-5007-2015	Frenguelli, Bruno/0000-0001-7214-3172; Harvey, Jenni/0000-0002-9858-001X; Mizielinska, Sarah/0000-0001-8052-600X; Connolly, Christopher/0000-0002-0445-8874				Almeida A, 2002, J NEUROCHEM, V81, P207, DOI 10.1046/j.1471-4159.2002.00827.x; Beck J, 2003, J NEUROSCI, V23, P5061; Brendza RP, 2005, J CLIN INVEST, V115, P428, DOI 10.1172/JCI200523269; Chinopoulos C, 2000, J NEUROSCI, V20, P2094; Faddis BT, 1997, J NEUROSCI, V17, P951; Fujimoto S, 2004, NEUROSCI RES, V50, P179, DOI 10.1016/j.neures.2004.06.013; Hall GF, 2000, J CELL SCI, V113, P1373; Hasbani MJ, 2001, J NEUROSCI, V21, P2393, DOI 10.1523/JNEUROSCI.21-07-02393.2001; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Ikegami K, 2004, BRAIN RES, V1030, P81, DOI 10.1016/j.brainres.2004.09.050; Ikegaya Y, 2001, J CELL SCI, V114, P4083; Jiang M, 2004, GENE THER, V11, P1303, DOI 10.1038/sj.gt.3302305; Joshi I, 2001, J NEUROPHYSIOL, V85, P414, DOI 10.1152/jn.2001.85.1.414; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Loo LS, 2006, J NEUROSCI, V26, P10177, DOI 10.1523/JNEUROSCI.2628-06.2006; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Nicholls DG, 2006, J BIOL CHEM, V281, P14864, DOI 10.1074/jbc.M510916200; Nicholls DG, 1999, ANN NY ACAD SCI, V893, P1, DOI 10.1111/j.1749-6632.1999.tb07813.x; Nicholls DG, 2005, CELL CALCIUM, V38, P311, DOI 10.1016/j.ceca.2005.06.011; Oliva AA, 2002, J NEUROSCI, V22, P8052; Rintoul GL, 2006, J NEUROCHEM, V97, P800, DOI 10.1111/j.1471-4159.2006.03788.x; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Spires TL, 2005, J NEUROSCI, V25, P7278, DOI 10.1523/JNEUROSCI.1879-05.2005; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Ward MW, 2005, J NEUROCHEM, V92, P1081, DOI 10.1111/j.1471-4159.2004.02928.x; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005	31	83	86	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26235	26244		10.1074/jbc.M704488200	http://dx.doi.org/10.1074/jbc.M704488200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616519	hybrid			2022-12-25	WOS:000249239600028
J	Chen, ZY; Asavaritikrai, P; Prchal, JT; Noguchi, CT				Chen, Zhi-Yong; Asavaritikrai, Pundit; Prchal, Josef T.; Noguchi, Constance Tom			Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS; RECEPTOR GENE; IN-VITRO; RETINAL DEGENERATION; CEREBRAL-ISCHEMIA; TRANSGENIC MICE; BRAIN; NEURONS; NEUROGENESIS	Erythropoietin (Epo) and its receptor (EpoR), critical for erythropoiesis, are expressed in the nervous system. Prior to death in utero because of severe anemia EpoR-null mice have fewer neural progenitor cells, and differentiated neurons are markedly sensitive to hypoxia, suggesting that during development Epo stimulates neural cell proliferation and prevents neuron apoptosis by promoting oxygen delivery to brain or by direct interaction with neural cells. Here we present evidence that neural progenitor cells express EpoR at higher levels compared with mature neurons; that Epo stimulates proliferation of embryonic neural progenitor cells; and that endogenous Epo contributes to neural progenitor cell proliferation and maintenance. EpoRnull mice were rescued with selective EpoR expression driven by the endogenous EpoR promoter in hematopoietic tissue but not in brain. Although these mice exhibited normal hematopoiesis and erythrocyte production and survived to adulthood, neural cell proliferation and viability were affected. Embryonic brain exhibited increased neural cell apoptosis, and neural cell proliferation was reduced in the adult hippocampus and subventricular zone. Neural cells from these animals were more sensitive to hypoxia/glutamate neurotoxicity than normal neurons in culture and in vivo. These observations demonstrate that endogenous Epo/EpoR signaling promotes cell survival in embryonic brain and contributes to neural cell proliferation in adult brain in regions associated with neurogenesis. Therefore, Epo exerts extra-hematopoietic function and contributes directly to brain development, maintenance, and repair by promoting cell survival and proliferation independent of insult, injury, or ischemia.	NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Med, Div Hematol Oncol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Baylor College of Medicine	Noguchi, CT (corresponding author), NIDDK, Mol Med Branch, NIH, Bldg 10,Rm 9N307,10 Ctr Dr,MSC-1822, Bethesda, MD 20892 USA.	cnoguchi@helix.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025061, ZIADK025061] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarts MM, 2004, CURR MOL MED, V4, P137, DOI 10.2174/1566524043479202; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Beleslin-Cokic BB, 2004, BLOOD, V104, P2073, DOI 10.1182/blood-2004-02-0744; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Cheng YH, 2002, EUR J NEUROSCI, V15, P3, DOI 10.1046/j.0953-816x.2001.01832.x; COLTON CA, 1995, EXP NEUROL, V132, P54, DOI 10.1016/0014-4886(95)90058-6; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Divoky V, 2001, P NATL ACAD SCI USA, V98, P986, DOI 10.1073/pnas.98.3.986; Dzietko M, 2004, NEUROBIOL DIS, V15, P177, DOI 10.1016/j.nbd.2003.10.006; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Grimm C, 2005, SEMIN CELL DEV BIOL, V16, P531, DOI 10.1016/j.semcdb.2005.03.004; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Jelkmann W, 2004, ANN HEMATOL, V83, P673, DOI 10.1007/s00277-004-0911-6; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu C, 1996, P ASSOC AM PHYSICIAN, V108, P449; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Ren JM, 2005, CNS NEUROL DISORD-DR, V4, P121, DOI 10.2174/1568007053544101; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schaffer DV, 2004, NEUROMOL MED, V5, P1, DOI 10.1385/NMM:5:1:001; Schnell PO, 2003, J NEUROCHEM, V85, P483, DOI 10.1046/j.1471-4159.2003.01696.x; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Studer L, 2000, J NEUROSCI, V20, P7377; Suzuki N, 2002, BLOOD, V100, P2279, DOI 10.1182/blood-2002-01-0124; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2006, J NEUROSCI, V26, P5996, DOI 10.1523/JNEUROSCI.5380-05.2006; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Young CL, 2004, CURR MOL MED, V4, P77, DOI 10.2174/1566524043479158; Yu XB, 2002, DEVELOPMENT, V129, P505	49	140	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25875	25883		10.1074/jbc.M701988200	http://dx.doi.org/10.1074/jbc.M701988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17604282	hybrid			2022-12-25	WOS:000249014100073
J	Racine, T; Barry, C; Roy, K; Dawe, SJ; Shmulevitz, M; Duncan, R				Racine, Trina; Barry, Chris; Roy, Kenneth; Dawe, Sandra J.; Shmulevitz, Maya; Duncan, Roy			Leaky scanning and scanning-independent ribosome migration on the tricistronic S1 mRNA of avian reovirus*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAULIFLOWER MOSAIC-VIRUS; OPEN READING FRAMES; TRANSLATION INITIATION; GENE-EXPRESSION; Y-PROTEINS; EUKARYOTIC RIBOSOMES; REINITIATION; ADENOVIRUS; CELLS; LEADER	The S1 genome segments of avian and Nelson Bay reovirus encode tricistronic mRNAs containing three sequential partially overlapping open reading frames ( ORFs). The translation start site of the 3 '-proximal ORF encoding the sigma C protein lies downstream of two ORFs encoding the unrelated p10 and p17 proteins and more than 600 nucleotides distal from the 5 '-end of the mRNA. It is unclear how translation of this remarkable tricistronic mRNA is regulated. We now show that the p10 and p17 ORFs are coordinately expressed by leaky scanning. Translation initiation events at these 5 '-proximal ORFs, however, have little to no effect on translation of the 3 '-proximal sigma CORF. Northern blotting, insertion of upstream stop codons or optimized translation start sites, 5 '-truncation analysis, and poliovirus 2A protease-mediated cleavage of eIF4G indicated sigma C translation derives from a full-length tricistronic mRNA using a mechanism that is eIF4G-dependent but leaky scanning- and translation reinitiation-independent. Further analysis of artificial bicistronic mRNAs failed to provide any evidence that sigma C translation derives from an internal ribosome entry site. Additional features of the S1 mRNA and the mechanism of sigma C translation also differ from current models of ribosomal shunting. Translation of the tricistronic reovirus S1 mRNA, therefore, is dependent both on leaky scanning and on a novel scanning-independent mechanism that allows translation initiation complexes to efficiently bypass two functional upstream ORFs.	Dalhousie Univ, Fac Med, Dept Microbiol & Immunol, Halifax, NS B3H 1X5, Canada	Dalhousie University	Duncan, R (corresponding author), Dalhousie Univ, Fac Med, Dept Microbiol & Immunol, Tupper Med Bldg, Halifax, NS B3H 1X5, Canada.	roy.duncan@dal.ca	Barry, Christopher/G-5843-2015	Barry, Christopher/0000-0002-5413-5918; Duncan, Roy/0000-0002-5162-5081				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; Barco A, 2000, J VIROL, V74, P2383, DOI 10.1128/JVI.74.5.2383-2392.2000; Benavente J, 2007, VIRUS RES, V123, P105, DOI 10.1016/j.virusres.2006.09.005; Bodelon G, 2001, VIROLOGY, V290, P181, DOI 10.1006/viro.2001.1159; Calkhoven CF, 2000, GENE DEV, V14, P1920; Calvo PG, 2005, J MOL BIOL, V354, P137, DOI 10.1016/j.jmb.2005.09.034; Costas C, 2005, J VIROL, V79, P2141, DOI 10.1128/JVI.79.4.2141-2150.2005; CURRAN J, 1989, EMBO J, V8, P521, DOI 10.1002/j.1460-2075.1989.tb03406.x; DAVIES MV, 1991, J BIOL CHEM, V266, P14714; de Breyne S, 2004, J BIOL CHEM, V279, P16571, DOI 10.1074/jbc.M312391200; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; Duncan R, 1998, VIROLOGY, V250, P263, DOI 10.1006/viro.1998.9371; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; Grande A, 2000, VIROLOGY, V274, P367, DOI 10.1006/viro.2000.0473; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Jackson RJ, 2005, BIOCHEM SOC T, V33, P1231, DOI 10.1042/BST0331231; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 2001, NUCLEIC ACIDS RES, V29, P5226, DOI 10.1093/nar/29.24.5226; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lloyd RE, 2006, VIRUS RES, V119, P76, DOI 10.1016/j.virusres.2005.10.016; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; Mudge SJ, 1998, GENE, V209, P45, DOI 10.1016/S0378-1119(98)00007-9; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pooggin MM, 2006, RNA, V12, P841, DOI 10.1261/rna.2285806; Pooggin MM, 2000, J BIOL CHEM, V275, P17288, DOI 10.1074/jbc.M001143200; Ryabova LA, 2000, GENE DEV, V14, P817; Ryabova LA, 2002, PROG NUCLEIC ACID RE, V72, P1, DOI 10.1016/S0079-6603(02)72066-7; Ryabova LA, 2006, VIRUS RES, V119, P52, DOI 10.1016/j.virusres.2005.10.017; Shmulevitz M, 2002, J VIROL, V76, P609, DOI 10.1128/JVI.76.2.609-618.2002; Shmulevitz M, 2000, EMBO J, V19, P902, DOI 10.1093/emboj/19.5.902; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Xi QR, 2004, GENE DEV, V18, P1997, DOI 10.1101/gad.1212504; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZHANG Y, 1989, J BIOL CHEM, V264, P10679	47	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25613	25622		10.1074/jbc.M703708200	http://dx.doi.org/10.1074/jbc.M703708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17604272	hybrid			2022-12-25	WOS:000249014100048
J	Wheeler, D; SneddonO, WB; Wang, B; Friedman, PA; Romero, G				Wheeler, David; Sneddon, W. Bruce; Wang, Bin; Friedman, Peter A.; Romero, Guillermo			NHERF-1 and the cytoskeleton regulate the traffic and membrane dynamics of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMAGE CORRELATION SPECTROSCOPY; RENAL PROXIMAL TUBULE; PARATHYROID-HORMONE RECEPTOR; COATED-PIT DYNAMICS; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; NA+/H+ EXCHANGE; LIVING CELLS; PDZ-DOMAIN; INTERNALIZATION	The sodium-hydrogen exchange regulatory factor 1 ( NHERF1/EBP50) interacts with the C terminus of several G proteincoupled receptors ( GPCRs). We examined the role of NHERF-1 and the cytoskeleton on the distribution, dynamics, and trafficking of the beta(2)- adrenergic receptor (beta(2) AR; a type A receptor), the parathyroid hormone receptor ( PTH1R; type B), and the calcium-sensing receptor ( CaSR; type C) using fluorescence recovery after photobleaching, total internal reflection fluorescence, and image correlation spectroscopy. beta(2) AR bundles were observed only in cells that expressed NHERF- 1, whereas the PTH1R was localized to bundles that parallel stress fibers independently of NHERF- 1. The CaSR was never observed in bundles. NHERF- 1 reduced the diffusion of the beta(2) AR and the PTH1R. The addition of ligand increased the diffusion coefficient and the mobile fraction of the PTH1R. Isoproterenol decreased the immobile fraction but did not affect the diffusion coefficient of the beta(2) AR. The diffusion of the CaSR was unaffected by NHERF- 1 or the addition of calcium. NHERF- 1 reduced the rate of ligand-induced internalization of the PTH1R. This phenomenon was accompanied by a reduction of the rate of arrestin binding to PTH1R in ligand-exposed cells. We conclude that some GPCRs, such as the beta(2) AR, are attached to the cytoskeleton primarily via the binding of NHERF- 1. Others, such as the PTH1R, bind the cytoskeleton via several interacting proteins, one of which is NHERF- 1. Finally, receptors such as the CaSR do not interact with the cytoskeleton in any significant manner. These interactions, or the lack thereof, govern the dynamics and trafficking of the receptor.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15228 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Med Sci Training Program, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Romero, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15228 USA.	ggr@pitt.edu		Wang, Bin/0000-0002-5396-6111	NIDDK NIH HHS [DK 54171, DK 69998] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069998, R01DK054171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bacia K, 2006, NAT METHODS, V3, P83, DOI 10.1038/NMETH822; Bates IR, 2006, BIOPHYS J, V91, P1046, DOI 10.1529/biophysj.106.084830; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chuang JZ, 2005, DEV CELL, V9, P75, DOI 10.1016/j.devcel.2005.04.003; Cunningham R, 2005, AM J PHYSIOL-RENAL, V289, pF933, DOI 10.1152/ajprenal.00005.2005; Cunninghan R, 2004, J BIOL CHEM, V279, P37815, DOI 10.1074/jbc.M405893200; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Grimaldi M, 1999, J BIOL CHEM, V274, P33557, DOI 10.1074/jbc.274.47.33557; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Head BP, 2006, J BIOL CHEM, V281, P26391, DOI 10.1074/jbc.M602577200; Hebert B, 2005, BIOPHYS J, V88, P3601, DOI 10.1529/biophysj.104.054874; Huang P, 2004, J BIOL CHEM, V279, P25002, DOI 10.1074/jbc.M313366200; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; Kim SA, 2005, BIOPHYS J, V88, P4319, DOI 10.1529/biophysj.104.055319; Liu F, 2001, AM J PHYSIOL-LUNG C, V280, pL1309, DOI 10.1152/ajplung.2001.280.6.L1309; Loebrich S, 2006, EMBO J, V25, P987, DOI 10.1038/sj.emboj.7600995; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mahon MJ, 2004, J BIOL CHEM, V279, P23550, DOI 10.1074/jbc.M313229200; Nicolini C, 2006, J AM CHEM SOC, V128, P192, DOI 10.1021/ja055779x; Perez V, 2005, EUR J NEUROSCI, V21, P26, DOI 10.1111/j.1460-9568.2004.03845.x; Plowman SJ, 2005, P NATL ACAD SCI USA, V102, P15500, DOI 10.1073/pnas.0504114102; Puthenveedu MA, 2006, CELL, V127, P113, DOI 10.1016/j.cell.2006.08.035; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Saito M, 2005, BIOCHEM J, V392, P75, DOI 10.1042/BJ20050618; SARNDAHL E, 1989, J CELL BIOL, V109, P2791, DOI 10.1083/jcb.109.6.2791; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; SIMSON R, 1995, BIOPHYS J, V69, P989, DOI 10.1016/S0006-3495(95)79972-6; Sneddon WB, 2004, ENDOCRINOLOGY, V145, P2815, DOI 10.1210/en.2003-1185; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Sugai M, 2003, BIOCHEM BIOPH RES CO, V311, P24, DOI 10.1016/j.bbrc.2003.09.157; Szaszi K, 2001, J BIOL CHEM, V276, P40761, DOI 10.1074/jbc.M106724200; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wade JB, 2003, AM J PHYSIOL-CELL PH, V285, pC1494, DOI 10.1152/ajpcell.00092.2003; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; Wiseman PW, 1999, BIOPHYS J, V76, P963, DOI 10.1016/S0006-3495(99)77260-7; Wiseman PW, 1997, FEBS LETT, V401, P43, DOI 10.1016/S0014-5793(96)01429-9	40	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25076	25087		10.1074/jbc.M701544200	http://dx.doi.org/10.1074/jbc.M701544200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17599914	hybrid			2022-12-25	WOS:000248933000063
J	Hagmann, P; Kurant, M; Gigandet, X; Thiran, P; Wedeen, VJ; Meuli, R; Thiran, JP				Hagmann, Patric; Kurant, Maciej; Gigandet, Xavier; Thiran, Patrick; Wedeen, Van J.; Meuli, Reto; Thiran, Jean-Philippe			Mapping Human Whole-Brain Structural Networks with Diffusion MRI	PLOS ONE			English	Article							SMALL-WORLD; CONNECTIONAL ORGANIZATION; WIRING OPTIMIZATION; SCHIZOPHRENIA; ARCHITECTURE; NEUROSCIENCE; MECHANICS; CIRCUITRY; MATTER; AREAS	Understanding the large-scale structural network formed by neurons is a major challenge in system neuroscience. A detailed connectivity map covering the entire brain would therefore be of great value. Based on diffusion MRI, we propose an efficient methodology to generate large, comprehensive and individual white matter connectional datasets of the living or dead, human or animal brain. This non-invasive tool enables us to study the basic and potentially complex network properties of the entire brain. For two human subjects we find that their individual brain networks have an exponential node degree distribution and that their global organization is in the form of a small world.	[Hagmann, Patric; Meuli, Reto] CHU Vaudois, Dept Radiol, CH-1011 Lausanne, Switzerland; [Hagmann, Patric; Meuli, Reto] Univ Lausanne, Lausanne, Switzerland; [Hagmann, Patric; Gigandet, Xavier; Thiran, Jean-Philippe] Ecole Polytech Fed Lausanne, Signal Proc Inst, CH-1015 Lausanne, Switzerland; [Kurant, Maciej; Thiran, Patrick] Ecole Polytech Fed Lausanne, Lab Comp Commun & Applicat, CH-1015 Lausanne, Switzerland; [Wedeen, Van J.] Harvard Univ, Sch Med, MGH Martinos Ctr Biomed Imaging, Charlestown, MA USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Harvard University	Hagmann, P (corresponding author), CHU Vaudois, Dept Radiol, CH-1011 Lausanne, Switzerland.	patric.hagmann@epfl.ch		Thiran, Jean-Philippe/0000-0003-2938-9657	Swiss National Science Foundation (SNSF); Center for Biomedical Imaging (CIBM) of the Geneva-Lausanne Universities; EPFL; foundations Leenaards and Louis-Jeantet	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Center for Biomedical Imaging (CIBM) of the Geneva-Lausanne Universities; EPFL; foundations Leenaards and Louis-Jeantet	This work was supported by the Swiss National Science Foundation (SNSF), Professor Pierre Schnyder and Mr Yves Paternot as well as the Center for Biomedical Imaging (CIBM) of the Geneva-Lausanne Universities and the EPFL, the foundations Leenaards and Louis-Jeantet. The sponsors had no role in the design or analysis of the study.	Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Amaral LAN, 2000, P NATL ACAD SCI USA, V97, P11149, DOI 10.1073/pnas.200327197; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Barrat A, 2004, P NATL ACAD SCI USA, V101, P3747, DOI 10.1073/pnas.0400087101; Bartzokis G, 2002, NEUROPSYCHOPHARMACOL, V27, P672, DOI 10.1016/S0893-133X(02)00364-0; Born RT, 2005, ANNU REV NEUROSCI, V28, P157, DOI 10.1146/annurev.neuro.26.041002.131052; Bota M, 2003, NAT NEUROSCI, V6, P795, DOI 10.1038/nn1096; Burns GAPC, 2000, PHILOS T R SOC B, V355, P55, DOI 10.1098/rstb.2000.0549; Callaghan P.T., 1991, PRINCIPLES NUCL MAGN, P492; Chen BL, 2006, P NATL ACAD SCI USA, V103, P4723, DOI 10.1073/pnas.0506806103; CHERNIAK C, 1994, J NEUROSCI, V14, P2418; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; CRICK F, 1993, NATURE, V361, P109, DOI 10.1038/361109a0; Eguiluz VM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018102; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Grill-Spector K, 2004, ANNU REV NEUROSCI, V27, P649, DOI 10.1146/annurev.neuro.27.070203.144220; Hagmann P., 2005, DIFFUSION MRI BRAIN; HAGMANN P, 2004, DIFFUSION SPECTRUM I, P623; Hilgetag CC, 2005, ANAT EMBRYOL, V210, P411, DOI 10.1007/s00429-005-0041-5; Hilgetag CC, 2000, PHILOS T ROY SOC B, V355, P91, DOI 10.1098/rstb.2000.0551; Hilgetag CC, 2004, NEUROINFORMATICS, V2, P353, DOI 10.1385/NI:2:3:353; Humphries MD, 2006, P ROY SOC B-BIOL SCI, V273, P503, DOI 10.1098/rspb.2005.3354; Kaiser M, 2004, NEUROCOMPUTING, V58, P297, DOI 10.1016/j.neucom.2004.01.059; Kaiser M, 2006, PLOS COMPUT BIOL, V2, P805, DOI 10.1371/journal.pcbi.0020095; KALNA G, 2006, CLUSTERING COEFCIENT; KENNEDY H, 1986, J COMP NEUROL, V247, P398, DOI 10.1002/cne.902470309; Kim BJ, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.168701; Klyachko VA, 2003, P NATL ACAD SCI USA, V100, P7937, DOI 10.1073/pnas.0932745100; Koch C, 1999, SCIENCE, V284, P96, DOI 10.1126/science.284.5411.96; Kubicki M, 2003, BIOL PSYCHIAT, V54, P1171, DOI 10.1016/S0006-3223(03)00419-0; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 1991, Magn Reson Q, V7, P1; Le Bihan D., 1995, DIFFUSION PERFUSION, V1st; Lin CP, 2003, NEUROIMAGE, V19, P482, DOI 10.1016/S1053-8119(03)00154-X; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; Rose SE, 2006, NEUROIMAGE, V32, P16, DOI 10.1016/j.neuroimage.2006.03.003; Saramaki J, 2006, GEN CLUSTERING COEFF; Scannell JW, 1999, CEREB CORTEX, V9, P277, DOI 10.1093/cercor/9.3.277; SCANNELL JW, 1995, J NEUROSCI, V15, P1463; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Simoncelli EP, 2001, ANNU REV NEUROSCI, V24, P1193, DOI 10.1146/annurev.neuro.24.1.1193; Sincich LC, 2005, ANNU REV NEUROSCI, V28, P303, DOI 10.1146/annurev.neuro.28.061604.135731; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O, 2004, NEUROINFORMATICS, V2, P145, DOI 10.1385/NI:2:2:145; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197	56	546	565	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e597	10.1371/journal.pone.0000597	http://dx.doi.org/10.1371/journal.pone.0000597			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611629	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451900014
J	Ryu, B; Kim, DS; DeLuca, AM; Alani, RM				Ryu, Byungwoo; Kim, Dave S.; DeLuca, Amena M.; Alani, Rhoda M.			Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma Progression	PLOS ONE			English	Article								Background. Gene expression profiling has revolutionized our ability to molecularly classify primary human tumors and significantly enhanced the development of novel tumor markers and therapies; however, progress in the diagnosis and treatment of melanoma over the past 3 decades has been limited, and there is currently no approved therapy that significantly extends lifespan in patients with advanced disease. Profiling studies of melanoma to date have been inconsistent due to the heterogeneous nature of this malignancy and the limited availability of informative tissue specimens from early stages of disease. Methodology/Principle Findings. In order to gain an improved understanding of the molecular basis of melanoma progression, we have compared gene expression profiles from a series of melanoma cell lines representing discrete stages of malignant progression that recapitulate critical characteristics of the primary lesions from which they were derived. Here we describe the unsupervised hierarchical clustering of profiling data from melanoma cell lines and melanocytes. This clustering identifies two distinctive molecular subclasses of melanoma segregating aggressive metastatic tumor cell lines from less-aggressive primary tumor cell lines. Further analysis of expression signatures associated with melanoma progression using functional annotations categorized these transcripts into three classes of genes: 1) Upregulation of activators of cell cycle progression, DNA replication and repair (CDCA2, NCAPH, NCAPG, NCAPG2, PBK, NUSAP1, BIRC5, ESCO2, HELLS, MELK, GINS1, GINS4, RAD54L, TYMS, and DHFR), 2) Loss of genes associated with cellular adhesion and melanocyte differentiation (CDH3, CDH1, c-KIT, PAX3, CITED1/MSG-1, TYR, MELANA, MC1R, and OCA2), 3) Upregulation of genes associated with resistance to apoptosis (BIRC5/survivin). While these broad classes of transcripts have previously been implicated in the progression of melanoma and other malignancies, the specific genes identified within each class of transcripts are novel. In addition, the transcription factor NF-KB was specifically identified as being a potential "master regulator'' of melanoma invasion since NF-KB binding sites were identified as consistent consensus sequences within promoters of progression-associated genes. Conclusions/Significance. We conclude that tumor cell lines are a valuable resource for the early identification of gene signatures associated with malignant progression in tumors with significant heterogeneity like melanoma. We further conclude that the development of novel data reduction algorithms for analysis of microarray studies is critical to allow for optimized mining of important, clinically-relevant datasets. It is expected that subsequent validation studies in primary human tissues using such an approach will lead to more rapid translation of such studies to the identification of novel tumor biomarkers and therapeutic targets.	[Ryu, Byungwoo; Kim, Dave S.; DeLuca, Amena M.; Alani, Rhoda M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Ryu, B (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21205 USA.	bryu1@jhmi.edu; ralani@jhmi.edu	Pillay, Nischalan/F-9536-2012	Alani, Rhoda/0000-0003-2741-2665; Ryu, Byungwoo/0000-0001-6334-6787	National Institutes of Health [CA107017, CA113779]; American Skin Association; Flight Attendant Medical Research Institute; Murren Family Foundation; Henry and Elaine Kaufman Foundation; NATIONAL CANCER INSTITUTE [K01CA113779, R01CA107017] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Skin Association; Flight Attendant Medical Research Institute; Murren Family Foundation; Henry and Elaine Kaufman Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	National Institutes of Health Grants CA107017 (RA) and CA113779 (BR), American Skin Association (R. A., A. D.), Flight Attendant Medical Research Institute (R. A.), The Murren Family Foundation (R. A.), and The Henry and Elaine Kaufman Foundation (R. A.).	Atkins Michael B., 1997, Current Opinion in Oncology, V9, P205; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Beullens M, 2005, J BIOL CHEM, V280, P40003, DOI 10.1074/jbc.M507274200; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bonitsis N., 2006, Experimental Oncology, V28, P187; Cilensek ZM, 2002, CANCER BIOL THER, V1, P380; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; Coopman PJ, 2006, CANCER LETT, V241, P159, DOI 10.1016/j.canlet.2005.11.004; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Gyorffy B, 2007, J INVEST DERMATOL, V127, P394, DOI 10.1038/sj.jid.5700543; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Herlyn D, 1991, Cancer Treat Res, V54, P105; HERLYN M, 1985, CANCER RES, V45, P5670; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925-4773(00)00569-4; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; HSU MYE, 1999, WISTAR WM MELANOMA C, P259; Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kong LY, 2006, BIOCHEM BIOPH RES CO, V339, P1204, DOI 10.1016/j.bbrc.2005.11.136; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; MANCIANTI ML, 1989, TUMOR PROGR MELANOMA, P369; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274; Nishimura EK, 1999, DEV BIOL, V215, P155, DOI 10.1006/dbio.1999.9478; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Quackenbush J, 2006, NEW ENGL J MED, V354, P2463, DOI 10.1056/NEJMra042342; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Roesch A, 2006, MODERN PATHOL, V19, P1378, DOI 10.1038/modpathol.3800663; Rofstad EK, 2000, CANCER RES, V60, P4932; Rumpler G, 2003, EXP DERMATOL, V12, P761, DOI 10.1111/j.0906-6705.2003.00082.x; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; SPRITZ RA, 1994, HUM MOL GENET, V3, P1469, DOI 10.1093/hmg/3.suppl_1.1469; Sun LQ, 2004, GENE DEV, V18, P1035, DOI 10.1101/gad.1176104; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Trinkle-Mulcahy L, 2006, J CELL BIOL, V172, P679, DOI 10.1083/jcb.200508154; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Ueno M, 2005, MOL CELL BIOL, V25, P10528, DOI 10.1128/MCB.25.23.10528-10532.2005; Vachtenheim J, 1999, CELL MOL BIOL, V45, P1075; Valyi-Nagy I, 1991, Basic Life Sci, V57, P315; Vega H, 2005, NAT GENET, V37, P468, DOI 10.1038/ng1548; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Wesley UV, 2005, CANCER RES, V65, P1325, DOI 10.1158/0008-5472.CAN-04-1852; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139	58	210	232	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e594	10.1371/journal.pone.0000594	http://dx.doi.org/10.1371/journal.pone.0000594			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611626	Green Published, gold			2022-12-25	WOS:000207451900011
J	Murthy, T; Rolfs, A; Hu, YH; Shi, ZW; Raphael, J; Moreira, D; Kelley, F; McCarron, S; Jepson, D; Taycher, E; Zuo, DM; Mohr, SE; Fernandez, M; Brizuela, L; LaBaer, J				Murthy, Tal; Rolfs, Andreas; Hu, Yanhui; Shi, Zhenwei; Raphael, Jacob; Moreira, Donna; Kelley, Fontina; McCarron, Seamus; Jepson, Daniel; Taycher, Elena; Zuo, Dongmei; Mohr, Stephanie E.; Fernandez, Mauricio; Brizuela, Leonardo; LaBaer, Joshua			A Full-Genomic Sequence-Verified Protein-Coding Gene Collection for Francisella tularensis	PLOS ONE			English	Article								The rapid development of new technologies for the high throughput ( HT) study of proteins has increased the demand for comprehensive plasmid clone resources that support protein expression. These clones must be full-length, sequence-verified and in a flexible format. The generation of these resources requires automated pipelines supported by software management systems. Although the availability of clone resources is growing, current collections are either not complete or not fully sequence-verified. We report an automated pipeline, supported by several software applications that enabled the construction of the first comprehensive sequence-verified plasmid clone resource for more than 96% of protein coding sequences of the genome of F. tularensis, a highly virulent human pathogen and the causative agent of tularemia. This clone resource was applied to a HT protein purification pipeline successfully producing recombinant proteins for 72% of the genes. These methods and resources represent significant technological steps towards exploiting the genomic information of F. tularensis in discovery applications.	[Murthy, Tal; Rolfs, Andreas; Hu, Yanhui; Shi, Zhenwei; Raphael, Jacob; Moreira, Donna; Kelley, Fontina; McCarron, Seamus; Jepson, Daniel; Taycher, Elena; Zuo, Dongmei; Mohr, Stephanie E.; Fernandez, Mauricio; Brizuela, Leonardo; LaBaer, Joshua] Harvard Univ, Sch Med, Harvard Inst Prote, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA; [Mohr, Stephanie E.; LaBaer, Joshua] Harvard Univ, Sch Med, DF HCC DNA Resource Core, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	LaBaer, J (corresponding author), Harvard Univ, Sch Med, Harvard Inst Prote, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA.	josh@hms.harvard.edu		Hu, Yanhui/0000-0003-1494-1402; Mohr, Stephanie/0000-0001-9639-7708	NIAID/NIH [AI057159]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057159] Funding Source: NIH RePORTER	NIAID/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work was supported by the NIAID/NIH grant for the New England Regional Center for Excellence #AI057159.	Braun P, 2003, TRENDS BIOTECHNOL, V21, P383, DOI 10.1016/S0167-7799(03)00189-6; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; Chambers SP, 2004, PROTEIN EXPRES PURIF, V36, P40, DOI 10.1016/j.pep.2004.03.003; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; Dieckman L, 2002, PROTEIN EXPRES PURIF, V25, P1, DOI 10.1006/prep.2001.1602; Ecker A, 2006, MOL BIOCHEM PARASIT, V145, P265, DOI 10.1016/j.molbiopara.2005.10.006; FORTIER AH, 1995, INFECT IMMUN, V63, P1478, DOI 10.1128/IAI.63.4.1478-1483.1995; Heyman JA, 1999, GENOME RES, V9, P383; Hu YH, 2007, GENOME RES, V17, P536, DOI 10.1101/gr.6037607; LaBaer J, 2004, GENOME RES, V14, P2190, DOI 10.1101/gr.2482804; Larsson P, 2005, NAT GENET, V37, P153, DOI 10.1038/ng1499; Matsuyama A, 2006, NAT BIOTECHNOL, V24, P841, DOI 10.1038/nbt1222; McLendon MK, 2006, ANNU REV MICROBIOL, V60, P167, DOI 10.1146/annurev.micro.60.080805.142126; Murthy TVS, 2004, PROTEIN EXPRES PURIF, V36, P217, DOI 10.1016/j.pep.2004.04.002; Park J, 2005, P NATL ACAD SCI USA, V102, P8114, DOI 10.1073/pnas.0503141102; Parrish JR, 2004, J PROTEOME RES, V3, P582, DOI 10.1021/pr0341134; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Serruto D, 2006, FEBS LETT, V580, P2985, DOI 10.1016/j.febslet.2006.04.084; Sjostedt A, 2006, MICROBES INFECT, V8, P561, DOI 10.1016/j.micinf.2005.08.001; Temple G, 2006, HUM MOL GENET, V15, pR31, DOI 10.1093/hmg/ddl048; Witt AE, 2006, J PROTEOME RES, V5, P599, DOI 10.1021/pr050395r	22	21	23	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e577	10.1371/journal.pone.0000577	http://dx.doi.org/10.1371/journal.pone.0000577			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593976	gold, Green Published			2022-12-25	WOS:000207451800021
J	Okuyama, T; Kurata, S; Tomimori, Y; Fukunishi, N; Sato, S; Osada, M; Tsukinoki, K; Jin, HF; Yamashita, A; Ito, M; Kobayashi, S; Hata, RI; Ikawa, Y; Katoh, I				Okuyama, T.; Kurata, S.; Tomimori, Y.; Fukunishi, N.; Sato, S.; Osada, M.; Tsukinoki, K.; Jin, H-F; Yamashita, A.; Ito, M.; Kobayashi, S.; Hata, R-I; Ikawa, Y.; Katoh, I.			p63(TP63) elicits strong trans-activation of the MFG-E8/lactadherin/BA46 gene through interactions between the TA and Delta N isoforms	ONCOGENE			English	Article						p63; MFG-E8; lactadherin; BA46; P53	MILK-FAT GLOBULE; SQUAMOUS-CELL CARCINOMA; P53 HOMOLOG P63; PROTEIN STABILITY; APOPTOTIC CELLS; STEM-CELLS; EXPRESSION; GLYCOPROTEIN; BINDING; CANCER	We report here that human MFGE8 encoding milk fat globule-EGF factor 8 protein (MFG-E8), also termed 46 kDa breast epithelial antigen and lactadherin, is transcriptionally activated by p63, or TP63, a p53 (TP53) family protein frequently overexpressed in head-and-neck squamous cell carcinomas, mammary carcinomas and so on. Despite that human MFG-E8 was originally identified as a breast cancer marker, and has recently been reported to provide peptides for cancer immunotherapy, its transcriptional control remains an open question. Observations in immunohistochemical analyses, a tetracycline-induced p63 expression system and keratinocyte cultures suggested a physiological link between p63 and MFGE8. By reporter assays with immediately upstream regions of MFGE8, we determined that the trans-activator (TA) isoforms of p63 activate MFGE8 transcription though a p53/p63 motif at -370, which was confirmed by a chromatin immunoprecipitation experiment. Upon siRNA-mediated p63 silencing in a squamous cell carinoma line, MFG-E8 production decreased to diminish Saos-2 cell adhesion. Interestingly, the Delta N-p63 isoform lacking the TA domain enhanced the MFGE8-activating function of TA-p63, if Delta N-p63 was dominant over TA-p63 as typically observed in undifferentiated keratinocytes and squamous cell carcinomas, implying a self-regulatory mechanism of p63 by the TA: Delta N association. MFG-E8 may provide a novel pathway of epithelial-nonepithelial cell interactions inducible by p63, probably in pathological processes.	[Jin, H-F; Yamashita, A.; Ito, M.; Katoh, I.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi 4063898, Japan; [Okuyama, T.; Tomimori, Y.; Ikawa, Y.; Katoh, I.] RIKEN, Ikawa Lab, Wako, Saitama 35101, Japan; [Okuyama, T.; Kobayashi, S.] Kyoritsu Univ Pharm, Dept Mol Physiol, Tokyo, Japan; [Kurata, S.] Tokyo Med & Dent Univ, Inst Med Res, Dept Redox Response Cell Biol, Tokyo, Japan; [Kurata, S.; Tsukinoki, K.; Hata, R-I] Kanagawa Dent Coll, Oral Hlth Sci Res Ctr, Yokosuka, Kanagawa 238, Japan; [Sato, S.] Tokyo Med & Dent Univ, Dept Immune Regulat, Tokyo, Japan; [Osada, M.] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo, Japan; [Jin, H-F; Ito, M.; Katoh, I.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi, Japan; [Jin, H-F; Yamashita, A.; Katoh, I.] Tokyo Med & Dent Univ, Dept Hematol, Tokyo, Japan	University of Yamanashi; RIKEN; Keio University; Tokyo Medical & Dental University (TMDU); Kanagawa Dental College; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Yamanashi; Tokyo Medical & Dental University (TMDU)	Katoh, I (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi 4063898, Japan.	iyoko@yamanashi.ac.jp						Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Carmon L, 2002, J CLIN INVEST, V110, P453, DOI 10.1172/JCI200214071; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; DiRenzo J, 2002, CANCER RES, V62, P89; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Gailit J, 1997, EXP CELL RES, V232, P118, DOI 10.1006/excr.1997.3512; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hoffmann Stephan, 2005, BMC Ophthalmol, V5, P16, DOI 10.1186/1471-2415-5-16; Hvarregaard J, 1996, EUR J BIOCHEM, V240, P628, DOI 10.1111/j.1432-1033.1996.0628h.x; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Koga F, 2003, BRIT J CANCER, V88, P740, DOI 10.1038/sj.bjc.6600764; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kruger W, 2000, BRIT J CANCER, V83, P874, DOI 10.1054/bjoc.2000.1404; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; LAROCCA D, 1991, CANCER RES, V51, P4994; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liu Y, 2005, CANCER GENE THER, V12, P304, DOI 10.1038/sj.cgt.7700785; Massion PP, 2003, CANCER RES, V63, P7113; MATHER IH, 1993, BIOCHEM MOL BIOL INT, V29, P545; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Osada M, 2001, BIOCHEM BIOPH RES CO, V283, P1135, DOI 10.1006/bbrc.2001.4905; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; PETERSON JA, 1990, HYBRIDOMA, V9, P221, DOI 10.1089/hyb.1990.9.221; Quade BJ, 2001, GYNECOL ONCOL, V80, P24, DOI 10.1006/gyno.2000.5953; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Shi JL, 2003, BLOOD, V101, P2628, DOI 10.1182/blood-2002-07-1951; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Smith RA, 2004, ANN BIOMED ENG, V32, P635, DOI 10.1023/B:ABME.0000030230.81832.99; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Watanabe T, 2005, CELL TISSUE RES, V321, P185, DOI 10.1007/s00441-005-1148-y; Wu GJ, 2005, CANCER RES, V65, P758; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	46	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					308	317		10.1038/sj.onc.1210646	http://dx.doi.org/10.1038/sj.onc.1210646			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637751				2022-12-25	WOS:000252256000006
J	Budhram-Mahadeo, V; Irshad, S; Bowen, S; Lee, S; Samady, L; Tonini, G; Latchman, D				Budhram-Mahadeo, Vs; Irshad, S.; Bowen, S.; Lee, Sa; Samady, L.; Tonini, Gp; Latchman, Ds			Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells	ONCOGENE			English	Article						breast cancer; neuroblastoma; cyclin D1; Brn-3b; gene expression	RETINAL GANGLION-CELLS; NEURONAL CELLS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; GROWTH; DIFFERENTIATION; PROMOTER; SERUM; MICE	Brn-3b transcription factor enhances proliferation of neuroblastoma (NB) and breast cancer cell lines in vitro and increases the rate and size of in vivo tumour growth, whereas reducing Brn-3b slows growth, both in vitro and in vivo. Brn-3b is elevated in > 65% of breast cancer biopsies, and here we demonstrate that Brn-3b is also elevated in NB tumours. We show a significant correlation between Brn-3b and cyclin D1 (CD1) in breast cancers and NB tumours and cell lines. Brn-3b directly transactivates the CD1 promoter in co-transfection experiments, whereas electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrate that Brn-3b protein binds to an octamer sequence located in the proximal CD1 promoter. Site-directed mutagenesis of this sequence resulted in loss of transactivation of the CD1 promoter by Brn-3b. Thus, Brn-3b may act to alter growth properties of breast cancer and NB cells by enhancing CD1 expression in these cells.	[Budhram-Mahadeo, Vs; Irshad, S.; Bowen, S.; Lee, Sa; Samady, L.; Latchman, Ds] UCL, Med Mol Biol Unit, Inst Child Hlth, London WC1N 1EH, England; [Tonini, Gp] Natl Inst Canc Res IST, Genoa, Italy	University of London; University College London; University of Genoa; IRCCS AOU San Martino IST	Budhram-Mahadeo, V (corresponding author), UCL, Med Mol Biol Unit, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk						ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 2001, INT J BIOCHEM CELL B, V33, P1027, DOI 10.1016/S1357-2725(01)00069-3; Budhram-Mahadeo VS, 2006, EXPERT OPIN THER TAR, V10, P15, DOI 10.1517/14728222.10.1.15; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; BUDHRAMMAHADEO V, 1995, NEUROSCI LETT, V185, P48, DOI 10.1016/0304-3940(94)11222-5; Dennis JH, 2001, ONCOGENE, V20, P4961, DOI 10.1038/sj.onc.1204491; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; Guo Y, 2005, ONCOGENE, V24, P2599, DOI 10.1038/sj.onc.1208326; Irshad S, 2004, J BIOL CHEM, V279, P21617, DOI 10.1074/jbc.M312506200; Israels E D, 2000, Oncologist, V5, P510, DOI 10.1634/theoncologist.5-6-510; Knudsen KE, 1999, CANCER RES, V59, P2297; Latchman DS, 1998, INT J BIOCHEM CELL B, V30, P1153, DOI 10.1016/S1357-2725(98)00090-9; LATCHMAN DS, 1998, GENE THER MOL BIOL, V2, P95; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mu XQ, 2001, NUCLEIC ACIDS RES, V29, P4983, DOI 10.1093/nar/29.24.4983; Redeuilh G, 2002, ONCOGENE, V21, P5773, DOI 10.1038/sj.onc.1205753; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Samady L, 2004, CANCER BIOL THER, V3, P317, DOI 10.4161/cbt.3.3.698; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith MD, 1996, INT J CANCER, V67, P653; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiang MQ, 1998, DEV BIOL, V197, P155, DOI 10.1006/dbio.1998.8868; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; Xiang MQ, 1996, VISUAL NEUROSCI, V13, P955, DOI 10.1017/S0952523800009184; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	38	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					145	154		10.1038/sj.onc.1210621	http://dx.doi.org/10.1038/sj.onc.1210621			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17637757				2022-12-25	WOS:000252118700015
J	Szczesna-Cordary, D; Jones, M; Moore, JR; Watt, J; Glenn, W; Kerrick, L; Xu, Y; Wang, Y; Wagg, C; Lopaschuk, GD				Szczesna-Cordary, Danuta; Jones, Michelle; Moore, Jeffrey R.; Watt, James; Glenn, W.; Kerrick, L.; Xu, Yuanyuan; Wang, Ying; Wagg, Cory; Lopaschuk, Gary D.			Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients	FASEB JOURNAL			English	Article						transgenic mice; Ca2+/Mg2+ binding to RLC; cardiac hypertrophy; in vitro motility assays; intact and skinned muscle fibers; energy metabolism	FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEAVY-MEROMYOSIN; CA2+ BINDING; NECK REGION; PPAR-ALPHA; FIBERS; DOMAIN; RLC; IDENTIFICATION; ACTIVATION	The glutamic acid to lysine mutation at the 22(nd) amino acid residue ( E22K) in the human cardiac myosin regulatory light chain ( RLC) gene causes familial hypertrophic cardiomyopathy ( FHC) with a phenotype of midventricular obstruction and septal hypertrophy. Our recent histopathology results have shown that the hearts of transgenic E22K mice ( Tg- E22K) resemble those of human patients, demonstrating enlarged interventricular septa and papillary muscles. In this study, we show no effect of the E22K mutation on the kinetics of mutated myosin in its ATP- powered interaction with fluorescently labeled single actin filaments compared to nontransgenic or transgenic wild- type ( Tg- WT) control mice. Likewise, no change in cross- bridge dissociation rates ( gapp) was observed in freshly skinned papillary muscle fibers. In contrast, maximal force and ATPase were decreased similar to 20% in Tg- E22K skinned papillary muscle fibers and intracellular [Ca2+] and force transients were significantly decreased in intact papillary muscle fibers from Tg- E22K compared to Tg- WT mice. Moreover, energy metabolism measured in isolated working Tg- E22K mouse hearts perfused under conditions of physiologically relevant levels of metabolic demand was similar in Tg- E22K and control hearts before and after 20 min of no- flow ischemia. Our results suggest that the pathological response observed in the E22K myocardium might be triggered by mutation induced changes in the properties of the RLC Ca2+- Mg2+ site, the state of the Ca2+/Mg2+ occupancy and consequently the Ca2+ buffering ability of the RLC. By decreasing the affinity of the RLC for Ca2+, the E22K mutation most likely promotes a Mg2+- saturated RLC producing less force and ATPase than the Ca2+-saturated RLC of WT fibers. Decreased Ca2+ binding may also lead to faster Ca2+ dissociation kinetics in Tg- E22K intact fibers resulting in decreased duration and amplitude of [Ca2+] and force transients. These changes when placed in vivo would result in higher workloads and consequently cardiac hypertrophy.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL USA; Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02215 USA; Univ Alberta, Cardiovasc Res Grp, Edmonton, AB T6G 2M7, Canada	University of Miami; University of Miami; Boston University; University of Alberta	Szczesna-Cordary, D (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, PO Box 016189, 1600 NW 10th Ave Rm 6113, Miami, FL 33101 USA.	dszczesna@med.miami.edu		Moore, Jeffrey/0000-0001-7190-9332	NHLBI NIH HHS [R01 HL071778-04, R01 HL071778, HL077280, HL071778, R01 HL071778-01A1, R01 HL077280] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071778, R01HL077280] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Baylor SM, 2000, NEWS PHYSIOL SCI, V15, P19; Belke DD, 1999, AM J PHYSIOL-REG I, V277, pR1210, DOI 10.1152/ajpregu.1999.277.4.R1210; Campbell FM, 2002, J BIOL CHEM, V277, P4098, DOI 10.1074/jbc.M106054200; DASILVA ACR, 1992, EUR J BIOCHEM, V204, P85; DIFFEE GM, 1995, BIOPHYS J, V68, P1443, DOI 10.1016/S0006-3495(95)80317-6; Dumka D, 2006, AM J PHYSIOL-HEART C, V291, pH2098, DOI 10.1152/ajpheart.00396.2006; Flavigny J, 1998, J MOL MED-JMM, V76, P208, DOI 10.1007/s001090050210; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983; HOLROYDE MJ, 1979, J BIOL CHEM, V254, P6478; Hougs L, 2005, EUR J HUM GENET, V13, P161, DOI 10.1038/sj.ejhg.5201310; Kabaeva ZT, 2002, EUR J HUM GENET, V10, P741, DOI 10.1038/sj.ejhg.5200872; KABAEVA ZT, 2002, THESIS HUMBOLDT U BE; KENDRICKJONES J, 1991, J CELL SCI, P55; LANKFORD EB, 1995, J CLIN INVEST, V95, P1409, DOI 10.1172/JCI117795; Lips DJ, 2003, EUR HEART J, V24, P883, DOI 10.1016/S0195-668X(02)00829-1; Lowey S, 2002, TRENDS CARDIOVAS MED, V12, P348, DOI 10.1016/S1050-1738(02)00181-0; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2000, CIRCULATION, V102, P858; MARON BJ, 2003, CARD ELECTROPHYSIOL, V6, P100; Mogensen J, 2001, J MED GENET, V38, P193, DOI 10.1136/jmg.38.3.193; Moore JR, 2004, J MUSCLE RES CELL M, V25, P29, DOI 10.1023/B:JURE.0000021394.48560.71; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; Morner S, 2003, J MOL CELL CARDIOL, V35, P841, DOI 10.1016/S0022-2828(03)00146-9; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Sambandam N, 2006, AM J PHYSIOL-HEART C, V290, pH87, DOI 10.1152/ajpheart.00285.2005; Svensson C, 1997, J CELL BIOCHEM, V67, P241, DOI 10.1002/(SICI)1097-4644(19971101)67:2<241::AID-JCB9>3.0.CO;2-X; SZCZESNA D, 1987, FEBS LETT, V210, P177, DOI 10.1016/0014-5793(87)81332-7; Szczesna D, 2001, J BIOL CHEM, V276, P7086, DOI 10.1074/jbc.M009823200; Szczesna-Cordary D, 2005, J CELL SCI, V118, P3675, DOI 10.1242/jcs.02492; Szczesna-Cordary D, 2004, J BIOL CHEM, V279, P3535, DOI 10.1074/jbc.M307092200; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WAGG C, 2006, BIOPH J, pA274; Wang Y, 1999, J MUSCLE RES CELL M, V20, P645, DOI 10.1023/A:1005559613516; Wang Y, 2006, J MOL BIOL, V361, P286, DOI 10.1016/j.jmb.2006.06.018; Wang YC, 2007, FASEB J, V21, P2205, DOI 10.1096/fj.06-7538com; Warshaw DM, 2000, J BIOL CHEM, V275, P37167, DOI 10.1074/jbc.M006438200	43	34	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3974	3985		10.1096/fj.07-8630com	http://dx.doi.org/10.1096/fj.07-8630com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17606808				2022-12-25	WOS:000251283500022
J	Paul, R; Abel, S; Wassmann, P; Beck, A; Heerklotz, H; Jenal, U				Paul, Ralf; Abel, Soren; Wassmann, Paul; Beck, Andreas; Heerklotz, Heiko; Jenal, Urs			Activation of the diguanylate cyclase PleD by phosphorylation-mediated dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL RESPONSE REGULATORS; CAULOBACTER-CRESCENTUS; SIGNAL-TRANSDUCTION; CELL-CYCLE; MIMICS PHOSPHORYLATION; DYNAMIC LOCALIZATION; ALLOSTERIC CONTROL; RECEIVER DOMAIN; DI-GMP; PROTEINS	Diguanylate cyclases (DGCs) are key enzymes of second messenger signaling in bacteria. Their activity is responsible for the condensation of two GTP molecules into the signaling compound cyclic di-GMP. Despite their importance and abundance in bacteria, catalytic and regulatory mechanisms of this class of enzymes are poorly understood. In particular, it is not clear if oligomerization is required for catalysis and if it represents a level for activity control. To address this question we perform in vitro and in vivo analysis of the Caulobacter crescentus diguanylate cyclase PleD. PleD is a member of the response regulator family with two N-terminal receiver domains and a C-terminal diguanylate cyclase output domain. PleD is activated by phosphorylation but the structural changes inflicted upon activation of PleD are unknown. We show that PleD can be specifically activated by beryllium fluoride in vitro, resulting in dimerization and c-di-GMP synthesis. Cross-linking and fractionation experiments demonstrated that the DGC activity of PleD is contained entirely within the dimer fraction, confirming that the dimer represents the enzymatically active state of PleD. In contrast to the catalytic activity, allosteric feedback regulation of PleD is not affected by the activation status of the protein, indicating that activation by dimerization and product inhibition represent independent layers of DGC control. Finally, we present evidence that dimerization also serves to sequester activated PleD to the differentiating Caulobacter cell pole, implicating protein oligomerization in spatial control and providing a molecular explanation for the coupling of PleD activation and subcellular localization.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Jenal, U (corresponding author), Univ Basel, Biozentrum, Kingelbergstr 70, CH-4056 Basel, Switzerland.	urs.jenal@unibas.ch		Wassmann, Paul/0000-0001-7391-1065; Heerklotz, Heiko/0000-0003-4615-7022; Abel, Soren/0000-0002-4041-6989				Aldridge P, 1999, MOL MICROBIOL, V32, P379, DOI 10.1046/j.1365-2958.1999.01358.x; Aldridge P, 2003, MOL MICROBIOL, V47, P1695, DOI 10.1046/j.1365-2958.2003.03401.x; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Bachhawat P, 2005, STRUCTURE, V13, P1353, DOI 10.1016/j.str.2005.06.006; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Christen B, 2006, J BIOL CHEM, V281, P32015, DOI 10.1074/jbc.M603589200; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Gomelsky M, 2002, TRENDS BIOCHEM SCI, V27, P497, DOI 10.1016/S0968-0004(02)02181-3; Hastings CA, 2003, BIOCHEMISTRY-US, V42, P9081, DOI 10.1021/bi0273866; HECHT GB, 1995, J BACTERIOL, V177, P6223, DOI 10.1128/jb.177.21.6223-6229.1995; Heinzel FP, 1997, J IMMUNOL, V158, P4381; Huitema E, 2006, CELL, V124, P1025, DOI 10.1016/j.cell.2006.01.019; HURLEY JH, 2003, SCI STKE, pPE1; Jacobs C, 2001, P NATL ACAD SCI USA, V98, P4095, DOI 10.1073/pnas.051609998; Jenal U, 2006, ANNU REV GENET, V40, P385, DOI 10.1146/annurev.genet.40.110405.090423; Lam H, 2006, CELL, V124, P1011, DOI 10.1016/j.cell.2005.12.040; Levi A, 2006, J BACTERIOL, V188, P5315, DOI 10.1128/JB.01725-05; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Sinha SC, 2007, REV PHYSIOL BIOCH P, V157, P105, DOI 10.1007/112_0603; Toro-Roman A, 2005, PROTEIN SCI, V14, P3077, DOI 10.1110/ps.051722805; Toro-Roman A, 2005, J MOL BIOL, V349, P11, DOI 10.1016/j.jmb.2005.03.059; Ulrich LE, 2005, TRENDS MICROBIOL, V13, P52, DOI 10.1016/j.tim.2004.12.006; Viollier PH, 2002, P NATL ACAD SCI USA, V99, P13831, DOI 10.1073/pnas.182411999; Wassmann P, 2007, STRUCTURE, V15, P915, DOI 10.1016/j.str.2007.06.016; Wemmer DE, 2005, J BACTERIOL, V187, P8229, DOI 10.1128/JB.187.24.8229-8230.2005; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Zhang XF, 2006, MOL MICROBIOL, V60, P658, DOI 10.1111/j.1365-2958.2006.05138.x; Zhang ZY, 2006, J AM CHEM SOC, V128, P7015, DOI 10.1021/ja0613714	34	137	143	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29170	29177		10.1074/jbc.M704702200	http://dx.doi.org/10.1074/jbc.M704702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17640875	hybrid			2022-12-25	WOS:000249788000012
J	Falasca, M; Hughes, WE; Dominguez, V; Sala, G; Fostira, F; Fang, MQ; Cazzolli, R; Shepherd, PR; James, DE; Maffucci, T				Falasca, Marco; Hughes, William E.; Dominguez, Veronica; Sala, Gianluca; Fostira, Florentia; Fang, Michelle Q.; Cazzolli, Rosanna; Shepherd, Peter R.; James, David E.; Maffucci, Tania			The role of phosphoinositide 3-kinase C2 alpha in insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE PTDINS(3)P; STIMULATED GLUCOSE-TRANSPORT; GLUT4 TRANSLOCATION; PLASMA-MEMBRANE; ALPHA-ISOFORM; C2 DOMAIN; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; CELL-MIGRATION	The members of the class II phosphoinositide 3-kinase (PI3K) family can be activated by several stimuli, indicating that these enzymes can regulate many intracellular processes. Nevertheless, to date, there has been no definitive identification of their in vivo product, their mechanism(s) of activation, or their precise intracellular roles. By metabolic labeling, we here identify phosphatidylinositol 3-phosphate as the sole in vivo product of the insulin-dependent activation of PI3K-C2 alpha, confirming the emerging role of such a phosphoinositide in signaling. We demonstrate that activation of PI3K-C2 alpha involves its recruitment to the plasma membrane and that activation is mediated by the GTPase TC10. This is the first report showing a membrane targeting-mediated mechanism of activation for PI3K-C2 alpha and that a small GTP-binding protein can activate a class II PI3K isoform. We also demonstrate that PI3K-C2 alpha contributes to maximal insulin-induced translocation of the glucose transporter GLUT4 to the plasma membrane and subsequent glucose uptake, definitely assessing the role of this enzyme in insulin signaling.	Univ London, Ctr Diabet & Metabol Med, Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, London E1 2AT, England; Garvan Inst Med Res, Phospholipid Biol Grp, Sydney, NSW 2010, Australia; Garvan Inst Med Res, Diabetes & Obesity Res program, Sydney, NSW 2010, Australia; Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1, New Zealand	University of London; Queen Mary University London; Garvan Institute of Medical Research; Garvan Institute of Medical Research; University of Auckland	Falasca, M (corresponding author), Univ London, Ctr Diabet & Metabol Med, Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, 4 Newark St, London E1 2AT, England.	m.falasca@qmul.ac.uk	Sala, Gianluca/C-2056-2017; Fostira, Florentia/Z-5730-2019; Falasca, Marco/S-4020-2016	Sala, Gianluca/0000-0002-4494-915X; James, David/0000-0001-5946-5257; Falasca, Marco/0000-0002-9801-7235; Hughes, William/0000-0002-7149-3987				Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Brown RA, 2001, BIOCHEM SOC T, V29, P535, DOI 10.1042/BST0290535; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chang L, 2007, ENDOCRINOLOGY, V148, P27, DOI 10.1210/en.2006-1167; Chaussade C, 2003, MOL ENDOCRINOL, V17, P2448, DOI 10.1210/me.2003-0261; Chiang SH, 2003, EMBO J, V22, P2679, DOI 10.1093/emboj/cdg262; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Falasca M, 2007, BIOCHEM SOC T, V35, P211, DOI 10.1042/BST0350211; Falasca Marco, 2006, Archives of Physiology and Biochemistry, V112, P274, DOI 10.1080/13813450601094664; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; Gaidarov I, 2005, J BIOL CHEM, V280, P40766, DOI 10.1074/jbc.M507731200; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gonzalez E, 2006, MOL BIOL CELL, V17, P4484, DOI 10.1091/mbc.E06-07-0585; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Hodgkinson CP, 2005, DIABETOLOGIA, V48, P1627, DOI 10.1007/s00125-005-1819-y; Inoue M, 2006, MOL BIOL CELL, V17, P2303, DOI 10.1091/mbc.E06-01-0030; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Ishiki M, 2005, J BIOL CHEM, V280, P28792, DOI 10.1074/jbc.M500501200; James DE, 2005, J CLIN INVEST, V115, P219, DOI 10.1172/JCI200524158; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Kawase K, 2006, DEV CELL, V11, P411, DOI 10.1016/j.devcel.2006.07.008; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kong AM, 2006, MOL CELL BIOL, V26, P6065, DOI 10.1128/MCB.00203-06; Koumanov F, 2005, CELL METAB, V2, P179, DOI 10.1016/j.cmet.2005.08.007; Ktori C, 2003, BIOCHEM BIOPH RES CO, V306, P139, DOI 10.1016/S0006-291X(03)00933-1; Li CH, 2004, CELL RES, V14, P480, DOI 10.1038/sj.cr.7290251; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005; Maffucci T, 2003, MOL ENDOCRINOL, V17, P1568, DOI 10.1210/me.2001-0211; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Meunier FA, 2005, MOL BIOL CELL, V16, P4841, DOI 10.1091/mbc.E05-02-0171; Mitra P, 2004, J BIOL CHEM, V279, P37431, DOI 10.1074/jbc.C400180200; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sindic A, 2001, J BIOL CHEM, V276, P17754, DOI 10.1074/jbc.M006533200; Soos MA, 2001, ARCH BIOCHEM BIOPHYS, V396, P244, DOI 10.1006/abbi.2001.2587; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; van Dam EM, 2005, MOL ENDOCRINOL, V19, P1067, DOI 10.1210/me.2004-0413; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Visnjic D, 2002, FEBS LETT, V529, P268, DOI 10.1016/S0014-5793(02)03357-4; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang Y, 2006, BIOCHEM J, V394, P581, DOI 10.1042/BJ20051471; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	71	118	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28226	28236		10.1074/jbc.M704357200	http://dx.doi.org/10.1074/jbc.M704357200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644513	hybrid			2022-12-25	WOS:000249455600072
J	Lichtinger, M; Ingram, R; Hornef, M; Bonifer, C; Rehli, M				Lichtinger, Monika; Ingram, Richard; Hornef, Mathias; Bonifer, Constanze; Rehli, Michael			Transcription factor PU.1 controls transcription start site positioning and alternative TLR4 promoter usage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; INTESTINAL EPITHELIAL-CELLS; EXPRESSION; GENE; INITIATION; BINDING; MICE; LIPOPOLYSACCHARIDE; MYELOPOIESIS; ACTIVATION	Human and mouse show markedly different sensitivities toward bacterial endotoxins, and recent evidence suggests that a species-specific regulation of the lipopolysaccharide receptor Toll-like receptor 4 ( Tlr4) may contribute to this phenomenon. To gain further insight into mechanisms of Tlr4 regulation, we conducted a detailed in vivo and in vitro study of the murine Tlr4 gene, including analysis of transcription start site location, transcription factor occupancy, and activities of its proximal regulatory sequences. Our analyses identified a PU. 1-dependent myeloid promoter, which is conserved between humans and mouse. We also identified an additional, distal promoter, located similar to 200 bp upstream of the myeloid-specific promoter, which is a functional target of E-box binding factors. In contrast to humans, where non-myeloid cells utilize both promoters, the distal Tlr4 promoter initiates all Tlr4 transcripts in murine non-myeloid cells, indicating that species-specific differences in TLR4 mRNA regulation may primarily exist in non-myeloid cell types. Interestingly, PU. 1 null murine myeloid progenitor cells predominantly use the distal promoter, and the conditional induction of PU. 1 expression in these cells leads to the rapid switch of transcription initiation to the proximal myeloid promoter. This indicates a direct role for PU. 1 in determining the transcriptional start site and in recruiting the basal transcription machinery to myeloid promoters.	Univ Regensburg, Sch Med, Dept Hematol & Oncol, D-93042 Regensburg, Germany; Univ Clin Freiburg, Dept Med Microbiol & Hygiene, D-79104 Freiburg, Germany; St James Univ Hosp, Sect Expt Haematol, Leeds LS9 7TF, W Yorkshire, England	University of Regensburg; University of Freiburg; Saint James's University Hospital	Rehli, M (corresponding author), Univ Regensburg, Sch Med, Dept Hematol & Oncol, D-93042 Regensburg, Germany.	michael.rehli@klinik.uni-regensburg.de	Bonifer, Constanze/B-3000-2009; Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Hornef, Mathias/0000-0001-6096-9110; Bonifer, Constanze/0000-0002-4267-0825	Biotechnology and Biological Sciences Research Council [BBS/B/07438] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bihl F, 2003, J IMMUNOL, V170, P6141, DOI 10.4049/jimmunol.170.12.6141; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Friedman AD, 2002, INT J HEMATOL, V75, P466, DOI 10.1007/BF02982108; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Heinz S, 2002, GENOMICS, V79, P608, DOI 10.1006/geno.2002.6743; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Huan CM, 2005, J BIOL CHEM, V280, P30225, DOI 10.1074/jbc.M502380200; Kalis C, 2003, EUR J IMMUNOL, V33, P798, DOI 10.1002/eji.200323431; Kiessling S, 2004, J BIOL CHEM, V279, P10304, DOI 10.1074/jbc.M312757200; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Krysinska H, 2007, MOL CELL BIOL, V27, P878, DOI 10.1128/MCB.01915-06; Lotz M, 2006, J EXP MED, V203, P973, DOI 10.1084/jem.20050625; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mehta A, 2006, GENE DEV, V20, P939, DOI 10.1101/gad.1388706; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Rehli M, 1999, J IMMUNOL, V162, P1559; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Roger T, 2005, BIOCHEM J, V387, P355, DOI 10.1042/BJ20041243; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy MF, 2006, GENES IMMUN, V7, P372, DOI 10.1038/sj.gene.6364309; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singh H, 1999, COLD SPRING HARB SYM, V64, P13, DOI 10.1101/sqb.1999.64.13; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; Tagoh H, 2006, METH MOL B, V325, P285; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tsatsanis C, 2006, J IMMUNOL, V176, P1869, DOI 10.4049/jimmunol.176.3.1869; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Wolf G, 2006, J AM SOC NEPHROL, V17, P1585, DOI 10.1681/ASN.2005070699; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554	37	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26874	26883		10.1074/jbc.M703856200	http://dx.doi.org/10.1074/jbc.M703856200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623651	hybrid			2022-12-25	WOS:000249304900027
J	Longin, S; Zwaenepoel, K; Louis, JV; Dilworth, S; Goris, J; Janssens, V				Longin, Sari; Zwaenepoel, Karen; Louis, Justin V.; Dilworth, Stephen; Goris, Jozef; Janssens, Veerle			Selection of protein phosphatase 2A regulatory Subunits is mediated by the C terminus of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE CARBOXYL METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; DOWN-REGULATION; SPLICE VARIANT; PP2A; METHYLATION; ASSOCIATION; METHYLESTERASE; IDENTIFICATION; APOPTOSIS	Protein phosphatase 2A (PP2A) is a family of multifunctional serine/threonine phosphatases all composed of a catalytic C, a structural A, and a regulatory B subunit. Assembly of the complex with the appropriate B subunit forms the key to the functional specificity and regulation of PP2A. Emerging evidence suggests a crucial role for methylation and phosphorylation of the PP2A C subunit in this process. In this study, we show that PP2A C subunit methylation was not absolutely required for binding the PR61/B ' and PR72/B '' subunit families, whereas binding of the PR55/B subunit family was determined by methylation and the nature of the C-terminal amino acid side chain. Moreover mutation of the phosphorylatable Tyr(307) or Thr(304) residues differentially affected binding of distinct B subunit family members. Down-regulation of the PP2A methyltransferase LCMT1 by RNA interference gradually reduced the cellular amount of methylated C subunit and induced a dynamic redistribution of the remaining methylated PP2A(C) between different PP2A trimers consistent with their methylation requirements. Persistent knockdown of LCMT1 eventually resulted in specific degradation of the PR55/B subunit and apoptotic cell death. Together these results establish a crucial foundation for understanding PP2A regulatory subunit selection.	Katholieke Univ Leuven, Fac Med, Dept Mol Biol, Prot Phosphorylat & Proteom Lab, B-3000 Louvain, Belgium; Hammersmith Hosp, Imperial Coll Fac Med, Dept Metab Med, London W12 0NN, England	KU Leuven; Imperial College London	Janssens, V (corresponding author), Katholieke Univ Leuven, Fac Med, Dept Mol Biol, Prot Phosphorylat & Proteom Lab, Campus Gasthuisberg O&N1,Herestr 49bus 901, B-3000 Louvain, Belgium.	Janssens@med.kuleuven.be	Janssens, Veerle/I-7059-2016	Janssens, Veerle/0000-0002-6772-8448				Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; Evans DRH, 2000, MOL GEN GENET, V264, P425; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Gentry MS, 2005, EUKARYOT CELL, V4, P1029, DOI 10.1128/EC.4.6.1029-1040.2005; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Gil-Bernabe AM, 2006, MOL CELL BIOL, V26, P4017, DOI 10.1128/MCB.01904-05; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Leulliot N, 2004, J BIOL CHEM, V279, P8351, DOI 10.1074/jbc.M311484200; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Longin S, 2004, BIOCHEM J, V380, P111, DOI 10.1042/BJ20031643; Longin S, 2006, ENZYMES, V24, P303, DOI 10.1016/S1874-6047(06)80013-2; Martens E, 2004, J MOL BIOL, V336, P971, DOI 10.1016/j.jmb.2003.12.047; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; Nunbhakdi-Craig V, 2007, J NEUROCHEM, V101, P959, DOI 10.1111/j.1471-4159.2007.04503.x; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Queralt E, 2006, CELL, V125, P719, DOI 10.1016/j.cell.2006.03.038; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P287, DOI 10.1093/jnen/63.4.287; Sontag E, 2004, J NEUROPATH EXP NEUR, V63, P1080, DOI 10.1093/jnen/63.10.1080; Stevens I, 2003, EUR J BIOCHEM, V270, P376, DOI 10.1046/j.1432-1033.2003.03398.x; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; XIE HY, 1993, J BIOL CHEM, V268, P13364; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185	42	131	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26971	26980		10.1074/jbc.M704059200	http://dx.doi.org/10.1074/jbc.M704059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635907	hybrid			2022-12-25	WOS:000249304900037
J	Ostrowski, SM; Wilkinson, BL; Golde, TE; Landreth, G				Ostrowski, Stephen M.; Wilkinson, Brandy L.; Golde, Todd E.; Landreth, Gary			Statins reduce amyloid-beta production through inhibition of protein Isoprenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; DIET-INDUCED HYPERCHOLESTEROLEMIA; GAMMA-SECRETASE CLEAVAGE; TRANSGENIC MOUSE MODEL; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; IN-VITRO; ENDOPLASMIC-RETICULUM; A-BETA; DEPENDENT MECHANISM	Epidemiological evidence suggests that long term treatment with hydroxymethylglutaryl- CoA reductase inhibitors, or statins, decreases the risk for developing Alzheimer disease (AD). However, statin-mediated AD protection cannot be fully explained by reduction of cholesterol levels. In addition to their cholesterol lowering effects, statins have pleiotropic actions and act to lower the concentrations of isoprenoid intermediates, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate. The Rho and Rab family small G-proteins require addition of these isoprenyl moieties at their C termini for normal GTPase function. In neuroblastoma cell lines, treatment with statins inhibits the membrane localization of Rho and Rab proteins at statin doses as low as 200 nM, without affecting cellular cholesterol levels. In addition, we show for the first time that at low, physiologically relevant, doses statins preferentially inhibit the isoprenylation of a subset of GTPases. The amyloid precursor protein (APP) is proteolytically cleaved to generate beta-amyloid ( A beta), which is the major component of senile plaques found in AD. We show that inhibition of protein isoprenylation by statins causes the accumulation of APP within the cell through inhibition of Rab family proteins involved in vesicular trafficking. Moreover, inhibition of Rho family protein function reduces levels of APP C-terminal fragments due to enhanced lysosomal dependent degradation. Statin inhibition of protein isoprenylation results in decreased A beta secretion. In summary, we show that statins selectively inhibit GTPase isoprenylation at clinically relevant doses, leading to reduced A beta production in an isoprenoid-dependent manner. These studies provide insight into the mechanisms by which statins may reduce AD pathogenesis.	Case Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Mayo Clin, Coll Med, Mayo Clin Jacksonville, Dept Neurosci, Jacksonville, FL 32224 USA	Case Western Reserve University; Case Western Reserve University; Mayo Clinic	Landreth, G (corresponding author), Case Sch Med, 10900 Euclid Ave,Rm E504, Cleveland, OH 44106 USA.	gel2@case.edu			NIGMS NIH HHS [T32 GM 07250] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; Bellosta S, 2000, DIABETES CARE, V23, pB72; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1980, J LIPID RES, V21, P505; Burns M, 2002, ANN NY ACAD SCI, V977, P367, DOI 10.1111/j.1749-6632.2002.tb04839.x; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; Cheng J, 2005, J BIOL CHEM, V280, P3731, DOI 10.1074/jbc.M410026200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Cicha I, 2004, ARTERIOSCL THROM VAS, V24, P2046, DOI 10.1161/01.ATV.0000145943.19099.a3; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Cordle A, 2005, J BIOL CHEM, V280, P34202, DOI 10.1074/jbc.M505268200; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Desire L, 2005, J BIOL CHEM, V280, P37516, DOI 10.1074/jbc.M507913200; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; ENDO A, 1992, J LIPID RES, V33, P1569; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; George AJ, 2004, NEUROBIOL DIS, V16, P124, DOI 10.1016/j.nbd.2004.01.009; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Ivessa NE, 1997, J BIOL CHEM, V272, P20828, DOI 10.1074/jbc.272.33.20828; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Khvotchev M, 2004, J BIOL CHEM, V279, P47101, DOI 10.1074/jbc.M408474200; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; KNOPS J, 1992, J BIOL CHEM, V267, P16022; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kouchi Z, 1998, EUR J BIOCHEM, V258, P291, DOI 10.1046/j.1432-1327.1998.2580291.x; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Larijani B, 2003, J BIOL CHEM, V278, P46798, DOI 10.1074/jbc.M307799200; LEONARD S, 1990, J BIOL CHEM, V265, P5157; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; PEFRINI S, 2005, PLOS MED, V2, pE18; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; Rockwood K, 2003, NEUROL RES, V25, P601, DOI 10.1179/016164103101202039; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Stewart R, 2007, ARCH NEUROL-CHICAGO, V64, P103, DOI 10.1001/archneur.64.1.103; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; TSUZUKI K, 1994, BRAIN RES, V659, P213, DOI 10.1016/0006-8993(94)90881-8; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wood WG, 2005, MOL NEUROBIOL, V31, P185, DOI 10.1385/MN:31:1-3:185; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zamvil SS, 2002, NEUROLOGY, V59, P970, DOI 10.1212/WNL.59.7.970; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	75	139	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26832	26844		10.1074/jbc.M702640200	http://dx.doi.org/10.1074/jbc.M702640200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17646164	hybrid			2022-12-25	WOS:000249304900023
J	Yuan, K; Hu, H; Guo, Z; Fu, G; Shaw, AP; Hu, R; Yao, X				Yuan, Kai; Hu, Haiying; Guo, Zhen; Fu, Guosheng; Shaw, Andrew P.; Hu, Renming; Yao, Xuebiao			Phospho-regulation of HsCdc14A by polo-like kinase 1 is essential for mitotic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC14A PHOSPHATASE; CHROMOSOME SEGREGATION; SPINDLE; PHOSPHORYLATION; LOCALIZATION; MICROTUBULES; KINETOCHORES	Chromosome segregation in mitosis is orchestrated by dynamic interactions between spindle microtubules and centromeres, which in turn are governed by protein kinase- and phosphatase-signaling cascades. Previous studies showed that overexpression of human phosphatase HsCdc14A, an antagonist of cyclin-dependent kinase 1, affects several aspects of cell division. However, the molecular mechanism underlying HsCdc14A regulation in mitosis has remained elusive. Here we show that HsCdc14A activity is regulated by an auto-inhibitory mechanism via its intra-molecular association. Our biochemical study demonstrated that Polo-like kinase 1 (PLK1) interacts with and phosphorylates HsCdc14A. This phosphorylation partially releases the auto-inhibition of HsCdc14A judged by its phosphatase activity in vitro. To examine the functional relevance of such phospho-regulation of HsCdc14A in vivo, a phospho-mimicking mutant of HsCdc14A was expressed in HeLa cells. Importantly, overexpression of the phospho-mimicking mutants caused aberrant chromosome alignment with a prometaphase delay, suggesting the temporal regulation of HsCdc14A activity is critical for orchestrating mitotic events. Given the fact that HsCdc14A forms an intra-molecular association and PLK1-mediated phospho-regulation promotes HsCdc14A phosphatase activity, we propose that PLK1-HsCdc14A interaction provides a temporal regulation of HsCdc14A in chromosome segregation during mitosis.	Fudan Univ, Sch Med, Hua Shan Hosp, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China; Hefei Natl Lab, Div Cellular Dynam, Hefei 230027, Peoples R China; Chinese Univ Sci & Technol, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA	Fudan University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine	Hu, R (corresponding author), Fudan Univ, Sch Med, Hua Shan Hosp, Dept Endocrinol & Metab, Shanghai 200040, Peoples R China.	renminghu@fudan.edu.cn; yaoxb@ustc.edu.cn	Yuan, Kai/A-1294-2009; Yuan, Kai/ABH-2688-2020	Yuan, Kai/0000-0001-7002-5703; 	NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER; NCI NIH HHS [CA 89019, CA 92080] Funding Source: Medline; NIDDK NIH HHS [DK 56292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahonen LJ, 2005, CURR BIOL, V15, P1078, DOI 10.1016/j.cub.2005.05.026; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Cho HP, 2005, MOL CELL BIOL, V25, P4541, DOI 10.1128/MCB.25.11.4541-4551.2005; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Stegmeier F, 2004, ANNU REV GENET, V38, P203, DOI 10.1146/annurev.genet.38.072902.093051; Trautmann S, 2002, CURR BIOL, V12, pR733, DOI 10.1016/S0960-9822(02)01250-2; Trinkle-Mulcahy L, 2006, CURR OPIN CELL BIOL, V18, P623, DOI 10.1016/j.ceb.2006.09.001; Vazquez-Novelle MD, 2005, J BIOL CHEM, V280, P29144, DOI 10.1074/jbc.M413328200; Visintin R, 2003, MOL BIOL CELL, V14, P4486, DOI 10.1091/mbc.E03-02-0095; Wang HM, 2004, J BIOL CHEM, V279, P54590, DOI 10.1074/jbc.M407588200; Xue Y, 2005, NUCLEIC ACIDS RES, V33, pW184, DOI 10.1093/nar/gki393; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; Yao XB, 1996, AM J PHYSIOL-CELL PH, V271, pC61, DOI 10.1152/ajpcell.1996.271.1.C61; Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200	19	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27414	27423		10.1074/jbc.M703555200	http://dx.doi.org/10.1074/jbc.M703555200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623655	hybrid			2022-12-25	WOS:000249304900083
J	Wang, J; Lester, HA; Dougherty, DA				Wang, Jinti; Lester, Henry A.; Dougherty, Dennis A.			Establishing an ion pair interaction in the homomeric rho 1 gamma-aminobutyric acid type a receptor that contributes to the gating pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SINGLE AMINO-ACID; 2ND TRANSMEMBRANE DOMAIN; CYS-LOOP RECEPTORS; AGONIST BINDING; EXTRACELLULAR DOMAIN; CHANNEL CONDUCTANCE; GABA(C) RECEPTORS; CHARGED RESIDUES; LIGAND-BINDING	gamma-Aminobutyric acid typeA(GABA(A)) receptors are members of the Cys-loop superfamily of ligand-gated ion channels. Upon agonist binding, the receptor undergoes a structural transition from the closed to the open state, but the mechanism of gating is not well understood. Here we utilized a combination of conventional mutagenesis and the high precision methodology of unnatural amino acid incorporation to study the gating interface of the human homopentameric p1 GABA(A) receptor. We have identified an ion pair interaction between two conserved charged residues, Glu(92) in loop 2 of the extracellular domain and Arg(258) in the pre-M1 region. We hypothesize that the salt bridge exists in the closed state by kinetic measurements and free energy analysis. Several other charged residues at the gating interface are not critical to receptor function, supporting previous conclusions that it is the global charge pattern of the gating interface that controls receptor function in the Cys-loop superfamily.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Dougherty, DA (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	dadougherty@caltech.edu			NINDS NIH HHS [NS 34407, NS 11756] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034407, R01NS011756, R01NS034407] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; ADAMS DJ, 1981, J GEN PHYSIOL, V78, P593, DOI 10.1085/jgp.78.6.593; AUERBACH A, 2003, SCI STKE, pRE11; Bormann J, 2000, TRENDS PHARMACOL SCI, V21, P16, DOI 10.1016/S0165-6147(99)01413-3; Boue-Grabot E, 1998, J NEUROCHEM, V70, P899; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cashin AL, 2005, J AM CHEM SOC, V127, P350, DOI 10.1021/ja0461771; Cashin AL, 2007, BIOCHEMISTRY-US, V46, P630, DOI 10.1021/bi061638b; Castaldo P, 2004, J BIOL CHEM, V279, P25598, DOI 10.1074/jbc.M311021200; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Chebib M, 2000, J MED CHEM, V43, P1427, DOI 10.1021/jm9904349; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; ENZ R, 1995, EUR J NEUROSCI, V7, P1495, DOI 10.1111/j.1460-9568.1995.tb01144.x; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lummis SCR, 2005, CHEM BIOL, V12, P993, DOI 10.1016/j.chembiol.2005.06.012; MEMENIMEN KA, 2006, ACS CHEM BIOL, V1, P227; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Qian HH, 1998, J NEUROBIOL, V37, P305, DOI 10.1002/(SICI)1097-4695(19981105)37:2<305::AID-NEU9>3.0.CO;2-6; Qian HH, 1999, J NEUROBIOL, V40, P67, DOI 10.1002/(SICI)1097-4695(199907)40:1<67::AID-NEU6>3.0.CO;2-4; Sala F, 2005, J BIOL CHEM, V280, P6642, DOI 10.1074/jbc.M411048200; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Vicente-Agullo F, 2001, BIOCHEMISTRY-US, V40, P8300, DOI 10.1021/bi010087g; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; WANG TL, 1995, J NEUROSCI, V15, P7684; Wegelius K, 1998, EUR J NEUROSCI, V10, P350, DOI 10.1046/j.1460-9568.1998.00023.x; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; Xiu XN, 2005, J BIOL CHEM, V280, P41655, DOI 10.1074/jbc.M508635200; Yang J, 2006, BIOPHYS J, V91, P2155, DOI 10.1529/biophysj.106.085431; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhu YJ, 2007, NEUROSCI LETT, V418, P205, DOI 10.1016/j.neulet.2007.03.020	37	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26210	26216		10.1074/jbc.M702314200	http://dx.doi.org/10.1074/jbc.M702314200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17606618	hybrid, Green Accepted			2022-12-25	WOS:000249239600025
J	Zimnicka, AM; Maryon, EB; Kaplan, JH				Zimnicka, Adriana M.; Maryon, Edward B.; Kaplan, Jack H.			Human copper transporter hCTR1 mediates basolateral uptake of copper into enterocytes - Implications for copper homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; CTR1; LOCALIZATION; EXPRESSION; PROTEIN; IRON; MEMBRANE; COMPLEMENTATION	Copper is essential for human growth and survival. Enterocytes mediate the absorption of dietary copper from the intestinal lumen into blood as well as utilizing copper for their biosynthetic needs. Currently, the pathways for copper entry into enterocytes remain poorly understood. We demonstrate that the basolateral copper uptake into intestinal cells greatly exceeds the apical uptake. The basolateral but not apical transport is mediated by the high affinity copper transporter hCTR1. This unanticipated conclusion is supported by cell surface biotinylation and confocal microscopy of endogenous hCTR1 in Caco2 cells as well as copper influx measurements that show saturable high affinity uptake at the basolateral but not the apical membrane. Basolateral localization of hCTR1 and polarized copper uptake are also conserved in T84 cells, models for intestinal crypt cells. The lateral localization of hCTR1 seen in intestinal cell lines is recapitulated in immunohistochemical staining of mouse intestinal sections. Biochemical and functional assays reveal the basolateral localization of hCTR1 also in renal Madin-Darby canine kidney cells and opossum kidney cells. Overexpression of hCTR1 in Madin-Darby canine kidney cells results in both apical and basolateral delivery of the overexpressed protein and greatly enhanced copper uptake at both cell surfaces. We propose a model of intestinal copper uptake in which basolateral hCTR1 plays a key role in the physiologically important delivery of copper from blood to intracellular proteins, whereas its role in the initial apical uptake of dietary copper is indirect.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kaplan, JH (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Mol Biol Res Bldg MC 669,900 S Ashland Ave, Chicago, IL 60607 USA.	kaplanj@uic.edu		Kaplan, Jack/0000-0002-7048-6574	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM067166] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aller SG, 2006, P NATL ACAD SCI USA, V103, P3627, DOI 10.1073/pnas.0509929103; Arredondo M, 2003, AM J PHYSIOL-CELL PH, V284, pC1525, DOI 10.1152/ajpcell.00480.2002; Balamurugan K, 2007, EMBO J, V26, P1035, DOI 10.1038/sj.emboj.7601543; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Eisses JF, 2005, J BIOL CHEM, V280, P37159, DOI 10.1074/jbc.M508822200; Eisses JF, 2005, J BIOL CHEM, V280, P9635, DOI 10.1074/jbc.M500116200; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hardman B, 2006, PLACENTA, V27, P968, DOI 10.1016/j.placenta.2005.10.011; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Kuo YM, 2006, J NUTR, V136, P21, DOI 10.1093/jn/136.1.21; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Laughery MD, 2007, AM J PHYSIOL-RENAL, V292, pF1718, DOI 10.1152/ajprenal.00360.2006; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Linder Maria C., 1996, American Journal of Clinical Nutrition, V63, p797S; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Maryon EB, 2007, J BIOL CHEM, V282, P20376, DOI 10.1074/jbc.M701806200; Nose Y, 2006, CELL METAB, V4, P235, DOI 10.1016/j.cmet.2006.08.009; Picard V, 2000, J BIOL CHEM, V275, P35738, DOI 10.1074/jbc.M005387200; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Sharp PA, 2003, INT J BIOCHEM CELL B, V35, P288, DOI 10.1016/S1357-2725(02)00134-6; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; Tennant J, 2002, FEBS LETT, V527, P239, DOI 10.1016/S0014-5793(02)03253-2; Uribe JM, 2002, AM J PHYSIOL-GASTR L, V283, pG923, DOI 10.1152/ajpgi.00237.2002; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	32	79	82	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26471	10.1074/jbc.M702653200	http://dx.doi.org/10.1074/jbc.M702653200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17627945	hybrid			2022-12-25	WOS:000249239600052
J	Puntheeranurak, T; Kasch, M; Xia, XB; Hinterdorfer, P; Kinne, RKH				Puntheeranurak, Theeraporn; Kasch, Myriam; Xia, Xiaobing; Hinterdorfer, Peter; Kinne, Rolf K. H.			Three surface subdomains form the vestibule of the Na+/glucose cotransporter SGLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; GLUCOSE-GALACTOSE MALABSORPTION; ATOMIC-FORCE; TRYPTOPHAN FLUORESCENCE; CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI; SUGAR-TRANSPORT; REENTRANT LOOP; BINDING-SITE; NA+	A combination of biophysical and biochemical approaches was employed to probe the topology, arrangement, and function of the large surface subdomains of SGLT1 in living cells. Using atomic force microscopy on the single molecule level, Chinese hamster ovary cells overexpressing SGLT1 were probed with atomic force microscopy tips carrying antibodies against epitopes of different subdomains. Specific single molecule recognition events were observed with antibodies against loop 6-7, loop 8-9, and loop 13-14, demonstrating the extracellular orientation of these subdomains. The addition of D-glucose in Na+-containing medium decreased the binding probability of the loop 8-9 antibody, suggesting a transport-related conformational change in the region between amino acids 339 and 356. Transport studies with mutants C345A, C351A, C355A, or C361S supported a role for these amino acids in determining the affinity of SGLT1 for D-glucose. MTSET, [2-(Trimethylammonium) ethyl] methanethiosulfonate and dithiothreitol inhibition patterns on alpha-methyl-glucoside uptake by COS-7 cells expressing C255A, C560A, or C608A suggested the presence of a disulfide bridge between Cys255 and Cys608. This assumption was corroborated by matrix-assisted laser desorption ionization time-of-flight mass spectrometry showing mass differences in peptides derived from transporters biotinylated in the absence and presence of dithiothreitol. These results indicate that loop 6-7 and loop 13-14 are connected by a disulfide bridge. This bridge brings also loop 8-9 into close vicinity with the former subdomains to create a vestibule for sugar binding.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Mahidol Univ, Natl Nanotechnol Ctr, Ctr Excellence, Bangkok 10400, Thailand; Mahidol Univ, Fac Sci, Dept Biol, Bangkok 10400, Thailand; Johannes Kepler Univ Linz, Inst Biophys, A-4040 Linz, Austria	Max Planck Society; Mahidol University; National Science & Technology Development Agency - Thailand; National Nanotechnology Center (NANOTEC); Mahidol University; Johannes Kepler University Linz	Kinne, RKH (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	rolf.kinne@mpi-dortmund.mpg.de	Hinterdorfer, Peter/C-4235-2013	Hinterdorfer, Peter/0000-0003-2583-1305				Althoff T, 2007, AM J PHYSIOL-REG I, V292, pR2391, DOI 10.1152/ajpregu.00454.2006; Baumgartner W, 2000, ULTRAMICROSCOPY, V82, P85, DOI 10.1016/S0304-3991(99)00154-0; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; Diez-Sampedro A, 2001, J BIOL CHEM, V276, P49188, DOI 10.1074/jbc.M108286200; Ebner A, 2007, BIOCONJUGATE CHEM, V18, P1176, DOI 10.1021/bc070030s; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Gagnon DG, 2006, J GEN PHYSIOL, V127, P145, DOI 10.1085/jgp.200509439; Gagnon DG, 2005, BBA-BIOMEMBRANES, V1712, P173, DOI 10.1016/j.bbamem.2005.04.007; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hinterdorfer P, 1996, P NATL ACAD SCI USA, V93, P3477, DOI 10.1073/pnas.93.8.3477; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Kipp H, 2003, AM J PHYSIOL-CELL PH, V285, pC737, DOI 10.1152/ajpcell.00041.2003; Krom BP, 2003, BIOCHEMISTRY-US, V42, P467, DOI 10.1021/bi026874a; Lin JT, 1998, BBA-BIOMEMBRANES, V1373, P309, DOI 10.1016/S0005-2736(98)00116-3; Lin JT, 1999, J MEMBRANE BIOL, V170, P243, DOI 10.1007/s002329900553; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Novakova R, 2001, J MEMBRANE BIOL, V184, P55, DOI 10.1007/s00232-001-0073-6; Panayotova-Heiermann M, 1999, FEBS LETT, V459, P386, DOI 10.1016/S0014-5793(99)01292-2; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; Pfister G, 2005, J CELL SCI, V118, P1587, DOI 10.1242/jcs.02292; Puntheeranurak T, 2007, BIOCHEMISTRY-US, V46, P2797, DOI 10.1021/bi061917z; Puntheeranurak T, 2006, J CELL SCI, V119, P2960, DOI 10.1242/jcs.03035; Raja MM, 2005, BIOCHEMISTRY-US, V44, P9123, DOI 10.1021/bi050323d; Raja MM, 2003, J BIOL CHEM, V278, P49154, DOI 10.1074/jbc.M306881200; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; THOMAS L, 1972, BIOCHIM BIOPHYS ACTA, V290, P125, DOI 10.1016/0005-2736(72)90057-0; TURK E, 1994, J BIOL CHEM, V269, P15204; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; TURNER RJ, 1983, J BIOL CHEM, V258, P3565; TURNER RJ, 1984, BIOCHIM BIOPHYS ACTA, V769, P23, DOI 10.1016/0005-2736(84)90005-1; Tyagi NK, 2005, BIOCHEMISTRY-US, V44, P15514, DOI 10.1021/bi051377q; Vayro S, 1998, BIOCHEM J, V332, P119, DOI 10.1042/bj3320119; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wright EM, 2007, J INTERN MED, V261, P32, DOI 10.1111/j.1365-2796.2006.01746.x; Wright EM, 1998, AM J PHYSIOL-GASTR L, V275, pG879, DOI 10.1152/ajpgi.1998.275.5.G879; Xia XB, 2005, ARCH BIOCHEM BIOPHYS, V438, P63, DOI 10.1016/j.abb.2005.04.010; Xia XB, 2003, BIOCHEMISTRY-US, V42, P6115, DOI 10.1021/bi020695b; Yagur-Kroll S, 2005, J BIOL CHEM, V280, P19306, DOI 10.1074/jbc.M410896200	45	21	22	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25222	25230		10.1074/jbc.M704190200	http://dx.doi.org/10.1074/jbc.M704190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17616521	hybrid			2022-12-25	WOS:000249014100007
J	Li, YF; Tang, RH; Puan, KJ; Law, SKA; Tan, SM				Li, Yan-Feng; Tang, Ren-Hong; Puan, Kia-Joo; Law, S. K. Alex; Tan, Suet-Mien			The cytosolic protein Talin induces an intermediate affinity integrin alpha(L)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE DOMAIN; ALPHA(L)BETA(2) HYBRID DOMAIN; MIGRATING T-LYMPHOCYTES; GLYCOPROTEIN-IIB-IIIA; INTEGRIN ALPHA(L)BETA(2); LEUKOCYTE INTEGRINS; MONOCLONAL-ANTIBODY; STRUCTURAL BASIS; ACTIVATION; ADHESION	The integrin alpha(L)beta(2) mediates leukocyte adhesion and migration that are required for a functional immune system. It is known that inside-out signaling triggers alpha(L)beta(2) conformational changes, which affect its ligand-binding affinity. At least three alpha(L)beta(2) affinity states (low, intermediate, and high) were described. The cytosolic protein talin connects alpha(L)beta(2) to the actin filament. The talin head domain is also known to activate alpha(L)beta(2) ligand binding. However, it remains to be determined whether talin promotes an intermediate or high affinity alpha(L)beta(2). In this study using transfectants and T cells, we showed that talin induced an intermediate affinity alpha(L)beta(2) that adhered constitutively to its ligand intercellular adhesion molecule (ICAM)-1 but not ICAM-3. Adhesion to ICAM-3 was induced when an additional exogenous activating agent was included. Similar profiles were observed with soluble ICAMs. In addition, the intermediate affinity alpha(L)beta(2) induced by talin allowed adhesion and migration of T cells on immobilized ICAMs.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; Natl Canc Ctr, Singapore 169610, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National Cancer Centre Singapore (NCCS)	Tan, SM (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	smtan@ntu.edu.sg	Tan, Suet/A-2224-2011; Law, Alex/A-2212-2011; li, yan/GTI-4638-2022	Tan, Suet-Mien/0000-0003-2371-8739				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; BARCLAY AN, 1997, LEUCOCYTE ANTIGEN FA, P177; Beals CR, 2001, J IMMUNOL, V167, P6113, DOI 10.4049/jimmunol.167.11.6113; CAI TQ, 1995, J BIOL CHEM, V270, P14358, DOI 10.1074/jbc.270.24.14358; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Cheng M, 2007, J BIOL CHEM, V282, P18225, DOI 10.1074/jbc.M701386200; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Drbal K, 2001, IMMUNOBIOLOGY, V203, P687, DOI 10.1016/S0171-2985(01)80017-6; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Krawczyk C, 2002, IMMUNITY, V16, P331, DOI 10.1016/S1074-7613(02)00291-1; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mathew EC, 2000, CLIN EXP IMMUNOL, V121, P133, DOI 10.1046/j.1365-2249.2000.01277.x; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Perez OD, 2003, NAT IMMUNOL, V4, P1083, DOI 10.1038/ni984; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Shamri R, 2005, NAT IMMUNOL, V6, P497, DOI 10.1038/ni1194; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Simonson WTN, 2006, J IMMUNOL, V177, P7707, DOI 10.4049/jimmunol.177.11.7707; Smith A, 2005, J CELL BIOL, V170, P141, DOI 10.1083/jcb.200412032; Song G, 2005, P NATL ACAD SCI USA, V102, P3366, DOI 10.1073/pnas.0500200102; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24310	24319		10.1074/jbc.M701860200	http://dx.doi.org/10.1074/jbc.M701860200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17591777	hybrid			2022-12-25	WOS:000248686600057
J	Liu, K; Mori, S; Takahashi, HK; Tomono, Y; Wake, H; Kanke, T; Sato, Y; Hiraga, N; Adachi, N; Yoshino, T; Nishibori, M				Liu, Keyue; Mori, Shuji; Takahashi, Hideo K.; Tomono, Yasuko; Wake, Hidenori; Kanke, Toru; Sato, Yasuharu; Hiraga, Norihito; Adachi, Naoto; Yoshino, Tadashi; Nishibori, Masahiro			Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats	FASEB JOURNAL			English	Article						target therapy; inflammation; blood-brain barrier; matrix metalloproteinase; inducible nitric oxide synthase	CEREBRAL-ARTERY OCCLUSION; TISSUE-PLASMINOGEN-ACTIVATOR; EMBOLIC FOCAL ISCHEMIA; TUMOR-NECROSIS-FACTOR; NEURITE OUTGROWTH; MATRIX-METALLOPROTEINASE; RHEUMATOID-ARTHRITIS; PROTEIN; RECEPTOR; AMPHOTERIN	The high mobility group box-1 (HMGB1), originally identified as an architectural nuclear protein, exhibits an inflammatory cytokine- like activity in the extracellular space. Here we show that treatment with neutralizing anti- HMGB1 monoclonal antibody ( mAb; 200 mu g, twice) remarkably ameliorated brain infarction induced by 2- h occlusion of the middle cerebral artery in rats, even when the mAb was administered after the start of reperfusion. Consistent with the 90% reduction in infarct size, the accompanying neurological deficits in locomotor function were significantly improved. Anti- HMGB1 mAb inhibited the increased permeability of the blood- brain barrier, the activation of microglia, the expression of TNF-alpha and iNOS, and suppressed the activity of MMP- 9, whereas it had little effect on blood flow. Intracerebroventricular injection of HMGB1 increased the severity of infarction. Immunohistochemical study revealed that HMGB1 immunoreactivity in the cell nuclei decreased or disappeared in the affected areas, suggesting the release of HMGB1 into the extracellular space. These results indicate that HMGB1 plays a critical role in the development of brain infarction through the amplification of plural inflammatory responses in the ischemic region and could be an outstandingly suitable target for the treatment. Intravenous injection of neutralizing anti- HMGB1 mAb provides a novel therapeutic strategy for ischemic stroke.	Okayama Univ, Grad Sch Med, Dept Pharmacol, Dent Pharmaceut Sci, Okayama 7008530, Japan; Shigei Med Inst, Okayama, Japan; Ehime Univ, Dept Anesthesiol & Resuscitol, Matsuyama, Ehime 790, Japan	Okayama University; Ehime University	Nishibori, M (corresponding author), Okayama Univ, Grad Sch Med, Dept Pharmacol, Dent Pharmaceut Sci, Okayama 7008530, Japan.	mbori@md.okayama-u.ac.jp		Takahashi, Hideo/0000-0001-9444-9746				Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Becker K, 2001, STROKE, V32, P206, DOI 10.1161/01.STR.32.1.206; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Danton GH, 2004, AM J NEURORADIOL, V25, P181; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Harris M, 2004, LANCET ONCOL, V5, P292, DOI 10.1016/S1470-2045(04)01467-6; Hiraga N, 2007, EUR J PHARMACOL, V557, P236, DOI 10.1016/j.ejphar.2006.11.020; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; Kaur J, 2004, J CEREBR BLOOD F MET, V24, P945, DOI 10.1097/01.WCB.0000137868.50767.E8; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161; Lindsberg PJ, 2003, CURR OPIN NEUROL, V16, P73, DOI 10.1097/00019052-200302000-00010; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maeda M, 2002, J CEREBR BLOOD F MET, V22, P1205, DOI 10.1097/01.wcb.0000037993.34930.72; Matsuo Y, 2001, STROKE, V32, P2143, DOI 10.1161/hs0901.94259; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; NISHI H, 1989, STROKE, V20, P1236, DOI 10.1161/01.STR.20.9.1236; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Pedrazzi M, 2006, J NEUROCHEM, V99, P827, DOI 10.1111/j.1471-4159.2006.04120.x; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Ren D, 2006, INFLAMM RES, V55, P207, DOI 10.1007/s00011-006-0072-2; Rouhiainen A, 2004, BLOOD, V104, P1174, DOI 10.1182/blood-2003-10-3536; ROUSSEL S, 1992, HYPERTENSION, V19, P40, DOI 10.1161/01.HYP.19.1.40; Sado Y, 1996, CELL BIOL INT, V20, P7, DOI 10.1006/cbir.1996.0003; Shimazu T, 2005, STROKE, V36, P353, DOI 10.1161/01.STR.0000152271.21943.a2; Singh R, 2005, CURR OPIN RHEUMATOL, V17, P274; Slevin M, 2005, J CELL MOL MED, V9, P85, DOI 10.1111/j.1582-4934.2005.tb00339.x; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC; Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zhao BQ, 2004, BLOOD, V103, P2610, DOI 10.1182/blood-2003-03-0835	50	279	299	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3904	3916		10.1096/fj.07-8770com	http://dx.doi.org/10.1096/fj.07-8770com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17628015				2022-12-25	WOS:000251283500016
J	Castaldi, L; Serra, C; Moretti, F; Messina, G; Paoletti, R; Sampaolesi, M; Torgovnick, A; Baiocchi, M; Padula, F; Pisaniello, A; Molinaro, M; Cossu, G; Levrero, M; Bouche, M				Castaldi, L.; Serra, C.; Moretti, F.; Messina, G.; Paoletti, R.; Sampaolesi, M.; Torgovnick, A.; Baiocchi, M.; Padula, F.; Pisaniello, A.; Molinaro, M.; Cossu, G.; Levrero, M.; Bouche, M.			Bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype	FASEB JOURNAL			English	Article						satellite cells; gene reprogramming; muscle deseases; cell therapy	NF-KAPPA-B; SKELETAL-MUSCLE; STEM-CELLS; SATELLITE CELLS; DIFFERENTIATION; ALPHA; MICE; REGENERATION; ACTIVATION; PRECURSORS	Satellite cells are the main source of myogenic progenitors in postnatal skeletal muscle, but their use in cell therapy for muscle disorders is limited because these cells cannot be delivered through circulation and they are rapidly exhausted in severe myopathies. The search for alternative donor cells is ongoing, but none of the candidates so far show all the features required for successful colonization and repair of diseased muscle. In this study, we show that bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, induces myogenic cells to acquire a gene expression profile and a differentiation potential consistent with the phenotype of a circulating precursors, while maintaining their myogenic potential. These effects are mediated, at least in part, by NF-kappa B activation through the Tyr42-I kappa B-alpha phosphorylation, as shown by the expression of the dominant negative mutant form of the p50 NF-kappa B subunit. Moreover, when bisperoxovanadium-treated cells are injected into the femoral artery of alpha-sarcoglican null dystrophic mice, they are able to circulate and to reach muscle tissue; importantly, they contribute to muscle regeneration, as shown by the expression of alpha-sarcoglican in some fibers. Our observations indicate that bisperoxovanadium, or similar compounds, may prove very valuable to obtain and to expand, from committed cells, multipotent cell populations suitable for gene-cell therapy applications and may help to understand the molecular basis of genome reprogramming and "stem-ness".	Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, I-00161 Rome, Italy; Univ Roma La Sapienza, Interuniv Inst Myol, I-00161 Rome, Italy; Fdn A Cesalpino, CRS Regina Elena Canc Inst, Milan, Italy; Dibit H San Raffaele, Stem Cell Res Inst, Milan, Italy; Ist Super Sanita, Hematol Lab, I-00161 Rome, Italy; San Raffaele Biomed Sci Pk, Inst Cell Biol & Tissue Engn, Rome, Italy; Univ Roma La Sapienza, Dept Internal Med, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS); Sapienza University Rome	Bouche, M (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, Via A Scarpa 14, I-00161 Rome, Italy.	marina.bouche@uniroma1.it	Sampaolesi, Maurilio/H-6509-2013; Messina, Graziella/A-1469-2014; Levrero, Massimo/G-5680-2016	Sampaolesi, Maurilio/0000-0002-2422-3757; Messina, Graziella/0000-0001-8189-0727; Levrero, Massimo/0000-0002-4978-0875; Baiocchi, Marta/0000-0003-0976-0690; Bouche, Marina/0000-0002-0938-5360				Barat C, 2003, J BIOL CHEM, V278, P6992, DOI 10.1074/jbc.M212433200; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; D'Andrea M, 2006, J CELL PHYSIOL, V207, P379, DOI 10.1002/jcp.20585; Delaisse JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374; Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hakelien AM, 2002, NAT BIOTECHNOL, V20, P460, DOI 10.1038/nbt0502-460; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Israeli D, 2004, J CELL PHYSIOL, V201, P409, DOI 10.1002/jcp.20088; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Latella L, 2000, CELL DEATH DIFFER, V7, P145, DOI 10.1038/sj.cdd.4400592; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Ouellet M, 2003, BIOCHEMISTRY-US, V42, P8260, DOI 10.1021/bi034013b; Palacios D, 2006, J CELL PHYSIOL, V207, P1, DOI 10.1002/jcp.20489; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pisaniello A, 2003, J CELL SCI, V116, P1589, DOI 10.1242/jcs.00358; Pomerantz J, 2004, NAT CELL BIOL, V6, P810, DOI 10.1038/ncb0904-810; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; Sampaolesi M, 2003, SCIENCE, V301, P487, DOI 10.1126/science.1082254; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Taranger CK, 2005, MOL BIOL CELL, V16, P5719, DOI 10.1091/mbc.e05-06-0572; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	45	17	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2007	21	13					3573	3583		10.1096/fj.06-7454com	http://dx.doi.org/10.1096/fj.06-7454com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17601985	Green Accepted			2022-12-25	WOS:000250517800020
J	Hata, S; Doi, N; Kitamura, F; Sorimachi, H				Hata, Shoji; Doi, Naoko; Kitamura, Fujiko; Sorimachi, Hiroyuki			Stomach-specific calpain, nCL-2/calpain 8, is active without calpain regulatory subunit and oligomerizes through C2-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC CALPAIN; TISSUE-SPECIFIC CALPAIN; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PROTEASE ACTIVITY; MU-CALPAIN; GENE; AUTOLYSIS; P94; ACTIVATION	Calpains constitute a family of intracellular Ca2+-regulated cysteine proteases that are indispensable in the regulation of a wide variety of cellular functions. The improper activation of calpain causes lethality or various disorders, such as muscular dystrophies and tumor formation. nCL-2/calpain 8 is predominantly expressed in the stomach, where it appears to be involved in membrane trafficking in the gastric surface mucus cells (pit cells). Although the primary structure of nCL-2 is quite similar to that of the ubiquitous m-calpain large subunit, the enzymatic properties of nCL-2 have never been reported. Here, to characterize nCL-2, the recombinant protein was prepared using an Escherichia coli expression system and purified to homogeneity. nCL-2 was stably produced as a soluble and active enzyme without the conventional calpain regulatory subunit (30K). Purified nCL-2 showed Ca2+-dependent activity, with half-maximal activity at about 0.3 mM Ca2+, similar to that of m-calpain, whereas its optimal pH and temperature were comparatively low. Immunoprecipitation analysis revealed that nCL-2 exists in both monomeric and homo-oligomeric forms, but not as a heterodimer with 30K or 30K-2, and that the oligomerization occurs through domains other than the 5EF-hand domain IV, most probably through domain III, suggesting a novel regulatory system for nCL-2.	Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Calpain Project, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Agcy, CREST, Saitama 3320012, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Sorimachi, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Calpain Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 113, Japan.	sorimach@rinshoken.or.jp	Sorimachi, Hiroyuki/C-6448-2009; Sorimachi, Hiroyuki/Q-6956-2017	Sorimachi, Hiroyuki/0000-0001-9509-6727; Sorimachi, Hiroyuki/0000-0001-9509-6727				Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bordone L, 2002, J BIOL CHEM, V277, P26673, DOI 10.1074/jbc.M112037200; Cao Y, 2001, DEV GROWTH DIFFER, V43, P563; Davis TL, 2007, J MOL BIOL, V366, P216, DOI 10.1016/j.jmb.2006.11.037; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; Duan WR, 2002, BIOCHEM BIOPH RES CO, V295, P261, DOI 10.1016/S0006-291X(02)00655-1; DUTT P, 2006, BMC DEV BIOL, V6, DOI DOI 10.1186/1471-1213X-1186-1183; Friedrich P, 2005, BIOL CHEM, V386, P609, DOI 10.1515/BC.2005.071; Friedrich P, 2004, EUR J NEUROSCI, V19, P1819, DOI 10.1111/j.1460-9568.2004.03313.x; Futai E, 1999, MOL GEN GENET, V260, P559, DOI 10.1007/s004380050929; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hata S, 2006, J BIOL CHEM, V281, P11214, DOI 10.1074/jbc.M509244200; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Lee HJ, 1998, BIOL CHEM, V379, P175, DOI 10.1515/bchm.1998.379.2.175; Lee HJ, 1999, ARCH BIOCHEM BIOPHYS, V362, P22, DOI 10.1006/abbi.1998.1021; Lid SE, 2002, P NATL ACAD SCI USA, V99, P5460, DOI 10.1073/pnas.042098799; Masumoto H, 1998, J BIOCHEM, V124, P957, DOI 10.1093/oxfordjournals.jbchem.a022213; Moldoveanu T, 2003, NAT STRUCT BIOL, V10, P371, DOI 10.1038/nsb917; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; Schad E, 2002, BIOCHEM J, V362, P383, DOI 10.1042/0264-6021:3620383; Shinozaki K, 1998, INT J MOL MED, V1, P797; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; Zimmerman UJP, 2000, IUBMB LIFE, V50, P63	41	27	28	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27847	27856		10.1074/jbc.M703168200	http://dx.doi.org/10.1074/jbc.M703168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17646163	hybrid			2022-12-25	WOS:000249455600033
J	Jin, HJ; Shen, XH; Baggett, BR; Kong, XM; LiWang, PJ				Jin, Hongjun; Shen, Xiaohong; Baggett, Brandi Renee; Kong, Xiangming; LiWang, Patricia J.			The human CC chemokine MIP-1 beta dimer is not competent to bind to the CCR5 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFLAMMATORY PROTEIN 1-BETA; FUSION INHIBITOR T-20; SIDE-CHAIN RESONANCES; C-13/N-15-ENRICHED PROTEINS; GLYCOSAMINOGLYCAN BINDING; FUNCTIONAL-RESPONSES; NMR ASSIGNMENTS; BACKBONE AMIDE; FACTOR-I	Chemokine dimerization has been the subject of much interest in recent years as evidence has accumulated that different quaternary states of chemokines play different biological roles; the monomer is believed to be the receptor-binding unit, whereas the dimer has been implicated in binding cell surface glycosaminoglycans. However, although several studies have provided evidence for this paradigm by making monomeric chemokine variants or dimer-impaired chemokines, few have provided direct evidence of the receptor function of a chemokine dimer. We have produced a covalent dimer of the CC chemokine macrophage inflammatory protein-1 beta (MIP-1 beta) by placing a disulfide bond at the center of its dimer interface through a single amino acid substitution (MIP-1 beta-A10C). This variant was shown to be a nondissociating dimer by SDS-PAGE and analytical ultracentrifugation. NMR reveals a structure largely the same as the wild type protein. In studies of glycosaminoglycan binding, MIP-1 beta-A10C binds to a heparin-Sepharose column as tightly as the wild type protein and more tightly than monomeric variants. However, MIP-1 beta-A10C neither binds nor activates the MIP-1 beta receptor CCR5. It was found that the ability to activate CCR5 was recovered upon reduction of the intermolecular disulfide cross-link by incubation with I mM dithiothreitol. This work provides the first definitive evidence that the CC chemokine MIP-1 beta dimer is not able to bind or activate its receptor and implicates the CC chemokine monomer as the sole receptor-interacting unit.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	LiWang, PJ (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	pliwang@tamu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI47832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bondue A, 2002, BIOCHEMISTRY-US, V41, P13548, DOI 10.1021/bi026087d; Chackerian B, 1999, P NATL ACAD SCI USA, V96, P2373, DOI 10.1073/pnas.96.5.2373; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Fernando H, 2004, J BIOL CHEM, V279, P36175, DOI 10.1074/jbc.C400283200; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; Jin HJ, 2005, BIOCHEM BIOPH RES CO, V338, P987, DOI 10.1016/j.bbrc.2005.10.062; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Koopmann W, 1999, J IMMUNOL, V163, P2120; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Leong SR, 1997, PROTEIN SCI, V6, P609; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; Lowman HB, 1997, PROTEIN SCI, V6, P598; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; McCornack MA, 2004, BIOCHEMISTRY-US, V43, P10090, DOI 10.1021/bi049751u; McCornack MA, 2003, J BIOL CHEM, V278, P1946, DOI 10.1074/jbc.M207440200; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; MEUNIER A, 1997, BIOCHEMISTRY-US, V36, P4412; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Rajarathnam K, 2006, BIOCHEMISTRY-US, V45, P7882, DOI 10.1021/bi0605944; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Sharma D, 2000, J BIOMOL NMR, V18, P165, DOI 10.1023/A:1008398416292; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Veldkamp CT, 2005, PROTEIN SCI, V14, P1071, DOI 10.1110/ps.041219505; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	49	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27976	27983		10.1074/jbc.M702654200	http://dx.doi.org/10.1074/jbc.M702654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644519	hybrid			2022-12-25	WOS:000249455600047
J	Morgan, MT; Bennett, MT; Drohat, AC				Morgan, Michael T.; Bennett, Matthew T.; Drohat, Alexander C.			Excision of 5-halogenated uracils by human thymine DNA glycosylase - Robust activity for DNA contexts other than CpG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EOSINOPHIL PEROXIDASE; GENETIC TOXICOLOGY; HYPOCHLOROUS ACID; N-GLYCOSYLASE; HUMAN-CELLS; HELA-CELLS; MISMATCH; REPAIR	Thymine DNA glycosylase(TDG) excises thymine from G-T mispairs and removes a variety of damaged bases (X) with a preference for lesions in a CpG center dot X context. We recently reported that human TDG rapidly excises 5-halogenated uracils, exhibiting much greater activity for CpG center dot FU, CpG center dot CIU, and CpG center dot BrU than for CpG center dot T. Here we examine the effects of altering the CpG context on the excision activity for U, T, FU, CIU, and BrU. We show that the maximal activity (k(max)) for G-X substrates depends significantly on the 5' base pair. For example, k(max) decreases by 6-, 11-, and 82-fold for TpG center dot CIU, GpG center dot CIU, and ApG center dot CIU, respectively, as compared with CpG center dot CIU. For the other G center dot X substrates, the 5'-neighbor effects have a similar trend but vary in magnitude. The activity for G center dot FU, G center dot CIU, and G center dot BrU, with any 5'-flanking pair, meets and in most cases significantly exceeds the CpG center dot T activity. Strikingly, human TDG activity is reduced 10(2.3)-10(4.3)-fold for AX relative to G center dot X pairs and reduced further for A center dot X pairs with a 5' pair other than C center dot G. The effect of altering the 5' pair and/or the opposing base (G-X versus A center dot X) is greater for substrates that are larger (bromodeoxyuridine, dT) or have a more stable N-glycosidic bond (such as dT). The largest CpG context effects are observed for the excision of thymine. The potential role played by human TDG in the cytotoxic effects of CIU and BrU incorporation into DNA, which can occur under inflammatory conditions and in the cytotoxicity of FU, a widely used anticancer agent, are discussed.	Univ Maryland, Sch Med, Marlene & Stewart Greenbaum Canc Ctr, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Drohat, AC (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	adroh001@umaryland.edu		Drohat, Alex/0000-0002-7458-8770	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072711] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM072711-03, R01-GM72711, R01 GM072711-02, R01 GM072711-01, R01 GM072711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu M, 2003, J BIOL CHEM, V278, P8739, DOI 10.1074/jbc.M211084200; An Q, 2007, CANCER RES, V67, P940, DOI 10.1158/0008-5472.CAN-06-2960; Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bennett MT, 2006, J AM CHEM SOC, V128, P12510, DOI 10.1021/ja0634829; Brandon ML, 2000, MUTAT RES-DNA REPAIR, V459, P161, DOI 10.1016/S0921-8777(99)00061-0; Chen HJC, 2002, CHEM RES TOXICOL, V15, P262, DOI 10.1021/tx015578g; Cortazar D, 2007, DNA REPAIR, V6, P489, DOI 10.1016/j.dnarep.2006.10.013; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; Fasman G. D, 1975, CRC HDB BIOCH MOL BI, V3rd; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hardeland U, 2003, NUCLEIC ACIDS RES, V31, P2261, DOI 10.1093/nar/gkg344; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; HEARTLEIN MW, 1983, MUTAT RES, V107, P103, DOI 10.1016/0027-5107(83)90081-7; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; Henderson JP, 2001, BIOCHEMISTRY-US, V40, P2052, DOI 10.1021/bi002015f; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Jiang Q, 2003, J BIOL CHEM, V278, P32834, DOI 10.1074/jbc.M304021200; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P11236, DOI 10.1021/bi026226r; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; KUBAREVA EA, 1995, GENE, V157, P167, DOI 10.1016/0378-1119(94)00771-J; LASKEN RS, 1984, J BIOL CHEM, V259, P1491; LEATHERBARROW RJ, 1998, GRAFIT, V5; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu PF, 2003, DNA REPAIR, V2, P199, DOI 10.1016/S1568-7864(02)00198-2; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; McCann JAB, 2003, J BIOL CHEM, V278, P29587, DOI 10.1074/jbc.M212474200; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; MORRIS SM, 1993, MUTAT RES, V297, P39, DOI 10.1016/0165-1110(93)90006-9; MORRIS SM, 1991, MUTAT RES, V258, P161, DOI 10.1016/0165-1110(91)90007-I; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; O'Neill RJ, 2003, J BIOL CHEM, V278, P20526, DOI 10.1074/jbc.M210860200; ONEILL JP, 1983, MUTAT RES, V109, P259, DOI 10.1016/0027-5107(83)90051-9; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sansom OJ, 2003, ONCOGENE, V22, P7130, DOI 10.1038/sj.onc.1206850; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; SHAPIRO R, 1969, BIOCHEMISTRY-US, V8, P1806, DOI 10.1021/bi00833a004; SHAPIRO R, 1972, BIOCHEMISTRY-US, V11, P23, DOI 10.1021/bi00751a005; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; SOWERS LC, 1988, J BIOL CHEM, V263, P14794; Steinacher R, 2005, CURR BIOL, V15, P616, DOI 10.1016/j.cub.2005.02.054; TRAUTNER TA, 1962, P NATL ACAD SCI USA, V48, P449, DOI 10.1073/pnas.48.3.449; Turner DP, 2006, CANCER RES, V66, P7686, DOI 10.1158/0008-5472.CAN-05-4488; VANSCHEPDAEL A, 1993, J CHROMATOGR A, V657, P208, DOI 10.1016/0021-9673(93)83054-V; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Wibley JEA, 2003, MOL CELL, V11, P1647, DOI 10.1016/S1097-2765(03)00235-1; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Wilson DM, 2007, MUTAT RES-FUND MOL M, V616, P11, DOI 10.1016/j.mrfmmm.2006.11.017; Yoon JH, 2003, NUCLEIC ACIDS RES, V31, P5399, DOI 10.1093/nar/gkg730; YU H, 1993, J BIOL CHEM, V268, P15935	66	73	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27578	27586		10.1074/jbc.M704253200	http://dx.doi.org/10.1074/jbc.M704253200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17602166	Green Accepted, hybrid			2022-12-25	WOS:000249455600005
J	Hodges, AR; Krementsova, EB; Trybus, KM				Hodges, Alex R.; Krementsova, Elena B.; Trybus, Kathleen M.			Engineering the processive run length of myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAND-OVER-HAND; DYNACTIN INCREASES; WEAK BINDING; MOTOR; ACTIN; MECHANISM; DOMAIN; COORDINATION; MICROTUBULES; MAGNESIUM	The processive motor myosin V has a high affinity for actin in the weak binding states when compared with non-processive myosins. Here we test whether this feature is essential for myosin V to walk processively along an actin filament. The net charge of loop 2, a surface loop implicated in the initial weak binding between myosin and actin, was increased or decreased to correspondingly change the affinity of myosin V for actin in the weak binding state, without changing the velocity of movement. Processive run lengths of single molecules were determined by total internal reflection fluorescence microscopy. Reducing the net positive charge of loop 2 significantly decreased both the affinity of myosin V for actin and the processive run length. Conversely, the addition of positive charge to loop 2 increased actin affinity and processive run length. We hypothesize that a high affinity for actin allows the detached head of a stepping myosin V to find its next actin binding site more quickly, thus decreasing the probability of run termination.	Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Physiol & Mol Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078097] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38113] Funding Source: Medline; NIGMS NIH HHS [GM 078097] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali MY, 2007, P NATL ACAD SCI USA, V104, P4332, DOI 10.1073/pnas.0611471104; Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Culver-Hanlon TL, 2006, NAT CELL BIOL, V8, P264, DOI 10.1038/ncb1370; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; Dunn AR, 2007, NAT STRUCT MOL BIOL, V14, P246, DOI 10.1038/nsmb1206; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 2005, CELL MOL LIFE SCI, V62, P1462, DOI 10.1007/s00018-005-5015-5; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Krementsova EB, 2006, J BIOL CHEM, V281, P6079, DOI 10.1074/jbc.M510041200; LI SJ, 1992, J BIOL CHEM, V267, P855; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Purcell TJ, 2005, P NATL ACAD SCI USA, V102, P13873, DOI 10.1073/pnas.0506441102; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sellers JR, 2006, CURR OPIN CELL BIOL, V18, P68, DOI 10.1016/j.ceb.2005.12.014; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Uemura S, 2004, NAT STRUCT MOL BIOL, V11, P877, DOI 10.1038/nsmb806; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2005, NAT CELL BIOL, V7, P861, DOI 10.1038/ncb1287; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Volkmann N, 2005, MOL CELL, V19, P595, DOI 10.1016/j.molcel.2005.07.015; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Warshaw DM, 2005, BIOPHYS J, V88, pL30, DOI 10.1529/biophysj.105.061903; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	34	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27192	27197		10.1074/jbc.M703968200	http://dx.doi.org/10.1074/jbc.M703968200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640878	hybrid			2022-12-25	WOS:000249304900060
J	Wang, Q; Tullius, TD; Levin, JR				Wang, Qun; Tullius, Thomas D.; Levin, Judith R.			Effects of discontinuities in the DNA template on abortive initiation and promoter escape by Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; IN-VITRO; ELONGATION COMPLEXES; NONTEMPLATE STRAND; CHAIN INITIATION; BRANCHED PATHWAY; ALPHA-SUBUNIT; UPSTREAM DNA	Using singly gapped or nicked templates containing the T7A1 promoter, we have measured several kinetic parameters related to the process of transcription initiation by Escherichia coli RNA polymerase, confirming and extending previous results using a population of randomly gapped templates. A reduced probability of transcript abortion at RNA lengths of 6 and 7 nucleotides and a lower ratio of abortive to productive initiation events was observed for some discontinuous templates, consistent with models attributing abortive initiation to the accumulation of strain in the initiating complex. The effect of DNA discontinuity on abortion of shorter RNA transcripts (2 - 3 nucleotides) was less pronounced; abortion at these short chain lengths may primarily be attributed to the low stability of the RNA-DNA hybrid. Certain discontinuities had significant effects on the intrinsic catalytic capacity of the open complex and also on the partitioning between productive and unproductive complexes, suggesting that subtle changes in the conformation of the open complex can profoundly affect its function. The rate and efficiency of promoter escape were not correlated with the stability of the open promoter complex despite previous suggestions to the contrary. We conclude that the stability of the open promoter complex is only one of several factors that contribute to the overall rate of promoter escape.	Boston Univ, Goucher Coll, Dept Biol Sci & Chem, Baltimore, MD 21204 USA; Boston Univ, Dept Chem, Boston, MA 02215 USA	Boston University; Boston University	Levin, JR (corresponding author), Boston Univ, Goucher Coll, Dept Biol Sci & Chem, 1021 Dulaney Valley Rd, Baltimore, MD 21204 USA.	jlevin@goucher.edu	Tullius, Thomas D./A-9685-2008	Tullius, Thomas D./0000-0003-4425-796X	NIGMS NIH HHS [GM 41930, R01 GM041930-14, R01 GM041930] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041930] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; Balasubramanian B, 1998, P NATL ACAD SCI USA, V95, P9738, DOI 10.1073/pnas.95.17.9738; Bar-Nahum G, 2001, CELL, V106, P443, DOI 10.1016/S0092-8674(01)00461-5; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Brodolin K, 2005, J MOL BIOL, V350, P930, DOI 10.1016/j.jmb.2005.05.048; BURNS H, 1994, NUCLEIC ACIDS RES, V22, P3840, DOI 10.1093/nar/22.19.3840; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Davis CA, 2005, P NATL ACAD SCI USA, V102, P285, DOI 10.1073/pnas.0405779102; ELLINGER T, 1994, J MOL BIOL, V239, P466, DOI 10.1006/jmbi.1994.1389; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; Grove A, 2002, EMBO J, V21, P704, DOI 10.1093/emboj/21.4.704; Guo H, 2003, P NATL ACAD SCI USA, V100, P3743, DOI 10.1073/pnas.0737062100; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Hochheimer YB, 2005, P NATL ACAD SCI USA, V102, P1157, DOI 10.1073/pnas.0408973102; Hsu LM, 2006, BIOCHEMISTRY-US, V45, P8841, DOI 10.1021/bi060247u; Hsu LLM, 2003, BIOCHEMISTRY-US, V42, P3777, DOI 10.1021/bi026954e; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; JOHNSON J, 1996, THESIS J HOPKINS U B; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; Kapanidis AN, 2006, SCIENCE, V314, P1144, DOI 10.1126/science.1131399; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Levin JR, 2000, J BIOL CHEM, V275, P6885, DOI 10.1074/jbc.275.10.6885; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MCMAHAN SA, 1994, BIOCHEMISTRY-US, V33, P12092, DOI 10.1021/bi00206a012; MILLS JB, 1994, BIOCHEMISTRY-US, V33, P1797, DOI 10.1021/bi00173a024; Mukhopadhyay J, 2001, CELL, V106, P453, DOI 10.1016/S0092-8674(01)00464-0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Roberts CW, 1996, CELL, V86, P495; Ross W, 2005, P NATL ACAD SCI USA, V102, P291, DOI 10.1073/pnas.0405814102; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; Susa M, 2002, J BIOL CHEM, V277, P15407, DOI 10.1074/jbc.M112481200; UPTAIN SM, 1997, STRUCTURAL FUNCTIONA; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Vo NV, 2003, BIOCHEMISTRY-US, V42, P3798, DOI 10.1021/bi026962v; Vo NV, 2003, BIOCHEMISTRY-US, V42, P3787, DOI 10.1021/bi0269613; Wang KY, 1997, BIOCHEMISTRY-US, V36, P11629, DOI 10.1021/bi971464l; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; Zaychikov E, 1997, J BIOL CHEM, V272, P2259	56	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26917	26927		10.1074/jbc.M702473200	http://dx.doi.org/10.1074/jbc.M702473200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650506	hybrid			2022-12-25	WOS:000249304900031
J	Mikolajczyk, J; Drag, M; Bekes, M; Cao, JT; Ronai, Z; Salvesen, GS				Mikolajczyk, Jowita; Drag, Marcin; Bekes, Miklos; Cao, John T.; Ronai, Ze'ev; Salvesen, Guy S.			Small ubiquitin-related modifier (SUMO)-specific proteases - Profiling the specificities and activities of human SENPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO-SPECIFIC PROTEASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; COMPLEX; FAMILY; PROTEINS; DEN1; MATURATION; ENZYMES; NEDD8	SENPs are proteases that participate in the regulation of SUMOylation by generating mature small ubiquitin-related modifiers ( SUMO) for protein conjugation ( endopeptidase activity) and removing conjugated SUMO from targets ( isopeptidase activity). Using purified recombinant catalytic domains of 6 of the 7 human SENPs, we demonstrate the specificity of their respective activities on SUMO-1, -2, and -3. The primary mode of recognition of substrates is via the SUMO domain, and the C-terminal tails direct endopeptidase specificity. Broadly speaking, SENP1 is the most efficient endopeptidase, whereas SENP2 and -5-7 have substantially higher isopeptidase than endopeptidase activities. We developed fluorogenic tetrapeptide substrates that are cleaved by SENPs, enabling us to characterize the environmental profiles of each enzyme. Using these synthetic substrates we reveal that the SUMO domain enhances catalysis of SENP1, -2, -5,-6, and -7, demonstrating substrate-induced activation of SENPs by SUMOs.	Burnham Inst Med Res, Program Apoptosis, La Jolla, CA 92037 USA; Burnham Inst Med Res, Program Cell Death Res, La Jolla, CA 92037 USA; Burnham Inst Med Res, Program Signal Transduct, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92093 USA; Wroclaw Tech Univ, Fac Chem, Div Med Chem & Microbiol, PL-50370 Wroclaw, Poland	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; Wroclaw University of Science & Technology	Mikolajczyk, J (corresponding author), Burnham Inst Med Res, Program Apoptosis, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jowita@burnham.org; gsalvesen@burnham.org		RONAI, ZEEV/0000-0002-3859-0400	NIAID NIH HHS [U01 AI061139] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061139] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Avvakumov GV, 2006, J BIOL CHEM, V281, P38061, DOI 10.1074/jbc.M606704200; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; Das C, 2006, P NATL ACAD SCI USA, V103, P4675, DOI 10.1073/pnas.0510403103; Di Bacco A, 2006, MOL CELL BIOL, V26, P4489, DOI 10.1128/MCB.02301-05; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Huang XY, 2001, BIOCHEMISTRY-US, V40, P11734, DOI 10.1021/bi010364j; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; LAEMMLI UK, 1974, VIROLOGY, V62, P483, DOI 10.1016/0042-6822(74)90409-7; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Mukhopadhyay D, 2006, J CELL BIOL, V174, P939, DOI 10.1083/jcb.200510103; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Renatus M, 2006, STRUCTURE, V14, P1293, DOI 10.1016/j.str.2006.06.012; Reverter D, 2005, J MOL BIOL, V345, P141, DOI 10.1016/j.jmb.2004.10.022; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Reverter D, 2006, NAT STRUCT MOL BIOL, V13, P1060, DOI 10.1038/nsmb1168; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; Shen LN, 2006, BIOCHEM J, V397, P279, DOI 10.1042/BJ20052030; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Wilson VG, 2005, SCI STKE, ppe32; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Xu Z, 2005, BIOCHEM J, V386, P325, DOI 10.1042/BJ20041210; Xu Z, 2006, BIOCHEM J, V398, P345, DOI 10.1042/BJ20060526; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	38	117	125	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26217	26224		10.1074/jbc.M702444200	http://dx.doi.org/10.1074/jbc.M702444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17591783	hybrid			2022-12-25	WOS:000249239600026
J	Barton, S; Jacak, R; Khare, SD; Ding, F; Dokholyan, NV				Barton, Sunjay; Jacak, Ron; Khare, Sagar D.; Ding, Feng; Dokholyan, Nikolay V.			The length dependence of the PolyQ-mediated protein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ENSEMBLE; MOLECULAR-DYNAMICS METHOD; NEURODEGENERATIVE DISEASES; POLYGLUTAMINE AGGREGATION; HUNTINGTONS-DISEASE; MONOMERIC POLYGLUTAMINE; FOLDING SIMULATIONS; GLUTAMINE REPEATS; MUTANT HUNTINGTIN; NEURONAL DEATH	Polyglutamine ( polyQ) repeat disorders are caused by the expansion of CAG tracts in certain genes, resulting in transcription of proteins with abnormally long polyQ inserts. When these inserts expand beyond 35-45 glutamines, affected proteins form toxic aggregates, leading to neuron death. Chymotrypsin inhibitor 2 ( CI2) with an inserted glutamine repeat has previously been used to model polyQ-mediated aggregation in vitro. However, polyQ insertion lengths in these studies have been kept below the pathogenic threshold. We perform molecular dynamics simulations to study monomer folding dynamics and dimer formation in CI2-polyQ chimeras with insertion lengths of up to 80 glutamines. Our model recapitulates the experimental results of previous studies of chimeric CI2 proteins, showing high folding cooperativity of monomers as well as protein association via domain swapping. Surprisingly, for chimeras with insertion lengths above the pathogenic threshold, monomer folding cooperativity decreases and the dominant mode for dimer formation becomes interglutamine hydrogen bonding. These results support a mechanism for pathogenic polyQ-mediated aggregation, in which expanded polyQ tracts destabilize affected proteins and promote the formation of partially unfolded intermediates. These unfolded intermediates form aggregates through associations by interglutamine interactions.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Swarthmore Coll, Dept Chem & Biochem, Swarthmore, PA 19081 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; Swarthmore College; University of Washington; University of Washington Seattle	Dokholyan, NV (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	dokh@med.unc.edu	Ding, Feng/G-6029-2011; Dokholyan, Nikolay/D-8081-2018; Dokholyan, Nikolay/B-2238-2009	Ding, Feng/0000-0003-1850-6336; Dokholyan, Nikolay/0000-0002-8225-4025; Dokholyan, Nikolay/0000-0002-8225-4025; Barton, Sunjay/0000-0001-7526-5845				Allen M. P., 1987, COMPUTER SIMULATIONS; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bhattacharyya AM, 2005, P NATL ACAD SCI USA, V102, P15400, DOI 10.1073/pnas.0501651102; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen YW, 1999, P NATL ACAD SCI USA, V96, P1257, DOI 10.1073/pnas.96.4.1257; Crick SL, 2006, P NATL ACAD SCI USA, V103, P16764, DOI 10.1073/pnas.0608175103; Ding F, 2006, STRUCTURE, V14, P5, DOI 10.1016/j.str.2005.09.008; Ding F, 2005, J MOL BIOL, V350, P1035, DOI 10.1016/j.jmb.2005.05.017; Ding F, 2005, BIOPHYS J, V88, P147, DOI 10.1529/biophysj.104.046375; Ding F, 2002, BIOPHYS J, V83, P3525, DOI 10.1016/S0006-3495(02)75352-6; Dokholyan NV, 1998, FOLD DES, V3, P577, DOI 10.1016/S1359-0278(98)00072-8; Finke JM, 2004, BIOPHYS J, V87, P1900, DOI 10.1529/biophysj.104.041533; Gordon-Smith DJ, 2001, BIOCHEM BIOPH RES CO, V280, P855, DOI 10.1006/bbrc.2000.4196; Hansmann UHE, 2002, INT J QUANTUM CHEM, V90, P1515, DOI 10.1002/qua.10352; Hansmann UHE, 2002, COMPUT PHYS COMMUN, V147, P604, DOI 10.1016/S0010-4655(02)00331-4; Khare SD, 2005, PLOS COMPUT BIOL, V1, P230, DOI 10.1371/journal.pcbi.0010030; Khoshnan A, 2002, P NATL ACAD SCI USA, V99, P1002, DOI 10.1073/pnas.022631799; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Ladurner AG, 1997, J MOL BIOL, V273, P330, DOI 10.1006/jmbi.1997.1304; PERUTZ MF, 1993, CURR BIOL, V3, P249, DOI 10.1016/0960-9822(93)90174-M; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5596, DOI 10.1073/pnas.042681599; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; RAPAPORT DC, 1997, ART MOL DYNAMICS SIM, P391; Rhee YM, 2003, BIOPHYS J, V84, P775, DOI 10.1016/S0006-3495(03)74897-8; Riley BE, 2006, GENE DEV, V20, P2183, DOI 10.1101/gad.1436506; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Smith SW, 1997, J COMPUT PHYS, V134, P16, DOI 10.1006/jcph.1996.5510; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Sugita Y, 1999, CHEM PHYS LETT, V314, P141, DOI 10.1016/S0009-2614(99)01123-9; Wang XL, 2006, PROTEINS, V63, P297, DOI 10.1002/prot.20761; Yang SC, 2004, P NATL ACAD SCI USA, V101, P13786, DOI 10.1073/pnas.0403724101; Zhou RH, 2001, P NATL ACAD SCI USA, V98, P14931, DOI 10.1073/pnas.201543998	37	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25487	25492		10.1074/jbc.M701600200	http://dx.doi.org/10.1074/jbc.M701600200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17591778	Green Published, hybrid			2022-12-25	WOS:000249014100034
J	Suzuki, S; Singhirunnusorn, P; Mori, A; Yamaoka, S; Kitajima, I; Saiki, I; Sakurai, H				Suzuki, Shunsuke; Singhirunnusorn, Pattama; Mori, Akinori; Yamaoka, Shoji; Kitajima, Isao; Saiki, Ikuo; Sakurai, Hiroaki			Constitutive activation of TAK1 by HTLV-1 tax-dependent overexpression of TAB2 induces activation of JNK-ATF2 but not IKK-NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; MEDIATED ACTIVATION; TERMINAL KINASE; PROTEIN; PATHWAY; IL-1; COMPLEXES; MEMBRANE; CATENIN; TRAF6	HTLV-1 Tax oncoprotein induces persistent activation of the transcription factor NF-kappa B and CREB (cAMP-response element-binding protein)/ATF. Transforming growth factor-beta-activated kinase 1 (TAK1) has been shown to play a critical role in these transcription factors. Here, we found that TAK1 was constitutively activated in Tax-positive HTLV-1-transformed T cells. Tax induced persistent overexpression of TAK1-binding protein 2 ( TAB2), but not TAB3, which is essential for TAK1 activation. Surprisingly, TAK1 was not involved in the activation of NF-kappa B. On the other hand, JNK and p38 mitogen-activated protein kinases were activated by TAK1. In addition, ATF2, but not CREB, was a target for the TAK1-JNK pathway, and p38 negatively regulated TAK1 activity through TAB1 phosphorylation. These results indicate that Tax-mediated TAK1 activation is important for the activation of ATF2 rather than NF-kappa B.	Toyama Univ, Inst Nat Med, Dic Pathogen Biochem, Toyama 9300194, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Tokyo 1138519, Japan; Toyama Univ, Dept Clin & Mol Pathol, Grad Sch Med & Pharmaceut Sci, Toyama 9300194, Japan; Toyama Univ, 21st Century Ctr Excellence Program, Toyama 9300194, Japan	University of Toyama; Tokyo Medical & Dental University (TMDU); University of Toyama; University of Toyama	Sakurai, H (corresponding author), Toyama Univ, Inst Nat Med, Dic Pathogen Biochem, 2630 Sugitani, Toyama 9300194, Japan.	hsakurai@inm.u-toyama.ac.jp	Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Gohda J, 2007, BIOCHEM BIOPH RES CO, V357, P225, DOI 10.1016/j.bbrc.2007.03.125; Hong S, 2007, J BIOL CHEM, V282, P12119, DOI 10.1074/jbc.M610392200; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Liu HH, 2006, P NATL ACAD SCI USA, V103, P11677, DOI 10.1073/pnas.0603089103; Miura H, 2005, EXP CELL RES, V308, P29, DOI 10.1016/j.yexcr.2005.04.005; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sato S, 2006, INT IMMUNOL, V18, P1405, DOI 10.1093/intimm/dxl082; Schlessinger J, 2006, CELL, V127, P45, DOI 10.1016/j.cell.2006.09.013; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Uemura N, 2006, J BIOL CHEM, V281, P7863, DOI 10.1074/jbc.M509834200; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wu XF, 2007, EMBO REP, V8, P510, DOI 10.1038/sj.embor.7400931; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	32	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25177	25181		10.1074/jbc.C700065200	http://dx.doi.org/10.1074/jbc.C700065200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17626013	hybrid			2022-12-25	WOS:000249014100002
J	Zhang, W; Watanabe, K; Wang, CCC; Tang, Y				Zhang, Wenjun; Watanabe, Kenji; Wang, Clay C. C.; Tang, Yi			Investigation of early tailoring reactions in the oxytetracycline biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II POLYKETIDE SYNTHASE; ENGINEERED BIOSYNTHESIS; STREPTOMYCES-RIMOSUS; GENE-CLUSTER; HETEROLOGOUS EXPRESSION; ANTIBIOTIC MITHRAMYCIN; AKLANONIC ACID; FATTY-ACID; TETRACYCLINES; CYCLIZATION	Tetracyclines are aromatic polyketides biosynthesized by bacterial type II polyketide synthases. The amidated tetracycline backbone is biosynthesized by the minimal polyketide synthases and an amidotransferase homologue OxyD. Biosynthesis of the key intermediate 6-methylpretetramid requires two early tailoring steps, which are cyclization of the linearly fused tetracyclic scaffold and regioselective C-methylation of the aglycon. Using a heterologous host (CH999)/ vector pair, we identified the minimum set of enzymes from the oxytetracycline biosynthetic pathway that is required to afford 6-methylpretetramid in vivo. Only two cyclases (OxyK and OxyN) are necessary to completely cyclize and aromatize the amidated tetracyclic aglycon. Formation of the last ring via C-1/C-18 aldol condensation does not require a dedicated fourth-ring cyclase, in contrast to the biosynthetic mechanism of other tetracyclic aromatic polyketides, such as daunorubicin and tetracenomycin. Acetyl-derived polyketides do not undergo spontaneous fourth- ring cyclization and form only anthracene carboxylic acids as demonstrated both in vivo and in vitro. OxyF was identified to be the C-6 C-methyltransferase that regioselectively methylates pretetramid to yield 6-methylpretetramid. Reconstitution of 6-methylpretetramid in a heterologous host sets the stage for a more systematic investigation of additional tetracycline downstream tailoring enzymes and is a key step toward the engineered biosynthesis of tetracycline analogs.	Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA; Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA	University of California System; University of California Los Angeles; University of Southern California	Tang, Y (corresponding author), Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA.	yitang@ucla.edu	Watanabe, Kenji/N-2012-2015; Wang, Clay/ABG-9056-2021	Watanabe, Kenji/0000-0002-0463-4831; Wang, Clay/0000-0003-2955-7569	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075857] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM75857] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Bililign T, 2004, CHEM BIOL, V11, P959, DOI 10.1016/j.chembiol.2004.04.016; BUTLER MJ, 1990, DEV IND MICROBIOL, V31, P41; Deseo MA, 2005, J ANTIBIOT, V58, P822, DOI 10.1038/ja.2005.110; ECKARDT K, 1985, J ANTIBIOT, V38, P1034, DOI 10.7164/antibiotics.38.1034; Hautala A, 2003, J ANTIBIOT, V56, P143, DOI 10.7164/antibiotics.56.143; Hertweck C, 2004, CHEM BIOL, V11, P461, DOI 10.1016/j.chembiol.2004.03.018; Hertweck C, 2007, NAT PROD REP, V24, P162, DOI 10.1039/b507395m; Hopwood D. A., 1985, GENETIC MANIPULATION; Hunter I. S., 2002, MICROBIAL SECONDARY, P141; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Jakobi K, 2004, J AM CHEM SOC, V126, P2298, DOI 10.1021/ja0390698; Kantola J, 2000, MICROBIOL-UK, V146, P155, DOI 10.1099/00221287-146-1-155; Kendrew SG, 1999, BIOCHEMISTRY-US, V38, P4794, DOI 10.1021/bi9827924; KIM ES, 1994, GENE, V141, P141, DOI 10.1016/0378-1119(94)90144-9; Korman TP, 2004, BIOCHEMISTRY-US, V43, P14529, DOI 10.1021/bi048133a; Kunzel E, 1997, CHEM-EUR J, V3, P1675, DOI 10.1002/chem.19970031017; Lee TS, 2005, J AM CHEM SOC, V127, P12254, DOI 10.1021/ja051429z; Lombo F, 2000, ANGEW CHEM INT EDIT, V39, P796, DOI 10.1002/(SICI)1521-3773(20000218)39:4<796::AID-ANIE796>3.0.CO;2-N; Lomovskaya N, 1998, J BACTERIOL, V180, P2379, DOI 10.1128/JB.180.9.2379-2386.1998; Lozano MJF, 2000, J BIOL CHEM, V275, P3065, DOI 10.1074/jbc.275.5.3065; MCCORMICK JR, 1965, J AM CHEM SOC, V87, P1794, DOI 10.1021/ja01086a034; MCCORMICK JR, 1968, J AM CHEM SOC, V90, P2201, DOI 10.1021/ja01010a063; MCCORMICK JR, 1969, J AM CHEM SOC, V91, P206, DOI 10.1021/ja01029a046; MCCORMICK JR, 1968, J AM CHEM SOC, V90, P7126, DOI 10.1021/ja01027a045; MCCORMICK JR, 1968, J AM CHEM SOC, V90, P7127, DOI 10.1021/ja01027a046; MCCORMICK JR, 1965, J AM CHEM SOC, V87, P1793, DOI 10.1021/ja01086a033; MCCORMICK JRD, 1963, J AM CHEM SOC, V85, P1692, DOI 10.1021/ja00894a037; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MCDOWALL KJ, 1990, GENETICS PRODUCT FOR, P105; Peric-Concha N, 2005, J BIOL CHEM, V280, P37455, DOI 10.1074/jbc.M503191200; Petkovic H, 1999, J BIOL CHEM, V274, P32829; Petkovic H, 2006, MICROBIOL MOL BIOL R, V70, P704, DOI 10.1128/MMBR.00004-06; Prado L, 1999, MOL GEN GENET, V261, P216, DOI 10.1007/s004380050960; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Rohr J, 1998, CHEM COMMUN, P437, DOI 10.1039/a707446h; SCHUMACHER RW, 1995, J NAT PROD, V58, P613, DOI 10.1021/np50118a024; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; Tang Y, 2004, PLOS BIOL, V2, P227, DOI 10.1371/journal.pbio.0020031; Thompson TB, 2004, J BIOL CHEM, V279, P37956, DOI 10.1074/jbc.M406144200; Winter JM, 2007, J BIOL CHEM, V282, P16362, DOI 10.1074/jbc.M611046200; Wohlert SE, 2001, J NAT PROD, V64, P1077, DOI 10.1021/np010067f; Xu Z, 2007, J AM CHEM SOC, V129, P6022, DOI 10.1021/ja069045b; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; Zawada RJX, 1999, CHEM BIOL, V6, P607; Zhang WJ, 2006, J NAT PROD, V69, P1633, DOI 10.1021/np060290i; Zhang WJ, 2006, APPL ENVIRON MICROB, V72, P2573, DOI 10.1128/AEM.72.4.2573-2580.2006	49	50	55	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25717	25725		10.1074/jbc.M703437200	http://dx.doi.org/10.1074/jbc.M703437200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17631493	hybrid			2022-12-25	WOS:000249014100059
J	Eisenmann, KM; West, RA; Hildebrand, D; Kitchen, SM; Peng, J; Sigler, R; Zhang, J; Siminovitch, KA; Alberts, AS				Eisenmann, Kathryn M.; West, Richard A.; Hildebrand, Dagmar; Kitchen, Susan M.; Peng, Jun; Sigler, Robert; Zhang, Jinyi; Siminovitch, Katherine A.; Alberts, Arthur S.			T cell responses in mammalian diaphanous-related formin mDia1 knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN; IMMUNOLOGICAL SYNAPSE; AUTOREGULATORY DOMAIN; ACTIN-POLYMERIZATION; MIGRATING CELLS; HUMAN HOMOLOG; ACTIVATION; RHOA; CYTOSKELETON	Activated T cells rapidly assemble filamentous ( F-) actin networks in response to ligation of the T cell receptor or upon interaction with adhesive stimuli in order to facilitate cell migration and the formation of the immune synapse. Branched filament assembly is crucial for this process and is dependent upon activation of the Arp2/3 complex by the actin nucleation- promoting factor Wiskott-Aldrich Syndrome protein ( WASp). Genetic disruption of the WAS gene has been linked to hematopoietic malignancies and various cytopenias. Although the contributions of WASp and Arp2/3 to T cell responses are fairly well characterized, the role of the mammalian Diaphanous ( mDia)related formins, which both nucleate and processively elongate non-branched F- actin, has not been demonstrated. Here, we report the effects on T cell development and function following the knock out of the murine Drf1 gene encoding the canonical formin p140mDia1. Drf1(-/-) mice develop lymphopenia characterized by diminished T cell populations in lymphoid tissues. Consistent with a role for p140mDia1 in the regulation of the actin cytoskeleton, isolated Drf1(-/-) splenic T cells adhered poorly to extracellular matrix proteins and migration in response to chemotactic stimuli was completely abrogated. Both integrin and chemokine receptor expression was unaffected by Drf1 (-/-) targeting. In response to proliferative stimuli, both thymic and splenic Drf1 (-/-) T cells failed to proliferate; ERK1/2 activation was also diminished in activated Drf1(-/-) T cells. These data suggest a central role for p140mDia1 in vivo in dynamic cytoskeletal remodeling events driving normal T cell responses.	Van Andel Res Inst, Lab Cell Structure & Signal Integrat, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Flow Cytometry Core Facil, Grand Rapids, MI 49503 USA; Div Pfizer, Esper Therapeut, Ann Arbor, MI 48108 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Toranomon Gen Hosp, Res Inst, Toronto, ON M5G 1X5, Canada	Van Andel Institute; Van Andel Institute; Pfizer; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Alberts, AS (corresponding author), Van Andel Res Inst, Lab Cell Structure & Signal Integrat, 333 Bostwick Ave,N E, Grand Rapids, MI 49503 USA.	art.alberts@vai.org	Siminovitch, Katherine/K-1475-2013	Eisenmann, Kathryn/0000-0002-5337-5928; West, Richard/0000-0003-1459-0825	NATIONAL CANCER INSTITUTE [R21CA107529] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA107529] Funding Source: Medline; NIGMS NIH HHS [F32 GM723313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Badour K, 2003, IMMUNOL REV, V192, P98, DOI 10.1034/j.1600-065X.2003.00031.x; Badour K, 2003, IMMUNITY, V18, P141, DOI 10.1016/S1074-7613(02)00516-2; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; Butler B, 2006, CURR BIOL, V16, P242, DOI 10.1016/j.cub.2005.12.033; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Eisenmann Kathryn M, 2005, Novartis Found Symp, V269, P206; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Gomez TS, 2007, IMMUNITY, V26, P177, DOI 10.1016/j.immuni.2007.01.008; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; Huang YP, 2004, J BIOL CHEM, V279, P28827, DOI 10.1074/jbc.R400012200; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kovar DR, 2006, CURR OPIN CELL BIOL, V18, P11, DOI 10.1016/J.CEB.2005.12.011; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Lacout C, 2003, BLOOD, V102, P1282, DOI 10.1182/blood-2002-07-2099; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Maillard MH, 2007, J EXP MED, V204, P381, DOI 10.1084/jem.20061338; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Nicholson-Dykstra S, 2005, CURR BIOL, V15, pR346, DOI 10.1016/j.cub.2005.04.029; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Snapper SB, 2003, NEW ENGL J MED, V348, P350, DOI 10.1056/NEJMcibr001155; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Vicente-Manzanares M, 2003, J IMMUNOL, V171, P1023, DOI 10.4049/jimmunol.171.2.1023; Vielkind S, 2005, J IMMUNOL, V175, P350, DOI 10.4049/jimmunol.175.1.350; Wallar BJ, 2006, J BIOL CHEM, V281, P4300, DOI 10.1074/jbc.M510277200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wallar BJ, 2007, EXP CELL RES, V313, P560, DOI 10.1016/j.yexcr.2006.10.033; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Zhang H, 2006, IMMUNITY, V25, P285, DOI 10.1016/j.immuni.2006.06.014; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329	46	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25152	25158		10.1074/jbc.M703243200	http://dx.doi.org/10.1074/jbc.M703243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17595162	hybrid			2022-12-25	WOS:000248933000070
J	Xu, SB; Witmer, PD; Lumayag, S; Kovacs, B; Valle, D				Xu, Shunbin; Witmer, P. Dane; Lumayag, Stephen; Kovacs, Beatrix; Valle, David			MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MAMMALIAN CIRCADIAN CLOCK; MESSENGER-RNA EXPRESSION; REGULATORY FACTOR-X; KINASE I-EPSILON; INNER-EAR; GENOMIC SCREEN; C-ELEGANS; CELL-DIFFERENTIATION; HEARING-LOSS; GENE CHX10	Although microRNAs ( miRNAs) provide a newly recognized level of regulation of gene expression, the miRNA transcriptome of the retina and the contributions of miRNAs to retinal development and function are largely unknown. To begin to understand the functions of miRNAs in retina, we compared miRNA expression profiles in adult mouse retina, brain, and heart by microarray analysis. Our results show that at least 78 miRNAs are expressed in adult mouse retina, 21 of which are potentially retina-specific. Among these, we identified a polycistronic, sensory organ-specific paralogous miRNA cluster that includes miR- 96, miR- 182, and miR- 183 on mouse chromosome 6qA3 with conservation of synteny to human chromosome 7q32.2. In situ hybridization showed that members of this cluster are expressed in photoreceptors, retinal bipolar and amacrine cells. Consistent with their genomic organization, these miRNAs have a similar expression pattern during development with abundance increasing postnatally and peaking in adult retina. Target prediction and in vitro functional studies showed that MITF, a transcription factor required for the establishment and maintenance of retinal pigmented epithelium, is a direct target of miR- 96 and miR- 182. Additionally, to identify miRNAs potentially involved in circadian rhythm regulation of the retina, we performed miRNA expression profiling with retinal RNA harvested at noon ( Zeitgeber time 5) and midnight ( Zeitgeber time 17) and identified a subgroup of 12 miRNAs, including members of the miR- 183/ 96/ 182 cluster with diurnal variation in expression pattern. Our results suggest that miR- 96 and miR- 182 are involved in circadian rhythm regulation, perhaps by modulating the expression of adenylyl cyclase VI ( ADCY6).	Rush Univ, Med Ctr, Dept Ophthalmol & Neurol Sci, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Ophthalmol & Neurol Sci, Chicago, IL 60632 USA; Johns Hopkins Univ Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Johns Hopkins Univ Sch Med, Predoctoral Training Program Human Genet, Baltimore, MD 21205 USA	Rush University; Rush University; Johns Hopkins University; Johns Hopkins University	Valle, D (corresponding author), Rush Univ, Med Ctr, Dept Ophthalmol & Neurol Sci, 1735 W Harrison St 318, Chicago, IL 60612 USA.	dvalle@jhmi.edu			NEI NIH HHS [T32EY07143] Funding Source: Medline; NIGMS NIH HHS [5T32GM07814] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; [Anonymous], 2005, J BIOL CHEM, DOI DOI 10.1074/jbc.M502716200; Barrett S, 1999, AM J MED GENET, V88, P609; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baumer N, 2003, DEVELOPMENT, V130, P2903, DOI 10.1242/dev.00450; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Cepko CL, 2000, METHOD ENZYMOL, V327, P118, DOI 10.1016/S0076-6879(00)27272-8; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Coogan AN, 2003, J NEUROSCI, V23, P3085; Deng M, 2006, GENE EXPR PATTERNS, V6, P857, DOI 10.1016/j.modgep.2006.02.005; Dubruille R, 2002, DEVELOPMENT, V129, P5487, DOI 10.1242/dev.00148; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Fritzsch B, 2001, DEV GENES EVOL, V211, P388, DOI 10.1007/s004270100166; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hagmann M, 1995, NUCLEIC ACIDS RES, V23, P4978, DOI 10.1093/nar/23.24.4978; Han S, 2005, J BIOL CHEM, V280, P38228, DOI 10.1074/jbc.M508130200; Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816; Higashide T, 2005, AM J OPHTHALMOL, V139, P203, DOI 10.1016/j.ajo.2004.07.021; Hipfner DR, 2002, GENETICS, V161, P1527; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOLLAND VF, 1989, J COMP NEUROL, V279, P13, DOI 10.1002/cne.902790103; Holt JR, 2002, CELL, V108, P371, DOI 10.1016/S0092-8674(02)00629-3; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Horsford DJ, 2005, DEVELOPMENT, V132, P177, DOI 10.1242/dev.01571; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Huang YJ, 2005, J NEUROSCI, V25, P843, DOI 10.1523/JNEUROSCI.4446-04.2005; HWANG PM, 1990, P NATL ACAD SCI USA, V87, P7395, DOI 10.1073/pnas.87.19.7395; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kamphuis W, 2005, BIOCHEM BIOPH RES CO, V330, P18, DOI 10.1016/j.bbrc.2005.02.118; Karali M, 2007, INVEST OPHTH VIS SCI, V48, P509, DOI 10.1167/iovs.06-0866; Kern JK, 2007, AUTISM, V11, P123, DOI 10.1177/1362361307075702; Kern JK, 2006, AUTISM, V10, P480, DOI 10.1177/1362361306066564; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kozmik Z, 2003, DEV CELL, V5, P773, DOI 10.1016/S1534-5807(03)00325-3; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Krutzfeldt J, 2006, NAT GENET, V38, pS14, DOI 10.1038/ng1799; Kwak SJ, 2006, DEV DYNAM, V235, P3026, DOI 10.1002/dvdy.20961; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lamb JA, 2005, J MED GENET, V42, P132, DOI 10.1136/jmg.2004.025668; Lanjuin A, 2003, DEV CELL, V5, P621, DOI 10.1016/S1534-5807(03)00293-4; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li X, 2005, CELL, V123, P1267, DOI 10.1016/j.cell.2005.10.040; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma KW, 2006, J BIOL CHEM, V281, P21250, DOI 10.1074/jbc.M600521200; Makarev E, 2006, MOL VIS, V12, P1386; Martinez-Morales JR, 2001, DEVELOPMENT, V128, P2019; Michalski N, 2007, J NEUROSCI, V27, P6478, DOI 10.1523/JNEUROSCI.0342-07.2007; Modamio-Hoybjor S, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.012500; Morsli H, 1999, DEVELOPMENT, V126, P2335; Morsli H, 1998, J NEUROSCI, V18, P3327; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; O'Brien EK, 2003, EVOL DEV, V5, P572, DOI 10.1046/j.1525-142X.2003.03062.x; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Peters LM, 2002, HUM MOL GENET, V11, P2877, DOI 10.1093/hmg/11.23.2877; Philippe A, 1999, HUM MOL GENET, V8, P805, DOI 10.1093/hmg/8.5.805; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Risch N, 1999, AM J HUM GENET, V65, P493, DOI 10.1086/302497; Rowan S, 2004, DEVELOPMENT, V131, P5139, DOI 10.1242/dev.01300; Ruan GX, 2006, P NATL ACAD SCI USA, V103, P9703, DOI 10.1073/pnas.0601940103; Ryan D, 2006, MOL VIS, V12, P1175; Sato TK, 2004, NEURON, V43, P527, DOI 10.1016/j.neuron.2004.07.018; Schellenberg GD, 2006, MOL PSYCHIATR, V11, P1049, DOI 10.1038/sj.mp.4001874; Schwarz M, 2000, DEVELOPMENT, V127, P4325; Shao YJ, 2002, AM J MED GENET, V114, P99, DOI 10.1002/ajmg.10153; Sontheimer EJ, 2005, CELL, V122, P9, DOI 10.1016/j.cell.2005.06.030; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Torres MA, 1996, DEVELOPMENT, V122, P3381; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Vandaele C, 2001, MECH DEVELOP, V103, P159, DOI 10.1016/S0925-4773(01)00340-9; Wada H, 1998, DEVELOPMENT, V125, P1113; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; Weston MD, 2006, BRAIN RES, V1111, P95, DOI 10.1016/j.brainres.2006.07.006; Wicker R, 2000, BBA-GENE STRUCT EXPR, V1493, P279, DOI 10.1016/S0167-4781(00)00187-1; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xu SB, 2004, MOL CELL BIOL, V24, P9137, DOI 10.1128/MCB.24.20.9137-9151.2004; Xu Y, 2007, CELL, V128, P59, DOI 10.1016/j.cell.2006.11.043; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; YOUNG RW, 1985, DEV BRAIN RES, V21, P229, DOI 10.1016/0165-3806(85)90211-1; Yu RT, 2000, P NATL ACAD SCI USA, V97, P2621, DOI 10.1073/pnas.050566897; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	117	375	428	3	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25053	25066		10.1074/jbc.M700501200	http://dx.doi.org/10.1074/jbc.M700501200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17597072	hybrid			2022-12-25	WOS:000248933000061
J	Voelkl, B; Huber, L				Voelkl, Bernhard; Huber, Ludwig			Imitation as Faithful Copying of a Novel Technique in Marmoset Monkeys	PLOS ONE			English	Article							CHIMPANZEES PAN-TROGLODYTES; MOVEMENT IMITATION	Imitative learning has received great attention due to its supposed role in the development of culture and the cognitive demands it poses on the individual. Evidence for imitation in non-human primate species, therefore, could shed light on the early origins of proto-cultural traits in the primate order. Imitation has been defined as the learning of an act by seeing it done or, more specifically, as the copying of a novel or otherwise improbable act. But despite a century of research and the detection of mirror neurons the empirical basis for this most advanced form of observational learning is weak. Few, if any, studies have shown that the observer has learned the response topography, i.e., the specific action by which the response is made. In an experimental set-up we confronted marmoset monkeys (Callithrix jacchus) with a conspecific model that was previously trained to open a plastic box in a peculiar way. Employing detailed motion analyses we show that the observers precisely copied the movement patterns of the novel action demonstrated by the model. A discriminant analysis classified 13 out of 14 observer movements (92.86%) as model movements and only one as non-observer movement. This evidence of imitation in non-human primates questions the dominant opinion that imitation is a human-specific ability. Furthermore, the high matching degree suggests that marmosets possess the neuronal mechanism to code the actions of others and to map them onto their own motor repertoire, rather than priming existing motor-templates.	[Voelkl, Bernhard; Huber, Ludwig] Univ Vienna, Dept Neurobiol & Cognit Res, Vienna, Austria	University of Vienna	Huber, L (corresponding author), Univ Vienna, Dept Neurobiol & Cognit Res, Vienna, Austria.	ludwig.huber@univie.ac.at	Voelkl, Bernhard/D-1390-2009	Voelkl, Bernhard/0000-0001-5454-2508; Huber, Ludwig/0000-0002-0217-136X	Austrian Science Fund [P 12011-BIO]; European Community [NEST 012929]	Austrian Science Fund(Austrian Science Fund (FWF)); European Community(European Commission)	This work has received funding from the Austrian Science Fund (P 12011-BIO) and the European Community (NEST 012929).	[Anonymous], 1956, LEARNING INSTINCT AN; BRASS M, 2005, TRENDS COGNITIVE NEU; Byrne RW, 1998, BEHAV BRAIN SCI, V21, P667, DOI 10.1017/S0140525X98001745; Byrne RW, 2003, PHILOS T R SOC B, V358, P529, DOI 10.1098/rstb.2002.1219; Call J, 2005, ANIM COGN, V8, P151, DOI 10.1007/s10071-004-0237-8; CUSTANCE DM, 1995, BEHAVIOUR, V132, P837, DOI 10.1163/156853995X00036; Ferrari PF, 2005, J COGNITIVE NEUROSCI, V17, P212, DOI 10.1162/0898929053124910; Ferrari PF, 2006, PLOS BIOL, V4, P1501, DOI 10.1371/journal.pbio.0040302; Fogassi L, 2005, SCIENCE, V308, P662, DOI 10.1126/science.1106138; Fragaszy D, 2004, LEARN BEHAV, V32, P24; Galef BG, 2004, LEARN BEHAV, V32, P53; Heyes C, 2001, TRENDS COGN SCI, V5, P253, DOI 10.1016/S1364-6613(00)01661-2; Heyes CM, 2000, ADV STUD BEHAV, V29, P215, DOI 10.1016/S0065-3454(08)60106-0; Huber L, 1998, BEHAV BRAIN SCI, V21, P694, DOI 10.1017/S0140525X9833174X; HURLEY S, 2006, PERSPECTIVES IMITATI; Iacoboni M, 2005, CURR OPIN NEUROBIOL, V15, P632, DOI 10.1016/j.conb.2005.10.010; Meltzoff AN, 1997, EARLY DEV PARENTING, V6, P179, DOI 10.1002/(SICI)1099-0917(199709/12)6:3/4<179::AID-EDP157>3.0.CO;2-R; MELTZOFF AN, IMITATIVE MIND DEV E; MOORE BR, 1992, BEHAVIOUR, V122, P231, DOI 10.1163/156853992X00525; Myowa-Yamakoshi M, 2000, J COMP PSYCHOL, V114, P381, DOI 10.1037/0735-7036.114.4.381; Paukner A, 2005, BIOL LETTERS, V1, P219, DOI 10.1098/rsbl.2004.0291; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G., 2005, PERSPECTIVES IMITATI, V1, P55, DOI DOI 10.1146/ANNUREV.NEURO.27.070203.144230; Rumiati RI, 2002, EXP BRAIN RES, V142, P425, DOI 10.1007/s00221-001-0956-x; Subiaul F, 2004, SCIENCE, V305, P407, DOI 10.1126/science.1099136; THORNDIKE EL, 1898, PSYCHOL REV MONOGR S, V2, P79; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; Voelkl B, 2000, ANIM BEHAV, V60, P195, DOI 10.1006/anbe.2000.1457; Whiten A, 2005, NATURE, V437, P52, DOI 10.1038/nature04023; Whiten A., 1992, ADV STUDY BEHAV; Wolpert DM, 2003, PHILOS T R SOC B, V358, P593, DOI 10.1098/rstb.2002.1238; Zentall TR, 2004, LEARN BEHAV, V32, P15, DOI 10.3758/BF03196003	32	79	81	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e611	10.1371/journal.pone.0000611	http://dx.doi.org/10.1371/journal.pone.0000611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622356	gold, Green Published			2022-12-25	WOS:000207452000018
J	Joo, CK; Kim, HS; Park, JY; Seomun, Y; Son, MJ; Kim, JT				Joo, C-K; Kim, H-S; Park, J-Y; Seomun, Y.; Son, M-J; Kim, J-T			Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways	ONCOGENE			English	Article						TGF-beta; EGFR; Src; ROS; NADPH oxidase; E-cadherin	PROTEIN-KINASE INHIBITORS; SMOOTH-MUSCLE-CELLS; TGF-BETA; EGF RECEPTOR; MESENCHYMAL TRANSITION; HYDROGEN-PEROXIDE; TYROSINE KINASES; GENE-EXPRESSION; MESANGIAL CELLS; C-SRC	Many of the signaling responses induced by transforming growth factor-beta (TGF-beta) are mediated by Smad proteins, but there is evidence that it can also signal independently of Smads. Here, we provide evidence that multiple signal pathways induced by TGF-beta 1-including Src family tyrosine kinases (SFKs), generation of reactive oxygen species (ROS), de novo protein synthesis and E-cadherin-dependent cell-cell interactions-transactivate the epidermal growth factor receptor (EGFR), which in turn regulates expression of c-Fos and c-Jun. Immunoprecipitation and immunofluorescence staining showed that EGFR was phosphorylated on tyrosine in response to TGF-beta 1. EGFR transactivation required the activation of SFKs and the production of ROS via NADPH oxidase, but was not dependent on metalloproteases or the release of EGF-like ligands. In addition, the production of ROS was dependent on signaling by specific SFKs as well as de novo protein synthesis. Stable transfection of E-cadherin into MDA-MB-231 cells as well as E-cadherin-blocking assays revealed that E-cadherin-mediated cell-cell interactions were also essential for EGFR transactivation. Finally, EGFR transactivation was involved in the expression of c-Fos and c-Jun via the extracellular signal-regulated kinase signaling cascade. Taken together our data suggest that ligand release-independent transactivation of EGFR may diversify early TGF-beta signaling and represent a novel pathway leading to TGF-beta-mediated gene expression.	[Joo, C-K; Kim, H-S; Park, J-Y; Seomun, Y.; Son, M-J; Kim, J-T] Catholic Univ Korea, Lab Visual Sci, Coll Med, Korea Eye Tissue & Gene Bank, Seoul 137040, South Korea; [Kim, J-T] KOCAT Inc, Bio Div, Seoul, South Korea	Catholic University of Korea	Kim, JT (corresponding author), Catholic Univ Korea, Lab Ophthalmol & Visual Sci, Coll Med, 505 Banpo Dong, Seoul 137040, South Korea.	superbio@kocat.com						Bahk YY, 2004, PROTEOMICS, V4, P3299, DOI 10.1002/pmic.200400980; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; CARMONOCUENCA I, 2005, J CELL PHYSL, V207, P322; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen HY, 1997, J CELL SCI, V110, P345; Chiu C, 2001, INT J MOL MED, V8, P251; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; FAN Z, 1994, J BIOL CHEM, V269, P27595; Ferguson KM, 2004, BIOCHEM SOC T, V32, P742, DOI 10.1042/BST0320742; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua H, 2003, J BIOL CHEM, V278, P33951, DOI 10.1074/jbc.M302823200; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAFON C, 1995, BBA-MOL CELL RES, V1266, P288, DOI 10.1016/0167-4889(95)00023-L; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Levy DE, 1998, J MED CHEM, V41, P199, DOI 10.1021/jm970494j; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Murillo MM, 2005, ONCOGENE, V24, P4580, DOI 10.1038/sj.onc.1208664; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Park SK, 2001, BIOCHEM BIOPH RES CO, V284, P966, DOI 10.1006/bbrc.2001.5058; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RHEE SG, 2000, SCI STKE, pE1; Rocic P, 2005, CIRC RES, V97, P850, DOI 10.1161/01.RES.0000190403.87462.bf; Samarakoon R, 2005, J CELL PHYSIOL, V204, P236, DOI 10.1002/jcp.20279; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Uchiyama-Tanaka Y, 2002, KIDNEY INT, V62, P799, DOI 10.1046/j.1523-1755.2002.00537.x; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zuo X, 2001, ELECTROPHORESIS, V22, P1603, DOI 10.1002/1522-2683(200105)22:9<1603::AID-ELPS1603>3.0.CO;2-I; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	58	45	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					614	628		10.1038/sj.onc.1210649	http://dx.doi.org/10.1038/sj.onc.1210649			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17637750				2022-12-25	WOS:000252674900006
J	Sheehan, KM; Gulmann, C; Eichler, GS; Weinstein, JN; Barrett, HL; Kay, EW; Conroy, RM; Liotta, LA; Petricoin, EF				Sheehan, K. M.; Gulmann, C.; Eichler, G. S.; Weinstein, J. N.; Barrett, H. L.; Kay, E. W.; Conroy, R. M.; Liotta, L. A.; Petricoin, E. F., III			Signal pathway pro. ling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition	ONCOGENE			English	Article						proteomics; protein microarray; colon cancer; stroma; microdissection	PHASE PROTEIN MICROARRAYS; GENE-EXPRESSION PROFILES; TISSUE INHIBITORS; CELL-LINES; CANCER; FIBROBLASTS; PROGRESSION; GROWTH; METALLOPROTEINASES; METASTASIS	Molecular crosstalk, including reciprocal stimulation, is theorized to take place between epithelial cancer cells and surrounding non-neoplastic stromal cells. This is the rationale for stromal therapy, which could eliminate support of a cancer by its genetically stable stroma. Epithelial-stromal crosstalk is so far poorly documented in vivo, and cell cultures and animal experiments may not provide accurate models. The current study details stromal-epithelial signalling pathways in 35 human colon cancers, and compares them with matched normal tissues using quantitative proteomic microarrays. Lysates prepared from separately microdissected epithelium and stroma were analysed using antibodies against 61 cell signalling proteins, most of which recognize activated phospho-isoforms. Analyses using unsupervised and supervised statistical methods suggest that cell signalling pathway profiles in stroma and epithelium appear more similar to each other in tumours than in normal colon. This supports the concept that coordinated crosstalk occurs between epithelium and stroma in cancer and suggests epithelial-mesenchymal transition. Furthermore, the data herein suggest that it is driven by cell proliferation pathways and that, specifically, several key molecules within the mitogen-activated protein kinase pathway may play an important role. Given recent findings of epithelial-mesenchymal transition in therapy-resistant tumour epithelium, these findings could have therapeutic implications for colon cancer.	[Sheehan, K. M.; Gulmann, C.; Barrett, H. L.] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland; [Sheehan, K. M.; Gulmann, C.] NIH, Natl Canc Inst, Canc Res Ctr, Pathol Lab,NCI FDA Clin Proteom Program, Bethesda, MD USA; [Sheehan, K. M.; Gulmann, C.; Barrett, H. L.; Kay, E. W.] Royal Coll Surgeons Ireland, Dept Pathol, Dublin 9, Ireland; [Eichler, G. S.; Weinstein, J. N.] NIH, Natl Canc Inst, Canc Res Ctr, Mol Pharmacol Lab, Bethesda, MD USA; [Conroy, R. M.] Royal Coll Surgeons Ireland, Dept Epidemiol, Dublin, Ireland; [Liotta, L. A.; Petricoin, E. F., III] George Mason Univ, Ctr Appl Proteom & Mol Med, Manassas, VA USA; [Petricoin, E. F., III] US FDA, NCI, Clin Proteom Program, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Royal College of Surgeons - Ireland; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal College of Surgeons - Ireland; George Mason University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Gulmann, C (corresponding author), Beaumont Hosp, Dept Pathol, Dublin 9, Ireland.	christian_gulmann@hotmail.com	Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682; Weinstein, John/0000-0001-9401-6908; Sheehan, Katherine/0000-0002-8969-3610	NATIONAL CANCER INSTITUTE [Z01BC007349] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAUJO RP, 2004, DRUG DISCOV TODAY TH, V1, P425, DOI DOI 10.1016/j.ddstr.2004.11.004; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brigati C, 2002, CLIN EXP METASTAS, V19, P247, DOI 10.1023/A:1015587423262; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derycke L, 2005, CANCER BIOTHER RADIO, V20, P579, DOI 10.1089/cbr.2005.20.579; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fend F, 1999, AM J PATHOL, V154, P61, DOI 10.1016/S0002-9440(10)65251-0; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gulmann C, 2006, J PATHOL, V208, P595, DOI 10.1002/path.1958; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019; Matrisian LM, 2001, CANCER RES, V61, P3844; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Notterman DA, 2001, CANCER RES, V61, P3124; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200; Sun YJ, 2005, MOL CANCER THER, V4, P51; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tomita T, 1996, DIS COLON RECTUM, V39, P1255, DOI 10.1007/BF02055119; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	52	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					323	331		10.1038/sj.onc.1210647	http://dx.doi.org/10.1038/sj.onc.1210647			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621268				2022-12-25	WOS:000252256000008
J	Kutuzov, MA; Andreeva, AV; Voyno-Yasenetskaya, TA				Kutuzov, Mikhail A.; Andreeva, Alexandra V.; Voyno-Yasenetskaya, Tatyana A.			Regulation of apoptosis signal-regulating kinase 1 degradation by G alpha 13	FASEB JOURNAL			English	Article						signal transduction; MAP kinases; heterotrimeric G proteins	NITRIC-OXIDE-SYNTHASE; INDUCED CELL-DEATH; DEPENDENT REGULATION; ASK1 UBIQUITINATION; CARDIOMYOCYTE DEATH; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; OXIDATIVE STRESS; INNATE IMMUNITY; PC12 CELLS	Apoptosis signal-regulating kinase (ASK1) is a mitogen-activated protein kinase (MAPK) that transduces apoptotic signals from a variety of stresses. We have shown previously that alpha subunits of heterotrimeric G12 and G13 proteins stimulate ASK1 kinase activity and ASK1-dependent apoptosis (1). Here, we report a novel mechanism of G-protein-dependent regulation of ASK1. We demonstrated that G alpha 13 forms a complex with ASK1 in an activation-independent manner. Both N-and C-terminal regulatory domains of ASK1 were essential for the efficient interaction, while its kinase domain was not required. Formation of the G alpha 13-ASK1 complex was enhanced by JNK-interacting leucine zipper protein, JLP. Constitutively activated G alpha 13Q226L increased ASK1 expression. Short-term activation of a serotonin 5-HT4 receptor that is coupled to G alpha 13 also increased ASK1 expression. Importantly, prolonged activation of 5-HT4 receptor in COS-7 cells or prolonged treatment of human umbilical vein endothelial cells with thrombin concomitantly down-regulated both G alpha 13 and ASK1. Data showed that G alpha 13Q226L reduced the rate of ASK1 degradation, decreased ASK1 ubiquitination, and reduced association of ASK1 with an E3 ubiquitin ligase CHIP, previously shown to mediate ASK1 degradation. Our findings indicate that ASK1 expression levels can be regulated by G alpha 13, at least in part via control of ASK1 ubiquitination and degradation.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, MC 868,909 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Kutuzov, Mikhail/0000-0003-3386-4350	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM065160, R01GM056159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-06078] Funding Source: Medline; NIGMS NIH HHS [GM-65160, GM-56159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adarichev VA, 2003, AM J PHYSIOL-CELL PH, V285, pC922, DOI 10.1152/ajpcell.00115.2003; Andreeva AV, 2006, MOL PHARMACOL, V69, P975, DOI 10.1124/mol.105.018846; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bilodeau ML, 2006, MOL PHARMACOL, V69, P677, DOI 10.1124/mol.105.022038; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hayakawa T, 2006, MICROBES INFECT, V8, P1098, DOI 10.1016/j.micinf.2005.12.001; He Y, 2006, J BIOL CHEM, V281, P5559, DOI 10.1074/jbc.M512338200; Hershko T, 2006, J BIOL CHEM, V281, P31309, DOI 10.1074/jbc.M601758200; Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1; Izumiya Y, 2003, CIRC RES, V93, P874, DOI 10.1161/01.RES.0000100665.67510.F5; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kashef K, 2005, BIOCHEMISTRY-US, V44, P14090, DOI 10.1021/bi050604l; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Kutuzov MA, 2005, J BIOL CHEM, V280, P25388, DOI 10.1074/jbc.M413202200; Liu JF, 2001, J SUPERCOND, V14, P3, DOI 10.1023/A:1007867802653; Liu QH, 2006, MOL CELL BIOL, V26, P3785, DOI 10.1128/MCB.26.10.3785-3797.2006; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishida K, 2006, ANTIOXID REDOX SIGN, V8, P1729, DOI 10.1089/ars.2006.8.1729; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sayama K, 1998, J INVEST DERMATOL, V110, P541; Sayama K, 2005, EUR J IMMUNOL, V35, P1886, DOI 10.1002/eji.200425827; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Watanabe T, 2005, BIOCHEM BIOPH RES CO, V333, P562, DOI 10.1016/j.bbrc.2005.05.151; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Zhao YG, 2007, J BIOL CHEM, V282, P7777, DOI 10.1074/jbc.M609146200	44	8	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3727	3736		10.1096/fj.06-8029com	http://dx.doi.org/10.1096/fj.06-8029com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17595347				2022-12-25	WOS:000250517800034
J	Kallio, JM; Linder, MB; Rouvinen, J				Kallio, Johanna M.; Linder, Markus B.; Rouvinen, Juha			Crystal structures of hydrophobin HFBII in the presence of detergent implicate the formation of fibrils and monolayer films	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHODERMA-REESEI; RESOLUTION STRUCTURE; SC3; MEMBRANE; WATER	Hydrophobins are small, amphiphilic proteins secreted by filamentous fungi. Their functionality arises from a patch of hydrophobic residues on the protein surface. Spontaneous self-assembly of hydrophobins leads to the formation of an amphiphilic layer that remarkably reduces the surface tension of water. We have determined by x-ray diffraction two new crystal structures of Trichoderma reesei hydrophobin HFBII in the presence of a detergent. The monoclinic crystal structure (2.2 angstrom resolution, R = 22, R-free = 28) is composed of layers of hydrophobin molecules where the hydrophobic surface areas of the molecules are aligned within the layer. Viewed perpendicular to the aligned hydrophobic surface areas, the molecules in the layer pack together to form six-membered rings, thus leaving small pores in the layer. Similar packing has been observed in the atomic force microscopy images of the self-assembled layers of class II hydrophobin, indicating that the crystal structure resembles that of natural hydrophobin film. The orthorhombic crystal structure (1.0 A resolution, R = 13, Rfree = 15) is composed of fiber-like arrays of protein molecules. Rodlet structures have been observed on amphiphilic layers formed by class I hydrophobins; fibrils of class II hydrophobins appear by vigorous shaking. We propose that the structure of the fibrils and/or rodlets is similar to that observed in the crystal structure.	Univ Joensuu, Dept Chem, FIN-80101 Joensuu, Finland; VTT Tech Res Ctr Finland, Espoo 02044, Finland	University of Eastern Finland; VTT Technical Research Center Finland	Kallio, JM (corresponding author), Univ Joensuu, Dept Chem, POB 111, FIN-80101 Joensuu, Finland.	johanna.kallio@joensuu.fi	Linder, Markus B/E-5879-2011; Linder, Markus/N-8043-2019; Hakanpää, Johanna M/A-6958-2011	Linder, Markus B/0000-0002-7271-6441; Linder, Markus/0000-0002-7271-6441; Hakanpää, Johanna M/0000-0003-0110-1439; Rouvinen, Juha/0000-0003-1843-5718; Kallio, Johanna/0000-0001-7330-8928				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; De Vocht ML, 2002, PROTEIN SCI, V11, P1199, DOI 10.1110/ps.4540102; Hakanpaa J, 2006, ACTA CRYSTALLOGR D, V62, P356, DOI 10.1107/S0907444906000862; Hakanpaa J, 2004, J BIOL CHEM, V279, P534, DOI 10.1074/jbc.M309650200; Hakanpaa J, 2004, ACTA CRYSTALLOGR D, V60, P163, DOI 10.1107/S0907444903024430; Hakanpaa J, 2006, PROTEIN SCI, V15, P2129, DOI 10.1110/ps.062326706; HEKTOR HJ, 2005, CURR OPIN BIOTECH, V16, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kwan AHY, 2006, P NATL ACAD SCI USA, V103, P3621, DOI 10.1073/pnas.0505704103; Linder MB, 2005, FEMS MICROBIOL REV, V29, P877, DOI 10.1016/j.femsre.2005.01.004; Linder MB, 2004, BIOCHEMISTRY-US, V43, P11873, DOI 10.1021/bi0488202; Ma H, 2006, MYCOL RES, V110, P879, DOI 10.1016/j.mycres.2006.06.010; Mackay JP, 2001, STRUCTURE, V9, P83, DOI 10.1016/S0969-2126(00)00559-1; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; NakariSetala T, 1996, EUR J BIOCHEM, V235, P248, DOI 10.1111/j.1432-1033.1996.00248.x; NakariSetala T, 1997, EUR J BIOCHEM, V248, P415, DOI 10.1111/j.1432-1033.1997.00415.x; Paananen A, 2003, BIOCHEMISTRY-US, V42, P5253, DOI 10.1021/bi034031t; Ritva S, 2003, J APPL CRYSTALLOGR, V36, P499, DOI 10.1107/S0021889803000578; Scholtmeijer K, 2001, APPL MICROBIOL BIOT, V56, P1, DOI 10.1007/s002530100632; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Szilvay GR, 2007, BIOCHEMISTRY-US, V46, P2345, DOI 10.1021/bi602358h; Szilvay GR, 2006, BIOCHEMISTRY-US, V45, P8590, DOI 10.1021/bi060620y; Torkkeli M, 2002, BIOPHYS J, V83, P2240, DOI 10.1016/S0006-3495(02)73984-2; Wang X, 2005, BIOPHYS J, V88, P3434, DOI 10.1529/biophysj.104.057794; Wang XQ, 2004, PROTEIN SCI, V13, P810, DOI 10.1110/ps.03367304; WESSELS JGH, 1994, ANNU REV PHYTOPATHOL, V32, P413, DOI 10.1146/annurev.py.32.090194.002213; WESSELS JGH, 1991, PLANT CELL, V3, P793; WOSTEN HAB, 1994, J BACTERIOL, V176, P7085; Wosten HAB, 2000, BBA-REV BIOMEMBRANES, V1469, P79, DOI 10.1016/S0304-4157(00)00002-2; Wosten HAB, 1999, CURR BIOL, V9, P85, DOI 10.1016/S0960-9822(99)80019-0; WOSTEN HAB, 1993, PLANT CELL, V5, P1567	33	48	53	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28733	28739		10.1074/jbc.M704238200	http://dx.doi.org/10.1074/jbc.M704238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17636262	hybrid			2022-12-25	WOS:000249642100047
J	Asano, R; Watanabe, Y; Kawaguchi, H; Fukazawa, H; Nakanishi, T; Umetsu, M; Hayashi, H; Katayose, Y; Unno, M; Kudo, T; Kumagai, I				Asano, Ryutaro; Watanabe, Yasuhiro; Kawaguchi, Hiroko; Fukazawa, Hidesuke; Nakanishi, Takeshi; Umetsu, Mitsuo; Hayashi, Hiroki; Katayose, Yu; Unno, Michiaki; Kudo, Toshio; Kumagai, Izumi			Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; MONOCLONAL-ANTIBODY; REFOLDING SYSTEM; EFFICIENT ROUTE; KINASE-ACTIVITY; DIABODY; EGFR; EFFICACY; ANTIGEN; HETERODIMERIZATION	We previously reported the marked in vitro and in vivo antitumor activity of hEx3, a humanized diabody (small recombinant bispecific antibody) with epidermal growth factor receptor (EGFR) and CD3 retargeting. Here, we fabricated a tetravalent IgG-like bispecific antibody with two kinds of single-chain Fv (scFv), i.e. humanized anti-EGFR scFv and anti-CD3 scFv, that contains the same four variable domains as hEx3, on the platform of human IgG1 (hEx3-scFv-Fc). hEx3-scFv-Fc prepared from mammalian cells showed specific binding to both EGFR and CD3 target antigens. At one-thousandth (0.1-100 fmol/ml) of the dose of normal hEx3, hEx3-scFv-Fc showed intense cytotoxicity to an EGFR-positive cell line in a growth-inhibition assay using lymphokine-activated killer cells with the T-cell phenotype (T-LAK cells). The enhanced antitumor effect was more clearly observed when peripheral blood mononuclear cells (PBMCs) were used as effector cells, indicating the utility of IgG-like fabrication. These results suggested that the intense antitumor activity is attributable to the multivalency and the presence of the fused human Fc, a hypothesis that was supported by the results of flow cytometry, PBMC proliferation assay, and protein kinase inhibition assay. Furthermore, the growth inhibition effects of hEx3-scFv-Fc were considerably superior to those of the approved therapeutic antibody, cetuximab, which recognizes the same EGFR antigen even when using PBMCs as effector cells. The high potency of hEx3-scFv-Fc may translate into improved antitumor therapy and lower costs of production because of the smaller doses needed.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 980, Japan; Tohoku Univ, Grad Sch Med, Dept Surg, Div Gastroenterol Surg, Sendai, Miyagi 980, Japan; Tohoku Univ, Cell Res Ctr Biomed Res, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan	Tohoku University; Tohoku University; Tohoku University	Kumagai, I (corresponding author), Aoba 6-6-11-606,Aoba-ku, Sendai, Miyagi, Japan.	kmiz@kuma.che.tohoku.ac.jp	Unno, Michiaki/A-8633-2010; Asano, Ryutaro/G-7822-2016; Unno, Michiaki/AAX-5246-2020	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416; Hayashi, Hiroki/0000-0001-9953-603X				Adair John R., 1994, Human Antibodies and Hybridomas, V5, P41; Asano R, 2002, J BIOCHEM, V132, P903, DOI 10.1093/oxfordjournals.jbchem.a003303; Asano R, 2002, FEBS LETT, V528, P70, DOI 10.1016/S0014-5793(02)03254-4; Asano R, 2006, CLIN CANCER RES, V12, P4036, DOI 10.1158/1078-0432.CCR-06-0059; BOHLEN H, 1993, CANCER RES, V53, P4310; Bremer E, 2005, J BIOL CHEM, V280, P10025, DOI 10.1074/jbc.M413673200; Cao Y, 2003, ADV DRUG DELIVER REV, V55, P171, DOI 10.1016/S0169-409X(02)00178-3; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Coloma MJ, 1997, J IMMUNOL, V158, P733; FischerColbrie J, 1997, ANTICANCER RES, V17, P613; GILL GN, 1984, J BIOL CHEM, V259, P7755; Hayashi H, 2004, CANCER IMMUNOL IMMUN, V53, P497, DOI 10.1007/s00262-003-0465-9; Jung G, 2001, INT J CANCER, V91, P225, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1038>3.3.CO;2-7; Kodama H, 2002, IMMUNOL LETT, V81, P99, DOI 10.1016/S0165-2478(01)00343-1; Kontermann RE, 2005, ACTA PHARMACOL SIN, V26, P1, DOI 10.1111/j.1745-7254.2005.00008.x; Kufer P, 2004, TRENDS BIOTECHNOL, V22, P238, DOI 10.1016/j.tibtech.2004.03.006; Levene AP, 2005, J ROY SOC MED, V98, P146, DOI 10.1258/jrsm.98.4.146; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Lu D, 2003, J IMMUNOL METHODS, V279, P219, DOI 10.1016/S0022-1759(03)00251-5; Marvin JS, 2005, ACTA PHARMACOL SIN, V26, P649, DOI 10.1111/j.1745-7254.2005.00119.x; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Pfosser A, 1999, INT J CANCER, V80, P612, DOI 10.1002/(SICI)1097-0215(19990209)80:4<612::AID-IJC21>3.0.CO;2-K; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Shahied LS, 2004, J BIOL CHEM, V279, P53907, DOI 10.1074/jbc.M407888200; Takemura S, 2000, PROTEIN ENG, V13, P583, DOI 10.1093/protein/13.8.583; Takemura S, 2002, CANCER IMMUNOL IMMUN, V51, P33, DOI 10.1007/s00262-001-0245-3; TOSI E, 1995, INT J CANCER, V62, P643, DOI 10.1002/ijc.2910620525; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Wu AM, 1996, IMMUNOTECHNOLOGY, V2, P21, DOI 10.1016/1380-2933(95)00027-5; Xie ZG, 2005, J IMMUNOL METHODS, V296, P95, DOI 10.1016/j.jim.2004.11.005; Zuo Z, 2000, PROTEIN ENG, V13, P361, DOI 10.1093/protein/13.5.361	34	46	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27659	27665		10.1074/jbc.M704719200	http://dx.doi.org/10.1074/jbc.M704719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644522	hybrid			2022-12-25	WOS:000249455600013
J	Ringgaard, S; Lowe, J; Gerdes, K				Ringgaard, Simon; Lowe, Jan; Gerdes, Kenn			Centromere pairing by a plasmid-encoded type I ParB protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-DNA SEGREGATION; PROKARYOTIC ACTIN HOMOLOG; PARTITIONING PROTEIN; CELL-CYCLE; R1; INCOMPATIBILITY; MECHANISM; OPERATOR; AUTOREGULATION; RECOGNITION	Thepar2 locus of Escherichia coli plasmid pB171 encodes two trans-acting proteins, ParA and ParB, and two cis-acting sites, parC1 and parC2, to which ParB binds cooperatively. ParA is related to MinD and oscillates in helical structures and thereby positions ParB/parC-carrying plasmids regularly over the nucleoid. ParB ribbon-helix-helix dimers bind cooperatively to direct repeats in parC1 and parC2. Using four different assays we obtain solid evidence that ParB can pair parC1- and parC2 encoding DNA fragments in vitro. Convincingly, electron microscopy revealed that ParB mediates binary pairing of parC fragments. In addition to binary complexes, ParB mediated the formation of higher order complexes consisting of several DNA fragments joined by ParB at centromere site parC. N-terminal truncated versions of ParB still possessing specific DNA binding activity were incompetent in pairing, hence identifying the N terminus of ParB as a requirement for ParB-mediated centromere pairing. These observations suggest that centromere pairing is an important intermediate step in plasmid partitioning mediated by the common type I loci.	Univ So Denmark, Dept Biochem & Mol Biol, Odense 5230, Denmark; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Newcastle, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Southern Denmark; MRC Laboratory Molecular Biology; Newcastle University - UK	Gerdes, K (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, Odense 5230, Denmark.	Kenn.Gerdes@newcastle.ac.uk	Gerdes, Kenn/AAS-5548-2021; Löwe, Jan/B-3882-2011; Gerdes, Kenn/M-2420-2014; Löwe, Jan/X-6998-2019	Gerdes, Kenn/0000-0002-7462-4612; Gerdes, Kenn/0000-0002-7462-4612; Ringgaard, Simon/0000-0002-4980-5964; Lowe, Jan/0000-0002-5218-6615	Medical Research Council [MC_U105184326] Funding Source: Medline; MRC [MC_U105184326] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adachi S, 2006, J MOL BIOL, V356, P850, DOI 10.1016/j.jmb.2005.11.088; Barilla D, 2005, EMBO J, V24, P1453, DOI 10.1038/sj.emboj.7600619; Barilla D, 2007, P NATL ACAD SCI USA, V104, P1811, DOI 10.1073/pnas.0607216104; Becker E, 2006, EMBO J, V25, P5919, DOI 10.1038/sj.emboj.7601443; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Bouet JY, 2006, MOL MICROBIOL, V62, P1447, DOI 10.1111/j.1365-2958.2006.05454.x; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; DAM M, 1994, J MOL BIOL, V236, P1289, DOI 10.1016/0022-2836(94)90058-2; Ebersbach G, 2005, ANNU REV GENET, V39, P453, DOI 10.1146/annurev.genet.38.072902.091252; Ebersbach G, 2005, MOL MICROBIOL, V56, P1430, DOI 10.1111/j.1365-2958.2005.04643.x; Ebersbach G, 2004, MOL MICROBIOL, V52, P385, DOI 10.1111/j.1365-2958.2004.04002.x; Ebersbach G, 2001, P NATL ACAD SCI USA, V98, P15078, DOI 10.1073/pnas.261569598; Ebersbach G, 2006, MOL MICROBIOL, V61, P1428, DOI 10.1111/j.1365-2958.2006.05322.x; Edgar R, 2001, MOL MICROBIOL, V42, P1363, DOI 10.1046/j.1365-2958.2001.02717.x; GALLIE DR, 1987, J MOL BIOL, V193, P465, DOI 10.1016/0022-2836(87)90260-9; Garner EC, 2004, SCIENCE, V306, P1021, DOI 10.1126/science.1101313; Garner EC, 2007, SCIENCE, V315, P1270, DOI 10.1126/science.1138527; Gerdes K, 2004, CELL, V116, P359, DOI 10.1016/S0092-8674(04)00116-3; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Golovanov AP, 2003, MOL MICROBIOL, V50, P1141, DOI 10.1046/j.1365-2958.2003.03750.x; Gomis-Ruth FX, 1998, EMBO J, V17, P7404, DOI 10.1093/emboj/17.24.7404; Hayes F, 2006, NAT REV MICROBIOL, V4, P133, DOI 10.1038/nrmicro1342; HE YY, 1992, NATURE, V359, P431, DOI 10.1038/359431a0; Jensen RB, 1999, EMBO J, V18, P4076, DOI 10.1093/emboj/18.14.4076; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Lim GE, 2005, P NATL ACAD SCI USA, V102, P17658, DOI 10.1073/pnas.0507222102; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Ringgaard S, 2007, J BIOL CHEM, V282, P3134, DOI 10.1074/jbc.M609092200; Tobe T, 1999, INFECT IMMUN, V67, P5455, DOI 10.1128/IAI.67.10.5455-5462.1999	32	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28216	28225		10.1074/jbc.M703733200	http://dx.doi.org/10.1074/jbc.M703733200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644524	hybrid			2022-12-25	WOS:000249455600071
J	Wakita, M; Masuda, S; Motohashi, K; Hisabori, T; Ohta, H; Takamiya, KI				Wakita, Masahiro; Masuda, Shinji; Motohashi, Ken; Hisabori, Toru; Ohta, Hiroyuki; Takamiya, Ken-Ichiro			The significance of type II and PrxQ peroxiredoxins for antioxidative stress response in the purple bacterium Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; GENE-EXPRESSION; THIOREDOXIN; REDOX; YEAST; RESISTANCE; TRANSPORT; HOMOLOG	Two peroxiredoxins, classified as Type II and PrxQ were characterized in the purple non-sulfur photosynthetic bacterium Rhodobacter sphaeroides. Both recombinant proteins showed remarkable thioredoxin-dependent peroxidase activity with broad substrate specificity in vitro. Nevertheless, PrxQ of R. sphaeroides, unlike typical PrxQs studied to date, does not contain one of the two conserved catalytic Cys residues. We found that R. sphaeroides PrxQ and other PrxQ-like proteins from several organisms conserve a different second Cys residue, indicating that these proteins should be categorized into a novel PrxQ subfamily. Disruption of either the Type II or PrxQ gene in R. sphaeroides had a dramatic effecton cell viability when the cells were grown under aerobic light or oxidative stress conditions created by exogenous addition of reactive oxygen species to the medium. Growth rates of the mutants were significantly decreased compared with that of wild type under aerobic but not anaerobic conditions. These results indicate that the peroxiredoxins are crucial for antioxidative stress response in this bacterium. The gene disruptants also demonstrated reduced levels of photopigment synthesis, suggesting that the peroxiredoxins are directly or indirectly involved in regulated synthesis of the photosynthetic apparatus.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Res Ctr Evolving Earth & Planets, Yokohama, Kanagawa 2268501, Japan; Japan Sci & Technol Agcy, ATP Syst Project Exploratory Res Adv Technol, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Masuda, S (corresponding author), Tokyo Inst Technol, Ctr Biol Resources & Informat, Yokohama, Kanagawa 2268501, Japan.	shmasuda@bio.titech.ac.jp	Ohta, Hiroyuki/B-1840-2014; Masuda, Shinji/A-2703-2014; Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Ohta, Hiroyuki/0000-0002-1068-3242; Masuda, Shinji/0000-0002-5349-4927; Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; Bauer C, 2003, PHILOS T R SOC B, V358, P147, DOI 10.1098/rstb.2002.1189; Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044; BORLAND CF, 1989, J PHOTOCH PHOTOBIO B, V3, P227; Dietz KJ, 2003, ANNU REV PLANT BIOL, V54, P93, DOI 10.1146/annurev.arplant.54.031902.134934; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; Finkemeier I, 2005, J BIOL CHEM, V280, P12168, DOI 10.1074/jbc.M413189200; Glaeser J, 2005, MICROBIOL-SGM, V151, P1927, DOI 10.1099/mic.0.27789-0; HALLIWELL B, 1999, FREE RADICAL BIO MED, P188; Hosoya-Matsuda N, 2005, J BIOL CHEM, V280, P840, DOI 10.1074/jbc.M411493200; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; KAPUT J, 1982, J BIOL CHEM, V257, P5054; Kiba A, 2005, PLANT CELL PHYSIOL, V46, P1007, DOI 10.1093/pcp/pci109; KIM K, 1985, J BIOL CHEM, V260, P5394; Kong W, 2000, BIOCHEM J, V351, P107, DOI 10.1042/0264-6021:3510107; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Masuda S, 2004, J BACTERIOL, V186, P235, DOI 10.1128/JB.186.1.235-239.2004; MATSUURA K, 1994, J PLANT RES, V107, P191, DOI 10.1007/BF02346017; MCEWAN AG, 1994, ANTON LEEUW INT J G, V66, P151, DOI 10.1007/BF00871637; MEINHARDT SW, 1985, ARCH BIOCHEM BIOPHYS, V236, P130, DOI 10.1016/0003-9861(85)90612-5; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Nagashima KVP, 1997, J MOL EVOL, V45, P131, DOI 10.1007/PL00006212; Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122; Pasternak C, 1997, MICROBIOL-UK, V143, P83, DOI 10.1099/00221287-143-1-83; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rouhier N, 2004, PLANT PHYSIOL, V134, P1027, DOI 10.1104/pp.103.035865; SHIMADA H, 1992, PLANT CELL PHYSIOL, V33, P471; Simon R., 1983, BIOTECHNOLOGY, V1, P37; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Wang G, 2006, BBA-GEN SUBJECTS, V1760, P1596, DOI 10.1016/j.bbagen.2006.05.005; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Wong CM, 2004, J BIOL CHEM, V279, P23207, DOI 10.1074/jbc.M402095200; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zamocky M, 2006, FEBS LETT, V580, P6655, DOI 10.1016/j.febslet.2006.11.017; Zeilstra-Ryalls JH, 2004, CELL MOL LIFE SCI, V61, P417, DOI 10.1007/s00018-003-3242-1; Zeller T, 2005, J BACTERIOL, V187, P7232, DOI 10.1128/JB.187.21.7232-7242.2005; Zeller T, 2004, MICROBIOL-SGM, V150, P3451, DOI 10.1099/mic.0.27308-0	41	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27792	27801		10.1074/jbc.M702855200	http://dx.doi.org/10.1074/jbc.M702855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644813	hybrid			2022-12-25	WOS:000249455600028
J	Hochgrafe, F; Mostertz, J; Pother, DC; Becher, D; Helmann, JD; Hecker, M				Hochgrafe, Falko; Mostertz, Joerg; Poether, Dierk-Christoph; Becher, Doerte; Helmann, John D.; Hecker, Michael			S-cysteinylation is a general mechanism for thiol protection of bacillus subtilis proteins after oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN DNA-BINDING; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ORGANOSULFUR METABOLISM; REDOX REGULATION; COENZYME-A; GLUTATHIONYLATION; IDENTIFICATION; THIOREDOXIN; PROTEOMICS; REGULATOR	S- Thiolation is crucial for protection and regulation of thiol-containing proteins during oxidative stress and is frequently achieved by the formation of mixed disulfides with glutathione. However, many Gram-positive bacteria including Bacillus subtilis lack the low molecular weight ( LMW) thiol glutathione. Here we provide evidence that S-thiolation by the LMW thiol cysteine represents a general mechanism in B. subtilis. In vivo labeling of proteins with [S-35] cysteine and nonreducing two-dimensional PAGE analyses revealed that a large subset of proteins previously identified as having redox-sensitive thiols are modified by cysteine in response to treatment with the thiol-specific oxidant diamide. By means of multidimensional shotgun proteomics, the sites of S-cysteinylation for six proteins could be identified, three of which are known to be S-glutathionylated in other organisms.	Ernst Moritz Arndt Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany; Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA	Ernst Moritz Arndt Universitat Greifswald; Cornell University	Hecker, M (corresponding author), Ernst Moritz Arndt Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany.	hecker@uni-greifswald.de	Pöther, Dierk-Christoph/A-4568-2017; Becher, Doerte/B-4454-2015	Pöther, Dierk-Christoph/0000-0001-7000-3520; Becher, Doerte/0000-0002-9630-5735; Helmann, John/0000-0002-3832-3249				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Bandow JE, 2002, J BACTERIOL, V184, P459, DOI 10.1128/JB.184.2.459-467.2002; Buttner K, 2001, ELECTROPHORESIS, V22, P2908, DOI 10.1002/1522-2683(200108)22:14<2908::AID-ELPS2908>3.0.CO;2-M; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Choi SY, 2006, J BACTERIOL, V188, P5741, DOI 10.1128/JB.00443-06; Cotgreave IA, 2002, METHOD ENZYMOL, V348, P175, DOI 10.1016/S0076-6879(02)48636-3; Erwin KN, 2005, J BACTERIOL, V187, P4042, DOI 10.1128/JB.187.12.4042-4049.2005; Even S, 2006, J BACTERIOL, V188, P2184, DOI 10.1128/JB.188.6.2184-2197.2006; Eymann C, 2004, PROTEOMICS, V4, P2849, DOI 10.1002/pmic.200400907; Fratelli M, 2004, EXPERT REV PROTEOMIC, V1, P365, DOI 10.1586/14789450.1.3.365; Ghezzi P, 2002, MOL IMMUNOL, V38, P773, DOI 10.1016/S0161-5890(01)00114-6; Guillouard I, 2002, J BACTERIOL, V184, P4681, DOI 10.1128/JB.184.17.4681-4689.2002; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Hochgrafe F, 2005, MOL MICROBIOL, V58, P409, DOI 10.1111/j.1365-2958.2005.04845.x; Hondorp ER, 2004, PLOS BIOL, V2, P1738, DOI 10.1371/journal.pbio.0020336; Hullo MF, 2007, J BACTERIOL, V189, P187, DOI 10.1128/JB.01273-06; Janek K, 2001, RAPID COMMUN MASS SP, V15, P1593, DOI 10.1002/rcm.417; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; LAHTI R, 1982, J GEN MICROBIOL, V128, P1023; Lee JW, 2007, P NATL ACAD SCI USA, V104, P8743, DOI 10.1073/pnas.0702081104; Leichert LIO, 2003, J BACTERIOL, V185, P1967, DOI 10.1128/JB.185.6.1967-1975.2003; Lillig CH, 2003, J BIOL CHEM, V278, P22325, DOI 10.1074/jbc.M302304200; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Nicely NI, 2007, BIOCHEMISTRY-US, V46, P3234, DOI 10.1021/bi062299p; SETLOW B, 1977, BIOCHEM BIOPH RES CO, V75, P45, DOI 10.1016/0006-291X(77)91286-4; STULKE J, 1993, J GEN MICROBIOL, V139, P2041, DOI 10.1099/00221287-139-9-2041; Weber H, 2004, MOL MICROBIOL, V52, P133, DOI 10.1111/j.1365-2958.2004.03971.x; Wolff S, 2006, MOL CELL PROTEOMICS, V5, P1183, DOI 10.1074/mcp.M600069-MCP200	34	82	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					25981	25985		10.1074/jbc.C700105200	http://dx.doi.org/10.1074/jbc.C700105200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17611193	hybrid			2022-12-25	WOS:000249239600001
J	Hatori, Y; Majima, E; Tsuda, T; Toyoshima, C				Hatori, Yuta; Majima, Eiji; Tsuda, Takeo; Toyoshima, Chikashi			Domain organization and movements in heavy metal ion pumps - Papain digestion of CopA, a Cu+-transporting ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; WILSONS-DISEASE PROTEIN; P-TYPE ATPASES; ARCHAEOGLOBUS-FULGIDUS; CALCIUM-PUMP; ESCHERICHIA-COLI; BINDING DOMAIN; PHOSPHOENZYME INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; LISTERIA-MONOCYTOGENES	To study domain organization and movements in the reaction cycle of heavy metal ion pumps, CopA, a bacterial Cu+-ATPase from Thermotoga maritima was cloned, overexpressed, and purified, and then subjected to limited proteolysis using papain. Stable analogs of intermediate states were generated using AMPPCP as a nonhydrolyzable ATP analog and AlFx as a phosphate analog, following conditions established for Ca2+-ATPase (SERCA1). Characteristic digestion patterns obtained for different analog intermediates show that CopA undergoes domain rearrangements very similar to those of SERCA1. Digestion sites were identified on the loops connecting the A-domain and the transmembrane helices M2 and M3 as well as on that connecting the N-terminal metal binding domain (NMBD) and the first transmembrane helix, Ma. These digestion sites were protected in the E1P center dot ADP and E2P analogs, whereas the M2-A-domain loop was cleaved specifically in the absence of ions to be transported, just as in SERCA1. ATPase activity was lost when the link between the NMBD and the transmembrane domain was cleaved, indicating that the NMBD plays a critical role in ATP hydrolysis in T. maritima CopA. The change in susceptibility of the loop between the NMBD and Ma helix provides evidence that the NMBD is associated to the A-domain and recruited into domain rearrangements and that the Ma helix is the counterpart of the M1 helix in SERCA1 and Mb and Mc are uniquely inserted before M2.	Univ Tokyo, Inst Mol & Cellular Biol, Tokyo 1130032, Japan; ProteNova Co Ltd, Naruto 7720051, Japan	University of Tokyo	Toyoshima, C (corresponding author), Univ Tokyo, Inst Mol & Cellular Biol, Tokyo 1130032, Japan.	ct@iam.u-tokyo.ac.jp	Toyoshima, Chikashi/R-4153-2019	Toyoshima, Chikashi/0000-0001-9640-0778				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ALLEN G, 1980, BIOCHEM J, V187, P545, DOI 10.1042/bj1870545; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Arguello JM, 2003, ANN NY ACAD SCI, V986, P212, DOI 10.1111/j.1749-6632.2003.tb07162.x; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; Bal N, 2003, BIOCHEM J, V369, P681, DOI 10.1042/BJ20021416; Bredeston LM, 2004, J BIOL CHEM, V279, P41619, DOI 10.1074/jbc.M403116200; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; Curran AC, 2000, J BIOL CHEM, V275, P30301, DOI 10.1074/jbc.M002047200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; Dmitriev O, 2006, P NATL ACAD SCI USA, V103, P5302, DOI 10.1073/pnas.0507416103; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Good N E, 1972, Methods Enzymol, V24, P53; Grotz N, 2006, BBA-MOL CELL RES, V1763, P595, DOI 10.1016/j.bbamcr.2006.05.014; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Inesi G, 2006, BIOCHEMISTRY-US, V45, P13769, DOI 10.1021/bi061255d; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; Ma HL, 2005, BIOCHEMISTRY-US, V44, P8090, DOI 10.1021/bi050332m; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Picard M, 2005, J BIOL CHEM, V280, P18745, DOI 10.1074/jbc.M501596200; POST RL, 1972, J BIOL CHEM, V247, P6530; Rice WJ, 2006, BIOCHEM BIOPH RES CO, V348, P124, DOI 10.1016/j.bbrc.2006.07.012; Sazinsky MH, 2006, BIOCHEMISTRY-US, V45, P9949, DOI 10.1021/bi0610045; Sazinsky MH, 2006, J BIOL CHEM, V281, P11161, DOI 10.1074/jbc.M510708200; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; SOENSEN TL, 2004, SCIENCE, V304, P1672; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONG SW, 1977, BIOCHEM BIOPH RES CO, V74, P1242, DOI 10.1016/0006-291X(77)91651-5; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Yang Y, 2007, BBA-BIOMEMBRANES, V1768, P495, DOI 10.1016/j.bbamem.2006.09.013	52	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25213	25221		10.1074/jbc.M703520200	http://dx.doi.org/10.1074/jbc.M703520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17616523	hybrid			2022-12-25	WOS:000249014100006
J	Sazinsky, MH; LeMoine, B; Orofino, M; Davydov, R; Bencze, KZ; Stemmler, TL; Hoffman, BM; Arguello, JM; Rosenzweig, AC				Sazinsky, Matthew H.; LeMoine, Benjamin; Orofino, Maria; Davydov, Roman; Bencze, Krisztina Z.; Stemmler, Timothy L.; Hoffman, Brian M.; Argueello, Jose M.; Rosenzweig, Amy C.			Characterization and structure of a Zn2+ and [2Fe-2S]-containing copper chaperone from Archaeoglobus fulgidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE PROTEIN; N-TERMINAL DOMAIN; HEAVY-METAL TRANSPORT; IRON-SULFUR PROTEINS; P-TYPE ATPASES; BINDING DOMAIN; MENKES-DISEASE; CU+-ATPASE; ATX1 METALLOCHAPERONE; ENTEROCOCCUS-HIRAE	Bacterial CopZ proteins deliver copper to P-1B- type Cu =ATPases that are homologous to the human Wilson and Menkes disease proteins. The genome of the hyperthermophile Archaeoglobus fulgidus encodes a putative CopZ copper chaperone that contains an unusual cysteine-rich N-terminal domain of 130 amino acids in addition to a C-terminal copper binding domain with a conserved CXXC motif. The N-terminal domain (CopZ- NT) is homologous to proteins found only in extremophiles and is the only such protein that is fused to a copper chaperone. Surprisingly, optical, electron paramagnetic resonance, and x- ray absorption spectroscopic data indicate the presence of a [2Fe- 2S] cluster in CopZ- NT. The intact CopZ protein binds two copper ions, one in each domain. The 1.8 angstrom resolution crystal structure of CopZ- NT reveals that the [2Fe-2S] cluster is housed within a novel fold and that the protein also binds a zinc ion at a four- cysteine site. CopZ can deliver Cu+ to the A. fulgidus CopA N- terminal metal binding domain and is capable of reducing Cu2+ to Cu+. This unique fusion of a redoxactive domain with a CXXC-containing copper chaperone domain is relevant to the evolution of copper homeostatic mechanisms and suggests new models for copper trafficking.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Worcester Polytechnic Institute; Northwestern University; Wayne State University	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA.	arguello@wpi.edu	; Arguello, Jose/D-1997-2012	LeMoine, Benjamin/0000-0001-9983-2488; Arguello, Jose/0000-0003-3940-6297	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL013531, R01HL013531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM073457, R01GM058518] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL013531, HL13531] Funding Source: Medline; NIDDK NIH HHS [DK068139, R01 DK068139, R01 DK068139-03] Funding Source: Medline; NIGMS NIH HHS [GM073457, R01 GM058518, GM58518] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achila D, 2006, P NATL ACAD SCI USA, V103, P5729, DOI 10.1073/pnas.0504472103; Ankudinov AL, 1997, PHYS REV B, V56, pR1712, DOI 10.1103/PhysRevB.56.R1712; Arguello JM, 2003, J MEMBRANE BIOL, V195, P93, DOI 10.1007/s00232-003-2048-2; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Banci L, 2003, J BIOL CHEM, V278, P50506, DOI 10.1074/jbc.M307389200; Banci L, 2001, BIOCHEMISTRY-US, V40, P15660, DOI 10.1021/bi0112715; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; Cobine PA, 2000, BIOCHEMISTRY-US, V39, P6857, DOI 10.1021/bi000015+; Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556; Cook JD, 2006, BIOCHEMISTRY-US, V45, P7767, DOI 10.1021/bi060424r; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; Crossnoe CR, 2002, J MOL BIOL, V318, P503, DOI 10.1016/S0022-2836(02)00051-7; Davydov A, 1997, J BIOL CHEM, V272, P7022, DOI 10.1074/jbc.272.11.7022; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hsi G, 2004, HUM GENET, V114, P165, DOI 10.1007/s00439-003-1045-y; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Kaim W, 1996, ANGEW CHEM INT EDIT, V35, P43, DOI 10.1002/anie.199600431; Kletzin A, 2004, J BIOENERG BIOMEMBR, V36, P77, DOI 10.1023/B:JOBB.0000019600.36757.8c; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE PA, 1981, REV MOD PHYS, V53, P769, DOI 10.1103/RevModPhys.53.769; Lieberman RL, 2006, INORG CHEM, V45, P8372, DOI 10.1021/ic060739v; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P7; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Lund O., CASP5 C; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mana-Capelli S, 2003, J BIOL CHEM, V278, P40534, DOI 10.1074/jbc.M306907200; Mandal AK, 2003, BIOCHEMISTRY-US, V42, P11040, DOI 10.1021/bi034806y; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Messerschmidt A., 2001, HDB METALLOPROTEINS; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RIGGSGELASCO PJ, 1995, COORDIN CHEM REV, V144, P245, DOI 10.1016/0010-8545(95)01144-E; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sarkar B, 1999, CHEM REV, V99, P2535, DOI 10.1021/cr980446m; Sazinsky MH, 2006, BIOCHEMISTRY-US, V45, P9949, DOI 10.1021/bi0610045; Sazinsky MH, 2006, J BIOL CHEM, V281, P11161, DOI 10.1074/jbc.M510708200; Solioz M, 2003, FEMS MICROBIOL REV, V27, P183, DOI 10.1016/S0168-6445(03)00053-6; Solomon EI, 2004, CHEM REV, V104, P419, DOI 10.1021/cr0206317; Stetter KO, 1999, FEBS LETT, V452, P22, DOI 10.1016/S0014-5793(99)00663-8; Sticht H, 1998, PROG BIOPHYS MOL BIO, V70, P95, DOI 10.1016/S0079-6107(98)00027-3; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Yatsunyk LA, 2007, J BIOL CHEM, V282, P8622, DOI 10.1074/jbc.M609533200	62	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25950	25959		10.1074/jbc.M703311200	http://dx.doi.org/10.1074/jbc.M703311200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17609202	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000249014100080
J	Versteeg, HH; Ruf, W				Versteeg, Henri H.; Ruf, Wolfram			Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VIIA; FACTOR-X; ACTIVATED PLATELETS; CATALYTIC FUNCTION; COFACTOR FUNCTION; LIPID RAFTS; CELL; SURFACE; COMPLEX; BINDING	Protein-disulfide isomerase ( PDI) switches tissue factor ( TF) from coagulation to signaling by targeting the allosteric Cys(186)-Cys(209) disulfide. Here, we further characterize the interaction of purified PDI with TF. We find that PDI enhances factor VIIa-dependent substrate factor X activation 5-10-fold in the presence of wild-type, oxidized soluble TF but not TF mutants that contain an unpaired Cys(186) or Cys(209). PDI-accelerated factor Xa generation was blocked by bacitracin but not influenced by inhibition of vicinal thiols, reduction of PDI, changes in redox gradients, or covalent thiol modification of reduced PDI by N-ethylmaleimide or methyl-methanethiosulfonate, which abolished PDI oxidoreductase but not chaperone activity. PDI had no effect on fully active TF on either negatively charged phospholipids or in activating detergent, indicating that PDI selectively acts upon cryptic TF to facilitate ternary complex formation and macromolecular substrate turnover. PDI activation was reduced upon mutation of TF residues in proximity to the macromolecular substrate binding site, consistent with a primary interaction of PDI with TF. PDI enhanced TF coagulant activity on microvesicles shed from cells, suggesting that PDI plays a role as an activating chaperone for circulating cryptic TF.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Ruf, W (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruf@scripps.edu	Versteeg, Henri/G-1783-2018	Versteeg, Henri/0000-0003-4294-175X	NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Bach RR, 2006, ARTERIOSCL THROM VAS, V26, P456, DOI 10.1161/01.ATV.0000202656.53964.04; Bajaj SP, 2006, J BIOL CHEM, V281, P24873, DOI 10.1074/jbc.M509971200; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Belting M, 2005, ARTERIOSCL THROM VAS, V25, P1545, DOI 10.1161/01.ATV.0000171155.05809.bf; CHEN K, 1995, BRIT J HAEMATOL, V90, P425, DOI 10.1111/j.1365-2141.1995.tb05169.x; Chen VM, 2006, BIOCHEMISTRY-US, V45, P12020, DOI 10.1021/bi061271a; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; Dietzen DJ, 2004, BLOOD, V103, P3038, DOI 10.1182/blood-2003-07-2399; Donate F, 2000, BIOCHEMISTRY-US, V39, P11467, DOI 10.1021/bi000986p; Dorfleutner A, 2004, MOL BIOL CELL, V15, P4416, DOI 10.1091/mbc.E03-09-0640; Dorfleutner A, 2003, BLOOD, V102, P3998, DOI 10.1182/blood-2003-04-1149; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Essex DW, 2006, CURR DRUG TARGETS, V7, P1233, DOI 10.2174/138945006778559193; Essex DW, 2003, BIOCHEMISTRY-US, V42, P129, DOI 10.1021/bi0205045; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; Essex DW, 2001, BIOCHEMISTRY-US, V40, P6070, DOI 10.1021/bi002454e; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; Falati S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782; FIORE MM, 1994, J BIOL CHEM, V269, P143; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; Karala AR, 2007, ANTIOXID REDOX SIGN, V9, P527, DOI 10.1089/ars.2006.1473; Kelly CR, 1996, BIOCHEM J, V315, P145, DOI 10.1042/bj3150145; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; Lahav J, 2003, BLOOD, V102, P2085, DOI 10.1182/blood-2002-06-1646; Lahav J, 2002, BLOOD, V100, P2472, DOI 10.1182/blood-2001-12-0339; LE DT, 1994, THROMB HAEMOSTASIS, V72, P848; LE DT, 1992, J BIOL CHEM, V267, P15447; Mackman N, 2004, ARTERIOSCL THROM VAS, V24, P1015, DOI 10.1161/01.ATV.0000130465.23430.74; Mandal SK, 2005, BLOOD, V105, P153, DOI 10.1182/blood-2004-03-0990; Mulder AB, 1996, BLOOD, V88, P1306, DOI 10.1182/blood.V88.4.1306.bloodjournal8841306; Norledge BV, 2003, PROTEINS, V53, P640, DOI 10.1002/prot.10445; Persson E, 2001, P NATL ACAD SCI USA, V98, P13583, DOI 10.1073/pnas.241339498; Petrovan RJ, 2002, BIOCHEMISTRY-US, V41, P9302, DOI 10.1021/bi0202169; Petrovan RJ, 2001, J BIOL CHEM, V276, P6616, DOI 10.1074/jbc.M004726200; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; Rogelj S, 2000, BIOCHEM BIOPH RES CO, V273, P829, DOI 10.1006/bbrc.2000.3029; Root P, 2004, BIOCHEM J, V382, P575, DOI 10.1042/BJ20040759; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1993, METHOD ENZYMOL, V222, P209; Schultz-Norton JR, 2006, MOL ENDOCRINOL, V20, P1982, DOI 10.1210/me.2006-0006; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Sliskovic I, 2005, J BIOL CHEM, V280, P8733, DOI 10.1074/jbc.M408080200; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Versteeg HH, 2006, SEMIN THROMB HEMOST, V32, P24, DOI 10.1055/s-2006-933337; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhang J, 2003, CIRCULATION, V108, P623, DOI 10.1161/01.CIR.0000078642.45127.7B	60	100	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25416	25424		10.1074/jbc.M702410200	http://dx.doi.org/10.1074/jbc.M702410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17613528	hybrid			2022-12-25	WOS:000249014100027
J	Ocorr, KA; Crawley, T; Gibson, G; Bodmer, R				Ocorr, Karen A.; Crawley, Timothy; Gibson, Greg; Bodmer, Rolf			Genetic Variation for Cardiac Dysfunction in Drosophila	PLOS ONE			English	Article								Background. Common diseases may be attributed to combinations of variant alleles, but there are few model systems where the interactions among such variants can be studied in controlled genetic crosses. While association studies are designed to detect common polymorphisms of moderate effect, new approaches are required to characterize the impact on disease of interactions among rare alleles. Methodology/Principal Findings. We show that wild populations of Drosophila melanogaster harbor rare polymorphisms of major effect (RAME) that predispose flies to a specific disease phenotype, age-dependent cardiac dysfunction. A screen of fifty inbred wild-type lines revealed a continuous spectrum of pacing-induced heart failure that generally increases in frequency with age. High-speed video analysis of the inbred lines with high rates of inducible heart failure indicates specific defects in cardiac function, including arrhythmias and contractile disorders ('cardiomyopathies'). A combination of bulked segregant analysis and single feature polymorphism (SFP) detection localizes one of the cardiac susceptibility loci to the 97C interval on the fly genome. Conclusions/Significance. Wild-type Drosophila, like humans, are predisposed to cardiac dysfunction. Identification of factors associated with these naturally occurring cardiac traits promises to provide important insights into the epidemiology of cardiac disease.	[Gibson, Greg] N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; [Ocorr, Karen A.; Crawley, Timothy; Bodmer, Rolf] Burnham Inst Med Res, Ctr Neurosci & Aging, La Jolla, CA USA	University of North Carolina; North Carolina State University; Sanford Burnham Prebys Medical Discovery Institute	Gibson, G (corresponding author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.	ggibson@unity.ncsu.edu; rolf@burnham.org		Ocorr, Karen/0000-0003-2593-0119	National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute at the National Institutes of Health	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Heart, Lung, and Blood Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the National Institute of General Medical Sciences and the National Heart, Lung, and Blood Institute at the National Institutes of Health.	Akasaka T, 2006, P NATL ACAD SCI USA, V103, P11999, DOI 10.1073/pnas.0603098103; Bier E, 2005, NAT REV GENET, V6, P9, DOI 10.1038/nrg1503; Bier E, 2004, GENE, V342, P1, DOI 10.1016/j.gene.2004.07.018; Borevitz JO, 2002, GENETICS, V160, P683; Borevitz Justin, 2006, V323, P137; Dowse H, 1995, J NEUROGENET, V10, P153, DOI 10.3109/01677069509083461; Gibson G, 2002, GENET RES, V80, P1, DOI 10.1017/S0016672302005839; Mackay TFC, 2004, CURR OPIN GENET DEV, V14, P253, DOI 10.1016/j.gde.2004.04.003; Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537; Nikoh N, 2004, GENETICS, V168, P1963, DOI 10.1534/genetics.104.028712; Ocorr K, 2007, P NATL ACAD SCI USA, V104, P3943, DOI 10.1073/pnas.0609278104; Palsson A, 2004, GENETICS, V167, P1199, DOI 10.1534/genetics.104.026252; RISCH N, 1996, SCIENCE, V273, P1517; Robbins J, 1999, GENET RES, V74, P121, DOI 10.1017/S0016672399003924; Taylor Matthew R, 2006, Novartis Found Symp, V274, P73; Wessel RJ, 2004, BIOTECHNIQUES, V37, P58, DOI 10.2144/04371ST01; Wessells RJ, 2004, NAT GENET, V36, P1275, DOI 10.1038/ng1476; Wolf MJ, 2006, P NATL ACAD SCI USA, V103, P1394, DOI 10.1073/pnas.0507359103	18	26	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e601	10.1371/journal.pone.0000601	http://dx.doi.org/10.1371/journal.pone.0000601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622346	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452000008
J	Hemond, CC; Kanwisher, NG; Op de Beeck, HP				Hemond, Christopher C.; Kanwisher, Nancy G.; Op de Beeck, Hans P.			A Preference for Contralateral Stimuli in Human Object- and Face-Selective Cortex	PLOS ONE			English	Article								Visual input from the left and right visual fields is processed predominantly in the contralateral hemisphere. Here we investigated whether this preference for contralateral over ipsilateral stimuli is also found in high-level visual areas that are important for the recognition of objects and faces. Human subjects were scanned with functional magnetic resonance imaging ( fMRI) while they viewed and attended faces, objects, scenes, and scrambled images in the left or right visual field. With our stimulation protocol, primary visual cortex responded only to contralateral stimuli. The contralateral preference was smaller in object- and face-selective regions, and it was smallest in the fusiform gyrus. Nevertheless, each region showed a significant preference for contralateral stimuli. These results indicate that sensitivity to stimulus position is present even in high-level ventral visual cortex.	[Hemond, Christopher C.; Kanwisher, Nancy G.; Op de Beeck, Hans P.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA; [Hemond, Christopher C.; Kanwisher, Nancy G.; Op de Beeck, Hans P.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; [Kanwisher, Nancy G.] Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Op de Beeck, Hans P.] Univ Leuven KU Leuven, Expt Psychol Lab, Louvain, Belgium	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); KU Leuven	Op de Beeck, HP (corresponding author), MIT, McGovern Inst Brain Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	hans.opdebeeck@psy.kuleuven.be	Hemond, Christopher/AAJ-7568-2020	Hemond, Christopher/0000-0002-2408-4638; Op de Beeck, Hans/0000-0002-2250-212X	McGovern Institute for Brain Research [EY13455, R21-NS0490SZ]; National Center for Research Resources [P41-RR14075, R01 RR16594-01A1, BIRN002]; Mental Illness and Neuroscience Discovery (MIND) Institute; (FEDRA) of Belgium [IUAP P6/29]; Human Frontier Science Program; Fund for Scientific Research - Flanders; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR016594, P41RR014075] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013455] Funding Source: NIH RePORTER	McGovern Institute for Brain Research; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Mental Illness and Neuroscience Discovery (MIND) Institute; (FEDRA) of Belgium; Human Frontier Science Program(Human Frontier Science Program); Fund for Scientific Research - Flanders(FWO); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by grants EY13455 and R21-NS0490SZ (N.G.K.), the McGovern Institute for Brain Research, the National Center for Research Resources (P41-RR14075, R01 RR16594-01A1 and the NCRR BIRN Morphometric Project BIRN002), the Mental Illness and Neuroscience Discovery ( MIND) Institute, and a federal research action (FEDRA) of Belgium ( grant IUAP P6/29). Hans P. Op de Beeck was supported by the Human Frontier Science Program and the Fund for Scientific Research - Flanders.	Brewer AA, 2005, NAT NEUROSCI, V8, P1102, DOI 10.1038/nn1507; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DiCarlo JJ, 2003, J NEUROPHYSIOL, V89, P3264, DOI 10.1152/jn.00358.2002; Eger E, 2004, NEUROIMAGE, V22, P232, DOI 10.1016/j.neuroimage.2003.12.028; Eger E, 2005, NEUROIMAGE, V26, P1128, DOI 10.1016/j.neuroimage.2005.03.010; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Grill-Spector K, 1999, NEURON, V24, P187, DOI 10.1016/S0896-6273(00)80832-6; Grill-Spector K, 1998, HUM BRAIN MAPP, V6, P316, DOI 10.1002/(SICI)1097-0193(1998)6:4<316::AID-HBM9>3.0.CO;2-6; Grill-Spector K, 2004, ANNU REV NEUROSCI, V27, P649, DOI 10.1146/annurev.neuro.27.070203.144220; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; Larsson J, 2006, J NEUROSCI, V26, P13128, DOI 10.1523/JNEUROSCI.1657-06.2006; Levy I, 2001, NAT NEUROSCI, V4, P533, DOI 10.1038/87490; MARSOLEK CJ, 1995, J EXP PSYCHOL HUMAN, V21, P375, DOI 10.1037/0096-1523.21.2.375; Newell FN, 2005, VISION RES, V45, P2065, DOI 10.1016/j.visres.2005.02.021; Niemeier M, 2005, CEREB CORTEX, V15, P325, DOI 10.1093/cercor/bhh134; Op De Beeck H, 2000, J COMP NEUROL, V426, P505, DOI 10.1002/1096-9861(20001030)426:4<505::AID-CNE1>3.0.CO;2-M; Op de Beeck HP, 2006, J NEUROSCI, V26, P13025, DOI 10.1523/JNEUROSCI.2481-06.2006; Pourtois G, 2005, J COGNITIVE NEUROSCI, V17, P1043, DOI 10.1162/0898929054475181; ROLLS ET, 2004, VISUAL NEUROSCIENCES, P1165; Rousselet GA, 2004, TRENDS COGN SCI, V8, P363, DOI 10.1016/j.tics.2004.06.003; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Vuilleumier P, 2002, NAT NEUROSCI, V5, P491, DOI 10.1038/nn839	22	120	120	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e574	10.1371/journal.pone.0000574	http://dx.doi.org/10.1371/journal.pone.0000574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593973	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451800018
J	Lefevre, J; Michaud, SE; Haddad, P; Dussault, S; Menard, C; Groleau, J; Turgeon, J; Rivard, A				Lefevre, Jonas; Michaud, Sophie-Elise; Haddad, Paola; Dussault, Sylvie; Menard, Catherine; Groleau, Jessika; Turgeon, Julie; Rivard, Alain			Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide	FASEB JOURNAL			English	Article						hypercholesterolemia; resveratrol	CIGARETTE-SMOKE EXPOSURE; GROWTH-FACTOR; MOUSE MODEL; RESVERATROL; ANGIOGENESIS; IMPAIRMENT; EXPRESSION; MIGRATION; VEGF; VASCULOGENESIS	Moderate consumption of red wine is associated with a decreased incidence of cardiovascular diseases in populations with relatively high amount of fat in the diet. However, the mechanisms involved in this protective effect are not completely understood. Here we show that moderate consumption of red wine ( equivalent to 2 glasses/ day in humans) but not ethanol only, improves blood flow recovery by 32% after hindlimb ischemia in hypercholesterolemic ApoE- deficient mice. In ischemic tissues, red wine consumption reduces oxidative stress and increases capillary density by 46%. Endothelial progenitor cells ( EPCs) have been shown to have an important role in postnatal neovascularization. We found that the number of EPCs is increased by 60% in ApoE mice exposed to red wine. Moreover, the migratory capacity of EPCs is significantly improved in red wine- drinking mice. The wine used in our study is a cabernet sauvignon from Langue-doc-Roussillon, France, which contains a relatively high concentration ( 4 - 6 mg/ L) of the polyphenolic antioxidant resveratrol. We demonstrate that resveratrol can rescue oxidized low- density lipoprotein ( oxLDL)- induced impairment of in vitro angiogenic activities in human umbilical vein endothelial cells ( HUVECs). Resveratrol exposure is also associated with increased activation of Akt/ eNOS together with a restoration of nitric oxide production in HUVECs exposed to oxLDL. Our study suggests that moderate consumption of red wine improves ischemia- induced neovascularization in high- cholesterol conditions by increasing the number and the functional activities of EPCs and by restoring the Akt- eNOS- NO pathway.	Univ Montreal, Ctr Hosp, Dept Cardiovasc Res, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Rivard, A (corresponding author), Univ Montreal, Ctr Hosp, 1560 Sherbrooke Est, Montreal, PQ H2L 4MI, Canada.	rivardal@total.net						Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bohm M, 2004, NEPHROL DIAL TRANSPL, V19, P11, DOI 10.1093/ndt/gfg340; Chen JZ, 2004, CLIN SCI, V107, P273, DOI 10.1042/CS20030389; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Couffinhal T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DEMROW HS, 1995, CIRCULATION, V91, P1182, DOI 10.1161/01.CIR.91.4.1182; Dernbach E, 2004, BLOOD, V104, P3591, DOI 10.1182/blood-2003-12-4103; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FITZPATRICK DF, 1993, AM J PHYSIOL, V265, pH774; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; FUHRMAN B, 1995, AM J CLIN NUTR, V61, P549, DOI 10.1093/ajcn/61.3.549; GOLDBERG DM, 1995, AM J ENOL VITICULT, V46, P159; GRONBECK M, 1995, BRIT MED J, V310, P1169; Iijima K, 2000, CIRCULATION, V101, P805, DOI 10.1161/01.CIR.101.7.805; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Lekakis J, 2005, EUR J CARDIOV PREV R, V12, P596, DOI 10.1097/00149831-200512000-00013; Michaud SE, 2003, FASEB J, V17, P1150, DOI 10.1096/fj.02-0172fje; Michaud SE, 2006, ATHEROSCLEROSIS, V187, P423, DOI 10.1016/j.atherosclerosis.2005.10.009; Michaud SE, 2006, J MOL CELL CARDIOL, V41, P275, DOI 10.1016/j.yjmcc.2006.05.004; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Ndiaye M, 2004, FASEB J, V18, DOI 10.1096/fj.04-2146fje; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Olas B, 2001, MICROBIOS, V105, P7; Orsini F, 1997, J NAT PROD, V60, P1082, DOI 10.1021/np970069t; Ou HC, 2006, CLIN CHIM ACTA, V364, P196, DOI 10.1016/j.cccn.2005.06.018; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Rivard A, 1998, MOL MED, V4, P429, DOI 10.1007/BF03401749; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Thum T, 2007, ARTERIOSCL THROM VAS, V27, P748, DOI 10.1161/01.ATV.0000258787.18982.73; Urbich C, 2002, CIRCULATION, V106, P981, DOI 10.1161/01.CIR.0000027107.54614.1A; Urpi-Sarda M, 2005, ANAL CHEM, V77, P3149, DOI 10.1021/ac0484272; VanBelle E, 1997, CIRCULATION, V96, P2667, DOI 10.1161/01.CIR.96.8.2667; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Wang J, 2006, FASEB J, V20, P2313, DOI 10.1096/fj.06-6281com	41	67	68	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3845	3852		10.1096/fj.06-7491com	http://dx.doi.org/10.1096/fj.06-7491com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17641150				2022-12-25	WOS:000251283500009
J	Rojas, RJ; Yohe, ME; Gershburg, S; Kawano, T; Kozasa, T; Sondek, J				Rojas, Rafael J.; Yohe, Marielle E.; Gershburg, Svetlana; Kawano, Takeharu; Kozasa, Tohru; Sondek, John			G alpha(q) directly activates p63RhoGEF and trio via a conserved extension of the Dbl homology-associated pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; RHO-GTPASES; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; CARDIAC MYOCYTES; FACTOR GEFT; HELA-CELLS; G-PROTEINS; RECEPTOR	The coordinated cross-talk from heterotrimeric G proteins to Rho GTPases is essential during a variety of physiological processes. Emerging data suggest that members of the G alpha(12/13) and G alpha(q/11) families of heterotrimeric G proteins signal downstream to RhoA via distinct pathways. Although studies have elucidated mechanisms governing G alpha(12/13)-mediated RhoA activation, proteins that functionally couple G alpha(q/11) to RhoA activation have remained elusive. Recently, the Dbl- family guanine nucleotide exchange factor (GEF) p63RhoGEF/GEFT has been described as a novel mediator of G alpha(q/11) signaling to RhoA based on its ability to synergize with G alpha(q/11) resulting in enhanced RhoA signaling in cells. Wehave used biochemical/biophysical approaches with purified protein components to better understand the mechanism by which activated G alpha(q) directly engages and stimulates p63RhoGEF. Basally, p63RhoGEF is autoinhibited by the Dbl homology (DH)-associated pleckstrin homology (PH) domain; activated G alpha(q) relieves this autoinhibition by interacting with a highly conserved C-terminal extension of the PH domain. This unique extension is conserved in the related Dbl- family members Trio and Kalirin and we show that the C-terminal Rho-specific DH-PH cassette of Trio is similarly activated by G alpha(q)	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1100 MEJ Bldg, Chapel Hill, NC 27599 USA.	sondek@med.unc.edu		Sondek, John/0000-0002-1127-8310	NIGMS NIH HHS [R01 GM062299, R01-GM62299, R01 GM062299-05A1, R01 GM6145408, P01-GM65533, P01 GM065533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299, P01GM065533, R01GM061454] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; Bateman J, 2001, J CELL SCI, V114, P1973; Bryan B, 2004, J BIOL CHEM, V279, P45824, DOI 10.1074/jbc.M406216200; Bryan BA, 2005, MOL CELL BIOL, V25, P11089, DOI 10.1128/MCB.25.24.11089-11101.2005; Bryan BA, 2006, J NEUROSCI RES, V83, P1151, DOI 10.1002/jnr.20814; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chhatriwala MK, 2007, J MOL BIOL, V368, P1307, DOI 10.1016/j.jmb.2007.02.060; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DiNitto JP, 2006, BBA-MOL CELL BIOL L, V1761, P850, DOI 10.1016/j.bbalip.2006.04.008; Dutt P, 2002, FEBS LETT, V531, P565, DOI 10.1016/S0014-5793(02)03625-6; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Guo XG, 2003, J BIOL CHEM, V278, P13207, DOI 10.1074/jbc.M208896200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; Johnston CA, 2005, STRUCTURE, V13, P1069, DOI 10.1016/j.str.2005.04.007; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Kreutz B, 2006, BIOCHEMISTRY-US, V45, P167, DOI 10.1021/bi051729t; Liu D, 2000, ONCOGENE, V19, P5964, DOI 10.1038/sj.onc.1203992; Lutz S, 2005, J BIOL CHEM, V280, P11134, DOI 10.1074/jbc.M411322200; Lutz S, 2004, N-S ARCH PHARMACOL, V369, P540, DOI 10.1007/s00210-004-0926-5; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; Penzes P, 2001, J NEUROSCI, V21, P8426, DOI 10.1523/JNEUROSCI.21-21-08426.2001; Rabiner CA, 2005, NEUROSCIENTIST, V11, P148, DOI 10.1177/1073858404271250; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Souchet M, 2002, J CELL SCI, V115, P629; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; Ueda H, 2001, J BIOL CHEM, V276, P42527, DOI 10.1074/jbc.M102529200; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yohe ME, 2007, J BIOL CHEM, V282, P13813, DOI 10.1074/jbc.M700185200	54	105	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29201	29210		10.1074/jbc.M703458200	http://dx.doi.org/10.1074/jbc.M703458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17606614	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000249788000016
J	Gardoni, F; Mauceri, D; Marcello, E; Sala, C; Di Luca, M; Jeromin, A				Gardoni, Fabrizio; Mauceri, Daniela; Marcello, Elena; Sala, Carlo; Di Luca, Monica; Jeromin, Andreas			SAP97 directs the localization of Kv4.2 to spines in hippocampal neurons - Regulation by CaMKII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-ASSOCIATED PROTEIN-97; NMDA RECEPTOR; KINASE-II; POTASSIUM CHANNEL; EXPRESSION; PHOSPHORYLATION; TRAFFICKING; PSD-95; MODULATION; SUBUNITS	The pore-forming alpha-subunit Kv4.2 is a key constituent of the A-type channel and critically involved in the regulation of dendritic excitability and plasticity. Here we show that Kv4.2 is enriched in the postsynaptic density (PSD) fraction and specifically interacts with synapse-associated protein 97 (SAP97). This interaction requires an intact C terminus of Kv4.2 and occurs via the PDZ domains of SAP97. Pharmacologically induced translocation of SAP97 to spines also drives Kv4.2 to the PSD, whereas SAP97 lentivirally based RNA interference reduces Kv4.2 in the PSD. In addition, calcium/calmodulin-dependent protein kinase II (CaMKII)-dependent SAP97 phosphorylation regulates the subcellular localization of Kv4.2. These results show that SAP97-CaMKII pathway plays an important role for the trafficking of Kv4.2 to dendrites and spines.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; Univ Milan, Cellular & Mol Pharmacol Sect, Inst Neurosci, CNR, I-20129 Milan, Italy; Univ Texas, Ctr Learning & Memory, Austin, TX 78712 USA	University of Milan; University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Texas System; University of Texas Austin	Jeromin, A (corresponding author), Allen Inst Brain Sci, 551 N 34th St, Seattle, WA 98103 USA.	andreasj@alleninstitute.org	DiLuca, Monica/A-7632-2012; Mauceri, Daniela/C-4969-2014; Marcello, Elena/A-4687-2015; Gardoni, Fabrizio/A-3135-2009; Sala, Carlo/A-2493-2009	DiLuca, Monica/0000-0003-2298-615X; Mauceri, Daniela/0000-0003-1225-4633; Marcello, Elena/0000-0003-0452-762X; Gardoni, Fabrizio/0000-0003-4598-5563; Sala, Carlo/0000-0003-0662-9523	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U24NS050606] Funding Source: NIH RePORTER; NINDS NIH HHS [U24NS050606] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Folco EJ, 2004, AM J PHYSIOL-HEART C, V287, pH681, DOI 10.1152/ajpheart.00152.2004; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2003, J BIOL CHEM, V278, P44745, DOI 10.1074/jbc.M303576200; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Jeromin A, 2003, J NEUROPHYSIOL, V90, P2741, DOI 10.1152/jn.00464.2003; Kunjilwar K, 2004, J BIOL CHEM, V279, P54542, DOI 10.1074/jbc.M409721200; Lai HC, 2006, NAT REV NEUROSCI, V7, P548, DOI 10.1038/nrn1938; Leonoudakis D, 2004, J BIOL CHEM, V279, P22331, DOI 10.1074/jbc.M400285200; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Mauceri D, 2007, J NEUROCHEM, V100, P1032, DOI 10.1111/j.1471-4159.2006.04267.x; Mauceri D, 2004, J BIOL CHEM, V279, P23813, DOI 10.1074/jbc.M402796200; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; Rhodes KJ, 2004, J NEUROSCI, V24, P7903, DOI 10.1523/JNEUROSCI.0776-04.2004; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Schluter OM, 2006, NEURON, V51, P99, DOI 10.1016/j.neuron.2006.05.016; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Varga AW, 2004, J NEUROSCI, V24, P3643, DOI 10.1523/JNEUROSCI.0154-04.2004; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200	29	37	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28691	28699		10.1074/jbc.M701899200	http://dx.doi.org/10.1074/jbc.M701899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17635915	hybrid			2022-12-25	WOS:000249642100043
J	Annis, DS; Gunderson, KA; Mosher, DF				Annis, Douglas S.; Gunderson, Kristin A.; Mosher, Deane F.			Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; C-TERMINAL REGION; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; BIOPHYSICAL CHARACTERIZATION; TYPE-1; REPEATS; ASSIGNMENTS; EXPRESSION; EPITOPES	Thrombospondins (TSPs) undergo conformational changes upon removal of calcium. The eight C-type and five N-type calcium-binding repeats of TSP-2 form a circuitous wire that, in 2 mM calcium, interacts at its ends with more N-terminal epidermal growth factor (EGF)-like modules, EGF2 and EGF3, and the C-terminal lectin-like module. These components, along with the other EGF-like module(s), form the signature domain of TSPs. Characterization of conformation-sensitive epitopes of monoclonal antibodies to human TSP-2 and its TSP-1 homolog have given insights into the structure of the signature domain in the absence of calcium. The epitope for 4B6.13 anti-TSP-2 was localized to His-722 and Leu-703 in repeat 1C of the wire; recognition only occurred in constructs that included EGF3, the rest of the wire, and the lectin-like module and in the presence of calcium. The epitope for C6.7 anti-TSP-1 was localized to Glu-609 in the EGF2 module. The C6.7 epitope was preferentially recognized when EGF2 was expressed in the context of EGF1, EGF3, the wire, and the lectin-like module. Preferential recognition of the C6.7 epitope did not require calcium. Rotary shadowing electron microscopy of TSP-1 has shown elongation of the stalk and diminution of the C-terminal globule. We propose a model whereby at low calcium concentrations the lectin-like module drops away from EGF3 concomitant with changes in conformation of the wire and loss of the 4B6.13 epitope. A critical feature of the model is interaction of repeat 12N of the wire with EGF2 in both the presence and absence of calcium.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, Rm 4285 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@wisc.edu			NHLBI NIH HHS [R01 HL 054462] Funding Source: Medline; NIAMS NIH HHS [P60 AR 20614] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; Adams JC, 2004, INT J BIOCHEM CELL B, V36, P1102, DOI 10.1016/j.biocel.2004.01.022; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Annis DS, 2006, J THROMB HAEMOST, V4, P459, DOI 10.1111/j.1538-7836.2006.01723.x; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Carlson CB, 2005, NAT STRUCT MOL BIOL, V12, P910, DOI 10.1038/nsmb997; Chen H, 1996, FEBS LETT, V387, P36, DOI 10.1016/0014-5793(96)00460-7; CHEN H, 1994, J BIOL CHEM, V269, P32226; Chen H, 1996, J BIOL CHEM, V271, P15993, DOI 10.1074/jbc.271.27.15993; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1982, J BIOL CHEM, V257, P2257; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Misenheimer TM, 2005, J BIOL CHEM, V280, P41229, DOI 10.1074/JBC.M504696200; Misenheimer TM, 2003, BIOCHEMISTRY-US, V42, P5125, DOI 10.1021/bi026983p; Misenheimer TM, 2001, J BIOL CHEM, V276, P45882, DOI 10.1074/jbc.M104218200; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; O'Leary JM, 2004, J BIOL CHEM, V279, P53857, DOI 10.1074/jbc.M409225200; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Wiltscheck R, 1997, PROTEIN SCI, V6, P1734, DOI 10.1002/pro.5560060814	29	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27067	27075		10.1074/jbc.M703804200	http://dx.doi.org/10.1074/jbc.M703804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17620335	hybrid			2022-12-25	WOS:000249304900048
J	Calvo, E; Tokumasu, F; Marinotti, O; Villeval, JL; Ribeiro, JMC; Francischetti, IMB				Calvo, Eric; Tokumasu, Fuyuki; Marinotti, Osvaldo; Villeval, Jean-Luc; Ribeiro, Jose M. C.; Francischetti, Ivo M. B.			Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin alpha 2 beta 1, and von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT FEMALE MOSQUITO; THROMBUS FORMATION; AGGREGATION INHIBITOR; ACTIVATION; INTEGRIN; ADHESION; GPVI; EXPRESSION; RECEPTOR; CLONING	Blood-sucking arthropods have evolved a number of inhibitors of platelet aggregation and blood coagulation. In this study we have molecularly and functionally characterized aegyptin, a member of the family of 30-kDa salivary allergens from Aedes aegypti, whose function remained elusive thus far. Aegyptin displays a unique sequence characterized by glycine, glutamic acid, and aspartic acid repeats and was shown to specifically block collagen-induced human platelet aggregation and granule secretion. Plasmon resonance experiments demonstrate that aegyptin binds to collagen types I-V (Kd approximate to 1 nM) but does not interact with vitronectin, fibronectin, laminin, fibrinogen, and von Willebrand factor (vWf). In addition, aegyptin attenuates platelet adhesion to soluble or fibrillar collagen. Furthermore, aegyptin inhibits vWf interaction with collagen type III under static conditions and completely blocks platelet adhesion to collagen under flow conditions at high shear rates. Notably, aegyptin prevents collagen but not convulxin binding to recombinant glycoprotein VI. These findings suggest that aegyptin recognizes specific binding sites for glycoprotein VI, integrin alpha 2 beta 1, and vWf, thereby preventing collagen interaction with its three major ligands. Aegyptin is a novel tool to study collagen-platelet interaction and a prototype for development of molecules with antithrombotic properties.	NIH, NIAID, Biol Sect, Lab Malaria & Vector, Bethesda, MD 20892 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Paris 11, INSERM, Inst Gustave Roussy, F-94805 Villejuif, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Irvine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Francischetti, IMB (corresponding author), NIH, NIAID, Biol Sect, Lab Malaria & Vector, 12735 Twinbrook Pkwy Rm 2E-28, Bethesda, MD 20892 USA.	ifrancischetti@niaid.nih.gov	Tokumasu, Fuyuki/GQP-4413-2022; Calvo, Eric/ABB-4935-2021	Tokumasu, Fuyuki/0000-0003-2790-1071; Calvo, Eric/0000-0001-7880-2730; Ribeiro, Jose/0000-0002-9107-0818; Marinotti, Osvaldo/0000-0002-7173-7160; Villeval, Jean-Luc/0000-0002-0562-925X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000099, Z01AI000810] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999, Z01 AI000810-11] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andersen JF, 2003, J BIOL CHEM, V278, P4611, DOI 10.1074/jbc.M211438200; Atkinson BT, 2003, J THROMB HAEMOST, V1, P1278, DOI 10.1046/j.1538-7836.2003.00245.x; Auger JM, 2005, FASEB J, V19, P825, DOI 10.1096/fj.04-1940fje; Barnes CS, 2001, SEMIN THROMB HEMOST, V27, P337, DOI 10.1055/s-2001-16887; Barnes MJ, 1999, EXP GERONTOL, V34, P513, DOI 10.1016/S0531-5565(99)00038-8; Calvo E, 2006, J BIOL CHEM, V281, P1935, DOI 10.1074/jbc.M510359200; Calvo E, 2004, INSECT MOL BIOL, V13, P73, DOI 10.1111/j.1365-2583.2004.00463.x; Cazares-Raga FE, 2007, INSECT MOL BIOL, V16, P187, DOI 10.1111/j.1365-2583.2006.00712.x; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; Chen H, 2003, MOL CELL BIOL, V23, P4764, DOI 10.1128/MCB.23.14.4764-4777.2003; CONNOLLY TM, 1992, J BIOL CHEM, V267, P6893; Cruz MA, 2005, BLOOD, V105, P1986, DOI 10.1182/blood-2004-04-1365; Davis JA, 2004, AM J SURG, V188, P778, DOI 10.1016/j.amjsurg.2004.08.061; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Francischetti IMB, 2007, J THROMB HAEMOST, V5, P155, DOI 10.1111/j.1538-7836.2006.02232.x; Francischetti IMB, 2000, J BIOL CHEM, V275, P12639, DOI 10.1074/jbc.275.17.12639; Francischetti IMB, 2002, BLOOD, V99, P3602, DOI 10.1182/blood-2001-12-0237; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Francischetti IMB, 2002, J EXP BIOL, V205, P2429; Furie B, 2005, J CLIN INVEST, V115, P3355, DOI 10.1172/JCI26987; Gibbins JM, 2004, J CELL SCI, V117, P3415, DOI 10.1242/jcs.01325; HARSFALVI J, 1995, BLOOD, V85, P705, DOI 10.1182/blood.V85.3.705.bloodjournal853705; Heemskerk JWM, 2005, TRENDS CARDIOVAS MED, V15, P86, DOI 10.1016/j.tcm.2005.03.003; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jariyapan N, 2006, J MED ENTOMOL, V43, P867, DOI 10.1603/0022-2585(2006)43[867:AGAGPI]2.0.CO;2; Jarvis GE, 2002, BRIT J PHARMACOL, V137, P107, DOI 10.1038/sj.bjp.0704834; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; KELLER PM, 1993, J BIOL CHEM, V268, P5450; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Lasser G, 2006, BLOOD, V107, P423, DOI 10.1182/blood-2005-04-1425; Lecut C, 2004, J BIOL CHEM, V279, P52293, DOI 10.1074/jbc.M406342200; Lisman T, 2006, BLOOD, V108, P3753, DOI 10.1182/blood-2006-03-011965; Mans BJ, 2002, J BIOL CHEM, V277, P21371, DOI 10.1074/jbc.M112060200; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; Moroi M, 1997, BLOOD, V90, P4413; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Munnix ICA, 2005, ARTERIOSCL THROM VAS, V25, P2673, DOI 10.1161/01.ATV.0000193568.71980.4a; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; Nazareth RA, 2006, THROMB HAEMOSTASIS, V96, P7, DOI 10.1160/TH06-02-0105; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Penz S, 2005, FASEB J, V19, P898, DOI 10.1096/fj.04-2748com; Raines EW, 2000, ANN NY ACAD SCI, V902, P39; Raynal N, 2006, J BIOL CHEM, V281, P3821, DOI 10.1074/jbc.M509818200; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; Ribeiro JMC, 2004, INSECT BIOCHEM MOLEC, V34, P543, DOI 10.1016/j.ibmb.2004.02.008; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; Ribeiro JMC, 2001, J EXP BIOL, V204, P3887; Ribeiro JMC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-6; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sarratt KL, 2005, BLOOD, V106, P1268, DOI 10.1182/blood-2004-11-4434; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Smethurst PA, 2007, J BIOL CHEM, V282, P1296, DOI 10.1074/jbc.M606479200; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Tokumasu F, 2003, J MICROSC-OXFORD, V211, P256, DOI 10.1046/j.1365-2818.2003.01219.x; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; VANZANTEN GH, 1995, ARTERIOSCL THROM VAS, V15, P1424, DOI 10.1161/01.ATV.15.9.1424; Vilahur G, 2004, THROMB HAEMOSTASIS, V92, P191, DOI 10.1160/TH03-11-0687; Watson SP, 2005, J THROMB HAEMOST, V3, P1752, DOI 10.1111/j.1538-7836.2005.01429.x	64	80	86	0	24	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26928	26938		10.1074/jbc.M705669200	http://dx.doi.org/10.1074/jbc.M705669200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17650501	hybrid, Green Accepted			2022-12-25	WOS:000249304900032
J	Lin, BC; Wang, M; Blackmore, C; Desnoyers, LR				Lin, Benjamin C.; Wang, Manping; Blackmore, Craig; Desnoyers, Luc R.			Liver-specific activities of FGF19 require Klotho beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; FIBROBLAST-GROWTH-FACTOR; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; TRANSGENIC MICE; METABOLIC-RATE; FIBROBLAST-GROWTH-FACTOR-19; EXPRESSION; CLONING	Hepatocyte function is regulated by members of the fibroblast growth factor (FGF) family of proteins, but little is known about the specific molecular mechanisms of this endocrine pathway. FGF19 regulates bile acid homeostasis and gall bladder filling; FGF19 binds only to FGF receptor 4 (FGFR4), but its liver-specific activity cannot be explained solely by the distribution of this receptor. Although it has been suggested that Klotho beta (KLB) may have a role in mediating FGF19 activity, we have provided for the first time definitive evidence that KLB is required for FGF19 binding to FGFR4, intracellular signaling, and downstream modulation of gene expression. We have shown that FGFR4 is widely distributed in mouse, whereas KLB distribution is more restricted. Liver was the only organ in which both genes were abundantly expressed. We show that in mice, FGF19 injection triggers liver-specific induction of c-Fos and repression of CYP7A1. The tissue-specific activity of FGF19 supports the unique intersection of KLB and FGFR4 distribution in liver. These studies define KLB as a novel FGFR4 co-receptor required for FGF19 liver specific functions.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Desnoyers, LR (corresponding author), 1 DNA Way, San Francisco, CA 94080 USA.	desnoyer@gene.com						Ashida Reiko, 2005, Inflammopharmacology, V13, P113, DOI 10.1163/156856005774423935; Chiang JYL, 2004, J HEPATOL, V40, P539, DOI 10.1016/j.jhep.2003.11.006; Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501; Fu L, 2004, ENDOCRINOLOGY, V145, P2594, DOI 10.1210/en.2003-1671; Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2005, J CLIN INVEST, V115, P2202, DOI 10.1172/JCI23076; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; LI YC, 1990, J BIOL CHEM, V265, P12012; Lundasen T, 2006, J INTERN MED, V260, P530, DOI 10.1111/j.1365-2796.2006.01731.x; Nicholes K, 2002, AM J PATHOL, V160, P2295, DOI 10.1016/S0002-9440(10)61177-7; Ogawa Y, 2007, P NATL ACAD SCI USA, V104, P7432, DOI 10.1073/pnas.0701600104; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; Trauner M, 2004, CURR OPIN GASTROEN, V20, P220, DOI 10.1097/00001574-200405000-00006; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485	25	209	230	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27277	27284		10.1074/jbc.M704244200	http://dx.doi.org/10.1074/jbc.M704244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627937	hybrid			2022-12-25	WOS:000249304900069
J	Nishi, K; Saigo, K				Nishi, Kenji; Saigo, Kaoru			Cellular internalization of green fluorescent protein fused with herpes simplex virus protein VP22 via a lipid raft-mediated endocytic pathway independent of caveolae and rho family GTPases but dependent on dynamin and Arf6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-FUSION PROTEINS; TRANSPORT VESICLES; ANCHORED PROTEINS; PLASMA-MEMBRANE; EARLY ENDOSOMES; CELLS; DELIVERY; PEPTIDE; TRANSDUCTION; RECEPTOR	VP22 is a structural protein of the herpes simplex virus and has been reported to possess unusual trafficking properties. Here we examined the mechanism of cellular uptake of VP22 using a fusion protein between the C-terminal half of VP22 and green fluorescent protein (GFP). Adsorption of VP22-GFP onto a cell surface required heparan sulfate proteoglycans and basic amino acids, in particular, Arg-164 of VP22. Inhibitor treatment, RNA interference, expression of dominant-negative mutant genes, and confocal microscopy all indicated that VP22-GFP enters cells through an endocytic pathway independent of clathrin and caveolae but dependent on dynamin and Arf6 activity. As with CD59 ( a lipid raft marker), cell-surface VP22-GFP signals were resistant to Triton X-100 treatment but only partially overlapped cell-surface CD59 signals. Furthermore, unlike other lipid raft-mediated endocytic pathways, no Rho family GTPase was required for VP22-GFP internalization. Internalized VP22 initially entered early endosomes and then moved to lysosomes and possibly recycling endosomes.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Nishi, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kennishi@biochem.s.u-tokyo.ac.jp; saigo@biochem.s.u-tokyo.ac.jp						AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Arnaoutova I, 2003, MOL BIOL CELL, V14, P4448, DOI 10.1091/mbc.E02-11-0758; Boenicke L, 2003, J MOL MED-JMM, V81, P205, DOI 10.1007/s00109-003-0421-3; Brewis ND, 2003, MOL THER, V7, P262, DOI 10.1016/S1525-0016(02)00054-0; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Cheng ZJ, 2006, MOL BIOL CELL, V17, P3197, DOI 10.1091/mbc.E05-12-1101; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Damm EM, 2005, J CELL BIOL, V168, P477, DOI 10.1083/jcb.200407113; Delaney KA, 2002, J BIOL CHEM, V277, P33439, DOI 10.1074/jbc.M205293200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gauthier NC, 2005, MOL BIOL CELL, V16, P4852, DOI 10.1091/mbc.E05-05-0398; Gauthier NC, 2004, J BIOL CHEM, V279, P9481, DOI 10.1074/jbc.M312040200; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hashimoto S, 2004, J BIOL CHEM, V279, P37677, DOI 10.1074/jbc.M404196200; Hinrichsen L, 2003, J BIOL CHEM, V278, P45160, DOI 10.1074/jbc.M307290200; Houndolo T, 2005, J BIOL CHEM, V280, P5598, DOI 10.1074/jbc.M411456200; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Kueltzo LA, 2000, J BIOL CHEM, V275, P33213, DOI 10.1074/jbc.M002476200; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065; Martinho RG, 1996, MOL BIOL CELL, V7, P1771, DOI 10.1091/mbc.7.11.1771; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Narita K, 2005, FASEB J, V19, P1558, DOI 10.1096/fj.04-2714fje; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Noguchi H, 2005, CELL TRANSPLANT, V14, P637, DOI 10.3727/000000005783982648; Normand N, 2001, J BIOL CHEM, V276, P15042, DOI 10.1074/jbc.M010294200; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Payne CK, 2007, TRAFFIC, V8, P389, DOI 10.1111/j.1600-0854.2007.00540.x; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; ROBERT GP, 2003, TRAFFIC, V4, P724; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sauvonnet N, 2005, J CELL BIOL, V168, P155, DOI 10.1083/jcb.200406174; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stroh C, 2003, ONCOGENE, V22, P5367, DOI 10.1038/sj.onc.1206544; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Ui-Tei K, 2000, FEBS LETT, V479, P79, DOI 10.1016/S0014-5793(00)01883-4; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Zavaglia D, 2003, MOL THER, V8, P840, DOI 10.1016/j.ymthe.2003.08.001	75	40	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27503	27517		10.1074/jbc.M703810200	http://dx.doi.org/10.1074/jbc.M703810200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17644515	hybrid			2022-12-25	WOS:000249304900091
J	Yang, HL; Cabral, F				Yang, Hailing; Cabral, Fernando			Heightened sensitivity to paclitaxel in class IVa beta-tubulin-transfected cells is lost as expression increases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ALPHA-TUBULIN; MICROTUBULE DYNAMICS; CONFERS RESISTANCE; STRUCTURAL BASIS; CHO-CELLS; ISOTYPES; MUTATIONS; BINDING; OVEREXPRESSION	Stably transfected Chinese hamster ovary cell lines expressing increasing levels of beta 4a, a class IV neuronal-specific beta-tubulin, were compared for effects on microtubule organization, assembly, and sensitivity to antimitotic drugs. It was found that beta 4a reduced microtubule assembly in proportion to its abundance and thereby caused supersensitivity to microtubule disruptive drugs such as colcemid, vinblastine, and nocodazole. However, the response to paclitaxel was more complex. Low expression of beta 4a caused supersensitivity to paclitaxel, whereas higher expression resulted in the loss of supersensitivity. The results suggest that beta 4a may possess an enhanced ability to bind paclitaxel that increases sensitivity to the drug and acts substoichiometrically. At high levels of beta 4a expression, however, microtubule disruptive effects counteract the assembly promoting pressure exerted by paclitaxel binding, and drug supersensitivity is lost. beta 4a-Tubulin differs from the more ubiquitous beta 4b isotype at relatively few amino acid residues, yet beta 4b expression has little effect on microtubule assembly or drug response. To determine which amino acids mediate the effects of beta 4a expression, beta 4a and beta 4b were altered by site-directed mutagenesis and expressed in Chinese hamster ovary cells. The introduction of N332S or N335S mutations into beta 4b-tubulin was sufficient to confer microtubule disruption and increased colcemid sensitivity. On the other hand, mutation of Ala(115) to serine in beta 4atubulin almost completely reversed heightened sensitivity to paclitaxel, but introduction of an S115A mutation into beta 4b had no effect, suggesting that a complex interaction of multiple amino acids are necessary to produce this phenotype.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System	Cabral, F (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fanin, Houston, TX 77030 USA.	fernando.r.cabral@uth.tmc.edu			NCI NIH HHS [CA 85935] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085935] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1983, J CELL BIOL, V97, P1055, DOI 10.1083/jcb.97.4.1055; AHMAD S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P252, DOI 10.1016/0167-4781(91)90112-Y; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; Barlow SB, 2002, J CELL SCI, V115, P3469; Bhattacharya R, 2004, MOL BIOL CELL, V15, P3123, DOI 10.1091/mbc.E04-01-0060; Blade K, 1999, J CELL SCI, V112, P2213; BOGGS B, 1987, MOL CELL BIOL, V7, P2700, DOI 10.1128/MCB.7.8.2700; BOLLAG DM, 1995, CANCER RES, V55, P2325; Burkhart C.A., 2001, BIOCHIM BIOPHYS ACTA, V1471, P1; CABRAL F, 1991, PHARMACOL THERAPEUT, V52, P159, DOI 10.1016/0163-7258(91)90006-8; Cabral F., 2000, DRUG RESIST UPDATE, V3, P1; CLEVELAND DW, 1987, J CELL BIOL, V104, P381, DOI 10.1083/jcb.104.3.381; DELANO WL, 2005, MACPYMOL; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Fulton C., 1976, CELL MOTILITY, P987; Gigant B, 2005, NATURE, V435, P519, DOI 10.1038/nature03566; GONZALEZGARAY ML, 1995, CELL MOTIL CYTOSKEL, V31, P259, DOI 10.1002/cm.970310403; Hari M, 2006, MOL CANCER THER, V5, P270, DOI 10.1158/1535-7163.MCT-05-0190; Hari M, 2003, CELL MOTIL CYTOSKEL, V56, P45, DOI 10.1002/cm.10132; Hari M, 2003, MOL CANCER THER, V2, P597; Jaffrezou JP, 1995, ONCOL RES, V7, P517; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JOSHI HC, 1990, CELL MOTIL CYTOSKEL, V16, P159, DOI 10.1002/cm.970160302; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Luduena RF, 1998, INT REV CYTOL, V178, P207; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Nettles JH, 2004, SCIENCE, V305, P866, DOI 10.1126/science.1099190; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Rosenbaum J, 2000, CURR BIOL, V10, pR801, DOI 10.1016/S0960-9822(00)00767-3; SAWADA T, 1989, J BIOL CHEM, V264, P3013; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; TAKOUDJU M, 1988, FEBS LETT, V227, P96, DOI 10.1016/0014-5793(88)80875-5; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; Wang HW, 2005, NATURE, V435, P911, DOI 10.1038/nature03606; Wang YQ, 2006, BIOCHEMISTRY-US, V45, P185, DOI 10.1021/bi051207d; Wang YQ, 2004, BIOCHEMISTRY-US, V43, P8965, DOI 10.1021/bi049637b; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260	43	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27058	27066		10.1074/jbc.M704101200	http://dx.doi.org/10.1074/jbc.M704101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627938	hybrid			2022-12-25	WOS:000249304900047
J	Hayakawa, H; Hayakawa, M; Kume, A; Tominaga, S				Hayakawa, Hiroko; Hayakawa, Morisada; Kume, Akihiro; Tominaga, Shin-ichi			Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VARIANT FORM; GENE-PRODUCT; MURINE MODEL; IL-1 RECEPTOR; TH2 CELLS; EXPRESSION; PROTEIN; IDENTIFICATION; TRANSCRIPTION	The ST2 gene produces a soluble secreted form and a transmembrane form, referred to as soluble ST2 and ST2L, respectively. A recent study has reported that interleukin (IL)-33 is a specific ligand of ST2L and induces production of T helper type 2 (Th2) cytokines. Although soluble ST2 is highly produced in sera of asthmatic patients and plays a critical role for production of Th2 cytokines, the function of soluble ST2 in relation to IL-33 signaling remains unclear. Here we show antagonistic effects of soluble ST2 on IL-33 signaling using a murine thymoma EL-4 cells stably expressing ST2L and a murine model of asthma. Soluble ST2 directly bound to IL-33 and suppressed activation of NF-kappa B in EL-4 cells stably expressing ST2L, suggesting that the complex of soluble ST2 and IL-33 fails to bind to ST2L. In a murine model of asthma, pretreatment with soluble ST2 reduced production of IL-4, IL-5, and IL-13 from IL-33-stimulated splenocytes. These results indicate that soluble ST2 acts as a negative regulator of Th2 cytokine production by the IL-33 signaling. Our study provides a molecular mechanism wherein soluble ST2 modulates the biological activity of IL-33 in allergic airway inflammation.	Jichi Med Univ, Dept Biochem, Tochigi 3290498, Japan; Jichi Med Univ, Div Genet Therapeut, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University	Hayakawa, M (corresponding author), Jichi Med Univ, Dept Biochem, 3311-1 Yakushiji, Tochigi 3290498, Japan.	morisada@jichi.ac.jp		Hayakawa, Morisada/0000-0002-1869-2450				Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Donovan CE, 1999, J IMMUNOL, V163, P6827; Gachter T, 1996, J BIOL CHEM, V271, P124; Gajewska BU, 2001, AM J RESP CELL MOL, V25, P326, DOI 10.1165/ajrcmb.25.3.4482; GIRI JG, 1994, J IMMUNOL, V153, P5802; Hayakawa M, 2005, BBA-GENE STRUCT EXPR, V1728, P53, DOI 10.1016/j.bbaexp.2005.01.012; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Iwahana H, 2004, BBA-GENE STRUCT EXPR, V1681, P1, DOI 10.1016/j.bbaexp.2004.08.013; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; Kuroiwa K, 2001, BIOCHEM BIOPH RES CO, V284, P1104, DOI 10.1006/bbrc.2001.5090; Lecart S, 2002, EUR J IMMUNOL, V32, P2979, DOI 10.1002/1521-4141(2002010)32:10<2979::AID-IMMU2979>3.0.CO;2-5; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Oshikawa K, 2002, CLIN EXP ALLERGY, V32, P1520, DOI 10.1046/j.1365-2745.2002.01494.x; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; SATO TA, 1993, J IMMUNOL, V150, P2717; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Sweet MJ, 2001, J IMMUNOL, V166, P6633, DOI 10.4049/jimmunol.166.11.6633; Tago K, 2001, EUR J BIOCHEM, V268, P6526, DOI 10.1046/j.1432-1327.2001.02603.x; Tago K, 2001, BIOCHEM BIOPH RES CO, V285, P1377, DOI 10.1006/bbrc.2001.5306; Tajima S, 2003, CHEST, V124, P1206, DOI 10.1378/chest.124.4.1206; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; Takezako N, 2006, BIOCHEM BIOPH RES CO, V341, P425, DOI 10.1016/j.bbrc.2005.12.206; Tominaga S, 1999, BIOCHEM BIOPH RES CO, V264, P14, DOI 10.1006/bbrc.1999.1469; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Tsutsui H, 2000, IMMUNOL REV, V174, P192, DOI 10.1034/j.1600-0528.2002.017418.x; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yanagisawa K, 1997, J BIOCHEM-TOKYO, V121, P95; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang JG, 1997, J BIOL CHEM, V272, P9474	38	413	446	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26369	26380		10.1074/jbc.M704916200	http://dx.doi.org/10.1074/jbc.M704916200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623648	hybrid			2022-12-25	WOS:000249239600042
J	Trisler, K; Looger, LL; Sharma, V; Baker, M; Benson, DE; Trauger, S; Schultz, PG; Smider, VV				Trisler, Kirk; Looger, Loren L.; Sharma, Vikram; Baker, Martin; Benson, David E.; Trauger, Sunia; Schultz, Peter G.; Smider, Vaughn V.			A metalloantibody that irreversibly binds a protein antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL LIBRARIES; MONOCLONAL-ANTIBODIES; BOTULINUM NEUROTOXIN; PROTEOLYTIC ANTIBODY; MOLECULAR EVOLUTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RATIONAL DESIGN; LIGHT-CHAIN; METAL	Antibody affinity is critically important in therapeutic applications, as well as steady state diagnostic assays. Picomolar affinity antibodies, approaching the association limit of protein-protein interactions, have been discovered for highly potent antigens, but even such high-affinity binders have off-rates sufficient to negate therapeutic efficacy. To cross this affinity threshold, antibodies that tether their targets in a manner other than reversible non-covalent interaction will be required. Here we report the design and construction of an antibody that forms an irreversible complex with a protein antigen in a metal-dependent reaction. The complex resists thermal and chemical denaturation, as well as attempts to remove the coordinating metal ion. Such irreversibly binding antibodies could facilitate the development of next generation "reactive antibody" therapeutics and diagnostics.	Scripps Howard Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; IntegriGen Inc, Novato, CA 94949 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Scripps Ctr Mass Spect, Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Wayne State University; Scripps Research Institute	Smider, VV (corresponding author), Scripps Howard Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,SR202, La Jolla, CA 92037 USA.	vvsmider@scripps.edu		Trauger, Sunia/0000-0002-1678-8715; Smider, Vaughn/0000-0003-3488-6383				ANGELES TS, 1993, BIOCHEM BIOPH RES CO, V197, P696, DOI 10.1006/bbrc.1993.2535; Armentano F, 2006, IMMUNOL LETT, V103, P51, DOI 10.1016/j.imlet.2005.10.008; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P6385, DOI 10.1073/pnas.90.14.6385; Benson DE, 2000, P NATL ACAD SCI USA, V97, P6292, DOI 10.1073/pnas.97.12.6292; BERK L, 1949, NEW ENGL J MED, V240, P754, DOI 10.1056/NEJM194905122401903; Blake DA, 1996, J BIOL CHEM, V271, P27677, DOI 10.1074/jbc.271.44.27677; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chmura AJ, 2001, P NATL ACAD SCI USA, V98, P8480, DOI 10.1073/pnas.151260298; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; Corneillie TM, 2003, J AM CHEM SOC, V125, P3436, DOI 10.1021/ja029363k; Cotton F. A., 1999, ADV INORGANIC CHEM; De Boeck M, 2003, MUTAT RES-FUND MOL M, V533, P135, DOI 10.1016/j.mrfmmm.2003.07.012; Delehanty JB, 2003, BIOCHEMISTRY-US, V42, P14173, DOI 10.1021/bi034839d; ECK MJ, 1989, J BIOL CHEM, V264, P17595; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Geylis V, 2006, AUTOIMMUN REV, V5, P33, DOI 10.1016/j.autrev.2005.06.007; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Hellinga HW, 1998, FOLD DES, V3, pR1, DOI 10.1016/S1359-0278(98)00001-7; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JASELSKIS B, 1958, J AM CHEM SOC, V80, P1283, DOI 10.1021/ja01539a003; KALOGERAKOS T, 1979, EUR J BIOCHEM, V93, P339, DOI 10.1111/j.1432-1033.1979.tb12828.x; KAVERI SV, 1991, MOL IMMUNOL, V28, P773, DOI 10.1016/0161-5890(91)90120-9; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; Lacroix-Desmazes S, 2005, P NATL ACAD SCI USA, V102, P4109, DOI 10.1073/pnas.0500586102; Lacroix-Desmazes S, 2002, NEW ENGL J MED, V346, P662, DOI 10.1056/NEJMoa011979; Leonard B, 2006, J IMMUNOL METHODS, V317, P56, DOI 10.1016/j.jim.2006.09.006; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; Miyanaga A, 2001, BIOCHEM BIOPH RES CO, V288, P1169, DOI 10.1006/bbrc.2001.5897; Nowakowski A, 2002, P NATL ACAD SCI USA, V99, P11346, DOI 10.1073/pnas.172229899; Okeley NM, 2000, CHEM BIOL, V7, pR159, DOI 10.1016/S1074-5521(00)00140-X; Ponomarenko NA, 2006, P NATL ACAD SCI USA, V103, P281, DOI 10.1073/pnas.0509849103; Rajpal A, 2005, P NATL ACAD SCI USA, V102, P8466, DOI 10.1073/pnas.0503543102; Ramsland PA, 2006, BIOCHEM J, V395, P473, DOI 10.1042/BJ20051739; Razai A, 2005, J MOL BIOL, V351, P158, DOI 10.1016/j.jmb.2005.06.003; REARDAN DT, 1985, NATURE, V316, P265, DOI 10.1038/316265a0; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Street AG, 1999, STRUCTURE, V7, pR105, DOI 10.1016/S0969-2126(99)80062-8; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; WELLS JA, 1979, P NATL ACAD SCI USA, V76, P4966, DOI 10.1073/pnas.76.10.4966; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2003, P NATL ACAD SCI USA, V100, P1490, DOI 10.1073/pnas.0437831100; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; ZHOU YQ, 1992, BIOPHYS CHEM, V42, P201, DOI 10.1016/0301-4622(92)85010-2	47	13	13	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26344	26353		10.1074/jbc.M704675200	http://dx.doi.org/10.1074/jbc.M704675200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17617633	hybrid			2022-12-25	WOS:000249239600039
J	Alberts, R; Terpstra, P; Li, Y; Breitling, R; Nap, JP; Jansen, RC				Alberts, Rudi; Terpstra, Peter; Li, Yang; Breitling, Rainer; Nap, Jan-Peter; Jansen, Ritsert C.			Sequence Polymorphisms Cause Many False cis eQTLs	PLOS ONE			English	Article							GENE-EXPRESSION; MODEL; GENOMICS	Many investigations have reported the successful mapping of quantitative trait loci (QTLs) for gene expression phenotypes (eQTLs). Local eQTLs, where expression phenotypes map to the genes themselves, are of especially great interest, because they are direct candidates for previously mapped physiological QTLs. Here we show that many mapped local eQTLs in genetical genomics experiments do not reflect actual expression differences caused by sequence polymorphisms in cis-acting factors changing mRNA levels. Instead they indicate hybridization differences caused by sequence polymorphisms in the mRNA region that is targeted by the microarray probes. Many such polymorphisms can be detected by a sensitive and novel statistical approach that takes the individual probe signals into account. Applying this approach to recent mouse and human eQTL data, we demonstrate that indeed many local eQTLs are falsely reported as "cis-acting'' or "cis'' and can be successfully detected and eliminated with this approach.	[Alberts, Rudi; Li, Yang; Breitling, Rainer; Nap, Jan-Peter; Jansen, Ritsert C.] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Groningen Bioinformat Ctr, Haren, Netherlands; [Terpstra, Peter; Jansen, Ritsert C.] Univ Groningen, Univ Med Ctr Groningen, Groningen Bioinformat Ctr, Groningen, Netherlands; [Nap, Jan-Peter] Univ Appl Sci, Hanze Univ Groningen, Inst Life Sci & Technol, Bioinformat Expertise Ctr, Groningen, Netherlands	University of Groningen; University of Groningen	Jansen, RC (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Groningen Bioinformat Ctr, Haren, Netherlands.	r.c.jansen@rug.nl	Jansen, Ritsert C/C-1160-2013; Li, Yang/HGT-8446-2022	Jansen, Ritsert C/0000-0003-2977-9110; Li, Yang/0000-0003-4022-7341; Breitling, Rainer/0000-0001-7173-0922	Netherlands Organisation for Scientific Research	Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO))	RA, RB, YL, and JPN received funding for this work from The Netherlands Organisation for Scientific Research.	Alberts R, 2005, GENETICS, V171, P1437, DOI 10.1534/genetics.105.045930; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497; Cheung VG, 2005, NATURE, V437, P1365, DOI 10.1038/nature04244; Doss S, 2005, GENOME RES, V15, P681, DOI 10.1101/gr.3216905; Gilad Y, 2005, GENOME RES, V15, P674, DOI 10.1101/gr.3335705; Gresham D, 2006, SCIENCE, V311, P1932, DOI 10.1126/science.1123726; Hsieh WP, 2003, GENETICS, V165, P747; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jansen RC, 2004, TRENDS GENET, V20, P223, DOI 10.1016/j.tig.2004.03.002; Jansen RC, 2001, TRENDS GENET, V17, P388, DOI 10.1016/S0168-9525(01)02310-1; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li Y, 2006, PLOS GENET, V2, P2155, DOI 10.1371/journal.pgen.0020222; Peirce JL, 2006, MAMM GENOME, V17, P643, DOI 10.1007/s00335-005-0187-8; Petretto E, 2006, PLOS GENET, V2, P1625, DOI 10.1371/journal.pgen.0020172; Rockman MV, 2006, NAT REV GENET, V7, P862, DOI 10.1038/nrg1964	17	107	108	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e622	10.1371/journal.pone.0000622	http://dx.doi.org/10.1371/journal.pone.0000622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637838	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452100012
J	Miles, J; Mitchell, JA; Chakalova, L; Goyenechea, B; Osborne, CS; O'Neill, L; Tanimoto, K; Engel, JD; Fraser, P				Miles, Joanne; Mitchell, Jennifer A.; Chakalova, Lyubomira; Goyenechea, Beatriz; Osborne, Cameron S.; O'Neill, Laura; Tanimoto, Keiji; Engel, James Douglas; Fraser, Peter			Intergenic Transcription, Cell-Cycle and the Developmentally Regulated Epigenetic Profile of the Human Beta-Globin Locus	PLOS ONE			English	Article								Several lines of evidence have established strong links between transcriptional activity and specific post-translation modifications of histones. Here we show using RNA FISH that in erythroid cells, intergenic transcription in the human beta-globin locus occurs over a region of greater than 250 kb including several genes in the nearby olfactory receptor gene cluster. This entire region is transcribed during S phase of the cell cycle. However, within this region there are similar to 20 kb sub-domains of high intergenic transcription that occurs outside of S phase. These sub-domains are developmentally regulated and enriched with high levels of active modifications primarily to histone H3. The sub-domains correspond to the beta-globin locus control region, which is active at all developmental stages in erythroid cells, and the region flanking the developmentally regulated, active globin genes. These results correlate high levels of non-S phase intergenic transcription with domain-wide active histone modifications to histone H3.	[Miles, Joanne; Mitchell, Jennifer A.; Chakalova, Lyubomira; Goyenechea, Beatriz; Osborne, Cameron S.; Fraser, Peter] Babraham Inst, Lab Chromatin & Gene Express, Cambridge, England; [O'Neill, Laura] Univ Birmingham, Inst Biomed Res, Sch Med, Birmingham, W Midlands, England; [Tanimoto, Keiji; Engel, James Douglas] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Birmingham; University of Michigan System; University of Michigan	Fraser, P (corresponding author), Babraham Inst, Lab Chromatin & Gene Express, Babraham Res Campus, Cambridge, England.	peter.fraser@bbsrc.ac.uk	Chakalova, Lyubomira/C-6810-2012; Tanimoto, Keiji/B-2600-2014; Osborne, Cameron/N-1398-2017	Osborne, Cameron/0000-0003-4126-2499; Tanimoto, Keiji/0000-0003-1971-6546; Fraser, Peter/0000-0002-0041-1227; Mitchell, Jennifer/0000-0002-7147-4604	Medical Research Council; Biotechnology and Biological Sciences Research Council UK; MRC [G117/530] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/B/00001151] Funding Source: researchfish; Medical Research Council [G117/530] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council and the Biotechnology and Biological Sciences Research Council UK.	Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bolland DJ, 2004, NAT IMMUNOL, V5, P630, DOI 10.1038/ni1068; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Calzolari R, 1999, EMBO J, V18, P949, DOI 10.1093/emboj/18.4.949; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Chakalova L, 2005, BLOOD, V105, P2154, DOI 10.1182/blood-2003-11-4069; Chakalova L, 2004, METHOD ENZYMOL, V375, P479; CHAKALOVA L, 2005, NATURE REV IN PRESS; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; DICKERMAN HW, 1976, ARCH BIOCHEM BIOPHYS, V177, P1, DOI 10.1016/0003-9861(76)90408-2; Drewell RA, 2002, P NATL ACAD SCI USA, V99, P16853, DOI 10.1073/pnas.222671199; FIBACH E, 1989, BLOOD, V73, P100; FIBACH E, 1990, AM J HEMATOL, V35, P151, DOI 10.1002/ajh.2830350303; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; Haussecker D, 2005, MOL CELL BIOL, V25, P9724, DOI 10.1128/MCB.25.21.9724-9733.2005; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Ho YG, 2006, MOL CELL, V23, P365, DOI 10.1016/j.molcel.2006.05.041; HUMBERT C, 1992, J CELL SCI, V103, P97; Jones EA, 2005, J IMMUNOL, V175, P7437, DOI 10.4049/jimmunol.175.11.7437; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kim A, 2004, P NATL ACAD SCI USA, V101, P7028, DOI 10.1073/pnas.0307985101; Leach KM, 2001, MOL CELL BIOL, V21, P2629, DOI 10.1128/MCB.21.8.2629-2640.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long QM, 1998, GENOMICS, V54, P542, DOI 10.1006/geno.1998.5608; Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883; O'Neill LP, 2003, METHODS, V31, P76, DOI 10.1016/S1046-2023(03)00090-2; Ogawa Y, 2003, MOL CELL, V11, P731, DOI 10.1016/S1097-2765(03)00063-7; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; Ragoczy T, 2006, GENE DEV, V20, P1447, DOI 10.1101/gad.1419506; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Rogan DF, 2004, P NATL ACAD SCI USA, V101, P2446, DOI 10.1073/pnas.0308327100; Routledge SJE, 2002, J MOL BIOL, V323, P601, DOI 10.1016/S0022-2836(02)01011-2; Schmitt S, 2005, GENE DEV, V19, P697, DOI 10.1101/gad.326205; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Schubeler D, 2000, GENE DEV, V14, P940; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN D, 1992, P NATL ACAD SCI USA, V89, P11219, DOI 10.1073/pnas.89.23.11219; WANSINK DG, 1994, J CELL SCI, V107, P1449; Xiang P, 2006, BIOCHEM BIOPH RES CO, V344, P623, DOI 10.1016/j.bbrc.2006.03.189	49	40	40	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e630	10.1371/journal.pone.0000630	http://dx.doi.org/10.1371/journal.pone.0000630			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637845	Green Published, gold			2022-12-25	WOS:000207452100019
J	Ichikawa, T; Suenaga, Y; Koda, T; Ozaki, T; Nakagawara, A				Ichikawa, T.; Suenaga, Y.; Koda, T.; Ozaki, T.; Nakagawara, A.			TAp63-dependent induction of growth differentiation factor 15 (GDF15) plays a critical role in the regulation of keratinocyte differentiation	ONCOGENE			English	Article						TAp63; GDF15; keratinocyte; differentiation	TGF-BETA SUPERFAMILY; MACROPHAGE INHIBITORY CYTOKINE-1; PROSTATE-DERIVED FACTOR; CANCER CELL-GROWTH; EPIDERMAL MORPHOGENESIS; TARGET GENE; P53 HOMOLOG; P63; MEMBER; EXPRESSION	Since p63-deficient mice display severe defects in formation of epidermis, p63 has been considered to be a multi-isoform p53 family member essential for epidermal development. However, it is still unclear how p63 could contribute to keratinocyte differentiation. In the present study, we have found that TAp63 alpha is induced in association with the upregulation and a secretion of growth differentiation factor 15 (GDF15) during the keratinocyte differentiation of HaCaT cells bearing p53 mutation. Short interference RNA-mediated knockdown of the endogenous TAp63 resulted in a remarkable reduction of GDF15. Luciferase reporter assay and reverse transcription-PCR analysis demonstrated that enforced expression of TAp63 alpha significantly increases the luciferase activity driven by GDF15 promoter and the expression of GDF15. Consistent with these results, the proximal p53/p63-binding site within the GDF15 promoter region was required for the TAp63 alpha-mediated transcriptional activation of GDF15, and TAp63 alpha was recruited onto this site. Furthermore, siRNA-mediated knockdown of the endogenous GDF15 permitted cell growth and inhibited the expression of the differentiation markers such as keratin 10 and involucrin in response to differentiation stimuli. Taken together, our present results provide a novel insight into understanding the molecular mechanisms behind TAp63 alpha-mediated keratinocyte differentiation.	[Ichikawa, T.; Suenaga, Y.; Ozaki, T.; Nakagawara, A.] Chiba Canc Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Ichikawa, T.; Koda, T.] Hisamitsu Pharmaceut Co Inc, Res Ctr Funct Genom, Chiba, Japan; [Suenaga, Y.; Ozaki, T.; Nakagawara, A.] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan	Chiba Cancer Center; Hisamitsu Pharmaceutical Co Ltd; Chiba University	Nakagawara, A (corresponding author), Chiba Canc Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp		Suenaga, Yusuke/0000-0001-6902-5386				Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; Ago T, 2006, CIRC RES, V98, P294, DOI 10.1161/01.RES.0000207919.83894.9d; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2006, CANCER RES, V66, P4983, DOI 10.1158/0008-5472.CAN-05-4067; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; King KE, 2006, CARCINOGENESIS, V27, P53, DOI 10.1093/carcin/bgi200; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nazarova N, 2004, INT J CANCER, V112, P951, DOI 10.1002/ijc.20510; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2007, BIOCHEM BIOPH RES CO, V354, P913, DOI 10.1016/j.bbrc.2007.01.089; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Roninson IB, 2003, CANCER RES, V63, P2705; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Uchida K, 2003, J CELL BIOCHEM, V88, P394, DOI 10.1002/jcb.10327; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	35	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					409	420		10.1038/sj.onc.1210658	http://dx.doi.org/10.1038/sj.onc.1210658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637746				2022-12-25	WOS:000252426100001
J	Raabe, EH; Laudenslager, M; Winter, C; Wasserman, N; Cole, K; LaQuaglia, M; Maris, DJ; Mosse, YP; Maris, JM				Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.			Prevalence and functional consequence of PHOX2B mutations in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; PHOX2B; MYCN; neural crest; tumor suppressor gene	CENTRAL-HYPOVENTILATION-SYNDROME; HOMEOBOX GENE PHOX2B; HEREDITARY NEUROBLASTOMA; TRANSCRIPTION; PHENOTYPE; SHOWS	PHOX2B is a homeodomain-containing protein that is involved in the development of the peripheral nervous system and is the major disease gene for the rare congenital breathing disorder congenital central hypoventilation syndrome (CCHS). Germline PHOX2B alterations were also recently discovered in neuroblastoma cases with CCHS and/or Hirschsprung disease, but a comprehensive survey for mutational frequency and functional consequence has not been performed. We therefore studied a large panel of hereditary neuroblastomas to understand the frequency and functional effects of PHOX2B mutations. Three of 47 individuals with presumed genetic predisposition to neuroblastoma showed a germline PHOX2B mutation (6.4%). Mutations were also discovered in 2 of 30 human neuroblastoma-derived cell lines, but none of 86 primary tumors from patients with sporadically occurring neuroblastoma. The vast majority of primary tumors showed abundant PHOX2B mRNA expression relative to the remainder of the transcriptome. Consistent with its role as an important neurodevelopmental gene, forced overexpression of wild-type PHOX2B in neuroblastoma cell lines suppressed cell proliferation and synergized with all-trans retinoic acid to promote differentiation. Patient-derived mutant PHOX2B constructs retained the ability to suppress cellular proliferation, but were not able to promote differentiation or activate expression of a known PHOX2B target gene in vitro. These findings show that PHOX2B alterations are a rare cause of hereditary neuroblastoma, but disruption of this neurodevelopmental pathway can interfere with transcription-dependent terminal differentiation. These data also suggest that the genetics of neuroblastoma initiation are complex, and highlight genes involved in normal noradrenergic development as candidate predisposition genes.	[Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Maris, J. M.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC902A,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	maris@chop.edu		Raabe, Eric/0000-0002-9368-7037	NATIONAL CANCER INSTITUTE [R01CA087847, U10CA098543, R01CA078545] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA98543, R01-CA87847, R01-CA78545] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Atienza JM, 2006, J BIOMOL SCREEN, V11, P634, DOI 10.1177/1087057106289334; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Beiske K, 2005, CANCER LETT, V228, P229, DOI 10.1016/j.canlet.2005.02.053; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Maris JM, 2002, CANCER RES, V62, P6651; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; McConville C, 2006, AM J MED GENET A, V140A, P1297, DOI 10.1002/ajmg.a.31278; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311	18	114	117	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					469	476		10.1038/sj.onc.1210659	http://dx.doi.org/10.1038/sj.onc.1210659			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637745				2022-12-25	WOS:000252426100007
J	Howard, G; Eiges, R; Gaudet, F; Jaenisch, R; Eden, A				Howard, G.; Eiges, R.; Gaudet, F.; Jaenisch, R.; Eden, A.			Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice	ONCOGENE			English	Article						DNA hypomethylation; transposable elements; Notch1; T-cell lymphoma	DNA HYPOMETHYLATION; C-MYC; METHYLATION; GENE; TRANSCRIPTION; CHROMOSOME-1; EXPRESSION; INDUCTION; LEUKEMIA; CANCER	Genomewide DNA hypomethylation is a consistent finding in human tumors, but the importance of this change for human tumorigenesis remains an open question. We have previously reported that mice carrying a hypomorphic allele for the maintenance DNA methyltransferase (Dnmt1(chip/-)) are hypomethylated and develop thymic lymphomas, demonstrating that genomewide DNA hypomethylation can induce tumors. Hypomethylated cells exhibit inherent chromosomal instability, which is revealed in the lymphomas as a consistent trisomy of chromosome 15. We now report another aspect of the molecular basis for tumor development upon DNA hypomethylation. Seven out of 16 hypomethylation-induced lymphomas were found to contain an intracisternal A particle (IAP) somatic insertion in the middle of the Notch1 genomic locus, leading to generation of an oncogenic form of Notch1 in the tumors. This finding suggests that the molecular basis for hypomethylation-induced tumors in this model involves chromosomal instability events accompanied by activation of endogenous retroviral elements. Our findings validate the proposed role of DNA methylation in suppression of transposable elements in mammalian cells and demonstrate the importance of DNA methylation for normal cell function as well as the potential consequences of spontaneously occurring or chemically induced DNA hypomethylation.	[Howard, G.; Eiges, R.; Eden, A.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Anim & Cell Biol, IL-91904 Jerusalem, Israel; [Gaudet, F.; Jaenisch, R.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Gaudet, F.; Jaenisch, R.] MIT, Dept Biol, Cambridge, MA USA	Hebrew University of Jerusalem; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Eden, A (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Anim & Cell Biol, IL-91904 Jerusalem, Israel.	eden@vms.huji.ac.il		eiges, rachel/0000-0001-8139-0933				AnsariLari MA, 1996, BIOTECHNIQUES, V21, P34; BOEKE JD, 1997, COLD SPRING LAB, P343; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; Druker R, 2004, NUCLEIC ACIDS RES, V32, P5800, DOI 10.1093/nar/gkh914; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2003, CANCER GENET CYTOGEN, V141, P97, DOI 10.1016/S0165-4608(02)00668-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JAHNER D, 1980, NATURE, V287, P456, DOI 10.1038/287456a0; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tsuda H, 2002, AM J PATHOL, V161, P859, DOI 10.1016/S0002-9440(10)64246-0; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zweidler-McKay PA, 2004, SEMIN CANCER BIOL, V14, P329, DOI 10.1016/j.semcancer.2004.04.012	29	232	239	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					404	408		10.1038/sj.onc.1210631	http://dx.doi.org/10.1038/sj.onc.1210631			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621273				2022-12-25	WOS:000252256000017
J	Baron-Menguy, C; Bocquet, A; Guihot, AL; Chappard, D; Amiot, MJ; Andriantsitohaina, R; Loufrani, L; Henrion, D				Baron-Menguy, Celine; Bocquet, Arnaud; Guihot, Anne-Laure; Chappard, Daniel; Amiot, Marie-Joseph; Andriantsitohaina, Ramaroson; Loufrani, Laurent; Henrion, Daniel			Effects of red wine polyphenols on postischemic neovascularization model in rats: low doses are proangiogenic, high doses anti-angiogenic	FASEB JOURNAL			English	Article						VEGF; remodeling; nitric oxide; blood flow	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; PORCINE CORONARY-ARTERIES; EDHF-MEDIATED RELAXATIONS; NITRIC-OXIDE PRODUCTION; DEPENDENT VASORELAXATION; FACTOR EXPRESSION; ACTIVATION; INHIBITION; THROMBIN	Polyphenols, present in green tea, grapes, or red wine, have paradoxical properties: they protect against cardiac and cerebral ischemia but inhibit angiogenesis in vitro. So we investigated the effects of polyphenols in vivo on postischemic neovascularization. Rats treated with low (0.2 mg . kg(-1) . day(-1)) or high (20 mg . kg(-1) . day(-1)) doses of red wine polyphenolic compounds (RWPC) were submitted to femoral artery ligature on the left leg. Two wks after ligature, high doses of RWPC (i.e., 7 glasses of red wine) reduced arterial, arteriolar, and capillary densities and blood flow in association with an inhibition of a PI3 kinase-Akt-endothelial NO synthase (eNOS) pathway, decreased VEGF expression, and lower metalloproteinase (MMP) activation. Low doses of RWPC ( i. e., 1/10th glass of red wine) increased the left/right (L/R) leg ratio to control level in association with an increased blood flow and microvascular density. This angiogenic effect was associated with an overexpression of PI3 kinase-Akt-eNOS pathway and an increased VEGF production without effect on MMP activation. Thus, low and high doses RWPC have respectively pro- and anti-angiogenic properties on postischemic neovascularization in vivo. This unique dual effect of RWPC offers important perspectives for the treatment and prevention of ischemic diseases ( low dose) or cancer growth ( high dose).	Fac Med, CNRS, UMR 6214, INSERM,Dept Neurovasc Integrated Biol, F-49045 Angers, France; Univ Angers, UFR Med, Angers, France; INSERM, EMI 0335, Angers, France; INRA 1260, INSERM, UMR 476, Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Henrion, D (corresponding author), Fac Med, CNRS, UMR 6214, INSERM,Dept Neurovasc Integrated Biol, F-49045 Angers, France.	daniel.henrion@univ-angers.fr	Henrion, Daniel/N-7023-2015; Daniel, chappard/AFK-4857-2022; AMIOT, MARIE JOSEPHE/N-8894-2019; Amiot, Marie Josephe/M-1203-2017; Henrion, Daniel/J-8141-2015; ANDRIANTSITOHAINA, Ramaroson/H-5286-2018; Amiot, Marie Josephe/C-4457-2015; Henrion, Daniel/AAK-1995-2021; Daniel, chappard/AAG-3528-2022	Henrion, Daniel/0000-0003-1094-0285; AMIOT, MARIE JOSEPHE/0000-0003-4563-4587; Amiot, Marie Josephe/0000-0003-4563-4587; Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285; andriantsitohaina, ramaroson/0000-0002-4770-3585				Albini A, 2005, FASEB J, V19, P527, DOI 10.1096/fj.05-5128fje; Andriambeloson E, 1997, BRIT J PHARMACOL, V120, P1053, DOI 10.1038/sj.bjp.0701011; Andriambeloson E, 1998, J NUTR, V128, P2324, DOI 10.1093/jn/128.12.2324; Barthomeuf C, 2006, FREE RADICAL BIO MED, V40, P581, DOI 10.1016/j.freeradbiomed.2005.09.015; Bassus S, 2001, ARTERIOSCL THROM VAS, V21, P1550, DOI 10.1161/hq0901.095148; Bernatova I, 2002, AM J PHYSIOL-HEART C, V282, pH942, DOI 10.1152/ajpheart.00724.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLVILLENASH PR, 1992, ANN RHEUM DIS, V51, P919, DOI 10.1136/ard.51.7.919; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Cordova AC, 2005, J AM COLL SURGEONS, V200, P428, DOI 10.1016/j.jamcollsurg.2004.10.030; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Curin Y, 2005, PHARMACOL REP, V57, P97; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Diebolt M, 2001, HYPERTENSION, V38, P159, DOI 10.1161/01.HYP.38.2.159; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Favot L, 2003, CARDIOVASC RES, V59, P479, DOI 10.1016/S0008-6363(03)00433-4; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Labrecque L, 2005, CARCINOGENESIS, V26, P821, DOI 10.1093/carcin/bgi024; Loufrani L, 2001, CIRCULATION, V103, P864, DOI 10.1161/01.CIR.103.6.864; Martin S, 2003, BIOCHEM PHARMACOL, V65, P669, DOI 10.1016/S0006-2952(02)01568-X; Martin S, 2002, BRIT J PHARMACOL, V135, P1579, DOI 10.1038/sj.bjp.0704603; Ndiaye M, 2004, BRIT J PHARMACOL, V142, P1131, DOI 10.1038/sj.bjp.0705774; Ndiaye M, 2003, BIOCHEM BIOPH RES CO, V310, P371, DOI 10.1016/j.bbrc.2003.09.028; Oak MH, 2004, CIRCULATION, V110, P1861, DOI 10.1161/01.CIR.0000142617.52881.F4; Oak MH, 2003, ARTERIOSCL THROM VAS, V23, P1001, DOI 10.1161/01.ATV.0000070101.70534.38; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Pechanova O, 2004, J HYPERTENS, V22, P1551, DOI 10.1097/01.hjh.0000133734.32125.c7; Perez-Vizcaino F, 2006, BIOCHEM BIOPH RES CO, V346, P919, DOI 10.1016/j.bbrc.2006.05.198; Pfosser A, 2005, CARDIOVASC RES, V65, P728, DOI 10.1016/j.cardiores.2004.10.019; Ranaivo HR, 2004, BRIT J PHARMACOL, V142, P671, DOI 10.1038/sj.bjp.0705833; Schaper W, 2003, ARTERIOSCL THROM VAS, V23, P1143, DOI 10.1161/01.ATV.0000069625.11230.96; Siddiqui IA, 2004, J CELL BIOCHEM, V91, P232, DOI 10.1002/jcb.10737; Szmitko PE, 2005, AM J PHYSIOL-HEART C, V288, pH2023, DOI 10.1152/ajpheart.00868.2004; Tamarat R, 2002, HYPERTENSION, V39, P830, DOI 10.1161/hy0302.104671; Wallerath T, 2003, J AM COLL CARDIOL, V41, P471, DOI 10.1016/S0735-1097(02)02826-7; Zenebe W, 2003, PHYSIOL RES, V52, P425	38	64	68	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3511	3521		10.1096/fj.06-7782com	http://dx.doi.org/10.1096/fj.06-7782com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17595348				2022-12-25	WOS:000250517800014
J	Young, JE; Gouw, L; Propp, S; Sopher, BL; Taylor, J; Lin, A; Hermel, E; Logvinova, A; Chen, SF; Chen, S; Bredesen, DE; Truant, R; Ptacek, LJ; La Spada, AR; Ellerby, LM				Young, Jessica E.; Gouw, Launce; Propp, Stephanie; Sopher, Bryce L.; Taylor, Jillian; Lin, Amy; Hermel, Evan; Logvinova, Anna; Chen, Sylvia F.; Chen, Shiming; Bredesen, Dale E.; Truant, Ray; Ptacek, Louis J.; La Spada, Albert R.; Ellerby, Lisa M.			Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTIN REDUCES TOXICITY; MACHADO-JOSEPH-DISEASE; CONE-ROD DYSTROPHY; NUCLEAR-LOCALIZATION; EXPANDED POLYGLUTAMINE; EMBRYONIC LETHALITY; ANDROGEN RECEPTOR; MUTANT HUNTINGTIN; MOUSE MODEL; CAG REPEAT	Spinocerebellar ataxia type 7 ( SCA7) is a polyglutamine ( polyQ) disorder characterized by specific degeneration of cerebellar, brainstem, and retinal neurons. Although they share little sequence homology, proteins implicated in polyQ disorders have common properties beyond their characteristic polyQ tract. These include the production of proteolytic fragments, nuclear accumulation, and processing by caspases. Here we report that ataxin-7 is cleaved by caspase-7, and we map two putative caspase-7 cleavage sites to Asp residues at positions 266 and 344 of the ataxin-7 protein. Site-directed mutagenesis of these two caspase-7 cleavage sites in the polyQ-expanded form of ataxin-7 produces an ataxin-7 D266N/D344N protein that is resistant to caspase cleavage. Although ataxin-7 displays toxicity, forms nuclear aggregates, and represses transcription in human embryonic kidney 293T cells in a polyQ length-dependent manner, expression of the non-cleavable D266N/D344N form of polyQ-expanded ataxin-7 attenuated cell death, aggregate formation, and transcriptional interference. Expression of the caspase-7 truncation product of ataxin-7-69Q or -92Q, which removes the putative nuclear export signal and nuclear localization signals of ataxin-7, showed increased cellular toxicity. We also detected N-terminal polyQ-expanded ataxin-7 cleavage products in SCA7 transgenic mice similar in size to those generated by caspase-7 cleavage. In a SCA7 transgenic mouse model, recruitment of caspase-7 into the nucleus by polyQ-expanded ataxin-7 correlated with its activation. Our results, thus, suggest that proteolytic processing of ataxin-7 by caspase-7 may contribute to SCA7 disease pathogenesis.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Neurol, San Francisco, CA 94143 USA; Univ Washington, Med Ctr, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Med Med Genet, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Neurol Neurogenet, Seattle, WA 98195 USA; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; Touro Univ Coll Osteopath Med, Vallejo, CA 94592 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Buck Institute for Research on Aging; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; McMaster University; Touro University California; Washington University (WUSTL)	Ellerby, LM (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	lellerby@buckinstitute.org	La Spada, Albert/AAG-8809-2020	Achenbach, Jillian/0000-0002-1054-3784	NEI NIH HHS [R01 EY012543, EY14061] Funding Source: Medline; NINDS NIH HHS [NS40251A] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014061, R01EY012543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brooks BP, 1997, NEUROBIOL DIS, V3, P313, DOI 10.1006/nbdi.1997.0126; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen NS, 1999, J NEUROCHEM, V72, P1890, DOI 10.1046/j.1471-4159.1999.0721890.x; Chen SM, 2004, HUM MOL GENET, V13, P53, DOI 10.1093/hmg/ddh005; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Einum DD, 2001, NEUROGENETICS, V3, P83, DOI 10.1007/s100480000100; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Garden GA, 2002, J NEUROSCI, V22, P4897, DOI 10.1523/JNEUROSCI.22-12-04897.2002; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GOUW LG, 1994, NEUROLOGY, V44, P1441, DOI 10.1212/WNL.44.8.1441; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hardy JA, 2004, P NATL ACAD SCI USA, V101, P12461, DOI 10.1073/pnas.0404781101; Helmlinger D, 2006, BIOCHEM SOC SYMP, V73, P155; Helmlinger D, 2006, PLOS BIOL, V4, P432, DOI 10.1371/journal.pbio.0040067; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Hermel E, 2004, CELL DEATH DIFFER, V11, P424, DOI 10.1038/sj.cdd.4401358; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lines MA, 2002, OPHTHALMOLOGY, V109, P1862, DOI 10.1016/S0161-6420(02)01187-9; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Mushegian AR, 2000, BIOCHEMISTRY-US, V39, P6809, DOI 10.1021/bi992694y; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Ross CA, 1997, MEDICINE, V76, P305, DOI 10.1097/00005792-199709000-00001; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Taylor J, 2006, J BIOL CHEM, V281, P2730, DOI 10.1074/jbc.M506751200; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yaoita Y, 2002, BIOCHEM BIOPH RES CO, V291, P79, DOI 10.1006/bbrc.2002.6408; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Yvert G, 2001, HUM MOL GENET, V10, P1679, DOI 10.1093/hmg/10.16.1679; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	60	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30150	30160		10.1074/jbc.M705265200	http://dx.doi.org/10.1074/jbc.M705265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17646170	hybrid			2022-12-25	WOS:000249981200045
J	Xie, LL; Jiang, Y; Ouyang, P; Chen, J; Doan, H; Herndon, B; Sylvester, JE; Zhang, K; Molteni, A; Reichle, M; Zhang, RQ; Haub, MD; Baybutt, RC; Wang, WQ				Xie, Linglin; Jiang, Yu; Ouyang, Ping; Chen, Jie; Doan, Hieu; Herndon, Betty; Sylvester, Jessica E.; Zhang, Ke; Molteni, Agostino; Reichle, Marie; Zhang, Rongqing; Haub, Mark D.; Baybutt, Richard C.; Wang, Weiqun			Effects of dietary calorie restriction or exercise on the PI3K and ras signaling pathways in the skin of mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; ENERGY RESTRICTION; INTESTINAL TUMORIGENESIS; MESSENGER-RNA; CANCER; PROTEIN; RATS; CARCINOGENESIS; INHIBITION; EXPRESSION	Weight control by exercise and dietary calorie restriction (DCR) has been associated with reduced cancer risk, but the underlying mechanisms are not well understood. This study was designed to compare the effects of weight loss by increasing physical activity or decreasing calorie intake on tumor promoter-induced Ras-MAPK and PI3K-Akt pathways. SENCAR mice were randomly assigned to one of the following five groups: ad libitum-fed sedentary control, ad libitum-fed exercise (AL+Exe), exercise but pair-fed at the amount as controls (PF+Exe), 20% DCR, and 20% DCR plus exercise (DCR+Exe). After 10 weeks, body weight and body fat significantly decreased in the groups of DCR, DCR + Exe, and PF + Exe when compared with the controls. AL + Exe did not induce weight loss due to, at least in part, increased food intake. Plasma IGF-1 levels reduced significantly in DCR and DCR+Exe but not PF+Exe. The protein H-Ras and activated Ras-GTP significantly decreased in TPA-induced skin tissues of DCR-fed mice but not exercised mice. PI3K protein, phosphoserine Akt, and p42/p44-MAPK were reduced, however, in both DCR and PF+Exe groups. Immunohistochemistry demonstrated that the significantly reduced H-Ras occurred in subcutaneous fat cells, while the reduced PI3K and PCNA took place only in the epidermis. Plasma leptin decreased in PF + Exe, DCR, and DCR + Exe, while the caspase-3 activity increased in DCR+Exe only. Genomic microarray analysis further indicated that the expression of 34 genes relevant to PI3K and 31 genes to the MAPK pathway were significantly regulated by either DCR or PF+Exe treatments. The reduced PI3K in PF+Exe mice was partially reversed by IGF-1 treatment. The overall results of this study demonstrated that DCR abrogated both Ras and PI3K signaling, which might inhibit TPA-induced proliferation and anti-apoptosis. Selective inhibition of PI3K by PF+Exe but not AL+Exe seems more attributable to the magnitude of the caloric deficit and/or body fat loss than diet versus exercise comparison.	Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA; Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA; Kansas State Univ, Dept Stat, Manhattan, KS 66506 USA; Univ Missouri, Sch Med, Kansas City, MO 64108 USA	Kansas State University; Kansas State University; Kansas State University; University of Missouri System; University of Missouri Kansas City	Wang, WQ (corresponding author), Kansas State Univ, Dept Human Nutr, Manhattan, KS 66506 USA.	wwang@ksu.edu	Haub, Mark/E-7846-2010		NATIONAL CANCER INSTITUTE [R01CA106397] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106397] Funding Source: Medline; NCRR NIH HHS [P20 RR15563] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Badman MK, 2005, SCIENCE, V307, P1909, DOI 10.1126/science.1109951; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Berstein L M, 2005, Adv Gerontol, V16, P51; Birt DF, 2001, CANCER EPIDEM BIOMAR, V10, P679; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; Dean DJ, 1998, AGING-CLIN EXP RES, V10, P303, DOI 10.1007/BF03339792; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Efron B, 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; Figlewicz DP, 2001, PHYSIOL BEHAV, V73, P229, DOI 10.1016/S0031-9384(01)00486-3; GARROW JS, 1995, EUR J CLIN NUTR, V49, P1; HAGAN H, 2003, EMBO REP, V3, P418; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; HURSTING SD, 1993, CANCER RES, V53, P2750; International Agency for Research on Cancer, 2002, IARC HDB CANC PREV, V6; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; KLURFELD DM, 1989, J NUTR, V119, P286, DOI 10.1093/jn/119.2.286; Kritchevsky D, 2003, J NUTR, V133, p3827S, DOI 10.1093/jn/133.11.3827S; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P445, DOI 10.1097/00008469-199512000-00002; Liu YH, 2002, CANCER EPIDEM BIOMAR, V11, P299; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lu J, 2007, EXP BIOL MED, V232, P473; Mai V, 2003, CANCER RES, V63, P1752; MARIANO B, 1987, ANNU REV BIOCHEM, V56, P779; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; Michna L, 2006, CARCINOGENESIS, V27, P2108, DOI 10.1093/carcin/bgl057; Miyazawa-Hoshimoto S, 2005, AM J PHYSIOL-ENDOC M, V288, pE1128, DOI 10.1152/ajpendo.00003.2004; Mukherjee P, 1999, JNCI-J NATL CANCER I, V91, P512, DOI 10.1093/jnci/91.6.512; Palmqvist R, 2002, GUT, V50, P642, DOI 10.1136/gut.50.5.642; POLLARD M, 1984, CANCER TREAT REP, V68, P405; Proebstle TM, 1996, EUR J CANCER, V32A, P1664, DOI 10.1016/0959-8049(95)00534-X; Przybyszewski J, 2001, CARCINOGENESIS, V22, P1421, DOI 10.1093/carcin/22.9.1421; Rambaratsingh RA, 2003, J BIOL CHEM, V278, P52792, DOI 10.1074/jbc.M308240200; ROEBUCK BD, 1981, CANCER RES, V41, P888; Roth GS, 2002, HORM METAB RES, V34, P378, DOI 10.1055/s-2002-33469; Rusch HP, 1944, CANCER RES, V4, P116; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smolle J, 1995, AM J DERMATOPATH, V17, P555, DOI 10.1097/00000372-199512000-00005; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; WEINDRUCH R, 1988, RETARDATION AGING DI, P73; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wu YP, 2003, CANCER RES, V63, P4384; Wu YP, 2002, CANCER RES, V62, P1030; Zhu ZJ, 2002, MOL CARCINOGEN, V35, P51, DOI 10.1002/mc.10073	54	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28025	28035		10.1074/jbc.M604857200	http://dx.doi.org/10.1074/jbc.M604857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17646168	Green Submitted, hybrid			2022-12-25	WOS:000249455600052
J	Bu, Y; Gelman, IH				Bu, Yahao; Gelman, Irwin H.			v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; HISTONE DEACETYLASE INHIBITORS; TRANSCRIPTION FACTOR USF; REPRESS TRANSCRIPTION; MOLECULAR-CLONING; TRICHOSTATIN-A; FACTOR FAMILY; SP1 SITE; EXPRESSION; PROTEIN	SSeCKS ( (S) under bar -rc (s) under bar uppr (e) under bar ssed (C) under bar (k) under bar inase (s) under bar ubstrate), also called gravin/AKAP12, is a large scaffolding protein with metastasis suppressor activity. Two major isoforms of SSeCKS are expressed in most cell and tissue types under the control of two independent promoters, designated alpha and beta, separated by 68 kb. SSeCKS transcript and protein levels are severely decreased in Src- and Ras-transformed fibroblasts and in many epithelial tumors. By dissecting its promoters with progressive deletion analysis, we identified the sequence between -106 and -49 in the alpha proximal promoter as the minimal v-Src-responsive element, which contains E- and GC-boxes bound by USF1 and Sp1/Sp3, respectively. Both E- and GC-boxes are crucial for v-Src-responsive and basal promoter activities. v-Src does not alter USF1 binding levels at the E- box, but it increases Sp1/Sp3 binding to the GC-box despite no change in their cellular protein abundance. SSeCKS alpha and beta transcript levels in v-Src/3T3 cells can be restored by treatment with the histone deacetylase inhibitor, trichostatin A, but not with the DNA demethylation agent, 5-azacytidine. Chromatin changes are found only on the alpha promoter even though the beta proximal promoter contains a similar E- and GC-box arrangement. Recruitment of HDAC1 is necessary and sufficient to cause repression of alpha proximal promoter activity, and the addition of Sp1 and/or Sp3 potentiates the repression. Our data suggest that suppression of the beta promoter is facilitated by Src- induced changes in the alpha promoter chromatinization mediated by a USF1-Sp1-Sp3 complex.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14209 USA	Roswell Park Cancer Institute	Gelman, IH (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14209 USA.	Irwin.gelman@roswellpark.org			NATIONAL CANCER INSTITUTE [R01CA094108, R55CA094108] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA094108, CA 94108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Camus A, 2001, MECH DEVELOP, V105, P79, DOI 10.1016/S0925-4773(01)00384-7; Cha HJ, 2001, CLIN EXP METASTAS, V18, P675, DOI 10.1023/A:1013190118556; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Choi MC, 2004, ONCOGENE, V23, P7095, DOI 10.1038/sj.onc.1207932; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; ENOMOTO H, 1994, ONCOGENE, V9, P2785; Erlichman J, 1999, EUR J BIOCHEM, V263, P797, DOI 10.1046/j.1432-1327.1999.00561.x; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Ge YB, 2003, J BIOL CHEM, V278, P49901, DOI 10.1074/jbc.M305085200; Gelman IH, 2006, MOL CANCER RES, V4, P151, DOI 10.1158/1541-7786.MCR-05-0252; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Grove BD, 2001, J VASC RES, V38, P163, DOI 10.1159/000051043; Gupta AK, 2002, AM J PHYSIOL-CELL PH, V283, pC1065, DOI 10.1152/ajpcell.00100.2002; Hadjiagapiou C, 2005, AM J PHYSIOL-GASTR L, V288, pG1118, DOI 10.1152/ajpgi.00312.2004; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hasleton MD, 2003, BIOCHEM J, V373, P925, DOI 10.1042/BJ20030388; Hsu MC, 2006, J BIOL CHEM, V281, P4718, DOI 10.1074/jbc.M510937200; Huang YC, 2006, J CELL PHYSIOL, V209, P363, DOI 10.1002/jcp.20741; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Longworth MS, 2006, ONCOGENE, V25, P4495, DOI 10.1038/sj.onc.1209473; Maehara K, 2002, BIOCHEM BIOPH RES CO, V295, P187, DOI 10.1016/S0006-291X(02)00646-0; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; OZAKI T, 1994, CANCER RES, V54, P646; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Pan J, 1996, FEBS LETT, V383, P21; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIERANI A, 1993, MOL CELL BIOL, V13, P3401, DOI 10.1128/MCB.13.6.3401; Provot S, 2000, ONCOGENE, V19, P4736, DOI 10.1038/sj.onc.1203837; QURESHI SA, 1992, ONCOGENE, V7, P121; Rombouts K, 2002, J HEPATOL, V37, P788, DOI 10.1016/S0168-8278(02)00275-1; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; Scholz G, 1996, MOL CELL BIOL, V16, P481; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Streb JW, 2005, J BIOL CHEM, V280, P4125, DOI 10.1074/jbc.M412466200; Streb JW, 2004, J BIOL CHEM, V279, P56014, DOI 10.1074/jbc.M408828200; Su B, 2006, CANCER RES, V66, P5599, DOI 10.1158/0008-5472.CAN-05-4123; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Sung J, 2005, CARCINOGENESIS, V26, P487, DOI 10.1093/carcin/bgh318; Tao JC, 2006, J BIOL CHEM, V281, P23932, DOI 10.1074/jbc.M601813200; Tost J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng050; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Xia W, 2001, CANCER RES, V61, P5644; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang XP, 2002, J LIPID RES, V43, P297; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; Zhao SJ, 2003, CANCER RES, V63, P2624	71	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26725	26739		10.1074/jbc.M702885200	http://dx.doi.org/10.1074/jbc.M702885200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626016	hybrid			2022-12-25	WOS:000249304900011
J	Ghanei, H; Abeyrathne, PD; Lam, JS				Ghanei, Hamed; Abeyrathne, Priyanka D.; Lam, Joseph S.			Biochemical characterization of MsbA from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MSBA; ATPASE ACTIVITY; ABC TRANSPORTER; P-GLYCOPROTEIN; DRUG-RESISTANCE; LIPOPOLYSACCHARIDE; BIOSYNTHESIS; BACTERIAL; SYSTEM; FAMILY	Lipopolysaccharide of Pseudomonas aeruginosa is a major constituent of the outer membrane, and it is composed of three distinct regions: lipid A, core oligosaccharide, and O antigen. Lipid A and core oligosaccharides ( OS) are synthesized and assembled at the cytoplasmic side of the inner membrane and then translocated to the periplasmic side of the membrane where lipid A-core becomes the acceptor of the O antigens. Here we show that MsbA encoded by pA4997 of the P. aeruginosa genome is a member of the ABC transporter family, but this protein has distinctive features when compared with other MsbA proteins. msbA is an essential gene in this organism since mutation in this gene is lethal to the bacterium. Disruption of the chromosomal msbA was achieved only when a functional copy of the gene was provided in trans. msbA from Escherichia-coli (msbA(Ec)) could not cross complement the msbA merodiploid cells of P. aeruginosa. MsbA was expressed and purified, and the kinetic of its ATPase activity is vastly different than that of MsbA(Ec). The activity of MsbA could be selectively stimulated by different truncated versions of core OS of P. aeruginosa LPS. Specifically, phosphate substituents in the lipid A-core are important for stimulating ATPase activity of MsbA. Expression of MsbAEc but not MsbA(Pa) conferred resistance to erythromycin in P. aeruginosa.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Lam, JS (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	jlam@uoguelph.ca						AUSUBEL F, 1997, SHORT PROTOCOL MOL B; BAUER AW, 1959, ARCH INTERN MED, V104, P208, DOI 10.1001/archinte.1959.00270080034004; Bedoux G, 2004, J MASS SPECTROM, V39, P505, DOI 10.1002/jms.611; Benabdelhak H, 2005, BIOCHEM J, V386, P489, DOI 10.1042/BJ20041282; Buxbaum E, 1999, EUR J BIOCHEM, V265, P54, DOI 10.1046/j.1432-1327.1999.00643.x; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DEHERTOGH DA, 1985, ANTIMICROB AGENTS CH, V27, P670, DOI 10.1128/AAC.27.4.670; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; DROGE W, 1970, EUR J BIOCHEM, V14, P175, DOI 10.1111/j.1432-1033.1970.tb00276.x; Ghosheh O, 2001, DRUG METAB DISPOS, V29, P1525; Hanrahan JW, 1996, J EXP ZOOL, V275, P283; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; Kuhnke G, 2006, MOL MEMBR BIOL, V23, P173, DOI 10.1080/09687860500473630; Lambert O, 1998, BIOPHYS J, V74, P918, DOI 10.1016/S0006-3495(98)74015-9; Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Lingwood D, 2006, COMP BIOCHEM PHYS A, V144, P451, DOI 10.1016/j.cbpa.2006.03.016; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Meredith TC, 2006, ACS CHEM BIOL, V1, P33, DOI 10.1021/cb0500015; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Orlowski S, 2006, CELL MOL LIFE SCI, V63, P1038, DOI 10.1007/s00018-005-5554-9; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; POON KKH, 2003, 103 GEN C AM SOC MIC; RAETZ CR, 2002, ANNU REV BIOCHEM, V71, P625; Rahim R, 2000, MICROBIOL-UK, V146, P2803, DOI 10.1099/00221287-146-11-2803; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Scott HN, 2003, PLASMID, V50, P74, DOI 10.1016/S0147-619X(03)00030-1; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SKOZA L, 1976, BIOCHEM J, V159, P457, DOI 10.1042/bj1590457; Steinfels E, 2002, BBA-BIOMEMBRANES, V1565, P1, DOI 10.1016/S0005-2736(02)00515-1; Toulmay A, 2007, BIOCHIMIE, V89, P249, DOI 10.1016/j.biochi.2006.07.020; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; van Veen HW, 2001, RES MICROBIOL, V152, P365, DOI 10.1016/S0923-2508(01)01208-6; Walsh AG, 2000, MOL MICROBIOL, V35, P718, DOI 10.1046/j.1365-2958.2000.01741.x; Wang XY, 2004, J BIOL CHEM, V279, P49470, DOI 10.1074/jbc.M409078200; WESTPHAL O, 1983, PROG ALLERGY, V33, P9; Woebking B, 2005, J BACTERIOL, V187, P6363, DOI 10.1128/JB.187.18.6363-6369.2005; Zhao X, 2002, ANTIMICROB AGENTS CH, V46, P2035, DOI 10.1128/AAC.46.6.2035-2037.2002; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	50	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26939	26947		10.1074/jbc.M702952200	http://dx.doi.org/10.1074/jbc.M702952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17644517	hybrid			2022-12-25	WOS:000249304900033
J	Pullikotil, P; Benjannet, S; Mayne, J; Seidah, NG				Pullikotil, Philomena; Benjannet, Suzanne; Mayne, Janice; Seidah, Nabil G.			The proprotein convertase SKI-1/S1P - Alternate translation and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED INTRAMEMBRANE PROTEOLYSIS; FEVER VIRUS GLYCOPROTEIN; ELEMENT-BINDING PROTEINS; TRANSCRIPTION FACTOR; CELLULAR TRAFFICKING; SECRETORY PATHWAY; SITE-1 PROTEASE; CLEAVAGE; FURIN; PRECURSOR	Subtilisin kexin isozyme-1 (SKI-1) represents the first mammalian member of secretory subtilisin-like processing enzymes that cleaves after nonbasic residues. It is synthesized as an inactive precursor that undergoes three sequential autocatalytic processing steps of its N-terminal prosegment and an ectodomain shedding at a site near the transmembrane domain. The various cellular functions of SKI-1 emphasize the need to understand the sites of its activation and shedding. We have previously shown that SKI-1 undergoes autocatalytic shedding at the sequence KHQKLL(9532) down arrow resulting in a membrane-bound stump called St-1 (amino acids 954-1052). However, little is known about the cellular localization of SKI-1 or its shed forms. In the present study, we have further identified a smaller C-terminal fragment St-2 generated closer to the transmembrane domain. By sequencing and mass spectrometric analysis, the start site and the molecular mass of St-2 were determined. Site- directed mutagenesis revealed the critical amino acid involved in this novel process. Mutation of Met(990) to M990A, M990I, and M990L failed to generate St-2, suggesting an internal alternate translation event at Met990, as confirmed by an in vitro transcription/translation assay. Confocal microscopy defined the subcellular localization of SKI-1 and its fragments. The data show that most of membrane-bound SKI-1 and its stumps St-1 and St-2 localize to the Golgi and can enter the endosomal/lysosomal compartments but do not sort to the cell surface. Deletion studies showed that the transmembrane domain of SKI-1 determines its trafficking. Finally, rSt-1 and rSt-2 seem to affect the processing of ATF6 by SKI-1, but cellular stress does not regulate the production of St-2.	Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Univ Ottawa, Ottawa Hosp, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute	Seidah, NG (corresponding author), Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				Addlagatta A, 2005, BIOCHEMISTRY-US, V44, P14741, DOI 10.1021/bi051691k; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Basak A, 2005, J MOL MED, V83, P844, DOI 10.1007/s00109-005-0710-0; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Beyer WR, 2003, J VIROL, V77, P2866, DOI 10.1128/JVI.77.5.2866-2872.2003; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; FISHMAN PH, 1992, FEBS LETT, V314, P371, DOI 10.1016/0014-5793(92)81508-J; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kim T, 2006, MOL BIOL CELL, V17, P789, DOI 10.1091/mbc.E05-08-0755; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 2001, SCI STKE, pE1; Kozak M, 2006, GENE, V382, P1, DOI 10.1016/j.gene.2006.06.004; Lenz O, 2001, P NATL ACAD SCI USA, V98, P12701, DOI 10.1073/pnas.221447598; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Nassoury N, 2007, TRAFFIC, V8, P718, DOI 10.1111/j.1600-0854.2007.00562.x; Nour N, 2005, MOL BIOL CELL, V16, P5215, DOI 10.1091/mbc.E05-06-0504; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Pasquato A, 2006, J BIOL CHEM, V281, P23471, DOI 10.1074/jbc.M513675200; Pullikotil P, 2004, J BIOL CHEM, V279, P17338, DOI 10.1074/jbc.M313764200; Raggo C, 2002, MOL CELL BIOL, V22, P5639, DOI 10.1128/MCB.22.16.5639-5649.2002; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 2003, BIOCHEM SOC SYMP, V70, P221, DOI 10.1042/bss0700221; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Richer MJ, 2004, P NATL ACAD SCI USA, V101, P10560, DOI 10.1073/pnas.0401406101; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sanchez AJ, 2006, J VIROL, V80, P514, DOI 10.1128/JVI.80.1.514-525.2006; Seidah NG, 2006, BIOL CHEM, V387, P871, DOI 10.1515/BC.2006.110; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; SEIDAH NG, 2002, ENZYMES, V22, P237; Stirling J, 2006, MOL BIOL CELL, V17, P413, DOI 10.1091/mbc.E05-06-0500; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toure BB, 2000, J BIOL CHEM, V275, P2349, DOI 10.1074/jbc.275.4.2349; Vincent MJ, 2003, J VIROL, V77, P8640, DOI 10.1128/JVI.77.16.8640-8649.2003; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Wouters S, 1999, FEBS LETT, V456, P97, DOI 10.1016/S0014-5793(99)00938-2; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; YE SQ, 1993, J BIOL CHEM, V268, P8497	54	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27402	27413		10.1074/jbc.M703200200	http://dx.doi.org/10.1074/jbc.M703200200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623657	hybrid			2022-12-25	WOS:000249304900082
J	Schenauer, MR; Yu, Y; Sweeney, MD; Leary, JA				Schenauer, Matthew R.; Yu, Yonghao; Sweeney, Matthew D.; Leary, Julie A.			CCR2 chemokines bind selectively to acetylated heparan sulfate octasaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN BINDING; LIGAND-BINDING; COMPLEXES; HOST; OLIGOMERIZATION; SPECIFICITY	Chemokines participate in well documented interactions with glycosaminoglycans (GAGs). Although many chemokine amino acid residues involved in binding have been identified, much less is known about the bound regions of GAG. Heparan sulfate (HS) is the predominant cell surface GAG, and its heterogeneous nature offers proteins a variety of structural motifs with which to interact. In the present study, we describe the interactions of three CC chemokines, MCP-1/CCL2, MCP-2/CCL8, and MCP-3/CCL7, with HS-derived oligosaccharides. To this end, we generated and characterized a complex HS octasaccharide library containing 17 different octasaccharide compositions based on acetyl and sulfate group content. Electrospray ionization mass spectrometry was used to detect chemokine-HS octasaccharide complexes in the bound state, and an affinity purification protocol was used to select and identify chemokine-binding octasaccharides from the complex mixture. The results indicate that HS octasaccharide sulfation is the foremost requirement for chemokine binding. However, within octasaccharides of constant charge density, acetylation is also observed to augment binding, suggesting that there may be as yet undiscovered specificity in the chemokine-HS interaction.	Univ Calif Davis, Dept Chem, Genome Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Mol & Cell Biol, Genome Ctr, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Leary, JA (corresponding author), Univ Calif Davis, Dept Chem, Genome Ctr, Davis, CA 95616 USA.	jaleary@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047356] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47356] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Crown SE, 2006, J BIOL CHEM, V281, P25438, DOI 10.1074/jbc.M601518200; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; GRIFFIN CC, 1995, CARBOHYD RES, V276, P183, DOI 10.1016/0008-6215(95)00166-Q; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Hileman RE, 1997, GLYCOBIOLOGY, V7, P231; Hofstadler SA, 2006, NAT REV DRUG DISCOV, V5, P585, DOI 10.1038/nrd2083; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lau EK, 2004, ADV PROTEIN CHEM, V68, P351; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; Loo JA, 1997, MASS SPECTROM REV, V16, P1; LOO JA, 1997, CHEM SOC REV, V26, P191; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Noti C, 2005, CHEM BIOL, V12, P731, DOI 10.1016/j.chembiol.2005.05.013; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Saad OM, 2005, ANAL CHEM, V77, P5902, DOI 10.1021/ac050793d; Saad OM, 2004, J AM SOC MASS SPECTR, V15, P1274, DOI 10.1016/j.jasms.2004.05.008; Sobott F, 2005, PHILOS T R SOC A, V363, P379, DOI 10.1098/rsta.2004.1498; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; Varki A., 1999, ESSENTIALS GLYCOBIOL, P145; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Yu YH, 2006, J AM SOC MASS SPECTR, V17, P524, DOI 10.1016/j.jasms.2005.12.008; Yu YH, 2005, J BIOL CHEM, V280, P32200, DOI 10.1074/jbc.M505738200	32	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25182	25188		10.1074/jbc.M703387200	http://dx.doi.org/10.1074/jbc.M703387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17597064	hybrid			2022-12-25	WOS:000249014100003
J	Wang, J; Malloy, PJ; Feldman, D				Wang, Jining; Malloy, Peter J.; Feldman, David			Interactions of the vitamin D receptor with the corepressor hairless - Analysis of hairless mutants in atrichia with papular lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNDERLIES CONGENITAL ATRICHIA; D-RESISTANT RICKETS; ZINC-FINGER DOMAIN; COMPOUND HETEROZYGOUS MUTATIONS; NUCLEAR HORMONE-RECEPTORS; GENE UNDERLYING ATRICHIA; LIGAND-BINDING DOMAIN; SPLICE-SITE MUTATION; MISSENSE MUTATION; TRANSCRIPTIONAL REGULATION	Atrichia with papular lesions (APL) and hereditary vitamin D-resistant rickets have a similar congenital hair loss disorder caused by mutations in hairless (HR) and vitamin D receptor (VDR) genes, respectively. HR is a VDR corepressor, and it has been hypothesized that (VDRHR)-H-. suppress gene expression during specific phases of the hair cycle. In this study, we examined the corepressor activity of HR mutants (E583V, C622G, N970S, V1056M, D1012N, V1136D, and Q1176X) previously described as the molecular cause of APL as well as HR variants (P69S, C397Y, A576V, E591G, R620Q, T1022A) due to non-synonymous polymorphisms in the HR gene. We found that the corepressor activities of all but one of the pathogenic HR mutants were completely abolished. HR mutant E583V exhibited normal corepressor activity, suggesting that it may not be pathogenic. In co-immunoprecipitation assays, all of the pathogenic HR mutants bound VDR but exhibited reduced binding to histone deacetylase 1 (HDAC1), suggesting that the impaired corepressor activity is due in part to defective interactions with HDACs. The HR variants exhibited two classes of corepressor activity, those with normal activity (C397Y, E591G, R620Q) and those with partially reduced activity (P69S, A576V, T1022A). All of the variants interacted with VDR and HDAC1 with the exception of P69S, which was degraded. When coexpressed with VDR, all of the HR pathogenic mutants and variants increased the level of VDR protein, demonstrating that this function of HR was not impaired by these mutations. This study of HR mutations provides evidence for the molecular basis of APL.	Stanford Univ, Sch Med, Div Endocrinol Gerontol & Metab, Dept Med, Stanford, CA 94305 USA	Stanford University	Malloy, PJ (corresponding author), Stanford Univ, Sch Med, Div Endocrinol Gerontol & Metab, Dept Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	malloy@cmgm.Stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042482, R01DK042482] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad W, 1999, J INVEST DERMATOL, V113, P281, DOI 10.1046/j.1523-1747.1999.00686.x; Ahmad W, 1998, AM J HUM GENET, V63, P984, DOI 10.1086/302069; Ahmad W, 1999, GENOMICS, V56, P141, DOI 10.1006/geno.1998.5699; Ahmad W, 1998, SCIENCE, V279, P720, DOI 10.1126/science.279.5351.720; Aita VM, 2000, EXP DERMATOL, V9, P157, DOI 10.1034/j.1600-0625.2000.009002157.x; Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Ashoor GG, 2005, J DERMATOL SCI, V40, P29, DOI 10.1016/j.jdermsci.2005.04.004; Beaudoin GMJ, 2005, P NATL ACAD SCI USA, V102, P14653, DOI 10.1073/pnas.0507609102; Betz RC, 2007, ARCH DERMATOL RES, V299, P157, DOI 10.1007/s00403-007-0747-8; BIKLE DD, 2006, CELL, V207, P340; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Chen CH, 2001, ENDOCRINOLOGY, V142, P5386, DOI 10.1210/en.142.12.5386; Cichon S, 1998, HUM MOL GENET, V7, P1671, DOI 10.1093/hmg/7.11.1671; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Djabali K, 2004, EXP DERMATOL, V13, P251, DOI 10.1111/j.0906-6705.2004.00174.x; Henn W, 2002, J AM ACAD DERMATOL, V47, P519, DOI 10.1067/mjd.2002.124609; Hillmer AM, 2002, BRIT J DERMATOL, V146, P601, DOI 10.1046/j.1365-2133.2002.04766.x; Hillmer AM, 2001, AM J HUM GENET, V69, P235, DOI 10.1086/321273; Hsieh JC, 2003, J BIOL CHEM, V278, P38665, DOI 10.1074/jbc.M304886200; Indelman M, 2003, BRIT J DERMATOL, V148, P553, DOI 10.1046/j.1365-2133.2003.05177.x; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; John P, 2005, ARCH DERMATOL RES, V297, P226, DOI 10.1007/s00403-005-0593-5; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; Klein I, 2002, J INVEST DERMATOL, V119, P920, DOI 10.1046/j.1523-1747.2002.00268.x; Knebel J, 2006, J CELL BIOCHEM, V99, P319, DOI 10.1002/jcb.20945; Kong J, 2002, J INVEST DERMATOL, V118, P631, DOI 10.1046/j.1523-1747.2002.01727.x; Kruse R, 1999, J INVEST DERMATOL, V113, P954, DOI 10.1046/j.1523-1747.1999.00790.x; Malloy PJ, 2004, J BONE MINER RES, V19, P1018, DOI 10.1359/jbmr.2004.19.6.1018; Malloy PJ, 2001, MOL GENET METAB, V73, P138, DOI 10.1006/mgme.2001.3181; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; Masse M, 2005, CLIN EXP DERMATOL, V30, P363, DOI 10.1111/j.1365-2230.2005.01762.x; Miller J, 2001, J INVEST DERMATOL, V117, P612, DOI 10.1046/j.0022-202x.2001.01438.x; Moraitis AN, 2002, MOL CELL BIOL, V22, P6831, DOI 10.1128/MCB.22.19.6831-6841.2002; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nam Y, 2006, GENOMICS, V87, P520, DOI 10.1016/j.ygeno.2005.12.005; O'Regan GM, 2007, BRIT J DERMATOL, V156, P744, DOI 10.1111/j.1365-2133.2006.07742.x; Paller AS, 2003, J INVEST DERMATOL, V121, P430, DOI 10.1046/j.1523-1747.2003.12370.x; Paradisi M, 2005, EUR J DERMATOL, V15, P332; Paradisi M, 2003, CLIN EXP DERMATOL, V28, P535, DOI 10.1046/j.1365-2230.2003.01333.x; Potter GB, 2002, MOL ENDOCRINOL, V16, P2547, DOI 10.1210/me.2002-0115; Potter GB, 2001, GENE DEV, V15, P2687, DOI 10.1101/gad.916701; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Skorija K, 2005, MOL ENDOCRINOL, V19, P855, DOI 10.1210/me.2004-0415; Sprecher E, 1998, AM J MED GENET, V80, P546, DOI 10.1002/(SICI)1096-8628(19981228)80:5<546::AID-AJMG28>3.0.CO;2-I; Sprecher E, 1999, J INVEST DERMATOL, V113, P687, DOI 10.1046/j.1523-1747.1999.00723.x; Sprecher E, 1999, AM J HUM GENET, V64, P1323, DOI 10.1086/302368; Thompson CC, 2006, CELL CYCLE, V5, P1913, DOI 10.4161/cc.5.17.3189; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Wali A, 2006, CLIN EXP DERMATOL, V31, P695, DOI 10.1111/j.1365-2230.2006.02165.x; Xie ZJ, 2006, ENDOCRINOLOGY, V147, P314, DOI 10.1210/en.2005-1111; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zarach JM, 2004, DEVELOPMENT, V131, P4189, DOI 10.1242/dev.01303; Zlotogorski A, 2002, J INVEST DERMATOL, V118, P881, DOI 10.1046/j.1523-1747.2002.01740.x; Zlotogorski A, 2002, J INVEST DERMATOL, V118, P887, DOI 10.1046/j.1523-1747.2001.01767.x; Zlotogorski A, 1998, HUM GENET, V103, P400, DOI 10.1007/s004390050840	58	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25231	25239		10.1074/jbc.M702939200	http://dx.doi.org/10.1074/jbc.M702939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17609203	hybrid			2022-12-25	WOS:000249014100008
J	Zhang, M; Fang, H; Zhou, J; Herring, BP				Zhang, Min; Fang, Hong; Zhou, Jiliang; Herring, B. Paul			A novel role of Brg1 in the regulation of SRF/MRTFA-dependent smooth muscle-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; CHROMATIN REMODELING COMPLEXES; LIGHT-CHAIN KINASE; CELL DIFFERENTIATION; MASTER REGULATOR; ATPASE SUBUNIT; SWI/SNF; TRANSCRIPTION; MYOCARDIN; PROTEIN	Serum response factor (SRF) is a key regulator of smooth muscle differentiation, proliferation, and migration. Myocardin-related transcription factor A (MRTFA) is a co-activator of SRF that can induce expression of SRF-dependent, smooth muscle-specific genes and actin/Rho-dependent genes, but not MAPK-regulated growth response genes. How MRTFA and SRF discriminate between these sets of target genes is still unclear. We hypothesized that SWI/SNF ATP-dependent chromatin remodeling complexes, containing Brahma-related gene 1 (Brg1) or Brahma (Brm), may play a role in this process. Results from Western blotting and qRT-PCR analysis demonstrated that dominant negative Brg1 blocked the ability of MRTFA to induce expression of smooth muscle-specific genes, but not actin/Rhodependent early response genes, in fibroblasts. In addition, dominant negative Brg1 attenuated expression of smooth muscle-specific genes in primary cultures of smooth muscle cells. MRTFA overexpression did not induce expression of smooth muscle-specific genes in SW13 cells, which lack endogenous Brg1 or Brm. Reintroduction of Brg1 or Brm into SW13 cells restored their responsiveness to MRTFA. Immunoprecipitation assays revealed that Brg1, SRF, and MRTFA form a complex in vivo, and Brg1 directly binds MRTFA, but not SRF, in vitro. Results from chromatin immunoprecipitation assays demonstrated that dominant negative Brg1 significantly attenuated the ability of MRTFA to increase SRF binding to the promoters of smooth muscle-specific genes, but not early response genes. Together these data suggest that Brg1/ Brm containing SWI/SNF complexes play a critical role in regulating expression of SRF/MRTFA-dependent smooth muscle-specific genes but not SRF/MRTFA-dependent early response genes.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pherring@iupui.edu	Zhang, Min/C-6939-2012		NHLBI NIH HHS [HL-58571] Funding Source: Medline; NIDDK NIH HHS [DK-65644, DK-61130, R01 DK061130-06A2, R01 DK061130] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061130, R01DK065644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2005, GENE DEV, V19, P2849, DOI 10.1101/gad.1364105; Cai Xinjiang, 2006, Expert Rev Cardiovasc Ther, V4, P789, DOI 10.1586/14779072.4.6.789; Cao DS, 2005, MOL CELL BIOL, V25, P364, DOI 10.1128/MCB.25.1.364-376.2005; Carson JA, 2000, J BIOL CHEM, V275, P39061, DOI 10.1074/jbc.M006532200; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang DF, 2007, P NATL ACAD SCI USA, V104, P157, DOI 10.1073/pnas.0605635103; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; Davis CA, 2006, MOL CELL BIOL, V26, P2626, DOI 10.1128/MCB.26.7.2626-2636.2006; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Inayoshi Y, 2005, J BIOCHEM, V138, P457, DOI 10.1093/jb/mvi147; Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015; Lockman K, 2004, J BIOL CHEM, V279, P42422, DOI 10.1074/jbc.M405432200; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McDonald OG, 2006, J CLIN INVEST, V116, P36, DOI 10.1172/JCI26505; Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Phiel CJ, 2001, J BIOL CHEM, V276, P34637, DOI 10.1074/jbc.M105826200; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; SchildPoulter C, 1996, NUCLEIC ACIDS RES, V24, P4751, DOI 10.1093/nar/24.23.4751; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Seo S, 2005, DEVELOPMENT, V132, P105, DOI 10.1242/dev.01548; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Villagra A, 2006, J BIOL CHEM, V281, P22695, DOI 10.1074/jbc.M511640200; Vradii D, 2006, J CELL PHYSIOL, V206, P112, DOI 10.1002/jcp.20432; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang ZG, 2003, P NATL ACAD SCI USA, V100, P7129, DOI 10.1073/pnas.1232341100; Yin F, 2006, AM J PHYSIOL-CELL PH, V290, pC1599, DOI 10.1152/ajpcell.00289.2005; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Yoshida T, 2007, AM J PHYSIOL-CELL PH, V292, pC886, DOI 10.1152/ajpcell.00449.2006; Zhang QJ, 2002, ARTERIOSCL THROM VAS, V22, P2030, DOI 10.1161/01.ATV.0000042206.98651.15; Zhou JL, 2005, J BIOL CHEM, V280, P10861, DOI 10.1074/jbc.M411586200	61	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25708	25716		10.1074/jbc.M701925200	http://dx.doi.org/10.1074/jbc.M701925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17599918	hybrid			2022-12-25	WOS:000249014100058
J	Matta, H; Mazzacurati, L; Schamus, S; Yang, T; Sun, Q; Chaudhary, PM				Matta, Hittu; Mazzacurati, Lucia; Schamus, Sandra; Yang, Tianbing; Sun, Qinmiao; Chaudhary, Preet M.			Kaposi's sarcoma-associated herpesvirus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the I kappa B kinase complex to selectively activate NF-kappa B without JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CRYSTAL-STRUCTURE; CELL-DEATH; PROTEIN; VFLIP; PATHWAY; HUMAN-HERPESVIRUS-8; EXPRESSION; LYMPHOMA; TRANSFORMATION	Kaposi's sarcoma herpesvirus oncoprotein vFLIP K13 is a potent activator of NF-kappa B and plays a key role in viral pathogenesis. K13 contains a putative TRAF-interacting motif, which is reportedly required for its interaction with TRAF2. The K13-TRAF2 interaction is believed to be essential for the recruitment of K13 to the I-kappa B kinase (IKK) complex and for K13-induced NF-kappa B and JNK activation. In addition, TRAF3 has been reported to be required for K13-induced NF-kappa B and JNK activation. We have re-examined the role of the TRAFs in K13 signaling and report that mutations in the putative TRAF-interacting motif of K13 have no deleterious effect on its ability to interact with the IKK complex or activation of the NF-kappa B pathway. Furthermore, endogenously expressed TRAF2 and TRAF3 do not interact with K13 and play no role in K13-induced NF-kappa B activation or its interaction with the IKK complex. Finally, K13 does not activate the JNK pathway. Our results support a model in which K13 bypasses the upstream components of the tumor necrosis factor receptor signaling pathway and directly interacts with the IKK complex to selectively activate the NF-kappa B pathway without affecting the JNK pathway. Selective NF-kappa B activation by K13 might represent a novel strategy employed by the virus to promote latency.	Univ Pittsburgh, Translat Res Core Facil, Hillman Canc Ctr, Dept Med,Div Hematol Oncol, Pittsburgh, PA 15213 USA; SW Texas State Univ, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Texas State University System; Texas State University San Marcos	Chaudhary, PM (corresponding author), Univ Pittsburgh, Translat Res Core Facil, Hillman Canc Ctr, Dept Med,Div Hematol Oncol, 5117 Ctr Ave,Suite 1 19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018	mazzacurati, lucia/0000-0002-8336-8032	NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Hogue CWV, 1997, TRENDS BIOCHEM SCI, V22, P314, DOI 10.1016/S0968-0004(97)01093-1; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Jarviluoma A, 2006, BBA-REV CANCER, V1766, P140, DOI 10.1016/j.bbcan.2006.05.001; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Li FY, 2006, J BIOL CHEM, V281, P2960, DOI 10.1074/jbc.M511074200; Liu CQ, 2001, J VIROL, V75, P10933, DOI 10.1128/JVI.75.22.10933-10940.2001; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2007, ONCOGENE, V26, P1656, DOI 10.1038/sj.onc.1209931; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun QM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-9; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wang SZE, 2004, J VIROL, V78, P4248, DOI 10.1128/JVI.78.8.4248-4267.2004; Yang JK, 2005, MOL CELL, V20, P939, DOI 10.1016/j.molcel.2005.10.023; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	35	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24858	24865		10.1074/jbc.M700118200	http://dx.doi.org/10.1074/jbc.M700118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17597077	hybrid			2022-12-25	WOS:000248933000042
J	Vedhachalam, C; Duong, PT; Nickel, M; Nguyen, D; Dhanasekaran, P; Saito, H; Rothblat, GH; Lund-Katz, S; Phillips, MC				Vedhachalam, Charulatha; Duong, Phu T.; Nickel, Margaret; Nguyen, David; Dhanasekaran, Padmaja; Saito, Hiroyuki; Rothblat, George H.; Lund-Katz, Sissel; Phillips, Michael C.			Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOA-I; CHOLESTEROL EFFLUX; DOMAIN-STRUCTURE; ABCA1-MEDIATED EFFLUX; ABCA1; HDL; ASSOCIATION; AFFINITY; REMOVAL; COMPLEXES	The ATP-binding cassette transporter A1 ( ABCA1) plays a critical role in the biogenesis of high density lipoprotein ( HDL) particles and in mediating cellular cholesterol efflux. The mechanism by which ABCA1 achieves these effects is not established, despite extensive investigation. Here, we present a model that explains the essential features, especially the effects of ABCA1 activity in inducing apolipoprotein ( apo) A-I binding to cells and the compositions of the discoidal HDL particles that are produced. The apo A-I/ABCA1 reaction scheme involves three steps. First, there is binding of a small regulatory pool of apo A-I to ABCA1, thereby enhancing net phospholipid translocation to the plasma membrane exofacial leaflet; this leads to unequal lateral packing densities in the two leaflets of the phospholipid bilayer. Second, the resultant membrane strain is relieved by bending and by creation of exovesiculated lipid domains. The formation of highly curved membrane surface promotes high affinity binding of apo A-I to these domains. Third, this pool of bound apo A- I spontaneously solubilizes the exovesiculated domain to create discoidal nascent HDL particles. These particles contain two, three, or four molecules of apo A- I and a complement of membrane phospholipid classes together with some cholesterol. A key feature of this mechanism is that membrane bending induced by ABCA1 lipid translocase activity creates the conditions required for nascent HDL assembly by apo A- I. Overall, this mechanism is consistent with the known properties of ABCA1 and apo A- I and reconciles many of the apparently discrepant findings in the literature.	Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA; Kobe Pharmaceut Univ, Dept Biophys Chem, Kobe, Hyogo 6588558, Japan	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Kobe Pharmaceutical University	Phillips, MC (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, 3615 Civ Ctr Blvd,Suite 1102, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu	应, 宁宁/G-9472-2011	Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn KW, 2004, BIOCHEMISTRY-US, V43, P827, DOI 10.1021/bi035697q; Alder-Baerens N, 2005, J BIOL CHEM, V280, P26321, DOI 10.1074/jbc.M413993200; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Attie AD, 2007, TRENDS BIOCHEM SCI, V32, P172, DOI 10.1016/j.tibs.2007.02.001; Brewer HB, 2004, ARTERIOSCL THROM VAS, V24, P1755, DOI 10.1161/01.ATV.0000142804.27420.5b; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chroni A, 2004, BIOCHEMISTRY-US, V43, P2126, DOI 10.1021/bi035813p; Cuchel M, 2006, CIRCULATION, V113, P2548, DOI 10.1161/CIRCULATIONAHA.104.475715; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Denis M, 2004, J BIOL CHEM, V279, P41529, DOI 10.1074/jbc.M406881200; Denis M, 2004, J BIOL CHEM, V279, P7384, DOI 10.1074/jbc.M306963200; Duong PT, 2006, J LIPID RES, V47, P832, DOI 10.1194/jlr.M500531-JLR200; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Fukuda M, 2007, J LIPID RES, V48, P882, DOI 10.1194/jlr.M600495-JLR200; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; GLOMSET JA, 1968, J LIPID RES, V9, P155; HAUSER H, 1973, J BIOL CHEM, V248, P8585; Jessup W, 2006, CURR OPIN LIPIDOL, V17, P247, DOI 10.1097/01.mol.0000226116.35555.eb; Krimbou L, 2006, CURR OPIN LIPIDOL, V17, P258, DOI 10.1097/01.mol.0000226117.43178.7c; Landry YD, 2006, J BIOL CHEM, V281, P36091, DOI 10.1074/jbc.M602247200; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Lillemeier BF, 2006, P NATL ACAD SCI USA, V103, P18992, DOI 10.1073/pnas.0609009103; Lin GR, 2000, ATHEROSCLEROSIS, V149, P359, DOI 10.1016/S0021-9150(99)00503-1; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; POWNALL HJ, 1981, BIOCHEMISTRY-US, V20, P6630, DOI 10.1021/bi00526a017; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; Saito H, 1997, J LIPID RES, V38, P287; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; SWANEY JB, 1980, J BIOL CHEM, V255, P877; Tanaka M, 2005, BIOCHEMISTRY-US, V44, P10689, DOI 10.1021/bi050853+; Tanaka M, 2006, BIOCHEMISTRY-US, V45, P10351, DOI 10.1021/bi060726t; Tang CR, 2006, J LIPID RES, V47, P107, DOI 10.1194/jlr.M500240-JLR200; Tang CR, 2004, J BIOL CHEM, V279, P7622, DOI 10.1074/jbc.M312571200; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Trompier D, 2006, J BIOL CHEM, V281, P20283, DOI 10.1074/jbc.M601072200; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Vedhachalam C, 2004, J BIOL CHEM, V279, P49931, DOI 10.1074/jbc.M406924200; Vedhachalam C, 2007, ARTERIOSCL THROM VAS, V27, P1603, DOI 10.1161/ATVBAHA.107.145789; Vedhachalam C, 2007, BIOCHEMISTRY-US, V46, P2583, DOI 10.1021/bi602407r; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Yokoyama S, 2006, ARTERIOSCL THROM VAS, V26, P20, DOI 10.1161/01.ATV.0000195789.39418.e8	60	266	276	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25123	25130		10.1074/jbc.M704590200	http://dx.doi.org/10.1074/jbc.M704590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604270	hybrid			2022-12-25	WOS:000248933000067
J	Zacksenhouse, M; Lebedev, MA; Carmena, JM; O'Doherty, JE; Henriquez, C; Nicolelis, MAL				Zacksenhouse, Miriam; Lebedev, Mikhail A.; Carmena, Jose M.; O'Doherty, Joseph E.; Henriquez, Craig; Nicolelis, Miguel A. L.			Cortical Modulations Increase in Early Sessions with Brain-Machine Interface	PLOS ONE			English	Article							PRIMARY MOTOR CORTEX; DORSAL; MODELS; REPRESENTATION; PREDICTION; MOVEMENTS; NEURONS; NOISE	Background. During planning and execution of reaching movements, the activity of cortical motor neurons is modulated by a diversity of motor, sensory, and cognitive signals. Brain-machine interfaces (BMIs) extract part of these modulations to directly control artificial actuators. However, cortical modulations that emerge in the novel context of operating the BMI are poorly understood. Methodology/Principal Findings. Here we analyzed the changes in neuronal modulations that occurred in different cortical motor areas as monkeys learned to use a BMI to control reaching movements. Using spike-train analysis methods we demonstrate that the modulations of the firing-rates of cortical neurons increased abruptly after the monkeys started operating the BMI. Regression analysis revealed that these enhanced modulations were not correlated with the kinematics of the movement. The initial enhancement in firing rate modulations declined gradually with subsequent training in parallel with the improvement in behavioral performance. Conclusions/Significance. We conclude that the enhanced modulations are related to computational tasks that are significant especially in novel motor contexts. Although the function and neuronal mechanism of the enhanced cortical modulations are open for further inquiries, we discuss their potential role in processing execution errors and representing corrective or explorative activity. These representations are expected to contribute to the formation of internal models of the external actuator and their decoding may facilitate BMI improvement.	[Zacksenhouse, Miriam] Technion Israel Inst Technol, Fac Mech Engn, IL-32000 Haifa, Israel; [Lebedev, Mikhail A.; Carmena, Jose M.; Nicolelis, Miguel A. L.] Duke Univ, Dept Neurobiol, Durham, NC USA; [Lebedev, Mikhail A.; Carmena, Jose M.; Henriquez, Craig; Nicolelis, Miguel A. L.] Duke Univ, Ctr Neuroengn, Durham, NC USA; [O'Doherty, Joseph E.; Henriquez, Craig; Nicolelis, Miguel A. L.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Nicolelis, Miguel A. L.] Duke Univ, Dept Psychol & Brain Sci, Durham, NC USA	Technion Israel Institute of Technology; Duke University; Duke University; Duke University; Duke University	Zacksenhouse, M (corresponding author), Technion Israel Inst Technol, Fac Mech Engn, IL-32000 Haifa, Israel.	mermz@tx.technion.ac.il	O'Doherty, Joseph E/D-5116-2009; Lebedev, Mikhail A/H-5066-2016	O'Doherty, Joseph E/0000-0001-8175-5699; Lebedev, Mikhail A/0000-0003-0355-8723; Zacksenhouse, Miriam/0000-0003-3022-5449	DARPA; James S. McDonnel Foundation; NIH; NSF; Christopher Reeve Paralysis Foundation	DARPA(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); James S. McDonnel Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Christopher Reeve Paralysis Foundation	This work was supported by grants from DARPA, the James S. McDonnel Foundation, NIH and NSF to MALN, the Christopher Reeve Paralysis Foundation to JMC, and the Fund for promotion of Research at the Technion to MZ.	ASHE J, 1994, CEREB CORTEX, V4, P590, DOI 10.1093/cercor/4.6.590; Bizzi E, 1998, TRENDS COGN SCI, V2, P97, DOI 10.1016/S1364-6613(98)01146-2; Borst A, 1999, NAT NEUROSCI, V2, P947, DOI 10.1038/14731; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; Chapin JK, 1999, NAT NEUROSCI, V2, P664, DOI 10.1038/10223; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; Dayan P., 2001, THEORETICAL NEUROSCI; Desmurget M, 2000, TRENDS COGN SCI, V4, P423, DOI 10.1016/S1364-6613(00)01537-0; Diedrichsen J, 2005, J NEUROSCI, V25, P9919, DOI 10.1523/JNEUROSCI.1874-05.2005; FANO U, 1947, PHYS REV, V72, P26, DOI 10.1103/PhysRev.72.26; Flanagan JR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-20-j0005.1999; Georgopoulos AP, 2000, CURR OPIN NEUROBIOL, V10, P238, DOI 10.1016/S0959-4388(00)00072-6; GEORGOPOULOS AP, 1992, SCIENCE, V256, P1692, DOI 10.1126/science.256.5064.1692; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Golub GH., 2013, MATRIX COMPUTATIONS; Gomez JE, 2000, EUR J NEUROSCI, V12, P3748, DOI 10.1046/j.1460-9568.2000.00232.x; Hansen P.C., 1998, RANK DEFICIENT DISCR; Harris CM, 1998, NATURE, V394, P780, DOI 10.1038/29528; Hoshi E, 2004, PROG BRAIN RES, V143, P507, DOI 10.1016/S0079-6123(03)43047-1; Johnson DH, 1996, J COMPUT NEUROSCI, V3, P275, DOI 10.1007/BF00161089; Johnson MTV, 2001, CURR OPIN NEUROBIOL, V11, P684, DOI 10.1016/S0959-4388(01)00269-0; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; Kawagoe A, 1999, IEEE T APPL SUPERCON, V9, P727, DOI 10.1109/77.783398; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; Kirby M, 2001, GEOMETRIC DATA ANAL; Krakauer JW, 1999, NAT NEUROSCI, V2, P1026, DOI 10.1038/14826; Laubach M, 2000, NATURE, V405, P567, DOI 10.1038/35014604; Lebedev MA, 2005, J NEUROSCI, V25, P4681, DOI 10.1523/JNEUROSCI.4088-04.2005; Lee JH, 2006, J NEUROSCI, V26, P3330, DOI 10.1523/JNEUROSCI.3898-05.2006; Li CSR, 2001, NEURON, V30, P593, DOI 10.1016/S0896-6273(01)00301-4; Mardia K., 1979, MULTIVARIATE ANAL, V15, P518; Moran DW, 1999, J NEUROPHYSIOL, V82, P2676, DOI 10.1152/jn.1999.82.5.2676; Nicolelis MAL, 2001, NATURE, V409, P403, DOI 10.1038/35053191; Nicolelis MAL, 2003, NAT REV NEUROSCI, V4, P417, DOI 10.1038/nrn1105; Padoa-Schioppa C, 2004, J NEUROPHYSIOL, V91, P449, DOI 10.1152/jn.00876.2002; Passaglia CL, 2004, J NEUROPHYSIOL, V92, P1023, DOI 10.1152/jn.01089.2003; Paz R, 2003, NAT NEUROSCI, V6, P882, DOI 10.1038/nn1097; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Scott SH, 2003, CURR OPIN NEUROBIOL, V13, P671, DOI 10.1016/j.conb.2003.10.012; SNYDER DL, 1975, POINT PROCESSES; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; Wise SP, 1998, EXP BRAIN RES, V121, P285, DOI 10.1007/s002210050462; Wolpert DM, 1998, TRENDS COGN SCI, V2, P338, DOI 10.1016/S1364-6613(98)01221-2	45	44	47	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e619	10.1371/journal.pone.0000619	http://dx.doi.org/10.1371/journal.pone.0000619			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637835	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452100009
J	Cai, XJ				Cai, Xinjiang			Molecular Evolution and Functional Divergence of the Ca(2+) Sensor Protein in Store-operated Ca(2+) Entry: Stromal Interaction Molecule	PLOS ONE			English	Article								Receptor-mediated Ca(2+) signaling in many non-excitable cells initially induces Ca(2+) release from intracellular Ca(2+) stores, followed by Ca(2+) influx across the plasma membrane. Recent findings have suggested that stromal interaction molecules (STIMs) function as the Ca(2+) sensor to detect changes of Ca(2+) content in the intracellular Ca(2+) stores. Human STIMs and invertebrate STIM share several functionally important protein domains, but diverge significantly in the C-terminus. To better understand the evolutionary significance of STIM activity, phylogenetic analysis of the STIM protein family was conducted after extensive database searching. Results from phylogeny and sequence analysis revealed early adaptation of the C-terminal divergent domains in Urochordata, before the expansion of STIMs in Vertebrata. STIMs were subsequently subjected to one round of gene duplication as early as in the Euteleostomi lineage in vertebrates, with a second round of fish-specific gene duplication. After duplication, STIM-1 and STIM-2 molecules appeared to have undergone purifying selection indicating strong evolutionary constraints within each group. Furthermore, sequence analysis of the EF-hand Ca(2+) binding domain and the SAM domain, together with functional divergence studies, identified critical regions/residues likely underlying functional changes, and provided evidence for the hypothesis that STIM-1 and STIM-2 might have developed distinct functional properties after duplication.	[Cai, Xinjiang] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Cai, XJ (corresponding author), Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA.	xinjiang.cai@duke.edu	Cai, Xinjiang/F-4843-2010	Cai, Xinjiang/0000-0001-8933-7133				Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bruno WJ, 2000, MOL BIOL EVOL, V17, P189, DOI 10.1093/oxfordjournals.molbev.a026231; CAI X, 2007, 2007 7 EUR S PROT SO, P133; Cai XJ, 2007, J MOL BIOL, V368, P1284, DOI 10.1016/j.jmb.2007.03.022; Cai XJ, 2006, MOL BIOL EVOL, V23, P550, DOI 10.1093/molbev/msj056; Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Grabarek Z, 2006, J MOL BIOL, V359, P509, DOI 10.1016/j.jmb.2006.03.066; Grimshaw SJ, 2004, J BIOL CHEM, V279, P2192, DOI 10.1074/jbc.M305605200; Gu X, 2002, BIOINFORMATICS, V18, P500, DOI 10.1093/bioinformatics/18.3.500; Gu X, 2001, MOL BIOL EVOL, V18, P453, DOI 10.1093/oxfordjournals.molbev.a003824; Hille B., 2001, ION CHANNELS EXCITAB, P814; HOLLAND PWH, 1994, DEVELOPMENT, P125; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KIM CA, 1993, NATURE, V362, P270; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Leveugle M, 2004, J MOL EVOL, V58, P168, DOI 10.1007/s00239-003-2538-y; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; Liao Y, 2007, P NATL ACAD SCI USA, V104, P4682, DOI 10.1073/pnas.0611692104; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; LORINNEBEL C, 2007, J PHYSL; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Meyer A, 2005, BIOESSAYS, V27, P937, DOI 10.1002/bies.20293; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; Nicholas K.B., 1997, EMBNEW NEWS, V4, P1; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Schultz J, 1997, PROTEIN SCI, V6, P249; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHAW GS, 1992, BIOCHEMISTRY-US, V31, P9572, DOI 10.1021/bi00155a009; Smyth JT, 2006, BBA-MOL CELL RES, V1763, P1147, DOI 10.1016/j.bbamcr.2006.08.050; Soboloff J, 2006, BBA-MOL CELL RES, V1763, P1161, DOI 10.1016/j.bbamcr.2006.09.023; Soboloff J, 2006, CURR BIOL, V16, P1465, DOI 10.1016/j.cub.2006.05.051; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Stathopulos PB, 2006, J BIOL CHEM, V281, P35855, DOI 10.1074/jbc.M608247200; STRANGE K, 2007, CELL CALCIU IN PRESS, DOI DOI 10.1016/J.CECA.2007.1002.1007; Suyama M, 2006, NUCLEIC ACIDS RES, V34, pW609, DOI 10.1093/nar/gkl315; Taylor CW, 2006, TRENDS BIOCHEM SCI, V31, P597, DOI 10.1016/j.tibs.2006.09.007; Taylor JS, 2004, ANNU REV GENET, V38, P615, DOI 10.1146/annurev.genet.38.072902.092831; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yan XH, 2006, J GEN PHYSIOL, V128, P443, DOI 10.1085/jgp.200609611; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yeromin AV, 2004, J GEN PHYSIOL, V123, P167, DOI 10.1085/jgp.200308982; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	51	38	38	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e609	10.1371/journal.pone.0000609	http://dx.doi.org/10.1371/journal.pone.0000609			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622354	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452000016
J	Preet, A; Ganju, RK; Groopman, JE				Preet, A.; Ganju, R. K.; Groopman, J. E.			Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo	ONCOGENE			English	Article						tetrahydrocannabinol(THC); lung cancer; A549; migration; invasion; EGFR	FOCAL-ADHESION KINASE; CANNABINOID RECEPTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ANGIOGENESIS; ACTIVATION; EXPRESSION	Delta(9)-Tetrahydrocannabinol (THC) is the primary cannabinoid of marijuana and has been shown to either potentiate or inhibit tumor growth, depending on the type of cancer and its pathogenesis. Little is known about the activity of cannabinoids like THC on epidermal growth factor receptor-overexpressing lung cancers, which are often highly aggressive and resistant to chemotherapy. In this study, we characterized the effects of THC on the EGF-induced growth and metastasis of human non-small cell lung cancer using the cell lines A549 and SW-1573 as in vitro models. We found that these cells express the cannabinoid receptors CB1 and CB2, known targets for THC action, and that THC inhibited EGF-induced growth, chemotaxis and chemoinvasion. Moreover, signaling studies indicated that THC may act by inhibiting the EGF-induced phosphorylation of ERK1/2, JNK1/2 and AKT. THC also induced the phosphorylation of focal adhesion kinase at tyrosine 397. Additionally, in in vivo studies in severe combined immunodeficient mice, there was significant inhibition of the subcutaneous tumor growth and lung metastasis of A549 cells in THC-treated animals as compared to vehicle-treated controls. Tumor samples from THC-treated animals revealed antiproliferative and antiangiogenic effects of THC. Our study suggests that cannabinoids like THC should be explored as novel therapeutic molecules in controlling the growth and metastasis of certain lung cancers.	[Preet, A.; Ganju, R. K.; Groopman, J. E.] Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu; jgroopma@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA109527] Funding Source: NIH RePORTER; NCI NIH HHS [CA109527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2006, CLIN CANCER RES, V12, p4446S, DOI 10.1158/1078-0432.CCR-06-0623; Beckmann JD, 2001, J CELL PHYSIOL, V189, P171, DOI 10.1002/jcp.10013; Bifulco M, 2006, BRIT J PHARMACOL, V148, P123, DOI 10.1038/sj.bjp.0706632; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; CABRAL GA, 1987, ARCH TOXICOL, V60, P438, DOI 10.1007/BF00302387; CABRAL GA, 2006, CANCER RES, V66, P6615; CABRAL GA, 2006, CANCER CELL, V9, P301; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; CLARKE N, 1998, MOL CELL BIOL, V21, P4016; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648; Diaz-Laviada I, 2005, MINI-REV MED CHEM, V5, P619, DOI 10.2174/1389557054368808; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Ghosh S, 2006, MOL IMMUNOL, V43, P2169, DOI 10.1016/j.molimm.2006.01.005; Guzman M., 2006, BR JR CANC, V95, P204; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Hauck CR, 2001, CANCER RES, V61, P7079; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kogan NM, 2005, MINI-REV MED CHEM, V5, P941, DOI 10.2174/138955705774329555; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Molina JR, 2006, CHEST, V130, P1211, DOI 10.1378/chest.130.4.1211; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vaccani A, 2005, BRIT J PHARMACOL, V144, P1032, DOI 10.1038/sj.bjp.0706134; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	38	108	109	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					339	346		10.1038/sj.onc.1210641	http://dx.doi.org/10.1038/sj.onc.1210641			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621270				2022-12-25	WOS:000252256000010
J	Jung, HJ; Kim, EH; Mun, JY; Park, S; Smith, ML; Han, SS; Seo, YR				Jung, H. J.; Kim, E. H.; Mun, J-Y; Park, S.; Smith, M. L.; Han, S. S.; Seo, Y. R.			Base excision DNA repair defect in Gadd45a-deficient cells	ONCOGENE			English	Article						gadd45a; base excision repair; APE1/Ref1; PCNA	P53-REGULATED PROTEIN GADD45; P53 TUMOR-SUPPRESSOR; NUCLEAR ANTIGEN PCNA; IN-VIVO; DAMAGE; ENDONUCLEASE; ASSOCIATION; IRRADIATION; EXPRESSION; APOPTOSIS	As one of a number of p53-regulated genes, Gadd45a (growth arrest and DNA damage inducible gene) has been shown to delay carcinogenesis and decrease mutation frequency. Gadd45a is known to regulate nucleotide excision DNA repair (NER) in response to UV radiation. Here, we report an emerging role for Gadd45a in base excision repair (BER). Gadd45a-null mouse embryo fibroblasts MEF and gadd45a-deficient human colon cancer cells exhibited slow BER after treatment with methyl methanesulfonate (MMS) a pure base-damaging agent. In addition, removal of AP sites by apurinic/apyrimidinic endonuclease 1/redox factor 1 (APE1/Ref1) was significantly delayed in gadd45a-null cells. Moreover, the localization of APE1/Ref1 within the nucleus was observed in gadd45a wild-type cells, whereas APE1 become mainly distributed in the cytoplasm, and there is a reduced interaction with proliferating cell nuclear antigen (PCNA) in Gadd45a-deficient cells. Inasmuch as p53 has been shown to regulate BER in addition to the NER pathway, our data suggest that p53-regulated gene Gadd45a contributes to the BER response by affecting the interaction of cellular APE1/Ref1 with PCNA. Gadd45a might be a key component gene of the p53 pathway involved in protection from carcinogenic base damage and maintenance of genomic stability, although the downstream mechanism including APE1/Ref1 will need further study.	Kyung Hee Univ, Sch Med, Inst Basic Med Sci, Dept Pharmacol, Seoul 130701, South Korea; Korea Univ, Sch Life Sci & Biotechnol, Seoul, South Korea; Indiana Univ, Sch Med, Indiana Univ Canc Ctr, Indianapolis, IN USA	Kyung Hee University; Korea University; Indiana University System; Indiana University-Purdue University Indianapolis	Seo, YR (corresponding author), Kyung Hee Univ, Sch Med, Inst Basic Med Sci, Dept Pharmacol, Dongdaemun-gu, Seoul 130701, South Korea.	dream21@khu.ac.kr						ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Bae I, 1996, CANCER RES, V56, P840; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Fan JG, 1999, MOL PHARMACOL, V56, P966, DOI 10.1124/mol.56.5.966; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Hanson S, 2005, ONCOGENE, V24, P1641, DOI 10.1038/sj.onc.1208351; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hildesheim J, 2002, CLIN CANCER RES, V8, P2475; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kelley MR, 2001, CLIN CANCER RES, V7, P824; Lee JH, 2003, BIOTECHNOL BIOPROC E, V8, P106, DOI 10.1007/BF02940265; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Offer H, 2001, CANCER RES, V61, P88; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Seo YR, 2004, EXP MOL MED, V36, P505, DOI 10.1038/emm.2004.64; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Xia LQ, 2005, J MOL BIOL, V346, P1259, DOI 10.1016/j.jmb.2005.01.014; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	29	57	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7517	7525		10.1038/sj.onc.1210557	http://dx.doi.org/10.1038/sj.onc.1210557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599061				2022-12-25	WOS:000251282100003
J	Rajagopalan, N; Pung, YF; Zhu, YZ; Wong, PTH; Kumar, PP; Kini, RM				Rajagopalan, Nandhakishore; Pung, Yuh Fen; Zhu, Yi Zhun; Wong, Peter Tsun Hon; Kumar, Prakash P.; Kini, R. Manjunatha			beta-Cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity	FASEB JOURNAL			English	Article						heart rate; bradycardia; adrenergic receptors; GPCR ligands; beta-blocker peptide	HEMOLYTIC-ACTIVITY; ALPHA-NEUROTOXINS; SNAKE; PROTEIN; INHIBITION; ANTAGONIST; TIROFIBAN; OHANIN; CHAIN	Snake venoms have provided a number of novel ligands with therapeutic potential. We have constructed a partial cDNA library from the mRNA of Ophiophagus hannah (king cobra) venom gland tissue and identified five new genes encoding proteins belonging to the three-finger toxin family of snake venom proteins. We have isolated and characterized one of these beta-sheet containing proteins with a mass of 7012.43 +/- 0.91 Da from the venom. The protein was nonlethal up to a dose of 10 mg/kg when injected intraperitoneally into Swiss albino mice. However, it induces labored breathing and death at a dose of 100 mg/kg. It does not show any hemolytic or anticoagulant activity. It caused a dose-dependent decrease of heart rate in vivo (anesthetized Sprague-Dawley rats) and also ex vivo (Langendorff isolated rat heart). This is in contrast to classical cardiotoxins from snake venom that increase the heart rate in animals. Radioligand displacement studies showed that this protein targets beta-adrenergic receptors with a binding affinity (K-i) of 5.3 and 2.3 mu M toward beta(1) and beta(2) subtypes, respectively, to bring about its effect, and hence, it was named as beta-cardiotoxin. This is the first report of a natural exogenous beta-blocker.	Natl Univ Singapore, Prot Sci Lab, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117548, Singapore; Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117548, Singapore; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	National University of Singapore; National University of Singapore; National University of Singapore; Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Prot Sci Lab, Dept Biol Sci, Fac Sci, Sci Dr 4, Singapore 117543, Singapore.	dbskumar@nus.edu.sg; dbskinim@nus.edu.sg	Kini, Manjunatha/H-8029-2012; Zhu, Yi Zhun/ABG-8449-2021; Pung, Yuh Fen/E-8959-2016; Kumar, Prakash P/A-6236-2009	Zhu, Yi Zhun/0000-0001-7700-8041; Pung, Yuh Fen/0000-0001-6195-3970; Kumar, Prakash P/0000-0002-0963-1664; Kini, Manjunatha/0000-0002-6100-3251				Arlock P, 2005, SCAND CARDIOVASC J, V39, P250, DOI 10.1080/14017430510035952; Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200; BOFFA MC, 1983, THROMB RES, V32, P635, DOI 10.1016/0049-3848(83)90066-X; CASTRO VROE, 1989, TOXICON, V27, P511, DOI 10.1016/0041-0101(89)90112-8; Cerra MC, 2006, BASIC RES CARDIOL, V101, P43, DOI 10.1007/s00395-005-0547-2; Chang CC, 1999, J BIOMED SCI, V6, P368, DOI 10.1159/000025412; Chen DS, 1997, BIOCHEM J, V325, P685, DOI 10.1042/bj3250685; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2; GATINEAU E, 1987, BIOCHEMISTRY-US, V26, P8046, DOI 10.1021/bi00399a004; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Griffith R. K, 2003, BURGERS MED CHEM DRU, V6, P1, DOI 10.1002/0471266949.bmc093; GROGNET JM, 1988, EUR J BIOCHEM, V172, P383, DOI 10.1111/j.1432-1033.1988.tb13898.x; Harrison PM, 1996, J MOL BIOL, V264, P603, DOI 10.1006/jmbi.1996.0664; He YY, 2004, TOXICON, V44, P295, DOI 10.1016/j.toxicon.2004.06.003; Hider R.C., 1991, P1; HIDER RC, 1982, TOXICON, V20, P175, DOI 10.1016/0041-0101(82)90188-X; Higuchi S, 1999, IMMUNOPHARMACOLOGY, V44, P129, DOI 10.1016/S0162-3109(99)00119-8; Hollenberg NK, 2005, AM J HYPERTENS, V18, p165S, DOI 10.1016/j.amjhyper.2005.09.010; Huang Fengyang, 2004, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V2, P187, DOI 10.2174/1568016043356309; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; Kondo K, 2002, CLIN PHARMACOKINET, V41, P187, DOI 10.2165/00003088-200241030-00003; Kumar TKS, 1997, J BIOMOL STRUCT DYN, V15, P431, DOI 10.1080/07391102.1997.10508957; Li J, 2006, BIOCHEM J, V398, P233, DOI 10.1042/BJ20060004; LOUW AI, 1978, BIOCHIM BIOPHYS ACTA, V512, P163, DOI 10.1016/0005-2736(78)90227-4; Marcinkiewicz C, 2005, CURR PHARM DESIGN, V11, P815, DOI 10.2174/1381612053381765; McClellan KJ, 1998, DRUGS, V56, P1067, DOI 10.2165/00003495-199856060-00017; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; Nirthanan S, 2003, TOXICON, V41, P397, DOI 10.1016/S0041-0101(02)00388-4; O'Shea J Conor, 2002, Expert Opin Pharmacother, V3, P1199; Plosker GL, 2003, PHARMACOECONOMICS, V21, P885, DOI 10.2165/00019053-200321120-00005; Potter LT, 2001, LIFE SCI, V68, P2541, DOI 10.1016/S0024-3205(01)01050-5; Pung YF, 2006, GENE, V371, P246, DOI 10.1016/j.gene.2005.12.002; Pung YF, 2005, J BIOL CHEM, V280, P13137, DOI 10.1074/jbc.M414137200; ROUMESTAND C, 1994, J MOL BIOL, V243, P719, DOI 10.1016/0022-2836(94)90043-4; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Sherman David G, 2002, Curr Med Res Opin, V18 Suppl 2, ps48; SUN JJ, 1986, TOXICON, V24, P233, DOI 10.1016/0041-0101(86)90149-2; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; Wu PL, 2006, J BIOL CHEM, V281, P7937, DOI 10.1074/jbc.M513035200; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206; Yasuda Osamu, 1994, Artery, V21, P287; [No title captured]	47	74	82	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3685	3695		10.1096/fj.07-8658com	http://dx.doi.org/10.1096/fj.07-8658com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17616557				2022-12-25	WOS:000250517800030
J	Banci, L; Bertini, I; Cantini, F; Ciofi-Baffoni, S; Cavet, JS; Dennison, C; Graham, AI; Harvie, DR; Robinson, NJ				Banci, Lucia; Bertini, Ivano; Cantini, Francesca; Ciofi-Baffoni, Simone; Cavet, Jennifer S.; Dennison, Christopher; Graham, Alison I.; Harvie, Duncan R.; Robinson, Nigel J.			NMR structural analysis of cadmium sensing by winged helix repressor CmtR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MTF-1; METALLOREGULATORY PROTEINS; METALLOTHIONEIN LOCUS; COPPER HOMEOSTASIS; METAL SELECTIVITY; CRYSTAL-STRUCTURE; SMTB; ZINC; DOMAIN; SENSITIVITY	CmtR from Mycobacterium tuberculosis is a winged helical DNA-binding repressor of the ArsR-SmtB metal-sensing family that senses cadmium and lead. Cadmium-CmtR is a dimer with the metal bound to Cys-102 from the C-terminal region of one subunit and two Cys associated with helix alpha R from the other subunit, forming a symmetrical pair of cadmium-binding sites. This is a significant novelty in the ArsR-SmtB family. The structure of the dimer could be solved at 312 K. The apoprotein at the same temperature is still a dimer, but it experiences a large conformational exchange at the dimer interface and within each monomer. This is monitored by an overall decrease of the number of nuclear Overhauser effects and by an increase of H2O-D2O exchange rates, especially at the dimeric interface, in the apo form with respect to the cadmium-bound state. The C-terminal tail region is completely unstructured in both apo and cadmium forms but becomes less mobile in the cadmium-bound protein due to the recruitment of Cys-102 as a metal-ligand. DNA binds to the apo dimer with a ratio 1: 3 at millimolar concentration. Addition of cadmium to the apo-CmtR-DNA complex causes DNA detachment, restoring the NMR spectrum of free cadmium-CmtR. Cadmium binding across the dimer interface impairs DNA association by excluding the apo-conformers suited to bind DNA.	Univ Florence, Ctr Risonanze Magnet, I-50019 Florence, Italy; Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Manchester, Dept Life Sci, Manchester M13 9PT, Lancs, England	University of Florence; Newcastle University - UK; University of Manchester	Bertini, I (corresponding author), Univ Florence, Dept Chem, Via Luigi Sacconi 6, I-50019 Florence, Italy.	ivanobertini@cerm.unifi.it	Wang, Yun/E-5806-2011; Cantini, Francesca/O-1220-2015; Robinson, Nigel J/J-6363-2012; Ciofi-Baffoni, Simone/AAH-9778-2021	Cantini, Francesca/0000-0003-0526-6732; Robinson, Nigel J/0000-0001-5586-1092; Dennison, Christopher/0000-0001-8665-052X; Graham, Alison Isobel/0000-0001-7334-9033; Ciofi Baffoni, Simone/0000-0002-2376-3321; Cavet, Jennifer/0000-0001-5913-7157; BANCI, LUCIA/0000-0003-0562-5774	Biotechnology and Biological Sciences Research Council [P18581, D19920] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Anderluh G, 2004, J BIOL CHEM, V279, P22002, DOI 10.1074/jbc.M313603200; Aravind L, 2005, FEMS MICROBIOL REV, V29, P231, DOI 10.1016/j.fmrre.2004.12.008; ARSENIEV A, 1988, J MOL BIOL, V201, P637, DOI 10.1016/0022-2836(88)90644-4; Banci L, 2005, P NATL ACAD SCI USA, V102, P7541, DOI 10.1073/pnas.0502450102; Banci L, 2003, ACCOUNTS CHEM RES, V36, P215, DOI 10.1021/ar010120r; BERTINI I, 2001, HDB METALOPROTEINS, V1; Blindauer CA, 2001, P NATL ACAD SCI USA, V98, P9593, DOI 10.1073/pnas.171120098; Cave JS, 2002, J BIOL CHEM, V277, P38441, DOI 10.1074/jbc.M207677200; Cavet JS, 2003, J BIOL CHEM, V278, P44560, DOI 10.1074/jbc.M307877200; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Eicken C, 2003, J MOL BIOL, V333, P683, DOI 10.1016/j.jmb.2003.09.007; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Golynskiy MV, 2005, BIOCHEMISTRY-US, V44, P3380, DOI 10.1021/bi0480741; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Harvie DR, 2006, MOL MICROBIOL, V59, P1341, DOI 10.1111/j.1365-2958.2006.05029.x; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HUCKLE JW, 1993, MOL MICROBIOL, V7, P177, DOI 10.1111/j.1365-2958.1993.tb01109.x; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PELTON JG, 1993, PROTEIN SCI, V2, P543; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Pennella MA, 2005, BIOMETALS, V18, P413, DOI 10.1007/s10534-005-3716-8; Pennella MA, 2006, J MOL BIOL, V356, P1124, DOI 10.1016/j.jmb.2005.12.019; Rangachari V, 2005, BIOCHEMISTRY-US, V44, P5672, DOI 10.1021/bi047825w; Riek R, 2000, TRENDS BIOCHEM SCI, V25, P462, DOI 10.1016/S0968-0004(00)01665-0; Rutherford JC, 2004, EUKARYOT CELL, V3, P1, DOI 10.1128/EC.3.1.1-13.2004; Sambrook J, 2001, MOL CLONING LAB MANU; Selvaraj A, 2005, GENE DEV, V19, P891, DOI 10.1101/gad.1301805; SHI WP, 1994, J BIOL CHEM, V269, P19826; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; TURNER JS, 1993, J BIOL CHEM, V268, P4494; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang Y, 2005, BIOCHEMISTRY-US, V44, P8976, DOI 10.1021/bi050094v; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; WU JH, 1993, J BIOL CHEM, V268, P52; Ye J, 2005, J BACTERIOL, V187, P4214, DOI 10.1128/JB.187.12.4214-4221.2005	42	37	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					30181	30188		10.1074/jbc.M701119200	http://dx.doi.org/10.1074/jbc.M701119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17599915	hybrid			2022-12-25	WOS:000249981200048
J	Klieber, MA; Underhill, C; Hammond, GL; Muller, YA				Klieber, Michael A.; Underhill, Caroline; Hammond, Geoffrey L.; Muller, Yves A.			Corticosteroid-binding globulin, a structural basis for steroid transport and proteinase-triggered release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERPIN CONFORMATIONAL-CHANGE; AMINO-ACID SUBSTITUTION; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; REACTIVE CENTER; HINGE REGION; MECHANISM; CORTISOL; ALPHA(1)-ANTITRYPSIN; AFFINITY	Corticosteroid-binding globulin (CBG) is a serine proteinase inhibitor (serpin) family member that transports glucocorticoids in blood and regulates their access to target cells. The 1.9 angstrom crystal structure of rat CBG shows that its steroid-binding site resembles the thyroxin-binding site in the related serpin, thyroxin-binding globulin, and mutagenesis studies have confirmed the contributions of key residues that constitute the steroid-binding pocket. Unlike thyroxin-bound thyroxin-binding globulin, the cortisol-bound CBG displays an "active" serpin conformation with the proteinase-sensitive, reactive center loop (RCL) fully expelled from the regulatory beta-sheet A. Moreover, the CBG structure allows us to predict that complete insertion of the proteolytically cleaved RCL into the serpin fold occurs in concert with a displacement and unwinding of helix D that would disrupt the steroid-binding site. This allosteric coupling between RCL positioning and occupancy of the CBG steroid-binding site, which resembles the ligand (glycosamino-glycan)dependent activation of the thrombin inhibitory serpins heparin cofactor II and anti-thrombin RCLs, ensures both optimal recognition of CBG by target proteinases and efficient release of steroid to sites of action.	Univ Erlangen Nurnberg, Dept Biol, Lehrstuhl Bioeth, D-91052 Erlangen, Germany; Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 4H4, Canada	University of Erlangen Nuremberg; Child & Family Research Institute; University of British Columbia; University of British Columbia	Muller, YA (corresponding author), Henkestr 91, D-91052 Erlangen, Germany.	ymuller@biologie.uni-erlangen.de	Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928; Hammond, Geoffrey/0000-0002-4639-7336				AVVAKUMOV GV, 1994, J STEROID BIOCHEM, V49, P191, DOI 10.1016/0960-0760(94)90010-8; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005; Delano W. L., 2003, PYMOL MOL GENETICS G; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Emptoz-Bonneton A, 2000, J CLIN ENDOCR METAB, V85, P361, DOI 10.1210/jc.85.1.361; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Garrel Dominique R., 1993, Wound Repair and Regeneration, V1, P10; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GRENOT C, 1994, BIOCHEMISTRY-US, V33, P8969, DOI 10.1021/bi00196a015; HAMMOND GL, 1990, J CLIN ENDOCR METAB, V71, P34, DOI 10.1210/jcem-71-1-34; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; Harrop SJ, 1999, STRUCTURE, V7, P43, DOI 10.1016/S0969-2126(99)80008-2; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Horvath AJ, 2005, J BIOL CHEM, V280, P43168, DOI 10.1074/jbc.M505598200; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kim SJ, 2001, J MOL BIOL, V306, P109, DOI 10.1006/jmbi.2000.4357; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Law RHP, 2005, J BIOL CHEM, V280, P22356, DOI 10.1074/jbc.M412043200; Mager DE, 2006, ADV DRUG DELIVER REV, V58, P1326, DOI 10.1016/j.addr.2006.08.002; McCoy AJ, 2003, J MOL BIOL, V326, P823, DOI 10.1016/S0022-2836(02)01382-7; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; ORAVA M, 1994, GENE, V144, P259, DOI 10.1016/0378-1119(94)90387-5; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Perl D, 2000, NAT STRUCT BIOL, V7, P380; Petersen HH, 2006, MOL CELL BIOL, V26, P7236, DOI 10.1128/MCB.00400-06; Reichheld SE, 2006, J MOL BIOL, V361, P382, DOI 10.1016/j.jmb.2006.06.035; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SMITH CL, 1991, J BIOL CHEM, V266, P18555; SMITH CL, 1992, J STEROID BIOCHEM, V42, P671, DOI 10.1016/0960-0760(92)90107-T; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; Strickler SS, 2006, BIOCHEMISTRY-US, V45, P2761, DOI 10.1021/bi0600143; VANBAELEN H, 1993, STEROIDS, V58, P275, DOI 10.1016/0039-128X(93)90072-U; WESTPHAL U, 1986, STEROID PROTEIN INTE, V2; Yamasaki M, 2002, J MOL BIOL, V315, P113, DOI 10.1006/jmbi.2001.5056; Zhou AW, 2006, P NATL ACAD SCI USA, V103, P13321, DOI 10.1073/pnas.0604080103; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	50	101	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29594	29603		10.1074/jbc.M705014200	http://dx.doi.org/10.1074/jbc.M705014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17644521	hybrid			2022-12-25	WOS:000249788000056
J	Lee, J; Kumagai, A; Dunphy, WG				Lee, Joon; Kumagai, Akiko; Dunphy, William G.			The Rad9-Hus1-Rad1 checkpoint interaction of TopBP1 with ATR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; XENOPUS EGG EXTRACTS; REPLICATION CHECKPOINT; POLYMERASE-ALPHA; HUMAN CLASPIN; CLAMP LOADER; CHK1; ACTIVATION; PHOSPHORYLATION; PROTEIN	TopBP1 serves as an activator of the ATR-ATRIP complex in response to the presence of incompletely replicated or damaged DNA. This process involves binding of ATR to the ATR-activating domain of TopBP1, which is located between BRCT domains VI and VII. TopBP1 displays increased binding to ATR-ATRIP in Xenopus egg extracts containing checkpoint-inducing DNA templates. We show that an N-terminal region of TopBP1 containing BRICT repeats I-II is essential for this checkpoint-stimulated binding of TopBP1 to ATR-ATRIP. The BRCT I-II region of TopBP1 also binds specifically to the Rad9-Hus1-Rad1 (9-1-1) complex in Xenopus egg extracts. This binding occurs via the C-terminal domain of Rad9 and depends upon phosphorylation of its Ser-373 residue. Egg extracts containing either a mutant of TopBP1 lacking the BRCT I-II repeats or a mutant of Rad9 with an alanine substitution at Ser-373 are defective in checkpoint regulation. Furthermore, an isolated C-terminal fragment from Rad9 is an effective inhibitor of checkpoint signaling in egg extracts. These findings suggest that interaction of the 9-1-1 complex with the BRCT I-II region of TopBP1 is necessary for binding of ATR-ATRIP to the ATR-activating domain of TopBP1 and the ensuing activation of ATR.	CALTECH, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Dunphy, WG (corresponding author), CALTECH, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070891, R37GM043974, R01GM043974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM043974, GM070891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Garcia V, 2005, DNA REPAIR, V4, P1227, DOI 10.1016/j.dnarep.2005.04.001; Greer DA, 2003, CANCER RES, V63, P4829; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hashimoto Y, 2006, GENES CELLS, V11, P993, DOI 10.1111/j.1365-2443.2006.00998.x; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Kumagai A, 2006, CELL CYCLE, V5, P1265, DOI 10.4161/cc.5.12.2834; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2006, MOL BIOL CELL, V17, P1559, DOI 10.1091/mbc.E05-09-0865; MacDougall CA, 2007, GENE DEV, V21, P898, DOI 10.1101/gad.1522607; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Majka J, 2006, MOL CELL, V24, P891, DOI 10.1016/j.molcel.2006.11.027; Majka J, 2006, J BIOL CHEM, V281, P27855, DOI 10.1074/jbc.M605176200; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Perry JA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-12; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; St Onge RP, 2003, J BIOL CHEM, V278, P26620, DOI 10.1074/jbc.M303134200; Wang H, 2002, GENETICS, V160, P1295; Yan S, 2006, J CELL BIOL, V173, P181, DOI 10.1083/jcb.200601076; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	43	216	218	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28036	28044		10.1074/jbc.M704635200	http://dx.doi.org/10.1074/jbc.M704635200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17636252	Green Accepted, hybrid			2022-12-25	WOS:000249455600053
J	Salanova, B; Choi, M; Rolle, S; Wellner, M; Luft, FC; Kettritz, R				Salanova, Birgit; Choi, Mira; Rolle, Susanne; Wellner, Maren; Luft, Friedrich C.; Kettritz, Ralph			beta 2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-kappa B activation of human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHED MEMBRANE MICROPARTICLES; LEUKOCYTE-PLATELET ADHESION; IIB-IIIA; MONOCLONAL-ANTIBODIES; WHOLE-BLOOD; P-SELECTIN; INTEGRINS; CELLS; FLOW; PHARMACOKINETICS	Microparticles from various cells are generated during inflammation. Platelet-derived microparticles (PMPs) harbor receptors that are not genuinely expressed by neutrophils. We tested whether or not functional glycoprotein IIb/IIIa (GPIIb/ IIIa) receptors can be acquired by neutrophils via PMPs and whether these receptors participate in pro-inflammatory signaling. Surface expression was analyzed by flow cytometry and confocal microscopy. NF-kappa B activation was analyzed by Western blot experiments, electrophoretic mobility shift assays, and reverse transcription-PCR. Cell adhesion and spreading were estimated by myeloperoxidase assay and light microscopy. We found that PMPs transfer GPIIb/IIIa receptors to isolated and whole blood neutrophils via PMPs. We used specific antibodies in granulocyte macrophage colony-stimulating factor-treated neutrophils and observed that acquired GPIlb/Illa receptors colocalized with beta 2-integrins and cooperated in NF-kappa B activation. We show that Src and Syk non-receptor tyrosine kinases, as well as the actin cytoskeleton, control NF-kappa B activation. In contrast to NF-kappa B, acquisition of GPIIb/IIIa receptors was not necessary to induce adhesion to fibronectin or phosphatidylinositol 3-kinase/Akt signaling. When granulocyte macrophage colony-stimulating factor-stimulated neutrophils were incubated on fibronectin, strong NF-kappa B activation was observed, but only after loading with PMPs. Blocking either beta 2-integrins or GPIIb/ IIIa receptors abrogated this effect. Therapeutic GPIIb/IIIa inhibitors were similarly effective. The compounds also inhibited NF-kappa B-dependent tumor necrosis factor-alpha mRNA up-regulation. The data implicate GPIIb/IIIa receptors as new therapeutic targets in neutrophil-induced inflammation.	Charite Univ Med Berlin, Fac Med, Max Delbruck Ctr Mol Med, Helios Klin,Franz Volhard Clin, D-13125 Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kettritz, R (corresponding author), Franz Volhard Clin, Div Nephrol, Schwanebecker Chaussee 50, D-13125 Berlin, Germany.	kettritz@charite.de		Choi, Mira/0000-0002-0286-1491; Luft, Friedrich/0000-0002-8635-1199; Kettritz, Ralph/0000-0001-5821-6718				ALTIERI DC, 1988, J IMMUNOL, V141, P2656; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BARRETT JS, 1994, CLIN PHARMACOL THER, V56, P377, DOI 10.1038/clpt.1994.152; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; Coller BS, 1999, AM HEART J, V138, pS1, DOI 10.1053/hj.1999.v138.99078; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Daniel L, 2006, KIDNEY INT, V69, P1416, DOI 10.1038/sj.ki.5000306; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; Faull RJ, 1996, J AM SOC NEPHROL, V7, P1091; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Forlow SB, 2000, BLOOD, V95, P1317, DOI 10.1182/blood.V95.4.1317.004k30_1317_1323; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GEMMELL CH, 1993, J BIOL CHEM, V268, P14586; Gilchrist IC, 2001, CIRCULATION, V104, P406, DOI 10.1161/hc2901.093504; Kettritz R, 2004, J BIOL CHEM, V279, P2657, DOI 10.1074/jbc.M309778200; KONSTANTOPOULOS K, 1995, CIRCULATION, V91, P1427, DOI 10.1161/01.CIR.91.5.1427; Konstantopoulos K, 1998, CIRCULATION, V98, P873, DOI 10.1161/01.CIR.98.9.873; Kuijper PHM, 1998, THROMB HAEMOSTASIS, V80, P443, DOI 10.1055/s-0037-1615227; LEE YJ, 1993, THROMB RES, V72, P295, DOI 10.1016/0049-3848(93)90138-E; Lo SC, 2006, J BIOMED SCI, V13, P787, DOI 10.1007/s11373-006-9107-5; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Martinez MC, 2005, AM J PHYSIOL-HEART C, V288, pH1004, DOI 10.1152/ajpheart.00842.2004; Merten M, 1999, CIRCULATION, V99, P2577, DOI 10.1161/01.CIR.99.19.2577; Nomura S, 2003, THROMB HAEMOSTASIS, V89, P506; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; RINDER CS, 1992, BLOOD, V79, P1201; RINDER HM, 1991, BLOOD, V78, P1730; Seshiah PN, 2002, CIRCULATION, V105, P174, DOI 10.1161/hc0202.102248; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; SHATTIL SJ, 1987, BLOOD, V70, P307; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Tan KT, 2005, ANN MED, V37, P61, DOI 10.1080/07853890410018943; Wagner DD, 2005, ARTERIOSCL THROM VAS, V25, P1321, DOI 10.1161/01.ATV.0000166521.90532.44	39	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27960	27969		10.1074/jbc.M704039200	http://dx.doi.org/10.1074/jbc.M704039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644514	hybrid			2022-12-25	WOS:000249455600045
J	Heiss, EH; Schilder, YDC; Dirsch, VM				Heiss, Elke H.; Schilder, Yvonne D. C.; Dirsch, Verena M.			Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENE-INDUCED SENESCENCE; SMOOTH-MUSCLE-CELLS; HISTONE H2AX PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; CELLULAR SENESCENCE; DNA-DAMAGE; CHEMOPREVENTIVE AGENT; TELOMERASE ACTIVITY; OXIDATIVE STRESS; ATM ACTIVATION	The induction of senescence, an irreversible growth arrest, in cancer cells is regarded as a mean to halt tumor progression. The phytoalexin resveratrol ( RV) is known to possess a variety of cancer-preventive, - therapeutic, and - chemosensitizing properties. We report here that chronic treatment with RV in a subapoptotic concentration induces senescence-like growth arrest in tumor cells. In contrast to the widely accepted antioxidant property of RV, we demonstrate that one causative stimulus for senescence induction by chronic RV is an increased level of reactive oxygen species (ROS). The ROS formed upon RV exposure include hydrogen peroxide and superoxide and originate largely from mitochondria. Consistently, co-incubation with the antioxidant N-acetyl cysteine interfered with RV-mediated reactivation of the senescence program. Molecular mediators on the way from increased ROS levels to the observed growth arrest include p38 MAPK, p53, and p21. Moreover, we provide evidence that RV-initiated replication stress, apparent by activation of the ataxia telangiectasia-mutated kinase pathway, is associated with increased ROS levels and senescence induction. This is the first report linking cell cycle effects with a pro-oxidant and pro-senescent effect of RV in cancer cells.	Univ Vienna, Dept Pharmacognosy, A-1090 Vienna, Austria	University of Vienna	Heiss, EH (corresponding author), Univ Vienna, Dept Pharmacognosy, Althanstr 14, A-1090 Vienna, Austria.	elke.heiss@univie.ac.at	Heiss, Elke/B-6086-2015	Heiss, Elke/0000-0001-7618-5505; Dirsch, Verena/0000-0002-9261-5293				Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Das KC, 2004, AM J PHYSIOL-LUNG C, V286, pL87, DOI 10.1152/ajplung.00203.2002; Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elbling L, 2005, FASEB J, V19, P807, DOI 10.1096/fj.04-2915fje; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fuggetta MP, 2006, J EXP CLIN CANC RES, V25, P189; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Furukawa A, 2003, BIOCHEM PHARMACOL, V66, P1769, DOI 10.1016/S0006-2952(03)00541-0; Furumoto K, 1998, LIFE SCI, V63, P935, DOI 10.1016/S0024-3205(98)00351-8; Haider UGB, 2003, MOL PHARMACOL, V63, P925, DOI 10.1124/mol.63.4.925; Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Kuki S, 2006, CIRC J, V70, P1076, DOI 10.1253/circj.70.1076; Lanzilli G, 2006, INT J ONCOL, V28, P641; Li YB, 2006, PHARMACOL RES, V53, P6, DOI 10.1016/j.phrs.2005.08.002; Lin HY, 2006, FASEB J, V20, P1742, DOI 10.1096/fj.06-5743fje; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Moon SK, 2006, BIOCHEM BIOPH RES CO, V350, P662, DOI 10.1016/j.bbrc.2006.09.092; Murias M, 2005, BIOCHEM PHARMACOL, V69, P903, DOI 10.1016/j.bcp.2004.12.001; Myohanen SK, 1998, CANCER RES, V58, P591; Naderi W, 2006, MECH AGEING DEV, V127, P25, DOI 10.1016/j.mad.2005.08.006; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Orallo F, 2006, CURR MED CHEM, V13, P87, DOI 10.2174/092986706775197953; Passos JF, 2005, EXP GERONTOL, V40, P466, DOI 10.1016/j.exger.2005.04.006; Passos JF, 2006, FREE RADICAL RES, V40, P1277, DOI 10.1080/10715760600917151; Probin V, 2006, J PHARMACOL EXP THER, V319, P551, DOI 10.1124/jpet.106.107771; Sareen D, 2006, INVEST OPHTH VIS SCI, V47, P3708, DOI 10.1167/iovs.06-0119; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Schultz J, 2004, J NATL CANCER I, V96, P1497, DOI 10.1093/jnci/96.20.1497; Sengottuvelan M, 2006, BBA-GEN SUBJECTS, V1760, P1175, DOI 10.1016/j.bbagen.2006.03.008; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Takahashi Y, 2004, LIFE SCI, V75, P301, DOI 10.1016/j.lfs.2003.12.014; Tanaka T, 2007, CELL PROLIFERAT, V40, P1; Tanaka T, 2006, CELL CYCLE, V5, P1940, DOI 10.4161/cc.5.17.3191; Tyagi A, 2005, CARCINOGENESIS, V26, P1978, DOI 10.1093/carcin/bgi165; Won JJ, 2006, NAT CHEM BIOL, V2, P369, DOI 10.1038/nchembio800; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	49	121	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26759	26766		10.1074/jbc.M703229200	http://dx.doi.org/10.1074/jbc.M703229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626009	hybrid			2022-12-25	WOS:000249304900015
J	Bewry, NN; Bolick, SCE; Wright, KL; Harton, JA				Bewry, Nadine N.; Bolick, Sophia C. E.; Wright, Kenneth L.; Harton, Jonathan A.			GTP-dependent recruitment of CIITA to the class II major histocompatibility complex promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; LEUCINE-RICH REPEATS; IFN-GAMMA; TRANSCRIPTIONAL COACTIVATOR; TRANSACTIVATOR CIITA; SELF-ASSOCIATION; EXPRESSION; MHC; GENE; ENHANCEOSOME	We previously established that the class II transactivator CIITA binds GTP and disruption of the GTP binding ability of CIITA results in increased cytoplasmic CIITA, loss of nuclear CIITA, and thus diminished class II major histocompatibility complex transcription. Because of its role in facilitating nuclear localization, whether GTP binding is also required for CIITA-mediated transactivation of major histocompatibility class II genes remains unclear. We now show that recruitment of CIITA to the human leukocyte antigen ( HLA)-DR promoter and activation of HLA-DR transcription is also GTP-dependent. After restoration of nuclear expression, CIITA mutants defective in GTP binding lack full transcriptional activation capacity. Although the availability of the activation domain of CIITA is unaltered, GTP mutants no longer cooperate with CREB-binding protein, p300, and pCAF and are defective in recruitment to the HLA-DR promoter.	Albany Med Ctr, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA	Albany Medical College; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Harton, JA (corresponding author), Albany Med Ctr, Ctr Immunol & Microbial Dis, 47 New Scotland Rd, Albany, NY 12208 USA.	hartonj@mail.amc.edu	Harton, Jonathan/F-2848-2010; Harton, Jonathan A/AAW-5283-2021	Harton, Jonathan/0000-0002-0350-1877; Harton, Jonathan A/0000-0002-0350-1877	NCI NIH HHS [K01CA095582, K01 CA095582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA095582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Gialitakis M, 2006, NUCLEIC ACIDS RES, V34, P765, DOI 10.1093/nar/gkj462; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Greer SF, 2004, J IMMUNOL, V173, P376, DOI 10.4049/jimmunol.173.1.376; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Harton JA, 2002, HUM IMMUNOL, V63, P588, DOI 10.1016/S0198-8859(02)00400-7; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Heo J, 2005, BIOCHEMISTRY-US, V44, P6573, DOI 10.1021/bi047443q; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; Krawczyk M, 2004, J IMMUNOL, V173, P6200, DOI 10.4049/jimmunol.173.10.6200; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Masternak K, 2000, GENE DEV, V14, P1156; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Mudhasani R, 2005, MOL IMMUNOL, V42, P673, DOI 10.1016/j.molimm.2004.09.021; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Raval A, 2003, J IMMUNOL, V170, P922, DOI 10.4049/jimmunol.170.2.922; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Rigaud G, 1996, J IMMUNOL, V156, P4254; Schnappauf F, 2003, EUR J IMMUNOL, V33, P2337, DOI 10.1002/eji.200323490; Sisk TJ, 2001, MOL CELL BIOL, V21, P4919, DOI 10.1128/MCB.21.15.4919-4928.2001; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Sisk TJ, 2003, INT IMMUNOL, V15, P1195, DOI 10.1093/intimm/dxg116; Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Wang Y, 2005, J IMMUNOL, V174, P5687, DOI 10.4049/jimmunol.174.9.5687; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	48	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26178	26184		10.1074/jbc.M611747200	http://dx.doi.org/10.1074/jbc.M611747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623662	hybrid			2022-12-25	WOS:000249239600021
J	George, SP; Wang, Y; Mathew, S; Srinivasan, K; Khurana, S				George, Sudeep P.; Wang, Yaohong; Mathew, Sijo; Srinivasan, Kamalakkannan; Khurana, Seema			Dimerization and actin-bundling properties of villin and its role in the assembly of epithelial cell brush borders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLAR CORE PROTEINS; F-ACTIN; IN-VIVO; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA(1); GEL-ELECTROPHORESIS; INTESTINAL-CELLS; MOLECULAR MASSES; PROXIMAL TUBULE; CALCIUM CONTROL	Villin is a major actin-bundling protein in the brush border of epithelial cells. In this study we demonstrate for the first time that villin can bundle actin filaments using a single F-actin binding site, because it has the ability to self-associate. Using fluorescence resonance energy transfer, we demonstrate villin self-association in living cells in microvilli and in growth factor-stimulated cells in membrane ruffles and lamellipodia. Using sucrose density gradient, size-exclusion chromatography, and matrix-assisted laser desorption ionization time-of-flight, the majority of villin was identified as a monomer or dimer. Villin dimers were also identified in Caco-2cells, which endogenously express villin and Madin-Darby canine kidney cells that ectopically express villin. Using truncation mutants of villin, site-directed mutagenesis, and fluorescence resonance energy transfer, an amino-terminal dimerization site was identified that regulated villin self-association in parallel conformation as well as actin bundling by villin. This detailed analysis describes for the first time microvillus assembly by villin, redefines the actin-bundling function of villin, and provides a molecular mechanism for actin bundling by villin, which could have wider implications for other actin cross-linking proteins that share a villin-like headpiece domain. Our study also provides a molecular basis to separate the morphologically distinct actin-severing and actin-bundling properties of villin.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Nash 402, Memphis, TN 38163 USA.	skhurana@utmem.edu		Khurana, Seema/0000-0002-6884-810X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065006, R01DK054755] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-65006, DK-54755] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athman R, 2005, CELL MICROBIOL, V7, P1109, DOI 10.1111/j.1462-5822.2005.00535.x; Athman R, 2002, AM J PHYSIOL-GASTR L, V283, pG496, DOI 10.1152/ajpgi.00207.2002; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; Brown D, 1997, AM J PHYSIOL-RENAL, V273, pF1003, DOI 10.1152/ajprenal.1997.273.6.F1003; Chatman L, 2006, GASTROENTEROLOGY, V130, pA534; COLUCCIO LM, 1989, J CELL BIOL, V108, P495, DOI 10.1083/jcb.108.2.495; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; DUDOUET B, 1987, J CELL BIOL, V105, P359, DOI 10.1083/jcb.105.1.359; Erickson MG, 2003, BIOPHYS J, V85, P599, DOI 10.1016/S0006-3495(03)74504-4; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FATH KR, 1995, CURR BIOL, V5, P591, DOI 10.1016/S0960-9822(95)00117-5; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; FINIDORI J, 1992, J CELL BIOL, V116, P1145, DOI 10.1083/jcb.116.5.1145; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; FRIEDERICH E, 1993, J CELL SCI, V105, P765; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; GLENNEY JR, 1981, J BIOL CHEM, V256, P8156; GLENNEY JR, 1981, P NATL ACAD SCI-BIOL, V78, P2810, DOI 10.1073/pnas.78.5.2810; GRONE HJ, 1986, AM J PATHOL, V124, P294; HEINTZELMAN MB, 1992, CURR TOP DEV BIOL, V26, P93, DOI 10.1016/S0070-2153(08)60442-1; HESTERBERG LK, 1983, J BIOL CHEM, V258, P359; HORVAT B, 1990, HISTOCHEMISTRY, V93, P661, DOI 10.1007/BF00272210; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; Khanna R, 2002, P NATL ACAD SCI USA, V99, P6637, DOI 10.1073/pnas.052155999; Khurana S, 2005, GASTROENTEROLOGY, V128, pA604; Kumar N, 2004, J BIOL CHEM, V279, P24915, DOI 10.1074/jbc.C400110200; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; LECOUNT TS, 1972, J CELL BIOL, V53, P601, DOI 10.1083/jcb.53.2.601; Loomis PA, 2003, J CELL BIOL, V163, P1045, DOI 10.1083/jcb.200309093; Louvard RAD, 2003, MOL BIOL CELL, V14, P4641, DOI 10.1091/mbc.E03-02-0091; Marks PW, 1998, J CELL SCI, V111, P2129; Meng JM, 2005, BIOCHEMISTRY-US, V44, P11963, DOI 10.1021/bi050850x; MISCH DW, 1980, EUR J CELL BIOL, V21, P269; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; PETERSON MD, 1992, J CELL SCI, V102, P581; Pfannstiel J, 2001, J BIOL CHEM, V276, P49476, DOI 10.1074/jbc.M104760200; Phillips MJ, 2003, LANCET, V362, P1112, DOI 10.1016/S0140-6736(03)14467-4; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; RANA AP, 1993, P NATL ACAD SCI USA, V90, P6651, DOI 10.1073/pnas.90.14.6651; RICHARD C, 1989, BIOMED CHROMATOGR, V3, P131, DOI 10.1002/bmc.1130030309; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; SHIBAYAMA T, 1987, J CELL BIOL, V105, P335, DOI 10.1083/jcb.105.1.335; STEELE JCH, 1978, ANAL BIOCHEM, V84, P218, DOI 10.1016/0003-2697(78)90502-X; Tomar A, 2004, MOL BIOL CELL, V15, P4807, DOI 10.1091/mbc.E04-05-0431; Tomar A, 2006, J BIOL CHEM, V281, P31972, DOI 10.1074/jbc.M604323200; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Wang YH, 2007, AM J PHYSIOL-CELL PH, V292, pC1775, DOI 10.1152/ajpcell.00420.2006; Wang YH, 2005, GASTROENTEROLOGY, V128, pA605; WEINMAN MD, 1989, GASTROENTEROLOGY, V97, P1193, DOI 10.1016/0016-5085(89)91690-9; White P, 2000, AM J PHYSIOL-RENAL, V278, pF886, DOI 10.1152/ajprenal.2000.278.6.F886; ZAHN H, 1958, MAKROMOLEKUL CHEM, V26, P153; Zhai LW, 2002, BIOCHEMISTRY-US, V41, P11750, DOI 10.1021/bi0263762; Zhai LW, 2001, J BIOL CHEM, V276, P36163, DOI 10.1074/jbc.C100418200	62	51	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26528	10.1074/jbc.M703617200	http://dx.doi.org/10.1074/jbc.M703617200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17606613	hybrid			2022-12-25	WOS:000249239600057
J	Waas, WF; Druzina, Z; Hanan, M; Schimmel, P				Waas, William F.; Druzina, Zhanna; Hanan, Melanie; Schimmel, Paul			Role of a tRNA base modification and its precursors in frameshifting in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; TRANSFER RIBONUCLEIC-ACID; YEAST SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; Y-BASE; RIBOSOMAL FRAMESHIFT; BINDING-SITES; ANTICODON; VIRUS	Little is known about the role of specific base modifications of transfer RNAs. Wyosine bases are tRNA(Phe)- specific modifications that are distinguished by differentiated, lateral side chains and base methylations appended to the core ring structure of a universally conserved G37, adjacent to the anticodon of Phe tRNAs. Based on previous data, we hypothesized that this modification was needed for - 1 frameshifting. Using a reporter system incorporating a SCV-LA yeast virus slippery site for detecting - 1 frameshifts in vivo, yeast strains were created that enabled chemical-genetic dissection of the role of different functional groups of wyebutosine that are added in a three-step post-transcriptional set of reactions. With this system, hypo-modification increased Phe-specific frameshifting, with incremental changes in frameshift efficiency after specific intermediates in the progression of wyebutosine synthesis. These data combined with investigations of wild-type and hypomodified tRNA binding to ribosomes suggest that frameshift efficiency is kinetically and not thermodynamically controlled. The progressive nature of frameshift efficiency with the stage of modification is consistent with a stepwise evolution and tuning of frameshift potential. The stepwise tuning of frameshift efficiency could explain why tRNAPhe in some eukaryotes is not fully modified but, rather, hypomodified to capture a specific frameshift potential.	Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; ALTWEGG M, 1979, NUCLEIC ACIDS RES, V7, P93, DOI 10.1093/nar/7.1.93; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; BLOBSTEIN SH, 1973, BIOCHEMISTRY-US, V12, P188, DOI 10.1021/bi00726a002; BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; Brierley I, 2006, VIRUS RES, V119, P29, DOI 10.1016/j.virusres.2005.10.008; Carlson BA, 2001, VIROLOGY, V279, P130, DOI 10.1006/viro.2000.0692; Carlson BA, 1999, VIROLOGY, V255, P2, DOI 10.1006/viro.1998.9569; de Pereda JM, 2004, J BIOL CHEM, V279, P8111, DOI 10.1074/jbc.M311449200; DINMAN JD, 1992, J VIROL, V66, P3669, DOI 10.1128/JVI.66.6.3669-3676.1992; DINMAN JD, 1995, YEAST, V11, P1115, DOI 10.1002/yea.320111202; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Gurvich OL, 2003, EMBO J, V22, P5941, DOI 10.1093/emboj/cdg561; Harger JW, 2003, RNA, V9, P1019, DOI 10.1261/rna.5930803; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; Hung M, 1998, J VIROL, V72, P4819, DOI 10.1128/JVI.72.6.4819-4824.1998; ICHO T, 1989, J BIOL CHEM, V264, P6716; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; Jacobs JL, 2007, NUCLEIC ACIDS RES, V35, P165, DOI 10.1093/nar/gkl1033; Kalhor HR, 2005, BIOCHEM BIOPH RES CO, V334, P433, DOI 10.1016/j.bbrc.2005.06.111; KAN LS, 1975, BIOCHEMISTRY-US, V14, P3278, DOI 10.1021/bi00685a038; Katunin V I, 1994, Mol Biol (Mosk), V28, P66; Konevega AL, 2004, RNA, V10, P90, DOI 10.1261/rna.5142404; KRZYZOSIAK WJ, 1983, NUCLEIC ACIDS RES, V11, P6913, DOI 10.1093/nar/11.19.6913; KUCHINO Y, 1982, NUCLEIC ACIDS RES, V10, P6421, DOI 10.1093/nar/10.20.6421; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Lopinski JD, 2000, MOL CELL BIOL, V20, P1095, DOI 10.1128/MCB.20.4.1095-1103.2000; MAELICKE A, 1973, BIOPOLYMERS, V12, P27, DOI 10.1002/bip.1973.360120104; McCloskey J A, 2000, Nucleic Acids Symp Ser, P267; McCloskey JA, 2001, NUCLEIC ACIDS RES, V29, P4699, DOI 10.1093/nar/29.22.4699; Meskauskas A, 2005, MOL CELL BIOL, V25, P10863, DOI 10.1128/MCB.25.24.10863-10874.2005; Meskauskas A, 2003, RNA, V9, P982, DOI 10.1261/rna.2165803; NAKANISHI K, 1971, NATURE-NEW BIOL, V234, P107, DOI 10.1038/newbio234107b0; Noma A, 2006, EMBO J, V25, P2142, DOI 10.1038/sj.emboj.7601105; Noon KR, 2003, J BACTERIOL, V185, P5483, DOI 10.1128/JB.185.18.5483-5490.2003; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Plant EP, 2006, RNA, V12, P666, DOI 10.1261/rna.2225206; Semenkov YP, 1996, P NATL ACAD SCI USA, V93, P12183, DOI 10.1073/pnas.93.22.12183; SMITH DWE, 1985, J BIOL CHEM, V260, P147; Soboleva N. G., 2003, Molekulyarnaya Biologiya (Moscow), V37, P121; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Stuart JW, 2003, J MOL BIOL, V334, P901, DOI 10.1016/j.jmb.2003.09.058; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; THEIBE R, 1973, FEBS LETT, V38, P27; THIEBE R, 1968, EUR J BIOCHEM, V5, P546, DOI 10.1111/j.1432-1033.1968.tb00404.x; TZENG TH, 1992, J VIROL, V66, P999, DOI 10.1128/JVI.66.2.999-1006.1992; Waas WF, 2005, J BIOL CHEM, V280, P37616, DOI 10.1074/jbc.M506939200; Zhou SL, 2004, BIOORG CHEM, V32, P82, DOI 10.1016/j.bioorg.2003.09.005	52	70	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26026	26034		10.1074/jbc.M703391200	http://dx.doi.org/10.1074/jbc.M703391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623669	hybrid			2022-12-25	WOS:000249239600006
J	Anavi-Goffer, S; Fleischer, D; Hurst, DP; Lynch, DL; Barnett-Norris, J; Shi, SP; Lewis, DL; Mukhopadhyay, S; Howlett, AC; Reggio, PH; Abood, ME				Anavi-Goffer, Sharon; Fleischer, Daniel; Hurst, Dow P.; Lynch, Diane L.; Barnett-Norris, Judy; Shi, Shanping; Lewis, Deborah L.; Mukhopadhyay, Somnath; Howlett, Allyn C.; Reggio, Patricia H.; Abood, Mary E.			Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; PROTEIN-COUPLED RECEPTOR; 4TH CYTOPLASMIC LOOP; C-TERMINAL TAIL; CONFORMATIONAL SWITCH; STRUCTURAL-PROPERTIES; SECONDARY STRUCTURE; INVERSE AGONIST; ACTIVATION; RHODOPSIN	The intracellular C- terminal helix 8 ( H8) of the CB1 cannabinoid receptor deviates from the highly conserved NPXXY( X)(5,6) F G- protein- coupled receptor motif, possessing a Leu instead of a Phe. We compared the signal transduction capabilities of CB1 with those of an L7.60F mutation and an L7.60I mutation that mimics the CB2 sequence. The two mutant receptors differed from wild type ( WT) in their ability to regulate G- proteins in the [ S-35] guanosine 5 ' - 3- O-( thio) triphosphate binding assay. The L7.60F receptor exhibited attenuated stimulation by agonists WIN- 55,212- 2 and CP- 55,940 but not HU- 210, whereas the L7.60I receptor exhibited impaired stimulation by all agonists tested as well as by the inverse agonist rimonabant. The mutants internalized more rapidly than WT receptors but could equally sequester G- proteins from the somatostatin receptor. Both the time course and maximal N- type Ca2(+) current inhibition by WIN- 55,212- 2 were reduced in the mutants. Reconstitution experiments with pertussis toxin- insensitive G- proteins revealed loss of coupling to G alpha (i3) but not G alpha (0A) in the L7.60I mutant, whereas the reduction in the time course for the L7.60F mutant was governed by G alpha (i3) .Furthermore, G alpha (i3) but not G alpha(0A) enhanced basal facilitation ratio, suggesting that G alpha(i3) is responsible for CB1 tonic activity. Co- immunoprecipitation studies revealed that both mutant receptors were associated with G alpha(i1) or G alpha(i2) but not with G alpha(i3). Molecular dynamics simulations of WT CB1 receptor and each mutant in a 1- palmitoyl- 2-oleoylphosphatidylcholine bilayer suggested that the packing of H8 is different in each. The hydrogen bonding patterns along the helix backbones of each H8 also are different, as are the geometries of the elbow region of H8 ( R7.56( 400)- K7.58( 402)). This study demonstrates that the evolutionary modification to NPXXY( X) (5,6) L contributes to maximal activity of the CB1 receptor and provides a molecular basis for the differential coupling observed with chemically different agonists.	Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA; Univ N Carolina, Dept Chem & Biochem, Greensboro, NC 27402 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; N Carolina Cent Univ, Neurosci Drug Abuse Res Program, Durham, NC 27707 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of North Carolina; University of North Carolina Greensboro; University System of Georgia; Augusta University; University of North Carolina; North Carolina Central University	Abood, ME (corresponding author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St Ste 220, San Francisco, CA 94107 USA.	aboodm@cpmcri.org	Anavi-Goffer, Sharon/H-6111-2019	Anavi-Goffer, Sharon/0000-0002-3364-5134; Abood, Mary/0000-0002-1744-2820; Howlett, Allyn/0000-0002-2810-0164	NIDA NIH HHS [U24 DA012385, R01 DA003690, DA039434, DA00489, DA12385, DA09978, DA05274, DA03690] Funding Source: Medline; NIMHD NIH HHS [P20 MD000175] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009978, R01DA003934, R01DA003690, U24DA012385] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P20MD000175] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARNETTNORRIS J, 2003, 2003 S CANN CORNW ON; BHANDARKAR M, 2003, NAMD USERS GUIDE; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; BRAMBLETT RD, 1995, LIFE SCI, V56, P1971, DOI 10.1016/0024-3205(95)00178-9; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Choi G, 2005, BBA-BIOMEMBRANES, V1668, P1, DOI 10.1016/j.bbamem.2004.10.011; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fay JF, 2005, BIOCHEMISTRY-US, V44, P8757, DOI 10.1021/bi0472651; Feller SE, 2000, J PHYS CHEM B, V104, P7510, DOI 10.1021/jp0007843; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Glass M, 1999, MOL PHARMACOL, V56, P1362, DOI 10.1124/mol.56.6.1362; GRACE CR, 2007, IN PRESS J STRUCT BI; Hassan SA, 2000, J PHYS CHEM B, V104, P6478, DOI 10.1021/jp993895e; Hassan SA, 2000, J PHYS CHEM B, V104, P6490, DOI 10.1021/jp9938967; Hassan SA, 2002, LECT NOTES COMP SCI, V24, P197; Houston DB, 1998, CELL SIGNAL, V10, P667, DOI 10.1016/S0898-6568(98)00013-8; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Huber T, 2002, J AM CHEM SOC, V124, P298, DOI 10.1021/ja011383j; Hurst D, 2006, J MED CHEM, V49, P5969, DOI 10.1021/jm060446b; HYSLOP PA, 1990, BIOCHEMISTRY-US, V29, P1025, DOI 10.1021/bi00456a027; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; Jin WZ, 1999, J NEUROSCI, V19, P3773; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kearn CS, 1999, J NEUROCHEM, V72, P2379, DOI 10.1046/j.1471-4159.1999.0722379.x; Konig B, 1997, LANGMUIR, V13, P525, DOI 10.1021/la960571y; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McAllister SD, 2004, J BIOL CHEM, V279, P48024, DOI 10.1074/jbc.M406648200; McAllister SD, 2003, J MED CHEM, V46, P5139, DOI 10.1021/jm0302647; Mukhopadhyay S, 2005, MOL PHARMACOL, V67, P2016, DOI 10.1124/mol.104.003558; Mukhopadhyay S, 2001, EUR J BIOCHEM, V268, P499, DOI 10.1046/j.1432-1327.2001.01810.x; Mukhopadhyay S, 1999, BIOCHEMISTRY-US, V38, P3447, DOI 10.1021/bi981767v; Mukhopadhyay S, 2000, MOL PHARMACOL, V57, P162; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Nie JJ, 2001, J NEUROSCI, V21, P8758, DOI 10.1523/JNEUROSCI.21-22-08758.2001; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pan XH, 1998, MOL PHARMACOL, V54, P1064, DOI 10.1124/mol.54.6.1064; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Roche JP, 1999, MOL PHARMACOL, V56, P611, DOI 10.1124/mol.56.3.611; Saiz L, 2001, BIOPHYS J, V81, P204, DOI 10.1016/S0006-3495(01)75692-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Santos N. M. D., 2006, J BIOL CHEM, V281, P12896; Schlenkrich Michael, 1996, P31; Shepherd CM, 2003, BIOCHEM J, V370, P233, DOI 10.1042/BJ20021255; Sim-Selley LJ, 2001, EUR J PHARMACOL, V414, P135, DOI 10.1016/S0014-2999(01)00784-1; Smaby JM, 1997, BIOPHYS J, V73, P1492, DOI 10.1016/S0006-3495(97)78181-5; Swift S, 2006, J BIOL CHEM, V281, P4109, DOI 10.1074/jbc.M509525200; Tao Q, 1998, J PHARMACOL EXP THER, V285, P651; Tetsuka M, 2004, ENDOCRINOLOGY, V145, P3712, DOI 10.1210/en.2003-1638; Turu G, 2007, J BIOL CHEM, V282, P7753, DOI 10.1074/jbc.C600318200; Ulfers AL, 2002, PROTEIN SCI, V11, P2526, DOI 10.1110/ps.0218402; Vasquez C, 1999, J NEUROSCI, V19, P9271; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; Xie XQ, 2005, J BIOL CHEM, V280, P3605, DOI 10.1074/jbc.M410294200; Zhong M, 2004, BIOCHEMISTRY-US, V43, P3490, DOI 10.1021/bi035899m	65	39	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25100	25113		10.1074/jbc.M703388200	http://dx.doi.org/10.1074/jbc.M703388200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17595161	hybrid			2022-12-25	WOS:000248933000065
J	Karrasch, T; Kim, JS; Jang, BI; Jobin, C				Karrasch, Thomas; Kim, Joo-Sung; Jang, Byung Ik; Jobin, Christian			The Flavonoid Luteolin Worsens Chemical-Induced Colitis in NF-kappa B-EGFP Transgenic Mice through Blockade of NF-kappa B-Dependent Protective Molecules	PLOS ONE			English	Article								Background. The flavonoid luteolin has anti-inflammatory properties both in vivo and in vitro. However, the impact of luteolin on experimental models of colitis is unknown. Methodology/Principal Findings. To address the therapeutic impact of luteolin, NF-kappa B-EGFP transgenic mice were fed a chow diet containing 2% luteolin-or isoflavone-free control chow (AIN-76), and acute colitis was induced using 3% dextran sodium sulfate (DSS). Additionally, development of spontaneous colitis was evaluated in IL-10(-/-); NF-kappa B-EGFP transgenic mice fed 2% luteolin chow diet or control chow diet. Interestingly, NF-kappa B-EGFP transgenic mice exposed to luteolin showed worse DSS-induced colitis (weight loss, histological scores) compared to control-fed mice, whereas spontaneous colitis in IL-10(-/-); NF-kappa B-EGFP mice was significantly attenuated. Macroscopic imaging of live resected colon showed enhanced EGFP expression (NF-kappa B activity) in luteolin-fed mice as compared to control-fed animals after DSS exposure, while cecal EGFP expression was attenuated in luteolin-fed IL-10(-/-) mice. Interestingly, confocal microscopy showed that EGFP positive cells were mostly located in the lamina propria and not in the epithelium. Caspase 3 activation was significantly enhanced whereas COX-2 gene expression was reduced in luteolin-fed, DSS-exposed NF-kappa B-EGFP transgenic mice as assessed by Western blot and immunohistochemical analysis. In vitro, luteolin sensitized colonic epithelial HT29 cells to TNF alpha-induced apoptosis, caspase 3 activation, DNA fragmentation and reduced TNF alpha-induced C-IAP1, C-IAP2 and COX-2 gene expression. Conclusions/Significance. We conclude that while luteolin shows beneficial effects on spontaneous colitis, it aggravates DSS-induced experimental colitis by blocking NF-kappa B-dependent protective molecules in enterocytes.	[Jobin, Christian] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA; Univ N Carolina, Ctr GI Biol & Dis, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jobin, C (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA.	Job@med.unc.edu	Kim, Jung M/D-3112-2015; Kim, Joo Sung/D-5765-2012	Kim, Jung M/0000-0002-6506-7519; 	NIH [ROI DK 47700, P30 DK034987]; American Institute of Cancer Research; Crohn's and Colitis Foundation of America; NCI [P50 CA106991]; NATIONAL CANCER INSTITUTE [P50CA106991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R01DK047700] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Institute of Cancer Research; Crohn's and Colitis Foundation of America; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH ROI DK 47700 and American Institute of Cancer Research grants to C. Jobin; by the Crohn's and Colitis Foundation of America fellowship to T. Karrasch; by NIH P30 DK034987 to CGIBD and in part by NCI UNC GI SPORE grant P50 CA106991 to C. Jobin.	Aggarwal BB, 2004, ANN NY ACAD SCI, V1030, P434, DOI 10.1196/annals.1329.054; Araki A, 2005, J GASTROENTEROL, V40, P16, DOI 10.1007/s00535-004-1492-9; Bent S, 2004, AM J MED, V116, P478, DOI 10.1016/j.amjmed.2003.10.036; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Brown SL, 2007, J CLIN INVEST, V117, P258, DOI 10.1172/JCI29159; Chen CC, 2004, MOL PHARMACOL, V66, P683; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; Cominelli F, 2004, NEW ENGL J MED, V351, P2045, DOI 10.1056/NEJMp048253; COOPER HS, 1993, LAB INVEST, V69, P238; Cui XF, 2000, BBA-GEN SUBJECTS, V1524, P178, DOI 10.1016/S0304-4165(00)00155-0; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; Egan LJ, 2004, P NATL ACAD SCI USA, V101, P2452, DOI 10.1073/pnas.0306734101; Egan LJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1028, DOI 10.1152/ajpcell.00167.2003; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Gupta RK, 2004, NAT BIOTECHNOL, V22, P653, DOI 10.1038/nbt0604-653; Haller D, 2004, J PEDIATR GASTR NUTR, V38, P123, DOI 10.1097/00005176-200402000-00004; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68; Hendricks JJA, 2004, J EXP MED, V200, P1667, DOI 10.1084/jem.20040819; Hibi T, 2003, J GASTROENTEROL, V38, P36; Hougee S, 2005, BIOCHEM PHARMACOL, V69, P241, DOI 10.1016/j.bcp.2004.10.002; Jian YT, 2005, WORLD J GASTROENTERO, V11, P1747, DOI 10.3748/wjg.v11.i12.1747; Jijon HB, 2005, EUR J IMMUNOL, V35, P718, DOI 10.1002/eji.200425688; Jobin C, 1997, J IMMUNOL, V158, P226; Jobin C, 2000, INFLAMM BOWEL DIS, V6, P206, DOI 10.1097/00054725-200008000-00007; Karrasch T, 2006, J CELL PHYSIOL, V207, P809, DOI 10.1002/jcp.20626; Karrasch T, 2007, J IMMUNOL, V178, P6522, DOI 10.4049/jimmunol.178.10.6522; Kawamori T, 1998, CANCER RES, V58, P409; Kim JS, 2005, IMMUNOLOGY, V115, P375, DOI 10.1111/j.1365-2567.2005.02156.x; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Loftus EV, 2002, GASTROENTEROL CLIN N, V31, P1, DOI 10.1016/S0889-8553(01)00002-4; Lorenz RG, 2005, SPRINGER SEMIN IMMUN, V27, P233, DOI 10.1007/s00281-005-0208-4; Maeda S, 2002, GUT, V50, P771, DOI 10.1136/gut.50.6.771; Magness ST, 2004, J IMMUNOL, V173, P1561, DOI 10.4049/jimmunol.173.3.1561; Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Ruiz PA, 2006, J NUTR, V136, P664, DOI 10.1093/jn/136.3.664; Sampson W, 2005, NEW ENGL J MED, V353, P337, DOI 10.1056/NEJMp058130; Sartor RB, 1997, AM J GASTROENTEROL, V92, pS5; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Sugimoto K, 2002, GASTROENTEROLOGY, V123, P1912, DOI 10.1053/gast.2002.37050; Tormakangas L, 2005, BIOCHEM PHARMACOL, V70, P1222, DOI 10.1016/j.bcp.2005.07.012; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Wendum D, 2004, VIRCHOWS ARCH, V445, P327, DOI 10.1007/s00428-004-1105-2; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; Xagorari A, 2001, J PHARMACOL EXP THER, V296, P181; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810	52	45	46	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e596	10.1371/journal.pone.0000596	http://dx.doi.org/10.1371/journal.pone.0000596			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611628	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451900013
J	Berenguer, C; Boudouresque, F; Dussert, C; Daniel, L; Muracciole, X; Grino, M; Rossi, D; Mabrouk, K; Figarella-Branger, D; Martin, PM; Ouafik, L				Berenguer, C.; Boudouresque, F.; Dussert, C.; Daniel, L.; Muracciole, X.; Grino, M.; Rossi, D.; Mabrouk, K.; Figarella-Branger, D.; Martin, P-M; Ouafik, L'Houcine			Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells	ONCOGENE			English	Article						prostate cancer; LNCaP cells; adrenomedullin; adrenomedullin receptors; neuroendocrine differentiation; LNCaP xenograft; androgen; regulation; cGMP-dependent protein kinase G	DEPENDENT PROTEIN-KINASE; CANCER CELLS; IN-VITRO; DIFFERENTIATION; GENE; ANGIOGENESIS; PROGRESSION; EXPRESSION; PEPTIDE; GROWTH	Neuroendocrine (NE) differentiation in prostate cancer (CaP) has been reported to be an early marker associated with the development of androgen independence. The mechanisms by which CaP acquires NE properties are poorly understood. In this study, a putative role of adrenomedullin (AM) in the NE differentiation was investigated. The expression of AM and AM receptors (calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) was evaluated after experimental manipulation of androgen status. Levels of AM mRNA and immunoreactive AM (ir-AM) increased four-to sevenfold in androgen-sensitive LNCaP cells after androgen withdrawal in vitro and in LNCaP xenograftsin animals after castration. Treatment of LNCaP cells with androgen analogue (dihydrotestosterone; 10(-9) M) prevented the increase in AM mRNA and ir-AM levels. Interestingly, the expression of CRLR, RAMP2 and RAMP3 is not regulated by androgen status. We demonstrate that in the presence of serum, AM is able to induce an NE phenotype in LNCaP cells via CRLR/ RAMP2 and RAMP3, which includes extension of neuritic processes and expression of the neuron-specific enolase (NSE), producing cGMP in a dose-dependent manner, which is mediated by a pertussis toxin-sensitive GTP-binding protein. 8-bromo-cGMP mimicked the effects of AM on cell differentiation. We demonstrate that AM induces a G-kinase I alpha translocation to the nucleus. The protein kinase G inhibitor KT-5823 inhibited the neurite outgrowth induced by both AM and 8-bromo-cGMP. In noncastrated animals, administration of AM enhanced expression of NSE and chromogranin A in LNCaP xenografts with a significant increase of NSE levels in serum and no changes in tumor growth. In castrated animals, intraperitoneal injection of AM resulted in a 240 +/- 18% ( P<0.001) increase in tumor volume 36 days after treatment, indicating that the nature of effect of AM in CaP depends on the presence or absence of endogenous androgen. Together, these results demonstrate that AM may function as a mediator of NE-like differentiation in culture as well as in vivo and indicate that its product ion may be important for tumor resurgence following androgen ablation.	[Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, F-13916 Marseille 20, France; [Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] INSERM E 359, Marseille, France; [Daniel, L.; Figarella-Branger, D.] Univ Aix Marseille 2, Fac Med, Lab Adhes & Signalisat EA3281, Marseille, France; [Muracciole, X.] Assistance Publ Hop Marseille, CHU Timone, Serv Radiotherapie, Marseille, France; [Grino, M.] INSERM, UMR 626, Marseille, France; [Rossi, D.] Assistance Publ Hop Marseille, CHU Nord, Serv Urol, Marseille, France; [Mabrouk, K.] CNRS, FRE 2738, Marseille, France; [Martin, P-M; Ouafik, L'Houcine] Assistance Publ Hop Marseille, CHU Nord, Lab Transfer Oncol Biol & Mol, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Ouafik, L (corresponding author), Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, Bd Pierre Dramard, F-13916 Marseille 20, France.	lhoucine.ouafik@univmed.fr	Grino, Michel/GYD-8559-2022; Grino, Michel/O-5361-2017; Grino, Michel/M-7548-2017; Muracciole, Xavier/P-5640-2016; daniel, laurent/R-2826-2016	daniel, laurent/0000-0002-7539-0109; Ouafik, L'Houcine/0000-0002-4848-1232				Abasolo I, 2003, MOL CELL ENDOCRINOL, V199, P179, DOI 10.1016/S0303-7207(02)00229-0; Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Chung TDK, 1999, PROSTATE, V38, P199; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; GKONOS PJ, 1995, UROL RES, V23, P81, DOI 10.1007/BF00307937; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Kim J, 2002, CANCER RES, V62, P1549; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Rocchi P, 2001, CANCER RES, V61, P1196; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E	19	34	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					506	518		10.1038/sj.onc.1210656	http://dx.doi.org/10.1038/sj.onc.1210656			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637748				2022-12-25	WOS:000252426100011
J	Shen, Q; Uray, IP; Li, Y; Krisko, TI; Strecker, TE; Kim, HT; Brown, PH				Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.			The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors	ONCOGENE			English	Article						AP-1 factor; proliferation arrest; cyclin D1; E2F factors; gene expression regulation; breast cancer cells	C-JUN; KINASE-ACTIVITY; BINDING-SITE; ACTIVATION; EXPRESSION; GENE; FOS; DIFFERENTIATION; OVEREXPRESSION; TRANSFORMATION	The activating protein-1 (AP-1) transcription factor transduces growth signals through signal transduction pathways to the nucleus, leading to the expression of genes involved in growth and malignant transformation in many cell types. We have previously shown that overexpression of a dominant negative form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcriptional activity, induces a G(1) cell cycle block and inhibits breast cancer cell growth in vitro and in vivo. We found that AP-1 blockade by Tam67 in MCF-7 breast cancer cells downregulates cyclin D1 transcriptional activity by at least two mechanisms: by suppressing transcription at the known AP-1 binding site (-934/-928) and by suppressing growth factor-induced expression through suppressing E2F activation at the E2F-responsive site (-726/-719). AP-1 blockade also led to reduced expression of E2F1 and E2F2, but not E2F4, at the mRNA and protein levels. Chromatin immunoprecipitation and supershift assays demonstrated that AP-1 blockade caused decreased binding of E2F1 protein to the E2F site in the cyclin D1 promoter. We also found that Tam67 suppressed the expression of the E2F1 dimerizing partner, DP1 and E2F-upregulated cell cycle genes (cyclins E, A, B and D3) and enhanced the expression of E2F-downregulated cell cycle genes (cyclins G2 and I). Reduced expression of other E2F-regulated genes was also seen with AP-1 blockade and E2F suppression. Thus, the AP-1 factor regulates the expression of cyclin D and E2F (the latter in turn regulates E2F-downstream genes), leading to cell cycle progression and breast cancer cell proliferation.	[Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.] Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; [Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.] Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Plaza,MS600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu	Krisko, Tibor/AAG-7595-2020	Krisko, Tibor/0000-0002-9414-5846; Shen, Qiang/0000-0002-1491-5434; Brown, Powel/0000-0002-3398-163X				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Botz J, 1996, MOL CELL BIOL, V16, P3401; BROWN PH, 1993, ONCOGENE, V8, P877; Bu X, 2005, ONCOGENE, V24, P2398, DOI 10.1038/sj.onc.1208466; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Han S, 2003, BREAST CANCER RES TR, V82, P11, DOI 10.1023/B:BREA.0000003843.53726.63; HERBER, 1994, ONCOGENE, V9, P2105; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Lavia P, 1999, BIOESSAYS, V21, P221; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen FH, 2006, TOXICOL LETT, V160, P185, DOI 10.1016/j.toxlet.2005.07.009; Shen Q, 2004, ONCOGENE, V23, P2454, DOI 10.1038/sj.onc.1207354; Shen Q, 2006, DEV BIOL, V295, P589, DOI 10.1016/j.ydbio.2006.03.042; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	26	92	94	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					366	377		10.1038/sj.onc.1210643	http://dx.doi.org/10.1038/sj.onc.1210643			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637753				2022-12-25	WOS:000252256000013
J	Li, QF; Huang, WR; Duan, HF; Wang, H; Wu, CT; Wang, LS				Li, Q-F; Huang, W-R; Duan, H-F; Wang, H.; Wu, C-T; Wang, L-S			Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells	ONCOGENE			English	Article						BCR/ABL; sphingosine kinase-1; Mcl-1; CML	ABL TYROSINE KINASE; BCR-ABL; HEMATOPOIETIC-CELLS; ACTIVATION; APOPTOSIS; SURVIVAL; GROWTH; TRANSFORMATION; PROGRESSION; PATHWAY	The signaling mechanisms responsible for BCR/ABL-induced regulation of Mcl-1 expression in chronic myelogenous leukemia (CML) cells remain unclear. In this study, we show that BCR/ABL could upregulate sphingosine kinase-1 (SPK1) expression via multiple signal pathways, including mitogen-activated protein kinase ( MAPK), phosphoinositide 3-kinase (PI3K) and Janus kinase 2 (JAK2), leading to increase cellular SPK1 activity in CML cells. Retrovirus-mediated overexpression of bcr-abl gene in NIH-3T3, Ba/F3 and HL-60 cells results in upregulation and increased cellular activity of SPK1, whereas treatment of CML cells with specific inhibitors of the BCR/ABL, PI3K, MAPK and JAK2 pathways decreases BCR/ABLinduced SPK1 expression and cellular activity. BCR/ABL also induces upregulation of Mcl-1 expression in CML cells. Inhibition of SPK1 by adenovirus-mediated transfer of small interfering RNA or N,N-dimethylsphingosine reduced expression of Mcl-1 in CML cells. Our data indicated that BCR/ABL induces SPK1 expression and increases its cellular activity, leading to upregulation of Mcl-1 in CML cells. SPK1 silencing enhances the STI571-induced apoptosis of CML cell lines. It is suggested that SPK1 may be a potential therapeutic target in CML.	[Li, Q-F; Duan, H-F; Wang, H.; Wu, C-T; Wang, L-S] Beijing Inst Radiat Med, Dept Expt Hematol, Beijing 100850, Peoples R China; [Huang, W-R] Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China	Academy of Military Medical Sciences - China; Chinese People's Liberation Army General Hospital	Wang, LS (corresponding author), Beijing Inst Radiat Med, Dept Expt Hematol, 27 Taiping Rd, Beijing 100850, Peoples R China.	wangls@nic.bmi.ac.cn						Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Cortez D, 1996, ONCOGENE, V13, P2589; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Duan HF, 2004, EXP CELL RES, V298, P593, DOI 10.1016/j.yexcr.2004.04.049; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Le Scolan E, 2005, BLOOD, V106, P1808, DOI 10.1182/blood-2004-12-4832; Limaye V, 2005, BLOOD, V105, P3169, DOI 10.1182/blood-2004-02-0452; Lu ZZ, 2006, EXP HEMATOL, V34, P1171, DOI 10.1016/j.exphem.2006.05.005; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Wattenberg BW, 2006, J LIPID RES, V47, P1128, DOI 10.1194/jlr.R600003-JLR200; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	22	59	72	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7904	7908		10.1038/sj.onc.1210587	http://dx.doi.org/10.1038/sj.onc.1210587			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599053				2022-12-25	WOS:000252163500008
J	Lien, HC; Hsiao, YH; Lin, YS; Yao, YT; Juan, HF; Kuo, WH; Hung, MC; Chang, KJ; Hsieh, FJ				Lien, H. C.; Hsiao, Y. H.; Lin, Y. S.; Yao, Y. T.; Juan, H. F.; Kuo, W. H.; Hung, Mien-Chie; Chang, K. J.; Hsieh, F. J.			Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition	ONCOGENE			English	Article						oligonucleotide microarray; metaplastic carcinoma of breast; epithelial-mesenchymal transition	PROGNOSTIC MARKERS; TGF-BETA; EXPRESSION; CANCER; CELLS; CARTILAGE; TISSUE; DIFFERENTIATION; MORPHOGENESIS; METASTASIS	Metaplastic carcinoma of the breast (MCB) is a poorly understood subtype of breast cancer. It is generally characterized by the coexistence of ductal carcinomatous and transdifferentiated sarcomatous components, but the underlying molecular alterations, possibly related to epithelial-mesenchymal transition (EMT), remain elusive. We performed transcriptional pro. ling using half-a-genome oligonucleotide microarrays to elucidate genetic profiles of MCBs and their differences to those of ductal carcinoma of breasts (DCBs) using discarded specimens of four MCBs and 34 DCBs. Unsupervised clustering disclosed distinctive expression profiles between MCBs and DCBs. Supervised analysis identified gene signatures discriminating MCBs from DCBs and between MCB subclasses. Notably, many of the discriminator genes were associated with downregulation of epithelial phenotypes and with synthesis, remodeling and adhesion of extracellular matrix, with some of them have known or inferred roles related to EMT. Importantly, several of the discriminator genes were upregulated in a mutant Snail-transfected MCF7 cell known to exhibit features of EMT, thereby indicating a crucial role for EMT in the pathogenesis of MCBs. Finally, the identification of SPARC and vimentin as poor prognostic factors reinforced the role of EMT in cancer progression. These data advance our understanding of MCB and offer clues to the molecular alterations underlying EMT.	[Kuo, W. H.; Chang, K. J.] Natl Taiwan Univ, Dept Surg, Coll Med, Taipei 10764, Taiwan; [Lien, H. C.; Yao, Y. T.] Natl Taiwan Univ, Dept Pathol, Coll Med, Taipei 10764, Taiwan; [Hsiao, Y. H.] Changhua Christian Hosp, Dept Obstet & Gynecol, Changhua, Taiwan; [Hsiao, Y. H.] Chang Jung Christian Univ, Inst Med Res, Tainan, Taiwan; [Lin, Y. S.] Welgene Biotech Co Ltd, Taipei, Taiwan; [Juan, H. F.; Hsieh, F. J.] Natl Taiwan Univ, Ctr Syst Biol & Bioinformat, Taipei 10764, Taiwan; [Juan, H. F.; Hsieh, F. J.] Natl Taiwan Univ, Dept Life Sci, Taipei 10764, Taiwan; [Hung, Mien-Chie] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX USA; [Hsieh, F. J.] Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University; Changhua Christian Hospital; Chang Jung Christian University; National Taiwan University; National Taiwan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Texas System; UTMD Anderson Cancer Center; National Taiwan University	Chang, KJ (corresponding author), Natl Taiwan Univ, Dept Surg, Coll Med, 1-1 Jen Ai Rd, Taipei 10764, Taiwan.	kingjen@ha.mc.ntu.edu.tw; fjhsieh@ha.mc.ntu.edu.tw	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Chang, King jen/0000-0001-9811-3422; KUO, WEN-HUNG/0000-0002-9881-4605; JUAN, HSUEH-FEN/0000-0003-4876-3309; LIEN, HUANG-CHUN/0000-0003-1472-1231				Al Sayed AD, 2006, ACTA ONCOL, V45, P188, DOI 10.1080/02841860500513235; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barnes PJ, 2005, BREAST CANCER RES TR, V91, P173, DOI 10.1007/s10549-004-7260-y; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Carter MR, 2006, AM J SURG PATHOL, V30, P300; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Fujiwara S, 2001, J BIOL CHEM, V276, P13340, DOI 10.1074/jbc.M011386200; Gersch RP, 2005, J ORTHOP RES, V23, P882, DOI 10.1016/j.orthres.2005.02.005; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Kusafuka K, 2004, J PATHOL, V203, P953, DOI 10.1002/path.1599; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Lien HC, 2004, J PATHOL, V204, P131, DOI 10.1002/path.1624; Liu Y, 2000, J CELL SCI, V113, P2363; Ma LJ, 2005, DEVELOPMENT, V132, P5601, DOI 10.1242/dev.02156; Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397; Pezzi CM, 2007, ANN SURG ONCOL, V14, P166, DOI 10.1245/s10434-006-9124-7; Pfister BE, 2001, BIOCHEM BIOPH RES CO, V286, P268, DOI 10.1006/bbrc.2001.5377; Reinholz MM, 2002, BREAST CANCER RES TR, V74, P255, DOI 10.1023/A:1016339120506; Reis JS, 2003, APPL IMMUNOHISTO M M, V11, P1, DOI 10.1097/00022744-200303000-00001; ROSAI J, 2004, ROSAI ACKERMANS SURG, P1828; Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011; Saika S, 2003, INVEST OPHTH VIS SCI, V44, P2094, DOI 10.1167/iovs.02-1059; Siddiq F, 2004, LUNG CANCER, V45, P197, DOI 10.1016/j.lungcan.2004.01.020; Soda H, 1998, ANTI-CANCER DRUG, V9, P327, DOI 10.1097/00001813-199804000-00006; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wilson CA, 2004, BREAST CANCER RES, V6, P192, DOI 10.1186/bcr917; Xu X, 2005, DEV DYNAM, V232, P75, DOI 10.1002/dvdy.20197; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhuang ZP, 1997, MODERN PATHOL, V10, P354	38	158	165	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7859	7871		10.1038/sj.onc.1210593	http://dx.doi.org/10.1038/sj.onc.1210593			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17603561	Green Published			2022-12-25	WOS:000252163500004
J	Zanardi, A; Ferrari, R; Leo, G; Maskos, U; Changeux, JP; Zoli, M				Zanardi, Alessio; Ferrari, Rosaria; Leo, Giuseppina; Maskos, Uwe; Changeux, Jean-Pierre; Zoli, Michele			Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment	FASEB JOURNAL			English	Article						nicotinic subunit knockout mice; quinolinic acid; Morris water maze; fear conditioning; hippocampus	ACETYLCHOLINE-RECEPTORS; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; MOLECULAR-MECHANISMS; BETA-2 SUBUNIT; MICE LACKING; RISK-FACTORS; NEURODEGENERATION; DEMENTIA; STIMULATION	Pharmacological activation of nicotinic acetylcholine receptors (nAChRs) exerts neuroprotective effects in cultured neurons and the intact animal. Much less is known about a physiological protective role of nAChRs. To understand whether endogenous activation of beta 2* nAChRs contributes to the maintenance of the functional and morphological integrity of neural tissue, adult beta 2 -/- mice were subjected to in vivo challenges that cause neurodegeneration and cognitive impairment (intrahippocampal injection of the excitotoxin quinolinic acid), or neuroprotection and cognitive potentiation (2-month exposure to an enriched environment). The excitotoxic insult caused an increased deficit in the Morris water maze learning curve and increased loss of hippocampal pyramidal cells in beta 2 -/- mice. Exposure to an enriched environment improved performance in contextual and cued fear conditioning and object recognition tests in beta 2 +/+, whereas the improvement was absent in beta 2 -/- mice. In addition, beta 2 +/+, but not beta 2 -/-, mice exposed to an enriched environment showed a significant hypertrophy of the CA1/3 regions. Thus, lack of beta 2* nAChRs increased susceptibility to an excitotoxic insult and diminished the positive effects of an enriched environment. These results may be relevant to understanding the pathophysiological consequences of the marked decrease in nAChRs that occurs in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. -Zanardi, A., Ferrari, R., Leo, G., Maskos, U., Changeux, J.-P., Zoli, M. Loss of high affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment.	Univ Modena & Reggio Emilia, Interuniv Ctr Study Aging, Dept Biomed Sci, Physiol Sect, Modena, Italy; Inst Pasteur, CNRS, UA 2182 Recepteurs Cognit, F-75724 Paris, France	Universita di Modena e Reggio Emilia; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Zoli, M (corresponding author), Univ Modena & Reggio Emilia, Dept Biomed Sci, Physiol Sect, Via Campi 287, I-41100 Modena, Italy.	mzoli@unimo.it	Zoli, Michele/C-8899-2016	Zoli, Michele/0000-0002-8034-2849; leo, giuseppina/0000-0001-5972-2268	Telethon [D.105] Funding Source: Medline	Telethon(Fondazione Telethon)		Almeida OP, 2002, ADDICTION, V97, P15, DOI 10.1046/j.1360-0443.2002.00016.x; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bancroft J.D., 1996, THEORY PRACTICE HIST, VVolume 6; Caldarone BJ, 2000, NEUROPHARMACOLOGY, V39, P2779, DOI 10.1016/S0028-3908(00)00137-4; Champtiaux N, 2003, J NEUROSCI, V23, P7820; Court J, 2001, BIOL PSYCHIAT, V49, P175, DOI 10.1016/S0006-3223(00)01116-1; Court JA, 2005, NEUROPATH APPL NEURO, V31, P522, DOI 10.1111/j.1365-2990.2005.00674.x; Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006; Degroot A, 2005, NEUROREPORT, V16, P63, DOI 10.1097/00001756-200501190-00015; FANSELOW MS, 1984, BEHAV NEUROSCI, V98, P79, DOI 10.1037/0735-7044.98.1.79; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Glatt SL, 1996, NEUROEPIDEMIOLOGY, V15, P20, DOI 10.1159/000109885; Gotti C, 2006, NEUROBIOL DIS, V23, P481, DOI 10.1016/j.nbd.2006.04.005; Hayashi Takeshi, 2006, Current Alzheimer Research, V3, P351, DOI 10.2174/156720506778249498; Hellstrom-Lindahl E, 2004, NEUROBIOL DIS, V15, P351, DOI 10.1016/j.nbd.2003.11.024; Hellstrom-Lindahl E, 2000, BEHAV BRAIN RES, V113, P159, DOI 10.1016/S0166-4328(00)00210-2; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; JANSON AM, 1993, NEUROSCIENCE, V97, P15; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kihara T, 1997, ANN NEUROL, V42, P159, DOI 10.1002/ana.410420205; Kihara T, 1998, BRAIN RES, V792, P331, DOI 10.1016/S0006-8993(98)00138-3; King SL, 2003, J NEUROSCI, V23, P3837; Klink R, 2001, J NEUROSCI, V21, P1452, DOI 10.1523/JNEUROSCI.21-05-01452.2001; Kramer AF, 2004, J GERONTOL A-BIOL, V59, P940; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Letenneur L, 2004, BIOMED PHARMACOTHER, V58, P95, DOI 10.1016/j.biopha.2003.12.004; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI 10.1002/neu.10151; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Martin-Ruiz CM, 1999, J NEUROCHEM, V73, P1635, DOI 10.1046/j.1471-4159.1999.0731635.x; Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Nanri M, 1998, JPN J PHARMACOL, V78, P463, DOI 10.1254/jjp.78.463; O'Neill AB, 1998, NEUROBIOL LEARN MEM, V69, P46, DOI 10.1006/nlme.1997.3803; O'Neill MJ, 2002, CNS NEUROL DISORD-DR, V1, P399, DOI 10.2174/1568007023339166; Olney JW, 1997, ARCH NEUROL-CHICAGO, V54, P1234, DOI 10.1001/archneur.1997.00550220042012; PARK GAS, 1992, NEUROSCI LETT, V143, P259, DOI 10.1016/0304-3940(92)90278-F; Paxinos G, 2001, MOUSE BRAIN SETEREOT; PAYLOR R, 1994, BEHAV NEUROSCI, V108, P810, DOI 10.1037/0735-7044.108.4.810; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Picciotto MR, 2002, J NEUROBIOL, V53, P641, DOI 10.1002/neu.10102; Prendergast MA, 2001, NEUROSCIENCE, V102, P75, DOI 10.1016/S0306-4522(00)00450-4; Quik M, 2006, J PHARMACOL EXP THER, V316, P481, DOI 10.1124/jpet.105.094375; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Rossi FM, 2001, P NATL ACAD SCI USA, V98, P6453, DOI 10.1073/pnas.101120998; SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Tees RC, 1999, BEHAV BRAIN RES, V105, P173, DOI 10.1016/S0166-4328(99)00074-1; Vaucher E, 2002, NEUROBIOL AGING, V23, P87, DOI 10.1016/S0197-4580(01)00250-0; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; ZOLI M, 1992, MICROSC RES TECHNIQ, V21, P315, DOI 10.1002/jemt.1070210408; Zoli M, 1998, J NEUROSCI, V18, P4461; Zoli M, 1999, EMBO J, V18, P1235, DOI 10.1093/emboj/18.5.1235	55	16	18	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4028	4037		10.1096/fj.07-8260com	http://dx.doi.org/10.1096/fj.07-8260com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17622669				2022-12-25	WOS:000251283500027
J	Hurley, TD; Yang, J; Zhang, LL; Goodwin, KD; Zou, Q; Cortese, M; Dunker, AK; DePaoli-Roach, AA				Hurley, Thomas D.; Yang, Jie; Zhang, Lili; Goodwin, Kristie D.; Zou, Qin; Cortese, Marc; Dunker, A. Keith; DePaoli-Roach, Anna A.			Structural basis for regulation of protein phosphatase 1 by inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; PHOSPHORYLASE-PHOSPHATASE; CRYSTAL-STRUCTURE; SYNERGISTIC PHOSPHORYLATION; PHOSPHOPROTEIN PHOSPHATASE; ACTIVATION; KINASE; IDENTIFICATION	The functional specificity of type 1 protein phosphatases (PP1) depends on the associated regulatory/targeting and inhibitory subunits. To gain insights into the mechanism of PP1 regulation by inhibitor-2, an ancient and intrinsically disordered regulator, we solved the crystal structure of the complex to 2.5 angstrom resolution. Our studies show that, when complexed with PP1c, I-2 acquires three regions of order: site 1, residues 12-17, binds adjacent to a region recognized by many PP1 regulators; site 2, amino acids 44-56, interacts along the RVXF binding groove through an unsuspected sequence, KSQKW; and site 3, residues 130-169, forms alpha-helical regions that lie across the substrate-binding cleft. Specifically, residues 148-151 interact at the catalytic center, displacing essential metal ions, accounting for both rapid inhibition and slower inactivation of PP1c. Thus, our structure provides novel insights into the mechanism of PP1 inhibition and subsequent reactivation, has broad implications for the physiological regulation of PP1, and highlights common inhibitory interactions among phosphoprotein phosphatase family members.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	DePaoli-Roach, AA (corresponding author), 635 Barnhill Dr, Indianapolis, IN 46202 USA.	adepaoli@iupui.edu	; Cortese, Marc/G-4026-2010	HURLEY, THOMAS/0000-0002-5942-1163; Cortese, Marc/0000-0002-5903-0525	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063285, R01DK036569] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R56LM007688, R01LM007688] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK036569, R01-DK063285] Funding Source: Medline; NLM NIH HHS [LM007688-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		[Anonymous], 2004, PERS VIS RAYTR VERS; BALLOU LM, 1985, CURR TOP CELL REGUL, V27, P183; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 2003, HDB CELLULAR SIGNALI, V1, P613; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; Garner, 1999, Genome Inform Ser Workshop Genome Inform, V10, P41; Gibbons JA, 2005, J BIOL CHEM, V280, P15903, DOI 10.1074/jbc.M500871200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Helps NR, 1999, FEBS LETT, V463, P72, DOI 10.1016/S0014-5793(99)01573-2; Helps NR, 1998, FEBS LETT, V438, P131, DOI 10.1016/S0014-5793(98)01286-1; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; Huang H, 2000, J BIOMOL NMR, V17, P359, DOI 10.1023/A:1008355428294; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; JURGENSEN S, 1984, J BIOL CHEM, V259, P5864; Kirchhefer U, 2005, CARDIOVASC RES, V68, P98, DOI 10.1016/j.cardiores.2005.05.019; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Leach C, 2003, J BIOL CHEM, V278, P26015, DOI 10.1074/jbc.M300782200; Li MG, 2007, BIOCHEMISTRY-US, V46, P2380, DOI 10.1021/bi602369m; Meiselbach H, 2006, CHEM BIOL, V13, P49, DOI 10.1016/j.chembiol.2005.10.009; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Osawa Y, 1996, EUR J BIOCHEM, V242, P793, DOI 10.1111/j.1432-1033.1996.0793r.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; VANDENHEEDE JR, 1980, J BIOL CHEM, V255, P1768; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Yang J, 2005, EMBO J, V24, P1, DOI 10.1038/sj.emboj.7600496; Zambrano CA, 2004, FREE RADICAL BIO MED, V36, P1393, DOI 10.1016/j.freeradbiomed.2004.03.007; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	55	146	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28874	28883		10.1074/jbc.M703472200	http://dx.doi.org/10.1074/jbc.M703472200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17636256	hybrid			2022-12-25	WOS:000249642100062
J	Turnock, DC; Izquierdo, L; Ferguson, MAJ				Turnock, Daniel C.; Izquierdo, Luis; Ferguson, Michael A. J.			The de Novo synthesis of GDP-fucose is essential for flagellar adhesion and cell growth in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SLEEPING SICKNESS; NUCLEOTIDE SUGAR TRANSPORTERS; LEISHMANIA-MEXICANA; MANNOSE PYROPHOSPHORYLASE; GALACTOSE METABOLISM; DRUG TARGET; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS; FUNCTIONAL EXPRESSION; CRUZI EPIMASTIGOTES; CLONING	The protozoan parasite Trypanosoma brucei causes human African sleeping sickness in sub-Saharan Africa. The parasite makes several essential glycoproteins, which has led to the investigation of the sugar nucleotides and glycosyltransferases required to synthesize these structures. Fucose is a common sugar in glycoconjugates from many organisms; however, the sugar nucleotide donor GDP-fucose was only recently detected in T. brucei, and the importance of fucose metabolism in this organism is not known. In this paper, we identified the genes encoding functional GDP-fucose biosynthesis enzymes in T. brucei and created conditional null mutants of TbGMD, the gene encoding the first enzyme in the pathway from GDP-mannose to GDP-fucose, in both bloodstream form and procyclic form parasites. Under nonpermissive conditions, both life cycle forms of the parasite became depleted in GDP-fucose and suffered growth arrest, demonstrating that fucose metabolism is essential to both life cycle stages. In procyclic form parasites, flagellar detachment from the cell body was also observed under nonpermissive conditions, suggesting that fucose plays a significant role in flagellar adhesion. Fluorescence microscopy of epitope-tagged TbGMD revealed that this enzyme is localized in glycosomes, despite the absence of PTS-1 or PTS-2 target sequences.	Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), MSI-WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Izquierdo, Luis/L-9291-2015; Ferguson, Michael A. J./F-7829-2010	Izquierdo, Luis/0000-0002-3704-9874; Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust [071463] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barboza M, 2005, FEBS J, V272, P3803, DOI 10.1111/j.1742-4658.2005.04787.x; Basombrio MA, 2002, J PARASITOL, V88, P489, DOI 10.1645/0022-3395(2002)088[0489:TDOTGG]2.0.CO;2; Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; BRUN R, 1979, ACTA TROP, V36, P289; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; Davis AJ, 2004, J BIOL CHEM, V279, P12462, DOI 10.1074/jbc.M312365200; de Lederkremer RM, 2001, CURR PHARM DESIGN, V7, P1165, DOI 10.2174/1381612013397519; DEJESUS AR, 1993, J CELL SCI, V106, P1023; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; FERGUSON MAJ, 1985, BIOCHIM BIOPHYS ACTA, V842, P39, DOI 10.1016/0304-4165(85)90290-9; FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; Guther MLS, 2003, BIOCHEMISTRY-US, V42, P14532, DOI 10.1021/bi034869g; Haynes PA, 1996, GLYCOBIOLOGY, V6, P869, DOI 10.1093/glycob/6.8.869; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Jarvinen N, 2001, EUR J BIOCHEM, V268, P6458, DOI 10.1046/j.0014-2956.2001.02601.x; Kessler PS, 2005, J BIOL CHEM, V280, P9030, DOI 10.1074/jbc.M412033200; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; Ma B, 2006, GLYCOBIOLOGY, V16, p158R, DOI 10.1093/glycob/cwl040; MacRae JI, 2006, MOL BIOCHEM PARASIT, V147, P126, DOI 10.1016/j.molbiopara.2006.02.011; Maki M, 2003, GLYCOBIOLOGY, V13, P295, DOI 10.1093/glycob/cwg035; Maki M, 2002, EUR J BIOCHEM, V269, P593, DOI 10.1046/j.0014-2956.2001.02688.x; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Muramatsu T, 2004, GLYCOCONJUGATE J, V21, P41, DOI 10.1023/B:GLYC.0000043746.77504.28; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nakayama K, 2003, GLYCOBIOLOGY, V13, P673, DOI 10.1093/glycob/cwg099; Nozaki T, 1996, MOL BIOCHEM PARASIT, V82, P245, DOI 10.1016/0166-6851(96)02741-7; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; Opperdoes FR, 2006, MOL BIOCHEM PARASIT, V147, P193, DOI 10.1016/j.molbiopara.2006.02.010; Park SH, 1998, J BIOL CHEM, V273, P5685, DOI 10.1074/jbc.273.10.5685; Pastuszak I, 1998, J BIOL CHEM, V273, P30165, DOI 10.1074/jbc.273.46.30165; Pedersen LL, 2003, CELL MOL LIFE SCI, V60, P259, DOI 10.1007/s000180300021; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Rabina J, 2001, GLYCOCONJUGATE J, V18, P799, DOI 10.1023/A:1021107602535; Rocha GM, 2006, J STRUCT BIOL, V154, P89, DOI 10.1016/j.jsb.2005.11.008; Roper JR, 2005, J BIOL CHEM, V280, P19728, DOI 10.1074/jbc.M502370200; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; SCHNEIDER P, 1994, J BIOL CHEM, V269, P18332; Smith PL, 2002, J CELL BIOL, V158, P801, DOI 10.1083/jcb.200203125; Smith TK, 2004, EMBO J, V23, P4701, DOI 10.1038/sj.emboj.7600456; SNARY D, 1981, MOL BIOCHEM PARASIT, V3, P343, DOI 10.1016/0166-6851(81)90035-9; Stewart J, 2005, INT J PARASITOL, V35, P861, DOI 10.1016/j.ijpara.2005.03.008; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; Tonetti M, 2003, J BIOL CHEM, V278, P21559, DOI 10.1074/jbc.M301543200; Turnock DC, 2007, EUKARYOT CELL, V6, P1450, DOI 10.1128/EC.00175-07; Urbaniak MD, 2006, EUKARYOT CELL, V5, P1906, DOI 10.1128/EC.00156-06; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	59	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28853	28863		10.1074/jbc.M704742200	http://dx.doi.org/10.1074/jbc.M704742200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17640865	hybrid			2022-12-25	WOS:000249642100060
J	Chen, Y; Anderson, DE; Rajagopalan, M; Erickson, HP				Chen, Yaodong; Anderson, David E.; Rajagopalan, Malini; Erickson, Harold P.			Assembly dynamics of mycobacterium tuberculosis FtsZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVISION PROTEIN FTSZ; BACTERIAL-CELL-DIVISION; ESCHERICHIA-COLI; NUCLEOTIDE TURNOVER; FITTING PROGRAMS; SMALL-MOLECULE; IN-VITRO; GTP; PROTOFILAMENT; HYDROLYSIS	We have investigated the assembly of FtsZ from Mycobacterium tuberculosis (MtbFtsZ). Electron microscopy confirmed the previous observation that MtbFtsZ assembled into long, two-stranded filaments at PH 6.5. However, we found that assembly at pH 7.2 or 7.7 produced predominantly short, one-stranded protofilaments, similar to those of Escherichia coli FtsZ (EcFtsZ). Near pH 7, which is close to the pH of M. tuberculosis cytoplasm, MtbFtsZ formed a mixture of single- and two-stranded filaments. We developed a fluorescence resonance energy transfer assay to measure the kinetics of initial assembly and the dynamic properties at steady state. Assembly of MtbFtsZ reached a plateau after 60-100 s, about 10 times slower than EcFtsZ. The initial assembly kinetics were similar at pH 6.5 and 7.7, despite the striking difference in the polymer structures. Both were fit with a cooperative assembly mechanism involving a weak dimer nucleus, similar to EcFtsZ but with slower kinetics. Subunit turnover and GTPase at steady state were also about 10 times slower for MtbFtsZ than for EcFtsZ. Specifically, the half-time for subunit turnover in vitro at PH 7.7 was 42 s for MtbFtsZ compared with 5.5 s for EcFtsZ. Photo-bleaching studies in vivo showed a range of turnover half-times with an average of 25 s for MtbFtsZ as compared with 9 s for EcFtsZ.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Univ Texas Hlth Ctr, Tyler, TX 75708 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu	Chen, Yaodong/X-8923-2019; Chen, Yaodong/C-6138-2011	Anderson, David/0000-0001-9334-6438; Chen, Yaodong/0000-0002-3751-0923	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048417, R21AI064502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI048417-06A1, AI48417, AI64502, R01 AI048417, R21 AI064502] Funding Source: Medline; NIGMS NIH HHS [R01 GM066014-04, R01 GM066014, GM66014] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2004, J BACTERIOL, V186, P5775, DOI 10.1128/JB.186.17.5775-5781.2004; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P1; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; Chen YD, 2005, J BIOL CHEM, V280, P22549, DOI 10.1074/jbc.M500895200; Chen YD, 2005, BIOPHYS J, V88, P505, DOI 10.1529/biophysj.104.044149; Dang Q, 1997, TRENDS BIOCHEM SCI, V22, P317, DOI 10.1016/S0968-0004(97)01062-1; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; Dziadek J, 2002, MICROBIOL-SGM, V148, P961, DOI 10.1099/00221287-148-4-961; Dziadek J, 2003, MICROBIOL-SGM, V149, P1593, DOI 10.1099/mic.0.26023-0; Flyvbjerg H, 1996, PHYS REV E, V54, P5538, DOI 10.1103/PhysRevE.54.5538; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Huang Q, 2006, J MED CHEM, V49, P463, DOI 10.1021/jm050920y; KASHKET ER, 1982, BIOCHEMISTRY-US, V21, P5534, DOI 10.1021/bi00265a024; Leung AKW, 2004, J MOL BIOL, V342, P953, DOI 10.1016/j.jmb.2004.07.061; Lu CL, 1999, CELL STRUCT FUNCT, V24, P285, DOI 10.1247/csf.24.285; Maddox PS, 2000, NAT CELL BIOL, V2, P36, DOI 10.1038/71357; Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; Rajagopalan M, 2005, BIOCHEM BIOPH RES CO, V331, P1171, DOI 10.1016/j.bbrc.2005.03.239; Rajagopalan M, 2005, FEMS MICROBIOL LETT, V250, P9, DOI 10.1016/j.femsle.2005.06.043; Rao M, 2001, MICROBIOL-UK, V147, P1017, DOI 10.1099/00221287-147-4-1017; Redick SD, 2005, J BACTERIOL, V187, P2727, DOI 10.1128/JB.187.8.2727-2736.2005; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Tadros M, 2006, FEBS LETT, V580, P4941, DOI 10.1016/j.febslet.2006.07.083; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Wang J, 2003, J BIOL CHEM, V278, P44424, DOI 10.1074/jbc.M307625200; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Zhang Y, 2003, J ANTIMICROB CHEMOTH, V52, P56, DOI 10.1093/jac/dkg287; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	35	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27736	27743		10.1074/jbc.M703788200	http://dx.doi.org/10.1074/jbc.M703788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17644520	Green Accepted, hybrid			2022-12-25	WOS:000249455600022
J	Johnson, AR; Pavlovsky, AG; Ortwine, DF; Prior, F; Man, CF; Bornemeier, DA; Banotai, CA; Mueller, WT; Mcconnell, P; Yan, C; Baragi, V; Lesch, C; Roark, WH; Wilson, M; Datta, K; Guzman, R; Han, HK; Dyer, RD				Johnson, Adam R.; Pavlovsky, Alexander G.; Ortwine, Daniel F.; Prior, Faith; Man, Chiu-Fai; Bornemeier, Dirk A.; Banotai, Craig A.; Mueller, W. Thomas; Mcconnell, Patrick; Yan, Chunhong; Baragi, Vijay; Lesch, Charles; Roark, W. Howard; Wilson, Michael; Datta, Kaushik; Guzman, Roberto; Han, Hyo-Kyung; Dyer, Richard D.			Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CATALYTIC DOMAIN; II COLLAGEN; EXPRESSION; MMP-13; OSTEOARTHRITIS; ARTHRITIS; POTENT; CLONING; DESIGN	Matrix metalloproteinase-13 (MMP13) is a Zn2+ -dependent protease that catalyzes the cleavage of type 11 collagen, the main structural protein in articular cartilage. Excess MMP13 activity causes cartilage degradation in osteoarthritis, making this protease an attractive therapeutic target. However, clinically tested MMP inhibitors have been associated with a painful, joint-stiffening musculoskeletal side effect that may be due to their lack of selectivity. In our efforts to develop a disease-modifying osteciarthritis drug, we have discovered MMP13 inhibitors that differ greatly from previous MMP inhibitors; they do not bind to the catalytic zinc ion, they are noncompetitive with respect to substrate binding, and they show extreme selectivity for inhibiting MMP13. By structure-based drug design, we generated an orally active MMP13 inhibitor that effectively reduces cartilage damage in vivo and does not induce joint fibroplasias in a rat model of musculoskeletal syndrome side effects. Thus, highly selective inhibition of MMP13 in patients may overcome the major safety and efficacy challenges that have limited previously tested non-selective NIMP inhibitors. MMP13 inhibitors such as the ones described here will help further define the role of this protease in arthritis and other diseases and may soon lead to drugs that safely halt cartilage damage in patients.	Pfizer Global Res & Dev, Dept Inflammat Mol Sci, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Discovery Technologies, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Inflammat Pharmacol, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Inflammat Chem, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept World Wide Safety Sci, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Pharmacokinet & Drug Metab, Ann Arbor, MI 48105 USA	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer	Johnson, AR (corresponding author), Pfizer Global Res & Dev, 700 Chesterfield Pkwy, St Louis, MO 63017 USA.	adam.johnson@pfizer.com		Bornemeier, Dirk/0000-0002-2271-6240				Aranapakam V, 2003, J MED CHEM, V46, P2376, DOI 10.1021/jm0205550; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bluteau G, 2002, BIORHEOLOGY, V39, P247; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Chen JM, 2000, J AM CHEM SOC, V122, P9648, DOI 10.1021/ja001547g; Clark IM, 2003, EXPERT OPIN THER TAR, V7, P19, DOI 10.1517/14728222.7.1.19; Drummond AH, 1999, ANN NY ACAD SCI, V878, P228, DOI 10.1111/j.1749-6632.1999.tb07688.x; Engel CK, 2005, CHEM BIOL, V12, P181, DOI 10.1016/j.chembiol.2004.11.014; Freemont AJ, 1999, ANN RHEUM DIS, V58, P357, DOI 10.1136/ard.58.6.357; Janusz MJ, 2002, OSTEOARTHR CARTILAGE, V10, P785, DOI 10.1053/joca.2002.0823; Joronen K, 2004, ANN RHEUM DIS, V63, P656, DOI 10.1136/ard.2003.009720; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lang R, 2001, J MOL BIOL, V312, P731, DOI 10.1006/jmbi.2001.4954; Leatherbarrow RJ, 2005, GRAFIT VERSION 5; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Milner JM, 2003, ARTHRITIS RHEUM-US, V48, P1057, DOI 10.1002/art.10873; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564; O'Brien PM, 2000, J MED CHEM, V43, P156, DOI 10.1021/jm9903141; Otterness IG, 1999, MATRIX BIOL, V18, P331, DOI 10.1016/S0945-053X(99)00026-8; OTWINOWSKI Z, 2000, METHOD ENZYMOL, V28, P235; Pavlovsky AG, 1999, PROTEIN SCI, V8, P1455, DOI 10.1110/ps.8.7.1455; Peterson JT, 2002, DRUG DEVELOP RES, V55, P29, DOI 10.1002/ddr.10032; PROCKOP DJ, 1960, ANAL BIOCHEM, V1, P228, DOI 10.1016/0003-2697(60)90050-6; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Renkiewicz R, 2003, ARTHRITIS RHEUM, V48, P1742, DOI 10.1002/art.11030; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEGEL IH, 1975, ENZYME KINETICS, P125; Skotnicki JS, 2003, CURR OPIN DRUG DISC, V6, P742; Spinale FG, 2000, CIRCULATION, V102, P1944, DOI 10.1161/01.CIR.102.16.1944; Uchinami H, 2006, HEPATOLOGY, V44, P420, DOI 10.1002/hep.21268; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WELGUS HG, 1983, J BIOL CHEM, V258, P4162; Wernicke D, 1996, J RHEUMATOL, V23, P590; Wernicke D, 2006, AUTOIMMUNITY, V39, P307, DOI 10.1080/08916930600807709; YE QZ, 1992, BIOCHEM BIOPH RES CO, V186, P143, DOI 10.1016/S0006-291X(05)80786-7; Zhang XL, 2000, J MOL BIOL, V301, P513, DOI 10.1006/jmbi.2000.3988	43	173	181	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27781	27791		10.1074/jbc.M703286200	http://dx.doi.org/10.1074/jbc.M703286200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623656	hybrid			2022-12-25	WOS:000249455600027
J	Mehta, NR; Lopez, PHH; Vyas, AA; Schnaar, RL				Mehta, Niirai R.; Lopez, Pablo H. H.; Vyas, Alka A.; Schnaar, Ronald L.			Gangliosides and Nogo receptors independently mediate myelin-associated glycoprotein inhibition of neurite outgrowth in different nerve cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CNS AXON REGENERATION; ADHESION MOLECULES; FAMILY-MEMBER; COMPLEX; GROWTH; MAG; RHO; LIGANDS; SIGNAL; BRAIN	In the injured nervous system, myelin-associated glycoprotein (MAG) on residual myelin binds to receptors on axons, inhibits axon outgrowth, and limits functional recovery. Conflicting reports identify gangliosides (GD1a and GT1b) and glycosylphosphatidylinositol-anchored Nogo receptors (NgRs) as exclusive axonal receptors for MAG. We used enzymes and pharmacological agents to distinguish the relative roles of gangliosides and NgRs in MAG-mediated inhibition of neurite outgrowth from three nerve cell types, dorsal root ganglion neurons (DRGNs), cerebellar granule neurons (CGNs), and hippocampal neurons. Primary rat neurons were cultured on control substrata and substrata adsorbed with full-length native MAG extracted from purified myelin. The receptors responsible for MAG inhibition of neurite outgrowth varied with nerve cell type. In DRGNs, most of the MAG inhibition was via NgRs, evidenced by reversal of inhibition by phosphatidylinositol-specific phospholipase C (PI-PLC), which cleaves glycosylphosphatidylinositol anchors, or by NEP1-40, a peptide inhibitor of NgR. A smaller percentage of MAG inhibition of DRGN outgrowth was via gangliosides, evidenced by partial reversal by addition of sialidase to cleave GDla and GT1b or by P4, an inhibitor of ganglioside biosynthesis. Combining either PI-PLC and sialiclase or NEP1-40 and P4 was additive. In contrast to DRGNs, in CGNs MAG inhibition was exclusively via gangliosides, whereas inhibition of hippocampal neuron outgrowth was mostly reversed by sialidase or P4 and only modestly reversed by PI-PLC or NEP1-40 in a nonadditive fashion. A soluble proteolytic fragment of native MAG, dMAG, also inhibited neurite outgrowth. In DRGNs, dMAG inhibition was exclusively NgR-dependent, whereas in CGNs it was exclusively ganglioside-dependent. An inhibitor of Rho kinase reversed MAG-mediated inhibition in all nerve cells, whereas a peptide inhibitor of the transducer p75(NTR) had cell-specific effects quantitatively similar to NgR blockers. Our data indicate that MAG inhibits axon outgrowth via two independent receptors, gangliosides and NgRs.	Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Schnaar, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu	Schnaar, Ronald L/S-8967-2016; López, Pablo/GXA-3179-2022	Schnaar, Ronald L/0000-0002-7701-5484; 	NIGMS NIH HHS [T32GM008763] Funding Source: Medline; NINDS NIH HHS [R37NS037096, R37 NS037096-26, R37 NS037096] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS037096] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE A, 1995, J LIPID RES, V36, P611; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; Fujitani M, 2005, J NEUROCHEM, V94, P15, DOI 10.1111/j.1471-4159.2005.03121.x; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Heffer-Lauc M, 2005, BBA-MOL CELL BIOL L, V1686, P200, DOI 10.1016/j.bbalip.2004.10.002; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Lauren J, 2007, J BIOL CHEM, V282, P5715, DOI 10.1074/jbc.M609797200; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li RX, 1998, GLYCOBIOLOGY, V8, P597, DOI 10.1093/glycob/8.6.597; Li WW, 2004, J BIOL CHEM, V279, P43780, DOI 10.1074/jbc.M401803200; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Lunn MPT, 2000, J NEUROCHEM, V75, P404, DOI 10.1046/j.1471-4159.2000.0750404.x; Marcus J, 2002, J CELL BIOL, V156, P567, DOI 10.1083/jcb.200111047; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Moustafa I, 2004, J BIOL CHEM, V279, P40819, DOI 10.1074/jbc.M404965200; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Pan BH, 2005, EXP NEUROL, V195, P208, DOI 10.1016/j.expneurol.2005.04.017; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; Powell SK, 1997, J NEUROBIOL, V32, P223, DOI 10.1002/(SICI)1097-4695(199702)32:2<223::AID-NEU7>3.0.CO;2-A; Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; SATO S, 1984, ANN NEUROL, V15, P264, DOI 10.1002/ana.410150310; Schnaar RL, 2004, ARCH BIOCHEM BIOPHYS, V426, P163, DOI 10.1016/j.abb.2004.02.019; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Spencer T, 2003, CURR OPIN NEUROBIOL, V13, P133, DOI 10.1016/S0959-4388(03)00012-6; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; Tang S, 2001, MOL CELL NEUROSCI, V18, P259, DOI 10.1006/mcne.2001.1020; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Venkatesh K, 2007, J CELL BIOL, V177, P393, DOI 10.1083/jcb.200702102; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	54	67	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27875	27886		10.1074/jbc.M704055200	http://dx.doi.org/10.1074/jbc.M704055200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640868	Green Accepted, hybrid			2022-12-25	WOS:000249455600036
J	Bao, S; Li, Y; Lei, X; Wohltmann, M; Jin, W; Bohrer, A; Semenkovich, CF; Ramanadham, S; Tabas, I; Turk, J				Bao, Shunzhong; Li, Yankun; Lei, Xiaoyong; Wohltmann, Mary; Jin, Wu; Bohrer, Alan; Semenkovich, Clay F.; Ramanadham, Sasanka; Tabas, Ira; Turk, John			Attenuated free cholesterol loading-induced apoptosis but preserved phospholipid composition of peritoneal macrophages from mice that do not express group VIA phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ARACHIDONIC-ACID RELEASE; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; MECHANISM-BASED DISCRIMINATION; ENDOPLASMIC-RETICULUM STRESS; INSULIN SECRETORY RESPONSES; PANCREATIC-ISLETS EXPRESS; FAS-MEDIATED APOPTOSIS; VASCULAR SMOOTH-MUSCLE; ELECTROSPRAY-IONIZATION; P388D(1) MACROPHAGES	Mouse macrophages undergo ER stress and apoptosis upon free cholesterol loading (FCL). We recently generated iPLA2 beta-null mice, and here we demonstrate that iPLA(2)beta- null macrophages have reduced sensitivity to FCL-induced apoptosis, although they and wild-type (WT) cells exhibit similar increases in the transcriptional regulator CHOP. iPLA(2)beta-null macrophages are also less sensitive to apoptosis induced by the sarcoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin and the scavenger receptor A ligand fucoidan, and restoring iPLA(2)beta expression with recombinant adenovirus increases apoptosis toward WT levels. WT and iPLA2 beta-null macrophages incorporate [H-3] arachidonic acid ([H-3] AA]) into glycerophosphocholine lipids equally rapidly and exhibit identical zymosan-induced, cPLA2 beta-catalyzed [H-3] AA release. In contrast, although WT macrophages exhibit robust [H-3] AA release upon FCL, this is attenuated in iPLA(2)beta-null macrophages and increases toward WT levels upon restoring iPLA(2)beta expression. Recent reports indicate that iPLA(2)beta modulates mitochondrial cytochrome c release, and we find that thapsigargin and fucoidan induce mitochondrial phospholipid loss and cytochrome c release into WT macrophage cytosol and that these events are blunted in iPLA(2)beta-null cells. Immunoblotting studies indicate that iPLA(2)beta associates with mitochondria in macrophages subjected to ER stress. AA incorporation into glycerophosphocholine lipids is unimpaired in iPLA(2)beta-null macrophages upon electrospray ionization-tandem mass spectrometry analyses, and their complex lipid composition is similar to WT cells. These findings suggest that iPLA(2)beta participates in ER stress-induced macrophage apoptosis caused by FCL or thapsigargin but that deletion of iPLA(2)beta does not impair macrophage arachidonate incorporation or phospholipid composition.	Washington Univ, Sch Med, Div Endocrinol Metabol & Lipid Res, St Louis, MO 63110 USA; Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat, New York, NY 10032 USA; Columbia Univ, Dept Cell Biol, New York, NY 10032 USA	Washington University (WUSTL); Columbia University; Columbia University; Columbia University	Turk, J (corresponding author), Washington Univ, Sch Med, Div Endocrinol Metabol & Lipid Res, Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	jturk@wustl.edu		Semenkovich, Clay/0000-0003-1163-1871	NCRR NIH HHS [P41 RR000954-30, P41 RR000954, P41 RR 00954] Funding Source: Medline; NHLBI NIH HHS [P01 HL057278, P01 HL 57278] Funding Source: Medline; NIDDK NIH HHS [R37 DK034388, P60 DK 20579, P60 DK020579-269005, P60 DK020579, P30 DK056341, P30 DK056341-07, P30 DK056341-06, R37 DK 34388, P30 DK 56341, R37 DK034388-23, P30 DK056341-069003] Funding Source: Medline; NIGMS NIH HHS [P41 GM103422] Funding Source: Medline; PHS HHS [R01 69455] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388, P60DK020579, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103422] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 2003, J IMMUNOL, V170, P5276, DOI 10.4049/jimmunol.170.10.5276; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Balsinde J, 2002, BIOCHEM J, V364, P695, DOI 10.1042/BJ20020142; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; Bao SZ, 2006, J BIOL CHEM, V281, P187, DOI 10.1074/jbc.M509105200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Barrett LE, 2006, P NATL ACAD SCI USA, V103, P5155, DOI 10.1073/pnas.0510477103; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Broekemeier KM, 2002, BIOCHEMISTRY-US, V41, P7771, DOI 10.1021/bi020157z; Brustovetsky T, 2005, J NEUROCHEM, V94, P980, DOI 10.1111/j.1471-4159.2005.03248.x; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; Gadd ME, 2006, J BIOL CHEM, V281, P6931, DOI 10.1074/jbc.M510845200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Guo ZH, 2003, J BIOL CHEM, V278, P1856, DOI 10.1074/jbc.M211075200; HALLBERG A, 1984, BIOCHIM BIOPHYS ACTA, V796, P328, DOI 10.1016/0005-2760(84)90134-6; Han XL, 2006, J AM SOC MASS SPECTR, V17, P264, DOI 10.1016/j.jasms.2005.11.003; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hsu FF, 2003, J MASS SPECTROM, V38, P752, DOI 10.1002/jms.491; Hsu FF, 1998, J AM SOC MASS SPECTR, V9, P516, DOI 10.1016/S1044-0305(98)00012-9; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; Hsu FF, 2003, J AM SOC MASS SPECTR, V14, P352, DOI 10.1016/S1044-0305(03)00064-3; Hyoda K, 2006, BIOCHEM BIOPH RES CO, V340, P286, DOI 10.1016/j.bbrc.2005.12.007; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuwae T, 1997, BBA-LIPID LIPID MET, V1344, P74, DOI 10.1016/S0005-2760(96)00135-X; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; Miyaji M, 2005, J EXP MED, V202, P249, DOI 10.1084/jem.20041685; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; MURPHY RC, 1990, METHOD ENZYMOL, V187, P90; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Perez R, 2004, J BIOL CHEM, V279, P40385, DOI 10.1074/jbc.M402562200; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; QIU ZH, 1993, J BIOL CHEM, V268, P24506; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ramanadham S, 2003, BIOCHEMISTRY-US, V42, P13929, DOI 10.1021/bi034843p; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; Ramanadham S, 2000, BBA-MOL CELL BIOL L, V1484, P251, DOI 10.1016/S1388-1981(00)00022-6; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Seegers HC, 2002, J PHARMACOL EXP THER, V302, P918, DOI 10.1124/jpet.302.3.918; Seimon TA, 2006, P NATL ACAD SCI USA, V103, P19794, DOI 10.1073/pnas.0609671104; Seleznev K, 2006, J BIOL CHEM, V281, P22275, DOI 10.1074/jbc.M604330200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Song HW, 2004, J AM SOC MASS SPECTR, V15, P1780, DOI 10.1016/j.jasms.2004.08.012; Song K, 2005, MOL ENDOCRINOL, V19, P504, DOI 10.1210/me.2004-0169; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Vivekananda J, 2001, AM J PHYSIOL-LUNG C, V281, pL98, DOI 10.1152/ajplung.2001.281.1.L98; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Wang ZP, 2005, J BIOL CHEM, V280, P6840, DOI 10.1074/jbc.M405287200; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023; Williams SD, 2000, J LIPID RES, V41, P1585; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yamaoka S, 2004, J BIOL CHEM, V279, P18688, DOI 10.1074/jbc.M401205200; Yang HC, 1999, J NEUROCHEM, V73, P1278, DOI 10.1046/j.1471-4159.1999.0731278.x; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	103	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27100	27114		10.1074/jbc.M701316200	http://dx.doi.org/10.1074/jbc.M701316200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627946	Green Accepted, hybrid			2022-12-25	WOS:000249304900051
J	Chew, V; Lam, KP				Chew, Valerie; Lam, Kong-Peng			Leupaxin negatively regulates B cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PAXILLIN LD MOTIFS; LYN-DEFICIENT MICE; ANTIGEN RECEPTOR; KINASE LYN; LIPID RAFTS; PTP-PEST; IL-2 EXPRESSION; ADAPTER PROTEIN; DOWN-REGULATION	The role of the paxillin superfamily of adaptor proteins in B cell antigen receptor (BCR) signaling has not been studied previously. We show here that leupaxin (LPXN), a member of this family, was tyrosine-phosphorylated and recruited to the plasma membrane of human BJAB lymphoma cells upon BCR stimulation and that it interacted with Lyn (a critical Src family tyrosine kinase in BCR signaling) in a BCR-induced manner. LPXN contains four leucine-rich sequences termed LD motifs, and serial truncation and specific domain deletion of LPXN indicated that its LD3 domain is involved in the binding of Lyn. Of a total of 11 tyrosine sites in LPXN, we mutated Tyr(22), Tyr(72), Tyr(198), and Tyr(257) to phenylalanine and demonstrated that LPXN was phosphorylated by Lyn only at Tyr(72) and that this tyrosine site is proximal to the LD3 domain. The overexpression of LPXN in mouse A20 B lymphoma cells led to the suppression of BCR-induced activation of JNK, p38 MAPK, and, to a lesser extent, Akt, but not ERK and NF kappa B, suggesting that LPXN can selectively repress BCR signaling. We further show that LPXN suppressed the secretion of interleukin-2 by BCR-activated A20 B cells and that this inhibition was abrogated in the Y72F LPXN mutant, indicating that the phosphorylation of Tyr(72) is critical for the biological function of LPXN. Thus, LPXN plays an inhibitory role in BCR signaling and B cell function.	Singapore Immunol Network, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN)	Lam, KP (corresponding author), Singapore Immunol Network, Lab 6-15,61 Biopolis Dr, Singapore 138673, Singapore.	lam_kong_peng@immunol.a-star.edu.sg	Lam, Kong-Peng/G-5374-2012	Lam, Kong-Peng/0000-0002-1316-4333				Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Cantrell D, 2002, SEMIN IMMUNOL, V14, P19, DOI 10.1006/smim.2001.0338; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Davidson D, 2001, EMBO J, V20, P3414, DOI 10.1093/emboj/20.13.3414; DeFranco AL, 1995, ANN NY ACAD SCI, V766, P195, DOI 10.1111/j.1749-6632.1995.tb26662.x; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gary-Gouy H, 2002, J IMMUNOL, V168, P232, DOI 10.4049/jimmunol.168.1.232; Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Ishino M, 2000, FEBS LETT, V474, P179, DOI 10.1016/S0014-5793(00)01597-0; Jhun BS, 2006, BIOCHEM BIOPH RES CO, V351, P986, DOI 10.1016/j.bbrc.2006.10.138; Kabak S, 2002, MOL CELL BIOL, V22, P2524, DOI 10.1128/MCB.22.8.2524-2535.2002; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; Motoda K, 2000, IMMUNOLOGY, V100, P370, DOI 10.1046/j.1365-2567.2000.00046.x; Ng CH, 2007, BLOOD, V110, P259, DOI 10.1182/blood-2006-10-055194; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Perchonock CE, 2006, MOL CELL BIOL, V26, P6005, DOI 10.1128/MCB.02067-05; Plas DR, 1998, J MOL MED-JMM, V76, P589, DOI 10.1007/s001090050254; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Rathore VB, 2007, BIOCHEM J, V403, P275, DOI 10.1042/BJ20061618; Robson JD, 2004, MOL CELL BIOL, V24, P2332, DOI 10.1128/MCB.24.6.2332-2343.2004; Romanova LY, 2004, J CELL SCI, V117, P3759, DOI 10.1242/jcs.01206; Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC2288, DOI 10.1152/ajpcell.00503.2006; Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC581, DOI 10.1152/ajpcell.00636.2005; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tsubata T, 2001, Int Rev Immunol, V20, P675, DOI 10.3109/08830180109045584; Tumbarello DA, 2002, FEBS LETT, V513, P114, DOI 10.1016/S0014-5793(01)03244-6; Watanabe N, 2005, MOL CELL BIOCHEM, V269, P13, DOI 10.1007/s11010-005-2149-6; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Xu YK, 2005, IMMUNITY, V22, P9, DOI 10.1016/j.immuni.2004.12.004; YAMAMOTO T, 1993, IMMUNOL REV, V132, P187, DOI 10.1111/j.1600-065X.1993.tb00843.x; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yamasaki S, 2004, SEMIN IMMUNOL, V16, P421, DOI 10.1016/j.smim.2004.08.021; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; Yu TC, 2004, ACTA BIOCH BIOPH SIN, V36, P741, DOI 10.1093/abbs/36.11.741; Zhang J, 2000, MOL CARCINOGEN, V27, P177, DOI 10.1002/(SICI)1098-2744(200003)27:3<177::AID-MC4>3.3.CO;2-J	56	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27181	27191		10.1074/jbc.M704625200	http://dx.doi.org/10.1074/jbc.M704625200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640867	hybrid			2022-12-25	WOS:000249304900059
J	Dinnen, RD; Drew, L; Petrylak, DP; Mao, YH; Cassai, N; Szmulewicz, J; Brandt-Rauf, P; Fine, RL				Dinnen, Richard D.; Drew, Lisa; Petrylak, Daniel P.; Mao, Yuehua; Cassai, Nicholas; Szmulewicz, Joseph; Brandt-Rauf, Paul; Fine, Robert L.			Activation of targeted necrosis by a p53 peptide - A novel death pathway that circumvents apoptotic resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; C-TERMINAL PEPTIDE; MUTANT P53; BCL-2; MITOCHONDRIA; SUPEROXIDE; INDUCTION; GROWTH; GENE	Cancer cells escape apoptosis by intrinsic or acquired mechanisms of drug resistance. An alternative strategy to circumvent resistance to apoptosis could be through redirection into other death pathways, such as necrosis. However, necrosis is a nonspecific, nontargeted process resulting in cell lysis and inflammation of both cancer and normal cells and is therefore not a viable alternative. Here, we report that a C-terminal peptide of p53, called p53p-Ant, induced targeted necrosis only in multiple mutant p53 human prostate cancer lines and not normal cells, because the mechanism of cytotoxicity by p53p-Ant is dependent on the presence of high levels of mutant p53. Topotecan-and paclitaxel-resistant prostate cancer lines were as sensitive to p53p-Ant-induced targeted necrosis as parental lines. A massive loss of ATP pools and intracellular generation of reactive oxygen species was involved in the mechanism of targeted necrosis, which was inhibited by O-2(center dot-) scavengers. We hypothesize that targeted necrosis by p53p-Ant is dependent on mutant p53, is mediated by O-2(center dot-) loss and ATP, and can circumvent chemotherapy resistance to apoptosis. Targeted necrosis, as an alternative pathway for selective killing of cancer cells, may overcome the problems of nonspecificity in utilizing the necrotic pathway.	Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Mailman Sch Publ Hlth, Dept Environm Hlth, New York, NY 10032 USA; Suny Downstate Med Ctr, Harbor Vet Affairs Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11203 USA	Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Fine, RL (corresponding author), Columbia Univ, Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, 650 W 168th St,BB 20-05, New York, NY 10032 USA.	rlf20@columbia.edu			PHS HHS [R01 85828] Funding Source: Medline; NIOSH CDC HHS [R01 OH 07590] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH007590] Funding Source: NIH RePORTER	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NIOSH CDC HHS; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Chen MW, 2002, ONCOGENE, V21, P7861, DOI 10.1038/sj.onc.1205991; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DiPaola RS, 1999, SEMIN ONCOL, V26, P112; Do TN, 2003, ONCOGENE, V22, P1431, DOI 10.1038/sj.onc.1206258; EFFERT PJ, 1992, J UROLOGY, V147, P789, DOI 10.1016/S0022-5347(17)37387-1; Eguchi Y, 1997, CANCER RES, V57, P1835; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Haldar S, 1996, CANCER RES, V56, P1253; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; Howell SB, 2000, MOL UROL, V4, P225; Hyer ML, 2002, CANCER BIOL THER, V1, P401, DOI 10.4161/cbt.1.4.15; ISAACS WB, 1991, CANCER RES, V51, P4716; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li Y, 2005, INT J CANCER, V115, P55, DOI 10.1002/ijc.20838; Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1; MacGrogan D, 1997, SEMIN CANCER BIOL, V8, P11, DOI 10.1006/scbi.1997.0048; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Miyake H, 2003, ONCOL REP, V10, P469; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Prabhakaran K, 2004, TOXICOL APPL PHARM, V195, P194, DOI 10.1016/j.taap.2003.11.012; RAFFO AJ, 1995, CANCER RES, V55, P4438; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Rokhlin OW, 1998, CANCER RES, V58, P5870; Schomber T, 2004, BLOOD, V103, P4511, DOI 10.1182/blood-2003-07-2397; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Senatus PB, 2006, MOL CANCER THER, V5, P20, DOI 10.1158/1535-7163.MCT-05-0181; Shih CM, 2004, J CELL BIOCHEM, V91, P384, DOI 10.1002/jcb.10761; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Urasaki Y, 2001, CANCER RES, V61, P1964; Wang LG, 2001, CANCER RES, V61, P7544	38	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26675	26686		10.1074/jbc.M701864200	http://dx.doi.org/10.1074/jbc.M701864200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636258	hybrid			2022-12-25	WOS:000249304900006
J	Goto, T; Abe, Y; Kakuta, Y; Takeshita, K; Imoto, T; Ueda, T				Goto, Takashi; Abe, Yoshito; Kakuta, Yoshimitsu; Takeshita, Kohei; Imoto, Taiji; Ueda, Tadashi			Crystal structure of tapes japonica lysozyme with substrate analogue - Structural basis of the catalytic mechanism and manifestation of its chitinase activity accompanied by quaternary structural change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE LYSOZYME; OYSTER CRASSOSTREA-VIRGINICA; INVERTEBRATE LYSOZYMES; ASTERIAS-RUBENS; HEN; ENZYME; RESOLUTION; REFINEMENT; EVOLUTION; PURIFICATION	Tapes japonica lysozyme (TJL) is classified as a member of the recently established i-type lysozyme family. In this study, we solved the crystal structure of TJL complexed with a trimer of N-acetylglucosamine to 1.6A resolution. Based on structure and mutation analyses, we demonstrated that Glu-18 and Asp-30 are the catalytic residues of TJL. Furthermore, the present findings suggest that the catalytic mechanism of TJL is a retaining mechanism that proceeds through a covalent sugar-enzyme intermediate. On the other hand, the quaternary structure in the crystal revealed a dimer formed by the electrostatic interactions of catalytic residues (Glu-18 and Asp-30) in one molecule with the positive residues at the C terminus in helix 6 of the other molecule. Gel chromatography analysis revealed that the TJL dimer remained intact under low salt conditions but that it dissociated to TJL monomers under high salt conditions. With increasing salt concentrations, the chitinase activity of TJL dramatically increased. Therefore, this study provides novel evidence that the lysozyme activity of TJL is modulated by its quaternary structure.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Higashi Ku, Fukuoka 8128592, Japan; Sojo Univ, Fac Biotechnol & Life Sci, Kumamoto 8600082, Japan	Kyushu University; Sojo University	Ueda, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128592, Japan.	ueda@phar.kyushu-u.ac.jp	Abe, Yoshito/D-8370-2012; Abe, Yoshito/AAH-6141-2021	Abe, Yoshito/0000-0002-0016-8490; Abe, Yoshito/0000-0002-0016-8490				Bachali S, 2004, EUR J BIOCHEM, V271, P237, DOI 10.1046/j.1432-1033.2003.03915.x; Bachali S, 2002, J MOL EVOL, V54, P652, DOI 10.1007/s00239-001-0061-6; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; Carballal MJ, 1997, J INVERTEBR PATHOL, V70, P96, DOI 10.1006/jipa.1997.4670; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556; DAHLQUIS.FW, 1969, BIOCHEMISTRY-US, V8, P694, DOI 10.1021/bi00830a035; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evrard C, 1998, J MOL BIOL, V276, P151, DOI 10.1006/jmbi.1997.1499; Fradkov A, 1996, FEBS LETT, V390, P145, DOI 10.1016/0014-5793(96)00644-8; FUKAMIZO T, 1982, J BIOCHEM-TOKYO, V91, P619, DOI 10.1093/oxfordjournals.jbchem.a133733; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ito Y, 1999, PROTEIN ENG, V12, P327, DOI 10.1093/protein/12.4.327; Ito Y, 1999, EUR J BIOCHEM, V259, P456, DOI 10.1046/j.1432-1327.1999.00064.x; JOLLES J, 1975, EUR J BIOCHEM, V54, P19, DOI 10.1111/j.1432-1033.1975.tb04108.x; Jolles J, 1996, J MOL EVOL, V43, P523, DOI 10.1007/BF02337523; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MCHENERY JG, 1979, COMP BIOCHEM PHYS B, V63, P25, DOI 10.1016/0305-0491(79)90228-1; Monzingo AF, 1996, NAT STRUCT BIOL, V3, P133, DOI 10.1038/nsb0296-133; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nilsen IW, 1999, FEBS LETT, V464, P153, DOI 10.1016/S0014-5793(99)01693-2; Nilsen IW, 2001, GENE, V269, P27, DOI 10.1016/S0378-1119(01)00457-7; Olsen OM, 2003, COMP BIOCHEM PHYS B, V136, P107, DOI 10.1016/S1096-4959(03)00174-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Stulik K, 2003, J BIOCHEM BIOPH METH, V56, P1, DOI 10.1016/S0165-022X(03)00053-8; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; Takeshita K, 2004, PROTEIN EXPRES PURIF, V36, P254, DOI 10.1016/j.pep.2004.05.001; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsujihata Y, 2000, J IMMUNOL, V165, P3606, DOI 10.4049/jimmunol.165.7.3606; UEDA T, 1991, J BIOCHEM-TOKYO, V110, P719, DOI 10.1093/oxfordjournals.jbchem.a123647; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WEAVER LH, 1995, J MOL BIOL, V245, P54, DOI 10.1016/S0022-2836(95)80038-7; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wicki J, 2002, METHOD ENZYMOL, V354, P84; Xue QG, 2007, CELL MOL LIFE SCI, V64, P82, DOI 10.1007/s00018-006-6386-y; Xue QG, 2004, COMP BIOCHEM PHYS B, V139, P11, DOI 10.1016/j.cbpc.2004.05.011; Yao M, 2006, ACTA CRYSTALLOGR D, V62, P189, DOI 10.1107/S0907444905038965; Yip VLY, 2004, ORG BIOMOL CHEM, V2, P2707, DOI 10.1039/b408880h	46	56	59	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27459	27467		10.1074/jbc.M704555200	http://dx.doi.org/10.1074/jbc.M704555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631496	hybrid			2022-12-25	WOS:000249304900087
J	Li, L; Kozlowski, K; Wegner, B; Rashid, T; Yeung, T; Holmes, C; Ballermann, BJ				Li, Laiji; Kozlowski, Kathy; Wegner, Binytha; Rashid, Tahsin; Yeung, Titus; Holmes, Charles; Ballermann, Barbara J.			Phosphorylation of TIMAP by glycogen synthase kinase-3 beta activates its associated protein phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ RECEPTOR; MYOSIN PHOSPHATASE; REGULATORY SUBUNIT; TARGETING SUBUNIT; ENDOTHELIAL-CELLS; SPLICING FACTORS; SMOOTH-MUSCLE; LIGHT-CHAIN; KINASE; INVITRO	TIMAP (TGF-beta 1 inhibited, membrane- associated protein) is a prenylated, endothelial cell- predominant protein phosphatase 1 (PP1c) regulatory subunit that localizes to the plasma membrane of filopodia. Here, we determined whether phosphorylation regulates TIMAP-associated PP1c function. Phosphorylation of TIMAP was observed in cells metabolically labeled with [P-32] orthophosphate and was reduced by inhibitors of protein kinase A (PKA) and glycogen synthase kinase-3 (GSK-3). In cell-free assays, immunopurified TIMAP was phosphorylated by PKA and, after PKA priming, by GSK-3 beta. Site-specific Ser to Ala substitution identified amino acid residues Ser(333)/Ser(337) as the likely PKA/ GSK- 3(+) phosphorylation site. Substitution of Ala for Val and Phe in the KVSF motif of TIMAP (TIMAP(V64A/F66A)) abolished PP1c binding and TIMAP-associated PP1c activity. TIMAP(V64A/ F66A) was hyper-phosphorylated in cells, indicating that TIMAP-associated PP1c auto-dephosphorylates TIMAP. Constitutively active GSK-3 beta stimulated phosphorylation of TIMAPV64A/ F66A, but not wild- type TIMAP, suggesting that the PKA/ GSK- 3 beta site may be subject to dephosphorylation by TIMAP-associated PP1c. Substitution of Asp or Glu for Ser at amino acid residues 333 and 337 to mimic phosphorylation reduced the PP1c association with TIMAP. Conversely, GSK-3 inhibitors augmented PP1c association with TIMAP-PP1c in cells. The 333/337 phosphomimic mutations also increased TIMAP-associated PP1c activity in vitro and against the non-integrin laminin receptor 1 in cells. Finally, TIMAP mutants with reduced PP1 cactivity strongly stimulated endothelial cell filopodia formation, an effect mimicked by the GSK-3 inhibitor LiCl. We conclude that TIMAP is a target for PKA-primed GSK-3 beta-mediated phosphorylation. This phosphorylation controls TIMAP association and activity of PP1c, in turn regulating extension of filopodia in endothelial cells.	Univ Alberta, Dept Med, Edmonton, AB T5R 0B7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T5R 0B7, Canada	University of Alberta; University of Alberta	Ballermann, BJ (corresponding author), Univ Alberta, Dept Med, CSB 11-132, Edmonton, AB T5R 0B7, Canada.	barbara.ballermann@ualberta.ca	Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381	NIDDK NIH HHS [DK50764] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050764] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLERMANN BJ, 1989, AM J PHYSIOL, V256, pC182, DOI 10.1152/ajpcell.1989.256.1.C182; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boudrez A, 2002, J BIOL CHEM, V277, P31834, DOI 10.1074/jbc.M204427200; Broek IV, 2001, BRIT J CANCER, V85, P1387, DOI 10.1054/bjoc.2001.2078; Cao WS, 2002, AM J PHYSIOL-CELL PH, V283, pC327, DOI 10.1152/ajpcell.00442.2001; Cohen PTW, 2002, J CELL SCI, V115, P241; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gebarowska D, 2002, AM J PATHOL, V160, P307, DOI 10.1016/S0002-9440(10)64374-X; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hirano Katsuya, 2004, Journal of Smooth Muscle Research, V40, P219, DOI 10.1540/jsmr.40.219; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Kim K, 2005, BIOCHEM BIOPH RES CO, V338, P1327, DOI 10.1016/j.bbrc.2005.10.089; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Shin HM, 2002, CIRC RES, V90, P546, DOI 10.1161/01.RES.0000012822.23273.EC; Skinner JA, 2001, BIOCHEM J, V356, P257, DOI 10.1042/0264-6021:3560257; Toth A, 2000, FEBS LETT, V484, P113, DOI 10.1016/S0014-5793(00)02138-4; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7; Yin SM, 2004, ARCH BIOCHEM BIOPHYS, V428, P165, DOI 10.1016/j.abb.2004.06.003; Yong J, 2006, J BIOL CHEM, V281, P31202, DOI 10.1074/jbc.M607287200	22	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25960	25969		10.1074/jbc.M703532200	http://dx.doi.org/10.1074/jbc.M703532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17609201	hybrid			2022-12-25	WOS:000249014100081
J	Prager, GW; Feral, CC; Kim, C; Han, J; Ginsberg, MH				Prager, Gerald W.; Feral, Chloe C.; Kim, Chungho; Han, Jaewon; Ginsberg, Mark H.			CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMIN BINDING; CELL-ADHESION; TALIN; ACTIVATION; TRANSDUCTION; KINASE; PROGRESSION; MODULATION; DROSOPHILA; PROTEINS	In mammals, beta 1 integrin adhesion receptors generate signals that mediate cell spreading, migration, proliferation, and survival. CD98, a heterodimeric transmembrane protein, physically associates with certain integrin beta subunit cytoplasmic domains (tails) via its heavy chain, CD98hc (SLC3A2), and loss of CD98hc impairs integrin signaling. Here we have used the lack of CD98hc interaction with the Drosophila integrin beta PS tail for a homology scanning analysis that implicated the C-terminal 8 residues of beta 3 (Thr(755)-Thr(802)) in CD98hc binding. We then identified point mutations in the beta 3 C terminus (T755K and T758M) that abolish CD98hc association and a double mutation in the corresponding residues in the beta PS tail (K839T, M842T), which resulted in gain of CD98hc interaction. Furthermore, the loss of function beta 3(T755K) mutation or the gain of function beta 3/beta PS(K839T, M842T) led to a loss or gain of integrin-mediated cell spreading, respectively. Thus, we have identified critical integrin residues required for CD98hc interaction and in doing so have shown that CD98c interaction with the integrin beta tail is required for its ability to mediate integrin signaling. These studies also provide new insights into how CD98hc may cooperate with other cytoplasmic domain binding proteins to modulate integrin functions and into the evolution of integrin signaling.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ginsberg, MH (corresponding author), Univ Calif San Diego, Dept Med, Leichtag Bldg,Rm 181,9500 Gilman Dr,Dept 0726, La Jolla, CA 92093 USA.	mhginsberg@ucsd.edu	Feral, Chloe C/O-5781-2016; Prager, Gerald/AAS-8674-2021; FERAL, Chloe/AAB-6111-2020	Feral, Chloe C/0000-0001-9756-2082; Prager, Gerald/0000-0002-7854-7781; FERAL, Chloe/0000-0001-9756-2082	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078784, P01HL031950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31950, HL078784] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NIGMS NIH HHS [U54 GM064346] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias-Salgado EG, 2005, J BIOL CHEM, V280, P29699, DOI 10.1074/jbc.M503508200; Baudoin C, 1998, GENE DEV, V12, P1202, DOI 10.1101/gad.12.8.1202; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Cai S, 2005, J CELL SCI, V118, P889, DOI 10.1242/jcs.01674; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Cohen LA, 2005, CURR CANCER DRUG TAR, V5, P629, DOI 10.2174/156800905774932798; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fenczik CA, 2001, J BIOL CHEM, V276, P8746, DOI 10.1074/jbc.M011239200; Feral CC, 2005, P NATL ACAD SCI USA, V102, P355, DOI 10.1073/pnas.0404852102; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grabbe C, 2004, DEVELOPMENT, V131, P5795, DOI 10.1242/dev.01462; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Henderson NC, 2004, J BIOL CHEM, V279, P54731, DOI 10.1074/jbc.M408700200; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kiema T, 2006, MOL CELL, V21, P337, DOI 10.1016/j.molcel.2006.01.011; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2000, J CELL SCI, V113, P3563; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Partridge AW, 2005, J BIOL CHEM, V280, P7294, DOI 10.1074/jbc.M412701200; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tsumura H, 2003, BIOCHEM BIOPH RES CO, V308, P847, DOI 10.1016/S0006-291X(03)01473-6; Uinuk-ool T, 2002, P NATL ACAD SCI USA, V99, P14356, DOI 10.1073/pnas.212527699; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wegener KL, 2007, CELL, V128, P171, DOI 10.1016/j.cell.2006.10.048; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059	43	48	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24477	24484		10.1074/jbc.M702877200	http://dx.doi.org/10.1074/jbc.M702877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17597067	hybrid			2022-12-25	WOS:000248686600075
J	van Weering, JRT; Toonen, RF; Verhage, M				van Weering, Jan R. T.; Toonen, Ruud F.; Verhage, Matthijs			The Role of Rab3a in Secretory Vesicle Docking Requires Association/Dissociation of Guanidine Phosphates and Munc18-1	PLOS ONE			English	Article								Rab3a is a small GTPase that binds selectively to secretory vesicles and switches between active, GTP-bound and inactive, GDP-bound conformations. In yeast, Rab and SM-genes interact genetically to promote vesicle targeting/fusion. We tested different Rab3a conformations and genetic interactions with the SM-gene munc18-1 on the docking function of Rab3a in mammalian chromaffin cells. We expressed Rab3a mutants locked in the GTP-or GDP-bound form in wild-type and munc18-1 null mutant cells and analyzed secretory vesicle distribution. We confirmed that wild-type Rab3a promotes vesicle docking in wild-type cells. Unexpectedly, both GTP- and GDP-locked Rab3a mutants did not promote docking. Furthermore, wildtype Rab3a did not promote docking in munc18-1 null cells and GTP- and GDP-Rab3a both decreased the amount of docked vesicles. The results show that GTP- and GDP-locked conformations do not support a Munc18-1 dependent role of Rab3a in docking. This suggests that nucleotide cycling is required to support docking and that this action of Rab3a is upstream of Munc18-1.	[van Weering, Jan R. T.; Toonen, Ruud F.; Verhage, Matthijs] Vrije Univ Amsterdam, Ctr Neurogen & Cognit Res, Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Verhage, M (corresponding author), Vrije Univ Amsterdam, Ctr Neurogen & Cognit Res, Amsterdam, Netherlands.	matthijs@cncr.vu.nl		van Weering, Jan/0000-0001-5259-4945; Toonen, Ruud/0000-0002-9900-4233; verhage, matthijs/0000-0002-6085-7503	 [ZonMW 903-42-095]		work was supported by ZonMW 903-42-095. No role of ZonMW in any of the mentioned stages of the study.	Ashery U, 1999, EUR J CELL BIOL, V78, P525, DOI 10.1016/S0171-9335(99)80017-X; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; de Wit H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000126; Leenders AGM, 2001, MOL BIOL CELL, V12, P3095, DOI 10.1091/mbc.12.10.3095; Martinez-Linares J, 2000, PROG T CHEM, V3, P3; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Nonet ML, 1997, J NEUROSCI, V17, P8061; Schluter OM, 2006, J NEUROSCI, V26, P1239, DOI 10.1523/JNEUROSCI.3553-05.2006; Schluter OM, 2004, J NEUROSCI, V24, P6629, DOI 10.1523/JNEUROSCI.1610-04.2004; Schluter OM, 2002, J BIOL CHEM, V277, P40919, DOI 10.1074/jbc.M203704200; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Star EN, 2005, J PHYSIOL-LONDON, V569, P103, DOI 10.1113/jphysiol.2005.092528; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Thiagarajan R, 2004, J PHYSIOL-LONDON, V555, P439, DOI 10.1113/jphysiol.2003.056333; Tsuboi T, 2006, J CELL SCI, V119, P2196, DOI 10.1242/jcs.02962; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	26	26	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e616	10.1371/journal.pone.0000616	http://dx.doi.org/10.1371/journal.pone.0000616			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637832	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452100006
J	Lemeer, S; Jopling, C; Naji, F; Ruijtenbeek, R; Slijper, M; Heck, AJR; den Hertog, J				Lemeer, Simone; Jopling, Chris; Naji, Faris; Ruijtenbeek, Rob; Slijper, Monique; Heck, Albert J. R.; den Hertog, Jeroen			Protein-Tyrosine Kinase Activity Profiling in Knock Down Zebrafish Embryos	PLOS ONE			English	Article								Background. Protein-tyrosine kinases (PTKs) regulate virtually all biological processes. PTKs phosphorylate substrates in a sequence-specific manner and relatively short peptide sequences determine selectivity. Here, we developed new technology to determine PTK activity profiles using peptide arrays. The zebrafish is an excellent model system to investigate signaling in the whole organism, given its wealth of genetic tools, including morpholino-mediated knock down technology. We used zebrafish embryo lysates to determine PTK activity profiles, thus providing the unique opportunity to directly compare the effect of protein knock downs on PTK activity profiles on the one hand and phenotypic changes on the other. Methodology. We used multiplex arrays of 144 distinct peptides, spotted on a porous substrate, allowing the sample to be pumped up and down, optimizing reaction kinetics. Kinase reactions were performed using complex zebrafish embryo lysates or purified kinases. Peptide phosphorylation was detected by fluorescent anti-phosphotyrosine antibody binding and the porous chips allowed semi-continuous recording of the signal. We used morpholinos to knock down protein expression in the zebrafish embryos and subsequently, we determined the effects on the PTK activity profiles. Results and Conclusion. Reproducible PTK activity profiles were derived from one-day-old zebrafiish embryos. Morpholino-mediated knock downs of the Src family kinases, Fyn and Yes, induced characteristic phenotypes and distinct changes in the PTK activity profiles. Interestingly, the peptide substrates that were less phosphorylated upon Fyn and Yes knock down were preferential substrates of purified Fyn and Yes. Previously, we demonstrated that Wnt11 knock down phenocopied Fyn/Yes knock down. Interestingly, Wnt11 knock down induced similar changes in the PTK activity profile as Fyn/Yes knock down. The control Nacre/Mitfa knock down did not affect the PTK activity profile significantly. Our results indicate that the novel peptide chip technology can be used to unravel kinase signaling pathways in vivo.	[Lemeer, Simone; Jopling, Chris; den Hertog, Jeroen] Hubrecht Inst, Utrecht, Netherlands; [Lemeer, Simone; Slijper, Monique; Heck, Albert J. R.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands; [Lemeer, Simone; Slijper, Monique; Heck, Albert J. R.] Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, Utrecht, Netherlands; [Naji, Faris; Ruijtenbeek, Rob] Pamgene Int BV, sHertogenbosch, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University; PamGene International BV	den Hertog, J (corresponding author), Hubrecht Inst, Utrecht, Netherlands.	hertog@niob.knaw.nl	Jopling, Chris/D-1728-2019; Lemeer, Simone/I-4363-2016; Heck, Albert/D-7098-2011	Heck, Albert/0000-0002-2405-4404; jopling, chris/0000-0003-0950-0063	Netherlands Proteomics Centre (NPC); Netherlands Organisation for Scientific Research (NWO); EU [HPRN-CT-2000-00085]	Netherlands Proteomics Centre (NPC); Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); EU(European Commission)	This work was supported in part by the Netherlands Proteomics Centre (NPC), an ASPASIA grant with financial aid from the Netherlands Organisation for Scientific Research (NWO) and an EU research training network (HPRN-CT-2000-00085).	Amatruda JF, 2002, CANCER CELL, V1, P229, DOI 10.1016/S1535-6108(02)00052-1; Bei YX, 2002, DEV CELL, V3, P113, DOI 10.1016/S1534-5807(02)00185-5; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Diks SH, 2004, J BIOL CHEM, V279, P49206, DOI 10.1074/jbc.M405028200; Jopling C, 2005, EMBO REP, V6, P426, DOI 10.1038/sj.embor.7400386; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1; Lowenberg M, 2005, BLOOD, V106, P1703, DOI 10.1182/blood-2004-12-4790; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Reimer U, 2002, CURR OPIN BIOTECH, V13, P315, DOI 10.1016/S0958-1669(02)00339-7; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; van Baal JWPM, 2006, CANCER RES, V66, P11605, DOI 10.1158/0008-5472.CAN-06-1370; van Beuningen R, 2001, CLIN CHEM, V47, P1931; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; WESTERFIELD M, 1995, ZEBRAFISH BOOK U; Wu Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh118; 2001, GENESIS, V31	17	44	50	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e581	10.1371/journal.pone.0000581	http://dx.doi.org/10.1371/journal.pone.0000581			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611617	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451900001
J	Yurov, YB; Iourov, IY; Vorsanova, SG; Liehr, T; Kolotii, AD; Kutsev, SI; Pellestor, F; Beresheva, AK; Demidova, IA; Kravets, VS; Monakhov, VV; Soloviev, IV				Yurov, Yuri B.; Iourov, Ivan Y.; Vorsanova, Svetlana G.; Liehr, Thomas; Kolotii, Alexei D.; Kutsev, Sergei I.; Pellestor, Franck; Beresheva, Alfia K.; Demidova, Irina A.; Kravets, Viktor S.; Monakhov, Viktor V.; Soloviev, Ilia V.			Aneuploidy and Confined Chromosomal Mosaicism in the Developing Human Brain	PLOS ONE			English	Article							IN-SITU HYBRIDIZATION; STRUCTURAL VARIATION; CELL-DEATH; NEURONS; TISSUE; PRINS	Background. Understanding the mechanisms underlying generation of neuronal variability and complexity remains the central challenge for neuroscience. Structural variation in the neuronal genome is likely to be one important mechanism for neuronal diversity and brain diseases. Large-scale genomic variations due to loss or gain of whole chromosomes ( aneuploidy) have been described in cells of the normal and diseased human brain, which are generated from neural stem cells during intrauterine period of life. However, the incidence of aneuploidy in the developing human brain and its impact on the brain development and function are obscure. Methodology/Principal Findings. To address genomic variation during development we surveyed aneuploidy/polyploidy in the human fetal tissues by advanced molecular-cytogenetic techniques at the single-cell level. Here we show that the human developing brain has mosaic nature, being composed of euploid and aneuploid neural cells. Studying over 600,000 neural cells, we have determined the average aneuploidy frequency as 1.25-1.45% per chromosome, with the overall percentage of aneuploidy tending to approach 30-35%. Furthermore, we found that mosaic aneuploidy can be exclusively confined to the brain. Conclusions/Significance. Our data indicates aneuploidization to be an additional pathological mechanism for neuronal genome diversification. These findings highlight the involvement of aneuploidy in the human brain development and suggest an unexpected link between developmental chromosomal instability, intercellural/intertissular genome diversity and human brain diseases.	[Yurov, Yuri B.; Iourov, Ivan Y.; Vorsanova, Svetlana G.; Beresheva, Alfia K.; Demidova, Irina A.; Monakhov, Viktor V.; Soloviev, Ilia V.] Russian Acad Med Sci, Natl Res Ctr Mental Hlth, Moscow, Russia; [Yurov, Yuri B.; Iourov, Ivan Y.; Vorsanova, Svetlana G.; Kolotii, Alexei D.; Beresheva, Alfia K.; Demidova, Irina A.; Kravets, Viktor S.] Inst Pediat & Children Surg, Moscow, Russia; [Liehr, Thomas] Inst Human Genet & Anthropol, Jena, Germany; [Kutsev, Sergei I.] Rostov State Med Univ, Rostov Na Donu, Russia; [Pellestor, Franck] Inst Human Genet, Montpellier, France	Russian Academy of Medical Sciences; Rostov State Medical University; Universite de Montpellier	Yurov, YB (corresponding author), Russian Acad Med Sci, Natl Res Ctr Mental Hlth, Moscow, Russia.	y_yurov@yahoo.com	Tikly, Mohammed/R-1885-2019; Vorsanova, Svetlana/I-2632-2017; Liehr, Thomas/H-2852-2019; Yurov, Yurii B/D-9051-2016; Kravets, Victor/L-4055-2017; Kutsev, Sergey I/L-3633-2018; Shiku, Hiroshi/U-7321-2019; IA, Demidova/AAA-7598-2019; Iourov, Ivan/O-7684-2014; Kolotii, Alexey/K-8178-2017	Tikly, Mohammed/0000-0001-7850-3538; Vorsanova, Svetlana/0000-0002-4869-5361; Liehr, Thomas/0000-0003-1672-3054; Yurov, Yurii B/0000-0002-9251-2286; Kravets, Victor/0000-0002-0996-3220; Kutsev, Sergey I/0000-0002-3133-8018; IA, Demidova/0000-0002-8143-7604; Iourov, Ivan/0000-0002-4134-8367; Kolotii, Alexey/0000-0002-7672-588X	INTAS [03-51-4060]; A-T Children?s Project [1060]; RGNF [060600639a]	INTAS(INTASEuropean Commission); A-T Children?s Project; RGNF	This work was supported by grant from INTAS (03-51-4060), A-T Children?s Project ( 1060) and RGNF (060600639a, Russian Federation). There is no the role of any sponsors or funders in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	BOER GJ, 1994, J NEUROL, V242, P1, DOI 10.1007/BF00920568; Cimini D, 2005, TRENDS CELL BIOL, V15, P442, DOI 10.1016/j.tcb.2005.06.008; Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Iourov IY, 2006, CURR GENOMICS, V7, P435, DOI 10.2174/138920206779116756; Iourov IY, 2006, INT REV CYTOL, V249, P143, DOI 10.1016/S0074-7696(06)49003-3; Iourov Ivan Y., 2006, V334, P123; Iourov IY, 2006, CHROMOSOME RES, V14, P223, DOI 10.1007/s10577-006-1037-6; Iourov IY, 2005, J HISTOCHEM CYTOCHEM, V53, P401, DOI 10.1369/jhc.4A6419.2005; KALOUSEK DK, 1983, SCIENCE, V221, P665, DOI 10.1126/science.6867735; Kingsbury MA, 2005, P NATL ACAD SCI USA, V102, P6143, DOI 10.1073/pnas.0408171102; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liehr T, 2002, INT J MOL MED, V9, P335; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Muotri AR, 2006, NATURE, V441, P1087, DOI 10.1038/nature04959; Pellestor Franck, 2006, V334, P151; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rakic S, 2000, EUR J NEUROSCI, V12, P2721, DOI 10.1046/j.1460-9568.2000.00153.x; Rehen SK, 2001, P NATL ACAD SCI USA, V98, P13361, DOI 10.1073/pnas.231487398; Rehen SK, 2005, J NEUROSCI, V25, P2176, DOI 10.1523/JNEUROSCI.4560-04.2005; Sharp AJ, 2006, ANNU REV GENOM HUM G, V7, P407, DOI 10.1146/annurev.genom.7.080505.115618; Watase K, 2003, NAT REV GENET, V4, P296, DOI 10.1038/nrg1045; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; Youssoufian H, 2002, NAT REV GENET, V3, P748, DOI 10.1038/nrg906; Yurov YB, 2001, BRAIN DEV-JPN, V23, pS186, DOI 10.1016/S0387-7604(01)00363-1; Yurov YB, 2005, J HISTOCHEM CYTOCHEM, V53, P385, DOI 10.1369/jhc.4A6430.2005; YUROV YB, 2007, J MED GENET, DOI DOI 10.1135/JMG.2007.049312	29	163	171	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e558	10.1371/journal.pone.0000558	http://dx.doi.org/10.1371/journal.pone.0000558			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593959	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451800004
J	Hao, H; d'Alincourt-Salazar, M; Kelley, KMM; Shatnawi, A; Mukherjee, S; Shah, YM; Ratnam, M				Hao, H.; d'Alincourt-Salazar, M.; Kelley, K. M. M.; Shatnawi, A.; Mukherjee, S.; Shah, Y. M.; Ratnam, M.			Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen	ONCOGENE			English	Article						estrogen; estrogen receptor; folate receptor; SERM; TAFII30; gene repression	NUCLEAR HORMONE-RECEPTORS; TATA-BINDING PROTEIN; BREAST-CANCER CELLS; THYROID-HORMONE; TRANSCRIPTIONAL REPRESSION; RETINOIC ACID; N-COR; EXPRESSION; ACTIVATION; COMPLEX	Estradiol (E-2) acts through the estrogen receptor ( ER) to downregulate many genes, and tamoxifen (Tam) largely reverses this repression but the underlying mechanisms are unclear. Repression of the folate receptor (FR)-alpha P4 core promoter by ER is enhanced by E-2 and reversed by Tam. This effect was unaffected by inhibition of new protein synthesis and required the E/F and the DNA-binding domains of ER without direct binding of ER to DNA. The repression by E-2/ER was not specific for either Sp1 or TATA elements but was loosely selective for the initiator and flanking sequence. Insertion of a response element or a relatively strong Sp1 cluster to recruit ER upstream of the core promoters caused a switch to activation by E-2/ER that was inhibited by Tam. In nuclear extracts, association of ER witha biotinylated core promoter fragment was promoted by E-2 but Tam blocked this effect. Repression/ de-repression of the P4 promoter and endogenous FR-alpha expression by E-2/Tam required SMRT and/ or NCoR. ER associated with the chromosomal P4 promoter and SMRT and NCoR associated with it in an ER-dependent manner; these associations were favored by E-2 but disrupted by Tam, in the short term, without changes in ER expression. TAFII30 was required for optimal P4 promoter activity and for the repressive association of ER. E-2 may thus maintain a low transcriptional status of genes by favoring direct TAFII30-dependent association of ER with the core promoter in a co-repressor complex containing SMRT and/ or NCoR; this repression is overridden in target genes containing an upstream element that strongly recruits ER. In addition to suppressing the activation of classical E-2 target genes, Tam may upregulate genes by passively dissociating the ER co-repressor complex.	[Hao, H.; d'Alincourt-Salazar, M.; Kelley, K. M. M.; Shatnawi, A.; Mukherjee, S.; Shah, Y. M.; Ratnam, M.] Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA		Ratnam, M (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, Block Hlth Sci Bldg,3035 Arlington Ave, Toledo, OH 43614 USA.	mratnam@meduohio.edu	shatnawi, Aymen/AAF-5661-2020		NCI NIH HHS [CA 80183, R01 CA080183, CA 103964, R01 CA103964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080183, R01CA103964] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Glass CK, 2000, GENE DEV, V14, P121; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hao H, 2003, BLOOD, V101, P4551, DOI 10.1182/blood-2002-10-3174; Hayashi SI, 2004, BIOMED PHARMACOTHER, V58, P1, DOI 10.1016/j.biopha.2003.09.005; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kelley KMM, 2003, CANCER RES, V63, P2820; Kershah SM, 2004, GYNECOL ONCOL, V92, P304, DOI 10.1016/j.ygyno.2003.10.007; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; McDonnell DP, 2005, CLIN CANCER RES, V11, p871S; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; Pink JJ, 1996, CANCER RES, V56, P2321; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; SAIKAWA Y, 1995, BIOCHEMISTRY-US, V34, P9951, DOI 10.1021/bi00031a018; SCHMITT M, 1995, J NEUROSCI RES, V40, P152, DOI 10.1002/jnr.490400203; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; STEINER MS, 1995, MOL ENDOCRINOL, V6, P15; Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120	42	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7872	7884		10.1038/sj.onc.1210592	http://dx.doi.org/10.1038/sj.onc.1210592			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599049				2022-12-25	WOS:000252163500005
J	Kieffer, I; Lorenzo, C; Dozier, C; Schmitt, E; Ducommun, B				Kieffer, I.; Lorenzo, C.; Dozier, C.; Schmitt, E.; Ducommun, B.			Differential mitotic degradation of the CDC25B phosphatase variants	ONCOGENE			English	Article						CDC25B phosphatase; degradation; mitosis; biosensors; FRET	CELL-CYCLE; BETA-TRCP; G(2)/M TRANSITION; AURORA-A; KEN-BOX; S-PHASE; PHOSPHORYLATION; PROTEIN; TRIGGERS; MITOSIS	CDC25 phosphatases control cell-cycle progression by dephosphorylating and activating cyclin-dependent kinases. CDC25B, one of the three members of this family in human cells, is thought to regulate initial mitotic events. CDC25B is an unstable protein whose proteasomal degradation is proposed to be controlled by beta-TrCP. Here, we have investigated the regulation of CDC25B during mitosis, using time-lapse video microscopy. We found that CDC25B expression is high during early mitosis, and that its degradation occurs after the metaphase-anaphase transition and cyclin B1 destruction. We also show that CDC25B degradation after metaphase is dependent on the integrity of the KEN-box and RRKSE motifs that are located within the alternatively spliced B domain, and that the CDC25B2 splice variant, that lacks this domain, is stable during mitosis. Furthermore, we show that the N-terminal region of CDC25B, encompassing the B domain, undergoes major conformational changes during mitosis that can be monitored by intramolecular fluorescence resonance energy transfer variation of specific CDC25B biosensors. This study demonstrates that CDC25B splice variants have differential mitotic stabilities, a feature that is likely to have major consequences on the local control of cyclin-dependent kinase-cyclin activities during mitotic progression.	[Kieffer, I.; Lorenzo, C.; Dozier, C.; Schmitt, E.; Ducommun, B.] Univ Toulouse 3, CNRS, LBCMCP UMR5088 IFR109, Inst Explorat Fonct Genomes, F-31062 Toulouse, France; [Ducommun, B.] CHU Purpan, F-40031 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP UMR5088 IFR109, Inst Explorat Fonct Genomes, 118 Route Narbonne, F-31062 Toulouse, France.	ducommun@cict.fr	DOZIER, Christine/P-1539-2014; DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2003, BIOL CELL, V95, P547, DOI 10.1016/j.biolcel.2003.08.001; Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cans C, 1999, MOL BIOL REP, V26, P53, DOI 10.1023/A:1006912105352; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Donzelli M, 2004, CELL CYCLE, V3, P469; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; Lemaire M, 2006, CELL CYCLE, V5, P1649, DOI 10.4161/cc.5.15.3006; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mirey G, 2005, CELL CYCLE, V4, P806, DOI 10.4161/cc.4.6.1716; MIYATA H, 2005, CANCER RES, V61, P3188; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Pfleger CM, 2000, GENE DEV, V14, P655; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015	40	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7847	7858		10.1038/sj.onc.1210596	http://dx.doi.org/10.1038/sj.onc.1210596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599046	Bronze			2022-12-25	WOS:000252163500003
J	Bolger, TA; Zhao, X; Cohen, TJ; Tsai, CC; Yao, TP				Bolger, Timothy A.; Zhao, Xuan; Cohen, Todd J.; Tsai, Chih-Cheng; Yao, Tso-Pang			The neurodegenerative disease protein ataxin-1 antagonizes the neuronal survival function of myocyte enhancer factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYGLUTAMINE-INDUCED DISEASE; CREB-BINDING PROTEIN; AXH DOMAIN; MEF2; IDENTIFICATION; NEUROTOXICITY; AGGREGATION; INHIBITION; REPRESSES; INTERACTS	Ataxin-1 is a neurodegenerative disorder protein whose mutant form causes spinocerebellar ataxia type-1 (SCA1). Evidence suggests that ataxin-1 may function as a transcription repressor. However, neither the importance of this putative transcriptional repression activity in neural cytotoxicity nor the transcriptional targets of ataxin-1 are known. Here we identify the MEF2-HDAC4 transcriptional complex involved in neuron survival as a target of ataxin-1. We show that ataxin-1 binds specifically to histone deacetylase-4 (HDAC4) and MEF2 and colocalizes with them in nuclear inclusion bodies. Significantly, these interactions are greatly reduced by the S776A mutation, which largely abrogates the cytotoxicity of ataxin-1. Supporting the importance of these interactions, we show that wild type ataxin-1 represses MEF2- dependent transcription, whereas the S776A mutant is less potent. Furthermore, overexpression of MEF2 can partially reverse cytotoxicity caused by ataxin-1. Our results identify the MEF2-HDAC4 complex as a target for ataxin-1 transcriptional repression activity and suggest a novel pathogenic mechanism whereby ataxin-1 sequesters and inhibits the neuronal survival factor MEF2.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Duke University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Yao, TP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	yao00001@mc.duke.edu						BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bolger TA, 2005, J NEUROSCI, V25, P9544, DOI 10.1523/JNEUROSCI.1826-05.2005; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290; Liu N, 2006, CELL, V127, P1299, DOI 10.1016/j.cell.2006.12.012; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Mizutani A, 2005, EMBO J, V24, P3339, DOI 10.1038/sj.emboj.7600785; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Orr HT, 2001, HUM MOL GENET, V10, P2307, DOI 10.1093/hmg/10.20.2307; Paulson H, 2003, NAT MED, V9, P825, DOI 10.1038/nm0703-825; Qi YP, 1997, J NEUROSCI, V17, P1217; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; STEFFAN JS, 2001, P NATL ACAD SCI USA, V413, P739; Takahashi-Fujigasaki J, 2006, NEUROPATH APPL NEURO, V32, P92, DOI 10.1111/j.1365-2990.2005.00705.x; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005	31	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29186	29192		10.1074/jbc.M704182200	http://dx.doi.org/10.1074/jbc.M704182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17646162	hybrid			2022-12-25	WOS:000249788000014
J	Thompson, D; Pusch, M; Whistler, JL				Thompson, Dawn; Pusch, Margareta; Whistler, Jennifer L.			Changes in G protein-coupled receptor sorting protein affinity regulate postendocytic targeting of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; ENDOCYTIC RECYCLING SIGNAL; BETA-2-ADRENERGIC RECEPTOR; MEMBRANE TRAFFICKING; INTERNALIZATION; RESENSITIZATION; DESENSITIZATION; IDENTIFICATION; ENDOSOMES; TOLERANCE	After activation, most G protein-coupled receptors (GPCRs) are regulated by a cascade of events involving desensitization and endocytosis. Internalized receptors can then be recycled to the plasma membrane, retained in an endosomal compartment, or targeted for degradation. The GPCR-associated sorting protein, GASP, has been shown to preferentially sort a number of native GPCRs to the lysosome for degradation after endocytosis. Here we show that a mutant beta(2) adrenergic receptor and a mutant mu opioid receptor that have previously been described as lacking "recycling signals" due to mutations in their C termini in fact bind to GASP and are targeted for degradation. We also show that a mutant dopamine D1 receptor, which has likewise been described as lacking a recycling signal, does not bind to GASP and is therefore not targeted for degradation. Together, these results indicate that alteration of receptors in their C termini can expose determinants with affinity for GASP binding and consequently target receptors for degradation.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Oakland, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Whistler, JL (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Oakland, CA 94608 USA.	Jennifer.whistler@ucsf.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH068442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015232] Funding Source: NIH RePORTER; NIDA NIH HHS [DA015232] Funding Source: Medline; NIMH NIH HHS [MH068442] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alvarez VA, 2002, J NEUROSCI, V22, P5769; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bartlett SE, 2005, P NATL ACAD SCI USA, V102, P11521, DOI 10.1073/pnas.0502418102; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carlton J, 2005, TRAFFIC, V6, P75, DOI 10.1111/j.1600-0854.2005.00260.x; Chen LW, 2003, LIFE SCI, V73, P115, DOI 10.1016/S0024-3205(03)00250-9; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Enquist J, 2007, MOL PHARMACOL, V71, P494, DOI 10.1124/mol.106.030858; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Hanyaloglu AC, 2005, EMBO J, V24, P2265, DOI 10.1038/sj.emboj.7600688; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Martini L, 2007, FASEB J, V21, P802, DOI 10.1096/fj.06-7132com; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Szeto HH, 2001, ANESTH ANALG, V93, P581, DOI 10.1097/00000539-200109000-00010; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Tappe-Theodor A, 2007, J NEUROSCI, V27, P4165, DOI 10.1523/JNEUROSCI.5648-06.2007; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Vargas GA, 2004, J BIOL CHEM, V279, P37461, DOI 10.1074/jbc.M401034200; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; VON ZM, 1992, J BIOL CHEM, V267, P3530; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308	26	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29178	29185		10.1074/jbc.M704014200	http://dx.doi.org/10.1074/jbc.M704014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17635908	hybrid			2022-12-25	WOS:000249788000013
J	Goo, SY; Han, YS; Kim, WH; Lee, KH; Park, SJ				Goo, Sung Young; Han, Yang Soo; Kim, Woo Hyang; Lee, Kyu-Ho; Park, Soon-Jung			Vibrio vulnificus IlpA-induced cytokine production is mediated by toll-like receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; BORRELIA-BURGDORFERI LIPOPROTEINS; CUTTING EDGE; EPITHELIAL-CELLS; BACTERIAL LIPOPROTEINS; MEMBRANE PROTEINS; ACTIVATION; LIPOPOLYSACCHARIDE; PATHOGENESIS; CLONING	Vibrio vulnificus is a pathogenic bacterium causing primary septicemia, which follows a classical septic shock pathway, including an overwhelming inflammatory cytokine response. In this study, we identified a putative lipoprotein of V. vulnifilcus, encoded by the i1pA gene, as one of the surface proteins that specifically reacted with the antibodies raised against outer membrane proteins of V. vulnificus. Using a mutant V. vulnificus in which its ilpA gene was knocked out, we found that ilpA is important in the production of interferon-gamma in human peripheral blood mononuclear cells. Production of tumor necrosis factor-a and interleukin-6 is also induced by the recombinant IlpA (rIlpA) in human monocytes. Lipidation of the rIlpA was observed by in vivo labeling in Escherichia coli. Experiments using the mutant IIpA, which is unable to be modified by lipidation, indicate that the lipid moiety of this protein has an essential property for cytokine production in human cells. Pretreatment of monocytes with antibodies against Toll-like receptor 2 (TLR2) inhibited production of both tumor necrosis factor-a and interleukin-6. The role of TLR2 in lIpA,-induced cytokine production was confirmed by an in vitro assay, in which only the TLR2-expressing cells showed a dramatic induction of nuclear factor-kappa B activity by rIlpA. In addition, rIlpA treatment resulted in induction of TLR2 transcription in human cell,;. In comparison with the wild type V vulnificus, the ilpA mutant showed a reduced mortality in mice. These results demonstrate that lIpA of V vulnificus functions as an immunostimulant to human cells via TLR2.	Yonsei Univ, Coll Med, Dept Environm Med Biol, Inst Trop Med,Brain Korea 21 Project, Seoul 120752, South Korea; Hankuk Univ Foreign Studies, Dept Environm Sci, Yongin 449791, South Korea	Yonsei University; Yonsei University Health System; Hankuk University Foreign Studies	Park, SJ (corresponding author), Yonsei Univ, Coll Med, Dept Environm Med Biol, Inst Trop Med,Brain Korea 21 Project, Seoul 120752, South Korea.	sjpark615@yuhs.ac.kr		Park, Soon-Jung/0000-0002-0423-1944				AISEN P, 1972, BIOCHEMISTRY-US, V11, P3461, DOI 10.1021/bi00768a021; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; BAHRANI K, 1990, BIOCHEM CELL BIOL, V68, P547, DOI 10.1139/o90-078; BLAKEWAY JM, 1979, INT J COSMETIC SCI, V1, P1, DOI 10.1111/j.1467-2494.1979.tb00197.x; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Chambaud I, 1999, TRENDS MICROBIOL, V7, P493, DOI 10.1016/S0966-842X(99)01641-8; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; ERIK SC, 2006, J INFECT DIS, V193, P849; Fan JJ, 2001, INFECT IMMUN, V69, P5943, DOI 10.1128/IAI.69.9.5943-5948.2001; Fichorova RN, 2001, INFECT IMMUN, V69, P5840, DOI 10.1128/IAI.69.9.5840-5848.2001; Fisette PL, 2003, J BIOL CHEM, V278, P46252, DOI 10.1074/jbc.M306587200; Gehring AJ, 2004, J IMMUNOL, V173, P2660, DOI 10.4049/jimmunol.173.4.2660; Goo SY, 2006, INFECT IMMUN, V74, P5586, DOI 10.1128/IAI.00171-06; GRAY LD, 1985, INFECT IMMUN, V48, P62, DOI 10.1128/IAI.48.1.62-72.1985; Harvey HA, 2002, INFECT IMMUN, V70, P5808, DOI 10.1128/IAI.70.10.5808-5815.2002; Hellman J, 2002, J BIOL CHEM, V277, P14274, DOI 10.1074/jbc.M109696200; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; HOGAN MM, 1988, J IMMUNOL, V141, P4196; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jan G, 1996, CURR MICROBIOL, V32, P38, DOI 10.1007/s002849900007; JOANNE LF, 1995, J IMMUNOL, V155, P2515; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim YR, 2003, BIOCHEM BIOPH RES CO, V304, P405, DOI 10.1016/S0006-291X(03)00613-2; KLONTZ KC, 1988, ANN INTERN MED, V109, P318, DOI 10.7326/0003-4819-109-4-318; KOTHARY MH, 1987, J GEN MICROBIOL, V133, P1783; Lee JH, 2004, INFECT IMMUN, V72, P4905, DOI 10.1128/IAI.72.8.4905-4910.2004; Linkous DA, 1999, FEMS MICROBIOL LETT, V174, P207, DOI 10.1111/j.1574-6968.1999.tb13570.x; MCPHERSON VL, 1991, MICROBIOS, V67, P141; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MILTON DL, 1992, J BACTERIOL, V174, P7235, DOI 10.1128/jb.174.22.7235-7244.1992; Muhlradt PF, 1998, INFECT IMMUN, V66, P4804; Paranjpye RN, 2005, INFECT IMMUN, V73, P1411, DOI 10.1128/IAI.73.3.1411-1422.2005; Paranjpye RN, 1998, INFECT IMMUN, V66, P5659, DOI 10.1128/IAI.66.12.5659-5668.1998; Pecora ND, 2006, J IMMUNOL, V177, P422, DOI 10.4049/jimmunol.177.1.422; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Rangel-Frausto MS, 2005, ARCH MED RES, V36, P672, DOI 10.1016/j.arcmed.2005.06.006; REED L. J., 1938, AMER JOUR HYG, V27, P493; SALGADO A, 1994, HAEMOSTASIS, V24, P132; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimizu T, 2005, J IMMUNOL, V175, P4641, DOI 10.4049/jimmunol.175.7.4641; Shin SH, 2002, FEMS IMMUNOL MED MIC, V33, P133, DOI 10.1111/j.1574-695X.2002.tb00582.x; Soler-Rodriguez AM, 2000, J IMMUNOL, V164, P2674, DOI 10.4049/jimmunol.164.5.2674; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STORM MS, 2000, MICROB INFECT, V2, P177; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; THEISEN M, 1992, INFECT IMMUN, V60, P826, DOI 10.1128/IAI.60.3.826-831.1992; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; WEIMAR W, 1985, ANTIVIR RES, V5, P49, DOI 10.1016/0166-3542(85)90014-2; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; WRIGHT AC, 1986, FEMS MICROBIOL LETT, V35, P255, DOI 10.1111/j.1574-6968.1986.tb01538.x; WU HC, 1986, CURR TOP MICROBIOL, V125, P127; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zuppardo AB, 1998, INFECT IMMUN, V66, P2601, DOI 10.1128/IAI.66.6.2601-2606.1998	61	27	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27647	27658		10.1074/jbc.M701876200	http://dx.doi.org/10.1074/jbc.M701876200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640874	hybrid			2022-12-25	WOS:000249455600012
J	Kale, S; Arjunan, P; Furey, W; Jordan, F				Kale, Sachin; Arjunan, Palaniappa; Furey, William; Jordan, Frank			A dynamic loop at the active center of the Escherichio coli pyruvate dehydrogenase complex E1 component modulates substrate utilization and chemical communication with the E2 component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIAMIN DIPHOSPHATE; REDUCTIVE ACETYLATION; MULTIENZYME COMPLEX; NUCLEOTIDE-SEQUENCE; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; 1',4'-IMINOPYRIMIDINE TAUTOMER; YEAST TRANSKETOLASE; LIPOYL DOMAINS; SUBUNIT; ESCHERICHIA-COLI-K12	Our crystallographic studies have shown that two active center loops (an inner loop formed by residues 401-413 and outer loop formed by residues 541-557) of the El component of the Escherichia coli pyruvate dehydrogenase complex become organized only on binding a substrate analog that is capable of forming a stable thiamin diphosphate-bound covalent intermediate. We showed that residue His-407 on the inner loop has a key role in the mechanism, especially in the reductive acetylation of the E. coli dihydrolipoamide transacetylase component, whereas crystallographic results showed a role of this residue in a disorder-order transformation of these two loops, and the ordered conformation gives rise to numerous new contacts between the inner loop and the active center. We present mapping of the conserved residues on the inner loop. Kinetic, spectroscopic, and crystallographic studies on some inner loop variants led us to conclude that charged residues flanking His-407 are important for stabilization/ordering of the inner loop thereby facilitating completion of the active site. The results further suggest that a disorder to order transition of the dynamic inner loop is essential for substrate entry to the active site, for sequestering active site chemistry from undesirable side reactions, as well as for communication between the El and E2 components of the E. coli pyruvate dehydrogenase multienzyme complex.	Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jordan, F (corresponding author), Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA.	frjordan@newark.rutgers.edu			NCRR NIH HHS [S10RR020932] Funding Source: Medline; NIGMS NIH HHS [GM 50380, GM61791] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR020932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061791] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 2006, J BIOL CHEM, V281, P15296, DOI 10.1074/jbc.M600656200; Baykal A, 2006, BIOORG CHEM, V34, P380, DOI 10.1016/j.bioorg.2006.09.006; Berg A, 1998, EUR J BIOCHEM, V252, P45, DOI 10.1046/j.1432-1327.1998.2520045.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fiedler E, 2001, J BIOL CHEM, V276, P16051, DOI 10.1074/jbc.M007936200; GRAHAM LD, 1989, BIOCHEMISTRY-US, V28, P1574, DOI 10.1021/bi00430a023; GUNSALUS IC, 1954, MECHANISM ENZYME ACT, P545; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan F, 2003, J AM CHEM SOC, V125, P12732, DOI 10.1021/ja0346126; KALE S, 2007, THESIS RUTGERS U NEW; Kitagawa M, 2005, DNA RES, V12, P291, DOI 10.1093/dnares/dsi012; KOIKE M, 1960, J BIOL CHEM, V235, P1924; KRISHNAMOORTHY C, 2006, ACTA CRYSTALLOGR D, V62, P1382; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; Massy V, 1963, ENZYMES, V7, P275; Nemeria N, 2005, J BIOL CHEM, V280, P21473, DOI 10.1074/jbc.M502691200; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 1998, BIOCHEMISTRY-US, V37, P911, DOI 10.1021/bi9722251; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Nemeria N, 2007, P NATL ACAD SCI USA, V104, P78, DOI 10.1073/pnas.0609973104; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YH, 2004, BIOCHEMISTRY-US, V43, P14037, DOI 10.1021/bi049027b; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; Wei W, 2003, PROTEIN EXPRES PURIF, V28, P140, DOI 10.1016/S1046-5928(02)00674-5; Wikner C, 1997, BIOCHEMISTRY-US, V36, P15643, DOI 10.1021/bi971606b; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	36	32	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28106	28116		10.1074/jbc.M704326200	http://dx.doi.org/10.1074/jbc.M704326200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635929	hybrid			2022-12-25	WOS:000249455600060
J	Cabrita, LD; Irving, JA; Pearce, MC; Whisstock, JC; Bottomley, SP				Cabrita, Lisa D.; Irving, James A.; Pearce, Mary C.; Whisstock, James C.; Bottomley, Stephen P.			Aeropin from the extremophile Pyrobaculum aerophilum bypasses the serpin misfolding trap	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ALPHA(1)-ANTITRYPSIN POLYMERIZATION; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; GUANIDINIUM CHLORIDE; FOLDING DEFECT; UNFOLDED STATE; F-HELIX; PROTEIN; STABILITY	Serpins are metastable proteinase inhibitors. Serpin metastability drives both a large conformational change that is utilized during proteinase inhibition and confers an inherent structural flexibility that renders serpins susceptible to aggregation under certain conditions. These include point mutations ( the basis of a number of important human genetic diseases), small changes in pH, and an increase in temperature. Many studies of serpins from mesophilic organisms have highlighted an inverse relationship: mutations that confer a marked increase in serpin stability compromise inhibitory activity. Here we present the first biophysical characterization of a metastable serpin from a hyperthermophilic organism. Aeropin, from the archaeon Pyrobaculum aerophilum, is both highly stable and an efficient proteinase inhibitor. We also demonstrate that because of high kinetic barriers, aeropin does not readily form the partially unfolded precursor to serpin aggregation. We conclude that stability and activity are not mutually exclusive properties in the context of the serpin fold, and propose that the increased stability of aeropin is caused by an unfolding pathway that minimizes the formation of an aggregation-prone intermediate ensemble, thereby enabling aeropin to bypass the misfolding fate observed with other serpins.	Monash Univ, Dept Biochem & Mol Biol, Brisbane, Qld 3800, Australia; Monash Univ, ARC Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia	Monash University; Monash University	Bottomley, SP (corresponding author), Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.	james.whisstock@med.monash.edu.au; steve.bottomley@med.monash.edu.au	Irving, James A/I-8467-2015; Irving, James/P-3860-2019	Irving, James/0000-0003-3204-6356; Whisstock, James/0000-0003-4200-5611; Cabrita, Lisa/0000-0003-2963-8078				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Bottomley SP, 1998, BIOCHEM BIOPH RES CO, V251, P1, DOI 10.1006/bbrc.1998.9254; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Cabrita LD, 2004, BIOCHEMISTRY-US, V43, P9834, DOI 10.1021/bi0491346; Cabrita LD, 2004, EUR BIOPHYS J BIOPHY, V33, P83, DOI 10.1007/s00249-003-0356-1; Cabrita LD, 2002, BIOCHEMISTRY-US, V41, P4575, DOI 10.1021/bi0158932; Chakravarty S, 2002, BIOCHEMISTRY-US, V41, P8152, DOI 10.1021/bi025523t; Chang WSW, 1997, PROTEIN SCI, V6, P89; Crowther DC, 2003, BIOCHEMISTRY-US, V42, P2355, DOI 10.1021/bi0259305; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Devlin GL, 2002, J MOL BIOL, V324, P859, DOI 10.1016/S0022-2836(02)01088-4; Devlin GL, 2003, J BIOL CHEM, V278, P48644, DOI 10.1074/jbc.M308376200; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; Dunstone MA, 2000, PROTEIN SCI, V9, P417; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; FANE B, 1991, J BIOL CHEM, V266, P11640; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fulton KF, 2005, J BIOL CHEM, V280, P8435, DOI 10.1074/jbc.M410206200; Gilis D, 2003, J MOL BIOL, V325, P581, DOI 10.1016/S0022-2836(02)01221-4; Greaves RB, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-18; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 2004, PROTEIN ENG DES SEL, V17, P325, DOI 10.1093/protein/gzh036; Irving JA, 2003, STRUCTURE, V11, P387, DOI 10.1016/S0969-2126(03)00057-1; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; KIM JH, 1995, J BIOL CHEM, V270, P8597, DOI 10.1074/jbc.270.15.8597; Kleiger G, 2001, BIOCHEMISTRY-US, V40, P14484, DOI 10.1021/bi011016k; Konagurthu AS, 2006, PROTEINS, V64, P559, DOI 10.1002/prot.20921; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; McHugh CA, 2004, PROTEIN SCI, V13, P2736, DOI 10.1110/ps.04897904; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; Pace C N, 1986, Methods Enzymol, V131, P266; Pearce MC, 2000, J BIOL CHEM, V275, P28513, DOI 10.1074/jbc.M004310200; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; Prasanna V, 1999, PROTEINS, V34, P356; Purkayastha P, 2005, BIOCHEMISTRY-US, V44, P2642, DOI 10.1021/bi048662e; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Suhre K, 2003, J BIOL CHEM, V278, P17198, DOI 10.1074/jbc.M301327200; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; Toth EA, 2000, J MOL BIOL, V301, P433, DOI 10.1006/jmbi.2000.3970; Tran ST, 2001, ARCH BIOCHEM BIOPHYS, V385, P322, DOI 10.1006/abbi.2000.2186; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; Whisstock JC, 2006, CURR OPIN STRUC BIOL, V16, P761, DOI 10.1016/j.sbi.2006.10.005; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363; Zhang Q, 2007, EMBO REP, V8, P658, DOI 10.1038/sj.embor.7400986	64	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26802	26809		10.1074/jbc.M705020200	http://dx.doi.org/10.1074/jbc.M705020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635906	hybrid			2022-12-25	WOS:000249304900020
J	Chen, YJ; Wang, YN; Chang, WC				Chen, Yun-Ju; Wang, Ying-Nai; Chang, Wen-Chang			ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; HISTONE ACETYLTRANSFERASE; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR P300; PROTEIN-KINASE; A431 CELLS; IN-VITRO; CBP; SP1; COMPLEX	We previously reported that the epidermal growth factor (EGF) regulates the gene expression of keratin 16 by activating the extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling which in turn enhances the recruitment of p300 to the keratin 16 promoter. The recruited p300 functionally cooperates with Sp1 and c-Jun to regulate the gene expression of keratin 16. This study investigated in detail the molecular events incurred upon p300 whereby EGF caused an enhanced interaction between p300 and Sp1. EGF apparently induced time- and dose-dependent phosphorylation of p300, both in vitro and in vivo, through the activation of ERK2. The six potential ERK2 phosphorylation sites, including three threonine and three serine residues as revealed by sequential analysis, were first identified in vitro. Confirmation of these six sites in vivo indicated that these three serine residues (Ser-2279, Ser-2315, and Ser-2366) on the C terminus of p300 were the major signaling targets of EGF. Furthermore, the C-terminal serine phosphorylation of p300 stimulated its histone acetyltransferase activity and enhanced its interaction with Sp1. These serine phosphorylation sites on p300 controlled the p300 recruitment to the keratin 16 promoter. When all three serine residues on p300 were replaced by alanine, EGF could no longer induce the gene expression of keratin 16. Taken together, these results strongly suggested that the ERK2-mediated C-terminal serine phosphorylation of p300 was a key event in the regulation of EGF-induced keratin 16 expression. These results also constituted the first report identifying the unique p300 phosphorylation sites induced by ERK2 in vivo.	Natl Cheng Kung Univ, Dept Pharmacol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 701, Taiwan; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Celplular Oncol, Houston, TX 77030 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; University of Texas System; UTMD Anderson Cancer Center	Chang, WC (corresponding author), Natl Cheng Kung Univ, Dept Pharmacol, Tainan 701, Taiwan.	wcchang@mail.ncku.edu.tw						Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Chan HM, 2001, J CELL SCI, V114, P2363; Chang WC, 2003, PROSTAG OTH LIPID M, V71, P277, DOI 10.1016/S1098-8823(03)00048-0; Chen LC, 2004, BBA-MOL CELL BIOL L, V1683, P38, DOI 10.1016/j.bbalip.2004.04.003; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P581, DOI 10.1056/NEJM199503023320907; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Gusterson RJ, 2004, INT J BIOCHEM CELL B, V36, P893, DOI 10.1016/j.biocel.2003.10.004; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Liu YW, 1997, BIOCHEM J, V324, P133, DOI 10.1042/bj3240133; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Machesney M, 1998, AM J PATHOL, V152, P1133; McClowry TL, 2002, J MED VIROL, V66, P96, DOI 10.1002/jmv.2116; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Wang YN, 2006, MOL PHARMACOL, V69, P85, DOI 10.1124/mol.105.016220; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; WETZELS RHW, 1991, AM J PATHOL, V138, P751; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zanger K, 2001, MOL CELL, V7, P551, DOI 10.1016/S1097-2765(01)00202-7	38	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27215	27228		10.1074/jbc.M700264200	http://dx.doi.org/10.1074/jbc.M700264200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623675	hybrid			2022-12-25	WOS:000249304900063
J	Kressler, D; Hock, MB; Kralli, A				Kressler, Dieter; Hock, M. Benjamin; Kralli, Anastasia			Coactivators PGC-1 beta and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTORS; N-COR; MOLECULAR DETERMINANTS; COREPRESSOR BINDING; PEPTIDE ANTAGONISTS; TISSUE-SPECIFICITY; ACTIVATION DOMAIN; STEROID-RECEPTORS; INTERACTION MOTIF; ALPHA ACTIVATION	PGC-1 beta is a transcriptional coactivator that enhances strongly and in a hormone-dependent manner the activity of the estrogen receptor alpha (ER alpha) while having only weak effects on similar steroid hormone receptors, such as ER alpha or the glucocorticoid receptor. Notably, PGC-1 beta enhances ER alpha transcriptional activity not only in response to agonist ligands, such as estradiol, but also to selective ER modulators, such as tamoxifen. Here, we dissect the molecular mechanisms underlying the ability of PGC-1 beta to act selectively on ER alpha and to promote the agonist activity of tamoxifen. We show that receptor selectivity is achieved by PGC-1 beta interactions with not just the ligand binding domain (LBD), which is highly conserved among nuclear receptors, but also the N-terminal domain and the hinge/AF-2a region of ER alpha, which are less well conserved. PGC-1 beta interacts directly with the hinge/AF-2a and LBD regions but indirectly and via the coactivator SRC-1 with the N-terminal domain. The three ER alpha surfaces and SRC-1 collectively enable efficient coactivation by PGC-1 beta. Similar ER alpha surfaces and interactions enable PGC-1 beta to coactivate transcription by tamoxifen-bound ER alpha. Surprisingly, PGC-1 beta coactivation of tamoxifen-bound ER alpha depends partially on one of the LXXLL motifs of PGC-1 beta and on Lys(362) of the ER alpha LBD (i. e. surfaces implicated in agonist-dependent interactions). Our findings suggest that tamoxifen-induced changes in the ER alpha LBD promote interactions with the coactivator PGC-1 beta, which then cooperates with SRC-1 to enable tamoxifen agonism.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Basel, Div Biochem, CH-4056 Basel, Switzerland	Scripps Research Institute; University of Basel	Kralli, A (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey PinesRd, La Jolla, CA 92037 USA.	kralli@scripps.edu	Kressler, Dieter/C-2218-2012	Kressler, Dieter/0000-0003-4855-3563	NIDDK NIH HHS [DK 064951] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064951] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Hentschke M, 2002, BIOCHEM BIOPH RES CO, V299, P872, DOI 10.1016/S0006-291X(02)02753-5; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McDonnell DP, 2001, ANN NY ACAD SCI, V949, P16; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200	56	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26897	26907		10.1074/jbc.M705596200	http://dx.doi.org/10.1074/jbc.M705596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631495	hybrid			2022-12-25	WOS:000249304900029
J	Kundu, P; Alioua, A; Stefani, E; Toro, L				Kundu, Pallob; Alioua, Abderrahmane; Stefani, Enrico; Toro, Ligia			Regulation of Mouse Slo Gene Expression - Multiple promoters, transcription start sites, and genomic action of estrogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; RNA-POLYMERASE-II; TISSUE-SPECIFIC EXPRESSION; RESPONSE ELEMENT SEQUENCE; LARGE-CONDUCTANCE; ALPHA-SUBUNIT; BETA-SUBUNIT; RECEPTOR; 17-BETA-ESTRADIOL; IDENTIFICATION	The large conductance, voltage- and Ca2+ -activated K+ channel plays key roles in diverse body functions influenced by estrogen, including smooth muscle and neural activities. Inmouse( m), estrogen up-regulates the transcript levels of its pore-forming alpha-subunit (Slo, KCNMA1), yet the underlying genomic mechanism(s) is( are) unknown. We first mapped the promoters and regulatory motifs within the mSlo 5 5 '-flanking sequence to subsequently identify genomic regions and mechanisms required for estrogen regulation. mSlo gene has at least two TATA-less promoters with distinct potencies that may direct mSlo transcription from multiple transcription start sites. These qualities mark mSlo as a prototype gene with promoter plasticity capable of generating multiple mRNAs and the potential to adapt to organismal needs. mSlo promoters contain multiple estrogen-responsive sequences, e. g. two quasi-perfect estrogen-responsive elements, ERE1 and ERE2, and Sp1 sites. Accordingly, mSlo promoter activity was highly enhanced by estrogen and blocked by estrogen antagonist ICI 182,780. When promoters are embedded in a 4.91-kb backbone, estrogen responsiveness involves a classical genomic mechanism, via ERE1 and ERE2, that may be complemented by Sp factors, particularly Sp1. Simultaneous but not individual ERE1 and ERE2 mutations caused significant loss of estrogen action. ERE2, which is closer to the proximal promoter, up-regulates this promoter via a classical genomic mechanism. ERE2 strategic position together with ERE1 and ERE2 independence and Sp contribution should ensure mSlo estrogen responsiveness. Thus, the mSlo gene seems to have uniquely evolved to warrant estrogen regulation. Estrogen-mediated mSlo genomic regulation has important implications on long term estrogenic effects affecting smooth muscle and neural functions.	Univ Calif Los Angeles, Div Mol Med, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Cardiovasc Res Labs, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kundu, P (corresponding author), Univ Calif Los Angeles, Div Mol Med, Dept Anesthesiol, BH 509A CHS,POB 957115, Los Angeles, CA 90095 USA.	pallob@ucla.edu			NHLBI NIH HHS [HL 54970] Funding Source: Medline; NICHD NIH HHS [HD 046510] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046510] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajic VB, 2004, NAT BIOTECHNOL, V22, P1467, DOI 10.1038/nbt1032; BECKER MN, 1995, J NEUROSCI, V15, P6250; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bohm RA, 2000, J EXP BIOL, V203, P693; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brenner R, 1996, J NEUROSCI, V16, P1827; Brenner R, 1996, DEV BIOL, V177, P536, DOI 10.1006/dbio.1996.0183; Burdyga T, 2005, NATURE, V437, P290, DOI 10.1038/nature04146; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Chang WM, 2000, J BIOL CHEM, V275, P3991, DOI 10.1074/jbc.275.6.3991; Chen YH, 2006, ENDOCRINOLOGY, V147, P4496, DOI 10.1210/en.2005-1655; Davuluri RV, 2001, NAT GENET, V29, P412, DOI 10.1038/ng780; Dhulipala PDK, 1999, BBA-GENE STRUCT EXPR, V1444, P254, DOI 10.1016/S0167-4781(98)00276-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong J, 2006, J BIOL CHEM, V281, P18825, DOI 10.1074/jbc.M512826200; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; Eghbali M, 2003, J BIOL CHEM, V278, P45311, DOI 10.1074/jbc.M306564200; Fleming JGW, 2006, ENDOCRINOLOGY, V147, P899, DOI 10.1210/en.2005-1120; Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458; Fukue Y, 2005, NUCLEIC ACIDS RES, V33, P3821, DOI 10.1093/nar/gki700; Gu N, 2007, J PHYSIOL-LONDON, V580, P859, DOI 10.1113/jphysiol.2006.126367; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Higgins KJ, 2006, ENDOCRINOLOGY, V147, P3285, DOI 10.1210/EN.2006-0081; Holdiman AJ, 2002, MOL CELL ENDOCRINOL, V192, P1, DOI 10.1016/S0303-7207(02)00136-3; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Jacobson D, 2003, BIOCHEM BIOPH RES CO, V303, P660, DOI 10.1016/S0006-291X(03)00408-X; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jamali K, 2003, ENDOCRINE, V20, P227, DOI 10.1385/ENDO:20:3:227; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Klinge CM, 2001, MOL CELL ENDOCRINOL, V174, P151, DOI 10.1016/S0303-7207(01)00382-3; Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356; Koos RD, 2005, ANN NY ACAD SCI, V1041, P233, DOI 10.1196/annals.1282.037; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lee MP, 2005, GENOME RES, V15, P1189, DOI 10.1101/gr.3873705; Lim CY, 2004, GENE DEV, V18, P1606, DOI 10.1101/gad.1193404; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu R, 2006, J PHYSIOL-LONDON, V570, P65, DOI 10.1113/jphysiol.2005.098913; Maston GA, 2006, ANNU REV GENOM HUM G, V7, P29, DOI 10.1146/annurev.genom.7.080505.115623; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; Ruttiger L, 2004, P NATL ACAD SCI USA, V101, P12922, DOI 10.1073/pnas.0402660101; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Sausbier M, 2004, P NATL ACAD SCI USA, V101, P9474, DOI 10.1073/pnas.0401702101; Schmid CD, 2006, NUCLEIC ACIDS RES, V34, pD82, DOI 10.1093/nar/gkj146; SCHUG J, 2003, CURRENT PROTOCOLS BI, P1; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Stokes K, 2004, J MOL ENDOCRINOL, V33, P315, DOI 10.1677/jme.1.01456; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Takai Daiya, 2003, In Silico Biology, V3, P235; Vernier-Magnin S, 2005, BBA-GENE STRUCT EXPR, V1731, P23, DOI 10.1016/j.bbaexp.2005.05.002; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Werner ME, 2005, J PHYSIOL-LONDON, V567, P545, DOI 10.1113/jphysiol.2005.093823; Yang F, 2004, J BIOL CHEM, V279, P35403, DOI 10.1074/jbc.M404055200; Zhu N, 2005, FEBS LETT, V579, P4856, DOI 10.1016/j.febslet.2005.07.069	61	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27478	27492		10.1074/jbc.M704777200	http://dx.doi.org/10.1074/jbc.M704777200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635926	hybrid			2022-12-25	WOS:000249304900089
J	Das, A; Boldogh, I; Lee, JW; Harrigan, JA; Hegde, ML; Piotrowski, J; Pinto, ND; Ramos, W; Greenberg, MM; Hazra, TK; Mitra, S; Bohr, VA				Das, Aditi; Boldogh, Istvan; Lee, Jae Wan; Harrigan, Jeanine A.; Hegde, Muralidhar L.; Piotrowski, Jason; Pinto, Nadja de Souza; Ramos, William; Greenberg, Marc M.; Hazra, Tapas K.; Mitra, Sankar; Bohr, Vilhelm A.			The human Werner syndrome protein stimulates repair of oxidative DNA base damage by the DNA glycosylase NEIL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCISION-REPAIR; MAMMALIAN-CELLS; POLYMERASE-BETA; HELICASE ACTIVITY; WRN HELICASE; POLY(ADP-RIBOSE) POLYMERASE-1; FLAP ENDONUCLEASE-1; IDENTIFICATION; 8-OXOGUANINE; ACETYLATION	The mammalian DNA glycosylase, NEIL1, specific for repair of oxidatively damaged bases in the genome via the base excision repair pathway, is activated by reactive oxygen species and prevents toxicity due to radiation. We show here that the Werner syndrome protein (WRN), a member of the RecQ family of DNA helicases, associates with NEIL1 in the early damage-sensing step of base excision repair. WRN stimulates NEIL1 in excision of oxidative lesions from bubble DNA substrates. The binary interaction between NEIL1 and WRN (K-D = 60 nM) involves C-terminal residues 288-349 of NEIL1 and the RecQ C-terminal (RQC) region of WRN, and is independent of the helicase activity WRN. Exposure to oxidative stress enhances the NEIL-WRN association concomitant with their strong nuclear co-localization. WRN-depleted cells accumulate some prototypical oxidized bases (e. g. 8-oxoguanine, FapyG, and FapyA) indicating a physiological function of WRN in oxidative damage repair in mammalian genomes. Interestingly, WRN deficiency does not have an additive effect on in vivo damage accumulation in NEIL1 knockdown cells suggesting that WRN participates in the same repair pathway as NEIL1.	NIH, NIA, LAb Mol Gerontol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21224 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Bohr, VA (corresponding author), NIH, NIA, LAb Mol Gerontol, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Souza-Pinto, Nadja C./C-3462-2013; Classen, Scott/AAY-8176-2020; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; Hegde, Muralidhar/0000-0001-7333-8123	NATIONAL CANCER INSTITUTE [R01CA081063, R01CA074954, R01CA102271, P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI062885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000727, P01AG021830, Z01AG000726] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA-074954, P01 CA 092584, R01 CA81063, R01 CA102271] Funding Source: Medline; NIAID NIH HHS [P01 AI062885] Funding Source: Medline; NIA NIH HHS [P01 AG021830, P01 AG 021803] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676, ES06676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn B, 2004, J BIOL CHEM, V279, P53465, DOI 10.1074/jbc.M409624200; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; BECKMAN M, 2006, SCI AGING KNOWLEDGE; Bhakat KK, 2006, MOL CELL BIOL, V26, P1654, DOI 10.1128/MCB.26.5.1654-1665.2006; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; BOSCHMAN GA, 1992, GENE CHROMOSOME CANC, V5, P375, DOI 10.1002/gcc.2870050413; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Das A, 2005, J BIOL CHEM, V280, P35272, DOI 10.1074/jbc.M505526200; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Doublie S, 2004, P NATL ACAD SCI USA, V101, P10284, DOI 10.1073/pnas.0402051101; Dziewulska-Szwajkowska D, 2004, COMP BIOCHEM PHYS B, V137, P115, DOI 10.1016/j.cbpc.2003.10.010; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guan X, 2007, NUCLEIC ACIDS RES, V35, P2463, DOI 10.1093/nar/gkm075; Haraguchi K, 2001, J AM CHEM SOC, V123, P8636, DOI 10.1021/ja0160952; Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hu JP, 2005, J BIOL CHEM, V280, P40544, DOI 10.1074/jbc.M508772200; Hu JS, 2005, P NATL ACAD SCI USA, V102, P18379, DOI 10.1073/pnas.0509380102; Jaruga P, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.6.e16; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Kumar A, 2006, BBA-GEN SUBJECTS, V1760, P1845, DOI 10.1016/j.bbagen.2006.08.004; Lee JW, 2005, J BIOL CHEM, V280, P39627, DOI 10.1074/jbc.M506112200; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Martin GM, 1997, PHILOS T R SOC B, V352, P1773, DOI 10.1098/rstb.1997.0161; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Mitra S, 1997, MOL CELLS, V7, P305; Mokkapati SK, 2004, BIOCHEMISTRY-US, V43, P11596, DOI 10.1021/bi049097i; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; NADA S, 1993, J BIOL CHEM, V268, P7660; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Ozgenc A, 2005, MUTAT RES-FUND MOL M, V577, P237, DOI 10.1016/j.mrfmmm.2005.03.020; Pagano G, 2005, BIOGERONTOLOGY, V6, P233, DOI 10.1007/s10522-005-2624-1; Puri N, 2003, J IMMUNOL, V171, P5345, DOI 10.4049/jimmunol.171.10.5345; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sattler U, 2003, EMBO REP, V4, P363, DOI 10.1038/sj.embor.embor796; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Szekely AM, 2005, MOL CELL BIOL, V25, P10492, DOI 10.1128/MCB.25.23.10492-10506.2005; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Vartanian V, 2006, P NATL ACAD SCI USA, V103, P1864, DOI 10.1073/pnas.0507444103; von Kobbe C, 2004, FASEB J, V18, P1970, DOI 10.1096/fj.04-1895fje; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Yannone SM, 2001, J BIOL CHEM, V276, P38242	66	91	94	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26591	10.1074/jbc.M703343200	http://dx.doi.org/10.1074/jbc.M703343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17611195	hybrid			2022-12-25	WOS:000249239600062
J	Kishii, R; Falzon, L; Yoshida, T; Kobayashi, H; Inouye, M				Kishii, Ryuta; Falzon, Liliana; Yoshida, Takeshi; Kobayashi, Hiroshi; Inouye, Masayori			Structural and functional studies of the HAMP domain of EnvZ, an osmosensing transmembrane histidine kinase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; SIGNAL-TRANSDUCTION; LINKER REGION; CHIMERIC CHEMORECEPTORS; MUTATIONAL ANALYSIS; BACILLUS-SUBTILIS; PROTEIN; SENSOR; BINDING; OMPR	The HAMP domain plays an essential role in signal transduction not only in histidine kinase but also in a number of other signal-transducing receptor proteins. Here we expressed the EnvZHAMPdomain (Arg(180)-Thr(235)) with the R218K mutation ( termed L-RK) or with LRK connected with domain A ( Arg180 Arg(289)) ( termed LARK) of EnvZ, an osmosensing transmembrane histidine kinase in Escherichia coli, by fusing it with protein S. The LRK and LARK proteins were purified after removing protein S. The CD analysis of the isolated L protein revealed that it consists of a random structure or is unstructured. This suggests that the EnvZ HAMP domain by itself is unable to form a stable structure and that this structural fragility may be important for its role in signal transduction. Interestingly the substitution of Ala(193) in the EnvZ HAMP domain with valine or leucine in Tez1A1, a chimeric protein of Tar and EnvZ, caused a constitutive OmpC phenotype. The CD analysis of LARK(A193L) revealed that this mutated HAMP domain possesses considerable secondary structures and that the thermostability of this entire LARK( A193L) became substantially lower than that of LARK or just domain A, indicating that the structure of the HAMP domain with the A193L mutation affects the stability of downstream domain A. This results in cooperative thermodenaturation of domain A with the mutated HAMP domain. These results are discussed in light of the recently solved NMR structure of the HAMP domain from a thermophilic bacterium (Hulko, M., Berndt, F., Gruber, M., Linder, J. U., Truffault, V., Schultz, A., Martin, J., Schultz, J. E., Lupas, A. N., and Coles, M. ( 2006) Cell 126, 929 - 940).	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Kyorin Pharmaceut Co Ltd, Discovery Res Labs, Tochigi 3290114, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Kyorin Pharmaceutical Co Ltd	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	inouye@umdnj.edu		Yoshida, Takeshi/0000-0003-0133-5067	NIGMS NIH HHS [GM076587A] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleman JA, 2003, J BACTERIOL, V185, P4872, DOI 10.1128/JB.185.16.4872-4882.2003; Appleman JA, 2003, J BACTERIOL, V185, P89, DOI 10.1128/JB.185.1.89-97.2003; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; Hulko M, 2006, CELL, V126, P929, DOI 10.1016/j.cell.2006.06.058; Inouye M., 2003, HISTIDINE KINASES SI, P25; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; Kristich CJ, 2004, J BACTERIOL, V186, P5950, DOI 10.1128/JB.186.17.5950-5955.2004; Kristich CJ, 2003, MOL MICROBIOL, V47, P1353, DOI 10.1046/j.1365-2958.2003.03375.x; Kumita H, 2003, BBA-PROTEINS PROTEOM, V1646, P136, DOI 10.1016/S1570-9639(02)00555-1; Ma QH, 2005, J BACTERIOL, V187, P193, DOI 10.1128/JB.187.1.193-201.2005; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; TAYLOR RK, 1983, J MOL BIOL, V166, P273, DOI 10.1016/S0022-2836(83)80085-0; TOKISHITA S, 1992, J BIOCHEM-TOKYO, V111, P707, DOI 10.1093/oxfordjournals.jbchem.a123823; Tomenius H, 2005, J BACTERIOL, V187, P7317, DOI 10.1128/JB.187.21.7317-7324.2005; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Ward SM, 2006, J BACTERIOL, V188, P3944, DOI 10.1128/JB.00117-06; WAUKAU J, 1992, J BACTERIOL, V174, P1522, DOI 10.1128/jb.174.5.1522-1527.1992; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808; Zhu Y, 2004, J BIOL CHEM, V279, P48152, DOI 10.1074/jbc.M401024200; Zhu Y, 2003, J BIOL CHEM, V278, P22812, DOI 10.1074/jbc.M300916200	38	25	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26401	26408		10.1074/jbc.M701342200	http://dx.doi.org/10.1074/jbc.M701342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17635923	hybrid			2022-12-25	WOS:000249239600045
J	Kong, L; Yu, XP; Bai, XH; Zhang, WF; Zhang, Y; Zhao, WM; Jia, JH; Tang, W; Zhou, YB; Liu, CJ				Kong, Li; Yu, Xiu-Ping; Bai, Xiao-Hui; Zhang, Wei-Fang; Zhang, Yan; Zhao, Wei-Ming; Jia, Ji-Hui; Tang, Wei; Zhou, Ya-Bin; Liu, Chuan-ju			RbAp48 is a critical mediator controlling the transforming activity of human papillomavirus type 16 in cervical cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; HISTONE DEACETYLASE; DEPENDENT APOPTOSIS; E6 ONCOPROTEINS; GENE-EXPRESSION; RETINOBLASTOMA; PROTEIN; GROWTH; TRANSCRIPTION; INACTIVATION	Although human papillomavirus (HPV) infections are the primary cause of cervical cancer, the molecular mechanism by which HPV induces cervical cancer remains largely unclear. We used two-dimensional electrophoresis with mass spectrometry to study protein expression profiling between HPV16-positive cervical mucosa epithelial H8 cells and cervical cancer Caski cells to identify 18 differentially expressed proteins. Among them, retinoblastoma-binding protein 4 (RbAp48) was selected, and its differentiation expression was verified with both additional cervical cancer-derived cell lines and human tissues of cervical intraepithelial neoplasia and cervical cancer. Suppression of RbAp48 using small interfering RNA approach in H8 cells significantly stimulated cell proliferation and colony formation and inhibited senescence-like phenotype. Remarkably, H8 cells acquired transforming activity if RpAp48 was suppressed, because H8 cells stably transfected with RbAp48 small interfering RNA led to tumor formation in nude mice. In addition, overexpression of RbAp48 significantly inhibited cell growth and tumor formation. This RbAp48-mediated transformation of HPV16 is probably because of the regulation by RbAp48 of tumor suppressors retinoblastoma and p53, apoptosis-related enzymes caspase-3 and caspase-8, and oncogenic genes, including E6, E7, cyclin D1 (CCND1), and c-MYC. In brief, RbAp48, previously unknown in cervical carcinogenesis, was isolated in a global screen and identified as a critical mediator controlling the transforming activity of HPV16 in cervical cancer.	Shandong Univ, Sch Med, Inst Pathogen Biol, Jinan 250012, Peoples R China; Shandong Univ, Sch Med, Jinan 250012, Peoples R China; NYU, Med Ctr, Dept Orthopaed Surg, New York, NY 10016 USA; Chinese Minist Educ, Key Lab Expt Teratol, Jinan 250012, Peoples R China; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	Shandong University; Shandong University; New York University; New York University	Yu, XP (corresponding author), Shandong Univ, Sch Med, Inst Pathogen Biol, Jinan 250012, Peoples R China.	yuxp@sdu.edu.cn; chuanju.liu@med.nyu.edu	Liu, Chuan-ju/AAT-8165-2021; Tang, Wei/A-6254-2016	Tang, Wei/0000-0002-4573-3502; liu, chuanju/0000-0002-7181-8032; Bai, Xiaohui/0000-0002-4027-7798	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022, R21AR052676, K01AR053210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG029388] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01 AR053210-01A2, R03 AR052022, R21 AR052676-02, R21 AR052676, K01 AR053210, R03 AR052022-02, R21 AR052676-01A1, AR052022, AR050620, R03 AR052022-03] Funding Source: Medline; NIA NIH HHS [R03 AG029388, R03 AG029388-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Au WW, 2007, GYNECOL ONCOL, V104, P276, DOI 10.1016/j.ygyno.2006.10.015; Bae SM, 2005, GYNECOL ONCOL, V99, P26, DOI 10.1016/j.ygyno.2005.05.041; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Castagna A, 2004, PROTEOMICS, V4, P3246, DOI 10.1002/pmic.200400835; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cheng Q, 2002, INT J CANCER, V98, P419, DOI 10.1002/ijc.10177; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Franco EL, 2003, CANCER J, V9, P348, DOI 10.1097/00130404-200309000-00004; Franco ELF, 1996, OBSTET GYN CLIN N AM, V23, P597; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Govan VA, 2005, ANN NY ACAD SCI, V1056, P328, DOI 10.1196/annals.1352.016; Greenbaum D, 2002, BIOINFORMATICS, V18, P585, DOI 10.1093/bioinformatics/18.4.585; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hayashi T, 2004, CELL, V118, P715, DOI 10.1016/j.cell.2004.09.002; Ishimaru N, 2006, MOL CELL BIOL, V26, P2924, DOI 10.1128/MCB.26.8.2924-2935.2006; Jia XW, 2006, CELL BIOL INT, V30, P183, DOI 10.1016/j.cellbi.2005.08.014; Jones EE, 2006, CURR MOL MED, V6, P795; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Laj A, 1999, MOL CELL BIOL, V19, P6632; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li GC, 2003, INT J CANCER, V105, P762, DOI 10.1002/ijc.11148; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; LUI CQ, 1999, ZHONG HUA BING LI XU, V28, P24; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Naghashfar Z, 1996, CANCER LETT, V100, P47, DOI 10.1016/0304-3835(95)04071-4; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Nicolas E, 2001, NUCLEIC ACIDS RES, V29, P3131, DOI 10.1093/nar/29.15.3131; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Torres-Roca JF, 2005, CANCER RES, V65, P7169, DOI 10.1158/0008-5472.CAN-05-0656; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wright Jason D, 2002, Curr Womens Health Rep, V2, P259; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yim EK, 2004, DNA CELL BIOL, V23, P826, DOI 10.1089/dna.2004.23.826; You W, 2005, OBSTET GYNECOL, V105, P1405, DOI 10.1097/01.AOG.0000163254.98217.91; Zhang TF, 2003, ANTICANCER RES, V23, P3735; Zhang TF, 2003, ANTICANCER RES, V23, P4621; ZHENG J, 1994, INT J CANCER, V58, P713, DOI 10.1002/ijc.2910580516; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	56	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26381	26391		10.1074/jbc.M702195200	http://dx.doi.org/10.1074/jbc.M702195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616526	hybrid			2022-12-25	WOS:000249239600043
J	Nilsen, T; Rosendal, KR; Sorensen, V; Wesche, J; Olsnes, S; Wiedlocha, A				Nilsen, Trine; Rosendal, Ken R.; Sorensen, Vigdis; Wesche, Jorgen; Olsnes, Sjur; Wiedlocha, Antoni			A nuclear export sequence located on a beta-strand in fibroblast growth factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOCYTOPLASMIC TRANSPORT; INTRACELLULAR PROTEIN; LOCALIZATION SIGNALS; ACTIVATION DOMAIN; IMPORTIN-BETA; FACTOR MUTANT; REV PROTEIN; TRANSLOCATION; PHOSPHORYLATION	Receptor-bound and endocytosed fibroblast growth factor-1 (FGF-1) is able to cross the vesicle membrane and translocate to cytosol and nucleus. This suggests an intracellular role of FGF-1, which also signals by activating transmembrane FGF receptors. Phosphorylation of internalized FGF-1 by nuclear protein kinase C delta induces rapid export from the nuclei by a leptomycin B-sensitive pathway. In the present work, we have searched for and identified a Leu-rich nuclear export sequence (NES) at the C terminus of FGF-1 required for its nuclear export and able to confer nuclear export activity to a reporter protein in an in vivo system. Mutants where hydrophobic amino acids within the NES were exchanged for alanine exhibited reduced or abolished nuclear export. As demonstrated in co-immunoprecipitation experiments, a complex containing FGF-1, exportin-1, and its co-factor Ran-GTP, was formed in vitro. Formation of this complex in vivo was demonstrated by a peroxisomal targeting assay. Formation of the FGF-1-exportin-1-Ran-GTP complex in vitro as well as nuclear export of FGF-1 in vivo was dependent on phosphorylation of FGF-1, and it was abolished by leptomycin B. The FGF-1 NES was found to be situated along a beta-strand, which has not been reported before, since NESs usually are alpha-helical.	Rikshosp Radiumhosp Med Ctr, Inst Canc Res, Ctr Canc Biomed, N-0310 Oslo, Norway	University of Oslo	Wiedlocha, A (corresponding author), Rikshosp Radiumhosp Med Ctr, Inst Canc Res, Ctr Canc Biomed, N-0310 Oslo, Norway.	antoni.wiedlocha@rr-research.no	Wesche, Jorgen/ABH-7524-2020	Christoffersen, Trine Eker/0000-0002-2908-133X; Wesche, Jorgen/0000-0002-9200-9162				Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; Klingenberg O, 2000, J CELL SCI, V113, P1827; Klingenberg O, 1998, J BIOL CHEM, V273, P11164, DOI 10.1074/jbc.273.18.11164; Klingenberg O, 1999, J BIOL CHEM, V274, P18081, DOI 10.1074/jbc.274.25.18081; Kolpakova E, 1998, BIOCHEM J, V336, P213, DOI 10.1042/bj3360213; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Malecki J, 2002, EMBO J, V21, P4480, DOI 10.1093/emboj/cdf472; Malecki J, 2004, MOL BIOL CELL, V15, P801, DOI 10.1091/mbc.E03-08-0589; Mizukoshi E, 1999, BIOCHEM J, V343, P461, DOI 10.1042/0264-6021:3430461; Munoz R, 1997, ONCOGENE, V15, P525, DOI 10.1038/sj.onc.1201226; Nilsen T, 2004, J BIOL CHEM, V279, P4794, DOI 10.1074/jbc.M309653200; NILSEN T, 2006, CELL BIOL LAB HDB, P275; Olsnes S, 2003, PHYSIOL REV, V83, P163, DOI 10.1152/physrev.00021.2002; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Petosa C, 2004, MOL CELL, V16, P761, DOI 10.1016/j.molcel.2004.11.018; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200; Siebrasse JP, 2002, J CELL BIOL, V158, P849, DOI 10.1083/jcb.200201130; Skjerpen CS, 2002, J BIOL CHEM, V277, P23864, DOI 10.1074/jbc.M112193200; Skjerpen CS, 2002, EMBO J, V21, P4058, DOI 10.1093/emboj/cdf402; Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405; Sorensen V, 2006, J CELL SCI, V119, P4332, DOI 10.1242/jcs.03209; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wesche J, 2005, BIOCHEMISTRY-US, V44, P6071, DOI 10.1021/bi047403m; Wesche J, 2000, BIOCHEMISTRY-US, V39, P15091, DOI 10.1021/bi001831k; Wickner W, 2005, SCIENCE, V310, P1452, DOI 10.1126/science.1113752; Wiedlocha A, 2005, MOL BIOL CELL, V16, P794; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; Wood MJ, 2004, NATURE, V430, P917, DOI 10.1038/nature02790; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	55	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26245	26256		10.1074/jbc.M611234200	http://dx.doi.org/10.1074/jbc.M611234200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616529	hybrid			2022-12-25	WOS:000249239600029
J	Wong, MM; Cox, LK; Chrivia, JC				Wong, Madeline M.; Cox, Linda K.; Chrivia, John C.			The chromatin remodeling protein, SRCAP, is critical for deposition of the histone variant H2A.Z at promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; ACETYLATION; GENES; TRANSCRIPTION; RECRUITMENT; COMPLEX; GENOME; HTZ1; ACTIVATION	Studies in Saccharomyces cerevisiae indicate the histone variant H2A. Z is deposited at promoters by the chromatin remodeling protein Swr1 and plays a critical role in the regulation of transcription. In higher eukaryotes, however, little is known about the distribution, method of deposition, and function of H2A. Z at promoters. Using biochemical studies, we demonstrated previously that SRCAP ( SNF-2-related CREB-binding protein activator protein), the human ortholog of Swr1, could catalyze deposition of H2A. Z into nucleosomes. To address whether SRCAP directs H2A. Z deposition in vivo, promoters targeted by SRCAP were identified by a chromatin immunoprecipitation ( ChIP)-on-chip assay. ChIP assays on a subset of these promoters confirmed the presence of SRCAP on inactive and active promoters. The highest levels of SRCAP were observed on the active SP-1, G3BP, and FAD synthetase promoters. Detailed analyses of these promoters indicate sites of SRCAP binding overlap or occur adjacent to the sites of H2A. Z deposition. Knockdown of SRCAP levels using siRNA resulted in loss of SRCAP at these promoters, decreased deposition of H2A. Z and acetylated H2A. Z, and a decrease in levels of SP-1, G3BP, and FAD synthetase mRNA. Thus, these studies provide the first evidence that SRCAP is recruited to promoters and is critical for the deposition of H2A.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Chrivia, JC (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	Chrivia@slu.edu			NIDDK NIH HHS [DK 066307] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Babiarz JE, 2006, GENE DEV, V20, P700, DOI 10.1101/gad.1386306; Bruce K, 2005, NUCLEIC ACIDS RES, V33, P5633, DOI 10.1093/nar/gki874; Chen IY, 2006, J BIOL CHEM, V281, P19369, DOI 10.1074/jbc.M601443200; Eissenberg JC, 2005, MOL CELL BIOL, V25, P6559, DOI 10.1128/MCB.25.15.6559-6569.2005; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Jackson JD, 2000, NUCLEIC ACIDS RES, V28, P3811, DOI 10.1093/nar/28.19.3811; Johnston H, 1999, J BIOL CHEM, V274, P16370, DOI 10.1074/jbc.274.23.16370; Keogh MC, 2006, GENE DEV, V20, P660, DOI 10.1101/gad.1388106; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Lambert JR, 2003, MOL ENDOCRINOL, V17, P1085, DOI 10.1210/me.2001-0183; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Monroy MA, 2003, MOL ENDOCRINOL, V17, P2519, DOI 10.1210/me.2003-0208; Myers FA, 2006, NUCLEIC ACIDS RES, V34, P4025, DOI 10.1093/nar/gkl543; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Ruhl DD, 2006, BIOCHEMISTRY-US, V45, P5671, DOI 10.1021/bi060043d; Viens A, 2006, MOL CELL BIOL, V26, P5325, DOI 10.1128/MCB.00584-06; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036	26	113	118	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26132	26139		10.1074/jbc.M703418200	http://dx.doi.org/10.1074/jbc.M703418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17617668	hybrid			2022-12-25	WOS:000249239600016
J	Frank, EG; Woodgate, R				Frank, Ekaterina G.; Woodgate, Roger			Increased catalytic activity and altered fidelity of human DNA polymerase iota in the presence of manganese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV-INDUCED LESIONS; IN-VITRO; NUCLEOTIDE INCORPORATION; DEPENDENT REPLICATION; TRANSLESION SYNTHESIS; ESCHERICHIA-COLI; METAL-IONS; POL-IOTA; BYPASS; ETA	All DNA polymerases require a divalent cation for catalytic activity. It is generally assumed that Mg2+ is the physiological cofactor for replicative DNA polymerases in vivo. However, recent studies suggest that certain repair polymerases, such as pol lambda, may preferentially utilize Mn2+ in vitro. Here we report on the effects of Mn2+ and Mg2+ on the enzymatic properties of human DNA polymerase iota (pol iota). pol iota exhibited the greatest activity in the presence of low levels of Mn2+ (0.05-0.25 mM). Peak activity in the presence of Mg2+ was observed in the range of 0.1-0.5 mM and was significantly reduced at concentrations > 2 mM. Steady-state kinetic analyses revealed that Mn2+ increases the catalytic activity of pol iota by similar to 30-60,000-fold through a dramatic decrease in the Km value for nucleotide incorporation. Interestingly, whereas pol iota preferentially misinserts G opposite T by a factor of similar to 1.4-2.5-fold over the correct base A in the presence of 0.25 and 5 mM Mg2+, respectively, the correct insertion of A is actually favored 2-fold over the misincorporation of G in the presence of 0.075 mM Mn2+. Low levels of Mn2+ also dramatically increased the ability of pol iota to traverse a variety of DNA lesions in vitro. Titration experiments revealed a strong preference of pol iota for Mn2+ even when Mg2+ is present in a > 10-fold excess. Our observations therefore raise the intriguing possibility that the cation utilized by pol iota in vivo may actually be Mn2+ rather than Mg2+, as tacitly assumed.	NICHD, Lab Genom Integr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Woodgate, R (corresponding author), NICHD, Lab Genom Integr, NIH, Bldg 6,Rm 1A13,9000 Rockville Pike, Bethesda, MD 20892 USA.	woodgate@nih.gov		Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ASH DE, 1982, J BIOL CHEM, V257, P9261; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; BESSMAN MJ, 1958, J BIOL CHEM, V233, P171; Blanca G, 2003, BIOCHEMISTRY-US, V42, P7467, DOI 10.1021/bi034198m; Choi JY, 2006, J BIOL CHEM, V281, P38244, DOI 10.1074/jbc.M608369200; Choi JY, 2006, J BIOL CHEM, V281, P12315, DOI 10.1074/jbc.M600112200; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Dumstorf CA, 2006, P NATL ACAD SCI USA, V103, P18083, DOI 10.1073/pnas.0605247103; ELDEIRY WS, 1984, P NATL ACAD SCI-BIOL, V81, P7378, DOI 10.1073/pnas.81.23.7378; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Frank EG, 2001, EMBO J, V20, P2914, DOI 10.1093/emboj/20.11.2914; Gee JB, 2001, PEDIATR NEUROL, V25, P304, DOI 10.1016/S0887-8994(01)00317-4; Goldschmidt V, 2006, NUCLEIC ACIDS RES, V34, P42, DOI 10.1093/nar/gkj411; GOODMAN MF, 1983, J BIOL CHEM, V258, P3469; Hays H, 2002, BIOCHEMISTRY-US, V41, P4771, DOI 10.1021/bi0120648; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 2005, P NATL ACAD SCI USA, V102, P10466, DOI 10.1073/pnas.0503859102; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 2006, MOL CELL BIOL, V26, P6435, DOI 10.1128/MCB.00851-06; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; Maga G, 2006, NUCLEIC ACIDS RES, V34, P1405, DOI 10.1093/nar/gkl032; MARKESBERY WR, 1984, NEUROBIOL AGING, V5, P19, DOI 10.1016/0197-4580(84)90081-2; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352; MILDVAN AS, 1979, CRC CR REV BIOCH MOL, V6, P219, DOI 10.3109/10409237909102564; Nair Deepak T, 2006, Nat Struct Mol Biol, V13, P619, DOI 10.1038/nsmb1118; Ohkumo T, 2006, MOL CELL BIOL, V26, P7696, DOI 10.1128/MCB.01076-06; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; RABKIN SD, 1983, P NATL ACAD SCI-BIOL, V80, P1541, DOI 10.1073/pnas.80.6.1541; SIROVER MA, 1976, BIOCHEM BIOPH RES CO, V70, P812, DOI 10.1016/0006-291X(76)90664-1; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Vaisman A, 2005, EMBO J, V24, P2957, DOI 10.1038/sj.emboj.7600786; Vaisman A, 2003, DNA REPAIR, V2, P991, DOI 10.1016/S1568-7864(03)00094-6; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; VERSIECK J, 1985, CRC CR REV CL LAB SC, V22, P97, DOI 10.3109/10408368509165788; Vidal AE, 2004, J BIOL CHEM, V279, P48360, DOI 10.1074/jbc.M406511200; Villani G, 2002, NUCLEIC ACIDS RES, V30, P3323, DOI 10.1093/nar/gkf463; WANG TSF, 1977, BIOCHEMISTRY-US, V16, P4927, DOI 10.1021/bi00641a029; Wang Y, 2007, CANCER RES, V67, P3018, DOI 10.1158/0008-5472.CAN-06-3073; Yang W, 2006, MOL CELL, V22, P5, DOI 10.1016/j.molcel.2006.03.013; Zakharova E, 2004, BIOCHEMISTRY-US, V43, P6587, DOI 10.1021/bi049615p; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	48	99	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24689	24696		10.1074/jbc.M702159200	http://dx.doi.org/10.1074/jbc.M702159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17609217	hybrid			2022-12-25	WOS:000248933000024
J	Wang, HT; Larris, B; Peiris, TH; Zhang, LP; Le Lay, J; Gao, Y; Greenbaum, LE				Wang, Haitao; Larris, Brian; Peiris, T. Harshani; Zhang, Liping; Le Lay, John; Gao, Yan; Greenbaum, Linda E.			C/EBP beta activates E2F-regulated genes in vivo via recruitment of the coactivator CREB-binding protein/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; E2F TRANSCRIPTION; HEPATOCYTE PROLIFERATION; DNA-REPLICATION; EMERGING ROLES; GROWTH; ALPHA; LIVER; PHOSPHORYLATION; EXPRESSION	The E2F transcription factors play an essential role in regulating the G(1)- to S-phase transition of the cell cycle. Previous studies have identified the importance of interactions between E2Fs and other transcription factors as a mechanism for transcriptional control of a subset of E2F regulated target genes. However, the mechanisms responsible for E2F target gene specificity remain incompletely understood. Here we report that in a mammalian in vivo model of synchronized proliferation, C/EBP beta occupancy on the promoters of E2F-regulated growth-related genes increases as a function of cell cycle progression. C/EPB beta binding to these promoters is associated with recruitment of the coactivator CBP/p300, histone H4 acetylation, and maximal activation of E2F target genes. Moreover, binding of CBP/p300 to E2F targets is markedly reduced in C/EBP beta null mice, resulting in reduced expression of E2F regulated genes. These findings identify C/EBP beta as a direct activator of E2F target genes in mammalian cell cycle progression through a mechanism that involves recruitment of CBP/p300. The demonstration of a functional link between C/EBP beta and CBP/p300 for E2F target gene activation provides a potential mechanism for how coactivators such as CBP/p300 can be selectively recruited to E2F target genes in response to tissue-specific growth stimuli.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greenbaum, LE (corresponding author), Univ Penn, Sch Med, Dept Med, 675 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	greenbal@mail.med.upenn.edu			NIDDK NIH HHS [DK-056669] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056669] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Buck M, 2003, HEPATOLOGY, V37, P731, DOI 10.1053/jhep.2003.50155; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Chan HM, 2001, J CELL SCI, V114, P2363; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; FAUSTO N, 1988, LIVER BIOL PATHOL, P53; Friedman JR, 2004, P NATL ACAD SCI USA, V101, P12986, DOI 10.1073/pnas.0402875101; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; Iyer VV, 2004, EXP CELL RES, V295, P128, DOI 10.1016/j.yexcr.2004.01.004; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; Pelizon C, 2003, TRENDS CELL BIOL, V13, P110, DOI 10.1016/S0962-8924(03)00024-2; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; Yoshida K, 2004, ONCOGENE, V23, P6250, DOI 10.1038/sj.onc.1207829; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	58	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24679	24688		10.1074/jbc.M705066200	http://dx.doi.org/10.1074/jbc.M705066200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17599912	hybrid			2022-12-25	WOS:000248933000023
J	Fasano, C; Terce, F; Niel, JP; Nguyen, HTT; Hiol, A; Bertrand-Michel, J; Mallet, N; Collet, X; Miolan, JP				Fasano, Caroline; Terce, Francois; Niel, Jean-Pierre; Nguyen, Hang Thi Thu; Hiol, Abel; Bertrand-Michel, Justine; Mallet, Nicole; Collet, Xavier; Miolan, Jean-Pierre			Neuronal Conduction of Excitation without Action Potentials Based on Ceramide Production	PLOS ONE			English	Article							GPI-ANCHORED PROTEINS; NEUTRAL SPHINGOMYELINASE; LIPID RAFTS; SPHINGOLIPID METABOLISM; MEMBRANE MICRODOMAINS; SIGNAL-TRANSDUCTION; NITRIC-OXIDE; CELL-DEATH; RECEPTOR; TRANSMISSION	Background. Action potentials are the classic mechanism by which neurons convey a state of excitation throughout their length, leading, after synaptic transmission, to the activation of other neurons and consequently to network functioning. Using an in vitro integrated model, we found previously that peripheral networks in the autonomic nervous system can organise an unconventional regulatory reflex of the digestive tract motility without action potentials. Methodology/Principal Findings. In this report, we used combined neuropharmacological and biochemical approaches to elucidate some steps of the mechanism that conveys excitation along the nerves fibres without action potentials. This mechanism requires the production of ceramide in membrane lipid rafts, which triggers in the cytoplasm an increase in intracellular calcium concentration, followed by activation of a neuronal nitric oxide synthase leading to local production of nitric oxide, and then to guanosine cyclic monophosphate. This sequence of second messengers is activated in cascade from rafts to rafts to ensure conduction of the excitation along the nerve fibres. Conclusions/Significance. Our results indicate that second messengers are involved in neuronal conduction of excitation without action potentials. This mechanism represents the first evidence-to our knowledge-that excitation is carried along nerves independently of electrical signals. This unexpected ceramide-based conduction of excitation without action potentials along the autonomic nerve fibres opens up new prospects in our understanding of neuronal functioning.	[Fasano, Caroline; Niel, Jean-Pierre; Miolan, Jean-Pierre] Univ Paul Cezanne, Inst Fed Rech Jean Roche IFR 11, Fac Sci & Tech, Lab Physiol Neurovegetat,UMR CNRS 6153,INRA 1147, Marseille, France; [Terce, Francois; Bertrand-Michel, Justine; Mallet, Nicole] Hop Purpan, INSERM, IFR Toulouse Genopole 30, U563, Toulouse, France; [Nguyen, Hang Thi Thu; Hiol, Abel] Univ Paul Cezanne, Fac Sci & Tech, Lab Chim Biol Appl, UMR INRA 1111, Marseille, France; [Collet, Xavier] Hop Purpan, CPTP, INSERM, Dept Lipoprot & Mediateurs Lipid,IFR 30,U563, Toulouse, France	INRAE; UDICE-French Research Universities; Aix-Marseille Universite; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; UDICE-French Research Universities; Aix-Marseille Universite; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Miolan, JP (corresponding author), Univ Paul Cezanne, Inst Fed Rech Jean Roche IFR 11, Fac Sci & Tech, Lab Physiol Neurovegetat,UMR CNRS 6153,INRA 1147, Marseille, France.	jean-pierre.miolan@univ-cezanne.fr	Tercé, François/M-5863-2018; Collet, Xavier/M-6938-2017; Nguyen, Hang/N-2441-2018	Tercé, François/0000-0003-4488-2167; Nguyen, Hang/0000-0001-7431-5126	Universite Paul Cezanne; Centre National de la Recherche Scientifique; Institut National de la Recherche Agronomique; Institut National de la Sante et de la Recherche Medicale; Toulouse Genopole	Universite Paul Cezanne; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Recherche Agronomique; Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Toulouse Genopole	This work was supported by the Universite Paul Cezanne, the Centre National de la Recherche Scientifique, the Institut National de la Recherche Agronomique, the Institut National de la Sante et de la Recherche Medicale, and Toulouse Genopole.	Ballou L.R, 1997, SPHINGOLIPID MEDIATE, P35; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; Braccia A, 2003, J BIOL CHEM, V278, P15679, DOI 10.1074/jbc.M211228200; BURROWS M, 1981, NEURONES IMPULSES, P199; Czarny M, 2004, AM J PHYSIOL-HEART C, V287, pH1344, DOI 10.1152/ajpheart.00222.2004; Czarny M, 2003, J BIOL CHEM, V278, P4424, DOI 10.1074/jbc.M210375200; de Chaves EP, 2001, J BIOL CHEM, V276, P36207, DOI 10.1074/jbc.M104282200; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; FAIN GL, 1981, NEURONES IMPULSES, P29; Fasano C, 2003, NEUROSCIENCE, V116, P753, DOI 10.1016/S0306-4522(02)00760-1; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GRAUBARD K, 1978, J NEUROPHYSIOL, V41, P1014, DOI 10.1152/jn.1978.41.4.1014; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; Kito Yoshihiko, 2003, Journal of Smooth Muscle Research, V39, P163, DOI 10.1540/jsmr.39.163; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; KREULEN DL, 1983, AM J PHYSIOL, V245, pG369, DOI 10.1152/ajpgi.1983.245.3.G369; Kuwabara M, 2003, J RADIAT RES, V44, P203, DOI 10.1269/jrr.44.203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu GL, 1999, CRIT REV CL LAB SCI, V36, P511, DOI 10.1080/10408369991239240; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Maekawa S, 2001, J BIOCHEM-TOKYO, V129, P691, DOI 10.1093/oxfordjournals.jbchem.a002908; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; MAZET B, 1993, J AUTONOM NERV SYST, V46, P135; Miolan JP, 1996, J AUTONOM NERV SYST, V58, P125, DOI 10.1016/0165-1838(95)00128-X; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nguyen HTT, 2006, BIOCHEM BIOPH RES CO, V342, P236, DOI 10.1016/j.bbrc.2006.01.141; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OCHS S, 1987, AXONAL TRANSPORT, P1; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Quinson N, 1999, J PHYSIOL-LONDON, V519, P223, DOI 10.1111/j.1469-7793.1999.0223o.x; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; SIMMERS AJ, 1981, NEURONES IMPULSES, P177; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Szurszewski Joseph H., 1994, P795; TYMIANSKI M, 1994, J CEREBR BLOOD F MET, V14, P911, DOI 10.1038/jcbfm.1994.122; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vieu C, 2002, J LIPID RES, V43, P510; Vieu C, 1996, J LIPID RES, V37, P1153; Yang SN, 2000, NEUROSCIENCE, V96, P253, DOI 10.1016/S0306-4522(99)00582-5; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	47	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e612	10.1371/journal.pone.0000612	http://dx.doi.org/10.1371/journal.pone.0000612			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637828	Green Published, gold			2022-12-25	WOS:000207452100002
J	Choi, HS; Kim, CS; Hwang, CK; Song, KY; Law, PY; Wei, LN; Loh, HH				Choi, Hack Sun; Kim, Chun Sung; Hwang, Cheol Kyu; Song, Kyu Young; Law, Ping-Yee; Wei, Li-Na; Loh, Horace H.			Novel function of the poly(C)-binding protein alpha CP3 as a transcriptional repressor of the mu opioid receptor gene	FASEB JOURNAL			English	Article						double-stranded poly(C) element; MOR transcription	RNA-BINDING PROTEINS; SINGLE-STRANDED-DNA; NUCLEAR RIBONUCLEOPROTEIN-K; SPLICE VARIANTS; ERYTHROID-DIFFERENTIATION; DISTAL PROMOTER; NEURONAL CELLS; POLIOVIRUS RNA; HNRNP-K; IDENTIFICATION	The alpha-complex proteins (alpha CP) are generally known as RNA- binding proteins that interact in a sequence- specific fashion with single- stranded poly(C). These proteins are mainly involved in various post- transcriptional regulations ( e. g., mRNA stabilization or translational activation/ silencing). Here we report a novel function of alpha CP3, a member of the alpha CP family. alpha CP3 bound to the double- stranded poly(C) element essential for the mu opioid receptor ( MOR) promoter and repressed the promoter activity at the transcriptional level. We identified alpha CP3 using affinity column chromatography containing the double-stranded poly( C) element and matrix-assisted laser desorption ionization time- of- flight ( MALDI- TOF) mass spectrometry. alpha CP3 binding to the poly(C) sequence of the MOR gene was sequence specific, as confirmed by the supershift assay. In cotransfection studies, alpha CP3 repressed the MOR promoter only when the poly( C) sequence was intact. Ectopic expression of alpha CP3 led to repression of the endogenous MOR transcripts in NS20Y cells. When alpha CP3 was disrupted using small interfering RNA ( siRNA) in NS20Y cells, the transcription of the endogenous target MOR gene was increased significantly. Our data suggest that alpha CP3 can function as a repressor of MOR transcription dependent on the MOR poly( C) sequence. We demonstrate for the first time a role of alpha CP3 as a transcriptional repressor in MOR gene regulation.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Choi, HS (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall, 321 Church St, Minneapolis, MN 55455 USA.	choix074@umn.edu		Song, Kyu Young/0000-0001-7313-514X	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, R01DA011190, R01DA001583, K02DA013926, R56DA000564, R01DA000564, R37DA001583] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00564, DA11806, DA11190, K02-DA13926, K05-DA00153, DA01583] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Chkheidze AN, 2003, MOL CELL BIOL, V23, P8405, DOI 10.1128/MCB.23.23.8405-8415.2003; Choe CY, 1998, J BIOL CHEM, V273, P34926, DOI 10.1074/jbc.273.52.34926; Choi HS, 2006, BIOCHEM BIOPH RES CO, V343, P1132, DOI 10.1016/j.bbrc.2006.03.084; Choi HS, 2005, MOL PHARMACOL, V67, P1674, DOI 10.1124/mol.104.008284; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Gamarnik AV, 1997, RNA, V3, P882; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Hwang CK, 2003, J BIOL CHEM, V278, P3742, DOI 10.1074/jbc.M208780200; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kim CS, 2004, J BIOL CHEM, V279, P46464, DOI 10.1074/jbc.M403633200; Ko JL, 2003, MOL BRAIN RES, V112, P153, DOI 10.1016/S0169-328X(03)00086-X; Ko JL, 2002, MOL BRAIN RES, V104, P184, DOI 10.1016/S0169-328X(02)00357-1; Ko JL, 2001, J BIOL CHEM, V276, P788, DOI 10.1074/jbc.M004279200; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; Makeyev AV, 2000, GENOMICS, V67, P301, DOI 10.1006/geno.2000.6244; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Ogata H, 1998, J BIOL CHEM, V273, P3060, DOI 10.1074/jbc.273.5.3060; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Pan YX, 2001, P NATL ACAD SCI USA, V98, P14084, DOI 10.1073/pnas.241296098; Pan YX, 2002, GENE, V295, P97, DOI 10.1016/S0378-1119(02)00825-9; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1791, DOI 10.1002/elps.11501601299; Ritchie SA, 2003, NUCLEIC ACIDS RES, V31, P1502, DOI 10.1093/nar/gkg246; Thakur S, 2003, MOL CELL BIOL, V23, P3774, DOI 10.1128/MCB.23.11.3774-3787.2003; Tommerup N, 1996, GENOMICS, V33, P149, DOI 10.1006/geno.1996.0176; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Wei LN, 2002, CURR OPIN PHARMACOL, V2, P69, DOI 10.1016/S1471-4892(01)00123-0; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	45	23	23	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3963	3973		10.1096/fj.07-8561com	http://dx.doi.org/10.1096/fj.07-8561com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625070				2022-12-25	WOS:000251283500021
J	Jones, GW; Nielsen-Leroux, C; Yang, Y; Yuan, Z; Dumas, VF; Monnerat, RG; Berry, C				Jones, Gareth W.; Nielsen-Leroux, Christina; Yang, Yankun; Yuan, Zhiming; Dumas, Vinicius Fiuza; Monnerat, Rose Gomes; Berry, Colin			A new Cry toxin with a unique two-component dependency from Bacillus sphaericus	FASEB JOURNAL			English	Article						insecticidal toxin; toxin evolution; toxin interactions	THURINGIENSIS SUBSP ISRAELENSIS; CULEX-PIPIENS DIPTERA; WESTERN CORN-ROOTWORM; MOSQUITOCIDAL TOXIN; BINARY TOXIN; LABORATORY CULTURE; CROSS-RESISTANCE; PLASMID TRANSFER; CRYSTAL TOXIN; STRAINS	Highly pathogenic strains of Bacillus sphaericus produce the mosquitocidal Bin proteins, but resistance to this toxin can be produced under laboratory and field conditions. Analysis of strains able to overcome this resistance revealed the presence of a previously undescribed type of two-component toxin. One subunit, Cry48Aa1, is related to the 3-domain crystal toxins of Bacillus thuringiensis. Uniquely for this type of protein, insect toxicity is only achieved in the presence of a second, accessory protein, Cry49Aa1. This protein is itself related to both the binary toxin of B. sphaericus and to Cry35 and Cry36 of B. thuringiensis, none of which require interaction with Cry48Aa1-like proteins for their activity. The necessity for both Cry48Aa1 and Cry49Aa1 components for pathogenicity, therefore, indicates an unprecedented interaction to generate toxicity. Despite high potency for purified Cry48Aa1/Cry49Aa1 proteins (LC50 for third instar Culex quinquefasciatus larvae: 15.9 ng/ml and 6.3 ng/ml respectively), bacteria producing them show suboptimal mosquitocidal activity due to low-level Cry48Aa1 production. This new toxin combination may indicate a fortuitous combination of members of the gene families that encode 3-domain Cry toxins and Binary-like toxins, permitting the "mix-and-match" evolution of a new component in the mosquitocidal armoury. -Jones, G. W., Nielsen-Leroux, C., Yang, Y., Yuan, Z., Dumas, V. F., Monnerat, R. G., Colin Berry, C. A new Cry toxin with a unique two-component dependency from Bacillus sphaericus.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales; Inst Pasteur, Dept Microbiol, Paris, France; Chinese Acad Sci, Wuhan Inst Virol, Wuhan, Peoples R China; Parque Estacao Biol, Embrapa Recursos Genet & Biotecnol, Brasilia, DF, Brazil	Cardiff University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)	Berry, C (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	berry@cf.ac.uk	Berry, Colin/A-4338-2010; Yang, Yankun/AAJ-3032-2020	Berry, Colin/0000-0002-9943-548X; Yang, Yankun/0000-0003-4815-6832; Plummer, Beverley/0000-0002-6559-7237; Jones, Gareth/0000-0002-0125-4841				Agaisse H, 1996, MOL MICROBIOL, V20, P633, DOI 10.1046/j.1365-2958.1996.5401046.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1971, PROBIT ANAL STAT TRE; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Baum JA, 2004, APPL ENVIRON MICROB, V70, P4889, DOI 10.1128/AEM.70.8.4889-4898.2004; BAUMANN L, 1988, J BACTERIOL, V170, P2045, DOI 10.1128/jb.170.5.2045-2050.1988; Bocs S, 2003, NUCLEIC ACIDS RES, V31, P3723, DOI 10.1093/nar/gkg590; BROADWELL AH, 1986, APPL ENVIRON MICROB, V52, P758, DOI 10.1128/AEM.52.4.758-764.1986; Charles JF, 1997, FEMS MICROBIOL LETT, V156, P153, DOI 10.1016/S0378-1097(97)00419-9; CLARK MA, 1990, J BACTERIOL, V172, P6759, DOI 10.1128/jb.172.12.6759-6763.1990; Cokmus C, 1997, J INVERTEBR PATHOL, V69, P197, DOI 10.1006/jipa.1997.4660; DAVIDSON EW, 1990, CAN J MICROBIOL, V36, P870, DOI 10.1139/m90-151; de Maagd RA, 2003, ANNU REV GENET, V37, P409, DOI 10.1146/annurev.genet.37.110801.143042; Ellis RT, 2002, APPL ENVIRON MICROB, V68, P1137, DOI 10.1128/AEM.68.3.1137-1145.2002; Gammon K, 2006, APPL ENVIRON MICROB, V72, P1766, DOI 10.1128/AEM.72.3.1766-1770.2006; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Helgason E, 2000, APPL ENVIRON MICROB, V66, P2627, DOI 10.1128/AEM.66.6.2627-2630.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JW, 1996, APPL ENVIRON MICROB, V62, P2174, DOI 10.1128/AEM.62.6.2174-2176.1996; MAHILLON J, 1994, GENETICA, V93, P13, DOI 10.1007/BF01435236; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Masson L, 2004, BIOCHEMISTRY-US, V43, P12349, DOI 10.1021/bi048946z; Monnerat RG, 2007, BIOL CONTROL, V41, P291, DOI 10.1016/j.biocontrol.2006.11.008; NICOLAS L, 1993, FEMS MICROBIOL LETT, V106, P275, DOI 10.1111/j.1574-6968.1993.tb05976.x; Nielsen-LeRoux C, 2001, APPL ENVIRON MICROB, V67, P5049, DOI 10.1128/AEM.67.11.5049-5054.2001; OEI C, 1992, J GEN MICROBIOL, V138, P1515, DOI 10.1099/00221287-138-7-1515; OEI C, 1990, FEMS MICROBIOL LETT, V72, P265, DOI 10.1111/j.1574-6968.1990.tb03900.x; Park HW, 1999, FEMS MICROBIOL LETT, V181, P319, DOI 10.1111/j.1574-6968.1999.tb08862.x; Park HW, 2005, AM J TROP MED HYG, V72, P732, DOI 10.4269/ajtmh.2005.72.732; Pei GF, 2002, APPL ENVIRON MICROB, V68, P3003, DOI 10.1128/AEM.68.6.3003-3009.2002; RUPAR MJ, 2003, NUCL ACIDS ENCODING; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Schwartz JL, 2001, J MEMBRANE BIOL, V184, P171, DOI 10.1007/s00232-001-0086-1; Silva MHNL, 2004, FEMS MICROBIOL LETT, V241, P185, DOI 10.1016/j.femsle.2004.10.018; Silva-Filha MH, 1999, INSECT BIOCHEM MOLEC, V29, P711, DOI 10.1016/S0965-1748(99)00047-8; SILVAFILHA MH, 1995, J ECON ENTOMOL, V88, P525, DOI 10.1093/jee/88.3.525; SINEGRE G, 1994, 8 EUR M SOC VECT EC, P17; Smith AW, 2005, J INVERTEBR PATHOL, V88, P27, DOI 10.1016/j.jip.2004.10.005; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THANABALU T, 1991, J BACTERIOL, V173, P2776, DOI 10.1128/JB.173.9.2776-2785.1991; Thanabalu T, 1996, GENE, V170, P85, DOI 10.1016/0378-1119(95)00836-5; Thomas DJI, 2000, APPL ENVIRON MICROB, V66, P118, DOI 10.1128/AEM.66.1.118-124.2000; Thomas DJI, 2001, APPL ENVIRON MICROB, V67, P330, DOI 10.1128/AEM.67.1.330-338.2001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tran LB, 2001, APPL ENVIRON MICROB, V67, P4488, DOI 10.1128/AEM.67.10.4488-4494.2001; Wirth MC, 2004, J MED ENTOMOL, V41, P935, DOI 10.1603/0022-2585-41.5.935; Yuan ZM, 2003, MED VET ENTOMOL, V17, P251, DOI 10.1046/j.1365-2915.2003.00429.x; Yuan ZM, 2000, BIOCONTROL SCI TECHN, V10, P41, DOI 10.1080/09583150029378	50	54	60	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4112	4120		10.1096/fj.07-8913com	http://dx.doi.org/10.1096/fj.07-8913com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17646596				2022-12-25	WOS:000251283500036
J	Sakamoto, K; Honda, T; Yokoya, S; Waguri, S; Kimura, J				Sakamoto, Kazuho; Honda, Takashi; Yokoya, Sachihiko; Waguri, Satoshi; Kimura, Junko			Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers	FASEB JOURNAL			English	Article						HMG-CoA reductase inhibitors; isoprenylation; myopathy; rhabdomyolysis; skeletal muscle	COA REDUCTASE INHIBITORS; COENZYME Q(10); CELL-DEATH; MUSCLE; LOVASTATIN; MYOPATHY; PHARMACOKINETICS; CYCLOSPORINE; APOPTOSIS; LYSOPHOSPHATIDYLCHOLINE	Three-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase inhibitors, known as statins, induce skeletal muscle injury including myalgia, myositis, and rhabdo-myolysis. The mechanism of this myotoxicity remains unknown. This study examined the effect of statins on single skeletal myofibers enzymatically isolated from the rat flexor digitorum brevis muscles. Fluvastatin and pravastatin induced the formation of numerous vacuoles in the myofibers after 72 h of treatment. This effect progressed in a time- and concentration-dependent manner and, consequently, cell death occurred after 120 h. Electron micrographs revealed craters along the sarcolemma and swelling of the sarcoplasmic reticula and mitochondria, in addition to intracellular vacuoles. When caffeine was added after 72 h of fluvastatin treatment, contractile shortening of statin-treated myofibers was significantly attenuated and blebs formed on the surface of the myofibers. The coapplication of geranylgeranylpyro-phosphate (GGPP) with fluvastatin prevented the morphological changes, while that of farnesylpyrophosphate (FPP) was ineffective. Furthermore, perillyl alcohol, an inhibitor of Rab geranylgeranyl transferase and geranylgeranyl transferase-I (GGTase-I), mimicked the effect of statins, while a specific GGTase-I inhibitor (GGTI-298) or a farnesyl transferase inhibitor (FTI-277) failed to do so. These results suggest that the inactivation of Rab GTPase, which involved in intracellular membrane transport, is a crucial factor in statin-induced-morphological abnormality in skeletal muscle fibers.-Sakamoto, K., Honda, T., Yokoya, S., Waguri, S., Kimura, J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers.	Fukushima Med Univ, Sch Med, Dept Pharmacol, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Med, Dept Cell Sci, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Med, Dept Anat & Histol, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Nursing, Dept Human Life Sci, Fukushima, Japan	Fukushima Medical University; Fukushima Medical University; Fukushima Medical University; Fukushima Medical University	Sakamoto, K (corresponding author), Fukushima Med Univ, Sch Med, Dept Pharmacol, Hikarigaoka 1, Fukushima 9601295, Japan.	kazuho@fmu.ac.jp						Alsheikh-Ali AA, 2005, CIRCULATION, V111, P3051, DOI 10.1161/CIRCULATIONAHA.105.555482; BEKOFF A, 1977, J PHYSIOL-LONDON, V271, P25, DOI 10.1113/jphysiol.1977.sp011988; Bergman M, 2003, J MUSCLE RES CELL M, V24, P417, DOI 10.1023/A:1027367022415; CARLSEN RC, 1985, CAN J PHYSIOL PHARM, V63, P958, DOI 10.1139/y85-158; CHUCRALLAH A, 1992, EUR NEUROL, V32, P293, DOI 10.1159/000116845; Cooper AA, 2006, SCIENCE, V313, P324, DOI 10.1126/science.1129462; Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515; Dirks AJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1208, DOI 10.1152/ajpcell.00226.2006; ENDO A, 1992, J LIPID RES, V33, P1569; Farmer JA, 2001, LANCET, V358, P1383, DOI 10.1016/S0140-6736(01)06489-3; FOLKERS K, 1990, P NATL ACAD SCI USA, V87, P8931, DOI 10.1073/pnas.87.22.8931; Goalstone ML, 1999, J BIOL CHEM, V274, P2880, DOI 10.1074/jbc.274.5.2880; GREENSPAN MD, 1988, DRUG METAB DISPOS, V16, P678; Grosshans BL, 2006, P NATL ACAD SCI USA, V103, P11821, DOI 10.1073/pnas.0601617103; Hargreaves IP, 2005, DRUG SAFETY, V28, P659, DOI 10.2165/00002018-200528080-00002; Holdaas H, 2006, INT J CLIN PHARM TH, V44, P163; Ichihara K, 2002, LANCET, V359, P2195, DOI 10.1016/S0140-6736(02)09098-0; Ivessa NE, 1997, J BIOL CHEM, V272, P20828, DOI 10.1074/jbc.272.33.20828; Kaufmann P, 2006, CELL MOL LIFE SCI, V63, P2415, DOI 10.1007/s00018-006-6235-z; Kivisto KT, 1998, BRIT J CLIN PHARMACO, V46, P49, DOI 10.1046/j.1365-2125.1998.00034.x; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kyrklund C, 2004, BRIT J CLIN PHARMACO, V57, P181, DOI 10.1046/j.1365-2125.2003.01972.x; LAAKSONEN R, 1995, CLIN PHARMACOL THER, V57, P62, DOI 10.1016/0009-9236(95)90266-X; Lackner MR, 2005, CANCER CELL, V7, P325, DOI 10.1016/j.ccr.2005.03.024; Lane KT, 2006, J LIPID RES, V47, P681, DOI 10.1194/jlr.R600002-JLR200; Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017-JLR200; Levy HB, 2006, ANN PHARMACOTHER, V40, P290, DOI 10.1345/aph.1G409; Li LB, 2002, MOL PHARMACOL, V62, P602, DOI 10.1124/mol.62.3.602; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lindahl A, 1996, CLIN PHARMACOL THER, V60, P493, DOI 10.1016/S0009-9236(96)90145-9; Maeda S, 2005, MOL PHARMACOL, V68, P414, DOI 10.1124/mol.104.000786; Matsuyama K, 2002, BIOL PHARM BULL, V25, P346, DOI 10.1248/bpb.25.346; Matzno S, 2005, J PHARM PHARMACOL, V57, P1475, DOI 10.1211/jpp.57.11.0014; Matzno S, 1997, J LIPID RES, V38, P1639; Naba Hiroyasu, 2004, Drug Metab Pharmacokinet, V19, P339, DOI 10.2133/dmpk.19.339; Nakagawa H, 1998, FEBS LETT, V438, P289, DOI 10.1016/S0014-5793(98)01320-9; Nakahara K, 1998, TOXICOL APPL PHARM, V152, P99, DOI 10.1006/taap.1998.8491; NAKAHARA K, 1994, BIOCHEM BIOPH RES CO, V202, P1579, DOI 10.1006/bbrc.1994.2112; Nishimoto T, 2003, BIOCHEM PHARMACOL, V66, P2133, DOI 10.1016/j.bcp.2003.08.011; Ogata Y, 2002, J CARDIOVASC PHARM, V40, P907, DOI 10.1097/00005344-200212000-00012; Omar MA, 2002, ANN PHARMACOTHER, V36, P288, DOI 10.1345/aph.1A289; Park JW, 2002, INT J CLIN PHARM TH, V40, P439; Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006-2952(97)00151-2; Rosenson RS, 2004, AM J MED, V116, P408, DOI 10.1016/j.amjmed.2003.10.033; Schaefer WH, 2004, TOXICOL APPL PHARM, V194, P10, DOI 10.1016/j.taap.2003.08.013; Seachrist JL, 2005, TOXICOL SCI, V88, P551, DOI 10.1093/toxsci/kfi305; SERAJUDDIN ATM, 1991, J PHARM SCI, V80, P830, DOI 10.1002/jps.2600800905; Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003; Smith CC, 2003, ARCH INTERN MED, V163, P688, DOI 10.1001/archinte.163.6.688; SMITH PF, 1991, J PHARMACOL EXP THER, V257, P1225; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thompson PD, 1997, METABOLISM, V46, P1206, DOI 10.1016/S0026-0495(97)90218-3; Ucar M, 2000, DRUG SAFETY, V22, P441, DOI 10.2165/00002018-200022060-00003; WACLAWIK AJ, 1993, J NEUROPATH EXP NEUR, V52, P542, DOI 10.1097/00005072-199309000-00012; Westwood FR, 2005, TOXICOL PATHOL, V33, P246, DOI 10.1080/01926230590908213; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; Yokoyama K, 2002, CIRCULATION, V105, P962, DOI 10.1161/hc0802.104457	58	50	51	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4087	4094		10.1096/fj.07-8713com	http://dx.doi.org/10.1096/fj.07-8713com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17634390				2022-12-25	WOS:000251283500033
J	Chamberlain, PP; Qian, X; Stiles, AR; Cho, J; Jones, DH; Lesley, SA; Grabau, EA; Shears, SB; Spraggon, G				Chamberlain, Philip P.; Qian, Xun; Stiles, Amanda R.; Cho, Jaiesoon; Jones, David H.; Lesley, Scott A.; Grabau, Elizabeth A.; Shears, Stephen B.; Spraggon, Glen			Integration of inositol phosphate signaling pathways via human ITPK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,3,4-TRISPHOSPHATE 5/6-KINASE; HEXAKISPHOSPHATE; PROTEINS; MODEL; PENTAKISPHOSPHATE; PURIFICATION; SPECIFICITY; EXPRESSION; 3-KINASE; CELLS	Inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) is a reversible, poly-specific inositol phosphate kinase that has been implicated as a modifier gene in cystic fibrosis. Upon activation of phospholipase C at the plasma membrane, inositol 1,4,5-trisphosphate enters the cytosol and is inter-converted by an array of kinases and phosphatases into other inositol phosphates with diverse and critical cellular activities. In mammals it has been established that inositol 1,3,4-trisphosphate, produced from inositol 1,4,5-trisphosphate, lies in a branch of the metabollic pathway that is separate from inositol 3,4,5,6-tetrakisphosphate, which inhibits plasma membrane chloride channels. We have determined the molecular mechanism for communication between these two pathways, showing that phosphate is transferred between inositol phosphates via ITPK1-bound nucleotide. Intersubstrate phosphate transfer explains how competing substrates are able to stimulate each others' catalysis by ITPK1. We further show that these features occur in the human protein, but not in plant or protozoan homologues. The high resolution structure of human ITPK1 identifies novel secondary structural features able to impart substrate selectivity and enhance nucleotide binding, thereby promoting intersubstrate phosphate transfer. Our work describes a novel mode of substrate regulation and provides insight into the enzyme evolution of a signaling mechanism from a metabolic role.	Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA; NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Virginia Polytech Inst & State Univ, Dept Plant Pathol, Blacksburg, VA 24061 USA	Novartis; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Virginia Polytechnic Institute & State University	Shears, SB (corresponding author), Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA.	shears@niehs.nih.gov; gspraggo@gnf.org	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 ES999999, Z01 ES080046-19] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; Artymiuk PJ, 1996, NAT STRUCT BIOL, V3, P128, DOI 10.1038/nsb0296-128; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Field J, 2000, MOL BIOCHEM PARASIT, V108, P119, DOI 10.1016/S0166-6851(00)00197-3; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Ho MWY, 2002, CURR TOP MEMBR, V53, P345, DOI 10.1016/S1063-5823(02)53041-6; Ho MWY, 2002, CURR BIOL, V12, P477, DOI 10.1016/S0960-9822(02)00713-3; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lesley SA, 2001, PROTEIN EXPRES PURIF, V22, P159, DOI 10.1006/prep.2001.1465; Lesley SA, 2002, P NATL ACAD SCI USA, V99, P11664, DOI 10.1073/pnas.142413399; Leyman A, 2007, CELL SIGNAL, V19, P1497, DOI 10.1016/j.cellsig.2007.01.024; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; Miller GJ, 2005, MOL CELL, V18, P201, DOI 10.1016/j.molcel.2005.03.016; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qian X, 2005, BIOCHEM J, V389, P389, DOI 10.1042/BJ20050297; Renstrom E, 2002, J BIOL CHEM, V277, P26717, DOI 10.1074/jbc.C200314200; Riley AM, 2006, FEBS LETT, V580, P324, DOI 10.1016/j.febslet.2005.12.016; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Shi JR, 2003, PLANT PHYSIOL, V131, P507, DOI 10.1104/pp.014258; SOBOLL S, 1978, EUR J BIOCHEM, V87, P377, DOI 10.1111/j.1432-1033.1978.tb12387.x; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Sun Y, 2003, J BIOL CHEM, V278, P43645, DOI 10.1074/jbc.M300674200; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; VAJANAPHANICH M, 1993, AM J PHYSIOL, V264, pC1210, DOI 10.1152/ajpcell.1993.264.5.C1210; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wilson MP, 1997, BIOCHEM BIOPH RES CO, V232, P678, DOI 10.1006/bbrc.1997.6355; Yang L, 2006, J CELL SCI, V119, P1320, DOI 10.1242/jcs.02836; Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200	38	30	34	5	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28117	28125		10.1074/jbc.M703121200	http://dx.doi.org/10.1074/jbc.M703121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17616525	hybrid, Green Accepted			2022-12-25	WOS:000249455600061
J	Athanasopoulos, AN; Schneider, D; Keiper, T; Alt, V; Pendurthi, UR; Liegibel, UM; Sommer, U; Nawroth, PP; Kasperk, C; Chavakis, T				Athanasopoulos, Athanasios N.; Schneider, Darius; Keiper, Tanja; Alt, Volker; Pendurthi, Usha R.; Liegibel, Ute M.; Sommer, Ulrike; Nawroth, Peter P.; Kasperk, Christian; Chavakis, Triantafyllos			Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in Osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; BONE-FORMATION; EXTRACELLULAR-MATRIX; CYR61 CCN1; ANGIOGENESIS; EXPRESSION; VEGF; PRODUCT; REPAIR; MECHANISMS	Angiogenesis is indispensable during fracture repair, and vascular endothelial growth factor ( VEGF) is critical in this process. CCN1 ( CYR61) is an extracellular matrix signaling molecule that has been implicated in neovascularization through its interactions with several endothelial integrin receptors. CCN1 has been shown to be up-regulated during the reparative phase of fracture healing; however, the role of CCN1 therein remains unclear. Here, the regulation of CCN1 expression in osteoblasts and the functional consequences thereof were studied. Stimulation of osteoblasts with VEGF resulted in a dose- and time-dependent up-regulation of CCN1 mRNA and protein. An up-regulation of both cell surface-associated CCN1 as well as extracellular matrix-associated CCN1 in osteoblasts was found. The supernatant of VEGF-prestimulated osteoblasts was chemotactic for endothelial cells, increasing their migration and stimulated capillary-like sprout formation. These effects could be attributed to the presence of CCN1 in the osteoblast supernatant as they were prevented by an antibody against CCN1 or by small interfering RNA-mediated knockdown of osteoblast CCN1. Moreover, the supernatant of VEGF-prestimulated osteoblasts induced angiogenesis in Matrigel plugs in vivo in a CCN1-dependent manner. In addition, blockade of CCN1 prevented bone fracture healing in mice. Taken together, the present work demonstrates a potential paracrine loop consisting of the VEGF-mediated up-regulation of CCN1 in osteoblasts that attracts endothelial cells and promotes angiogenesis. Such a loop could be operative during fracture healing.	NCI, EIB, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Heidelberg, Dept Internal Med 1, D-69120 Heidelberg, Germany; Univ Hosp Giessen Marburg, Dept Trauma Surg, D-35385 Giessen, Germany; Univ Texas, Hlth Ctr Tyler, Biomed Res Div, Tyler, TX USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg; University Hospital of Giessen & Marburg; University of Texas System; University of Texas at Tyler	Chavakis, T (corresponding author), NCI, EIB, Natl Inst Hlth, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Chavakis, Triantafyllos/ABE-8845-2020		NHLBI NIH HHS [R01 HL058869-06, R01 HL058869, R01 HL058869-05A3] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010664] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanasopoulos AN, 2006, BLOOD, V107, P2720, DOI 10.1182/blood-2005-08-3140; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Barcelos LS, 2005, J LEUKOCYTE BIOL, V78, P352, DOI 10.1189/jlb.1104682; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Chavakis T, 2004, FASEB J, V18, P1306, DOI 10.1096/fj.03-1009fje; DECKER B, 1995, ANAT RECORD, V242, P310, DOI 10.1002/ar.1092420304; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050-1738(00)00074-8; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Haigh JJ, 2000, DEVELOPMENT, V127, P1445; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kasperk C, 1997, CALCIFIED TISSUE INT, V61, P464, DOI 10.1007/s002239900369; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Korff T, 1999, J CELL SCI, V112, P3249; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Liegibel UM, 2002, J EXP MED, V196, P1387, DOI 10.1084/jem.20021017; Mandracchia V J, 2001, Clin Podiatr Med Surg, V18, P55; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Pendurthi UR, 2005, CANCER RES, V65, P9705, DOI 10.1158/0008-5472.CAN-05-0982; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Radke S, 2006, J ORTHOP RES, V24, P945, DOI 10.1002/jor.20097; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Shimoaka T, 2004, J BIOL CHEM, V279, P15314, DOI 10.1074/jbc.M312525200; Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955-2964.2006; Street J, 2000, CLIN ORTHOP RELAT R, P224, DOI 10.1097/00003086-200009000-00033; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; TRUETA J, 1963, J BONE JOINT SURG BR, V45, P402, DOI 10.1302/0301-620X.45B2.402; TRUETA J, 1960, J BONE JOINT SURG BR, V42, P367, DOI 10.1302/0301-620X.42B2.367; Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953; Winet H, 1996, BONE, V19, pS39, DOI 10.1016/S8756-3282(96)00133-0; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Zelzer E, 2002, DEVELOPMENT, V129, P1893; Zhou DM, 2005, J APPL PHYSIOL, V98, P2344, DOI 10.1152/japplphysiol.01093.2004	45	72	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26746	26753		10.1074/jbc.M705200200	http://dx.doi.org/10.1074/jbc.M705200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626014	hybrid, Green Accepted			2022-12-25	WOS:000249304900013
J	Lauer-Fields, JL; Cudic, M; Wei, S; Mari, F; Fields, GB; Brew, K				Lauer-Fields, Janelle L.; Cudic, Mare; Wei, Shuo; Mari, Frank; Fields, Gregg B.; Brew, Keith			Engineered sarafotoxins as tissue inhibitor of metalloproteinases-like matrix metalloproteinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; NMR-SPECTROSCOPY; SECONDARY STRUCTURE; MASS-SPECTROMETRY; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ENDOTHELIN; TIMP-1; PEPTIDE	The sarafotoxins and endothelins are similar to 25-residue peptides that spontaneously fold into a defined tertiary structure with specific pairing of four cysteines into two disulfide bonds. Their structures show an interesting topological similarity to the core of the metalloproteinase interaction sites of the tissue inhibitors of metalloproteinases. Previous work indicates that sarafotoxins and endothelins can be engineered to eliminate or greatly reduce their vasopressive action and that their structural framework can withstand multiple sequence changes. When sarafotoxin 6b, which possesses modest matrix metalloproteinase inhibitory activity, was C-terminally truncated to remove its toxic vasopressive activity, the metalloproteinase inhibitory activity was essentially abolished. However, further changes, based on the sequences of peptides selected from libraries of sarafotoxin variants or suggested by analogy with tissue inhibitors of metalloproteinases, progressively enhanced the matrix metalloproteinase inhibitory activity. Peptide variants with multiple substitutions folded correctly and formed native disulfide bonds. Improvements in matrix metalloproteinase affinity have generated a peptide with micromolar K-i values for matrix metalloproteinase-1 and -9 that are selective inhibitors of different metalloproteinases. Characterization of its solution structure indicates a close similarity to sarafotoxin but with a more extended C-terminal helix. The effects of N- acetylation and other changes, as well as docking studies, support the hypothesis that the engineered sarafo-toxins bind to matrix metalloproteinases in a manner analogous to the tissue inhibitors of metalloproteinases.	Florida Atlantic Univ, Coll Biomed Sci, Boca Raton, FL 33431 USA; Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA	State University System of Florida; Florida Atlantic University; State University System of Florida; Florida Atlantic University	Brew, K (corresponding author), Florida Atlantic Univ, Coll Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.	kbrew@fau.edu	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; Wei, Shuo/0000-0001-8203-4922	NATIONAL CANCER INSTITUTE [R01CA098799] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NCI NIH HHS [CA 98799, R01 CA098799] Funding Source: Medline; NCRR NIH HHS [P41 RR 001081] Funding Source: Medline; NIAMS NIH HHS [AR 40994] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham David, 2005, Current Vascular Pharmacology, V3, P369; AIMOTO S, 1990, BIOCHEM INT, V21, P1051; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Arumugam S, 2003, J MOL BIOL, V327, P719, DOI 10.1016/S0022-2836(03)00180-3; ATKINS AR, 1994, INT J PEPT PROT RES, V44, P372; ATKINS AR, 1995, BIOCHEMISTRY-US, V34, P2026, DOI 10.1021/bi00006a024; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; CODY WL, 1995, BIOPOLYMERS, V37, P89, DOI 10.1002/bip.360370205; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DUCANCEL F, 1993, J BIOL CHEM, V268, P3052; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fernandez-Patron C, 1999, CIRC RES, V85, P906; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Gray GA, 1996, PHARMACOL THERAPEUT, V72, P109, DOI 10.1016/S0163-7258(96)00101-5; Hayashi MAF, 2004, PEPTIDES, V25, P1243, DOI 10.1016/j.peptides.2004.05.010; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Iyer S, 2007, J BIOL CHEM, V282, P364, DOI 10.1074/jbc.M607625200; JANES RW, 1994, NAT STRUCT BIOL, V1, P311, DOI 10.1038/nsb0594-311; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KIMURA S, 1988, BIOCHEM BIOPH RES CO, V156, P1182, DOI 10.1016/S0006-291X(88)80757-5; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lauer-Fields JL, 2007, J BIOL CHEM, V282, P142, DOI 10.1074/jbc.M605236200; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; Maskos K, 2007, J MOL BIOL, V366, P1222, DOI 10.1016/j.jmb.2006.11.072; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; MILLS RG, 1991, FEBS LETT, V282, P247, DOI 10.1016/0014-5793(91)80488-O; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NAKAJIMA K, 1989, J CARDIOVASC PHARM, V13, pS8, DOI 10.1097/00005344-198900135-00004; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Price WS, 1999, ANNU REP NMR SPECTRO, V38, P289, DOI 10.1016/S0066-4103(08)60040-X; Quinton L, 2005, ANAL CHEM, V77, P6630, DOI 10.1021/ac050575k; RAMALINGAM K, 1993, BIOCHEMISTRY-US, V32, P11155, DOI 10.1021/bi00092a027; Ramnath Nithya, 2004, Curr Oncol Rep, V6, P96, DOI 10.1007/s11912-004-0020-7; Schneidman-Duhovny D, 2003, PROTEINS, V52, P107, DOI 10.1002/prot.10397; SOKOLOVSKY M, 1990, P NATL ACAD SCI USA, V87, P4702, DOI 10.1073/pnas.87.12.4702; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; van den Hooven HW, 2001, BIOCHEMISTRY-US, V40, P3458, DOI 10.1021/bi0023089; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	54	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26948	26955		10.1074/jbc.M611612200	http://dx.doi.org/10.1074/jbc.M611612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626018	hybrid			2022-12-25	WOS:000249304900034
J	Reddy, MCM; Palaninathan, SK; Shetty, ND; Owen, JL; Watson, MD; Sacchettini, JC				Reddy, Manchi C. M.; Palaninathan, Satheesh K.; Shetty, Nishant D.; Owen, Joshua L.; Watson, Misty D.; Sacchettini, James C.			High resolution crystal structures of Mycobacterium tuberculosis adenosine kinase - Insights into the mechanism and specificity of this novel prokaryotic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTAVALENT IONS DEPENDENCY; ESCHERICHIA-COLI; TOXOPLASMA-GONDII; METABOLISM; RIBOKINASE; 2-METHYLADENOSINE; IDENTIFICATION; RECOGNITION; INHIBITORS; EVOLUTION	Adenosine kinase (ADK) catalyzes the phosphorylation of adenosine (Ado) to adenosine monophosphate (AMP). It is part of the purine salvage pathway that has been identified only in eukaryotes, with the single exception of Mycobacterium spp. Whereas it is not clear if Mycobacterium tuberculosis (Mtb) ADK is essential, it has been shown that the enzyme can selectively phosphorylate nucleoside analogs to produce products toxic to the cell. We have determined the crystal structure of Mtb ADK unliganded as well as ligand (Ado) bound at 1.5- and 1.9-angstrom resolution, respectively. The structure of the binary complexes with the inhibitor 2-fluoroadenosine (F-Ado) bound and with the adenosine 5'-(beta,gamma- methylene) triphosphate (AMPPCP) (non-hydrolyzable ATP analog) bound were also solved at 1.9- A resolution. These four structures indicate that Mtb ADK is a dimer formed by an extended beta sheet. The active site of the unliganded ADK is in an open conformation, and upon Ado binding a lid domain of the protein undergoes a large conformation change to close the active site. In the closed conformation, the lid forms direct interactions with the substrate and residues of the active site. Interestingly, AMP-PCP binding alone was not sufficient to produce the closed state of the enzyme. The binding mode of F-Ado was characterized to illustrate the role of additional non-bonding interactions in Mtb ADK compared with human ADK.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI068135] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI 68135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrow EW, 2003, J ANTIMICROB CHEMOTH, V52, P801, DOI 10.1093/jac/dkg444; Basso LA, 1998, J INFECT DIS, V178, P769, DOI 10.1086/515362; Basso LA, 2001, BIOCHEMISTRY-US, V40, P8196, DOI 10.1021/bi010584x; BORK P, 1993, PROTEIN SCI, V2, P31; BROCKMAN RW, 1980, CANCER RES, V40, P3610; Chen CK, 2002, MICROBIOL-SGM, V148, P289, DOI 10.1099/00221287-148-1-289; CHRISTOPHER JA, 1998, CTR MACROMOLECULAR D; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cook WJ, 2000, PROTEIN SCI, V9, P704; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Duncan K, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P297; Hao WH, 1996, BIOCHEM MOL BIOL INT, V38, P889; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kantardjieff KA, 2002, ACTA CRYSTALLOGR D, V58, P735, DOI 10.1107/S0O907444901019588; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Long MC, 2006, BIOCHEM PHARMACOL, V71, P1671, DOI 10.1016/j.bcp.2006.03.006; Long MC, 2007, J ANTIMICROB CHEMOTH, V59, P118, DOI 10.1093/jac/dkl448; Long MC, 2003, J BACTERIOL, V185, P6548, DOI 10.1128/JB.185.22.6548-6555.2003; Maj MC, 2002, BIOCHEMISTRY-US, V41, P4059, DOI 10.1021/bi0119161; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER RL, 1979, J BIOL CHEM, V254, P2346; Ogata CM, 1998, NAT STRUCT BIOL, V5, P638, DOI 10.1038/1330; Ohshima N, 2004, J MOL BIOL, V340, P477, DOI 10.1016/j.jmb.2004.04.074; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park BK, 2001, ANNU REV PHARMACOL, V41, P443, DOI 10.1146/annurev.pharmtox.41.1.443; Parker WB, 2004, TUBERCULOSIS, V84, P327, DOI 10.1016/j.tube.2004.02.004; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PITTILLO R F, 1964, Antimicrob Agents Chemother (Bethesda), V10, P474; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Sigrell JA, 1997, PROTEIN SCI, V6, P2474; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; Spychala J, 1996, P NATL ACAD SCI USA, V93, P1232, DOI 10.1073/pnas.93.3.1232; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; *WHO, 1993, WORLD HEALTH FORUM, V14, P438; WU LF, 1991, J BACTERIOL, V173, P3117, DOI 10.1128/JB.173.10.3117-3127.1991; Zhang Y, 2004, STRUCTURE, V12, P1809, DOI 10.1016/j.str.2004.07.020	44	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27334	27342		10.1074/jbc.M703290200	http://dx.doi.org/10.1074/jbc.M703290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17597075	hybrid			2022-12-25	WOS:000249304900075
J	Rimon, A; Tzubery, T; Padan, E				Rimon, Abraham; Tzubery, Tzvi; Padan, Etana			Monomers of the NhaA Na+/H+ antiporter of Escherichia coli are fully functional yet dimers are beneficial under extreme stress conditions at alkaline pH in the presence of Na+ or Li+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CONFORMATIONAL-CHANGE; HUMAN ERYTHROCYTE-MEMBRANE; ANION TRANSPORT PROTEIN; PROJECTION STRUCTURE; OLIGOMERIC STATE; CORYNEBACTERIUM-GLUTAMICUM; STRUCTURAL INTERACTIONS; QUATERNARY STRUCTURE; ANGSTROM RESOLUTION; ION-TRANSPORT	NhaA, the Na+/ H+ antiporter of Escherichia coli, exists in the native membrane as a homodimer of which two monomers have been suggested to be attached by a beta-hairpin at the periplasmic side of the membrane. Constructing a mutant deleted of the beta-hairpin, NhaA/Delta( Pro(45)- Asn(58)), revealed that in contrast to the dimeric mobility of native NhaA, the mutant has the mobility of a monomer in a blue native gel. Intermolecular cross-linking that monitors dimers showed that the mutant exists only as monomers in the native membrane, proteoliposomes, and when purified in beta-dodecyl maltoside micelles. Furthermore, pull-down experiments revealed that, whereas as expected for a dimer, hemagglutinin-tagged wild-type NhaA co-purified with His-tagged NhaA on a Ni2+- NTA affinity column, a similar version of the mutant did not. Remarkably, under routine stress conditions ( 0.1 M LiCl, pH 7 or 0.6 M NaCl, pH 8.3), the monomeric form of NhaA is fully functional. It conferred salt resistance to NhaA- and NhaB-deleted cells, and whether in isolated membrane vesicles or reconstituted into proteoliposomes exhibited Na+/ H+ antiporter activity and pH regulation very similar to wild- type dimers. Remarkably, under extreme stress conditions ( 0.1 M LiCl or 0.7 M NaCl at pH 8.5), the dimeric native NhaA was much more efficient than the monomeric mutant in conferring extreme stress resistance.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	etana@vms.huji.ac.il						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brett CL, 2005, AM J PHYSIOL-CELL PH, V288, pC223, DOI 10.1152/ajpcell.00360.2004; CASEY JR, 1991, J BIOL CHEM, V266, P15726; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; Galili L, 2004, J BIOL CHEM, V279, P23104, DOI 10.1074/jbc.M400288200; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; Gerchman Y, 1999, J BIOL CHEM, V274, P24617, DOI 10.1074/jbc.274.35.24617; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Hilger D, 2005, BIOPHYS J, V89, P1328, DOI 10.1529/biophysj.105.062232; HILGER D, 2007, IN PRESS BIOPHYS J; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; IANOWSKI R, 2001, NAT STRUCT BIOL, V8, P316; Kozachkov L, 2007, BIOCHEMISTRY-US, V46, P2419, DOI 10.1021/bi602393s; Kramer R, 2004, BBA-BIOENERGETICS, V1658, P31, DOI 10.1016/j.bbabio.2004.05.006; Maris AE, 2005, J MOL BIOL, V350, P843, DOI 10.1016/j.jmb.2005.05.057; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; MURAKAMI S, 2006, NATURE; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; ORLOWSKI I, 2004, PFLUGERS ARCH, V447, P549; Padan E, 2005, BBA-BIOMEMBRANES, V1717, P67, DOI 10.1016/j.bbamem.2005.09.010; Padan E, 2004, BBA-BIOENERGETICS, V1658, P2, DOI 10.1016/j.bbabio.2004.04.018; PADAN E, 1989, J BIOL CHEM, V264, P20297; Padan E, 2001, BBA-BIOENERGETICS, V1505, P144, DOI 10.1016/S0005-2728(00)00284-X; Padan E, 1998, FEBS LETT, V441, P53, DOI 10.1016/S0014-5793(98)01524-5; PINNER E, 1993, J BIOL CHEM, V268, P1729; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Rimon A, 2002, BIOCHEMISTRY-US, V41, P14897, DOI 10.1021/bi0261342; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 2003, BLUE NATIVE ELECTROP, P105; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Screpanti E, 2006, J MOL BIOL, V362, P192, DOI 10.1016/j.jmb.2006.07.019; Slepkov ER, 2007, BIOCHEM J, V401, P623, DOI 10.1042/BJ20061062; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; Tsuboi Y, 2003, J BIOL CHEM, V278, P21467, DOI 10.1074/jbc.M301932200; Tzubery T, 2004, J BIOL CHEM, V279, P3265, DOI 10.1074/jbc.M309021200; Van Dort HM, 2001, J BIOL CHEM, V276, P46968, DOI 10.1074/jbc.M107855200; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; Venturi M, 2000, J BIOL CHEM, V275, P4734, DOI 10.1074/jbc.275.7.4734; Venturi M., 2002, PRACTICAL GUIDE MEMB, P179; Vinothkumar KR, 2006, J BIOL CHEM, V281, P4795, DOI 10.1074/jbc.M508993200; Vinothkumar KR, 2005, EMBO J, V24, P2720, DOI 10.1038/sj.emboj.7600727; Wakabayashi S, 2003, J BIOL CHEM, V278, P43580, DOI 10.1074/jbc.M306690200; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Yamaguchi T, 2005, TRENDS PLANT SCI, V10, P615, DOI 10.1016/j.tplants.2005.10.002; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	65	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26810	26821		10.1074/jbc.M704469200	http://dx.doi.org/10.1074/jbc.M704469200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635927	hybrid			2022-12-25	WOS:000249304900021
J	Corratge, C; Zimmermann, S; Lambilliotte, RRL; Plassard, C; Marmeisse, R; Thibaud, JB; Lacombe, B; Sentenac, H				Corratge, Claire; Zimmermann, Sabine; Lambilliotte, Raphael; Plassard, Claude; Marmeisse, Roland; Thibaud, Jean-Baptiste; Lacombe, Benoit; Sentenac, Herve			Molecular and functional characterization of a Na+-K+ transporter from the Trk family in the ectomycorrhizal fungus Hebeloma cylindrosporumk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY POTASSIUM; PINE PINUS-PINASTER; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; GLYCINE RESIDUES; ION-TRANSPORT; YEAST; CHANNEL; GENE; SELECTIVITY	Ectomycorrhizal symbiosis between fungi and woody plants strongly improves plant mineral nutrition and constitutes a major biological process in natural ecosystems. Molecular identification and functional characterization of fungal transport systems involved in nutrient uptake are crucial steps toward understanding the improvement of plant nutrition and the symbiotic relationship itself. In the present report a transporter belonging to the Trk family is identified in the model ectomycorrhizal fungus Hebeloma cylindrosporum and named HcTrk1. The Trk family is still poorly characterized, although it plays crucial roles in K+ transport in yeasts and filamentous fungi. In Saccharomyces cerevisiae K+ uptake is mainly dependent on the activity of Trk transporters thought to mediateH(+): K+ symport. The ectomycorrhizal HcTrk1 transporter was functional when expressed in Xenopus oocytes, enabling the first electrophysiological characterization of a transporter from the Trk family. HcTrk1 mediates instantaneously activating inwardly rectifying currents, is permeable to both K+ and Na+, and displays channellike functional properties. The whole set of data and particularly a phenomenon reminiscent of the anomalous mole fraction effect suggest that the transport does not occur according to the classical alternating access model. Permeation appears to occur through a single-file pore, where interactions between Na+ and K+ might result in Na+: K+ co-transport activity. HcTrk1 is expressed in external hyphae that explore the soil when the fungus grows in symbiotic condition. Thus, it could play a major role in both the K+ and Na+ nutrition of the fungus ( and of the plant) in nutrient-poor soils.	INRA, CNRS, UMR 5004, SupAgro,UMII, F-34060 Montpellier, France; CNRS, UCBL 1, Ecol Microbienne, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); VetAgro Sup	Sentenac, H (corresponding author), INRA, CNRS, UMR 5004, SupAgro,UMII, Pl Viala, F-34060 Montpellier, France.	sentenac@supagro.inra.fr	Lacombe, Benoit/B-1202-2013	Sentenac, Herve/0000-0003-3641-4822; THIBAUD, Jean-Baptiste/0000-0002-0824-6465; corratge-faillie, claire/0000-0002-5738-6712; Plassard, Claude/0000-0002-5844-438X; Lacombe, Benoit/0000-0001-9924-3093; Marmeisse, Roland/0000-0003-1653-3517; Zimmermann, Sabine D./0000-0002-5020-1447				Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Aidley D.J., 1996, ION CHANNELS MOL ACT; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON JA, 1991, GENE, V99, P39, DOI 10.1016/0378-1119(91)90031-6; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; Banuelos MA, 2000, MOL MICROBIOL, V37, P671, DOI 10.1046/j.1365-2958.2000.02040.x; Benito B, 2004, EUKARYOT CELL, V3, P359, DOI 10.1128/EC.3.2.359-368.2004; Benjdia M, 2006, NEW PHYTOL, V170, P401, DOI 10.1111/j.1469-8137.2006.01672.x; Berthomieu P, 2003, EMBO J, V22, P2004, DOI 10.1093/emboj/cdg207; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; Bertl A, 2003, MOL MICROBIOL, V47, P767, DOI 10.1046/j.1365-2958.2003.03335.x; Burgess T, 1996, MYCORRHIZA, V6, P189, DOI 10.1007/s005720050125; CAMACHO M, 1981, CURR MICROBIOL, V6, P295, DOI 10.1007/BF01566880; Casarin V, 2003, AGRONOMIE, V23, P461, DOI 10.1051/agro:2003020; Chalot M, 2002, PLANT SOIL, V244, P165, DOI 10.1023/A:1020240709543; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEBAUD JC, 1987, NEW PHYTOL, V105, P429, DOI 10.1111/j.1469-8137.1987.tb00880.x; DeFelice LJ, 2004, NATURE, V432, P279, DOI 10.1038/432279a; DeFelice LJ, 2007, ANNU REV PHYSIOL, V69, P87, DOI 10.1146/annurev.physiol.69.031905.164816; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gadsby DC, 2004, NATURE, V427, P795, DOI 10.1038/427795a; Gassmann W, 1996, PLANT J, V10, P869, DOI 10.1046/j.1365-313X.1996.10050869.x; Haro R, 2003, BBA-BIOMEMBRANES, V1613, P1, DOI 10.1016/S0005-2736(03)00132-9; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; Haro R, 2002, BBA-BIOMEMBRANES, V1564, P114, DOI 10.1016/S0005-2736(02)00408-X; Haro R, 1999, MOL MICROBIOL, V31, P511, DOI 10.1046/j.1365-2958.1999.01192.x; Harrison MJ, 2005, ANNU REV MICROBIOL, V59, P19, DOI 10.1146/annurev.micro.58.030603.123749; Heckman DS, 2001, SCIENCE, V293, P1129, DOI 10.1126/science.1061457; Hille B, 2001, ION CHANNELS EXCITAB, P1; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jargeat P, 2000, MOL GEN GENET, V263, P948, DOI 10.1007/PL00008695; Jargeat P, 2003, CURR GENET, V43, P199, DOI 10.1007/s00294-003-0387-2; Javelle A, 2001, FEBS LETT, V505, P393, DOI 10.1016/S0014-5793(01)02802-2; Jongmans AG, 1997, NATURE, V389, P682, DOI 10.1038/39493; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Kiefer E, 2000, PLANT MOL BIOL REP, V18, P33, DOI 10.1007/BF02825291; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; Kuroda T, 2004, J MEMBRANE BIOL, V198, P177, DOI 10.1007/s00232-004-0671-1; Lacombe B, 1998, J MEMBRANE BIOL, V166, P91, DOI 10.1007/s002329900451; Lambilliotte R, 2004, NEW PHYTOL, V164, P505, DOI 10.1111/j.1469-8137.2004.01185.x; Landeweert R, 2001, TRENDS ECOL EVOL, V16, P248, DOI 10.1016/S0169-5347(01)02122-X; Lauger P., 1991, ELECTROGENIC ION PUM; LichtenbergFrate H, 1996, J MEMBRANE BIOL, V152, P169, DOI 10.1007/s002329900095; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; Maathuis FJM, 1996, PHYSIOL PLANTARUM, V96, P158, DOI 10.1111/j.1399-3054.1996.tb00197.x; MARDIN F, 2007, NEW PHYSL, V176, P225; Marmeisse R, 2004, NEW PHYTOL, V163, P481, DOI 10.1111/j.1469-8137.2004.01148.x; MARX DH, 1969, PHYTOPATHOLOGY, V59, P153; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; Maser P, 2002, FEBS LETT, V531, P157, DOI 10.1016/S0014-5793(02)03488-9; Molina ML, 2006, J BIOL CHEM, V281, P18837, DOI 10.1074/jbc.M600342200; Nielsen CB, 2004, PLOS BIOL, V2, P2234, DOI 10.1371/journal.pbio.0020422; PLASSARD C, 1994, CAN J BOT, V72, P189, DOI 10.1139/b94-026; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAPIOR S, 1987, T BRIT MYCOL SOC, V89, P41, DOI 10.1016/S0007-1536(87)80055-4; Rivetta A, 2005, BIOPHYS J, V89, P2412, DOI 10.1529/biophysj.105.066712; Rodriguez-Navarro A, 2000, BBA-REV BIOMEMBRANES, V1469, P1, DOI 10.1016/S0304-4157(99)00013-1; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; RYGIEWICZ PT, 1984, PLANT PHYSIOL, V76, P918, DOI 10.1104/pp.76.4.918; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEROMM P, 1990, NEW PHYTOL, V114, P93, DOI 10.1111/j.1469-8137.1990.tb00378.x; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SIMON L, 1993, NATURE, V363, P67, DOI 10.1038/363067a0; SMITH SE, 1997, MYCORRHIZAL SYMBOSIS; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Stein W., 1990, CHANNELS CARRIERS PU; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; Tholema N, 2005, J BIOL CHEM, V280, P41146, DOI 10.1074/jbc.M507647200; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; Very AA, 2003, ANNU REV PLANT BIOL, V54, P575, DOI 10.1146/annurev.arplant.54.031902.134831; Zeng GF, 2004, J BIOL CHEM, V279, P3003, DOI 10.1074/jbc.M309760200	79	44	44	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26057	26066		10.1074/jbc.M611613200	http://dx.doi.org/10.1074/jbc.M611613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626012	Green Published, hybrid			2022-12-25	WOS:000249239600009
J	Roggero, CM; Blas, GA; Dai, H; Tomes, CN; Rizo, J; Mayorga, LS				Roggero, Carlos M.; De Blas, Gerardo A.; Dai, Han; Tomes, Claudia N.; Rizo, Josep; Mayorga, Luis S.			Complexin/synaptotagmin interplay controls acrosomal exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEUROTRANSMITTER RELEASE; SYNAPTOTAGMIN-I; 3-DIMENSIONAL STRUCTURE; TRANSMITTER RELEASE; C(2)A DOMAIN; CA2+ BINDING; COMPLEXINS; SPERM; CELLS	Regulated secretion is a fundamental process underlying the function of many cell types. In particular, acrosomal exocytosis in mammalian sperm is essential for egg fertilization. Regulated secretion requires SNARE proteins and, in neurons, also synaptotagmin I and complexin. Recent reports suggest that complexin imposes a fusion block that is released by Ca2+ and synaptotagmin I. However, no direct evidence for this model in secreting cells has been provided and whether this complexin/synaptotagmin interplay functions in other types of secretion is unknown. In this report, we show that the C2B domain of synaptotagmin VI and an anti-complexin antibody blocked the formation of trans SNARE complexes in permeabilized human sperm, and that this effect was reversed by adding complexin. In contrast, an excess of complexin stopped exocytosis at a later step, when SNAREs were assembled in loose trans complexes. Interestingly, this blockage was released by the addition of the synaptotagmin VI C2B domain in the presence of Ca2+. We have previously demonstrated that the activity of this domain is regulated by protein kinase C-mediated phosphorylation. Here, we show that a phosphomimetic mutation in the polybasic region of the C2B domain strongly affects its Ca2+ and phospholipids binding properties. Importantly, this mutation completely abrogates its ability to rescue the complexin block. Our results show that the functional interplay between complexin and synaptotagmin has a central role in a physiological secretion event, and that this interplay can be modulated by phosphorylation of the C2B domain.	Univ Nacl Cuyo, Fac Ciencias Med, Inst Histol & Embriol IHEM CONICET, Lab Biol Celulary & Mol, RA-5500 Mendoza, Argentina; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mayorga, LS (corresponding author), Casilla Correo 56, RA-5500 Mendoza, Argentina.	lmayorga@fcm.uncu.edu.ar	Roggero, Carlos/AAX-4354-2020	Mayorga, Luis S/0000-0002-5995-0671	NINDS NIH HHS [NS40944] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040944] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abderrahmani A, 2004, J CELL SCI, V117, P2239, DOI 10.1242/jcs.01041; Arac D, 2006, NAT STRUCT MOL BIOL, V13, P209, DOI 10.1038/nsmb1056; BORDEN CR, 2005, MOL CEL NEUROSCI, V29, P42; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Dai H, 2007, J MOL BIOL, V367, P848, DOI 10.1016/j.jmb.2007.01.040; Darszon A, 2006, REPRODUCTION, V131, P977, DOI 10.1530/rep.1.00612; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; De Blas GA, 2005, PLOS BIOL, V3, P1801, DOI 10.1371/journal.pbio.0030323; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2002, J NEUROSCI, V22, P8438; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Giraudo CG, 2006, SCIENCE, V313, P676, DOI 10.1126/science.1129450; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Loewen CA, 2006, MOL BIOL CELL, V17, P5211, DOI 10.1091/mbc.E06-07-0622; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Redecker P, 2003, J HISTOCHEM CYTOCHEM, V51, P809, DOI 10.1177/002215540305100612; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Rickman C, 2006, MOL BIOL CELL, V17, P283, DOI 10.1091/mbc.E05-07-0620; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Roggero CM, 2005, DEV BIOL, V285, P422, DOI 10.1016/j.ydbio.2005.07.007; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schaub JR, 2006, NAT STRUCT MOL BIOL, V13, P748, DOI 10.1038/nsmb1124; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tadokoro S, 2005, J CELL SCI, V118, P2239, DOI 10.1242/jcs.02338; Tang J, 2006, CELL, V126, P1175, DOI 10.1016/j.cell.2006.08.030; TOMES C, 2006, MOL MECH EXOCYTOSIS, P117; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; Yanagimachi R., 1994, P189; Zhao LM, 2007, MOL REPROD DEV, V74, P750, DOI 10.1002/mrd.20660	39	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26335	26343		10.1074/jbc.M700854200	http://dx.doi.org/10.1074/jbc.M700854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17613520	hybrid			2022-12-25	WOS:000249239600038
J	Sari, F; Braus, GH; Irniger, S				Sari, Fatih; Braus, Gerhard H.; Irniger, Stefan			A process independent of the anaphase-promoting complex contributes to instability of the yeast S phase cyclin Clb5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; APC-DEPENDENT PROTEOLYSIS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; DESTRUCTION BOX; MITOTIC CYCLIN; PERSISTS UNTIL; G1 CYCLINS; DEGRADATION	Proteolytic destruction of many cyclins is induced by a multisubunit ubiquitin ligase termed the anaphase promoting complex/ cyclosome (APC/C). In the budding yeast Saccharomyces cerevisiae, the S phase cyclin Clb5 and the mitotic cyclins Clb1-4 are known as substrates of this complex. The relevance of APC/C in proteolysis of Clb5 is still under debate. Importantly, a deletion of the Clb5 destruction box has little influence on cell cycle progression. To understand Clb5 degradation in more detail, we applied in vivo pulse labeling to determine the half-life of Clb5 at different cell cycle stages and in the presence or absence of APC/C activity. Clb5 is significantly unstable, with a half-life of similar to 8-10 min, at cell cycle periods when APC/C is inactive and in mutants impaired in APC/C function. A Clb5 version lacking its cyclin destruction box is similarly unstable. The half-life of Clb5 is further decreased in a destruction box-dependent manner to 3-5 min in mitotic or G(1) cells with active APC/C. Clb5 instability is highly dependent on the function of the proteasome. We conclude that Clb5 proteolysis involves two different modes for targeting of Clb5 to the proteasome, an APC/C-dependent and an APC/C-independent mechanism. These different modes apparently have overlapping functions in restricting Clb5 levels in a normal cell cycle, but APC/C function is essential in the presence of abnormally high Clb5 levels.	Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany; Leibniz Univ Hannover, Inst Microbiol, D-30167 Hannover, Germany	University of Gottingen; Leibniz University Hannover	Irniger, S (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.	sirnige@gwdg.de	Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Asher G, 2006, BIOESSAYS, V28, P844, DOI 10.1002/bies.20447; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Huang JN, 2001, J CELL BIOL, V154, P85, DOI 10.1083/jcb.200102007; Irniger S, 1997, J CELL SCI, V110, P1523; Jackson LP, 2006, MOL CELL BIOL, V26, P2456, DOI 10.1128/MCB.26.6.2456-2466.2006; Jacobson MD, 2000, MOL CELL BIOL, V20, P4483, DOI 10.1128/MCB.20.13.4483-4493.2000; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Thornton BR, 2004, CELL CYCLE, V3, P629; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yeong FM, 2001, MOL CELL BIOL, V21, P5071, DOI 10.1128/MCB.21.15.5071-5081.2001; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	38	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26614	10.1074/jbc.M703744200	http://dx.doi.org/10.1074/jbc.M703744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17620341	hybrid			2022-12-25	WOS:000249239600064
J	Atlason, PT; Garside, ML; Meddows, E; Whiting, P; McIlhinney, RAJ				Atlason, Palmi T.; Garside, Molly L.; Meddows, Elisabeth; Whiting, Paul; McIlhinney, R. A. Jeffrey			N-methyl-d-aspartate (NMDA) receptor subunit NR1 forms the substrate for oligomeric assembly of the NMDA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; GLYCINE BINDING DOMAIN; AMINO-ACID-RESIDUES; MOLECULAR DETERMINANTS; SURFACE EXPRESSION; GLUTAMATE RECEPTORS; IDENTIFICATION; RETENTION; SITE	The time course of the assembly of the N-methyl-D-aspartate receptor was examined in a cell line expressing it under the control of the dexamethasone promoter. These studies suggested a delay between the appearance of the NR1 and NR2A subunits and their stable association as examined by co-immunoprecipitation of NR1 and NR2A. This prompted us to examine the stability and folding of the individual subunits using nonreduced polyacrylamide gels and the sulfhydryl cross-linker BMH. Both studies showed that the NR1 subunit was expressed in a monomer and dimer form, whereas both NR2 and NR3 showed substantial aggregation on both nonreduced gels and after cross-linking. Protein degradation experiments showed that NR1 was relatively stable, whereas NR2 and NR3 were more rapidly degraded. When co-expressed with NR1, NR2 was more stable. Fluorescence recovery after photobleaching experiments showed that, under conditions of reduced ATP, the diffusion rate of NR2 and NR3 in the endoplasmic reticulum was reduced, whereas that of NR1 was unaffected. Together these data show that NR1 folds stably when expressed alone, unlike NR2 and NR3, and provides the substrate for assembly of the N-methyl-D-aspartate receptor.	MRC, Anatom Neuropharmacol Unit, Oxford OX1 3TH, England; Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Univ London, Royal Holloway Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England	Merck & Company; University of London; Royal Holloway University London	McIlhinney, RAJ (corresponding author), MRC, Anatom Neuropharmacol Unit, Oxford OX1 3TH, England.	jeff.mcilhinney@pharm.ox.ac.uk		Whiting, Paul/0000-0002-4121-1379	Medical Research Council [MC_U138162357] Funding Source: Medline; MRC [MC_U138162357] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Awobuluyi M, 2007, MOL PHARMACOL, V71, P112, DOI 10.1124/mol.106.03070; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Chan WY, 2001, MOL CELL NEUROSCI, V17, P577, DOI 10.1006/mcne.2001.0965; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; Chazot PL, 1997, J NEUROCHEM, V68, P507; CIABARRA AM, 1995, J NEUROSCI, V15, P6498; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; Dingledine R, 1999, PHARMACOL REV, V51, P7; Esapa CT, 2007, HUM MOL GENET, V16, P327, DOI 10.1093/hmg/ddl472; Esapa CT, 2005, HUM MOL GENET, V14, P295, DOI 10.1093/hmg/ddi026; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Furukawa H, 2005, NATURE, V438, P185, DOI 10.1038/nature04089; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; GARSIDE M, 2005, PHYSL SCI, P181; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; GRIMWOOD S, 1995, J NEUROCHEM, V64, P525; Grimwood S, 1996, J NEUROCHEM, V66, P2239; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Ivanovic A, 1998, J BIOL CHEM, V273, P19933, DOI 10.1074/jbc.273.32.19933; Kendrick SJ, 1996, J NEUROCHEM, V67, P608; Kinarsky L, 2005, J PHARMACOL EXP THER, V313, P1066, DOI 10.1124/jpet.104.082990; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; Madry C, 2007, BIOCHEM BIOPH RES CO, V354, P102, DOI 10.1016/j.bbrc.2006.12.153; Matsuda K, 2003, J NEUROSCI, V23, P10064; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; Miyazaki J, 1999, BIOCHEM J, V340, P687, DOI 10.1042/0264-6021:3400687; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Neugebauer R, 2003, BIOCHEM BIOPH RES CO, V305, P476, DOI 10.1016/S0006-291X(03)00768-X; Nishi M, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0003.2001; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Perez-Otano I, 2001, J NEUROSCI, V21, P1228; Qiu S, 2005, J BIOL CHEM, V280, P24923, DOI 10.1074/jbc.M413915200; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Sun LX, 1998, FEBS LETT, V441, P392, DOI 10.1016/S0014-5793(98)01590-7; Tichelaar W, 2004, J MOL BIOL, V344, P435, DOI 10.1016/j.jmb.2004.09.048; Varney MA, 1996, J PHARMACOL EXP THER, V279, P367	47	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25299	25307		10.1074/jbc.M702778200	http://dx.doi.org/10.1074/jbc.M702778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606616	hybrid			2022-12-25	WOS:000249014100015
J	Ishikita, H				Ishikita, Hiroshi			Influence of the protein environment on the redox potentials of flavodoxins from Clostridium beijerinckii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION POTENTIALS; DESULFOVIBRIO-VULGARIS HILDENBOROUGH; FLAVIN MONONUCLEOTIDE COFACTOR; REACTION CENTERS; MODULATION; ENERGETICS; SEMIQUINONE; ELECTRON; BINDING; PH	The flavin mononucleotide (FMN) quinones in flavodoxin have two characteristic redox potentials, namely, E-m(FMNH+/FMNH-) for the one-electron reduction of the protonatedFMN (E1) and E-m(FMN/FMNH+) for the proton-coupled one-electron reduction (E2). These redox potentials in native and mutant flavodoxins obtained from Clostridium beijerinckii were calculated by considering the protonation states of all titratable sites as well as the energy contributed at the pK(a) value of FMN during protonation at the N5 nitrogen (pK(a)(N5)). E1 is sensitive to the subtle differences in the protein environments in the proximity of FMN. The protein dielectric volume that prevents the solvation of charged FMN quinones is responsible for the downshift of 130-160 mV of the E1 values with respect to that in an aqueous solution. The influence of the negatively charged 5'-phosphate group of FMN quinone on E1 could result in a maximum shift of 90 mV. A dramatic difference of 130 mV in the calculated E2 values of FMN quinone of the native and G57T mutant flavodoxins is due to the difference in the pK(a)(N5) values. This is due to the difference in the influence exerted by the carbonyl group of the protein backbone at residue 57.	Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA	University of Southern California	Ishikita, H (corresponding author), Univ So Calif, Dept Chem, 417 SGM Bldg, Los Angeles, CA 90089 USA.	hzi1@usc.edu	Ishikita, Hiroshi/G-9864-2018	Ishikita, Hiroshi/0000-0002-5849-8150				ANDERSON RF, 1983, BIOCHIM BIOPHYS ACTA, V722, P158, DOI 10.1016/0005-2728(83)90169-X; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Bradley LH, 1999, BIOCHEMISTRY-US, V38, P12377, DOI 10.1021/bi991172f; Bradley LH, 2001, BIOCHEMISTRY-US, V40, P8686, DOI 10.1021/bi010571j; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CURLEY GP, 1991, EUR J BIOCHEM, V202, P1091, DOI 10.1111/j.1432-1033.1991.tb16475.x; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; Gunner MR, 2006, BBA-BIOENERGETICS, V1757, P942, DOI 10.1016/j.bbabio.2006.06.005; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Ishikita H, 2005, J BIOL CHEM, V280, P12446, DOI 10.1074/jbc.M413531200; Ishikita H, 2005, J AM CHEM SOC, V127, P1963, DOI 10.1021/ja045058i; Ishikita H, 2003, J BIOL CHEM, V278, P52002, DOI 10.1074/jbc.M306434200; Ishikita H, 2007, J AM CHEM SOC, V129, P1210, DOI 10.1021/ja066208n; Ishikita H, 2006, P NATL ACAD SCI USA, V103, P9855, DOI 10.1073/pnas.0601446103; Jestin I, 1998, J AM CHEM SOC, V120, P8150, DOI 10.1021/ja980603z; Kasim M, 2000, BIOCHEMISTRY-US, V39, P15322, DOI 10.1021/bi001519a; Kato M, 2006, PROTEINS, V64, P829, DOI 10.1002/prot.21012; Kumler WD, 1943, J AM CHEM SOC, V65, P2355, DOI 10.1021/ja01252a028; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; Mayhew SG, 1999, EUR J BIOCHEM, V265, P698, DOI 10.1046/j.1432-1327.1999.00767.x; McCarthy AA, 2002, BIOCHEMISTRY-US, V41, P10950, DOI 10.1021/bi020225h; Michaelis L, 1935, CHEM REV, V16, P243, DOI 10.1021/cr60054a004; Moonen CTW, 1984, FLAVINS FLAVOPROTEIN, P493; Niemz A, 1999, ACCOUNTS CHEM RES, V32, P44, DOI 10.1021/ar980046l; Popovic DM, 2002, J AM CHEM SOC, V124, P3775, DOI 10.1021/ja016249d; Pueyo JJ, 1996, BIOCHEM J, V313, P855, DOI 10.1042/bj3130855; Rabenstein B, 1998, EUR BIOPHYS J BIOPHY, V27, P626, DOI 10.1007/s002490050174; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; Tommos C, 1999, BIOCHEMISTRY-US, V38, P9495, DOI 10.1021/bi990609g; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; Watanabe T., 1991, CHLOROPHYLLS, P287; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; WILLIAMSON G, 1985, BIOCHEMISTRY-US, V24, P7790, DOI 10.1021/bi00347a043; Wodrich MD, 2007, ORG LETT, V9, P1851, DOI 10.1021/ol070354w; Zhou ZM, 1996, BIOCHEMISTRY-US, V35, P15980, DOI 10.1021/bi962124n; Zhou ZM, 1996, BIOCHEMISTRY-US, V35, P12443, DOI 10.1021/bi9610865; ZHOU ZM, 1995, BIOCHEMISTRY-US, V34, P3183, DOI 10.1021/bi00010a007	40	21	22	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25240	25246		10.1074/jbc.M702788200	http://dx.doi.org/10.1074/jbc.M702788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17602164	hybrid			2022-12-25	WOS:000249014100009
J	Huang, YY; Tran, PT; Oliferenko, S; Balasubramanian, MK				Huang, Yinyi; Tran, P. T.; Oliferenko, Snezhana; Balasubramanian, Mohan K.			Assembly of Microtubules and Actomyosin Rings in the Absence of Nuclei and Spindle Pole Bodies Revealed by a Novel Genetic Method	PLOS ONE			English	Article								Background. The nucleus and the centrosomes (spindle pole bodies; SPBs in yeast) are believed to play key roles in the organization of various cellular structures, such as the actomyosin ring and microtubules. The ability to generate cells lacking nuclei and centrosomes (SPBs) is key to the elucidation of the role of these structures in various cellular processes. Methodology/Principal Findings. Here we describe a genetic method, using the Schizosaccharomyces pombe cdc16-116 mutant, to reliably and efficiently generate fission yeast cells lacking nuclei and SPBs. We use this approach to show that the assembly of microtubules does not require nuclear associated microtubule organizing centers and SPBs. We also show that actomyosin rings can assemble albeit inefficiently in the absence of nuclei and SPBs. Conclusion. We conclude that key cytoskeletal elements can be assembled in the absence of nuclei and SPBs. In addition, the approach we describe, taken together with physical approaches such as centrifugation, should facilitate the investigation of the role of the nucleus and SPBs in the assembly and inheritance of various cellular structures and organelles.	[Huang, Yinyi; Oliferenko, Snezhana; Balasubramanian, Mohan K.] Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117548, Singapore; [Huang, Yinyi; Balasubramanian, Mohan K.] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Tran, P. T.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	National University of Singapore; National University of Singapore; University of Pennsylvania	Balasubramanian, MK (corresponding author), Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117548, Singapore.	mohan@tll.org.sg	Tran, Phong/F-1357-2015; Tran, Phong/GZA-8504-2022	Tran, Phong/0000-0002-2410-2277; Balasubramanian, Mohan/0000-0002-1292-8602; Oliferenko, Snezhana/0000-0002-8138-6851	TLL Summer Fellowship; NIH [RO1 GM70899]; Temasek Life Sciences Laboratory; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070899] Funding Source: NIH RePORTER	TLL Summer Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Temasek Life Sciences Laboratory(National University of Singapore); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a TLL Summer Fellowship and NIH RO1 GM70899 to PTT, and research funds from to the Temasek Life Sciences Laboratory to MKB.	Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; Bucciarelli E, 2003, J CELL BIOL, V160, P993, DOI 10.1083/jcb.200211029; Carazo-Salas RE, 2006, NAT CELL BIOL, V8, P1102, DOI 10.1038/ncb1479; Cerutti L, 1999, J CELL SCI, V112, P2313; Daga RR, 2006, NAT CELL BIOL, V8, P1108, DOI 10.1038/ncb1480; Daga RR, 2005, P NATL ACAD SCI USA, V102, P8228, DOI 10.1073/pnas.0409021102; Faruki S, 2002, CELL MOTIL CYTOSKEL, V52, P107, DOI 10.1002/cm.10036; Flory MR, 2002, CELL GROWTH DIFFER, V13, P47; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; Heitz MJ, 2001, J CELL SCI, V114, P4521; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Krapp A, 2004, CURR BIOL, V14, pR722, DOI 10.1016/j.cub.2004.08.049; Li TW, 2000, BIOCHEM BIOPH RES CO, V272, P270, DOI 10.1006/bbrc.2000.2767; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; Mishra M, 2005, CURR BIOL, V15, P1376, DOI 10.1016/j.cub.2005.06.070; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Naqvi NI, 2000, NAT CELL BIOL, V2, P855, DOI 10.1038/35041107; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; Rajagopalan S, 2004, CURR BIOL, V14, P69, DOI 10.1016/j.cub.2003.12.027; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Tran PT, 2004, METHODS, V33, P220, DOI 10.1016/j.ymeth.2003.11.017; West RR, 1998, MOL BIOL CELL, V9, P2839, DOI 10.1091/mbc.9.10.2839; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287; Zhang DH, 1996, NATURE, V382, P466, DOI 10.1038/382466a0	26	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e618	10.1371/journal.pone.0000618	http://dx.doi.org/10.1371/journal.pone.0000618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637834	Green Published, gold			2022-12-25	WOS:000207452100008
J	Kiselev, AO; Stamm, WE; Yates, JR; Lampe, MF				Kiselev, Andrey O.; Stamm, Walter E.; Yates, John R.; Lampe, Mary F.			Expression, Processing, and Localization of PmpD of Chlamydia trachomatis Serovar L2 during the Chlamydial Developmental Cycle	PLOS ONE			English	Article							OUTER-MEMBRANE PROTEINS; GENOME SEQUENCE; DIFFERENTIAL EXPRESSION; SURFACE-PROTEINS; IN-VITRO; PNEUMONIAE; AUTOTRANSPORTER; IDENTIFICATION; SECRETION; GENES	Background. While families of polymorphic membrane protein (pmp) genes have been identified in several Chlamydia species, their function remains mostly unknown. These proteins are of great interest, however, because of their location in the outer membrane and possible role in chlamydial virulence. Methodology/Principal Finding. We analyzed the relative transcription of the pmpD gene, a member of the pmp gene family in C. trachomatis serovar L2, and its protein product translation and processing during the chlamydial developmental cycle. By real-time reverse transcription polymerase chain reaction, the pmpD gene was found to be upregulated at 16 to 24 four hours after infection. Using polyclonal antibodies generated against the predicted passenger domain of PmpD, we demonstrated that it is initially localized on the surface of reticulate bodies, followed by its secretion outside Chlamydia starting at 24 hours after infection. In elementary bodies, we found a approximate to 157 kDa PmpD only inside the cell. Both events, the upregulation of pmpD gene transcription and PmpD protein processing and secretion, are coincidental with the period of replication and differentiation of RBs into EBs. We also demonstrated that, in the presence of penicillin, the cleavage and secretion of the putative passenger domain was suppressed. Conclusion/Significance. Our results are in agreement with the general concept that PmpD is an autotransporter protein which is post-translationally processed and secreted in the form of the putative passenger domain outside Chlamydia at mid-to- late point after infection, coinciding with the development of RBs into EBs.	[Kiselev, Andrey O.; Lampe, Mary F.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Stamm, Walter E.; Lampe, Mary F.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA; [Yates, John R.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Scripps Research Institute	Lampe, MF (corresponding author), Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.	lampe@u.washington.edu	d'Alessandro, Aldo/AAH-6554-2019; Niglio, Tarcisio/K-2496-2018	Niglio, Tarcisio/0000-0001-6555-2453	University of Washington	University of Washington(University of Washington)	This work was supported by a Royalty Research Fund grant from the University of Washington.	BARBOUR AG, 1982, J BACTERIOL, V151, P420, DOI 10.1128/JB.151.1.420-428.1982; Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100; BIRKELUND S, 1989, INFECT IMMUN, V57, P2683, DOI 10.1128/IAI.57.9.2683-2690.1989; Carlson JH, 2005, INFECT IMMUN, V73, P6407, DOI 10.1128/IAI.73.10.6407-6418.2005; Christiansen G, 2000, J INFECT DIS, V181, pS528, DOI 10.1086/315633; Crane DD, 2006, P NATL ACAD SCI USA, V103, P1894, DOI 10.1073/pnas.0508983103; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; Dautin N, 2007, EMBO J, V26, P1942, DOI 10.1038/sj.emboj.7601638; Desvaux M, 2004, RES MICROBIOL, V155, P53, DOI 10.1016/j.resmic.2003.10.002; Douglas AL, 2000, GENE, V247, P209, DOI 10.1016/S0378-1119(00)00094-9; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Eppens EF, 1997, EMBO J, V16, P4295, DOI 10.1093/emboj/16.14.4295; Fling SP, 2001, P NATL ACAD SCI USA, V98, P1160, DOI 10.1073/pnas.98.3.1160; GATLIN CL, 1998, PROTEIN IDENTIFICATI; Gomes JP, 2005, MICROBES INFECT, V7, P410, DOI 10.1016/j.micinf.2004.11.014; Goodall JC, 2001, EUR J IMMUNOL, V31, P1513, DOI 10.1002/1521-4141(200105)31:5<1513::AID-IMMU1513>3.0.CO;2-U; Grimwood J, 1999, Microb Comp Genomics, V4, P187, DOI 10.1089/omi.1.1999.4.187; Henderson IR, 2004, MICROBIOL MOL BIOL R, V68, P692, DOI 10.1128/MMBR.68.4.692-744.2004; Henderson IR, 2001, TRENDS MICROBIOL, V9, P573, DOI 10.1016/S0966-842X(01)02234-X; Hogan RJ, 2003, MICROB PATHOGENESIS, V34, P11, DOI 10.1016/S0882-4010(02)00187-0; Jose J, 2006, APPL MICROBIOL BIOT, V69, P607, DOI 10.1007/s00253-005-0227-z; Jose J, 2005, BIOCHEM BIOPH RES CO, V333, P1218, DOI 10.1016/j.bbrc.2005.06.028; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; KUO D, 1994, BIOCHEMISTRY-US, V33, P8347, DOI 10.1021/bi00193a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE MF, 1998, P 9 INT S HUM CHLAM, P555; LEE CK, 1978, ANTIMICROB AGENTS CH, V13, P441, DOI 10.1128/AAC.13.3.441; Lindquist EA, 1998, P 9 INT S HUM CHLAM, P259; Longbottom D, 1998, INFECT IMMUN, V66, P1317, DOI 10.1128/IAI.66.4.1317-1324.1998; Mathews SA, 1999, FEBS LETT, V458, P354, DOI 10.1016/S0014-5793(99)01182-5; Montigiani S, 2002, INFECT IMMUN, V70, P368, DOI 10.1128/IAI.70.1.368-379.2002; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; Mygind T, 2004, FEMS IMMUNOL MED MIC, V40, P129, DOI 10.1016/S0928-8244(03)00300-6; Nicholson TL, 2003, J BACTERIOL, V185, P3179, DOI 10.1128/JB.185.10.3179-3189.2003; Niessner A, 2003, J INFECT DIS, V188, P108, DOI 10.1086/375827; Pedersen AS, 2001, FEMS MICROBIOL LETT, V203, P153, DOI 10.1016/S0378-1097(01)00341-X; Read TD, 2003, NUCLEIC ACIDS RES, V31, P2134, DOI 10.1093/nar/gkg321; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; SUCHLAND RJ, 1991, J CLIN MICROBIOL, V29, P1333, DOI 10.1128/JCM.29.7.1333-1338.1991; Tanzer RJ, 2001, J BACTERIOL, V183, P2686, DOI 10.1128/JB.183.8.2686-2690.2001; Tanzer RJ, 2001, INFECT IMMUN, V69, P2428, DOI 10.1128/IAI.69.4.2428-2434.2001; Thomson NR, 2005, GENOME RES, V15, P629, DOI 10.1101/gr.3684805; Vandahl BBS, 2005, CELL MICROBIOL, V7, P825, DOI 10.1111/j.1462-5822.2005.00514.x; Vandahl BB, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-36; Vretou E, 2001, MICROBIOL-SGM, V147, P3303, DOI 10.1099/00221287-147-12-3303; Wehrl W, 2004, MOL MICROBIOL, V51, P319, DOI 10.1046/j.1365-2958.2003.03838.x	48	39	39	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e568	10.1371/journal.pone.0000568	http://dx.doi.org/10.1371/journal.pone.0000568			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593967	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451800012
J	Zhao, C; Inoue, J; Imoto, I; Otsuki, T; Iida, S; Ueda, R; Inazawa, J				Zhao, C.; Inoue, J.; Imoto, I.; Otsuki, T.; Iida, S.; Ueda, R.; Inazawa, J.			POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17	ONCOGENE			English	Article						multiple myeloma; POU2AF1; amplification TNFRSF17; array-CGH	CYCLIN D1 GENE; IDENTIFICATION; LYMPHOMA; PLASMA; OVEREXPRESSION; HYBRIDIZATION; ABNORMALITIES; BOB.1/OBF.1; ABERRATIONS; ACTIVATION	Multiple myeloma (MM), a progressive hematological neoplasm, is thought to result from multiple genetic events affecting the terminal plasma cell. However, genetic aberrations related to MM are seldom reported. Using our in-house array-based comparative genomic hybridization system to locate candidate target genes with following their expression analysis, we identified POU2AF1 at 11q23.1 as a probable amplification target in MM cell lines. POU2AF1 is a B-cell-specific transcriptional coactivator, which interacts with octamer-binding transcription factors Oct-1 and Oct-2, and augments their function. Downregulation of POU2AF1 expression by specific small-interfering RNA (siRNA) inhibited MM cell growth, whereas ectopic expression of POU2AF1 promoted growth of MM cells. Among putative transcriptional targets for POU2AF1, B-cell maturation factor, TNFRSF17, enhanced its transcription by POU2AF1, and POU2AF1 directly bound to an octamer site within the 50 region of TNFRSF17. Expression level of TNFRSF17 was closely correlated with that of POU2AF1 in cell lines and primary samples of MM, and decreasing TNFRSF17 expression by means of TNFRSF17 siRNA inhibited MM cell growth. Taken together, our results suggest that POU2AF1, when activated by amplification or other mechanisms, may contribute to progression of MM by accelerating growth of MM cells through direct transactivation of one of its target genes, TNFRSF17.	[Zhao, C.; Inoue, J.; Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; [Zhao, C.; Inazawa, J.] 21st Century Ctr Excellence Program Mol Destruct, Tokyo, Japan; [Inoue, J.; Imoto, I.; Inazawa, J.] Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Saitama, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan; [Otsuki, T.] Kawasaki Med Sch, Dept Hyg, Okayama, Japan; [Iida, S.; Ueda, R.] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Aichi, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); Kawasaki Medical School; Nagoya City University	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Zhao, Chen/D-8664-2012; Imoto, Issei/AAD-5799-2020					Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Cigudosa JC, 1998, BLOOD, V91, P3007, DOI 10.1182/blood.V91.8.3007.3007_3007_3010; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Cremer FW, 2005, CANCER GENET CYTOGEN, V161, P116, DOI 10.1016/j.cancergencyto.2005.02.015; Cremer FW, 2005, GENE CHROMOSOME CANC, V44, P194, DOI 10.1002/gcc.20231; Fonseca R, 2002, BLOOD, V100, P1417, DOI 10.1182/blood.V100.4.1417.h81602001417_1417_1424; Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876; Gonzalez MB, 2004, HAEMATOLOGICA, V89, P1213; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Gutierrez NC, 2001, LEUKEMIA, V15, P840, DOI 10.1038/sj.leu.2402116; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; Heckman CA, 2006, ONCOGENE, V25, P888, DOI 10.1038/sj.onc.1209127; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Hoechtlen-Vollmar W, 2000, BRIT J HAEMATOL, V109, P30, DOI 10.1046/j.1365-2141.2000.02007.x; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; KABAT D, 1972, SCIENCE, V175, P134, DOI 10.1126/science.175.4018.134; Kim U, 2003, P NATL ACAD SCI USA, V100, P8868, DOI 10.1073/pnas.1033108100; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; LADANYI M, 1992, AM J PATHOL, V141, P949; Largo C, 2006, HAEMATOL-HEMATOL J, V91, P184; Lins K, 2003, EMBO J, V22, P2188, DOI 10.1093/emboj/cdg199; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Miura K, 2003, CANCER SCI, V94, P350, DOI 10.1111/j.1349-7006.2003.tb01445.x; Moreau LA, 2006, CLIN CANCER RES, V12, P5693, DOI 10.1158/1078-0432.CCR-06-1500; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood-2003-06-2043; Robetorye RS, 2002, J MOL DIAGN, V4, P123, DOI 10.1016/S1525-1578(10)60693-9; Samardzic T, 2002, MOL CELL BIOL, V22, P8320, DOI 10.1128/MCB.22.23.8320-8331.2002; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; SCHUSCHEREBA ST, 2001, P SOC PHOTO-OPT INS, V2, P1; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Sonoki T, 1998, INT J HEMATOL, V68, P459; Standal T, 2004, HAEMATOLOGICA, V89, P174; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Teitell MA, 2003, TRENDS IMMUNOL, V24, P546, DOI 10.1016/j.it.2003.08.002; TRICOT G, 1995, BLOOD, V86, P4250, DOI 10.1182/blood.V86.11.4250.bloodjournal86114250; Yu X, 2001, IMMUNITY, V14, P157, DOI 10.1016/S1074-7613(09)00090-9; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	48	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					63	75		10.1038/sj.onc.1210637	http://dx.doi.org/10.1038/sj.onc.1210637			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17621271				2022-12-25	WOS:000252118700007
J	Anastasi, S; Baietti, MF; Frosi, Y; Alema, S; Segatto, O				Anastasi, S.; Baietti, M. F.; Frosi, Y.; Alema, S.; Segatto, O.			The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity	ONCOGENE			English	Article						EGFR; RALT; MIG6; feedback inhibition; negative signalling; tumour suppression	GROWTH-FACTOR RECEPTOR; NEGATIVE REGULATOR; TYROSINE KINASE; ERBB RECEPTORS; ENDOCYTOSIS; DOMAIN; SIGNAL; INHIBITION; RALT; UBIQUITYLATION	Physiological signalling by the epidermal growth factor receptor ( EGFR) controls developmental processes and tissue homeostasis, whereas aberrant EGFR activity drives oncogenic cell transformation. Under normal conditions, the EGFR must therefore generate outputs of defined strength and duration. To this aim, cells balance EGFR activity via different modalities of negative signalling. Increasing attention is being drawn on transcriptionally controlled feedback inhibitors of EGFR, namely RALT/MIG6, LRIG1, SOCS4 and SOCS5. Genetic studies in mice have revealed the essential role of Ralt/Mig6 in regulating Egfr-driven skin morphogenesis and tumour formation, yet the mechanisms through which RALT abrogates EGFR activity are still undefined. We report that RALT suppresses EGFR function by inhibiting its catalytic activity. The evolutionarily conserved ErbB-binding region (EBR) is necessary and sufficient to carry out RALT-dependent suppression of EGFR kinase activity in vitro and in intact cells. The mechanism involves binding of the EBR to the 953RYLVIQ958 sequence, which is located in the alpha I helix of the EGFR kinase and has been shown to participate in allosteric control of EGFR catalytic activity. Our results uncover a novel mechanism of temporal regulation of EGFR activity in vertebrate organisms.	[Anastasi, S.; Baietti, M. F.; Frosi, Y.; Segatto, O.] Regina Elena Inst Canc Res, Immunol Lab, Dept Expt Oncol, I-00158 Rome, Italy; [Alema, S.] CNR, Inst Cell Biol, I-00016 Monterotondo, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)	Anastasi, S (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Dept Expt Oncol, Via Delle Messi Oro 156-158, I-00158 Rome, Italy.	anastasi@ifo.it; segatto@ifo.it	anastasi, sergio/AAB-9585-2020; Baietti, Maria Francesca/AAA-6749-2019	anastasi, sergio/0000-0003-1009-6117; Baietti, Maria Francesca/0000-0002-1495-226X; Alema, Stefano/0000-0002-9869-6354; Segatto, Oreste/0000-0003-2561-1142				Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Ballaro C, 2005, EMBO REP, V6, P755, DOI 10.1038/sj.embor.7400458; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Haslekas C, 2005, MOL BIOL CELL, V16, P5832, DOI 10.1091/mbc.E05-05-0456; Hendriks BS, 2003, CANCER RES, V63, P1130; HSU CYJ, 1991, J BIOL CHEM, V266, P603; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kochupurakkal BS, 2005, J BIOL CHEM, V280, P8503, DOI 10.1074/jbc.M413919200; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790	39	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7833	7846		10.1038/sj.onc.1210590	http://dx.doi.org/10.1038/sj.onc.1210590			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599051				2022-12-25	WOS:000252163500002
J	Barbaric, S; Luckenbach, T; Schmid, A; Blaschke, D; Horz, W; Korber, P				Barbaric, Slobodan; Luckenbach, Tim; Schmid, Andrea; Blaschke, Dorothea; Hoerz, Wolfram; Korber, Philipp			Redundancy of chromatin remodeling pathways for the induction of the yeast PHO5 promoter in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE CHAPERONE ASF1; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; POSITIONED NUCLEOSOMES; SNF2 FAMILY; H2A VARIANT; TARGET SITE; SWI-SNF; GENE; COMPLEX	Induction of the yeast PHO5 and PHO8 genes leads to a prominent chromatin transition at their promoter regions as a prerequisite for transcription activation. Although induction of PHO8 is strictly dependent on Snf2 and Gcn5, there is no chromatin remodeler identified so far that would be essential for the opening of PHO5 promoter chromatin. Nonetheless, the nonessential but significant involvement of cofactors; can be identified if the chromatin opening kinetics are delayed in the respective mutants. Using this approach, we have tested individually all 15 viable Snf2 type ATPase deletion mutants for their effect on PHO5 promoter induction and opening. Only the absence of Snf2 and Ino80 showed a strong delay in chromatin remodeling kinetics. The snf2 ino80 double mutation had a synthetic kinetic effect but eventually still allowed strong PHO5 induction. The same was true for the snf2 gcn5 and ino80 gcn5 double mutants. This strongly suggests a complex network of redundant and mutually independent parallel pathways that lead to the remodeling of the PHO5 promoter. Further, chromatin remodeling kinetics at a transcriptionally inactive TATA box-mutated PHO5 promoter were affected neither under wild type conditions nor in the absence of Snf2 or Gcn5. This demonstrates the complete independence of promoter chromatin opening from downstream PHO5 transcription processes. Finally, the histone variant Htz1 has no prominent role for the kinetics of PHO5 promoter chromatin remodeling.	Univ Munich, Adolf Butenadt Inst, D-80336 Munich, Germany; Univ Zagreb, Fac Food Technol & Biotechnol, Biochem Lab, Zagreb 10000, Croatia	University of Munich; University of Zagreb	Korber, P (corresponding author), Univ Munich, Adolf Butenadt Inst, 44 Schillerstr, D-80336 Munich, Germany.	pkorber@lmu.de	Korber, Philipp/AAN-7633-2021	Korber, Philipp/0000-0001-7526-6549				Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Albert I, 2007, NATURE, V446, P572, DOI 10.1038/nature05632; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Auesukaree C, 2004, J BIOL CHEM, V279, P17289, DOI 10.1074/jbc.M312202200; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; Barbaric S, 2003, MOL CELL BIOL, V23, P3468, DOI 10.1128/MCB.23.10.3468-3476.2003; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; Collart MA, 1996, MOL CELL BIOL, V16, P6668; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; Dhasarathy A, 2005, MOL CELL BIOL, V25, P2698, DOI 10.1128/MCB.25.7.2698-2707.2005; Ebbert R, 1999, MOL MICROBIOL, V32, P741, DOI 10.1046/j.1365-2958.1999.01390.x; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Ertinger G., 1998, THESIS U MUNCHEN; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Gregory PD, 1999, METH MOL B, V119, P417; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Guillemette B, 2006, BIOCHEM CELL BIOL, V84, P528, DOI 10.1139/O06-077; HAGUENAUERTSAPIS R, 1984, MOL CELL BIOL, V4, P2668, DOI 10.1128/MCB.4.12.2668; Hertel CB, 2005, MOL CELL BIOL, V25, P10755, DOI 10.1128/MCB.25.24.10755-10767.2005; Huang SD, 2005, GENETICS, V169, P1859, DOI 10.1534/genetics.104.038695; Jonsdottir S, 2000, ROBOT CIM-INT MANUF, V16, P465, DOI 10.1016/S0736-5845(00)00018-1; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Korber P, 2006, J BIOL CHEM, V281, P5539, DOI 10.1074/jbc.M513340200; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Li B, 2005, P NATL ACAD SCI USA, V102, P18385, DOI 10.1073/pnas.0507975102; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Liu X, 2006, GENOME RES, V16, P1517, DOI 10.1101/gr.5655606; Lorch Y, 2006, P NATL ACAD SCI USA, V103, P3090, DOI 10.1073/pnas.0511050103; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Martens JA, 2005, GENE DEV, V19, P2695, DOI 10.1101/gad.1367605; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; Moshkin YM, 2002, GENE DEV, V16, P2621, DOI 10.1101/gad.231202; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Nourani A, 2004, EMBO J, V23, P2597, DOI 10.1038/sj.emboj.7600230; Peterson CL, 2000, FEBS LETT, V476, P68, DOI 10.1016/S0014-5793(00)01673-2; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Raisner RM, 2006, CURR OPIN GENET DEV, V16, P119, DOI 10.1016/j.gde.2006.02.005; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Reinke H, 2001, MOL CELL, V7, P529, DOI 10.1016/S1097-2765(01)00200-3; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Roberts SM, 1997, GENETICS, V147, P451; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Springer M, 2003, PLOS BIOL, V1, P261, DOI 10.1371/journal.pbio.0000028; Stafford GA, 2001, MOL CELL BIOL, V21, P4568, DOI 10.1128/MCB.21.14.4568-4578.2001; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; Thomas MR, 2005, P NATL ACAD SCI USA, V102, P9565, DOI 10.1073/pnas.0501122102; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Uhler JP, 2007, P NATL ACAD SCI USA, V104, P8011, DOI 10.1073/pnas.0702431104; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036	87	74	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27610	27621		10.1074/jbc.M700623200	http://dx.doi.org/10.1074/jbc.M700623200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17631505	hybrid			2022-12-25	WOS:000249455600008
J	Goedken, M; McCormick, S; Leidal, KG; Suzuki, K; Kameoka, Y; Astern, JM; Huang, M; Cherkasov, A; Nauseef, WM				Goedken, Melissa; McCormick, Sally; Leidal, Kevin G.; Suzuki, Kazuo; Kameoka, Yosuke; Astern, Joshua M.; Huang, Meilan; Cherkasov, Artem; Nauseef, William M.			Impact of two novel mutations on the structure and functoon of human myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS EMPLOY; PROSTHETIC HEME MODIFICATION; MYELOID LYSOSOMAL-ENZYME; PEROXIDE-CHLORIDE SYSTEM; PROTEIN COVALENT BONDS; RAY CRYSTAL-STRUCTURE; LEUKEMIA-CELL LINE; ALPHA-AMINO-ACIDS; HYDROGEN-PEROXIDE; REACTIVE ALDEHYDES	The heme protein myeloperoxidase (MPO) contributes critically to O-2-dependent neutrophil antimicrobial activity. Two Japanese adults were identified with inherited MPO deficiency because of mutations at Arg-499 or Gly-501, conserved residues near the proximal histidine in the heme pocket. Because of the proximity of these residues to a critical histidine in the heme pocket, we examined the biosynthesis, function, and spectral properties of the peroxidase stably expressed in human embryonic kidney cells. Biosynthesis of normal MPO by human embryonic kidney cells faithfully mirrored events previously identified in cells expressing endogenous MPO. Mutant apopro-MPO was 90 kDa and interacted normally with the molecular chaperones ERp57, calreticulin, and calnexin in the endoplasmic reticulum. However, mutant precursors were not proteolytically processed into subunits of MPO, although secretion of the unprocessed precursors occurred normally. Although delta-[C-14]aminolevulinic acid incorporation demonstrated formation of pro-MPO in both mutants, neither protein was enzymatically active. The Soret band for each mutant was shifted from the normal 430 to similar to 412 nm, confirming that heme was incorporated but suggesting that the number of covalent bonds or other structural aspects of the heme pocket were disrupted by the mutations. These studies demonstrate that despite heme incorporation, mutations in the heme environs compromised the oxidizing potential of MPO.	Univ Iowa, Vet Affairs Med Ctr, Dept Med, Inflammat Program, Iowa City, IA 52241 USA; Natl Inst Infect Dis, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Biomed Innovat, Div Biomed Resources, Lab Genet Resources, Ibaraki 5670085, Japan; Univ N Carolina, Kidney Ctr, Chapel Hill, NC 27599 USA; Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; National Institute of Infectious Diseases (NIID); National Institute of Health Sciences - Japan; University of North Carolina; University of North Carolina Chapel Hill; University of British Columbia	Nauseef, WM (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Inflammat Program, D160 MTF,2501 Crosspk Rd, Coralville, IA 52241 USA.	william-nauseef@uiowa.edu	Cherkasov, Artem/A-2134-2012	Nauseef, William/0000-0003-4032-757X	NHLBI NIH HHS [HL 53592] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053592] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)		Andersson E, 1998, J BIOL CHEM, V273, P4747, DOI 10.1074/jbc.273.8.4747; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; Battistuzzi G, 2006, BIOCHEMISTRY-US, V45, P12750, DOI 10.1021/bi061647k; BEERS RF, 1952, J BIOL CHEM, V195, P133; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; Brogioni S, 2006, J RAMAN SPECTROSC, V37, P263, DOI 10.1002/jrs.1442; Bulow E, 2002, J LEUKOCYTE BIOL, V71, P279; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; DeGioia L, 1996, J BIOL INORG CHEM, V1, P476; DeLeo FR, 1998, J CLIN INVEST, V101, P2900, DOI 10.1172/JCI2649; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Dunford H. B., 1999, HEME PEROXIDASES; Dypbukt JM, 2005, FREE RADICAL BIO MED, V39, P1468, DOI 10.1016/j.freeradbiomed.2005.07.008; ELZANOWSKA H, 1995, FREE RADICAL BIO MED, V18, P437, DOI 10.1016/0891-5849(94)00150-I; Erdbrugger U, 2006, KIDNEY INT, V69, P1799, DOI 10.1038/sj.ki.5000354; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Ferrari RP, 2000, PEROXIDASE MULTIGENE FAMILY OF ENZYMES, P114; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Furtmuller PC, 2000, EUR J BIOCHEM, V267, P5858, DOI 10.1046/j.1432-1327.2000.01491.x; Furtmuller PG, 2006, ARCH BIOCHEM BIOPHYS, V445, P199, DOI 10.1016/j.abb.2005.09.017; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansson M, 2006, ARCH BIOCHEM BIOPHYS, V445, P214, DOI 10.1016/j.abb.2005.08.009; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; Huang LS, 2006, J BIOL CHEM, V281, P18983, DOI 10.1074/jbc.M602307200; Huang LS, 2006, ARCH BIOCHEM BIOPHYS, V446, P77, DOI 10.1016/j.abb.2005.11.011; Huang LS, 2005, J AM CHEM SOC, V127, P5345, DOI 10.1021/ja050278x; Hurst JK, 1999, ACCOUNTS CHEM RES, V32, P520, DOI 10.1021/ar9703488; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; Kameoka Y, 2004, JPN J INFECT DIS, V57, pS12; KETTLE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P379, DOI 10.1016/0167-4889(90)90146-5; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Kooter IM, 1999, J BIOL CHEM, V274, P26794, DOI 10.1074/jbc.274.38.26794; Kooter IM, 1997, J BIOL INORG CHEM, V2, P191, DOI 10.1007/s007750050124; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Marchetti C, 2004, HUM MUTAT, V23, P496, DOI 10.1002/humu.20027; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; Moguilevsky N, 2000, PEROXIDASE MULTIGENE FAMILY OF ENZYMES, P38; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NAUSEEF WM, 1988, HEMATOL ONCOL CLIN N, V2, P135; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NAUSEEF WM, 1986, BLOOD, V68, P442; NAUSEEF WM, 1994, J BIOL CHEM, V269, P1212; Nauseef WM, 1999, J LAB CLIN MED, V134, P215, DOI 10.1016/S0022-2143(99)90200-7; NAUSEEF WM, 1989, BLOOD, V73, P290; Nauseef WM, 2000, REDOX REP, V5, P197, DOI 10.1179/135100000101535753; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; Nauseef WM, 1998, J BIOL CHEM, V273, P7107, DOI 10.1074/jbc.273.12.7107; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; NAUSEEF WM, 2003, CALRETICULIN, P63; Ohashi YY, 2004, GENE, V327, P195, DOI 10.1016/j.gene.2003.11.023; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PERSAD AS, 2006, GENE EXPRESSION, V13, P1; STRAUSS RR, 1971, INFECT IMMUN, V3, P595, DOI 10.1128/IAI.3.4.595-602.1971; vanDalen CJ, 1997, BIOCHEM J, V327, P487; Winterbourn CC, 1997, ARCH BIOCHEM BIOPHYS, V338, P15, DOI 10.1006/abbi.1996.9773; WOLCOTT RG, 1994, J BIOL CHEM, V269, P9721; YAMADA M, 1990, BIOCHEM BIOPH RES CO, V166, P852, DOI 10.1016/0006-291X(90)90888-T; YAMADA M, 1981, BIOCHEMISTRY-US, V20, P766, DOI 10.1021/bi00507a018; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6	79	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27994	28003		10.1074/jbc.M701984200	http://dx.doi.org/10.1074/jbc.M701984200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650507	Green Published, hybrid			2022-12-25	WOS:000249455600049
J	Mani, RS; Fanta, M; Karimi-Busheri, F; Silver, E; Virgen, CA; Caldecott, KW; Cass, CE; Weinfeld, M				Mani, Raiam S.; Fanta, Mesfin; Karimi-Busheri, Feridoun; Silver, Elizabeth; Virgen, Cesar A.; Caldecott, Keith W.; Cass, Carol E.; Weinfeld, Michael			XRCC1 stimulates polynucleotide kinase by enhancing its damage discrimination and displacement from DNA repair intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; TIME-RESOLVED FLUORESCENCE; BASE EXCISION-REPAIR; RAT-LIVER; POLY(ADP-RIBOSE) POLYMERASE; IRRADIATED THYMOCYTES; PROTEIN XRCC1; TRANSFER-RNA; LIGASE-III; END-GROUPS	Human polynucleotide kinase (hPNK) is required for processing and rejoining DNA strand break termini. The 5'-DNA kinase and 3'-phosphatase activities of hPNK can be stimulated by the "scaffold" protein XRCC1, but the mechanism remains to be fully elucidated. Using a variety of fluorescence techniques, we examined the interaction of hPNK with XRCC1 and substrates that model DNA single-strand breaks. hPNK binding to substrates with 5'-OH termini was only similar to 5-fold tighter than that to identical DNA molecules with 5'-phosphate termini, suggesting that hPNK remains bound to the product of its enzymatic activity. The presence of XRCC1 did not influence the binding of hPNK to substrates with 5'-OH termini, but sharply reduced the interaction of hPNK with DNA bearing a 5'-phosphate terminus. These data, together with kinetic data obtained at limiting enzyme concentration, indicate a dual function for the interaction of XRCC1 with hPNK. First, XRCC1 enhances the capacity of hPNK to discriminate between strand breaks with 5'-OH termini and those with 5'-phosphate termini; and second, XRCC1 stimulates hPNK activity by displacing hPNK from the phosphorylated DNA product.	Cross Canc Inst, Dept Expt Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Alberta; University of Alberta; University of Sussex	Weinfeld, M (corresponding author), Cross Canc Inst, Dept Expt Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	michaelw@cancerboard.ab.ca	Cass, Carol E/F-5861-2010; Caldecott, Keith/S-4245-2019; Karimi-Busheri, Feridoun/AAX-7541-2020	Caldecott, Keith/0000-0003-4255-9016; Karimi-Busheri, Feridoun/0000-0002-1936-0503	MRC [G0600776, G0001259] Funding Source: UKRI; Medical Research Council [G0600776, G0001259] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BERNARDI G, 1968, ADV ENZYMOL RAMB, V31, P1; Bernstein NK, 2005, MOL CELL, V17, P657, DOI 10.1016/j.molcel.2005.02.012; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; COQUERELLE T, 1973, INT J RADIAT BIOL, V24, P397, DOI 10.1080/09553007314551251; D'Alfonso L, 2003, EUR J BIOCHEM, V270, P2497, DOI 10.1046/j.1432-1033.2003.03621.x; Dobson CJ, 2006, NUCLEIC ACIDS RES, V34, P2230, DOI 10.1093/nar/gkl275; Eastberg JH, 2004, NUCLEIC ACIDS RES, V32, P653, DOI 10.1093/nar/gkh212; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Fan JS, 2004, NUCLEIC ACIDS RES, V32, P2193, DOI 10.1093/nar/gkh556; Flora K, 1998, BIOPHYS J, V75, P1084, DOI 10.1016/S0006-3495(98)77598-8; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; HABRAKEN Y, 1988, EUR J BIOCHEM, V171, P59, DOI 10.1111/j.1432-1033.1988.tb13758.x; HENNER WD, 1983, J BIOL CHEM, V258, P711; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1998, NUCLEIC ACIDS RES, V26, P4395, DOI 10.1093/nar/26.19.4395; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Karimi-Busheri F, 2007, CANCER RES, V67, P6619, DOI 10.1158/0008-5472.CAN-07-0480; KarimiBusheri F, 1997, J CELL BIOCHEM, V64, P258, DOI 10.1002/(SICI)1097-4644(199702)64:2<258::AID-JCB9>3.0.CO;2-W; Koch CA, 2004, EMBO J, V23, P3874, DOI 10.1038/sj.emboj.7600375; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; LENNARTZ M, 1975, INT J RADIAT BIOL, V27, P577, DOI 10.1080/09553007514550611; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; MANI RS, 1993, BIOCHEMISTRY-US, V32, P11217, DOI 10.1021/bi00092a035; Mani RS, 2006, BIOCHEMISTRY-US, V45, P3534, DOI 10.1021/bi052652b; Mani RS, 2004, BIOCHEMISTRY-US, V43, P16505, DOI 10.1021/bi048615m; Mani RS, 2003, BIOCHEMISTRY-US, V42, P12077, DOI 10.1021/bi030127b; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Parsons JL, 2005, FEBS J, V272, P5753, DOI 10.1111/j.1742-4658.2005.04962.x; PHEIFFER BH, 1982, BIOCHEM BIOPH RES CO, V109, P1297, DOI 10.1016/0006-291X(82)91918-0; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Rasouli-Nia A, 2004, P NATL ACAD SCI USA, V101, P6905, DOI 10.1073/pnas.0400099101; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003	42	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28004	28013		10.1074/jbc.M704867200	http://dx.doi.org/10.1074/jbc.M704867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17650498	hybrid			2022-12-25	WOS:000249455600050
J	Tsegaye, Y; Richardson, CG; Bravo, JE; Mulcahy, BJ; Lynch, DV; Markham, JE; Jaworski, JG; Chen, M; Cahoon, EB; Dunn, TM				Tsegaye, Yoseph; Richardson, Christopher G.; Bravo, Janis E.; Mulcahy, Brendan J.; Lynch, Daniel V.; Markham, Jonathan E.; Jaworski, Jan G.; Chen, Ming; Cahoon, Edgar B.; Dunn, Teresa M.			Arabidopsis mutants lacking long chain base phosphate lyase are fumonisin-sensitive and accumulate trihydroxy-18 : 1 long chain base phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SACCHAROMYCES-CEREVISIAE; SPHINGOSINE-1-PHOSPHATE LYASE; SPHINGOLIPID METABOLISM; HEAT-STRESS; THALIANA; YEAST; EXPRESSION; APOPTOSIS; PROTEIN	The sphingoid long chain bases (LCBs) and their phosphorylated derivatives (LCB-Ps) are important signaling molecules in eukaryotic organisms. The cellular levels of LCB-Ps are tightly controlled by the coordinated action of the LCB kinase activity responsible for their synthesis and the LCB-P phosphatase and lyase activities responsible for their catabolism. Although recent studies have implicated LCB-Ps as regulatory molecules in plants, in comparison with yeast and mammals, much less is known about their metabolism and function in plants. To investigate the functions of LCB-Ps in plants, we have undertaken the identification and characterization of Arabidopsis genes that encode the enzymes of LCB-P metabolism. In this study the Arabidopsis At1g27980 gene was shown to encode the only detectable LCB-P lyase activity in Arabidopsis. The LCB-P lyase activity was characterized, and mutant plant lines lacking the lyase were generated and analyzed. Whereas in other organisms loss of LCB-P lyase activity is associated with accumulation of high levels of LCB/LCB-Ps and developmental abnormalities, the sphingolipid profiles of the mutant plants were remarkably similar to those of wild-type plants, and no developmental abnormalities were observed. Thus, these studies indicate that the lyase plays a minor role in maintenance of sphingolipid metabolism during normal plant development and growth. However, a clear role for the lyase was revealed upon perturbation of sphingolipid synthesis by treatment with the inhibitor of ceramide synthase, fumonisin B-1.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20184 USA; Williams Coll, Dept Biol, Williamstown, MA 01267 USA; Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Uniformed Services University of the Health Sciences - USA; Williams College; Donald Danforth Plant Science Center	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20184 USA.	tdunn@usuhs.mil	Jaworski, Jan/N-2255-2014	Jaworski, Jan/0000-0003-3309-4915; Markham, Jennifer/0000-0003-2397-3131				ABBAS HK, 1994, PLANT PHYSIOL, V106, P1085, DOI 10.1104/pp.106.3.1085; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Asai T, 2000, PLANT CELL, V12, P1823, DOI 10.1105/tpc.12.10.1823; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Coursol S, 2005, PLANT PHYSIOL, V137, P724, DOI 10.1104/pp.104.055806; Coursol S, 2003, NATURE, V423, P651, DOI 10.1038/nature01643; Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979; Dunn TM, 2004, ANN BOT-LONDON, V93, P483, DOI 10.1093/aob/mch071; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Habeler G, 2002, NUCLEIC ACIDS RES, V30, P80, DOI 10.1093/nar/30.1.80; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Ikeda M, 2004, BIOCHEM BIOPH RES CO, V325, P338, DOI 10.1016/j.bbrc.2004.10.036; Kim S, 2000, GENETICS, V156, P1519; Lester RL, 2001, ANAL BIOCHEM, V298, P283, DOI 10.1006/abio.2001.5368; Li GC, 2001, DEVELOPMENT, V128, P3473; Liang H, 2003, GENE DEV, V17, P2636, DOI 10.1101/gad.1140503; Liu K, 2005, BIOCHEM SOC T, V33, P1170, DOI 10.1042/BST0331170; Lynch DV, 2004, NEW PHYTOL, V161, P677, DOI 10.1111/j.1469-8137.2004.00992.x; Markham JE, 2007, RAPID COMMUN MASS SP, V21, P1304, DOI 10.1002/rcm.2962; Markham JE, 2006, J BIOL CHEM, V281, P22684, DOI 10.1074/jbc.M604050200; Mendel J, 2003, J BIOL CHEM, V278, P22341, DOI 10.1074/jbc.M302857200; NG C, 2001, NATURE, V410, P569; Niu Y, 2007, J INTEGR PLANT BIOL, V49, P323, DOI 10.1111/j.1744-7909.2007.00446.x; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Spassieva SD, 2002, PLANT J, V32, P561, DOI 10.1046/j.1365-313X.2002.01444.x; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WEIGEL D, 2002, ARABIDOPSIS LAB MANU, P55; Worrall D, 2003, TRENDS PLANT SCI, V8, P317, DOI 10.1016/S1360-1385(03)00128-6; Wright BS, 2003, ARCH BIOCHEM BIOPHYS, V415, P184, DOI 10.1016/S0003-9861(03)00261-3; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	47	60	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28195	28206		10.1074/jbc.M705074200	http://dx.doi.org/10.1074/jbc.M705074200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635905	hybrid			2022-12-25	WOS:000249455600069
J	Mohler, PJ; Zhu, MY; Blade, AM; Ham, AJL; Shelness, GS; Swift, LL				Mohler, Peter J.; Zhu, Mei-Ying; Blade, Anna M.; Ham, Amy-Joan L.; Shelness, Gregory S.; Swift, Larry L.			Identification of a novel isoform of microsomal triglyceride transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-B; ABETALIPOPROTEINEMIA GENE; LIVER-MICROSOMES; SIGNAL PEPTIDES; EXPRESSION; LOCALIZATION; MOUSE; LIPOPROTEINS; KNOCKOUT	Microsomal triglyceride transfer protein (MTP) has been studied extensively, primarily because of its role in the assembly of very low density lipoproteins by the liver and chylomicrons by the intestine. Recent studies have suggested that MTP may also play key roles in other cellular processes. In this paper we report the identification of a novel splice variant of MTP in mice. This isoform, MTP-B, has a unique first exon located similar to 2.7 kilobases upstream of canonical MTP (MTP-A) exon 1. The alternative exon encodes 35 amino acids compared with 20 amino acids encoded by exon 1 of MTP-A. MTP-B represents similar to 90% of total MTP mRNA in mouse adipocytes and 3T3-L1 cells and < 5% in mouse liver and intestine. Expression of the alternate isoform in mouse liver was confirmed by mass spectrometry. Co-transfection of COS cells with truncated forms of apoB and either MTP-A or MTP-B demonstrated that both isoforms are effective in the assembly and secretion of nascent apoB-containing lipoproteins. Confocal microscopy of 3T3-L1 cells transfected with enhanced green fluorescent protein or DsRed fusions of the two proteins revealed that MTP-A is localized to the endoplasmic reticulum, whereas MTP-B localizes primarily to the Golgi complex in these cells. We conclude that MTP-B functions similarly to MTP-A in lipoprotein assembly. However, in nonlipoproteinsecreting cells, such as the adipocyte, MTP-B may have different localization properties, perhaps reflecting a distinct role in lipid storage and mobilization.	Vanderbilt Univ, Sch Med, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Univ Iowa, Sch Med, Dept Internal Med, Iowa City, IA 52242 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Wake Forest University; University of Iowa	Swift, LL (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr, Dept Pathol, 1161 21st Ave S, Nashville, TN 37232 USA.	larry.swift@vanderbilt.edu			NHLBI NIH HHS [HL 49373, HL 57984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL057984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; Brozovic S, 2004, NAT MED, V10, P535, DOI 10.1038/nm1043; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; CUHEL M, 2007, NEW ENGL J MED, V356, P148; Dougan SK, 2007, J EXP MED, V204, P533, DOI 10.1084/jem.20062006; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; HAM AL, 2005, ENCY MASS SPECTROM A, V3, P10; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Hill KE, 2007, J BIOL CHEM, V282, P10972, DOI 10.1074/jbc.M700436200; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; JAMIL H, 1996, P NATL ACAD SCI USA, V93, P1191; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200; Nakamuta M, 1996, GENOMICS, V33, P313, DOI 10.1006/geno.1996.0200; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Sellers JA, 2001, J LIPID RES, V42, P1897; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Shelton JM, 2000, J LIPID RES, V41, P532; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; Slight I, 2004, EXP CELL RES, V300, P11, DOI 10.1016/j.yexcr.2004.05.038; Swift LL, 2005, FEBS LETT, V579, P3183, DOI 10.1016/j.febslet.2005.05.009; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; Tabb DL, 2006, NAT PROTOC, V1, P2213, DOI 10.1038/nprot.2006.330; Valyi-Nagy K, 2002, LIPIDS, V37, P879, DOI 10.1007/s11745-002-0974-3; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	38	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26981	26988		10.1074/jbc.M700500200	http://dx.doi.org/10.1074/jbc.M700500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635917	hybrid			2022-12-25	WOS:000249304900038
J	Stuart, LM; Bell, SA; Stewart, CR; Silver, JM; Richard, J; Goss, JL; Tseng, AA; Zhang, A; El Khoury, JB; Moore, KJ				Stuart, Lynda M.; Bell, Susan A.; Stewart, Cameron R.; Silver, Jessica M.; Richard, James; Goss, Julie L.; Tseng, Anita A.; Zhang, Ailiang; El Khoury, Joseph B.; Moore, Kathryn J.			CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-TRANSFORMED CELLS; ALZHEIMERS-DISEASE; TYROSINE PHOSPHORYLATION; PLASMODIUM-FALCIPARUM; SCAVENGER RECEPTOR; PHAGOCYTOSIS; IDENTIFICATION; TRANSDUCTION; MONOCYTES; PROTEINS	The pattern recognition receptor CD36 initiates a signaling cascade that promotes microglial activation and recruitment to beta-amyloid deposits in the brain. In the present study we identify the focal adhesion-associated proteins p130Cas, Pyk2, and paxillin as novel members of the tyrosine kinase signaling pathway downstream of CD36 and show that assembly of this complex is essential for microglial migration. In primary microglia and macrophages exposed to beta-amyloid, the scaffolding protein p130Cas is rapidly tyrosine-phosphorylated and co-localizes with CD36 to membrane ruffles contemporaneous with F-actin polymerization. These beta-amyloid-stimulated events are not detected in CD36 null cells and are dependent on CD36 activation of Src family tyrosine kinases. Fyn, a Src kinase known to interact with CD36, co-precipitates with p130Cas and is an essential upstream intermediate in the signaling pathways leading to phosphorylation of the p130Cas substrate domain. Furthermore, the p130Cas-interacting kinase Pyk2 and the cytoskeletal adapter protein paxillin also demonstrate CD36-dependent phosphorylation, identifying these focal adhesion molecules as additional members of this beta-amyloid signaling cascade. Disruption of this p130Cas complex by small interfering RNA silencing inhibits p44/42 mitogen-activated protein kinase phosphorylation and microglial migration, illustrating the importance of this pathway in microglial activation and recruitment. Together, these data are the first to identify the signaling cascade that directly links CD36 to the actin cytoskeleton and, thus, implicates it in diverse processes such as cellular migration, adhesion, and phagocytosis.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA 02114 USA; Univ Edinburgh, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Edinburgh	Moore, KJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, 55 Fruit St,GRJ1308, Boston, MA 02114 USA.	kmoore@molbio.mgh.harvard.edu	Moore, Kathryn/ABE-6416-2020; Stewart, Cameron R/E-6823-2011	Moore, Kathryn/0000-0003-2505-2547; Stewart, Cameron/0000-0002-3395-7859; Shaw, Anita/0000-0002-1004-2226	NIA NIH HHS [R01 AG 20255] Funding Source: Medline; Wellcome Trust [068089/Z/02/Z] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG020255] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Combs CK, 1999, J NEUROSCI, V19, P928; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Gan L, 2004, J BIOL CHEM, V279, P5565, DOI 10.1074/jbc.M306183200; Gustavsson A, 2004, J BIOL CHEM, V279, P22893, DOI 10.1074/jbc.M309693200; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howlett GJ, 2006, CURR OPIN LIPIDOL, V17, P541, DOI 10.1097/01.mol.0000245260.63505.4f; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Janciauskiene S, 2001, ATHEROSCLEROSIS, V158, P41, DOI 10.1016/S0021-9150(00)00767-X; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Kunjathoor VV, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-23; Ly NP, 2005, P NATL ACAD SCI USA, V102, P14729, DOI 10.1073/pnas.0506233102; McGilvray ID, 2000, BLOOD, V96, P3231, DOI 10.1182/blood.V96.9.3231; Medeiros LA, 2004, J BIOL CHEM, V279, P10643, DOI 10.1074/jbc.M311735200; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100; Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ricciarelli R, 2004, FREE RADICAL BIO MED, V36, P1018, DOI 10.1016/j.freeradbiomed.2004.01.007; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wilkinson B, 2006, J BIOL CHEM, V281, P20842, DOI 10.1074/jbc.M600627200; Yipp BG, 2003, BLOOD, V101, P2850, DOI 10.1182/blood-2002-09-2841	36	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27392	27401		10.1074/jbc.M702887200	http://dx.doi.org/10.1074/jbc.M702887200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623670	hybrid			2022-12-25	WOS:000249304900081
J	Klaile, E; Muller, MM; Kannicht, C; Otto, W; Singer, BB; Reutter, W; Obrink, B; Lucka, L				Klaile, Esther; Muller, Mario M.; Kannicht, Christoph; Otto, Wolfgang; Singer, Bernhard B.; Reutter, Werner; Obrink, Bjorn; Lucka, Lothar			The cell adhesion receptor carcinoembryonic antigen-related cell adhesion molecule 1 regulates nucleocytoplasmic trafficking of DNA polymerase delta-interacting protein 38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT CYTOPLASMIC DOMAIN; C-CAM; BILIARY GLYCOPROTEIN; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; NUCLEAR ANTIGEN; CEACAM1; GROWTH; ASSOCIATION; MITOCHONDRIAL	The homophilic cell-cell adhesion receptor CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1, CD66a) acts as a regulator of contact-dependent cell survival, differentiation, and growth. It is involved in the control of proliferation in hematopoietic and epithelial cells and can act as a tumor suppressor. In this study, we identify DNA polymerase delta-interacting protein 38 (PDIP38) as a novel binding partner for CEACAM1-L and CEACAM1-S. We show that PDIP38 can occur in the nucleus, in the cytoplasm and at the plasma membrane in NBT-II, IEC18, RBE, and HeLa cells and that the distribution in NBT-II cells is influenced by the confluency of the cells. We also demonstrate that the interaction of CEACAM1 and PDIP38 is of functional importance in NBT-II cells, which co-express the long and the short CEACAM1 isoform. In subconfluent, proliferating NBT-II cells, perturbation of CEACAM1 by antibody clustering induces increased binding to PDIP38 and results in rapid recruitment of PDIP38 to the plasma membrane. The same treatment of confluent, quiescent NBT-II cells leads to a different response, i.e. translocation of PDIP38 to the nucleus. Together, our data show that PDIP38 can shuttle between the cytoplasmic and the nuclear compartments and that its subcellular localization is regulated by CEACAM1, implicating that PDIP38 may constitute a novel downstream target of CEACAM1 signaling.	Univ Med Berlin, Charite, Inst Biochem & Molekularbiol, D-14195 Berlin, Germany; Octapharma Pre Clin Res & Dev, Mol Biochem Dept, D-14195 Berlin, Germany; Univ Hosp Essen, Inst Anat, D-45147 Essen, Germany; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Octapharma; University of Duisburg Essen; Karolinska Institutet	Klaile, E (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, Von Eulers vag 3, SE-17177 Stockholm, Sweden.	esther.klaile@ki.se	Singer, Bernhard B./AAP-9999-2020	Muller, Mario/0000-0002-1898-5691; Klaile, Esther/0000-0001-7389-6862				Arakaki N, 2006, BBA-GEN SUBJECTS, V1760, P1364, DOI 10.1016/j.bbagen.2006.05.012; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BECKER A, 1986, BIOL CHEM H-S, V367, P681, DOI 10.1515/bchm3.1986.367.2.681; Booth JW, 2003, J BIOL CHEM, V278, P14037, DOI 10.1074/jbc.M211879200; BRUMMER J, 1995, ONCOGENE, V11, P1649; Budt M, 2002, BIOL CHEM, V383, P803, DOI 10.1515/BC.2002.084; Budt M, 2002, BIOCHEM BIOPH RES CO, V292, P749, DOI 10.1006/bbrc.2002.6704; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Chen CJ, 2007, J BIOL CHEM, V282, P5749, DOI 10.1074/jbc.M610903200; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Greicius G, 2003, J LEUKOCYTE BIOL, V74, P126, DOI 10.1189/jlb.1202594; HSIEH JT, 1995, CANCER RES, V55, P190; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Klaile E, 2005, J CELL SCI, V118, P5513, DOI 10.1242/jcs.02660; Kleinerman DI, 1996, CANCER RES, V56, P3431; Kuespert K, 2006, CURR OPIN CELL BIOL, V18, P565, DOI 10.1016/j.ceb.2006.08.008; Kunath T, 1995, ONCOGENE, V11, P2375; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lin SH, 1999, SEMIN ONCOL, V26, P227; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; Ordonez C, 2000, CANCER RES, V60, P3419; Scheffrahn I, 2005, EXP CELL RES, V307, P427, DOI 10.1016/j.yexcr.2005.03.030; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Singer BB, 2005, EUR J IMMUNOL, V35, P1949, DOI 10.1002/eji.200425691; Singer BB, 2000, CANCER RES, V60, P1236; SINGER BB, UCSD NATURE MOL PAGE; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Valgardsdottir R, 2001, J BIOL CHEM, V276, P32056, DOI 10.1074/jbc.M011629200; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499; Wikstrom K, 1996, EXP CELL RES, V227, P360, DOI 10.1006/excr.1996.0285; Xie B, 2005, J BIOL CHEM, V280, P22375, DOI 10.1074/jbc.M414597200; Yu QG, 2006, J BIOL CHEM, V281, P39179, DOI 10.1074/jbc.M608864200; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	48	26	27	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26629	10.1074/jbc.M701807200	http://dx.doi.org/10.1074/jbc.M701807200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623671	hybrid			2022-12-25	WOS:000249239600066
J	Yang, SY; Fugmann, SD; Gramlich, HS; Schatz, DG				Yang, Shu Yuan; Fugmann, Sebastian D.; Gramlich, Hillary S.; Schatz, David G.			Activation-induced cytidine deaminase-mediated sequence diversification is transiently targeted to newly integrated DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE CONVERSION; HEAVY-CHAIN LOCUS; B-CELL LINE; SOMATIC HYPERMUTATION; ANTIBODY HEAVY; AID; MUTATION; PROMOTER; TRANSCRIPTION; INTERMEDIATE	The molecular features that allow activation-induced cytidine deaminase (AID) to target Ig and certain non-Ig genes are not understood, although transcription has been implicated as one important parameter. We explored this issue by testing the mutability of a non-Ig transcription cassette in Ig and non-Ig loci of the chicken B cell line DT40. The cassette did not act as a stable long term mutation target but was able to be mutated in an AID-dependent manner for a limited time post-integration. This indicates that newly integrated DNA has molecular characteristics that render it susceptible to modification by AID, with implications for how targeting and mis-targeting of AID occurs.	Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Schatz, DG (corresponding author), 300 Cedar St,Box 208011, New Haven, CT 06520 USA.	david.schatz@yale.edu	Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI066130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000387, Z01AG000387] Funding Source: NIH RePORTER; NIAID NIH HHS [AI066130] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arakawa H, 2004, PLOS BIOL, V2, P967, DOI 10.1371/journal.pbio.0020179; Arakawa H, 2001, BMC Biotechnol, V1, P7, DOI 10.1186/1472-6750-1-7; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bachl J, 2001, J IMMUNOL, V166, P5051, DOI 10.4049/jimmunol.166.8.5051; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Di Noia JM, 2004, EUR J IMMUNOL, V34, P504, DOI 10.1002/eji.200324631; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Gourzi P, 2006, IMMUNITY, V24, P779, DOI 10.1016/j.immuni.2006.03.021; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; Harris RS, 2002, CURR BIOL, V12, P435, DOI 10.1016/S0960-9822(02)00717-0; Kanayama N, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj013; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; PARVARI R, 1990, P NATL ACAD SCI USA, V87, P3072, DOI 10.1073/pnas.87.8.3072; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Rada C, 2001, EMBO J, V20, P4570, DOI 10.1093/emboj/20.16.4570; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; REYNAUD CA, 1994, ADV IMMUNOL, V57, P353, DOI 10.1016/S0065-2776(08)60676-8; Ruckerl F, 2004, MOL IMMUNOL, V41, P1135, DOI 10.1016/j.molimm.2004.06.030; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; Saribasak H, 2006, J IMMUNOL, V176, P365, DOI 10.4049/jimmunol.176.1.365; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Simpson LJ, 2003, EMBO J, V22, P1654, DOI 10.1093/emboj/cdg161; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; Wang CL, 2004, P NATL ACAD SCI USA, V101, P7352, DOI 10.1073/pnas.0402009101; Woo CJ, 2003, IMMUNITY, V19, P479, DOI 10.1016/S1074-7613(03)00261-9; Yang SY, 2006, J EXP MED, V203, P2919, DOI 10.1084/jem.20061835; YELAMOS J, 1995, NATURE, V376, P225; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556	34	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25308	25313		10.1074/jbc.M704231200	http://dx.doi.org/10.1074/jbc.M704231200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17613522	hybrid			2022-12-25	WOS:000249014100016
J	Varmeh-Ziaie, S; Manfredi, JJ				Varmeh-Ziaie, Shohreh; Manfredi, James J.			The dual specificity phosphatase Cdc25B, but not the closely related Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEIN-BINDING; DNA-DAMAGE; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC LOCALIZATION; NUCLEAR EXPORT; CDK REGULATION; CYCLIN A/CDK2; HUMAN-CELLS; MITOSIS; PHOSPHORYLATION	Cdc25B and Cdc25C are closely related dual specificity phosphatases that activate cyclin-dependent kinases by removal of inhibitory phosphorylations, thereby triggering entry into mitosis. Cdc25B, but not Cdc25C, has been implicated as an oncogene and been shown to be overexpressed in a variety of human tumors. Surprisingly, ectopic expression of Cdc25B, but not Cdc25C, inhibits cell proliferation in long term assays. Chimeric proteins generated from the two phosphatases show that the anti-proliferative activity is associated with the C-terminal end of Cdc25B. Indeed, the catalytic domain of Cdc25B is sufficient to suppress cell viability in a manner partially dependent upon its C-terminal 26 amino acids that is shown to influence substrate binding. Mutation analysis demonstrates that both the phosphatase activity of Cdc25B as well as its ability to interact with its substrates contribute to the inhibition of cell proliferation. These results demonstrate key differences in the biological activities of Cdc25B and Cdc25C caused by differential substrate affinity and recognition. This also argues that the antiproliferative activity of Cdc25B needs to be overcome for it to act as an oncogene during tumorigenesis.	CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.	james.manfredi@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA086001, R56CA086001] Funding Source: NIH RePORTER; NCI NIH HHS [CA086001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Chen W, 2000, BIOCHEMISTRY-US, V39, P10781, DOI 10.1021/bi000909u; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Giles N, 2003, J BIOL CHEM, V278, P28580, DOI 10.1074/jbc.M304027200; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Lammer C, 1998, J CELL SCI, V111, P2445; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; St Clair S, 2004, MOL CELL, V16, P725; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Uchida S, 2004, J CELL SCI, V117, P3011, DOI 10.1242/jcs.01086; Uchida S, 2006, J BIOCHEM, V139, P761, DOI 10.1093/jb/mvj079; Wilborn M, 2001, BIOCHEMISTRY-US, V40, P14200, DOI 10.1021/bi015638h; Xu X, 1996, J BIOL CHEM, V271, P5118	40	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24633	24641		10.1074/jbc.M703105200	http://dx.doi.org/10.1074/jbc.M703105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591782	hybrid			2022-12-25	WOS:000248933000018
J	Tang, CSM; Epstein, RJ				Tang, Clara S. M.; Epstein, Richard J.			A Structural Split in the Human Genome	PLOS ONE			English	Article								Background. Promoter-associated CpG islands (PCIs) mediate methylation-dependent gene silencing, yet tend to co-locate to transcriptionally active genes. To address this paradox, we used data mining to assess the behavior of PCI-positive (PCI+) genes in the human genome. Results. PCI+ genes exhibit a bimodal distribution: (1) a 'housekeeping-like' subset characterized by higher GC content and lower intron length/number, and (2) a 'pseudogene paralog' subset characterized by lower GC content and higher intron length/number (p<0.001). These subsets are functionally distinguishable, with the former gene group characterized by higher expression levels and lower evolutionary rate (p<0.001). PCI-negative (PCI-) genes exhibit higher evolutionary rate and narrower expression breadth than PCI+ genes (p<0.001), consistent with more frequent tissue-specific inactivation. Conclusions. Adaptive evolution of the human genome appears driven in part by declining transcription of a subset of PCI+ genes, predisposing to both CpG -> RTpA mutation and intron insertion. We propose a model of evolving biological complexity in which environmentally-selected gains or losses of PCI methylation respectively favor positive or negative selection, thus polarizing PCI+ gene structures around a genomic core of ancestral PCI-genes.	[Tang, Clara S. M.; Epstein, Richard J.] Univ Hong Kong, Dept Med, Lab Computat Oncol, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong	Epstein, RJ (corresponding author), Univ Hong Kong, Dept Med, Lab Computat Oncol, Pokfulam, Hong Kong, Peoples R China.	repstein@hku.hk		Tang, Clara/0000-0003-0265-2638				Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; BEUTLER E, 1989, P NATL ACAD SCI USA, V86, P192, DOI 10.1073/pnas.86.1.192; Brun ME, 2003, GENE, V312, P41, DOI 10.1016/S0378-1119(03)00530-4; Caiafa P, 2005, J CELL BIOCHEM, V94, P257, DOI 10.1002/jcb.20325; Copley RR, 2003, CURR OPIN GENET DEV, V13, P623, DOI 10.1016/j.gde.2003.10.004; Dimitri P, 2003, MOL BIOL EVOL, V20, P503, DOI 10.1093/molbev/msg048; Epstein RJ, 2000, GENE, V245, P291, DOI 10.1016/S0378-1119(00)00042-1; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Frankham R, 2005, J EVOLUTION BIOL, V18, P750, DOI 10.1111/j.1420-9101.2005.00885.x; Horvath JE, 2001, HUM MOL GENET, V10, P2215, DOI 10.1093/hmg/10.20.2215; Jabbari K, 2004, GENE, V333, P143, DOI 10.1016/j.gene.2004.02.043; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kurek R, 2000, GENETICA, V109, P113, DOI 10.1023/A:1026552604229; Li YC, 2004, MOL BIOL EVOL, V21, P991, DOI 10.1093/molbev/msh073; Lin K, 2003, J MOL EVOL, V57, P538, DOI 10.1007/s00239-003-2507-5; Lynch Michael, 2003, Journal of Structural and Functional Genomics, V3, P35, DOI 10.1023/A:1022696612931; Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951; Meza TJ, 2002, TRANSGENIC RES, V11, P133, DOI 10.1023/A:1015244400941; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Philippe H, 2003, IUBMB LIFE, V55, P257, DOI 10.1080/1521654031000123330; Reams AB, 2004, ANNU REV MICROBIOL, V58, P119, DOI 10.1146/annurev.micro.58.030603.123806; Rogers SL, 2006, J IMMUNOL, V177, P414, DOI 10.4049/jimmunol.177.1.414; Smith NGC, 1998, GENETICS, V150, P823; TANG CS, 2006, GENOMICS; Vinogradov AE, 2005, TRENDS GENET, V21, P639, DOI 10.1016/j.tig.2005.09.002; VINOGRADOV AE, 2006, NUCL ACIDS RES; Wagner A, 2005, FEBS LETT, V579, P1772, DOI 10.1016/j.febslet.2005.01.063; WOLF SF, 1985, NATURE, V314, P467, DOI 10.1038/314467a0; Yoshikawa T, 2006, BIOL PHARM BULL, V29, P105, DOI 10.1248/bpb.29.105; Yusa K, 2004, MOL CELL BIOL, V24, P4004, DOI 10.1128/MCB.24.9.4004-4018.2004	30	12	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e603	10.1371/journal.pone.0000603	http://dx.doi.org/10.1371/journal.pone.0000603			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622348	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452000010
J	Meng, F; Wehbe-Janek, H; Henson, R; Smith, H; Patel, T				Meng, F.; Wehbe-Janek, H.; Henson, R.; Smith, H.; Patel, T.			Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes	ONCOGENE			English	Article						noncoding RNA; cytokine; liver cancer	CHOLANGIOCARCINOMA CELL-LINE; PROMOTER METHYLATION; CANCER-CELLS; KINASE; GROWTH; ACTIVATION; EXPRESSION; GENE; IDENTIFICATION; CONTRIBUTES	Interleukin-6 (IL-6) is overexpressed and contributes to tumor cell growth in cholangiocarcinoma. Enforced IL-6 production can alter the expression of specific microRNAs ( miRNAs) involved in tumor growth, and moreover can modulate expression of methylation-dependent genes. Thus, we assessed the methylation-dependent regulation of miRNA expression in human malignant cholangiocytes stably transfected to overexpress IL-6. The expression of the methyltransferases DNA methyltransferase enzyme-1 and HASJ4442 was increased by IL-6 overexpression, but was decreased by the methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). Expression pro. ling identified seven miRNAs that were significantly downregulated by IL-6 overexpression (<0.4-fold) and upregulated (>2- fold) by 5-aza-CdR. One of these, miR-370, is embedded in a CpG island. Although 5-aza-CdR increased miR-370 expression by 2.1-fold in malignant cells, the expression in nonmalignant cells was unchanged. The oncogene mitogen- activated protein kinase kinase kinase 8 (MAP3K8) was identified as a target of miR-370, and its expression was decreased by 5-aza-CdR in cholangiocarcinoma cells. Overexpression of IL-6 reduced miR-370 expression and reinstated MAP3K8 expression in vitro as well as in tumor cell xenografts in vivo. Thus, IL-6 may contribute to tumor growth by modulation of expression of selected miRNAs, such as miR-370. These studies de. ne a mechanism by which inflammation-associated cytokines can epigenetically modulate gene expression and directly contribute to tumor biology.	[Meng, F.; Patel, T.] Ohio State Univ, Med Ctr, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Meng, F.; Wehbe-Janek, H.; Henson, R.; Smith, H.; Patel, T.] Texas A&M Univ, Coll Med, Syst Hlth Sci Ctr, Scott & White Clin,Dept Internal Med, Temple, TX 76508 USA	University System of Ohio; Ohio State University; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Patel, T (corresponding author), Ohio State Univ, Med Ctr, Coll Med, Dept Internal Med, N2 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA.	tushar.patel@osumc.edu	patel, tushar/A-6382-2008		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069370] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK069370, R01 DK069370, R01 DK069370-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOKI M, 1993, J BIOL CHEM, V268, P22723; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Meng F, 2006, J HEPATOL, V44, P1055, DOI 10.1016/j.jhep.2005.10.030; Meng FM, 2005, AM J PHYSIOL-CELL PH, V289, pC971, DOI 10.1152/ajpcell.00081.2005; OHARA R, 1995, J CELL SCI, V108, P97; OKADA K, 1994, J GASTROEN HEPATOL, V9, P462, DOI 10.1111/j.1440-1746.1994.tb01275.x; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Patel T, 2006, NAT CLIN PRACT GASTR, V3, P33, DOI 10.1038/ncpgasthep0389; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Tadlock L, 2001, HEPATOLOGY, V33, P43, DOI 10.1053/jhep.2001.20676; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Yamagiwa Y, 2003, HEPATOLOGY, V38, P158, DOI 10.1053/jhep.2003.50257	31	188	214	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					378	386		10.1038/sj.onc.1210648	http://dx.doi.org/10.1038/sj.onc.1210648			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621267				2022-12-25	WOS:000252256000014
J	Nakajima, A; Kojima, Y; Nakayama, M; Yagita, H; Okumura, K; Nakano, H				Nakajima, A.; Kojima, Y.; Nakayama, M.; Yagita, H.; Okumura, K.; Nakano, H.			Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells	ONCOGENE			English	Article						c-FLIP; tumor necrosis factor; reactive oxygen species; c-Jun N-terminal kinase; apoptosis; necrosis	NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; INHIBITORY PROTEIN; CYTOCHROME-C; DEATH; KINASE; AUTOPHAGY; NECROSIS; PATHWAY; REQUIREMENT	Nuclear factor-kappa B (NF-kappa B) inhibits cell death through suppression of the caspase cascade, the c-Jun N-terminal kinase (JNK) pathway, and reactive oxygen species (ROS) accumulation. To suppress this antiapoptotic function of NF-kappa B might be a promising strategy to increase susceptibility of tumor cells to stress-induced cell death. We have recently shown that tumor necrosis factor (TNF)alpha induces caspase-dependent and -independent JNK activation and ROS accumulation in cellular FLICE-inhibitory protein (c-Flip)(-/-) murine embryonic fibroblasts (MEFs). To apply this observation to tumor therapy, we knocked down c-FLIP by RNA interference in various tumor cells. Consistent with the results using c-Flip(-/-) MEFs, we found that TNF alpha stimulation induced caspase-dependent prolonged JNK activation and ROS accumulation, followed by apoptotic and necrotic cell death in various tumor cells. Furthermore, TNF alpha and Fas induced the cleavage of mitogen-activated protein kinase/ ERK kinase kinase (MEKK)1, resulting in generation of a constitutive active form of MEKK1 leading to JNK activation in c-FLIP knockdown cells. Given that ROS accumulation and necrotic cell death enhance inflammation followed by compensatory proliferation of tumor cells, selective suppression of caspase-dependent ROS accumulation will be an alternative strategy to protect cells from ROS-dependent DNA damage and compensatory tumor progression.	[Nakajima, A.; Kojima, Y.; Nakayama, M.; Yagita, H.; Okumura, K.; Nakano, H.] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Nakajima, A (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hnakano@med.juntendo.ac.jp		Nakano, Hiroyasu/0000-0003-4843-1427; Nakayama, Masafumi/0000-0002-9839-7143				Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nakajima A, 2006, EMBO J, V25, P5549, DOI 10.1038/sj.emboj.7601423; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rudel T, 1998, J IMMUNOL, V160, P7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9	31	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					76	84		10.1038/sj.onc.1210624	http://dx.doi.org/10.1038/sj.onc.1210624			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599041				2022-12-25	WOS:000252118700008
J	Schneider, L; Essmann, F; Kletke, A; Rio, P; Hanenberg, H; Schulze-Osthoff, K; Nurnberg, B; Piekorz, RP				Schneider, L.; Essmann, F.; Kletke, A.; Rio, P.; Hanenberg, H.; Schulze-Osthoff, K.; Nuernberg, B.; Piekorz, R. P.			TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21(WAF)-mediated cell cycle arrest	ONCOGENE			English	Article						TACC3; paclitaxel; mitosis; apoptosis; p53; p21(WAF)	SPINDLE ASSEMBLY CHECKPOINT; SMOOTH-MUSCLE-CELLS; ACIDIC COILED-COIL; INDUCED APOPTOSIS; POLE ORGANIZATION; MITOTIC ARREST; CANCER-CELLS; P21; P53; D1	Regulators of the mitotic spindle apparatus are attractive cellular targets for antitumor therapy. The centrosomal protein transforming acidic coiled coil (TACC) 3 is required for spindle assembly and proper chromosome segregation. In this study, we employed an inducible RNA interference approach to downregulate TACC3 expression. We show that TACC3 knock-down in NIH3T3 fibroblasts caused aneuploidy, but failed to overtly impair mitotic progression. TACC3 depletion rather triggered a postmitotic p53-p21(WAF) pathway and led to a reversible cell cycle arrest. Similar effects were induced by low concentrations of paclitaxel, a spindle poison used in antitumor therapy. Interestingly, however, and unlike in TACC3-proficient cells, paclitaxel was able to induce strong polyploidy and subsequent apoptosis in TACC3-depleted cells. Even though paclitaxel treatment was associated with the activation of the survival kinase Akt and an antiapoptotic expression of cytoplasmic p21(WAF) and cyclin D1, this inhibition of cell death was abrogated by depletion of TACC3. Thus, our data identify TACC3 as a potential target to overcome p21(WAF)-associated protection of transformed cells against paclitaxel-induced cell death.	[Schneider, L.; Kletke, A.; Nuernberg, B.; Piekorz, R. P.] Univ Klinikum Dusseldorf, Inst Biochem & Molekularbiol 2, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Klinikum Dusseldorf, Inst Mol Med, Dusseldorf, Germany; [Rio, P.; Hanenberg, H.] Univ Klinikum Dusseldorf, Klin Kindeer Oncol Haematol, Dusseldorf, Germany; [Rio, P.; Hanenberg, H.] Univ Klinikum Dusseldorf, Klin Immunol, Dusseldorf, Germany; [Hanenberg, H.] Indiana Univ, Sch Med, Riley Hosp Children, Dept Pediat,Wells Ctr & Pediat Res, Indianapolis, IN 46204 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Piekorz, RP (corresponding author), Univ Klinikum Dusseldorf, Inst Biochem & Molekularbiol 2, D-40225 Dusseldorf, Germany.	roland.piekorz@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020; Rio, Paula/G-8681-2015; Schneider, Leonid/H-3275-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456; Rio, Paula/0000-0002-5424-5543; Schneider, Leonid/0000-0002-6204-9470; Nurnberg, Bernd/0000-0002-5995-6555				Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Blagosklonny MV, 2006, CELL CYCLE, V5, P1574, DOI 10.4161/cc.5.14.3113; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 2004, CELL CYCLE, V3, P1050; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Chen JG, 2002, CANCER RES, V62, P1935; CHEN XB, 1995, CANCER RES, V55, P4257; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cully M, 2005, CANCER RES, V65, P10363, DOI 10.1158/0008-5472.CAN-05-1633; DelSal G, 1996, ONCOGENE, V12, P177; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Han EKH, 1999, APOPTOSIS, V4, P213, DOI 10.1023/A:1009618824145; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Ikui AE, 2005, CELL CYCLE, V4, P1385, DOI 10.4161/cc.4.10.2061; Janicke RU, 2007, CELL CYCLE, V6, P407; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Judson PL, 1999, CANCER RES, V59, P2425; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Kadura S, 2005, CELL MOTIL CYTOSKEL, V61, P145, DOI 10.1002/cm.20072; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Leurs C, 2003, HUM GENE THER, V14, P509, DOI 10.1089/104303403764539305; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olashaw N, 2004, CELL CYCLE, V3, P263; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Srsen V, 2006, J CELL BIOL, V174, P625, DOI 10.1083/jcb.200606051; Stewart ZA, 1999, CANCER RES, V59, P3831; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003	47	34	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					116	125		10.1038/sj.onc.1210628	http://dx.doi.org/10.1038/sj.onc.1210628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599038				2022-12-25	WOS:000252118700012
J	Doufexis, M; Storr, HL; King, PJ; Clark, AJL				Doufexis, Marina; Storr, Helen L.; King, Peter J.; Clark, Adrian J. L.			Interaction of the melanocortin 2 receptor with nucleoporin 50: evidence for a novel pathway between a G-protein-coupled receptor and the nucleus	FASEB JOURNAL			English	Article						ACTH; GPCR	ADRENOCORTICAL TUMOR-CELLS; ACTH RECEPTOR; GLOMERULOSA CELLS; ADRENAL-CORTEX; EXPRESSION; RAT; KINASE; GENE; STEROIDOGENESIS; TRANSCRIPTION	The adrenocorticotropin (ACTH) receptor (melanocortin 2 receptor, or MC2R) is the smallest G-protein-coupled receptor that, when activated by the peptide hormone ACTH, stimulates cAMP production and adrenal steroidogenesis. Receptor expression is dependent on a specific membrane trafficking process involving an accessory protein (melanocortin 2 receptor accessory protein, or MRAP) and other unidentified components. In an attempt to discover novel receptor interacting proteins, the C-terminal tail of the MC2R was used to screen a mouse adrenal Y6 cell cDNA library using the bacterial two-hybrid system. This identified the nucleoporin Nup 50 (Npap60) as the major full-length interacting protein. Interaction was confirmed by a GST pulldown assay and by coimmunoprecipitation in human H295R cells (which express both proteins endogenously). Deletion analysis identified the region between residues 143 and 466 in Nup50 as being required for interaction with the MC2R. Stimulation of H295R cells with ACTH (10(-6) M) was followed by a gradual translocation of the Nup50-MC2R complex from the membrane to the nucleus after 30 min. This time course is most consistent with MC2R internalization dynamics and may suggest a novel role for Nup50.-Doufexis, M., Storr, H. L., King, P. J., Clark, A. J. L. Interaction of the melanocortin 2 receptor with nucleoporin 50: evidence for a novel pathway between a G-protein-coupled receptor and the nucleus.	Ctr Endocrinol, William Harvey Res Inst, London, England	University of London; Queen Mary University London	Clark, AJL (corresponding author), Univ London Queen Mary Coll, Ctr Endocrinol, William Harvey Res Inst, London EC1A 7BE, England.	a.j.clark@qmul.ac.uk		Storr, Helen/0000-0002-9963-1931				Baig AH, 2002, ENDOCR RES, V28, P281, DOI 10.1081/ERC-120016798; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Boivin B, 2003, J BIOL CHEM, V278, P29153, DOI 10.1074/jbc.M301738200; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; Cammas FM, 1997, MOL ENDOCRINOL, V11, P867, DOI 10.1210/me.11.7.867; Chorvatova A, 2000, ENDOCRINOLOGY, V141, P684, DOI 10.1210/en.141.2.684; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Dove Simon L, 2004, Methods Mol Biol, V261, P231; DURROUX T, 1991, ENDOCRINOLOGY, V129, P2139, DOI 10.1210/endo-129-4-2139; Enyeart JJ, 2005, VITAM HORM, V70, P265, DOI 10.1016/S0083-6729(05)70008-X; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fan F, 1997, GENOMICS, V40, P444, DOI 10.1006/geno.1996.4557; Forti FL, 2002, BIOCHEMISTRY-US, V41, P10133, DOI 10.1021/bi0258086; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Guan TL, 2000, MOL CELL BIOL, V20, P5619, DOI 10.1128/MCB.20.15.5619-5630.2000; HALKERSTON IDK, 1975, ADV CYCLIC NUCLEOTID, V6, P100; Jo Y, 2004, ENDOCRINOLOGY, V145, P5629, DOI 10.1210/en.2004-0941; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kobayashi H, 2006, J ENDOCRINOL, V189, P671, DOI 10.1677/joe.1.06419; KOJIMA I, 1985, J BIOL CHEM, V260, P4248; Le T, 2001, ENDOCRINOLOGY, V142, P4282, DOI 10.1210/en.142.10.4282; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; Matsuura Y, 2005, EMBO J, V24, P3681, DOI 10.1038/sj.emboj.7600843; Metherell LA, 2005, NAT GENET, V37, P166, DOI 10.1038/ng1501; Morris DG, 2003, J CLIN ENDOCR METAB, V88, P6080, DOI 10.1210/jc.2002-022048; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Nankova BB, 2003, NEUROSCI LETT, V344, P149, DOI 10.1016/S0304-3940(03)00361-6; NAVILLE D, 1994, MOL CELL ENDOCRINOL, V106, P131, DOI 10.1016/0303-7207(94)90194-5; Noon LA, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740017; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; SCHIMMER BP, 1995, J CELL PHYSIOL, V163, P164, DOI 10.1002/jcp.1041630119; Slominski A, 1996, J CLIN ENDOCR METAB, V81, P2746, DOI 10.1210/jc.81.7.2746; Smitherman M, 2000, MOL CELL BIOL, V20, P5631, DOI 10.1128/MCB.20.15.5631-5642.2000; Wang XJ, 2000, J BIOL CHEM, V275, P20204, DOI 10.1074/jbc.M003113200; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; Yamamoto S, 1998, MICROSC RES TECHNIQ, V40, P479, DOI 10.1002/(SICI)1097-0029(19980301)40:6<479::AID-JEMT8>3.0.CO;2-K; Yamazaki T, 1998, ENDOCRINOLOGY, V139, P4765, DOI 10.1210/en.139.12.4765	40	15	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					4095	4100		10.1096/fj.06-7927com	http://dx.doi.org/10.1096/fj.06-7927com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625072	Green Accepted			2022-12-25	WOS:000251283500034
J	Perri, SR; Annabi, B; Galipeau, J				Perri, Sabrina R.; Annabi, Borhane; Galipeau, Jacques			Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton	FASEB JOURNAL			English	Article						TAMs; actin disruption; tissue remodeling	TUMOR-ASSOCIATED MACROPHAGES; ENDOTHELIAL-CELL GROWTH; BREAST-CANCER; CHEMOATTRACTANT PROTEIN-1; ANTICANCER THERAPIES; INDUCE APOPTOSIS; MESSENGER-RNA; NITRIC-OXIDE; PROGRESSION; ANGIOGENESIS	In light of the involvement of tumor-associated macrophages ( TAM) in the promotion of tumor growth and metastasis, strategies to prevent TAM recruitment within the tumor microenvironment are currently under investigation. The recent observation that angiostatin reduces macrophage infiltration in an atherosclerosis model prompted our laboratory to further explore the use of human plasminogen angiostatin ( hK1 - 3) protein as a macrophage modulatory agent. We demonstrate that hK1 - 3 blocks migration of murine peritoneal macrophages ( 91% decrease, P< 0.00005) and human monocytes ( 85% decrease, P< 0.05) in vitro. Cell viability of hK1 - 3- treated cells is not affected, as determined by fluorochrome- labeled inhibitors of caspase- propidium iodide ( FLICA/ PI) flow cytometry analysis. Furthermore, confocal microscopy of phalloidin- stained cells reveals that hK1 - 3 leads to disruption of actin filopodia/ lamellipodia in human monocytes and induces distinct podosome accumulation in mature differentiated macrophages. Paradoxically, we observed a 3.5- fold increase in secretion and a 3- to 5.5- fold increase in gelatinolytic activity of macrophage-produced matrix metalloproteinase- 9, which we suggest is a cellular response to compensate for the dominant static effect of hK1 - 3 on actin. We also demonstrate that hK1 - 3 induces the phosphorylation of extracellular signal- regulated kinase ( ERK1/ 2) in human monocytes. hK1 - 3- mediated macrophage immobilization has the potential to be exploited therapeutically in pathological conditions associated with cellular hypoxia, such as cancer and atherosclerosis.	McGill Univ, Lady Davis Inst Med Res, Div Expt Med, Montreal, PQ H3T 1E2, Canada; Univ Quebec, Dept Chem, Montreal, PQ, Canada; Jewish Gen Hosp, Dept Med, Div Hematol Oncol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; University of Quebec; University of Quebec Montreal; McGill University	Galipeau, J (corresponding author), Lady Davis Inst Med Res, 3755 Cote-Ste-Catherine Rd, Montreal, PQ H3T 1E2, Canada.	jacques.galipeau@mcgill.ca	Galipeau, Jacques/R-9909-2019	Galipeau, Jacques/0000-0002-9374-1996				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Annabi B, 2006, ANTI-CANCER DRUG, V17, P429, DOI 10.1097/01.cad.0000203388.68034.06; Azenshtein E, 2005, CANCER LETT, V217, P73, DOI 10.1016/j.canlet.2004.05.024; Babb SG, 1997, CELL MOTIL CYTOSKEL, V37, P308; Barbera-Guillem E, 2002, CANCER RES, V62, P7042; Benelli R, 2001, FASEB J, V15, P267, DOI 10.1096/fj.01-0651fje; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bolat F, 2006, J EXP CLIN CANC RES, V25, P365; BOTTAZZI B, 1983, SCIENCE, V220, P210, DOI 10.1126/science.6828888; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dirkx AEM, 2006, J LEUKOCYTE BIOL, V80, P1183, DOI 10.1189/jlb.0905495; Dudani AK, 2005, BIOCHEM CELL BIOL, V83, P28, DOI 10.1139/O04-109; Dudani AK, 2007, MOL CELL BIOCHEM, V300, P197, DOI 10.1007/s11010-006-9384-3; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Evans JG, 2006, EUR J CELL BIOL, V85, P145, DOI 10.1016/j.ejcb.2005.08.006; Evans JG, 2003, J CELL BIOL, V161, P697, DOI 10.1083/jcb.200212037; Genersch E, 2000, J CELL SCI, V113, P4319; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Ishigami S, 2003, ANTICANCER RES, V23, P4079; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Knowles Helen, 2004, Novartis Found Symp, V256, P189; Kolaczkowska E, 2006, IMMUNOBIOLOGY, V211, P137, DOI 10.1016/j.imbio.2005.08.004; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Lewis C, 2005, AM J PATHOL, V167, P627, DOI 10.1016/S0002-9440(10)62038-X; Linder S, 2000, J CELL SCI, V113, P4165; Lu YB, 2005, J LEUKOCYTE BIOL, V78, P259, DOI 10.1189/jlb.0904498; Lucas R, 1998, BLOOD, V92, P4730; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Mantovani A, 2006, BLOOD, V108, P408, DOI 10.1182/blood-2006-05-019430; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NOONAN DM, 2006, RETROVIROLOGY S1, V3, pS80; Oosterling SJ, 2005, J PATHOL, V207, P147, DOI 10.1002/path.1830; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Perri SR, 2007, MOL CANCER THER, V6, P441, DOI 10.1158/1535-7163.MCT-06-0434; Perri SR, 2005, CANCER RES, V65, P8359, DOI 10.1158/0008-5472.CAN-05-0508; Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Saio M, 2001, J IMMUNOL, V167, P5583, DOI 10.4049/jimmunol.167.10.5583; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Shimura S, 2000, CANCER RES, V60, P5857; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636; Takanami I, 1999, ONCOLOGY-BASEL, V57, P138, DOI 10.1159/000012021; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Ueno T, 2000, CLIN CANCER RES, V6, P3282; Wang H, 2006, CANCER RES, V66, P7211, DOI 10.1158/0008-5472.CAN-05-4331; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; Zetter BR, 2001, J CELL BIOL, V152, pF35, DOI 10.1083/jcb.152.6.F35	60	26	31	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3928	3936		10.1096/fj.07-8158com	http://dx.doi.org/10.1096/fj.07-8158com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17622568				2022-12-25	WOS:000251283500018
J	Koh, Y; Matsumi, S; Das, D; Amano, M; Davis, DA; Li, JF; Leschenko, S; Baldridge, A; Shioda, T; Yarchoan, R; Ghosh, AK; Mitsuya, H				Koh, Yasuhiro; Matsumi, Shintaro; Das, Debananda; Amano, Masayuki; Davis, David A.; Li, Jianfeng; Leschenko, Sofiya; Baldridge, Abigail; Shioda, Tatsuo; Yarchoan, Robert; Ghosh, Arun K.; Mitsuya, Hiroaki			Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DESIGN; INTERFACE PEPTIDES; CRYSTAL-STRUCTURE; RESISTANCE; PROTEINASE; MONOMER; TMC114; PI; TIPRANAVIR; STABILITY	Dimerization of HIV-1 protease subunits is essential for its proteolytic activity, which plays a critical role in HIV-1 replication. Hence, the inhibition of protease dimerization represents a unique target for potential intervention of HIV-1. We developed an intermolecular fluorescence resonance energy transfer-based HIV-1-expression assay employing cyan and yellow fluorescent protein-tagged protease monomers. Using this assay, we identified non-peptidyl small molecule inhibitors of protease dimerization. These inhibitors, including darunavir and two experimental protease inhibitors, blocked protease dimerization at concentrations of as low as 0.01 mu M and blocked HIV-1 replication with IC50 values of 0.0002-0.48 mu M. These agents also inhibited the proteolytic activity of mature protease. Other approved anti-HIV-1 agents examined except tipranavir, a CCR5 inhibitor, and soluble CD4 failed to block the dimerization event. Once protease monomers dimerize to become mature protease, mature protease is not dissociated by this dimerization inhibition mechanism, suggesting that these agents block dimerization at the nascent stage of protease maturation. The proteolytic activity of mature protease that managed to undergo dimerization despite the presence of these agents is likely to be inhibited by the same agents acting as conventional protease inhibitors. Such a dual inhibition mechanism should lead to highly potent inhibition of HIV-1.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Infect Dis, Kumamoto 8608556, Japan; NCI, NIH, Expt Retrovirol Sect, Bethesda, MD 20892 USA; NCI, NIH, Retroviral Dis Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA; Purdue Univ, Dept Chem & Med Chem, W Lafayette, IN 47907 USA; Osaka Univ, Dept Viral Infect, Res Inst Microbial Dis, Osaka 5650871, Japan	Kumamoto University; Kumamoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Purdue University System; Purdue University; Purdue University West Lafayette Campus; Osaka University	Mitsuya, H (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hmitsuya@helix.nih.gov	Amano, Masayuki/N-7407-2016; Li, Jianfeng/F-5057-2014	Amano, Masayuki/0000-0003-0516-9502; Li, Jianfeng/0000-0002-8838-3872	NATIONAL CANCER INSTITUTE [Z01SC006738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053386, R37GM053386] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM53386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 2007, ANTIMICROB AGENTS CH, V51, P2143, DOI 10.1128/AAC.01413-06; BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; Bannwarth L, 2006, J MED CHEM, V49, P4657, DOI 10.1021/jm060576k; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Bastiaens PIH, 1996, P NATL ACAD SCI USA, V93, P8407, DOI 10.1073/pnas.93.16.8407; Bowman MJ, 2005, CHEM BIOL, V12, P439, DOI 10.1016/j.chembiol.2005.02.004; Carr A, 2003, NAT REV DRUG DISCOV, V2, P624, DOI 10.1038/nrd1151; Davis DA, 2006, ANTIVIR RES, V72, P89, DOI 10.1016/j.antiviral.2006.03.015; De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.6.2314-2321.2005; Fang GW, 1999, NAT MED, V5, P239, DOI 10.1038/5607; Frutos S, 2007, BIOPOLYMERS, V88, P164, DOI 10.1002/bip.20685; Gatanaga H, 2002, J BIOL CHEM, V277, P5952, DOI 10.1074/jbc.M108005200; Ghosh AK, 2004, J ORG CHEM, V69, P7822, DOI 10.1021/jo049156y; Ghosh AK, 2002, ANTIVIR RES, V54, P29, DOI 10.1016/S0166-3542(01)00209-1; Ghosh AK, 2006, J MED CHEM, V49, P5252, DOI 10.1021/jm060561m; Hicks CB, 2006, LANCET, V368, P466, DOI 10.1016/S0140-6736(06)69154-X; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; Hoetelmans RM, 2003, 10 C RETR OPP INF BO; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KONVALINKA J, 1995, J VIROL, V69, P7180, DOI 10.1128/JVI.69.11.7180-7186.1995; Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007; Kovalevsky AY, 2006, J MED CHEM, V49, P1379, DOI 10.1021/jm050943c; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; Levy Y, 2004, J MOL BIOL, V340, P67, DOI 10.1016/j.jmb.2004.04.028; Levy Y, 2003, J PHYS CHEM B, V107, P3068, DOI 10.1021/jp0219956; Louis JM, 2003, J BIOL CHEM, V278, P6085, DOI 10.1074/jbc.M209726200; Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004; MAIBAUM J, 1988, J MED CHEM, V31, P625, DOI 10.1021/jm00398a022; Miller JF, 2006, BIOORG MED CHEM LETT, V16, P1788, DOI 10.1016/j.bmcl.2006.01.035; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Muzammil S, 2007, J VIROL, V81, P5144, DOI 10.1128/JVI.02706-06; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; Poveda E, 2006, AIDS, V20, P1558, DOI 10.1097/01.aids.0000237375.23692.f4; Prabu-Jeyabalan M, 2006, J VIROL, V80, P3607, DOI 10.1128/JVI.80.7.3607-3616.2006; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Simon V, 2003, NAT REV MICROBIOL, V1, P181, DOI 10.1038/nrmicro772; SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Thaisrivongs S, 1996, J MED CHEM, V39, P4349, DOI 10.1021/jm960541s; Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1358.2002; Youle M, 2006, HIV CLIN TRIALS, V7, P86, DOI 10.1310/2XVK-PBGL-735N-WH72	48	102	107	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28709	28720		10.1074/jbc.M703938200	http://dx.doi.org/10.1074/jbc.M703938200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17635930	hybrid			2022-12-25	WOS:000249642100045
J	Lanvin, O; Bianco, S; Kersual, N; Chalbos, D; Vanacker, JM				Lanvin, Olivia; Bianco, Stephanie; Kersual, Nathalie; Chalbos, Dany; Vanacker, Jean-Marc			Potentiation of ICI182,780 (fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; STEROID-HORMONE RECEPTORS; HUMAN LACTOFERRIN GENE; BREAST-CANCER CELLS; ERR-ALPHA; REGULATED TRANSCRIPTION; DEPENDENT DEGRADATION; NUCLEAR RECEPTORS; ORPHAN RECEPTOR; EXPRESSION	ICI182,780 (Fulvestrant) is a pure anti-estrogen used in adjuvant therapies of breast cancer. This compound not only inhibits the transcriptional activities of the estrogen receptor-alpha (ER alpha) but also induces its proteasome-dependent degradation. The latter activity is believed to be required for the antiproliferative effects of ICI182,780. Estrogen receptor-related receptor-alpha (ERR alpha) is an orphan member of the nuclear receptor superfamily that is expressed in a wide range of tissues including breast tumors, in which its high expression correlates with poor prognosis. Although not regulated by any natural ligand, ERR alpha can be deactivated by the synthetic molecule XCT790. Here we demonstrate that this compound also induces a proteasome degradation of ERR alpha. We also show that although it does not act directly on the steady-state level of ER alpha, XCT790 potentiates the ICI182,780-induced ER alpha degradation. We suggest that treatment with XCT790 could thus enhance the efficacy of ICI182,780 in ER alpha-dependent pathologies such as breast cancer.	Univ Lyon, Inst Genom Font, F-69003 Lyon, France; Univ Lyon 1, Ecole Normale Super, CNRS, INRA, F-69364 Lyon, France; INSERM, U826, F-34298 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vanacker, JM (corresponding author), Univ Lyon 1, ENS, CNRS, Inst Genom Font,UMR 5242,INRA, Batiment Rech,CRLC Val Daurelle Paul Lamarque, F-34298 Montpellier 5, France.	jean-marc.vanacker@ens-lyon.fr						Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203; Ariazi EA, 2002, CANCER RES, V62, P6510; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; Callige Mathilde, 2006, Nucl Recept Signal, V4, pe004; Carrier JC, 2004, J BIOL CHEM, V279, P52052, DOI 10.1074/jbc.M410337200; Cavallini A, 2005, EUR J CANCER, V41, P1487, DOI 10.1016/j.ejca.2005.04.008; Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934; Fan MY, 2002, MOL ENDOCRINOL, V16, P315, DOI 10.1210/me.16.2.315; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Herzog B, 2006, J BIOL CHEM, V281, P99, DOI 10.1074/jbc.M509276200; Horard B, 2004, J MOL ENDOCRINOL, V33, P87, DOI 10.1677/jme.0.0330087; Horard B, 2003, J MOL ENDOCRINOL, V31, P349, DOI 10.1677/jme.0.0310349; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Kallen J, 2004, J BIOL CHEM, V279, P49330, DOI 10.1074/jbc.M407999200; Kraus RJ, 2002, J BIOL CHEM, V277, P24826, DOI 10.1074/jbc.M202952200; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; LAUDET V, 2002, NUCL RECEPTOR FACTBO; Li L, 2006, J BIOL CHEM, V281, P1978, DOI 10.1074/jbc.M508545200; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LONG X, J BIOL CHEM, V281, P9607; Lu DS, 2001, CANCER RES, V61, P6755; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nichol D, 2006, J BIOL CHEM, V281, P32140, DOI 10.1074/jbc.M604803200; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Shigeta H, 1997, J MOL ENDOCRINOL, V19, P299, DOI 10.1677/jme.0.0190299; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Sun PM, 2005, J MOL MED, V83, P457, DOI 10.1007/s00109-005-0639-3; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; Vanacker JM, 1998, CELL GROWTH DIFFER, V9, P1007; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Verma S, 2004, MOL CELL BIOL, V24, P8716, DOI 10.1128/MCB.24.19.8716-8726.2004; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101; Yang C, 1998, CANCER RES, V58, P5695; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	51	60	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28328	28334		10.1074/jbc.M704295200	http://dx.doi.org/10.1074/jbc.M704295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17631492	hybrid			2022-12-25	WOS:000249642100006
J	Munesue, S; Yoshitomi, Y; Kusano, Y; Koyama, Y; Nishiyama, A; Nakanishi, H; Miyazaki, K; Ishimaru, T; Miyaura, S; Okayama, M; Oguri, K				Munesue, Seiichi; Yoshitomi, Yasuo; Kusano, Yuri; Koyama, Yoshie; Nishiyama, Akiko; Nakanishi, Hayao; Miyazaki, Kaoru; Ishimaru, Takeshi; Miyaura, Shuichi; Okayama, Minoru; Oguri, Kayoko			A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HEPATOCYTE GROWTH-FACTOR; ACTIN-CYTOSKELETAL ORGANIZATION; LUNG-CARCINOMA CELLS; TUMOR-METASTASIS; BINDING; SURFACE; EXPRESSION; MIGRATION; PROGELATINASE	The syndecans comprise a family of cell surface heparan sulfate proteoglycans exhibiting complex biological functions involving the interaction of heparan sulfate side chains with a variety of soluble and insoluble heparin-binding extracellular ligands. Here we demonstrate an inverse correlation between the expression level of syndecan-2 and the metastatic potential of three clones derived from Lewis lung carcinoma 3LL. This correlation was proved to be a causal relationship, because transfection of syndecan-2 into the higher metastatic clone resulted in the suppression of both spontaneous and experimental metastases to the lung. Although the expression levels of matrix metalloproteinase-2 (MMP-2) and its cell surface activators, such as membrane-type I matrix metalloproteinase and tissue inhibitor of metalloproteinase-2, were similar regardless of the metastatic potentials of the clones, elevated activation of MMP-2 was observed in the higher metastatic clone. Removal of heparan sulfate from the cell surface of low metastatic cells by treatment with heparitinase-I promoted MMP-2 activation, and transfection of syndecan-2 into highly metastatic cells suppressed MMP-2 activation. Furthermore, transfection of mutated syndecan-2 lacking glycosaminoglycan attachment sites into highly metastatic cells did not have any suppressive effect on MMP-2 activation, suggesting that this suppression was mediated by the heparan sulfate side chains of syndecan-2. Actually, MMP-2 was found to exhibit a strong binding ability to heparin, the dissociation constant value being 62 nM. These results indicate a novel function of syndecan-2, which acts as a suppressor for MMP-2 activation, causing suppression of metastasis in at least the metastatic system used in the present study.	Kyoto Sangyo Univ, Fac Engn, Dept Biotechnol, Kyoto 603, Japan; Natl Hosp Organnizat, Nagoya Med Ctr, Clin Res Ctr, Nagoya, Aichi 460, Japan; Aichi Canc Ctr, Div Oncol Pathol, Nagoya, Aichi 464, Japan; Yokohama City Univ, Kihara Inst Biol Res, Yokohama, Kanagawa 232, Japan; Seikagaku Corp, Cent Res Lab, Tokyo 207, Japan	Kyoto Sangyo University; Nagoya Medical Center; Aichi Cancer Center; Yokohama City University; Seikagaku Corporation	Oguri, K (corresponding author), Kyoto Sangyo Univ, Fac Engn, Dept Biotechnol, Kyoto 603, Japan.	ogurik@nnh.hosp.go.jp						Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Gallay P, 2004, MICROBES INFECT, V6, P617, DOI 10.1016/j.micinf.2004.02.004; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Isnard N, 2003, CELL BIOL INT, V27, P779, DOI 10.1016/S1065-6995(03)00167-7; ITANO N, 1993, J BIOCHEM, V114, P862, DOI 10.1093/oxfordjournals.jbchem.a124269; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Karihaloo A, 2004, MOL CELL BIOL, V24, P8745, DOI 10.1128/MCB.24.19.8745-8752.2004; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; McKenzie E, 2000, BIOCHEM BIOPH RES CO, V276, P1170, DOI 10.1006/bbrc.2000.3586; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Munesue S, 2002, BIOCHEM J, V363, P201, DOI 10.1042/0264-6021:3630201; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKANISHI H, 1992, VIRCHOWS ARCH A, V420, P163, DOI 10.1007/BF02358808; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Smorenburg SM, 2001, PHARMACOL REV, V53, P93; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Su G, 2006, AM J PATHOL, V168, P2014, DOI 10.2353/ajpath.2006.050800; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; YANG BH, 1995, ANAL BIOCHEM, V228, P299, DOI 10.1006/abio.1995.1354; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshitomi Y, 2004, CANCER LETT, V207, P165, DOI 10.1016/j.canlet.2003.11.037	39	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28164	28174		10.1074/jbc.M609812200	http://dx.doi.org/10.1074/jbc.M609812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623663	hybrid			2022-12-25	WOS:000249455600066
J	Deng, WG; Jayachandran, G; Wu, G; Xu, K; Roth, JA; Ji, L				Deng, Wu-Guo; Jayachandran, Gitanjali; Wu, Guanglin; Xu, Kai; Roth, Jack A.; Ji, Lin			Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2 beta in human lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE EXPRESSION; HUMAN BREAST-CANCER; CATALYTIC SUBUNIT; RNA COMPONENT; FACTOR AP-2; CUTANEOUS MELANOMA; CARCINOMA-CELLS; UP-REGULATION; HTERT; GENE	The up-regulated expression and telomerase activity of human telomerase reverse transcriptase ( hTERT) are hallmarks of tumorigenesis. The hTERT promoter has been shown to promote hTERT gene expression selectively in tumor cells but not in normal cells. However, little is known about how tumor cells differentially activate hTERT transcription and induce telomerase activity. In this study, we identified activating enhancerbinding protein-2 beta(AP-2 beta) as a novel transcription factor that specifically binds to and activates the hTERT promoter in human lung cancer cells. AP-2 beta was detected in hTERT promoter DNA-protein complexes formed in nuclear extracts prepared only from lung cancer cells but not from normal cells. We verified the tumor-specific binding activity of AP-2 beta for the hTERT promoter in vitro and in vivo and detected high expression levels of AP-2 beta in lung cancer cells. We found that ectopic expression of AP-2 beta reactivated hTERT promoter-driven reporter green fluorescent protein (GFP) gene and endogenous hTERT gene expression in normal cells, enhanced GFP gene expression in lung cancer cells, and prolonged the life span of primary lung bronchial epithelial cells. Furthermore, we found that inhibition of endogenous expression by AP-2 beta gene-specific small interfering RNAs effectively attenuated hTERT promoter-driven GFP expression, suppressed telomerase activity, accelerated telomere shortening, and inhibited tumor cell growth by induction of apoptosis in lung cancer cells. Our results demonstrate the tumor-specific activation of the hTERT promoter by AP-2 beta and imply the potential of AP-2 beta as a novel tumor marker or a cancer therapeutic target.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ji, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Unit 445,1515 Holcombe Blvd, Houston, TX 77030 USA.	lji@mdanderson.org		Deng, wuguo/0000-0002-1193-1500	NCI NIH HHS [R01CA116322, CA70970, CA16672, U01CA105352-01, P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116322, U01CA105352, P50CA070907, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bilsland AE, 2006, CANCER RES, V66, P1363, DOI 10.1158/0008-5472.CAN-05-1941; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boldrini L, 2002, INT J MOL MED, V10, P589; Carpenter EL, 2006, EXPERT OPIN BIOL TH, V6, P1031, DOI 10.1517/14712598.6.10.1031; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Deng WG, 2003, J IMMUNOL, V171, P6581, DOI 10.4049/jimmunol.171.12.6581; Deng WG, 2003, ANAL BIOCHEM, V323, P12, DOI 10.1016/j.ab.2003.08.007; Deng WG, 2006, BLOOD, V108, P518, DOI 10.1182/blood-2005-09-3691; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Janknecht R, 2004, FEBS LETT, V564, P9, DOI 10.1016/S0014-5793(04)00356-4; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirkpatrick KL, 2003, EUR J SURG ONCOL, V29, P321, DOI 10.1053/ejso.2002.1374; Kirkpatrick KL, 2003, BREAST CANCER RES TR, V77, P277, DOI 10.1023/A:1021849217054; Li H, 2006, ONCOGENE, V25, P5405, DOI 10.1038/sj.onc.1209534; Li H, 2006, CELL RES, V16, P169, DOI 10.1038/sj.cr.7310023; Li HL, 2006, NEOPLASIA, V8, P568, DOI 10.1593/neo.06367; Ma HW, 2003, MOL CANCER RES, V1, P739; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakano K, 1998, AM J PATHOL, V153, P857, DOI 10.1016/S0002-9440(10)65627-1; Onoda N, 2004, SURG TODAY, V34, P389, DOI 10.1007/s00595-003-2729-6; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Pellikainen J, 2002, CLIN CANCER RES, V8, P3487; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Ueda K, 2006, CANCER RES, V66, P9682, DOI 10.1158/0008-5472.CAN-06-1483; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	44	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26460	10.1074/jbc.M610579200	http://dx.doi.org/10.1074/jbc.M610579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17630431	hybrid			2022-12-25	WOS:000249239600051
J	Geretti, E; Shimizu, A; Kurschat, P; Klagsbrun, M				Geretti, Elena; Shimizu, Akio; Kurschat, Peter; Klagsbrun, Michael			Site-directed mutagenesis in the b-neuropilin-2 domain selectively enhances its affinity to VEGF(165), but not to semaphorin 3F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL DEVELOPMENT; EXON 7-ENCODED DOMAIN; TUMOR-GROWTH; VASCULAR DEVELOPMENT; STRUCTURAL BASIS; POOR-PROGNOSIS; AXON GUIDANCE; NEUROPILIN-1; VEGF	Neuropilins (NRPs) are 130-kDa receptors that bind and respond to the class 3 semaphorin family of axon guidance molecules (SEMAs) and to members of the vascular endothelial growth factor ( VEGF) family of angiogenic factors. Two NRPs have been reported so far, NRP1 and NRP2. Unlike NRP1, little is known about NRP2 interactions with its ligands, VEGF(165) and SEMA3F. Cell binding studies reveal that VEGF(165) and SEMA3F bind NRP2 with similar affinities, 5.2 and 3.9 nM, respectively, and are competitive NRP2 ligands. Immunoprecipitation studies show that the B (b1b2) extracellular domain of NRP2 is sufficient for VEGF165 binding, whereas SEMA3F requires both the A (a1a2) and B domains. To identify residues of B-NRP2 involved in VEGF165 binding, point mutations were introduced by site-directed mutagenesis. VEGF165 is a basic protein. Reduction of the electronegative potential of B-NRP2 by exchanging acidic residues for uncharged alanine (B-NRP2 E284A, E291A) in the 280-290 b1-NRP2 loop resulted in a 2-fold reduction in VEGF165 affinity. Conversely, enhancing the electronegative potential (B-NRP2 R287E, N290D and R287E, N290S) significantly increased VEGF165 affinity for B-NRP2 by 8- and 6.6-fold, respectively. The mutagenesis did not affect SEMA3F/B-NRP2 interactions. These results demonstrate that it is possible to alter VEGF165 affinity for NRP2 without affecting SEMA3F affinity. They also identify NRP2 residues involved in VEGF165 binding and suggest that modifications of B-NRP2 could lead to potentially high affinity selective inhibitors of VEGF(165)/NRP2 interactions.	Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Vasc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Klagsbrun, M (corresponding author), Karp Bldg 12210,300 Longwood Ave, Boston, MA 02115 USA.	michael.klagsbrun@childrens.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA037392, R56CA037392, P01CA045548, R37CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA37392, CA45548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates D, 2003, DEV BIOL, V255, P77, DOI 10.1016/S0012-1606(02)00045-3; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Bielenberg DR, 2004, J CLIN INVEST, V114, P1260, DOI 10.1172/JCI200421378; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Eichmann A, 2005, INT J DEV BIOL, V49, P259, DOI 10.1387/ijdb.041941ae; Eichmann A, 2005, GENE DEV, V19, P1013, DOI 10.1101/gad.1305405; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Fujisawa H, 2004, J NEUROBIOL, V59, P24, DOI 10.1002/neu.10337; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P29922; Gluzman-Poltorak Z, 2001, J BIOL CHEM, V276, P18688, DOI 10.1074/jbc.M006909200; Goishi K, 2004, CURR TOP DEV BIOL, V62, P127; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Hansel DE, 2004, AM J SURG PATHOL, V28, P347, DOI 10.1097/00000478-200403000-00007; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200; Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com; Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Klagsbrun M, 2005, CYTOKINE GROWTH F R, V16, P535, DOI 10.1016/j.cytogfr.2005.05.002; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nakamura F, 2002, ADV EXP MED BIOL, V515, P55; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; Osada H, 2004, ANTICANCER RES, V24, P547; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Renzi MJ, 1999, J NEUROSCI, V19, P7870; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Starzec A, 2006, LIFE SCI, V79, P2370, DOI 10.1016/j.lfs.2006.08.005; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Vander Kooi CW, 2007, P NATL ACAD SCI USA, V104, P6152, DOI 10.1073/pnas.0700043104; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200; Yaniv K, 2006, NAT MED, V12, P711, DOI 10.1038/nm1427; Yuan L, 2002, DEVELOPMENT, V129, P4797	58	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25698	25707		10.1074/jbc.M702942200	http://dx.doi.org/10.1074/jbc.M702942200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17595163	hybrid			2022-12-25	WOS:000249014100057
J	Fonseca, BD; Smith, EM; Lee, VHY; MacKintosh, C; Proud, CG				Fonseca, Bruno D.; Smith, Ewan M.; Lee, Vivian H. -Y.; MacKintosh, Carol; Proud, Christopher G.			PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH AKT SUBSTRATE; P70 S6 KINASE; MTOR; PHOSPHORYLATION; BINDING; RAPTOR; INSULIN; GROWTH; 4E-BP1; IDENTIFICATION	Signaling through the mammalian target of rapamycin complex 1 (mTORC1) is positively regulated by amino acids and insulin. PRAS40 associates with mTORC1 (which contains raptor) but not mTORC2. PRAS40 interacts with raptor, and this requires an intact TOR-signaling (TOS) motif in PRAS40. Like TOS motif-containing proteins such as eIF4E-binding protein 1 (4E-BP1), PRAS40 is a substrate for phosphorylation by mTORC1. Consistent with this, starvation of cells of amino acids or treatment with rapamycin alters the phosphorylation of PRAS40. PRAS40 binds 14-3-3 proteins, and this requires both amino acids and insulin. Binding of PRAS40 to 14-3-3 proteins is inhibited by TSC1/2 (negative regulators of mTORC1) and stimulated by Rheb in a rapamycin-sensitive manner. This confirms that PRAS40 is a target for regulation by mTORC1. Small interfering RNA-mediated knockdown of PRAS40 impairs both the amino acid- and insulin-stimulated phosphorylation of 4E-BP1 and the phosphorylation of S6. However, this has no effect on the phosphorylation of Akt or TSC2 (an Akt substrate). These data place PRAS40 downstream of mTORC1 but upstream of its effectors, such as S6K1 and 4E-BP1.	Univ British Columbia, Inst Life Sci, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ Dundee, Coll Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ British Columbia, Med Res Council Phosphorylat Unit, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of Dundee; University of British Columbia	Proud, CG (corresponding author), Univ British Columbia, Inst Life Sci, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	cgpr@interchange.ubc.ca	MacKintosh, Carol/B-8210-2011	MacKintosh, Carol/0000-0001-9166-589X; Proud, Christopher/0000-0003-0704-6442; Smith, Ewan/0000-0002-3992-3748	Medical Research Council [MC_U127084354] Funding Source: Medline; MRC [MC_U127084354] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Eguchi S, 2006, GENES CELLS, V11, P757, DOI 10.1111/j.1365-2443.2006.00977.x; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hutchins JRA, 2002, FEBS LETT, V528, P267, DOI 10.1016/S0014-5793(02)03327-6; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Le Bacquer O, 2007, J CLIN INVEST, V117, P387, DOI 10.1172/JCI29528; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Madhunapantula SV, 2007, CANCER RES, V67, P3626, DOI 10.1158/0008-5472.CAN-06-4234; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Palmer D, 2007, J BIOL CHEM, V282, P9411, DOI 10.1074/jbc.M606936200; Saito Atsushi, 2005, Curr Atheroscler Rep, V7, P268, DOI 10.1007/s11883-005-0018-0; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Sun L, 2007, J BIOL CHEM, V282, P3766, DOI 10.1074/jbc.M607347200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yuan H, 2002, J VIROL, V76, P10685, DOI 10.1128/JVI.76.21.10685-10691.2002	41	198	202	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24514	24524		10.1074/jbc.M704406200	http://dx.doi.org/10.1074/jbc.M704406200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604271	hybrid			2022-12-25	WOS:000248933000005
J	Lee, HR; Helquist, SA; Kool, ET; Johnson, KA				Lee, Harold R.; Helquist, Sandra A.; Kool, Eric T.; Johnson, Kenneth A.			Base pair hydrogen bonds are essential for proofreading selectivity by the human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; NONPOLAR ISOSTERE; MINOR-GROOVE; REPLICATION; EXONUCLEASE; FIDELITY; DIFLUOROTOLUENE; ADENINE; ACID	We have characterized the role of Watson-Crick hydrogen bonding in the 3'-terminal base pair on the 3'-5'exonuclease activity of the human mitochondrial DNA polymerase. Nonpolar nucleoside analogs of thymidine (dF) and deoxyadenosine (dQ) were used to eliminate hydrogen bonds while maintaining base pair size and shape. Exonuclease reactions were examined using pre-steady state kinetic methods. The time dependence of removal of natural nucleotides from the primer terminus paired opposite the nonpolar analogs dF and dQ were best fit to a double exponential function. The double exponential kinetics as well as the rates of excision (3-6s(-1) fast phase, 0.16 -0.3 s(-1) slow phase) are comparable with those observed during mismatch removal of natural nucleotides even when the analog was involved in a sterically correct base pair. Additionally, incorporation of the next correct base beyond a nonpolar analog was slow (0.04 -0.22 s(-1)), so that more than 95% of terminal base pairs were removed rather than extended. The polymerase responds to all 3'-terminal base pairs containing a nonpolar analog as if it were a mismatch regardless of the identity of the paired base, and kinetic partitioning between polymerase and exonuclease sites failed to discriminate between correct and incorrect base pairs. Thus, sterics alone are insufficient, whereas hydrogen bond formation is essential for proper proofreading selectivity by the mitochondrial polymerase. The enzyme may use the alignment and prevention of fraying provided by proper hydrogen bonding and minor groove hydrogen bonding interactions as critical criteria for correct base pair recognition.	[Lee, Harold R.; Johnson, Kenneth A.] Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, Austin, TX 78712 USA; [Helquist, Sandra A.; Kool, Eric T.] Stanford Univ, Dept Chem, Stanford, CA 94305 USA	University of Texas System; University of Texas Austin; Stanford University	Johnson, KA (corresponding author), Univ Texas Austin, Dept Chem & Biochem, Inst Cellular & Mol Biol, 2500 Speedway, Austin, TX 78712 USA.	kajohnson@mail.utexas.edu		Kool, Eric/0000-0002-7310-2935	NIGMS NIH HHS [R01 GM044613, GM 044613, GM 072705, R01 GM044613-17A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072705, R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUTLAG D, 1972, J BIOL CHEM, V247, P241; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Guckian KM, 2000, J AM CHEM SOC, V122, P6841, DOI 10.1021/ja994164v; Guckian KM, 2000, J AM CHEM SOC, V122, P2213, DOI 10.1021/ja9934854; Guckian KM, 1998, J ORG CHEM, V63, P9652, DOI 10.1021/jo9805100; Guckian KM, 1998, NAT STRUCT BIOL, V5, P954, DOI 10.1038/2930; Henry AA, 2003, CURR OPIN CHEM BIOL, V7, P727, DOI 10.1016/j.cbpa.2003.10.011; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; KOUCHAKDJIAN M, 1988, J MOL BIOL, V202, P139, DOI 10.1016/0022-2836(88)90526-8; Leconte AM, 2006, J AM CHEM SOC, V128, P6780, DOI 10.1021/ja060853c; Lee HR, 2008, J BIOL CHEM, V283, P14402, DOI 10.1074/jbc.M705007200; Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200; Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+; Morales JC, 2000, BIOCHEMISTRY-US, V39, P2626, DOI 10.1021/bi992173a; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; SCHWEITZER BA, 1994, J ORG CHEM, V59, P7238, DOI 10.1021/jo00103a013; Spratt TE, 1997, BIOCHEMISTRY-US, V36, P13292, DOI 10.1021/bi971253g; Spratt TE, 2001, BIOCHEMISTRY-US, V40, P2647, DOI 10.1021/bi002641c; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	24	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14411	14416		10.1074/jbc.M705006200	http://dx.doi.org/10.1074/jbc.M705006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	17650503	Green Published, hybrid			2022-12-25	WOS:000255941400028
J	Suzuki, E; Imoto, I; Pimkhaokham, A; Nakagawa, T; Kamata, N; Kozaki, K; Amagasa, T; Inazawa, J				Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kamata, N.; Kozaki, K-i; Amagasa, T.; Inazawa, J.			PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation	ONCOGENE			English	Article						array-CGH; oral squamous-cell carcinoma; PRTFDC1; homozygous deletion; methylation	EPIGENETIC MECHANISMS; CANCER; METHYLATION; INACTIVATION; ABERRATIONS; EXPRESSION	Array-based comparative genomic hybridization (array-CGH) has good potential for the high-throughput identification of genetic aberrations in cell genomes. In the course of a program to screen a panel of oral squamous-cell carcinoma (OSCC), cell lines for genomic copy-number aberrations by array-CGH using our in-house arrays, we identified a 3-Mb homozygous deletion at 10p12 in 1 of 18 cell lines (5.6%). Among seven genes located within this region, expression of PRTFDC1 mRNA was not detected in 50% (9/18) or decreased in 5.6% (1/18) of OSCC cell lines, but detected in normal oral epithelia and restored in gene-silenced OSCC cells without its homozygous loss after treatment with 5-aza-2 '-deoxycytidine. Among 17 cell lines without a homozygous deletion, the hypermethylation of the PRTFDC1 CpG island, which showed promoter activity, was observed in all nine cell lines with no or reduced PRTFDC1 expression (52.9%). Methylation of this CpG island was also observed in primary OSCC tissues (8/47, 17.0%). In addition, restoration of PRTFDC1 in OSCC cells lacking its expression inhibited cell growth in colony-formation assays, whereas knockdown of PRTFDC1 expression in OSCC cells expressing the gene promoted cell growth. These results suggest that epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island leads to a loss of PRTFDC1 function, which might be involved in squamous cell oral carcinogenesis.	[Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; [Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; [Suzuki, E.; Amagasa, T.] Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Tokyo 1138510, Japan; [Imoto, I.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; [Imoto, I.; Kozaki, K-i; Inazawa, J.] Japan Sci & Technol Corp, CREST, Saitama, Japan; [Pimkhaokham, A.] Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Bangkok, Thailand; [Kamata, N.] Hiroshima Univ, Div Cervico Gnathostomatol, Dept Oral & Maxillofacial Surg, Grad Sch Biomed Sci,Minami Ku, Hiroshima, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Century Ctr Excellence Program Mol Destruct & Rec, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Chulalongkorn University; Hiroshima University; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Kozaki, Ken-ichi/M-6281-2014; Pimkhaokham, Atiphan/AAQ-4177-2021; Imoto, Issei/AAD-5799-2020	Kozaki, Ken-ichi/0000-0003-3286-819X; Pimkhaokham, Atiphan/0000-0002-0170-243X				Akanuma D, 1999, ORAL ONCOL, V35, P476, DOI 10.1016/S1368-8375(99)00020-2; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Brinkman BMN, 2006, CURR OPIN ONCOL, V18, P228, DOI 10.1097/01.cco.0000219250.15041.f8; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujimoto R., 2004, J JPN ORAL MUCO MEMB, V8, P1, DOI [10.6014/jjomm1995.8.1, DOI 10.6014/jjomm1995.8.1]; Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hermsen MAJA, 1997, ORAL ONCOL, V33, P414, DOI 10.1016/S0964-1955(97)00031-6; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Jin C, 2006, CANCER GENET CYTOGEN, V164, P44, DOI 10.1016/j.cancergencyto.2005.06.008; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kolb A, 2003, BIOCHEM BIOPH RES CO, V306, P1099, DOI 10.1016/S0006-291X(03)01104-5; Kusumoto Y, 2004, J PERIODONTOL, V75, P370, DOI 10.1902/jop.2004.75.3.370; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Nagpal JK, 2003, ORAL ONCOL, V39, P213, DOI 10.1016/S1368-8375(02)00162-8; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nicklas JA, 2006, ENVIRON MOL MUTAGEN, V47, P212, DOI 10.1002/em.20187; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Saigusa K, 2007, ONCOGENE, V26, P1110, DOI 10.1038/sj.onc.1210148; Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5; Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Takada H, 2006, ONCOGENE, V25, P6554, DOI 10.1038/sj.onc.1209657; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Wolff E, 1998, ORAL ONCOL, V34, P186, DOI 10.1016/S1368-8375(97)00079-1; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	33	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7921	7932		10.1038/sj.onc.1210589	http://dx.doi.org/10.1038/sj.onc.1210589			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599052				2022-12-25	WOS:000252163500011
J	Peng, Y; Stewart, D; Li, W; Hawkins, M; Kulak, S; Ballermann, B; Jahroudi, N				Peng, Y.; Stewart, D.; Li, W.; Hawkins, M.; Kulak, S.; Ballermann, B.; Jahroudi, N.			Irradiation modulates association of NF-Y with histone-modifying cofactors PCAF and HDAC	ONCOGENE			English	Article						NF-Y; HDAC; PCAF; von Willebrand factor; irradiation	WILLEBRAND-FACTOR PROMOTER; PROTEIN PHOSPHATASES; ENDOTHELIAL-CELLS; MDR1 GENE; INDUCTION; RECRUITMENT; ACTIVATION; INHIBITORS	Post-irradiation complications including thrombus formation result from increased procoagulant activity of vascular endothelial cells and elevated levels of von Willebrand factor (VWF) contribute to this process. We have previously demonstrated that irradiation induction of the VWF is mediated through interaction of NF-Y transcription factor with its cognate binding site in the VWF promoter. We have also demonstrated that irradiation increases the association of NF-Y with histone acetyltransferase p300/CBP-associated factor (PCAF). We now report that irradiation decreases the association of NF-Y with histone deacetylase 1 (HDAC1). We demonstrate that irradiation-induced changes in association of NF-Y with HDAC1 and PCAF lead to increased PCAF recruitment to the VWF promoter, increased association of acetylated histone H4 with the VWF promoter and subsequently increased transcription. We also demonstrate that this process is correlated to dephosphorylation of HDAC1 and is inhibited by calyculin A, an inhibitor of protein phosphatase1.	Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Albert Einstein Coll Med, Dept Med, Bronx, NY USA	University of Alberta; Yeshiva University; Albert Einstein College of Medicine	Jahroudi, N (corresponding author), Univ Alberta, Dept Med, 370-HMRC, Edmonton, AB T6G 2S2, Canada.	nadia.jahroudi@ualberta.ca	Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381	NHLBI NIH HHS [HL-67729] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067729] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bertagna A, 2001, THROMB HAEMOSTASIS, V85, P837; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289; Edwards E, 2002, CANCER RES, V62, P4671; FAJARDO LF, 1996, VASCULAR BRACHYTHERA, P74; Guo C, 2007, CELL SIGNAL, V19, P504, DOI 10.1016/j.cellsig.2006.08.001; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Rodeghiero F, 2002, HAEMOPHILIA, V8, P292, DOI 10.1046/j.1365-2516.2002.00611.x; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8	24	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7576	7583		10.1038/sj.onc.1210565	http://dx.doi.org/10.1038/sj.onc.1210565			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599060				2022-12-25	WOS:000251282100010
J	Mainardi, JL; Hugonnet, JE; Rusconi, F; Fourgeaud, M; Dubosth, L; Moumi, AN; Delfosse, V; Mayer, C; Gutmann, L; Rice, LB; Arthur, M				Mainardi, Jean-Luc; Hugonnet, Jean-Emmanuel; Rusconi, Filippo; Fourgeaud, Martine; Dubosth, Lionel; Moumi, Angele Nguekam; Delfosse, Vanessa; Mayer, Claudine; Gutmann, Laurent; Rice, Louis B.; Arthur, Michel			Unexpected inhibition of peptidoglycan LD-transpeptidase from enterococcus faecium by the beta-lactam imipenem	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; RESISTANCE; MECHANISM; L,D-TRANSPEPTIDASES; IDENTIFICATION; EXPRESSION	The beta-lactam antibiotics mimic the D-alanyl(4)-D-alanine(5) extremity of peptidoglycan precursors and act as "suicide" substrates of the DD-transpeptidases that catalyze the last cross-linking step of peptidoglycan synthesis. We have previously shown that bypass of the DD-transpeptidases by the LD-transpeptidase of Enterococcus faecium (Ldt(fm)) leads to high level resistance to ampicillin. Ldtfm is specific for the L-lysyl(3)-D-alanine(4) bond of peptidoglycan precursors containing a tetrapeptide stem lacking D-alanine(5). This specificity was proposed to account for resistance, because the substrate of Ldt(fm) does not mimic beta-lactams in contrast to the D-alanyl(4)-D-alanine(5) extremity of pentapeptide stems used by the DD-transpeptidases. Here, we unexpectedly show that imipenem, a beta-lactam of the carbapenem class, totally inhibited Ldtfm at a low drug concentration that was sufficient to inhibit growth of the bacteria. Peptidoglycan cross-linking was also inhibited, indicating that Ldt(fm) is the in vivo target of imipenem. Stoichiometric and covalent modification of Ldt(fm) by imipenem was detected by mass spectrometry. The modification was mapped into the trypsin fragment of Ldt(fm) containing the catalytic Cys residue, and the Cys to Ala substitution prevented imipenem binding. The mass increment matched the mass of imipenem, indicating that inactivation of Ldt(fm) is likely to involve rupture of the beta-lactam ring and acylation of the catalytic Cys residue. Thus, the spectrum of activity of beta-lactams is not restricted to transpeptidases of the DD-specificity, as previously thought. Combination therapy with imipenem and ampicillin could therefore be active against E. faecium strains having the dual capacity to manufacture peptidoglycan with transpeptidases of the LD- and DD-specificities.	INSERM, U872, LRMA Pole 4, F-75006 Paris, France; Univ Paris 06, Ctr Rech Cordeliers, UMR S872, F-75006 Paris, France; Univ Paris 05, UMR S872, F-75006 Paris, France; Assistance Publ Hosp Paris, Hop Europeen Georges Pompidou, F-75015 Paris, France; CNRS, UMR 5153, F-75231 Paris, France; INSERM, U565, F-75231 Paris, France; Museum Natl Hist Nat, Mass Spectrometry Facil, USM 0503, F-75231 Paris, France; Museum Natl Hist Nat, Plateforme Spectrometrie Masse & Proteom Museum, Dept Rech Dev & Diversite Mol, USM0502, F-75005 Paris, France; CNRS, UMR 8041, F-75005 Paris, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med & Res Serv, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Arthur, M (corresponding author), INSERM, U872, LRMA Pole 4, Equipe 12, F-75006 Paris, France.	michel.arthur@bhdc.jussieu.fr	HUGONNET, Jean-Emmanuel/H-3581-2014; MAINARDI, Jean-Luc/E-2714-2014; Arthur, Michel/G-3680-2013; HUGONNET, Jean-Emmanuel/ABC-7914-2021	HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; MAINARDI, Jean-Luc/0000-0002-4159-0129; Arthur, Michel/0000-0003-1007-636X; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Rusconi, Filippo Matteo/0000-0003-1822-0397; Delfosse, Vanessa/0000-0002-7436-7935	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; ARTHUR M, 1994, ANTIMICROB AGENTS CH, V38, P1899, DOI 10.1128/AAC.38.9.1899; Bellais S, 2006, J BIOL CHEM, V281, P11586, DOI 10.1074/jbc.M600114200; Biarrotte-Sorin S, 2006, J MOL BIOL, V359, P533, DOI 10.1016/j.jmb.2006.03.014; BillotKlein D, 1997, J BACTERIOL, V179, P4684, DOI 10.1128/jb.179.15.4684-4688.1997; Cremniter J, 2006, J BIOL CHEM, V281, P32254, DOI 10.1074/jbc.M606920200; FONTANA R, 1983, J BACTERIOL, V155, P1343, DOI 10.1128/JB.155.3.1343-1350.1983; Goffin C, 2002, MICROBIOL MOL BIOL R, V66, P702, DOI 10.1128/MMBR.66.4.702-738.2002; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359; JAMIN M, 1995, ESSAYS BIOCHEM, V29, P1; KLARE I, 1992, ANTIMICROB AGENTS CH, V36, P783, DOI 10.1128/AAC.36.4.783; Macheboeuf P, 2006, FEMS MICROBIOL REV, V30, P673, DOI 10.1111/j.1574-6976.2006.00024.x; Magnet S, 2007, J BACTERIOL, V189, P3927, DOI 10.1128/JB.00084-07; Magnet S, 2007, J BIOL CHEM, V282, P13151, DOI 10.1074/jbc.M610911200; Mainard JL, 2002, J BIOL CHEM, V277, P35801, DOI 10.1074/jbc.M204319200; Mainardi JL, 2005, J BIOL CHEM, V280, P38146, DOI 10.1074/jbc.M507384200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Rice LB, 2004, ANTIMICROB AGENTS CH, V48, P3028, DOI 10.1128/AAC.48.8.3028-3032.2004; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933	24	90	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30414	30422		10.1074/jbc.M704286200	http://dx.doi.org/10.1074/jbc.M704286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17646161	hybrid			2022-12-25	WOS:000250136300009
J	Cinar, B; Mukhopadhyay, NK; Meng, GY; Freeman, MR				Cinar, Bekir; Mukhopadhyay, Nishit K.; Meng, Gaoyuan; Freeman, Michael R.			Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; LIPID RAFTS; PLASMA-MEMBRANE; CARCINOMA-CELLS; ACTIVATION; PATHWAY; GROWTH; ESTROGEN	The serine-threonine kinase, Akt1/protein kinase B alpha is an important mediator of growth, survival, and metabolic signaling. Recent studies have implicated cholesterol-rich, lipid raft microdomains in survival signals mediated by Akt1. Here we address the role of lipid raft membranes as a potential site of intersection of androgenic and Akt1 signaling. A subpopulation of androgen receptor (AR) was found to localize to a lipid raft subcellular compartment in LNCaP prostate cancer cells. Endogenous AR interacted with endogenous Akt1 preferentially in lipid raft fractions and androgen substantially enhanced the interaction between the two proteins. The association of AR with Akt1 was inhibited by the anti-androgen, bicalutamide, but was not affected by inhibition of phosphoinositide 3-kinase (PI3K). Androgen promoted endogenous Akt1 activity in lipid raft fractions, in a PI3K-independent manner, within 10 min of treatment. Fusion of a lipid raft targeting sequence to AR enhanced localization of the receptor to rafts, and stimulated Akt1 activity in response to androgen, while reducing the cells' dependence on constitutive signaling through PI3K for cell survival. These findings suggest that signals channeled through AR and Akt1 intersect by a mechanism involving formation within lipid raft membranes of an androgen-responsive, extranuclear AR/Akt1 complex. Our results indicate that cholesterol-rich membrane microdomains play a role in transmitting nongenomic signals involving androgen and the Akt pathway in prostate cancer cells.	Harvard Univ, Childrens Hosp Boston, Urol Dis Res Ctr, Dept Urol Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp Boston, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Freeman, MR (corresponding author), John F Enders Res Labs, Suite 1161,300 Longwood Ave, Boston, MA 02115 USA.	michael.freeman@childrens.harvard.edu	CİNAR, BEKIR MURAT/AAL-4474-2021	CİNAR, BEKIR MURAT/0000-0002-7906-5039; Cinar, Bekir/0000-0003-4028-7600	NATIONAL CANCER INSTITUTE [R01CA112303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047556, P50DK065298] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112303] Funding Source: Medline; NIDDK NIH HHS [R01 DK087806, P50 DK65298, R37 DK47556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acconcia F, 2005, MOL BIOL CELL, V16, P231, DOI 10.1091/mbc.e04-07-0547; Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Barsoum I, 2006, TRENDS ENDOCRIN MET, V17, P223, DOI 10.1016/j.tem.2006.06.009; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Bonaccorsi L, 2004, INT J CANCER, V112, P78, DOI 10.1002/ijc.20362; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Cinar B, 2004, BIOCHEM J, V379, P421, DOI 10.1042/BJ20031661; Cinar B, 2001, CANCER RES, V61, P7310; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Davies MA, 1999, CANCER RES, V59, P2551; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freeman MR, 2005, TRENDS ENDOCRIN MET, V16, P273, DOI 10.1016/j.tem.2005.06.002; Gatson JW, 2006, ENDOCRINOLOGY, V147, P2028, DOI 10.1210/en.2005-1395; Gill A, 2004, MOL ENDOCRINOL, V18, P97, DOI 10.1210/me.2003-0326; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; JAGLA M, 2007, IN PRESS ENDOCRINOLO; Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306; Korzeniowski M, 2003, BIOCHEMISTRY-US, V42, P5358, DOI 10.1021/bi027135x; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lin JQ, 1999, CANCER RES, V59, P2891; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lutz LB, 2001, P NATL ACAD SCI USA, V98, P13728, DOI 10.1073/pnas.241471598; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Na SY, 2003, J IMMUNOL, V171, P1285, DOI 10.4049/jimmunol.171.3.1285; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Rai D, 2005, MOL ENDOCRINOL, V19, P1606, DOI 10.1210/me.2004-0468; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509; Wen Y, 2000, CANCER RES, V60, P6841; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Zhou J, 2005, CANCER RES, V65, P9906, DOI 10.1158/0008-5472.CAN-05-1481; Zhuang LY, 2005, J CLIN INVEST, V115, P959; Zhuang LY, 2002, CANCER RES, V62, P2227	49	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29584	29593		10.1074/jbc.M703310200	http://dx.doi.org/10.1074/jbc.M703310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17635910	hybrid			2022-12-25	WOS:000249788000055
J	Davies, KJA; Ermak, G; Rothermel, BA; Pritchard, M; Heitman, J; Ahnn, J; Henrique-Silva, F; Crawford, D; Canaider, S; Strippoli, P; Carinci, P; Min, KT; Fox, DS; Cunningham, KW; Bassel-Duby, R; Olson, EN; Zhang, Z; Williams, RS; Gerber, HP; Perez-Riba, M; Seo, H; Cao, X; Klee, CB; Redondo, JM; Maltais, LJ; Bruford, EA; Povey, S; Molkentin, JD; McKeon, FD; Duh, EJ; Crabtree, GR; Cyert, MS; de la Luna, S; Estivill, X				Davies, Kelvin J. A.; Ermak, Gennady; Rothermel, Beverley A.; Pritchard, Melanie; Heitman, Joseph; Ahnn, Joohong; Henrique-Silva, Flavio; Crawford, Dana; Canaider, Silvia; Strippoli, Pierluigi; Carinci, Paolo; Min, Kyung-Tai; Fox, Deborah S.; Cunningham, Kyle W.; Bassel-Duby, Rhonda; Olson, Eric N.; Zhang, Zhuohua; Williams, R. Sanders; Gerber, Hans-Peter; Perez-Riba, Merce; Seo, Hisao; Cao, Xia; Klee, Claude B.; Redondo, Juan Miguel; Maltais, Lois J.; Bruford, Elspeth A.; Povey, Sue; Molkentin, Jeffery D.; McKeon, Frank D.; Duh, Elia J.; Crabtree, Gerald R.; Cyert, Martha S.; de la Luna, Susana; Estivill, Xavier			Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin	FASEB JOURNAL			English	Article						calcipressin; oxidative stress; Down syndrome; Alzheimer disease; MCIP; NFAT	SYNDROME CRITICAL REGION; DOWN-SYNDROME; DSCR1 ADAPT78; INHIBITS CALCINEURIN; ALZHEIMERS-DISEASE; IN-VIVO; PHOSPHATASE CALCINEURIN; CRYPTOCOCCUS-NEOFORMANS; INTERACTING PROTEIN-1; ENDOGENOUS INHIBITOR		Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Monash Univ, Monash Inst Med Res, Ctr Funct Genom & Human Dis, Clayton, Vic 3168, Australia; Duke Univ, Med Ctr, Dept Mol Genet, Durham, NC USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea; Univ Fed Sao Carlos, Dept Genet & Evolut, Sao Carlos, SP, Brazil; Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Univ Bologna, Dept Histol Embryol & Appl Biol, Bologna, Italy; NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp, Res Inst Children, New Orleans, LA USA; Childrens Hosp, Louisiana State Hlth Sci Ctr, Dept Pediat, New Orleans, LA USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75230 USA; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Inst Recerca Oncol, IDIBELL, Med & Mol Genet Ctr, Barcelona, Spain; Nagoya Univ, Environm Med Res Inst, Div Mol & Cellular Adaptat, Dept Endocrinol & Metab,Chikusa Ku, Nagoya, Aichi 464, Japan; NCI, Biochem Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; CNIC, Madrid, Spain; Jackson Lab, MGI, Mouse Genom Nomenclature Comm, Bar Harbor, ME 04609 USA; UCL, Dept Biol, Galton Lab, HUGO Gene Nomenclature Comm, London, England; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; ICREA, Barcelona, Spain; CRG, Genes & Dis Program, Gene Funct Grp, Barcelona, Spain; CRG, CeGen Barcelona Genotyping Node, Barcelona, Catalonia, Spain; Pompeu Fabra Univ, Dept Life Sci, Barcelona, Catalonia, Spain	University of Southern California; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Monash University; Duke University; Duke University; Gwangju Institute of Science & Technology (GIST); Universidade Federal de Sao Carlos; Albany Medical College; University of Bologna; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Children's Hospital of New Orleans; Children's Hospital of New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanford Burnham Prebys Medical Discovery Institute; Duke University; Roche Holding; Genentech; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Nagoya University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Jackson Laboratory; University of London; University College London; Cincinnati Children's Hospital Medical Center; Harvard University; Harvard Medical School; Johns Hopkins University; Stanford University; Stanford University; Stanford University; ICREA; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA.	kelvin@usc.edu	Redondo, Juan Miguel/H-6351-2015; de la Luna, Susana/E-9553-2015; Henrique-Silva, Flavio/A-1937-2013; Bruford, Elspeth/AAU-4961-2020; Estivill, Xavier/E-2957-2012; Estivill, Xavier/A-3125-2013; Heitman, Joseph/ABC-6006-2021	Redondo, Juan Miguel/0000-0001-5779-9122; de la Luna, Susana/0000-0001-7765-916X; Bruford, Elspeth/0000-0002-8380-5247; Estivill, Xavier/0000-0002-0723-2256; Cyert, Martha/0000-0003-3825-7437; Perez-Riba, Merce/0000-0003-1604-4617; STRIPPOLI, PIERLUIGI/0000-0001-8769-8832; min, kyung-tai/0000-0003-0983-4258; Davies, Kelvin/0000-0001-7790-3003; Molkentin, Jeffery/0000-0002-3558-6529	ICREA Funding Source: Custom	ICREA(ICREA)		Abbasi S, 2006, J BIOL CHEM, V281, P7717, DOI 10.1074/jbc.M510775200; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Aubareda A, 2006, CELL SIGNAL, V18, P1430, DOI 10.1016/j.cellsig.2005.11.006; Canaider S, 2006, GENE, V372, P128, DOI 10.1016/j.gene.2005.12.029; Cano E, 2005, J BIOL CHEM, V280, P29435, DOI 10.1074/jbc.M506205200; Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093; Cao X, 2002, BIOCHEM J, V367, P459, DOI 10.1042/BJ20011797; Casas C, 2001, MECH DEVELOP, V101, P289, DOI 10.1016/S0925-4773(00)00583-9; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Chang KT, 2003, P NATL ACAD SCI USA, V100, P15794, DOI 10.1073/pnas.2536696100; Cook CN, 2005, J ALZHEIMERS DIS, V8, P63; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; Ejima A, 2004, GENETICS, V168, P2077, DOI 10.1534/genetics.104.029934; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Ermak G, 2004, FASEB J, V18, P62, DOI 10.1096/fj.03-0451com; Ermak G, 2006, FEBS J, V273, P2100, DOI 10.1111/j.1742-4658.2006.05217.x; Ermak G, 2003, IUBMB LIFE, V55, P29, DOI 10.1080/1521654031000066820; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; Fox DS, 2005, EUKARYOT CELL, V4, P1526, DOI 10.1128/EC.4.9.1526-1538.2005; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Garbers C, 1996, EMBO J, V15, P2115, DOI 10.1002/j.1460-2075.1996.tb00565.x; Genesca L, 2003, BIOCHEM J, V374, P567, DOI 10.1042/BJ20030267; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; Harris CD, 2005, CELL MOL LIFE SCI, V62, P2477, DOI 10.1007/s00018-005-5085-4; HARRIS CD, 2007, IN PRESS FEBS J; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Kingsbury TJ, 2000, GENE DEV, V14, P1595; KORENBERG JR, 1994, P NATL ACAD SCI USA, V91, P4997, DOI 10.1073/pnas.91.11.4997; Leahy KP, 2000, ARCH BIOCHEM BIOPHYS, V379, P221, DOI 10.1006/abbi.2000.1897; Lee JI, 2003, J MOL BIOL, V328, P147, DOI 10.1016/S0022-2836(03)00237-7; Lin HY, 2003, FREE RADICAL BIO MED, V35, P528, DOI 10.1016/S0891-5849(03)00358-7; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Miyazaki T, 1996, J BIOL CHEM, V271, P14567, DOI 10.1074/jbc.271.24.14567; MULERO C, 2007, IN PRESS CELL RES; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; Sanna B, 2006, P NATL ACAD SCI USA, V103, P7327, DOI 10.1073/pnas.0509340103; SINET PM, 1994, BIOMED PHARMACOTHER, V48, P247, DOI 10.1016/0753-3322(94)90140-6; Strippoli P, 2000, GENE, V257, P223, DOI 10.1016/S0378-1119(00)00407-8; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; U M, 2004, LEUKEMIA, V18, P1850, DOI 10.1038/sj.leu.2403516; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61	51	134	138	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3023	3028		10.1096/fj.06-7246com	http://dx.doi.org/10.1096/fj.06-7246com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17595344				2022-12-25	WOS:000249781600004
J	Konopka, G; Tekiela, J; Iverson, M; Wells, C; Duncan, SA				Konopka, Genevieve; Tekiela, Jackie; Iverson, Moriah; Wells, Clive; Duncan, Stephen A.			Junctional adhesion molecule-A is critical for the formation of pseudocanaliculi and modulates E-cadherin expression in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CANINE KIDNEY-CELLS; JAM FAMILY-MEMBERS; TIGHT JUNCTION; GROWTH-FACTOR; HEPG2 CELLS; IMMUNOGLOBULIN SUPERFAMILY; HEPATOCARCINOMA CELLS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS	Hepatocytes are polarized epithelial cells whose function depends upon their ability to distinguish between the apical and basolateral surfaces that are located at intercellular tight junctions. It has been proposed that the signaling cascades originating at these junctions influence cellular activity by controlling gene expression in the cell nucleus. To assess the validity of this proposal with regard to hepatocytes, we depleted expression of the tight junction protein junctional adhesion molecule-A (JAM-A) in the HepG2 human hepatocellular carcinoma cell line. Reduction of JAM-A resulted in a striking change in cell morphology, with cells forming sheets 1-2 cells thick instead of the normal multilayered clusters. In the absence of JAM-A, other tight junction proteins were mislocalized, and pseudo-canaliculi, which form the apical face of the hepatocyte, were consequently absent. There was a strong transcriptional induction of the adherens junction protein E-cadherin in cells with reduced levels of JAM-A. This increase in E-cadherin was partially responsible for the observed alterations in cell morphology and mislocalization of tight junction proteins. We therefore propose the existence of a novel mechanism of cross-talk between specific components of tight and adherens junctions that can be utilized to regulate adhesion between hepatic cells.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Duncan, SA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.	duncans@mcw.edu		Konopka, Genevieve/0000-0002-3363-7302; Duncan, Stephen/0000-0002-2507-7827	NIDDK NIH HHS [R01 DK055743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Ara C, 2004, CELL COMMUN ADHES, V11, P13, DOI 10.1080/15419060490471757; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Battle MA, 2006, P NATL ACAD SCI USA, V103, P8419, DOI 10.1073/pnas.0600246103; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Carloni V, 1998, GASTROENTEROLOGY, V115, P433, DOI 10.1016/S0016-5085(98)70210-0; Carloni V, 2001, HEPATOLOGY, V34, P42, DOI 10.1053/jhep.2001.25224; Cera MR, 2004, J CLIN INVEST, V114, P729, DOI 10.1172/JCI200421231; CHIU JH, 1990, HEPATOLOGY, V11, P834, DOI 10.1002/hep.1840110519; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Cohen D, 2007, MOL BIOL CELL, V18, P2203, DOI 10.1091/mbc.E07-02-0095; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cooke VG, 2006, ARTERIOSCL THROM VAS, V26, P2005, DOI 10.1161/01.ATV.0000234923.79173.99; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; Duncan SA, 1997, DEVELOPMENT, V124, P279; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; GOODENOUGH DA, 1970, J CELL BIOL, V45, P272, DOI 10.1083/jcb.45.2.272; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Ishigami A, 2005, CELL TISSUE RES, V320, P243, DOI 10.1007/s00441-004-1073-5; Kang LI, 2007, INT J BIOCHEM CELL B, V39, P576, DOI 10.1016/j.biocel.2006.10.016; Khandoga A, 2005, BLOOD, V106, P725, DOI 10.1182/blood-2004-11-4416; Kubitz R, 2001, HEPATOLOGY, V34, P340, DOI 10.1053/jhep.2001.25959; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu Y, 2000, J CELL SCI, V113, P2363; Lubeseder-Martellato C, 2002, AM J PATHOL, V161, P1749, DOI 10.1016/S0002-9440(10)64452-5; LUFT JH, 1966, FED PROC, V25, P1773; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Mandell KJ, 2006, INVEST OPHTH VIS SCI, V47, P2408, DOI 10.1167/iovs.05-0745; Mandell KJ, 2004, J BIOL CHEM, V279, P16254, DOI 10.1074/jbc.M309483200; Mandell KJ, 2005, J BIOL CHEM, V280, P11665, DOI 10.1074/jbc.M412650200; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Nejjari M, 1999, INT J CANCER, V83, P518, DOI 10.1002/(SICI)1097-0215(19991112)83:4<518::AID-IJC14>3.3.CO;2-H; Parris JJ, 2005, DEV DYNAM, V233, P1517, DOI 10.1002/dvdy.20481; POUCELL S, 1992, HEPATOLOGY, V16, P1061, DOI 10.1002/hep.1840160433; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Rehder D, 2006, EXP CELL RES, V312, P3389, DOI 10.1016/j.yexcr.2006.07.004; Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schmitt M, 2004, J HEPATOL, V41, P274, DOI 10.1016/j.jhep.2004.04.035; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; Shoda J, 2004, J LIPID RES, V45, P1813, DOI 10.1194/jlr.M400132-JLR200; Siwkowski AM, 2004, MOL PHARMACOL, V66, P572; SORMUNEN R, 1993, LAB INVEST, V68, P652; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; Sprenger CC, 1999, CANCER RES, V59, P2370; Takaki Y, 2001, CELL TISSUE RES, V305, P399, DOI 10.1007/s004410100397; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; van der Wouden JM, 2002, EMBO J, V21, P6409, DOI 10.1093/emboj/cdf629; VANBUULOFFERS SC, 1994, ENDOCRINOLOGY, V135, P977, DOI 10.1210/en.135.3.977; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yamagata K, 2004, NEUROBIOL DIS, V17, P491, DOI 10.1016/j.nbd.2004.08.001; Yamamoto T, 2004, EXP CELL RES, V299, P427, DOI 10.1016/j.yexcr.2004.06.011; Yano T, 2001, CARCINOGENESIS, V22, P1593, DOI 10.1093/carcin/22.10.1593; Zegers MMP, 1998, BIOCHEM J, V336, P257, DOI 10.1042/bj3360257; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	84	37	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28137	28148		10.1074/jbc.M703592200	http://dx.doi.org/10.1074/jbc.M703592200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623668	hybrid			2022-12-25	WOS:000249455600063
J	Krilleke, D; DeErkenez, A; Schubert, W; Giri, I; Robinson, GS; Ng, YS; Shima, DT				Krilleke, Dominik; DeErkenez, Andrea; Schubert, William; Giri, Indrajit; Robinson, Gregory S.; Ng, Yin-Shan; Shima, David T.			Molecular mapping and functional characterization of the VEGF164 heparin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TISSUE FACTOR EXPRESSION; CRYSTAL-STRUCTURE; EXTRACELLULAR-MATRIX; ANGSTROM RESOLUTION; TYROSINE KINASE; TUMOR-CELLS; RECEPTOR; NEUROPILIN-1; KDR	The longer splice isoforms of vascular endothelial growth factor-A (VEGF-A), including mouse VEGF164, contain a highly basic heparin-binding domain (HBD), which imparts the ability of these isoforms to be deposited in the heparan sulfate-rich extracellular matrix and to interact with the prototype sulfated glycosaminoglycan, heparin. The shortest isoform, VEGF120, lacks this highly basic domain and is freely diffusible upon secretion Although the HBD has been attributed significant relevance to VEGF-A biology, the molecular determinants of the heparin-binding site are unknown. We used site-directed mutagenesis to identify amino acid residues that are critical for heparin binding activity of the VEGF164 HBD. We focused on basic residues and found Arg-13, Arg-14, and Arg-49 to be critical for heparin binding and interaction with extracellular matrix in tissue samples. We also examined the cellular and biochemical consequences of abolishing heparin-binding function, measuring the ability of the mutants to interact with VEGF receptors, induce endothelial cell gene expression, and trigger microvessel outgrowth. Induction of tissue factor expression, vessel outgrowth, and binding to VEGFR2 were unaffected by the HBD mutations. In contrast, the HBD mutants showed slightly decreased binding to the NRP1 (neuropilin-1) receptor, and analyses suggested the heparin and NRP1 binding sites to be distinct but overlapping. Finally, mutations that affect the heparin binding activity also led to an unexpected reduction in the affinity of VEGF164 binding specifically to VEGF164. This finding provides a potential basis for previous observations suggesting enhanced potency of VEGF164 versus VEGF120 in VEGFR1-mediated signaling in inflammatory cells.	UCL, Inst Ophthalmol, London EC1V 9EL, England; OSI Eyetech, Lexington, MA 02421 USA; Endothelial Cell Biol Lab, Canc Res UK, London WC2A 3PX, England	University of London; University College London; Cancer Research UK	Shima, DT (corresponding author), UCL, Inst Ophthalmol, Mortimer St, London EC1V 9EL, England.	d.shima@ucl.ac.uk	Ng, Wing Yin/HHN-1743-2022	Ng, Yin Shan/0000-0002-4982-1999				Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Cheng LL, 2004, J BIOL CHEM, V279, P30654, DOI 10.1074/jbc.M402488200; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5; Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200; Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Koopmann W, 1999, J IMMUNOL, V163, P2120; Lander A D, 1994, Chem Biol, V1, P73, DOI 10.1016/1074-5521(94)90043-4; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOSIA RF, 1990, LAB INVEST, V63, P115; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200; Robinson CJ, 2001, J CELL SCI, V114, P853; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200; Shintani Y, 2006, EMBO J, V25, P3045, DOI 10.1038/sj.emboj.7601188; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stauffer ME, 2002, J BIOMOL NMR, V23, P57, DOI 10.1023/A:1015346504499; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wung JL, 1996, BIOTECHNIQUES, V21, P808; Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200; Zhu Wen-Hui, 2002, Angiogenesis, V5, P81, DOI 10.1023/A:1021509004829	66	71	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28045	28056		10.1074/jbc.M700319200	http://dx.doi.org/10.1074/jbc.M700319200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17626017	hybrid			2022-12-25	WOS:000249455600054
J	Edderkaoui, M; Hong, P; Lee, JK; Pandol, SJ; Gukovskaya, AS				Edderkaoui, Mouad; Hong, Peggy; Lee, Jong K.; Pandol, Stephen J.; Gukovskaya, Anna S.			Insulin-like growth factor-I receptor mediates the prosurvival effect of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX PROTEINS; PANCREATIC-CANCER CELLS; FOCAL ADHESION KINASE; IGF-I; ALPHA-V-BETA-3 INTEGRIN; APOPTOSIS; PHOSPHORYLATION; PROLIFERATION; STATISTICS	We recently showed that extracellular matrix ( ECM) proteins, which are abundant in desmoplastic pancreatic tumor, are as potent as growth factors in inhibiting apoptosis in pancreatic cancer ( PaCa) cells. Here we show that fibronectin, a major ECM component, engages insulin-like growth factor-I receptor ( IGF-IR) to inhibit PaCa cell death. We found that fibronectin-induced protection from apoptosis is fully mediated by IGF-IR and is independent of IGF-I. Pharmacologic and molecular inhibitions of IGF-IR stimulated apoptosis and prevented the prosurvival effect of fibronectin in PaCa cells. Our data indicate that fibronectin protects from apoptosis through trans-activation of IGF-IR. We showed that fibronectin stimulated complex formation between its receptor beta 3 integrin and protein-tyrosine phosphatase SHP-2. This process of complex formation, in turn, prevents SHP- 2 from dephosphorylating IGF-IR resulting in sustained phosphorylation of IGF-IR and leading to the downstream activation of Akt kinase, up-regulation of antiapoptotic BclxL, and inhibition of apoptosis. Among ECM proteins tested only fibronectin and laminin but not vitronectin and collagen I stimulated trans-activation of IGF-IR. Interaction of fibronectin with beta 3 but not beta 1 integrin receptors mediates the survival pathway. In contrast, fibronectin-induced adhesion is mediated through beta 1 integrin receptor and is IGF-IR-independent. Thus, our results indicate that the prosurvival effect of fibronectin in PaCa cells is mediated by trans-activation of IGF-IR induced by the beta 3 integrin receptor. The data suggest IGF-IR as a key target for prevention of the prosurvival effects of ECM proteins and growth factors in pancreatic cancer.	W Los Angeles Vet Affairs Hlth Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90073 USA; Sungkyunkwan Univ, Sch Med, Seoul 135710, South Korea	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; Sungkyunkwan University (SKKU)	Gukovskaya, AS (corresponding author), W Los Angeles Vet Affairs Hlth Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA.	agukovsk@ucla.edu	Jee, Yong-Seok/AAJ-5187-2020	Gukovskaya, Anna/0000-0003-3737-5335; Edderkaoui, Mouad/0000-0002-2549-8242	NCI NIH HHS [R01 CA 119025-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA119025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; BERGMANN U, 1995, CANCER RES, V55, P2007; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Edderkaoui M, 2005, AM J PHYSIOL-GASTR L, V289, pG1137, DOI 10.1152/ajpgi.00197.2005; El Annabi S, 2001, FEBS LETT, V507, P247, DOI 10.1016/S0014-5793(01)02981-7; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han SW, 2006, ONCOGENE, V25, P4341, DOI 10.1038/sj.onc.1209460; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Karna E, 2002, INT J EXP PATHOL, V83, P239, DOI 10.1046/j.1365-2613.2002.00237.x; Linder S, 2001, HEPATO-GASTROENTEROL, V48, P1321; Ling Y, 2005, J BIOL CHEM, V280, P3151, DOI 10.1074/jbc.M411035200; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Maile LA, 2003, MOL BIOL CELL, V14, P3519, DOI 10.1091/mbc.E03-04-0239; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; MOLLENHAUER J, 1987, Pancreas, V2, P14, DOI 10.1097/00006676-198701000-00003; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; Novosyadlyy R, 2006, LAB INVEST, V86, P710, DOI 10.1038/labinvest.3700426; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Perugini RA, 1998, CRIT REV EUKAR GENE, V8, P377, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.70; Sekharam M, 2003, CANCER RES, V63, P7708; Tai YT, 2003, CANCER RES, V63, P5850; TRIKHA M, 1994, CANCER RES, V54, P4993; Vaquero EC, 2003, GASTROENTEROLOGY, V125, P1188, DOI 10.1016/S0016-5085(03)01203-4; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Watanabe I, 2003, PANCREAS, V26, P326, DOI 10.1097/00006676-200305000-00003; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6	30	38	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26646	26655		10.1074/jbc.M702836200	http://dx.doi.org/10.1074/jbc.M702836200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627944	hybrid			2022-12-25	WOS:000249304900003
J	Kaur, D; McNeil, MR; Khoo, KH; Chatterjee, D; Crick, DC; Jackson, M; Brennan, PJ				Kaur, Devinder; McNeil, Michael R.; Khoo, Kay-Hooi; Chatterjee, Delphi; Crick, Dean C.; Jackson, Mary; Brennan, Patrick J.			New insights into the biosynthesis of mycobacterial lipomannan arising from deletion of a conserved gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; PHOSPHATIDYLINOSITOL MANNOSIDES; ACYLATION STATE; CELL-WALL; LIPOARABINOMANNAN BIOSYNTHESIS; ARABINAN BIOSYNTHESIS; BOVIS BCG; TUBERCULOSIS; MANNOSYLTRANSFERASE; IDENTIFICATION	Genetic construction of a mutant strain (designated MSMEG4245) of Mycobacterium smegmatis, defective in a broadly conserved gene for a putative glycosyltransferase of the glycosyltransferase-C superfamily, results in a phenotype marked by the virtual absence of the phosphatidylinositol-containing lipomannan and lipoarabinomannan, replaced instead by a novel truncated form of lipomannan. The normal spectrum of phosphatidylinositol mannosides, long presumed precursors of these lipoglycans, was retained. Matrix-assisted laser desorption/ionization- time of flight/mass spectrometry of the mutated form of lipomannan shows a family of phosphatidylinositol-anchored lipomannans with from only 5 to 20 Manp residues as compared with lipomannan from the wild type strain consisting of 21-34 Manp residues but with few changes in the branching pattern. Thus, MSMEG4245 is apparently a key mannosyltransferase, required for the proper elongation of lipomannan to its normal state and subsequent synthesis of lipoarabinomannan. The corresponding ortholog in Mycobacterium tuberculosis H37Rv has been identified as Rv2174. This previously unrecognized feature of the biosynthesis of lipomannan/lipoarabinomannan allows a significant revision of structural and biosynthetic schemata and provides a molecular basis of selectivity in biosynthesis, as conferred by the MSMEG4245 gene.	Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France	Colorado State University; Academia Sinica - Taiwan; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Brennan, PJ (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	patrick.brennan@colostate.edu	Jackson, Mary/D-5345-2017; Khoo, Kay-Hooi/E-1989-2019; Crick, Dean/H-8251-2017; McNeil, Michael/G-3325-2019	Jackson, Mary/0000-0002-9212-0258; Khoo, Kay-Hooi/0000-0003-2906-406X; Crick, Dean/0000-0001-9281-7058; 	NIAID NIH HHS [AI 18357, R01 AI064798, AI 064798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, R01AI018357, R01AI064798, R22AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alderwick LJ, 2006, J BIOL CHEM, V281, P15653, DOI 10.1074/jbc.M600045200; Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; Berg S, 2007, GLYCOBIOLOGY, V17, p35R, DOI 10.1093/glycob/cwm010; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CRICK DC, 2004, TUBERCULOSIS, P115; DELL A, 1994, METHOD ENZYMOL, V230, P108; Dinadayala P, 2006, J BIOL CHEM, V281, P20027, DOI 10.1074/jbc.M603395200; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2006, CHEM BIOL, V13, P39, DOI 10.1016/j.chembiol.2005.10.013; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; Gokhale RS, 2007, NAT PROD REP, V24, P267, DOI 10.1039/b616817p; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; Kang BK, 1998, INFECT IMMUN, V66, P2769, DOI 10.1128/IAI.66.6.2769-2777.1998; Kang JY, 2005, J BIOL CHEM, V280, P9489, DOI 10.1074/jbc.M413867200; Kaur D, 2002, MICROBIOL-SGM, V148, P3049, DOI 10.1099/00221287-148-10-3049; Kaur D, 2006, P NATL ACAD SCI USA, V103, P13664, DOI 10.1073/pnas.0603049103; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kovacevic S, 2006, J BIOL CHEM, V281, P9011, DOI 10.1074/jbc.M511709200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Morita YS, 2006, J BIOL CHEM, V281, P25143, DOI 10.1074/jbc.M604214200; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; TSAI PK, 1984, J BIOL CHEM, V259, P3805; VanderVen BC, 2005, SCIENCE, V309, P941, DOI 10.1126/science.1114347; Whitfield C, 2006, ANNU REV BIOCHEM, V75, P39, DOI 10.1146/annurev.biochem.75.103004.142545; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	44	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27133	27140		10.1074/jbc.M703389200	http://dx.doi.org/10.1074/jbc.M703389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17606615	hybrid			2022-12-25	WOS:000249304900054
J	Rosenkilde, MM; Gerlach, LO; Hatse, S; Skerlj, RT; Schols, D; Bridger, GJ; Schwartz, TW				Rosenkilde, Mette M.; Gerlach, Lars-Ole; Hatse, Sigrid; Skerlj, Renato T.; Schols, Dominique; Bridger, Gary J.; Schwartz, Thue W.			Molecular mechanism of action of Monocyclam versus Bicyclam non-peptide antagonists in the CXCR4 chemokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PHENYLENEBIS(METHYLENE)-LINKED BIS-TETRAAZAMACROCYCLES; SELECTIVE-INHIBITION; REPLICATION; AMD3100; HIV-1; BINDING; POTENT; PHARMACOKINETICS; MUTAGENESIS	AMD3465 is a novel, nonpeptide CXCR4 antagonist and a potent inhibitor of HIV cell entry in that one of the four-nitrogen cyclam rings of the symmetrical, prototype bicyclam antagonist AMD3100 has been replaced by a two-nitrogen N-pyridinylmethylene moiety. This substitution induced an 8-fold higher affinity as determined against I-125-12G5 monoclonal CXCR4 antibody binding, and a 22-fold higher potency in inhibition of CXCL12-induced signaling through phosphatidylinositol accumulation. Mutational mapping of AMD3465 and a series of analogs of this in a library of 23 mutants covering the main ligand binding pocket of the CXCR4 receptor demonstrated that the single cyclam ring of AMD3465 binds in the pocket around AspIV:20 (Asp(171)), in analogy with AMD3100, whereas the N-pyridinylmethylene moiety mimics the other cyclam ring through interactions with the two acidic anchor-point residues in transmembrane (TM)-VI (AspVI:23/Asp(262)) and TM-VII (GluVII:06/Glu(288)). Importantly, AMD3465 has picked up novel interaction sites, for example, His(281) located at the interface of extracellular loop 3 and TM-VII and HisIII:05 (His(113)) in the middle of the binding pocket. It is concluded that the simple N-pyridinylmethylene moiety of AMD3465 substitutes for one of the complex cyclam moieties of AMD3100 through an improved and in fact expanded interaction pattern mainly with residues located in the extracellular segments of TM-VI and -VII of the CXCR4 receptor. It is suggested that the remaining cyclam ring of AMD3465, which ensures the efficacious blocking of the receptor, in a similar manner can be replaced by chemical moieties allowing for, for example, oral bioavailability.	Univ Copenhagen, Mol Pharmacol Lab, Panum Inst, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark; AnorMED, Langley, BC V2Y 1N5, Canada; 7TM Pharma, DK-2970 Horsholm, Denmark; Katholieke Univ Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, B-300 Louvain, Belgium	University of Copenhagen; KU Leuven	Rosenkilde, MM (corresponding author), Univ Copenhagen, Mol Pharmacol Lab, Panum Inst, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark.	Rosenkilde@molpharm.dk	Schols, Dominique/AAC-1309-2021; Schols, Dominique/S-9057-2017	Schols, Dominique/0000-0003-3256-5850; Schols, Dominique/0000-0003-3256-5850; Rosenkilde, Mette Marie/0000-0001-9600-3254; Schwartz, Thue W./0000-0002-0261-6904				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Bjorndal A, 1997, J VIROL, V71, P7478; Bridger GJ, 1996, J MED CHEM, V39, P109, DOI 10.1021/jm950584t; Bridger GJ, 1999, J MED CHEM, V42, P3971, DOI 10.1021/jm990211i; BRIDGER GJ, 1995, J MED CHEM, V38, P366, DOI 10.1021/jm00002a019; Cho C, 2002, J NEUROVIROL, V8, P573, DOI 10.1080/13550280290101003; Choi HJ, 1998, J AM CHEM SOC, V120, P10622, DOI 10.1021/ja980504l; DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668; DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286; Este JA, 1999, MOL PHARMACOL, V55, P67, DOI 10.1124/mol.55.1.67; Gerlach LO, 2003, BIOCHEMISTRY-US, V42, P710, DOI 10.1021/bi0264770; Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200; Hatse S, 2005, BIOCHEM PHARMACOL, V70, P752, DOI 10.1016/j.bcp.2005.05.035; Hatse S, 2001, MOL PHARMACOL, V60, P164, DOI 10.1124/mol.60.1.164; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; Hendrix CW, 2004, JAIDS-J ACQ IMM DEF, V37, P1253, DOI 10.1097/01.qai.0000137371.80695.ef; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; IZATT RM, 1991, CHEM REV, V91, P1721, DOI 10.1021/cr00008a003; JOAO HC, 1995, J MED CHEM, V38, P3865, DOI 10.1021/jm00019a017; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Larochelle A, 2006, BLOOD, V107, P3772, DOI 10.1182/blood-2005-09-3592; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Rosenkilde MM, 2004, J BIOL CHEM, V279, P3033, DOI 10.1074/jbc.M309546200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SCHOLS D, 2003, 10 C RETR VIR OPP IN; Signoret N, 1998, J CELL SCI, V111, P2819; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; TASKER PA, 1975, J CRYST MOL STRUCT, V5, P329, DOI 10.1007/BF01270621; Unutmaz D, 1997, P NATL ACAD SCI USA, V94, P1615, DOI 10.1073/pnas.94.5.1615; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	33	97	98	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27354	27365		10.1074/jbc.M704739200	http://dx.doi.org/10.1074/jbc.M704739200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17599916	hybrid			2022-12-25	WOS:000249304900077
J	Wen, XY; Duus, KM; Friedrich, TD; de Noronha, CMC				Wen, Xiaoyun; Duus, Karen M.; Friedrich, Thomas D.; de Noronha, Carlos M. C.			The HIV1 protein vpr acts to promote G(2) cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DNA-BINDING PROTEIN; NUCLEAR IMPORT; V PROTEIN; VIRION INCORPORATION; MUTATIONAL ANALYSIS; NONDIVIDING CELLS; CDT1 DEGRADATION; LOCALIZATION; DAMAGE	The roles of the HIV1 protein Vpr in virus replication and pathogenesis remain unclear. Expression of Vpr in dividing cells causes cell cycle arrest in G(2). Vpr also facilitates low titer infection of terminally differentiated macrophages, enhances transcription, promotes apoptosis, and targets cellular uracil N-glycosylase for degradation. Using co-immunoprecipitation and tandem mass spectroscopy, we found that HIV1 Vpr engages a DDB1- and cullin4A-containing ubiquitin-ligase complex through VprBP/DCAF1. HIV2 Vpr has two Vpr-like proteins, Vpr and Vpx, which cause G(2) arrest and facilitate macrophage infection, respectively. HIV2 Vpr, but not Vpx, engages the same set of proteins. We further demonstrate that the interaction between Vpr and the ubiquitin-ligase components as well as further assembly of the ubiquitin-ligase are necessary for Vpr-mediatedG(2) arrest. Our data support a model in which Vpr engages the ubiquitin ligase to deplete a cellular factor that is required for cell cycle progression into mitosis. Vpr, thus, functions like the HIV1 proteins Vif and Vpu to usurp cellular ubiquitin ligases for viral functions.	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	Albany Medical College	de Noronha, CMC (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, Med Sci Bldg 216,MC-151, Albany, NY 12208 USA.	DeNoroC@mail.AMC.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073178] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI073178] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Arias EE, 2006, NAT CELL BIOL, V8, P84, DOI 10.1038/ncb1346; BALLIET JW, 1994, VIROLOGY, V200, P623, DOI 10.1006/viro.1994.1225; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DeHart JL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-57; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Hu J, 2006, J BIOL CHEM, V281, P3753, DOI 10.1074/jbc.C500464200; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Jung SO, 2001, MOL CELLS, V12, P84; Kewalramani VN, 1996, VIROLOGY, V218, P326, DOI 10.1006/viro.1996.0201; Le Rouzic E, 2007, CELL CYCLE, V6, P182, DOI 10.4161/cc.6.2.3732; Li T, 2006, CELL, V124, P105, DOI 10.1016/j.cell.2005.10.033; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Liu C, 2005, EMBO J, V24, P3940, DOI 10.1038/sj.emboj.7600854; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; Precious B, 2005, J VIROL, V79, P13434, DOI 10.1128/JVI.79.21.13434-13441.2005; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Schrofelbauer B, 2007, P NATL ACAD SCI USA, V104, P4130, DOI 10.1073/pnas.0610167104; Schrofelbauer B, 2005, J VIROL, V79, P10978, DOI 10.1128/JVI.79.17.10978-10987.2005; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; TRISTEM M, 1992, EMBO J, V11, P3405, DOI 10.1002/j.1460-2075.1992.tb05419.x; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; YAMSHITA M, 2005, PLOS PATHOG, V1; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028	57	126	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27046	27057		10.1074/jbc.M703955200	http://dx.doi.org/10.1074/jbc.M703955200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17620334	hybrid			2022-12-25	WOS:000249304900046
J	Knecht, W; Cottrell, GS; Amadesi, S; Mohlin, J; Skaregarde, A; Gedda, K; Peterson, A; Chapman, K; Hollenberg, MD; Vergnolle, N; Bunnett, NW				Knecht, Wolfgang; Cottrell, Graeme S.; Amadesi, Silvia; Mohlin, Johanna; Skaregarde, Anita; Gedda, Karin; Peterson, Anders; Chapman, Kevin; Hollenberg, Morley D.; Vergnolle, Nathalie; Bunnett, Nigel W.			Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN; CAPSAICIN RECEPTOR; MOLECULAR-CLONING; PROTEASE-ACTIVATED-RECEPTOR-2 SENSITIZES; NEUROGENIC MECHANISM; THERMAL HYPERALGESIA; INHIBITOR RESISTANCE; VANILLOID RECEPTOR-1; PAIN PATHWAY; ION-CHANNEL	Although principally produced by the pancreas to degrade dietary proteins in the intestine, trypsins are also expressed in the nervous system and in epithelial tissues, where they have diverse actions that could be mediated by protease-activated receptors ( PARs). We examined the biological actions of human trypsin IV ( or mesotrypsin) and rat p23, inhibitor-resistant forms of trypsin. The zymogens trypsinogen IV and pro-p23 were expressed in Escherichia coli and purified to apparent homogeneity. Enteropeptidase cleaved both zymogens, liberating active trypsin IV and p23, which were resistant to soybean trypsin inhibitor and aprotinin. Trypsin IV cleaved N-terminal fragments of PAR(1), PAR(2), and PAR(4) at sites that would expose the tethered ligand (PAR(1) = PAR(4) > PAR(2)). Trypsin IV increased [Ca2(+)] (i) in transfected cells expressing human PAR(1) and PAR(2) with similar potencies (PAR(1), 0.5 mu M; PAR(2), 0.6 mu M). p23 also cleaved fragments of PAR(1) and PAR(2) and signaled to cells expressing these receptors. Trypsin IV and p23 increased [Ca2(+)] i in rat dorsal root ganglion neurons that responded to capsaicin and which thus mediate neurogenic inflammation and nociception. Intraplantar injection of trypsin IV and p23 in mice induced edema and granulocyte infiltration, which were not observed in PAR(1) (-/-)(trypsin IV) and PAR(2) (-/-) ( trypsin IV and p23) mice. Trypsin IV and p23 caused thermal hyperalgesia and mechanical allodynia and hyperalgesia in mice, and these effects were absent in PAR(2) (-/-) mice but maintained in PAR1 (-/-) mice. Thus, trypsin IV and p23 are inhibitor- resistant trypsins that can cleave and activate PARs, causing PAR(1)- and PAR(2)- dependent inflammation and PAR(2)- dependent hyperalgesia.	Univ Calif San Francisco, San Francisco, CA 94143 USA; AstraZeneca Res & Dev, Mol Pharmacol & Lead Generat, Molndal 43183, Sweden; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calgary, Dept Med, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; INSERM, Ctr Physiopathol Touluse Purpan, U563, F-310300 Toulouse, France; Univ Toulouse 3, F-31000 Toulouse, France	University of California System; University of California San Francisco; AstraZeneca; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Calgary; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bunnett, NW (corresponding author), Univ Calif San Francisco, 513 Parnassus Ave, San Francisco, CA 94143 USA.	nigel.bunnett@ucsf.edu	Vergnolle, Nathalie/C-7677-2018; Hollenberg, Morley/AFV-6966-2022	Vergnolle, Nathalie/0000-0003-1825-6015; Cottrell, Graeme/0000-0001-9098-7627; Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK57480, DK43207, DK39957] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039957, R56DK043207, R01DK043207, R01DK039957] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amadesi S, 2004, J NEUROSCI, V24, P4300, DOI 10.1523/JNEUROSCI.5679-03.2004; Amadesi S, 2006, J PHYSIOL-LONDON, V575, P555, DOI 10.1113/jphysiol.2006.111534; Asfaha S, 2002, BRIT J PHARMACOL, V135, P1101, DOI 10.1038/sj.bjp.0704568; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Coelho AM, 2002, GASTROENTEROLOGY, V122, P1035, DOI 10.1053/gast.2002.32387; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Cottrell GS, 2007, GASTROENTEROLOGY, V132, P2422, DOI 10.1053/j.gastro.2007.03.101; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; de Garavilla L, 2001, BRIT J PHARMACOL, V133, P975, DOI 10.1038/sj.bjp.0704152; Diederichs S, 2004, CANCER RES, V64, P5564, DOI 10.1158/0008-5472.CAN-04-2004; EMI M, 1986, GENE, V41, P305; Fukuoka S, 2002, BBA-MOL BASIS DIS, V1588, P106, DOI 10.1016/S0925-4439(02)00153-9; Gallatz Katalin, 2007, Ideggyogy Sz, V60, P118; Grant AD, 2007, J PHYSIOL-LONDON, V578, P715, DOI 10.1113/jphysiol.2006.121111; Grishina Z, 2005, BRIT J PHARMACOL, V146, P990, DOI 10.1038/sj.bjp.0706410; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; Kawabata A, 2001, NEUROREPORT, V12, P715, DOI 10.1097/00001756-200103260-00020; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Kunitz M, 1939, J GEN PHYSIOL, V22, P429, DOI 10.1085/jgp.22.4.429; Loew D, 2000, BIOCHEMISTRY-US, V39, P10812, DOI 10.1021/bi0003341; Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172; Medveczky P, 2006, FEBS LETT, V580, P545, DOI 10.1016/j.febslet.2005.12.067; Minn A, 1998, GLIA, V22, P338, DOI 10.1002/(SICI)1098-1136(199804)22:4<338::AID-GLIA3>3.0.CO;2-#; Nakayama T, 2003, BRIT J PHARMACOL, V138, P121, DOI 10.1038/sj.bjp.0705008; Nemeth AL, 2007, FEBS J, V274, P1610, DOI 10.1111/j.1742-4658.2007.05708.x; Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Oikonomopoulou K, 2006, J BIOL CHEM, V281, P32095, DOI 10.1074/jbc.M513138200; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; Rowen L, 2005, MOL BIOL EVOL, V22, P1712, DOI 10.1093/molbev/msi166; Sahin-Toth M, 2005, PROTEIN PEPTIDE LETT, V12, P457, DOI 10.2174/0929866054395356; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Szepessy E, 2006, FEBS J, V273, P2942, DOI 10.1111/j.1742-4658.2006.05305.x; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Szmola R, 2003, J BIOL CHEM, V278, P48580, DOI 10.1074/jbc.M310301200; Toth J, 2007, NEUROCHEM RES, V32, P1423, DOI 10.1007/s11064-007-9327-8; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang YF, 2006, J NEUROCHEM, V99, P759, DOI 10.1111/j.1471-4159.2006.04105.x; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YAMASHINA I, 1956, ACTA CHEM SCAND, V10, P739, DOI 10.3891/acta.chem.scand.10-0739; Yamashita K, 2003, CANCER RES, V63, P6575	58	84	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26089	26100		10.1074/jbc.M703840200	http://dx.doi.org/10.1074/jbc.M703840200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623652	hybrid			2022-12-25	WOS:000249239600012
J	McConlogue, L; Buttini, M; Anderson, JP; Brigham, EF; Chen, KS; Freedman, SB; Games, D; Johnson-Wood, K; Lee, M; Zeller, M; Liu, W; Motter, R; Sinha, S				McConlogue, Lisa; Buttini, Manuel; Anderson, John P.; Brigham, Elizabeth F.; Chen, Karen S.; Freedman, Stephen B.; Games, Dora; Johnson-Wood, Kelly; Lee, Michael; Zeller, Michelle; Liu, Weiqun; Motter, Ruth; Sinha, Sukanto			Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR-PROTEIN; BETA-SECRETASE BACE1; MOUSE MODEL; A-BETA; MEMORY DEFICITS; ASPARTYL PROTEASE; KNOCKOUT MICE; IN-VIVO; DISEASE; CLEAVAGE	The aspartyl protease beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates processing of amyloid precursor protein (APP) into amyloid beta ( A beta) peptide, the major component of Alzheimer disease ( AD) plaques. To determine the role that BACE1 plays in the development of A beta-driven AD-like pathology, we have crossed PDAPP mice, a transgenic mouse model of AD overexpressing human mutated APP, onto mice with either a homozygous or heterozygous BACE1 gene knockout. Analysis of PDAPP/BACE(-/-) mice demonstrated that BACE1 is absolutely required for both A beta generation and the development of age-associated plaque pathology. Furthermore, synaptic deficits, a neurodegenerative pathology characteristic of AD, were also reversed in the bigenic mice. To determine the extent of BACE1 reduction required to significantly inhibit pathology, PDAPP mice having a heterozygous BACE1 gene knock-out were evaluated for A beta generation and for the development of pathology. Although the 50% reduction in BACE1 enzyme levels caused only a 12% decrease in A beta levels in young mice, it nonetheless resulted in a dramatic reduction in A beta plaques, neuritic burden, and synaptic deficits in older mice. Quantitative analyses indicate that brain A beta levels in young APP transgenic mice are not the sole determinant for the changes in plaque pathology mediated by reduced BACE1. These observations demonstrate that partial reductions of BACE1 enzyme activity and concomitant A beta levels lead to dramatic inhibition of A beta-driven AD-like pathology, making BACE1 an excellent target for therapeutic intervention in AD.	Elan Pharmaceut, San Francisco, CA 94010 USA; Elan Pharmaceut, Dept Biol, San Francisco, CA 94080 USA; Elan Pharmaceut, Dept Pharmacol, San Francisco, CA 94080 USA		McConlogue, L (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, San Francisco, CA 94010 USA.	lisa.mcconlogue@elan.com		Buttini, Manuel/0000-0003-1805-0279				Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bornemann KD, 2000, ANN NY ACAD SCI, V908, P260; Buttini M, 2005, J NEUROSCI, V25, P9096, DOI 10.1523/JNEUROSCI.1697-05.2005; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chen KS, 1998, PROG BRAIN RES, V117, P327; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Danner S, 2002, NEUROBIOL AGING, V23, pS241; DEKOSKY ST, 1990, ANN NEUROL, V27, P457, DOI 10.1002/ana.410270502; DICKSON DW, 1988, AM J PATHOL, V132, P86; Dickson TC, 2001, NEUROSCIENCE, V105, P99, DOI 10.1016/S0306-4522(01)00169-5; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Grace EA, 2002, NEUROSCIENCE, V114, P265, DOI 10.1016/S0306-4522(02)00241-5; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007; Kitazume S, 2005, J BIOL CHEM, V280, P8589, DOI 10.1074/jbc.M409417200; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KOBAYASHI D, 2007, IN PRESS NEUROBIOL A; Laird FM, 2005, J NEUROSCI, V25, P11693, DOI 10.1523/JNEUROSCI.2766-05.2005; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; McPhie DL, 2001, MOL BRAIN RES, V97, P103, DOI 10.1016/S0169-328X(01)00294-7; Mucke L, 1996, ANN NY ACAD SCI, V777, P82, DOI 10.1111/j.1749-6632.1996.tb34405.x; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ohno M, 2006, EUR J NEUROSCI, V23, P251, DOI 10.1111/j.1460-9568.2005.04551.x; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; RABE L, 2006, INT C ALZH DIS REL D; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shi XP, 2005, J ALZHEIMERS DIS, V7, P139; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Spires TL, 2004, REV NEUROSCIENCE, V15, P267, DOI 10.1515/REVNEURO.2004.15.4.267; Terry R., 1999, ALZHEIMER DIS, V2nd Edn, P187; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	58	240	282	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26326	26334		10.1074/jbc.M611687200	http://dx.doi.org/10.1074/jbc.M611687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616527	hybrid			2022-12-25	WOS:000249239600037
J	Smardon, AM; Kane, PM				Smardon, Anne M.; Kane, Patricia M.			RAVE is essential for the efficient assembly of the C subunit with the vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-ATPASE; GENE DELETION; VMA5P; LOCALIZATION; STATOR; ACIDIFICATION; COMPLEXES; VERSATILE; ROTATION; MUTANTS	The RAVE complex is required for stable assembly of the yeast vacuolar proton-translocating ATPase ( V-ATPase) during both biosynthesis of the enzyme and regulated reassembly of disassembled V-1 and V-0 sectors. It is not yet known how RAVE effects V-ATPase assembly. Previous work has shown that V-1 peripheral or stator stalk subunits E and G are critical for binding of RAVE to cytosolic V-1 complexes, suggesting that RAVE may play a role in docking of the V1 peripheral stalk to the V-0 complex at the membrane. Here we provide evidence for an interaction between the RAVE complex and V-1 subunit C, another subunit that has been assigned to the peripheral stalk. The C subunit is unique in that it is released from both V-1 and V-0 sectors during disassembly, suggesting that subunit C may control the regulated assembly of the V-ATPase. Mutants lacking subunit C have assembly phenotypes resembling that of RAVE mutants. Both are able to assemble V-1/ V-0 complexes in vivo, but these complexes are highly unstable in vitro, and V-ATPase activity is extremely low. We show that in the absence of the RAVE complex, subunit C is not able to stably assemble with the vacuolar ATPase. Our data support a model where RAVE, through its interaction with subunit C, is facilitating V-1 peripheral stalk subunit interactions with V-0 during V-ATPase assembly.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St,Syracuse, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063742] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063742, R01 GM63742] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELTRAN C, 1992, ACTA PHYSIOL SCAND, V146, P41; Brace EJ, 2006, EUKARYOT CELL, V5, P2104, DOI 10.1128/EC.00347-05; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; Dietz KJ, 2001, J EXP BOT, V52, P1969, DOI 10.1093/jexbot/52.363.1969; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Drory O, 2004, EMBO REP, V5, P1148, DOI 10.1038/sj.embor.7400294; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Grabar TB, 2003, J BIOL CHEM, V278, P34751, DOI 10.1074/jbc.M303361200; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; HARPER JW, 1993, CELL, V75, P805; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HO MN, 1993, J BIOL CHEM, V268, P221; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Ochotny N, 2006, J BIOL CHEM, V281, P26102, DOI 10.1074/jbc.M601118200; Ohira M, 2006, J BIOL CHEM, V281, P22752, DOI 10.1074/jbc.M601441200; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sambade M, 2005, GENETICS, V170, P1539, DOI 10.1534/genetics.105.042812; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Sherman F., 1982, METHODS YEAST GENETI; Sipos G, 2004, MOL BIOL CELL, V15, P3196, DOI 10.1091/mbc.E03-10-0755; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang ZY, 2006, FEBS LETT, V580, P2006, DOI 10.1016/j.febslet.2006.03.001	50	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26185	26194		10.1074/jbc.M703627200	http://dx.doi.org/10.1074/jbc.M703627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623654	hybrid			2022-12-25	WOS:000249239600022
J	Wu, WJ; Baxter, JE; Wattam, SL; Hayward, DG; Fardilha, M; Knebel, A; Ford, EM; Silva, EFDE; Fry, AM				Wu, Wenjuan; Baxter, Joanne E.; Wattam, Samantha L.; Hayward, Daniel G.; Fardilha, Margarida; Knebel, Axel; Ford, Eleanor M.; da Cruz e Silva, Edgar F.; Fry, Andrew M.			Alternative splicing controls nuclear translocation of the cell cycle-regulated Nek2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIMA-RELATED KINASE; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; CENTROSOMAL KINASE; CRYSTALLOGRAPHIC ANALYSIS; MOUSE SPERMATOCYTES; KARYOPHERIN ALPHA; MITOTIC REGULATOR; MITOSIS; LOCALIZATION	Nek2 is a cell cycle-regulated serine/threonine protein kinase that is up-regulated in human cancers. Functionally, it is implicated in control of centrosome separation and bipolar spindle formation in mitotic cells and chromatin condensation in meiotic cells. Two major splice variants have been described in vertebrates, Nek2A and Nek2B, that differ in their non-catalytic C termini. Recently, a third splice variant, Nek2C, was identified that lacks an eight-amino acid internal sequence within the C-terminal domain of Nek2A. This excision occurs at the same position as the Nek2A/Nek2B splice point. As predicted from their high degree of similarity, we show here that Nek2C shares many properties with Nek2A including kinase activity, dimerization, protein phosphatase 1 interaction, mitotic degradation, microtubule binding, and centrosome localization. Unexpectedly, though, the non-centrosomal pool of protein exhibits a marked difference in distribution for the three splice variants. Nek2C is mainly nuclear, Nek2B is mainly cytoplasmic, and Nek2A is evenly distributed within nuclei and cytoplasm. Mutagenesis experiments revealed a functional bipartite nuclear localization sequence (NLS) that spans the splice site leading to Nek2C having a strong NLS, Nek2A having a weak NLS, and Nek2B having no NLS. Finally, we identified a 28-kDa protein in nuclear extracts as a potential novel substrate of Nek2. Thus, alternative splicing provides an unusual mechanism for modulating Nek2 localization, enabling it to have both nuclear and cytoplasmic functions.	Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Aveiro, Ctr Biol Celuar, Lab Transducao Sinais, P-3810193 Aveiro, Portugal; Kinasource Ltd, Dundee DD1 5AN, Scotland	University of Leicester; Universidade de Aveiro	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England.	amf5@le.ac.uk	Wu, wenjuan/GPX-6968-2022; da Cruz e Silva, Edgar/G-2647-2010; da cruz e silva, edgar/C-3681-2008; Fardilha, Margarida/G-3182-2010	Fardilha, Margarida/0000-0001-7459-9173; Knebel, Axel/0000-0002-9197-6054	Biotechnology and Biological Sciences Research Council [BB/C000013/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Amador FC, 2004, NEUROTOXICOL TERATOL, V26, P387, DOI 10.1016/j.ntt.2003.12.007; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Cohen P, 2006, BIOCHEM J, V393, P1, DOI 10.1042/BJ20051545; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Di Agostino S, 2004, MOL BIOL CELL, V15, P1224, DOI 10.1091/mbc.E03-09-0638; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fardilha M, 2004, ANN NY ACAD SCI, V1030, P468, DOI 10.1196/annals.1329.059; Fletcher L, 2005, BBA-MOL CELL RES, V1744, P89, DOI 10.1016/j.bbamcr.2005.01.007; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1997, METHOD ENZYMOL, V283, P270; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hames RS, 2005, MOL BIOL CELL, V16, P1711, DOI 10.1091/mbc.E04-08-0688; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Noguchi K, 2004, J BIOL CHEM, V279, P32716, DOI 10.1074/jbc.M404104200; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Rellos P, 2007, J BIOL CHEM, V282, P6833, DOI 10.1074/jbc.M609721200; Rhee K, 1997, DEVELOPMENT, V124, P2167; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Shu X, 2005, HUM MOL GENET, V14, P1183, DOI 10.1093/hmg/ddi129; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Yao JH, 2004, FEBS LETT, V575, P112, DOI 10.1016/j.febslet.2004.08.047; Yin MJ, 2003, J BIOL CHEM, V278, P52454, DOI 10.1074/jbc.M308080200	46	51	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26431	26440		10.1074/jbc.M704969200	http://dx.doi.org/10.1074/jbc.M704969200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626005	hybrid			2022-12-25	WOS:000249239600048
J	Pedone, KH; Hepler, JR				Pedone, Katherine H.; Hepler, John R.			The importance of N-terminal polycysteine and polybasic sequences for G(14)alpha and G(16)alpha palmitoylation, plasma membrane localization, and signaling function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; G-PROTEIN PALMITOYLATION; PHOSPHOLIPASE-C; GQ-ALPHA; LIPID MODIFICATIONS; DEFICIENT MUTANTS; AMINO-TERMINUS; ASSOCIATION; RECEPTOR; ACTIVATION	Plasma membrane targeting of G protein alpha (G alpha) subunits is essential for competent receptor-to-G protein signaling. Many G alpha are tethered to the plasma membrane by covalent lipid modifications at their N terminus. Additionally, it is hypothesized that G(q) family members (G(q)alpha, G(11)alpha, G(14)alpha, and G(16)alpha) in particular utilize a polybasic sequence of amino acids in their N terminus to promote membrane attachment and protein palmitoylation. However, this hypothesis has not been tested, and nothing is known about other mechanisms that control subcellular localization and signaling properties of G(14)alpha and G(16)alpha. Here we report critical biochemical factors that mediate membrane attachment and signaling function of G(14)alpha and G(16)alpha. We find that G(14)alpha and G(16)alpha are palmitoylated at distinct polycysteine sequences in their N termini and that the polycysteine sequence along with the adjacent polybasic region are both important for G(16)alpha-mediated signaling at the plasma membrane. Surprisingly, the isolated N termini of G(14)alpha and G(16)alpha expressed as peptides fused to enhanced green fluorescent protein each exhibit differential requirements for palmitoylation and membrane targeting; individual cysteine residues, but not the polybasic regions, determine lipid modification and subcellular localization. However, full-length G(16)alpha, more so than G(14)alpha, displays a functional dependence on single cysteines for membrane localization and activity, and its full signaling potential depends on the integrity of the polybasic sequence. Together, these findings indicate that G(14)alpha and G(16)alpha are palmitoylated at distinct polycysteine sequences, and that the adjacent polybasic domain is not required for G alpha palmitoylation but is important for localization and functional activity of heterotrimeric-G proteins.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hepler, JR (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	jhepler@emory.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037112, R01NS049195] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61847] Funding Source: Medline; NINDS NIH HHS [R01NS049195, R01NS037112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bernstein Leah S., 2003, V237, P195; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103; Drmota T, 1999, BIOCHEM J, V340, P529, DOI 10.1042/0264-6021:3400529; Drmota T, 1998, J BIOL CHEM, V273, P21699, DOI 10.1074/jbc.273.34.21699; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Evanko DS, 2005, CELL SIGNAL, V17, P1218, DOI 10.1016/j.cellsig.2004.12.008; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hayashi N, 1997, J BIOL CHEM, V272, P7639, DOI 10.1074/jbc.272.12.7639; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Hollinger S, 2001, J NEUROCHEM, V79, P941, DOI 10.1046/j.1471-4159.2001.00629.x; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Johansson BB, 2005, FEBS J, V272, P5365, DOI 10.1111/j.1742-4658.2005.04934.x; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; Kosloff M, 2003, EMBO J, V22, P459, DOI 10.1093/emboj/cdg054; Kosloff M, 2002, BIOCHEMISTRY-US, V41, P14518, DOI 10.1021/bi026729x; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Levitzki A, 2002, CHEMBIOCHEM, V3, P815, DOI 10.1002/1439-7633(20020902)3:9<815::AID-CBIC815>3.0.CO;2-E; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2000, J NEUROSCI, V20, P2774; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Shu FJ, 2007, CELL SIGNAL, V19, P163, DOI 10.1016/j.cellsig.2006.06.002; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; Takida S, 2004, FEBS LETT, V567, P209, DOI 10.1016/j.febslet.2004.04.062; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Tesmer VM, 2005, SCIENCE, V310, P1686, DOI 10.1126/science.1118890; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wise A, 1997, FEBS LETT, V407, P257, DOI 10.1016/S0014-5793(97)00300-1; Zhang ZX, 2004, J BIOL CHEM, V279, P33937, DOI 10.1074/jbc.M403404200	61	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25199	25212		10.1074/jbc.M610297200	http://dx.doi.org/10.1074/jbc.M610297200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17620339	hybrid			2022-12-25	WOS:000249014100005
J	Sinnis, P; Coppi, A; Toida, T; Toyoda, H; Kinoshita-Toyoda, A; Xie, J; Kemp, MM; Linhardt, RJ				Sinnis, Photini; Coppi, Alida; Toida, Toshihiko; Toyoda, Hidenao; Kinoshita-Toyoda, Akiko; Xie, Jin; Kemp, Melissa M.; Linhardt, Robert J.			Mosquito heparan sulfate and its potential role in malaria infection and transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCUMSPOROZOITE PROTEIN; ANOPHELES-STEPHENSI; SPOROZOITE INVASION; SALIVARY-GLANDS; AEDES-AEGYPTI; BINDING; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; RECEPTORS; REGION	Heparan sulfate has been isolated for the first time from the mosquito Anopheles stephensi, a known vector for Plasmodium parasites, the causative agents of malaria. Chondroitin sulfate, but not dermatan sulfate or hyaluronan, was also present in the mosquito. The glycosaminoglycans were isolated, from salivary glands and midguts of the mosquito in quantities sufficient for disaccharide microanalysis. Both of these organs are invaded at different stages of the Plasmodium life cycle. Mosquito heparan sulfate was found to contain the critical trisulfated disaccharide sequence, -> 4)beta-D-GlcNS6S(1 -> 4)-alpha-L-IdoA2S(1 ->, that is commonly found in human liver heparan sulfate, which serves as the receptor for apolipoprotein E and is also believed to be responsible for binding to the circumsporozoite protein found on the surface of the Plasmodium sporozoite. The heparan sulfate isolated from the whole mosquito binds to circumsporozoite protein, suggesting a role within the mosquito for infection and transmission of the Plasmodium parasite.	Rensselaer Polytech Inst, Ctr Biocatalysis & Interdisciplinary Studies, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Chem Biol & Chem Engn, Troy, NY 12180 USA; NYU, Sch Med, Dept Med Parasitol, New York, NY 10010 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Chiba 2638522, Japan	Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; New York University; Chiba University	Linhardt, RJ (corresponding author), Rensselaer Polytech Inst, Ctr Biocatalysis & Interdisciplinary Studies, Troy, NY 12180 USA.	linhar@rpi.edu			NHLBI NIH HHS [R01 HL052622, HL52622, R01 HL062244-05A1, R01 HL052622-09, R01 HL062244-07, HL62244, R01 HL062244] Funding Source: Medline; NIAID NIH HHS [R01 AI056840, AI056840, R01 AI056840-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060-19, GM38060, R01 GM038060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrighi RBG, 2002, INT J PARASITOL, V32, P91, DOI 10.1016/S0020-7519(01)00298-3; Barreau C, 1995, EXP PARASITOL, V81, P332, DOI 10.1006/expr.1995.1124; Barth H, 2003, J BIOL CHEM, V278, P41003, DOI 10.1074/jbc.M302267200; Barth H, 2006, J VIROL, V80, P10579, DOI 10.1128/JVI.00941-06; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Brennan JDG, 2000, P NATL ACAD SCI USA, V97, P13859, DOI 10.1073/pnas.250472597; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Cesaretti M, 2004, GLYCOBIOLOGY, V14, P1275, DOI 10.1093/glycob/cwh128; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Dong J, 2001, BIOCHEMISTRY-US, V40, P2826, DOI 10.1021/bi002417n; Edens RE, 2001, ARCH BIOCHEM BIOPHYS, V391, P278, DOI 10.1006/abbi.2001.2398; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FOSTER WA, 1980, MALARIA, V2, P122; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; Hernaiz MJ, 2002, CARBOHYD POLYM, V48, P153, DOI 10.1016/S0144-8617(01)00229-6; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Ibrahimi OA, 2005, MOL CELL BIOL, V25, P671, DOI 10.1128/MCB.25.2.671-684.2005; Korochkina S, 2006, CELL MICROBIOL, V8, P163, DOI 10.1111/j.1462-5822.2005.00611.x; Linhardt RJ, 2004, ACCOUNTS CHEM RES, V37, P431, DOI 10.1021/ar030138x; Linhardt RJ, 2003, J MED CHEM, V46, P2551, DOI 10.1021/jm030176m; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; LYON M, 1994, J BIOL CHEM, V269, P11208; MADA A, 1992, ANAL SCI, V8, P793, DOI 10.2116/analsci.8.793; MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481; Myung JM, 2004, MOL BIOCHEM PARASIT, V133, P53, DOI 10.1016/j.molbiopara.2003.09.002; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; PETERSLIBEU C, 2001, J BIOL CHEM, V276, P39138; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; Pradel G, 2002, MOL MICROBIOL, V45, P637, DOI 10.1046/j.1365-2958.2002.03057.x; Rathore D, 2003, J BIOL CHEM, V278, P40905, DOI 10.1074/jbc.M306250200; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; REISEN WK, 1982, J MED ENTOMOL, V19, P98, DOI 10.1093/jmedent/19.1.98; Ribeiro JMC, 2003, INSECT BIOCHEM MOLEC, V33, P865, DOI 10.1016/S0965-1748(03)00080-8; Rider CC, 1997, GLYCOCONJUGATE J, V14, P639, DOI 10.1023/A:1018596728605; Rostand KS, 1997, INFECT IMMUN, V65, P1; Sawitzky D, 1996, MED MICROBIOL IMMUN, V184, P155, DOI 10.1007/BF02456129; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Siden-Kiamos I, 2004, INSECT BIOCHEM MOLEC, V34, P679, DOI 10.1016/j.ibmb.2004.03.026; Sidjanski SP, 1997, MOL BIOCHEM PARASIT, V90, P33, DOI 10.1016/S0166-6851(97)00124-2; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Valenzuela JG, 2003, INSECT BIOCHEM MOLEC, V33, P717, DOI 10.1016/S0965-1748(03)00067-5; Vongchan P, 2005, BBA-GEN SUBJECTS, V1721, P1, DOI 10.1016/j.bbagen.2004.09.007; WARBURG A, 1992, SCIENCE, V255, P448, DOI 10.1126/science.1734521; Warda M, 2003, COMP BIOCHEM PHYS C, V136, P357, DOI 10.1016/j.cca.2003.10.009; Warda M, 2003, COMP BIOCHEM PHYS B, V134, P189, DOI 10.1016/S1096-4959(02)00250-6; Warda M, 2006, GLYCOCONJUGATE J, V23, P555, DOI 10.1007/s10719-006-7668-1; Zieler H, 1999, J EXP BIOL, V202, P485	52	63	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25376	25384		10.1074/jbc.M704698200	http://dx.doi.org/10.1074/jbc.M704698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17597060	Green Accepted, hybrid			2022-12-25	WOS:000249014100023
J	Nie, CL; Wei, Y; Chen, XY; Liu, YY; Dui, W; Liu, Y; Davies, MC; Tendler, SJB; He, RG				Nie, Chun Lai; Wei, Yan; Chen, Xinyong; Liu, Yan Ying; Dui, Wen; Liu, Ying; Davies, Martyn C.; Tendler, Saul J. B.; He, Rong Giao			Formaldehyde at Low Concentration Induces Protein Tau into Globular Amyloid-Like Aggregates In Vitro and In Vivo	PLOS ONE			English	Article								Recent studies have shown that neurodegeneration is closely related to misfolding and aggregation of neuronal tau. Our previous results show that neuronal tau aggregates in formaldehyde solution and that aggregated tau induces apoptosis of SH-SY5Y and hippocampal cells. In the present study, based on atomic force microscopy (AFM) observation, we have found that formaldehyde at low concentrations induces tau polymerization whilst acetaldehyde does not. Neuronal tau misfolds and aggregates into globular-like polymers in 0.01-0.1% formaldehyde solutions. Apart from globular-like aggregation, no fibril-like polymerization was observed when the protein was incubated with formaldehyde for 15 days. SDS-PAGE results also exhibit tau polymerizing in the presence of formaldehyde. Under the same experimental conditions, polymerization of bovine serum albumin (BSA) or alpha-synuclein was not markedly detected. Kinetic study shows that tau significantly misfolds and polymerizes in 60 minutes in 0.1% formaldehyde solution. However, presence of 10% methanol prevents protein tau from polymerization. This suggests that formaldehyde polymerization is involved in tau aggregation. Such aggregation process is probably linked to the tau's special "worm-like'' structure, which leaves the epsilon-amino groups of Lys and thiol groups of Cys exposed to the exterior. Such a structure can easily bond to formaldehyde molecules in vitro and in vivo. Polymerizing of formaldehyde itself results in aggregation of protein tau. Immunocytochemistry and thioflavin S staining of both endogenous and exogenous tau in the presence of formaldehyde at low concentrations in the cell culture have shown that formaldehyde can induce tau into amyloid-like aggregates in vivo during apoptosis. The significant protein tau aggregation induced by formaldehyde and the severe toxicity of the aggregated tau to neural cells may suggest that toxicity of methanol and formaldehyde ingestion is related to tau misfolding and aggregation.	[Nie, Chun Lai; Wei, Yan; Liu, Yan Ying; Dui, Wen; Liu, Ying; He, Rong Giao] Chinese Acad Sci, Inst Biophys, Grad Sch, State Key Lab Brain & Cognit Sci, Beijing 100080, Peoples R China; [Chen, Xinyong; Davies, Martyn C.; Tendler, Saul J. B.] Univ Nottingham, Sch Pharm, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England	Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Chinese Academy of Sciences, CAS; University of Nottingham	He, RG (corresponding author), Chinese Acad Sci, Inst Biophys, Grad Sch, State Key Lab Brain & Cognit Sci, Beijing 100080, Peoples R China.	herq@sun5.ibp.ac.cn	Liu, Ying/D-8933-2013	Liu, Ying/0000-0003-0802-3832; Davies, Martyn/0000-0001-7695-0596	NSFB [06J11]; NSFC [90206041, 30570536, 30621004];  [2006CB500703];  [2006CB911003]	NSFB(Beijing Natural Science Foundation); NSFC(National Natural Science Foundation of China (NSFC)); ; 	This project was supported by NSFB (06J11), the NSFC (Nos. 90206041, 30570536 and 30621004) and 973- Project (2006CB500703 and 2006CB911003).	Alonso AD, 2001, J BIOL CHEM, V276, P37967; Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; Barceloux DG, 2002, J TOXICOL-CLIN TOXIC, V40, P415; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Burns M, 2002, ANN NY ACAD SCI, V977, P367, DOI 10.1111/j.1749-6632.2002.tb04839.x; Chen K, 2006, J NEUROCHEM, V99, P1413, DOI 10.1111/j.1471-4159.2006.04181.x; Chen XP, 2000, CHEM COMMUN, P233, DOI 10.1039/a909162i; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; CULLEN KM, 1995, NEUROPATH APPL NEURO, V21, P312, DOI 10.1111/j.1365-2990.1995.tb01065.x; Dalle-Donne I, 2003, TRENDS MOL MED, V9, P169, DOI 10.1016/S1471-4914(03)00031-5; Davi G, 2005, ANTIOXID REDOX SIGN, V7, P256, DOI 10.1089/ars.2005.7.256; Dayan AD, 2001, HUM EXP TOXICOL, V20, P439, DOI 10.1191/096032701682693062; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; Eells JT, 2000, NEUROTOXICOLOGY, V21, P321; ERKRATH KD, 1981, Z RECHTSMED, V87, P233; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Feng Z, 2006, FREE RADICAL BIO MED, V40, P101, DOI 10.1016/j.freeradbiomed.2005.08.014; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; GARNER CD, 1995, TOXICOL APPL PHARM, V130, P101, DOI 10.1006/taap.1995.1014; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Gubisne-Haberle D, 2004, J PHARMACOL EXP THER, V310, P1125, DOI 10.1124/jpet.104.068601; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; Heck HD, 1999, TOXICOL APPL PHARM, V160, P86, DOI 10.1006/taap.1999.8764; Hua Q, 2003, CELL MOL LIFE SCI, V60, P413, DOI 10.1007/s000180300034; Huang CJ, 2005, PROTEIN EXPRES PURIF, V42, P173, DOI 10.1016/j.pep.2005.02.014; Jiang WL, 2000, BIOTECHNOL BIOENG, V70, P507, DOI 10.1002/1097-0290(20001205)70:5<507::AID-BIT5>3.3.CO;2-3; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; MCLAUGHLIN AC, 1974, J BIOL CHEM, V249, P1445; Mirzaei H, 2006, J CHROMATOGR A, V1134, P122, DOI 10.1016/j.chroma.2006.08.096; Moreno-Herrero F, 2004, BIOPHYS J, V86, P517, DOI 10.1016/S0006-3495(04)74130-2; Nie Chun Lai, 2007, BMC Neurosci, V8, P9, DOI 10.1186/1471-2202-8-9; Nie CL, 2005, PROTEIN PEPTIDE LETT, V12, P75, DOI 10.2174/0929866053405931; Niemela Onni, 1999, Frontiers in Bioscience, V4, pD506, DOI 10.2741/Niemela; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PLUMMER TH, 1963, J BIOL CHEM, V238, P1396; POMERANTZ M, 1982, J ORG CHEM, V47, P2217, DOI 10.1021/jo00132a056; Qu MH, 2004, NEUROREPORT, V15, P2723; Quievryn G, 2000, CARCINOGENESIS, V21, P1573, DOI 10.1093/carcin/21.8.1573; Rait VK, 2004, LAB INVEST, V84, P292, DOI 10.1038/labinvest.3700045; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SHCHERBAKOVA L N, 1986, Byulleten' Eksperimental'noi Biologii i Meditsiny, V102, P573; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001; VALENTINE WM, 1990, VET CLIN N AM-SMALL, V20, P515, DOI 10.1016/S0195-5616(90)50042-X; Von B. M., 2000, P NATL ACAD SCI USA, V97, P5129; Yu PH, 2006, AM J PATHOL, V168, P718, DOI 10.2353/ajpath.2006.050970; Yu PH, 2001, MED HYPOTHESES, V57, P175, DOI 10.1054/mehy.2001.1329	56	65	69	4	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e629	10.1371/journal.pone.0000629	http://dx.doi.org/10.1371/journal.pone.0000629			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637844	Green Submitted, gold, Green Published			2022-12-25	WOS:000207452100018
J	Kress, CL; Konopleva, M; Martinez-Garcia, V; Krajewska, M; Lefebvre, S; Hyer, ML; McQueen, T; Andreeff, M; Reed, JC; Zapata, JM				Kress, Christina L.; Konopleva, Marina; Martinez-Garcia, Vanesa; Krajewska, Maryla; Lefebvre, Sophie; Hyer, Marc L.; McQueen, Teresa; Andreeff, Michael; Reed, John C.; Zapata, Juan M.			Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma	PLOS ONE			English	Article								Background. The synthetic triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid ( CDDO) and derivatives display antitumor activity against a variety of cultured tumor cell lines and in mouse xenografts. In this report, we have studied the effects of CDDO and its imidazolide derivative (CDDO-Im) on chronic lymphocytic leukemia (CLL), using patients' CLL cells and a mouse model of CLL and small B cell lymphoma (SBL). Principal Findings. CDDO and CDDO-Im efficiently induced apoptosis of malignant human and mouse B-cells ex vivo, although CDDO-Im was over 10-fold more potent than CDDO. Treating mice with CLL/SBL with liposome-formulated CDDO or CDDO-Im resulted in significant reductions of B cells in blood, spleen and lung. CDDO-Im was shown to be more potent than CDDO, while treatment with empty liposomes had no impact on disease. CDDO-Im treatment initially resulted in an increase of circulating B cells, which correlates with a reduction in resident lymphocytes in spleen, and lungs, suggesting that CDDO-Im induces mobilization of tumor cells from lymphoid organs and infiltrated tissues into the circulation. Analysis of blood cells recovered from treated mice also showed that CDDO-Im is a potent inducer of tumor cells death in vivo. Furthermore, CDDO-Im efficiently eradicated mouse CLL/SBL cells but had little effect on the viability of normal B and T cells in vivo. Significance. The presented data demonstrate that triterpenoids CDDO and CDDO-Im reduce leukemia and lymphoma burden in vivo in a transgenic mouse model of CLL/SBL, and support the clinical testing of CDDO-based synthetic triterpenoids in patients with CLL.	[Kress, Christina L.; Martinez-Garcia, Vanesa; Krajewska, Maryla; Lefebvre, Sophie; Hyer, Marc L.; Reed, John C.; Zapata, Juan M.] Burnham Inst Med Res, La Jolla, CA USA; [Konopleva, Marina; McQueen, Teresa; Andreeff, Michael] Univ Texas MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA; [Martinez-Garcia, Vanesa; Zapata, Juan M.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid, Spain	Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Zapata, JM (corresponding author), Burnham Inst Med Res, La Jolla, CA USA.	jmzapata@cbm.uam.es	Zapata, Juan M/J-6304-2014	Zapata, Juan M/0000-0002-0110-0009	National Institutes of Health [AI070859, CA81534, CA089346, CA100632]; Leukemia and Lymphoma Society of America [SAF2004-7675]; Spanish Ministerio de Educacion y Ciencia; NATIONAL CANCER INSTITUTE [P50CA100632, R01CA089346, P01CA081534, P20CA081534] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); Spanish Ministerio de Educacion y Ciencia(Spanish Government); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health grants AI070859, CA81534, CA089346, CA100632, Leukemia Specialized Programs of Research Excellence ( SPORE), the Leukemia and Lymphoma Society of America, SAF2004-7675, Programa Ramon y Cajal and a fellowship from the Spanish Ministerio de Educacion y Ciencia.	Ahmad R, 2006, J BIOL CHEM, V281, P35764, DOI 10.1074/jbc.M607160200; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chintharlapalli S, 2005, MOL PHARMACOL, V68, P119, DOI 10.1124/mol.105.011437; Dzubak P, 2006, NAT PROD REP, V23, P394, DOI 10.1039/b515312n; Elter T, 2006, EXPERT OPIN PHARMACO, V7, P1641, DOI 10.1517/14656566.7.12.1641; Han SS, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-22; Honda T, 1998, BIOORG MED CHEM LETT, V8, P2711, DOI 10.1016/S0960-894X(98)00479-X; Honda T, 2002, BIOORG MED CHEM LETT, V12, P1027, DOI 10.1016/S0960-894X(02)00105-1; Honda T, 2000, J MED CHEM, V43, P4233, DOI 10.1021/jm0002230; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Ikeda T, 2004, MOL CANCER THER, V3, P39, DOI 10.2463/mrms.3.39; Inoue S, 2004, LEUKEMIA, V18, P948, DOI 10.1038/sj.leu.2403328; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; Kay NE, 2006, SEMIN HEMATOL, V43, pS50, DOI 10.1053/j.seminhematol.2005.12.011; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kipps T J, 1997, Curr Opin Hematol, V4, P268; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Konopleva M, 2006, MOL CANCER THER, V5, P317, DOI 10.1158/1535-7163.MCT-05-0350; Konopleva M, 2005, LEUKEMIA, V19, P1350, DOI 10.1038/sj.leu.2403828; Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402; Konopleva M, 2002, BLOOD, V99, P326, DOI 10.1182/blood.V99.1.326; Lapillonne H, 2003, CANCER RES, V63, P5926; Melichar B, 2004, GYNECOL ONCOL, V93, P149, DOI 10.1016/j.ygyno.2004.01.008; Place AE, 2003, CLIN CANCER RES, V9, P2798; REED JC, 2001, CHRONIC LYMPHOID LEU, P111; Samudio I, 2006, MOL PHARMACOL, V69, P1182, DOI 10.1124/mol.105.018051; Samudio I, 2005, J BIOL CHEM, V280, P36273, DOI 10.1074/jbc.M507518200; Shishodia S, 2006, CLIN CANCER RES, V12, P1828, DOI 10.1158/1078-0432.CCR-05-2044; STADHEIM TA, 2002, J BIOL CHEM IN PRESS; Suh NJ, 1999, CANCER RES, V59, P336; Suh WS, 2003, LEUKEMIA, V17, P2122, DOI 10.1038/sj.leu.2403112; Yue P, 2006, CANCER BIOL THER, V5, P492, DOI 10.4161/cbt.5.5.2565; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zapata JM, 2004, P NATL ACAD SCI USA, V101, P16600, DOI 10.1073/pnas.0407541101; Zapata JM, 2003, EXPERT OPIN THER TAR, V7, P411, DOI 10.1517/14728222.7.3.411; ZAPATA JM, 2002, TRAF1 LORD RING; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	37	25	50	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e559	10.1371/journal.pone.0000559	http://dx.doi.org/10.1371/journal.pone.0000559			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593960	Green Submitted, gold, Green Published			2022-12-25	WOS:000207451800005
J	Santos-Lopes, SS; Pereira, RW; Wilson, IJ; Pena, SDJ				Santos-Lopes, Simone S.; Pereira, Rinaldo W.; Wilson, Ian J.; Pena, Sergio D. J.			A Worldwide Phylogeography for the Human X Chromosome	PLOS ONE			English	Article							HUMAN GENOME; HUMAN-POPULATIONS; LINKAGE DISEQUILIBRIUM; MAP; MICROSATELLITES; RECOMBINATION; DIVERSITY; INFERENCE; HOTSPOTS; HISTORY	Background. We reasoned that by identifying genetic markers on human X chromosome regions where recombination is rare or absent, we should be able to construct X chromosome genealogies analogous to those based on Y chromosome and mitochondrial DNA polymorphisms, with the advantage of providing information about both male and female components of the population. Methodology/Principal Findings. We identified a 47 Kb interval containing an Alu insertion polymorphism (DXS225) and four microsatellites in complete linkage disequilibrium in a low recombination rate region of the long arm of the human X chromosome. This haplotype block was studied in 667 males from the HGDP-CEPH Human Genome Diversity Panel. The haplotypic diversity was highest in Africa (0.99260.0025) and lowest in the Americas (0.839 +/- 0.0378), where no insertion alleles of DXS225 were observed. Africa shared few haplotypes with other geographical areas, while those exhibited significant sharing among themselves. Median joining networks revealed that the African haplotypes were numerous, occupied the periphery of the graph and had low frequency, whereas those from the other continents were few, central and had high frequency. Altogether, our data support a single origin of modern man in Africa and migration to occupy the other continents by serial founder effects. Coalescent analysis permitted estimation of the time of the most recent common ancestor as 182,000 years ( 56,700-479,000) and the estimated time of the DXS225 Alu insertion of 94,400 years ( 24,300-310,000). These dates are fully compatible with the current widely accepted scenario of the origin of modern mankind in Africa within the last 195,000 years and migration out-of-Africa circa 55,000-65,000 years ago. Conclusions/Significance. A haplotypic block combining an Alu insertion polymorphism and four microsatellite markers on the human X chromosome is a useful marker to evaluate genetic diversity of human populations and provides a highly informative tool for evolutionary studies.	[Santos-Lopes, Simone S.; Pereira, Rinaldo W.; Pena, Sergio D. J.] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil; [Pereira, Rinaldo W.] Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Brasilia, DF, Brazil; [Wilson, Ian J.] Univ Newcastle, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England	Universidade Federal de Minas Gerais; Universidade Catolica de Brasilia; Newcastle University - UK	Pena, SDJ (corresponding author), Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.	spena@dcc.ufmg.br	Pereira, Rinaldo W/B-9255-2011	Pereira, Rinaldo W/0000-0003-3704-2848; Wilson, Ian/0000-0001-6893-2873	CNPq-Brazil; Royal Society Relocation Fellowship	CNPq-Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Royal Society Relocation Fellowship	Supported by CNPq-Brazil through the Universal Grants program and the "Institutos do Milenio'' program. Further support to Ian Wilson from the Royal Society Relocation Fellowship scheme.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Cavalli-Sforza LL, 2003, NAT GENET, V33, P266, DOI 10.1038/ng1113; Conrad DF, 2006, NAT GENET, V38, P1251, DOI 10.1038/ng1911; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EXCOFFIER L, 1992, GENETICS, V131, P491; HEDRICK PW, 1987, GENETICS, V117, P331; Jobling MA, 2003, NAT REV GENET, V4, P598, DOI 10.1038/nrg1124; Leopoldino AM, 2003, HUM MUTAT, V21, P71, DOI 10.1002/humu.10153; Li N, 2003, GENETICS, V165, P2213; Liu H, 2006, AM J HUM GENET, V79, P230, DOI 10.1086/505436; McDougall I, 2005, NATURE, V433, P733, DOI 10.1038/nature03258; Mellars P, 2006, SCIENCE, V313, P796, DOI 10.1126/science.1128402; Mountain JL, 2002, GENOME RES, V12, P1766, DOI 10.1101/gr.238602; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Nagaraja R, 1997, GENOME RES, V7, P210, DOI 10.1101/gr.7.3.210; PENA SDJ, 2007, PHARMACOGENOMICS ADM; Pereira RW, 2006, GENET MOL RES, V5, P63; Prugnolle F, 2005, CURR BIOL, V15, pR159, DOI 10.1016/j.cub.2005.02.038; Ramachandran S, 2005, P NATL ACAD SCI USA, V102, P15942, DOI 10.1073/pnas.0507611102; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rosenberg NA, 2006, ANN HUM GENET, V70, P841, DOI 10.1111/j.1469-1809.2006.00285.x; Santos FR, 1999, AM J HUM GENET, V64, P619, DOI 10.1086/302242; Schaffner SF, 2004, NAT REV GENET, V5, P43, DOI 10.1038/nrg1247; Schneider S., 2000, ARLEQUIN SOFTWARE PO; STORTO L, 2005, POVOS INDIGENAS BRAS; Torroni A, 2006, TRENDS GENET, V22, P339, DOI 10.1016/j.tig.2006.04.001; Wilkins JF, 2006, BIOESSAYS, V28, P290, DOI 10.1002/bies.20378; Wilson IJ, 1998, GENETICS, V150, P499; Wilson IJ, 2003, J R STAT SOC A STAT, V166, P155, DOI 10.1111/1467-985X.00264; Xu HY, 2005, GENETICS, V170, P305, DOI 10.1534/genetics.104.036855; Yu N, 2002, GENETICS, V161, P269	35	12	13	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e557	10.1371/journal.pone.0000557	http://dx.doi.org/10.1371/journal.pone.0000557			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593958	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451800003
J	Li, WQ; Wu, G; Wan, Y				Li, Wenqi; Wu, George; Wan, Yong			The dual effects of Cdh1/APC in myogenesis	FASEB JOURNAL			English	Article						Skp2; Myf5; ubiquitylation and muscle differentiation	ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE WITHDRAWAL; SKELETAL-MUSCLE DIFFERENTIATION; UBIQUITIN LIGASE; DESTRUCTION BOX; MYOBLAST DIFFERENTIATION; PROLIFERATING MYOBLASTS; MAMMALIAN-CELLS; FACTOR MYF5; DNA-DAMAGE	Ubiquitin-dependent proteolysis plays an important role in regulating fundamental biological functions, including cell division and cellular differentiation. Previous studies implicate the ubiquitin-proteasome system ( UPS) in myogenic differentiation through regulating cell cycle progression and modulating myogenic factors such as MyoD and Myf5. Certain ubiquitin protein ligases, including the SCF complex and APC, have been suggested to govern terminal muscle differentiation. However, the underlying mechanism of regulation of both the cell cycle and myogenic factors by the UPS during this process remains unclear. We have dissected the role of the UPS in myogenic differentiation using an in vitro muscle differentiation system based on C2C12 cells. We demonstrate that Cdh1-APC regulates two critical proteins, Skp2 and Myf5, for proteolysis during muscle differentiation. The targeting of Skp2 by Cdh1-APC for destruction results in elevation of p21 and p27, which are crucial for coordinating cellular division and differentiation. Degradation of Myf5 by Cdh1-APC facilitates myogenic fusion. Knockdown of Cdh1 by siRNA significantly attenuates muscle differentiation. Taken together, Cdh1- APC is an important ubiquitin E3 ligase that modulates muscle differentiation through coordinating cell cycle progression and initiating the myogenic differentiation program.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wan, Y (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Ste 2-6C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yow4@pitt.edu			NCI NIH HHS [CA115943] Funding Source: Medline; NIGMS NIH HHS [GM070681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM070681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amack JD, 2001, HUM MOL GENET, V10, P1879, DOI 10.1093/hmg/10.18.1879; Ashe M, 2004, J BIOL CHEM, V279, P664, DOI 10.1074/jbc.M308810200; Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bowerman B, 2006, DEVELOPMENT, V133, P773, DOI 10.1242/dev.02276; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen Z, 2006, MOL VIS, V12, P983; Delfini MC, 2000, DEVELOPMENT, V127, P5213; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; DeRenzo C, 2004, TRENDS CELL BIOL, V14, P420, DOI 10.1016/j.tcb.2004.07.005; Dyer MA, 2001, NAT REV NEUROSCI, V2, P333, DOI 10.1038/35072555; Epting CL, 2004, J CELL SCI, V117, P6185, DOI 10.1242/jcs.01548; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Finley Daniel, 2004, Cell, VS116, pS29, DOI 10.1016/S0092-8674(03)00971-1; Gardrat F, 1997, MOL BIOL REP, V24, P77, DOI 10.1023/A:1006877214153; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Jackson PK, 2004, TRENDS CELL BIOL, V14, P331, DOI 10.1016/j.tcb.2004.05.005; Joazeiro CAP, 2006, CANCER RES, V66, P7840, DOI 10.1158/0008-5472.CAN-06-2033; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lindon C, 2000, MOL CELL BIOL, V20, P8923, DOI 10.1128/MCB.20.23.8923-8932.2000; Lindon C, 1998, J CELL BIOL, V140, P111, DOI 10.1083/jcb.140.1.111; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Nastasi T, 2004, DEV CELL, V6, P269, DOI 10.1016/S1534-5807(04)00020-6; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; Puente LG, 2006, MOL CELL PROTEOMICS, V5, P2244, DOI 10.1074/mcp.M600134-MCP200; Qi W, 2007, J BIOL CHEM, V282, P3672, DOI 10.1074/jbc.M609376200; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Tamamori-Adachi M, 2004, J BIOL CHEM, V279, P50429, DOI 10.1074/jbc.M403084200; Tannu NS, 2004, MOL CELL PROTEOMICS, V3, P1065, DOI 10.1074/mcp.M400020-MCP200; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wan Y, 2001, P NATL ACAD SCI USA, V98, P13066, DOI 10.1073/pnas.231487598; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2005, BIOCHEMISTRY-US, V44, P14553, DOI 10.1021/bi051071j; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wirth KG, 2004, GENE DEV, V18, P88, DOI 10.1101/gad.285404; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	62	30	31	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3606	3617		10.1096/fj.07-8159com	http://dx.doi.org/10.1096/fj.07-8159com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17601983				2022-12-25	WOS:000250517800023
J	Almeida, M; Han, L; Martin-Millan, M; Plotkin, LI; Stewart, SA; Roberson, PK; Kousteni, S; O'Brien, CA; Bellido, T; Parfitt, AM; Weinstein, RS; Jilka, RL; Manolagas, SC				Almeida, Maria; Han, Li; Martin-Millan, Marta; Plotkin, Lilian I.; Stewart, Scott A.; Roberson, Paula K.; Kousteni, Stavroula; O'Brien, Charles A.; Bellido, Teresita; Parfitt, A. Michael; Weinstein, Robert S.; Jilka, Robert L.; Manolagas, Stavros C.			Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MURINE BONE-MARROW; ESTROGEN-DEFICIENCY; OSTEOBLAST DIFFERENTIATION; PLASMA ESTRADIOL; CELL APOPTOSIS; MICE; DENSITY; MASS; GLUCOCORTICOIDS	Both aging and loss of sex steroids have adverse effects on skeletal homeostasis, but whether and how they may influence each others negative impact on bone remains unknown. We report herein that both female and male C57BL/6 mice progressively lost strength (as determined by load-to-failure measurements) and bone mineral density in the spine and femur between the ages of 4 and 31 months. These changes were temporally associated with decreased rate of remodeling as evidenced by decreased osteoblast and osteoclast numbers and decreased bone formation rate; as well as increased osteoblast and osteocyte apoptosis, increased reactive oxygen species levels, and decreased glutathione reductase activity and a corresponding increase in the phosphorylation of p53 and p66(shc), two key components of a signaling cascade that are activated by reactive oxygen species and influences apoptosis and lifespan. Exactly the same changes in oxidative stress were acutely reproduced by gonadectomy in 5-month-old females or males and reversed by estrogens or androgens in vivo as well as in vitro. We conclude that the oxidative stress that underlies physiologic organismal aging in mice may be a pivotal pathogenetic mechanism of the age-related bone loss and strength. Loss of estrogens or androgens accelerates the effects of aging on bone by decreasing defense against oxidative stress.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA; Cent Arkansas Vet hlth Care Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Manolagas, SC (corresponding author), 4301 W Markham,587, Little Rock, AR 72205 USA.	manolagasstavros@uams.edu	Plotkin, Lilian/H-7188-2019; O'Brien, Charles A./AAL-5078-2020	Plotkin, Lilian/0000-0002-9537-4544; Almeida, Maria/0000-0002-6722-9200; Warren, Aaron D./0000-0002-0042-9021	NIAMS NIH HHS [R01 AR053643-02, R01 AR053643, R01 AR049794, R01 AR053643-03, R01 AR053643-01A2, R01 AR046191, R01 AR051187, R01 AR053643-04] Funding Source: Medline; NIA NIH HHS [P01 AG013918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046191, R01AR049794, R01AR053643, R01AR051187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107; Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464; Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Almeida M, 2006, J BONE MINER RES, V21, pS95; Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; Baba T, 2005, J BIOL CHEM, V280, P16417, DOI 10.1074/jbc.M500924200; Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200; Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Burr DB, 1998, J BIOMECH, V31, P337, DOI 10.1016/S0021-9290(98)00016-5; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200; CHEN XD, 2007, IN PRESS J BONE MINE; Chiang K, 2004, LIFE SCI, V75, P2425, DOI 10.1016/j.lfs.2004.04.035; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; Darblade B, 2002, CIRC RES, V90, P413, DOI 10.1161/hh0402.105096; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Deroo BJ, 2004, ENDOCRINOLOGY, V145, P5485, DOI 10.1210/en.2004-0471; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Duan YB, 2003, J BONE MINER RES, V18, P1766, DOI 10.1359/jbmr.2003.18.10.1766; Duan YB, 1999, J BONE MINER RES, V14, P1796, DOI 10.1359/jbmr.1999.14.10.1796; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Heaney RP, 2003, BONE, V33, P457, DOI 10.1016/S8756-3282(03)00236-9; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; Hurh YJ, 2004, J TOXICOL ENV HEAL A, V67, P1939, DOI 10.1080/15287390490514598; Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004-1058; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039; KLEEREKOPER M, 1985, CALCIFIED TISSUE INT, V37, P594, DOI 10.1007/BF02554913; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550-06; Kutner, 1990, APPL LINEAR STAT MOD; Lacombe A, 2006, P NATL ACAD SCI USA, V103, P3793, DOI 10.1073/pnas.0505827103; Lapointe JR, 2005, ENDOCRINOLOGY, V146, P2583, DOI 10.1210/en.2004-1373; Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004-1021; Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Li XM, 2002, GENOMICS, V79, P734, DOI 10.1006/geno.2002.6760; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Manolagas S.C, 2006, BONEKEY OSTEOVISION, V3, P5, DOI DOI 10.1138/20060193; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manolagas SC, 2004, KIDNEY INT, V66, pS41, DOI 10.1111/j.1523-1755.2004.09107.x; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANOLAGAS SC, 1996, PRINCIPLES BONE BIOL; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mishra DP, 2005, J BIOL CHEM, V280, P6181, DOI 10.1074/jbc.M405970200; MOBBS CV, 1985, ENDOCRINOLOGY, V116, P813, DOI 10.1210/endo-116-2-813; Moor AN, 2004, EXP EYE RES, V78, P933, DOI 10.1016/j.exer.2004.01.001; NELSON JF, 1975, ACTA ENDOCRINOL-COP, V80, P744, DOI 10.1530/acta.0.0800744; NELSON JF, 1992, ENDOCRINOLOGY, V130, P805, DOI 10.1210/en.130.2.805; O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003-0990; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Qiu SJ, 2003, J BONE MINER RES, V18, P1657, DOI 10.1359/jbmr.2003.18.9.1657; QUARRIE JK, 2004, SCI AGING KNOWLEDGE, pRE5; Quintanilla RA, 2005, J BIOL CHEM, V280, P11615, DOI 10.1074/jbc.M411936200; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Schulz E, 2004, J CLIN ENDOCR METAB, V89, P4246, DOI 10.1210/jc.2003-030964; SEEMAN TE, 1994, ENDOCR REV, V15, P233, DOI 10.1210/er.15.2.233; Silva MJ, 1997, BONE, V21, P191, DOI 10.1016/S8756-3282(97)00100-2; Smith RG, 2005, ENDOCR REV, V26, P203, DOI 10.1210/er.2002-0017; Sudoh N, 2001, CIRCULATION, V103, P724; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vanderschueren D, 2000, BONE, V27, P611, DOI 10.1016/S8756-3282(00)00363-X; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Weinstein RS, 2004, ENDOCRINOLOGY, V145, P1980, DOI 10.1210/en.2003-1133; Wergedal JE, 2005, BONE, V36, P111, DOI 10.1016/j.bone.2004.09.012; XI H, 1993, TOXICOL APPL PHARM, V120, P29, DOI 10.1006/taap.1993.1083; Yen CH, 2001, LIFE SCI, V70, P403, DOI 10.1016/S0024-3205(01)01486-2	82	478	498	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27285	27297		10.1074/jbc.M702810200	http://dx.doi.org/10.1074/jbc.M702810200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623659	Green Accepted, hybrid			2022-12-25	WOS:000249304900070
J	Manevich, E; Grabovsky, V; Feigelson, SW; Alon, R				Manevich, Eugenia; Grabovsky, Valentin; Feigelson, Sara W.; Alon, Ronen			Talin 1 and paxillin facilitate distinct steps in rapid VLA-4-mediated adhesion strengthening to vascular cell adhesion molecule 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY UP-REGULATION; INTEGRIN ACTIVATION; CYTOPLASMIC DOMAIN; CELL-ADHESION; FERM DOMAIN; L-SELECTIN; BINDING; ARREST; LFA-1; FLOW	VLA-4 (alpha(4)beta(1)) is a key integrin in lymphocytes, interacting with endothelial vascular cell adhesion molecule 1 (VCAM-1) on blood vessels and stroma. To dissect the contribution of the two cytoskeletal VLA-4 adaptor partners paxillin and talin to VLA-4 adhesiveness, we transiently knocked them down in Jurkat T cells and primary resting human T cells by small interfering RNA silencing. Paxillin was required for VLA-4 adhesiveness to low density VCAM-1 under shear stress conditions and was found to control mechanical stability of bonds mediated by the alpha(4) subunit but did not affect the integrin affinity or avidity to VCAM-1 in shear-free conditions. Talin 1 maintained VLA-4 in a high affinity conformation, thereby promoting rapid VLA-4 adhesion strengthening to VCAM-1 under both shear stress and shear-free conditions. Talin 1, but not paxillin, was required for VLA-4 to undergo optimal stimulation by the prototypic chemokine, CXCL12, under shear stress conditions. Interestingly, talin 1 and paxillin played the same distinct roles in VLA-4 adhesions of primary T lymphocytes, although VLA-4 affinity to VCAM-1 was at least 200-fold lower in these cells than in Jurkat cells. Collectively, our results suggest that whereas paxillin is a mechanical regulator of VLA-4 bonds generated in the absence of chemokine signals and low VCAM-1 occupancy, talin 1 is a versatile VLA-4 affinity regulator implicated in both spontaneous and chemokine-triggered rapid adhesions to VCAM-1.	Weizmann Inst Sci, Dept Chem Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Alon, R (corresponding author), Weizmann Inst Sci, Dept Chem Immunol, IL-76100 Rehovot, Israel.	ronen.alon@weizmann.ac.il	ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				Alon R, 2005, J CELL BIOL, V171, P1073, DOI 10.1083/jcb.200503155; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Alon R, 2007, IMMUNITY, V26, P17, DOI 10.1016/j.immuni.2007.01.002; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2004, BIOCHEM SOC T, V32, P434, DOI 10.1042/BST0320434; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; de Chateau M, 2001, BIOCHEMISTRY-US, V40, P13972, DOI 10.1021/bi011582f; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Finger EB, 1996, J IMMUNOL, V157, P5085; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Hyduk SJ, 2007, BLOOD, V109, P176, DOI 10.1182/blood-2006-01-029199; Hyduk SJ, 2004, BLOOD, V104, P2818, DOI 10.1182/blood-2003-12-4402; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; Laudanna C, 2006, THROMB HAEMOSTASIS, V95, P5, DOI 10.1160/TH05-07-0482; Lim YC, 2000, MICROCIRCULATION, V7, P201, DOI 10.1038/sj.mn.7300103; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Menasche G, 2007, MOL CELL BIOL, V27, P4070, DOI 10.1128/MCB.02011-06; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; Nebl T, 2000, CURR BIOL, V10, pR351, DOI 10.1016/S0960-9822(00)00465-6; Nilsson S, 2006, EXP CELL RES, V312, P844, DOI 10.1016/j.yexcr.2005.12.001; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Puklin-Faucher E, 2006, J CELL BIOL, V175, P349, DOI 10.1083/jcb.200602071; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Rosenthal-Allieri MA, 2005, J IMMUNOL, V175, P1214, DOI 10.4049/jimmunol.175.2.1214; Shamri R, 2005, NAT IMMUNOL, V6, P497, DOI 10.1038/ni1194; Shao JY, 1999, BIOPHYS J, V77, P587, DOI 10.1016/S0006-3495(99)76915-8; Shao JY, 1998, P NATL ACAD SCI USA, V95, P6797, DOI 10.1073/pnas.95.12.6797; Shimaoka M, 2006, P NATL ACAD SCI USA, V103, P13991, DOI 10.1073/pnas.0605716103; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tanentzapf G, 2006, J CELL SCI, V119, P1632, DOI 10.1242/jcs.02859; Tanentzapf G, 2006, NAT CELL BIOL, V8, P601, DOI 10.1038/ncb1411; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	59	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25338	25348		10.1074/jbc.M700089200	http://dx.doi.org/10.1074/jbc.M700089200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17597073	hybrid			2022-12-25	WOS:000249014100019
J	Panagiotakos, G; Alshamy, G; Chan, B; Abrams, R; Greenberg, E; Saxena, A; Bradbury, M; Edgar, M; Gutin, P; Tabar, V				Panagiotakos, Georgia; Alshamy, George; Chan, Bill; Abrams, Rory; Greenberg, Edward; Saxena, Amit; Bradbury, Michelle; Edgar, Mark; Gutin, Philip; Tabar, Viviane			Long-Term Impact of Radiation on the Stem Cell and Oligodendrocyte Precursors in the Brain	PLOS ONE			English	Article								Background. The cellular basis of long term radiation damage in the brain is not fully understood. Methods and Findings. We administered a dose of 25Gy to adult rat brains while shielding the olfactory bulbs. Quantitative analyses were serially performed on different brain regions over 15 months. Our data reveal an immediate and permanent suppression of SVZ proliferation and neurogenesis. The olfactory bulb demonstrates a transient but remarkable SVZ-independent ability for compensation and maintenance of the calretinin interneuron population. The oligodendrocyte compartment exhibits a complex pattern of limited proliferation of NG2 progenitors but steady loss of the oligodendroglial antigen O4. As of nine months post radiation, diffuse demyelination starts in all irradiated brains. Counts of capillary segments and length demonstrate significant loss one day post radiation but swift and persistent recovery of the vasculature up to 15 months post XRT. MRI imaging confirms loss of volume of the corpus callosum and early signs of demyelination at 12 months. Ultrastructural analysis demonstrates progressive degradation of myelin sheaths with axonal preservation. Areas of focal necrosis appear beyond 15 months and are preceded by widespread demyelination. Human white matter specimens obtained post-radiation confirm early loss of oligodendrocyte progenitors and delayed onset of myelin sheath fragmentation with preserved capillaries. Conclusions. This study demonstrates that long term radiation injury is associated with irreversible damage to the neural stem cell compartment in the rodent SVZ and loss of oligodendrocyte precursor cells in both rodent and human brain. Delayed onset demyelination precedes focal necrosis and is likely due to the loss of oligodendrocyte precursors and the inability of the stem cell compartment to compensate for this loss.	[Panagiotakos, Georgia; Alshamy, George; Chan, Bill; Abrams, Rory; Greenberg, Edward; Saxena, Amit; Gutin, Philip; Tabar, Viviane] Sloan Kettering Inst Canc Res, Dept Neurosurg, New York, NY USA; [Bradbury, Michelle] Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY USA; [Edgar, Mark] Sloan Kettering Inst Canc Res, Dept Pathol, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Tabar, V (corresponding author), Sloan Kettering Inst Canc Res, Dept Neurosurg, New York, NY USA.	tabarv@mskcc.org	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Abrams, Rory/0000-0002-9675-4012; PANAGIOTAKOS, GEORGIA/0000-0001-9444-2480; Saxena, Amit/0000-0003-0098-1083	NINDS; NIH; Michael T. McCarthy Foundation	NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael T. McCarthy Foundation	Funding provided in part by grants from the NINDS, NIH and the Michael T. McCarthy Foundation.	Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Bansal R, 1997, ADV EXP MED BIOL, V429, P69; Belka C, 2001, BRIT J CANCER, V85, P1233, DOI 10.1054/bjoc.2001.2100; Bentzen SM, 2006, NAT REV CANCER, V6, P702, DOI 10.1038/nrc1950; Blakemore WF, 2000, J NEUROSCI RES, V61, P288, DOI 10.1002/1097-4547(20000801)61:3<288::AID-JNR6>3.0.CO;2-#; Bu J, 2004, GLIA, V48, P51, DOI 10.1002/glia.20055; CAVANAGH JB, 1972, J NEUROL SCI, V15, P471, DOI 10.1016/0022-510X(72)90172-4; Chari DM, 2002, GLIA, V37, P307, DOI 10.1002/glia.10038; DEANGELIS LM, 2002, INTRACRANIAL TUMORS; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P1841, DOI 10.1002/1097-0142(19851001)56:7+<1841::AID-CNCR2820561325>3.0.CO;2-C; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FIKE JR, 1988, INT J RADIAT ONCOL, V14, P63, DOI 10.1016/0360-3016(88)90052-1; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Gensert JM, 2001, J NEUROBIOL, V48, P75, DOI 10.1002/neu.1043.abs; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Hodges H, 1998, BEHAV BRAIN RES, V91, P99, DOI 10.1016/S0166-4328(97)00108-3; Hopewell JW, 1999, FRONT RADIAT THER ON, V33, P265; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.3.CO;2-Z; Lee GD, 2005, BRAIN RES BULL, V65, P317, DOI 10.1016/j.brainresbull.2004.11.024; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; LJUBIMOVA NV, 1991, BRIT J RADIOL, V64, P934, DOI 10.1259/0007-1285-64-766-934; Lyubimova N, 2004, BRIT J RADIOL, V77, P488, DOI 10.1259/bjr/15169876; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Mouton PR, 2002, J MICROSC-OXFORD, V206, P54, DOI 10.1046/j.1365-2818.2002.01006.x; OI S, 1990, Neurologia Medico-Chirurgica, V30, P36, DOI 10.2176/nmc.30.36; Otsuka S, 2006, RADIAT RES, V165, P582, DOI 10.1667/RR3539.1; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; Polito A, 2005, J ANAT, V207, P707, DOI 10.1111/j.1469-7580.2005.00454.x; REINHOLD HS, 1990, INT J RADIAT ONCOL, V18, P37, DOI 10.1016/0360-3016(90)90264-K; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Sano K, 2000, NEUROL MED-CHIR, V40, P495, DOI 10.2176/nmc.40.495; Schmitz C, 2005, NEUROSCIENCE, V130, P935, DOI 10.1016/j.neuroscience.2004.08.034; Suzuki K, 2003, ONCOGENE, V22, P6988, DOI 10.1038/sj.onc.1206881; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Tada E, 1999, EXP NEUROL, V160, P66, DOI 10.1006/exnr.1999.7172; VANDERKOGEL AJ, 2001, RAD INJURY NERVOUS S, P91	42	127	134	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e588	10.1371/journal.pone.0000588	http://dx.doi.org/10.1371/journal.pone.0000588			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622341	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452000003
J	Sonkoly, E; Wei, TL; Janson, PCJ; Saaf, A; Lundeberg, L; Tengvall-Linder, M; Norstedt, G; Alenius, H; Homey, B; Scheynius, A; Stahle, M; Pivarcsi, A				Sonkoly, Eniko; Wei, Tianling; Janson, Peter C. J.; Saaf, Annika; Lundeberg, Lena; Tengvall-Linder, Maria; Norstedt, Gunnar; Alenius, Harri; Homey, Bernhard; Scheynius, Annika; Stahle, Mona; Pivarcsi, Andor			MicroRNAs: Novel Regulators Involved in the Pathogenesis of Psoriasis?	PLOS ONE			English	Article								MicroRNAs are a recently discovered class of posttranscriptional regulators of gene expression with critical functions in health and disease. Psoriasis is the most prevalent chronic inflammatory skin disease in adults, with a substantial negative impact on the patients' quality of life. Here we show for the first time that psoriasis-affected skin has a specific microRNA expression profile when compared with healthy human skin or with another chronic inflammatory skin disease, atopic eczema. Among the psoriasis-specific microRNAs, we identified leukocyte-derived microRNAs and one keratinocyte-derived microRNA, miR-203. In a panel of 21 different human organs and tissues, miR-203 showed a highly skin-specific expression profile. Among the cellular constituents of the skin, it was exclusively expressed by keratinocytes. The up-regulation of miR-203 in psoriatic plaques was concurrent with the down-regulation of an evolutionary conserved target of miR-203, suppressor of cytokine signaling 3 (SOCS-3), which is involved in inflammatory responses and keratinocyte functions. Our results suggest that microRNA deregulation is involved in the pathogenesis of psoriasis and contributes to the dysfunction of the cross talk between resident and infiltrating cells. Taken together, a new layer of regulatory mechanisms is involved in the pathogenesis of chronic inflammatory skin diseases.	[Sonkoly, Eniko; Wei, Tianling; Lundeberg, Lena; Stahle, Mona; Pivarcsi, Andor] Karolinska Inst, Dept Med, Dermatol & Venereol Unit, Stockholm, Sweden; [Janson, Peter C. J.; Tengvall-Linder, Maria; Scheynius, Annika] Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden; [Saaf, Annika; Norstedt, Gunnar] Karolinska Inst, Ctr Mol Med, Dept Mol Med & Surg, Stockholm, Sweden; [Alenius, Harri] Finnish Inst Occupat Hlth, Unit Excellence Immunotoxicol, Helsinki, Finland; [Homey, Bernhard] Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Finnish Institute of Occupational Health; Heinrich Heine University Dusseldorf	Sonkoly, E (corresponding author), Karolinska Inst, Dept Med, Dermatol & Venereol Unit, Stockholm, Sweden.	eniko.sonkoly@ki.se; andor.pivarcsi@ki.se	Pivarcsi, Andor/J-5801-2017	Pivarcsi, Andor/0000-0003-2196-1102; Alenius, Harri/0000-0003-0106-8923; Sonkoly, Eniko/0000-0002-4909-5413; Norstedt, Gunnar/0000-0002-7759-3241	Swedish Medical Research Council; Stockholm County Council; Karolinska Institutet; Cancer and Allergy Foundation; Edvard Welanders Foundation; Swedish Psoriasis Association; Sigurd och Elsa Goljes Minne Foundation; Tore Nilsons Foundation; Hesselman Foundation; Konsul ThC Bergh Foundation; Wenner-Gren Foundation; Marie Curie Intra-European	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Cancer and Allergy Foundation; Edvard Welanders Foundation; Swedish Psoriasis Association; Sigurd och Elsa Goljes Minne Foundation; Tore Nilsons Foundation; Hesselman Foundation; Konsul ThC Bergh Foundation; Wenner-Gren Foundation; Marie Curie Intra-European(European Commission)	Financial support is acknowledged from the Swedish Medical Research Council, Stockholm County Council, and the Karolinska Institutet, the Cancer and Allergy Foundation, Edvard Welanders Foundation, the Swedish Psoriasis Association, Sigurd och Elsa Goljes Minne, Tore Nilsons, Hesselman, and the Konsul ThC Bergh Foundations. Moreover, E. S. and A. P. were supported by the Wenner-Gren Foundation, and A. P. was supported by the Marie Curie Intra-European Fellowship.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Carlen LM, 2005, J INVEST DERMATOL, V124, P63, DOI 10.1111/j.0022-202X.2004.23501.x; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Czech MP, 2006, NEW ENGL J MED, V354, P1194, DOI 10.1056/NEJMcibr060065; Dimon-Gadal S, 2000, J INVEST DERMATOL, V114, P984, DOI 10.1046/j.1523-1747.2000.00962.x; Fischer M, 2006, J CLIN INVEST, V116, P2748, DOI 10.1172/JCI24274; Goren I, 2006, J INVEST DERMATOL, V126, P477, DOI 10.1038/sj.jid.5700063; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Lebwohl M, 2003, LANCET, V361, P1197, DOI 10.1016/S0140-6736(03)12954-6; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nickoloff BJ, 1999, AM J PATHOL, V155, P145, DOI 10.1016/S0002-9440(10)65109-7; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Pivarcsi A, 2003, INT IMMUNOL, V15, P721, DOI 10.1093/intimm/dxg068; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Stratis A, 2006, J CLIN INVEST, V116, P2094, DOI 10.1172/JCI27179; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Zhou XH, 2003, PHYSIOL GENOMICS, V13, P69, DOI 10.1152/physiolgenomics.00157.2002	22	573	636	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e610	10.1371/journal.pone.0000610	http://dx.doi.org/10.1371/journal.pone.0000610			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622355	Green Submitted, gold, Green Published			2022-12-25	WOS:000207452000017
J	Boulay, JL; Miserez, AR; Zweifel, C; Sivasankaran, B; Kana, V; Ghaffari, A; Luyken, C; Sabel, M; Zerrouqi, A; Wasner, M; Van Meir, E; Tolnay, M; Reifenberger, G; Merlo, A				Boulay, Jean-Louis; Miserez, Andre R.; Zweifel, Christian; Sivasankaran, Balasubramanian; Kana, Veronika; Ghaffari, Anthony; Luyken, Cordelia; Sabel, Michael; Zerrouqi, Abdessamad; Wasner, Morten; Van Meir, Erwin; Tolnay, Markus; Reifenberger, Guido; Merlo, Adrian			Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors	PLOS ONE			English	Article								The structural complexity of chromosome 1p centromeric region has been an obstacle for fine mapping of tumor suppressor genes in this area. Loss of heterozygosity (LOH) on chromosome 1p is associated with the longer survival of oligodendroglioma ( OD) patients. To test the clinical relevance of 1p loss in glioblastomas (GBM) patients and identifiy the underlying tumor suppressor locus, we constructed a somatic deletion map on chromosome 1p in 26 OG and 118 GBM. Deletion hotspots at 4 microsatellite markers located at 1p36.3, 1p36.1, 1p22 and 1p11 defined 10 distinct haplotypes that were related to patient survival. We found that loss of 1p centromeric marker D1S2696 within NOTCH2 intron 12 was associated with favorable prognosis in OD ( P = 0.0007) as well as in GBM ( P = 0.0175), while 19q loss, concomitant with 1p LOH in OD, had no influence on GBM survival ( P = 0.918). Assessment of the intra-chromosomal ratio between NOTCH2 and its 1q21 pericentric duplication N2N (N2/N2N-test) allowed delineation of a consistent centromeric breakpoint in OD that also contained a minimally lost area in GBM. OD and GBM showed distinct deletion patterns that converged to the NOTCH2 gene in both glioma subtypes. Moreover, the N2/N2N-test disclosed homozygous deletions of NOTCH2 in primary OD. The N2/N2N test distinguished OD from GBM with a specificity of 100% and a sensitivity of 97%. Combined assessment of NOTCH2 genetic markers D1S2696 and N2/N2N predicted 24-month survival with an accuracy (0.925) that is equivalent to histological classification combined with the D1S2696 status (0.954) and higher than current genetic evaluation by 1p/19q LOH (0.762). Our data propose NOTCH2 as a powerful new molecular test to detect prognostically favorable gliomas.	[Boulay, Jean-Louis; Zweifel, Christian; Sivasankaran, Balasubramanian; Kana, Veronika; Ghaffari, Anthony; Merlo, Adrian] Univ Hosp, Mol Neurooncol Lab, Dept Res, Basel, Switzerland; [Miserez, Andre R.] Diagene Inc, Res Labs, Reinach, Switzerland; [Zweifel, Christian; Ghaffari, Anthony; Wasner, Morten; Merlo, Adrian] Univ Hosp, Neurosurg Clin, Basel, Switzerland; [Luyken, Cordelia; Sabel, Michael; Reifenberger, Guido] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany; [Luyken, Cordelia; Sabel, Michael; Reifenberger, Guido] Univ Dusseldorf, Dept Neurosurg, Dusseldorf, Germany; [Zerrouqi, Abdessamad; Van Meir, Erwin] Emory Univ, Mol Neurooncol Lab, Dept Neurosurg, Atlanta, GA 30322 USA; [Tolnay, Markus] Univ Hosp, Inst Pathol, Basel, Switzerland	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Emory University	Merlo, A (corresponding author), Univ Hosp, Mol Neurooncol Lab, Dept Res, Basel, Switzerland.	amerlo@uhbs.ch	Reifenberger, Guido/AAE-3599-2019; Sivasankaran, Balasubramanian/D-1527-2015; Miserez, André R./A-8581-2008	Sivasankaran, Balasubramanian/0000-0001-6207-5516; Van Meir, Erwin G./0000-0003-2444-7707; Zerrouqi, Abdessamad/0000-0002-2628-473X; Kana, Veronika/0000-0002-9362-3156	Swiss National Cancer League / Oncosuisse [OCS-01613-12-2004]; Regional Cancer League of both Basel-Stadt and Baselland [7-2004]; German Cancer Aid [70-3088-Sa1]	Swiss National Cancer League / Oncosuisse; Regional Cancer League of both Basel-Stadt and Baselland; German Cancer Aid(Deutsche Krebshilfe)	This work was supported by the Swiss National Cancer League / Oncosuisse (OCS-01613-12-2004), the Regional Cancer League of both Basel-Stadt and Baselland ( No. 7-2004) and the German Cancer Aid (70-3088-Sa1).	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bello MJ, 2000, CANCER GENET CYTOGEN, V116, P142, DOI 10.1016/S0165-4608(99)00122-3; Bigner SH, 1999, AM J PATHOL, V155, P375, DOI 10.1016/S0002-9440(10)65134-6; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Duan ZJ, 2004, MOL CELL BIOL, V24, P58, DOI 10.1128/MCB.24.1.58-70.2004; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Gregory SG, 2006, NATURE, V441, P315, DOI 10.1038/nature04727; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; GRIGORIEV A, 1994, GENOMICS, V22, P482, DOI 10.1006/geno.1994.1416; Hubmann R, 2002, BLOOD, V99, P3742, DOI 10.1182/blood.V99.10.3742; Husemann K, 1999, J NEUROPATH EXP NEUR, V58, P1041, DOI 10.1097/00005072-199910000-00002; Irvin DK, 2001, J COMP NEUROL, V436, P167, DOI 10.1002/cne.1059.abs; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Kleihues P, 2000, CANCER, V88, P2887, DOI 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F; Kraus JA, 2001, ACTA NEUROPATHOL, V101, P311; Lebrun C, 2004, NEUROLOGY, V62, P1783, DOI 10.1212/01.WNL.0000125196.88449.89; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Merlo A, 2003, NEUROSURG REV, V26, P145, DOI 10.1007/s10143-003-0267-8; Mirimanoff RO, 2006, J CLIN ONCOL, V24, P2563, DOI 10.1200/JCO.2005.04.5963; Mukasa A, 2002, ONCOGENE, V21, P3961, DOI 10.1038/sj.onc.1205495; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; SHAW EG, 1992, J NEUROSURG, V76, P428, DOI 10.3171/jns.1992.76.3.0428; Tanaka M, 2003, NEUROSCI LETT, V353, P87, DOI 10.1016/j.neulet.2003.08.080	35	54	55	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e576	10.1371/journal.pone.0000576	http://dx.doi.org/10.1371/journal.pone.0000576			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593975	Green Submitted, Green Published, gold			2022-12-25	WOS:000207451800020
J	Haraguchi, K; Ohsugi, M; Abe, Y; Semba, K; Akiyama, T; Yamamoto, T				Haraguchi, K.; Ohsugi, M.; Abe, Y.; Semba, K.; Akiyama, T.; Yamamoto, T.			Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3 beta-mediated phosphorylation of beta-catenin	ONCOGENE			English	Article						Wnt; beta-catenin; GSK-3 beta; Ajuba; phosphorylation	LIM PROTEIN FHL2; CYCLIN D1; AXIN; CANCER; EMBRYOGENESIS; FIBROBLASTS; ACTIVATION; INTERACTS; NUCLEUS; CELLS	The Wnt signaling pathway is essential for embryonic development and carcinogenesis. Upon Wnt stimulation, beta-catenin is stabilized and associates with T-cell factor or lymphoid enhancing factor, thereby activating transcription of target genes. In the absence of Wnt stimulation, the level of beta-catenin is reduced via glycogen synthase kinase (GSK)-beta b-mediated phosphorylation and subsequent proteasome-dependent degradation. Here, we report the identification of Ajuba as a negative regulator of the Wnt signaling pathway. Ajuba is a member of LIM domain-containing proteins that contribute to cell fate determination and regulate cell proliferation and differentiation. We found that enforced expression of Ajuba destabilized beta-catenin and suppressed target gene expression. Ajuba promoted GSK-3 beta-mediated phosphorylation of beta-catenin by reinforcing the association between beta-catenin and GSK-3 beta. Furthermore, Wnt stimulation induced both accumulation of beta-catenin and destabilization of Ajuba. Our findings suggest that Ajuba is important for regulation of the Wnt signaling pathway.	[Haraguchi, K.; Ohsugi, M.; Abe, Y.; Yamamoto, T.] Univ Tokyo, Inst Med Sci, Div Oncol, Tokyo 1088639, Japan; [Semba, K.] Univ Tokyo, Inst Med Sci, Div Cell & Mol Biol, Tokyo 1088639, Japan; [Akiyama, T.] Univ Tokyo, Inst Mol & Cell Biol, Lab Mol & Genet Informat, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428; Abe, Yoshinori/0000-0003-3894-494X				Adachi S, 2004, CANCER RES, V64, P8496, DOI 10.1158/0008-5472.CAN-04-2254; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; CADIGAM KM, 1998, GENE DEV, V14, P156; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kanungo J, 2000, MOL BIOL CELL, V11, P3299, DOI 10.1091/mbc.11.10.3299; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Shibamoto S, 1998, GENES CELLS, V3, P659; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tago K, 2000, GENE DEV, V14, P1741; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200	26	44	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					274	284		10.1038/sj.onc.1210644	http://dx.doi.org/10.1038/sj.onc.1210644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621269				2022-12-25	WOS:000252256000003
J	To-Ho, KW; Cheung, HW; Ling, MT; Wong, YC; Wang, X				To-Ho, K. W.; Cheung, H. W.; Ling, M-T; Wong, Y. C.; Wang, X.			MAD2 Delta C induces aneuploidy and promotes anchorage-independent growth in human prostate epithelial cells	ONCOGENE			English	Article						MAD2; mitotic; prostate epithelial cells; transformation	COMPARATIVE GENOMIC HYBRIDIZATION; NASOPHARYNGEAL CARCINOMA-CELLS; MITOTIC CHECKPOINT; CANCER-CELLS; CHROMOSOME MISSEGREGATION; PREMATURE ANAPHASE; MAMMALIAN-CELLS; SHORT TELOMERES; RAS MUTATION; MAD2 PROTEIN	The mitotic arrest deficient 2 (MAD2) is suggested to play a key role in a functional mitotic checkpoint because of its inhibitory effect on anaphase-promoting complex/cyclosome (APC/C) during mitosis. The binding of MAD2 to mitotic checkpoint regulators MAD1 and Cdc20 is thought to be crucial for its function and loss of which leads to functional inactivation of the MAD2 protein. However, little is known about the biological significance of this MAD2 mutant in human cells. In this study, we stably transfected a C-terminal-deleted MAD2 gene (MAD2 Delta C) into a human prostate epithelial cell line, Hpr-1 and studied its effect on chromosomal instability, cell proliferation, mitotic checkpoint control and soft agar colony-forming ability. We found that MAD2DC was able to induce aneuploidy through promoting chromosomal duplication, which was a result of an impaired mitotic checkpoint and cytokinesis, suggesting a crucial role of MAD2-mediated mitotic checkpoint in chromosome stability in human cells. In addition, the MAD2 Delta C-transfected cells displayed anchorage- independent growth in soft agar after challenged by 7,12-dimethylbenz[A]anthracene (DMBA), demonstrating a cancer-promoting effect of a defective mitotic checkpoint in human cells. Furthermore, the DMBA-induced transformation was accompanied by a complete loss of DNA damage-induced p53 response and activation of the MAPK pathway in MAD2 Delta C cells. These results indicate that a defective mitotic checkpoint alone is not a direct cause of tumorigenesis, but it may predispose human cells to carcinogen-induced malignant transformation. The evidence presented here provides a link between MAD2 inactivation and malignant transformation of epithelial cells.	[To-Ho, K. W.; Cheung, H. W.; Ling, M-T; Wong, Y. C.; Wang, X.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Wang, X (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, 1-F Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk						Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; BUTZ K, 1995, ONCOGENE, V10, P927; Cheung BW, 2005, CANCER RES, V65, P1450, DOI 10.1158/0008-5472.CAN-04-0567; Cho ES, 2002, YONSEI MED J, V43, P145, DOI 10.3349/ymj.2002.43.2.145; Choo CK, 1999, PROSTATE, V40, P150, DOI 10.1002/(SICI)1097-0045(19990801)40:3<150::AID-PROS2>3.0.CO;2-7; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; DE AA, 2005, CURR BIOL, V15, P214; Deliveliotis C, 2003, WORLD J UROL, V21, P171, DOI 10.1007/s00345-003-0345-0; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Deng W, 2003, GENE CHROMOSOME CANC, V37, P92, DOI 10.1002/gcc.10190; Di Cristofaro J, 2006, HUM PATHOL, V37, P824, DOI 10.1016/j.humpath.2006.01.030; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; Eid MA, 1998, CANCER RES, V58, P2461; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fung MKL, 2006, BRIT J CANCER, V95, P475, DOI 10.1038/sj.bjc.6603284; Gioeli D, 1999, CANCER RES, V59, P279; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Haapala K, 2001, CANCER GENET CYTOGEN, V131, P74, DOI 10.1016/S0165-4608(01)00491-5; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Johannsdottir HK, 2004, ANTICANCER RES, V24, P2681; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; OSAKA M, 1995, CANCER LETT, V91, P25, DOI 10.1016/0304-3835(94)03714-T; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Phillips JL, 2001, CANCER RES, V61, P8143; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Stewart SL, 2004, CANCER RES, V64, P8177, DOI 10.1158/0008-5472.CAN-04-1702; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takahashi N, 1999, SOFTWARE STUDIES, V2, P55; Wang XH, 1998, CANCER RES, V58, P5019; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Webb HD, 1996, CANCER GENET CYTOGEN, V88, P126, DOI 10.1016/0165-4608(95)00305-3; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhao YF, 2006, CARCINOGENESIS, V27, P1692, DOI 10.1093/carcin/bgl037; Zitzelsberger H, 1996, CANCER GENET CYTOGEN, V90, P37, DOI 10.1016/0165-4608(96)00065-9	54	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					347	357		10.1038/sj.onc.1210633	http://dx.doi.org/10.1038/sj.onc.1210633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621272				2022-12-25	WOS:000252256000011
J	Jeffers, LJ; Coull, BJ; Stack, SJ; Morrison, CG				Jeffers, L. J.; Coull, B. J.; Stack, S. J.; Morrison, C. G.			Distinct BRCT domains in Mcph1/Brit1 mediate ionizing radiation-induced focus formation and centrosomal localization	ONCOGENE			English	Article						DNA-damage response; microcephalin; BRCT; cell cycle checkpoint; centrosome	DOUBLE-STRAND BREAKS; HISTONE H2AX; DNA-DAMAGE; CHROMOSOME CONDENSATION; NUCLEAR FOCI; PROTEIN; MICROCEPHALIN; CHECKPOINT; REPAIR; UBIQUITINATION	Microcephalin (MCPH1/BRIT1) forms ionizing radiation-induced nuclear foci (IRIF) and is required for DNA damage-responsive S and G(2)-M-phase checkpoints. MCPH1 contains three BRCT domains. Here we report the cloning of chicken Mcph1 (cMcph1) and functional analysis of its individual BRCT domains. Full-length cMcph1 localized to centrosomes throughout the cell cycle and formed IRIF that colocalized with gamma-H2AX. The tandem C-terminal BRCT2 and BRCT3 domains of cMcph1 were necessary for IRIF formation, while the N-terminal BRCT1 was required for centrosomal localization in irradiated cells. Centrosomal targeting of cMcph1 was independent of ATM, Brca1 or Chk1. cMcph1 formed IRIF in ATM- and Brca1-deficient cells, but not in H2AX-deficient cells. Inability to form cMcph1 IRIF impaired the cellular response to DNA damage. These results suggest that the role of microcephalin in the vertebrate DNA damage response is controlled by interaction of the C-terminal BRCT domains with gamma-H2AX.	[Jeffers, L. J.; Coull, B. J.; Stack, S. J.; Morrison, C. G.] Natl Univ Ireland Galway, Dept Biochem & NCBES, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Dept Biochem & NCBES, Univ Rd, Galway, Ireland.	ciaran.morrison@nuigalway.ie	Morrison, Ciaran/B-6568-2008; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Coull, Barry/0000-0001-5438-7085				Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bond J, 2005, NAT GENET, V37, P353, DOI 10.1038/ng1539; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Haren L, 2006, J CELL BIOL, V172, P505, DOI 10.1083/jcb.200510028; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Neitzel H, 2002, AM J HUM GENET, V70, P1015, DOI 10.1086/339518; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; RAI R, 2006, CANCER CELL, V10, P1; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sonoda E, 2007, DNA REPAIR, V6, P280, DOI 10.1016/j.dnarep.2006.10.025; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Xu XZ, 2004, J BIOL CHEM, V279, P34091, DOI 10.1074/jbc.C400139200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	26	68	70	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					139	144		10.1038/sj.onc.1210595	http://dx.doi.org/10.1038/sj.onc.1210595			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599047				2022-12-25	WOS:000252118700014
J	Hishiki, T; Ohshima, T; Ego, T; Shimotohno, K				Hishiki, Takayuki; Ohshima, Takayuki; Ego, Takeshi; Shimotohno, Kunitada			BCL3 acts as a negative regulator of transcription from the human T-cell leukemia virus type 1 long terminal repeat through interactions with TORC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HTLV-I TAX; BINDING-PROTEIN; HISTONE ACETYLTRANSFERASE; GENE-EXPRESSION; C-JUN; PROMOTER; CREB; DNA; PHOSPHORYLATION	By associating with cyclic AMP-responsive element-binding protein (CREB), the human T-cell leukemia virus type 1 (HTLV-1) Tax protein activates transcription from the HTLV-1 long terminal repeat (LTR), which contains multiple cyclic AMP-responsive elements. The transducers of regulated CREB activity (TORCs) were a recently identified family of CREB co-activators that bind to CREB to enhance CRE-mediated transcription. TORC3, a TORC family protein, dramatically enhances Tax-mediated transcription from the LTR. In this study, we performed a yeast two-hybrid screen using the N-terminal region of TORC3 as bait and identified B-cell chronic lymphatic leukemia protein 3 (BCL3) as a protein interacting with TORC3. This interaction was confirmed by glutathione S-transferase pulldown assays and co-immunoprecipitation experiments with detection by Western blotting. The ankyrin repeat domain of BCL3 interacted with TORC3. By using a luciferase assay, we determined that BCL3 inhibited transcription from the HTLV-1 LTR in a manner dependent on TORC3. Knockdown of endogenous BCL3 using RNA interference enhanced transcriptional activation of CRE. Treatment with trichostatin A, a potent inhibitor of the transcriptional co-repressor HDAC, partially reversed the inhibitory effect of BCL3. These results suggest that BCL3 functions as a repressor of HTLV-1 LTR-mediated transcription through interactions with TORC3. In addition to stimulating transcription from the HTLV-1 LTR, Tax also enhances BCL3 expression; thus, transcription from the LTR is regulated by both positive and negative feedback mechanisms.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Virol Oncol,Lab Human Tumor Viruses, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Tokushima Bunri Univ, Fac Pharmaceut Sci, Sanuki City, Kagawa 7692193, Japan	Kyoto University; Kyoto University; Tokushima Bunri University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Virol Oncol,Lab Human Tumor Viruses, 53 Kawaharacho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				Akagi T, 1996, ONCOGENE, V12, P1645; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Jamaluddin M, 2005, J VIROL, V79, P15302, DOI 10.1128/JVI.79.24.15302-15313.2005; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5; Kashanchi F, 2005, ONCOGENE, V24, P5938, DOI 10.1038/sj.onc.1208973; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Koga H, 2004, J BIOL CHEM, V279, P52978, DOI 10.1074/jbc.M409021200; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	47	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28335	28343		10.1074/jbc.M702656200	http://dx.doi.org/10.1074/jbc.M702656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17644518	hybrid			2022-12-25	WOS:000249642100007
J	Sismey-Ragatz, AE; Green, DE; Otto, NJ; Rejzek, M; Field, RA; DeAngelis, PL				Sismey-Ragatz, Alison E.; Green, Dixy E.; Otto, Nigel J.; Rejzek, Martin; Field, Robert A.; DeAngelis, Paul L.			Chemoenzymatic synthesis with distinct Pasteurella heparosan synthases - Monodisperse polymers and unnatural structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN OLIGOSACCHARIDES; IDENTIFICATION; EVOLUTION; HEPARIN; COMPLEX	Heparosan (-GlcUA-beta 1,4-GlcNAc-alpha 1,4-)(n) is a member of the glycosaminoglycan polysaccharide family found in the capsule of certain pathogenic bacteria as well as the precursor for the vertebrate polymers, heparin and heparan sulfate. The two heparosan synthases from the Gram-negative bacteria Pasteurella multocida, PmHS1 and PmHS2, were efficiently expressed and purified using maltose-binding protein fusion constructs. These relatively homologous synthases displayed distinct catalytic characteristics. PmHS1, but not PmHS2, was able to produce large molecular mass (100-800 kDa) monodisperse polymers in synchronized, stoichiometrically controlled reactions in vitro. PmHS2, but not PmHS1, was able to utilize many unnatural UDP-sugar analogs (including substrates with acetamido-containing uronic acids or longer acyl chain hexosamine derivatives) in vitro. Overall these findings reveal potential differences in the active sites of these two Pasteurella enzymes. In the future, these catalysts should allow the creation of a variety of heparosan and heparinoids with utility for medical applications.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	University of Oklahoma System; University of Oklahoma Health Sciences Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu		Field, Rob/0000-0001-8574-0275	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062244] Funding Source: NIH RePORTER; Engineering and Physical Sciences Research Council [GR/S82046/01] Funding Source: researchfish; NHLBI NIH HHS [HL062244] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chen M, 2006, BIOCHEMISTRY-US, V45, P12358, DOI 10.1021/bi060844g; DeAngelis PL, 2004, J BACTERIOL, V186, P8529, DOI 10.1128/JB.186.24.8529-8532.2004; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DeAngelis PL, 2002, ANAT RECORD, V268, P317, DOI 10.1002/ar.10163; DeAngelis PL, 2002, J BIOL CHEM, V277, P7209, DOI 10.1074/jbc.M112130200; Duncan MB, 2006, BIOCHEM BIOPH RES CO, V339, P1232, DOI 10.1016/j.bbrc.2005.11.142; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Hodson N, 2000, J BIOL CHEM, V275, P27311; Ikegami-Kawai M, 2002, ANAL BIOCHEM, V311, P157, DOI 10.1016/S0003-2697(02)00425-6; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Jing W, 2004, J BIOL CHEM, V279, P42345, DOI 10.1074/jbc.M402744200; Kane TA, 2006, J BIOL CHEM, V281, P33192, DOI 10.1074/jbc.M606897200; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Liu ZY, 2002, CHEMBIOCHEM, V3, P348, DOI 10.1002/1439-7633(20020402)3:4<348::AID-CBIC348>3.0.CO;2-K; Rejzek M, 2007, CARBOHYD RES, V342, P460, DOI 10.1016/j.carres.2006.10.016; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Williams KJ, 2006, J BIOL CHEM, V281, P5391, DOI 10.1074/jbc.M510439200; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	22	68	74	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28321	28327		10.1074/jbc.M701599200	http://dx.doi.org/10.1074/jbc.M701599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17627940	hybrid			2022-12-25	WOS:000249642100005
J	Hostetter, DR; Loeb, CRK; Chu, F; Craik, CS				Hostetter, Daniel R.; Loeb, Carly R. K.; Chu, Feixia; Craik, Charles S.			Hip is a pro-survival substrate of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTL-MEDIATED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; HEAT-SHOCK PROTEINS; CELL-DEATH; INHIBITS APOPTOSIS; CASPASE ACTIVATION; HSC70 COCHAPERONE; KEY MEDIATORS; TARGET-CELLS; PROTEASE	The extended substrate specificity of granzyme B (GrB) was used to identify substrates among the chaperone superfamily. This approach identified Hsp90 and Bag1-L as novel GrB substrates, and an additional GrB cleavage site was identified in the Hsc70/Hsp70-Interacting Protein, Hip. Hsp90, Bag1L, and Hip were validated as GrB substrates in vitro, and mutational analysis confirmed the additional cleavage site in Hip. Because the role of Hip in apoptosis is unknown, its proteolysis by GrB was used as a basis to test whether it has anti-apoptotic activity. Previous work on Hip was limited to in vitro characterization; therefore, it was important to demonstrate Hip cleavage in a physiological context and to show its relevance to natural killer (NK) cell-mediated death. Hip is cleaved at both GrB cleavage sites during NK-mediated cell death in a caspase-independent manner, and its cleavage is due solely to GrB and not other granule components. Furthermore, Hip is not cleaved upon stimulation of the Fas receptor in the Jurkat T-cell line, suggesting that Hip is a substrate unique to GrB. RNA interference-mediated reduction of Hip within the K562 cell line rendered the cells more susceptible to NK cell-mediated lysis, indicating that proteolysis by GrB of Hip contributes to death induction. The small effect of RNA interference-mediated Hip deficiency on cytotoxicity is in agreement with the inherent redundancy of NK cell-mediated cell death. The identification of additional members of the chaperone superfamily as GrB substrates and the validation of Hip as an anti-apoptotic protein contribute to understanding the interplay between stress response and apoptosis.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; Univ Calif San Francisco, Tetrad Grad Program, Dept Biochem & Biophys, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.	craik@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [P01CA072006, P30CA082103] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA82103, CA072006] Funding Source: Medline; PHS HHS [15804, 12961, 01614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Andrade F, 2003, ACTA HAEMATOL-BASEL, V111, P28, DOI 10.1159/000074484; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Backes C, 2005, NUCLEIC ACIDS RES, V33, pW208, DOI 10.1093/nar/gki433; Barnes JD, 2005, APOPTOSIS, V10, P301, DOI 10.1007/s10495-005-0804-8; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Beere HM, 2005, J CLIN INVEST, V115, P2633, DOI 10.1172/JCI26471; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Boyd Sarah E., 2005, Journal of Bioinformatics and Computational Biology, V3, P551, DOI 10.1142/S021972000500117X; Boyd SE, 2004, 2004 IEEE COMPUTATIONAL SYSTEMS BIOINFORMATICS CONFERENCE, PROCEEDINGS, P372; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Bredemeyer AJ, 2006, J BIOL CHEM, V281, P37130, DOI 10.1074/jbc.M607969200; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Goping IS, 2006, J CELL SCI, V119, P858, DOI 10.1242/jcs.02791; Guo F, 2005, BLOOD, V105, P1246, DOI 10.1182/blood-2004-05-2041; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HOHFELD J, 1995, CELL, V83, P589; Irmer H, 1997, J BIOL CHEM, V272, P2230; Karpinich NO, 2006, J CELL PHYSIOL, V208, P55, DOI 10.1002/jcp.20638; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kudoh M, 2002, CANCER RES, V62, P1904; LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087; Loeb CRK, 2006, J BIOL CHEM, V281, P28326, DOI 10.1074/jbc.M604544200; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Rotonda J, 2001, CHEM BIOL, V8, P357, DOI 10.1016/S1074-5521(01)00018-7; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Sarin A, 1998, J IMMUNOL, V161, P2810; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; Smith DF, 2004, CELL STRESS CHAPERON, V9, P109, DOI 10.1379/CSC-31.1; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; TEAM RDC, 2005, R LANGUAGE ENV STAT; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Tyndall JDA, 2005, CHEM REV, V105, P973, DOI 10.1021/cr040669e; Velten M, 2000, BIOCHEMISTRY-US, V39, P307, DOI 10.1021/bi9917535; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; Waterhouse NJ, 2006, IMMUNOL CELL BIOL, V84, P72, DOI 10.1111/j.1440-1711.2005.01416.x; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Willoughby CA, 2002, BIOORG MED CHEM LETT, V12, P2197, DOI 10.1016/S0960-894X(02)00363-3; Yang JY, 2005, MOL BIOL CELL, V16, P3511, DOI 10.1091/mbc.E05-01-0080	47	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27865	27874		10.1074/jbc.M704312200	http://dx.doi.org/10.1074/jbc.M704312200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17620340	hybrid			2022-12-25	WOS:000249455600035
J	Chi, YH; Haller, K; Peloponese, JM; Jeang, KT				Chi, Ya-Hui; Haller, Kerstin; Peloponese, Jean-Marie, Jr.; Jeang, Kuan-Teh			Histone acetyltransferase hALP and nuclear membrane protein hsSUN1 function in de-condensation of mitotic chromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-A; CHROMATIN-STRUCTURE; BUILDING-BLOCKS; GENE-EXPRESSION; ENVELOPE; ACETYLATION; LOCALIZATION; DYNAMICS; ACTIVATION; COMPONENTS	Replicated mammalian chromosomes condense to segregate during anaphase, and they de-condense at the conclusion of mitosis. Currently, it is not understood what the factors and events are that specify de-condensation. Here, we demonstrate that chromosome de-condensation needs the function of an inner nuclear membrane (INM) protein hsSUN1 and a membrane-associated histone acetyltransferase ( HAT), hALP. We propose that nascently reforming nuclear envelope employs hsSUN1 and hALP to acetylate histones for de-compacting DNA at the end of mitosis.	NIAID, NIH, Mol Microbiol Lab, Mol Virol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Chi, Ya-Hui/ABE-8550-2020; Chi, Ya-Hui/B-1080-2010; Jeang, Kuan-Teh/A-2424-2008	Chi, Ya-Hui/0000-0002-9216-0938; Peloponese, Jean-Marie/0000-0002-9677-9703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI001023, ZIAAI001023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Buendia B, 1997, EXP CELL RES, V230, P133, DOI 10.1006/excr.1996.3395; Buendia B, 2001, CELL MOL LIFE SCI, V58, P1781, DOI 10.1007/PL00000818; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Burke B, 2001, NAT CELL BIOL, V3, pE273, DOI 10.1038/ncb1201-e273; Burke B, 2001, TRAFFIC, V2, P675, DOI 10.1034/j.1600-0854.2001.21001.x; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; DE IC, 2005, BIOESSAYS, V27, P164; Dechat T, 2004, J CELL SCI, V117, P6117, DOI 10.1242/jcs.01529; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Fahrenkrog B, 2004, TRENDS BIOCHEM SCI, V29, P175, DOI 10.1016/j.tibs.2004.02.006; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Gassmann R, 2005, CHROMOSOMA, V113, P385, DOI 10.1007/s00412-004-0326-0; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174/1566524013363537; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Haque F, 2006, MOL CELL BIOL, V26, P3738, DOI 10.1128/MCB.26.10.3738-3751.2006; Haraguchi T, 2000, J CELL SCI, V113, P779; Hasan S, 2006, FEBS LETT, V580, P1263, DOI 10.1016/j.febslet.2006.01.039; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Hodzic DM, 2004, J BIOL CHEM, V279, P25805, DOI 10.1074/jbc.M313157200; Holaska JM, 2002, CURR OPIN CELL BIOL, V14, P357, DOI 10.1016/S0955-0674(02)00329-0; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Kikuno R, 2002, NUCLEIC ACIDS RES, V30, P166, DOI 10.1093/nar/30.1.166; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lee KK, 2002, MOL BIOL CELL, V13, P892, DOI 10.1091/mbc.01-06-0294; Lopez-Soler RI, 2001, J CELL BIOL, V154, P61, DOI 10.1083/jcb.200101025; Lv JJ, 2003, BIOCHEM BIOPH RES CO, V311, P506, DOI 10.1016/j.bbrc.2003.09.235; Malone CJ, 1999, DEVELOPMENT, V126, P3171; Margalit A, 2005, J CELL BIOCHEM, V95, P454, DOI 10.1002/jcb.20433; Marshall WF, 2002, CURR BIOL, V12, pR185, DOI 10.1016/S0960-9822(02)00724-8; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; Mattout-Drubezki A, 2003, CELL MOL LIFE SCI, V60, P2053, DOI 10.1007/s00018-003-3038-3; Moir RD, 2000, J CELL BIOL, V151, P1155, DOI 10.1083/jcb.151.6.1155; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Padmakumar VC, 2005, J CELL SCI, V118, P3419, DOI 10.1242/jcs.02471; Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Shumaker DK, 2003, CURR OPIN CELL BIOL, V15, P358, DOI 10.1016/S0955-0674(03)00050-4; Somech R, 2005, J CELL SCI, V118, P4017, DOI 10.1242/jcs.02521; Somech R, 2005, PEDIATR RES, V57, p8R, DOI 10.1203/01.PDR.0000159566.54287.6C; Starr DA, 2003, J CELL SCI, V116, P211, DOI 10.1242/jcs.00248; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Taddei A, 2004, ANNU REV GENET, V38, P305, DOI 10.1146/annurev.genet.37.110801.142705; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Ulbert S, 2006, J CELL BIOL, V173, P469, DOI 10.1083/jcb.200512078; Wang Q, 2006, DNA CELL BIOL, V25, P554, DOI 10.1089/dna.2006.25.554; Worman HJ, 2004, J CLIN INVEST, V113, P349, DOI 10.1172/JCI200420832; Yang L, 1997, J CELL BIOL, V137, P1199, DOI 10.1083/jcb.137.6.1199	59	80	83	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27447	27458		10.1074/jbc.M703098200	http://dx.doi.org/10.1074/jbc.M703098200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631499	hybrid, Green Submitted			2022-12-25	WOS:000249304900086
J	Chou, CC; Chang, CW; Liu, JH; Chen, LF; Hsiao, CD; Chen, HW				Chou, Chih-Chine; Chang, Chingwen; Liu, Jyung-Hurng; Chen, Liang-Fu; Hsiao, Chwan-Deng; Chen, Hungwen			Small ubiquitin-like modifier modification regulates the DNA binding activity of glial cell missing Drosophila homolog a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO-1 MODIFICATION; TRANSCRIPTIONAL REPRESSION; GCMA; PROTEIN; SUMOYLATION; COMPLEX; DEGRADATION; PROTEASOME; SYNCYTIN; KINASE	Glial cell missing Drosophila homolog a (GCMa) is an essential transcription factor for placental development, which controls the differentiation of the syncytiotrophoblast layer. Although the activity of GCMa can be post-translationally regulated by protein phosphorylation, ubiquitination, and acetylation, it is unknown whether GCMa activity can be regulated by sumoylation. In this report, we investigated the role of sumoylation in the regulation of GCMa activity. We demonstrated that Ubc9, the E2 component of the sumoylation machinery, specifically interacts with the N-terminal domain of GCMa and promotes GCMa sumoylation on lysine 156. Moreover, GCMa-mediated transcriptional activation was repressed by sumoylation but was enhanced in the presence of the SUMO-specific protease, SENP1. The repressive effect of sumoylation on GCMa transcriptional activity was attributed to decreased DNA binding activity of GCMa. Furthermore, structural analysis revealed a steric clash between the SUMO1 moiety of sumoylated GCMa and the DNA-binding surfaces of GCMa, which may destabilize the interaction between GCMa and its cognate DNA sequence. Our study demonstrates that GCMa is a new sumoylation substrate and its activity is down-regulated by sumoylation.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Taiwan Univ, Grad Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, HW (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	hwchen@gate.sinica.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Chang, Ching-Wen/N-7867-2018; Hsiao, Chwan-Deng/D-7327-2013; Liu, Jyung-Hurng/C-1340-2010	Hsiao, Chwan-Deng/0000-0002-7012-1532; Chang, Ching-Wen/0000-0002-5693-3809; Liu, Jyung-Hurng/0000-0002-7173-0372				Anckar J, 2006, MOL CELL BIOL, V26, P955, DOI 10.1128/MCB.26.3.955-964.2006; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Boyer-Guittaut M, 2005, J BIOL CHEM, V280, P9937, DOI 10.1074/jbc.M414149200; Chang C, 2004, BIOL REPROD, V71, P1956, DOI 10.1095/biolreprod.104.033340; Chang CW, 2005, MOL CELL BIOL, V25, P8401, DOI 10.1128/MCB.25.19.8401-8414.2005; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chuang HC, 2006, NUCLEIC ACIDS RES, V34, P1459, DOI 10.1093/nar/gkl048; Cohen SX, 2003, EMBO J, V22, P1835, DOI 10.1093/emboj/cdg182; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee H, 2006, GENE DEV, V20, P784, DOI 10.1101/gad.1392006; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; Schreiber J, 1998, NUCLEIC ACIDS RES, V26, P2337, DOI 10.1093/nar/26.10.2337; Spengler ML, 2006, J BIOL CHEM, V281, P5567, DOI 10.1074/jbc.M600035200; Yang CS, 2005, J BIOL CHEM, V280, P10083, DOI 10.1074/jbc.M413986200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yu CC, 2002, J BIOL CHEM, V277, P50062, DOI 10.1074/jbc.M209316200	28	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27239	27249		10.1074/jbc.M700351200	http://dx.doi.org/10.1074/jbc.M700351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17646165	Green Published, hybrid			2022-12-25	WOS:000249304900065
J	Hoffmann, M; Hornung, E; Busch, S; Kassner, N; Ternes, P; Braus, GH; Feussner, I				Hoffmann, Mareike; Hornung, Ellen; Busch, Silke; Kassner, Nina; Ternes, Philipp; Braus, Gerhard H.; Feussner, Ivo			A small membrane-peripheral region close to the active center determines regioselectivity of membrane-bound fatty acid desaturases from Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN DESATURASE; CRYSTAL-STRUCTURE; SPECIFICITY; TOPOLOGY; METABOLISM; PLANTS; SEEDS; GENE; IVY	Fatty acid desaturases catalyze the introduction of double bonds at specific positions of an acyl chain and are categorized according to their substrate specificity and regioselectivity. The current understanding of membrane-bound desaturases is based on mutant studies, biochemical topology analysis, and the comparison of related enzymes with divergent functionality. Because structural information is lacking, the principles of membrane-bound desaturase specificity are still not understood despite of substantial research efforts. Here we compare two membrane-bound fatty acid desaturases from Aspergillus nidulans: a strictly monofunctional oleoyl-Delta 12 desaturase and a processive bifunctional oleoyl-Delta 12/ linoleoyl-omega 3 desaturase. The high similarities in the primary sequences of the enzymes provide an ideal starting point for the systematic analysis of factors determining substrate specificity and bifunctionality. Based on the most current topology models, both desaturases were divided into nine domains, and the domains of the monofunctional Delta 12 desaturase were systematically exchanged for their respective corresponding matches of the bifunctional sister enzyme. Catalytic capacities of hybrid enzymes were tested by heterologous expression in yeast, followed by biochemical characterization of the resulting fatty acid patterns. The individual exchange of two domains of a length of 18 or 49 amino acids each resulted in bifunctional Delta 12/ omega 3 activity of the previously monofunctional parental enzyme. Sufficient determinants of fatty acid desaturase substrate specificity and bifunctionality could, thus, be narrowed down to a membrane-peripheral region close to the catalytic site defined by conserved histidine-rich motifs in the topology model.	Albrecht von Haller Inst Pflanzenwissensch, Abt Biochem Pflanze, D-37077 Gottingen, Germany; Inst Mikrobiol & Genet, Abt Mol Mikrobiol & Genet, D-37077 Gottingen, Germany; Univ Utrecht, Fac Scheikunde, HR Kruytgebouw N601, NL-3584 CH Utrecht, Netherlands	Utrecht University	Feussner, I (corresponding author), Albrecht von Haller Inst Pflanzenwissensch, Abt Biochem Pflanze, Justus Von Liebig Weg 11, D-37077 Gottingen, Germany.	ifeussn@gwdg.de	Braus, Gerhard H/G-3999-2012; Braus, Gerhard/ABC-6293-2021; Feussner, Ivo/H-9320-2013	Braus, Gerhard H/0000-0002-3117-5626; Braus, Gerhard/0000-0002-3117-5626; Feussner, Ivo/0000-0002-9888-7003; Ternes, Philipp/0000-0003-0886-5474				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Broadwater JA, 2002, J BIOL CHEM, V277, P15613, DOI 10.1074/jbc.M200231200; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; Calvo AM, 2001, J BIOL CHEM, V276, P25766, DOI 10.1074/jbc.M100732200; Christie WW, 1998, LIPIDS, V33, P343, DOI 10.1007/s11745-998-0214-x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DAMUDE HG, 2005, Patent No. 2005047479; Damude HG, 2006, P NATL ACAD SCI USA, V103, P9446, DOI 10.1073/pnas.0511079103; Diaz AR, 2002, J BIOL CHEM, V277, P48099, DOI 10.1074/jbc.M208960200; Domergue F, 2003, PLANT PHYSIOL, V131, P1648, DOI 10.1104/pp.102.018317; Fox BG, 2004, ACCOUNTS CHEM RES, V37, P421, DOI 10.1021/ar030186h; Galagan JE, 2005, NATURE, V438, P1105, DOI 10.1038/nature04341; Guy JE, 2007, J BIOL CHEM, V282, P19863, DOI 10.1074/jbc.M702520200; Hastings N, 2001, P NATL ACAD SCI USA, V98, P14304, DOI 10.1073/pnas.251516598; Heilmann I, 2004, P NATL ACAD SCI USA, V101, P10266, DOI 10.1073/pnas.0402200101; Heinz Ernst, 1993, P33; Hornung E, 2005, BBA-MOL CELL BIOL L, V1738, P105, DOI 10.1016/j.bbalip.2005.11.004; Hornung E, 2005, BBA-MOL CELL BIOL L, V1686, P181, DOI 10.1016/j.bbalip.2004.11.001; Hornung E, 2002, EUR J BIOCHEM, V269, P4852, DOI 10.1046/j.1432-1033.2002.03184.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; Man WC, 2006, J BIOL CHEM, V281, P1251, DOI 10.1074/jbc.M508733200; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Sayanova O, 2006, J BIOL CHEM, V281, P36533, DOI 10.1074/jbc.M605158200; Shanklin J, 2000, CURR OPIN PLANT BIOL, V3, P243, DOI 10.1016/S1369-5266(00)00071-6; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Somerville C., 2000, BIOCH MOL BIOL PLANT, P456; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Sperling P, 2003, PROSTAG LEUKOTR ESS, V68, P73, DOI 10.1016/S0952-3278(02)00258-2; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; URSIN VM, 2003, Patent No. 03099216; VANBEILEN JB, 1992, J BIOL CHEM, V267, P9194; Whittle E, 2005, J BIOL CHEM, V280, P28169, DOI 10.1074/jbc.M504205200	36	31	42	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26666	26674		10.1074/jbc.M705068200	http://dx.doi.org/10.1074/jbc.M705068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636265	hybrid			2022-12-25	WOS:000249304900005
J	Komissarov, AA; Zhou, A; Declerck, PJ				Komissarov, Andrey A.; Zhou, Aiwu; Declerck, Paul J.			Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ACUTE MYOCARDIAL-INFARCTION; ENDOTHELIAL-CELL MATRIX; ISCHEMIC-HEART-DISEASE; SOMATOMEDIN-B-DOMAIN; PROTEINASE INHIBITION; ANGINA-PECTORIS; MONOCLONAL-ANTIBODIES; ALPHA(1)-PROTEINASE INHIBITOR; CENTER LOOP	Mechanism-based inhibition of proteinases by serpins involves enzyme acylation and fast insertion of the reactive center loop (RCL) into the central beta-sheet of the serpin, resulting in mechanical inactivation of the proteinase. We examined the effects of ligands specific to alpha-helix F (alpha HF) of plasminogen activator inhibitor-1 (PAI-1) on the stoichiometry of inhibition ( SI) and limiting rate constant (k(lim)) of RCL insertion for reactions with beta-trypsin, tissue-type plasminogen activator (tPA), and urokinase. The somatomedin B domain of vitronectin (SMBD) did not affect SI for any proteinase or klim for tPA but decreased the klim for beta-trypsin. In contrast to SMBD, monoclonal antibodies MA-55F4C12 and MA-33H1F7, the epitopes of which are located at the opposite side of alpha HF, decreased klim and increased SI for every enzyme. These effects were enhanced in the presence of SMBD. RCL insertion for beta-trypsin and tPA is limited by different subsequent steps of PAI-1 mechanism as follows: enzyme acylation and formation of a loop-displaced acyl complex (LDA), respectively. Stabilization of LDA through the disruption of the exosite interactions between PAI-1 and tPA induced an increase in the klim but did not affect the SI. Thus it is unlikely that LDA contributes significantly to the outcome of the serpin reaction. These results demonstrate that the rate of RCL insertion is not necessarily correlated with SI and indicate that an intermediate, different from LDA, which forms during the late steps of PAI-1 mechanism, and could be stabilized by ligands specific to alpha HF, controls bifurcation between the inhibitory and the substrate pathways.	Portland State Univ, Dept Chem, Portland, OR 97207 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Katholieke Univ Leuven, Lab Pharmaceut Biol, B-3000 Louvain, Belgium	Portland State University; University of Cambridge; KU Leuven	Komissarov, AA (corresponding author), Portland State Univ, Dept Chem, POB 751, Portland, OR 97207 USA.	akomiss@pdx.edu	Zhou, Aiwu/G-4700-2010; Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105; ZHOU, Aiwu/0000-0002-2555-5091				Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; AZNAR J, 1988, BRIT HEART J, V59, P535; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 2001, J BIOL CHEM, V276, P44912, DOI 10.1074/jbc.M103077200; Bjorquist P, 1999, BBA-PROTEIN STRUCT M, V1431, P24, DOI 10.1016/S0167-4838(99)00031-X; Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; DAWSON S, 1992, ATHEROSCLEROSIS, V95, P105, DOI 10.1016/0021-9150(92)90014-8; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Dementiev A, 2003, J BIOL CHEM, V278, P37881, DOI 10.1074/jbc.M305195200; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gils A, 2004, THROMB HAEMOSTASIS, V91, P425, DOI 10.1160/TH03-12-0764; Gils A, 1998, BBA-PROTEIN STRUCT M, V1387, P291, DOI 10.1016/S0167-4838(98)00139-3; GRIMAUDO V, 1992, THROMB HAEMOSTASIS, V67, P397; Hack CE, 2001, SEMIN THROMB HEMOST, V27, P633, DOI 10.1055/s-2001-18867; Held C, 1997, CIRCULATION, V95, P2380, DOI 10.1161/01.CIR.95.10.2380; Hoffmeister HM, 1999, ATHEROSCLEROSIS, V144, P151, DOI 10.1016/S0021-9150(99)00049-0; HUBER K, 1990, THROMB HAEMOSTASIS, V63, P336; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ibarra CA, 2004, J BIOL CHEM, V279, P3643, DOI 10.1074/jbc.M310601200; Ioannidou-Papayannaki E, 2000, ACTA CARDIOL, V55, P247, DOI 10.2143/AC.55.4.2005747; Johansson L, 2000, STROKE, V31, P26, DOI 10.1161/01.STR.31.1.26; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; Komissarov AA, 2005, J BIOL CHEM, V280, P1482, DOI 10.1074/jbc.M408608200; Komissarov AA, 2004, J BIOL CHEM, V279, P23007, DOI 10.1074/jbc.M401383200; Komissarov AA, 2002, J BIOL CHEM, V277, P43858, DOI 10.1074/jbc.M204110200; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LEE MH, 1993, BLOOD, V81, P2357; Li XQ, 2007, J BIOL CHEM, V282, P5318, DOI 10.1074/jbc.M611396200; Matsui H, 2001, HAEMOSTASIS, V31, P106; Minowa H, 1999, HAEMOSTASIS, V29, P286; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 1997, FEBS LETT, V416, P373, DOI 10.1016/S0014-5793(97)01242-8; Nordenhem A, 2005, THROMB RES, V116, P223, DOI 10.1016/j.thromres.2004.12.007; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; PEDERSEN OD, 1995, THROMB HAEMOSTASIS, V73, P835; PEDERSEN OD, 1994, CORONARY ARTERY DIS, V5, P617, DOI 10.1097/00019501-199407000-00010; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Rezaie AR, 2001, J BIOL CHEM, V276, P15567, DOI 10.1074/jbc.C100123200; Saigo M, 2001, THROMB HAEMOSTASIS, V86, P1197, DOI 10.1055/s-0037-1616051; Schousboe SL, 2000, THROMB HAEMOSTASIS, V83, P742, DOI 10.1055/s-0037-1613903; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Shindo J, 2001, CORONARY ARTERY DIS, V12, P573, DOI 10.1097/00019501-200111000-00008; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; Thogersen AM, 1998, CIRCULATION, V98, P2241, DOI 10.1161/01.CIR.98.21.2241; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; vanMeijer M, 1997, THROMB HAEMOSTASIS, V77, P516; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; Verbeke K, 2004, J THROMB HAEMOST, V2, P298, DOI 10.1111/j.1538-7933.2004.00583.x; Vervloet MG, 1998, SEMIN THROMB HEMOST, V24, P33, DOI 10.1055/s-2007-995821; Vleugels N, 2000, BBA-PROTEIN STRUCT M, V1476, P20, DOI 10.1016/S0167-4838(99)00224-1; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; Wiman B, 1999, SCAND J CLIN LAB INV, V59, P23; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; Wind T, 2002, BIOL CHEM, V383, P21, DOI 10.1515/BC.2002.003; Wind T, 2001, EUR J BIOCHEM, V268, P1095, DOI 10.1046/j.1432-1327.2001.2680041095.x; Wu Qingyu, 2002, Current Drug Targets - Cardiovascular and Haematological Disorders, V2, P27, DOI 10.2174/1568006023337727; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	76	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26306	26315		10.1074/jbc.M702089200	http://dx.doi.org/10.1074/jbc.M702089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17613529	hybrid			2022-12-25	WOS:000249239600035
J	Mckay, MM; Morrison, DK				Mckay, Melissa M.; Morrison, Deborah K.			Caspase-dependent cleavage disrupts the ERK cascade scaffolding function of KSR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; CYTOCHROME-C RELEASE; MAMMARY-GLAND; MAPK SCAFFOLD; GENE ENCODES; CELL-DEATH; APOPTOSIS; RAS; PATHWAY	Kinase suppressor of Ras 1 (KSR1) is a protein scaffold that facilitates ERK cascade activation at the plasma membrane, a critical step in the signal transduction process that allows cells to respond to survival, proliferative, and differentiative cues. Here, we report that KSR1 undergoes caspase-dependent cleavage in apoptotic cells and that cleavage destroys the scaffolding function of the full-length KSR1 protein and generates a stable C-terminal fragment that can inhibit ERK activation. KSR1 is cleaved in response to multiple apoptotic stimuli and occurs in vivo during the involution of mouse mammary tissues, a morphogenic process requiring cellular apoptosis. In addition, we find that in comparison with KSR1 (-/-) mouse embryonic fibroblasts expressing wild type KSR1 (WT-KSR1), cells expressing a cleavage-resistant KSR1 protein (DEVA-KSR1) exhibit reduced apoptotic signaling in response to tumor necrosis factor- alpha/ cycloheximide treatment. The effect of DEVA-KSR1 expression was found to correlate with increased levels of active phosphoERK and could be significantly reversed by treating cells with the MEK inhibitor U0126. In contrast, reduced phosphoERK levels and enhanced apoptotic signaling were observed in cells constitutively expressing the C-terminal KSR1 fragment (CTF-KSR1). Moreover, we find that cleavage of WTKSR1 correlates with a dramatic reduction in active phosphoERK levels. These findings identify KSR1 as a caspase target and suggest that cleavage of the KSR1 scaffold represents another mechanism whereby caspases down-regulate ERK survival signaling to promote cellular apoptosis.	NCI Frederick, Natl Inst Hlth, Ctr Canc Res, Lab Cell & Dev Signaling, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Morrison, DK (corresponding author), NCI Frederick, Natl Inst Hlth, Ctr Canc Res, Lab Cell & Dev Signaling, POB B, Ft Detrick, MD 21702 USA.	dmorrison@ncifcrf.gov						Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Green KA, 2004, CELL MOL LIFE SCI, V61, P1867, DOI 10.1007/s00018-004-3366-y; Hindley A, 2002, J CELL SCI, V115, P1575; Kabore AF, 2004, CURR CANCER DRUG TAR, V4, P147, DOI 10.2174/1568009043481551; Khosravi-Far R, 2004, CANCER BIOL THER, V3, P1051, DOI 10.4161/cbt.3.11.1173; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Lawlor MA, 2001, J CELL SCI, V114, P2903; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Piazzolla D, 2005, J CELL BIOL, V171, P1013, DOI 10.1083/jcb.200504137; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Ritt DA, 2007, CURR BIOL, V17, P179, DOI 10.1016/j.cub.2006.11.061; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Thornberry NA, 2000, METHOD ENZYMOL, V322, P100; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vermeulen K, 2005, ANN HEMATOL, V84, P627, DOI 10.1007/s00277-005-1065-x; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Watson CJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1401; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yan F, 2004, J CLIN INVEST, V114, P1272, DOI 10.1172/JCI200421022; Yan F, 2001, CANCER RES, V61, P963; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X	47	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26225	26234		10.1074/jbc.M702692200	http://dx.doi.org/10.1074/jbc.M702692200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17613518	hybrid			2022-12-25	WOS:000249239600027
J	Wang, KR; Nemoto, T; Yokota, Y				Wang, Kui-Rong; Nemoto, Tomoyuki; Yokota, Yoshifumi			RFX1 mediates the serum-induced immediate early response of Id2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; B-VIRUS ENHANCER; FACTOR-INDUCIBLE GENE; DNA-BINDING PROTEIN; REGULATORY FACTOR; GROWTH-FACTOR; C-MYC; TRANSCRIPTION FACTORS; DIMERIZATION DOMAIN; REPRESSION DOMAINS	Id2, a negative regulator of basic helix-loop-helix transcription factors, is involved in regulating cell differentiation and proliferation. To obtain insight into the role of Id2 in cell cycle control, we investigated the mechanisms underlying the immediate early response of Id2 expression to serum stimulation in NIH3T3 cells. Luciferase reporter analysis with deletion and point mutants demonstrated the serum response element of Id2 (Id2-SRE) to be a consensus binding site for RFX1 ((r) under bar egulatory (f) under bar actor for (X) under bar -box (1) under bar) present 3.0 kb upstream of the transcription initiation site of Id2. Gel shift and chromatin immunoprecipitation assays confirmed the binding of RFX1 to Id2-SRE in vitro and in vivo, respectively. In both assays, RFX1 binding was observed not only in serum-stimulated cells, but also in serum-starved cells. Knockdown of RFX1 by RNA interference disturbed the immediate early response of Id2 expression in cells and abrogated the Id2-SRE-mediated induction of luciferase activity by serum. These alterations were rescued by the introduction of RNA interference-resistant RFX1 into cells. On the other hand, in the Id2-SRE-mediated reporter assay, RFX1 with an N-terminal deletion abrogated the serum response, whereas RFX1 with a C-terminal deletion enhanced the reporter activity in serum-starved cells. Furthermore, HDAC1 was recruited to Id2-SRE in serum-starved cells. These results demonstrate that RFX1 mediates the immediate early response of the Id2 gene by serum stimulation and suggest that the function of RFX1 is regulated intramolecularly in its suppression in growth-arrested cells. Our results unveil a novel transcriptional control of immediate early gene expression.	Univ Fukui, Fac Med Sci, Dept Biochem & Bioinformat Sci, Fukui 9101193, Japan; Univ Fukui, Res & Educ Program Life Sci, Dept Gen Med, Div Neurol & Gastroenterol, Fukui 9101193, Japan	University of Fukui; University of Fukui	Yokota, Y (corresponding author), Univ Fukui, Fac Med Sci, Dept Biochem & Bioinformat Sci, 23-3 Matsuoka Shimaoaizuki, Fukui 9101193, Japan.	yokota@u-fukui.ac.jp						Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DOTZLAW H, 1992, MOL ENDOCRINOL, V6, P773, DOI 10.1210/me.6.5.773; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fan JS, 2006, NUCLEIC ACIDS RES, V34, P1492, DOI 10.1093/nar/gkj510; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gonda H, 2003, J EXP MED, V198, P1427, DOI 10.1084/jem.20030802; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARA E, 1994, J BIOL CHEM, V269, P2139; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Karaya K, 2005, NUCLEIC ACIDS RES, V33, P1924, DOI 10.1093/nar/gki339; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Katan-Khaykovich Y, 2001, EUR J BIOCHEM, V268, P3108, DOI 10.1046/j.1432-1327.2001.02211.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kurooka H, 2005, J BIOL CHEM, V280, P4313, DOI 10.1074/jbc.M412614200; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; Lubelsky Y, 2005, MOL CELL BIOL, V25, P10665, DOI 10.1128/MCB.25.23.10665-10673.2005; Ma KW, 2006, J BIOL CHEM, V281, P21250, DOI 10.1074/jbc.M600521200; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Morotami-Yano K, 2002, J BIOL CHEM, V277, P836, DOI 10.1074/jbc.M108638200; Murphy DJ, 2004, MOL CELL BIOL, V24, P2083, DOI 10.1128/MCB.24.5.2083-2090.2004; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; Nilsson JA, 2004, CANCER RES, V64, P7296, DOI 10.1158/0008-5472.CAN-04-2133; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Xu Y, 2006, J BIOL CHEM, V281, P9260, DOI 10.1074/jbc.M511724200; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	43	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26167	26177		10.1074/jbc.M703448200	http://dx.doi.org/10.1074/jbc.M703448200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17630394	hybrid			2022-12-25	WOS:000249239600020
J	Clarkson, NG; Simmonds, SJ; Puklavec, MJ; Brown, MH				Clarkson, Nicholas G.; Simmonds, Stephen J.; Puklavec, Michael J.; Brown, Marion H.			Direct and indirect interactions of the cytoplasmic region of CD244 (2B4) in mice and humans with FYN kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED LYMPHOPROLIFERATIVE DISEASE; NATURAL-KILLER-CELLS; GENE-PRODUCT SAP/SH2D1A; HUMAN NK CELLS; SH2 DOMAIN; CUTTING EDGE; LYMPHOCYTE-ACTIVATION; PROTEIN INTERACTIONS; ANTIGEN RECOGNITION; INHIBITORY RECEPTOR	Engagement of the receptor CD244 (2B4) by its ligand CD48 has inhibitory and activating potential, and this differs depending on experimental systems in mouse and human. We show that, in both mouse and human upon engagement of its ligand CD48, CD244 can give a negative signal to natural killer cells, implying conservation of function between the two species. The signaling mechanisms used by CD244 in both human and mouse are conserved as shown by quantitative analyses of the direct molecular interactions of the SH2 domains of the adaptors SLAM-associated protein ( SAP) and EAT-2 and of FYNkinase with CD244 together with the indirect interactions of the FYN SH2 domain with EAT-2. Functional experiments support the biochemical hierarchy of interactions and show that EAT-2 is not inhibitory per se. The data are consistent with a model in which the mechanism of signal transduction by CD244 is to regulate FYN kinase recruitment and/or activity and the outcome of CD48/CD244 interactions is determined by which other receptors are engaged.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Brown, MH (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	Marion.Brown@path.ox.ac.uk			Medical Research Council [G0400808] Funding Source: Medline; MRC [G0400808] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Assarsson E, 2005, J IMMUNOL, V175, P2045, DOI 10.4049/jimmunol.175.4.2045; Bloch-Queyrat C, 2005, J EXP MED, V202, P181, DOI 10.1084/jem.20050449; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Calpe S, 2006, IMMUNOGENETICS, V58, P15, DOI 10.1007/s00251-005-0056-3; Cao E, 2006, IMMUNITY, V25, P559, DOI 10.1016/j.immuni.2006.06.020; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; Chen RY, 2006, MOL CELL BIOL, V26, P5559, DOI 10.1128/MCB.00357-06; Chen RY, 2004, MOL CELL BIOL, V24, P5144, DOI 10.1128/MCB.24.12.5144-5156.2004; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Chuang HC, 2005, BLOOD, V106, P3090, DOI 10.1182/blood-2005-04-1406; Colonna M, 2005, NAT IMMUNOL, V6, P961, DOI 10.1038/ni1005-961; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Dupre L, 2005, BLOOD, V105, P4383, DOI 10.1182/blood-2004-08-3269; Eissmann P, 2005, BLOOD, V105, P4722, DOI 10.1182/blood-2004-09-3796; Endt J, 2007, EUR J IMMUNOL, V37, P193, DOI 10.1002/eji.200636341; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; Hassan NJ, 2006, MOL CELL BIOL, V26, P6727, DOI 10.1128/MCB.00688-06; Ingham RJ, 2005, J BIOL CHEM, V280, P34133, DOI 10.1074/jbc.M507831200; Kambayashi T, 2001, J IMMUNOL, V167, P6706, DOI 10.4049/jimmunol.167.12.6706; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; Lee KM, 2006, BLOOD, V107, P3181, DOI 10.1182/blood-2005-01-0185; Lee KM, 2004, J EXP MED, V199, P1245, DOI 10.1084/jem.20031989; Li CJ, 2003, J BIOL CHEM, V278, P3852, DOI 10.1074/jbc.M206649200; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; Liu BA, 2006, MOL CELL, V22, P851, DOI 10.1016/j.molcel.2006.06.001; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; Morandi B, 2005, J IMMUNOL, V175, P3690, DOI 10.4049/jimmunol.175.6.3690; Morra M, 2001, EMBO J, V20, P5840, DOI 10.1093/emboj/20.21.5840; Nakajima H, 1999, EUR J IMMUNOL, V29, P1676, DOI 10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Romero X, 2004, TISSUE ANTIGENS, V64, P132, DOI 10.1111/j.1399-0039.2004.00247.x; Roncagalli R, 2005, NAT IMMUNOL, V6, P1002, DOI 10.1038/ni1242; Saborit-Villarroya IN, 2005, J IMMUNOL, V175, P4226, DOI 10.4049/jimmunol.175.7.4226; Schatzle JD, 1999, P NATL ACAD SCI USA, V96, P3870, DOI 10.1073/pnas.96.7.3870; Sivori S, 2002, P NATL ACAD SCI USA, V99, P4526, DOI 10.1073/pnas.072065999; Sweeney MC, 2005, BIOCHEMISTRY-US, V44, P14932, DOI 10.1021/bi051408h; Tangye SG, 1999, J IMMUNOL, V162, P6981; Tassi I, 2005, J IMMUNOL, V175, P7996, DOI 10.4049/jimmunol.175.12.7996; Tassi I, 2006, IMMUNOL REV, V214, P92, DOI 10.1111/j.1600-065X.2006.00463.x; Thorley-Lawson DA, 2005, J ALLERGY CLIN IMMUN, V116, P251, DOI 10.1016/j.jaci.2005.05.038; Vaidya SV, 2005, J IMMUNOL, V174, P800, DOI 10.4049/jimmunol.174.2.800; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; Veillette A, 2006, NAT REV IMMUNOL, V6, P56, DOI 10.1038/nri1761; Wahle JA, 2006, J IMMUNOL, V176, P7165, DOI 10.4049/jimmunol.176.12.7165; Wild MK, 1999, J EXP MED, V190, P31, DOI 10.1084/jem.190.1.31	49	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25385	25394		10.1074/jbc.M704483200	http://dx.doi.org/10.1074/jbc.M704483200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17599905	hybrid			2022-12-25	WOS:000249014100024
J	Im, H; Manolopoulou, M; Malito, E; Shen, Y; Zhao, J; Neant-Fery, M; Sun, CY; Meredith, SC; Sisodia, SS; Leissring, MA; Tang, WJ				Im, Hookang; Manolopoulou, Marika; Malito, Enrico; Shen, Yuequan; Zhao, Ji; Neant-Fery, Marie; Sun, Ching-Yu; Meredith, Stephen C.; Sisodia, Sangram S.; Leissring, Malcolm A.; Tang, Wei-Jen			Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; GAMMA-SECRETASE COMPLEX; ALZHEIMERS-DISEASE; MOLECULAR-GRAPHICS; CELL-CULTURES; DEGRADATION; GENE; INSULYSIN; PEPTIDE; SUSCEPTIBILITY	Insulin-degrading enzyme ( IDE) is a zinc metalloprotease that hydrolyzes amyloid-beta ( A beta) and insulin, which are peptides associated with Alzheimer disease ( AD) and diabetes, respectively. Our previous structural analysis of substrate-bound human 113-kDa IDE reveals that the N- and C-terminal domains of IDE, IDE-N and IDE-C, make substantial contact to form an enclosed catalytic chamber to entrap its substrates. Furthermore, IDE undergoes a switch between the closed and open conformations for catalysis. Here we report a substrate-free IDE structure in its closed conformation, revealing the molecular details of the active conformation of the catalytic site of IDE and new insights as to how the closed conformation of IDE may be kept in its resting, inactive conformation. We also show that A beta is degraded more efficiently by IDE carrying destabilizing mutations at the interface of IDE-N and IDE-C ( D426C and K899C), resulting in an increase in V-max with only minimal changes to K-m. Because ATP is known to activate the ability of IDE to degrade short peptides, we investigated the interaction between ATP and activating mutations. We found that these mutations rendered IDE less sensitive to ATP activation, suggesting that ATP might facilitate the transition from the closed state to the open conformation. Consistent with this notion, we found that ATP induced an increase in hydrodynamic radius, a shift in electrophoretic mobility, and changes in secondary structure. Together, our results highlight the importance of the closed conformation for regulating the activity of IDE and provide new molecular details that will facilitate the development of activators and inhibitors of IDE.	Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; Scripps Res Inst, Dept Biochem, Jupiter, FL 33458 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA	University of Chicago; Scripps Research Institute; University of Chicago; University of Chicago	Tang, WJ (corresponding author), Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.	wtang@uchicago.edu	LEISSRING, MALCOLM/AAW-5361-2021	LEISSRING, MALCOLM/0000-0001-7185-4255; Tang, Wei-Jen/0000-0002-8267-8995	NIGMS NIH HHS [GM81539, R01 GM081539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bennett RG, 2003, DIABETES, V52, P2315, DOI 10.2337/diabetes.52.9.2315; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; BONDY CA, 1994, J CLIN INVEST, V93, P966, DOI 10.1172/JCI117103; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camberos MD, 2007, EXP BIOL MED, V232, P281; Camberos MC, 2001, EXP BIOL MED, V226, P334, DOI 10.1177/153537020122600411; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Falkevall A, 2006, J BIOL CHEM, V281, P29096, DOI 10.1074/jbc.M602532200; Farris W, 2005, BIOCHEMISTRY-US, V44, P6513, DOI 10.1021/bi0476578; Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4; Florez JC, 2006, DIABETES, V55, P128, DOI 10.2337/diabetes.55.1.128; Groves CJ, 2003, DIABETES, V52, P1300, DOI 10.2337/diabetes.52.5.1300; Gu HF, 2004, DIABETES, V53, P2137, DOI 10.2337/diabetes.53.8.2137; Hamel FG, 2003, ENDOCRINOLOGY, V144, P2404, DOI 10.1210/en.2002-0007; Hersh LB, 2006, CELL MOL LIFE SCI, V63, P2432, DOI 10.1007/s00018-006-6238-9; Johnson KA, 2006, EMBO J, V25, P1977, DOI 10.1038/sj.emboj.7601080; Karamohamed S, 2003, DIABETES, V52, P1562, DOI 10.2337/diabetes.52.6.1562; Kim M, 2007, J BIOL CHEM, V282, P7825, DOI 10.1074/jbc.M609168200; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; Leissring MA, 2006, NATURE, V443, P761, DOI 10.1038/nature05210; Li P, 2006, BIOCHEM BIOPH RES CO, V343, P1032, DOI 10.1016/j.bbrc.2006.03.083; Lynch JA, 2006, J NEUROSCI RES, V83, P1262, DOI 10.1002/jnr.20809; MASKOS K, 2004, HDB METALLOPROTEINS, V3, P190; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; MIRSKY A, 1949, ARCH BIOCHEM, V20, P1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OGAWA W, 1992, J BIOL CHEM, V267, P1310; OTWINOWSKI Z, 1994, ACTA CRYSTALLOGR D, V50, P760; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Qiu WQ, 2006, NEUROBIOL AGING, V27, P190, DOI 10.1016/j.neurobiolaging.2005.01.004; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Saric T, 2003, MOL CELL ENDOCRINOL, V204, P11, DOI 10.1016/S0303-7207(03)00154-0; Sciarretta KL, 2005, BIOCHEMISTRY-US, V44, P6003, DOI 10.1021/bi0474867; Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143; Shinall H, 2005, BIOCHEMISTRY-US, V44, P15345, DOI 10.1021/bi050650l; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Song ES, 2004, J BIOL CHEM, V279, P54216, DOI 10.1074/jbc.M411177200; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200; Song ES, 2005, J BIOL CHEM, V280, P17701, DOI 10.1074/jbc.M501896200; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; Yao HB, 2006, ARCH BIOCHEM BIOPHYS, V451, P175, DOI 10.1016/j.abb.2006.04.011	52	103	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25453	25463		10.1074/jbc.M701590200	http://dx.doi.org/10.1074/jbc.M701590200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17613531	hybrid			2022-12-25	WOS:000249014100031
J	Holland, AJ; Bottger, F; Stemmann, O; Taylor, SS				Holland, Andrew J.; Boettger, Franziska; Stemmann, Olaf; Taylor, Stephen S.			Protein phosphatase 2A and separase form a complex regulated by separase autocleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; SPINDLE CHECKPOINT; KINETOCHORE LOCALIZATION; ANAPHASE INITIATION; MITOTIC CHECKPOINT; CYCLE PROGRESSION; FISSION YEAST; BUDDING YEAST; AUTO-CLEAVAGE	The onset of anaphase is triggered by the activation of a site-specific protease called separase. Separase cleaves the chromosomal cohesins holding the duplicated sister chromatids together, allowing sisters to simultaneously separate and segregate to opposite ends of the cell before division. Activated separase cleaves not only cohesin, but also itself; however, the biological significance of separase self-cleavage has remained elusive. Before anaphase, separase is inhibited by at least two mechanisms. The first involves the binding of securin, whereas the second requires the phosphorylation-dependent binding of cyclin-dependent kinase 1 (Cdk1)/cyclin B1. Because securin and Cdk1/cyclin B1 interact with separase in a mutually exclusive manner, the degradation of both these inhibitors plays an important role in activating separase at anaphase. Here we identify a new separase interacting partner, a specific subtype of the heterotrimeric protein phosphatase 2A (PP2A). PP2A associates with separase through the B' (B56) regulatory subunit and does so independently of securin and cyclin B1 binding. The association of PP2A with separase requires a 55-amino acid domain closely juxtaposed to separase autocleavage sites. Strikingly, mutation of these cleavage sites increases PP2A binding, suggesting that separase cleavage disrupts the interaction of PP2A with separase. Furthermore, expression of a non-cleavable separase, but not a non-cleavable mutant that cannot bind PP2A, causes a premature loss of centromeric cohesion. Together these observations provide a new mechanistic insight into a physiological function for separase self-cleavage.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	University of Manchester; Max Planck Society	Taylor, SS (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	stephen.taylor@manchester.ac.uk	Taylor, Stephen/GZL-6499-2022	Stemmann, Olaf/0000-0003-3044-2515; Taylor, Stephen/0000-0003-4621-9326				Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Gil-Bernabe AM, 2006, MOL CELL BIOL, V26, P4017, DOI 10.1128/MCB.01904-05; Gorr IH, 2005, MOL CELL, V19, P135, DOI 10.1016/j.molcel.2005.05.022; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Holland AJ, 2006, J CELL SCI, V119, P3325, DOI 10.1242/jcs.03083; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Huang XX, 2005, MOL BIOL CELL, V16, P4725, DOI 10.1091/mbc.E05-03-0190; Jager H, 2004, CELL CYCLE, V3, P182; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kumada K, 2006, J CELL BIOL, V172, P835, DOI 10.1083/jcb.200511126; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Mei JJ, 2001, CURR BIOL, V11, P1197, DOI 10.1016/S0960-9822(01)00325-6; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Papi M, 2005, NAT CELL BIOL, V7, P1029, DOI 10.1038/ncb1303; Pfleghaar K, 2005, PLOS BIOL, V3, P2127, DOI 10.1371/journal.pbio.0030416; Queralt E, 2006, CELL, V125, P719, DOI 10.1016/j.cell.2006.03.038; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2001, J CELL SCI, V114, P4385; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; Toyoda Y, 2006, MOL BIOL CELL, V17, P2287, DOI 10.1091/mbc.E05-11-1089; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Viadiu H, 2005, NAT STRUCT MOL BIOL, V12, P552, DOI 10.1038/nsmb935; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Wirth KG, 2006, J CELL BIOL, V172, P847, DOI 10.1083/jcb.200506119; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zou H, 2002, FEBS LETT, V528, P246, DOI 10.1016/S0014-5793(02)03238-6; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	41	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24623	24632		10.1074/jbc.M702545200	http://dx.doi.org/10.1074/jbc.M702545200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604273	hybrid			2022-12-25	WOS:000248933000017
J	Wang, W; Di, XM; D'Agostino, RB; Torti, SV; Torti, FM				Wang, Wei; Di, Xiumin; D'Agostino, Ralph B., Jr.; Torti, Suzy V.; Torti, Frank M.			Excess capacity of the iron regulatory protein system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RESPONSIVE ELEMENT; NITRIC-OXIDE; TRANSLATIONAL REGULATION; RNA-BINDING; DEPENDENT REGULATION; UNTRANSLATED REGION; TARGETED DELETION; NITROGEN MONOXIDE; MOLECULAR CONTROL	Iron regulatory proteins (IRP1 and IRP2) are master regulators of cellular iron metabolism. IRPs bind to iron-responsive elements (IREs) present in the untranslated regions of mRNAs encoding proteins of iron storage, uptake, transport, and export. Because simultaneous knockout of IRP1 and IRP2 is embryonically lethal, it has not been possible to use dual knockouts to explore the consequences of loss of both IRP1 and IRP2 in mammalian cells. In this report, we describe the use of small interfering RNA to assess the relative contributions of IRP1 and IRP2 in epithelial cells. Stable cell lines were created in which either IRP1, IRP2, or both were knocked down. Knockdown of IRP1 decreased IRE binding activity but did not affect ferritin H and transferrin receptor 1 (TfR1) expression, whereas knockdown of IRP2 marginally affected IRE binding activity but caused an increase in ferritin H and a decrease in TfR1. Knockdown of both IRPs resulted in a greater reduction of IRE binding activity and more severe perturbation of ferritin H and TfR1 expression compared with single IRP knockdown. Even though the knockdown of IRP-1, IRP-2, or both was efficient, resulting in nondetectable protein and under 5% of wild type levels of mRNA, all stable knockdowns retained an ability to modulate ferritin H and TfR1 appropriately in response to iron challenge. However, further knockdown of IRPs accomplished by transient transfection of small interfering RNA in stable knockdown cells completely abolished the response of ferritin H and TfR1 to iron challenge, demonstrating an extensive excess capacity of the IRP system.	Wake Forest Univ Hlth Sci, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Torti, SV (corresponding author), Wake Forest Univ Hlth Sci, Dept Biochem, Winston Salem, NC 27157 USA.	storti@wfubmc.edu	Dagostino, Ralph/C-4060-2017	Dagostino, Ralph/0000-0002-3550-8395	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042412] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK42412] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; Brown NM, 1998, P NATL ACAD SCI USA, V95, P15235, DOI 10.1073/pnas.95.26.15235; Caltagirone A, 2001, J BIOL CHEM, V276, P19738, DOI 10.1074/jbc.M100245200; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Clarke SL, 2006, EMBO J, V25, P544, DOI 10.1038/sj.emboj.7600954; Cooperman SS, 2005, BLOOD, V106, P1084, DOI 10.1182/blood-2004-12-4703; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Cozzi A, 2004, BLOOD, V103, P2377, DOI 10.1182/blood-2003-06-1842; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Fillebeen C, 2003, MOL CELL BIOL, V23, P6973, DOI 10.1128/MCB.23.19.6973-6981.2003; Galy B, 2005, BLOOD, V106, P2580, DOI 10.1182/blood-2005-04-1365; Galy B, 2006, NAT GENET, V38, P967, DOI 10.1038/ng0906-967; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Imanishi D, 2000, J IMMUNOL, V165, P3907, DOI 10.4049/jimmunol.165.7.3907; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; Kim SW, 2002, P NATL ACAD SCI USA, V99, P12214, DOI 10.1073/pnas.192316099; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Lin E, 2001, J BIOL CHEM, V276, P27685, DOI 10.1074/jbc.M100941200; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Meyron-Holtz EG, 2004, SCIENCE, V306, P2087, DOI 10.1126/science.1103786; Meyron-Holtz EG, 2004, EMBO J, V23, P386, DOI 10.1038/sj.emboj.7600041; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; Phillips JD, 1996, BLOOD, V87, P2983, DOI 10.1182/blood.V87.7.2983.bloodjournal8772983; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Popovic Z, 2005, MOL CELL BIOCHEM, V268, P67, DOI 10.1007/s11010-005-3167-0; RICHARDSON DR, 1995, BLOOD, V86, P3211; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; Roy CN, 2002, J CELL PHYSIOL, V190, P218, DOI 10.1002/JCP.10056; Smith SR, 2004, ANN NY ACAD SCI, V1012, P65, DOI 10.1196/annals.1306.006; Soum E, 2003, BIOCHEMISTRY-US, V42, P7648, DOI 10.1021/bi030041i; Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467; Wang J, 2004, MOL CELL BIOL, V24, P954, DOI 10.1128/MCB.24.3.954-965.2004; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	53	54	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24650	24659		10.1074/jbc.M703167200	http://dx.doi.org/10.1074/jbc.M703167200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604281	hybrid			2022-12-25	WOS:000248933000020
J	Yi, XP; Hargett, SR; Liu, HJ; Frankel, LK; Bricker, TM				Yi, Xiaoping; Hargett, Stefan R.; Liu, Haijun; Frankel, Laurie K.; Bricker, Terry M.			The PsbP protein is required for photosystem II complex assembly/stability and photoautotrophy in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN EVOLUTION; STRONG CONTINUOUS ILLUMINATION; MANGANESE-STABILIZING PROTEIN; KDA EXTRINSIC PROTEIN; CHLOROPHYLL FLUORESCENCE; EVOLVING COMPLEX; POLYPHASIC RISE; MUTANTS; KINETICS; BINDING	Interfering RNA was used to suppress the expression of the genes At1g06680 and At2g30790 in Arabidopsis thaliana, which encode the PsbP-1 and PsbP-2 proteins, respectively, of photosystem II (PS II). A phenotypic series of transgenic plants was recovered that expressed intermediate and low amounts of PsbP. Chlorophyll fluorescence induction and Q(A)(-) decay kinetics analyses were performed. Decreasing amounts of expressed PsbP protein led to the progressive loss of variable fluorescence and a marked decrease in the fluorescence quantum yield (F-V/F-M). This was primarily due to the loss of the J to I transition. Analysis of the fast fluorescence rise kinetics indicated no significant change in the number of PS II beta centers present in the mutants. Analysis of Q(A)(-) decay kinetics in the absence of 3-(3,4-dichlorophenyl)-1,1-dimethylurea indicated a defect in electron transfer from Q(A)(-) toQ(B), whereas experiments performed in the presence of this herbicide indicated that charge recombination between Q(A)(-) and the oxygen-evolving complex was seriously retarded in the plants that expressed low amounts of the PsbP protein. These results demonstrate that the amount of functional PS II reaction centers is compromised in the plants that exhibited intermediate and low amounts of the PsbP protein. Plants that lacked detectable PsbP were unable to survive in the absence of sucrose, indicating that the PsbP protein is required for photoautotrophy. Immunological analysis of the PS II protein complement indicated that significant losses of the CP47 and D2 proteins, and intermediate losses of the CP43 and D1 proteins, occurred in the absence of the PsbP protein. This demonstrates that the extrinsic protein PsbP is required for PS II core assembly/stability.	Louisiana State Univ, Dept Biol Sci Biochem & Mol Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Bricker, TM (corresponding author), Louisiana State Univ, Dept Biol Sci Biochem & Mol Biol, 206 Life Sci Bldg,Baton Rouge, Baton Rouge, LA 70803 USA.	btbric@lsu.edu		Liu, Haijun/0000-0003-0537-0302				Allahverdiyeva Y, 2004, EUR J BIOCHEM, V271, P3523, DOI 10.1111/j.0014-2956.2004.04287.x; ANDERSSON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P21, DOI 10.1016/0005-2728(84)90212-3; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Bricker TM, 2005, ADV PHOTO RESPIRAT, V22, P95; Bricker TM, 2003, BIOCHEMISTRY-US, V42, P2056, DOI 10.1021/bi020652v; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; Bricker TM, 1998, PHOTOSYNTH RES, V56, P157, DOI 10.1023/A:1006068615220; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6150, DOI 10.1021/bi00186a014; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P515, DOI 10.1016/0005-2728(84)90050-1; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; ETTINGER WF, 1991, J CELL BIOL, V115, P321, DOI 10.1083/jcb.115.2.321; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gould GM, 1906, J AMER MED ASSOC, V47, P734; HAILTON AJ, 1999, SCIENCE, V286, P950; Hashimoto A, 1996, FEBS LETT, V391, P29; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; Ifuku K, 2005, PLANT PHYSIOL, V139, P1175, DOI 10.1104/pp.105.068643; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; KAVELAKI K, 1991, PHOTOSYNTH RES, V29, P149, DOI 10.1007/BF00036218; Lavergne J, 1996, OXYGENIC PHOTOSYNTHE, P265; Liu HJ, 2007, BIOCHEMISTRY-US, V46, P7607, DOI 10.1021/bi700107w; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; MAYFIELD SP, 1989, PLANT MOL BIOL, V12, P683, DOI 10.1007/BF00044159; MAYFIELD SP, 1987, P NATL ACAD SCI USA, V84, P749, DOI 10.1073/pnas.84.3.749; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; MELIS A, 1976, PHOTOCHEM PHOTOBIOL, V23, P343, DOI 10.1111/j.1751-1097.1976.tb07259.x; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MURATA N, 1984, BIOCHIM BIOPHYS ACTA, V765, P363, DOI 10.1016/0005-2728(84)90177-4; Nedbal L, 1999, J PHOTOCH PHOTOBIO B, V48, P154, DOI 10.1016/S1011-1344(99)00032-9; Nelson N, 2006, ANNU REV PLANT BIOL, V57, P521, DOI 10.1146/annurev.arplant.57.032905.105350; NEUBAUER C, 1987, Z NATURFORSCH C, V42, P1246; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Reifarth F, 1997, BIOCHEMISTRY-US, V36, P11769, DOI 10.1021/bi9709654; ROBINSON HH, 1983, FEBS LETT, V153, P221, DOI 10.1016/0014-5793(83)80152-5; ROELOFS TA, 1992, BIOPHYS J, V61, P1147, DOI 10.1016/S0006-3495(92)81924-0; Rova EM, 1996, J BIOL CHEM, V271, P28918, DOI 10.1074/jbc.271.46.28918; SCHREIBER U, 1987, Z NATURFORSCH C, V42, P1255; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Strasser RJ, 1992, RES PHOTOSYNTHESIS, P29; Strasser RJ, 1991, REGULATION CHLOROPLA, P423; Summerfield TC, 2005, BIOCHEMISTRY-US, V44, P805, DOI 10.1021/bi048394k; THIELEN APGM, 1981, BIOCHIM BIOPHYS ACTA, V637, P439, DOI 10.1016/0005-2728(81)90049-9; Thornton LE, 2005, ADV PHOTO RESPIRAT, V22, P121; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982; Weiss W., 1984, ADV PHOTOSYNTHESIS R, P167; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; WOLLENBERGER L, 1994, BBA-BIOENERGETICS, V1184, P93, DOI 10.1016/0005-2728(94)90158-9; Yi XP, 2006, J BIOL CHEM, V281, P26260, DOI 10.1074/jbc.M603582200; Yi XP, 2005, J BIOL CHEM, V280, P16170, DOI 10.1074/jbc.M501550200	54	94	94	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24833	24841		10.1074/jbc.M705011200	http://dx.doi.org/10.1074/jbc.M705011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604269	hybrid, Green Published			2022-12-25	WOS:000248933000039
J	Faria, CA; Wackers, FL; Pritchard, J; Barrett, DA; Turlings, TCJ				Faria, Cristina A.; Waeckers, Felix L.; Pritchard, Jeremy; Barrett, David A.; Turlings, Ted C. J.			High Susceptibility of Bt Maize to Aphids Enhances the Performance of Parasitoids of Lepidopteran Pests	PLOS ONE			English	Article								Concerns about possible undesired environmental effects of transgenic crops have prompted numerous evaluations of such crops. So-called Bt crops receive particular attention because they carry bacteria-derived genes coding for insecticidal proteins that might negatively affect non-target arthropods. Here we show a remarkable positive effect of Bt maize on the performance of the corn leaf aphid Rhopalosiphum maidis, which in turn enhanced the performance of parasitic wasps that feed on aphid honeydew. Within five out of six pairs that were evaluated, transgenic maize lines were significantly more susceptible to aphids than their near-isogenic equivalents, with the remaining pair being equally susceptible. The aphids feed from the phloem sieve element content and analyses of this sap in selected maize lines revealed marginally, but significantly higher amino acid levels in Bt maize, which might partially explain the observed increased aphid performance. Larger colony densities of aphids on Bt plants resulted in an increased production of honeydew that can be used as food by beneficial insects. Indeed, Cotesia marginiventris, a parasitoid of lepidopteran pests, lived longer and parasitized more pest caterpillars in the presence of aphid-infested Bt maize than in the presence of aphid-infested isogenic maize. Hence, depending on aphid pest thresholds, the observed increased susceptibility of Bt maize to aphids may be either a welcome or an undesirable side effect.	[Faria, Cristina A.; Turlings, Ted C. J.] Univ Neuchatel, Inst Zool, CH-2007 Neuchatel, Switzerland; [Waeckers, Felix L.] Univ Lancaster, Lancaster Environm Ctr, Lancaster, England; [Pritchard, Jeremy] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England; [Barrett, David A.] Univ Nottingham, Sch Pharm, Ctr Analyt Biosci, Nottingham NG7 2RD, England	University of Neuchatel; Lancaster University; University of Birmingham; University of Nottingham	Turlings, TCJ (corresponding author), Univ Neuchatel, Inst Zool, CH-2007 Neuchatel, Switzerland.	ted.turlings@unine.ch	Barrett, David A/C-9922-2011; Turlings, Ted CJ/E-8671-2012	Barrett, David A/0000-0001-6900-9474; Turlings, Ted CJ/0000-0002-8315-785X	Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This study was funded by the Swiss National Centre of Competence in Research "Plant Survival'', research program of the Swiss National Science Foundation.	ADAMS JB, 1972, APHID TECHNOLOGY, P48; Ashouri A, 2001, ENVIRON ENTOMOL, V30, P524, DOI 10.1603/0046-225X-30.3.524; Awmack CS, 2002, ANNU REV ENTOMOL, V47, P817, DOI 10.1146/annurev.ento.47.091201.145300; Awmack CS, 2004, GLOBAL CHANGE BIOL, V10, P1414, DOI 10.1111/j.1365-2486.2004.00800.x; BENNETT RN, 1994, NEW PHYTOL, V127, P617, DOI 10.1111/j.1469-8137.1994.tb02968.x; Bernal CC, 2002, ENTOMOL EXP APPL, V102, P21, DOI 10.1023/A:1015278618586; Bourguet Denis, 2002, Environmental Biosafety Research, V1, P49, DOI 10.1051/ebr:2002005; Conner AJ, 2003, PLANT J, V33, P19, DOI 10.1046/j.0960-7412.2002.001607.x; DREYER DL, 1987, PLANT CELL ENVIRON, V10, P353; Dutton A, 2003, BIOCONTROL, V48, P611, DOI 10.1023/A:1026313719424; Dutton A, 2002, ECOL ENTOMOL, V27, P441, DOI 10.1046/j.1365-2311.2002.00436.x; England S, 1997, ENVIRON ENTOMOL, V26, P1437, DOI 10.1093/ee/26.6.1437; Evans EW, 2000, ENTOMOL EXP APPL, V94, P141, DOI 10.1023/A:1003914509181; FARIA CA, 2006, BASIC APPL ECOLOGY; FERGUSON JE, 1979, PLANT PHYSIOL, V63, P416, DOI 10.1104/pp.63.3.416; GIROUSSE C, 1994, ENTOMOL EXP APPL, V70, P227, DOI 10.1007/BF02380556; GIVOVICH A, 1994, J CHEM ECOL, V20, P1923, DOI 10.1007/BF02066233; Head G, 2001, ENTOMOL EXP APPL, V99, P37, DOI 10.1023/A:1018913429026; HOCKING H, 1966, J AUSTR ENTOMOLOGICA, V6, P83; HOFTE H, 1989, MICROBIOL REV, V53, P242; Jauset AM, 2000, ANN ENTOMOL SOC AM, V93, P1116, DOI 10.1603/0013-8746(2000)093[1116:KOAHPO]2.0.CO;2; Karley AJ, 2002, J EXP BIOL, V205, P3009; KAZEMI MH, 1992, ANN APPL BIOL, V121, P1, DOI 10.1111/j.1744-7348.1992.tb03981.x; Kok EJ, 2003, TRENDS BIOTECHNOL, V21, P439, DOI 10.1016/j.tibtech.2003.08.003; KRING TJ, 1986, CROP PROT, V5, P125, DOI 10.1016/0261-2194(86)90093-1; Krober T., 1991, Biocontrol News and Information, V12, P357; Lee JC, 2004, ENTOMOL EXP APPL, V111, P189, DOI 10.1111/j.0013-8703.2004.00165.x; LESZCZYNSKI B, 1995, ENTOMOL EXP APPL, V76, P157, DOI 10.1007/BF02383213; Lovei GL, 2005, ENTOMOL EXP APPL, V114, P1, DOI 10.1111/j.0013-8703.2005.00235.x; Lozzia G. C., 1998, Bollettino di Zoologia Agraria e di Bachicoltura, V30, P153; Lumbierres B, 2004, ECOL ENTOMOL, V29, P309, DOI 10.1111/j.0307-6946.2004.00597.x; MACINTOSH SC, 1990, J INVERTEBR PATHOL, V56, P258, DOI 10.1016/0022-2011(90)90109-J; MARKWELL TJ, 1993, NEW ZEAL J ECOL, V17, P85; MOLLER H, 1987, NEW ZEAL J ECOL, V10, P167; Nie CR, 2005, AUST J AGR RES, V56, P833, DOI 10.1071/AR04321; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; NIRAZ S, 1985, INSECT SCI APPL, V6, P253, DOI 10.1017/S1742758400004513; Pons X, 2005, EUR J ENTOMOL, V102, P73, DOI 10.14411/eje.2005.010; Raps A, 2001, MOL ECOL, V10, P525, DOI 10.1046/j.1365-294x.2001.01236.x; ROBERTS JJ, 1983, J ECON ENTOMOL, V76, P1320, DOI 10.1093/jee/76.6.1320; Romeis J, 2006, NAT BIOTECHNOL, V24, P63, DOI 10.1038/nbt1180; SANDSTROM J, 1994, J INSECT PHYSIOL, V40, P947, DOI 10.1016/0022-1910(94)90133-3; SHAW JR, 1984, PLANT PHYSIOL, V75, P207, DOI 10.1104/pp.75.1.207; Tosh CR, 2001, ENTOMOL EXP APPL, V99, P121, DOI 10.1023/A:1019267205797; UNWIN DM, 1978, PHYSIOL ENTOMOL, V3, P71, DOI 10.1111/j.1365-3032.1978.tb00135.x; VANDENWOLLENBERG AL, 1977, PSYCHOMETRIKA, V42, P207, DOI 10.1007/BF02294050; Wackers FL, 2000, OIKOS, V90, P197, DOI 10.1034/j.1600-0706.2000.900124.x; Wackers FL, 2001, J INSECT PHYSIOL, V47, P1077, DOI 10.1016/S0022-1910(01)00088-9; WEBSTER JA, 1994, J ECON ENTOMOL, V87, P231, DOI 10.1093/jee/87.1.231; WEIBULL J, 1987, ANN APPL BIOL, V111, P729, DOI 10.1111/j.1744-7348.1987.tb02031.x; Wilkinson TL, 2003, ENTOMOL EXP APPL, V106, P103, DOI 10.1046/j.1570-7458.2003.00014.x; Zhu XL, 2005, ELECTROPHORESIS, V26, P911, DOI 10.1002/elps.200410259	52	78	87	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e600	10.1371/journal.pone.0000600	http://dx.doi.org/10.1371/journal.pone.0000600			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622345	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452000007
J	Lutz, NW; Viola, A; Malikova, I; Confort-Gouny, S; Audoin, B; Ranjeva, JP; Pelletier, J; Cozzone, PJ				Lutz, Norbert W.; Viola, Angele; Malikova, Irina; Confort-Gouny, Sylviane; Audoin, Bertrand; Ranjeva, Jean-Philippe; Pelletier, Jean; Cozzone, Patrick J.			Inflammatory Multiple-Sclerosis Plaques Generate Characteristic Metabolic Profiles in Cerebrospinal Fluid	PLOS ONE			English	Article								Background. Multiple sclerosis (MS), an inflammatory disease of the central nervous system, manifests itself in numerous forms and stages. A number of brain metabolic alterations have been reported for MS patients vs. control subjects. However, metabolite profiles of cerebrospinal fluid (CSF) are not consistent among the published MS studies, most probably due to variations in the patient cohorts studied. We undertook the first investigation of highly homogeneous MS patient cohorts to determine characteristic effects of inflammatory MS plaques on the CSF metabolome, including only patients with clinically isolated syndrome (CIS) with or without inflammatory brain plaques, and controls. Methodology/Principal Findings. CSF obtained by lumbar puncture was analyzed by proton magnetic resonance spectroscopy. 27 metabolites were quantified. Differences between groups of control subjects (n = 10), CIS patients with (n = 21) and without (n = 12) inflammatory plaques were evaluated by univariate statistics and principal component analysis (PCA). Seven metabolites showed statistically significant inter-group differences (p < 0.05). Interestingly, a significant increase in beta-hydroxyisobutyrate (BHIB) was detected in CIS with vs. without active plaques, but not when comparing either CIS group with control subjects. Moreover, a significant correlation was found, for the first time, between CSF lactate concentration and the number of inflammatory MS brain plaques. In contrast, fructose concentrations were equally enhanced in CIS with or without active plaques. PCA based on all 27 metabolites yielded group-specific clusters. Conclusions/Significance. CSF metabolic profiles suggest a close link between MS plaque activity in CIS patients on the one hand and organic-acid metabolism on the other. Our detection of increased BHIB levels points to a hitherto unsuspected role for this compound in MS with active plaques, and serves as a basis for further investigation. The metabolic effects described in our study are crucial elements in the explanation of biochemical mechanisms involved in specific MS manifestations.	[Lutz, Norbert W.; Viola, Angele; Malikova, Irina; Confort-Gouny, Sylviane; Audoin, Bertrand; Ranjeva, Jean-Philippe; Pelletier, Jean; Cozzone, Patrick J.] Univ Aix Marseille 2, CNRS, UMR 6612, Ctr Resonance Magnet Biol & Med,Fac Med Timone, Marseille, France; [Malikova, Irina; Audoin, Bertrand; Pelletier, Jean] Hop Enfants La Timone, Serv Neurol, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lutz, NW (corresponding author), Univ Aix Marseille 2, CNRS, UMR 6612, Ctr Resonance Magnet Biol & Med,Fac Med Timone, Marseille, France.	Norbert.Lutz@medecine.univ-mrs.fr		Ranjeva, Jean-Philippe/0000-0001-8073-102X	ARSEP; Serono France; CNRS [CNRS 6612]	ARSEP; Serono France; CNRS(Centre National de la Recherche Scientifique (CNRS))	Financial support from ARSEP (2005 award), Serono France and CNRS (UMR CNRS 6612) is gratefully acknowledged.	Aasly J, 1997, ACTA NEUROL SCAND, V95, P9, DOI 10.1111/j.1600-0404.1997.tb00060.x; Bernard-Helary K, 2002, GLIA, V37, P379, DOI 10.1002/glia.10046; Bruck W, 2005, CURR OPIN NEUROL, V18, P221; Caudie C, 2000, ANN BIOL CLIN-PARIS, V58, P376; Desplat S, 2000, REV NEUROL-FRANCE, V156, P885; Filippi M, 2001, J NEUROL, V248, P1019, DOI 10.1007/s004150170020; Fishman R. A, 1993, CEREBROSPINAL FLUID; FUJISHIMA M, 1984, J NEUROL, V231, P71, DOI 10.1007/BF00313719; Ghosh A, 2005, J BIOL CHEM, V280, P11114, DOI 10.1074/jbc.M410894200; HOFFMANN GF, 1995, J INHERIT METAB DIS, V18, P189, DOI 10.1007/BF00711763; Kirschenlohr HL, 2006, NAT MED, V12, P705, DOI 10.1038/nm1432; KOSCHOREK F, 1993, NEUROSURG REV, V16, P307, DOI 10.1007/BF00383842; Lassmann H, 2003, J NEUROL SCI, V206, P187, DOI 10.1016/S0022-510X(02)00421-5; LEE SHC, 1986, BIOCHEM J, V233, P621, DOI 10.1042/bj2330621; LETTO J, 1986, BIOCHEM J, V240, P909, DOI 10.1042/bj2400909; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Loder C, 2002, MED HYPOTHESES, V59, P594, DOI 10.1016/S0306-9877(02)00261-X; LOPEZVILLEGAS D, 1995, MAGNET RESON MED, V34, P32, DOI 10.1002/mrm.1910340107; Lutz NW, 2007, BIOCHEM BIOPH RES CO, V354, P160, DOI 10.1016/j.bbrc.2006.12.169; Lutz NW, 1998, FEBS LETT, V425, P345, DOI 10.1016/S0014-5793(98)00262-2; Maillet S, 1998, BRAIN RES PROTOC, V3, P123, DOI 10.1016/S1385-299X(98)00033-6; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McEwen BS, 2004, EUR J PHARMACOL, V490, P13, DOI 10.1016/j.ejphar.2004.02.041; Nicoli F, 1996, CR ACAD SCI III-VIE, V319, P623; POSNER JB, 1967, ARCH NEUROL-CHICAGO, V16, P492, DOI 10.1001/archneur.1967.00470230044005; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; SHARMA R, 2000, INT SOC MAGN RES MED, P623; SIMON J, 1999, GIT SPEZIAL SEPARATI, V1, P20; Simone IL, 1996, J NEUROL SCI, V144, P182, DOI 10.1016/S0022-510X(96)00224-9; Sokal RR, 1995, BIOMETRY; Srinivasan R, 2005, BRAIN, V128, P1016, DOI 10.1093/brain/awh467; Viola A, 2002, AM J NEURORADIOL, V23, P480; Weljie AM, 2006, ANAL CHEM, V78, P4430, DOI 10.1021/ac060209g; Wray H L, 1966, Diabetologia, V2, P82, DOI 10.1007/BF00423014; Wuerfel J, 2004, BRAIN, V127, P111, DOI 10.1093/brain/awh007; ZUPPING R, 1971, ARCH NEUROL-CHICAGO, V25, P33, DOI 10.1001/archneur.1971.00490010043006	36	72	74	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e595	10.1371/journal.pone.0000595	http://dx.doi.org/10.1371/journal.pone.0000595			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611627	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451900012
J	McBride, SM; Fischetti, VA; LeBlanc, DJ; Moellering, RC; Gilmore, MS				McBride, Shonna M.; Fischetti, Vincent A.; LeBlanc, Donald J.; Moellering, Robert C., Jr.; Gilmore, Michael S.			Genetic Diversity among Enterococcus faecalis	PLOS ONE			English	Article							VANCOMYCIN-RESISTANT ENTEROCOCCI; HIGH-LEVEL RESISTANCE; LACTAMASE-PRODUCING ENTEROCOCCI; PLASMIDS DETERMINING HEMOLYSIN; GRAM-POSITIVE BACTERIA; BILE-SALT HYDROLASE; STREPTOCOCCUS-FAECALIS; BETA-LACTAMASE; ANTIBIOTIC-RESISTANCE; GLYCOPEPTIDE-RESISTANCE	Enterococcus faecalis, a ubiquitous member of mammalian gastrointestinal flora, is a leading cause of nosocomial infections and a growing public health concern. The enterococci responsible for these infections are often resistant to multiple antibiotics and have become notorious for their ability to acquire and disseminate antibiotic resistances. In the current study, we examined genetic relationships among 106 strains of E. faecalis isolated over the past 100 years, including strains identified for their diversity and used historically for serotyping, strains that have been adapted for laboratory use, and isolates from previously described E. faecalis infection outbreaks. This collection also includes isolates first characterized as having novel plasmids, virulence traits, antibiotic resistances, and pathogenicity island (PAI) components. We evaluated variation in factors contributing to pathogenicity, including toxin production, antibiotic resistance, polymorphism in the capsule (cps) operon, pathogenicity island (PAI) gene content, and other accessory factors. This information was correlated with multi-locus sequence typing (MLST) data, which was used to define genetic lineages. Our findings show that virulence and antibiotic resistance traits can be found within many diverse lineages of E. faecalis. However, lineages have emerged that have caused infection outbreaks globally, in which several new antibiotic resistances have entered the species, and in which virulence traits have converged. Comparing genomic hybridization profiles, using a microarray, of strains identified by MLST as spanning the diversity of the species, allowed us to identify the core E. faecalis genome as consisting of an estimated 2057 unique genes.	[McBride, Shonna M.; Gilmore, Michael S.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02115 USA; [Fischetti, Vincent A.] Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA; [LeBlanc, Donald J.] Pfizer Inc, Global Res & Dev, Antibacterial Mol Sci, Ann Arbor, MI USA; [Moellering, Robert C., Jr.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Rockefeller University; Pfizer; Harvard University; Beth Israel Deaconess Medical Center	Gilmore, MS (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02115 USA.	michael.gilmore@schepens.harvard.edu	McBride, Shonna/H-6174-2013	McBride, Shonna/0000-0001-6221-714X				Aanensen DM, 2005, NUCLEIC ACIDS RES, V33, pW728, DOI 10.1093/nar/gki415; ACKERMANN HW, 1975, CAN J MICROBIOL, V21, P571, DOI 10.1139/m75-080; Anfinsen C.B., 1971, ENZYMES, V4; ARENDT EK, 1994, APPL ENVIRON MICROB, V60, P1875, DOI 10.1128/AEM.60.6.1875-1883.1994; Arthur M, 1996, J INFECTION, V32, P11, DOI 10.1016/S0163-4453(96)80003-X; Avery OT, 1919, J EXP MED, V29, P215, DOI 10.1084/jem.29.2.215; BANAI M, 1983, J BACTERIOL, V155, P1094, DOI 10.1128/JB.155.3.1094-1104.1983; Begley M, 2005, INFECT IMMUN, V73, P894, DOI 10.1128/IAI.73.2.894-904.2005; Begley M, 2005, FEMS MICROBIOL REV, V29, P625, DOI 10.1016/j.femsre.2004.09.003; Bentley SD, 2006, PLOS GENET, V2, P262, DOI 10.1371/journal.pgen.0020031; BENVENISTE R, 1973, ANNU REV BIOCHEM, V42, P471, DOI 10.1146/annurev.bi.42.070173.002351; Birkeauc KE, 1927, P SOC EXP BIOL MED, V24, P541; Birkhaug KE, 1927, J INFECT DIS, V40, P549, DOI 10.1093/infdis/40.5.549; BLEIWEIS AS, 1964, J BACTERIOL, V88, P653, DOI 10.1128/JB.88.3.653-659.1964; Booth MC, 2001, INFECT IMMUN, V69, P345, DOI 10.1128/IAI.69.1.345-352.2001; BRIDGE PD, 1982, INT J SYST BACTERIOL, V32, P410, DOI 10.1099/00207713-32-4-410; BROCK TD, 1963, J BACTERIOL, V86, P708, DOI 10.1128/JB.86.4.708-712.1963; BROCK TD, 1963, J BACTERIOL, V86, P702, DOI 10.1128/JB.86.4.702-707.1963; CHOW JW, 1993, ANTIMICROB AGENTS CH, V37, P2474, DOI 10.1128/AAC.37.11.2474; CLEWELL DB, 1974, J BACTERIOL, V117, P283, DOI 10.1128/JB.117.1.283-289.1974; CLEWELL DB, 1982, J BACTERIOL, V152, P1220; Coburn PS, 2003, CELL MICROBIOL, V5, P661, DOI 10.1046/j.1462-5822.2003.00310.x; COBURN PS, 2006, MOL MICROBIOL   1205; COLLINS MD, 1984, INT J SYST BACTERIOL, V34, P220, DOI 10.1099/00207713-34-2-220; DASHKEVICZ MP, 1989, APPL ENVIRON MICROB, V55, P11, DOI 10.1128/AEM.55.1.11-16.1989; DUNNY GM, 1975, J BACTERIOL, V124, P784, DOI 10.1128/JB.124.2.784-790.1975; DUNNY GM, 1978, P NATL ACAD SCI USA, V75, P3479, DOI 10.1073/pnas.75.7.3479; DUNNY GM, 1979, PLASMID, V2, P454, DOI 10.1016/0147-619X(79)90029-5; Dussurget O, 2002, MOL MICROBIOL, V45, P1095, DOI 10.1046/j.1365-2958.2002.03080.x; DUTKAMALEN S, 1995, J CLIN MICROBIOL, V33, P1434, DOI 10.1128/JCM.33.5.1434-1434.1995; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; DUTKAMALEN S, 1990, ANTIMICROB AGENTS CH, V34, P1875, DOI 10.1128/AAC.34.10.1875; Engelbert M, 2004, INFECT IMMUN, V72, P3628, DOI 10.1128/IAI.72.6.3628-3633.2004; EVANS AC, 1947, J BACTERIOL, V54, P495, DOI 10.1128/JB.54.4.495-512.1947; EVERS S, 1993, GENE, V124, P143, DOI 10.1016/0378-1119(93)90779-3; FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P731, DOI 10.1128/JCM.27.4.731-734.1989; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; FINLAND M, 1950, AM J CLIN PATHOL, V20, P208; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; FLETCHER C, 1984, BRIT MED J, V289, P1721, DOI 10.1136/bmj.289.6460.1721; FONTANA R, 1992, CLIN INFECT DIS, V15, P486, DOI 10.1093/clind/15.3.486; Francia MV, 2002, J BACTERIOL, V184, P5187, DOI 10.1128/JB.184.18.5187-5193.2002; GARDNER P, 1969, LANCET, V2, P774; Giard JC, 2002, FEMS MICROBIOL LETT, V206, P235, DOI 10.1111/j.1574-6968.2002.tb11015.x; Giard JC, 2000, J BACTERIOL, V182, P4512, DOI 10.1128/JB.182.16.4512-4520.2000; GILMORE MS, 1994, J BACTERIOL, V176, P7335, DOI 10.1128/JB.176.23.7335-7344.1994; GOLD OG, 1975, ARCH ORAL BIOL, V20, P473, DOI 10.1016/0003-9969(75)90236-8; Hancock L, 2002, J BACTERIOL, V184, P5819, DOI 10.1128/JB.184.21.5819-5825.2002; Hancock L. E., 2006, Gram-positive pathogens, P299; Hancock LE, 2003, J BACTERIOL, V185, P4393, DOI 10.1128/JB.185.15.4393-4401.2003; Hancock LE, 2002, P NATL ACAD SCI USA, V99, P1574, DOI 10.1073/pnas.032448299; Hancock LE, 2004, J BACTERIOL, V186, P5629, DOI 10.1128/JB.186.17.5629-5639.2004; HANCOCK LE, 2001, IDENTIFICATION CHARA; Harrington SM, 2004, J CLIN MICROBIOL, V42, P5895, DOI 10.1128/JCM.42.12.5895-5898.2004; Huebner J, 1999, INFECT IMMUN, V67, P1213, DOI 10.1128/IAI.67.3.1213-1219.1999; Hufnagel M, 2005, CLIN DIAGN LAB IMMUN, V12, P930, DOI 10.1128/CDLI.12.8.930-934.2005; Hufnagel M, 2004, J CLIN MICROBIOL, V42, P2548, DOI 10.1128/JCM.42.6.2548-2557.2004; HUYCKE MM, 1991, ANTIMICROB AGENTS CH, V35, P1626, DOI 10.1128/AAC.35.8.1626; Hwang MSH, 2005, APPL ENVIRON MICROB, V71, P5182, DOI 10.1128/AEM.71.9.5182-5191.2005; IKE Y, 1992, J BACTERIOL, V174, P8172, DOI 10.1128/JB.174.24.8172-8177.1992; IKE Y, 1984, J BACTERIOL, V158, P777, DOI 10.1128/JB.158.3.777-783.1984; JACOB AE, 1974, J BACTERIOL, V117, P360, DOI 10.1128/JB.117.2.360-372.1974; JACOB AE, 1975, J BACTERIOL, V121, P863, DOI 10.1128/JB.121.3.863-872.1975; Jefferies JMC, 2004, J CLIN MICROBIOL, V42, P5681, DOI 10.1128/JCM.42.12.5681-5688.2004; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; Johnston JW, 2004, INFECT IMMUN, V72, P5858, DOI 10.1128/IAI.72.10.5858-5867.2004; Kayaoglu G, 2004, CRIT REV ORAL BIOL M, V15, P308, DOI 10.1177/154411130401500506; KORNBERG HA, 1948, ANAL CHEM, V20, P81, DOI 10.1021/ac60013a022; Kozlowicz BK, 2006, INT J MED MICROBIOL, V296, P141, DOI 10.1016/j.ijmm.2006.01.040; LEBLANC DJ, 1983, INFECT IMMUN, V40, P1015, DOI 10.1128/IAI.40.3.1015-1022.1983; LEBLANC DJ, 1982, J BACTERIOL, V150, P835, DOI 10.1128/JB.150.2.835-843.1982; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; Luan SL, 2005, J CLIN MICROBIOL, V43, P3727, DOI 10.1128/JCM.43.8.3727-3733.2005; Lucchini S, 1999, J VIROL, V73, P8647, DOI 10.1128/JVI.73.10.8647-8656.1999; LUGINBUHL LM, 1987, PEDIATR INFECT DIS J, V6, P1022, DOI 10.1097/00006454-198706110-00003; MACCALLUM WG, 1899, J EXP MED, V4, P421; Macovei L, 2006, APPL ENVIRON MICROB, V72, P4028, DOI 10.1128/AEM.00034-06; Maekawa S, 1996, Kansenshogaku Zasshi, V70, P168; MAEKAWA S, 1992, MICROBIOL IMMUNOL, V36, P671, DOI 10.1111/j.1348-0421.1992.tb02070.x; MAKI DG, 1988, MEDICINE, V67, P248, DOI 10.1097/00005792-198807000-00005; Manson JM, 2003, J CLIN MICROBIOL, V41, P3331, DOI 10.1128/JCM.41.7.3331-3333.2003; Manson JM, 2003, ANTIMICROB AGENTS CH, V47, P204, DOI 10.1128/AAC.47.1.204-210.2003; Mathur S, 2005, INT J FOOD MICROBIOL, V105, P281, DOI 10.1016/j.ijfoodmicro.2005.03.008; MCDONALD JS, 1975, P AM ASS VET LAB DIA, V18, P251; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; Melles DC, 2004, J CLIN INVEST, V114, P1732, DOI 10.1172/JCI200423083; MIELE A, 1995, ANTIMICROB AGENTS CH, V39, P1772, DOI 10.1128/AAC.39.8.1772; MOELLERI.RC, 1971, J CLIN INVEST, V50, P2580, DOI 10.1172/JCI106758; Moellering R C Jr, 1970, Antimicrob Agents Chemother (Bethesda), V10, P335; MOELLERING RC, 1979, J INFECT DIS, V140, P203, DOI 10.1093/infdis/140.2.203; MOELLERING RC, 1971, J LAB CLIN MED, V77, P821; Moellering RC, 2006, CLIN INFECT DIS, V42, pS3, DOI 10.1086/491708; MOELLERING RC, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90088-8; MOELLERING RC, 1992, CLIN INFECT DIS, V14, P1173, DOI 10.1093/clinids/14.6.1173; Mundy LM, 2000, CLIN MICROBIOL REV, V13, P513, DOI 10.1128/CMR.13.4.513-522.2000; MURRAY BE, 1991, J INFECT DIS, V163, P780, DOI 10.1093/infdis/163.4.780; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Mylonakis E, 2002, INFECT IMMUN, V70, P4678, DOI 10.1128/IAI.70.8.4678-4681.2002; Nallapareddy SR, 2005, J BACTERIOL, V187, P5709, DOI 10.1128/JB.187.16.5709-5718.2005; Nallapareddy SR, 2002, J CLIN MICROBIOL, V40, P868, DOI 10.1128/JCM.40.3.868-876.2002; Oh TG, 1998, J BACTERIOL, V180, P5788, DOI 10.1128/JB.180.21.5788-5791.1998; OLIVER DR, 1977, J BACTERIOL, V130, P948, DOI 10.1128/JB.130.2.948-950.1977; Oprea SF, 2004, J ANTIMICROB CHEMOTH, V53, P626, DOI 10.1093/jac/dkh138; PATTERSON JE, 1988, ANTIMICROB AGENTS CH, V32, P122, DOI 10.1128/AAC.32.1.122; PATTERSON JE, 1988, J INFECT DIS, V158, P212, DOI 10.1093/infdis/158.1.212; PATTERSON JE, 1990, ANTIMICROB AGENTS CH, V34, P302, DOI 10.1128/AAC.34.2.302; PATTERSON JE, 1989, ANTIMICROB AGENTS CH, V33, P251, DOI 10.1128/AAC.33.2.251; PATTERSON JE, 1988, J INFECT DIS, V158, P1144, DOI 10.1093/infdis/158.5.1144; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; Peacock SJ, 2002, INFECT IMMUN, V70, P4987, DOI 10.1128/IAI.70.9.4987-4996.2002; Perreten V, 1997, SYST APPL MICROBIOL, V20, P27, DOI 10.1078/072320204322970944; Peset V, 2000, EUR J CLIN MICROBIOL, V19, P742, DOI 10.1007/s100960000360; Qin X, 2000, INFECT IMMUN, V68, P2579, DOI 10.1128/IAI.68.5.2579-2586.2000; RICE LB, 1991, ANTIMICROB AGENTS CH, V35, P272, DOI 10.1128/AAC.35.2.272; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Rince A, 2003, INT J FOOD MICROBIOL, V88, P207, DOI 10.1016/S0168-1605(03)00182-X; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; ROBERTS IS, 1995, MICROBIOL-SGM, V141, P2023, DOI 10.1099/13500872-141-9-2023; Roberts MC, 2005, FEMS MICROBIOL LETT, V245, P195, DOI 10.1016/j.femsle.2005.02.034; Roberts MC, 1999, ANTIMICROB AGENTS CH, V43, P2823, DOI 10.1128/AAC.43.12.2823; ROSAN B, 1964, ARCH ORAL BIOL, V9, P291, DOI 10.1016/0003-9969(64)90061-5; Ruiz-Garbajosa P, 2006, J CLIN MICROBIOL, V44, P2220, DOI 10.1128/JCM.02596-05; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; SAMBROOKJOSEPH RW, 2001, MOL CLONING, P999; Schatz A, 1944, P SOC EXP BIOL MED, V55, P66, DOI 10.3181/00379727-55-14461; Schwarz FV, 2001, PLASMID, V46, P170, DOI 10.1006/plas.2001.1544; Schwarz S, 2004, FEMS MICROBIOL REV, V28, P519, DOI 10.1016/j.femsre.2004.04.001; Shankar N, 2002, NATURE, V417, P746, DOI 10.1038/nature00802; Shankar N, 2006, J CLIN MICROBIOL, V44, P4200, DOI 10.1128/JCM.01218-06; SHARPE ME, 1964, J GEN MICROBIOL, V36, P151, DOI 10.1099/00221287-36-1-151; SHARPE ME, 1952, J GEN MICROBIOL, V6, P150; SHATTOCK PMF, 1949, J GEN MICROBIOL, V3, P80, DOI 10.1099/00221287-3-1-80; Shattock PMF, 1943, J HYG-CAMBRIDGE, V43, P173, DOI 10.1017/S0022172400012791; Shepard BD, 2002, MICROBES INFECT, V4, P215, DOI 10.1016/S1286-4579(01)01530-1; Shepard BD, 2002, INFECT IMMUN, V70, P4344, DOI 10.1128/IAI.70.8.4344-4352.2002; Singh KV, 1998, J INFECT DIS, V178, P1416, DOI 10.1086/314453; SPEER BS, 1992, CLIN MICROBIOL REV, V5, P387, DOI 10.1128/CMR.5.4.387-399.1992; SU YA, 1991, INFECT IMMUN, V59, P415, DOI 10.1128/IAI.59.1.415-420.1991; THAL LA, 1993, ANTIMICROB AGENTS CH, V37, P134, DOI 10.1128/AAC.37.1.134; THAL LA, 1994, ANTIMICROB AGENTS CH, V38, P1152, DOI 10.1128/AAC.38.5.1152; TOALA P, 1969, AM J MED SCI, V258, P416, DOI 10.1097/00000441-196912000-00006; Todd EW, 1934, J PATHOL BACTERIOL, V39, P299, DOI 10.1002/path.1700390207; TOMICH PK, 1980, J BACTERIOL, V141, P1366, DOI 10.1128/JB.141.3.1366-1374.1980; TOMICH PK, 1979, ANTIMICROB AGENTS CH, V15, P828, DOI 10.1128/AAC.15.6.828; TRIEUCUOT P, 1983, GENE, V23, P331, DOI 10.1016/0378-1119(83)90022-7; TRIEUCUOT P, 1993, ANTIMICROB AGENTS CH, V37, P2593, DOI 10.1128/AAC.37.12.2593; UTTLEY AHC, 1988, LANCET, V1, P57; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173, DOI 10.1017/S0950268800030478; Waar K, 2002, J INFECT DIS, V185, P1121, DOI 10.1086/339682; WALKER JC, 1958, BIOGRAPHICAL MEMOIRS, P113; Weigel LM, 2003, SCIENCE, V302, P1569, DOI 10.1126/science.1090956; WHEELER SM, 1945, AM J DIS CHILD, V70, P207, DOI 10.1001/archpedi.1945.02020220008002; YAGI Y, 1983, J GEN MICROBIOL, V129, P1207; Yoshioka M, 1995, Kansenshogaku Zasshi, V69, P189; Yoshioka M, 1995, Kansenshogaku Zasshi, V69, P181; ZERVOS MJ, 1987, J CLIN MICROBIOL, V25, P2443, DOI 10.1128/JCM.25.12.2443-2444.1987; ZERVOS MJ, 1986, ANTIMICROB AGENTS CH, V30, P78, DOI 10.1128/AAC.30.1.78; ZSCHECK KK, 1991, ANTIMICROB AGENTS CH, V35, P1736, DOI 10.1128/AAC.35.9.1736	159	207	209	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e582	10.1371/journal.pone.0000582	http://dx.doi.org/10.1371/journal.pone.0000582			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611618	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451900002
J	Krishnan, A; Giuliani, A; Tomita, M				Krishnan, Arun; Giuliani, Alessandro; Tomita, Masaru			Indeterminacy of Reverse Engineering of Gene Regulatory Networks: The Curse of Gene Elasticity	PLOS ONE			English	Article							CELLULAR CONTROL PROCESSES; STEADY-STATES; FEEDBACK; CANALIZATION; MATHEMATICS; SIMULATION; EVOLUTION; SYSTEMS	Background. Gene Regulatory Networks (GRNs) have become a major focus of interest in recent years. A number of reverse engineering approaches have been developed to help uncover the regulatory networks giving rise to the observed gene expression profiles. However, this is an overspecified problem due to the fact that more than one genotype ( network wiring) can give rise to the same phenotype. We refer to this phenomenon as "gene elasticity.'' In this work, we study the effect of this particular problem on the pure, data-driven inference of gene regulatory networks. Methodology. We simulated a four-gene network in order to produce "data'' ( protein levels) that we use in lieu of real experimental data. We then optimized the network connections between the four genes with a view to obtain the original network that gave rise to the data. We did this for two different cases: one in which only the network connections were optimized and the other in which both the network connections as well as the kinetic parameters ( given as reaction probabilities in our case) were estimated. We observed that multiple genotypes gave rise to very similar protein levels. Statistical experimentation indicates that it is impossible to differentiate between the different networks on the basis of both equilibrium as well as dynamic data. Conclusions. We show explicitly that reverse engineering of GRNs from pure expression data is an indeterminate problem. Our results suggest the unsuitability of an inferential, purely data-driven approach for the reverse engineering transcriptional networks in the case of gene regulatory networks displaying a certain level of complexity.	[Krishnan, Arun; Tomita, Masaru] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan; [Giuliani, Alessandro] Ist Super Sanita, Environm & Hlth Dept, I-00161 Rome, Italy	Keio University; Istituto Superiore di Sanita (ISS)	Krishnan, A (corresponding author), Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.	krishnan@ttck.keio.ac.jp	Giuliani, Alessandro/AAF-1740-2020; Giuliani, Alessandro/K-7589-2016	Giuliani, Alessandro/0000-0002-4640-804X; Giuliani, Alessandro/0000-0002-4640-804X	Tsuruoka city and Yamagata prefecture governments	Tsuruoka city and Yamagata prefecture governments	Arun Krishnan and Masaru Tomita would like to acknowledge the Tsuruoka city and Yamagata prefecture governments for funding for this project.	Babu MM, 2004, CURR OPIN STRUC BIOL, V14, P283, DOI 10.1016/j.sbi.2004.05.004; BARJOSEPH Z, 2003, NAT BIOTECHNOL, V21, P1295; BODEN J, 1997, J THEOR BIOL, V188, P391; BROOMHEAD DS, 1986, PHYSICA D, V20, P217, DOI 10.1016/0167-2789(86)90031-X; CHIPPERFIELD A, 2001, GENETIC ALGORITHM TO; DARROCH JN, 1985, BIOMETRIKA, V72, P241, DOI 10.2307/2336077; De Jong H, 2002, J COMPUT BIOL, V9, P67, DOI 10.1089/10665270252833208; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gardner TS, 2005, PHYS LIFE REV, V2, P65, DOI 10.1016/j.plrev.2005.01.001; Gibson G, 2000, BIOESSAYS, V22, P372, DOI 10.1002/(SICI)1521-1878(200004)22:4<372::AID-BIES7>3.0.CO;2-J; GRIFFITH JS, 1968, J THEOR BIOL, V20, P202, DOI 10.1016/0022-5193(68)90189-6; GRIFFITH JS, 1968, J THEOR BIOL, V20, P209, DOI 10.1016/0022-5193(68)90190-2; Hayot F, 2005, J THEOR BIOL, V234, P133, DOI 10.1016/j.jtbi.2004.11.010; Ingram PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-108; Le Novere N, 2001, BIOINFORMATICS, V17, P575, DOI 10.1093/bioinformatics/17.6.575; Lewontin RC, 1974, GENETIC BASIS EVOLUT; Liang Shoudan, 1998, REVEAL GEN REVERSE E; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; Mestl T, 1996, PHYSICA D, V98, P33, DOI 10.1016/0167-2789(96)00086-3; MESTL T, 1995, J THEOR BIOL, V176, P291, DOI 10.1006/jtbi.1995.0199; Plahte E, 1998, J MATH BIOL, V36, P321, DOI 10.1007/s002850050103; Preisendorfer R.W., 1988, DEV ATMOS SCI, V17; Qi Yuan, 2006, PLoS Comput Biol, V2, pe174, DOI 10.1371/journal.pcbi.0020174; Rice SH, 1998, EVOLUTION, V52, P647, DOI 10.1111/j.1558-5646.1998.tb03690.x; Rutherford SL, 2000, BIOESSAYS, V22, P1095, DOI 10.1002/1521-1878(200012)22:12&lt;1095::AID-BIES7&gt;3.0.CO;2-A; Schmalhausen II., 1986, FACTORS EVOLUTION TH; SMITH H, 1987, J MATH BIOL, V25, P169, DOI 10.1007/BF00276388; Smolen P, 2000, B MATH BIOL, V62, P247, DOI 10.1006/bulm.1999.0155; SNOUSSI E, 1993, B MATH BIOL, V55, P973, DOI 10.1016/S0092-8240(05)80199-5; Soinov LA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r6; Somogyi R, 1996, COMPLEXITY, V1, P45, DOI DOI 10.1002/CPLX.6130010612; Teichmann SA, 2004, NAT GENET, V36, P492, DOI 10.1038/ng1340; THOMAS R, 1995, B MATH BIOL, V57, P247, DOI 10.1007/BF02460618; Tyson J., 1978, PROG THEOR BIOL, V5, P1; VONFOERSTER H, 1981, OBSERVING SYSTEMS SE; Waddington C., 1957, STRATEGY GENES; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896	38	30	31	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e562	10.1371/journal.pone.0000562	http://dx.doi.org/10.1371/journal.pone.0000562			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593963	Green Published, gold, Green Submitted			2022-12-25	WOS:000207451800008
J	Song, LP; Zhang, J; Wu, SF; Huang, Y; Zhao, Q; Cao, JP; Wu, YL; Wang, LS; Chen, GQ				Song, L-P; Zhang, J.; Wu, S-F; Huang, Y.; Zhao, Q.; Cao, J-P; Wu, Y-L; Wang, L-S; Chen, G-Q			Hypoxia-inducible factor-1 alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent	ONCOGENE			English	Article						leukemia; differentiation; HIF-1 alpha; C/EBP alpha	PHOSPHOLIPID SCRAMBLASE-1 GENE; TEL-ARNT FUSION; OXYGEN-TENSION; RETINOIC ACID; C/EBP-ALPHA; EXPRESSION; ARREST; TRANSLOCATION	Hypoxia or hypoxia mimetic has been shown to induce differentiation together with the accumulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein of myeloid leukemic cells and normal hematopoietic progenitors. To provide direct evidence for the role of HIF-1 alpha in acute myeloid leukemia (AML) cell differentiation and its mechanisms, we generated myeloid leukemic U937T transformants, in which HIF-1 alpha was tightly induced by tetracycline withdrawal. The results showed that the conditional HIF-1 alpha induction triggered granulocytic differentiation of these transformants, while the suppression of HIF-1 alpha expression by specific short hairpin RNAs (shRNAs) effectively inhibited hypoxia-induced differentiation of U937 cells, as evidenced by morphology, maturation-related antigens as well as expressions of myeloid differentiation signatures and hematopoietic cells- specific cytokine receptors. The specific shRNAs-inhibited expression of HIF-1 beta, an essential partner for transcription activity of HIF-1 alpha failed, while the inhibition of hematopoietic differentiation-critical CCAAT/enhancer-binding protein-a (C/EBPa) significantly eliminated HIF-1 alpha-mediated myeloid leukemic cell differentiation. Collectively, this work provided several lines of direct evidence for the role of HIF-1 alpha protein through its nontranscriptional activity in myeloid cell differentiation, in which C/EBP alpha elicitsa role as an effector downstream to HIF-1 alpha. These discoveries would shed new insights for understanding mechanisms underlying leukemogenesis and designing the new therapeutic strategy for differentiation induction of AML.	[Song, L-P; Zhang, J.; Wu, S-F; Zhao, Q.; Cao, J-P; Chen, G-Q] SJTU SM, Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China; [Song, L-P; Zhang, J.; Wu, S-F; Zhao, Q.; Cao, J-P; Chen, G-Q] SJTU SM, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China; [Huang, Y.; Wu, Y-L; Wang, L-S; Chen, G-Q] SJTU SM, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, GQ (corresponding author), Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn						Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Chen GQ, 1997, BLOOD, V89, P3345; Cheng LRL, 2006, FOLIA PHONIATR LOGO, V58, P5, DOI 10.1159/000090474; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Hong SH, 2004, J BIOL CHEM, V279, P16996, DOI 10.1074/jbc.M311752200; Huang Y, 2006, ONCOGENE, V25, P6618, DOI 10.1038/sj.onc.1209677; Huang Y, 2003, LEUKEMIA, V17, P2065, DOI 10.1038/sj.leu.2403141; James SY, 1997, BIOCHEM PHARMACOL, V54, P625, DOI 10.1016/S0006-2952(97)00195-0; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Mueller BU, 2006, CURR OPIN HEMATOL, V13, P7, DOI 10.1097/01.moh.0000190110.08156.96; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; SCOTT LM, 1992, BLOOD, V80, P1725; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	25	48	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					519	527		10.1038/sj.onc.1210670	http://dx.doi.org/10.1038/sj.onc.1210670			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637739				2022-12-25	WOS:000252426100012
J	Chang, TW; Chen, CC; Chen, KY; Su, JH; Chang, JH; Chang, MC				Chang, T-W; Chen, C-C; Chen, K-Y; Su, J-H; Chang, J-H; Chang, M-C			Ribosomal phosphoprotein P0 interacts with GCIP and overexpression of P0 is associated with cellular proliferation in breast and liver carcinoma cells	ONCOGENE			English	Article						ribosomal P0; GCIP; DIP1/HHM; cyclin D1; breast cancer; hepatocellular carcinoma	GTPASE-ASSOCIATED DOMAIN; LOOP-HELIX PROTEIN; HUMAN HOMOLOG; EXPRESSION; P2; MAID; RNA; P1; HEPATOCARCINOGENESIS; COMPONENTS	The ribosomal acidic P0 protein, an essential component of the eukaryotic ribosomal stalk, was found to interact with the helix-loop-helix protein human Grap2 and cyclin D interacting protein (GCIP)/D-type cyclin-interacting protein 1/human homolog of MAID protein. Using in vivo and in vitro binding assays, we show that P0 can interact with the N and C termini of GCIP via its N-terminal 39-114 amino-acid residues. Although the P0-GCIP complex was detected mainly in cytoplasmic fraction, polysome pro. le analysis indicated that the P0-GCIP complex did not coelute with either polysomes or 60S ribosomes, suggesting that GCIP associates with the free form of P0 in the cytoplasm. Transfection of GCIP into MCF-7 cells resulted in decreased levels of pRb phosphorylation. Cotransfection of P0 with GCIP, however, resulted in GCIP-mediated reduction of pRb phosphorylation level which was repressed by P0. Furthermore, overexpression of P0 in breast cancer and hepatocellular cancer cell lines promoted cell growth and colony formation compared to control transfectants. Overexpression of P0 also increased cyclin D1 expression and phosphorylation of pRb at Ser780. Interestingly, P0 mRNA was overexpressed in 12 of 20 pairs of breast cancer/ normal breast specimens (60%). Together, these data indicate that P0 overexpression may cause tumorigenesis in breast and liver tissues at least in part by inhibiting GCIP-mediated tumor suppression.	[Chang, T-W; Chang, M-C] Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, Tainan 704, Taiwan; [Chang, T-W] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan 704, Taiwan; [Chen, C-C; Chen, K-Y; Chang, J-H; Chang, M-C] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biotechnol, Tainan 704, Taiwan; [Su, J-H] Chia Na Univ Pharm & Sci, Coll Med, Dept Biotechnol, Tainan, Taiwan; [Chang, J-H] Natl Cheng Kung Univ, Coll Med, Dept Parasitol, Tainan 704, Taiwan; [Chang, M-C] Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Chang, MC (corresponding author), Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, 138 Sheng Li Rd, Tainan 704, Taiwan.	mcchang@mail.ncku.edu.tw		Chen, Kuanyu/0000-0001-9350-2699				BARNARD GF, 1992, CANCER RES, V52, P3067; Chang MS, 2000, BIOCHEM BIOPH RES CO, V279, P732, DOI 10.1006/bbrc.2000.3992; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; GRABOWSKI DT, 1992, CARCINOGENESIS, V13, P259, DOI 10.1093/carcin/13.2.259; Hosokawa Y, 1996, J LAB CLIN MED, V127, P246, DOI 10.1016/S0022-2143(96)90092-X; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kondoh N, 1999, CANCER RES, V59, P4990; Ma W, 2006, ONCOGENE, V25, P4207, DOI 10.1038/sj.onc.1209450; Ma WB, 2007, J CELL BIOCHEM, V100, P1376, DOI 10.1002/jcb.21140; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; Shimizu T, 2002, NUCLEIC ACIDS RES, V30, P2620, DOI 10.1093/nar/gkf379; Sonnenberg-Riethmacher E, 2007, HEPATOLOGY, V45, P404, DOI 10.1002/hep.21461; Takami T, 2005, GASTROENTEROLOGY, V128, P1369, DOI 10.1053/j.gastro.2005.03.014; Tchorzewski M, 2003, INT J BIOCHEM CELL B, V35, P203, DOI 10.1016/S1357-2725(02)00133-4; Terai S, 2000, HEPATOLOGY, V32, P357, DOI 10.1053/jhep.2000.9092; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; Wu SB, 2005, CRYOBIOLOGY, V50, P71, DOI 10.1016/j.cryobiol.2004.11.001; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Yao Y, 2000, EXP CELL RES, V257, P22, DOI 10.1006/excr.2000.4884	20	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					332	338		10.1038/sj.onc.1210651	http://dx.doi.org/10.1038/sj.onc.1210651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621266				2022-12-25	WOS:000252256000009
J	Ueki, N; Zhang, L; Haymann, MJ				Ueki, N.; Zhang, L.; Haymann, M. J.			Ski can negatively regulates macrophage differentiation through its interaction with PU.1	ONCOGENE			English	Article						ski oncoprotein; PU.1; HDAC3; hematopoiesis; leukemogenesis; transcriptional repression	TRANSFORMING-GROWTH-FACTOR; TRANSCRIPTION FACTOR PU.1; ACUTE MYELOID-LEUKEMIA; CO-REPRESSOR; ERYTHROID-DIFFERENTIATION; V-SKI; HEMATOPOIETIC-CELLS; LINEAGE COMMITMENT; DNA-BINDING; ONCOPROTEIN	In the hematopoietic cell system, the oncoprotein Ski dramatically affects growth and differentiation programs, in some cases leading to malignant leukemia. However, little is known about the interaction partners or signaling pathways involved in the Ski-mediated block of differentiation in hematopoietic cells. Here we show that Ski interacts with PU.1, a lineage-specific transcription factor essential for terminal myeloid differentiation, and thereby represses PU.1-dependent transcriptional activation. Consistent with this, Ski inhibits the biological function of PU.1 to promote myeloid cells to differentiate into macrophage colony-stimulating factor receptor (M-CSFR)positive macrophages. Using a Ski mutant deficient in PU.1 binding, we demonstrate that Ski-PU.1 interaction is critical for Ski's ability to repress PU.1-dependent transcription and block macrophage differentiation. Furthermore, we provide evidence that Ski-mediated repression of PU.1 is due to Ski's ability to recruit histone deacetylase 3 to PU.1 bound to DNA. Since inactivation of PU.1 is closely related to the development of myeloid leukemia and Ski strongly inhibits PU.1 function, we propose that aberrant Ski expression in certain types of myeloid cell lineages might contribute to leukemogenesis.	[Ueki, N.; Zhang, L.; Haymann, M. J.] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haymann, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, R01 CA042573-20, R01 CA042573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Ano S, 2004, J BIOL CHEM, V279, P2993, DOI 10.1074/jbc.M303816200; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BEUG H, 1995, ONCOGENE, V11, P59; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; Dahl R, 2007, J BIOL CHEM, V282, P6473, DOI 10.1074/jbc.M607613200; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Jepsen K, 2002, J CELL SCI, V115, P689; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kronenwett R, 2005, ONCOGENE, V24, P5313, DOI 10.1038/sj.onc.1208596; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Metcalf D, 2006, P NATL ACAD SCI USA, V103, P1486, DOI 10.1073/pnas.0510616103; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Reed JA, 2001, CANCER RES, V61, P8074; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Ritter M, 2006, LEUKEMIA, V20, P437, DOI 10.1038/sj.leu.2404093; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Ueki N, 2004, MOL CELL BIOL, V24, P10118, DOI 10.1128/MCB.24.23.10118-10125.2004; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	39	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					300	307		10.1038/sj.onc.1210654	http://dx.doi.org/10.1038/sj.onc.1210654			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621263	Green Accepted			2022-12-25	WOS:000252256000005
J	Kumar, S; Ponnazhagan, S				Kumar, Sanjay; Ponnazhagan, Selvarangan			Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression	FASEB JOURNAL			English	Article						tissue regeneration; cell therapy; bone targeting	ADHESION MOLECULE-1; ENGRAFTMENT; DIFFERENTIATION; MOBILIZATION; FIBRONECTIN; INHIBITION; DOMAIN-4; BINDING; VLA-4; STAGE	The pluripotent nature of mesenchymal stem cells ( MSC) widens their potential for tissue regeneration and as vehicles for cell therapy in molecular medicine. Although the MSC are relatively easier to obtain and propagate in culture, a major impediment remains in their engraftment to target tissues on autologous transfer. We report here that transient, ectopic expression of alpha 4 integrin (CD49d) on MSC greatly increases bone homing in an immunocompetent mouse model. Heterodimerization of the alpha 4 integrin with endogenous beta 1 integrin (CD29) was confirmed to influence this targeting. In addition to retaining their stem cell property, the engrafted MSC were also found to form osteoblasts and osteocytes in the growth plate of recipient mouse limb bones ( femur/ tibia) in vivo. These findings provide evidence for a novel strategy to achieve bone homing of genetically engineered MSC, which may broadly benefit in targeted therapies for osteopenic bone defects and cancer bone metastasis.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ponnazhagan, S (corresponding author), Univ Alabama Birmingham, Dept Pathol, 701 19th St South, LHRB 513, Birmingham, AL 35294 USA.	pons@uab.edu			NATIONAL CANCER INSTITUTE [R01CA098817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050251] Funding Source: NIH RePORTER; NCI NIH HHS [CA-98817] Funding Source: Medline; NIAMS NIH HHS [AR-50251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Bergstrom DE, 1998, GENOMICS, V48, P304, DOI 10.1006/geno.1997.5176; Bonig H, 2006, BLOOD, V107, P79, DOI 10.1182/blood-2005-05-2023; Catalina MD, 1999, BLOOD, V93, P580, DOI 10.1182/blood.V93.2.580.402k16_580_589; Chateauvieux S, 2007, PHYSIOL GENOMICS, V29, P128, DOI 10.1152/physiolgenomics.00197.2006; Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008-5472.CAN-04-2033; De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165-2478(03)00108-1; Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jacobsen K, 1996, BLOOD, V87, P73; Jin H, 2006, J CLIN INVEST, V116, P652, DOI 10.1172/JCI24751; Kalajzic I, 2003, J CELL BIOCHEM, V88, P1168, DOI 10.1002/jcb.10459; KILGER G, 1995, J BIOL CHEM, V270, P5979, DOI 10.1074/jbc.270.11.5979; Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200; Kumar S, 2005, BBA-GENE STRUCT EXPR, V1731, P95, DOI 10.1016/j.bbaexp.2005.08.007; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MATSUSHIMA T, 1996, TRENDS CHEM PHYS, V4, P1; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; Pacary E, 2006, J CELL SCI, V119, P2667, DOI 10.1242/jcs.03004; PETERS SO, 1995, EXP HEMATOL, V23, P461; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Prosper F, 1998, J CLIN INVEST, V101, P2456, DOI 10.1172/JCI188; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; SCHADENDORF D, 1993, J PATHOL, V170, P429, DOI 10.1002/path.1711700405; Schweitzer KM, 1996, AM J PATHOL, V148, P165; Stewart FM, 1998, BLOOD, V91, P3681; Woodside DG, 2006, J IMMUNOL, V176, P5041, DOI 10.4049/jimmunol.176.8.5041; Zanjani ED, 1999, BLOOD, V94, P2515, DOI 10.1182/blood.V94.7.2515.419k15_2515_2522; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	31	112	116	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3917	3927		10.1096/fj.07-8275com	http://dx.doi.org/10.1096/fj.07-8275com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17622670				2022-12-25	WOS:000251283500017
J	Ranquet, C; Ollagnier-de-Choudens, S; Loiseau, L; Barras, F; Fontecave, M				Ranquet, Caroline; Ollagnier-de-Choudens, Sandrine; Loiseau, Laurent; Barras, Frederic; Fontecave, Marc			Cobalt stress in Escherichia coli - The effect on the iron-sulfur proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; TRANSFER-RNA; SALMONELLA-TYPHIMURIUM; CYSTEINE DESULFURASE; MIAB PROTEIN; INACTIVATION; SCAFFOLD; ISCA; IDENTIFICATION; BIOGENESIS	Cobalt is toxic for cells, but mechanisms of this toxicity are largely unknown. The biochemical and genetic experiments reported here demonstrate that iron-sulfur proteins are greatly affected in cobalt-treated Escherichia coli cells. Exposure of a wild-type strain to intracellular cobalt results in the inactivation of three selected iron-sulfur enzymes, the tRNA methylthio-transferase, aconitase, and ferrichrome reductase. Consistently, mutant strains lacking the [Fe-S] cluster assembly SUF machinery are hypersensitive to cobalt. Last, expression of iron uptake genes is increased in cells treated with cobalt. In vitro studies demonstrated that cobalt does not react directly with fully assembled [Fe-S] clusters. In contrast, it reacts with labile ones present in scaffold proteins (IscU, SufA) involved in iron-sulfur cluster biosynthesis. We propose a model wherein cobalt competes out iron during synthesis of [Fe-S] clusters in metabolically essential proteins.	Univ Grenoble 1, Lab Chim & Biol Metaux, iRTSV LCBM, CNRS,CEA Grenoble,UMR 5249, F-38054 Grenoble 09, France; CNRS, Chim Bacterienne Lab, UPR 9043, IBSM, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fontecave, M (corresponding author), Univ Grenoble 1, Lab Chim & Biol Metaux, iRTSV LCBM, CNRS,CEA Grenoble,UMR 5249, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr		Barras, Frederic/0000-0003-3458-2574; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Balasubramanian R, 2006, J BACTERIOL, V188, P3182, DOI 10.1128/JB.188.9.3182-3191.2006; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P201, DOI 10.1081/CLT-100102420; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GEHRKE CW, 1989, J CHROMATOGR, V471, P3, DOI 10.1016/S0021-9673(00)94152-9; Gully D, 2003, FEBS LETT, V548, P90, DOI 10.1016/S0014-5793(03)00746-4; HANTKE K, 1987, MOL GEN GENET, V210, P135, DOI 10.1007/BF00337769; JARVIS JQ, 1992, J OCCUP ENVIRON MED, V34, P620; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lamrani S, 1999, MOL MICROBIOL, V32, P327, DOI 10.1046/j.1365-2958.1999.01352.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Lever A. B. P., 1984, INORGANIC ELECT SPEC; Loiseau L, 2005, J BIOL CHEM, V280, P26760, DOI 10.1074/jbc.M504067200; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; MANIATIS T, 1982, MOL CLONING LAB MAN; McCall KA, 2000, ANAL BIOCHEM, V284, P307, DOI 10.1006/abio.2000.4706; Miller, 1972, EXPT MOL GENETICS; Muller K, 1998, EUR J BIOCHEM, V258, P1001, DOI 10.1046/j.1432-1327.1998.2581001.x; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-de-Choudens S, 2004, J BIOL INORG CHEM, V9, P828, DOI 10.1007/s00775-004-0581-9; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; Petros AK, 2006, INORG CHEM, V45, P9941, DOI 10.1021/ic052190q; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Rodrigue A, 2005, J BACTERIOL, V187, P2912, DOI 10.1128/JB.187.8.2912-2916.2005; Sambrook J, 1988, MOL CLONING LAB MANU; Silberg JJ, 2004, J BIOL CHEM, V279, P53924, DOI 10.1074/jbc.M410117200; SJOGREN I, 1980, THORAX, V35, P653, DOI 10.1136/thx.35.9.653; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; VENKATESWERLU G, 1970, BIOCHEM J, V118, P497, DOI 10.1042/bj1180497	52	129	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30442	30451		10.1074/jbc.M702519200	http://dx.doi.org/10.1074/jbc.M702519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17642475	hybrid			2022-12-25	WOS:000250136300012
J	Moskovich, O; Fishelson, Z				Moskovich, Oren; Fishelson, Zvi			Live cell imaging of outward and inward vesiculation induced by the complement C5b-9 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; PROTEIN-KINASE-C; PLASMA-MEMBRANE; NUCLEATED CELLS; SUBLYTIC COMPLEMENT; EXTRACELLULAR CA-2+; HUMAN-NEUTROPHILS; LYSIS; RESISTANCE; EXPRESSION	Cells resist death induced by the complement membrane attack complex ( MAC, C5b-9) by removal of the MAC from their surface by an outward and/or inward vesiculation. To gain an insight into the route of MAC removal, human C9 was tagged with Alexa Fluor 488 and traced within live cells. Tagged C9-AF488 was active in lysis of erythrocytes and K562 cells. Upon treatment of K562 cells with antibody and human serum containing C9-AF488, C9-AF488 containing MAC bound to the cells. Within 5-10 min, the cells started shedding C5b-9-loaded vesicles (0.05-1 mu m) by outward vesiculation. Concomitantly, C9-AF488 entered the cells and accumulated in a perinuclear, late recycling compartment, co-localized with endocytosed transferrin-Texas Red. Similar results were obtained with fixed cells in which the MAC was labeled with antibodies directed to a C5b-9 neoepitope. Inhibition of protein kinase C reduced endocytosis of C5b-9. Kinetic analysis demonstrated that peripheral, trypsin-sensitive C5b-9 was cleared from cells at a slower rate relative to fully inserted, trypsin-resistant C5b-9. MAC formation is controlled by CD59, a ubiquitously expressed membrane complement regulator. Analysis at a cell population level showed that the amount of C5b-9-AF488 bound to K562 cells after complement activation was highly heterogeneous and inversely correlated with the CD59 level of expression. Efficient C9-AF488 vesiculation was observed in cells expressing low CD59 levels, suggesting that the protective impact of MAC elimination by vesiculation increases as the level of expression of CD59 decreases.	Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Fishelson, Z (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel.	lifish@post.tau.ac.il						Bentley CC, 2005, CELL MICROBIOL, V7, P945, DOI 10.1111/j.1462-5822.2005.00525.x; BHAKDI S, 1980, J IMMUNOL, V124, P2451; Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007; CARNEY DF, 1990, J IMMUNOL, V145, P623; CARNEY DF, 1985, J IMMUNOL, V134, P1804; CARNEY DF, 1986, J IMMUNOL, V137, P263; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Deng JS, 2003, INFECT IMMUN, V71, P6402, DOI 10.1128/IAI.71.11.6402-6410.2003; Donev RM, 2006, CANCER RES, V66, P2451, DOI 10.1158/0008-5472.CAN-05-3191; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; Fishelson Z, 2001, INT IMMUNOL, V13, P983, DOI 10.1093/intimm/13.8.983; Fishelson Z, 1989, MECHANISMS ACTION TH, P273; Idkowiak-Baldys J, 2006, J BIOL CHEM, V281, P22321, DOI 10.1074/jbc.M512540200; Jurianz K, 2001, INT J CANCER, V93, P848, DOI 10.1002/ijc.1406; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; KIM SH, 1987, J IMMUNOL, V138, P1530; KOSKI CL, 1983, P NATL ACAD SCI-BIOL, V80, P3816, DOI 10.1073/pnas.80.12.3816; Kraus S, 2001, CLIN EXP IMMUNOL, V123, P366, DOI 10.1046/j.1365-2249.2001.01477.x; Kraus S, 2000, EUR J IMMUNOL, V30, P1272; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MERI S, 1990, IMMUNOLOGY, V71, P1; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; MORGAN BP, 1986, J IMMUNOL, V136, P3402; Morgan BP, 2005, XENOTRANSPLANTATION, V12, P258, DOI 10.1111/j.1399-3089.2005.00237.x; MORGAN BP, 1987, J IMMUNOL, V138, P246; MORGAN BP, 1989, BIOCHEM J, V264, P1; MORGAN BP, 1985, BIOCHEM J, V231, P205, DOI 10.1042/bj2310205; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Nilsson M, 2006, THROMB HAEMOSTASIS, V95, P982, DOI 10.1160/TH05-08-0572; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHANIAN S H, 1981, Critical Reviews in Immunology, V1, P165; PAPADIMITRIOU JC, 1994, VIRCHOWS ARCH, V424, P677, DOI 10.1007/BF01069750; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Pilzer D, 2005, INT IMMUNOL, V17, P1239, DOI 10.1093/intimm/dxh300; PODACK ER, 1984, MOL IMMUNOL, V21, P589, DOI 10.1016/0161-5890(84)90044-0; REITER Y, 1992, EUR J IMMUNOL, V22, P1207, DOI 10.1002/eji.1830220515; REITER Y, 1995, J IMMUNOL, V155, P2203; REITER Y, 1992, MOL IMMUNOL, V29, P771, DOI 10.1016/0161-5890(92)90187-3; Robertson SE, 2006, MOL BIOL CELL, V17, P645, DOI 10.1091/mbc.E05-07-0662; Sampaziotis F, 2002, MED HYPOTHESES, V58, P136, DOI 10.1054/mehy.2001.1476; SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0; Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021; SIMS PJ, 1986, BLOOD, V68, P556; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Sreedhar AS, 2003, J BIOL CHEM, V278, P35231, DOI 10.1074/jbc.M301371200; STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381; TSCHOPP J, 1984, J BIOL CHEM, V259, P1922; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406	48	77	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2007	282	41					29977	29986		10.1074/jbc.M703742200	http://dx.doi.org/10.1074/jbc.M703742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	217XS	17644516	hybrid			2022-12-25	WOS:000249981200027
J	Miras, S; Salvi, D; Piette, L; Seigneurin-Berny, D; Grunwald, D; Reinbothe, C; Joyard, J; Reinbothe, S; Rolland, N				Miras, Stephane; Salvi, Daniel; Piette, Laurie; Seigneurin-Berny, Daphne; Grunwald, Didier; Reinbothe, Christiane; Joyard, Jacques; Reinbothe, Steffen; Rolland, Norbert			Toc159- and Toc75-independent import of a transit sequence-less precursor into the inner envelope of chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOCHLOROPHYLLIDE OXIDOREDUCTASE-A; PROTEIN IMPORT; OUTER-MEMBRANE; IN-VITRO; PEPTIDE; BINDING; INSERTION; RECEPTOR; IDENTIFICATION; TRANSLOCATION	Chloroplast envelope quinone oxidoreductase (ceQORH) is an inner plastid envelope protein that is synthesized without cleavable chloroplast transit sequence for import. In the present work, we studied the in vitro-import characteristics of Arabidopsis ceQORH. We demonstrate that ceQORH import requires ATP and is dependent on proteinaceous receptor components exposed at the outer plastid surface. Competition experiments using small subunit precursor of ribulose-bisphosphate carboxylase/oxygenase and precursor of ferredoxin, as well as antibody blocking experiments, revealed that ceQORH import does not involve the main receptor and translocation channel proteins Toc159 and Toc75, respectively, which operate in import of proteins into the chloroplast. Molecular dissection of the ceQORH amino acid sequence by site-directed mutagenesis and subsequent import experiments in planta and in vitro highlighted that ceQORH consists of different domains that act concertedly in regulating import. Collectively, our results provide unprecedented evidence for the existence of a specific import pathway for transit sequence-less inner plastid envelope membrane proteins into chloroplasts.	Univ Grenoble 1, IRTSVUMR 5168, Lab Physiol Cellulaire Vegetale,CEA, CNRS UMR 5168, F-38054 Grenoble 9, France; Univ Grenoble 1, IRTSV, CEA, INSERM U607,Lab Canaux Calc Fonct & Pathol, F-38054 Grenoble 9, France; Univ Grenoble 1, CERMO, Lab Plastes & Differentiat Cellulaire, F-38041 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Rolland, N (corresponding author), Univ Grenoble 1, IRTSVUMR 5168, Lab Physiol Cellulaire Vegetale,CEA, CNRS UMR 5168, 17 Rue Martyrs, F-38054 Grenoble 9, France.	norbert.rolland@cea.fr	ROLLAND, Norbert/B-4405-2012; Reinbothe, Steffen/AAW-9893-2021; SEIGNEURIN-BERNY, Daphne/C-8412-2017	ROLLAND, Norbert/0000-0003-1959-6636; SEIGNEURIN-BERNY, Daphne/0000-0002-7436-9885				Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bolter B, 1998, FEBS LETT, V441, P59, DOI 10.1016/S0014-5793(98)01525-7; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Chen KH, 2000, PLANT PHYSIOL, V122, P813, DOI 10.1104/pp.122.3.813; Chigri F, 2006, P NATL ACAD SCI USA, V103, P16051, DOI 10.1073/pnas.0607150103; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Eckart K, 2002, EMBO REP, V3, P557, DOI 10.1093/embo-reports/kvf110; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; Gutensohn M, 2006, J PLANT PHYSIOL, V163, P333, DOI 10.1016/j.jplph.2005.11.009; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hofmann NR, 2005, TRENDS PLANT SCI, V10, P450, DOI 10.1016/j.tplants.2005.07.009; Hormann F, 2004, J BIOL CHEM, V279, P34756, DOI 10.1074/jbc.M402817200; Ivanova Y, 2004, MOL BIOL CELL, V15, P3379, DOI 10.1091/mbc.E03-12-0923; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; Jarvis P, 2004, CURR BIOL, V14, pR1064, DOI 10.1016/j.cub.2004.11.049; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; JOYARD J, 1983, J BIOL CHEM, V258, P1; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; Kessler F, 2004, TRENDS CELL BIOL, V14, P334, DOI 10.1016/j.tcb.2004.05.004; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kim C, 2005, PLANT J, V42, P329, DOI 10.1111/j.1365-313X.2005.02374.x; Kindle KL, 1998, PLANT PHYSIOL, V116, P1179, DOI 10.1104/pp.116.3.1179; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Kouranov A, 1999, J BIOL CHEM, V274, P25181, DOI 10.1074/jbc.274.35.25181; Kubis S, 2004, PLANT CELL, V16, P2059, DOI 10.1105/tpc.104.023309; Lee DW, 2006, PLANT PHYSIOL, V140, P466, DOI 10.1104/pp.105.074575; Miras S, 2002, J BIOL CHEM, V277, P47770, DOI 10.1074/jbc.M207477200; Nada A, 2004, J CELL SCI, V117, P3975, DOI 10.1242/jcs.01265; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; Pinnaduwage P, 1996, J BIOL CHEM, V271, P32907, DOI 10.1074/jbc.271.51.32907; Reinbothe S, 2000, P NATL ACAD SCI USA, V97, P9795, DOI 10.1073/pnas.160242597; Reinbothe S, 2005, PLANT J, V42, P1, DOI 10.1111/j.1365-313X.2005.02353.x; REINBOTHE S, 1995, PLANT CELL, V7, P1933, DOI 10.1105/tpc.7.11.1933; Reinbothe S, 2004, P NATL ACAD SCI USA, V101, P2197, DOI 10.1073/pnas.0307284101; REINBOTHE S, 1990, PLANTA, V181, P176, DOI 10.1007/BF02411535; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Reumann S, 2005, MOL MEMBR BIOL, V22, P73, DOI 10.1080/09687860500041916; Richter S, 2002, J BIOL CHEM, V277, P43888, DOI 10.1074/jbc.M206020200; Samson F, 2002, NUCLEIC ACIDS RES, V30, P94, DOI 10.1093/nar/30.1.94; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schleiff E, 2005, EMBO REP, V6, P1023, DOI 10.1038/sj.embor.7400563; Schleiff E, 2001, BBA-MOL CELL RES, V1541, P22, DOI 10.1016/S0167-4889(01)00152-5; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; THEG SM, 1989, J BIOL CHEM, V264, P6730; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; Tsai LY, 1999, J BIOL CHEM, V274, P18735, DOI 10.1074/jbc.274.26.18735; Tu SL, 2000, PLANT CELL, V12, P1951, DOI 10.1105/tpc.12.10.1951; Tu SL, 2004, PLANT CELL, V16, P2078, DOI 10.1105/tpc.104.023952; VANTHOF R, 1993, J BIOL CHEM, V268, P4037	70	62	68	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2007	282	40					29482	29492		10.1074/jbc.M611112200	http://dx.doi.org/10.1074/jbc.M611112200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	215DH	17636260	hybrid, Green Published			2022-12-25	WOS:000249788000045
J	Ramaen, O; Joubert, A; Simister, P; Belgareh-Touze, N; Olivares-Sanchez, MC; Zeeh, JC; Chantalat, S; Golinelli-Cohen, MP; Jackson, CL; Biou, V; Cherfils, J				Ramaen, Odile; Joubert, Alexandra; Simister, Philip; Belgareh-Touze, Naima; Olivares-Sanchez, Maria Conception; Zeeh, Jean-Christophe; Chantalat, Sophie; Golinelli-Cohen, Marie-Pierre; Jackson, Catherine L.; Biou, Valerie; Cherfils, Jacqueline			Interactions between conserved domains within homodimers in the BIG1, BIG2, and GBF1 arf guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTORS; TRANS-GOLGI NETWORK; BREFELDIN-A; MEMBRANE ASSOCIATION; SEC7 DOMAIN; PROTEIN; LOCALIZATION; TRAFFICKING; ENDOCYTOSIS; MUTATIONS	Guanine nucleotide exchange factors carrying a Sec7 domain (ArfGEFs) activate the small GTP-binding protein Arf, a major regulator of membrane remodeling and protein trafficking in eukaryotic cells. Only two of the seven subfamilies of ArfGEFs (GBF and BIG) are found in all eukaryotes. In addition to the Sec7 domain, which catalyzes GDP/GTP exchange on Arf, the GBF and BIG ArfGEFs have five common homology domains. Very little is known about the functions of these noncatalytic domains, but it is likely that they serve to integrate upstream signals that define the conditions of Arf activation. Here we describe interactions between two conserved domains upstream of the Sec7 domain (DCB and HUS) that determine the architecture of the N-terminal regions of the GBF and BIG ArfGEFs using a combination of biochemical, yeast two-hybrid, and cellular assays. Our data demonstrate a strong interaction between DCB domains within GBF1, BIG1, and BIG2 to maintain homodimers and an interaction between DCB and HUS domains within each homodimer. The DCB/HUS interaction is mediated by the HUS box, the most conserved motif in large ArfGEFs after the Sec7 domain. In support of the in vitro data, we show that both the DCB and the HUS domains are necessary for GBF1 dimerization in mammalian cells and that the DCB domain is essential for yeast viability. We propose that the dimeric DCB-HUS structural unit exists in all members of the GBF and BIG ArfGEF groups and in the related Mon2p family and probably serves an important regulatory role in Arf activation.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Cherfils, J (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	cherfils@lebs.cnrs-gif.fr	Golinelli, Marie-Pierre/K-4287-2013; Jackson, Catherine/T-5688-2019; Jackson, Catherine/A-3421-2013; Olivares, Conchi/H-2794-2015	Golinelli, Marie-Pierre/0000-0002-6738-8631; Jackson, Catherine/0000-0002-0843-145X; Olivares, Conchi/0000-0001-7518-3858				Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Efe JA, 2005, J CELL SCI, V118, P4751, DOI 10.1242/jcs.02599; Garcia-Mata R, 2003, MOL BIOL CELL, V14, P2250, DOI 10.1091/mbc.E02-11-0730; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gillingham AK, 2006, J BIOL CHEM, V281, P2273, DOI 10.1074/jbc.M510176200; Grebe M, 2000, PLANT CELL, V12, P343, DOI 10.1105/tpc.12.3.343; Ishizaki R, 2006, GENES CELLS, V11, P949, DOI 10.1111/j.1365-2443.2006.00991.x; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jochum A, 2002, MOL CELL BIOL, V22, P4914, DOI 10.1128/MCB.22.13.4914-4928.2002; Kawamoto K, 2002, TRAFFIC, V3, P483, DOI 10.1034/j.1600-0854.2002.30705.x; Li HW, 2003, P NATL ACAD SCI USA, V100, P1627, DOI 10.1073/pnas.0337678100; Mansour SJ, 1999, P NATL ACAD SCI USA, V96, P7968, DOI 10.1073/pnas.96.14.7968; Monetta P, 2007, MOL BIOL CELL, V18, P2400, DOI 10.1091/mbc.E06-11-1005; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Mouratou B, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-20; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Padilla PI, 2003, P NATL ACAD SCI USA, V100, P2322, DOI 10.1073/pnas.2628047100; Park SK, 2005, MOL BIOL CELL, V16, P3786, DOI 10.1091/mbc.E05-04-0289; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Peyroche A, 2001, J CELL SCI, V114, P2241; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; Shin HW, 2004, J BIOCHEM, V136, P761, DOI 10.1093/jb/mvh185; Shin HW, 2004, MOL BIOL CELL, V15, P5283, DOI 10.1091/mbc.E04-05-0388; Shinotsuka C, 2002, BIOCHEM BIOPH RES CO, V294, P254, DOI 10.1016/S0006-291X(02)00456-4; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; Wessels E, 2007, J VIROL, V81, P5238, DOI 10.1128/JVI.02680-06; Wessels E, 2006, DEV CELL, V11, P191, DOI 10.1016/j.devcel.2006.06.005; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Xu KF, 2005, P NATL ACAD SCI USA, V102, P2784, DOI 10.1073/pnas.0409871102; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567; Zeeh JC, 2006, J BIOL CHEM, V281, P11805, DOI 10.1074/jbc.M600149200; Zhao XH, 2002, MOL BIOL CELL, V13, P119, DOI 10.1091/mbc.01-08-0420	37	39	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28834	28842		10.1074/jbc.M705525200	http://dx.doi.org/10.1074/jbc.M705525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17640864	Green Submitted, hybrid			2022-12-25	WOS:000249642100058
J	Hidvegi, T; Mirnics, K; Hale, P; Ewing, M; Beckett, C; Perlmutter, DH				Hidvegi, Tuncla; Mirnics, Karoly; Hale, Pamela; Ewing, Michael; Beckett, Caroline; Perlmutter, David H.			Regulator of G signaling 16 is a marker for the distinct encloplasmic reticulum stress state associated with aggregated mutant alpha(1)-antitrypsin Z in the classical form of alpha(1)-antitrypsin deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; GENE-EXPRESSION DATA; ENDOPLASMIC-RETICULUM; ALPHA-1-ANTITRYPSIN DEFICIENCY; LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; IN-VIVO; ACCUMULATION; PATHWAY; DEGRADATION	In the classical form of alpha-antitrypsin deficiency, a mutant protein accumulates in a polymerized form in the encloplasmic reticulum (ER) of liver cells causing liver damage and carcinogenesis by a gain-of-toxic function mechanism. Recent studies have indicated that the accumulation of mutant alpha-antitrypsin Z in the ER specifically activates the autophagic response but not the unfolded protein response and that autophagy plays a critical role in disposal of insoluble alpha-antitrypsin Z. In this study, we used genomic analysis of the liver in a novel transgenic mouse model with inducible expression to screen for changes in gene expression that would potentially define how the liver responds to accumulation of this mutant protein. There was no unfolded protein response. Of several distinct gene expression profiles, marked up-regulation of regulator of G signaling (RS16) was particularly notable. RGS16 did not increase when model systems were exposed to classical inducers of ER stress, including tunicamycin and calcium ionophore, or when a nonpolymerogenic alpha-antitrypsin mutant accumulated in the ER. RGS16 was up-regulated in livers from patients with alpha-antitrypsin deficiency, and the degree of up-regulation correlated with the hepatic levels of insoluble alpha-antitrypsin Z protein. Taken together, these results indicate that expression of RGS16 is an excellent marker for the distinct form of "ER stress" that occurs in alpha-antitrypsin deficiency, presumably determined by the aggregation-prone properties of the mutant protein that characterizes the deficiency.	Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Vanderbilt Univ, Kennedy Ctr Human Dev, Dept Psychiat, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University	Perlmutter, DH (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, 3705 Fifth Ave, Pittsburgh, PA 15213 USA.	David.Perlmutter@chp.edu	Mirnics, Karoly/E-6730-2010; Hidvegi, Tunda/A-8041-2008	Mirnics, Karoly/0000-0002-5521-0254; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL037784] Funding Source: Medline; NIDDK NIH HHS [DK052526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Fremin C, 2007, HEPATOLOGY, V45, P1035, DOI 10.1002/hep.21551; Gohla A, 2007, P NATL ACAD SCI USA, V104, P3003, DOI 10.1073/pnas.0611434104; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; Huang Jie, 2006, Comp Hepatol, V5, P8, DOI 10.1186/1476-5926-5-8; Kamauchi S, 2005, FEBS J, V272, P3461, DOI 10.1111/j.1742-4658.2005.04770.x; Kamimoto T, 2006, J BIOL CHEM, V281, P4467, DOI 10.1074/jbc.M509409200; Kimata Y, 2006, GENES CELLS, V11, P59, DOI 10.1111/j.1365-2443.2005.00921.x; Kruse KB, 2006, AM J PATHOL, V168, P1299, DOI 10.2353/ajpath.2006.051097; Kruse KB, 2006, MOL BIOL CELL, V17, P203, DOI 10.1091/mbc.e04-09-0779; Lawless MW, 2004, J IMMUNOL, V172, P5722, DOI 10.4049/jimmunol.172.9.5722; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Lepre J, 2004, BIOINFORMATICS, V20, P1033, DOI 10.1093/bioinformatics/bth035; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Nair S, 2007, TOXICOL LETT, V168, P21, DOI 10.1016/j.toxlet.2006.10.012; Pattingre S, 2003, J BIOL CHEM, V278, P20995, DOI 10.1074/jbc.M300917200; Perlmutter DH, 2006, AUTOPHAGY, V2, P258, DOI 10.4161/auto.2882; Perlmutter DH, 2006, PEDIATR RES, V60, P233, DOI 10.1203/01.pdr.0000228350.61496.90; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rudnick DA, 2005, HEPATOLOGY, V42, P1001, DOI 10.1002/hep.20931; Rudnick DA, 2004, HEPATOLOGY, V39, P1048, DOI 10.1002/hep.20118; Rudnick DA, 2005, HEPATOLOGY, V42, P514, DOI 10.1002/hep.20815; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; SVEGER T, 1988, ACTA PAEDIATR SCAND, V77, P847, DOI 10.1111/j.1651-2227.1988.tb10767.x; Teckman JH, 2004, AM J PHYSIOL-GASTR L, V286, pG851, DOI 10.1152/ajpgi.00175.2003; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1	34	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27769	27780		10.1074/jbc.M704330200	http://dx.doi.org/10.1074/jbc.M704330200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635928	hybrid			2022-12-25	WOS:000249455600026
J	Almeida, M; Han, L; Martin-Millan, M; O'Brien, CA; Manolagas, SC				Almeida, Maria; Han, Li; Martin-Millan, Marta; O'Brien, Charles A.; Manolagas, Stavros C.			Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to Forkhead box O-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; BONE MASS; DIFFERENTIATED OSTEOBLASTS; OSTEOCYTE DEATH; MICE DEFICIENT; FACTOR FOXO3A; MURINE MODEL; DNA-REPAIR; PATHWAY; PROGENITORS	We have elucidated that oxidative stress is a pivotal pathogenetic factor of age-related bone loss and strength in mice, leading to, among other changes, a decrease in osteoblast number and bone formation. To gain insight into the molecular mechanism by which oxidative stress exerts such adverse effects, we have tested the hypothesis that induction of the Forkhead box O (FoxO) transcription factors by reactive oxygen species may antagonize Wnt signaling, an essential stimulus for osteoblastogenesis. In support of this hypothesis, we report herein that the expression of FoxO target genes increases, whereas the expression of Wnt target genes decreases, with increasing age in C57BL/6 mice. Moreover, we show that in osteoblastic cell models, oxidative stress (exemplified by H2O2) promotes the association of FoxOs with beta-catenin, beta-catenin is required for the stimulation of FoxO target genes by H2O2, and H2O2 promotes FoxO-mediated transcription at the expense of Wnt-/T-cell factor-mediated transcription and osteoblast differentiation. Furthermore, beta-catenin overexpression is sufficient to prevent FoxO-mediated suppression of T-cell factor transcription. These results demonstrate that diversion of the limited pool of beta-catenin from T-cell factor- to FoxO-mediated transcription in osteoblastic cells may account, at least in part, for the attenuation of osteoblastogenesis and bone formation by the age-dependent increase in oxidative stress.	Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Manolagas, SC (corresponding author), 4301 W Markham 587, Little Rock, AR 72205 USA.	manolagasstavros@uams.edu	O'Brien, Charles A./AAL-5078-2020	Warren, Aaron D./0000-0002-0042-9021; Almeida, Maria/0000-0002-6722-9200	NIAMS NIH HHS [R01 AR 51187] Funding Source: Medline; NIA NIH HHS [P01 AG 13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; CHEN XD, 2007, IN PRESS J BONE MINE; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Di Gregorio GB, 2001, J CLIN INVEST, V107, P803, DOI 10.1172/JCI11653; DUNSTAN CR, 1993, CALCIFIED TISSUE INT, V53, pS113, DOI 10.1007/BF01673417; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; FROST HM, 1960, J BONE JOINT SURG AM, V42, P138, DOI 10.2106/00004623-196042010-00011; Funato Y, 2006, NAT CELL BIOL, V8, P501, DOI 10.1038/ncb1405; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Katoh M, 2004, INT J ONCOL, V25, P1495; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Levasseur R, 2003, ENDOCRINOLOGY, V144, P2761, DOI 10.1210/en.2002-0071; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; MANOLAGAS SC, 2007, IN PRESS MOL ENDOCRI; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Staal F J, 2000, Hematol J, V1, P3, DOI 10.1038/sj.thj.6200001; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	52	381	407	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27298	27305		10.1074/jbc.M702811200	http://dx.doi.org/10.1074/jbc.M702811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623658	hybrid			2022-12-25	WOS:000249304900071
J	Gelinas, JN; Banko, JL; Hou, L; Sonenberg, N; Weeber, EJ; Klann, E; Nguyen, PV				Gelinas, Jennifer N.; Banko, Jessica L.; Hou, Lingfei; Sonenberg, Nahum; Weeber, Edwin J.; Klann, Eric; Nguyen, Peter V.			ERK and mTOR signaling couple beta-adrenergic receptors to translation initiation machinery to gate induction of protein synthesis-dependent long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL CA1 REGION; EXTRACELLULAR-REGULATED KINASE; SYNAPTIC PLASTICITY; LATE-PHASE; FREQUENCY STIMULATION; FACTOR 4E; MEMORY; ACTIVATION; PHOSPHORYLATION; PATHWAY	beta-Adrenergic receptors critically modulate long-lasting synaptic plasticity and long-term memory in the mammalian hippocampus. Persistent long-term potentiation of synaptic strength requires protein synthesis and has been correlated with some forms of hippocampal long-term memory. However, the intracellular processes that initiate protein synthesis downstream of the beta-adrenergic receptor are unidentified. Here we report that activation of beta-adrenergic receptors recruits ERK and mammalian target of rapamycin signaling to facilitate long-term potentiation maintenance at the level of translation initiation. Treatment of mouse hippocampal slices with a beta-adrenergic receptor agonist results in activation of eukaryotic initiation factor 4E and the eukaryotic initiation factor 4E kinase Mnk1, along with inhibition of the translation repressor 4E-BP. This coordinated activation of translation machinery requires concomitant ERK and mammalian target of rapamycin signaling. Taken together, our data identify distinct signaling pathways that converge to regulate beta-adrenergic receptor-dependent protein synthesis during long-term synaptic potentiation in the hippocampus. We suggest that beta-adrenergic receptors play a crucial role in gating the induction of long-lasting synaptic plasticity at the level of translation initiation, a mechanism that may underlie the ability of these receptors to influence the formation of long- lasting memories.	Univ Alberta, Sch Med, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Sch Med, Dept Psychiat, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Sch Med, Ctr Neurosci, Edmonton, AB T6G 2H7, Canada; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Alberta; University of Alberta; University of Alberta; Vanderbilt University; Vanderbilt University; Baylor College of Medicine; McGill University	Nguyen, PV (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	peter.nguyen@ualberta.ca	Banko, Jessica L/I-9354-2012; Weeber, Edwin J/A-5396-2012	Nguyen, Peter/0000-0002-1419-5975	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022574] Funding Source: NIH RePORTER; NIA NIH HHS [AG 022574] Funding Source: Medline; NINDS NIH HHS [NS 047384, NS 0304007] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; Banko JL, 2006, J NEUROSCI, V26, P2167, DOI 10.1523/JNEUROSCI.5196-05.2006; Banko JL, 2005, J NEUROSCI, V25, P9581, DOI 10.1523/JNEUROSCI.2423-05.2005; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cammalleri M, 2003, P NATL ACAD SCI USA, V100, P14368, DOI 10.1073/pnas.2336098100; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEADWYLER SA, 1987, SYNAPSE, V1, P90, DOI 10.1002/syn.890010112; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; DUNWIDDIE TV, 1992, J NEUROSCI, V12, P506; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Gelinas JN, 2005, J NEUROSCI, V25, P3294, DOI 10.1523/JNEUROSCI.4175-04.2005; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Govindarajan A, 2006, NAT REV NEUROSCI, V7, P575, DOI 10.1038/nrn1937; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Izquierdo I, 1998, NEUROBIOL LEARN MEM, V69, P219, DOI 10.1006/nlme.1998.3825; Ji JZ, 2003, BEHAV NEUROSCI, V117, P1378, DOI 10.1037/0735-7044.117.6.1378; Ji JZ, 2003, EUR J NEUROSCI, V17, P1947, DOI 10.1046/j.1460-9568.2003.02620.x; Johnson-Farley NN, 2005, J NEUROCHEM, V92, P72, DOI 10.1111/j.1471-4159.2004.02832.x; Johnston D., 1995, FDN CELLULAR NEUROPH; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Klann E, 2004, LEARN MEMORY, V11, P365, DOI 10.1101/lm.79004; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; MADER S, 1995, MOL CELL BIOL, V15, P4990; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Murchison CF, 2004, CELL, V117, P131, DOI 10.1016/S0092-8674(04)00259-4; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; STANTON PK, 1984, J NEUROSCI, V4, P3080; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Walling SG, 2004, J NEUROSCI, V24, P598, DOI 10.1523/JNEUROSCI.4426-03.2004; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1	52	88	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27527	27535		10.1074/jbc.M701077200	http://dx.doi.org/10.1074/jbc.M701077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635924	hybrid			2022-12-25	WOS:000249304900093
J	Nguyen, AD; McDonald, JG; Bruick, RK; DeBose-Boyd, RA				Nguyen, Andrew D.; McDonald, Jeffrey G.; Bruick, Richard K.; DeBose-Boyd, Russell A.			Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of Insigs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; CLEAVAGE-ACTIVATING PROTEIN; COENZYME-A REDUCTASE; ELEMENT-BINDING PROTEINS; STEROL-SENSING DOMAIN; FATTY-ACID SYNTHESIS; HAMSTER OVARY CELLS; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; CHOLESTEROL-BIOSYNTHESIS	Endoplasmic reticulum-associated degradation of the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase represents one mechanism by which cholesterol synthesis is controlled in mammalian cells. The key reaction in this degradation is binding of reductase to Insig proteins in the endoplasmic reticulum, which is stimulated by the cholesterol precursor lanosterol. Conversion of lanosterol to cholesterol requires removal of three methyl groups, which consumes nine molecules of dioxygen. Here, we report that oxygen deprivation (hypoxia) slows demethylation of lanosterol and its metabolite 24,25-dihydrolanosterol, causing both sterols to accumulate in cells. In addition, hypoxia increases the amount of Insig-1 and Insig-2 in a response mediated by hypoxia-inducible factor (HIF)-1 alpha. Accumulation of lanosterol together with increased Insigs accelerates degradation of reductase, which ultimately slows a ratedetermining step in cholesterol synthesis. These results define a novel oxygen-sensing mechanism mediated by the combined actions of methylated intermediates in cholesterol synthesis and the hypoxia-activated transcription factor HIF-1 alpha.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeBose-Boyd, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	Russell.DeBose-Boyd@utsouthwestern.edu		Nguyen, Andrew/0000-0002-9492-9472	NCI NIH HHS [CA 115962] Funding Source: Medline; NHLBI NIH HHS [HL 70441, HL 20948] Funding Source: Medline; NIGMS NIH HHS [T32 GM 008203, GM 069338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115962] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, K01HL070441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338, T32GM008203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH K, 1952, Harvey Lect, V48, P68; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Dolt KS, 2007, BIOCHEM BIOPH RES CO, V354, P148, DOI 10.1016/j.bbrc.2006.12.159; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gaylor JL, 2002, BIOCHEM BIOPH RES CO, V292, P1139, DOI 10.1006/bbrc.2001.2008; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gong Y, 2006, CELL METAB, V3, P15, DOI 10.1016/j.cmet.2005.11.014; HORIE M, 1990, J BIOL CHEM, V265, P18075; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kim H, 2003, MECH AGEING DEV, V124, P941, DOI 10.1016/S0047-6374(03)00166-0; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Lee PCW, 2005, J BIOL CHEM, V280, P25242, DOI 10.1074/jbc.M502989200; Lee PCW, 2007, J LIPID RES, V48, P318, DOI 10.1194/jlr.M600476-JLR200; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUKODANI J, 1990, ARTERIOSCLEROSIS, V10, P106, DOI 10.1161/01.ATV.10.1.106; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; SPENCE JT, 1977, J BIOL CHEM, V252, P5852; Summons RE, 2006, PHILOS T R SOC B, V361, P951, DOI 10.1098/rstb.2006.1837; Sung FL, 2007, CANCER LETT, V253, P74, DOI 10.1016/j.canlet.2007.01.012; SWINNEY DC, 1994, BIOCHEMISTRY-US, V33, P4702, DOI 10.1021/bi00181a030; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; WALKER KAM, 1993, J MED CHEM, V36, P2235, DOI 10.1021/jm00067a022; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WILLIAMS MT, 1977, CANCER RES, V37, P1377; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	61	88	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27436	27446		10.1074/jbc.M704976200	http://dx.doi.org/10.1074/jbc.M704976200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635920	hybrid			2022-12-25	WOS:000249304900085
J	Patel, PD; Bochar, DA; Turner, DL; Meng, F; Mueller, HM; Pontrello, CG				Patel, Paresh D.; Bochar, Daniel A.; Turner, David L.; Meng, Fan; Mueller, Helena M.; Pontrello, Crystal G.			Regulation of tryptophan hydroxylase-2 gene expression by a bipartite RE-1 silencer of Transcription/Neuron restrictive silencing factor (REST/NRSF) binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL GENE; NEURONAL GENES; MESSENGER-RNA; TARGET GENES; TRANSMISSION DISEQUILIBRIUM; POLYMORPHIC VARIANTS; NEUROBLASTOMA-CELLS; SEROTONIN SYNTHESIS; MAJOR DEPRESSION; RECEPTOR GENE	Tryptophan hydroxylase-2 (TPH2) is the rate-limiting enzyme in raphe serotonin biosynthesis, and polymorphisms of TPH2 are implicated in vulnerability to psychiatric disorders. Dynamic transcription regulation of TPH2 may underlie differences in vulnerability. We identified a transcription element in the TPH2 promoter that resembles the binding motif for RE-1 silencer of transcription ( REST; also known as NRSF) transcription factor. REST limits tissue expression of non-neuronal genes through a canonical 21-bp motif called the NRSE ( neuron-restrictive silencing element). The NRSE in TPH2 is a novel bipartite variant interrupted by a 6-base insertion. We confirmed that this bipartite NRSE permits transcriptional repression by REST identical to canonical NRSE in rat C6-glioma cells. Synthetic permutations of the motif revealed considerable flexibility in the juxtaposition of the two halves of bipartite NRSE. Computational analysis revealed many bipartite NRSE variants conserved between mouse and human genomes. A subgroup of these was found to bind REST by chromatin immunoprecipitation. Messenger RNAs for TPH2 and potassium channel H6, another gene with a bipartite NRSE, were up-regulated by dominant-negative REST in C6-glioma cells. These findings, which indicate that TPH2 expression is part of the developmental program regulated by REST and suggest that many previously unrecognized genes may be regulated by REST through the novel motif, have implications for the mechanism of REST action.	Univ Michigan, Med Ctr, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Calif Riverside, Program Neurosci, Riverside, CA 92521 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California Riverside	Patel, PD (corresponding author), Univ Michigan, Med Ctr, Mol & Behav Neurosci Inst, 5053 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	pdpatel@umich.edu	Bochar, Daniel A/A-9224-2009	Patel, Paresh/0000-0002-9145-4475	NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH063992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038698] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 063992] Funding Source: Medline; NINDS NIH HHS [NS 38698] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Belyaev ND, 2004, J BIOL CHEM, V279, P556, DOI 10.1074/jbc.M310353200; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; Blier P, 1999, NEUROPSYCHOPHARMACOL, V21, pS91, DOI 10.1016/S0893-133X(99)00036-6; Brookes K, 2006, MOL PSYCHIATR, V11, P934, DOI 10.1038/sj.mp.4001869; Brown HJ, 2006, NEUROSCI LETT, V398, P314, DOI 10.1016/j.neulet.2006.01.019; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Clark JA, 2005, BIOL PSYCHIAT, V57, P943, DOI 10.1016/j.biopsych.2005.01.013; Delgado PL, 1999, BIOL PSYCHIAT, V46, P212, DOI 10.1016/S0006-3223(99)00014-1; Delorme R, 2006, BIOL PSYCHIAT, V60, P202, DOI 10.1016/j.biopsych.2005.12.014; Drews VL, 2005, GENOMICS, V85, P245, DOI 10.1016/j.ygeno.2004.09.002; HAMON M, 1981, J PHYSIOL-PARIS, V77, P269; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Kang HC, 2005, FEBS J, V272, P1265, DOI 10.1111/j.1742-4658.2005.04564.x; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kinsey AM, 2001, MOL BRAIN RES, V88, P194, DOI 10.1016/S0169-328X(01)00034-1; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Kuhn DM, 2000, ANN NY ACAD SCI, V914, P92, DOI 10.1111/j.1749-6632.2000.tb05187.x; Kuwabara T, 2004, CELL, V116, P779, DOI 10.1016/S0092-8674(04)00248-X; Lemonde S, 2004, J NEUROCHEM, V88, P857, DOI 10.1046/j.1471-4159.2003.02223.x; Lietz M, 1998, BIOL CHEM, V379, P1301; Lucki I, 1998, BIOL PSYCHIAT, V44, P151, DOI 10.1016/S0006-3223(98)00139-5; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Lunyak VV, 2005, CELL, V121, P499, DOI 10.1016/j.cell.2005.05.003; Matthews K, 2001, SYNAPSE, V40, P1, DOI 10.1002/1098-2396(200104)40:1<1::AID-SYN1020>3.0.CO;2-E; Mossner R, 2006, INT J NEUROPSYCHOPH, V9, P437, DOI 10.1017/S1461145705005997; Mori N, 2002, NEUROBIOL AGING, V23, P255, DOI 10.1016/S0197-4580(01)00286-X; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Nishimura E, 1996, NEUROSCI LETT, V211, P101, DOI 10.1016/0304-3940(96)12722-1; Palm K, 1998, J NEUROSCI, V18, P1280; Patel PD, 2004, BIOL PSYCHIAT, V55, P428, DOI 10.1016/j.biopsych.2003.09.002; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Plaisance V, 2005, J BIOL CHEM, V280, P401, DOI 10.1074/jbc.M411825200; Reuter M, 2007, J COGNITIVE NEUROSCI, V19, P401, DOI 10.1162/jocn.2007.19.3.401; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Rozen S, 2000, Methods Mol Biol, V132, P365; Sanchez RL, 2005, MOL BRAIN RES, V135, P194, DOI 10.1016/j.molbrainres.2004.12.011; SCHEUCH K, 2007, IN PRESS BIOL PSYCHI; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Sheehan K, 2005, MOL PSYCHIATR, V10, P944, DOI 10.1038/sj.mp.4001698; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Szyf M, 2005, FRONT NEUROENDOCRIN, V26, P139, DOI 10.1016/j.yfrne.2005.10.002; Walitza S, 2005, MOL PSYCHIATR, V10, P1126, DOI 10.1038/sj.mp.4001734; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Zhang XD, 2004, SCIENCE, V305, P217, DOI 10.1126/science.1097540; Zhang XD, 2005, NEURON, V45, P11, DOI 10.1016/j.neuron.2004.12.014; Zhou ZF, 2005, ARCH GEN PSYCHIAT, V62, P1109, DOI 10.1001/archpsyc.62.10.1109	55	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26717	26724		10.1074/jbc.M705120200	http://dx.doi.org/10.1074/jbc.M705120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17613521	hybrid			2022-12-25	WOS:000249304900010
J	Bohm, S; Endres, S; Scheer, H; Zhao, KH				Boehm, Stephan; Endres, Stefanie; Scheer, Hugo; Zhao, Kai-Hong			Biliprotein chromophore attachment - Chaperone-like function of the PecE subunit of alpha-phycoerythrocyanin lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; IN-VITRO ATTACHMENT; C HEME LYASE; CYTOCHROME-C; AGMENELLUM-QUADRUPLICATUM; MASTIGOCLADUS-LAMINOSUS; PHYCOBILIPROTEIN LYASE; PHYTOCHROME MODELS; ENERGY-TRANSFER; PHYCOCYANIN	Biliproteins are post-translationally modified by chromophore addition. In phycoerythrocyanin, the heterodimeric lyase PecE/F covalently attaches phycocyanobilin (PCB) to cysteine-alpha 84 of the apoprotein PecA, with concomitant isomerization to phycoviolobilin. We found that: (a) PecA adds autocatalytically PCB, yielding a low absorbance, low fluorescence PCB center dot PecA adduct, termed P645 according to its absorption maximum; (b) In the presence of PecE, a high absorbance, high fluorescence PCB center dot PecA adduct is formed, termed P641; (c) PecE is capable of transforming P645 to P641; (d) When in stop-flow experiments, PecA and PecE were preincubated before chromophore addition, a red-shifted intermediate ( P650, tau = 32 ms) was observed followed by a second, which was blue-shifted (P605, tau = 0.5 s), and finally a third ( P638, tau = 14 s) that yielded the adduct ( P641, tau = 20 min); (e) The reaction was slower, and P605 was missing, if PecA and PecE were not preincubated; (f) Gel filtration gave no evidence of a stable complex between PecA and PecE; however, complex formation is induced by adding PCB; and (g) Ared-shifted intermediate was also formed, but more slowly, with phycoerythrobilin, and denaturation showed that this is not yet covalently bound. We conclude, therefore, that PecA and PecE form a weak complex that is stabilized by PCB, that the first reaction step involves a conformational change and/or protonation of PCB, and that PecE has a chaperone-like function on the chromoprotein.	Univ Munich, Bereich Botan, Dept Biol 1, D-80638 Munich, Germany; Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430074, Peoples R China	University of Munich; Huazhong University of Science & Technology	Scheer, H (corresponding author), Univ Munich, Bereich Botan, Dept Biol 1, Menzinger Str 67, D-80638 Munich, Germany.	hugo.scheer@lmu.de						Adir N, 2002, BBA-BIOENERGETICS, V1556, P168, DOI 10.1016/S0005-2728(02)00359-6; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BOHM S, 2006, THESIS U MUNICH GERM; Borucki B, 2005, J BIOL CHEM, V280, P34358, DOI 10.1074/jbc.M505493200; Borucki B, 2003, BIOCHEMISTRY-US, V42, P13684, DOI 10.1021/bi035511n; BRASLAVSKY SE, 1991, J AM CHEM SOC, V113, P7322, DOI 10.1021/ja00019a033; BRASLAVSKY SE, 1983, ANGEW CHEM INT EDIT, V22, P656, DOI 10.1002/anie.198306561; BREJC K, 1995, J MOL BIOL, V249, P424, DOI 10.1006/jmbi.1995.0307; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DEBRECZENY MP, 1995, J PHYS CHEM-US, V99, P8412, DOI 10.1021/j100020a080; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; FAIRCHILD CD, 1992, P NATL ACAD SCI USA, V89, P7017, DOI 10.1073/pnas.89.15.7017; FAIRCHILD CD, 1994, J BIOL CHEM, V269, P28988; Falk H., 1989, CHEM LINEAR OLIGOPYR; Feissner RE, 2006, MOL MICROBIOL, V60, P563, DOI 10.1111/j.1365-2958.2006.05132.x; Foerstendorf H, 1997, FEBS LETT, V402, P173, DOI 10.1016/S0014-5793(96)01521-9; Foerstendorf H, 2001, BIOCHEMISTRY-US, V40, P14952, DOI 10.1021/bi0156916; GANTT E, 1986, PHOTOSYNTHESIS 3, P327; GLAZER AN, 1973, J BIOL CHEM, V248, P5679; GLAZER AN, 1988, METHOD ENZYMOL, V167, P304; Hu IC, 2006, BIOCHEMISTRY-US, V45, P7092, DOI 10.1021/bi052067a; Jiang T, 2001, BIOPHYS J, V81, P1171, DOI 10.1016/S0006-3495(01)75774-8; Kahn K, 1997, J BACTERIOL, V179, P998, DOI 10.1128/jb.179.4.998-1006.1997; Kneip C, 1998, J RAMAN SPECTROSC, V29, P939, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<939::AID-JRS320>3.3.CO;2-O; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; KUFER W, 1989, PHYSIOL PLANTARUM, V75, P389, DOI 10.1111/j.1399-3054.1989.tb04643.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 1997, P NATL ACAD SCI USA, V94, P11792, DOI 10.1073/pnas.94.22.11792; LUND P, 2001, FRONTIERS MOL BIOL, V37; MacColl R., 1987, PHYCOBILIPROTEINS; Main ERG, 2005, CURR OPIN STRUC BIOL, V15, P464, DOI 10.1016/j.sbi.2005.07.003; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; Nield J, 2003, J STRUCT BIOL, V141, P149, DOI 10.1016/S1047-8477(02)00609-3; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Park CM, 2000, BIOCHEMISTRY-US, V39, P6349, DOI 10.1021/bi992916s; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; Reuter W, 1999, P NATL ACAD SCI USA, V96, P1363, DOI 10.1073/pnas.96.4.1363; Ritter S, 1999, J STRUCT BIOL, V126, P86, DOI 10.1006/jsbi.1999.4106; SAUER K, 1987, PHOTOCHEM PHOTOBIOL, V46, P427, DOI 10.1111/j.1751-1097.1987.tb04790.x; SCHEER H, 1982, MOL ASPECTS PHOTOSYN, P7; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; Schluchter W. M., 1999, PHOTOTROPHIC PROKARY, P83; Shen G., 2004, PS 2004 LIGHT HARV S, P14; SIDLER W, 1994, BIOL CYANOBACTERIA, P139; Stec B, 1999, BIOPHYS J, V76, P2912, DOI 10.1016/S0006-3495(99)77446-1; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; Stevens JM, 2005, BIOCHEM SOC T, V33, P792, DOI 10.1042/BST0330792; Storf M, 2001, BIOCHEMISTRY-US, V40, P12444, DOI 10.1021/bi010776s; STORF M, 2003, THESIS U MUNICH; TEGMOLARSSON IM, 1981, J AM CHEM SOC, V103, P7152, DOI 10.1021/ja00414a019; Terauchi K, 2004, MOL MICROBIOL, V51, P567, DOI 10.1046/j.1365-2958.2003.03853.x; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Turkarslan S, 2006, MOL MICROBIOL, V60, P537, DOI 10.1111/j.1365-2958.2006.05148.x; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Zhao KH, 2006, J BIOL CHEM, V281, P8573, DOI 10.1074/jbc.M513796200; Zhao KH, 2005, BIOCHEMISTRY-US, V44, P8126, DOI 10.1021/bi0500168; Zhao KH, 2005, BBA-BIOENERGETICS, V1706, P81, DOI 10.1016/j.bbabio.2004.09.008; Zhao KH, 2004, BIOCHEMISTRY-US, V43, P11576, DOI 10.1021/bi0491548; Zhao KH, 2004, BBA-BIOENERGETICS, V1657, P131, DOI 10.1016/j.bbabio.2004.04.010; Zhao KH, 2002, EUR J BIOCHEM, V269, P4542, DOI 10.1046/j.1432-1033.2002.03148.x; Zhao KH, 2000, FEBS LETT, V469, P9, DOI 10.1016/S0014-5793(00)01245-X	72	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25357	25366		10.1074/jbc.M702669200	http://dx.doi.org/10.1074/jbc.M702669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17595164	hybrid			2022-12-25	WOS:000249014100021
J	Mogal, AP; van der Meer, R; Crooke, PS; Abdulkadir, SA				Mogal, Ashish P.; van der Meer, Riet; Crooke, Philip S.; Abdulkadir, Sarki A.			Haploinsufficient prostate tumor suppression by Nkx3.1 - A role for chromatin accessibility in dosage-sensitive gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROCHROMATIC GENE; HISTONE ACETYLATION; HAPLO-INSUFFICIENT; TRICHOSTATIN-A; ADIPOSE-TISSUE; EXPRESSION; CANCER; ACTIVATION; P53; MECHANISMS	Transcription factor haploin sufficiency plays a role in the pathogenesis of many diseases, including cancer. In a mouse model of prostate tumor initiation, loss of a single allele of the tumor suppressor Nkx3.1 stochastically inactivates the expression of a class of dosage-sensitive target genes. Here we show that dosage sensitivity is associated with the differential histone H3/H4 acetylation states of Nkx3.1 target genes. When histone acetylation is induced in Nkx3.1 (+)/ (-) mouse prostates with the histone deacetylase inhibitor Trichostatin A, Nkx3.1 can bind to and reactivate the expression of dosage-sensitive target genes. We incorporated our findings into a mathematical model that entails the association of Nkx3.1 with histone acetyltransferase activity. Subsequent experiments indicate that Nkx3.1 associates with and recruits the histone acetyltransferase p300/CREB-binding protein-associated factor to chromatin. Finally, we demonstrate a role for the dosage-sensitive target gene intelectin/omentin in suppressing prostate tumorigenicity. Our results reveal how the interplay between transcription factor dosage and chromatin affects target gene expression in tumor initiation.	Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Math, Nashville, TN 37240 USA	Vanderbilt University; Vanderbilt University	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu	Crooke, Philip S/B-5406-2008	Crooke, Philip S/0000-0003-3872-3290; Crooke, Philip/0000-0002-7086-1522	NATIONAL CANCER INSTITUTE [R01CA094858] Funding Source: NIH RePORTER; NCI NIH HHS [CA94858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdulkadir SA, 2005, ANN NY ACAD SCI, V1059, P33, DOI 10.1196/annals.1339.018; Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Cook DL, 1998, P NATL ACAD SCI USA, V95, P15641, DOI 10.1073/pnas.95.26.15641; Cook WD, 2000, ONCOGENE, V19, P3434, DOI 10.1038/sj.onc.1203653; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karmakar R, 2006, PHYS BIOL, V3, P200, DOI 10.1088/1478-3975/3/3/005; Kasper S, 2000, BBA-PROTEIN STRUCT M, V1482, P249, DOI 10.1016/S0167-4838(00)00170-9; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Lei QY, 2006, CANCER CELL, V9, P367, DOI 10.1016/j.ccr.2006.03.031; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Mogal A, 2006, MOL CELL PROBE, V20, P81, DOI 10.1016/j.mcp.2005.09.008; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Schaffler A, 2005, BBA-GENE STRUCT EXPR, V1732, P96, DOI 10.1016/j.bbaexp.2005.11.005; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Steadman DJ, 2000, NUCLEIC ACIDS RES, V28, P2389, DOI 10.1093/nar/28.12.2389; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tsuji S, 2001, J BIOL CHEM, V276, P23456, DOI 10.1074/jbc.M103162200; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Yang RZ, 2006, AM J PHYSIOL-ENDOC M, V290, pE1253, DOI 10.1152/ajpendo.00572.2004; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	31	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25790	25800		10.1074/jbc.M702438200	http://dx.doi.org/10.1074/jbc.M702438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17602165	hybrid			2022-12-25	WOS:000249014100066
J	Price, KL; Millen, KS; Lummis, SCR				Price, Kerry L.; Millen, Katherine S.; Lummis, Sarah C. R.			Transducing agonist binding to channel gating involves different interactions in 5-HT3 and GABA(C) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC RECEPTORS; CRYSTAL-STRUCTURE; CHARGED RESIDUES; ION-CHANNEL; PROTEIN; ACTIVATION; BARNASE; REVEALS; DOMAIN	5-Hydroxytryptamine ( 5-HT)(3) and gamma-aminobutyric acid, type C ( GABA(C)) receptors are members of the Cys-loop superfamily of neurotransmitter receptors, which also includes nicotinic acetylcholine, GABA(A), and glycine receptors. The details of how agonist binding to these receptors results in channel opening is not fully understood but is known to involve charged residues at the extracellular/ transmembrane interface. Here we have examined the roles of such residues in 5-HT3 and GABAC receptors. Charge reversal experiments combined with data from activation by the partial agonist beta-alanine show that in GABA(C) receptors there is a salt bridge between Glu-92 ( in loop 2) and Arg-258 ( in the pre-M1 region), which is involved in receptor gating. The equivalent residues in the 5-HT3 receptor are important for receptor expression, but charge reversal experiments do not restore function, indicating that there is not a salt bridge here. There is, however, an interaction between Glu-215 ( loop 9) and Arg-246 ( pre-M1) in the 5- HT3 receptor, although the coupling energy determined from mutant cycle analysis is lower than might be expected for a salt bridge. Overall the data show that charged residues at the extracellular/ transmembrane domain interfaces in 5- HT3 and GABA(C) receptors are important and that specific, but not equivalent, molecular interactions between them are involved in the gating process. Thus, we propose that the molecular details of interactions in the transduction pathway between the binding site and the pore can differ between different Cys-loop receptors.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; MRC, Mol Biol Lab, Div Neurobiol, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	sl120@cam.ac.uk		Price, Kerry/0000-0002-5563-4567	Wellcome Trust [051097] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Castaldo P, 2004, J BIOL CHEM, V279, P25598, DOI 10.1074/jbc.M311021200; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lummis SCR, 2005, NATURE, V438, P248, DOI 10.1038/nature04130; Mercado J, 2006, J NEUROSCI, V26, P2031, DOI 10.1523/JNEUROSCI.4555-05.2006; Price KL, 2004, J BIOL CHEM, V279, P23294, DOI 10.1074/jbc.M314075200; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Vaughan CK, 2002, ACTA CRYSTALLOGR D, V58, P591, DOI 10.1107/S0907444902001567; Vicente-Agullo F, 2001, BIOCHEMISTRY-US, V40, P8300, DOI 10.1021/bi010087g; WANG J, 2007, J BIOL CHEM     0702; Xiu XN, 2005, J BIOL CHEM, V280, P41655, DOI 10.1074/jbc.M508635200; Zhang L, 2002, J BIOL CHEM, V277, P46256, DOI 10.1074/jbc.M207683200	21	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25623	25630		10.1074/jbc.M702524200	http://dx.doi.org/10.1074/jbc.M702524200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606617	hybrid			2022-12-25	WOS:000249014100049
J	Chen, R; Yang, L; McIntyre, TM				Chen, Rui; Yang, Lili; McIntyre, Thomas M.			Cytotoxic phospholipid oxidation products - Cell death from mitochondrial damage and the intrinsic caspase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; FACTOR-ACETYLHYDROLASE-II; OXIDIZED PHOSPHOLIPIDS; INDUCED APOPTOSIS; PERMEABILITY TRANSITION; ATHEROSCLEROTIC PLAQUES; ENDOTHELIAL-CELLS; HUMAN PLASMA	Phospholipid oxidation products accumulate in the necrotic core of atherosclerotic lesions, in apoptotic cells, and circulate in oxidized low density lipoprotein. Phospholipid oxidation generates toxic products, but little is known about which specific products are cytotoxic, their receptors, or the mechanism(s) that induces cell death. We find the most common phospholipid oxidation product of oxidized low density lipoprotein, phosphatidylcholine with esterified sn-2-azelaic acid, induced apoptosis at low micromolar concentrations. The synthetic ether phospholipid hexadecyl azelaoyl phosphatidylcholine (HAzPC) was rapidly internalized, and overexpression of PLA2g7 (PAF acetylhydrolase) that specifically hydrolyzes such oxidized phospholipids suppressed apoptosis. Internalized HAzPC associated with mitochondria, and cytochrome c, and apoptosis-inducing factor escaped from mitochondria to the cytoplasm and nucleus, respectively, in cells exposed to HAzPC. Isolated mitochondria exposed to HAzPC rapidly swelled and released cytochrome c and apoptosis-inducing factor. Other phospholipid oxidation products induced swelling, but HAzPC was the most effective and was twice as effective as its diacyl homolog. Cytoplasmic cytochrome c completes the apoptosome, and activated caspase 9 and 3 were present in cells exposed to HAzPC. Irreversible inhibition of caspase 9 blocked downstream caspase 3 activation and prevented apoptosis. Mitochondrial damage initiated this apoptotic cascade, because overexpression of Bcl-X-L, an anti-apoptotic protein localized to mitochondria, blocked cytochrome c escape and apoptosis. Thus, exogenous phospholipid oxidation products target intracellular mitochondria to activate the intrinsic apoptotic cascade.	Cleveland Clin, Coll Med, Dept Cell Biol, Lerner Res Inst,NE10, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	McIntyre, TM (corresponding author), Cleveland Clin, Coll Med, Dept Cell Biol, Lerner Res Inst,NE10, 9500 Euclid Ave, Cleveland, OH 44195 USA.	mcintyt@ccf.org			NHLBI NIH HHS [R01 HL044513-19, R01 HL044513, HL44513, R01 HL044513-18, R01 HL044513-20, R01 HL044513-17] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asmis R, 2003, CIRC RES, V92, pE20, DOI 10.1161/01.RES.0000051886.43510.90; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonin F, 2004, J BIOL CHEM, V279, P52425, DOI 10.1074/jbc.M410967200; Carpenter KLH, 2003, FEBS LETT, V553, P145, DOI 10.1016/S0014-5793(03)01007-X; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Finkelstein EI, 2005, AM J PHYSIOL-LUNG C, V289, pL1019, DOI 10.1152/ajplung.00227.2005; FRANKEL EN, 1984, PROG LIPID RES, V23, P197, DOI 10.1016/0163-7827(84)90011-0; Fruhwirth GO, 2006, BBA-MOL CELL BIOL L, V1761, P1060, DOI 10.1016/j.bbalip.2006.06.001; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hirashima Y, 2000, BRAIN RES, V885, P128, DOI 10.1016/S0006-8993(00)02852-3; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kim HE, 2005, P NATL ACAD SCI USA, V102, P17545, DOI 10.1073/pnas.0507900102; Knapp S, 2007, J IMMUNOL, V178, P993, DOI 10.4049/jimmunol.178.2.993; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; Kogure K, 2003, CHEM PHYS LIPIDS, V126, P29, DOI 10.1016/S0009-3084(03)00091-4; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; Landar A, 2006, BIOCHEM J, V394, P185, DOI 10.1042/BJ20051259; Littlewood TD, 2003, CURR OPIN LIPIDOL, V14, P469, DOI 10.1097/00041433-200310000-00007; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Loidl A, 2003, J BIOL CHEM, V278, P32921, DOI 10.1074/jbc.M306088200; Madamanchi NR, 2007, CIRC RES, V100, P460, DOI 10.1161/01.RES.0000258450.44413.96; Marques M, 2002, J INVEST DERMATOL, V119, P913, DOI 10.1046/j.1523-1747.2002.01859.x; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; Moumtzi A, 2007, J LIPID RES, V48, P565, DOI 10.1194/jlr.M600394-JLR200; Nakajima K, 2006, CLIN CHIM ACTA, V367, P36, DOI 10.1016/j.cca.2005.12.013; Nishi K, 2002, ARTERIOSCL THROM VAS, V22, P1649, DOI 10.1161/01.ATV.0000033829.14012.18; Ogden F, 1998, J NEUROSCI RES, V53, P677, DOI 10.1002/(SICI)1097-4547(19980915)53:6<677::AID-JNR6>3.0.CO;2-2; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Ravandi A, 2004, LIPIDS, V39, P97, DOI 10.1007/s11745-004-1207-5; Salvayre R, 2002, BBA-MOL CELL BIOL L, V1585, P213, DOI 10.1016/S1388-1981(02)00343-8; Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008; SCHMITT A, 1995, BBA-LIPID LIPID MET, V1256, P284, DOI 10.1016/0005-2760(95)00032-8; Seleznev K, 2006, J BIOL CHEM, V281, P22275, DOI 10.1074/jbc.M604330200; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Sun LJ, 2006, MITOCHONDRION, V6, P136, DOI 10.1016/j.mito.2006.04.003; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Tokumura A, 1996, LIPIDS, V31, P1251, DOI 10.1007/BF02587909; Uhlson C, 2002, CHEM RES TOXICOL, V15, P896, DOI 10.1021/tx010183i; Vindis C, 2005, ARTERIOSCL THROM VAS, V25, P639, DOI 10.1161/01.ATV.0000154359.60886.33; Waddington EI, 2003, ATHEROSCLEROSIS, V167, P111, DOI 10.1016/S0021-9150(02)00391-X; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Watanabe N, 2006, AM J PATHOL, V168, P1737, DOI 10.2353/ajpath.2006.050648; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Wintergerst ES, 2000, EUR J BIOCHEM, V267, P6050, DOI 10.1046/j.1432-1327.2000.01682.x; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	50	74	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24842	24850		10.1074/jbc.M702865200	http://dx.doi.org/10.1074/jbc.M702865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17597068	Green Accepted, hybrid			2022-12-25	WOS:000248933000040
J	Muraoka, M; Miki, T; Ishida, N; Hara, T; Kawakita, M				Muraoka, Masatoshi; Miki, Toshiaki; Ishida, Nobuhiro; Hara, Takahiko; Kawakita, Masao			Variety of nucleotide sugar transporters with respect to the interaction with nucleoside mono- and diphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONIC ACID; GOLGI-APPARATUS MEMBRANE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; N-ACETYLGALACTOSAMINE; GDP-MANNOSE; RAT-LIVER; GUANOSINE DIPHOSPHATASE; SUBSTRATE-SPECIFICITY; FRINGE CONNECTION	Nucleotide sugar transporters have long been assumed to be antiporters that exclusively use nucleoside monophosphates as antiport substrates. Here we present evidence indicating that two other types of nucleotide sugar transporters exist that differ in their antiport substrate specificity. Biochemical studies using microsomes derived from Saccharomyces cerevisiae cells expressing either human ( h) UGTrel7 or the Drosophila (d) FRC ( Fringe connection) transporter revealed that (i) efflux of pre-loaded UDP-glucuronic acid from the yeast microsomes expressing hUGTrel7 was strongly enhanced by UDP-GlcNAc added in the external medium, but not by UMP or UDP, suggesting that hUGTrel7 may be described as a UDP-sugar/UDPsugar antiporter, and (ii) addition of UDP-sugars, UDP, or UMP in the external medium stimulated the efflux of preloaded UDPGlcNAc from the yeast microsomes expressing dFRC to a comparable extent, suggesting that UDP, as well as UMP, may serve as an antiport substrate of dFRC. Antiport of UDP-sugars with these specific substrates was reproduced and definitively confirmed using proteoliposomes reconstituted from solubilized and purified transporters. Possible physiological implications of these observations are discussed.	Tokyo Metropolitan Inst Med Sci, Stem Cell Project, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Single Mol Project, Tokyo 1138613, Japan; Chiba Inst Sci, Dept Environm Syst Sci, Chiba 2880025, Japan; Kogakuin Univ, Dept Appl Chem, Tokyo 1920015, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Kogakuin University	Muraoka, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Stem Cell Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	muraoka@rinshoken.or.jp						ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; ADAMS A, 1997, METHODS YEAST GENTIC; Aoki K, 2003, J BIOL CHEM, V278, P22887, DOI 10.1074/jbc.M302620200; Banhegyi G, 1996, BIOCHEM J, V315, P171, DOI 10.1042/bj3150171; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; BERRY C, 1976, BIOCHEM SOC T, V4, P650, DOI 10.1042/bst0040650; BOSSUYT X, 1994, BIOCHEM J, V302, P261, DOI 10.1042/bj3020261; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Kawakita M, 1998, J BIOCHEM, V123, P777; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1992, J BIOL CHEM, V267, P103; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; POGELL BM, 1961, J BIOL CHEM, V236, P293; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; Segawa H, 2005, J BIOL CHEM, V280, P2028, DOI 10.1074/jbc.M404915200; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; SONE N, 1977, J BIOCHEM-TOKYO, V81, P519, DOI 10.1093/oxfordjournals.jbchem.a131485; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; Sun-Wada GH, 1998, J BIOCHEM, V123, P912; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006; Yano H, 2005, P NATL ACAD SCI USA, V102, P13467, DOI 10.1073/pnas.0506681102	31	16	17	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24615	24622		10.1074/jbc.M611358200	http://dx.doi.org/10.1074/jbc.M611358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17599910	hybrid			2022-12-25	WOS:000248933000016
J	Sequeira, SJ; Ranganathan, AC; Adam, AP; Iglesias, BV; Farias, EF; Aguirre-Ghiso, JA				Sequeira, Sharon J.; Ranganathan, Aparna C.; Adam, Alejandro P.; Iglesias, Bibiana V.; Farias, Eduardo F.; Aguirre-Ghiso, Julio A.			Inhibition of Proliferation by PERK Regulates Mammary Acinar Morphogenesis and Tumor Formation	PLOS ONE			English	Article							UNFOLDED PROTEIN RESPONSE; INDUCED GENE-EXPRESSION; EPITHELIAL-CELL LINE; MESSENGER-RNA; ALPHA(6)BETA(4) INTEGRIN; TRANSLATIONAL CONTROL; BREAST-CANCER; ACTIVATION; APOPTOSIS; KINASE	Endoplasmic reticulum ( ER) stress signaling can be mediated by the ER kinase PERK, which phosphorylates its substrate eIF2 alpha. This in turn, results in translational repression and the activation of downstream programs that can limit cell growth through cell cycle arrest and/or apoptosis. These responses can also be initiated by perturbations in cell adhesion. Thus, we hypothesized that adhesion-dependent regulation of PERK signaling might determine cell fate. We tested this hypothesis in a model of mammary acini development, a morphogenetic process regulated in part by adhesion signaling. Here we report a novel role for PERK in limiting MCF10A mammary epithelial cell proliferation during acinar morphogenesis in 3D Matrigel culture as well as in preventing mammary tumor formation in vivo. We show that loss of adhesion to a suitable substratum induces PERK-dependent phosphorylation of eIF2a and selective upregulation of ATF4 and GADD153. Further, inhibition of endogenous PERK signaling during acinar morphogenesis, using two dominant-negative PERK mutants (PERK-Delta C or PERK-K618A), does not affect apoptosis but results instead in hyper-proliferative and enlarged lumen-filled acini, devoid of proper architecture. This phenotype correlated with an adhesion-dependent increase in translation initiation, Ki67 staining and upregulation of Laminin-5, ErbB1 and ErbB2 expression. More importantly, the MCF10A cells expressing PERK Delta C, but not a vector control, were tumorigenic in vivo upon orthotopic implantation in denuded mouse mammary fat pads. Our results reveal that the PERK pathway is responsive to adhesion-regulated signals and that it is essential for proper acinar morphogenesis and in preventing mammary tumor formation. The possibility that deficiencies in PERK signaling could lead to hyperproliferation of the mammary epithelium and increase the likelihood of tumor formation, is of significance to the understanding of breast cancer.	[Sequeira, Sharon J.; Ranganathan, Aparna C.; Adam, Alejandro P.; Iglesias, Bibiana V.; Aguirre-Ghiso, Julio A.] SUNY Albany, Dept Biomed Sci, Sch Publ Hlth, Rensselaer, NY USA; [Sequeira, Sharon J.; Ranganathan, Aparna C.; Adam, Alejandro P.; Iglesias, Bibiana V.; Aguirre-Ghiso, Julio A.] SUNY Albany, Ctr Excellence Canc Genom, Rensselaer, NY USA; [Farias, Eduardo F.] Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Icahn School of Medicine at Mount Sinai	Aguirre-Ghiso, JA (corresponding author), SUNY Albany, Dept Biomed Sci, Sch Publ Hlth, Rensselaer, NY USA.	jaguirre-ghiso@albany.edu	Adam, Alejandro/M-6541-2013	Adam, Alejandro/0000-0001-6285-7235; Aguirre-Ghiso, Julio/0000-0002-6694-6507	Samuel Waxman Cancer Research Foundation; NIH/National Cancer Institute [CA109182]; Ruth L. Kirschstein National Research Service Award; NIH [CA119018]; NATIONAL CANCER INSTITUTE [R01CA119018, R01CA109182] Funding Source: NIH RePORTER	Samuel Waxman Cancer Research Foundation; NIH/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from the Samuel Waxman Cancer Research Foundation Tumor Dormancy Program and an NIH/National Cancer Institute grant CA109182 (to JAAG), a Ruth L. Kirschstein National Research Service Award (NIH/National Cancer Institute) Fellowship (to ACR) and an NIH grant CA119018 (to EFF).	Bagheri-Yarmand R, 2003, J BIOL CHEM, V278, P17421, DOI 10.1074/jbc.M300761200; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BENECKE BJ, 1980, J CELL PHYSIOL, V103, P247, DOI 10.1002/jcp.1041030209; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Biason-Lauber A, 2002, DIABETES, V51, P2301, DOI 10.2337/diabetes.51.7.2301; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Coller HA, 2006, PLOS BIOL, V4, P329, DOI 10.1371/journal.pbio.0040083; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Faraldo MM, 2001, EMBO REP, V2, P431, DOI 10.1093/embo-reports/kve086; FARMER SR, 1978, CELL, V15, P627, DOI 10.1016/0092-8674(78)90031-4; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gan BY, 2006, J BIOL CHEM, V281, P37321, DOI 10.1074/jbc.M605241200; Gorrini C, 2005, P NATL ACAD SCI USA, V102, P9200, DOI 10.1073/pnas.0409513102; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harris J, 1999, DIS BREAST; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ranganathan AC, 2006, CANCER BIOL THER, V5, P729, DOI 10.4161/cbt.5.7.2968; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Siegel J, 1998, INT J ONCOL, V13, P1259; Sonenberg N, 2000, TRANSLATIONAL CONTRO; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; SOULE HD, 1990, CANCER RES, V50, P6075; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Yoon SO, 2006, CANCER RES, V66, P2732, DOI 10.1158/0008-5472.CAN-05-2941; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	64	59	58	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e615	10.1371/journal.pone.0000615	http://dx.doi.org/10.1371/journal.pone.0000615			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637831	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452100005
J	Reyes, CL; Rutenber, E; Walter, P; Stroud, RM				Reyes, Christopher L.; Rutenber, Earl; Walter, Peter; Stroud, Robert M.			X-ray Structures of the Signal Recognition Particle Receptor Reveal Targeting Cycle Intermediates	PLOS ONE			English	Article							MEMBRANE ASSOCIATION; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; NG DOMAIN; SRP; FTSY; PROTEIN; FFH; DIFFRACTION; MECHANISM	The signal recognition particle (SRP) and its conjugate receptor (SR) mediate cotranslational targeting of a subclass of proteins destined for secretion to the endoplasmic reticulum membrane in eukaryotes or to the plasma membrane in prokaryotes. Conserved active site residues in the GTPase domains of both SRP and SR mediate discrete conformational changes during formation and dissociation of the SRP? SR complex. Here, we describe structures of the prokaryotic SR, FtsY, as an apo protein and in two different complexes with a non-hydrolysable GTP analog (GMPPNP). These structures reveal intermediate conformations of FtsY containing GMPPNP and explain how the conserved active site residues position the nucleotide into a non-catalytic conformation. The basis for the lower specificity of binding of nucleotide in FtsY prior to heterodimerization with the SRP conjugate Ffh is also shown. We propose that these structural changes represent discrete conformational states assumed by FtsY during targeting complex formation and dissociation.	[Reyes, Christopher L.; Stroud, Robert M.] Univ Calif San Francisco, Dept Biochem & Biophys, Grad Grp Biophys, San Francisco, CA 94143 USA; [Rutenber, Earl; Walter, Peter] Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Stroud, RM (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Grad Grp Biophys, San Francisco, CA 94143 USA.	stroud@msg.ucsf.edu			National Institutes of Health [GM 60641, GM 32384]; Ford Foundation; NIGMS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032384, R37GM032384, R01GM060641] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ford Foundation; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grants GM 60641 to RMS and is by GM 32384 to PW. PW is an investigator of the Howard Hughes Medical Institute. Christopher Reyes was supported by a Ford Foundation Minority Fellowship and the NIGMS Minority Graduate Fellowship.	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; deLeeuw E, 1997, FEBS LETT, V416, P225, DOI 10.1016/S0014-5793(97)01238-6; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; Focia PJ, 2006, J MOL BIOL, V360, P631, DOI 10.1016/j.jmb.2006.05.031; Focia PJ, 2004, SCIENCE, V303, P373, DOI 10.1126/science.1090827; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Freymann DM, 1999, NAT STRUCT BIOL, V6, P793, DOI 10.1038/11572; Gariani T, 2006, J STRUCT BIOL, V153, P85, DOI 10.1016/j.jsb.2005.10.003; GAWRONSKISALERN.J, 2006, PROTEINS; GAWRONSKISALERN.J, 2006, J STRUCT BIOL; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jagath JR, 2000, J MOL BIOL, V295, P745, DOI 10.1006/jmbi.1999.3427; *JOINT CTR STRUCT, 2007, CRYST STRUCT CELL DI; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Montoya G, 1997, PROTEINS, V28, P285, DOI 10.1002/(SICI)1097-0134(199706)28:2<285::AID-PROT15>3.0.CO;2-E; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padmanabhan S, 2001, STRUCTURE, V9, P859, DOI 10.1016/S0969-2126(01)00641-4; Peluso P, 2001, BIOCHEMISTRY-US, V40, P15224, DOI 10.1021/bi011639y; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Shan SO, 2004, PLOS BIOL, V2, P1572, DOI 10.1371/journal.pbio.0020320; Shan SO, 2003, P NATL ACAD SCI USA, V100, P4480, DOI 10.1073/pnas.0737693100; Shepotinovskaya IV, 2002, BBA-PROTEIN STRUCT M, V1597, P107, DOI 10.1016/S0167-4838(02)00287-X; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Zelazny A, 1997, P NATL ACAD SCI USA, V94, P6025, DOI 10.1073/pnas.94.12.6025; Zhang JT, 2000, BIOCHEM J, V348, P597, DOI 10.1042/0264-6021:3480597	33	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e607	10.1371/journal.pone.0000607	http://dx.doi.org/10.1371/journal.pone.0000607			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622352	Green Published, gold			2022-12-25	WOS:000207452000014
J	Holst, CR; Bou-Reslan, H; Gore, BB; Wong, K; Grant, D; Chalasani, S; Carano, RA; Frantz, GD; Tessier-Lavigne, M; Bolon, B; French, DM; Ashkenazi, A				Holst, Charles R.; Bou-Reslan, Hani; Gore, Bryan B.; Wong, Karen; Grant, Deanna; Chalasani, Sreedevi; Carano, Richard A.; Frantz, Gretchen D.; Tessier-Lavigne, Marc; Bolon, Brad; French, Dorothy M.; Ashkenazi, Avi			Secreted Sulfatases Sulf1 and Sulf2 Have Overlapping yet Essential Roles in Mouse Neonatal Survival	PLOS ONE			English	Article								Background. Heparan sulfate proteoglycans (HSPGs) use highly sulfated polysaccharide side-chains to interact with several key growth factors and morphogens, thereby regulating their accessibility and biological activity. Various sulfotransferases and sulfatases with differing specificities control the pattern of HSPG sulfation, which is functionally critical. Among these enzymes in the mouse are two secreted 6-O-endosulfatases, Sulf1 and Sulf2, which modify HSPGs in the extracellular matrix and on the cell surface. The roles of Sulf1 and Sulf2 during normal development are not well understood. Methods/Results. To investigate the importance of Sulf1 and Sulf2 for embryonic development, we generated mice genetically deficient in these genes and assessed the phenotypes of the resulting secreted sulfatase-deficient mice. Surprisingly, despite the established crucial role of HSPG interactions during development, neither Sulf1- nor Sulf2-deficient mice showed significant developmental flaws. In contrast, mice deficient in both Sulf1and Sulf2 exhibited highly penetrant neonatal lethality. Loss of viability was associated with multiple, although subtle, developmental defects, including skeletal and renal abnormalities. Conclusions. These results show that Sulf1 and Sulf2 play overlapping yet critical roles in mouse development and are redundant and essential for neonatal survival.	[Holst, Charles R.; Ashkenazi, Avi] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Bou-Reslan, Hani; Carano, Richard A.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA; [Gore, Bryan B.; Wong, Karen; Tessier-Lavigne, Marc] Genentech Inc, Dept Res Drug Discovery, San Francisco, CA 94080 USA; [Grant, Deanna] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; [Chalasani, Sreedevi; Frantz, Gretchen D.; French, Dorothy M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Gore, Bryan B.] Stanford Univ, Grad Program Neurosci, Stanford, CA 94305 USA; [Bolon, Brad] GEMpath Inc, Cedar City, UT USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Stanford University	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589; Holst, Charles/0000-0001-8010-1677	Genentech, Inc.	Genentech, Inc.(Roche HoldingGenentech)	Genentech, Inc. funded this research project.	Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Cole F, 2003, CURR BIOL, V13, P411, DOI 10.1016/S0960-9822(03)00088-5; Compagni A, 2003, DEV CELL, V5, P217, DOI 10.1016/S1534-5807(03)00198-9; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Hajihosseini MK, 2004, DEVELOPMENT, V131, P325, DOI 10.1242/dev.00940; Jena N, 1997, EXP CELL RES, V230, P28, DOI 10.1006/excr.1996.3411; Kamimura K, 2006, J CELL BIOL, V174, P773, DOI 10.1083/jcb.200603129; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lamanna WC, 2007, J BIOTECHNOL, V129, P290, DOI 10.1016/j.jbiotec.2007.01.022; Lamanna WC, 2006, BIOCHEM J, V400, P63, DOI 10.1042/BJ20060848; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lum DH, 2007, MOL CELL BIOL, V27, P678, DOI 10.1128/MCB.01279-06; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; McLaughlin D, 2003, MECH DEVELOP, V120, P1481, DOI 10.1016/j.mod.2003.08.008; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nagamine S, 2005, DEV BRAIN RES, V159, P135, DOI 10.1016/j.devbrainres.2005.07.006; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Uchimura Kenji, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-2; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Wang O, 2001, DEVELOPMENT, V128, P3867; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	46	98	99	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e575	10.1371/journal.pone.0000575	http://dx.doi.org/10.1371/journal.pone.0000575			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593974	Green Published, Green Submitted, gold			2022-12-25	WOS:000207451800019
J	Alcala, S; Klee, M; Fernandez, J; Fleischer, A; Pimental-Muinos, F				Alcala, S.; Klee, M.; Fernandez, J.; Fleischer, A.; Pimental-Muinos, Fx			A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release	ONCOGENE			English	Article						high-throughput screening; atypical cell death; apoptosis; permeability transition; phosphate carrier	PERMEABILITY TRANSITION-PORE; APOPTOSIS; PROTEIN; COMPLEXES; COMPONENT; GENES	Functional annotation of complex genomes requires the development of novel experimental platforms with increased capacity. Here, we describe a high-throughput system designed to identify cDNAs whose overexpression induces morphologically distinct cell death modalities. The methodology incorporates two robotized steps, and relies on coexpression of library clones with GFP to reveal the morphological features presented by the dying cells. By using this system we screened 135 000 cDNA clones and obtained 90 independent molecules. Interestingly, three death categories were identified, namely; apoptotic, vacuolated and autophagic. Among the pro-apoptotic clones, we found four members of the mitochondrial carrier family: the phosphate and adenine nucleotide (type 3) transporters, and the mitochondrial carrier homologs (MTCHs) 1 and 2. Expression of these molecules induced cytochrome c release and caspase-9-dependent death. One of them, the phosphate carrier, was able to interact with members of the permeability transition pore complex ANT1 and VDAC1, and its binding to ANT1 was stabilized in the presence of apoptotic activators. Depletion of this carrier by siRNA delayed cytochrome c mobilization and apoptosis. These results attribute a previously undescribed apoptotic function to the phosphate carrier and, more generally, suggest that a common property of various mitochondrial transporters was exploited during evolution to regulate apoptosis.	[Alcala, S.; Klee, M.; Fernandez, J.; Fleischer, A.; Pimental-Muinos, Fx] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Pimental-Muinos, F (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel Unamuno, Salamanca 37007, Spain.	fxp@usal.es	Fleischer, Aarne/ABE-6966-2020; Pimentel-Muinos, Felipe/K-4557-2014	Fleischer, Aarne/0000-0003-4146-3303; Alcala, Sonia/0000-0002-7644-4973; Pimentel-Muinos, Felipe/0000-0002-0258-2855				Albayrak T, 2003, BIOCHEM BIOPH RES CO, V304, P772, DOI 10.1016/S0006-291X(03)00653-3; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Chanda SK, 2003, P NATL ACAD SCI USA, V100, P12153, DOI 10.1073/pnas.1934839100; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kiss-Toth E, 2004, CYTOKINE GROWTH F R, V15, P97, DOI 10.1016/j.cytogfr.2004.02.002; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Poncet D, 2006, J CELL BIOL, V174, P985, DOI 10.1083/jcb.200604069; Schobel S, 2006, INT J DEV NEUROSCI, V24, P141, DOI 10.1016/j.ijdevneu.2005.11.003; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Ting Adrian, 2005, Novartis Found Symp, V267, P219; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Xu XM, 2002, J BIOL CHEM, V277, P48913, DOI 10.1074/jbc.M209613200; Yerushalmi GM, 2002, NEOPLASIA, V4, P510, DOI 10.1038/sj.neo.7900272; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006	35	67	71	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					44	54		10.1038/sj.onc.1210600	http://dx.doi.org/10.1038/sj.onc.1210600			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17621274				2022-12-25	WOS:000252118700005
J	Zhao, Y; Hamza, M; Leong, H; Lim, CB; Pan, YF; Cheung, E; Soo, KC; Iyer, N				Zhao, Y.; Hamza, Ms; Leong, H. S.; Lim, C-B; Pan, Y-F; Cheung, E.; Soo, K-C; Iyer, Ng			Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells	ONCOGENE			English	Article						KLF5; survival kinase; 5FU; bad phosphorylation	KLF5 TRANSCRIPTION FACTOR; FACTOR FAMILY; GENE; REGULATORS; GROWTH; AKT; PROLIFERATION; ACTIVATION; ONCOGENES; PATHWAY	Although Kruppel-like factor 5 (KLF5) is a transcription factor that has been implicated in pathways critical to carcinogenesis, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. Here, we describe a novel role for KLF5 in a p53-independent apoptotic pathway. Using RNA-interference technology, we show that cells deficient in KLF5 have increased sensitivity to DNA damage, regardless of p53 status. Both p53 and p53-dependent factors are unaffected by KLF5 depletion. Instead, the apoptotic phenotype consequent to damage is associated with reduced bad phosphorylation, and downregulation of Pim1. Consistently, transfection of wild-type Pim1 is sufficient to rescue this phenotype. Previous data have shown a number of putative Sp1-binding consensus sequences on the Pim1 promoter. Remarkably, chromatin immunoprecipitation studies show that KLF5 binds to the Pim1 promoter, and that binding increases soon after damage. These results identify a novel, p53-independent apoptotic pathway through which KLF5 functions in response to DNA damage. Therapeutic deregulation of this pathway could be used to modulate chemosensitivity.	[Zhao, Y.; Leong, H. S.; Lim, C-B; Soo, K-C; Iyer, Ng] Natl Canc Ctr, Wee Kim Wee Lab Surg Oncol, Dept Surg Oncol, Singapore 169610, Singapore; [Hamza, Ms; Pan, Y-F; Cheung, E.] Genome Inst Singapore, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Iyer, N (corresponding author), Natl Canc Ctr, Wee Kim Wee Lab Surg Oncol, Dept Surg Oncol, 11 Hosp Dr, Singapore 169610, Singapore.	gopaliyer@yahoo.com	Hamza, Sabry/B-8184-2011; Zhao, Yan/A-2197-2011	Pan, You-Fu/0000-0002-9996-8892; Zhao, Yan/0000-0003-0397-4049				Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CN, 2005, J CLIN ONCOL, V23, P7286, DOI 10.1200/JCO.2004.00.2253; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Nagai R, 2003, ADV EXP MED BIOL, V538, P57; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rainio EM, 2005, VIROLOGY, V333, P201, DOI 10.1016/j.virol.2005.01.001; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Suzuki T, 2005, ARTERIOSCL THROM VAS, V25, P1135, DOI 10.1161/01.ATV.0000165656.65359.23; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102	34	50	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					1	8		10.1038/sj.onc.1210625	http://dx.doi.org/10.1038/sj.onc.1210625			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17603560				2022-12-25	WOS:000252118700001
J	Tosini, G; Davidson, AJ; Fukuhara, C; Kasamatsu, M; Castamon-Cervantes, O				Tosini, Gianluca; Davidson, Alec J.; Fukuhara, Chiaki; Kasamatsu, Manami; Castamon-Cervantes, Oscar			Localization of a circadian clock in mammalian photoreceptors	FASEB JOURNAL			English	Article						melatonin; circadian rhythms; clock genes; retina; rat	ACETYLTRANSFERASE MESSENGER-RNA; N-ACETYLTRANSFERASE; RAT RETINA; MOUSE RETINA; MELATONIN SYNTHESIS; DOPAMINE RELEASE; GENE-EXPRESSION; KAINIC ACID; RHYTHMS; PROTEIN	Several studies have demonstrated that the mammalian retina contains an autonomous circadian clock. Dopaminergic and other inner retinal neurons express many of the clock genes, whereas some of these genes seem to be absent from the photoreceptors. This observation has led to the suggestion that in mammalian retina the circadian pacemaker driving retinal rhythms is located in the inner nuclear layer. However, other evidence points to the photoreceptor layer as the site of the mammalian retinal clock. The goal of the present study was to demonstrate the presence of a functional circadian clock in photoreceptors. First, using laser capture microdissection and reverse transcriptase- polymerase chain reaction, we investigated which of the clock genes are expressed in rat photoreceptors. We then prepared photoreceptor layer cultures from the retina to test whether these isolated cultures were viable and could drive circadian rhythms. Our data indicated that Per1, Per3, Cry1, Cry2, Clock, Bmall, Rev-erb alpha, and Rora RNAs were present in the photoreceptors, whereas we were unable to amplify mRNA for Per2 and Npas2. Photoreceptor layers obtained from Period1- luciferase rats expressed a robust circadian rhythm in bioluminescence and melatonin synthesis. These results demonstrate that mammalian photoreceptors contain the circadian pacemaker driving rhythmic melatonin synthesis.	Morehouse Sch Med, Inst Neurosci, Circadian Rhythms & Sleep Disorders Program, Atlanta, GA USA	Morehouse School of Medicine	Tosini, G (corresponding author), Morehouse Sch Med, Inst Neurosci, 720 Westview Dr SW, Atlanta, GA 30310 USA.	gtosini@msm.edu		tosini, gianluca/0000-0003-3645-4533	NCI NIH HHS [CA116261, R21 CA116261] Funding Source: Medline; NINDS NIH HHS [R56 NS043459, R01 NS043459, R01 NS043459-05A2, NS 34194, U54 NS034194, NS-43459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA116261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043459, R56NS043459, U54NS034194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOATRIGHT JH, 1994, VISUAL NEUROSCI, V11, P1013, DOI 10.1017/S0952523800003941; CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S; Chansard M, 2007, NEUROSCIENCE, V145, P812, DOI 10.1016/j.neuroscience.2006.12.037; Chaurasia SS, 2005, J NEUROCHEM, V92, P158, DOI 10.1111/j.1471-4159.2004.02874.x; Chen W, 2000, MOL BRAIN RES, V81, P43, DOI 10.1016/S0169-328X(00)00160-1; Chidlow G, 2003, BRAIN RES, V963, P298, DOI 10.1016/S0006-8993(02)04052-0; Davidson AJ, 2006, INT J CANCER, V118, P1623, DOI 10.1002/ijc.21591; Dinet V, 2007, J PINEAL RES, V42, P83, DOI 10.1111/j.1600-079X.2006.00387.x; Doyle SE, 2002, VISUAL NEUROSCI, V19, P593, DOI 10.1017/S0952523802195058; Doyle SE, 2002, J NEUROCHEM, V83, P211, DOI 10.1046/j.1471-4159.2002.01149.x; DUBOCOVICH ML, 1983, NATURE, V306, P782, DOI 10.1038/306782a0; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004; Garbarino-Pico E, 2004, J BIOL CHEM, V279, P51172, DOI 10.1074/jbc.M309248200; Garcia-Fernandez JA, 2007, NEUROSCI LETT, V419, P55, DOI 10.1016/j.neulet.2007.03.054; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Green CB, 2004, J BIOL RHYTHM, V19, P91, DOI 10.1177/0748730404263002; Gustincich S, 2004, P NATL ACAD SCI USA, V101, P5069, DOI 10.1073/pnas.0400913101; IUVONE PM, 1986, BRAIN RES, V369, P168, DOI 10.1016/0006-8993(86)90525-1; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Kamphuis W, 2005, BIOCHEM BIOPH RES CO, V330, P18, DOI 10.1016/j.bbrc.2005.02.118; Liang J, 2004, NEUROREPORT, V15, P1497, DOI 10.1097/01.wnr.0000131007.59315.66; Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Namihira M, 2001, NEUROREPORT, V12, P471, DOI 10.1097/00001756-200103050-00010; NguyenLegros J, 1996, J NEUROCHEM, V67, P2514; Niki T, 1998, BIOCHEM BIOPH RES CO, V248, P115, DOI 10.1006/bbrc.1998.8916; Nir I, 2000, BRAIN RES, V870, P118, DOI 10.1016/S0006-8993(00)02409-4; PIERCE ME, 1993, NEURON, V10, P579, DOI 10.1016/0896-6273(93)90161-J; Ribelayga C, 2004, J PHYSIOL-LONDON, V554, P467, DOI 10.1113/jphysiol.2003.053710; Ruan GX, 2006, P NATL ACAD SCI USA, V103, P9703, DOI 10.1073/pnas.0601940103; Sakamoto K, 2000, NEUROREPORT, V11, P3995, DOI 10.1097/00001756-200012180-00018; Sakamoto K, 2006, MOL VIS, V12, P117; Sakamoto K, 2004, J NEUROCHEM, V90, P1019, DOI 10.1111/j.1471-4159.2004.02571.x; Sakamoto K, 1998, NEUROSCI LETT, V245, P113, DOI 10.1016/S0304-3940(98)00189-X; Sakamoto K, 2005, EUR J NEUROSCI, V22, P3536; SAKAMOTO K, 2005, EUR J NEUROSCI, V22, P3544; TERMAN JS, 1993, BRAIN RES, V605, P256; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; Tosini G, 2002, CELL TISSUE RES, V309, P119, DOI 10.1007/s00441-002-0578-z; Tosini G, 2000, NEUROSCI LETT, V286, P119, DOI 10.1016/S0304-3940(00)01117-4; Witkovsky P, 2003, J NEUROSCI, V23, P7670; Yujnovsky I, 2006, P NATL ACAD SCI USA, V103, P6386, DOI 10.1073/pnas.0510691103; ZAWILSKA JB, 1992, NEUROSCI LETT, V135, P71, DOI 10.1016/0304-3940(92)90138-W	45	102	102	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2007	21	14					3866	3871		10.1096/fj.07-8371com	http://dx.doi.org/10.1096/fj.07-8371com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17621597	Green Accepted			2022-12-25	WOS:000251283500011
J	Ding, G; Sonoda, H; Yu, H; Kajimoto, T; Goparaju, SK; Jahangeer, S; Okada, T; Nakamura, S				Ding, Guo; Sonoda, Hirofumi; Yu, Huan; Kajimoto, Taketoshi; Goparaju, Sravan K.; Jahangeer, Saleem; Okada, Taro; Nakamura, Shun-ichi			Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; DNA-DAMAGE; SIGNAL; ACTIVATION; RECEPTOR; LOCALIZATION; EXPRESSION; CELLS	Sphingosine kinase (SPHK) is a key enzyme producing important messenger sphingosine 1-phosphate and is implicated in cell proliferation and suppression of apoptosis. Because the extent of agonist-induced activation of SPHK is modest, signaling via SPHK may be regulated through its localization at specific intracellular sites. Although the SPHK1 isoform has been extensively studied and characterized, the regulation of expression and function of the other isoform, SPHK2, remain largely unexplored. Here we describe an important post-translational modification, namely, phosphorylation of SPHK2 catalyzed by protein kinase D (PKD), which regulates its localization. Upon stimulation of HeLa cells by tumor promoter phorbol 12-myristate 13-acetate, a serine residue in a novel and putative nuclear export signal, identified for the first time, in SPHK2 was phosphorylated followed by SPHK2 export from the nucleus. Constitutively active PKD phosphorylated this serine residue in the nuclear export signal both in vivo and in vitro. Moreover, down-regulation of PKDs through RNA interference resulted in the attenuation of both basal and phorbol 12-myristate 13-acetateinduced phosphorylation, which was followed by the accumulation of SPHK2 in the nucleus in a manner rescued by PKD overexpression. These results indicate that PKD is a physiologically relevant enzyme for SPHK2 phosphorylation, which leads to its nuclear export for subsequent cellular signaling.	Kobe Univ, Grad Sch Med, Div Biochem, Dept Mol & Cellular Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Nakamura, S (corresponding author), Kobe Univ, Grad Sch Med, Div Biochem, Dept Mol & Cellular Biol,Chuo Ku, Kusunoki Cho 7-5-1, Kobe, Hyogo 6500017, Japan.	snakamur@kobe-u.ac.jp	Goparaju, Sravan/H-3422-2011	Sonoda, Hirofumi/0000-0003-3353-1783				Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Carrero G, 2004, METHOD ENZYMOL, V375, P415; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; French KJ, 2003, CANCER RES, V63, P5962; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Ikuta T, 2004, J BIOL CHEM, V279, P19209, DOI 10.1074/jbc.M310492200; Inagaki Y, 2003, BIOCHEM BIOPH RES CO, V311, P168, DOI 10.1016/j.bbrc.2003.09.194; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	45	109	111	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27493	27502		10.1074/jbc.M701641200	http://dx.doi.org/10.1074/jbc.M701641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635916	hybrid			2022-12-25	WOS:000249304900090
J	Maeda, H; Sahara, H; Mori, Y; Torigo, T; Kamiguchi, K; Tamura, Y; Tamura, Y; Hirata, K; Sato, N				Maeda, Hideki; Sahara, Hiroeki; Mori, Yoko; Torigo, Toshihiko; Kamiguchi, Kenjiro; Tamura, Yutaka; Tamura, Yasuaki; Hirata, Kouichi; Sato, Noriyuki			Biological heterogeneity of the peptide- binding motif of the 70-kDa heat shock protein by surface plasmon resonance analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; HSP70; IMMUNOTHERAPY; CELLS; SPECIFICITY; DNAK; EXPRESSION; GP96	70-kDa heat shock protein family is a molecular chaperone that binds to a variety of client proteins and peptides in the cytoplasm. Several studies have revealed binding motifs between 70-kDa heat shock protein family and cytoplasmic proteins by conventional techniques such as phage display library screening. However, little is known about the binding motif based on kinetic parameters determined by surface plasmon resonance analysis. We investigated the major inducible cytosolic 70-kDa heat shock protein (Hsp70)-binding motif with the human leukocyte antigen B*2702-derived peptide Bw4 (RENL-RIALRY) by using a Biacore system based on surface plasmon resonance analysis. The K-D value of Hsp70-Bw4 interaction was 1.8 x 10(-6) M. Analyses with truncated Bw4 variant peptides showed the binding motif of Hsp70 to be seven residues, LRI-ALRY. To further study the characteristics of this motif, 126 peptides derived from Bw4, each with single amino acid substitution, were synthesized and analyzed for Hsp70 binding affinity. Interestingly, the Hsp70 binding affinity was abrogated when the residues were substituted for by acidic (Asp and Glu) ones at any position. In contrast, if the substitute residue was aromatic (Trp, Tyr, and Phe) or an Arg residue at any position, Hsp70 binding affinity was maintained. Thus, this study presents a new binding motif between Hsp70 and peptides derived from the natural protein human leukocyte antigen B*2702 and may also elucidate some characteristics of the Hsp70 binding characteristic, enhancing our understanding of Hsp70-binding determinants that may influence diverse cellular and physiological processes.	Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Chiba Univ, Grad Sch Med, Dept Bioinformat, Chiba 2608670, Japan; Sapporo Med Univ, Sch Med, Dept Surg, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Marine Biomed Inst, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Chiba University; Sapporo Medical University; Sapporo Medical University	Sahara, H (corresponding author), S 1 W 17,Chuo Ku, Sapporo, Hokkaido 0608556, Japan.	hsahara@sapmed.ac.jp						Belli F, 2002, J CLIN ONCOL, V20, P4169, DOI 10.1200/JCO.2002.09.134; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; Eisenlohr LC, 2007, NAT REV IMMUNOL, V7, P403, DOI 10.1038/nri2077; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Gething MJ, 1995, COLD SPRING HARB SYM, V60, P417, DOI 10.1101/SQB.1995.060.01.046; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Haug M, 2007, EUR J IMMUNOL, V37, P1053, DOI 10.1002/eji.200636811; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Lammert E, 1997, EUR J IMMUNOL, V27, P923, DOI 10.1002/eji.1830270418; Li Z, 1994, Behring Inst Mitt, P37; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; Maier JT, 2002, IMMUNOGENETICS, V54, P67, DOI 10.1007/s00251-002-0444-x; Massa M, 2007, ARTHRITIS RHEUM, V56, P1648, DOI 10.1002/art.22567; MILNER CM, 1990, IMMUNOGENETICS, V32, P242; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P111; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Nishikawa H, 2005, J EXP MED, V201, P681, DOI 10.1084/jem.20041959; Nossner E, 1996, J EXP MED, V183, P339, DOI 10.1084/jem.183.2.339; Park SG, 2001, J VIROL, V75, P6962, DOI 10.1128/JVI.75.15.6962-6968.2001; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Qian JF, 2005, CLIN CANCER RES, V11, P8808, DOI 10.1158/1078-0432.CCR-05-1553; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Sato K, 2001, BLOOD, V98, P1852, DOI 10.1182/blood.V98.6.1852; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Zhang Xinsheng, 2003, Biological Procedures Online, V5, P170, DOI 10.1251/bpo59; Zhang XS, 2005, VIROLOGY, V337, P162, DOI 10.1016/j.virol.2005.03.035; Zhang XS, 2002, J VIROL, V76, P8737, DOI 10.1128/JVI.76.17.8737-8746.2002; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	39	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26956	26962		10.1074/jbc.M703436200	http://dx.doi.org/10.1074/jbc.M703436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17626008	hybrid			2022-12-25	WOS:000249304900035
J	Niedziela-Majka, A; Chesnik, MA; Tomko, EJ; Lohman, TM				Niedziela-Majka, Anita; Chesnik, Marla A.; Tomko, Eric J.; Lohman, Timothy M.			Bacillus stearothermophilus PcrA monomer is a single-stranded DNA translocase but not a processive helicase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; BACTERIOPHAGE-T4 DDA HELICASE; ATP-DEPENDENT TRANSLOCATION; ESCHERICHIA-COLI; UVRD HELICASE; MISMATCH REPAIR; RECBCD ENZYME; STEP-SIZE; NUCLEOPROTEIN FILAMENTS; CRYSTAL-STRUCTURES	Structural studies of the Bacillus stearothermophilus PcrA protein along with biochemical studies of the single-stranded (ss) DNA translocation activity of PcrA monomers have led to the suggestion that a PcrA monomer possesses processive helicase activity in vitro. Yet definitive studies testing whether the PcrA monomer possesses processive helicase activity have not been performed. Here we show, using single turnover kinetic methods, that monomers of PcrA are able to translocate along ssDNA, in the 3 ' to 5 ' direction, rapidly and processively, whereas these same monomers display no detectable helicase activity under the same solution conditions in vitro. The PcrA monomer ssDNA translocation activity, although necessary, is not sufficient for processive helicase activity, and thus the translocase and helicase activities of PcrA are separable. These results also suggest that the helicase activity of PcrA needs to be activated either by self-assembly or through interactions with accessory proteins. This same behavior is displayed by both the Escherichia coli Rep and UvrD monomers. Hence, all three of these SF1 enzymes are ssDNA translocases as monomers but do not display processive helicase activity in vitro unless activated. The fact that the translocase and helicase activities are separable suggests that each activity may be used for different functions in vivo.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Lohman, TM (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid, St Louis, MO 63110 USA.	lohman@biochem.wustl.edu			NIGMS NIH HHS [GM 45948, T32 GM 08492, R01 GM045948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948, T32GM008492] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; ARTHUR HM, 1980, MOL GEN GENET, V180, P185, DOI 10.1007/BF00267368; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 1999, BBA-GENE STRUCT EXPR, V1444, P424, DOI 10.1016/S0167-4781(99)00024-X; Boule JB, 2005, NATURE, V438, P57, DOI 10.1038/nature04091; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; Bruand C, 2000, MOL MICROBIOL, V35, P204, DOI 10.1046/j.1365-2958.2000.01700.x; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; Eoff RL, 2006, NAT STRUCT MOL BIOL, V13, P242, DOI 10.1038/nsmb1055; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Fischer CJ, 2004, J MOL BIOL, V344, P1265, DOI 10.1016/j.jmb.2004.10.004; Flores MJ, 2005, MOL MICROBIOL, V57, P1664, DOI 10.1111/j.1365-2958.2005.04753.x; Flores MJ, 2004, EMBO REP, V5, P983, DOI 10.1038/sj.embor.7400262; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Holbrook JA, 1999, BIOCHEMISTRY-US, V38, P8409, DOI 10.1021/bi990043w; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P6032, DOI 10.1021/bi020122z; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOHMAN TM, 2003, DNA HELICASES MOTORS, P303; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; Lucius AL, 2002, J MOL BIOL, V324, P409, DOI 10.1016/S0022-2836(02)01067-7; Mackintosh SG, 2006, NUCLEIC ACIDS RES, V34, P4154, DOI 10.1093/nar/gkl501; Maluf NK, 2003, J BIOL CHEM, V278, P31930, DOI 10.1074/jbc.M304223200; Maluf NK, 2003, J MOL BIOL, V325, P889, DOI 10.1016/S0022-2836(02)01276-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MASCOTTI DP, 1995, BIOCHEMISTRY-US, V34, P2908, DOI 10.1021/bi00009a022; Matson SW, 2006, NUCLEIC ACIDS RES, V34, P4089, DOI 10.1093/nar/gkl450; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Rasnik I, 2004, J MOL BIOL, V336, P395, DOI 10.1016/j.jmb.2003.12.031; REINBERG D, 1983, J BIOL CHEM, V258, P529; Robertson AB, 2006, J BIOL CHEM, V281, P19949, DOI 10.1074/jbc.M601604200; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Sikora B, 2006, J BIOL CHEM, V281, P36110, DOI 10.1074/jbc.M604412200; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 1998, NUCLEIC ACIDS RES, V26, P2374, DOI 10.1093/nar/26.10.2374; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; STRAUME M, 1992, METHOD ENZYMOL, V210, P117; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Tomko EJ, 2007, MOL CELL, V26, P335, DOI 10.1016/j.molcel.2007.03.024; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Williams DJ, 2000, METHOD ENZYMOL, V321, P330; WONG I, 1992, J BIOL CHEM, V267, P7596; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Zhang WK, 2007, J MOL BIOL, V371, P336, DOI 10.1016/j.jmb.2007.05.050; Zhang XD, 2006, J BIOL CHEM, V281, P12655, DOI 10.1074/jbc.M513089200	78	91	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27076	27085		10.1074/jbc.M704399200	http://dx.doi.org/10.1074/jbc.M704399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631491	hybrid			2022-12-25	WOS:000249304900049
J	Szeto, SSW; Reinke, SN; Sykes, BD; Lemire, BD				Szeto, Samuel S. W.; Reinke, Stacey N.; Sykes, Brian D.; Lemire, Bernard D.			Ubiquinone-binding site mutations in the Saccharomyces cerevisiae succinate dehydrogenase generate superoxide and lead to the accumulation of succinate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; MITOCHONDRIAL SUCCINATE; RESPIRATORY-CHAIN; ESCHERICHIA-COLI; OXIDATIVE STRESS; SDHD GENE; FUMARATE-HYDRATASE; ELECTRON-TRANSFER; ANCHOR SUBUNIT; II SUCCINATE	The mitochondrial succinate dehydrogenase (SDH) is an essential component of the electron transport chain and of the tricarboxylic acid cycle. Also known as complex II, this tetrameric enzyme catalyzes the oxidation of succinate to fumarate and reduces ubiquinone. Mutations in the human SDHB, SDHC, and SDHD genes are tumorigenic, leading to the development of several types of tumors, including paraganglioma and pheochromocytoma. The mechanisms linking SDH mutations to oncogenesis are still unclear. In this work, we used the yeast SDH to investigate the molecular and catalytic effects of tumorigenic or related mutations. We mutated Arg(47) of the Sdh3p subunit to Cys, Glu, and Lys and Asp(88) of the Sdh4p subunit to Asn, Glu, and Lys. Both Arg47 and Asp88 are conserved residues, and Arg47 is a known site of cancer causing mutations in humans. All of the mutants examined have reduced ubiquinone reductase activities. The SDH3 R47K, SDH4 D88E, and SDH4 D88N mutants are sensitive to hyperoxia and paraquat and have elevated rates of superoxide production in vitro and in vivo. We also observed the accumulation and secretion of succinate. Succinate can inhibit prolyl hydroxylase enzymes, which initiate a proliferative response through the activation of hypoxia-inducible factor 1 alpha. We suggest that SDH mutations can promote tumor formation by contributing to both reactive oxygen species production and to a proliferative response normally induced by hypoxia via the accumulation of succinate.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca		Reinke, Stacey/0000-0002-0758-0330				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Bayley JP, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-1; Bayley JP, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-39; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Betarbet R, 2002, BIOESSAYS, V24, P308, DOI 10.1002/bies.10067; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; DEKOK J, 1975, BIOCHIM BIOPHYS ACTA, V387, P441, DOI 10.1016/0005-2728(75)90084-5; Dibrov E, 1998, J BIOL CHEM, V273, P32042, DOI 10.1074/jbc.273.48.32042; Fedotcheva NI, 2006, FREE RADICAL BIO MED, V41, P56, DOI 10.1016/j.freeradbiomed.2006.02.012; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; GUZY RD, 2006, J BIOL CHEM, V91, P807; Habano W, 2003, ONCOL REP, V10, P1375; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; Horsefield R, 2006, J BIOL CHEM, V281, P7309, DOI 10.1074/jbc.M508173200; Huang LS, 2005, ACTA CRYSTALLOGR D, V61, P380, DOI 10.1107/S0907444905000181; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; Johnson-Cadwell LI, 2007, J NEUROCHEM, V101, P1619, DOI 10.1111/j.1471-4159.2007.04516.x; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; KITA K, 1989, J BIOL CHEM, V264, P2672; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; Mashego MR, 2005, FEMS YEAST RES, V5, P419, DOI 10.1016/j.femsyr.2004.11.008; Milunsky JM, 2001, AM J MED GENET, V100, P311, DOI 10.1002/ajmg.1270; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Oyedotun KS, 2004, J BIOL CHEM, V279, P9424, DOI 10.1074/jbc.M311876200; Oyedotun KS, 2004, J BIOL CHEM, V279, P9432, DOI 10.1074/jbc.M311877200; Oyedotun KS, 1999, BBA-BIOENERGETICS, V1411, P170, DOI 10.1016/S0005-2728(99)00040-7; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Saude EJ, 2006, METABOLOMICS, V2, P113, DOI 10.1007/s11306-006-0023-5; Schiavi F, 2005, JAMA-J AM MED ASSOC, V294, P2057, DOI 10.1001/jama.294.16.2057; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Selak MA, 2006, BBA-BIOENERGETICS, V1757, P567, DOI 10.1016/j.bbabio.2006.05.015; SILKIN Y, 2007, BIOCHIM BIOPHYS ACTA, V2, P143; SINGER TP, 1965, FLAVINS FLAVOPROTEIN, P391; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Solans A, 2006, HUM MOL GENET, V15, P3063, DOI 10.1093/hmg/ddl248; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; Tran QM, 2006, J BIOL CHEM, V281, P32310, DOI 10.1074/jbc.M607476200; Walker DW, 2006, P NATL ACAD SCI USA, V103, P16382, DOI 10.1073/pnas.0607918103; Yanase S, 2002, MECH AGEING DEV, V123, P1579, DOI 10.1016/S0047-6374(02)00093-3; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	63	81	83	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27518	27526		10.1074/jbc.M700601200	http://dx.doi.org/10.1074/jbc.M700601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636259	hybrid			2022-12-25	WOS:000249304900092
J	Cheng, A; Bollan, KA; Greenwood, SM; Irving, AJ; Connolly, CN				Cheng, Aixin; Bollan, Karen A.; Greenwood, Sam M.; Irving, Andrew J.; Connolly, Christopher N.			Differential subcellular localization of RIC-3 Isoforms and their role in determining 5-HT3 receptor composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; CELL-SURFACE EXPRESSION; 5-HYDROXYTRYPTAMINE TYPE-3 RECEPTORS; FUNCTIONAL EXPRESSION; RETENTION SIGNAL; MAMMALIAN-CELLS; SEROTONIN; SUBUNIT; PROTEIN; TRAFFICKING	RIC-3 has been identified as a chaperone molecule involved in promoting the functional expression of nicotinic acetylcholine and 5-HT3 receptors in mammalian cells. In this study, we examined the effects of RIC-3a ( isoform a) and a truncated isoform ( isoform d) on RIC-3 localization, mobility, and aggregation and its effect on 5-HT3 receptor composition in mammalian cells. Human RIC-3a possesses an amino-terminal signal sequence that targets it to the endoplasmic reticulum where it is distributed within the reticular network, often forming large diffuse "slicks" and bright "halo" structures. RIC-3a is highly mobile within and between these compartments. Despite the propensity for RIC-3a to aggregate, its expression enhances the level of surface 5-HT3A (homomeric) receptors. In contrast, RIC-3a exerts an inhibitory action on the surface expression of heteromeric 5-HT3A/B receptors. RIC-3d exhibits an altered subcellular distribution, being localized to the endoplasmic reticulum, large diffuse slicks, tubulo-vesicular structures, and the Golgi. Bidirectional trafficking between the endoplasmic reticulum and Golgi suggests that RIC-3d constitutively cycles between these two compartments. In support of the large coiled-coil domain of RIC-3a being responsible for protein aggregation, RIC-3d, lacking this cytoplasmic domain, does not aggregate or induce the formation of bright aggregates. Regardless of these differences, isoform d is still capable of enhancing homomeric, and inhibiting heteromeric, 5-HT3 receptor expression. Thus, both isoforms of RIC-3 play a role in determining 5-HT3 receptor composition.	Univ Dundee, Ninewells Med Sch, Div Pathol & Neurosci, Neurosci Inst, Dundee DD1 9SY, Scotland	University of Dundee	Connolly, CN (corresponding author), Univ Dundee, Ninewells Med Sch, Div Pathol & Neurosci, Neurosci Inst, Dundee DD1 9SY, Scotland.	c.n.connolly@dundee.ac.uk		Connolly, Christopher/0000-0002-0445-8874				Ashby MC, 2004, TRENDS NEUROSCI, V27, P257, DOI 10.1016/j.tins.2004.03.010; Ben-Ami HC, 2005, J BIOL CHEM, V280, P28053, DOI 10.1074/jbc.M504369200; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boyd GW, 2003, J BIOL CHEM, V278, P27681, DOI 10.1074/jbc.M304938200; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Castillo M, 2005, J BIOL CHEM, V280, P27062, DOI 10.1074/jbc.M503746200; Castillo M, 2006, J MOL NEUROSCI, V30, P153, DOI 10.1385/JMN:30:1:153; Cheng AX, 2005, J BIOL CHEM, V280, P22502, DOI 10.1074/jbc.M414341200; Collingridge GL, 2004, NAT REV NEUROSCI, V5, P952, DOI 10.1038/nrn1556; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; Connolly CN, 2004, BIOCHEM SOC T, V32, P529, DOI 10.1042/BST0320529; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Dubin AE, 1999, J BIOL CHEM, V274, P30799, DOI 10.1074/jbc.274.43.30799; Exley R, 2006, J NEUROCHEM, V98, P876, DOI 10.1111/j.1471-4159.2006.03915.x; Fletcher S, 1998, TRENDS PHARMACOL SCI, V19, P212, DOI 10.1016/S0165-6147(98)01210-3; Fortun J, 2003, J NEUROSCI, V23, P10672; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; HUSSY N, 1994, J PHYSIOL-LONDON, V481, P311, DOI 10.1113/jphysiol.1994.sp020441; Ilegems E, 2004, J BIOL CHEM, V279, P53346, DOI 10.1074/jbc.M407467200; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Lansdell SJ, 2005, MOL PHARMACOL, V68, P1431, DOI 10.1124/mol.105.017459; Morales M, 2001, J COMP NEUROL, V438, P163, DOI 10.1002/cne.1307; Niesler B, 2007, MOL PHARMACOL, V72, P8, DOI 10.1124/mol.106.032144; Reeves DC, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-27; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Thompson AJ, 2006, CURR PHARM DESIGN, V12, P3615, DOI 10.2174/138161206778522029; Vandenberghe W, 2005, J NEUROSCI, V25, P1095, DOI 10.1523/JNEUROSCI.3568-04.2005; Williams ME, 2005, J BIOL CHEM, V280, P1257, DOI 10.1074/jbc.M410039200; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039	32	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26158	26166		10.1074/jbc.M703899200	http://dx.doi.org/10.1074/jbc.M703899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17609200	hybrid			2022-12-25	WOS:000249239600019
J	El-Shewy, HM; Lee, MH; Obeid, LM; Jaffa, AA; Luttrell, LM				El-Shewy, Hesham M.; Lee, Mi-Hye; Obeid, Lina M.; Jaffa, Ayad A.; Luttrell, Louis M.			The insulin-like growth factor type 1 and insulin-like growth factor type 2/Mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE-CELLS; FACTOR-II RECEPTOR; FACTOR-II/MANNOSE-6-PHOSPHATE RECEPTOR; BINDING-PROTEINS; SIGNALING PATHWAYS; DEPENDENT PATHWAY; ACTIVATION; RELAXIN	Insulin-like growth factor types 1 and 2 ( IGF-1; IGF-2) and insulin-like peptides are all members of the insulin superfamily of peptide hormones but bind to several distinct classes of membrane receptor. Like the insulin receptor, the IGF-1 receptor is a heterotetrameric receptor tyrosine kinase, whereas the IGF-2/ mannose 6-phosphate receptor is a single transmembrane domain protein that is thought to function primarily as clearance receptors. We recently reported that IGF-1 and IGF-2 stimulate the ERK1/2 cascade by triggering sphingosine kinase-dependent "transactivation" of G protein-coupled sphingosine-1-phosphate receptors. To determine which IGF receptors mediate this effect, we tested seven insulin family peptides, IGF-1, IGF-2, insulin, and insulin-like peptides 3, 4, 6, and 7, for the ability to activate ERK1/2 in HEK293 cells. Only IGF-1 and IGF-2 potently activated ERK1/2. Although IGF-2 was predictably less potent than IGF-1 in activating the IGF-1 receptor, they were equipotent stimulators of ERK1/2. Knockdown of IGF-1 receptor expression by RNA interference reduced the IGF-1 response to a greater extent than the IGF-2 response, suggesting that IGF-2 did not signal exclusively via the IGF-1 receptor. In contrast, IGF-2 receptor knockdown markedly reduced IGF-2 stimulated ERK1/2 phosphorylation, with no effect on the IGF-1 response. As observed previously, both the IGF-1 and the IGF-2 responses were sensitive to pertussis toxin and the sphingosine kinase inhibitor, dimethylsphingosine. These data indicate that endogenous IGF-1 and IGF-2 receptors can independently initiate ERK1/2 signaling and point to a potential physiologic role for IGF-2 receptors in the cellular response to IGF-2.	Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Res Serv Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina	Luttrell, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St 816 St CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		obeid, lina/0000-0002-0734-0847; Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58283] Funding Source: Medline; NIGMS NIH HHS [GM62887] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; DEL PL, 1997, SCIENCE, V278, P687; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Dupont Joelle, 2003, Birth Defects Research, V69, P257, DOI 10.1002/bdrc.10022; El-Shewy HM, 2006, J BIOL CHEM, V281, P31399, DOI 10.1074/jbc.M605339200; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hassan AB, 2003, AM J PATHOL, V162, P3, DOI 10.1016/S0002-9440(10)63791-1; Hawkes C, 2006, J NEUROSCI, V26, P585, DOI 10.1523/JNEUROSCI.2730-05.2006; Hawkes C, 2004, BRAIN RES REV, V44, P117, DOI 10.1016/j.brainresrev.2003.11.002; Hawkes C, 2003, J COMP NEUROL, V458, P113, DOI 10.1002/cne.10578; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Janez A, 2000, J BIOL CHEM, V275, P26870; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KOJIMA I, 1988, BIOCHEM BIOPH RES CO, V154, P9, DOI 10.1016/0006-291X(88)90642-0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Lok S, 2000, BIOL REPROD, V62, P1593, DOI 10.1095/biolreprod62.6.1593; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; Patel TB, 2004, PHARMACOL REV, V56, P371, DOI 10.1124/pr.56.3.4; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Saito T, 2004, ENDOCRINOLOGY, V145, P4232, DOI 10.1210/en.2004-0401; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Shin HS, 2003, CIRC RES, V93, P302, DOI 10.1161/01.RES.0000086803.64109.9E; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14	51	47	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26150	26157		10.1074/jbc.M703276200	http://dx.doi.org/10.1074/jbc.M703276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17620336	hybrid			2022-12-25	WOS:000249239600018
J	Hughes, E; Clayton, JC; Kitmitto, A; Esmann, M; Middleton, DA				Hughes, Eleri; Clayton, Jonathan C.; Kitmitto, Ashraf; Esmann, Mikael; Middleton, David A.			Solid-state NMR and functional measurements indicate that the conserved tyrosine residues of sarcolipin are involved directly in the inhibition of SERCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; MAGNETIC-RESONANCE-SPECTROSCOPY; ORIENTED LIPID-BILAYERS; CALCIUM-TRANSPORT; MEMBRANE-PROTEIN; PHOSPHOLAMBAN; ATPASE; RECONSTITUTION; OVEREXPRESSION; ASSOCIATION	The transmembrane protein sarcolipin regulates calcium storage in the sarcoplasmic reticulum of skeletal and cardiac muscle cells by modulating the activity of sarco(endo) plasmic reticulum Ca2+- ATPases (SERCAs). The highly conserved C-terminal region ((27)RSYQY-COOH) of sarcolipin helps to target the protein to the sarcoplasmic reticulum membrane and may also participate in the regulatory interaction between sarcolipin and SERCA. Here we used solid-state NMR measurements of local protein dynamics to illuminate the direct interaction between the Tyr(29) and Tyr(31) side groups of sarcolipin and skeletal muscle Ca2+- ATPase (SERCA1a) embedded in dioleoylphosphatidylcholine bilayers. Further solidstate NMR experiments together with functional measurements on SERCA1a in the presence of NAc-RSYQY, a peptide representing the conserved region of sarcolipin, suggest that the peptide binds to the same site as the parent protein at the luminal face of SERCA1a, where it reduces V-max for calcium transport and inhibits ATP hydrolysis with an IC50 of similar to 200 mu M. The inhibitory effect of NAc-RSYQY is remarkably sequence-specific, with the native aromatic residues being essential for optimal inhibitory activity. This combination of physical and functional measurements highlights the importance of aromatic and polar residues in the C-terminal region of sarcolipin for regulating calcium cycling and muscle contractility.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Sch Med, Div Cardiovasc & Endocrine Sci, Manchester M13 9PT, Lancs, England; Aarhus Univ, Inst Physiol & Biophys, Dept Biophys, DK-8000 Aarhus, Denmark	University of Liverpool; University of Manchester; University of Manchester; Aarhus University	Middleton, DA (corresponding author), Univ Liverpool, Sch Biol Sci, Crown St, Liverpool L69 7ZB, Merseyside, England.	middleda@liv.ac.uk						Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; Babu GJ, 2006, J BIOL CHEM, V281, P3972, DOI 10.1074/jbc.M508998200; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Buffy JJ, 2006, BIOCHEMISTRY-US, V45, P10939, DOI 10.1021/bi060728d; Buffy JJ, 2006, J MOL BIOL, V358, P420, DOI 10.1016/j.jmb.2006.02.005; Cady SD, 2007, J AM CHEM SOC, V129, P5719, DOI 10.1021/ja070305e; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; Gramolini AO, 2004, P NATL ACAD SCI USA, V101, P16807, DOI 10.1073/pnas.0407815101; Hellstern S, 2001, J BIOL CHEM, V276, P30845, DOI 10.1074/jbc.M102495200; Hughes E, 2005, BIOCHEMISTRY-US, V44, P4055, DOI 10.1021/bi0482351; Hughes E, 2003, J BIOL CHEM, V278, P20835, DOI 10.1074/jbc.M212208200; KARON BS, 1995, ANAL BIOCHEM, V227, P328, DOI 10.1006/abio.1995.1288; KIM HW, 1990, J BIOL CHEM, V265, P1702; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Klodos I, 2002, KIDNEY INT, V62, P2097, DOI 10.1046/j.1523-1755.2002.00654.x; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; Mascioni A, 2002, BIOCHEMISTRY-US, V41, P475, DOI 10.1021/bi011243m; Minamisawa S, 2003, J BIOL CHEM, V278, P9570, DOI 10.1074/jbc.M213132200; NAGASH S, 2000, BIOCHEM J, V351, P195; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Oxenoid K, 2005, P NATL ACAD SCI USA, V102, P10870, DOI 10.1073/pnas.0504920102; Patching SG, 2004, J AM CHEM SOC, V126, P3072, DOI 10.1021/ja037163i; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stokes DL, 2000, EUR J BIOCHEM, V267, P5274, DOI 10.1046/j.1432-1327.2000.01569.x; SZYMANSKA G, 1991, MEMBRANE BIOCHEM, V9, P191; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; Takegoshi K, 2001, CHEM PHYS LETT, V344, P631, DOI 10.1016/S0009-2614(01)00791-6; Tatulian SA, 2002, BIOCHEMISTRY-US, V41, P741, DOI 10.1021/bi011148d; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Traaseth NJ, 2006, BIOCHEMISTRY-US, V45, P13827, DOI 10.1021/bi0607610; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; Uemura N, 2004, EUR J CLIN INVEST, V34, P723, DOI 10.1111/j.1365-2362.2004.01422.x; Waterborg Jakob H., 1996, P7, DOI 10.1007/978-1-60327-259-9_2; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; Zamoon J, 2005, P NATL ACAD SCI USA, V102, P4747, DOI 10.1073/pnas.0406039102	43	19	19	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26603	10.1074/jbc.M611668200	http://dx.doi.org/10.1074/jbc.M611668200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616528	hybrid			2022-12-25	WOS:000249239600063
J	Kizhatil, K; Davis, JQ; Davis, L; Hoffman, J; Hogan, BLM; Bennett, V				Kizhatil, Krishnakumar; Davis, Jonathan Q.; Davis, Lydia; Hoffman, Jan; Hogan, Brigid L. M.; Bennett, Vann			Ankyrin-G is a molecular partner of E-cadherin in epithelial cells and early embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; MEMBRANE CYTOSKELETAL COMPLEX; CYTOPLASMIC DOMAIN; ALPHA-CATENIN; PREIMPLANTATION EMBRYOS; CRYSTAL-STRUCTURE; LATERAL MEMBRANE; DILEUCINE MOTIF; BETA-CATENIN; ADHESION	E-cadherin is a ubiquitous component of lateral membranes in epithelial tissues and is required to form the first lateral membrane domains in development. Here, we identify ankyrin-G as a molecular partner of E-cadherin and demonstrate that ankyrin-G and beta-2-spectrin are required for accumulation of E-cadherin at the lateral membrane in both epithelial cells and early embryos. Ankyrin-G binds to the cytoplasmic domain of E-cadherin at a conserved site distinct from that of E-catenin. Ankyrin- G also recruits beta-2-spectrin to E-cadherin-beta-catenin complexes, thus providing a direct connection between E-cadherin and the spectrin/actin skeleton. In addition to restricting the membrane mobility of E-cadherin, ankyrin-G and beta-2-spectrin also are required for exit of E-cadherin from the trans-Golgi network in a microtubule-dependent pathway. Ankyrin- G and beta-2-spectrin co-localize with E-cadherin in preimplantation mouse embryos. Moreover, knockdown of either ankyrin-G or beta-2-spectrin in one cell of a two-cell embryo blocks accumulation of E-cadherin at sites of cell-cell contact. E-cadherin thus requires both ankyrin-G and beta-2-spectrin for its cellular localization in early embryos as well as cultured epithelial cells. We have recently reported that ankyrin-G and beta-2-spectrin collaborate in biogenesis of the lateral membrane (Kizhatil ,K., Yoon, W., Mohler, P. J., Davis, L. H., Hoffman, J. A., and Bennett, V. (2007) J. Biol. Chem. 282, 2029 - 2037). Together with the current findings, these data suggest a ankyrin/spectrin-based mechanism for coordinating membrane assembly with extracellular interactions of E-cadherin at sites of cell-cell contact.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Bennett, V (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	benne012@mc.duke.edu	Kizhatil, Krish/AAR-5868-2021	Kizhatil, Krishnakumar/0000-0003-3755-6101				Abdi KM, 2006, J BIOL CHEM, V281, P5741, DOI 10.1074/jbc.M506697200; Chang SH, 2003, J BIOL CHEM, V278, P6879, DOI 10.1074/jbc.M211137200; Chu YS, 2004, J CELL BIOL, V167, P1183, DOI 10.1083/jcb.200403043; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; DAVIS L, 1989, J BIOL CHEM, V264, P9665; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; Gates J, 2005, CELL, V123, P769, DOI 10.1016/j.cell.2005.11.009; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Johnson MH, 2004, SEMIN CELL DEV BIOL, V15, P583, DOI 10.1016/j.semcdb.2004.04.002; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Kizhatil K, 2007, J BIOL CHEM, V282, P2029, DOI 10.1074/jbc.M608921200; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lee G, 2006, NATURE, V440, P246, DOI 10.1038/nature04437; Lemaillet G, 2003, J BIOL CHEM, V278, P27333, DOI 10.1074/jbc.M303327200; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; Lopez C, 2005, J BIOL CHEM, V280, P8221, DOI 10.1074/jbc.M413351200; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Miyashita Y, 2007, J BIOL CHEM, V282, P11540, DOI 10.1074/jbc.M608351200; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Papoulas O, 2005, NAT CELL BIOL, V7, P612, DOI 10.1038/ncb1264; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Pradhan D, 2001, J BIOL CHEM, V276, P4175, DOI 10.1074/jbc.M009259200; REIMA I, 1985, DIFFERENTIATION, V30, P68, DOI 10.1111/j.1432-0436.1985.tb00515.x; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SOBEL JS, 1985, J CELL BIOL, V100, P333, DOI 10.1083/jcb.100.1.333; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Thevananther S, 1998, J BIOL CHEM, V273, P23952, DOI 10.1074/jbc.273.37.23952; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	45	98	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26552	10.1074/jbc.M703158200	http://dx.doi.org/10.1074/jbc.M703158200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17620337	hybrid			2022-12-25	WOS:000249239600059
J	Uezu, A; Horiuchi, A; Kanda, K; Kikuchi, N; Umeda, K; Tsujita, K; Suetsugu, S; Araki, N; Yamamoto, H; Takenawa, T; Nakanishi, H				Uezu, Akiyoshi; Horiuchi, Ayaka; Kanda, Kousuke; Kikuchi, Naoya; Umeda, Kazuaki; Tsujita, Kazuya; Suetsugu, Shiro; Araki, Norie; Yamamoto, Hideyuki; Takenawa, Tadaomi; Nakanishi, Hiroyuki			SGIP1 alpha is an endocytic protein that directly interacts with phospholipids and Eps15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; COATED PITS; ACTIN CYTOSKELETON; MEMBRANE CURVATURE; ENTH/ANTH DOMAINS; TUBULIN-BINDING; PLASMA-MEMBRANE; VESICLE; DYNAMIN; CELL	SGIP1 has been shown to be an endophilin-interacting protein that regulates energy balance, but its function is not fully understood. Here, we identified its splicing variant of SGIP1 and named it SGIP1 alpha. SGIP1 alpha bound to phosphatidylserine and phosphoinositides and deformed the plasma membrane and liposomes into narrow tubules, suggesting the involvement in vesicle formation during endocytosis. SGIP1 alpha furthermore bound to Eps15, an important adaptor protein of clathrin-mediated endocytic machinery. SGIP1 alpha was colocalized with Eps15 and the AP-2 complex. Upon epidermal growth factor (EGF) stimulation, SGIP1 alpha was colocalized with EGF at the plasma membrane, indicating the localization of SGIP1 alpha at clathrin-coated pits/vesicles. SGIP1 alpha overexpression reduced transferrin and EGF endocytosis. SGIP1 alpha knockdown reduced transferrin endocytosis but not EGF endocytosis; this difference may be due to the presence of redundant pathways in EGF endocytosis. These results suggest that SGIP1 alpha plays an essential role in clathrin-mediated endocytosis by interacting with phospholipids and Eps15.	Kumamoto Univ, Grad Sch Med Sci, Dept Mol Pharmacol, Kumamoto 8608556, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan	Kumamoto University; University of Tokyo; Kumamoto University	Nakanishi, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Pharmacol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hnakanis@gpo.kumamoto-u.ac.jp	Nakanishi, Hiroyuki/AAD-9324-2020; Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/ABB-6033-2020	Nakanishi, Hiroyuki/0000-0003-3982-3314; Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; Nakanishi, Hiroyuki/0000-0002-9765-0266				BALABAN N, 1992, CELL MOTIL CYTOSKEL, V21, P138, DOI 10.1002/cm.970210207; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; De Zeeuw CI, 1997, NEURON, V19, P1187, DOI 10.1016/S0896-6273(00)80411-0; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hussain NK, 2003, J BIOL CHEM, V278, P28823, DOI 10.1074/jbc.M300995200; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; Johannessen LE, 2006, MOL CELL BIOL, V26, P389, DOI 10.1128/MCB.26.2.389-401.2006; Kamioka Y, 2004, J BIOL CHEM, V279, P40091, DOI 10.1074/jbc.M404899200; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; KREMER L, 1988, ANAL BIOCHEM, V175, P91, DOI 10.1016/0003-2697(88)90365-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morgan JR, 2003, J BIOL CHEM, V278, P33583, DOI 10.1074/jbc.M304346200; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Murph MM, 2003, J CELL SCI, V116, P1969, DOI 10.1242/jcs.00397; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; POHL T, 1990, METHOD ENZYMOL, V182, P68; Puri C, 2005, MOL BIOL CELL, V16, P2704, DOI 10.1091/mbc.e04-07-0596; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Strachan LR, 2004, J CELL BIOL, V167, P545, DOI 10.1083/jcb.200405024; Subtil A, 1997, J CELL SCI, V110, P2441; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Traub LM, 2005, BBA-MOL CELL RES, V1744, P415, DOI 10.1016/j.bbamcr.2005.04.005; Trevaskis J, 2005, ENDOCRINOLOGY, V146, P3757, DOI 10.1210/en.2005-0282; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	43	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26481	10.1074/jbc.M703815200	http://dx.doi.org/10.1074/jbc.M703815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17626015	hybrid			2022-12-25	WOS:000249239600053
J	De la Vieja, A; Reed, MD; Ginter, CS; Carrasco, N				De la Vieja, Antonio; Reed, Mia D.; Ginter, Christopher S.; Carrasco, Nancy			Amino acid residues in transmembrane segment IX of the Na+/I- symporter play a role in its Na+ dependence and are critical for transport activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM/IODIDE SYMPORTER; IODIDE TRANSPORT; MOLECULAR ANALYSIS; NIS; SODIUM; FAMILY; NEUROTRANSMITTER; IDENTIFICATION; COTRANSPORTER; MUTATION	The Na+/I- symporter (NIS) is a key plasma membrane glycoprotein that mediates Na+-dependent active I- transport in the thyroid, lactating breast, and other tissues. The OH group of the side chain at position 354 in transmembrane segment (TMS) IX of NIS has been demonstrated to be essential for NIS function, as revealed by the study of the congenital I- transport defect-causing T354P NIS mutation. TMS IX has the most beta-OH group-containing amino acids (Ser and Thr) of any TMS in NIS. We have thoroughly characterized the functional significance of all Ser and Thr in TMS IX in NIS, as well as of other residues in TMSIX that are highly conserved in other transporters of the SLC5A protein family. Here we show that five beta-OH group-containing residues (Thr-351, Ser-353, Thr-354, Ser-356, and Thr-357) and Asn-360, all of which putatively face the same side of the helix in TMS IX, plus Asp-369, located in the membrane/cytosol interface, play key roles in NIS function and seem to be involved in Na+ binding/translocation.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Carrasco, N (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	carrasco@aecom.yu.edu	De la Vieja, Antonio/I-4774-2013; Carrasco, Nancy/AAH-1053-2019	De la Vieja, Antonio/0000-0002-1187-1907; Carrasco, Nancy/0000-0003-4137-6162	NCI NIH HHS [CA098390] Funding Source: Medline; NIDDK NIH HHS [DK41544] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 07491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; de Castro E, 2006, NUCLEIC ACIDS RES, V34, pW362, DOI 10.1093/nar/gkl124; DE la Vieja A, 2000, PHYSIOL REV, V80, P1083, DOI 10.1152/physrev.2000.80.3.1083; De la Vieja A, 2005, MOL ENDOCRINOL, V19, P2847, DOI 10.1210/me.2005-0162; De la Vleja A, 2004, J CELL SCI, V117, P677, DOI 10.1242/jcs.00898; de Wardener HE, 2004, KIDNEY INT, V66, P2454, DOI 10.1111/j.1523-1755.2004.66018.x; Doege H, 1998, BIOCHEM J, V329, P289, DOI 10.1042/bj3290289; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Levy O, 1998, FEBS LETT, V429, P36, DOI 10.1016/S0014-5793(98)00522-5; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; MAZZAFERRI EL, 2005, THYROID FUNDAMENTAL, P934; Pajor AM, 2001, J BIOL CHEM, V276, P29961, DOI 10.1074/jbc.M011387200; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Wright EM, 2004, PFLUG ARCH EUR J PHY, V447, P510, DOI 10.1007/s00424-003-1063-6; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710	25	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25290	25298		10.1074/jbc.M700147200	http://dx.doi.org/10.1074/jbc.M700147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606623	hybrid			2022-12-25	WOS:000249014100014
J	Siddiqui, N; Mangus, DA; Chang, TC; Palermino, JM; Shyu, AB; Gehring, K				Siddiqui, Nadeem; Mangus, David A.; Chang, Tsung-Cheng; Palermino, Jeanne-Marie; Shyu, Ann-Bin; Gehring, Kalle			Poly(A) nuclease interacts with the c-terminal domain of polyadenylate-binding protein domain from poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; MESSENGER-RNA DEADENYLASE; PABC DOMAIN; SEQUENCE ALIGNMENT; YEAST; IDENTIFICATION; GENE; SUBUNIT; COMPLEX; RECOGNITION	The poly( A)- binding protein ( PABP) is an essential protein found in all eukaryotes and is involved in an extensive range of cellular functions, including translation, mRNA metabolism, and mRNA export. Its C- terminal region contains a peptideinteracting PABC domain that recruits proteins containing a highly specific PAM- 2 sequence motif to the messenger ribonucleoprotein complex. In humans, these proteins, including Paip1, Paip2, eRF3 ( eukaryotic release factor 3), Ataxin-2, and Tob2, are all found to regulate translation through varying mechanisms. The following reports poly( A) nuclease ( PAN) as a PABC-interacting partner in both yeast and humans. Their interaction is mediated by a PAM- 2 motif identified within the PAN3 subunit. This site was identified in various fungal and animal species suggesting that the interaction is conserved throughout evolution. Our results indicate that PABP is directly involved in recruiting a deadenylase to the messenger ribonucleoprotein complex. This demonstrates a novel role for the PABC domain in mRNA metabolic processes and gives further insight into the function of PABP in mRNA maturation, export, and turnover.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	McGill University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	kalle.gehring@mcgill.ca	Chang, Tsung-Cheng/C-2761-2008; Gehring, Kalle/N-2945-2019; Gehring, Kalle/I-4403-2013	Chang, Tsung-Cheng/0000-0003-4706-0468; Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; Amrani N, 1997, MOL CELL BIOL, V17, P3694, DOI 10.1128/MCB.17.7.3694; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; Barnard DC, 2005, MOL CELL BIOL, V25, P7605, DOI 10.1128/MCB.25.17.7605-7615.2005; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bravo J, 2005, MOL GENET GENOMICS, V272, P651, DOI 10.1007/s00438-004-1090-9; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Brune C, 2005, RNA, V11, P517, DOI 10.1261/rna.7291205; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chekanova JA, 2003, RNA, V9, P1476, DOI 10.1261/rna.5128903; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Deo RC, 2001, P NATL ACAD SCI USA, V98, P4414, DOI 10.1073/pnas.071552198; Dunn EF, 2005, GENE DEV, V19, P90, DOI 10.1101/gad.1267005; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Hosoda N, 2006, MOL CELL BIOL, V26, P3085, DOI 10.1128/MCB.26.8.3085-3097.2006; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Kerwitz Y, 2003, EMBO J, V22, P3705, DOI 10.1093/emboj/cdg347; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Kozlov G, 2004, EMBO J, V23, P272, DOI 10.1038/sj.emboj.7600048; Kozlov Guennadi, 2002, Journal of Biological Chemistry, V277, P22822, DOI 10.1074/jbc.M201230200; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Lim NS, 2006, J BIOL CHEM, V281, P14376, DOI 10.1074/jbc.M600307200; Mangus DA, 2004, MOL CELL BIOL, V24, P5521, DOI 10.1128/MCB.24.12.5521-5533.2004; Mangus DA, 2004, MOL CELL BIOL, V24, P4196, DOI 10.1128/MCB.24.10.4196-4206.2004; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Mangus DA, 1998, MOL CELL BIOL, V18, P7383, DOI 10.1128/MCB.18.12.7383; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; McGinnis S, 2004, NUCLEIC ACIDS RES, V32, pW20, DOI 10.1093/nar/gkh435; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Ralser M, 2005, J MOL BIOL, V346, P203, DOI 10.1016/j.jmb.2004.11.024; Roy G, 2002, MOL CELL BIOL, V22, P3769, DOI 10.1128/MCB.22.11.3769-3782.2002; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Siddiqui N, 2003, PROTEIN SCI, V12, P1925, DOI 10.1110/ps.0390103; Siddiqui N, 2007, BIOCHEMISTRY-US, V46, P4221, DOI 10.1021/bi061986d; SIKORSKI RS, 1989, GENETICS, V122, P19; STEEL LF, 1987, MOL CELL BIOL, V7, P965, DOI 10.1128/MCB.7.3.965; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; Wang XF, 2004, PLANT MOL BIOL, V54, P85, DOI 10.1023/B:PLAN.0000028771.70969.6b; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016	60	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25067	25075		10.1074/jbc.M701256200	http://dx.doi.org/10.1074/jbc.M701256200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17595167	hybrid			2022-12-25	WOS:000248933000062
J	Kalderon, N; Muruganandham, M; Koutcher, JA; Potuzak, M				Kalderon, Nurit; Muruganandham, Manickam; Koutcher, Jason A.; Potuzak, Melissa			Therapeutic Strategy for Acute Spinal Cord Contusion Injury: Cell Elimination Combined with Microsurgical Intervention	PLOS ONE			English	Article								Background. No cure is available for human spinal cord injury. Cell elimination by localized radiation therapy that is timed within 2-3 weeks postinjury can facilitate repair of structure and function in transected rat spinal cord. In pilot studies in contusion spinal cord injury, a model similar to crush/fracture injury in human, we did not observe the expected beneficial effects of radiation therapy. Long forgotten data show that in contusion/crush injury, fluid accumulation from hemorrhage is critical. Alfred Reginald Allen observed that the most devastating sequelae in contusive injury are secondary to fluid accumulation which could be alleviated by surgical intervention, midline slits (myelotomy) at the lesion site. Methods and Findings. Here, we tested whether release of fluid buildup by microsurgery (partial myelotomy) would affect the structural outcome of radiation therapy in the severely contused rat spinal cord. Surgical intervention alone significantly enhanced tissue and functional preservation in the contused cord, thus confirming Allen's observations. Combining partial myelotomy with radiation therapy that is specifically timed postinjury elicited substantial beneficial therapeutic outcome; it led to significant increase in tissue repair/preservation compared with the group that received surgical intervention only, as determined by histology and in vivo MRI. Altogether, the combined treatments led to a 1.8 fold increase in tissue repair/preservation as compared with the contused group. Conclusions. The data suggest that a clinical protocol could be developed to treat acute human spinal cord injury through conventional clinical procedures, a combination of microsurgical manipulation and radiation therapy. These also suggest it is imperative to first prevent the secondary damage caused by fluid accumulation for a cure to be possible.	[Kalderon, Nurit; Potuzak, Melissa] Sloan Kettering Inst Canc Res, Mol Pharmacol & Chem Program, New York, NY USA; [Muruganandham, Manickam; Koutcher, Jason A.] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; [Koutcher, Jason A.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Kalderon, N (corresponding author), Spinal Cord Injury Repair Lab, New York, NY USA.	kalderon@spinalcordcure.org			NIH/NINDS [RO1 NS39375]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039375] Funding Source: NIH RePORTER	NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH/NINDS grant RO1 NS39375 (N.K.). No sponsors or funders.	Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Allen AR, 1911, JAMA 57, P878, DOI [10.1001/jama.1911.04260090100008, DOI 10.1001/JAMA.1911.04260090100008]; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bilgen M, 2001, MAGNET RESON MED, V45, P614, DOI 10.1002/mrm.1083; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Campbell J B, 1973, Surg Neurol, V1, P102; COOPER PR, 1985, J NEUROSURG, V63, P492, DOI 10.3171/jns.1985.63.4.0492; Corbetta M, 2002, P NATL ACAD SCI USA, V99, P17066, DOI 10.1073/pnas.262669099; de Leon RD, 2002, BRAIN RES REV, V40, P267, DOI 10.1016/S0165-0173(02)00209-6; FALCONER JC, 1994, MAGNET RESON MED, V32, P484, DOI 10.1002/mrm.1910320410; FREEMAN LW, 1953, ANN SURG, V137, P433, DOI 10.1097/00000658-195304000-00001; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11185, DOI 10.1073/pnas.93.20.11185; Kalderon N, 2005, CURR PHARM DESIGN, V11, P1237, DOI 10.2174/1381612053507477; Kalderon N, 2001, BRAIN RES, V904, P199, DOI 10.1016/S0006-8993(01)02402-7; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11179, DOI 10.1073/pnas.93.20.11179; Khan DC, 1999, CANCER INVEST, V17, P110; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; MARCUS RB, 1990, INT J RADIAT ONCOL, V19, P3, DOI 10.1016/0360-3016(90)90126-5; Markham JW., 1951, HIST NEUROLOGICAL SU, P364; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Merola A, 2002, J ORTHOP TRAUMA, V16, P155, DOI 10.1097/00005131-200203000-00003; Narayana P, 1999, MAGN RESON MED, V41, P315, DOI 10.1002/(SICI)1522-2594(199902)41:2<315::AID-MRM15>3.0.CO;2-B; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Qi HX, 2004, SOMATOSENS MOT RES, V21, P229, DOI 10.1080/08990220400012588; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; SCHULTHEISS TE, 1990, INT J RADIAT ONCOL, V19, P219, DOI 10.1016/0360-3016(90)90157-F; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Timoszyk WK, 2002, J NEUROPHYSIOL, V88, P3108, DOI 10.1152/jn.01050.2001; Wu CWH, 2000, NEURON, V28, P967, DOI 10.1016/S0896-6273(00)00167-7; Zeman RJ, 2001, EXP NEUROL, V172, P228, DOI 10.1006/exnr.2001.7803	36	22	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e565	10.1371/journal.pone.0000565	http://dx.doi.org/10.1371/journal.pone.0000565			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637827	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452100001
J	Kawasaki, Y; Sagara, M; Shibata, Y; Shirouzu, M; Yokoyama, S; Akiyama, T				Kawasaki, Y.; Sagara, M.; Shibata, Y.; Shirouzu, M.; Yokoyama, S.; Akiyama, T.			Identification and characterization of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42	ONCOGENE			English	Article						tumor suppressor; APC; Asef; GEF; Rac1; Cdc42	TUMOR-SUPPRESSOR APC; COLORECTAL-CANCER; ACTIN CYTOSKELETON; MIGRATION; PROTEIN; LINK	The tumor suppressor adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumors. APC interacts with the Rac1-specific guanine-nucleotide exchange factor (GEF) Asef, which contains an APC-binding region (ABR) in addition to Dbl homology (DH), Pleckstrin (PH) and Src homology 3 (SH3) domains. APC stimulates the GEF activity of Asef, and thereby regulates cell adhesion and migration. Here, we have identified a second Asef, termed Asef2, that shows significant structural and functional similarities to Asef. We found that both the N-terminal ABR and SH3 domains of Asef2 are responsible for its interaction with APC. When expressed in HeLa cells, a mutant Asef2 lacking the ABR and SH3 domains, Asef2-Delta ABR/SH3, induced increases in the levels of the active forms of Rac1 and Cdc42. Full-length Asef2 also showed this activity when co-transfected with truncated mutant APC expressed in colorectal tumor cells. Consistent with this, either Asef2-Delta ABR/SH3 or Asef2 plus truncated mutant APC stimulated lamellipodia formation in MDCK cells and filopodia formation in HeLa cells. Furthermore, RNA interference experiments showed that Asef2 is required for migration of colorectal tumor cells expressing truncated APC. These results suggest that similar to Asef, Asef2 plays an important role in cell migration, and that Asef2 activated by truncated mutant APC is required for aberrant migration of colorectal tumor cells.	[Kawasaki, Y.; Sagara, M.; Shibata, Y.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; [Shirouzu, M.; Yokoyama, S.] RIKEN Genom Sci Ctr, Yokohama Inst, Bunkyo Ku, Tokyo, Japan; [Yokoyama, S.] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan	University of Tokyo; RIKEN; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@imcbns.iam.u-tokyo.ac.jp	Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Gotthardt K, 2007, BIOL CHEM, V388, P67, DOI 10.1515/BC.2007.008; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamann MJ, 2007, MOL CELL BIOL, V27, P1380, DOI 10.1128/MCB.01608-06; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murayama K, 2007, J BIOL CHEM, V282, P4238, DOI 10.1074/jbc.C600234200; Oshima H, 1997, CANCER RES, V57, P1644; Polakis P, 2000, GENE DEV, V14, P1837; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; VAN AL, 1997, GENE DEV, V11, P2295; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	20	55	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7620	7627		10.1038/sj.onc.1210574	http://dx.doi.org/10.1038/sj.onc.1210574			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599059				2022-12-25	WOS:000251537800003
J	Hayashi, Y; Okino, N; Kakuta, Y; Shikanai, T; Tani, M; Narimatsu, H; Ito, M				Hayashi, Yasuhiro; Okino, Nozomu; Kakuta, Yoshimitsu; Shikanai, Toshihide; Tani, Motohiro; Narimatsu, Hisashi; Ito, Makoto			Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; GLUCOSYLCERAMIDE SYNTHASE; MOLECULAR-CLONING; GLUCOSIDASE; MEMBRANE; GENE; GLUCOCEREBROSIDASE; IDENTIFICATION; PURIFICATION; EXPRESSION	Using C6-NBD-glucosylceramide ( GlcCer) as a substrate, we detected the activity of a conduritol B epoxide-insensitive neutral glycosylceramidase in cytosolic fractions of zebrafish embryos, mouse and rat brains, and human fibroblasts. The candidates for the enzyme were assigned to the Klotho (KL), whose family members share a beta-glucosidase-like domain but whose natural substrates are unknown. Among this family, only the KL-related protein (KLrP) is capable of degrading C6-NBD-GlcCer when expressed in CHOP cells, in which Myc-tagged KLrP was exclusively distributed in the cytosol. In addition, knockdown of the endogenous KLrP by small interfering RNA increased the cellular level of GlcCer. The purified recombinant KLrP hydrolyzed 4-methylumbelliferyl-glucose, C6-NBD-GlcCer, and authentic GlcCer at pH 6.0. The enzyme also hydrolyzed the corresponding galactosyl derivatives, but each k(cat)/K-m was much lower than that for glucosyl derivatives. The x-ray structure of KLrP at 1.6 A resolution revealed that KLrP is a (beta/alpha) 8 TIM barrel, in which Glu(165) and Glu(373) at the carboxyl termini of beta-strands 4 and 7 could function as an acid/base catalyst and nucleophile, respectively. The substrate-binding cleft of the enzyme was occupied with palmitic acid and oleic acid when the recombinant protein was crystallized in a complex with glucose. GlcCer was found to fit well the cleft of the crystal structure of KLrP. Collectively, KLrP was identified as a cytosolic neutral glycosylceramidase that could be involved in a novel nonlysosomal catabolic pathway of GlcCer.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Med Glycosci, Tsukuba, Ibaraki 3058568, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648555, Japan; JST, CREST, Tokyo, Japan	Kyushu University; Kyushu University; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Okino, Nozomu/AAY-2635-2021; Narimatsu, Hisashi/M-4757-2018; Shikanai, Toshihide/H-4242-2015; Ito, Makoto/Q-6164-2019	Narimatsu, Hisashi/0000-0002-8402-133X; ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; Beutler E, 2004, J LAB CLIN MED, V144, P65, DOI 10.1016/j.lab.2004.03.013; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Boot RG, 2007, J BIOL CHEM, V282, P1305, DOI 10.1074/jbc.M610544200; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Graaf M. D., 2001, BIOCHEM J, V356, P907; Hayashi Y, 2005, ANAL BIOCHEM, V345, P181, DOI 10.1016/j.ab.2005.05.029; Hays WS, 1996, BIOCHEM J, V319, P829, DOI 10.1042/bj3190829; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Ito S, 2002, BBA-GENE STRUCT EXPR, V1576, P341, DOI 10.1016/S0167-4781(02)00281-6; KOBAYASHI T, 1981, J BIOL CHEM, V256, P7768; KOERNER TAW, 1979, J BIOL CHEM, V254, P2326; Kohyama-Koganeya A, 2004, J BIOL CHEM, V279, P35995, DOI 10.1074/jbc.M400444200; Kolachala VL, 2006, BBA-GEN SUBJECTS, V1760, P1102, DOI 10.1016/j.bbagen.2006.03.010; Kolter T, 2005, ANNU REV CELL DEV BI, V21, P81, DOI 10.1146/annurev.cellbio.21.122303.120013; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARTEN H, 2001, J BIOL CHEM, V276, P37929; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Mitsutake S, 1998, J BIOCHEM-TOKYO, V123, P859; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overkleeft HS, 1998, J BIOL CHEM, V273, P26522, DOI 10.1074/jbc.273.41.26522; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Premkumar L, 2005, J BIOL CHEM, V280, P23815, DOI 10.1074/jbc.M502799200; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Sumida T, 2002, J BIOCHEM, V132, P237, DOI 10.1093/oxfordjournals.jbchem.a003216; Tani M, 1999, J BIOCHEM-TOKYO, V125, P746; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANWEELY S, 1993, BIOCHIM BIOPHYS ACTA, V1181, P55, DOI 10.1016/0925-4439(93)90090-N; Yahata K, 2000, J MOL MED, V78, P389, DOI 10.1007/s001090000131; Yildiz Y, 2006, J CLIN INVEST, V116, P2985, DOI 10.1172/JCI29224	39	76	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30889	30900		10.1074/jbc.M700832200	http://dx.doi.org/10.1074/jbc.M700832200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17595169	hybrid			2022-12-25	WOS:000250136300057
J	Beisswenger, C; Coyne, CB; Shchepetov, M; Weiser, JN				Beisswenger, Christoph; Coyne, Carolyn B.; Shchepetov, Mikhail; Weiser, Jeffrey N.			Role of p38 MAP kinase and transforming growth factor-beta signaling in transepithelial migration of invasive bacterial pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NONTYPABLE HAEMOPHILUS-INFLUENZAE; AIRWAY EPITHELIAL-CELLS; LIPOTEICHOIC ACID LTA; STREPTOCOCCUS-PNEUMONIAE; P38 MAPK; ENDOTHELIAL PERMEABILITY; MUCIN TRANSCRIPTION; TIGHT JUNCTIONS; LUNG	Streptococcus pneumoniae and Haemophilus influenzae are human pathogens that often asymptomatically colonize the mucosal surface of the upper respiratory tract, but also occasionally cause invasive disease. The ability of these species to traverse the epithelium of the airway mucosa was modeled in vitro using polarized respiratory epithelial cells in culture. Migration across the epithelial barrier was preceded by loss of transepithelial resistance. Membrane products of S. pneumoniae that included lipoteichoic acid induced disruption of the epithelial barrier in a Toll-like receptor 2-dependent manner. This result correlates with a recent genetic study that associates increased TLR2 signaling with increased rates of invasive pneumococcal disease in humans. Loss of transepithelial resistance by the TLR2 ligand correlated with activation of p38 MAP kinase and transforming growth factor ( TGF)-beta signaling. Activation of p38 MAPK and TGF-beta signaling in epithelial cells upon nasal infection with S. pneumoniae was also demonstrated in vivo. Inhibition of either p38 MAPK or TGF-beta signaling was sufficient to inhibit the migration of S. pneumoniae or H. influenzae. Our data shows that diverse bacteria utilize common mechanisms, including MAPK and TGF-beta signaling pathways to disrupt epithelial barriers and promote invasion.	Univ Penn, Dept Microbiol & Pediat, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Weiser, JN (corresponding author), Univ Penn, Dept Microbiol & Pediat, Sch Med, Philadelphia, PA 19104 USA.	weiser@mail.med.upenn.edu	Beisswenger, Christoph/GRO-6580-2022	Weiser, Jeffrey/0000-0001-7168-8090	NIAID NIH HHS [AI138446, AI44231] Funding Source: Medline; NIDDK NIH HHS [P30 DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI044231, R01AI044231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Birukova AA, 2005, FEBS LETT, V579, P4031, DOI 10.1016/j.febslet.2005.06.018; Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; Chen ML, 2006, INFECT IMMUN, V74, P6581, DOI 10.1128/IAI.00958-06; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Chow EK, 2005, EMBO J, V24, P4071, DOI 10.1038/sj.emboj.7600867; Clements RT, 2005, AM J PHYSIOL-LUNG C, V288, pL294, DOI 10.1152/ajplung.00213.2004; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; Ehrhardt C, 2002, CELL TISSUE RES, V308, P391, DOI 10.1007/s00441-002-0548-5; Gould JM, 2002, J INFECT DIS, V186, P361, DOI 10.1086/341658; Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005; Han SH, 2003, INFECT IMMUN, V71, P5541, DOI 10.1128/IAI.71.10.5541-5548.2003; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Kapus A, 2006, BIOCHEM CELL BIOL, V84, P870, DOI 10.1139/O06-202; Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976; Kim JY, 2005, INFECT IMMUN, V73, P7107, DOI 10.1128/IAI.73.11.7107-7112.2005; KLEIN RA, 1994, CARBOHYD RES, V256, P189, DOI 10.1016/0008-6215(94)84209-4; Lee J, 2006, NAT CELL BIOL, V8, P1327, DOI 10.1038/ncb1500; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; McCool TL, 2002, J EXP MED, V195, P359, DOI 10.1084/jem.20011576; Medici D, 2006, MOL BIOL CELL, V17, P1871, DOI 10.1091/mbc.E05-08-0767; Mikami F, 2006, J BIOL CHEM, V281, P22397, DOI 10.1074/jbc.M602124200; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; N'Guessan PD, 2006, AM J PHYSIOL-LUNG C, V290, pL1131, DOI 10.1152/ajplung.00383.2005; Nelson AL, 2007, INFECT IMMUN, V75, P83, DOI 10.1128/IAI.01475-06; Ratner AJ, 2006, J BIOL CHEM, V281, P12994, DOI 10.1074/jbc.M511431200; Ratner AJ, 2005, P NATL ACAD SCI USA, V102, P3429, DOI 10.1073/pnas.0500599102; RAYNER CFJ, 1995, INFECT IMMUN, V63, P442, DOI 10.1128/IAI.63.2.442-447.1995; Ring A, 1998, J CLIN INVEST, V102, P347, DOI 10.1172/JCI2406; Schmeck B, 2006, AM J PHYSIOL-LUNG C, V290, pL730, DOI 10.1152/ajplung.00271.2005; Schmeck B, 2004, J BIOL CHEM, V279, P53241, DOI 10.1074/jbc.M313702200; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Soong G, 2004, J CLIN INVEST, V113, P1482, DOI 10.1172/JCI200420773; Swords WE, 2001, CELL MICROBIOL, V3, P525, DOI 10.1046/j.1462-5822.2001.00132.x; van Schilfgaarde M, 1999, MICROB PATHOGENESIS, V26, P249, DOI 10.1006/mpat.1998.0269; VANSCHILFGAARDE M, 1995, INFECT IMMUN, V63, P4729, DOI 10.1128/IAI.63.12.4729-4737.1995; Wang XR, 2002, J IMMUNOL, V168, P810, DOI 10.4049/jimmunol.168.2.810; Weiser JN, 2003, P NATL ACAD SCI USA, V100, P4215, DOI 10.1073/pnas.0637469100	42	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28700	28708		10.1074/jbc.M703576200	http://dx.doi.org/10.1074/jbc.M703576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17650505	hybrid			2022-12-25	WOS:000249642100044
J	Conners, R; Konarev, AV; Forsyth, J; Lovegrove, A; Marsh, J; Joseph-Horne, T; Shewry, P; Brady, RL				Conners, Rebecca; Konarev, Alexander V.; Forsyth, Jane; Lovegrove, Alison; Marsh, Justin; Joseph-Horne, Timothy; Shewry, Peter; Brady, R. Leo			An unusual helix-turn-helix protease inhibitory motif in a novel trypsin inhibitor from seeds of veronica (Veronica hederifolia L.)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITORS; CRYSTAL-STRUCTURE; STRUCTURAL MOTIF; ACTIVE-SITE; CYCLOTIDES; RESOLUTION; DISCOVERY; PEPTIDES; GEOMETRY; COMPLEX	The storage tissues of many plants contain protease inhibitors that are believed to play an important role in defending the plant from invasion by pests and pathogens. These proteinaceous inhibitor molecules belong to a number of structurally distinct families. We describe here the isolation, purification, initial inhibitory properties, and three-dimensional structure of a novel trypsin inhibitor from seeds of Veronica hederifolia (VhTI). The VhTI peptide inhibits trypsin with a submicromolar apparent K-i and is expected to be specific for trypsin-like serine proteases. VhTI differs dramatically in structure from all previously described families of trypsin inhibitors, consisting of a helix-turn-helix motif, with the two a helices tightly associated by two disulfide bonds. Unusually, the crystallized complex is in the form of a stabilized acyl-enzyme intermediate with the scissile bond of the VhTI inhibitor cleaved and the resulting N-terminal portion of the inhibitor remaining attached to the trypsin catalytic serine 195 by an ester bond. A synthetic, truncated version of the VhTI peptide has also been produced and co-crystallized with trypsin but, surprisingly, is seen to be uncleaved and consequently forms a noncovalent complex with trypsin. The VhTI peptide shows that effective enzyme inhibitors can be constructed from simple helical motifs and provides a new scaffold on which to base the design of novel serine protease inhibitors.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; All Russian Inst Plant Protect, R-196608 St Petersburg AL5 2JQ, Russia; Rothamsted Res, Harpenden AL5 2JQ, Herts, England	University of Bristol; All-Russian Institute of Plant Protection; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Brady, RL (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.	L.Brady@bris.ac.uk	Conners, Rebecca/C-2608-2013; Konarev, Alexander/Y-9620-2019; Konarev, Alexander/G-2126-2015	Konarev, Alexander/0000-0002-5148-2850; Konarev, Alexander/0000-0002-5148-2850; Conners, Rebecca/0000-0002-8653-1771	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004157, BB/C502414/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1999, SEED PROTEINS; BIRK Y, 2003, PLANT PROTEASE INHIB, P23; BODE W, 1992, PROTEIN SCI, V1, P426; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Katona G, 2002, J BIOL CHEM, V277, P21962, DOI 10.1074/jbc.M200676200; KONAREV A V, 1986, Biokhimiya, V51, P195; Konarev AV, 2004, PHYTOCHEMISTRY, V65, P3003, DOI 10.1016/j.phytochem.2004.08.022; Konarev AV, 2002, PHYTOCHEMISTRY, V59, P279, DOI 10.1016/S0031-9422(01)00463-0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI MJ, 1986, NUTR TOXICOLOGICAL S; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; McBride JD, 2002, BIOPOLYMERS, V66, P79, DOI 10.1002/bip.10228; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mulvenna JP, 2005, J BIOL CHEM, V280, P32245, DOI 10.1074/jbc.M506060200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otlewski J, 2005, EMBO J, V24, P1303, DOI 10.1038/sj.emboj.7600611; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shewry PR, 1997, ADV BOT RES, V26, P135, DOI 10.1016/S0065-2296(08)60120-2; Simonsen SM, 2005, PLANT CELL, V17, P3176, DOI 10.1105/tpc.105.034678; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; Wilmouth RC, 2001, NAT STRUCT BIOL, V8, P689, DOI 10.1038/90401; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	37	43	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27760	27768		10.1074/jbc.M703871200	http://dx.doi.org/10.1074/jbc.M703871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640870	hybrid, Green Published			2022-12-25	WOS:000249455600025
J	Nishimura, K; Segawa, H; Goto, T; Morishita, M; Masago, A; Takahashi, H; Ohmiya, Y; Sakaguchi, T; Asada, M; Imamura, T; Shimotono, K; Takayama, K; Yoshida, T; Nakanishi, M				Nishimura, Ken; Segawa, Hiroaki; Goto, Takahiro; Morishita, Mariko; Masago, Akinori; Takahashi, Hitoshi; Ohmiya, Yoshihiro; Sakaguchi, Takemasa; Asada, Masahiro; Imamura, Toru; Shimotono, Kunitada; Takayama, Kozo; Yoshida, Tetsuya; Nakanishi, Mahito			Persistent and stable gene expression by a cytoplasmic RNA replicon based on a noncytopathic variant Sendai virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIG-I; MESSENGER-RNA; V-PROTEINS; ACTIVATION; EFFICIENT; VECTORS; CDNA; LUCIFERASE; INITIATION; INDUCTION	Persistent and stable expression of foreign genes has been achieved in mammalian cells by integrating the genes into the host chromosomes. However, this approach has several shortcomings in practical applications. For example, large scale production of protein pharmaceutics frequently requires laborious amplification of the inserted genes to optimize the gene expression. The random chromosomal insertion of exogenous DNA also results occasionally in malignant transformation of normal tissue cells, raising safety concerns in medical applications. Here we report a novel cytoplasmic RNA replicon capable of expressing installed genes stably without chromosome insertion. This system is based on the RNA genome of a noncytopathic variant Sendai virus strain, Cl.151. We found that this variant virus establishes stable symbiosis with host cells by escaping from retinoic acid-inducible gene I-interferon regulatory factor 3-mediated antiviral machinery. Using a cloned genome cDNA of Sendai virus Cl. 151, we developed a recombinant RNA installed with exogenous marker genes that was maintained stably in the cytoplasm as a high copy replicon (about 4 x 104 copies/cell) without interfering with normal cellular function. Strong expression of the marker genes persisted for more than 6 months in various types of cultured cells and for at least two months in rat colonic mucosa without any apparent side effects. This stable RNA replicon is a potentially valuable genetic platform for various biological applications.	Natl Inst Adv Ind Sci & Technol, Biotherapeut Res Lab, Tsukuba, Ibaraki 3058562, Japan; Natl Inst Adv Ind Sci & Technol, Signalling Mol Res Lab, Tsukuba, Ibaraki 3058562, Japan; Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1028471, Japan; Hoshi Univ, Dept Pharmaceut, Shinagawa Ku, Tokyo 1428501, Japan; Osaka Univ, Res Inst Microbial Dis, Osaka, Japan; Kyoto Univ, Inst Virus Res, Dept Oncol, Sakyo Ku, Kyoto 6068507, Japan; Natl Inst Adv Ind Sci & Technol, Res Inst Cell Engn, Osaka 5638577, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Virol, Minami Ku, Hiroshima 7348551, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Japan Society for the Promotion of Science; Hoshi University; Osaka University; Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); Hiroshima University	Nakanishi, M (corresponding author), Natl Inst Adv Ind Sci & Technol, Biotherapeut Res Lab, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.	mahito-nakanishi@aist.go.jp	Sakaguchi, Takemasa/H-1488-2019; ASADA, MASAHIRO/M-4086-2018; Nakanishi, Mahito/I-9888-2018	Sakaguchi, Takemasa/0000-0002-3754-1252; ASADA, MASAHIRO/0000-0001-6092-2080; Nakanishi, Mahito/0000-0002-7068-7587; Nishimura, Ken/0000-0002-0716-4142				Bitzer M, 2003, J GENE MED, V5, P543, DOI 10.1002/jgm.426; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Eguchi A, 2000, J BIOL CHEM, V275, P17549, DOI 10.1074/jbc.M910004199; Enjuanes L, 2003, N COMP BIOC, V38, P151; Fujita S, 2006, BIOL PHARM BULL, V29, P1728, DOI 10.1248/bpb.29.1728; Garcin D, 1998, VIROLOGY, V243, P340, DOI 10.1006/viro.1998.9063; Goto T, 2006, PHARM RES-DORDR, V23, P384, DOI 10.1007/s11095-005-9175-7; Griesenbach U, 2005, CURR OPIN MOL THER, V7, P346; Gubbay O, 2001, J GEN VIROL, V82, P2895, DOI 10.1099/0022-1317-82-12-2895; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; Hasan MK, 1997, J GEN VIROL, V78, P2813, DOI 10.1099/0022-1317-78-11-2813; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Inoue M, 2004, J GENE MED, V6, P1069, DOI 10.1002/jgm.597; Iseni F, 2002, EMBO J, V21, P5141, DOI 10.1093/emboj/cdf513; Izsvak Z, 2004, MOL THER, V9, P147, DOI 10.1016/j.ymthe.2003.11.009; Jackson DA, 2006, MOL THER, V14, P613, DOI 10.1016/j.ymthe.2006.03.026; JOLLY DJ, 1999, COLD SPRING HARBOR M, V36, P209; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; KATO K, 1991, J BIOL CHEM, V266, P3361; KIRCHMAIER AL, 1995, J VIROL, V69, P1280, DOI 10.1128/JVI.69.2.1280-1283.1995; Komatsu T, 2004, VIROLOGY, V325, P137, DOI 10.1016/j.virol.2004.04.025; KONDO T, 1993, J BIOL CHEM, V268, P21924; Kovacs GR, 2003, J VIROL METHODS, V111, P29, DOI 10.1016/S0166-0934(03)00132-0; Lamb R. A., 2001, Fundamental virology, P689; MATSUMOTO T, 1961, J IMMUNOL, V87, P590; MATSUMOTO T, 1954, NAGOYA J MED SCI, V17, P93; MURRAY MG, 1986, ANAL BIOCHEM, V158, P165, DOI 10.1016/0003-2697(86)90605-6; Nakajima Y, 2004, BIOSCI BIOTECH BIOCH, V68, P565, DOI 10.1271/bbb.68.565; Nienhuis AW, 2006, MOL THER, V13, P1031, DOI 10.1016/j.ymthe.2006.03.001; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737; Strahle L, 2003, J VIROL, V77, P7903, DOI 10.1128/JVI.77.14.7903-7913.2003; Strahle L, 2006, VIROLOGY, V351, P101, DOI 10.1016/j.virol.2006.03.022; TAKAGI T, 1995, J BIOCHEM-TOKYO, V118, P390, DOI 10.1093/oxfordjournals.jbchem.a124919; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; VIDAL S, 1990, J VIROL, V64, P239, DOI 10.1128/JVI.64.1.239-246.1990; Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026; Yoneda A, 2000, NAT BIOTECHNOL, V18, P641, DOI 10.1038/76487; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; YOSHIDA T, 1979, VIROLOGY, V92, P139, DOI 10.1016/0042-6822(79)90220-4; Yoshizaki M, 2006, J GENE MED, V8, P1151, DOI 10.1002/jgm.938	45	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27383	27391		10.1074/jbc.M702028200	http://dx.doi.org/10.1074/jbc.M702028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623660	hybrid			2022-12-25	WOS:000249304900080
J	Yamaguchi, H; Sasaki, K; Satomi, Y; Shimbara, T; Kageyama, H; Mondal, MS; Toshinai, K; Date, Y; Gonzalez, LJ; Shioda, S; Takao, T; Nakazato, M; Minamino, N				Yamaguchi, Hideki; Sasaki, Kazuki; Satomi, Yoshinori; Shimbara, Takuya; Kageyama, Haruaki; Mondal, Muhtashan S.; Toshinai, Koji; Date, Yukari; Gonzalez, Luis J.; Shioda, Seiji; Takao, Toshifumi; Nakazato, Masamitsu; Minamino, Naoto			Peptidomic identification and biological validation of neuroendocrine regulatory peptide-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; PORCINE BRAIN; VGF; BIOSYNTHESIS; EXPRESSION; CALCITONIN; SECRETION; GHRELIN; REVEALS; OREXIN	Recent advances in peptidomics have enabled the identification of previously uncharacterized peptides. However, sequence information alone does not allow us to identify candidates for bioactive peptides. To increase an opportunity to discover bioactive peptides, we have focused on C-terminal amidation, a post-translational modification shared by many bioactive peptides. We analyzed peptides secreted from human medullary thyroid carcinoma TT cells that produce amidated peptides, and we identified two novel amidated peptides, designated neuroendocrine regulatory peptide (NERP)-1 and NERP-2. NERPs are derived from distinct regions of the neurosecretory protein that was originally identified as a product of a nerve growth factor-responsive gene in PC12 cells. Mass spectrometric analysis of the immunoprecipitate using specific antibodies as well as reversed phase-high performance liquid chromatography coupled with radioimmunoassay analysis of brain extract demonstrated the endogenous presence of NERP-1 and NERP-2 in the rat. NERPs are abundant in the paraventricular and supraoptic nuclei of the rat hypothalamus and colocalized frequently with vasopressin but rarely with oxytocin. NERPs dose-dependently suppressed vasopressin release induced by intracerebroventricular injection of hypertonic NaCl or angiotensin II in vivo. NERPs also suppressed basal and angiotensin II-induced vasopressin secretion from hypothalamic explants in vitro. Bioactivity of NERPs required C-terminal amidation. Anti-NERP IgGs canceled plasma vasopressin reduction in response to water loading, indicating that NERPs could be potent endogenous suppressors of vasopressin release. These findings suggest that NERPs are novel modulators in body fluid homeostasis.	Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, Miyazaki 8891692, Japan; Natl Cardiovasc Ctr Hosp & Res Inst, Dept Pharmacol, Osaka 5658565, Japan; Osaka Univ, Inst Prot Res, Lab Prot Profiling & Funct Proteom, Osaka 5650871, Japan; Showa Univ, Sch Med, Dept Anat, Shinagawa Ku, Tokyo 1428555, Japan; Ctr Genet Engn & Biotechnol, Div Phys Chem, Havana, Cuba	University of Miyazaki; National Cerebral & Cardiovascular Center - Japan; Osaka University; Showa University; Centro de Ingenieria Genetica y Biotecnologia	Nakazato, M (corresponding author), Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, Miyazaki 8891692, Japan.	nakazato@med.miyazaki-u.ac.jp; minamino@ri.ncvc.go.jp	Toshinai, Koji/D-1598-2011	Toshinai, Koji/0000-0002-3412-5798; Gonzalez, Luis Javier/0000-0002-8875-3642; Satomi, Yoshinori/0000-0002-8991-1040				Alder J, 2003, J NEUROSCI, V23, P10800; Bartolomucci A, 2006, P NATL ACAD SCI USA, V103, P14584, DOI 10.1073/pnas.0606102103; Beak SA, 1998, J CLIN INVEST, V101, P1334, DOI 10.1172/JCI610; Benson DL, 1996, DEV BRAIN RES, V96, P219, DOI 10.1016/0165-3806(96)00108-3; BONDY CA, 1989, CELL MOL NEUROBIOL, V9, P427, DOI 10.1007/BF00712791; Carrette O, 2003, PROTEOMICS, V3, P1486, DOI 10.1002/pmic.200300470; Che FY, 2006, J MOL NEUROSCI, V28, P265, DOI 10.1385/JMN:28:3:265; Clynen E, 2001, EUR J BIOCHEM, V268, P1929, DOI 10.1046/j.1432-1327.2001.02067.x; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Fernandez-de-Cossio J, 2000, ELECTROPHORESIS, V21, P1694, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1694::AID-ELPS1694>3.0.CO;2-W; GIES U, 1994, J NEUROSCI, V14, P2861; GKONOS PJ, 1986, J BIOL CHEM, V261, P4386; Huang JTJ, 2006, PLOS MED, V3, P2145, DOI 10.1371/journal.pmed.0030428; Katafuchi T, 2003, J BIOL CHEM, V278, P12046, DOI 10.1074/jbc.M207970200; Levi A, 2004, CELL MOL NEUROBIOL, V24, P517, DOI 10.1023/B:CEMN.0000023627.79947.22; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; Lim J, 2006, J NEUROCHEM, V96, P1169, DOI 10.1111/j.1471-4159.2005.03614.x; Ludwig M, 2002, PROG BRAIN RES, V139, P247; Minamino N, 2003, J CHROMATOGR B, V792, P33, DOI 10.1016/S1570-0232(03)00280-0; Mondal MS, 1999, BIOCHEM BIOPH RES CO, V256, P495, DOI 10.1006/bbrc.1999.0362; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; Sasaki K, 2002, CANCER RES, V62, P4894; Schrader M, 2001, TRENDS BIOTECHNOL, V19, pS55, DOI 10.1016/S0167-7799(01)01800-5; Succu S, 2004, EUR J NEUROSCI, V20, P3035, DOI 10.1111/j.1460-9568.2004.03781.x; Svensson M, 2003, J PROTEOME RES, V2, P213, DOI 10.1021/pr020010u; TATEMOTO K, 1980, NATURE, V285, P417, DOI 10.1038/285417a0; Toshinai K, 2003, ENDOCRINOLOGY, V144, P1506, DOI 10.1210/en.2002-220788; Wells T, 1992, J Physiol Pharmacol, V43, P59; YAMASHITA H, 2002, HORMONES BRAIN BEHAV, V160, P1; Yuan XL, 2005, J MASS SPECTROM, V40, P176, DOI 10.1002/jms.737; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	33	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26354	26360		10.1074/jbc.M701665200	http://dx.doi.org/10.1074/jbc.M701665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17609209	hybrid			2022-12-25	WOS:000249239600040
J	Lu, CY; Mukai, M; Lin, Y; Wu, GH; Poole, RK; Yeh, SR				Lu, Changyuan; Mukai, Masahiro; Lin, Yu; Wu, Guanghui; Poole, Robert K.; Yeh, Syun-Ru			Structural and functional properties of a single domain hemoglobin from the food-borne pathogen Campylobactor jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; ESCHERICHIA-COLI FLAVOHEMOGLOBIN; LIGAND-PROTEIN INTERACTIONS; OXYGEN-BINDING HEMOGLOBIN; DISTAL HEME POCKET; TRUNCATED HEMOGLOBIN; NITRIC-OXIDE; MYCOBACTERIUM-TUBERCULOSIS; CARBON-MONOXIDE; HORSERADISH-PEROXIDASE	Campylobacter jejuni contains two globins, a truncated hemoglobin, Ctb, and a single domain hemoglobin, Cgb. The physiological function of Ctb remains unclear, whereas Cgb has been linked to NO detoxification. With resonance Raman scattering, the iron-histidine stretching mode of Cgb was identified at 251 cm(-1). This frequency is unusually high, suggesting an imidazolate character of the proximal histidine as a result of the H- bonding network linking the catalytic triad involving the F8His, H23Glu, and G5Tyr residues. In the CO-complex, two conformers were identified with the nu(C-O)/nu(Fe-CO) at 529/ 1914 cm(-1) and 492/ 1963 cm(-1). The former is assigned to a "closed" conformation, in which the heme-bound CO is stabilized by the H-bond(s) donated from the B10Tyr- E7Gln residues, whereas the latter is assigned to an " open" conformer, in which the H-bonding interaction is absent. The presence of the two alternative conformations demonstrates the plasticity of the protein matrix. In the O-2-complex, the iron-O-2 stretching frequency was identified at 554 cm(-1), which is unusually low, indicating that the heme- bound O2 is stabilized by strong H- bond(s) donated by the B10Tyr- E7Gln residues. This scenario is consistent with its low O-2 off-rate 0.87 s(-1)). Taken together the data suggest that the NO-detoxifying activity of Cgb is facilitated by the imidazolate character of the proximal F8His and the distal positive polar environment provided by the B10Tyr- E7Gln. They may offer electronic "push" and "pull," respectively, for the O-O bond cleavage reaction required for the isomerization of the presumed peroxynitrite intermediate to the product, nitrate.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Yeshiva University; Albert Einstein College of Medicine; Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Sheffield	Yeh, SR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	syeh@aecom.yu.edu	Wu, Guanghui/A-3757-2016	Wu, Guanghui/0000-0002-9374-3190; Yeh, Syun-Ru/0000-0002-9858-386X	BBSRC [BB/E010504/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E010504/1] Funding Source: Medline; NHLBI NIH HHS [HL65465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMUSTAFA J, 1995, J BIOL CHEM, V270, P10449, DOI 10.1074/jbc.270.18.10449; ALMUSTAFA J, 1994, BIOCHEMISTRY-US, V33, P2191, DOI 10.1021/bi00174a028; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Bonamore A, 2003, J BIOL CHEM, V278, P22272, DOI 10.1074/jbc.M301285200; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Das TK, 2000, J PHYS CHEM B, V104, P10750, DOI 10.1021/jp000452y; DAs TK, 2006, J BIOL CHEM, V281, P11471, DOI 10.1074/jbc.M512054200; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Egawa T, 2005, J INORG BIOCHEM, V99, P72, DOI 10.1016/j.jinorgbio.2004.10.017; Elvers KT, 2004, J BACTERIOL, V186, P5332, DOI 10.1128/JB.186.16.5332-5341.2004; Elvers KT, 2005, MOL MICROBIOL, V57, P735, DOI 10.1111/j.1365-2958.2005.04723.x; Faramarzi MA, 2006, FEMS MICROBIOL LETT, V259, P47, DOI 10.1111/j.1574-6968.2006.00245.x; Farres J, 2005, BIOCHEMISTRY-US, V44, P4125, DOI 10.1021/bi047389d; Franzen S, 1998, J AM CHEM SOC, V120, P4658, DOI 10.1021/ja973212d; Frey AD, 2005, TRENDS BIOTECHNOL, V23, P69, DOI 10.1016/j.tibtech.2004.12.002; Frey AD, 2003, FEMS MICROBIOL REV, V27, P525, DOI 10.1016/S0168-6445(03)00056-1; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 2006, J INORG BIOCHEM, V100, P542, DOI 10.1016/j.jinorgbio.2005.12.012; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; GEWITZ HS, 1976, PLANTA, V131, P149, DOI 10.1007/BF00389987; GEWITZ HS, 1976, PLANTA, V131, P145, DOI 10.1007/BF00389986; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; Gunasekar PG, 2000, J NEUROSCI RES, V61, P570, DOI 10.1002/1097-4547(20000901)61:5<570::AID-JNR12>3.0.CO;2-V; HU SZ, 1993, BIOCHEMISTRY-US, V32, P10125, DOI 10.1021/bi00089a031; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; KERR EA, 1984, FEBS LETT, V178, P31, DOI 10.1016/0014-5793(84)81233-8; Kundu S, 2004, BIOCHEMISTRY-US, V43, P6241, DOI 10.1021/bi049848g; Kushkuley B, 1997, BBA-PROTEIN STRUCT M, V1341, P238, DOI 10.1016/S0167-4838(97)00082-4; Lu CY, 2007, J BIOL CHEM, V282, P13627, DOI 10.1074/jbc.M609397200; Marzocchi MP, 2003, J RAMAN SPECTROSC, V34, P725, DOI 10.1002/jrs.1037; Milani M, 2005, J INORG BIOCHEM, V99, P97, DOI 10.1016/j.jinorgbio.2004.10.035; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; OSHINO R, 1973, EUR J BIOCHEM, V39, P581, DOI 10.1111/j.1432-1033.1973.tb03157.x; Ouellet H, 2003, BIOCHEMISTRY-US, V42, P5764, DOI 10.1021/bi0270337; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; Sawai H, 2005, BIOCHEMISTRY-US, V44, P13257, DOI 10.1021/bi050997o; SMULEVICH G, 1986, BIOCHEMISTRY-US, V25, P4426, DOI 10.1021/bi00363a038; Spiro TG, 2005, J INORG BIOCHEM, V99, P34, DOI 10.1016/j.jinorgbio.2004.09.026; SPIRO TG, 1985, ADV PROTEIN CHEM, V37, P111, DOI 10.1016/S0065-3233(08)60064-9; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Terentis AC, 2002, J BIOL CHEM, V277, P15788, DOI 10.1074/jbc.M200457200; Uchida T, 2005, J BIOL CHEM, V280, P21358, DOI 10.1074/jbc.M412350200; UNO T, 1987, J BIOL CHEM, V262, P4549; Wainwright LM, 2006, BIOCHEMISTRY-US, V45, P6003, DOI 10.1021/bi052247k; Wainwright LM, 2005, MICROBIOL-SGM, V151, P4079, DOI 10.1099/mic.0.28266-0; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Wu GH, 2003, ADV MICROB PHYSIOL, V47, P255, DOI 10.1016/S0065-2911(03)47005-7; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Zbylut SD, 2002, J AM CHEM SOC, V124, P6751, DOI 10.1021/ja012578u; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	60	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25917	25928		10.1074/jbc.M704415200	http://dx.doi.org/10.1074/jbc.M704415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17606611	hybrid			2022-12-25	WOS:000249014100077
J	Lai, YJ; Lin, WC; Lin, FT				Lai, Yun-Ju; Lin, Weei-Chin; Lin, Fang-Tsyr			PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE-PHOSPHATASE SHP-2; ZYXIN-RELATED PROTEIN; PTP-BL; PDZ MOTIFS; RECEPTOR; MOTILITY; PHOSPHORYLATION; IDENTIFICATION; FAMILY	The LIM domain-containing TRIP6 (Thyroid Hormone Receptor-interacting Protein 6) is a focal adhesion molecule known to regulate lysophosphatidic acid (LPA)-induced cell migration through interaction with the LPA(2) receptor. LPA stimulation targets TRIP6 to the focal adhesion complexes and promotes c-Src-dependent phosphorylation of TRIP6 at Tyr-55, which creates a docking site for the Crk Src homology 2 domain, thereby promoting LPA-induced morphological changes and cell migration. Here we further demonstrate that a switch from c-Src-mediated phosphorylation to PTPL1/Fas-associated phosphatase-1-dependent dephosphorylation serves as an inhibitory feedback control mechanism of TRIP6 function in LPA-induced cell migration. PTPL1 dephosphorylates phosphotyrosine 55 of TRIP6 in vitro and inhibits LPA-induced tyrosine phosphorylation of TRIP6 in cells. This negative regulation requires a direct protein-protein interaction between these two molecules and the phosphatase activity of PTPL1. In contrast to c-Src, PTPL1 prevents TRIP6 turnover at the sites of adhesions. As a result, LPA-induced association of TRIP6 with Crk and the function of TRIP6 to promote LPA-induced morphological changes and cell migration are inhibited by PTPL1. Together, these results reveal a novel mechanism by which PTPL1 phosphatase plays a counteracting role in regulating TRIP6 function in LPA-induced cell migration.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lin, FT (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 360A,1918 Univ Blvd, Birmingham, AL 35294 USA.	flin@uab.edu			NATIONAL CANCER INSTITUTE [R01CA100857, R01CA100848] Funding Source: NIH RePORTER; NCI NIH HHS [CA100848, R01 CA100848, R01 CA100857] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Cuppen E, 2000, EUR J CELL BIOL, V79, P283, DOI 10.1078/S0171-9335(04)70031-X; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Herrmann L, 2003, MOL BIOL CELL, V14, P230, DOI 10.1091/mbc.E02-04-0191; Kimber WA, 2003, BIOCHEM J, V376, P525, DOI 10.1042/BJ20031154; Lai YJ, 2005, MOL CELL BIOL, V25, P5859, DOI 10.1128/MCB.25.14.5859-5868.2005; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nakai Y, 2000, EUR J BIOCHEM, V267, P7170, DOI 10.1046/j.1432-1327.2000.01818.x; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Panetti TS, 2001, PROSTAG OTH LIPID M, V64, P93, DOI 10.1016/S0090-6980(01)00102-2; Rigacci S, 2002, J BIOL CHEM, V277, P41631, DOI 10.1074/jbc.M201709200; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Takizawa N, 2006, J CELL BIOL, V174, P447, DOI 10.1083/jcb.200512051; Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang ZY, 2006, J BIOL CHEM, V281, P1746, DOI 10.1074/jbc.M509590200	32	25	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24381	24387		10.1074/jbc.M701499200	http://dx.doi.org/10.1074/jbc.M701499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17591779	hybrid, Green Accepted			2022-12-25	WOS:000248686600064
J	Nashev, LG; Chandsawangbhuwana, C; Balazs, Z; Atanasov, AG; Dick, B; Frey, FJ; Baker, ME; Odermatt, A				Nashev, Lyubomir G.; Chandsawangbhuwana, Charlie; Balazs, Zoltan; Atanasov, Atanas G.; Dick, Bernhard; Frey, Felix J.; Baker, Michael E.; Odermatt, Alex			Hexose-6-phosphate Dehydrogenase Modulates 11 beta-Hydroxysteroid Dehydrogenase Type 1-Dependent Metabolism of 7-keto- and 7 beta-hydroxy-neurosteroids	PLOS ONE			English	Article								Background. The role of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) in the regulation of energy metabolism and immune system by locally reactivating glucocorticoids has been extensively studied. Experiments determining initial rates of enzyme activity revealed that 11 beta-HSD1 can catalyze both the reductase and the dehydrogenase reaction in cell lysates, whereas it predominantly catalyzes the reduction of cortisone to cortisol in intact cells that also express hexose-6-phosphate dehydrogenase (H6PDH), which provides cofactor NADPH. Besides its role in glucocorticoid metabolism, there is evidence that 11 beta-HSD1 is involved in the metabolism of 7-keto- and 7-hydroxy-steroids; however the impact of H6PDH on this alternative function of 11 beta-HSD1 has not been assessed. Methodology. We investigated the 11 beta-HSD1-dependent metabolism of the neurosteroids 7-keto-, 7 alpha-hydroxy- and 7 beta-hydroxy-dehydroepiandrosterone ( DHEA) and 7-keto- and 7 beta-hydroxy-pregnenolone, respectively, in the absence or presence of H6PDH in intact cells. 3D-structural modeling was applied to study the binding of ligands in 11 beta-HSD1. Principal Findings. We demonstrated that 11 beta-HSD1 functions in a reversible way and efficiently catalyzed the interconversion of these 7-keto- and 7-hydroxy-neurosteroids in intact cells. In the presence of H6PDH, 11 beta-HSD1 predominantly converted 7-keto-DHEA and 7-ketopregnenolone into their corresponding 7 beta-hydroxy metabolites, indicating a role for H6PDH and 11 beta-HSD1 in the local generation of 7 beta-hydroxy-neurosteroids. 3D-structural modeling offered an explanation for the preferred formation of 7-hydroxy-neurosteroids. Conclusions. Our results from experiments determining the steady state concentrations of glucocorticoids or 7-oxygenated neurosteroids suggested that the equilibrium between cortisone and cortisol and between 7-keto- and 7-hydroxy-neurosteroids is regulated by 11 beta-HSD1 and greatly depends on the coexpression with H6PDH. Thus, the impact of H6PDH on 11 beta-HSD1 activity has to be considered for understanding both glucocorticoid and neurosteroid action in different tissues.	[Nashev, Lyubomir G.; Balazs, Zoltan; Odermatt, Alex] Univ Basel, Inst Mol & Syst Toxicol, Basel, Switzerland; [Nashev, Lyubomir G.; Balazs, Zoltan; Dick, Bernhard; Frey, Felix J.; Odermatt, Alex] Univ Bern, Dept Hypertens & Nephrol, Bern, Switzerland; [Chandsawangbhuwana, Charlie; Baker, Michael E.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Atanasov, Atanas G.] Univ Bern, Inst Pathol, Div Immunopathol, Bern, Switzerland	University of Basel; University of Bern; University of California System; University of California San Diego; University of Bern	Odermatt, A (corresponding author), Univ Basel, Inst Mol & Syst Toxicol, Basel, Switzerland.	alex.odermatt@unibas.ch	Atanasov, Atanas G./C-5535-2013	Atanasov, Atanas G./0000-0003-2545-0967; Baker, Michael/0000-0003-4387-3269; Odermatt, Alex/0000-0002-6820-2712	Cloetta Research Foundation; Swiss National Science Foundation [310000-112279]; Roche Research Foundation [2004-276]; Novartis Research Foundation	Cloetta Research Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Roche Research Foundation; Novartis Research Foundation	This study was supported by the Cloetta Research Foundation, the Swiss National Science Foundation ( No 310000-112279) and the Roche Research Foundation ( No 2004-276). A.O. is a Novartis Research Foundation Professor. Financial support was obtained for salaries, coverage of infrastructure and consumables. There was no influence of the funding institution on the research performed.	AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Agarwal AK, 2005, ENDOCRINOLOGY, V146, P2531, DOI 10.1210/en.2005-0061; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; Apostolova G, 2005, AM J PHYSIOL-ENDOC M, V288, pE957, DOI 10.1152/ajpendo.00442.2004; Arampatzis S, 2005, J MOL ENDOCRINOL, V35, P89, DOI 10.1677/jme.1.01736; Arnold P, 2003, MOL CELL ENDOCRINOL, V201, P177, DOI 10.1016/S0303-7207(02)00304-0; Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065; ATANASOV AG, 2007, ENDOCR META IN PRESS; Banhegyi G, 2004, J BIOL CHEM, V279, P27017, DOI 10.1074/jbc.M404159200; Baulieu EE, 1998, P NATL ACAD SCI USA, V95, P4089, DOI 10.1073/pnas.95.8.4089; Bujalska IJ, 2005, J MOL ENDOCRINOL, V34, P675, DOI 10.1677/jme.1.01718; Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205; Chalbot S, 2002, STEROIDS, V67, P1121, DOI 10.1016/S0039-128X(02)00072-7; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; de Quervain DJF, 2004, HUM MOL GENET, V13, P47, DOI 10.1093/hmg/ddg361; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Frick C, 2004, J BIOL CHEM, V279, P31131, DOI 10.1074/jbc.M313666200; Hampl, 1997, Endocr Regul, V31, P211; Hermanowski-Vosatka A, 2005, J EXP MED, V202, P517, DOI 10.1084/jem.20050119; Hewitt KN, 2005, ENDOCRINOLOGY, V146, P2539, DOI 10.1210/en.2005-0117; Hult M, 2004, CELL MOL LIFE SCI, V61, P992, DOI 10.1007/s00018-003-3476-y; Jamieson PM, 2000, J ENDOCRINOL, V165, P685, DOI 10.1677/joe.0.1650685; Khan N, 2004, ARCH BIOCHEM BIOPHYS, V429, P50, DOI 10.1016/j.abb.2004.05.023; Kim SB, 2003, J CLIN ENDOCR METAB, V88, P5199, DOI 10.1210/jc.2003-030646; LARDY H, 1995, P NATL ACAD SCI USA, V92, P6617, DOI 10.1073/pnas.92.14.6617; Lathe R, 2002, STEROIDS, V67, P967, DOI 10.1016/S0039-128X(02)00044-2; Lavery GG, 2006, J BIOL CHEM, V281, P6546, DOI 10.1074/jbc.M512635200; Maser E, 2006, MOL CELL ENDOCRINOL, V248, P34, DOI 10.1016/j.mce.2005.10.019; Matsunaga M, 2004, P NATL ACAD SCI USA, V101, P17282, DOI 10.1073/pnas.0407176101; Miller WL, 2002, MOL CELL ENDOCRINOL, V198, P7, DOI 10.1016/S0303-7207(02)00363-5; Muller C, 2006, J STEROID BIOCHEM, V100, P95, DOI 10.1016/j.jsbmb.2006.03.001; Muller C, 2006, J STEROID BIOCHEM, V99, P215, DOI 10.1016/j.jsbmb.2005.12.001; Nobel CSI, 2002, PROTEIN EXPRES PURIF, V26, P349, DOI 10.1016/S1046-5928(02)00547-8; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Pringle AK, 2003, EUR J NEUROSCI, V18, P117, DOI 10.1046/j.1460-9568.2003.02734.x; Robinzon B, 2005, ARCH BIOCHEM BIOPHYS, V442, P33, DOI 10.1016/j.abb.2005.07.010; Robinzon B, 2003, ARCH BIOCHEM BIOPHYS, V412, P251, DOI 10.1016/S0003-9861(03)00056-0; Rose K, 2001, J BIOL CHEM, V276, P23937, DOI 10.1074/jbc.M011564200; Schuster D, 2006, J MED CHEM, V49, P3454, DOI 10.1021/jm0600794; Schweizer RAS, 2004, J BIOL CHEM, V279, P18415, DOI 10.1074/jbc.M313615200; Shi J, 2000, STEROIDS, V65, P124, DOI 10.1016/S0039-128X(99)00094-X; Song W, 1998, J BIOL CHEM, V273, P16223, DOI 10.1074/jbc.273.26.16223; TANAHASHI K, 1980, J HISTOCHEM CYTOCHEM, V28, P1175, DOI 10.1177/28.11.7430614; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Wang MH, 2006, CURR OPIN INVEST DR, V7, P319; Weill-Engerer S, 2003, BRAIN RES, V969, P117, DOI 10.1016/S0006-8993(03)02288-1; Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1; Yau JLW, 2003, NEUROSCIENCE, V121, P307, DOI 10.1016/S0306-4522(03)00438-X; Zhang JD, 2005, BIOCHEMISTRY-US, V44, P6948, DOI 10.1021/bi047599q	49	36	36	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e561	10.1371/journal.pone.0000561	http://dx.doi.org/10.1371/journal.pone.0000561			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593962	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451800007
J	Ciuffini, L; Castellani, L; Salvati, E; Galletti, S; Falcone, G; Alema, S				Ciuffini, L.; Castellani, L.; Salvati, E.; Galletti, S.; Falcone, G.; Alema, S.			Delineating v-Src downstream effector pathways in transformed myoblasts	ONCOGENE			English	Article						v-Src; myogenic differentiation; p38 MAPK; Ras-MEK signalling	SKELETAL-MUSCLE DIFFERENTIATION; SIGNALING PATHWAYS; MYOGENIC DIFFERENTIATION; CELL-TRANSFORMATION; GENE-EXPRESSION; FAMILY KINASES; MAP KINASE; RAS; P38; ACTIVATION	In this study, we delineate the intracellular signalling pathways modulated by a conditional v-Src tyrosine kinase that lead to unrestrained proliferation and block of differentiation of primary avian myoblasts. By inhibiting Ras-MAPK kinase and phosphatidylinositol 3-kinase with different means, we find that both pathways play crucial roles in controlling v-Src-sustained growth factor and anchorage independence for proliferation. The Ras-MAPK kinase pathway also contributes to block of differentiation independently of cell proliferation since inhibition of this pathway both in proliferating and growth-arrested v-Src-transformed myoblasts induces expression of muscle-specific genes, fusion into multinucleated myotubes and assembly of specialized contractile structures. Importantly, we find that the p38 MAPK pathway is inhibited by v-Src in myoblasts and its forced activation results in growth inhibition and expression of differentiation, indicating p38 MAPK as a critical target of v-Src in growth transformation and myogenic differentiation. Furthermore, we show that downregulation of p38 MAPK activation may occur via Ras-MAPK kinase, thus highlighting a cross-regulation between the two pathways. Finally, we report that the simultaneous inhibition of MAPK kinase and calpain, combined to activation of p38 MAPK, are sufficient to reconstitute largely the differentiation potential of v-Src-transformed myoblasts.	[Ciuffini, L.; Castellani, L.; Salvati, E.; Galletti, S.; Falcone, G.; Alema, S.] CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; [Castellani, L.] Univ Cassino, Dipartimento Sci Motor & Salute, I-03043 Cassino, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Cassino	Falcone, G (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	gfalcone@ibc.cnr.it; alema@ibc.cnr.it	Falcone, Germana/A-3735-2016	Castellani, Loriana/0000-0002-8519-3504; Salvati, Erica/0000-0002-3373-7442; Falcone, Germana/0000-0002-3508-7623				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 2006, J BIOL CHEM, V281, P15249, DOI 10.1074/jbc.M601390200; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FALCONE G, 1992, ONCOGENE, V7, P1913; Falcone G, 2003, ONCOGENE, V22, P8302, DOI 10.1038/sj.onc.1206915; Faust D, 2005, ONCOGENE, V24, P7941, DOI 10.1038/sj.onc.1208948; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Li RH, 1996, P NATL ACAD SCI USA, V93, P7522, DOI 10.1073/pnas.93.15.7522; Lluis F, 2006, TRENDS CELL BIOL, V16, P36, DOI 10.1016/j.tcb.2005.11.002; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	44	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					528	539		10.1038/sj.onc.1210665	http://dx.doi.org/10.1038/sj.onc.1210665			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637741				2022-12-25	WOS:000252426100013
J	Shao, C; Folkard, M; Prise, KM				Shao, C.; Folkard, M.; Prise, K. M.			Role of TGF-beta 1 and nitric oxide in the bystander response of irradiated glioma cells	ONCOGENE			English	Article						targeted irradiation; bystander signaling; TGF-beta 1; nitric oxide; glioma	CHARGED-PARTICLE MICROBEAM; MEDIATED INTERCELLULAR COMMUNICATION; INDUCED GENOMIC INSTABILITY; GROWTH-FACTOR BETA-1; IONIZING-RADIATION; ALPHA-PARTICLES; HUMAN FIBROBLASTS; TGF-BETA; COUNTED PARTICLES; EPITHELIAL-CELLS	The radiation-induced bystander effect (RIBE) increases the probability of cellular response and therefore has important implications for cancer risk assessment following low-dose irradiation and for the likelihood of secondary cancers after radiotherapy. However, our knowledge of bystander signaling factors, especially those having long half-lives, is still limited. The present study found that, when a fraction of cells within a glioblastoma population were individually irradiated with helium ions from a particle microbeam, the yield of micronuclei (MN) in the nontargeted cells was increased, but these bystander MN were eliminated by treating the cells with either aminoguanidine (an inhibitor of inducible nitric oxide (NO) synthase) or anti-transforming growth factor beta 1 (anti-TGF-beta 1), indicating that NO and TGF-beta 1 are involved in the RIBE. Intracellular NO was detected in the bystander cells, and additional TGF-b1 was detected in the medium from irradiated T98G cells, but it was diminished by aminoguanidine. Consistent with this, an NO donor, diethylamine nitric oxide (DEANO), induced TGF-beta 1 generation in T98G cells. Conversely, treatment of cells with recombinant TGF-beta 1 could also induce NO and MN in T98G cells. Treatment of T98G cells with anti-TGF-beta 1 inhibited the NO production when only 1% of cells were targeted, but not when 100% of cells were targeted. Our results indicate that, downstream of radiation-induced NO, TGF-beta 1 can be released from targeted T98G cells and plays a key role as a signaling factor in the RIBE by further inducing free radicals and DNA damage in the nontargeted bystander cells.	[Prise, K. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Shao, C.; Folkard, M.; Prise, K. M.] Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2RN, Middx, England; [Shao, C.] Fudan Univ, Inst Radiat Med, Shanghai 200433, Peoples R China	Queens University Belfast; University of Oxford; Fudan University	Prise, KM (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	k.prise@qub.ac.uk	Prise, Kevin/N-7872-2015	Prise, Kevin/0000-0001-6134-7946; Shao, Chunlin/0000-0001-9336-9912	Cancer Research UK [A7047] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Arnold SF, 1999, RADIAT RES, V152, P487, DOI 10.2307/3580144; Ayache N, 2002, OSTEOARTHR CARTILAGE, V10, P344, DOI 10.1053/joca.2001.0499; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Barcellos-Hoff MH, 2005, SEMIN CANCER BIOL, V15, P138, DOI 10.1016/j.semcancer.2004.08.010; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; BLANCO FJ, 1995, J IMMUNOL, V154, P4018; Boerma M, 2002, INT J RADIAT BIOL, V78, P219, DOI 10.1080/09553000110094797; Burdak-Rothkamm S, 2007, ONCOGENE, V26, P993, DOI 10.1038/sj.onc.1209863; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Gizatullina ZZ, 2003, BIOCHEM BIOPH RES CO, V304, P643, DOI 10.1016/S0006-291X(03)00654-5; Hamby ME, 2006, GLIA, V54, P566, DOI 10.1002/glia.20411; Han JX, 2006, RADIAT RES, V165, P283, DOI 10.1667/RR3516.1; Iyer R, 2000, CANCER RES, V60, P1290; Jobling ME, 2006, RADIAT RES, V166, P839, DOI 10.1667/RR0695.1; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lyng FM, 2006, RADIAT RES, V165, P400, DOI 10.1667/RR3527.1; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Matsumoto H, 2000, INT J RADIAT BIOL, V76, P1649; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Nesti LJ, 2007, J CELL BIOCHEM, V101, P348, DOI 10.1002/jcb.21180; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Schmidt A, 2003, CARDIOVASC RES, V58, P671, DOI 10.1016/S0008-6363(03)00322-5; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2003, CANCER RES, V63, P8437; Shao CL, 2006, RADIAT RES, V166, P479, DOI 10.1667/RR3600.1; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2004, J RADIAT RES, V45, P97, DOI 10.1269/jrr.45.97; Shao CL, 2003, RADIAT ENVIRON BIOPH, V42, P183, DOI 10.1007/s00411-003-0202-y; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Vodovotz Y, 1999, CANCER RES, V59, P2142; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	51	163	169	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					434	440		10.1038/sj.onc.1210653	http://dx.doi.org/10.1038/sj.onc.1210653			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17621264	Green Accepted			2022-12-25	WOS:000252426100003
J	Li, Q; Falsey, RR; Gaitonde, S; Sotello, V; Kislin, K; Martinez, JD				Li, Q.; Falsey, R. R.; Gaitonde, S.; Sotello, V.; Kislin, K.; Martinez, J. D.			Genetic analysis of p53 nuclear importation	ONCOGENE			English	Article						p53; temperature sensitive; mutant; nuclear localization	LOCALIZATION; PROTEIN; SIGNAL	A key step in activation of the p53 tumor suppressor is its transport into the nucleus; however, despite intensive study of p53, the regulation of its subcellular localization is still poorly understood. Here we examined the p53 nuclear importation using a series of mutant cell lines that were resistant to the growth inhibitory effects of temperature-sensitive murine p53 (tsp53). Examination of the p53 subcellular localization in these cell lines showed that the protein was cytoplasmic in most of them. Using a digitonin-permeabilized cell in vitro nuclear import system, we show that cytosols from these cell lines do not support nuclear translocation of a p53 nuclear localization signal (NLS)-containing substrate protein, but promote nuclear localization of a SV40TAgNLS-containing substrate. Complementation assays and use of the mutant cells themselves in the in vitro assays demonstrate that both soluble and insoluble protein components are involved in p53 nuclear import. Collectively, our results suggest that there is a p53 NLS-selective nuclear import pathway and that both soluble and insoluble proteins are involved in its function.	[Li, Q.; Sotello, V.; Martinez, J. D.] Univ Arizona, Dept Cell Biol & Anat, Arizona Canc Ctr, Tucson, AZ 85724 USA; [Falsey, R. R.; Gaitonde, S.; Kislin, K.] Univ Arizona, Canc Biol Interdisciplinary Program, Tucson, AZ 85724 USA; [Falsey, R. R.] Univ Arizona, Undergrad Biol Res Program, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Cell Biol & Anat, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	jmartinez@azcc.arizona.edu			NCI NIH HHS [CA090776, R01 CA090776-03, R01 CA090776, P30 CA023074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090776, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Goldman SC, 1996, AM J PATHOL, V148, P1381; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; NISHI K, 1994, J BIOL CHEM, V269, P6320; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027	11	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7885	7893		10.1038/sj.onc.1210597	http://dx.doi.org/10.1038/sj.onc.1210597			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599045	Green Accepted			2022-12-25	WOS:000252163500006
J	Taboubi, S; Milanini, J; Delamarre, E; Parat, F; Garrouste, F; Pommier, G; Takasaki, J; Hubaud, JC; Kovacic, H; Lehmann, M				Taboubi, Salma; Milanini, Julie; Delamarre, Estelle; Parat, Fabrice; Garrouste, Francoise; Pommier, Gilbert; Takasaki, Jun; Hubaud, Jean-Claude; Kovacic, Herve; Lehmann, Maxime			G alpha(q/11)-coupled P2Y(2) nucleotide receptor inhibits human keratinocyte spreading and migration	FASEB JOURNAL			English	Article						GPCR; wound healing; PI3K/Akt; MAPK; UTP	MUSCLE CELL-MIGRATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR NUCLEOTIDES; EPIDERMAL HOMEOSTASIS; ACTIN POLYMERIZATION; HACAT KERATINOCYTES; INDUCE CHEMOTAXIS; EPITHELIAL-CELLS; FOCAL ADHESION	Reepithelialization is a critical step in wound healing. It is initiated by keratinocyte migration at the wound edges. After wounding, extracellular nucleotides are released by keratinocytes and other skin cells. Here, we report that activation of P2Y(2) nucleotide receptor by ATP/UTP inhibits keratinocyte cell spreading and induces lamellipodium withdrawal. Kymography analysis demonstrates that these effects correlate with a durable decrease of lamellipodium dynamics. P2Y2 receptor activation also induces a dramatic dismantling of the actin network, the loss of alpha 3 integrin expression at the cell periphery, and the dissolution of focal contacts as indicated by the alteration of alpha v integrins and focal contact protein distribution. In addition, activation of P2Y(2)R prevents growth factor-induced phosphorylation of Erk(1,2) and Akt/ PkB. The use of a specific pharmacological inhibitor (YM-254890), the depletion of G alpha((q/ 11)) by siRNA, or the expression of a constitutively active G alpha(( q/ 11)) mutant (Q209L) show that activation of G alpha((q/ 11)) is responsible for these ATP/UTP-induced effects. Finally, we report that ATP delays growth factor-induced wound healing of keratinocyte monolayers. Collectively, these findings provide evidence for a unique and important role for extracellular nucleotides as efficient autocrine/paracrine regulators of keratinocyte shape and migration during wound healing. -Taboubi, S., Milanini, J., Delamarre, E., Parat, F., Garrouste, F., Pommier, G., Takasaki, J., Hubaud, J-C., Kovacic, H., Lehmann, M. G alpha((q/ 11))coupled P2Y2 Nucleotide Receptor Inhibits Human Keratinocyte Spreading and Migration.	Univ Aix Marseille 1, CISMET, FRE, CNRS,Fac Pharm, Marseille, France; Astellas Pharma Inc, Drug Discovery Res & Mol Med Res Lab, Ibaraki, Japan; DIPTA, Aix En Provence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Astellas Pharmaceuticals	Lehmann, M (corresponding author), CISMET, FRE, CNRS, Fac Pharm, 27 Bd Jean Moulin, F-13005 Marseille, France.	maxime.lehmann@pharmacie.univ-mrs.fr	kovacic, hervé/ABF-2451-2020	Kovacic, Herve/0000-0001-6509-4210; Milanini, Julie/0000-0002-5861-2830				Arthur DB, 2005, P NATL ACAD SCI USA, V102, P19138, DOI 10.1073/pnas.0505913102; Atkinson PJ, 2006, MOL PHARMACOL, V69, P174, DOI 10.1124/mol.105.014258; Bagchi S, 2005, J BIOL CHEM, V280, P39050, DOI 10.1074/jbc.M504819200; Ballou LM, 2006, BIOCHEM J, V394, P557, DOI 10.1042/BJ20051493; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Burnstock G, 2006, BRIT J PHARMACOL, V147, pS172, DOI 10.1038/sj.bjp.0706429; Burrell HE, 2005, J BIOL CHEM, V280, P29667, DOI 10.1074/jbc.M505381200; Burrell HE, 2003, J INVEST DERMATOL, V120, P440, DOI 10.1046/j.1523-1747.2003.12050.x; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chaulet H, 2001, CIRC RES, V89, P772, DOI 10.1161/hh2101.098617; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Czajkowski R, 2004, BRIT J PHARMACOL, V141, P497, DOI 10.1038/sj.bjp.0705639; Decline F, 2001, J CELL SCI, V114, P811; Denda M, 2002, J INVEST DERMATOL, V119, P1034, DOI 10.1046/j.1523-1747.2002.19505.x; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424-006-0069-2; Fan GF, 2003, J BIOL CHEM, V278, P52432, DOI 10.1074/jbc.M310982200; Greig AVH, 2003, EXP DERMATOL, V12, P860, DOI 10.1111/j.0906-6705.2003.00110.x; Greig AVH, 2003, J INVEST DERMATOL, V120, P1007, DOI 10.1046/j.1523-1747.2003.12261.x; Haase I, 2003, J CELL SCI, V116, P3227, DOI 10.1242/jcs.00610; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; Howes AL, 2003, J BIOL CHEM, V278, P40343, DOI 10.1074/jbc.M305964200; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Kaczmarek E, 2005, THROMB HAEMOSTASIS, V93, P735, DOI 10.1160/TH04-09-0576; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Klepeis VE, 2004, J CELL BIOCHEM, V93, P1115, DOI 10.1002/jcb.20258; Koizumi S, 2004, BIOCHEM J, V380, P329, DOI 10.1042/BJ20031089; Laforest S, 2005, MOL CELL NEUROSCI, V30, P418, DOI 10.1016/j.mcn.2005.08.006; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lee WK, 2001, J DERMATOL SCI, V25, P97, DOI 10.1016/S0923-1811(00)00117-1; Lenz G, 2001, J NEUROCHEM, V77, P1001, DOI 10.1046/j.1471-4159.2001.00299.x; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Motley ED, 2003, HYPERTENSION, V41, P775, DOI 10.1161/01.HYP.0000051891.90321.12; Pankow S, 2006, J CELL SCI, V119, P4033, DOI 10.1242/jcs.03175; Pasquier E, 2005, CANCER RES, V65, P2433, DOI 10.1158/0008-5472.CAN-04-2624; Pillois X, 2002, CIRC RES, V90, P678, DOI 10.1161/01.RES.0000013700.98464.8E; Pintor J, 2004, OPHTHAL PHYSL OPT, V24, P186, DOI 10.1111/j.1475-1313.2004.00182.x; Pullar CE, 2006, FASEB J, V20, P76, DOI 10.1096/fj.05-4188com; Pullar CE, 2006, J CELL SCI, V119, P592, DOI 10.1242/jcs.02772; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; Rigot V, 1998, J CELL SCI, V111, P3119; RODIUS S, 2004, UNPUB LOSS INTEGRIN; Russell AJ, 2003, J CELL SCI, V116, P3543, DOI 10.1242/jcs.00663; Santoro MM, 2005, EXP CELL RES, V304, P274, DOI 10.1016/j.yexcr.2004.10.033; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Taniguchi M, 2003, J ANTIBIOT, V56, P358, DOI 10.7164/antibiotics.56.358; Ueda H, 2004, EXP CELL RES, V298, P207, DOI 10.1016/j.yexcr.2004.04.015; Verghese MW, 1996, J BIOL CHEM, V271, P15597, DOI 10.1074/jbc.271.26.15597; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wu EHT, 2006, FEBS J, V273, P2388, DOI 10.1111/j.1742-4658.2006.05245.x; Yin J, 2007, J CELL SCI, V120, P815, DOI 10.1242/jcs.03389; Yoshida H, 2006, EUR J PHARMACOL, V540, P1, DOI 10.1016/j.ejphar.2006.04.008	67	39	40	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					4047	4058		10.1096/fj.06-7476com	http://dx.doi.org/10.1096/fj.06-7476com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17609252				2022-12-25	WOS:000251283500029
J	Bush-Pelc, LA; Marino, F; Chen, Z; Pineda, AO; Mathews, FS; Di Cera, E				Bush-Pelc, Leslie A.; Marino, Francesca; Chen, Zhiwei; Pineda, Agustin O.; Mathews, F. Scott; Di Cera, Enrico			Important role of the Cys-191-Cys-220 disulfide bond in thrombin function and allostery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-ACTIVATED ENZYME; HUMAN ALPHA-THROMBIN; CRYSTAL-STRUCTURE; PROTEIN-C; ANTICOAGULANT THROMBIN; SUBSTRATE RECOGNITION; POTENT ANTICOAGULANT; MUTANT W215A/E217A; CATALYTIC-ACTIVITY; MOLECULAR-SURFACE	Little is known on the role of disulfide bonds in the catalytic domain of serine proteases. The Cys-191-Cys-220 disulfide bond is located between the 190 strand leading to the oxyanion hole and the 220-loop that contributes to the architecture of the primary specificity pocket and the Na+ binding site in allosteric proteases. Removal of this bond in thrombin produces an similar to 100-fold loss of activity toward several chromogenic and natural substrates carrying Arg or Lys at P1. Na+ activation is compromised, and no fluorescence change can be detected in response to Na+ binding. A 1.54-angstrom resolution structure of the C191A/C220A mutant in the free form reveals a conformation similar to the Na+-free slow form of wild type. The lack of disulfide bond exposes the side chain of Asp-189 to solvent, flips the backbone Oatom of Gly-219, and generates disorder in portions of the 186 and 220 loops defining the Na+ site. This conformation, featuring perturbation of the Na+ site but with the active site accessible to substrate, offers a possible representation of the recently identified E* form of thrombin. Disorder in the 186 and 220 loops and the flip of Gly-219 are corrected by the active site inhibitor H-D-Phe-Pro-Arg-CH2Cl, as revealed by the 1.8-angstrom resolution structure of the complex. We conclude that the Cys-191-Cys-220 disulfide bond confers stability to the primary specificity pocket by shielding Asp-189 from the solvent and orients the backbone O atom of Gly-219 for optimal substrate binding. In addition, the disulfide bond stabilizes the 186 and 220 loops that are critical for Na+ binding and activation.	Washington Univ, Sch Med, Dept Biochem & Mol Bio Phys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Bio Phys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu			NHLBI NIH HHS [HL 49413, HL 58141, HL 73813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL073813, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhavan S, 2000, THROMB HAEMOSTASIS, V84, P989; Akhavan S, 1999, BRIT J HAEMATOL, V105, P667, DOI 10.1046/j.1365-2141.1999.01423.x; Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Bah A, 2006, J BIOL CHEM, V281, P40049, DOI 10.1074/jbc.M608600200; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; Bode W, 2006, BLOOD CELL MOL DIS, V36, P122, DOI 10.1016/j.bcmd.2005.12.027; BODE W, 1992, PROTEIN SCI, V1, P426; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush LA, 2006, J BIOL CHEM, V281, P7183, DOI 10.1074/jbc.M512082200; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; Di Cera E, 2007, PHYS CHEM CHEM PHYS, V9, P1292, DOI 10.1039/b616819a; DIBELLA EE, 1995, J BIOL CHEM, V270, P163, DOI 10.1074/jbc.270.1.163; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Gruber A, 2007, BLOOD, V109, P3733, DOI 10.1182/blood-2006-07-035147; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HAGEMAN TC, 1975, ARCH BIOCHEM BIOPHYS, V171, P327, DOI 10.1016/0003-9861(75)90039-9; Ishikawa K, 2002, STRUCTURE, V10, P877, DOI 10.1016/S0969-2126(02)00779-7; Kenesi E, 2003, BIOCHEM BIOPH RES CO, V309, P749, DOI 10.1016/j.bbrc.2003.08.064; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; Lefkowitz JB, 2000, BRIT J HAEMATOL, V108, P182, DOI 10.1046/j.1365-2141.2000.01810.x; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page MJ, 2006, BIOCHEMISTRY-US, V45, P2987, DOI 10.1021/bi052481a; Papaconstantinou ME, 2005, J BIOL CHEM, V280, P29393, DOI 10.1074/jbc.C500248200; Pineda AO, 2006, J BIOL CHEM, V281, P32922, DOI 10.1074/jbc.M605530200; Pineda AO, 2004, BIOPHYS CHEM, V112, P253, DOI 10.1016/j.bpc.2004.07.027; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Silva FP, 2006, BIOPHYS CHEM, V119, P282, DOI 10.1016/j.bpc.2005.10.001; Singh RR, 2003, BBA-PROTEINS PROTEOM, V1651, P85, DOI 10.1016/S1570-9639(03)00238-3; Sun WY, 2000, BLOOD, V95, P711, DOI 10.1182/blood.V95.2.711; Varallyay V, 1997, BIOCHEM BIOPH RES CO, V230, P592, DOI 10.1006/bbrc.1996.6009; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; Vindigni A, 1998, PROTEIN SCI, V7, P1728, DOI 10.1002/pro.5560070807; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; Wang ECW, 1997, PROTEIN ENG, V10, P405, DOI 10.1093/protein/10.4.405; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Xu H, 2005, J BIOL CHEM, V280, P7956, DOI 10.1074/jbc.M412869200; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	48	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27165	27170		10.1074/jbc.M703202200	http://dx.doi.org/10.1074/jbc.M703202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636263	hybrid			2022-12-25	WOS:000249304900057
J	Dimitrov, JD; Roumenina, LT; Doltchinkova, VR; Mihaylova, NM; Lacroix-Desmazes, S; Kaveri, SV; Vassilev, TL				Dimitrov, Jordan D.; Roumenina, Lubka T.; Doltchinkova, Virjinia R.; Mihaylova, Nikolina M.; Lacroix-Desmazes, Sebastien; Kaveri, Srinivas V.; Vassilev, Tchavdar L.			Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOPORPHYRIN-IX; ANTIGEN-BINDING; STRUCTURAL PLASTICITY; AUTOANTIBODIES; OXIDATION; IMMUNOGLOBULIN; RECOGNITION; PLASMA; SERUM; IONS	Various pathological processes are accompanied by release of high amounts of free heme into the circulation. We demonstrated by kinetic, thermodynamic, and spectroscopic analyses that antibodies have an intrinsic ability to bind heme. This binding resulted in a decrease in the conformational freedom of the antibody paratopes and in a change in the nature of the noncovalent forces responsible for the antigen binding. The antibodies use the molecular imprint of the heme molecule to interact with an enlarged panel of structurally unrelated epitopes. Upon heme binding, monoclonal as well as pooled immunoglobulin G gained an ability to interact with previously unrecognized bacterial antigens and intact bacteria. IgG-heme complexes had an enhanced ability to trigger complement-mediated bacterial killing. It was also shown that heme, bound to immunoglobulins, acted as a cofactor in redox reactions. The potentiation of the antibacterial activity of IgG after contact with heme may represent a novel and inducible innate-type defense mechanism against invading pathogens.	Bulgarian Acad Sci, Stephan Angeloff Inst Microbiol, Dept Immunol, Sofia 1113, Bulgaria; Univ Sofia, Dept Biochem, Sofia 1164, Bulgaria; Univ Sofia, Dept Biophys & Radiol, Sofia 1164, Bulgaria; Univ Paris 06, Ctr Rech Cordeliers, UMR S872, F-75006 Paris, France; Univ Paris 05, UMR S872, F-75006 Paris, France; INSERM, U872, F-75006 Paris, France	Bulgarian Academy of Sciences; Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences; University of Sofia; University of Sofia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Vassilev, TL (corresponding author), Bulgarian Acad Sci, Stephan Angeloff Inst Microbiol, Dept Immunol, Acad G Bonchev St,Block 26, Sofia 1113, Bulgaria.	jdd@microbio.bas.bg; vassilev@microbio.bas.bg	Doltchinkova, Virjinia/AAK-2672-2020; Dimitrov, Jordan/N-2141-2014; Roumenina, Lubka/P-5906-2019; Roumenina, Lubka/L-2638-2017; Mihaylova, Nikolina/HHM-8871-2022; Mihaylova, Nikolina M/K-3386-2013	Roumenina, Lubka/0000-0002-9940-0324; Dimitrov, Jordan/0000-0001-8536-8995; Doltchinkova, Virjinia/0000-0003-3096-7311; Lacroix-Desmazes, Sebastien/0000-0001-5625-8447				AFT RL, 1983, J BIOL CHEM, V258, P2069; AFT RL, 1984, J BIOL CHEM, V259, P301; Amzel LM, 2000, METHOD ENZYMOL, V323, P167; Arruda MA, 2005, MEM I OSWALDO CRUZ, V100, P799, DOI 10.1590/S0074-02762005000700022; Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023; Atamna H, 2006, P NATL ACAD SCI USA, V103, P3381, DOI 10.1073/pnas.0600134103; Balla J, 2003, NEPHROL DIAL TRANSPL, V18, P8, DOI 10.1093/ndt/gfg1034; BHOITESOLOMON V, 1990, FEBS LETT, V266, P9, DOI 10.1016/0014-5793(90)81493-8; Bian K, 2003, P NATL ACAD SCI USA, V100, P5712, DOI 10.1073/pnas.0931291100; Bouvet JP, 2001, J AUTOIMMUN, V16, P163, DOI 10.1006/jaut.2000.0472; Brancaleon L, 2004, BIOPHYS CHEM, V109, P351, DOI 10.1016/j.bpc.2003.12.008; Brancaleon L, 2002, BIOPHYS CHEM, V96, P77, DOI 10.1016/S0301-4622(02)00035-2; Camejo G, 1998, J LIPID RES, V39, P755; Carroll MC, 2005, ADV IMMUNOL, V86, P137, DOI 10.1016/S0065-2776(04)86004-8; Caughey WS, 1998, P NATL ACAD SCI USA, V95, P12117, DOI 10.1073/pnas.95.21.12117; COCHRAN AG, 1990, J AM CHEM SOC, V112, P9414, DOI 10.1021/ja00181a065; Comporti M, 2002, FREE RADICAL BIO MED, V32, P568, DOI 10.1016/S0891-5849(02)00759-1; DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dimitrov JD, 2007, SCAND J IMMUNOL, V65, P230, DOI 10.1111/j.1365-3083.2006.01893.x; Dimitrov JD, 2006, J BIOL CHEM, V281, P439, DOI 10.1074/jbc.M509190200; Dimitrov JD, 2007, MOL IMMUNOL, V44, P1854, DOI 10.1016/j.molimm.2006.10.002; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; FAZEKAS G, 1990, EUR J IMMUNOL, V20, P2719, DOI 10.1002/eji.1830201229; Ghosh K, 2005, BIOCHEMISTRY-US, V44, P16729, DOI 10.1021/bi0511585; Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160; Grinshtein N, 2003, BIOCHEMISTRY-US, V42, P6977, DOI 10.1021/bi020647r; Howlett D, 1997, FEBS LETT, V417, P249, DOI 10.1016/S0014-5793(97)01290-8; INNIS WSA, 1985, BIOCHEM MED METAB B, V34, P151, DOI 10.1016/0006-2944(85)90106-1; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; Kettle AJ, 2004, J BIOL CHEM, V279, P18521, DOI 10.1074/jbc.M400334200; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; LECLERC E, 1993, ARCH BIOCHEM BIOPHYS, V306, P163, DOI 10.1006/abbi.1993.1495; Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3; Manivel V, 2002, J IMMUNOL, V169, P888, DOI 10.4049/jimmunol.169.2.888; McIntyre JA, 2006, AUTOIMMUN REV, V5, P76, DOI 10.1016/j.autrev.2005.07.009; McIntyre JA, 2004, THROMB RES, V114, P579, DOI 10.1016/j.thromres.2004.08.008; McIntyre JA, 2005, J AUTOIMMUN, V24, P311, DOI 10.1016/j.jaut.2005.03.005; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; MORRIS SJ, 1987, BIOCHEMISTRY-US, V26, P2175, DOI 10.1021/bi00382a016; MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811; Nguyen HP, 2003, NAT STRUCT BIOL, V10, P1019, DOI 10.1038/nsb1014; NOVOGRODSKY A, 1989, J IMMUNOL, V143, P3981; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Schuermann JP, 2005, J MOL BIOL, V347, P965, DOI 10.1016/j.jmb.2005.02.008; SEARS DA, 1970, J CLIN INVEST, V49, P5, DOI 10.1172/JCI106222; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2; Sinha N, 2002, CURR PROTEIN PEPT SC, V3, P601, DOI 10.2174/1389203023380431; Spolaore B, 2005, BIOCHEMISTRY-US, V44, P16079, DOI 10.1021/bi051374d; STENZEL KH, 1981, J IMMUNOL, V127, P2469; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Tracz MJ, 2007, J AM SOC NEPHROL, V18, P414, DOI 10.1681/ASN.2006080894; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; WATSON CD, 1988, BIOCHEM INT, V16, P1067; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Wentworth AD, 2000, P NATL ACAD SCI USA, V97, P10930, DOI 10.1073/pnas.97.20.10930; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; Xu Y, 2007, P NATL ACAD SCI USA, V104, P3681, DOI 10.1073/pnas.0611094104; Yin J, 2003, J MOL BIOL, V330, P651, DOI 10.1016/S0022-2836(03)00631-4; Zhang M, 2007, MOL IMMUNOL, V44, P103, DOI 10.1016/j.molimm.2006.06.022; Zhou ZH, 2007, CELL HOST MICROBE, V1, P51, DOI 10.1016/j.chom.2007.01.002	68	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26696	26706		10.1074/jbc.M702751200	http://dx.doi.org/10.1074/jbc.M702751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636257	hybrid			2022-12-25	WOS:000249304900008
J	Frauenschuh, A; Power, CA; Deruaz, M; Ferreira, BR; Silva, JS; Teixeira, MM; Dias, JM; Martin, T; Wells, TNC; Proudfoot, AEI				Frauenschuh, Achim; Power, Christine A.; Deruaz, Maud; Ferreira, Beatriz R.; Silva, Joao S.; Teixeira, Mauro M.; Dias, Joao M.; Martin, Thierry; Wells, Timothy N. C.; Proudfoot, Amanda E. I.			Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOPIC-DERMATITIS; IDENTIFICATION; RECEPTORS; TRANSMISSION; MIP-1-BETA; RANTES; SALIVA	Ticks are blood-feeding parasites that secrete a number of immuno-modulatory factors to evade the host immune response. Saliva isolated from different species of ticks has recently been shown to contain chemokine neutralizing activity. To characterize this activity, we constructed a cDNA library from the salivary glands of the common brown dog tick, Rhipicephalus sanguineus. Pools of cDNA clones from the library were transfected into HEK293 cells, and the conditioned media from the transfected cells were tested for chemokine binding activity by chemical cross-linking to radiolabeled CCL3 followed by SDS-PAGE. By de-convolution of a single positive pool of 270 clones, we identified a full-length cDNA encoding a protein of 114 amino acids, which after signal peptide cleavage was predicted to yield a mature protein of 94 amino acids that we called Evasin-1. Recombinant Evasin-1 was produced in HEK293 cells and in insect cells. Using surface plasmon resonance we were able to show that Evasin-1 was exquisitely selective for 3 CC chemokines, CCL3 and CCL4 and the closely related chemokine CCL18, with K-D values of 0.16, 0.81, and 3.21 nM, respectively. The affinities for CCL3 and CCL4 were confirmed in competition receptor binding assays. Analysis by size exclusion chromatography demonstrated that Evasin-1 was monomeric and formed a 1: 1 complex with CCL3. Thus, unlike the other chemokine-binding proteins identified to date from viruses and from the parasitic worm Schistosoma mansoni, Evasin-1 is highly specific for a subgroup of CC chemokines, which may reflect a specific role for these chemokines in host defense against parasites.	Merck Serona Geneva Res Ctr, CH-1211 Geneva, Switzerland; Univ Sao Paulo, Sch Med, Dept Biochem & Immunol, BR-14049900 Ribeirao Preto, Brazil; Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-1270901 Belo Horizonte, MG, Brazil	Universidade de Sao Paulo; Universidade Federal de Minas Gerais	Power, CA (corresponding author), Merck Serona Geneva Res Ctr, 9 Chemin Mines, CH-1211 Geneva, Switzerland.	christine.power@merckserono.net; amanda.proudfoot@merckserono.net	Ferreira, Beatriz Rossetti/C-2003-2012; Silva, Joao/A-4484-2008; Teixeira, Mauro M/A-4587-2008	Ferreira, Beatriz Rossetti/0000-0002-6781-2236; Silva, Joao/0000-0002-3410-3927; Teixeira, Mauro M/0000-0002-6944-3008; Wells, Timothy/0000-0001-9796-847X				Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Alexander JM, 2002, CELL, V111, P343, DOI 10.1016/S0092-8674(02)01007-3; Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Alouani S, 2000, METH MOL B, V138, P135; Brossard M, 2004, PARASITOLOGY, V129, pS161, DOI 10.1017/S0031182004004834; Bryant NA, 2003, EMBO J, V22, P833, DOI 10.1093/emboj/cdg092; Burns JM, 2002, J BIOL CHEM, V277, P2785, DOI 10.1074/jbc.M109884200; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Ferreira BR, 1996, VET PARASITOL, V62, P161, DOI 10.1016/0304-4017(95)00838-1; Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Hajnicka V, 2005, PARASITOLOGY, V130, P333, DOI 10.1017/S0031182004006535; Hajnicka V, 2001, PARASITE IMMUNOL, V23, P483, DOI 10.1046/j.1365-3024.2001.00403.x; JONES LD, 1989, J GEN VIROL, V70, P1895, DOI 10.1099/0022-1317-70-7-1895; Kocakova P, 2003, FOLIA PARASIT, V50, P79, DOI 10.14411/fp.2003.014; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Nuttall PA, 1998, PARASITOLOGY, V116, pS65, DOI 10.1017/S003118200008495X; Pivarcsi A, 2005, CURR ALLERGY ASTHM R, V5, P284, DOI 10.1007/s11882-005-0068-y; Proudfoot AEI, 2000, METH MOL B, V138, P75; RIBEIRO JMC, 1985, J EXP MED, V161, P332, DOI 10.1084/jem.161.2.332; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Schoeler GB, 2001, ANN TROP MED PARASIT, V95, P755, DOI 10.1080/0003498012011118; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Smith P, 2005, J EXP MED, V202, P1319, DOI 10.1084/jem.20050955; Tasaki Y, 1999, GENOMICS, V55, P353, DOI 10.1006/geno.1998.5670; Van Berkel V, 2000, J VIROL, V74, P6741, DOI 10.1128/JVI.74.15.6741-6747.2000	30	98	101	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27250	27258		10.1074/jbc.M704706200	http://dx.doi.org/10.1074/jbc.M704706200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640866	hybrid			2022-12-25	WOS:000249304900066
J	Kalamajski, S; Oldberg, A				Kalamajski, Sebastian; Oldberg, Ake			Fibromodulin binds collagen type I via Glu-353 and Lys-355 in leucine-rich repeat 11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SMALL PROTEOGLYCANS; DECORIN; LUMICAN; PROTEIN; IDENTIFICATION; EXPRESSION; BIGLYCAN; REVEALS; FIBRILLOGENESIS	Fibromodulin belongs to the small leucine-rich repeat proteoglycan family, interacts with collagen type I, and controls collagen fibrillogenesis and assembly. Here, we show that a major fibromodulin-binding site for collagen type I is located in leucine-rich repeat 11 in the C terminus of the leucine-rich repeat domain. We identified Glu-353 and Lys-355 in repeat 11 as essential for binding, and the synthetic peptide RLDGNEIKR, including Glu-353 and Lys-355, inhibits the binding of fibromodulin to collagen in vitro. Fibromodulin and lumican compete for the same binding region on collagen, and fibromodulin can inhibit the binding of lumican to collagen type I. However, the peptide RLDGNEIKR does not inhibit the binding of lumican to collagen, suggesting separate but closely situated fibromodulin- and lumican-binding sites in collagen. The collagen-binding Glu-353 and Lys-355 residues in fibromodulin are exposed on the exterior of the beta-sheet-loop structure of the leucine-rich repeat, which resembles the location of interacting residues in other leucine-rich repeat proteins, e. g. decorin.	Lund Univ, Dept Expt Med Sci, S-22184 Lund, Sweden	Lund University	Oldberg, A (corresponding author), Lund Univ, Dept Expt Med Sci, BMC B12, S-22184 Lund, Sweden.	Ake.Oldberg@med.lu.se		Kalamajski, Sebastian/0000-0002-6600-9302				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; Baffi MO, 2006, DEV BIOL, V296, P363, DOI 10.1016/j.ydbio.2006.06.002; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; Bevilacqua MA, 2005, J BIOL CHEM, V280, P31809, DOI 10.1074/jbc.M414677200; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chen CZ, 1997, P NATL ACAD SCI USA, V94, P1761, DOI 10.1073/pnas.94.5.1761; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; Faraonio R, 2002, CELL DEATH DIFFER, V9, P862, DOI 10.1038/sj.cdd.4401053; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; Font B, 1996, MATRIX BIOL, V15, P341, DOI 10.1016/S0945-053X(96)90137-7; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Geng YQ, 2006, MATRIX BIOL, V25, P484, DOI 10.1016/j.matbio.2006.08.259; Gill MR, 2002, OSTEOARTHR CARTILAGE, V10, P751, DOI 10.1053/joca.2002.0527; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hakkinen L, 1996, J DENT RES, V75, P1767, DOI 10.1177/00220345960750101001; Heathfield TF, 2004, J BIOL CHEM, V279, P6286, DOI 10.1074/jbc.M307765200; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Kalamajski S, 2007, J BIOL CHEM, V282, P16062, DOI 10.1074/jbc.M700073200; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; Mayr C, 2005, BLOOD, V105, P1566, DOI 10.1182/blood-2004-04-1233; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; Shimizu A, 2004, J BIOL CHEM, V279, P16285, DOI 10.1074/jbc.M307230200; Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200; Svensson L, 2000, FEBS LETT, V470, P178, DOI 10.1016/S0014-5793(00)01314-4; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712	40	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26740	26745		10.1074/jbc.M704026200	http://dx.doi.org/10.1074/jbc.M704026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623650	hybrid			2022-12-25	WOS:000249304900012
J	Madsen, DH; Engelholm, LH; Ingvarsen, S; Hillig, T; Wagenaar-Miller, RA; Kjoller, L; Gardsvoll, H; Hoyer-Hansen, G; Holmbeck, K; Bugge, TH; Behrendt, N				Madsen, Daniel H.; Engelholm, Lars H.; Ingvarsen, Signe; Hillig, Thore; Wagenaar-Miller, Rebecca A.; Kjoller, Lars; Gardsvoll, Henrik; Hoyer-Hansen, Gunilla; Holmbeck, Kenn; Bugge, Thomas H.; Behrendt, Niels			Extracellular Collagenases and the Endocytic receptor, urokinase plasminogen activator receptor-associated Protein/Endo180, cooperate in fibroblast-mediated collagen degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; MANNOSE RECEPTOR; I COLLAGEN; TRANSMEMBRANE GLYCOPROTEIN; BINDING-PROPERTIES; LECTIN RECEPTOR; ENDO180; CELLS; CANCER; FIBRONECTIN	The collagens of the extracellular matrix are the most abundant structural proteins in the mammalian body. In tissue remodeling and in the invasive growth of malignant tumors, collagens constitute an important barrier, and consequently, the turnover of collagen is a rate-limiting process in these events. A recently discovered turnover route with importance for tumor growth involves intracellular collagen degradation and is governed by the collagen receptor, urokinase plasminogen activator receptor-associated protein (uPARAP or Endo 180). The interplay between this mechanism and extracellular collagenolys is is not known. In this report, we demonstrate the existence of a new, composite collagen breakdown pathway. Thus, fibroblast-mediated collagen degradation proceeds preferentially as a sequential mechanism in which extracellular collagenolysis is followed by uPARAP/Endo180-mediated endocytosis of large collagen fragments. First, we show that collagen that has been pre-cleaved by a mammalian collagenase is taken up much more efficiently than intact, native collagen by uPARAP/Endo 180-positive cells. Second, we demonstrate that this preference is governed by the acquisition of a gelatin-like structure by the collagen, occurring upon collagenase-mediated cleavage under native conditions. Third, we demonstrate that the growth of uPARAP/Endo 180-deficient fibroblasts on a native collagen matrix leads to substantial extracellular accumulation of well defined collagen fragments, whereas, wild-type fibroblasts possess the ability to direct an organized and complete degradation sequence comprising both the initial cleavage, the endocytic uptake, and the intracellular breakdown of collagen.	Finsen Lab, DK-2200 Copenhagen, Denmark; NIH, NIDCR, Craniofacial & Skeletal Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Behrendt, N (corresponding author), Finsen Lab, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	niels.behrendt@finsenlab.dk		Behrendt, Niels/0000-0003-1833-3922; Wagenaar-Miller, Rebecca/0000-0002-5807-0111; Holmbeck, Kenn/0000-0002-4472-3257; Engelholm, Lars/0000-0002-6616-1232; Madsen, Daniel Hargboel/0000-0002-3183-6201; Hillig, Thore/0000-0002-2085-5183; Ingvarsen, Signe Ziir/0000-0001-7800-6443	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699, ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699, Z01DE000676] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Behrendt N, 2004, BIOL CHEM, V385, P103, DOI 10.1515/BC.2004.031; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; BEHRENDT N, 1993, FEBS LETT, V336, P394, DOI 10.1016/0014-5793(93)80844-K; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; Curino AC, 2005, J CELL BIOL, V169, P977, DOI 10.1083/jcb.200411153; DANIELSEN CC, 1987, BIOCHEM J, V247, P725, DOI 10.1042/bj2470725; East L, 2002, J BIOL CHEM, V277, P50469, DOI 10.1074/jbc.M208985200; East L, 2003, EMBO REP, V4, P710, DOI 10.1038/sj.embor.embor882; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ENGEL J, 1962, ARCH BIOCHEM BIOPHYS, V97, P150, DOI 10.1016/0003-9861(62)90057-7; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; Engelholm LH, 2001, LAB INVEST, V81, P1403, DOI 10.1038/labinvest.3780354; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Gardsvoll H, 2007, PROTEIN EXPRES PURIF, V52, P384, DOI 10.1016/j.pep.2006.11.013; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HIGHBERGER JH, 1979, BIOCHEM BIOPH RES CO, V89, P202, DOI 10.1016/0006-291X(79)90964-1; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Honardoust HA, 2006, HISTOPATHOLOGY, V49, P634, DOI 10.1111/j.1365-2559.2006.02559.x; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Howard MJ, 2002, J BIOL CHEM, V277, P32320, DOI 10.1074/jbc.M203631200; ISACKE CM, 1990, MOL CELL BIOL, V10, P2606, DOI 10.1128/MCB.10.6.2606; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kjoller L, 2004, EXP CELL RES, V293, P106, DOI 10.1016/j.yexcr.2003.10.008; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Lee HJ, 2006, MOL BIOL CELL, V17, P4812, DOI 10.1091/mbc.E06-06-0486; Leitinger B, 2007, MATRIX BIOL, V26, P146, DOI 10.1016/j.matbio.2006.10.007; Martinez-Pomares L, 2006, EUR J IMMUNOL, V36, P1074, DOI 10.1002/eji.200535685; MCDONALD JA, 1982, J CELL BIOL, V92, P485, DOI 10.1083/jcb.92.2.485; Messent AJ, 1998, J CELL SCI, V111, P1127; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Mousavi SA, 2005, BIOCHEM J, V387, P39, DOI 10.1042/BJ20040966; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; Napper CE, 2006, BIOCHEM J, V395, P579, DOI 10.1042/BJ20052027; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Sameni M, 2001, BIOL CHEM, V382, P785, DOI 10.1515/BC.2001.094; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schnack N. B., 2002, INT J CANCER, V98, P656; Sheikh H, 2000, J CELL SCI, V113, P1021; STARK M, 1968, EUR J BIOCHEM, V6, P534, DOI 10.1111/j.1432-1033.1968.tb00477.x; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; Sturge J, 2003, J CELL BIOL, V162, P789, DOI 10.1083/jcb.200302124; Sturge J, 2006, J CELL BIOL, V175, P337, DOI 10.1083/jcb.200602125; Sulek J, 2007, J HISTOCHEM CYTOCHEM, V55, P347, DOI 10.1369/jhc.6A7133.2006; Thomas EK, 2005, J BIOL CHEM, V280, P22596, DOI 10.1074/jbc.M501155200; Wienke D, 2003, MOL BIOL CELL, V14, P3592, DOI 10.1091/mbc.E02-12-0814; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	59	102	105	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27037	27045		10.1074/jbc.M701088200	http://dx.doi.org/10.1074/jbc.M701088200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17623673	hybrid			2022-12-25	WOS:000249304900045
J	Gao, Y; Wang, HY				Gao, Yuan; Wang, Hsien-Yu			Inositol pentakisphosphate mediates Wnt/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TRIMERIC G-PROTEIN; ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; POLYPHOSPHATE MULTIKINASE; 1,3,4-TRISPHOSPHATE 5/6-KINASE; XENOPUS EMBRYOS; WNT; DROSOPHILA; CK2	Wnt3a stimulates lymphoid enhancer factor/T-cell factor protein-sensitive transcription, i.e. the canonical pathway, in mouse F9 embryonal tetratocarcinoma cells expressing rat Frizzled-1. We explored the potential roles for inositol polyphosphates as mediators of Wnt signaling in the canonical pathway. Wnt3a triggers G-protein-linked phosphatidylinositol signaling, transiently generating inositol polyphosphates, especially inositol pentakisphosphate (IP5) accumulation. Knock-down of G alpha(q) abolishes, whereas expression of the Q209L constitutively active mutant of G alpha(q) mimics, the effects of Wnt3a on IP5 generation and downstream signaling. Phospholipase C beta-1 and C beta-3 mediate the G protein signal to the level of phosphatidylinositol signaling. Knockdown and inhibitor studies of the enzymes responsible for generating IP5 reveal inositol 1,4,5-trisphosphate 3-kinase and inositol polyphosphate multikinase as key mediators in the production of IP5. Wnt3a stimulation of the canonical pathway requires accumulation of IP5, which acts to inhibit the activity of glycogen synthase kinase-3 beta, whereas stimulating casein kinase 2. Blockade of Wnt3a stimulation of IP5 generation blocks beta-catenin accumulation, activation of lymphoid enhancer factor/T-cell factor protein-sensitive transcription, and promotion of primitive endoderm formation in response to Wnt3a. Phosphatidylinositol signaling mediates Wnt3a action in the canonical pathway, acting to generate inositol pentakisphosphate, a key second messenger of Wnt3a.	SUNY Stony Brook, Ctr Hlth Sci, Sch Med, Dept Physiol Biophys,Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Ctr Hlth Sci, Sch Med, Dept Physiol Biophys,Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA.	wangh@pharm.stonybrook.edu			NIGMS NIH HHS [GM 069375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chang SC, 2006, BIOCHEM BIOPH RES CO, V339, P209, DOI 10.1016/j.bbrc.2005.10.201; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; DASILVA CP, 1994, J BIOL CHEM, V269, P12521; Dominguez I, 2005, MOL CELL BIOCHEM, V274, P125, DOI 10.1007/s11010-005-3073-5; Frederick JP, 2005, P NATL ACAD SCI USA, V102, P8454, DOI 10.1073/pnas.0503706102; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Gao Y, 2006, J BIOL CHEM, V281, P18394, DOI 10.1074/jbc.M601112200; Hammerlein A, 2005, CELL MOL LIFE SCI, V62, P606, DOI 10.1007/s00018-005-4507-7; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hildesheim J, 2005, J BIOL CHEM, V280, P17221, DOI 10.1074/jbc.M410440200; Homma MK, 2002, P NATL ACAD SCI USA, V99, P5959, DOI 10.1073/pnas.092143199; Irvine RF, 2005, J PHYSIOL-LONDON, V566, P295, DOI 10.1113/jphysiol.2005.087387; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P586, DOI 10.1038/nrm1152; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Katanaev VL, 2006, P NATL ACAD SCI USA, V103, P6524, DOI 10.1073/pnas.0601853103; Katanaev VL, 2006, CELL CYCLE, V5, P2464, DOI 10.4161/cc.5.21.3410; Kim YH, 2006, J CELL PHYSIOL, V207, P689, DOI 10.1002/jcp.20609; Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maizel A, 2002, DEVELOPMENT, V129, P3545; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Malbon CC, 2004, FRONT BIOSCI-LANDMRK, V9, P1048, DOI 10.2741/1308; Mayr GW, 2005, J BIOL CHEM, V280, P13229, DOI 10.1074/jbc.M500545200; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Olsten MEK, 2004, BIOCHEM CELL BIOL, V82, P681, DOI 10.1139/O04-116; PATTERSON RL, 1907, ANNU REV BIOCHEM, V73, P437; Pattni K, 2004, CELL SIGNAL, V16, P643, DOI 10.1016/j.cellsig.2003.10.009; PITTET D, 1989, J BIOL CHEM, V264, P18489; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Sarmah B, 2005, DEV CELL, V9, P133, DOI 10.1016/j.devcel.2005.05.002; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Seeds AM, 2007, BIOCHEM SOC SYMP, V74, P183, DOI 10.1042/BSS2007c16; Seldin DC, 2005, MOL CELL BIOCHEM, V274, P63, DOI 10.1007/s11010-005-3078-0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Solyakov L, 2004, J BIOL CHEM, V279, P43403, DOI 10.1074/jbc.M403239200; Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200; Sun Y, 2003, J BIOL CHEM, V278, P43645, DOI 10.1074/jbc.M300674200; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; Verbsky J, 2005, P NATL ACAD SCI USA, V102, P8448, DOI 10.1073/pnas.0503656102; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wang S, 2006, CURR BIOL, V16, P2239, DOI 10.1016/j.cub.2006.09.034; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	62	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26490	10.1074/jbc.M702106200	http://dx.doi.org/10.1074/jbc.M702106200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17595165	hybrid			2022-12-25	WOS:000249239600054
J	Aguirre, JI; Plotkin, LI; Gortazar, AR; Millan, MM; O'Brien, CA; Manolagas, SC; Bellido, T				Aguirre, J. Ignacio; Plotkin, Lilian I.; Gortazar, Arancha R.; Millan, Marta Martin; O'Brien, Charles A.; Manolagas, Stavros C.; Bellido, Teresita			A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA ER-ALPHA; PLASMA-MEMBRANE; MECHANICAL STRAIN; ADAPTIVE RESPONSE; BONE-FORMATION; APOPTOSIS; BETA; ACTIVATION; IDENTIFICATION; LOCALIZATION	Bone senses and adapts to meet mechanical needs by means of an extensive mechanotransduction network comprising osteocytes ( former osteoblasts entrapped in mineral) and their cytoplasmic projections through which osteocytes communicate with osteoblasts and osteoclasts on the bone surface. Mechanical stimulation promotes osteocyte ( and osteoblast) survival by activating the extracellular signal-regulated kinases, ERKs. Estrogens have similar effects and, intriguingly, the adaptive response of bone to mechanical forces is defective in mice lacking estrogen receptor ( ER) alpha or ER beta. We report that ERKs are not activated by stretching in osteocytic and osteoblastic cells in which both ER alpha and ER beta have been knocked out or knocked down and this is reversed partially by transfection of either one of the two human ERs and fully by transfection of both receptors. ERK activation in response to stretching is also recovered by transfecting the ligand-binding domain ( E) of either receptor or an ER alpha mutant that does not bind estrogens. Furthermore, mechano-responsiveness is restored by transfecting the E alpha targeted to the plasma membrane, but not to the nucleus, whereas ER alpha mutants with impaired plasma membrane localization or binding to caveolin-1 fail to confer ERK activation in response to stretching. Lastly, the ER antagonist ICI 182,780 abrogates ERK activation and the anti-apoptotic effect of mechanical stimulation. We conclude that in addition to their role as ligand-dependent mediators of the effects of estrogens, the ERs participate in the transduction of mechanical forces into pro-survival signaling in bone cells, albeit in a ligand-independent manner.	Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72202 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Bellido, T (corresponding author), Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72202 USA.	tmbellido@uams.edu	Gortazar, Arancha/G-5385-2017; O'Brien, Charles A./AAL-5078-2020; Plotkin, Lilian/H-7188-2019	Gortazar, Arancha/0000-0001-5072-3141; Plotkin, Lilian/0000-0002-9537-4544	NIAMS NIH HHS [K02-AR02127] Funding Source: Medline; NIA NIH HHS [P01-AG13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304; Acconcia F, 2005, MOL BIOL CELL, V16, P231, DOI 10.1091/mbc.e04-07-0547; Acconcia F, 2003, IUBMB LIFE, V55, P33, DOI 10.1080/1521654031000081256; Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107; Bakker A, 2004, BIOCHEM BIOPH RES CO, V320, P1163, DOI 10.1016/j.bbrc.2004.06.056; Boonyaratanakornkit V, 2004, ESSAYS BIOCHEM, V40, P105, DOI 10.1042/bse0400105; Boyce BF, 2002, PRINCIPLES BONE BIOL, V1, P151; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Damien E, 1998, J BONE MINER RES, V13, P1275, DOI 10.1359/jbmr.1998.13.8.1275; Dufour C, 2007, EXP CELL RES, V313, P394, DOI 10.1016/j.yexcr.2006.10.021; Dupont S, 2000, DEVELOPMENT, V127, P4277; Edwards Dean P, 2003, Mol Interv, V3, P12, DOI 10.1124/mi.3.1.12; Ekena K, 1996, J BIOL CHEM, V271, P20053, DOI 10.1074/jbc.271.33.20053; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FROST HM, 1987, BONE MINER, V2, P73; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a; Lee KCL, 2004, J ENDOCRINOL, V182, P193, DOI 10.1677/joe.0.1820193; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin RB, 2000, BONE, V26, P1, DOI 10.1016/S8756-3282(99)00241-0; Martin RB, 1998, SKELETAL TISSUE MECH; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Monroe DG, 2003, J ENDOCRINOL, V176, P349, DOI 10.1677/joe.0.1760349; O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003-0990; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Plotkin LI, 2005, AM J PHYSIOL-CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004; Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Song RXD, 2007, ENDOCRINOLOGY, V148, P4091, DOI 10.1210/en.2007-0240; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wolff J., 1892, LAW BONE REMODELING; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Zaman G, 2000, BONE, V27, P233, DOI 10.1016/S8756-3282(00)00324-0	48	110	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25501	25508		10.1074/jbc.M702231200	http://dx.doi.org/10.1074/jbc.M702231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17609204	hybrid			2022-12-25	WOS:000249014100036
J	DikanovO, SA; Hollan, JT; Endeward, B; Kolling, DRJ; Samoilova, RI; Prisner, TF; Crofts, AR				DikanovO, Sergei A.; Hollan, J. Todd; Endeward, Burkhard; Kolling, Derrick R. J.; Samoilova, Rimma I.; Prisner, Thomas F.; Crofts, Antony R.			Hydrogen bonds between nitrogen donors and the semiquinone in the Q(i)-site of the bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN ECHO; PRIMARY ACCEPTOR QUINONE; MITOCHONDRIAL CYTOCHROME BC(1); BACTERIAL REACTION CENTERS; PURE QUADRUPOLE-RESONANCE; RHODOBACTER-SPHAEROIDES; PARAMAGNETIC-RESONANCE; ENVELOPE MODULATION; RESPIRATORY-CHAIN; CRYSTAL-STRUCTURE	The ubisemiquinone stabilized at the Q(i)-site of the bc(1) complex of Rhodobacter sphaeroides forms a hydrogen bond with a nitrogen from the local protein environment, tentatively identified as ring N from His-217. The interactions of N-14 and N-15 have been studied by X-band (similar to 9.7 GHz) and S-band (3.4 GHz) pulsed EPR spectroscopy. The application of S-band spectroscopy has allowed us to determine the complete nuclear quadrupole tensor of the 14N involved in H-bond formation and to assign it unambiguously to the N (epsilon) of His-217. This tensor has distinct characteristics in comparison with H-bonds between semiquinones and N-delta in other quinone-processing sites. The experiments with 15N showed that the N (epsilon) of His-217 was the only nitrogen carrying any considerable unpaired spin density in the ubiquinone environment, and allowed calculation of the isotropic and anisotropic couplings with the N (epsilon) of His-217. From these data, we could estimate the unpaired spin density transferred onto 2s and 2p orbitals of nitrogen and the distance from the nitrogen to the carbonyl oxygen of 2.38 +/- 0.13 A. The hyperfine coupling of other protein nitrogens with semiquinone is < 0.1MHz. This did not exclude the nitrogen of the Asn-221 as a possible hydrogen bond donor to the methoxy oxygen of the semiquinone. Amechanistic role for this residue is supported by kinetic experiments with mutant strains N221T, N221H, N221I, N221S, N221P, and N221D, all of which showed some inhibition but retained partial turnover.	Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Goethe Univ Frankfurt, Inst Phys & Theoret Chem, D-60438 Frankfurt, Germany; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Goethe University Frankfurt; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS; University of Illinois System; University of Illinois Urbana-Champaign	Crofts, AR (corresponding author), Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA.	a-crofts@life.uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487; Endeward, Burkhard/0000-0001-7790-1024; Prisner, Thomas F./0000-0003-2850-9573	FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062954, R01GM035438] Funding Source: NIH RePORTER	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; ASHBY CIH, 1978, J AM CHEM SOC, V100, P6057, DOI 10.1021/ja00487a014; ASTASHKIN AV, 1995, J CHEM PHYS, V102, P5583, DOI 10.1063/1.469289; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; BOSCH MK, 1995, CHEM PHYS LETT, V239, P306, DOI 10.1016/0009-2614(95)00481-I; Crofts AR, 2006, BBA-BIOENERGETICS, V1757, P1019, DOI 10.1016/j.bbabio.2006.02.009; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Crofts AR, 2004, PHOTOSYNTH RES, V80, P223, DOI 10.1023/B:PRES.0000030444.52579.10; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P493; CROFTS AR, 2005, BIOPHYSICAL STRUCTUR, P123; de Vries S., 1982, FUNCTION QUINONES EN, P235; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; DIKANOV SA, 1995, J MAGN RESON SER A, V116, P125, DOI 10.1006/jmra.1995.1199; Dikanov SA, 2004, J BIOL CHEM, V279, P15814, DOI 10.1074/jbc.M313417200; DIKANOV SA, 1982, CHEM PHYS LETT, V90, P149, DOI 10.1016/0009-2614(82)83630-0; Dikanov SA, 2006, J BIOL CHEM, V281, P27416, DOI 10.1074/jbc.M604103200; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; Flores M, 2007, BIOPHYS J, V92, P671, DOI 10.1529/biophysj.106.092460; Fritscher J, 2006, APPL MAGN RESON, V30, P251, DOI 10.1007/BF03166200; Fritscher J, 2004, PHYS CHEM CHEM PHYS, V6, P4950, DOI 10.1039/b408764j; FUESS H, 1977, ACTA CRYSTALLOGR B, V33, P654, DOI 10.1107/S0567740877004415; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; Guergova-Kuras M, 1999, PROTEIN EXPRES PURIF, V15, P370, DOI 10.1006/prep.1998.1018; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; HOLLAND JT, 2007, THESIS U ILLINOIS UR; Huang LS, 2005, J MOL BIOL, V351, P573, DOI 10.1016/j.jmb.2005.05.053; HUNT MJ, 1976, J MAGN RESON, V22, P295, DOI 10.1016/0022-2364(76)90304-8; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JEFFREY GA, 1997, INTRO HYDROGEN BONDI, P184; JIANG F, 1990, J AM CHEM SOC, V112, P9035, DOI 10.1021/ja00181a002; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Lendzian F, 1996, BER BUNSEN PHYS CHEM, V100, P2036, DOI 10.1002/bbpc.19961001219; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MacMillan F, 1995, MAGN RESON CHEM, V33, pS81, DOI 10.1002/mrc.1260331314; MCDOWELL CA, 1986, J MAGN RESON, V69, P283, DOI 10.1016/0022-2364(86)90079-X; MEINHARDT SW, 1984, ADV PHOTOSYNTHESIS R, V1, P649; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MORTON JR, 1978, J MAGN RESON, V30, P577, DOI 10.1016/0022-2364(78)90284-6; Mulkidjanian AY, 2007, PHOTOCH PHOTOBIO SCI, V6, P19, DOI 10.1039/b517522d; O'Malley PJ, 1998, J AM CHEM SOC, V120, P11732, DOI 10.1021/ja981755x; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; Rich PR, 2004, BBA-BIOENERGETICS, V1658, P165, DOI 10.1016/j.bbabio.2004.04.021; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SALERNO JC, 1989, J BIOL CHEM, V264, P15398; Sinnecker S, 2004, J AM CHEM SOC, V126, P3280, DOI 10.1021/ja0392014; Sinnecker S, 2006, PHYS CHEM CHEM PHYS, V8, P5659, DOI 10.1039/b612568a; Slichter C. P., 1990, PRINCIPLES MAGNETIC, P485; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; TOWNES CH, 1949, J CHEM PHYS, V17, P782, DOI 10.1063/1.1747400; WEBER A, 1998, P 29 C AMPERE 13 ISM, V2, P1138; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yap LL, 2007, J BIOL CHEM, V282, P8777, DOI 10.1074/jbc.M611595200; Yap LL, 2006, J BIOL CHEM, V281, P16879, DOI 10.1074/jbc.M602544200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	70	30	30	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25831	25841		10.1074/jbc.M702333200	http://dx.doi.org/10.1074/jbc.M702333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17616531	Green Accepted, hybrid			2022-12-25	WOS:000249014100069
J	Chang, WH; Tu, CL; Cheng, ZQ; Rodriguez, L; Chen, TH; Gassmann, M; Bettler, B; Margeta, M; Jan, LY; Shoback, D				Chang, Wenhan; Tu, Chialing; Cheng, Zhiqiang; Rodriguez, Luis; Chen, Tsui-Hua; Gassmann, Martin; Bettler, Bernhard; Margeta, Marta; Jan, Lily Y.; Shoback, Dolores			Complex formation with the type B gamma-aminobutyric acid receptor affects the expression and signal transduction of the extracellular calcium-sensing receptor - Studies with hek-293 cells and neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-PLATE CHONDROCYTES; GABA(B) RECEPTORS; CA2+-SENSING RECEPTOR; PHOSPHOLIPASE-C; ENDOCRINE-CELLS; AMINO-ACIDS; RAT; HETERODIMERIZATION; LOCALIZATION	We co-immunoprecipitated the Ca2(+)- sensing receptor ( CaR) and type B gamma- aminobutyric acid receptor ( GABA-B-R) from human embryonic kidney ( HEK)- 293 cells expressing these receptors and from brain lysates where both receptors are present. CaRs extensively co-localized with the two subunits of the GABA- B-R ( R1 and R2) in HEK- 293 cell membranes and intracellular organelles. Coexpressing CaRs and GABA- B- R1s in HEK- 293 cells suppressed the total cellular and cell surface expression of CaRs and inhibited phospholipase C activation in response to high extracellular [ Ca2(+)] ([ Ca2(+)] (e)). In contrast, coexpressing CaRs and GABA- B- R2s enhanced CaR expression and signaling responses to raising [ Ca2(+)] (e). The latter effects of the GABA- B- R2 on the CaR were blunted by coexpressing the GABA- B- R1. Coexpressing the CaR with GABA- B- R1 or R2 enhanced the total cellular and cell surface expression of the GABA- B- R1 or R2, respectively. Studies with truncated CaRs indicated that the N- terminal extracellular domain of the CaR participated in the interaction of the CaR with the GABA- B- R1 and R2. In cultured mouse hippocampal neurons, CaRs co-localized with the GABA- B- R1 and R2. CaRs and GABA- B- R1s also co-immunoprecipitated from brain lysates. The expression of the CaR was increased in lysates from GABA- B- R1 knock-out mouse brains and in cultured hippocampal neurons with their GABA- B- R1 genes deleted in vitro. Thus, CaRs and GABA- B- R subunits can form heteromeric complexes in cells, and their interactions affect cell surface expression and signaling of CaR, which may contribute to extracellular Ca2(+)- dependent receptor activation in target tissues.	Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA; Univ Basel, Inst Physiol, CH-4056 Basel, Switzerland; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem, San Francisco, CA 94158 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Basel; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Chang, WH (corresponding author), Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, Endocrine Res Unit, 111N San Francisco,4150 Cloement St, San Francisco, CA 94121 USA.	Wenhan.Chang@ucsf.edu	bettler, bernhard/AAO-8018-2020; Centeno, Patricia Pacios/O-8368-2016	Tu, Chia-Ling/0000-0002-7323-7733; Jan, Lily/0000-0003-3938-8498; Bettler, Bernhard/0000-0003-0842-8207; Margeta, Marta/0000-0001-6889-2488; Gassmann, Martin/0000-0001-6201-3032	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021353] Funding Source: NIH RePORTER; NIAMS NIH HHS [R21 AR054441] Funding Source: Medline; NIA NIH HHS [R01 AG21353] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Bai M, 1999, INT J MOL MED, V4, P115; Bai M, 2004, CELL CALCIUM, V35, P197, DOI 10.1016/j.ceca.2003.10.018; Bai M, 2004, CELL SIGNAL, V16, P175, DOI 10.1016/S0898-6568(03)00128-1; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Benes FM, 2001, NEUROPSYCHOPHARMACOL, V25, P1, DOI 10.1016/S0893-133X(01)00225-1; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; Braun M, 2004, J GEN PHYSIOL, V123, P191, DOI 10.1085/jgp.200308966; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Castelli MP, 1999, LIFE SCI, V64, P1321, DOI 10.1016/S0024-3205(99)00067-3; Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012; Chang WH, 2000, J BIOL CHEM, V275, P19955, DOI 10.1074/jbc.M909613199; Chang WH, 1998, J BONE MINER RES, V13, P570, DOI 10.1359/jbmr.1998.13.4.570; Chang WH, 2001, J BIOL CHEM, V276, P44129, DOI 10.1074/jbc.M104834200; Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883; Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101; Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014; Fernandez-Pascual S, 2004, BIOCHEM J, V379, P721, DOI 10.1042/BJ20031826; Franklin IK, 2004, J GEN PHYSIOL, V123, P185, DOI 10.1085/jgp.200409016; Fujimori S, 2002, BIOCHEM BIOPH RES CO, V293, P1445, DOI 10.1016/S0006-291X(02)00405-9; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; GILON P, 1990, HISTOCHEMISTRY, V93, P645, DOI 10.1007/BF00272208; GILON P, 1988, BIOL CELL, V62, P265, DOI 10.1016/0248-4900(88)90021-4; GILON P, 1991, HISTOCHEMISTRY, V96, P355, DOI 10.1007/BF00271357; Goslin K., 1998, CULTURING NERVE CELL, P339; Haller C, 2004, GENESIS, V40, P125, DOI 10.1002/gene.20073; House MG, 1997, J BONE MINER RES, V12, P1959, DOI 10.1359/jbmr.1997.12.12.1959; Jiang YF, 2004, J BIOL CHEM, V279, P14147, DOI 10.1074/jbc.M307422200; Kanbara K, 2005, J ANDROL, V26, P485, DOI 10.2164/jandrol.04185; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Pagano A, 2001, J NEUROSCI, V21, P1189; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Riccardi D, 1996, AM J PHYSIOL-RENAL, V271, pF951, DOI 10.1152/ajprenal.1996.271.4.F951; Rodriguez L, 2005, ENDOCRINOLOGY, V146, P5294, DOI 10.1210/en.2005-0256; Rodriguez L, 2005, ENDOCRINOLOGY, V146, P4597, DOI 10.1210/en.2005-0437; Tamayama T, 2005, MOL CELL BIOCHEM, V273, P117, DOI 10.1007/s11010-005-8159-6; Wang FY, 2004, WORLD J GASTROENTERO, V10, P3608, DOI 10.3748/wjg.v10.i24.3608; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yano S, 2004, CELL CALCIUM, V35, P257, DOI 10.1016/j.ceca.2003.10.008; Yoshioka K, 2001, P NATL ACAD SCI USA, V98, P7617, DOI 10.1073/pnas.121587098	46	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25030	25040		10.1074/jbc.M700924200	http://dx.doi.org/10.1074/jbc.M700924200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591780	hybrid			2022-12-25	WOS:000248933000059
J	Mikenberg, I; Widera, D; Kaus, A; Kaltschmidt, B; Kaltschmidt, C				Mikenberg, Ilja; Widera, Darius; Kaus, Aljoscha; Kaltschmidt, Barbara; Kaltschmidt, Christian			Transcription Factor NF-kappa B Is Transported to the Nucleus via Cytoplasmic Dynein/Dynactin Motor Complex in Hippocampal Neurons	PLOS ONE			English	Article								Background. Long-term changes in synaptic plasticity require gene transcription, indicating that signals generated at the synapse must be transported to the nucleus. Synaptic activation of hippocampal neurons is known to trigger retrograde transport of transcription factor NF-kappa B. Transcription factors of the NF-kappa B family are widely expressed in the nervous system and regulate expression of several genes involved in neuroplasticity, cell survival, learning and memory. Principal Findings. In this study, we examine the role of the dynein/dynactin motor complex in the cellular mechanism targeting and transporting activated NF-kappa B to the nucleus in response to synaptic stimulation. We demonstrate that overexpression of dynamitin, which is known to dissociate dynein from microtubules, and treatment with microtubule-disrupting drugs inhibits nuclear accumulation of NF-kappa B p65 and reduces NF-kappa B-dependent transcription activity. In this line, we show that p65 is associated with components of the dynein/dynactin complex in vivo and in vitro and that the nuclear localization sequence (NLS) within NF-kappa B p65 is essential for this binding. Conclusion. This study shows the molecular mechanism for the retrograde transport of activated NF-kappa B from distant synaptic sites towards the nucleus.	[Mikenberg, Ilja; Widera, Darius; Kaus, Aljoscha; Kaltschmidt, Barbara; Kaltschmidt, Christian] Univ Witten Herdecke, Inst Neurobiochem, Witten, Germany	Witten Herdecke University	Kaltschmidt, C (corresponding author), Univ Bielefeld, Fak Biol, Lehrstuhl Zellbiol Tiere, D-4800 Bielefeld, Germany.	c.kaltschmidt@uni-bielefeld.de	Widera, Darius/J-4237-2012	Widera, Darius/0000-0003-1686-130X	Deutsche Forschungsgemeinschaft (DFG); Gerhard C. Starck Stiftung; Institute for Biochemistry, University of Giessen, Germany [pBI-EGFP-TAP-p65]; Columbia University Medical Center	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Gerhard C. Starck Stiftung; Institute for Biochemistry, University of Giessen, Germany; Columbia University Medical Center	This study was supported by the Deutsche Forschungsgemeinschaft (DFG) and by Gerhard C. Starck Stiftung.; We acknowledge the kind gifts of pBI-EGFP-TAP-p65 from Lienhard M. Schmitz, Institute for Biochemistry, University of Giessen, Germany and pCMV beta-Dynamitin from Richard Vallee, Columbia University Medical Center. Expert technical assistance by Maria Prullage and Julia Pfeiffer is gratefully acknowledged. We thank Marina Rodnina, Hans-Joachim Lipps and Wolfgang Wintermeyer for helpful and essential advice on the biochemical assays.	Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; Albensi BC, 2000, SYNAPSE, V35, P151; AMBRON RT, 1992, J NEUROSCI, V12, P2813; BASKIN LS, 1982, BIOCHIM BIOPHYS ACTA, V684, P263, DOI 10.1016/0005-2736(82)90015-3; Bhakar AL, 2002, J NEUROSCI, V22, P8466; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Boylan K, 2000, MOL BIOL CELL, V11, P3791, DOI 10.1091/mbc.11.11.3791; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Campbell EA, 2003, ADV DRUG DELIVER REV, V55, P761, DOI 10.1016/S0169-409X(03)00049-8; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Hanz S, 2003, NEURON, V40, P1095, DOI 10.1016/S0896-6273(03)00770-0; Hanz S, 2004, NEUROSCIENTIST, V10, P404, DOI 10.1177/1073858404267884; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HORDERN JS, 1979, VIROLOGY, V97, P131, DOI 10.1016/0042-6822(79)90379-9; JOSHI S, 1990, J BIOL CHEM, V265, P14518; Kaltschmidt B, 2006, MOL CELL BIOL, V26, P2936, DOI 10.1128/MCB.26.8.2936-2946.2006; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Lam MHC, 2002, MOL ENDOCRINOL, V16, P390, DOI 10.1210/me.16.2.390; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; MEFFERT MK, 2003, NAT NEUROSCI; MELLONI RH, 1995, J COMP NEUROL, V357, P15, DOI 10.1002/cne.903570103; Merlo E, 2005, LEARN MEMORY, V12, P23, DOI 10.1101/lm.82705; Merlo E, 2002, NEUROSCIENCE, V112, P161, DOI 10.1016/S0306-4522(02)00049-0; Mesika A, 2005, HUM GENE THER, V16, P200, DOI 10.1089/hum.2005.16.200; Mikenberg I, 2006, EUR J CELL BIOL, V85, P529, DOI 10.1016/j.ejcb.2006.02.007; O'Mahony A, 2006, MOL CELL BIOL, V26, P7283, DOI 10.1128/MCB.00510-06; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Romano A, 2006, EUR J NEUROSCI, V24, P1507, DOI 10.1111/j.1460-9568.2006.05022.x; Salman H, 2005, BIOPHYS J, V89, P2134, DOI 10.1529/biophysj.105.060160; SCHWEIZER E, 1982, BIOCHEMISTRY-US, V21, P6807, DOI 10.1021/bi00269a029; Shah JV, 2000, MOL BIOL CELL, V11, P3495, DOI 10.1091/mbc.11.10.3495; Thompson KR, 2004, NEURON, V44, P997, DOI 10.1016/j.neuron.2004.11.025; Tokito MK, 1996, MOL BIOL CELL, V7, P1167, DOI 10.1091/mbc.7.8.1167; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Wellmann H, 2001, J BIOL CHEM, V276, P11821, DOI 10.1074/jbc.M009253200; Yeh SH, 2004, MOL PHARMACOL, V65, P1286, DOI 10.1124/mol.65.5.1286; Yeh SH, 2002, J BIOL CHEM, V277, P46720, DOI 10.1074/jbc.M206258200	60	84	86	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e589	10.1371/journal.pone.0000589	http://dx.doi.org/10.1371/journal.pone.0000589			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622342	gold, Green Submitted, Green Published, Green Accepted			2022-12-25	WOS:000207452000004
J	Bhattacharyya, R; Noch, EK; Khalili, K				Bhattacharyya, R.; Noch, E. K.; Khalili, K.			A novel role of Rac1 GTPase in JCV T-antigen-mediated beta-catenin stabilization	ONCOGENE			English	Article						beta-catenin; T-antigen; JC virus; Rho; Wnt pathway; medulloblastoma	CELL-ADHESION; BRAIN-TUMORS; RHO; PROTEINS; UBIQUITINATION; LOCALIZATION; INVOLVEMENT; INTERACTS; BINDING; PATHWAY	Wnt signaling follows canonical and non-canonical pathways to regulate a variety of processes during cellular homeostasis and development. The large T-antigen (T-Ag) of the human neurotropic JC virus, has been shown to modulate the Wnt-signaling pathway via interaction with beta-catenin, one of the most important components of the canonical Wnt pathway. Here, we have identified an alternative non-canonical pathway that allows T-Ag to recruit Rac1 for stabilizing beta-catenin by inhibiting its ubiquitin-dependent proteasomal degradation. We demonstrate that inhibition of Rac1 by its dominant negative mutant, RacN17, abrogates T-Ag-mediated stabilization of b-catenin yet exhibits no impact on the transcriptional activity of b-catenin. Results from immunocytochemistry revealed that together with T-Ag, a pool of beta-catenin appears at the cell surface, particularly at the membrane ruffles where active Rac1 is positioned. Interestingly, cooperativity between T-Ag and beta-catenin leads to activation of Rac1, which in turn, stimulates its association with beta-catenin. These observations unravel the interplay between beta-catenin and Rac1 that is initiated by T-Ag and results in stabilization of beta-catenin and its presence in cell membrane ruffles.	[Bhattacharyya, R.; Noch, E. K.; Khalili, K.] Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA.	kkhalili@temple.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bachar-Dahan L, 2006, MOL BIOL CELL, V17, P2572, DOI 10.1091/mbc.E06-01-0052; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BUTEL JS, 1989, ANN NY ACAD SCI, V567, P104, DOI 10.1111/j.1749-6632.1989.tb16463.x; Gan DD, 2004, ONCOGENE, V23, P483, DOI 10.1038/sj.onc.1207018; Hwang SL, 2005, ACTA NEUROCHIR, V147, P551, DOI 10.1007/s00701-005-0515-5; Khalili K, 2006, ADV EXP MED BIOL, V577, P274; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Senadheera D, 2001, INT J MOL MED, V8, P127; Shackelford J, 2004, MOL CELL BIOL, V24, P5089, DOI 10.1128/MCB.24.12.5089-5093.2004; Shollar D, 2004, ONCOGENE, V23, P5459, DOI 10.1038/sj.onc.1207728; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; White MK, 2005, BRAIN RES REV, V50, P69, DOI 10.1016/j.brainresrev.2005.04.007; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046	20	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7628	7636		10.1038/sj.onc.1210576	http://dx.doi.org/10.1038/sj.onc.1210576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17637758				2022-12-25	WOS:000251537800004
J	Quereda, V; Martinalbo, J; Dubus, P; Carnero, A; Malumbres, M				Quereda, V.; Martinalbo, J.; Dubus, P.; Carnero, A.; Malumbres, M.			Genetic cooperation between p21(Cip1) and INK4 inhibitors in cellular senescence and tumor suppression	ONCOGENE			English	Article						cell-cycle inhibition; cyclin-dependent kinase; senescence; tumor development; p21(Cip1) and INK4 inhibitors	CYCLIN-DEPENDENT KINASES; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; ONCOGENIC RAS; SKIN CARCINOGENESIS; MURINE FIBROBLASTS; MAMMALIAN-CELLS; CDK INHIBITORS; G(1) CONTROL; MICE	Cell-cycle inhibitors of the Cip/Kip and INK4 families are involved in cellular senescence and tumor suppression. Some of these proteins, p21(Cip1), p16(INK4a) and p15(INK4b), are coexpressed in response to antiproliferative signals such as cellular senescence resulting in cell-cycle arrest. To understand the roles of these inhibitors and their synergistic effect, we have characterized the growth properties and senescent behavior of primary cells deficient in p21Cip1 and expressing an endogenous Cdk4(R24C) (cyclin-dependent kinase) mutant (Cdk4R24C knock-in cells) insensitive to INK4 proteins. Inactivation of both p21Cip1 and INK4 pathways strongly cooperate in suppressing cellular senescence in vitro. These double mutant cells behavior as immortal cultures and display high sensitivity to cellular transformation by oncogenes. Moreover, mice double mutant in the INK4 and p21Cip1 pathways (Cdk4R24C; p21(Cip1)-null mice) display an increased incidence of specific sarcomas, suggesting a significant cooperation between these two families of cell-cycle inhibitors in senescence responses and tumor suppression in vivo.	[Quereda, V.; Martinalbo, J.; Malumbres, M.] Ctr Nacl Invest Oncol, Cell Div, E-28029 Madrid, Spain; [Quereda, V.; Martinalbo, J.; Malumbres, M.] Ctr Nacl Invest Oncol, Canc Grp, E-28029 Madrid, Spain; [Dubus, P.] Univ Bordeaux 2, EA2406, F-33076 Bordeaux, France; [Carnero, A.] CNIO, Assays Dev Grp, Madrid, Spain	UDICE-French Research Universities; Universite de Bordeaux; Centro Nacional de Investigaciones Oncologicas (CNIO)	Malumbres, M (corresponding author), Ctr Nacl Invest Oncol, Cell Div, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	acarnero@cnio.es; malumbres@cnio.es	IBIS, CANCER/P-3323-2015; Quereda, Victor/J-8120-2019; Malumbres, Marcos/E-8834-2011	Quereda, Victor/0000-0002-9966-9104; Malumbres, Marcos/0000-0002-0829-6315; Dubus, Pierre/0000-0003-1803-4711; Carnero, Amancio/0000-0003-4357-3979				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bearss DJ, 2002, CANCER RES, V62, P2077; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005; Franciotta D, 1998, CEPHALALGIA, V18, P4, DOI 10.1046/j.1468-2982.1998.1801001-5.x; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gregory V, 2002, VIROLOGY, V300, P1, DOI 10.1006/viro.2002.1513; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Korenjak M, 2005, CURR OPIN GENET DEV, V15, P520, DOI 10.1016/j.gde.2005.07.001; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Malumbres Marcos, 2003, Prog Cell Cycle Res, V5, P5; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Martin J A, 2001, Iowa Orthop J, V21, P1; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Medcalf ASC, 1996, CANCER RES, V56, P4582; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yang WC, 2001, CANCER RES, V61, P565; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	60	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7665	7674		10.1038/sj.onc.1210578	http://dx.doi.org/10.1038/sj.onc.1210578			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599058				2022-12-25	WOS:000251537800008
J	Hung, HC; Maurer, C; Kay, SA; Weber, F				Hung, Hsiu-Cheng; Maurer, Christian; Kay, Steve A.; Weber, Frank			Circadian transcription depends on limiting amounts of the transcription co-activator nejire/CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME QUANTITATIVE PCR; GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; DROSOPHILA-MELANOGASTER; CLOCK; CBP; ACTIVATION; CBP/P300; PATHWAYS; MUTATION	The circadian clock orchestrates physiological and behavioral activities, including metabolism, neuronal activity, and cell proliferation in synchrony with the environmental cycle of day and night. Here we show that the Drosophila ortholog of the CBP/ p300 family of transcription co-activators, nejire (nej), is an intrinsic component of the circadian clock that performs regulatory functions for circadian controlled transcription. Screening of overexpression mutants revealed that gain of nej function was associated with a loss of behavioral and molecular rhythms. Overexpression of NEJ suppresses the long period phenotype of a mutation in the clock gene period (per). NEJ physically interacts through two binding sites with CLOCK and the CLOCK center dot CYCLE (CLK center dot CYC) complex. Induction of CLK center dot CYC-dependent transcripts upon induction of nej expression from a heat-shock promoter showed that NEJ is limiting. Reduced CLK center dot CYC-mediated transcription in a nej hypomorphic mutant indicates an essential function of NEJ/CBP for CLK center dot CYC activity and a regulation of circadian transcription by availability of the co-activator. Competition for recruitment of NEJ/CBP provides a potential mechanism for cross-talk between circadian transcription and other CBP-dependent physiological processes.	Univ Heidelberg, Biochem Zent Heidelberg, D-69120 Heidelberg, Germany; Scripps Res Inst, La Jolla, CA 92037 USA	Ruprecht Karls University Heidelberg; Scripps Research Institute	Weber, F (corresponding author), Univ Heidelberg, Biochem Zent Heidelberg, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	Frank.Weber@bzh.uni-heidelberg.de	Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER; NIMH NIH HHS [MH51573] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 2003, EMBO J, V22, P3367, DOI 10.1093/emboj/cdg318; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; Costa SL, 1996, CELL GROWTH DIFFER, V7, P1479; Curtis AM, 2004, J BIOL CHEM, V279, P7091, DOI 10.1074/jbc.M311973200; Cyran SA, 2003, CELL, V112, P329, DOI 10.1016/S0092-8674(03)00074-6; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Ganguly-Fitzgerald I, 2006, SCIENCE, V313, P1775, DOI 10.1126/science.1130408; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glossop NRJ, 2003, NEURON, V37, P249, DOI 10.1016/S0896-6273(03)00002-3; Goodman RH, 2000, GENE DEV, V14, P1553; Hamblen MJ, 1998, GENETICS, V149, P165; Hardin PE, 2005, CURR BIOL, V15, pR714, DOI 10.1016/j.cub.2005.08.019; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim EY, 2002, NEURON, V34, P69, DOI 10.1016/S0896-6273(02)00639-6; Lee C, 1999, MOL CELL BIOL, V19, P5316; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; Lim C, 2007, MOL CELL BIOL, V27, P4876, DOI 10.1128/MCB.02155-06; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marek KW, 2000, NEURON, V25, P537, DOI 10.1016/S0896-6273(00)81058-2; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Pennartz CMA, 2002, NATURE, V416, P286, DOI 10.1038/nature728; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rosato E, 2006, EUR J HUM GENET, V14, P729, DOI 10.1038/sj.ejhg.5201547; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Takahata S, 2000, GENES CELLS, V5, P739, DOI 10.1046/j.1365-2443.2000.00363.x; Weber F, 2006, J NEUROCHEM, V98, P248, DOI 10.1111/j.1471-4159.2006.03865.x; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097	35	37	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 26	2007	282	43					31349	31357		10.1074/jbc.M702319200	http://dx.doi.org/10.1074/jbc.M702319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	222PK	17635913	hybrid			2022-12-25	WOS:000250309200024
J	Yegneswaran, S; Kojima, Y; Nguyen, PM; Gale, AJ; Heeb, MJ; Griffin, JH				Yegneswaran, Subramanian; Kojima, Yumi; Nguyen, Phuong M.; Gale, Andrew J.; Heeb, Mary J.; Griffin, John H.			Factor va residues 311-325 represent an activated protein C binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; PEPTIDE-BOND CLEAVAGES; BOVINE FACTOR-V; BLOOD-COAGULATION; PROTHROMBINASE COMPLEX; MEDIATED CLEAVAGES; FACTOR VA(R506Q); INACTIVATION; SITE; FLUORESCENCE	Activated protein C (APC) inactivates factor Va (fVa) by pro-teolytically cleaving fVa heavy chain at Arg(506), Arg(306), and Arg(679). Factor Xa (fXa) protects fVa from inactivation by APC. To test the hypothesis that fXa and APC share overlapping fVa binding sites, 15 amino acid-overlapping peptides representing the heavy chain (residues 1-709) of fVa were screened for inhibition of fVa inactivation by APC. As reported, VP311-325, a peptide comprising residues 311-325 in fVa, dose-dependently and potently inhibited fVa-dependent prothrombin activation by fXa in the absence of APC. This peptide also inhibited the inactivation of fVa by APC, suggesting that this region of fVa interacts with APC. The peptide inhibited the APC-dependent cleavage of both Arg(506) and Arg(306) because inhibition was observed with plasma-derived fVa and recombinant R506Q and RR306/679QQ fVa. VP311-325 altered the fluorescence emission of dansyl-active site-labeled APC(i) but not a dansyl-active site-labeled thrombin control, showing that the peptide binds to APCi. This peptide also inhibited the resonance energy transfer between membrane-bound fluorescein-labeled fVa (donor) and rhodamine-active site-labeled S360C-APC (acceptor). These data suggest that peptide VP311-325 represents both an APC and fXa binding region in fVa.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jgriffin@scripps.edu		Griffin, John/0000-0002-4302-2547				Autin L, 2006, PROTEINS, V63, P440, DOI 10.1002/prot.20848; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; Friedrich U, 2001, J BIOL CHEM, V276, P24122, DOI 10.1074/jbc.M011567200; Gale AJ, 2000, BLOOD, V96, P585; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Heeb MJ, 1999, EUR J BIOCHEM, V260, P64, DOI 10.1046/j.1432-1327.1999.00137.x; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; Koppaka V, 1996, BIOPHYS J, V70, P2930, DOI 10.1016/S0006-3495(96)79863-6; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LU RL, 1989, J BIOL CHEM, V264, P12956; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Nicolaes GAF, 2002, ARTERIOSCL THROM VAS, V22, P530, DOI 10.1161/01.ATV.0000012665.51263.B7; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; Norstrom EA, 2006, J BIOL CHEM, V281, P31486, DOI 10.1074/jbc.M606441200; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; Steen M, 2002, J BIOL CHEM, V277, P50022, DOI 10.1074/jbc.M205609200; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; YE J, 1991, J BIOL CHEM, V266, P23016; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1; Yegneswaran S, 2004, J BIOL CHEM, V279, P49019, DOI 10.1074/jbc.M406645200	34	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28353	28361		10.1074/jbc.M704316200	http://dx.doi.org/10.1074/jbc.M704316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17646160	hybrid			2022-12-25	WOS:000249642100009
J	Jang, BC; Sung, SH; Park, JG; Park, JW; Bae, JH; Shin, DH; Park, GY; Han, SB; Suh, SI				Jang, Byeong-Churl; Sung, Su-Haeng; Park, Jong-Gu; Park, Jong-Wook; Bae, Jae Hoon; Shin, Dong Hoon; Park, Gi-Young; Han, Seung-Bum; Suh, Seong-Il			Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL REGULATION; ENDOPLASMIC-RETICULUM; NEURONAL CELLS; MESSENGER-RNA; UP-REGULATION; KAPPA-B; PROSTAGLANDIN; ACTIVATION	COX-2 and its products, including prostaglandin E-2, are involved in many inflammatory processes. Glucosamine (GS) is an amino monosaccharide and has been widely used for alternative regimen of (osteo) arthritis. However, the mechanism of action of GS on COX-2 expression remains unclear. Here we describe a new action mechanism of glucosamine hydrochloride (GS-HCl) to tackle endogenous and agonist-driven COX-2 at protein level. GS-HCl (but not GS sulfate, N-acetyl GS, or galactosamine HCl) resulted in a shift in the molecular mass of COX-2 from 72-74 to 66-70 kDa and concomitant inhibition of prostaglandin E2 production in a concentration-dependent manner in interleukin (IL)-1 beta-treated A549 human lung epithelial cells. Remarkably, GS-HCl-mediated decrease in COX-2 molecular mass was associated with inhibition of COX-2 N-glycosylation during translation, as assessed by the effect of tunicamycin, the protein N-glycosylation inhibitor, or of cycloheximide, the translation inhibitor, on COX-2 modification. Specifically, the effect of low concentration of GS-HCl (I mm) or of tunicamycin (0.1 mu g/ml) to produce the aglycosylated COX-2 was rescued by the proteasomal inhibitor MG132 but not by the lysosomal or caspase inhibitors. However, the proteasomal inhibitors did not show an effect at 5 mm GS-HCl, which produced the aglycosylated or completely deglycosylated form of COX-2. Notably, GS-HCl (5 mm) also facilitated degradation of the higher molecular species of COX-2 in IL-1 beta-treated A549 cells that was retarded by MG132. GS-HCl (5 mm) was also able to decrease the molecular mass of endogenous and IL-1 beta- or tumor necrosis factor-a-driven COX-2 in different human cell lines, including Hep2 (bronchial) and H292 (laryngeal). However, GS-HCl did not affect COX-1 protein expression. These results demonstrate for the first time that GS-HCl inhibits COX-2 activity by preventing COX-2 co-translational N-glycosylation and by facilitating COX-2 protein turnover during translation in a proteasome-dependent manner.	Keimyung Univ, Sch Med, Chron Dis Res Ctr, Inst Med Sci, Taejon 700712, South Korea; Keimyung Univ, Sch Med, Dept Rehabil Med, Taejon 700712, South Korea; Keimyung Univ, Sch Med, Div Pulm & Dev Internal Med, Taejon 700712, South Korea	Keimyung University; Keimyung University; Keimyung University	Jang, BC (corresponding author), Keimyung Univ, Sch Med, Chron Dis Res Ctr, Inst Med Sci, 194 Dongsan-dong,Jung-gu, Taejon 700712, South Korea.	jangbc12@kmu.ac.kr; seong@dsmc.or.kr						Arias EB, 2004, DIABETES, V53, P921, DOI 10.2337/diabetes.53.4.921; Chen JJ, 2005, MOL BIOL CELL, V16, P5579, DOI 10.1091/mbc.E05-08-0778; Chen JT, 2006, INVEST OPHTH VIS SCI, V47, P664, DOI 10.1167/iovs.05-1008; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Comunale MA, 2004, PROTEOMICS, V4, P826, DOI 10.1002/pmic.200300625; D'Alessandris C, 2004, FASEB J, V18, P959, DOI 10.1096/fj.03-0725fje; DAVIDSON MB, 1994, BBA-GEN SUBJECTS, V1201, P113, DOI 10.1016/0304-4165(94)90159-7; Fenton JI, 2000, OSTEOARTHR CARTILAGE, V8, P258, DOI 10.1053/joca.1999.0299; Figueiredo-Pereira ME, 2002, J BIOL CHEM, V277, P25283, DOI 10.1074/jbc.M109145200; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIA T, 1992, P NATL ACAD SCI USA, V89, P7384; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Hua J, 2005, INFLAMM RES, V54, P127, DOI 10.1007/s00011-004-1333-6; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Largo R, 2003, OSTEOARTHR CARTILAGE, V11, P290, DOI 10.1016/S1063-4584(03)00028-1; Li GT, 2005, P NATL ACAD SCI USA, V102, P15809, DOI 10.1073/pnas.0507155102; Liu WV, 2003, CANCER RES, V63, P3632; Mbonye UR, 2006, J BIOL CHEM, V281, P35770, DOI 10.1074/jbc.M608281200; Nakamura H, 2004, CLIN EXP RHEUMATOL, V22, P293; Nemeth JF, 2001, BIOCHEMISTRY-US, V40, P3109, DOI 10.1021/bi002313c; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Qiu W, 2006, J LIPID RES, V47, P1749, DOI 10.1194/jlr.M500363-JLR200; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3263, DOI 10.1210/jc.87.7.3263; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Whelan SA, 2003, CIRC RES, V93, P1047, DOI 10.1161/01.RES.0000103190.20260.37; Williams Gary W, 2005, Curr Pain Headache Rep, V9, P377, DOI 10.1007/s11916-005-0017-4; Woo KJ, 2006, BIOCHEM BIOPH RES CO, V342, P1334, DOI 10.1016/j.bbrc.2006.02.105	38	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27622	27632		10.1074/jbc.M610778200	http://dx.doi.org/10.1074/jbc.M610778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635918	Green Published, hybrid			2022-12-25	WOS:000249455600009
J	Knappe, M; Bodevin, S; Selinka, HC; Spillmann, D; Streeck, RE; Chen, XJS; Lindahl, U; Sapp, M				Knappe, Maren; Bodevin, Sabrina; Selinka, Hans-Christoph; Spillmann, Dorothe; Streeck, Rolf E.; Chen, Xiaojiang S.; Lindahl, Ulf; Sapp, Martin			Surface-exposed amino acid residues of HPV16 l1 protein mediating interaction with cell surface heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-33; HERPES-SIMPLEX-VIRUS; MINOR CAPSID PROTEIN; INITIAL INTERACTION; GLYCOPROTEIN-C; BINDING; RECEPTOR; PARTICLES; INFECTION; GLYCOSAMINOGLYCANS	Efficient infection of cells by human papillomaviruses (HPVs) and pseudovirions requires primary interaction with cell surface proteoglycans with apparent preference for species carrying heparan sulfate (HS) side chains. To identify residues contributing to virus/cell interaction, we performed point mutational analysis of the HPV16 major capsid protein, L1, targeting surface-exposed amino acid residues. Replacement of lysine residues 278, 356, or 361 for alanine reduced cell binding and infectivity of pseudovirions. Various combinations of these amino acid exchanges further decreased cell attachment and infectivity with residual infectivity of less than 5% for the triple mutant, suggesting that these lysine residues cooperate in HS binding. Single, double, or triple exchanges for arginine did not impair infectivity, demonstrating that interaction is dependent on charge distribution rather than sequence-specific. The lysine residues are located within a pocket on the capsomere surface, which was previously proposed as the putative receptor binding site. Fab fragments of binding-neutralizing antibody H16.56E that recognize an epitope directly adjacent to lysine residues strongly reduced HS-mediated cell binding, further corroborating our findings. In contrast, mutation of basic surface residues located in the cleft between capsomeres outside this pocket did not significantly reduce interaction with HS or resulted in assembly-deficient proteins. Computer-simulated heparin docking suggested that all three lysine residues can form hydrogen bonds with 2-O-, 6-O-, and N-sulfate groups of a single HS molecule with a minimal saccharide domain length of eight monomer units. This prediction was experimentally confirmed in binding experiments using capsid protein, heparin molecules of defined length, and sulfate group modifications.	Univ Mainz, Inst Med Microbiol, D-55101 Mainz, Germany; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ So Calif, Dept Mol & Computat Biol, Los Angeles, CA 90089 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Ctr Mol & Tumor Virol,Dept MIcrobiol & Immunol, Shreveport, LA 71130 USA	Johannes Gutenberg University of Mainz; Uppsala University; University of Southern California; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Knappe, M (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, 1501 Kings Highway, Shreveport, LA 71130 USA.	msapp1@lsuhsc.edu		Selinka, Hans-Christoph/0000-0001-6112-2368	NCRR NIH HHS [P20-RR018724] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018724] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bergsdorf C, 2003, FEBS LETT, V536, P120, DOI 10.1016/S0014-5793(03)00039-5; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Booy FP, 1998, J MOL BIOL, V281, P95, DOI 10.1006/jmbi.1998.1920; Buck CB, 2005, J VIROL, V79, P2839, DOI 10.1128/JVI.79.5.2839-2846.2005; Buck CB, 2004, J VIROL, V78, P751, DOI 10.1128/JVI.78.2.751-757.2004; Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; Culp TD, 2006, J VIROL, V80, P8940, DOI 10.1128/JVI.00724-06; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Evander M, 1997, J VIROL, V71, P2449, DOI 10.1128/JVI.71.3.2449-2456.1997; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Giroglou T, 2001, VACCINE, V19, P1783, DOI 10.1016/S0264-410X(00)00370-4; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; Goodfellow IG, 2001, J VIROL, V75, P4918, DOI 10.1128/JVI.75.10.4918-4921.2001; Handa A, 2000, J GEN VIROL, V81, P2077, DOI 10.1099/0022-1317-81-8-2077; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713; Ho Y, 2005, J MOL BIOL, V349, P1060, DOI 10.1016/j.jmb.2005.04.024; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; Jackson T, 2003, VIRUS RES, V91, P33, DOI 10.1016/S0168-1702(02)00258-7; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; Kern A, 2003, J VIROL, V77, P11072, DOI 10.1128/JVI.77.20.11072-11081.2003; Klimstra WB, 1998, J VIROL, V72, P7357, DOI 10.1128/JVI.72.9.7357-7366.1998; Kreuger J, 2003, METHOD ENZYMOL, V363, P327; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Krusat T, 1997, ARCH VIROL, V142, P1247, DOI 10.1007/s007050050156; Leder C, 2001, J VIROL, V75, P9201, DOI 10.1128/JVI.75.19.9201-9209.2001; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; Mardberg K, 2002, J GEN VIROL, V83, P291, DOI 10.1099/0022-1317-83-2-291; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; Modis Y, 2002, EMBO J, V21, P4754, DOI 10.1093/emboj/cdf494; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; Opie SR, 2003, J VIROL, V77, P6995, DOI 10.1128/JVI.77.12.6995-7006.2003; Roden RBS, 1996, J VIROL, V70, P3298, DOI 10.1128/JVI.70.5.3298-3301.1996; Rommel O, 2005, J MED VIROL, V75, P114, DOI 10.1002/jmv.20245; Roth SD, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-83; Saphire ACS, 2000, J BIOL CHEM, V275, P4298, DOI 10.1074/jbc.275.6.4298; Selinka HC, 2003, J VIROL, V77, P12961, DOI 10.1128/JVI.77.24.12961-12967.2003; Selinka HC, 2002, VIROLOGY, V299, P279, DOI 10.1006/viro.2001.1493; SELINKA HC, 2003, PAPILLOMAVIRUS REP, V14, P259; Shafti-Keramat S, 2003, J VIROL, V77, P13125, DOI 10.1128/JVI.77.24.13125-13135.2003; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Tiwari V, 2004, J GEN VIROL, V85, P805, DOI 10.1099/vir.0.19641-0; Trybala E, 1996, VIROLOGY, V218, P35, DOI 10.1006/viro.1996.0163; VOLPERS C, 1994, VIROLOGY, V200, P504, DOI 10.1006/viro.1994.1213; VOLPERS C, 1995, J GEN VIROL, V76, P2661, DOI 10.1099/0022-1317-76-11-2661; VOLPERS C, 1995, J VIROL, V69, P3258, DOI 10.1128/JVI.69.6.3258-3264.1995; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Zautner AE, 2006, J VIROL, V80, P6629, DOI 10.1128/JVI.01988-05	62	100	103	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27913	27922		10.1074/jbc.M705127200	http://dx.doi.org/10.1074/jbc.M705127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17640876	hybrid			2022-12-25	WOS:000249455600040
J	Leich, F; Stohr, N; Rietz, A; Ulbrich-Hofmann, R; Arnold, U				Leich, Franziska; Stoehr, Nadine; Rietz, Anne; Ulbrich-Hofmann, Renate; Arnold, Ulrich			Endocytotic internalization as a crucial factor for the cytotoxicity of Ribonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC RIBONUCLEASE; INHIBITOR INTERACTION; BIOLOGICAL ACTIONS; CATALYTIC ACTIVITY; ANTITUMOR-ACTIVITY; STERIC BLOCKADE; CATHEPSIN-S; CELLS; RNASE; PROTEIN	The cytotoxic action of ribonucleases (RNases) requires the interaction of the enzyme with the cellular membrane, its internalization, translocation to the cytosol, and the degradation of ribonucleic acid. The interplay of these processes as well as the role of the thermodynamic and proteolytic stability, the catalytic activity, and the evasion from the intracellular ribonuclease inhibitor (RI) has not yet been fully elucidated. As cytosolic internalization is indispensable for the cytotoxicity of extracellular ribonucleases, we investigated the extent of cytosolic internalization of a cytotoxic, RI-evasive RNase A variant (G88R-RNase A) and of various similarly cytotoxic but RI-sensitive RNase A tandem enzyme variants in comparison to the internalization of the non-cytotoxic and RI-sensitive RNase A. After incubation of K-562 cells with the RNase A variants for 36 h, the internalized amount of RNases was analyzed by rapid cell disruption followed by subcellular fractionation and semiquantitative immunoblotting. The data indicate that an enhanced cellular uptake and an increased entry of the RNases into the cytosol can outweigh the abolishment of catalytic activity by RI. As all RNase A variants proved to be resistant to the proteases present in the different subcellular fractions for more than 100 h, our results suggest that the cytotoxic potency of RNases is determined by an efficient internalization into the cytosol.	Univ Halle Wittenberg, Dept Biochem & Biotechnol, Halle, Germany; Univ Halle Wittenberg, Inst Biochem & Biotechnol, D-06120 Halle, Germany; Univ Halle Wittenberg, Interdisciplinary Ctr Appl Med & Human Biol Res, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Arnold, U (corresponding author), Univ Halle Wittenberg, Dept Biochem & Biotechnol, Kurt-Mothes Str 3, Halle, Germany.	ulrich.arnold@biochemtech.uni-halle.de						Arnold U, 2006, BIOTECHNOL LETT, V28, P1615, DOI 10.1007/s10529-006-9145-0; Benito A, 2005, MOL BIOSYST, V1, P294, DOI 10.1039/b502847g; BOHLEY P, 1969, FEBS LETT, V5, P233, DOI 10.1016/0014-5793(69)80341-8; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Bosch M, 2004, BIOCHEMISTRY-US, V43, P2167, DOI 10.1021/bi035729+; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; De Lorenzo C, 2002, FEBS LETT, V516, P208, DOI 10.1016/S0014-5793(02)02527-9; De Lorenzo C, 2007, FEBS LETT, V581, P296, DOI 10.1016/j.febslet.2006.12.034; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; Ellis RJ, 2006, BIOL CHEM, V387, P485, DOI 10.1515/BC.2006.064; Fuchs SM, 2005, PROTEIN SCI, V14, P1538, DOI 10.1110/ps.051393805; Futami J, 2005, J BIOSCI BIOENG, V99, P95, DOI 10.1263/jbb.99.95; Futami J, 2001, BIOCHEMISTRY-US, V40, P7518, DOI 10.1021/bi010248g; Gaur D, 2001, J BIOL CHEM, V276, P24978, DOI 10.1074/jbc.M102440200; Haigis MC, 2003, J CELL SCI, V116, P313, DOI 10.1242/jcs.00214; Krauss J, 2005, BIOCHEM BIOPH RES CO, V331, P595, DOI 10.1016/j.bbrc.2005.03.215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; Lee JE, 2005, BIOCHEMISTRY-US, V44, P15760, DOI 10.1021/bi051668z; Leich F, 2006, J MOL BIOL, V358, P1305, DOI 10.1016/j.jmb.2006.03.007; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Libonati M, 2004, BIOCHEM J, V380, P311, DOI 10.1042/BJ20031922; Makarov AA, 2003, FEBS LETT, V540, P15, DOI 10.1016/S0014-5793(03)00225-4; Matousek J, 2003, J BIOL CHEM, V278, P23817, DOI 10.1074/jbc.M302711200; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Monti DM, 2004, J BIOL CHEM, V279, P39195, DOI 10.1074/jbc.C400311200; Naddeo N, 2005, FEBS LETT, V579, P2663, DOI 10.1016/j.febslet.2005.03.087; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; Newton DL, 1997, PROTEIN ENG, V10, P463, DOI 10.1093/protein/10.4.463; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; Newton DL, 2001, CRIT REV ONCOL HEMAT, V39, P79, DOI 10.1016/S1040-8428(01)00116-0; Pavlakis N, 2006, EXPERT OPIN BIOL TH, V6, P391, DOI 10.1517/14712598.6.4.391; Piccoli R, 1999, P NATL ACAD SCI USA, V96, P7768, DOI 10.1073/pnas.96.14.7768; Pouckova P, 2006, NEOPLASMA, V53, P79; Rodriguez M, 2007, J CELL SCI, V120, P1405, DOI 10.1242/jcs.03427; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Schmid H, 1997, BIOL CHEM, V378, P61, DOI 10.1515/bchm.1997.378.2.61; SCHMID H, 1993, RENAL PHYSIOL BIOCH, V16, P222; Schmid H, 2002, BIOL CHEM, V383, P1277, DOI 10.1515/BC.2002.143; Schroter CJ, 1999, J IMMUNOL METHODS, V227, P161, DOI 10.1016/S0022-1759(99)00079-4; Smith MR, 1999, EXP CELL RES, V247, P220, DOI 10.1006/excr.1998.4317; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; Tada H, 2004, FEBS LETT, V568, P39, DOI 10.1016/j.febslet.2004.05.007; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	50	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27640	27646		10.1074/jbc.M702240200	http://dx.doi.org/10.1074/jbc.M702240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635931	hybrid			2022-12-25	WOS:000249455600011
J	Lewis, AL; Cao, H; Patel, SK; Diaz, S; Ryan, W; Carlin, AF; Thon, V; Lewis, WG; Varki, A; Chen, X; Nizet, V				Lewis, Amanda L.; Cao, Hongzhi; Patel, Silpa K.; Diaz, Sandra; Ryan, Wesley; Carlin, Aaron F.; Thon, Vireak; Lewis, Warren G.; Varki, Ajit; Chen, Xi; Nizet, Victor			NeuA sialic acid O-acetylesterase activity modulates O-acetylation of capsular polysaccharide in Group B Streptococcus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; CHEMOENZYMATIC SYNTHESIS; PSEUDOMONAS-AERUGINOSA; SOMATIC ANTIGENS; SERUM RESISTANCE; FORM VARIATION; C3 DEPOSITION; SEROGROUP-Y; SYNTHETASE; GENE	Group B Streptococcus (GBS) is a common cause of neonatal sepsis and meningitis. A major GBS virulence determinant is its sialic acid (Sia)-capped capsular polysaccharide. Recently, we discovered the presence and genetic basis of capsular Sia O-acetylation in GBS. We now characterize a GBS Sia O-acetylesterase that modulates the degree of GBS surface O-acetylation. The GBS Sia O-acetylesterase operates cooperatively with the GBS CMP-Sia synthetase, both part of a single polypeptide encoded by the neuA gene. NeuA de-O-acetylation of free 9-O-acetyl-N-acetylneuraminic acid (Neu5,9AC(2)) was enhanced by CTP and Mg2+, the substrate and co-factor, respectively, of the N-terminal GBS CMP-Sia synthetase domain. In contrast, the homologous bifunctional NeuA esterase from Escherichia coli K1 did not display cofactor dependence. Further analyses showed that in vitro, GBS NeuA can operate via two alternate enzymatic pathways: de-O-acetylation of Neu5,9AC(2) followed by CMP activation of Neu5Ac or activation of Neu5,9AC(2) followed by de-O-acetylation of CMP-Neu5,9AC(2). Consistent with in vitro esterase assays, genetic deletion of GBS neuA led to accumulation of intracellular O-acetylated Sias, and overexpression of GBS NeuA reduced O-acetylation of Sias on the bacterial surface. Site-directed mutagenesis of conserved asparagine residue 301 abolished esterase activity but preserved CMP-Sia synthetase activity, as evidenced by hyper-O-acetylation of capsular polysaccharide Sias on GBS expressing only the N301A NeuAallele. These studies demonstrate a novel mechanism regulating the extent of capsular Sia O-acetylation in intact bacteria and provide a genetic strategy for manipulating GBS O-acetylation in order to explore the role of this modification in GBS pathogenesis and immunogenicity.	Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA USA; Univ Calif San Diego, Dept Med, La Jolla, CA USA; Univ Calif San Diego, Sch Med, Dept Cell & Mol Med, La Jolla, CA USA; Univ Calif San Diego, Skaggs Res Inst, Dept Biochem, La Jolla, CA 92037 USA; Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Novartis; University of California System; University of California Davis	Varki, A (corresponding author), Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.	a1varki@ucsd.edu	Carlin, Aaron/AAK-3806-2021; Nizet, Victor/AAF-3190-2019; Chen, Xi/H-1811-2018; Lewis, Warren G/W-4369-2019	Chen, Xi/0000-0002-3160-614X; Lewis, Warren G/0000-0003-1210-6403; CAO, HONGZHI/0000-0003-4736-3143; Nizet, Victor/0000-0003-3847-0422; Lewis, Amanda/0000-0001-6195-3030	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD051796] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373, R01GM076360, R37GM032373] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL57345, P01 HL057345] Funding Source: Medline; NICHD NIH HHS [R01-HD051796, R01 HD051796] Funding Source: Medline; NIGMS NIH HHS [R01 GM032373, GM32373, R01 GM076360-02, R01 GM076360, R01-GM076360, R37 GM032373] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoh CC, 2004, PROG LIPID RES, V43, P534, DOI 10.1016/j.plipres.2004.09.002; AMBROSE MG, 1992, BIOCHEMISTRY-US, V31, P775, DOI 10.1021/bi00118a019; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Aoyagi Y, 2005, J IMMUNOL, V174, P418, DOI 10.4049/jimmunol.174.1.418; BAKER CJ, 1976, NEW ENGL J MED, V294, P753, DOI 10.1056/NEJM197604012941404; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; BUTOR C, 1993, J BIOL CHEM, V268, P10197; Carlin AF, 2007, J BACTERIOL, V189, P1231, DOI 10.1128/JB.01155-06; Chaffin DO, 2000, J BACTERIOL, V182, P4466, DOI 10.1128/JB.182.16.4466-4477.2000; Chaffin DO, 2002, MOL MICROBIOL, V45, P109, DOI 10.1046/j.1365-2958.2002.02988.x; Charland N, 1996, FEMS IMMUNOL MED MIC, V14, P195, DOI 10.1111/j.1574-695X.1996.tb00287.x; Claus H, 2004, MOL MICROBIOL, V51, P227, DOI 10.1046/j.1365-2958.2003.03819.x; Daines DA, 2000, FEMS MICROBIOL LETT, V189, P281, DOI 10.1111/j.1574-6968.2000.tb09244.x; Deszo EL, 2005, P NATL ACAD SCI USA, V102, P5564, DOI 10.1073/pnas.0407428102; Edwards M, 2006, INFECTIOUS DIS FETUS, P404; EDWARDS MS, 1982, J IMMUNOL, V128, P1278; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; Fahr C, 2001, J INVEST DERMATOL, V116, P254, DOI 10.1046/j.1523-1747.2001.01237.x; Feng L, 2005, J BACTERIOL, V187, P758, DOI 10.1128/JB.187.2.758-764.2005; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; GANGULI S, 1994, J BACTERIOL, V176, P4583, DOI 10.1128/JB.176.15.4583-4589.1994; Haft RF, 1996, MOL MICROBIOL, V19, P555, DOI 10.1046/j.1365-2958.1996.395931.x; Hammerschmidt S, 1996, MOL MICROBIOL, V20, P1211, DOI 10.1111/j.1365-2958.1996.tb02641.x; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HUESO P, 1988, ITAL J BIOCHEM, V37, P302; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Jurcisek J, 2005, INFECT IMMUN, V73, P3210, DOI 10.1128/IAI.73.6.3210-3218.2005; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KEAN EL, 1966, J BIOL CHEM, V241, P5643; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIREL YA, 1994, EUR J BIOCHEM, V221, P239, DOI 10.1111/j.1432-1033.1994.tb18734.x; KNIREL YA, 1986, EUR J BIOCHEM, V157, P129, DOI 10.1111/j.1432-1033.1986.tb09648.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Krishna M, 1997, J EXP MED, V185, P1997, DOI 10.1084/jem.185.11.1997; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; Lewis AL, 2006, J BIOL CHEM, V281, P11186, DOI 10.1074/jbc.M513772200; Lewis AL, 2004, P NATL ACAD SCI USA, V101, P11123, DOI 10.1073/pnas.0403010101; Liu GC, 2004, J BIOL CHEM, V279, P17738, DOI 10.1074/jbc.M400143200; Lo YC, 2003, J MOL BIOL, V330, P539, DOI 10.1016/S0022-2836(03)00637-5; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MARQUES MB, 1992, INFECT IMMUN, V60, P3986, DOI 10.1128/IAI.60.10.3986-3993.1992; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; Paoletti LC, 2003, EXPERT OPIN BIOL TH, V3, P975, DOI 10.1517/14712598.3.6.975; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Shen YQ, 2004, BIOL CHEM, V385, P145, DOI 10.1515/BC.2004.033; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; STEENBERGEN SM, 1990, MOL MICROBIOL, V4, P603, DOI 10.1111/j.1365-2958.1990.tb00629.x; Steenbergen SM, 2006, J BACTERIOL, V188, P6195, DOI 10.1128/JB.00466-06; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; VANN WF, 1978, J BACTERIOL, V133, P1300, DOI 10.1128/JB.133.3.1300-1306.1978; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1985, J BIOL CHEM, V260, P6600; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Vogel U, 1997, INFECT IMMUN, V65, P4022, DOI 10.1128/IAI.65.10.4022-4029.1997; WESSELS MR, 1989, P NATL ACAD SCI USA, V86, P8983, DOI 10.1073/pnas.86.22.8983; Yu H, 2006, BIOTECHNOL LETT, V28, P107, DOI 10.1007/s10529-005-4955-z; Yu H, 2004, BIOORGAN MED CHEM, V12, P6427, DOI 10.1016/j.bmc.2004.09.030; Yu H, 2006, ANGEW CHEM INT EDIT, V45, P3938, DOI 10.1002/anie.200600572	61	42	45	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27562	27571		10.1074/jbc.M700340200	http://dx.doi.org/10.1074/jbc.M700340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17646166	Green Accepted, hybrid			2022-12-25	WOS:000249455600003
J	Gills, JJ; Castillo, SS; Zhang, CY; Petukhov, PA; Memmott, RM; Hollingshead, M; Warfel, N; Han, JH; Kozikowski, AP; Dennis, PA				Gills, Joell J.; Castillo, S. Sianna; Zhang, Chunyu; Petukhov, Pavel A.; Memmott, Regan M.; Hollingshead, Melinda; Warfel, Noel; Han, Jiahuai; Kozikowski, Alan P.; Dennis, Phillip A.			Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38 alpha, through MKK3/6-independent and -dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; PLECKSTRIN HOMOLOGY DOMAIN; CYCLE CHECKPOINT PATHWAY; PROTEIN-KINASE; CANCER-CELLS; SIGNAL-TRANSDUCTION; ANTITUMOR-ACTIVITY; APOPTOSIS; IMATINIB; AUTOPHOSPHORYLATION	Previously, we identified five active phosphatidylinositol ether lipid analogues (PIAs) that target the pleckstrin homology domain of Akt and selectively induce apoptosis in cancer cells with high levels of Akt activity. To examine specificity, PIAs were screened against a panel of 29 purified kinases. No kinase was inhibited, but one isoform of p38, p38 alpha, was uniformly activated 2-fold. Molecular modeling of p38 alpha revealed the presence of two regions that could interact with PIAs, one in the activation loop and a heretofore unappreciated region in the upper lobe that resembles a pleckstrin homology domain. In cells, two phases of activation were observed, an early phase that was independent of the upstream kinase MKK3/6 and inhibited by the p38 inhibitor SB203580 and a latter phase that was coincident with MKK3/6 activation. In short term xenograft experiments that employed immunohistochemistry and immunoblotting, PIA administration increased phosphorylation of p38 but not MKK3/6 in tumors in a statistically significant manner. Although PIAs rapidly activated p38 with similar time and dose dependence as Akt inhibition, p38 activation and Akt inhibition were independent events induced by PIAs. Using SB203580 or p38 alpha(-/-) cells, we showed that p38 alpha is not required for PIA-induced apoptosis but is required forH(2)O(2)- and anisomycin-induced apoptosis. Nonetheless, activation of p38a contributes to PIA-induced apoptosis, because reconstitution of p38a into p38 alpha(-/-) cells increased apoptosis. These studies indicate that p38 alpha is activated by PIAs through a novel mechanism and show that p38 alpha activation contributes to PIA-induced cell death. Independent modulation of Akt and p38 alpha could account for the profound cytotoxicity of PIAs.	NIH, NCI, Ctr Canc Res, Med Oncol Branch, Bethesda, MD 20889 USA; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; NIH, NCI, Div Canc Treatment & Diagnosis, Dev Therapeut Program, Frederick, MD 21701 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Scripps Research Institute	Dennis, PA (corresponding author), NIH, NCI, Ctr Canc Res, Med Oncol Branch, Bethesda, MD 20889 USA.	pdennis@nih.gov	Zhang, Chun-yu/HDP-5776-2022; Han, J/G-4671-2010	Memmott, Regan/0000-0001-5881-9252; Warfel, Noel/0000-0001-6410-9011	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01 CO 12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010450] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; CANMAN CE, 1994, CANCER RES, V54, P5054; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Castillo SS, 2004, CANCER RES, V64, P2782, DOI 10.1158/0008-5472.CAN-03-1530; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diskin R, 2004, J BIOL CHEM, V279, P47040, DOI 10.1074/jbc.M404595200; Diskin R, 2007, J MOL BIOL, V365, P66, DOI 10.1016/j.jmb.2006.08.043; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Gills JJ, 2006, MOL CANCER THER, V5, P713, DOI 10.1158/1535-7163.MCT-05-0484; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Habiro A, 2004, BIOCHEM BIOPH RES CO, V316, P71, DOI 10.1016/j.bbrc.2004.02.017; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kumar P, 2004, J BIOL CHEM, V279, P43352, DOI 10.1074/jbc.M405777200; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Meuillet EJ, 2004, ONCOL RES, V14, P513, DOI 10.3727/0965040042380487; Meuillet EJ, 2003, MOL CANCER THER, V2, P389; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Warfel NA, 2006, CLIN CANCER RES, V12, P3502, DOI 10.1158/1078-0432.CCR-05-1837; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	40	45	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27020	27029		10.1074/jbc.M701108200	http://dx.doi.org/10.1074/jbc.M701108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17631503	hybrid			2022-12-25	WOS:000249304900043
J	Sinani, D; Adle, DJ; Kim, H; Lee, J				Sinani, Devis; Adle, David J.; Kim, Heejeong; Lee, Jaekwon			Distinct mechanisms for ctr1-mediated copper and cisplatin transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; OVARIAN-CARCINOMA CELLS; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; CELLULAR PHARMACOLOGY; WILSON-DISEASE; HUMAN CTR1; YEAST	The Ctr1 family of integral membrane proteins is necessary for high affinity copper uptake in eukaryotes. Ctr1 is also involved in cellular accumulation of cisplatin, a platinum-based anticancer drug. Although the physiological role of Ctr1 has been revealed, the mechanism of action of Ctr1 remains to be elucidated. To gain a better understanding of Ctr1-mediated copper and cisplatin transport, we have monitored molecular dynamics and transport activities of yeast Saccharomyces cerevisiae Ctr1 and its mutant alleles. Co-expression of functional Ctr1 monomers fused with either cyan or yellow fluorescent protein resulted in fluorescence resonance energy transfer ( FRET), which is consistent with multimer assembly of Ctr1. Copper near the Km value of Ctr1 enhanced FRET in a manner that correlated with cellular copper transport. In vitro crosslinking of Ctr1 confirmed that copper-induced FRET reflects conformational changes within pre-existing Ctr1 complexes. FRET assays in membrane-disrupted cells and protein extracts showed that intact cell structure is necessary for Ctr1 activity. Despite Ctr1-dependent cellular accumulation, cisplatin did not change Ctr1 FRET nor did it attenuate copper-induced FRET. A Ctr1 allele defective in copper transport enhanced cellular cisplatin accumulation. N-terminal methionine-rich motifs that are dispensable for copper transport play a critical role for cisplatin uptake. Taken together, our data reveal functional roles for structural remodeling of the Ctr1 multimeric complex in copper transport and suggest distinct mechanisms employed by Ctr1 for copper and cisplatin transport.	Univ Nebraska, Dept Biochem, Redox Biol Ctr, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Lee, J (corresponding author), Univ Nebraska, Dept Biochem, Redox Biol Ctr, N210 Beadle Ctr, Lincoln, NE 68588 USA.	jlee7@unlnotes.unl.edu			NCRR NIH HHS [P20 RR 17675] Funding Source: Medline; NIDDK NIH HHS [R01 DK079209, DK 79209] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK079209] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aller SG, 2006, P NATL ACAD SCI USA, V103, P3627, DOI 10.1073/pnas.0509929103; Aller SG, 2004, J BIOL CHEM, V279, P53435, DOI 10.1074/jbc.M409421200; Ausubel F.M., 1987, CURRENT PROTOCOL MOL; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Cerpa Waldo, 2005, Molecular Aspects of Medicine, V26, P405, DOI 10.1016/j.mam.2005.07.011; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; De Freitas J, 2003, BIOMETALS, V16, P185, DOI 10.1023/A:1020771000746; DEROME L, 1987, FEMS MICROBIOL LETT, V43, P283, DOI 10.1016/0378-1097(87)90413-7; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; Eisses JF, 2005, J BIOL CHEM, V280, P37159, DOI 10.1074/jbc.M508822200; Eisses JF, 2005, J BIOL CHEM, V280, P9635, DOI 10.1074/jbc.M500116200; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; FARNWORTH PG, 1989, CHEM-BIOL INTERACT, V69, P319, DOI 10.1016/0009-2797(89)90118-X; Giaccone G, 2000, DRUGS, V59, P9, DOI 10.2165/00003495-200059004-00002; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Guo Y, 2004, J BIOL CHEM, V279, P46393, DOI 10.1074/jbc.M407777200; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Holzer AK, 2004, CLIN CANCER RES, V10, P6744, DOI 10.1158/1078-0432.CCR-04-0748; Holzer AK, 2004, MOL PHARMACOL, V66, P817, DOI 10.1124/mol.104.001198; Holzer AK, 2006, CANCER RES, V66, P10944, DOI 10.1158/0008-5472.CAN-06-1710; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Jiang JF, 2005, INORG CHEM, V44, P9787, DOI 10.1021/ic051180m; Kaler SG, 1998, AM J CLIN NUTR, V67, p1029S, DOI 10.1093/ajcn/67.5.1029S; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Komatsu M, 2000, CANCER RES, V60, P1312; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Lee SH, 2006, INTERMETALLICS, V14, P1, DOI 10.1016/j.intermet.2005.02.010; Lin XJ, 2002, MOL PHARMACOL, V62, P1154, DOI 10.1124/mol.62.5.1154; Linder M, 1991, BIOCH COPPER; MEHRA RK, 1991, J CELL BIOCHEM, V45, P30, DOI 10.1002/jcb.240450109; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; O'Dwyer PJ, 2000, DRUGS, V59, P19, DOI 10.2165/00003495-200059004-00003; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rees EM, 2004, J BIOL CHEM, V279, P54221, DOI 10.1074/jbc.M411669200; Safaei R, 2005, CRIT REV ONCOL HEMAT, V53, P13, DOI 10.1016/j.critrevonc.2004.09.007; Samimi G, 2004, MOL PHARMACOL, V66, P25, DOI 10.1124/mol.66.1.25; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Singh A, 2006, J BIOL CHEM, V281, P13355, DOI 10.1074/jbc.M512042200; Uriu-Adams Janet Y., 2005, Molecular Aspects of Medicine, V26, P268, DOI 10.1016/j.mam.2005.07.015; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; ZELAZOWSKI AJ, 1984, ARCH BIOCHEM BIOPHYS, V229, P246; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	76	83	88	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26775	26785		10.1074/jbc.M703973200	http://dx.doi.org/10.1074/jbc.M703973200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627943	hybrid, Green Published			2022-12-25	WOS:000249304900017
J	Evdokimov, AA; Sclavi, B; Zinoviev, VV; Malygin, EG; Hattman, S; Buckle, M				Evdokimov, Alexey A.; Sclavi, Bianca; Zinoviev, Victor V.; Malygin, Ernst G.; Hattman, Stanley; Buckle, Malcolm			Study of bacteriophage T4-encoded dam DNA (Adenine-N-6)-methyltransferase binding with substrates by rapid laser UV cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-STEADY-STATE; ESCHERICHIA-COLI; PHAGE-T4 DNA; FLUORESCENCE SPECTROSCOPY; METHYLTRANSFERASE; METHYLATION; RECOGNITION; BASE; IDENTIFICATION; SEQUENCE	DNA methyltransferases of the Dam family ( including bacteriophage T4-encoded Dam DNA (adenine- N-6)-methyltransferase ( T4Dam)) catalyze methyl group transfer from S-adenosyl-L-methionine ( AdoMet), producing S-adenosyl-Lhomocysteine ( AdoHcy) and methylated adenine residues in palindromic GATC sequences. In this study, we describe the application of direct ( i. e. no exogenous cross-linking reagents) laser UV cross-linking as a universal non-perturbing approach for studying the characteristics of T4Dam binding with substrates in the equilibrium and transient modes of interaction. UV irradiation of the enzyme center dot substrate complexes using an Nd3(+): yttrium aluminum garnet laser at 266nm resulted in up to 3 and > 15% yields of direct T4Dam cross-linking to DNA and AdoMet, respectively. Consequently, we were able to measure equilibrium constants and dissociation rates for enzyme center dot substrate complexes. In particular, we demonstrate that both reaction substrates, specific DNA and AdoMet( or product AdoHcy), stabilized the ternary complex. The improved substrate affinity for the enzyme in the ternary complex significantly reduced dissociation rates ( up to 2 orders of magnitude). Several of the parameters obtained ( such as dissociation rate constants for the binary T4Dam center dot AdoMet complex and for enzyme complexes with a non-fluorescent hemimethylated DNA duplex) were previously inaccessible by other means. However, where possible, the results of laser UV cross-linking were compared with those of fluorescence analysis. Our study suggests that rapid laser UV cross-linking efficiently complements standard DNA methyltransferase-related tools and is a method of choice to probe enzyme-substrate interactions in cases in which data cannot be acquired by other means.	Fedral State Res Inst State Res Ctr Virol & Biote, Novosibirsk 630559, Russia; Ecole Normale Super, CNRS, Lab Biotechnol & Pharmacol Genet Appliq, UMR 8113, F-94235 Cachan, France; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	State Research Center of Virology & Biotechnology VECTOR; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; University of Rochester	Buckle, M (corresponding author), Fedral State Res Inst State Res Ctr Virol & Biote, Novosibirsk 630559, Russia.	buckle@lbpa.ens-cachan.fr	Sclavi, Bianca/AAT-4554-2021; Ernst, Malygin/A-6741-2014; Evdokimov, Alexey/A-6485-2014; sclavi, bianca/F-8536-2010	Sclavi, Bianca/0000-0002-3883-8592; 	FIC NIH HHS [TW05755] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005755] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Adams GM, 1997, BIOCHEMISTRY-US, V36, P8284, DOI 10.1021/bi961885n; AHMAD I, 1994, GENE, V142, P67, DOI 10.1016/0378-1119(94)90356-5; Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; Beck C, 2002, BIOCHEMISTRY-US, V41, P14103, DOI 10.1021/bi025979a; Bheemanaik S, 2006, BIOCHEM J, V399, P177, DOI 10.1042/BJ20060854; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; Casadesus J, 2006, MICROBIOL MOL BIOL R, V70, P830, DOI 10.1128/MMBR.00016-06; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; COPELAND RA, 2000, ENZYMES PRCTICAL INT; Dimitrov SI, 2000, METH MOL B, V148, P395; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; Fersht A., 1985, ENZYME STRUCTURE MEC; FINTA C, 1995, GENE, V164, P65, DOI 10.1016/0378-1119(95)00439-D; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hattman S, 2004, PROG NUCLEIC ACID RE, V77, P67, DOI 10.1016/S0079-6603(04)77003-8; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; Holz B, 1999, J BIOL CHEM, V274, P15066, DOI 10.1074/jbc.274.21.15066; Horton JR, 2006, J MOL BIOL, V358, P559, DOI 10.1016/j.jmb.2006.02.028; Horton JR, 2005, CELL, V121, P349, DOI 10.1016/j.cell.2005.02.021; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; Liebert K, 2004, J MOL BIOL, V341, P443, DOI 10.1016/j.jmb.2004.05.033; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; MAEGLEY KA, 1992, J BIOL CHEM, V267, P18527; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Malygin EG, 1999, NUCLEIC ACIDS RES, V27, P1135, DOI 10.1093/nar/27.4.1135; Malygin EG, 1997, NUCLEIC ACIDS RES, V25, P4393, DOI 10.1093/nar/25.21.4393; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; Malygin EG, 2004, J BIOL CHEM, V279, P50012, DOI 10.1074/jbc.M409786200; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; Mashhoon N, 2004, J BIOL CHEM, V279, P52075, DOI 10.1074/jbc.M408182200; Mashhoon N, 2006, J BIOMOL SCREEN, V11, P497, DOI 10.1177/1087057106287933; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; Pingoud V, 2005, MOL BIOSYST, V1, P135, DOI 10.1039/b503091a; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; POWELL LM, 1993, J MOL BIOL, V234, P60, DOI 10.1006/jmbi.1993.1563; REICH NO, 1990, J BIOL CHEM, V265, P8929; SCHLAGMAN SL, 1983, GENE, V22, P139, DOI 10.1016/0378-1119(83)90098-7; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SOM S, 1990, J BIOL CHEM, V265, P4278; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3962, DOI 10.1093/nar/28.20.3962; Tuzikov FV, 1997, MOL BIOL+, V31, P73; Urig S, 2002, J MOL BIOL, V319, P1085, DOI 10.1016/S0022-2836(02)00371-6; Vilkaitis G, 2000, J BIOL CHEM, V275, P38722, DOI 10.1074/jbc.M005278200; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WENZEL C, 1993, NUCLEIC ACIDS RES, V21, P4604, DOI 10.1093/nar/21.19.4604; Wong DL, 2000, BIOCHEMISTRY-US, V39, P15410, DOI 10.1021/bi001164v; Yang Z, 2003, NAT STRUCT BIOL, V10, P849, DOI 10.1038/nsb973; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481; Zinoviev VV, 2003, J BIOL CHEM, V278, P7829, DOI 10.1074/jbc.M210769200	54	6	6	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26067	26076		10.1074/jbc.M700866200	http://dx.doi.org/10.1074/jbc.M700866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17630395	hybrid			2022-12-25	WOS:000249239600010
J	Genge, BR; Wu, LNY; Wuthier, RE				Genge, Brian R.; Wu, Licia N. Y.; Wuthier, Roy E.			In vitro Modeling of matrix vesicle nucleation - Synergistic stimulation of mineral formation by annexin a5 and phosphatidylserine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-PLATE CARTILAGE; PHOSPHOLIPID-PHOSPHATE COMPLEXES; AMORPHOUS CALCIUM-PHOSPHATE; EPIPHYSEAL CARTILAGE; X COLLAGEN; OCTACALCIUM PHOSPHATE; CRYSTAL-STRUCTURE; LIPID-COMPOSITION; MEMBRANE-BINDING; CALCIFICATION	Annexins A5, A2, and A6 ( Anx-A5, -A2, and -A6) are quantitatively major proteins of the matrix vesicle nucleational core that is responsible for mineral formation. Anx-A5 significantly activated the induction and propagation of mineral formation when incorporated into synthetic nucleation complexes made of amorphous calcium phosphate ( ACP) and Anx-A5 or of phosphatidylserine ( PS) plus ACP ( PS-CPLX) and Anx-A5. Incorporation of Anx-A5 markedly shortened the induction time, greatly increasing the rate and overall amount of mineral formed when incubated in synthetic cartilage lymph. Constructed by the addition of Ca2(+) to PS, emulsions prepared in an intracellular phosphate buffer matched in ionic composition to the intracellular fluid of growth plate chondrocytes, these bio-mimetic PS- CPLX nucleators had little nucleational activity. However, incorporation of Anx-A5 transformed them into potent nucleators, with significantly greater activity than those made from ACP without PS. The ability of Anx-A5 to enhance the nucleation and growth of mineral appears to stem from its ability to form two-dimensional crystalline arrays on PS- containing monolayers. However, some stimulatory effect also may result from its ability to exclude Mg2(+) and HCO3- from nucleation sites. Comparing the various annexins for their ability to activate PS- CPLX nucleation yields the following: avian cartilage Anx-A5 > human placental Anx-A5 > avian liver Anx-A5 >= avian cartilage Anx-A6 >> cartilage Anx-A2. The stimulatory effect of human placental Anx-A5 and avian cartilage Anx-A6 depended on the presence of PS, since in its absence they either had no effect or actually inhibited the nucleation activity of ACP. Anx-A2 did not significantly enhance mineralization.	Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Wuthier, RE (corresponding author), Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, 631 Sumter St, Columbia, SC 29208 USA.	wuthier@mail.chem.sc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983, R01AR042359] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42359, AR18983] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON MB, 1964, J BIOL CHEM, V239, P70; ALI SY, 1970, P NATL ACAD SCI USA, V67, P1513, DOI 10.1073/pnas.67.3.1513; ANDERSON HC, 1988, RHEUM DIS CLIN N AM, V14, P303; ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81; ANDERSON HC, 1984, SCANNING ELECTRON MI, V2, P953; ANGHILERI LJ, 1972, EXPERIENTIA, V28, P1086, DOI 10.1007/BF01918690; Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; ARSENAULT AL, 1988, CALCIFIED TISSUE INT, V42, P119, DOI 10.1007/BF02556344; Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Avila-Sakar AJ, 2000, J STRUCT BIOL, V130, P54, DOI 10.1006/jsbi.2000.4246; Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; BLUMENTHAL NC, 1977, CALC TISS RES, V23, P245, DOI 10.1007/BF02012793; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; BOSKEY AL, 1978, P SOC EXP BIOL MED, V157, P590; BOYAN BD, 1984, CALCIFIED TISSUE INT, V36, P214, DOI 10.1007/BF02405320; BOYANSALYERS BD, 1980, CALCIFIED TISSUE INT, V30, P167, DOI 10.1007/BF02408622; Brachvogel B, 2003, MOL CELL BIOL, V23, P2907, DOI 10.1128/MCB.23.8.2907-2913.2003; BRECEVIC L, 1972, CALC TISS RES, V10, P82, DOI 10.1007/BF02012538; BROWN WE, 1962, NATURE, V196, P1048, DOI 10.1038/1961048b0; Capila I, 2001, STRUCTURE, V9, P57, DOI 10.1016/S0969-2126(00)00549-9; Chernov AA, 1998, ACTA CRYSTALLOGR A, V54, P859, DOI 10.1107/S0108767398008587; COTMORE JM, 1971, SCIENCE, V172, P1339, DOI 10.1126/science.172.3990.1339; DEMEL RA, 1987, BIOCHEMISTRY-US, V26, P8659, DOI 10.1021/bi00400a025; Fernandez ME, 2003, ACTA CRYSTALLOGR B, V59, P175, DOI 10.1107/S0108768103002167; FOLITO E, 2006, FASEB J, V20, P1498; Freye-Minks C, 2003, BIOCHEMISTRY-US, V42, P620, DOI 10.1021/bi026742h; GENGE BR, 1992, J BONE MINER RES, V7, P807, DOI 10.1002/jbmr.5650070710; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GENGE BR, 1991, J BIOL CHEM, V266, P10678; Genge BR, 2007, ANAL BIOCHEM, V367, P159, DOI 10.1016/j.ab.2007.04.029; Gottschalk PG, 2005, ANAL BIOCHEM, V343, P54, DOI 10.1016/j.ab.2005.04.035; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; IANNOTTI JP, 1994, CLIN ORTHOP RELAT R, P222; IRVING JT, 1961, ARCH ORAL BIOL, V5, P323, DOI 10.1016/0003-9969(61)90067-X; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KAY MI, 1964, NATURE, V204, P1050, DOI 10.1038/2041050a0; Kirsch T, 1997, BIOCHEMISTRY-US, V36, P3359, DOI 10.1021/bi9626867; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; LINSENMAYER TF, 1988, PATHOL IMMUNOPATH R, V7, P14, DOI 10.1159/000157085; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN FM, 1987, J BIOL CHEM, V262, P10481; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; NASH HA, 1964, P NATL ACAD SCI USA, V51, P476, DOI 10.1073/pnas.51.3.476; Oling F, 2001, J STRUCT BIOL, V133, P55, DOI 10.1006/jsbi.2000.4337; ORTLUND E, 2004, ANNEXINS, V1, P183; Patel DR, 2005, BIOCHEMISTRY-US, V44, P2833, DOI 10.1021/bi047642+; PERESS NS, 1974, CALC TISS RES, V14, P275, DOI 10.1007/BF02060301; POSNER AS, 1975, J DENT RES, V54, pB88, DOI 10.1177/00220345750540023301; POSNER AS, 1977, CALC TISS RES, V22, P208; Reviakine I, 2001, LANGMUIR, V17, P1680, DOI 10.1021/la001342l; ROJAS E, 1992, BONE MINER, V17, P214, DOI 10.1016/0169-6009(92)90739-Z; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SAUER GR, 1988, J BIOL CHEM, V263, P13718; SAUER GR, 1994, CALCIFIED TISSUE INT, V54, P414, DOI 10.1007/BF00305529; SAUER GR, 1989, BONE MINER, V7, P233, DOI 10.1016/0169-6009(89)90080-9; SCHMID TM, 1990, ANN NY ACAD SCI, V580, P64, DOI 10.1111/j.1749-6632.1990.tb17918.x; TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261; TANIMURA A, 1983, P SOC EXP BIOL MED, V172, P173; Taylor MG, 1998, CELL MOL LIFE SCI, V54, P196, DOI 10.1007/s000180050143; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wen Y, 1999, BIOCHEM BIOPH RES CO, V258, P713, DOI 10.1006/bbrc.1999.0678; Wu LNY, 1997, CLIN ORTHOP RELAT R, P310; Wu LNY, 2003, J INORG BIOCHEM, V94, P221, DOI 10.1016/S0162-0134(03)00003-5; WU LNY, 1993, J BIOL CHEM, V268, P25084; Wu LNY, 1996, CONNECT TISSUE RES, V35, P309, DOI 10.3109/03008209609029205; Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1977, CALC TISS RES, V23, P125, DOI 10.1007/BF02012777; WUTHIER RE, 1975, CALC TISS RES, V19, P197, DOI 10.1007/BF02564004; WUTHIER RE, 1985, CALCIFIED TISSUE INT, V37, P401, DOI 10.1007/BF02553710; WUTHIER RE, 1968, J LIPID RES, V9, P68; WUTHIER RE, 1977, CALC TISS RES, V24, P163, DOI 10.1007/BF02223311	75	58	58	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26035	26045		10.1074/jbc.M701057200	http://dx.doi.org/10.1074/jbc.M701057200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17613532	hybrid			2022-12-25	WOS:000249239600007
J	Hara, N; Yamada, K; Shibata, T; Osago, H; Hashimoto, T; Tsuchiya, M				Hara, Nobumasa; Yamada, Kazuo; Shibata, Tomoko; Osago, Harumi; Hashimoto, Tatsuya; Tsuchiya, Mikako			Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-ENHANCING FACTOR; ADENINE-DINUCLEOTIDE; TRANSCRIPTION FACTORS; PYRIDINE-NUCLEOTIDES; DEACETYLASE ACTIVITY; AXONAL DEGENERATION; SIRT1 DEACETYLASE; HUMAN-LYMPHOCYTES; HUMAN-FIBROBLASTS; ANIMAL TISSUES	NAD plays critical roles in various biological processes through the function of SIRT1. Although classical studies in mammals showed that nicotinic acid (NA) is a better precursor than nicotinamide (Nam) in elevating tissue NAD levels, molecular details of NAD synthesis from NA remain largely unknown. We here identified NA phosphoribosyltransferase (NAPRT) in humans and provided direct evidence of tight link between NAPRT and the increase in cellular NAD levels. The enzyme was abundantly expressed in the small intestine, liver, and kidney in mice and mediated [C-14] NAD synthesis from [C-14] NA in human cells. In cells expressing endogenous NAPRT, the addition of NA but not Nam almost doubled cellular NAD contents and decreased cytotoxicity by H2O2. Both effects were reversed by knockdown of NAPRT expression. These results indicate that NAPRT is essential for NA to increase cellular NAD levels and, thus, to prevent oxidative stress of the cells. Kinetic analyses revealed that NAPRT, but not Nam phosphoribosyltransferase (NamPRT, also known as pre-B-cell colony-enhancing factor or visfatin), is insensitive to the physiological concentration of NAD. Together, we conclude that NA elevates cellular NAD levels through NAPRT function and, thus, protects the cells against stress, partly due to lack of feedback inhibition of NAPRT but not NamPRT by NAD. The ability of NA to increase cellular NAD contents may account for some of the clinically observed effects of the vitamin and further implies a novel application of the vitamin to treat diseases such as those associated with the depletion of cellular NAD pools.	Shimane Med Univ, Fac Med, Dept Biochem, Izumo, Shimane 6938501, Japan; Shimane Med Univ, Fac Med, Ctr Integrated Res Sci, Izumo, Shimane 6938501, Japan	Shimane University; Shimane University	Hara, N (corresponding author), Shimane Med Univ, Fac Med, Dept Biochem, 89-1, Izumo, Shimane 6938501, Japan.	nhara@med.shimane-u.ac.jp						Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carlson LA, 2005, J INTERN MED, V258, P94, DOI 10.1111/j.1365-2796.2005.01528.x; COLLINS PB, 1972, J BIOL CHEM, V247, P778; DIETRICH LS, 1968, J VITAMINOL, VS 14, P123, DOI 10.5925/jnsv1954.14.Supplement_123; DIETRICH LS, 1972, BIOCHEMISTRY-US, V11, P1691, DOI 10.1021/bi00759a025; DIETRICH LS, 1966, J BIOL CHEM, V241, P188; ELLIOTT GC, 1982, BIOCHEM BIOPH RES CO, V104, P996, DOI 10.1016/0006-291X(82)91348-1; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; Hara N, 2003, J BIOL CHEM, V278, P10914, DOI 10.1074/jbc.M209203200; Hasmann M, 2003, CANCER RES, V63, P7436; HAYAKAWA T, 1984, AGR BIOL CHEM TOKYO, V48, P455, DOI 10.1080/00021369.1984.10866149; HAYAKAWA T, 1984, AGR BIOL CHEM TOKYO, V48, P445, DOI 10.1080/00021369.1984.10866148; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ishiyama M., 1995, In Vitro Toxicology, V8, P187; JACKSON TM, 1995, J NUTR, V125, P1455; Karpe F, 2004, LANCET, V363, P1892, DOI 10.1016/S0140-6736(04)16359-9; KELLER J, 1971, EUR J BIOCHEM, V22, P263, DOI 10.1111/j.1432-1033.1971.tb01540.x; Kitani T, 2003, FEBS LETT, V544, P74, DOI 10.1016/S0014-5793(03)00476-9; LIN LFH, 1972, J BIOL CHEM, V247, P8023; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; NIEDEL J, 1973, J BIOL CHEM, V248, P3500; Offermanns S, 2006, TRENDS PHARMACOL SCI, V27, P384, DOI 10.1016/j.tips.2006.05.008; Ogata S, 1997, BIOSCI BIOTECH BIOCH, V61, P2116, DOI 10.1271/bbb.61.2116; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297; ROSENBLOOM FM, 1968, J BIOL CHEM, V243, P1166; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; SHIBATA K, 1986, AGR BIOL CHEM TOKYO, V50, P3037, DOI 10.1080/00021369.1986.10867882; Shingu T, 2003, J NEUROSURG, V98, P154, DOI 10.3171/jns.2003.98.1.0154; SMITH LD, 1969, J BIOL CHEM, V244, P68; Trueblood NA, 2000, AM J PHYSIOL-HEART C, V279, pH764, DOI 10.1152/ajpheart.2000.279.2.H764; van der Veer E, 2005, CIRC RES, V97, P25, DOI 10.1161/01.RES.0000173298.38808.27; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; WILLIAMS GT, 1985, EXP CELL RES, V160, P419, DOI 10.1016/0014-4827(85)90189-2; Yamada K, 2006, ANAL BIOCHEM, V352, P282, DOI 10.1016/j.ab.2006.02.017; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	51	149	158	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24574	24582		10.1074/jbc.M610357200	http://dx.doi.org/10.1074/jbc.M610357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604275	hybrid			2022-12-25	WOS:000248933000011
J	Morokuma, Y; Nakamura, N; Kato, A; Notoya, M; Yamamoto, Y; Sakai, Y; Fukuda, H; Yamashina, S; Hirata, Y; Hirose, S				Morokuma, Yuri; Nakamura, Nobuhiro; Kato, Akira; Notoya, Michitaka; Yamamoto, Yoko; Sakai, Yasuhiro; Fukuda, Hidekazu; Yamashina, Shohei; Hirata, Yukio; Hirose, Shigehisa			MARCH-XI, a novel transmembrane ubiquitin ligase implicated in ubiquitin-dependent protein sorting in developing spermatids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; DOWN-REGULATION; ACROSOME FORMATION; COMPLEX; SPERMIOGENESIS; RAT; TRAFFICKING; EXPRESSION; SIGNALS; VESICLE	A mechanism by which ubiquitinated cargo proteins are sorted into multivesicular bodies (MVBs) from plasma and trans-Golgi network (TGN) membranes is well established in yeast and mammalian somatic cells. However, the ubiquitin-dependent sorting pathway has not been clearly defined in germ cells. In this study we identified a novel member of the transmembrane RING-finger family of proteins, termed membrane-associated RING-CH (MARCH)-XI, that is expressed predominantly in developing spermatids and weakly in brain and pituitary. MARCH-XI possesses an E3 ubiquitin ligase activity that targets CD4 for ubiquitination. Immunoelectron microscopy of rat round spermatids showed that MARCH-XI is localized to TGN-derived vesicles and MVBs. Fluorescence staining of rat round spermatids and immunoprecipitation of rat testis demonstrated that MARCH-XI forms complexes with the adaptor protein complex-1 and with fucose-containing glycoproteins including ubiquitinated forms. Furthermore, the C-terminal region of MARCH-XI mediates its interaction with mu 1-adaptin and Veli through a tyrosine-based motif and a PDZ binding motif, respectively. Our data suggest that MARCH-XI acts as a ubiquitin ligase with a role in ubiquitin-mediated protein sorting in the TGN-MVB transport pathway, which may be involved in mammalian spermiogenesis.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Dent Univ Grad Sch, Dept Clin & Mol Endocrinol, Tokyo 1138519, Japan; Kitasato Univ, Sch Med, Dept Anat, Sagamihara, Kanagawa 2288555, Japan	Tokyo Institute of Technology; Kitasato University	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259-B-19 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp	Nakamura, Nobuhiro/C-4265-2015; Kato, Akira/E-6328-2010	Nakamura, Nobuhiro/0000-0002-0249-2665; Kato, Akira/0000-0002-9083-1443				Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Bartee E, 2006, PLOS PATHOG, V2, P975, DOI 10.1371/journal.ppat.0020107; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; CLERMONT Y, 1985, ANAT REC, V213, P33, DOI 10.1002/ar.1092130106; Clermont Y., 1993, FRONT ENDOCRINOL, P332; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Fukuda H, 2006, J BIOCHEM, V139, P137, DOI 10.1093/jb/mvj012; Goto E, 2003, J BIOL CHEM, V278, P14657, DOI 10.1074/jbc.M211285200; GRIFFITHS G, 1981, EUR J CELL BIOL, V26, P52; Habasque C, 2002, MOL HUM REPROD, V8, P419, DOI 10.1093/molehr/8.5.419; Haraguchi CM, 2004, J HISTOCHEM CYTOCHEM, V52, P1393, DOI 10.1369/jhc.4A6275.2004; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hoer S, 2007, FEBS LETT, V581, P45, DOI 10.1016/j.febslet.2006.11.075; Kang-Decker N, 2001, SCIENCE, V294, P1531, DOI 10.1126/science.1063665; Kato A, 2004, DEV BIOL, V269, P196, DOI 10.1016/j.ydbio.2004.01.026; Lehner PJ, 2005, IMMUNOL REV, V207, P112, DOI 10.1111/j.0105-2896.2005.00314.x; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; MartinezMenarguez JA, 1996, J HISTOCHEM CYTOCHEM, V44, P313, DOI 10.1177/44.4.8601690; MARTINEZMENARGUEZ JA, 1993, EUR J CELL BIOL, V61, P21; MartinezMenarguez JA, 1996, EUR J CELL BIOL, V71, P137; Meyer C, 2001, J CELL SCI, V114, P4469; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Moreno RD, 2000, DEV BIOL, V219, P334, DOI 10.1006/dbio.2000.9606; Moreno RD, 2000, BIOL REPROD, V63, P89, DOI 10.1095/biolreprod63.1.89; Moreno RD, 2003, MOL REPROD DEV, V66, P202, DOI 10.1002/mrd.10342; Nakamura N, 2005, MOL BIOL CELL, V16, P1696, DOI 10.1091/mbc.E04-03-0216; Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790; Ohmura-Hoshino M, 2006, J IMMUNOL, V177, P341, DOI 10.4049/jimmunol.177.1.341; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Olsen O, 2005, J CELL BIOL, V170, P1127, DOI 10.1083/jcb.200503011; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Ramalho-Santos J, 2002, BIOL REPROD, V67, P1043, DOI 10.1095/biolreprod67.4.1043; Ramalho-Santos J, 2001, BIOL RES, V34, P147; Ramalho-Santos J, 2001, EXP CELL RES, V267, P45, DOI 10.1006/excr.2000.5119; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; SAKAI Y, 1990, DEV GROWTH DIFFER, V32, P389; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shelly M, 2003, DEV CELL, V5, P475, DOI 10.1016/j.devcel.2003.08.001; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; TANG XM, 1982, AM J ANAT, V163, P283, DOI 10.1002/aja.1001630402; Tseng TC, 2001, BBA-GENE STRUCT EXPR, V1518, P249, DOI 10.1016/S0167-4781(01)00191-9; Valdivia RH, 2002, DEV CELL, V2, P283, DOI 10.1016/S1534-5807(02)00127-2; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899	50	48	53	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24806	24815		10.1074/jbc.M700414200	http://dx.doi.org/10.1074/jbc.M700414200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17604280	hybrid			2022-12-25	WOS:000248933000036
J	Kiani, F; Schwarzl, S; Fischer, S; Efferth, T				Kiani, Farooq; Schwarzl, Sonja; Fischer, Stefan; Efferth, Thomas			Three-Dimensional Modeling of Glucose-6-phosphate Dehydrogenase-Deficient Variants from German Ancestry	PLOS ONE			English	Article								Background. Loss of function of dimeric glucose-6-phosphate dehydrogenase (G6PD) represents the most common inborn error of metabolism throughout the world affecting an estimated 400 million people. In Germany, this enzymopathy is very rare. Methodology/Principal Findings. On the basis of G6PD crystal structures, we have analyzed six G6PD variants of German ancestry by three-dimensional modeling. All mutations present in the German population are either close to one of the three G6P or NADP(+) units or to the interface of the two monomers. Two of the three mutated amino acids of G6PD Vancouver are closer to the binding site of NADP+. The G6PD Aachen mutation is also closer to the second NADP+ unit. The G6PD Wayne mutation is closer to the G6P binding region. These mutations may affect the binding of G6P and NADP+ units. Three mutations, i.e. G6PD Munich, G6PD Riverside and G6PD Gastonia, lie closer to the interface of the two monomers. These may also affect the interface of two monomers. Conclusion. None of these G6PD variants share mutations with the common G6PD variants known from the Mediterranean, Near East, or Africa indicating that they have developed independently. The G6PD variants have been compared with mutants from other populations and the implications for survival of G6PD variants from natural selection have been discussed.	[Efferth, Thomas] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Kiani, Farooq; Schwarzl, Sonja; Fischer, Stefan] Heidelberg Univ, Interdisciplinary Ctr Biocomp, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Efferth, T (corresponding author), German Canc Res Ctr, D-6900 Heidelberg, Germany.	t.efferth@dkfz.de		Efferth, Thomas/0000-0002-3096-3292; Kiani, Farooq/0000-0001-8773-3634	intramural grants	intramural grants	This work has been funded by intramural grants.	ALALI AK, 1989, ANN CLIN BIOCHEM, V26, P477, DOI 10.1177/000456328902600603; Au SWN, 2000, STRUCTURE, V8, P293, DOI 10.1016/S0969-2126(00)00104-0; Bannert N, 1969, Monatsschr Kinderheilkd, V117, P675; BENOHR HC, 1970, KLIN WOCHENSCHR, V48, P71, DOI 10.1007/BF01484619; BENOHR HC, 1971, DEUT MED WOCHENSCHR, V96, P1029, DOI 10.1055/s-0028-1108377; BEUTLER E, 1991, ACTA HAEMATOL-BASEL, V86, P179; Beutler E, 2002, BLOOD CELL MOL DIS, V28, P93, DOI 10.1006/bcmd.2002.0490; BEUTLER E, 1991, J BIOL CHEM, V266, P4145; BEUTLER E, 1991, NEW ENGL J MED, V324, P169; BUSCH D, 1970, KLIN WOCHENSCHR, V48, P74, DOI 10.1007/BF01484620; CALABRO V, 1990, HUM GENET, V86, P49; CANCEDDA R, 1973, EUR J BIOCHEM, V34, P199, DOI 10.1111/j.1432-1033.1973.tb02746.x; EBER SW, 1985, BLUT, V51, P109, DOI 10.1007/BF00320119; Efferth T, 2004, BLOOD, V104, P2608, DOI 10.1182/blood-2004-06-2135; Efferth T, 2000, BLOOD CELL MOL DIS, V26, P101, DOI 10.1006/bcmd.2000.0281; GAHR M, 1974, EUR J CLIN INVEST, V4, P187, DOI 10.1111/j.1365-2362.1974.tb00390.x; GAHR M, 1976, BRIT J HAEMATOL, V33, P363, DOI 10.1111/j.1365-2141.1976.tb03552.x; GAHR M, 1977, KLIN WOCHENSCHR, V55, P379, DOI 10.1007/BF01488623; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; GLORIABOTTINI F, 1980, EXPERIENTIA, V36, P541, DOI 10.1007/BF01965786; GRAY GR, 1973, LANCET, V2, P530; HELGE H, 1966, DEUT MED WOCHENSCHR, V91, P1584, DOI 10.1055/s-0028-1111556; HIRONO A, 1994, BLOOD, V83, P3363; HIRONO A, 1989, P NATL ACAD SCI USA, V86, P10015, DOI 10.1073/pnas.86.24.10015; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JablonskaSkwiecinska E, 1997, EUR J HUM GENET, V5, P22, DOI 10.1159/000484727; KAHN A, 1976, HUM GENET, V32, P171, DOI 10.1007/BF00291500; Kotaka M, 2005, ACTA CRYSTALLOGR D, V61, P495, DOI 10.1107/S0907444905002350; KURDIHAIDAR B, 1990, AM J HUM GENET, V47, P1013; MAEDA M, 1992, AM J HUM GENET, V51, P386; Miwa S, 1996, AM J HEMATOL, V51, P122, DOI 10.1002/(SICI)1096-8652(199602)51:2<122::AID-AJH5>3.0.CO;2-#; NAFA K, 1994, HUM GENET, V94, P513; NOWICKI L, 1974, KLIN WOCHENSCHR, V52, P478, DOI 10.1007/BF01468536; PAI GS, 1980, P NATL ACAD SCI-BIOL, V77, P2810, DOI 10.1073/pnas.77.5.2810; PEKRUN A, 1989, BLUT, V58, P11, DOI 10.1007/BF00320229; RAVINDRANATH Y, 1987, AM J HEMATOL, V24, P357, DOI 10.1002/ajh.2830240405; Ruwende C, 1998, J MOL MED, V76, P581, DOI 10.1007/s001090050253; Scopes DA, 1998, EUR J BIOCHEM, V251, P382, DOI 10.1046/j.1432-1327.1998.2510382.x; SMITH JE, 1966, P SOC EXP BIOL MED, V122, P671; Vulliamy T, 1997, BLOOD CELL MOL DIS, V23, P302, DOI 10.1006/bcmd.1997.0147; VUOPIO P, 1975, SCAND J HAEMATOL, V15, P145; WALLER HD, 1966, KLIN WOCHENSCHR, V44, P122, DOI 10.1007/BF01746562; WEIDTMAN V, 1966, KLIN WOCHENSCHR, V44, P446, DOI 10.1007/BF01727460; WEINREICH J, 1968, KLIN WOCHENSCHR, V46, P146, DOI 10.1007/BF01727373; WITT I, 1972, KLIN WOCHENSCHR, V50, P205, DOI 10.1007/BF01487145; XU WM, 1995, BLOOD, V85, P257, DOI 10.1182/blood.V85.1.257.bloodjournal851257; GERBER MOL DESIGN	47	10	11	4	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e625	10.1371/journal.pone.0000625	http://dx.doi.org/10.1371/journal.pone.0000625			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637841	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452100015
J	Takeyama, K; Monti, S; Manis, JP; Dal Cin, P; Getz, G; Beroukhim, R; Dutt, S; Aster, JC; Alt, FW; Golub, TR; Shipp, MA				Takeyama, K.; Monti, S.; Manis, J. P.; Dal Cin, P.; Getz, G.; Beroukhim, R.; Dutt, S.; Aster, J. C.; Alt, F. W.; Golub, T. R.; Shipp, M. A.			Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas	ONCOGENE			English	Article						DNA damage; 53BP1; lymphoma; genetic abnormalities; high-density single nucleotide polymorphism array	CLASS-SWITCH RECOMBINATION; DNA-DAMAGE; HUMAN GENOME; PROTEIN 53BP1; BCL6; P53; SUPPRESS; BREAKS; TRANSLOCATIONS; TRANSCRIPTION	p53-Binding protein 1 (53BP1) encodes a critical checkpoint protein that localizes to sites of DNA double-strand breaks (DSBs) and participates in DSB repair. Mice that are 53bp1 deficient or hemizygous have an increased incidence of lymphoid malignancies. However, 53BP1 abnormalities in primary human tumors have not been described. By combining high-density single nucleotide polymorphism (HD SNP) array data and gene expression profiles, we found 9 of 63 newly diagnosed human diffuse large B-cell lymphomas (DLBCLs) with single copy loss of the chromosome 15q15 region including the 53BP1 locus; these nine tumors also had significantly lower levels of 53BP1 transcripts. 53BP1 single copy loss found with the HD SNP array platform was subsequently confirmed by fluorescence in situ hybridization. These studies highlight the role of 53BP1 copy loss in primary human DLBCLs and the value of integrative analyses in detecting this genetic lesion in human tumors.	[Takeyama, K.; Beroukhim, R.; Shipp, M. A.] Dana Fraber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Monti, S.; Getz, G.; Beroukhim, R.; Golub, T. R.] Broad Inst Massachusetts Inst Technol, Cambridge, MA USA; [Monti, S.; Getz, G.; Beroukhim, R.; Golub, T. R.] Harvard Univ, Cambridge, MA 02138 USA; [Manis, J. P.; Dutt, S.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; [Dal Cin, P.; Aster, J. C.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Alt, F. W.] Childrens Hosp, Howard Hughes Med Inst, CBR Inst Biomed Res, Boston, MA 02115 USA; [Alt, F. W.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA; [Golub, T. R.] Dana Fraber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Shipp, MA (corresponding author), Dana Fraber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	margaret_shipp@dfci.harvard.edu			NCI NIH HHS [K08 CA122833-01A1, P01 CA92625, P01 CA092625, K08 CA122833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA122833, P01CA092625] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-19; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BEROUKHIM R, UNPUB GENOME WIDE AN; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Takahashi H, 2006, CLIN CANCER RES, V12, P3265, DOI 10.1158/1078-0432.CCR-06-0076; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wu XS, 2005, NAT IMMUNOL, V6, P964, DOI 10.1038/ni1005-964; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	30	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					318	322		10.1038/sj.onc.1210650	http://dx.doi.org/10.1038/sj.onc.1210650			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637749				2022-12-25	WOS:000252256000007
J	Rossiter, H; Barresi, C; Ghannadan, M; Gruber, F; Mildner, M; Fodinger, D; Tschachler, E				Rossiter, Heidemarie; Barresi, Caterina; Ghannadan, Minoo; Gruber, Florian; Mildner, Michael; Fodinger, Dagmar; Tschachler, Erwin			Inactivation of VEGF in mammary gland epithelium severely compromises mammary gland development and function	FASEB JOURNAL			English	Article						angiogenesis; lactation; alveologenesis; mammary gland differentiation	ENDOTHELIAL-GROWTH-FACTOR; MICROVASCULAR PERMEABILITY; EXPRESSION; PREGNANCY; PROTEINS; MILK; CELLS; CONNEXIN-26; RECEPTORS; DIFFERENTIATION	To investigate the role of the angiogenic cytokine vascular endothelial growth factor ( VEGF) during pregnancy and lactation, we used mice in which VEGF had been inactivated in mammary gland epithelial cells. Pups born to mutant mothers failed to thrive, displaying little milk in their stomachs. However, when they were transferred to control mothers they developed normally. Investigation of the mammary gland morphology revealed that lobulo- alveolar expansion into the fat pad was not complete in lactating mutant glands, and an accumulation of fat globules was evident in their secretory epithelium. In contrast to control glands, lactating mutant glands failed to up- regulate mRNAs for genes involved in milk secretion. Blood vessel density was comparable in pregnant mice of both groups but was only half that of controls in lactating mutant mice. FITC- labeled albumin injected intravenously (i.v.) into lactating mice extravasated rapidly and accumulated in the mammary gland epithelial cells in control animals, but was almost completely retained within the vessels in the mutants. Injection of recombinant VEGF i.v. reversed this effect. These findings demonstrate that mammary epithelium- derived VEGF is partially dispensable for angiogenesis during pregnancy and lactation, and by regulating vascular function during lactation, this factor is crucial to mammary gland differentiation and milk production.	Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; Ctr Rec Invest Epidermiques & Sensorielles, Neuilly Sur Seine, France	Medical University of Vienna	Tschachler, E (corresponding author), Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria.	erwin.tschachler@meduniwien.ac.at		Mildner, Michael/0000-0002-6892-925X; Gruber, Florian/0000-0003-1094-5641; Tschachler, Erwin/0000-0002-0248-1798				ABDUL AM, 1996, J VET MED SCI, V58, P29; Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bry C, 2004, DEV BIOL, V267, P418, DOI 10.1016/j.ydbio.2003.11.022; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; Chen J, 2002, AM J PHYSIOL-CELL PH, V282, pC1053, DOI 10.1152/ajpcell.00292.2001; Djonov V, 2001, MICROSC RES TECHNIQ, V52, P182, DOI 10.1002/1097-0029(20010115)52:2<182::AID-JEMT1004>3.3.CO;2-D; Dunbar ME, 2001, MICROSC RES TECHNIQ, V52, P163, DOI 10.1002/1097-0029(20010115)52:2<163::AID-JEMT1002>3.0.CO;2-R; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gerber HP, 1999, DEVELOPMENT, V126, P1149; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Hovey RC, 2004, ADV EXP MED BIOL, V554, P219; Hovey RC, 2001, MOL ENDOCRINOL, V15, P819, DOI 10.1210/me.15.5.819; Kadl A, 2002, VASC PHARMACOL, V38, P219, DOI 10.1016/S1537-1891(02)00172-6; Locke D, 2004, EXP CELL RES, V298, P643, DOI 10.1016/j.yexcr.2004.05.003; Locke D, 2000, J CELL PHYSIOL, V183, P228; MATSUMOTO M, 1992, J VET MED SCI, V54, P937, DOI 10.1292/jvms.54.937; MATSUMOTO M, 1994, J VET MED SCI, V56, P65, DOI 10.1292/jvms.56.65; McManaman JL, 2003, ADV DRUG DELIVER REV, V55, P629, DOI 10.1016/S0169-409X(03)00033-4; Mikaelian I, 2006, VET PATHOL, V43, P36, DOI 10.1354/vp.43-1-36; Minshall RD, 2002, HISTOCHEM CELL BIOL, V117, P105, DOI 10.1007/s00418-001-0367-x; Muller-Decker K, 2005, AM J PATHOL, V166, P575, DOI 10.1016/S0002-9440(10)62279-1; Nishimura S, 2002, CYTOKINE, V18, P191, DOI 10.1006/cyto.2002.1032; Odorisio T, 2002, J CELL SCI, V115, P2559; Ogg SL, 2004, P NATL ACAD SCI USA, V101, P10084, DOI 10.1073/pnas.0402930101; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pepper MS, 2000, DEV DYNAM, V218, P507, DOI 10.1002/1097-0177(200007)218:3<507::AID-DVDY1012>3.0.CO;2-5; PEREZARMENDARIZ EM, 1995, DEV GROWTH DIFFER, V37, P421; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Rossiter H, 2004, CANCER RES, V64, P3508, DOI 10.1158/0008-5472.CAN-03-2581; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Siafakas CG, 1999, PEDIATR RES, V45, P652, DOI 10.1203/00006450-199905010-00007; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Visvader JE, 2006, CANCER RES, V66, P9798, DOI 10.1158/0008-5472.CAN-06-2254; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Vuorela P, 2000, AM J CLIN NUTR, V72, P1196; Yamanaka I, 2001, HISTOCHEM CELL BIOL, V115, P277; YASUGI T, 1989, ARCH HISTOL CYTOL, V52, P115, DOI 10.1679/aohc.52.115	45	47	48	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3994	4004		10.1096/fj.07-8720com	http://dx.doi.org/10.1096/fj.07-8720com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17625068				2022-12-25	WOS:000251283500024
J	Evseenko, DA; Murthi, P; Paxton, JW; Reid, G; Emerald, BS; Mohankumar, KM; Lobie, PE; Brennecke, SP; Kalionis, B; Keelan, JA				Evseenko, Denis A.; Murthi, Padma; Paxton, James W.; Reid, Glen; Emerald, B. Starling; Mohankumar, K. M.; Lobie, Peter E.; Brennecke, Shaun P.; Kalionis, Bill; Keelan, J. A.			The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction	FASEB JOURNAL			English	Article						breast cancer resistance protein; cytokines; ceramide	CANCER RESISTANCE PROTEIN; FUNCTIONAL-ACTIVITY; VILLOUS DEVELOPMENT; CELL-SURVIVAL; TNF-ALPHA; CERAMIDE; APOPTOSIS; EFFLUX; BCRP; PREGNANCIES	The efflux pump ATP binding cassette superfamily member G2 (ABCG2)/breast cancer resistance protein ( BCRP) is highly expressed in human placenta. We have investigated the role of BCRP in the protection of the human placental trophoblasts from apoptosis and its expression in idiopathic fetal growth restriction, a condition associated with abnormal placental apoptosis. Inhibition of BCRP activity with the selective inhibitor Ko143 augmented cytokine ( tumor necrosis factor-alpha/interferon-gamma)-induced apoptosis and phosphatidylserine externalization in primary trophoblast and trophoblast-like BeWo cells. Silencing of BCRP expression in BeWo cells significantly increased their sensitivity to apoptotic injury in response to cytokines and exogenous C6 and C8 ceramides. BCRP silencing also increased intracellular ceramide levels after cytokine exposure but did not affect cellular protoporphyrin IX concentrations or sensitivity to activators of the intrinsic apoptotic pathway. BCRP expression in placentas from pregnancies complicated by idiopathic fetal growth restriction was decreased compared with controls, suggesting reduced transport of its substrates from the placenta. We conclude that BCRP may play a hitherto unrecognized survival role in the placenta, protecting the trophoblast against cytokine-induced apoptosis and possibly other extrinsic activators via modulation of ceramide signaling. Decreased placental BCRP expression may result in reduced viability and hence functional deficit, contributing to the fetal growth restriction phenotype.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Univ Auckland, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland 1, New Zealand; Genesis Res & Dev Corp, Auckland, New Zealand; Royal Hosp Women, Dept Perinatal Med, Pregnancy Res Ctr, Carlton, Vic, Australia; Royal Hosp Women, Dept Obstet & Gynaecol, Carlton, Vic, Australia; Univ Melbourne, Carlton, Vic 3053, Australia	University of Auckland; University of Auckland; University of Melbourne	Keelan, JA (corresponding author), Univ Auckland, Liggins Inst, Private Bag 92019, Auckland 1, New Zealand.	j.keelan@auckland.ac.nz	Brennecke, Shaun/AFV-3919-2022; Murthi, Padma/AAY-5395-2021; KALIONIS, BILL/B-4766-2011; Keelan, JA/G-2170-2011; David, Starling Emerald Bright/R-6034-2019; Kumarasamypet Murugesan, Mohankumar/F-4231-2012	Brennecke, Shaun/0000-0003-3070-6971; Keelan, JA/0000-0002-5403-6266; David, Starling Emerald Bright/0000-0001-6875-2258; Reid, Glen/0000-0001-6465-5223; Paxton, James/0000-0002-2530-7047; KM, Mohankumar/0000-0001-9407-1800				Abbott Brian L, 2006, Clin Adv Hematol Oncol, V4, P63; Allikmets R, 1998, CANCER RES, V58, P5337; Bakketeig LS, 1998, EUR J CLIN NUTR, V52, pS94; BAMBERG C, 2004, FETAL NEONATAL MED, V9, P387; Bartha JL, 2003, ACTA OBSTET GYN SCAN, V82, P1099, DOI 10.1046/j.1600-0412.2003.00259.x; Black S, 2004, CELL DEATH DIFFER, V11, P90, DOI 10.1038/sj.cdd.4401307; Blumenstein M, 2002, PLACENTA, V23, P735, DOI 10.1053/plac.2002.0868; Brodsky Dara, 2004, J Intensive Care Med, V19, P307, DOI 10.1177/0885066604269663; Ceckova M, 2006, CLIN EXP PHARMACOL P, V33, P58, DOI 10.1111/j.1440-1681.2006.04324.x; Chaddha Vandana, 2004, Semin Fetal Neonatal Med, V9, P357, DOI 10.1016/j.siny.2004.03.006; Choudhuri S, 2006, INT J TOXICOL, V25, P231, DOI 10.1080/10915810600746023; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Evseenko DA, 2007, PLACENTA, V28, pS116, DOI 10.1016/j.placenta.2006.12.003; Evseenko DA, 2006, AM J PHYSIOL-REG I, V290, pR1357, DOI 10.1152/ajpregu.00630.2005; Evseenko DA, 2007, DRUG METAB DISPOS, V35, P595, DOI 10.1124/dmd.106.011478; Gagnon R, 2003, EUR J OBSTET GYN R B, V110, pS99, DOI 10.1016/S0301-2115(03)00179-9; Gentil B, 2003, MOL CELL BIOCHEM, V254, P203, DOI 10.1023/A:1027359832177; Ghering AB, 2006, J LIPID RES, V47, P2781, DOI 10.1194/jlr.M600380-JLR200; Ghidini A, 1996, Obstet Gynecol Surv, V51, P376, DOI 10.1097/00006254-199606000-00023; GUARAN RL, 1994, AUST NZ J OBSTET GYN, V34, P39, DOI 10.1111/j.1479-828X.1994.tb01037.x; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hojjati MR, 2005, J BIOL CHEM, V280, P10284, DOI 10.1074/jbc.M412348200; Holcberg G, 2001, EUR J OBSTET GYN R B, V94, P69, DOI 10.1016/S0301-2115(00)00321-3; Johnstone ED, 2005, PLACENTA, V26, P548, DOI 10.1016/j.placenta.2004.08.012; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651; Jonker JW, 2005, STEM CELLS, V23, P1059, DOI 10.1634/stemcells.2005-0150; Jonker JW, 2005, NAT MED, V11, P127, DOI 10.1038/nm1186; Kilani RT, 2007, REPRODUCTION, V133, P257, DOI 10.1530/REP-06-0080; Kingdom J, 2000, EUR J OBSTET GYN R B, V92, P35, DOI 10.1016/S0301-2115(00)00423-1; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Laskowska M, 2006, J MATERN-FETAL NEO M, V19, P347, DOI 10.1080/14767050600637937; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayhew TM, 2004, PLACENTA, V25, P829, DOI 10.1016/j.placenta.2004.04.011; Morrish DW, 1998, J REPROD IMMUNOL, V39, P179, DOI 10.1016/S0165-0378(98)00021-7; Myatt L, 2006, J PHYSIOL-LONDON, V572, P25, DOI 10.1113/jphysiol.2006.104968; Otake M, 2003, BRIT J CANCER, V89, P730, DOI 10.1038/sj.bjc.6601135; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Paumi CM, 2003, BIOCHEMISTRY-US, V42, P5429, DOI 10.1021/bi027347u; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Sanchez-Vera I, 2005, OBSTET GYNECOL, V106, P345, DOI 10.1097/01.AOG.0000171112.95083.86; Straszewski-Chavez SL, 2005, ENDOCR REV, V26, P877, DOI 10.1210/er.2005-0003; SULLARDS MC, 2001, SCI STKE, V67, pPL1; van Meer G, 2006, FEBS LETT, V580, P1171, DOI 10.1016/j.febslet.2005.12.019; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WOEHLECKE H, 2003, BIOCHEM J, V376, P789; Wollmann HA, 1998, HORM RES, V49, P1, DOI 10.1159/000053079	51	86	88	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2007	21	13					3592	3605		10.1096/fj.07-8688com	http://dx.doi.org/10.1096/fj.07-8688com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	225KW	17595345				2022-12-25	WOS:000250517800022
J	Cohen, S; Cahan, R; Ben-Dov, E; Nisnevitch, M; Zaritsky, A; Firer, MA				Cohen, Shmuel; Cahan, Rivka; Ben-Dov, Eitan; Nisnevitch, Marina; Zaritsky, Arieh; Firer, Michael A.			Specific targeting to murine myeloma cells of Cyt1Aa toxin from Bacillus thuringiensis subspecies israelensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTA DELTA-ENDOTOXIN; BIOCHEMICAL-CHARACTERIZATION; TOXICITY; GENES; PLASMID; DESTRUCTION; INCLUSIONS; SPHAERICUS; RESISTANCE; MECHANISM	Multiple myeloma is currently an incurable cancer of plasma B cells often characterized by overproduction of abnormally high quantities of a patient-specific, clonotypic immunoglobulin "M-protein." The M-protein is expressed on the cell membrane and secreted into the blood. We previously showed that ligand-toxin conjugates (LTC) incorporating the ribosome-inactivating Ricin-A toxin were very effective in specific cytolysis of the anti-ligand antibody-bearing target cells used as models for multiple myeloma. Here, we report on the incorporation of the membrane-disruptive Cyt1Aa toxin from Bacillus thuringiensis subsp. israelensis into LTCs targeted to murine myeloma cells. Proteolytically activated Cyt1Aa was conjugated chemically or genetically through either its amino or carboxyl termini to the major peptidic epitope VHFFKNIVTPRTP (p87-99) of the myelin basic protein. The recombinant fusion-encoding genes were cloned and expressed in acrystalliferous B. thuringiensis subsp. israelensis through the shuttle vector pHT315. Both chemically conjugated and genetically fused LTCs were toxic to anti-myelin basic protein-expressing murine hybridoma cells, but the recombinant conjugates were more active. LTCs comprising the Cyt1Aa toxin might be useful anticancer agents. As a membrane-acting toxin, Cyt1Aa is not likely to induce development of resistant cell lines.	Coll Judea & Samaria, Dept Chem Engn & Biotechnol, IL-44837 Ariel, Israel; Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Achva Acad Coll, IL-79800 Mobile Post Shikmim, Israel	Ariel University; Ben Gurion University	Firer, MA (corresponding author), Coll Judea & Samaria, Dept Chem Engn & Biotechnol, IL-44837 Ariel, Israel.	firer@research.yosh.ac.il	Zaritsky, Arieh/K-2578-2012; Nisnevitch, Marina/K-8481-2012; FIrer, Michael/H-4467-2019	Zaritsky, Arieh/0000-0001-9333-6854; Nisnevitch, Marina/0000-0001-8493-713X; FIrer, Michael/0000-0002-8430-0486; Cahan, Rivka/0000-0001-9783-4033; Ben-Dov, Eitan/0000-0001-7685-6727				Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Alyahyaee SAS, 1996, BIOCONJUGATE CHEM, V7, P451, DOI 10.1021/bc960030k; Alyahyaee SAS, 1995, MICROBIOL-UK, V141, P3141, DOI 10.1099/13500872-141-12-3141; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Ben-Dov E, 1999, PLASMID, V42, P186, DOI 10.1006/plas.1999.1415; Berry C, 2002, APPL ENVIRON MICROB, V68, P5082, DOI 10.1128/AEM.68.10.5082-5095.2002; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BONE EJ, 1989, FEMS MICROBIOL LETT, V58, P171, DOI 10.1111/j.1574-6968.1989.tb03039.x; Butko P, 1996, BIOCHEMISTRY-US, V35, P11355, DOI 10.1021/bi960970s; Butko P, 2003, APPL ENVIRON MICROB, V69, P2415, DOI 10.1128/AEM.69.5.2415-2422.2003; CRICKMORE N, 1995, FEMS MICROBIOL LETT, V131, P249; DEBRO L, 1986, J BACTERIOL, V165, P258, DOI 10.1128/jb.165.1.258-268.1986; Du JP, 1999, BIOCHEM J, V338, P185, DOI 10.1042/0264-6021:3380185; Firer MA, 2003, LEUKEMIA LYMPHOMA, V44, P681, DOI 10.1080/1042819031000063381; Khasdan V, 2001, ENVIRON MICROBIOL, V3, P798, DOI 10.1046/j.1462-2920.2001.00253.x; Khasdan V, 2003, FEMS MICROBIOL LETT, V227, P189, DOI 10.1016/S0378-1097(03)00679-7; KONI PA, 1994, MICROBIOL-SGM, V140, P1869, DOI 10.1099/13500872-140-8-1869; Laptev R, 2006, BRIT J CANCER, V95, P189, DOI 10.1038/sj.bjc.6603241; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; MacDonald GC, 2005, CURR OPIN DRUG DISC, V8, P177; Malumbres Marcos, 2006, Clin Transl Oncol, V8, P399, DOI 10.1007/s12094-006-0193-7; Manasherob R, 2003, MICROBIOL-SGM, V149, P3553, DOI 10.1099/mic.0.26271-0; Manceva SD, 2005, BIOCHEMISTRY-US, V44, P589, DOI 10.1021/bi048493y; Margalith Y, 2000, AGR ENVIRONM SER, P243; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Park HW, 2003, APPL ENVIRON MICROB, V69, P1331, DOI 10.1128/AEM.69.2.1331-1334.2003; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pommier Yves, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P429, DOI 10.2174/1568011043352777; Rihova B, 1997, CRIT REV BIOTECHNOL, V17, P149, DOI 10.3109/07388559709146611; SAMBROOK J, 2001, MOL CLONING LAB MANU, P312; Shukla GS, 2006, EXPERT OPIN BIOL TH, V6, P39, DOI 10.1517/14712598.6.1.39; STEWART GSAB, 1981, BIOCHEM J, V198, P101, DOI 10.1042/bj1980101; Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004; THOMAS WE, 1983, J CELL SCI, V60, P181; WARD ES, 1988, J MOL BIOL, V202, P527, DOI 10.1016/0022-2836(88)90283-5; Wirth MC, 2007, ENVIRON MICROBIOL, V9, P1393, DOI 10.1111/j.1462-2920.2007.01255.x; Wirth MC, 2001, APPL ENVIRON MICROB, V67, P3280, DOI 10.1128/AEM.67.7.3280-3284.2001; WU D, 1994, MOL MICROBIOL, V13, P965, DOI 10.1111/j.1365-2958.1994.tb00488.x; Yang HH, 2003, J CLIN ONCOL, V21, P4239, DOI 10.1200/JCO.2003.06.001	41	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28301	28308		10.1074/jbc.M703567200	http://dx.doi.org/10.1074/jbc.M703567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17626007	hybrid			2022-12-25	WOS:000249642100003
J	Pangrsic, T; Potokar, M; Stenovec, M; Kreft, M; Fabbretti, E; Nistri, A; Pryazhnikov, E; Khiroug, L; Giniatullin, R; Zorec, R				Pangrsic, Tina; Potokar, Maja; Stenovec, Matjaz; Kreft, Marko; Fabbretti, Elsa; Nistri, Andrea; Pryazhnikov, Evgeny; Khiroug, Leonard; Giniatullin, Rashid; Zorec, Robert			Exocytotic release of ATP from cultured Astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE-CORE VESICLES; VESICULAR GLUTAMATE; SYNAPTIC CURRENTS; RECEPTORS; P2X(3); DESENSITIZATION; OSCILLATIONS; MICROSCOPY; SECRETION; TRANSPORT	Astrocytes appear to communicate with each other as well as with neurons via ATP. However, the mechanisms of ATP release are controversial. To explore whether stimuli that increase [Ca2+](i) also trigger vesicular ATP release from astrocytes, we labeled ATP-containing vesicles with the fluorescent dye quinacrine, which exhibited a significant co-localization with atrial natriuretic peptide. The confocal microscopy study revealed that quinacrine-loaded vesicles displayed mainly non-directional spontaneous mobility with relatively short track lengths and small maximal displacements, whereas 4% of vesicles exhibited directional mobility. After ionomycin stimulation only non-directional vesicle mobility could be observed, indicating that an increase in [Ca2+](i) attenuated vesicle mobility. Total internal reflection fluorescence (TIRF) imaging in combination with epifluorescence showed that a high percentage of fluorescently labeled vesicles underwent fusion with the plasma membrane after stimulation with glutamate or ionomycin and that this event was Ca2+-dependent. This was confirmed by patch-clamp studies on HEK-293T cells transfected with P2X(3) receptor, used as sniffers for ATP release from astrocytes. Glutamate stimulation of astrocytes was followed by an increase in the incidence of small transient inward currents in sniffers, reminiscent of postsynaptic quantal events observed at synapses. Their incidence was highly dependent on extracellular Ca2+. Collectively, these findings indicate that glutamate-stimulated ATP release from astrocytes was most likely exocytotic and that after stimulation the fraction of quinacrine-loaded vesicles, spontaneously exhibiting directional mobility, disappeared.	Univ Ljubljana, Fac Med, Lab Neuroendocrinol Mol Cell Physiol, Inst Pathophysiol,Fac Med, SI-1000 Ljubljana, Slovenia; Celica Biomed Ctr, SI-1000 Ljubljana, Slovenia; Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland; SISSA, Int Sch Adv Studies, I-34014 Trieste, Italy	University of Ljubljana; University of Helsinki; International School for Advanced Studies (SISSA)	Zorec, R (corresponding author), Univ Ljubljana, Fac Med, Lab Neuroendocrinol Mol Cell Physiol, Inst Pathophysiol,Fac Med, Zaloska 4, SI-1000 Ljubljana, Slovenia.	robert.zorec@mf.uni-lj.si	Giniatullin, Rashid/Y-9687-2018; Zorec, Robert/AAD-7180-2021	Zorec, Robert/0000-0002-7478-3875; Giniatullin, Rashid/0000-0002-1580-6280				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Anderson CM, 2004, J NEUROCHEM, V88, P246, DOI 10.1046/j.1471-4159.2003.02204.x; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 1998, J NEUROSCI, V18, P6822; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Axelrod D, 2003, METHOD ENZYMOL, V361, P1; Bal-Price A, 2002, GLIA, V40, P312, DOI 10.1002/glia.10124; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Evanko DS, 2004, GLIA, V47, P233, DOI 10.1002/glia.20050; Fabbretti E, 2004, J BIOL CHEM, V279, P53109, DOI 10.1074/jbc.M409772200; Fabbro A, 2004, J PHYSIOL-LONDON, V560, P505, DOI 10.1113/jphysiol.2004.068924; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fellin T, 2006, PHYSIOLOGY, V21, P208, DOI 10.1152/physiol.00161.2005; Grandolfo M, 2005, NEUROREPORT, V16, P381, DOI 10.1097/00001756-200503150-00015; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Jarvis MF, 2002, P NATL ACAD SCI USA, V99, P17179, DOI 10.1073/pnas.252537299; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kolikova J, 2006, BRAIN CELL BIOL, V35, P75, DOI 10.1007/s11068-006-9000-1; Kreft M, 2004, GLIA, V46, P437, DOI 10.1002/glia.20018; Krzan M, 2003, J NEUROSCI, V23, P1580; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; Ng YK, 2002, J PHYSIOL-LONDON, V542, P395, DOI 10.1113/jphysiol.2002.021733; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pangrsic T, 2006, J NEUROCHEM, V99, P514, DOI 10.1111/j.1471-4159.2006.04042.x; Pankratov Y, 2003, MOL CELL NEUROSCI, V24, P842, DOI 10.1016/S1044-7431(03)00233-1; Parpura V, 1995, FEBS LETT, V377, P489, DOI 10.1016/0014-5793(95)01401-2; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Potokar M, 2005, BIOCHEM BIOPH RES CO, V329, P678, DOI 10.1016/j.bbrc.2005.02.030; Potokar M, 2007, TRAFFIC, V8, P12, DOI 10.1111/j.1600-0854.2006.00509.x; Queiroz G, 1997, NEUROSCIENCE, V78, P1203, DOI 10.1016/S0306-4522(96)00637-9; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Schutz GJ, 2004, MICROSC RES TECHNIQ, V63, P159, DOI 10.1002/jemt.20016; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Shakiryanova D, 2005, NAT NEUROSCI, V8, P173, DOI 10.1038/nn1377; Simonetti M, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-11; Sokolova E, 2004, BRIT J PHARMACOL, V141, P1048, DOI 10.1038/sj.bjp.0705701; Stenovec M, 2004, FASEB J, V18, P1270, DOI 10.1096/fj.03-1397fje; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Striedinger K, 2007, GLIA, V55, P652, DOI 10.1002/glia.20494; Wacker I, 1997, J CELL SCI, V110, P1453; Wilhelm A, 2004, NEUROSCI RES, V48, P249, DOI 10.1016/j.neures.2003.11.002; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	53	187	191	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28749	28758		10.1074/jbc.M700290200	http://dx.doi.org/10.1074/jbc.M700290200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17627942	hybrid			2022-12-25	WOS:000249642100049
J	Tang, M; Cecconi, C; Bustamante, C; Rio, DC				Tang, Mei; Cecconi, Ciro; Bustamante, Carlos; Rio, Donald C.			Analysis of P element transposase protein-DNA interactions during the early stages of transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC COMPLEX; DROSOPHILA-MELANOGASTER; MU-TRANSPOSASE; V(D)J RECOMBINATION; IN-VITRO; BINDING; ARCHITECTURE; TN5; CATALYSIS; COFACTOR	P elements are a family of transposable elements found in Drosophila that move by using a cut-and-paste mechanism and that encode a transposase protein that uses GTP as a cofactor for transposition. Here we used atomic force microscopy to visualize the initial interaction of transposase protein with P element DNA. The transposase first binds to one of the two P element ends, in the presence or absence of GTP, prior to synapsis. In the absence of GTP, these complexes remain stable but do not proceed to synapsis. In the presence of GTP or nonhydrolyzable GTP analogs, synapsis happens rapidly, whereas DNA cleavage is slow. Both atomic force microscopy and standard biochemical methods have been used to show that the P element transposase exists as a pre-formed tetramer that initially binds to either one of the two P element ends in the absence of GTP prior to synapsis. This initial single end binding may explain some of the aberrant P element-induced rearrangements observed in vivo, such as hybrid end insertion. The allosteric effect of GTP in promoting synapsis by P element transposase may be to orient a second site-specific DNA binding domain in the tetramer allowing recognition of a second high affinity transposase-binding site at the other transposon end.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet Genomics & Dev, Berkeley, CA 94720 USA; Univ Calif Berkeley, Ctr Integrat Genomics, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Univ Modena & Reggio Emilia, CNR, INFM, S3, I-41100 Modena, Italy; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Universita di Modena e Reggio Emilia; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Rio, DC (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet Genomics & Dev, Berkeley, CA 94720 USA.	don_rio@berkeley.edu	Cecconi, Ciro/K-5028-2016	Cecconi, Ciro/0000-0002-6101-2609; Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061987] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; Auge-Gouillou C, 2005, J MOL BIOL, V351, P117, DOI 10.1016/j.jmb.2005.05.019; Auge-Gouillou C, 2005, MOL CELL BIOL, V25, P2861, DOI 10.1128/MCB.25.7.2861-2870.2005; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CURR OPIN GENET DEV, V3, P708, DOI 10.1016/S0959-437X(05)80087-5; Beall EL, 1998, EMBO J, V17, P2122, DOI 10.1093/emboj/17.7.2122; Beall EL, 1997, GENE DEV, V11, P2137, DOI 10.1101/gad.11.16.2137; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Catto LE, 2006, NUCLEIC ACIDS RES, V34, P1711, DOI 10.1093/nar/gkl076; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIG NL, 2002, MOBILE DNA, V2; Craigie R, 1996, CELL, V85, P137, DOI 10.1016/S0092-8674(00)81089-2; Curcio MJ, 2003, NAT REV MOL CELL BIO, V4, P865, DOI 10.1038/nrm1241; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Engels W.R, 1989, MOBILE DNA, P437; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Gray YHM, 1996, GENETICS, V144, P1601; Gueguen E, 2005, TRENDS MICROBIOL, V13, P543, DOI 10.1016/j.tim.2005.09.002; Halford SE, 2004, ANNU REV BIOPH BIOM, V33, P1, DOI 10.1146/annurev.biophys.33.110502.132711; Halford SE, 2004, NUCLEIC ACIDS RES, V32, P3040, DOI 10.1093/nar/gkh624; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hickman AB, 2005, NAT STRUCT MOL BIOL, V12, P715, DOI 10.1038/nsmb970; HOLMES V, 2001, THESIS U CALIFORNIA; Jones JM, 2004, IMMUNOL REV, V200, P233, DOI 10.1111/j.0105-2896.2004.00168.x; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Lee CC, 1996, MOL CELL BIOL, V16, P5616; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Lipkow K, 2004, MOL CELL BIOL, V24, P8301, DOI 10.1128/MCB.24.18.8301-8311.2004; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Mul YM, 1997, EMBO J, V16, P4441, DOI 10.1093/emboj/16.14.4441; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; Preston CR, 1996, GENETICS, V144, P1623; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; Reznikoff WS, 2003, MOL MICROBIOL, V47, P1199, DOI 10.1046/j.1365-2958.2003.03382.x; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; Richardson JM, 2006, EMBO J, V25, P1324, DOI 10.1038/sj.emboj.7601018; Rio Donald C., 2002, P484; Rodgers KK, 1999, NUCLEIC ACIDS RES, V27, P2938, DOI 10.1093/nar/27.14.2938; Steiniger-White M, 2004, CURR OPIN STRUC BIOL, V14, P50, DOI 10.1016/j.sbi.2004.01.008; Tang M, 2005, GENE DEV, V19, P1422, DOI 10.1101/gad.1317605; Venken KJT, 2005, NAT REV GENET, V6, P167, DOI 10.1038/nrg1553; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Williams TL, 2004, J BIOL CHEM, V279, P5135, DOI 10.1074/jbc.M308156200; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yang JY, 1996, CELL, V85, P447, DOI 10.1016/S0092-8674(00)81122-8; Zhang L, 2001, NUCLEIC ACIDS RES, V29, P3566, DOI 10.1093/nar/29.17.3566	56	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					29002	29012		10.1074/jbc.M704106200	http://dx.doi.org/10.1074/jbc.M704106200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17644523	hybrid			2022-12-25	WOS:000249642100074
J	Bennett, A; Liu, J; Van Ryk, D; Bliss, D; Arthos, J; Henderson, RM; Subramaniam, S				Bennett, Adam; Liu, Jun; Van Ryk, Donald; Bliss, Donald; Arthos, James; Henderson, Robert M.; Subramaniam, Sriram			Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CROSS-CLADE NEUTRALIZATION; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; ELECTRON TOMOGRAPHY; T-CELLS; TYPE-1; CD4; RECEPTOR; VIRIONS	Identifying structural determinants of human immunodeficiency virus (HIV) neutralization is an important component of rational drug and vaccine design. We used cryoelectron tomography and atomic force microscopy to characterize the structure of an extremely potent HIV-neutralizing protein, D1D2-Ig alpha tp (abbreviated as D1D2-IgP), a polyvalent antibody construct that presents dodecameric CD4 in place of the Fab regions. We show that D1D2-IgP has a novel structure, displaying greater flexibility of its antibody arms than the closely related IgM. Using simian immunodeficiency virus in complex with D1D2-IgP, we present unequivocal evidence that DlD2-IgP can cross-link surface spikes on the same virus and on neighboring viruses. The observed binding to the viral envelope spikes is the result of specific CD4-gp120 interaction, because binding was not observed with MICA-IgP, a construct that is identical to DlD2-IgP except that major histocompatibility complex Class I-related Chain A (MICA) replaces the CD4 moiety. CD4-mediated binding was also associated with a significantly elevated proportion of ruptured viruses. The ratio of inactivated to CD4-liganded gp120-gp41 spikes can be much greater than 1:1, because all gp120-gp41 spikes on the closely apposed surfaces of cross-linked viruses should be incapable of accessing the target cell surface and mediating entry, as a result of inter-virus spike cross-linking. These results implicate flexibility rather than steric bulk or polyvalence per se as a structural explanation for the extreme potency of DlD2-IgP and thus suggest polyvalence presented on a flexible scaffold as a key design criterion for small molecule HIV entry inhibitors.				ss1@nih.gov		Subramaniam, Sriram/0000-0003-4231-4115; Bennett, Adam/0000-0003-0357-8089	NATIONAL CANCER INSTITUTE [Z01BC010825, ZIABC010825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000883, ZIAAI000883] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arthos J, 2002, J BIOL CHEM, V277, P11456, DOI 10.1074/jbc.M111191200; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; DAAR ES, 1991, AM J MED, V90, pS22, DOI 10.1016/0002-9343(91)90407-O; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Fazel S, 1997, INT IMMUNOL, V9, P1149, DOI 10.1093/intimm/9.8.1149; Furtado PB, 2004, J MOL BIOL, V338, P921, DOI 10.1016/j.jmb.2004.03.007; HANSMA HG, 1994, ANNU REV BIOPH BIOM, V23, P115, DOI 10.1146/annurev.bb.23.060194.000555; Kadow J, 2006, CURR OPIN INVESTIG D, V7, P721; KOLAR GR, 2003, FUNDAMENTALS IMMUNOL; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2005, NATURE, V433, P815, DOI 10.1038/433815a; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trubey CM, 2003, J VIROL, V77, P12699, DOI 10.1128/JVI.77.23.12699-12709.2003; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wang JS, 2005, ORG BIOMOL CHEM, V3, P1781, DOI 10.1039/b415159c; Winkler H, 2006, ULTRAMICROSCOPY, V106, P240, DOI 10.1016/j.ultramic.2005.07.007; Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.2634931100; Zhu P, 2001, J VIROL, V75, P6682, DOI 10.1128/JVI.75.14.6682-6686.2001; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	31	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27754	27759		10.1074/jbc.M702025200	http://dx.doi.org/10.1074/jbc.M702025200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17599917	hybrid			2022-12-25	WOS:000249455600024
J	Ravaud, S; Robert, X; Watzlawick, H; Haser, R; Mattes, R; Aghajari, N				Ravaud, Stephanie; Robert, Xavier; Watzlawick, Hildegard; Haser, Richard; Mattes, Ralf; Aghajari, Nushin			Trehalulose synthase native and carbohydrate complexed structures provide insights into sucrose isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMYLASE FAMILY; CRYSTAL-STRUCTURES; ISOMALTULOSE SYNTHASE; CYCLODEXTRIN GLYCOSYLTRANSFERASE; ALTEROMONAS-HALOPLANCTIS; NEISSERIA-POLYSACCHAREA; GLYCOSYL HYDROLASES; SYNTHESIZING ENZYME; ERWINIA-RHAPONTICI; DENTAL-CARIES	Various diseases related to the overconsumption of sugar make a growing need for sugar substitutes. Because sucrose is an inexpensive and readily available D-glucose donor, the industrial potential for enzymatic synthesis of the sucrose isomers trehalulose and/or isomaltulose from sucrose is large. The product specificity of sucrose isomerases that catalyze this reaction depends essentially on the possibility for tautomerization of sucrose, which is required for trehalulose formation. For optimal use of the enzyme, targeting controlled synthesis of these functional isomers, it is necessary to minimize the side reactions. This requires an extensive analysis of substrate binding modes and of the specificity-determining sites in the structure. The 1.6-2.2-angstrom resolution three-dimensional structures of native and mutant complexes of a trehalulose synthase from Pseudomonas mesoacidophila MX-45 mimic successive states of the enzyme reaction. Combined with mutagenesis studies they give for the first time thorough insights into substrate recognition and processing and reaction specificities of these enzymes. Among the important outcomes of this study is the revelation of an aromatic clamp defined by Phe(256) and Phe(280) playing an essential role in substrate recognition and in controlling the reaction specificity, which is further supported by mutagenesis studies. Furthermore, this study highlights essential residues for binding the glucosyl and fructosyl moieties. The introduction of subtle changes informed by comparative three-dimensional structural data observed within our study can lead to fundamental modifications in the mode of action of sucrose isomerases and hence provide a template for industrial catalysts.	CNRS, Univ Lyon, Inst Biol Chem Proteins, Lab BioCristallog, F-69373 Lyon, France; Univ Stuttgart, Inst Ind Genet, D-7000 Stuttgart, Germany	Centre National de la Recherche Scientifique (CNRS); University of Stuttgart	Aghajari, N (corresponding author), Heidelberg Univ, Ctr Biochim, Dept Biol Struct, Bergheimer Str 58, D-69120 Heidelberg, Germany.	n.aghajari@ibcp.fr	ROBERT, Xavier/C-3879-2015; Aghajari, Nushin B.H./P-1906-2016	ROBERT, Xavier/0000-0002-6174-8595; Aghajari, Nushin B.H./0000-0002-2245-2679				Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEETHAM PSJ, 1984, BIOCHEM J, V220, P213, DOI 10.1042/bj2200213; Cutfield SM, 1999, J MOL BIOL, V294, P771, DOI 10.1006/jmbi.1999.3287; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DeLano W, 2002, PYMOL 0 99; DUCROS V, 1995, STRUCTURE, V3, P939, DOI 10.1016/S0969-2126(01)00228-3; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Hamada S, 2002, PURE APPL CHEM, V74, P1293, DOI 10.1351/pac200274071293; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang JH, 1998, J IND MICROBIOL BIOT, V21, P22, DOI 10.1038/sj.jim.2900552; Jensen MH, 2004, BIOCHEMISTRY-US, V43, P3104, DOI 10.1021/bi0357762; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; Lichtenthaler FW, 2004, CR CHIM, V7, P65, DOI 10.1016/j.crci.2004.02.002; Mattes R., 1998, US Patent, Patent No. 5786140; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mirza O, 2001, BIOCHEMISTRY-US, V40, P9032, DOI 10.1021/bi010706l; MIYATA Y, 1992, BIOSCI BIOTECH BIOCH, V56, P1680, DOI 10.1271/bbb.56.1680; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; NAGAI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1789, DOI 10.1271/bbb.58.1789; NAGAIMIYATA Y, 1993, BIOSCI BIOTECH BIOCH, V57, P2049, DOI 10.1271/bbb.57.2049; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OOSHIMA T, 1991, CARIES RES, V25, P277, DOI 10.1159/000261376; Oslancova A, 2002, CELL MOL LIFE SCI, V59, P1945, DOI 10.1007/PL00012517; PARK YK, 1992, BIOTECHNOL LETT, V14, P547, DOI 10.1007/BF01023938; Ravaud S, 2005, ACTA CRYSTALLOGR F, V61, P100, DOI 10.1107/S1744309104030623; RAVAUD S, 2005, BIOL CELL MOL BIOL S, V60, P99; Robert X, 2003, STRUCTURE, V11, P973, DOI 10.1016/S0969-2126(03)00151-5; Roussel A, 1992, TURBO FRODO BIOGRAPH; Salvucci ME, 2003, COMP BIOCHEM PHYS B, V135, P385, DOI 10.1016/S1096-4959(03)00092-7; Skov LK, 2001, J BIOL CHEM, V276, P25273, DOI 10.1074/jbc.M010998200; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; Takazoe I., 1989, Progress in Sweeteners., P143; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; van der Veen BA, 2004, FEBS LETT, V560, P91, DOI 10.1016/S0014-5793(04)00077-8; Veronese T, 1998, FEBS LETT, V441, P348, DOI 10.1016/S0014-5793(98)01582-8; Veronese T, 1999, ENZYME MICROB TECH, V24, P263, DOI 10.1016/S0141-0229(98)00115-X; Wu LQ, 2005, APPL ENVIRON MICROB, V71, P1581, DOI 10.1128/AEM.71.3.1581-1590.2005; YAMADA K, 1985, NUTR REP INT, V32, P1211; Yoshioka Y, 1997, J MOL BIOL, V271, P619, DOI 10.1006/jmbi.1997.1222; Zhang DH, 2003, J BIOL CHEM, V278, P35428, DOI 10.1074/jbc.M302616200; Zhang DH, 2003, FEBS LETT, V534, P151, DOI 10.1016/S0014-5793(02)03835-8; Zhang DH, 2002, APPL ENVIRON MICROB, V68, P2676, DOI 10.1128/AEM.68.6.2676-2682.2002	58	58	63	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28126	28136		10.1074/jbc.M704515200	http://dx.doi.org/10.1074/jbc.M704515200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17597061	hybrid			2022-12-25	WOS:000249455600062
J	El Gazzar, M; Yoza, BK; Hu, JYQ; Cousart, SL; McCall, CE				El Gazzar, Mohamed; Yoza, Barbara K.; Hu, Jean Y. -Q.; Cousart, Sue L.; McCall, Charles E.			Epigenetic silencing of tumor necrosis factor alpha during endotoxin tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HISTONE H3 PHOSPHORYLATION; HUMAN MONOCYTIC CELLS; GENE-REGULATION; C-JUN; TRANSCRIPTIONAL ACTIVATION; HETEROCHROMATIN PROTEIN-1; INFLAMMATORY GENES; DNA METHYLATION; CHROMATIN	Sustained silencing of potentially autotoxic acute proinflammatory genes like tumor necrosis factor alpha( TNF alpha) occurs in circulating leukocytes following the early phase of severe systemic inflammation. Aspects of this gene reprogramming suggest the involvement of epigenetic processes. We used THP-1 human promonocytes, which mimic gene silencing when rendered endotoxin-tolerant in vitro, to test whether TNF alpha proximal promoter nucleosomes and transcription factors adapt to an activation-specific profile by developing characteristic chromatin-based silencing marks. We found increased TNF alpha mRNA levels in endotoxin-responsive cells that was preceded by dissociation of heterochromatin-binding protein 1 alpha, demethylation of nucleosomal histone H3 lysine 9 ( H3( Lys(9))), increased phosphorylation of the adjacent serine 10 ( H3( Ser(10))), and recruitment of NF-kappa B RelA/p65 to the TNF alpha promoter. In contrast, endotoxin-tolerant cells repressed production of TNF alpha mRNA, retained binding of heterochromatin-binding protein 1 alpha, sustained methylation of H3( Lys9), reduced phosphorylation of H3( Ser10), and showed diminished binding of NF-kappa B RelA/p65 to the TNF alpha promoter. Similar levels of NF-kappa B p50 occurred at the TNF alpha promoter in the basal state, during active transcription, and in the silenced phenotype. RelB, which acts as a repressor of TNF alpha transcription, remained bound to the promoter during silencing. These results support an immunodeficiency paradigm where epigenetic changes at the promoter of acute proinflammatory genes mediate their repression during the late phase of severe systemic inflammation.	Wake Forest Univ, Sch Med, Sect Mol Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	El Gazzar, M (corresponding author), Wake Forest Univ, Sch Med, Sect Mol Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	melgazza@wfubmc.edu			NIAID NIH HHS [R01 AI 09169, R01 AI 065791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065791, R01AI009169] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albig W, 1998, FEBS LETT, V435, P245, DOI 10.1016/S0014-5793(98)01084-9; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Arnalich F, 2000, INFECT IMMUN, V68, P1942, DOI 10.1128/IAI.68.4.1942-1945.2000; Barthel R, 2003, J IMMUNOL, V171, P3612, DOI 10.4049/jimmunol.171.7.3612; Berger F, 2003, CHROMOSOME RES, V11, P277, DOI 10.1023/A:1022844127716; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Boekhoudt GH, 2003, J IMMUNOL, V170, P4139, DOI 10.4049/jimmunol.170.8.4139; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Cavaillon JM, 2003, SCAND J INFECT DIS, V35, P535, DOI 10.1080/00365540310015935; Cavaillon JM, 2003, J ENDOTOXIN RES, V9, P101, DOI 10.1179/096805103125001487; Chan C, 2005, J IMMUNOL, V175, P461, DOI 10.4049/jimmunol.175.1.461; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Dormann HL, 2006, CELL CYCLE, V5, P2842, DOI 10.4161/cc.5.24.3540; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Esteve PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; GRANOWITZ EV, 1993, J IMMUNOL, V151, P1637; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Kuprash DV, 1999, J IMMUNOL, V162, P4045; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; LE DB, 1996, EMBO J, V15, P6701; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Marienfeld R, 2003, J BIOL CHEM, V278, P19852, DOI 10.1074/jbc.M301945200; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; McCall CE, 2007, AM J RESP CRIT CARE, V175, P763, DOI 10.1164/rccm.200610-1436CP; Miao F, 2004, J BIOL CHEM, V279, P18091, DOI 10.1074/jbc.M311786200; MUNOZ C, 1991, EUR J IMMUNOL, V21, P2177, DOI 10.1002/eji.1830210928; Natoli G, 2006, FEBS LETT, V580, P2843, DOI 10.1016/j.febslet.2006.02.072; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Vanden Berghe W, 2003, ADV EXP MED BIOL, V544, P181; Verschure PJ, 2005, MOL CELL BIOL, V25, P4552, DOI 10.1128/MCB.25.11.4552-4564.2005; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Xia YY, 1999, MOL CELL BIOL, V19, P7688; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yoza BK, 2006, J IMMUNOL, V177, P4080, DOI 10.4049/jimmunol.177.6.4080; Yoza BK, 2000, SHOCK, V13, P236, DOI 10.1097/00024382-200003000-00011	77	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26857	26864		10.1074/jbc.M704584200	http://dx.doi.org/10.1074/jbc.M704584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17646159	hybrid			2022-12-25	WOS:000249304900025
J	Kimmich, N; Das, A; Sevrioukova, I; Meharenna, Y; Sligar, SG; Poulos, TL				Kimmich, Novelle; Das, Aditi; Sevrioukova, Irina; Meharenna, Yergalem; Sligar, Stephen G.; Poulos, Thomas L.			Electron transfer between cytochrome p450cin and its FMN-containing redox partner, cindoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PUTIDAREDOXIN BINDING; BACILLUS-MEGATERIUM; ESCHERICHIA-COLI; P-450 REDUCTASE; SUBSTRATE; KINETICS; SYSTEM; IDENTIFICATION; EXPRESSION	Cytochrome P450 reductase, which delivers electrons from NADPH to microsomal P450s, consists of a single polypeptide that contains both FAD and FMN. The bacterial P450cin utilizes a similar electron transport system except the FAD/FMN reductase consists of two separate polypeptides where the FMN protein, cindoxin, shuttles electrons between the FAD-containing cindoxin reductase and P450cin. Here we characterize the kinetics and specificity of electron transfer between cindoxin and P450cin as well as discuss the influence of possible binding surface interactions using homology models.	Univ Calif Irvine, Dept Mol Biol, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Biochem, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Physiol, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Biophys, Irvine, CA 92612 USA; Univ Illinois, Coll Med, Ctr Biophys & Computat Biol, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Ctr Biophys & Computat Biol, Dept Chem, Urbana, IL 61801 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol, Irvine, CA 92612 USA.	poulos@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688, R01GM031756, R37GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 067367, GM 31756, GM 33688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguey-Zinsou KF, 2003, CHEM COMMUN, P418, DOI 10.1039/b211567k; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Dutton P L, 1978, Methods Enzymol, V54, P411; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; Hannemann F, 2007, BBA-GEN SUBJECTS, V1770, P330, DOI 10.1016/j.bbagen.2006.07.017; Hawkes DB, 2002, J BIOL CHEM, V277, P27725, DOI 10.1074/jbc.M203382200; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HUANG YY, 1986, BIOCHEMISTRY-US, V25, P1390, DOI 10.1021/bi00354a030; LIGHT TS, 1972, ANAL CHEM, V44, P1038, DOI 10.1021/ac60314a021; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; Louerat-Oriou B, 1998, EUR J BIOCHEM, V258, P1040, DOI 10.1046/j.1432-1327.1998.2581040.x; Meharenna YT, 2004, BIOCHEMISTRY-US, V43, P9487, DOI 10.1021/bi049293p; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Nagano S, 2004, J BIOL CHEM, V279, P42844, DOI 10.1074/jbc.M404217200; NARHI LO, 1988, MOL CELL BIOCHEM, V79, P63, DOI 10.1007/BF00229399; NARHI LO, 1987, J BIOL CHEM, V262, P6683; Puchkaev AV, 2005, ARCH BIOCHEM BIOPHYS, V434, P169, DOI 10.1016/j.abb.2004.10.022; Roberts GA, 2003, J BIOL CHEM, V278, P48914, DOI 10.1074/jbc.M309630200; SAGARA Y, 1992, FEBS LETT, V300, P208, DOI 10.1016/0014-5793(92)80847-A; Schiffler B, 2004, J BIOL CHEM, V279, P34269, DOI 10.1074/jbc.M402798200; Sevrioukova IF, 2003, J MOL BIOL, V333, P377, DOI 10.1016/j.jmb.2003.08.028; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; Tosha T, 2004, J BIOL CHEM, V279, P42836, DOI 10.1074/jbc.M404216200; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; YASUKOCHI Y, 1979, J BIOL CHEM, V254, P7097	26	27	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27006	27011		10.1074/jbc.M703790200	http://dx.doi.org/10.1074/jbc.M703790200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17606612	hybrid			2022-12-25	WOS:000249304900041
J	Stadthagen, G; Sambou, T; Guerin, M; Barilone, N; Boudou, F; Kordulakova, J; Charles, P; Alzari, PM; Lemassu, A; Daffe, M; Puzo, G; Gicquel, B; Riviere, M; Jackson, M				Stadthagen, Gustavo; Sambou, Tounkang; Guerin, Marcelo; Barilone, Nathalie; Boudou, Frederic; Kordulakova, Jana; Charles, Patricia; Alzari, Pedro M.; Lemassu, Anne; Daffe, Mamadou; Puzo, Germain; Gicquel, Brigitte; Riviere, Michel; Jackson, Mary			Genetic basis for the biosynthesis of methylglucose lipopolysaccharides in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITOYL-COENZYME-A; METHYLMANNOSE POLYSACCHARIDE; REVISED STRUCTURE; SMEGMATIS; ACID; POLYMETHYLPOLYSACCHARIDES; 6-O-METHYL-D-GLUCOSE; METHYLTRANSFERASE; IDENTIFICATION; PURIFICATION	Mycobacteria produce two unusual polymethylated polysaccharides, the 6-O-methylglucosyl-containing lipopolysaccharides (MGLP) and the 3-O-methylmannose polysaccharides, which have been shown to regulate fatty acid biosynthesis in vitro. A cluster of genes dedicated to the synthesis of MGLP was identified in Mycobacterium tuberculosis and Mycobacterium smegmatis. Overexpression of the putative glycosyltransferase gene Rv3032 in M. smegmatis greatly stimulated MGLP production, whereas the targeted disruption of Rv3032 in M. tuberculosis and that of the putative methyltransferase gene MSMEG2349 in M. smegmatis resulted in a dramatic reduction in the amounts of MGLP synthesized and in the accumulation of precursors of these molecules. Disruption of Rv3032 also led to a significant decrease in the glycogen content of the tubercle bacillus, indicating that the product of this gene is likely to be involved in the elongation of more than one alpha-(1 -> 4)-glucan in this bacterium. Results thus suggest that Rv3032 encodes the alpha-(1 -> 4)- glucosyltransferase responsible for the elongation of MGLP, whereas MSMEG2349 encodes the O-methyltransferase required for the 6-O-methylation of these compounds.	Inst Pasteur, Unite Genet Mycobacterienne, F-75015 Paris, France; Inst Pasteur, Unite Biochim Struct, F-75015 Paris, France; CNRS, Inst Pharmacol & Biol Struct, Dept Mecanismes Mol infect Mycobacteriennes, F-31077 Toulouse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Jackson, M (corresponding author), Colorado State Univ, Dept Microbiol Immunol& Pathol, Ft Collins, CO 80523 USA.	Mary.Jackson@colostate.edu	Guerin, Marcelo M/N-7245-2016; Kordulakova, Jana/I-3887-2014; Jackson, Mary/D-5345-2017	Guerin, Marcelo M/0000-0001-9524-3184; Kordulakova, Jana/0000-0003-2834-0165; Jackson, Mary/0000-0002-9212-0258; Alzari, Pedro/0000-0002-4233-1903; Lemassu, Anne/0000-0002-9323-2497	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064798] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI064798, 5R01 AI 064798-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berg S, 2007, GLYCOBIOLOGY, V17, p35R, DOI 10.1093/glycob/cwm010; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BUEDING E, 1964, J BIOL CHEM, V239, P4018; Dinadayala P, 2004, J BIOL CHEM, V279, P12369, DOI 10.1074/jbc.M308908200; ELBEIN AD, 1973, J BACTERIOL, V113, P863, DOI 10.1128/JB.113.2.863-873.1973; FERGUSON JA, 1970, J BIOL CHEM, V245, P4213; FORSBERG LS, 1982, J BIOL CHEM, V257, P3555; GRAY GR, 1971, J BIOL CHEM, V246, P6835; GRELLERT E, 1972, J BIOL CHEM, V247, P3236; HARRIS LS, 1977, J BIOL CHEM, V252, P2470; HINDSGAUL O, 1984, BIOCHEMISTRY-US, V23, P577, DOI 10.1021/bi00298a028; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Jackson M, 2001, Methods Mol Med, V54, P59, DOI 10.1385/1-59259-147-7:059; KAMISANGO K, 1987, J BIOL CHEM, V262, P4580; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; LEE YC, 1964, J BIOL CHEM, V239, P3602; LEE YC, 1966, J BIOL CHEM, V241, P1899; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; LORNITZO FA, 1968, BIOCHIM BIOPHYS ACTA, V158, P329, DOI 10.1016/0304-4165(68)90286-9; MAGGIO JE, 1980, P NATL ACAD SCI-BIOL, V77, P2582, DOI 10.1073/pnas.77.5.2582; MAITRA SK, 1977, J BIOL CHEM, V252, P2459; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; Murakami T, 2006, J BACTERIOL, V188, P5915, DOI 10.1128/JB.00390-06; Newton GL, 2003, J BACTERIOL, V185, P3476, DOI 10.1128/JB.185.11.3476-3479.2003; POMMIER MT, 1986, J GEN MICROBIOL, V132, P2433; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; Tatituri RVV, 2007, J BIOL CHEM, V282, P4561, DOI 10.1074/jbc.M608695200; Tuffal G, 1998, GLYCOBIOLOGY, V8, P675, DOI 10.1093/glycob/8.7.675; TUFFAL G, 1995, EUR J BIOCHEM, V233, P377, DOI 10.1111/j.1432-1033.1995.377_1.x; Tuffal G, 1998, ANAL CHEM, V70, P1853, DOI 10.1021/ac971101r; TUNG KK, 1973, J BIOL CHEM, V248, P7126; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; WEISMAN LS, 1984, J BIOL CHEM, V259, P3457; WEISMAN LS, 1984, J BIOL CHEM, V259, P3464; YABUSAKI KK, 1978, P NATL ACAD SCI USA, V75, P691, DOI 10.1073/pnas.75.2.691; YABUSAKI KK, 1979, J BIOL CHEM, V254, P2314; YABUSAKI KK, 1979, J BIOL CHEM, V254, P7282; YAMADA H, 1979, J BIOL CHEM, V254, P1972	38	44	51	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27270	27276		10.1074/jbc.M702676200	http://dx.doi.org/10.1074/jbc.M702676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17640872	Green Published, hybrid			2022-12-25	WOS:000249304900068
J	Veit, G; Zimina, EP; Franzke, CW; Kutsch, S; Siebolds, U; Gordon, MK; Bruckner-Tuderman, L; Koch, M				Veit, Guido; Zimina, Elena P.; Franzke, Claus-Werner; Kutsch, Stefanie; Siebolds, Udo; Gordon, Marion K.; Bruckner-Tuderman, Leena; Koch, Manuel			Shedding of collagen XXIII is mediated by furin and depends on the plasma membrane microenvironment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOHIDROTIC ECTODERMAL DYSPLASIA; CELL-SURFACE; LIPID RAFTS; PROPROTEIN CONVERTASE; CHOLESTEROL DEPLETION; ECTODYSPLASIN-A; GOLGI-APPARATUS; PROTEIN; ECTODOMAIN; PRECURSOR	Collagen XXIII belongs to the class of type II orientated transmembrane collagens. A common feature of these proteins is the presence of two forms of the molecule: a membrane-bound form and a shed form. Here we demonstrate that, in mouse lung, collagen XXIII is found predominantly as the full-length form, whereas in brain, it is present mostly as the shed form, suggesting that shedding is tissue-specific and tissue-regulated. To analyze the shedding process of collagen XXIII, a cell culture model was established. Mutations introduced into two putative proprotein convertase cleavage sites showed that altering the second cleavage site inactivated much of the shedding. This supports the idea that furin, a major physiological protease, is predominantly responsible for shedding. Furthermore, our studies indicate that collagen XXIII is localized in lipid rafts in the plasma membrane and that ectodomain shedding is altered by a cholesterol-dependent mechanism. Moreover, newly synthesized collagen XXIII either is cleaved inside the Golgi/trans-Golgi network or reaches the cell surface, where it becomes protected from processing by being localized in lipid rafts. These mechanisms allow the cell to regulate the amounts of cell surface-bound and secreted collagen XXIII.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Univ Cologne, Inst Pathol, D-50924 Cologne, Germany; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Rutgers State Univ, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA	University of Cologne; University of Cologne; University of Cologne; University of Freiburg; University of Cologne; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Koch, M (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmannstr 52, D-50931 Cologne, Germany.	Manuel.Koch@uni-koeln.de	Koch, Manuel/AAG-9914-2021; Veit, Guido/C-9596-2009	Koch, Manuel/0000-0002-2962-7814; Veit, Guido/0000-0002-6758-2696	NEI NIH HHS [R01 EY009056, EY 09056] Funding Source: Medline; NIEHS NIH HHS [ES 05022] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Elomaa O, 2001, HUM MOL GENET, V10, P953, DOI 10.1093/hmg/10.9.953; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; HURTLEY SM, 1992, TRENDS BIOCHEM SCI, V17, P325, DOI 10.1016/0968-0004(92)90303-Q; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Koch M, 2006, J BIOL CHEM, V281, P21546, DOI 10.1074/jbc.M604131200; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Mayer G, 2004, J HISTOCHEM CYTOCHEM, V52, P567, DOI 10.1177/002215540405200502; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schneider P, 2001, J BIOL CHEM, V276, P18819, DOI 10.1074/jbc.M101280200; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Shogomori H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Vaisanen T, 2006, J BIOL CHEM, V281, P33352, DOI 10.1074/jbc.M605896200; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Zhang ZG, 2006, J CELL SCI, V119, P1886, DOI 10.1242/jcs.02921; Zimina EP, 2005, J BIOL CHEM, V280, P34019, DOI 10.1074/jbc.M503751200	48	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27424	27435		10.1074/jbc.M703425200	http://dx.doi.org/10.1074/jbc.M703425200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17627939	hybrid			2022-12-25	WOS:000249304900084
J	Ha, SD; Ng, D; Lamothe, J; Valvano, MA; Han, JH; Kim, SO				Ha, Soon-Duck; Ng, Dennis; Lamothe, Julie; Valvano, Miguel A.; Han, Jiahuai; Kim, Sung Ouk			Mitochondrial proteins bnip3 and Bnip3L are involved in anthrax lethal toxin-induced macrophage cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BACILLUS-ANTHRACIS; MESSENGER-RNA; INHALATIONAL ANTHRAX; MURINE MACROPHAGES; KINASE-KINASE; HOST RESPONSE; TNF-ALPHA; SUSCEPTIBILITY; SPORES	Anthrax lethal toxin (LeTx) induces rapid cell death of RAW246.7 macrophages. We recently found that a small population of these macrophages is spontaneously and temporally refractory to LeTx-induced cytotoxicity. Analysis of genomewide transcripts of a resistant clone before and after regaining LeTx sensitivity revealed that a reduction of two closely related mitochondrial proteins, Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (Bnip3) and Bnip3-like (Bnip3L), correlates with LeTx resistance. Down-regulation of Bnip3 and Bnip3L was also found in "toxin-induced resistance" whereby sublethal doses of LeTx induce resistance to subsequent exposure to cytolytic toxin doses. The role of Bnip3 and Bnip3L in LeTx-induced cell death was confirmed by showing that overexpression of either Bnip3 or Bnip3L rendered the resistant cells susceptible to LeTx, whereas down-regulation of Bnip3 and Bnip3L in wildtype macrophages conferred resistance. The down-regulation of Bnip3 and Bnip3L mRNAs by LeTx occurred at both transcriptional and mRNA stability levels. Inhibition of the p38 pathway by lethal factor was responsible for the destabilization of Bnip3/Bnip3L mRNAs as confirmed by showing that p38 inhibitors stabilized Bnip3 and Bnip3L mRNAs and conferred resistance to LeTx cytotoxicity. Therefore, Bnip3/Bnip3L play a crucial role in LeTx-induced cytotoxicity, and down-regulation of Bnip3/Bnip3L is a mechanism of spontaneous or toxin-induced resistance of macrophages.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada; Univ Western Ontario, Infect Dis Res Grp, Siebens Drake Res Inst, London, ON N6G 2V4, Canada; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Scripps Research Institute	Kim, SO (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada.	sung.kim@schulich.uwo.ca	Kim, Sung Ouk/AAO-1795-2020; Han, J/G-4671-2010; KIM, Sung Ouk/A-1309-2008; Valvano, Miguel A/G-8759-2012	Kim, Sung Ouk/0000-0002-0282-6661; Valvano, Miguel A/0000-0001-8229-3641				ALBRINK WS, 1959, AM J PATHOL, V35, P1055; Alileche A, 2006, CELL CYCLE, V5, P100, DOI 10.4161/cc.5.1.2283; An HJ, 2006, J BIOL CHEM, V281, P33939, DOI 10.1074/jbc.M605819200; Baldari CT, 2006, TRENDS IMMUNOL, V27, P434, DOI 10.1016/j.it.2006.07.002; Batty S, 2006, CELL MICROBIOL, V8, P130, DOI 10.1111/j.1462-5822.2005.00606.x; BHATNAGAR R, 1989, INFECT IMMUN, V57, P2107, DOI 10.1128/IAI.57.7.2107-2114.1989; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Brittingham KC, 2005, J IMMUNOL, V174, P5545, DOI 10.4049/jimmunol.174.9.5545; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cordoba-Rodriguez R, 2004, J BIOL CHEM, V279, P20563, DOI 10.1074/jbc.C300539200; Cote CK, 2006, INFECT IMMUN, V74, P469, DOI 10.1128/IAI.74.1.469-480.2006; Cote CK, 2004, MICROB PATHOGENESIS, V37, P169, DOI 10.1016/j.micpath.2004.06.013; DAI ZH, 1995, MOL MICROBIOL, V16, P1171, DOI 10.1111/j.1365-2958.1995.tb02340.x; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Firoved AM, 2005, AM J PATHOL, V167, P1309, DOI 10.1016/S0002-9440(10)61218-7; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Fukao T, 2004, LANCET INFECT DIS, V4, P166, DOI 10.1016/S1473-3099(04)00940-5; Galvez AS, 2006, J BIOL CHEM, V281, P1442, DOI 10.1074/jbc.M509056200; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; Guidi-Rontani C, 2001, MOL MICROBIOL, V42, P931, DOI 10.1046/j.1365-2958.2001.02695.x; Gutting BW, 2005, TOXICOL IN VITRO, V19, P221, DOI 10.1016/j.tiv.2004.08.007; Hanna P, 1999, J APPL MICROBIOL, V87, P285, DOI 10.1046/j.1365-2672.1999.00891.x; Hanna P, 1998, CURR TOP MICROBIOL, V225, P13; HANNA PC, 1992, MOL BIOL CELL, V3, P1269, DOI 10.1091/mbc.3.11.1269; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; HANNA PC, 1994, MOL MED, V1, P7; Hu HJ, 2006, CELL MICROBIOL, V8, P1634, DOI 10.1111/j.1462-5822.2006.00738.x; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; Kassam A, 2005, CELL MICROBIOL, V7, P281, DOI 10.1111/j.1462-5822.2004.00458.x; Khabar KSA, 2005, J INTERF CYTOK RES, V25, P1, DOI 10.1089/jir.2005.25.1; Kim SO, 2003, J BIOL CHEM, V278, P7413, DOI 10.1074/jbc.M209279200; Kim SO, 2006, CELL MICROBIOL, V8, P1958, DOI 10.1111/j.1462-5822.2006.00763.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; McAllister RD, 2003, AM J PATHOL, V163, P1735, DOI 10.1016/S0002-9440(10)63532-8; Moayeri M, 2004, INFECT IMMUN, V72, P4439, DOI 10.1128/IAI.72.8.4439-4447.2004; Moayeri M, 2004, CURR OPIN MICROBIOL, V7, P19, DOI 10.1016/j.mib.2003.12.001; Moayeri M, 2003, J CLIN INVEST, V112, P670, DOI [10.1172/JCI200317991, 10.1172/JCI17991]; Muehlbauer SM, 2007, CELL CYCLE, V6, P758, DOI 10.4161/cc.6.6.3991; Pandey J, 2004, MICROBES INFECT, V6, P835, DOI 10.1016/j.micinf.2004.04.013; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Popov SG, 2002, BIOCHEM BIOPH RES CO, V293, P349, DOI 10.1016/S0006-291X(02)00227-9; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Salles II, 2003, P NATL ACAD SCI USA, V100, P12426, DOI 10.1073/pnas.2134042100; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Shin S, 2000, CELL BIOL TOXICOL, V16, P137, DOI 10.1023/A:1007646227674; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; Tang GQ, 1999, INFECT IMMUN, V67, P3055, DOI 10.1128/IAI.67.6.3055-3060.1999; Tournier JN, 2007, CELL MICROBIOL, V9, P555, DOI 10.1111/j.1462-5822.2006.00866.x; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Watters JW, 2001, CURR BIOL, V11, P1503, DOI 10.1016/S0960-9822(01)00476-6; WELKOS SL, 1986, INFECT IMMUN, V51, P795, DOI 10.1128/IAI.51.3.795-800.1986; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200	61	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26275	26283		10.1074/jbc.M703668200	http://dx.doi.org/10.1074/jbc.M703668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623653	hybrid			2022-12-25	WOS:000249239600032
J	Yoon, S; Lee, MY; Park, SW; Moon, JS; Koh, YK; Ahn, YH; Park, BW; Kim, KS				Yoon, Sarah; Lee, Min-Young; Park, Sahng Wook; Moon, Jong-Seok; Koh, Yoo-Kyung; Ahn, Yong-Ho; Park, Byeong-Woo; Kim, Kyung-Sup			Up-regulation of Acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NEOPLASTIC TRANSFORMATION; ANTIBIOTIC CERULENIN; ACTIVATION; INHIBITION; PROTEIN; EXPRESSION; ONCOGENE; ERBB2; PATHWAY	Expression of the HER2 oncogene is increased in similar to 30% of human breast carcinomas and is closely correlated with the expression of fatty acid synthase ( FASN). In the present study, we determined the mechanism by which FASN and acetyl-CoA carboxylase alpha(ACC alpha) could be induced by HER2 overexpression. SK-BR-3 and BT-474 cells, breast cancer cells that overexpress HER2, expressed higher levels of FASN and ACC alpha compared with MCF-7 and MDA-MB-231 breast cancer cells in which HER2 expression is low. The induction of FASN and ACC alpha in BT474 cells were not mediated by the activation of SREBP-1. Exogenous HER2 expression in MDA-MB-231 cells induced the expression of FASN and ACC alpha, and the HER2- mediated increase in ACC alpha and FASN was inhibited by both LY294002, a phosphatidylinositol 3-kinase inhibitor, and rapamycin, a mammalian target of rapamycin ( mTOR) inhibitor. In addition, the activation of mTOR by the overexpression of RHEB in MDA-MB-231 cells increased the synthetic rates of both FASN and ACC alpha. On the other hand, FASN and ACC alpha were reduced in BT-474 cells by a blockade of the mTOR signaling pathway. These changes observed in their protein levels were not accompanied by changes in their mRNA levels. The 5' -and 3'-untranslated regions of both FASN and ACC alpha mRNAs were involved in selective translational induction that was mediated by mTOR signal transduction. These results strongly suggest that the major mechanism of HER2- mediated induction of FASN and ACC alpha in the breast cancer cells used in this study is translational regulation primarily through the mTOR signaling pathway.	Ctr Chron Metab Dis Res, Inst Genet Sci, Dept Biochem & Mol Biol, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System	Kim, KS (corresponding author), Ctr Chron Metab Dis Res, Inst Genet Sci, Dept Biochem & Mol Biol, Brain Korea 21 Project Med Sci, Seoul, South Korea.	kyungsup59@yumc.yonsei.ac.kr	AHN, Yong Ho/H-6712-2017	AHN, Yong Ho/0000-0002-4133-0757; Park, Byeong-Woo/0000-0003-1353-2607; Park, Sahng Wook/0000-0002-9594-7074				ALIMANDI M, 1995, ONCOGENE, V10, P1813; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Dendukuri N, 2007, CAN MED ASSOC J, V176, P1429, DOI 10.1503/cmaj.061011; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JENSEN V, 1995, J PATHOL, V176, P343, DOI 10.1002/path.1711760405; Johnston SRD, 2005, CLIN CANCER RES, V11, p889S; Jordan NJ, 2004, BREAST CANCER RES TR, V87, P167, DOI 10.1023/B:BREA.0000041623.21338.47; Kim Kyung-Sup, 1992, Yonsei Medical Journal, V33, P199; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; KUHAJDA FP, 1989, NEW ENGL J MED, V321, P636, DOI 10.1056/NEJM198909073211003; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; Mao JQ, 2003, P NATL ACAD SCI USA, V100, P7515, DOI 10.1073/pnas.1332670100; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Menendez JA, 2005, INT J CANCER, V115, P19, DOI 10.1002/ijc.20754; Menendez JA, 2005, MED HYPOTHESES, V64, P342, DOI 10.1016/j.mehy.2004.07.022; Menendez JA, 2004, MOL CARCINOGEN, V41, P164, DOI 10.1002/mc.20054; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Menendez JA, 2004, BREAST CANCER RES TR, V84, P183, DOI 10.1023/B:BREA.0000018409.59448.60; Menendez JA, 2004, INT J ONCOL, V24, P591; Menendez JA, 2006, CURR OPIN CLIN NUTR, V9, P346, DOI 10.1097/01.mco.0000232893.21050.15; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Oh SY, 2003, J BIOL CHEM, V278, P28410, DOI 10.1074/jbc.M300553200; Proud CG, 2004, BIOCHEM BIOPH RES CO, V313, P429, DOI 10.1016/j.bbrc.2003.07.015; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1817; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Yang YA, 2003, EXP CELL RES, V282, P132, DOI 10.1016/S0014-4827(02)00023-X; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	55	158	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26122	26131		10.1074/jbc.M702854200	http://dx.doi.org/10.1074/jbc.M702854200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17631500	hybrid			2022-12-25	WOS:000249239600015
J	Stiernet, P; Nenquin, M; Moulin, P; Jonas, JC; Henquin, JC				Stiernet, Patrick; Nenquin, Myriam; Moulin, Pierre; Jonas, Jean-Christophe; Henquin, Jean-Claude			Glucose-induced cytosolic pH changes in beta-cells and insulin secretion are not causally related - Studies in islets lacking the Na+/H+ exchanger NHE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PANCREATIC-ISLETS; INTRACELLULAR PH; B-CELLS; CYTOPLASMIC CA2+; COUPLING FACTORS; HIT-T15 CELLS; K+ CHANNEL; IN-VITRO; RELEASE; AMILORIDE	The contribution of Na+/H+ exchange ( achieved by NHE proteins) to the regulation of beta-cell cytosolic pH(c), and the role of pHc changes in glucose-induced insulin secretion are disputed and were examined here. Using real-time PCR, we identified plasmalemmal NHE1 and intracellular NHE7 as the two most abundant NHE isoforms in mouse islets. We, therefore, compared insulin secretion, cytosolic free Ca2+ ([Ca2+](c)) and pHc in islets from normal mice and mice bearing an inactivating mutation of NHE1 (Slc9A1-swe/swe). The experiments were performed in HCO3-/CO2 or HEPES/ NaOH buffers. PCR and functional approaches showed that NHE1 mutant islets do not express compensatory pH-regulating mechanisms. NHE1 played a greater role than HCO3- dependent mechanisms in the correction of an acidification imposed by a pulse of NH4Cl. In contrast, basal pHc ( in low glucose) and the alkalinization produced by high glucose were independent of NHE1. Dimethylamiloride, a classic blocker of Na+/H+ exchange, did not affect pHc but increased insulin secretion in NHE1 mutant islets, indicating unspecific effects. In control islets, glucose similarly increased [Ca2(+)](c) and insulin secretion in HCO3- and HEPES buffer, although pH(c) changed in opposite directions. The amplification of insulin secretion that glucose produces when [Ca2+](c) is clamped at an elevated level by KCl was also unrelated to pH(c) and pH(c) changes. All effects of glucose on [Ca2+](c) and insulin secretion proved independent of NHE1. In conclusion, NHE1 protects beta-cells against strong acidification, but has no role in stimulus-secretion coupling. The changes in pHc produced by glucose involve HCO3--dependent mechanisms. Variations in beta-cell pHc are not causally related to changes in insulin secretion.	Univ Catholique Louvain, Fac Med, Unit Endocrinol & Metab, B-1200 Brussels, Belgium; Univ Catholique Louvain, Fac Med, Unit Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Henquin, JC (corresponding author), Univ Catholique Louvain, Fac Med, Unit Endocrinol & Metab, UCL 55-30, B-1200 Brussels, Belgium.	henquin@endo.ucl.ac.be	Jonas, Jean-Christophe/C-6766-2011	Jonas, Jean-Christophe/0000-0001-9882-5438				Aizawa T, 2002, DIABETES, V51, pS96, DOI 10.2337/diabetes.51.2007.S96; BATLLE DC, 1993, AM J PHYSIOL, V264, pC932, DOI 10.1152/ajpcell.1993.264.4.C932; Bertrand G, 2002, J BIOL CHEM, V277, P32883, DOI 10.1074/jbc.M205326200; BEST L, 1988, BIOCHEM PHARMACOL, V37, P4611, DOI 10.1016/0006-2952(88)90328-0; Bollensdorff C, 2001, N-S ARCH PHARMACOL, V364, P351, DOI 10.1007/s002100100466; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, P803; CARROLL PB, 1988, FEBS LETT, V234, P208, DOI 10.1016/0014-5793(88)81335-8; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; Doliba NM, 2007, AM J PHYSIOL-ENDOC M, V292, pE1507, DOI 10.1152/ajpendo.00282.2006; Fridlyand LE, 2005, AM J PHYSIOL-ENDOC M, V289, pE839, DOI 10.1152/ajpendo.00595.2004; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; GILON P, 1992, J BIOL CHEM, V267, P20713; GRAPENGIESSER E, 1989, BIOCHIM BIOPHYS ACTA, V1014, P219, DOI 10.1016/0167-4889(89)90215-2; Gunawardana SC, 2002, DIABETES, V51, P105, DOI 10.2337/diabetes.51.1.105; GUNAWARDANA WD, 2004, BMC ENDOCR DISORD, V4, P1; Harris C, 1999, INT J MOL MED, V3, P315; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Henquin JC, 2006, DIABETES, V55, P441, DOI 10.2337/diabetes.55.02.06.db05-1051; Henquin JC, 2003, EUR J CLIN INVEST, V33, P742, DOI 10.1046/j.1365-2362.2003.01207.x; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; JUNTTIBERGGREN L, 1991, J BIOL CHEM, V266, P23537; LEBRUN P, 1986, BIOCHIM BIOPHYS ACTA, V886, P448, DOI 10.1016/0167-4889(86)90181-3; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; LINDSTROM P, 1986, BIOCHEM J, V239, P199, DOI 10.1042/bj2390199; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LYNCH AM, 1989, BIOCHIM BIOPHYS ACTA, V1012, P166, DOI 10.1016/0167-4889(89)90091-8; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; MacDonald PE, 2005, PHILOS T R SOC B, V360, P2211, DOI 10.1098/rstb.2005.1762; MartinezZaguilan R, 1996, AM J PHYSIOL-CELL PH, V270, pC1438, DOI 10.1152/ajpcell.1996.270.5.C1438; Masereel B, 2003, EUR J MED CHEM, V38, P547, DOI 10.1016/S0223-5234(03)00100-4; Matschinsky FM, 2006, DIABETES, V55, P1; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; Moulin P, 2007, J MOL ENDOCRINOL, V38, P409, DOI 10.1677/jme.1.02164; Nabe K, 2006, ENDOCRINOLOGY, V147, P2717, DOI 10.1210/en.2005-1260; Nakamura N, 2005, J BIOL CHEM, V280, P1561, DOI 10.1074/jbc.M410041200; Newgard CB, 2002, DIABETES, V51, pS389, DOI 10.2337/diabetes.51.2007.S389; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; PACE CS, 1983, J MEMBRANE BIOL, V73, P39, DOI 10.1007/BF01870339; PACE CS, 1986, METABOLISM, V35, P176, DOI 10.1016/0026-0495(86)90120-4; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; Rustenbeck I, 1997, N-S ARCH PHARMACOL, V356, P410, DOI 10.1007/PL00005070; Salgado AP, 1996, J BIOL CHEM, V271, P8738, DOI 10.1074/jbc.271.15.8738; Sempoux C, 2003, DIABETES, V52, P784, DOI 10.2337/diabetes.52.3.784; SHEPHERD RM, 1995, J BIOL CHEM, V270, P7915, DOI 10.1074/jbc.270.14.7915; SMITH JS, 1983, DIABETES, V32, P61, DOI 10.2337/diabetes.32.1.61; Stiernet P, 2006, J BIOL CHEM, V281, P22142, DOI 10.1074/jbc.M513224200; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; TAGUCHI N, 1995, ENDOCRINOLOGY, V136, P3942, DOI 10.1210/en.136.9.3942; TREBILCOCK R, 1990, MOL CELL ENDOCRINOL, V71, P21, DOI 10.1016/0303-7207(90)90070-O; Wang CZ, 2000, J BIOL CHEM, V275, P35486, DOI 10.1074/jbc.C000456200; Wang D, 2003, NAT CELL BIOL, V5, P1117, DOI 10.1038/ncb1072	56	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24538	24546		10.1074/jbc.M702862200	http://dx.doi.org/10.1074/jbc.M702862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17599909	Green Submitted, hybrid			2022-12-25	WOS:000248933000007
J	Baena, A; Mootnick, AR; Falvo, JV; Tsytsykova, AV; Ligeiro, F; Diop, OM; Brieva, C; Gagneux, P; O'Brien, SJ; Ryder, OA; Goldfeld, AE				Baena, Andres; Mootnick, Alan R.; Falvo, James V.; Tsytsykova, Alla V.; Ligeiro, Filipa; Diop, Ousmane M.; Brieva, Claudia; Gagneux, Pascal; O'Brien, Stephen J.; Ryder, Oliver A.; Goldfeld, Anne E.			Primate TNF Promoters Reveal Markers of Phylogeny and Evolution of Innate Immunity	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA GENE; SINGLE-NUCLEOTIDE POLYMORPHISMS; COMPARATIVE SEQUENCE-ANALYSIS; TRANSCRIPTION FACTOR-BINDING; MONKEY SAIMIRI-SCIUREUS; NEW-WORLD MONKEYS; DNA EVIDENCE; EXPRESSION PATTERNS; MOLECULAR PHYLOGENY	Background. Tumor necrosis factor (TNF) is a critical cytokine in the immune response whose transcriptional activation is controlled by a proximal promoter region that is highly conserved in mammals and, in particular, primates. Specific single nucleotide polymorphisms (SNPs) upstream of the proximal human TNF promoter have been identified, which are markers of human ancestry. Methodology/Principal findings. Using a comparative genomics approach we show that certain fixed genetic differences in the TNF promoter serve as markers of primate speciation. We also demonstrate that distinct alleles of most human TNF promoter SNPs are identical to fixed nucleotides in primate TNF promoters. Furthermore, we identify fixed genetic differences within the proximal TNF promoters of Asian apes that do not occur in African ape or human TNF promoters. Strikingly, protein-DNA binding assays and gene reporter assays comparing these Asian ape TNF promoters to African ape and human TNF promoters demonstrate that, unlike the fixed differences that we define that are associated with primate phylogeny, these Asian ape-specific fixed differences impair transcription factor binding at an Sp1 site and decrease TNF transcription induced by bacterial stimulation of macrophages. Conclusions/significance. Here, we have presented the broadest interspecies comparison of a regulatory region of an innate immune response gene to date. We have characterized nucleotide positions in Asian ape TNF promoters that underlie functional changes in cell type-and stimulus-specific activation of the TNF gene. We have also identified ancestral TNF promoter nucleotide states in the primate lineage that correspond to human SNP alleles. These findings may reflect evolution of Asian and African apes under a distinct set of infectious disease pressures involving the innate immune response and TNF.	[Baena, Andres; Falvo, James V.; Tsytsykova, Alla V.; Ligeiro, Filipa; Goldfeld, Anne E.] Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; [Mootnick, Alan R.] Gibbon Conservat Ctr, Santa Clarita, CA USA; [Diop, Ousmane M.] Inst Pasteur, Lab Retrovirol, Dakar, Senegal; [Brieva, Claudia] Univ Nacl Colombia, Fac Med Vet & Zootecn, Unidad Rescate & Rehabil Anim Silvestres, Bogota, Colombia; [Gagneux, Pascal] Univ Calif San Diego, Dept Med & Cellular & Mol Med, Project Explaining Origin Humans, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; [O'Brien, Stephen J.] NCI, Lab Genom Divers, Frederick, MD 21701 USA; [Ryder, Oliver A.] Zool Soc San Diego, San Diego, CA USA; [Ryder, Oliver A.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar; Universidad Nacional de Colombia; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Zoological Society of San Diego; University of California System; University of California San Diego	Goldfeld, AE (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA.	goldfeld@cbrinstitute.org	Goldfeld, Anne/AAF-1818-2019; OBRIEN, STEPHEN/ABD-1346-2020	Baena, Andres/0000-0003-1309-1020; OBRIEN, STEPHEN/0000-0001-7857-0757	NIH [GM076685, HL59838]; NSF [0094993]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076685] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the NIH to A. E. G. (GM076685 and HL59838) and an NSF grant (0094993) to O.A.R.	Ackerman HC, 2003, GENES IMMUN, V4, P476, DOI 10.1038/sj.gene.6364008; Aguillon JC, 2006, IMMUNOBIOLOGY, V211, P75, DOI 10.1016/j.imbio.2005.09.005; Allen RD, 1999, MOL IMMUNOL, V36, P1017, DOI 10.1016/S0161-5890(99)00127-3; ALPER CA, 1982, CLIN IMMUNOL IMMUNOP, V24, P276, DOI 10.1016/0090-1229(82)90238-0; Baena A, 2002, GENES IMMUN, V3, P482, DOI 10.1038/sj.gene.6363898; Bailes E, 2003, SCIENCE, V300, P1713, DOI 10.1126/science.1080657; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055; Boffelli D, 2004, NAT REV GENET, V5, P456, DOI 10.1038/nrg1350; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Brandon-Jones D, 2004, INT J PRIMATOL, V25, P97, DOI 10.1023/B:IJOP.0000014647.18720.32; BRINKMAN BMN, 1995, HUM GENET, V96, P493; Caceres M, 2003, P NATL ACAD SCI USA, V100, P13030, DOI 10.1073/pnas.2135499100; Carroll SB, 2005, PLOS BIOL, V3, P1159, DOI 10.1371/journal.pbio.0030245; Carroll SB, 2003, NATURE, V422, P849, DOI 10.1038/nature01495; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Cooper GM, 2003, CURR OPIN GENET DEV, V13, P604, DOI 10.1016/j.gde.2003.10.001; DALFONSO S, 1994, IMMUNOGENETICS, V39, P150; Delgado JC, 2003, IMMUNOGENETICS, V55, P497, DOI 10.1007/s00251-003-0604-7; Ebersberger I, 2002, AM J HUM GENET, V70, P1490, DOI 10.1086/340787; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Enard W, 2004, ANNU REV GENOM HUM G, V5, P351, DOI 10.1146/annurev.genom.5.061903.180040; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Felsenstein J., 1993, PHYLIP PHYLOGENETIC; Fischer A, 2006, CURR BIOL, V16, P1133, DOI 10.1016/j.cub.2006.04.033; Gagneux P, 2001, MOL PHYLOGENET EVOL, V18, P2, DOI 10.1006/mpev.2000.0799; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gilad Y, 2006, NATURE, V440, P242, DOI 10.1038/nature04559; Gilad Y, 2003, P NATL ACAD SCI USA, V100, P3324, DOI 10.1073/pnas.0535697100; Glazko GV, 2003, MOL BIOL EVOL, V20, P424, DOI 10.1093/molbev/msg050; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Goldfeld AE, 2000, GENE, V261, P19, DOI 10.1016/S0378-1119(00)00477-7; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Green RE, 2006, NATURE, V444, P330, DOI 10.1038/nature05336; GROVES C, MAMMAL SPECIES WORLD; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; Hacia JG, 2001, TRENDS GENET, V17, P637, DOI 10.1016/S0168-9525(01)02494-5; Hahn MW, 2004, GENETICS, V167, P867, DOI 10.1534/genetics.103.025726; Hajeer AH, 2001, HUM IMMUNOL, V62, P1191, DOI 10.1016/S0198-8859(01)00322-6; HAMANN A, 1995, BIOCHEM BIOPH RES CO, V211, P833, DOI 10.1006/bbrc.1995.1887; Harland W.B., 1990, GEOLOGIC TIME SCALE; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Haudek SB, 1997, MOL IMMUNOL, V34, P1041, DOI 10.1016/S0161-5890(97)00124-7; Haudek SB, 1998, IMMUNOGENETICS, V48, P202, DOI 10.1007/s002510050424; Heissig F, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-r57; Hellmann I, 2003, GENOME RES, V13, P831, DOI 10.1101/gr.944903; Heraud JM, 2002, IMMUNOGENETICS, V54, P20, DOI 10.1007/s00251-002-0443-y; Hernandez EC, 2002, IMMUNOGENETICS, V54, P645, DOI 10.1007/s00251-002-0512-2; Higuchi T, 1998, TISSUE ANTIGENS, V51, P605, DOI 10.1111/j.1399-0039.1998.tb03002.x; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hollegaard MV, 2006, GENES IMMUN, V7, P269, DOI 10.1038/sj.gene.6364301; Karaman MW, 2003, GENOME RES, V13, P1619, DOI 10.1101/gr.1289803; Khaitovich P, 2005, SCIENCE, V309, P1850, DOI 10.1126/science.1108296; KLEIN J, 1986, NATURAL HIST MAJOR H; Kumar S, 2005, P NATL ACAD SCI USA, V102, P18842, DOI 10.1073/pnas.0509585102; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Leung JY, 2000, P NATL ACAD SCI USA, V97, P6614, DOI 10.1073/pnas.97.12.6614; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; McConkey EH, 2000, SCIENCE, V289, P1295; Merien F, 2003, VET IMMUNOL IMMUNOP, V92, P37, DOI 10.1016/S0165-2427(03)00018-7; Mittermeier Russell A., 2006, Primate Conservation, V20, P1, DOI 10.1896/0898-6207.20.1.1; Mootnick A, 2005, INT J PRIMATOL, V26, P971, DOI 10.1007/s10764-005-5332-4; Mootnick Alan R., 2006, Primate Conservation, V21, P103, DOI 10.1896/0898-6207.21.1.103; Muir CC, 2000, J MOL EVOL, V51, P471, DOI 10.1007/s002390010110; Muller S, 2003, HUM GENET, V113, P493, DOI 10.1007/s00439-003-0997-2; Mummidi S, 2000, J BIOL CHEM, V275, P18946, DOI 10.1074/jbc.M000169200; Noonan JP, 2006, SCIENCE, V314, P1113, DOI 10.1126/science.1131412; Olson MV, 2003, NAT REV GENET, V4, P20, DOI 10.1038/nrg981; Opazo JC, 2006, MOL PHYLOGENET EVOL, V40, P274, DOI 10.1016/j.ympev.2005.11.015; Ovcharenko I, 2004, GENOME RES, V14, P1191, DOI 10.1101/gr.1773104; Page SL, 2001, MOL PHYLOGENET EVOL, V18, P14, DOI 10.1006/mpev.2000.0895; Patterson N, 2006, NATURE, V441, P1103, DOI 10.1038/nature04789; Posch PE, 2003, GENES IMMUN, V4, P547, DOI 10.1038/sj.gene.6364023; Raaum RL, 2005, J HUM EVOL, V48, P237, DOI 10.1016/j.jhevol.2004.11.007; Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789; Rockman MV, 2005, PLOS BIOL, V3, P2208, DOI 10.1371/journal.pbio.0030387; Rockman MV, 2003, CURR BIOL, V13, P2118, DOI 10.1016/j.cub.2003.11.025; Roos C, 2001, MOL PHYLOGENET EVOL, V19, P486, DOI 10.1006/mpev.2001.0939; Ruvolo M, 1997, MOL BIOL EVOL, V14, P248, DOI 10.1093/oxfordjournals.molbev.a025761; Schrago CG, 2003, MOL BIOL EVOL, V20, P1620, DOI 10.1093/molbev/msg172; SCHRAGO CG, 2006, AM J PHYS ANTHR; Stauffer RL, 2001, J HERED, V92, P469, DOI 10.1093/jhered/92.6.469; Stedman HH, 2004, NATURE, V428, P415, DOI 10.1038/nature02358; Swofford D., 1998, PAUP PHYLOGENETIC AN; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; Takacs Z, 2005, MOL PHYLOGENET EVOL, V36, P456, DOI 10.1016/j.ympev.2005.03.032; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Tsytsykova AV, 2007, J BIOL CHEM, V282, P11629, DOI 10.1074/jbc.M611418200; Tsytsykova AV, 2002, MOL CELL BIOL, V22, P2620, DOI 10.1128/MCB.22.8.2620-2631.2002; Uglialoro AM, 1998, TISSUE ANTIGENS, V52, P359, DOI 10.1111/j.1399-0039.1998.tb03056.x; Varki A, 2005, GENOME RES, V15, P1746, DOI 10.1101/gr.3737405; VILLINGER F, 1995, J IMMUNOL, V155, P3946; Waldron-Lynch F, 2001, GENES IMMUN, V2, P82, DOI 10.1038/sj.gene.6363738; Webster MT, 2003, MOL BIOL EVOL, V20, P278, DOI 10.1093/molbev/msg037; Wienberg J, 2004, CURR OPIN GENET DEV, V14, P657, DOI 10.1016/j.gde.2004.10.001; Wildman DE, 2003, P NATL ACAD SCI USA, V100, P7181, DOI 10.1073/pnas.1232172100; Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; Wimmer R, 2002, CHROMOSOME RES, V10, P55, DOI 10.1023/A:1014222311431; Woolhouse MEJ, 2002, NAT GENET, V32, P569, DOI 10.1038/ng1202-569; Xu XF, 1996, J MOL EVOL, V43, P431, DOI 10.1007/PL00006103; Yunis EJ, 2003, TISSUE ANTIGENS, V62, P1, DOI 10.1034/j.1399-0039.2003.00098.x; Zhang YW, 2001, J MOL EVOL, V52, P516, DOI 10.1007/s002390010182; Zhi L, 1996, CURR BIOL, V6, P1326, DOI 10.1016/S0960-9822(02)70719-7; Zimmerman PA, 1996, IMMUNOGENETICS, V44, P485, DOI 10.1007/BF02602813	111	20	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e621	10.1371/journal.pone.0000621	http://dx.doi.org/10.1371/journal.pone.0000621			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637837	gold, Green Submitted, Green Published			2022-12-25	WOS:000207452100011
J	Amengual, B; Bourhy, H; Lopez-Roig, M; Serra-Cobo, J				Amengual, Blanca; Bourhy, Herve; Lopez-Roig, Marc; Serra-Cobo, Jordi			Temporal Dynamics of European Bat Lyssavirus Type 1 and Survival of Myotis myotis Bats in Natural Colonies	PLOS ONE			English	Article							RABIES VIRUS; INFECTION; POPULATIONS; EVOLUTION; EXCRETION; RACCOONS	Many emerging RNA viruses of public health concern have recently been detected in bats. However, the dynamics of these viruses in natural bat colonies is presently unknown. Consequently, prediction of the spread of these viruses and the establishment of appropriate control measures are hindered by a lack of information. To this aim, we collected epidemiological, virological and ecological data during a twelve-year longitudinal study in two colonies of insectivorous bats (Myotis myotis) located in Spain and infected by the most common bat lyssavirus found in Europe, the European bat lyssavirus subtype 1 (EBLV-1). This active survey demonstrates that cyclic lyssavirus infections occurred with periodic oscillations in the number of susceptible, immune and infected bats. Persistence of immunity for more than one year was detected in some individuals. These data were further used to feed models to analyze the temporal dynamics of EBLV-1 and the survival rate of bats. According to these models, the infection is characterized by a predicted low basic reproductive rate (R-0 = 1.706) and a short infectious period ( D = 5.1 days). In contrast to observations in most non-flying animals infected with rabies, the survival model shows no variation in mortality after EBLV-1 infection of M. myotis. These findings have considerable public health implications in terms of management of colonies where lyssavirus-positive bats have been recorded and confirm the potential risk of rabies transmission to humans. A greater understanding of the dynamics of lyssavirus in bat colonies also provides a model to study how bats contribute to the maintenance and transmission of other viruses of public health concern.	[Amengual, Blanca; Lopez-Roig, Marc; Serra-Cobo, Jordi] Univ Barcelona, Fac Biol, Dept Biol Anim, Barcelona, Spain; [Amengual, Blanca; Bourhy, Herve] Inst Pasteur, WHO Collaborating Ctr Reference & Res Rabies, UPRE Lyssavirus Dynam & Host Adaptat, Paris, France	University of Barcelona; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Serra-Cobo, J (corresponding author), Univ Barcelona, Fac Biol, Dept Biol Anim, Barcelona, Spain.	serracobo@areambiental.com	Serra-Cobo, Jordi/G-4673-2016; Bourhy, Hervé/F-5272-2010		Conselleria de Sanitat i Consum (Govern Illes Balears, Spain)	Conselleria de Sanitat i Consum (Govern Illes Balears, Spain)	The Conselleria de Sanitat i Consum (Govern Illes Balears, Spain) financed this study.	Aguilar-Setien A, 2005, EPIDEMIOL INFECT, V133, P517, DOI 10.1017/S0950268805003705; Amengual B, 1997, J GEN VIROL, V78, P2319, DOI 10.1099/0022-1317-78-9-2319; ANDERSON R M, 1991; AUBERT MFA, 1991, ANN RECH VET, V22, P77; Bacon P.J., 1985, P109; BAER GM, 1967, J INFECT DIS, V117, P82, DOI 10.1093/infdis/117.1.82; Bickham JW, 2004, MOL PHYLOGENET EVOL, V33, P333, DOI 10.1016/j.ympev.2004.06.012; BIGLER WJ, 1973, AM J EPIDEMIOL, V98, P326, DOI 10.1093/oxfordjournals.aje.a121562; Bourhy H, 2005, Euro Surveill, V10, P213, DOI 10.2807/esm.10.11.00575-en; BOURHY H, 1992, J CLIN MICROBIOL, V30, P2419, DOI 10.1128/JCM.30.9.2419-2426.1992; Brookes SM, 2005, EMERG INFECT DIS, V11, P572, DOI 10.3201/eid1104.040920; Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06; Childs JE, 2000, P NATL ACAD SCI USA, V97, P13666, DOI 10.1073/pnas.240326697; COX FEG, 1993, MODERN PARASITOLOGY, P288; COYNE MJ, 1989, AM J VET RES, V50, P2148; Davis PL, 2006, INFECT GENET EVOL, V6, P464, DOI 10.1016/j.meegid.2006.02.007; Davis PL, 2005, J VIROL, V79, P10487, DOI 10.1128/JVI.79.16.10487-10497.2005; Echevarria JE, 2001, J CLIN MICROBIOL, V39, P3678, DOI 10.1128/JCM.39.10.3678-3683.2001; FEKADU M, 1988, REV INFECT DIS, V10, pS678; Fooks AR, 2003, J MED VIROL, V71, P281, DOI 10.1002/jmv.10481; Grenfell B, 2002, P NATL ACAD SCI USA, V99, P3365, DOI 10.1073/pnas.062049599; HARRIS S, 2004, RABIES EUROPE MEDITE, P221; Harris SL, 2006, BIOL CONSERV, V131, P193, DOI 10.1016/j.biocon.2006.04.006; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; Lina PHC, 2006, DEV BIOLOGICALS, V125, P245; Mitchell-Jones AJ, 1999, ATLAS EUROPEAN MAMMA, P484; Muller T, 2004, J VET MED B, V51, P49, DOI 10.1111/j.1439-0450.2003.00725.x; Pollock KH, 1990, WILDLIFE MONOGR, V107, P3; Reynes JM, 2004, EMERG INFECT DIS, V10, P2231, DOI 10.3201/eid1012.040459; RONSHOLT L, 2002, RABIES B EUROPE, V2, P15; Rupprecht CE, 2002, LANCET INFECT DIS, V2, P327, DOI 10.1016/S1473-3099(02)00287-6; Serra-Cobo J, 2002, EMERG INFECT DIS, V8, P413, DOI 10.3201/eid0804.010263; Shankar V, 2004, J WILDLIFE DIS, V40, P403, DOI 10.7589/0090-3558-40.3.403; Tepsumethanon V, 2004, CLIN INFECT DIS, V39, P278, DOI 10.1086/421556; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Van der Poel WHM, 2005, EMERG INFECT DIS, V11, P1854, DOI 10.3201/eid1112.041200; VAUGHN JB, 1965, J AMER MED ASSOC, V193, P363, DOI 10.1001/jama.1965.03090050039010; Vazquez S, 2006, DEV BIOLOGICALS, V125, P257; Wellenberg GJ, 2002, ARCH VIROL, V147, P349, DOI 10.1007/s705-002-8324-3; White GC, 1999, BIRD STUDY, V46, P120, DOI 10.1080/00063659909477239; 2003, RABIES B EUROPE, V27, P1	41	69	71	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e566	10.1371/journal.pone.0000566	http://dx.doi.org/10.1371/journal.pone.0000566			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593965	gold, Green Submitted, Green Published			2022-12-25	WOS:000207451800010
J	Liska, D; Dufour, S; Zern, TL; Taksali, S; Cali, AMG; Dziura, J; Shulman, GI; Pierpont, BM; Caprio, S				Liska, David; Dufour, Sylvie; Zern, Tosca L.; Taksali, Sara; Cali, Anna M. G.; Dziura, James; Shulman, Gerald I.; Pierpont, Bridget M.; Caprio, Sonia			Interethnic Differences in Muscle, Liver and Abdominal Fat Partitioning in Obese Adolescents	PLOS ONE			English	Article								The prevalence of insulin resistance and type 2 diabetes (T2D) in obese youth is rapidly increasing, especially in Hispanics and African Americans compared to Caucasians. Insulin resistance is known to be associated with increases in intramyocellular (IMCL) and hepatic fat content. We determined if there are ethnic differences in IMCL and hepatic fat content in a multiethnic cohort of 55 obese adolescents. We used 1 H magnetic resonance spectroscopy (MRS) to quantify IMCL levels in the soleus muscle, oral glucose tolerance testing to estimate insulin sensitivity, magnetic resonance imaging (MRI) to measure abdominal fat distribution. Liver fat content was measured by fast-MRI. Despite similar age and % total body fat among the groups, IMCL was significantly higher in the Hispanics (1.71% [1.43%, 2.0%]) than in the African-Americans (1.04% [0.75%, 1.34%], p = 0.013) and the Caucasians (1.2% [0.94%, 1.5%], p = 0.04). Liver fat content was undetectable in the African Americans whereas it was two fold higher than normal in both Caucasians and Hispanics. Visceral fat was significantly lower in African Americans (41.5 cm(2) [34.6, 49.6]) and was similar in Caucasians (65.2 cm(2) [55.9, 76.0]) and Hispanics (70.5 cm(2) [59.9, 83.1]). In a multiple regression analysis, we found that ethnicity independent of age, gender and % body fat accounts for 10% of the difference in IMCL. Our study indicates that obese Hispanic adolescents have a greater IMCL lipid content than both Caucasians and African Americans, of comparable weight, age and gender. Excessive accumulation of fat in the liver was found in both Caucasian and Hispanic groups as opposed to virtually undetectable levels in the African Americans. Thus, irrespective of obesity, there seem to be some clear ethnic differences in the amount of lipid accumulated in skeletal muscle, liver and abdominal cavity.	[Caprio, Sonia] Yale Univ, Sch Med, Dept Pediat, Howard Hughes Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Gen Clin Res Ctr, New Haven, CT USA	Howard Hughes Medical Institute; Yale University; Yale University	Caprio, S (corresponding author), Yale Univ, Sch Med, Dept Pediat, Howard Hughes Inst, New Haven, CT 06510 USA.	sonia.caprio@yale.edu	Shulman, Gerald I./P-7176-2019; Liska, David/L-9180-2019	Shulman, Gerald I./0000-0003-1529-5668; Liska, David/0000-0002-8632-6065	National Institutes of Health (NIH) [R01-HD40787, R01-HD28016, K24-HD01464, P01-DK068229]; Yale General Clinical Research Center [M01-RR00125, R01-EB006494]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD028016, R01HD040787] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K24HD001464] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB006494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK068229] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yale General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by grants from the National Institutes of Health (NIH) R01-HD40787, R01-HD28016, and K24-HD01464 to Dr. Caprio, P01-DK068229 American Distinguished Clinical Investigator Award to Dr. Shulman, and M01-RR00125 to the Yale General Clinical Research Center, and R01-EB006494 (Bioimage Suite).	Abate N, 2003, J DIABETES COMPLICAT, V17, P39, DOI 10.1016/S1056-8727(02)00190-3; Arslanian SA, 2002, DIABETES, V51, P3014, DOI 10.2337/diabetes.51.10.3014; Arslanian SA, 2002, J PEDIATR ENDOCR MET, V15, P509; Bacha F, 2005, PEDIATR DIABETES, V6, P100, DOI 10.1111/j.1399-543X.2005.00108.x; Beha A, 2006, AM J PHYSIOL-ENDOC M, V290, pE989, DOI 10.1152/ajpendo.00459.2005; Carey DGP, 1996, INT J OBESITY, V20, P722; Dabelea D, 1999, ENDOCRIN METAB CLIN, V28, P709, DOI 10.1016/S0889-8529(05)70098-0; Fishbein MH, 1997, MAGN RESON IMAGING, V15, P287, DOI 10.1016/S0730-725X(96)00224-X; Goran MI, 2002, DIABETES CARE, V25, P2184, DOI 10.2337/diacare.25.12.2184; Gower BA, 1999, DIABETES, V48, P1515, DOI 10.2337/diabetes.48.8.1515; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; PAPADEMETRIS X, BIOIMAGE SUITE INTEG; Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603; Roden M, 2005, INT J OBESITY, V29, pS111, DOI 10.1038/sj.ijo.0803102; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Schwimmer JB, 2005, PEDIATRICS, V115, pE561, DOI 10.1542/peds.2004-1832; Shen J, 1997, MAGNET RESON MED, V38, P834, DOI 10.1002/mrm.1910380521; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; SZCEZPANIAK LS, 2005, AM J PHYSIOL-ENDOC M, V288, pE462; United States Census Bureau, 2004, US INT PROJ AG SEX R; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049; Yeckel CW, 2004, J CLIN ENDOCR METAB, V89, P1096, DOI 10.1210/jc.2003-031503	23	97	97	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e569	10.1371/journal.pone.0000569	http://dx.doi.org/10.1371/journal.pone.0000569			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593968	gold, Green Published, Green Submitted			2022-12-25	WOS:000207451800013
J	Caldon, C; Lee, C; Sutherland, R; Musgrove, E				Caldon, Ce; Lee, Csl; Sutherland, Rl; Musgrove, Ea			Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation	ONCOGENE			English	Article						Wt1; progesterone; cyclin D1; proliferation; lipogenesis	SUPPRESSOR GENE WT1; DEPENDENT KINASE INHIBITORS; CYCLIN D1; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTOR; EXPRESSION; PROGRESSION; ESTROGEN; RECEPTOR; INDUCTION	Progesterone regulates the proliferation and differentiation of normal mammary epithelium. In breast cancer cells, progesterone and its synthetic analogs, progestins, induce long-term growth inhibition and differentiation. However, the mechanisms responsible are not fully understood. When T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (16 alpha-ethoxy-21-hydroxy-19-norpregn-4-en-3,20-dione), all isoforms of Wilms' tumor protein 1 (Wt1) mRNA and protein were rapidly downregulated. We reasoned that the decrease in Wt1 levels may contribute to the long-term antiproliferative and differentiative effects of progestins as proliferation and differentiation are known end points of Wt1 action. Consistent with this idea, Wt1 small interfering RNA led to a decrease in S phase and cyclin D1 levels, and increased Oil-Red-O staining, indicating increased lipogenesis. Conversely, overexpression of Wt1 attenuated the decrease in S phase induced by ORG 2058 at 48-96 h. This was accompanied by the sustained expression of cyclin D1 despite progestin treatment, and increased levels of retinoblastoma (Rb) phosphorylation at sites targeted by cyclin D1-Cdk4 (Ser249/ Thr252). Wt1 overexpression also attenuated the ORG 2058-mediated increase in fatty acid synthase levels and reduced lipogenesis. Thus, Wt1 downregulation was sufficient to mimic the effects of progestin and was necessary for complete progestin-mediated proliferative arrest and subsequent differentiation. Furthermore, Wt1 overexpression modulated the effects of progestins but not anti-estrogens or androgens. These results indicate that Wt1 is an important early target of progestins that regulates both proliferation and differentiation in breast cancer cells.	[Caldon, Ce; Lee, Csl; Sutherland, Rl; Musgrove, Ea] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Caldon, Ce; Sutherland, Rl; Musgrove, Ea] Univ New S Wales, Fac Med, St Vincents Clin Sch, Kensington, NSW 2033, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Caldon, C (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	e.musgrove@garvan.org.au	Caldon, Liz/C-1559-2009; Sutherland, Robert L/A-8378-2008	Caldon, Liz/0000-0003-1392-3472; 				Anthony FW, 2003, J SOC GYNECOL INVEST, V10, P509, DOI 10.1016/S1071-5576(03)00147-3; Baudry D, 2000, CLIN CANCER RES, V6, P3957; Bray JD, 2005, J STEROID BIOCHEM, V97, P328, DOI 10.1016/j.jsbmb.2005.06.032; Burwell EA, 2007, ONCOGENE, V26, P3423, DOI 10.1038/sj.onc.1210127; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; Englert C, 1997, CANCER RES, V57, P1429; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Graham JD, 2005, MOL ENDOCRINOL, V19, P2713, DOI 10.1210/me.2005-0126; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Han YQ, 2004, ONCOGENE, V23, P6933, DOI 10.1038/sj.onc.1207609; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hui R, 2002, CANCER RES, V62, P6916; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 1999, NUCLEIC ACIDS RES, V27, P2889, DOI 10.1093/nar/27.14.2889; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Nakatsuka S, 2006, MODERN PATHOL, V19, P804, DOI 10.1038/modpathol.3800588; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; ORMANDY CJ, 1992, INT J CANCER, V50, P777, DOI 10.1002/ijc.2910500519; Rae FK, 2004, ONCOGENE, V23, P3067, DOI 10.1038/sj.onc.1207360; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Reizner N, 2005, J MOL ENDOCRINOL, V35, P135, DOI 10.1677/jme.1.01761; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Siehl JM, 2004, ANN HEMATOL, V83, P745, DOI 10.1007/s00277-004-0941-0; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tuna M, 2005, ONCOGENE, V24, P1648, DOI 10.1038/sj.onc.1208345; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, DEVELOPMENT, V132, P1327, DOI 10.1242/dev.01682; Wagner N, 2002, CELL GROWTH DIFFER, V13, P297; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Zaia A, 2001, ANTICANCER RES, V21, P1; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9	52	25	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					126	138		10.1038/sj.onc.1210622	http://dx.doi.org/10.1038/sj.onc.1210622			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599043				2022-12-25	WOS:000252118700013
J	Chetty, C; Bhoopathi, P; Lakka, SS; Rao, JS				Chetty, C.; Bhoopathi, P.; Lakka, S. S.; Rao, J. S.			MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line	ONCOGENE			English	Article						CD95 (APO/Fas); Fas-L; cytochrome c; apoptosis; MMP-2; TIMP-3	TISSUE INHIBITOR; METALLOPROTEINASE INHIBITORS; ANTITUMOR-ACTIVITY; GASTRIC-CANCER; CYTOCHROME-C; DEATH DOMAIN; TUMOR-GROWTH; EXPRESSION; GENE; OVEREXPRESSION	We have previously reported that the downregulation of MMP-2 by adenovirus-mediated delivery of MMP-2 siRNA (Ad-MMP-2) reduced spheroid invasion and angiogenesis in vitro, and, metastasis and tumor growth in vivo. In this study, we investigated the mechanism of Ad-MMP-2-mediated growth inhibition in vitro and in vivo. Ad-MMP-2 infection led to the induction of apoptosis as determined by TUNEL assay, Annexin-V staining and PARP-1 cleavage in a dose-dependent manner in A549 cells. Ad-MMP-2 decreased the content of the antiapoptotic members of the Bcl-2 family proteins (Bcl-2 and Bcl-xL) and increased the content of the proapoptotic members of the Bcl-2 family (Bax and Bcl-xS) as determined by immunoblotting analysis. Furthermore, Ad-MMP-2-mediated apoptosis was accompanied by increase in truncated Bid, release of cytochrome c and the activation of caspase-8, - 9 and -3. Immunoblot analysis showed that Ad-MMP-2 infection caused upregulation of Fas/Fas-L and FADD, and Anti-Fas-L antibody reversed Ad-MMP-2-induced apoptosis. Tissue inhibitor of metalloproteinases ( TIMP)- 3, an endogenous inhibitor of MMP-2, which cleaves Fas-L and activates the Fas/Fas-L inducing apoptotic pathway, was increased in Ad-MMP-2-treated cells. Adenovirus-mediated expression of MMP-2 siRNA in human lung xenografts in vivo resulted in increased immunostaining of Fas, Fas-L, cleaved Bid and TIMP-3. This is the first report, to our knowledge, showing that MMP-2 inhibition upregulates TIMP-3 levels, which in turn, promotes apoptosis in lung cancer.	[Chetty, C.; Bhoopathi, P.; Lakka, S. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Program Canc Biol, Peoria, IL 61656 USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu	bhoopathi, praveen/A-9410-2010		NCI NIH HHS [R01 CA092393, R01 CA075557-09, CA92393, R01 CA095058, CA95058, CA116708, R01 CA095058-03, CA75557, R01 CA075557, R01 CA116708-02, R01 CA116708, R01 CA092393-04] Funding Source: Medline; NINDS NIH HHS [NS57529, R01 NS057529-01, R01 NS057529, R01 NS047699, NS47699, R01 NS047699-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116708, R01CA092393, R01CA075557, R01CA095058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699, R01NS057529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Bramhall SR, 2002, BRIT J CANCER, V86, P1864, DOI 10.1038/sj.bjc.6600310; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; CAWSTON TE, 1995, BRIT MED BULL, V51, P385, DOI 10.1093/oxfordjournals.bmb.a072968; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; CHINNAIYAN AM, 1995, CELL, V81, P512; Drynda A, 2005, J IMMUNOL, V174, P6524, DOI 10.4049/jimmunol.174.10.6524; Evans JD, 2001, BRIT J CANCER, V85, P1865, DOI 10.1054/bjoc.2001.2168; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li WQ, 1998, J IMMUNOL, V161, P5000; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Mitsiades N, 2001, EXPERT OPIN INV DRUG, V10, P1075, DOI 10.1517/13543784.10.6.1075; Nyormoi O, 2003, CELL DEATH DIFFER, V10, P558, DOI 10.1038/sj.cdd.4401209; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Uramoto H, 1999, EUR J CANCER, V35, P1462, DOI 10.1016/S0959-8049(99)00157-4	32	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7675	7683		10.1038/sj.onc.1210584	http://dx.doi.org/10.1038/sj.onc.1210584			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599056	Green Accepted			2022-12-25	WOS:000251537800009
J	Newbery, HJ; Loh, DH; O'Donoghue, JE; Tomlinson, VAL; Chau, YY; Boyd, JA; Bergmann, JH; Brownstein, D; Abbott, CM				Newbery, H. J.; Loh, D. H.; O'Donoghue, J. E.; Tomlinson, V. A. L.; Chau, Y.-Y.; Boyd, J. A.; Bergmann, J. H.; Brownstein, D.; Abbott, C. M.			Translation elongation factor eEF1A2 is essential for post-weaning survival in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOID-TISSUE INVOLUTION; FACTOR 1-ALPHA; ANIMAL-MODEL; WASTED WST; EXPRESSION; GENE; MOUSE; FACTOR-1-ALPHA; S1; EEF1A-2/S1	Translation elongation factor eEF1A, formerly known as EF-1 alpha, exists as two variant forms; eEF1A1, which is almost ubiquitously expressed, and eEF1A2, whose expression is restricted to muscle and brain at the level of whole tissues. Expression analysis of these genes has been complicated by a general lack of availability of antibodies that specifically recognize each variant form. Wasted mice (wst/wst) have a 15.8-kilo-base deletion that abolishes activity of eEF1A2, but before this study it was unknown whether the deletion also affected neighboring genes. We have generated a panel of anti-peptide antibodies and used them to show that eEF1A2 is expressed at high levels in specific cell types in tissues previously thought not to express this variant, such as pancreatic islet cells and enteroendocrine cells in colon crypts. Expression of eEF1A1 and eEF1A2 is shown to be generally mutually exclusive, and we relate the expression pattern of eEF1A2 to the phenotype seen in wasted mice. We then carried out a series of transgenic experiments to establish whether the expression of other genes is affected by the deletion in wasted mice. We show that aspects of the phenotype such as motor neuron degeneration relate precisely to the relative expression of eEF1A1 and eEF1A2, whereas the immune system abnormalities are likely to result from a stress response. We conclude that loss of eEF1A2 function is solely responsible for the abnormalities seen in these mice.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Queens Med Res Inst, Res Anim Pathol Core Facil, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Abbott, CM (corresponding author), Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.	C.Abbott@ed.ac.uk	Abbott, Catherine M/C-7306-2013	O'Donoghue, Jean/0000-0001-6549-3430; Loh, Dawn/0000-0001-7876-5757; Abbott, Catherine/0000-0001-8794-7173				ABBOTT C, 1994, GENOMICS, V20, P94, DOI 10.1006/geno.1994.1131; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; BARONE KS, 1993, CELL IMMUNOL, V148, P226, DOI 10.1006/cimm.1993.1105; Bohnsack MT, 2002, EMBO J, V21, P6205, DOI 10.1093/emboj/cdf613; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; Chambers DM, 1998, P NATL ACAD SCI USA, V95, P4463, DOI 10.1073/pnas.95.8.4463; Chang RY, 2007, J CELL BIOCHEM, V100, P267, DOI 10.1002/jcb.20969; Chuang SM, 2005, MOL CELL BIOL, V25, P403, DOI 10.1128/MCB.25.1.403-413.2005; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Dominguez-Gerpe L, 1998, MECH AGEING DEV, V104, P195, DOI 10.1016/S0047-6374(98)00070-0; DominguezGerpe L, 1997, LIFE SCI, V61, P1019, DOI 10.1016/S0024-3205(97)00606-1; Fukuzuka K, 2000, AM J PHYSIOL-REG I, V278, pR1005, DOI 10.1152/ajpregu.2000.278.4.R1005; Gilmour LMR, 2002, CLIN CANCER RES, V8, P3933; HORI T, 1993, CLIN IMMUNOL IMMUNOP, V68, P243, DOI 10.1006/clin.1993.1125; Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762; Jamsai D, 2003, MOL BIOTECHNOL, V23, P29, DOI 10.1385/MB:23:1:29; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; KAISERLIAN D, 1985, J IMMUNOL, V135, P1126; Khalyfa A, 2001, J BIOL CHEM, V276, P22915, DOI 10.1074/jbc.M101011200; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; KOHMURA N, 1994, MOL CELL BIOL, V14, P6915, DOI 10.1128/MCB.14.10.6915; LEE S, 1995, EXP CELL RES, V219, P589, DOI 10.1006/excr.1995.1268; LEE S, 1992, J BIOL CHEM, V267, P24064; LEE S, 1993, J BIOL CHEM, V268, P24453; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lund A, 1996, GENOMICS, V36, P359, DOI 10.1006/geno.1996.0475; LUTSEP HL, 1989, J NEUROPATH EXP NEUR, V48, P519, DOI 10.1097/00005072-198909000-00003; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; Nakamura M, 1998, RECEPTOR CHANNEL, V5, P255; Newbery HJ, 2005, J NEUROPATH EXP NEUR, V64, P295, DOI 10.1093/jnen/64.4.295; OXFORD M, 2000, NUCLEIC ACIDS RES, V28, pE84; Pan J, 2004, DEV BRAIN RES, V149, P1, DOI 10.1016/j.devbrainres.2003.10.011; Potter M, 1998, CELL IMMUNOL, V188, P111, DOI 10.1006/cimm.1998.1346; Pruett SB, 2000, BRAIN BEHAV IMMUN, V14, P270, DOI 10.1006/brbi.2000.0605; Rotimi CN, 2004, DIABETES, V53, P838, DOI 10.2337/diabetes.53.3.838; Ruest LB, 2002, J BIOL CHEM, V277, P5418, DOI 10.1074/jbc.M110685200; Shamovsky I, 2006, NATURE, V440, P556, DOI 10.1038/nature04518; SHULTZ LD, 1982, NATURE, V297, P402, DOI 10.1038/297402a0; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; TEZUKA H, 1986, MUTAT RES, V161, P83, DOI 10.1016/0027-5107(86)90102-8; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Watanabe H, 2000, J NEUROCHEM, V75, P28, DOI 10.1046/j.1471-4159.2000.0750028.x	44	50	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2007	282	39					28951	28959		10.1074/jbc.M703962200	http://dx.doi.org/10.1074/jbc.M703962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	213BY	17640869	hybrid			2022-12-25	WOS:000249642100069
J	Magnani, R; Nayak, NR; Mazarei, M; Dirk, LMA; Houtz, RL				Magnani, Roberta; Nayak, Nihar R.; Mazarei, Mitra; Dirk, Lynnette M. A.; Houtz, Robert L.			Polypeptide substrate specificity of PsLSMT - A set domain protein methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; GAMMA-TOCOPHEROL METHYLTRANSFERASE; LARGE SUBUNIT; P53 ACTIVITY; PURIFICATION; METHYLATION; GENE; EXPRESSION; MECHANISM; CHROMATOGRAPHY	Rubisco large subunit methyltransferase (PsLSMT) is a SET domain protein responsible for the trimethylation of Lys-14 in the large subunit of Rubisco. The polypeptide substrate specificity determinants for pea Rubisco large subunit methyltransferase were investigated using a fusion protein construct between the first 23 amino acids from the large subunit of Rubisco and human carbonic anhydrase II. A total of 40 conservative and non-conservative amino acid substitutions flanking the target Lys-14 methylation site (positions P-3 to P+3) were engineered in the fusion protein. The catalytic efficiency (k(cat)/ K-m) of PsLSMT was determined using each of the substitutions and a polypeptide consensus recognition sequence deduced from the results. The consensus sequence, represented by X-(Gly/Ser)-(Phe/Tyr)-Lys-(Ala/Lys/Arg)-(Gly/Ser)-pi, where X is any residue, Lys is the methylation site, and pi is any aromatic or hydrophobic residue, was used to predict potential alternative substrates for PsLSMT. Four chloroplast-localized proteins were identified including gamma-tocopherol methyltransferase (gamma-TMT). In vitro methylation assays using PsLSMT and a bacterially expressed form of gamma-TMT from Perilla frutescens confirmed recognition and methylation of gamma-TMT by PsLSMT in vitro. RNA interference-mediated knockdown of the PsLSMT homologue (NtLSMT) in transgenic tobacco plants resulted in a 2-fold decrease of alpha-tocopherol, the product of gamma-TMT. The results demonstrate the efficacy of consensus sequence-driven identification of alternative substrates for PsLSMT as well as identification of functional attributes of protein methylation catalyzed by LSMT.	Univ Kentucky, Dept Hort Plant Physiol Biochem, Program Mol Biol, Lexington, KY 40546 USA; Univ Tennessee, Dept Plant Sci, Knoxville, TN 37996 USA	University of Kentucky; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Houtz, RL (corresponding author), Univ Kentucky, Dept Hort Plant Physiol Biochem, Program Mol Biol, 401D Plant Sci Bldg, Lexington, KY 40546 USA.	rhoutz@uky.edu		Mazarei, Mitra/0000-0002-6116-7758				Banerjee AL, 2004, PROTEIN EXPRES PURIF, V37, P450, DOI 10.1016/j.pep.2004.06.031; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Collazo E, 2005, ANAL BIOCHEM, V342, P86, DOI 10.1016/j.ab.2005.04.007; Couture JF, 2006, CURR OPIN STRUC BIOL, V16, P753, DOI 10.1016/j.sbi.2006.10.002; Couture JF, 2006, NAT STRUCT MOL BIOL, V13, P140, DOI 10.1038/nsmb1045; Couture JF, 2005, GENE DEV, V19, P1455, DOI 10.1101/gad.1318405; DellaPenna D, 2005, J PLANT PHYSIOL, V162, P729, DOI 10.1016/j.jplph.2005.04.004; Dirk LMA, 2007, BIOCHEMISTRY-US, V46, P3905, DOI 10.1021/bi6023644; Dirk LMA, 2006, ENZYMES, V24, P179, DOI 10.1016/S1874-6047(06)80009-0; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; DURBAN E, 1978, J BIOL CHEM, V253, P1427; ELLIS RJ, 1979, TRENDS BIOCHEM SCI, V4, P241, DOI 10.1016/0968-0004(79)90212-3; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Grimm R, 1997, FEBS LETT, V408, P350, DOI 10.1016/S0014-5793(97)00462-6; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Houtz RL, 2003, ARCH BIOCHEM BIOPHYS, V414, P150, DOI 10.1016/S0003-9861(03)00122-X; HOUTZ RL, 1989, P NATL ACAD SCI USA, V86, P1855, DOI 10.1073/pnas.86.6.1855; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; ISHIKO H, 1992, PHYTOCHEMISTRY, V31, P1499, DOI 10.1016/0031-9422(92)83094-F; KLEIN RR, 1995, PLANT MOL BIOL, V27, P249, DOI 10.1007/BF00020181; Koch M, 2003, EUR J BIOCHEM, V270, P84, DOI 10.1046/j.1432-1033.2003.03364.x; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; MCCURRY SD, 1982, METHOD ENZYMOL, V90, P515; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Patnaik D, 2004, J BIOL CHEM, V279, P53248, DOI 10.1074/jbc.M409604200; Sanchez-Machado DI, 2006, J CHROMATOGR A, V1105, P111, DOI 10.1016/j.chroma.2005.07.048; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SHIGEOKA S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P220, DOI 10.1016/0005-2760(92)90311-I; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; Trievel RC, 2004, CRIT REV EUKAR GENE, V14, P147, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.10; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; WANG P, 1995, PROTEIN EXPRES PURIF, V6, P528, DOI 10.1006/prep.1995.1070; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Xiao B, 2006, ENZYMES, V24, P155, DOI 10.1016/S1874-6047(06)80008-9; Ying ZT, 1996, PLANT MOL BIOL, V32, P663, DOI 10.1007/BF00020207; Ying ZT, 1999, J BIOL CHEM, V274, P36750, DOI 10.1074/jbc.274.51.36750; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zhang K, 2005, CELL, V122, P723, DOI 10.1016/j.cell.2005.06.021	45	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27857	27864		10.1074/jbc.M702069200	http://dx.doi.org/10.1074/jbc.M702069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635932	hybrid			2022-12-25	WOS:000249455600034
J	van Wonderen, JH; Knight, C; Oganesyan, VS; George, SJ; Zumft, WG; Cheesman, MR				van Wonderen, Jessica H.; Knight, Christopher; Oganesyan, Vasily S.; George, Simon J.; Zumft, Walter G.; Cheesman, Myles R.			Activation of the cytochrome cd(1) nitrite reductase from Paracoccus pantotrophus - Reaction of oxidized enzyme with substrate drives a ligand switch at heme c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MAGNETIC CIRCULAR-DICHROISM; PSEUDOMONAS-AERUGINOSA; THIOSPHAERA-PANTOTROPHA; THIOBACILLUS-DENITRIFICANS; HORSERADISH-PEROXIDASE; OXIDE REDUCTASE; PURIFICATION; SPECTROSCOPY; EPR	Cytochromes cd(1) are dimeric bacterial nitrite reductases, which contain two hemes per monomer. On reduction of both hemes, the distal ligand of heme d(1) dissociates, creating a vacant coordination site accessible to substrate. Heme c, which transfers electrons from donor proteins into the active site, has histidine/methionine ligainds except in the oxidized enzyme from Paracoccus pantotrophus where both ligands are histidine. During reduction of this enzyme, Tyr(25) dissociates from the distal side of heme d(1), and one heme c ligand is replaced by methionine. Activity is associated with histidine/methionine coordination at heme c, and it is believed that P.pantotrophus cytochrome cd(1) is unreactive toward substrate without reductive activation. However, we report here that the oxidized enzyme will react with nitrite to yield a novel species in which heme d(1) is EPR-silent. Magnetic circular dichroism studies indicate that heme d(1) is low-spin Fell, but EPR-silent as a result of spin coupling to a radical species formed during the reaction with nitrite. This reaction drives the switch to histidine/methionine ligation at Fell, heme c. Thus the enzyme is activated by exposure to its physiological substrate without the necessity of passing through the reduced state. This reactivity toward nitrite is also observed for oxidized cytochrome cd(1) from Pseudomonas stutzeri suggesting a more general involvement of the EPR-silent Fe-III heme d(1) species in nitrite reduction.	Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Ctr Metalloprotein Spectroscopy & Biol, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ Karlsruhe, Inst Appl Biosci, Div Mol Microbiol, D-76128 Karlsruhe, Germany; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of East Anglia; University of East Anglia; Helmholtz Association; Karlsruhe Institute of Technology; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Cheesman, MR (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England.	m.cheesman@uea.ac.uk	van Wonderen, Jessica/A-9728-2013	George, Simon/0000-0002-4864-5479	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Allen JWA, 2002, BIOCHEM J, V366, P883, DOI 10.1042/BJ20020795; Allen JWA, 2000, BIOCHEM BIOPH RES CO, V279, P674, DOI 10.1006/bbrc.2000.4009; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BESSON S, 1995, ANAEROBE, V1, P219, DOI 10.1006/anae.1995.1021; Cheesman MR, 1996, J AM CHEM SOC, V118, P7373, DOI 10.1021/ja960344i; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; Cheesman MR, 2004, J AM CHEM SOC, V126, P4157, DOI 10.1021/ja038858m; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cheesman MR, 1998, BIOCHEMISTRY-US, V37, P3994, DOI 10.1021/bi972437y; COYLE CL, 1985, EUR J BIOCHEM, V153, P459, DOI 10.1111/j.1432-1033.1985.tb09324.x; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; Fulop V, 2001, ADV INORG CHEM, V51, P163; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; GUDAT JC, 1973, BIOCHIM BIOPHYS ACTA, V292, P376, DOI 10.1016/0005-2728(73)90044-3; HILL KE, 1978, J BIOL CHEM, V253, P489; HOUSEMANN ALP, 1995, BIOCHEMISTRY-US, V32, P4430; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; HUYNH BH, 1982, J BIOL CHEM, V257, P9576; JOHNSON MK, 1980, BIOCHEM J, V189, P285, DOI 10.1042/bj1890285; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; LEGALL J, 1979, BIOCHEM BIOPH RES CO, V87, P355, DOI 10.1016/0006-291X(79)91804-7; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; MUHOBERAC BB, 1980, FED PROC, V39, P2061; MUHOBERAC BB, 1983, J BIOL CHEM, V258, P3019; Nurizzo D, 1999, J BIOL CHEM, V274, P14997, DOI 10.1074/jbc.274.21.14997; Nurizzo D, 1998, BIOCHEMISTRY-US, V37, P13987, DOI 10.1021/bi981348y; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; Rinaldo S, 2007, J BIOL CHEM, V282, P14761, DOI 10.1074/jbc.M700933200; Roldan MD, 1998, J BIOL CHEM, V273, P28785, DOI 10.1074/jbc.273.44.28785; SAMYN B, 1994, EUR J BIOCHEM, V219, P585, DOI 10.1111/j.1432-1033.1994.tb19974.x; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; SILVESTRINI MC, 1979, BIOCHEM J, V183, P701, DOI 10.1042/bj1830701; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SINGH J, 1974, BIOCHIM BIOPHYS ACTA, V333, P28, DOI 10.1016/0005-2728(74)90159-5; Sjogren T, 2001, J BIOL CHEM, V276, P29450, DOI 10.1074/jbc.M103657200; SUTHERLAND J, 1986, BIOCHEM J, V233, P893, DOI 10.1042/bj2330893; THOMSON AJ, 1993, METHOD ENZYMOL, V226, P199, DOI 10.1016/0076-6879(93)26011-W; VICKERY LE, 1978, BIOCHEM BIOPH RES CO, V80, P458, DOI 10.1016/0006-291X(78)90699-X; Walker FA, 1999, COORDIN CHEM REV, V185-6, P471, DOI 10.1016/S0010-8545(99)00029-6; WALSH TA, 1981, J INORG BIOCHEM, V14, P15, DOI 10.1016/S0162-0134(00)80011-2; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; WALSH TA, 1981, J INORG BIOCHEM, V14, P1, DOI 10.1016/S0162-0134(00)80010-0; Wang YN, 1996, J AM CHEM SOC, V118, P3972, DOI 10.1021/ja9538647; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P394; YAMANAKA T, 1961, BIOCHIM BIOPHYS ACTA, V53, P294, DOI 10.1016/0006-3002(61)90442-5; Zajicek RS, 2006, BIOCHEMISTRY-US, V45, P11208, DOI 10.1021/bi0604983; Zajicek RS, 2005, BIOCHEM SOC T, V33, P147, DOI 10.1042/BST0330147; Zajicek RS, 2004, FEBS LETT, V565, P48, DOI 10.1016/j.febslet.2004.03.072; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	58	15	16	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28207	28215		10.1074/jbc.M701242200	http://dx.doi.org/10.1074/jbc.M701242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17623666	hybrid			2022-12-25	WOS:000249455600070
J	Hillebrand, M; Verrier, SE; Ohlenbusch, A; Schafer, A; Soling, HD; Wouters, FS; Gartner, J				Hillebrand, Merle; Verrier, Sophie E.; Ohlenbusch, Andreas; Schaefer, Annika; Soeling, Hans-Dieter; Wouters, Fred S.; Gaertner, Jutta			Live cell FRET microscopy - Homo-and heterodimerization of two human peroxisomal ABC transporters, the adrenoleukodystrophy protein (ALDP, ABCD1) and PMP70 (ABCD3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; BINDING CASSETTE TRANSPORTERS; STEROL CARRIER PROTEIN-2; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE; MUTATIONS; IDENTIFICATION; PHENOTYPE; INTERACT	The adrenoleukodystrophy protein ( ALDP) and the 70-kDa peroxisomal membrane protein (PMP70) are half-ATP-binding cassette (ABC) transporters in the mammalian peroxisome membrane. Mutations in the gene encoding ALDP result in a devastating neurodegenerative disorder, X-linked adrenoleukodystrophy (X-ALD) that is associated with elevated levels of very long chain fatty acids because of impaired peroxisomal beta-oxidation. The interactions of peroxisomal ABC transporters, their role in the peroxisomal membrane, and their functions in disease pathogenesis are poorly understood. Studies on ABC transporters revealed that half-transporters have to dimerize to gain functionality. So far, conflicting observations are described for ALDP. By the use of in vitro methods ( yeast two-hybrid and immunoprecipitation assays) on the one hand, it was shown that ALDP can form homodimers as well as heterodimers with PMP70 and ALDR, while on the other hand, it was demonstrated that ALDP and PMP70 exclusively homodimerize. To circumvent the problems of artificial interactions due to biochemical sample preparation in vitro, we investigated protein-protein interaction of ALDP in its physiological environment by FRET microscopy in intact living cells. The statistical relevance of FRET data was determined in two different ways using probability distribution shift analysis and Kolmogorov-Smirnov statistics. We demonstrate in vivo that ALDP and PMP70 form homodimers as well as ALDP/PMP70 heterodimers where ALDP homodimers predominate. Using C-terminal deletion constructs of ALDP, we demonstrate that the last 87 C-terminal amino acids harbor the most important protein domain mediating these interactions, and that the N-terminal transmembrane region of ALDP has an additional stabilization effect on ALDP homodimers. Loss of ALDP homo- or heterodimerization is highly relevant for understanding the disease mechanisms of X-ALD.	Univ Gottingen, Fac Med, Dept Pediat & Pediat Neurol, D-37075 Gottingen, Germany; Max Planck Inst Biophys, Dept Neurobiol, D-37075 Gottingen, Germany; European Neurosci Inst, Cell Biophys Grp, D-37073 Gottingen, Germany	University of Gottingen; Max Planck Society	Gartner, J (corresponding author), Univ Gottingen, Fac Med, Dept Pediat & Pediat Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.	gaertnj@med.uni-goettingen.de						Aubourg P, 2000, GLIA, V29, P186, DOI 10.1002/(SICI)1098-1136(20000115)29:2<186::AID-GLIA13>3.0.CO;2-5; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; Dansen TB, 1999, BIOCHEM J, V339, P193, DOI 10.1042/0264-6021:3390193; Demidenko E, 2004, LECT NOTES COMPUT SC, V3046, P933; Esposito A, 2007, NEUROBIOL DIS, V26, P521, DOI 10.1016/j.nbd.2007.01.014; EWART GD, 1994, J BIOL CHEM, V269, P10370; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gartner J, 1998, NEUROPEDIATRICS, V29, P3, DOI 10.1055/s-2007-973526; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Germann U A, 1993, Semin Cell Biol, V4, P63; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; Gueugnon F, 2006, BIOCHEM BIOPH RES CO, V341, P150, DOI 10.1016/j.bbrc.2005.12.152; Guimaraes CP, 2005, J HUM GENET, V50, P99, DOI 10.1007/s10038-004-0226-4; Guimaraes CP, 2004, BBA-MOL BASIS DIS, V1689, P235, DOI 10.1016/j.bbadis.2004.04.001; Halbach A, 2005, J BIOL CHEM, V280, P21176, DOI 10.1074/jbc.M501750200; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V237, P152, DOI 10.1006/bbrc.1997.7102; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Kashiwayama Y, 2005, BBA-MOL CELL RES, V1746, P116, DOI 10.1016/j.bbamcr.2005.10.006; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kemp S, 2001, HUM MUTAT, V18, P499, DOI 10.1002/humu.1227; Landgraf P, 2003, EUR J CELL BIOL, V82, P401, DOI 10.1078/0171-9335-00331; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Moser HW, 1997, BRAIN, V120, P1485, DOI 10.1093/brain/120.8.1485; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roerig P, 2001, FEBS LETT, V492, P66, DOI 10.1016/S0014-5793(01)02235-9; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Shani N, 1996, P NATL ACAD SCI USA, V93, P11901, DOI 10.1073/pnas.93.21.11901; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Tanaka AR, 2002, J BIOL CHEM, V277, P40142, DOI 10.1074/jbc.M205079200; van Endert PM, 2002, TRENDS BIOCHEM SCI, V27, P454, DOI 10.1016/S0968-0004(02)02090-X; VANGEEL BM, 1994, NEUROLOGY, V44, P2343, DOI 10.1212/WNL.44.12.2343; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weller S, 2005, AM J HUM GENET, V76, P987, DOI 10.1086/430637; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9	43	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26997	27005		10.1074/jbc.M702122200	http://dx.doi.org/10.1074/jbc.M702122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17609205	hybrid			2022-12-25	WOS:000249304900040
J	Kozlov, G; Peschard, P; Zimmerman, B; Lin, T; Moldoveanu, T; Mansur-Azzam, N; Gehring, K; Park, M				Kozlov, Guennadi; Peschard, Pascal; Zimmerman, Brandon; Lin, Tong; Moldoveanu, Tudor; Mansur-Azzam, Nura; Gehring, Kalle; Park, Morag			Structural basis for UBA-mediated dimerization of c-Cbl ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DOMAIN BINDING-SITE; HIV-1 VPR; RECEPTOR; ADAPTER; COMPLEX; MET; ACTIVATION; REFINEMENT; INTERACTS	Ligand-induced down-regulation by the ubiquitin-protein ligases, c-Cbl and Cbl-b, controls signaling downstream from many receptor-tyrosine kinases (RTK). Cbl proteins bind to phosphotyrosine residues on activated RTKs to affect ligand-dependent ubiquitylation of these receptors targeting them for degradation in the lysosome. Both c-Cbl and Cbl-b contain a ubiquitin-associated (UBA) domain, which is important for Cbl dimerization and tyrosine phosphorylation; however, the mechanism of UBA-mediated dimerization and its requirement for Cbl biological activity is unclear. Here, we report the crystal structure of the UBA domain of c-Cbl refined to 2.1-angstrom resolution. The structure reveals the protein is a symmetric dimer tightly packed along a large hydrophobic surface formed by helices 2 and 3. NMR chemical shift mapping reveals heterodimerization can occur with the related Cbl-b UBA domain via the same surface employed for homodimerization. Disruption of c-Cbl dimerization by site-directed mutagenesis impairs c-Cbl phosphorylation following activation of the Met/hepatocyte growth factor RTK and c-Cbl-dependent ubiquitination of Met. This provides direct evidence for a role of Cbl dimerization in terminating signaling following activation of RTKs.	McGill Univ, Dept Biochem Med, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Mol Oncol Grp, Ctr Hlth, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Gehring, K (corresponding author), McGill Univ, Dept Biochem Med, Montreal, PQ H3A 2T5, Canada.	kalle.gehring@mcgill.ca; morag.park@mcgill.ca	Moldoveanu, Tudor/N-8173-2018; Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Moldoveanu, Tudor/0000-0003-0791-318X; Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184; Peschard, Pascal/0000-0001-6395-5566	NCRR NIH HHS [RR 01646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bayrer JR, 2005, J BIOL CHEM, V280, P32989, DOI 10.1074/jbc.M507990200; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; BLAKE TJ, 1992, ONCOGENE, V7, P757; Chang YG, 2006, PROTEIN SCI, V15, P1248, DOI 10.1110/ps.051995006; Chim N, 2004, PROTEINS, V54, P784, DOI 10.1002/prot.10636; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Dikic I, 2003, CELL MOL LIFE SCI, V60, P1805, DOI 10.1007/s00018-003-3029-4; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Hubbard SR, 2002, FRONT BIOSCI, V7, pD330, DOI 10.2741/hubbard; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Lowe ED, 2006, ACTA CRYSTALLOGR D, V62, P177, DOI 10.1107/S0907444905037777; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Peschard P, 2007, ONCOGENE, V26, P1276, DOI 10.1038/sj.onc.1210201; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2007, MOL CELL, V27, P474, DOI 10.1016/j.molcel.2007.06.023; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Sasaki T, 2005, BIOCHEM BIOPH RES CO, V336, P530, DOI 10.1016/j.bbrc.2005.08.126; Schiering N, 2000, BIOCHEMISTRY-US, V39, P13376, DOI 10.1021/bi0012336; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Trempe JF, 2005, EMBO J, V24, P3178, DOI 10.1038/sj.emboj.7600797; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Yuan XM, 2004, EMBO J, V23, P1463, DOI 10.1038/sj.emboj.7600152	40	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27547	27555		10.1074/jbc.M703333200	http://dx.doi.org/10.1074/jbc.M703333200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17635922	hybrid			2022-12-25	WOS:000249304900095
J	Westin, MAK; Hunt, MC; Alexson, SEH				Westin, Maria A. K.; Hunt, Mary C.; Alexson, Stefan E. H.			Peroxisomes contain a specific Phytanoyl-CoA/Pristanoyl-CoA thioesterase acting as a novel auxiliary enzyme in alpha- and beta-oxidation of methyl-branched fatty acids in mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-ALPHA; RAT-LIVER PEROXISOMES; MOLECULAR-CLONING; LIPID-METABOLISM; PRISTANIC ACID; CARNITINE OCTANOYLTRANSFERASE; SUBCELLULAR-LOCALIZATION; PURIFICATION; EXPRESSION; DISORDERS	Phytanic acid and pristanic acid are derived from phytol, which enter the body via the diet. Phytanic acid contains a methyl group in position three and, therefore, cannot undergo beta-oxidation directly but instead must first undergo alpha-oxidation to pristanic acid, which then enters beta-oxidation. Both these pathways occur in peroxisomes, and in this study we have identified a novel peroxisomal acyl-CoA thioesterase named ACOT6, which we show is specifically involved in phytanic acid and pristanic acid metabolism. Sequence analysis of ACOT6 revealed a putative peroxisomal targeting signal at the C-terminal end, and cellular localization experiments verified it as a peroxisomal enzyme. Subcellular fractionation experiments showed that peroxisomes contain by far the highest phytanoyl-CoA/ pristanoyl-CoA thioesterase activity in the cell, which could be almost completely immunoprecipitated using an ACOT6 antibody. Acot6 mRNA was mainly expressed in white adipose tissue and was co-expressed in tissues with Acox3 ( the pristanoyl-CoA oxidase). Furthermore, Acot6 was identified as a target gene of the peroxisome proliferator-activated receptor alpha ( PPAR alpha) and is up-regulated in mouse liver in a PPAR alpha-dependent manner.	Karolinska Univ Hosp Huddinge, Div Clin Chem, Dept Lab Med, Karolinska Inst, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Alexson, SEH (corresponding author), Karolinska Univ Hosp Huddinge, Div Clin Chem, Dept Lab Med, Karolinska Inst, SE-14186 Stockholm, Sweden.	stefan.alexson@ki.se		Watter, Maria/0000-0001-9047-5517; Hunt, Mary/0000-0001-6415-2992				AVIGAN J, 1966, BIOCHEM BIOPH RES CO, V24, P838, DOI 10.1016/0006-291X(66)90324-X; AVIGAN J, 1966, BIOCHIM BIOPHYS ACTA, V125, P607, DOI 10.1016/0005-2760(66)90051-8; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASE JFA, 1967, BIOCHEM J, V104, P510, DOI 10.1042/bj1040510; Croes K, 1999, J LIPID RES, V40, P601; FARRELL SO, 1983, ARCH BIOCHEM BIOPHYS, V222, P123, DOI 10.1016/0003-9861(83)90509-X; Ferdinandusse S, 1999, BIOCHEM BIOPH RES CO, V263, P213, DOI 10.1006/bbrc.1999.1340; Ferdinandusse S, 2000, J LIPID RES, V41, P1890; Foulon V, 1999, P NATL ACAD SCI USA, V96, P10039, DOI 10.1073/pnas.96.18.10039; Gloerich J, 2005, J LIPID RES, V46, P716, DOI 10.1194/jlr.M400337-JLR200; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; Jansen GA, 2001, BIOCHEM BIOPH RES CO, V283, P674, DOI 10.1006/bbrc.2001.4835; Jansen GA, 2006, BBA-MOL CELL RES, V1763, P1403, DOI 10.1016/j.bbamcr.2006.07.012; Johnson DW, 2003, J CHROMATOGR B, V798, P159, DOI 10.1016/j.jchromb.2003.09.014; Kotti TJ, 2000, J BIOL CHEM, V275, P20887, DOI 10.1074/jbc.M002067200; LEBON AM, 1988, LIPIDS, V23, P424, DOI 10.1007/BF02535514; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; MEIJER J, 1991, J SUBMICR CYTOL PATH, V23, P185; MIZE CE, 1966, J LIPID RES, V7, P692; Mukherji M, 2003, PROG LIPID RES, V42, P359, DOI 10.1016/S0163-7827(03)00016-X; Ofman R, 2002, BIOCHEM BIOPH RES CO, V290, P629, DOI 10.1006/bbrc.2001.6245; SCHMITZ W, 1994, EUR J BIOCHEM, V38, P2991; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; van den Brink DM, 2006, CELL MOL LIFE SCI, V63, P1752, DOI 10.1007/s00018-005-5463-y; Van Veldhoven PP, 2001, BIOCHEM SOC T, V29, P292, DOI 10.1042/BST0290292; VANVELDHOVEN PP, 1994, EUR J BIOCHEM, V222, P795; Verhoeven NM, 1998, FEBS LETT, V429, P225, DOI 10.1016/S0014-5793(98)00574-2; Verhoeven NM, 2001, PROG LIPID RES, V40, P453, DOI 10.1016/S0163-7827(01)00011-X; Wanders RJA, 2004, AM J MED GENET A, V126A, P355, DOI 10.1002/ajmg.a.20661; WANDERS RJA, 1992, BIOCHIM BIOPHYS ACTA, V1125, P274, DOI 10.1016/0005-2760(92)90056-2; Wanders RJA, 2006, BBA-MOL CELL RES, V1763, P1707, DOI 10.1016/j.bbamcr.2006.08.010; Watkins PA, 1996, J LIPID RES, V37, P2288; Westin MAK, 2005, J BIOL CHEM, V280, P38125, DOI 10.1074/jbc.M508479200; Westin MAK, 2004, J BIOL CHEM, V279, P21841, DOI 10.1074/jbc.M313863200; Willemsen MAAP, 2001, BRAIN, V124, P1426, DOI 10.1093/brain/124.7.1426; Zhang XG, 2006, BIOCHEM BIOPH RES CO, V346, P1307, DOI 10.1016/j.bbrc.2006.06.042; Zomer AWM, 2000, J LIPID RES, V41, P1801; Zomer AWM, 2003, ADV EXP MED BIOL, V544, P247	43	20	22	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26707	26716		10.1074/jbc.M703718200	http://dx.doi.org/10.1074/jbc.M703718200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17613526	hybrid			2022-12-25	WOS:000249304900009
J	Conchonaud, F; Nicolas, S; Amoureux, MC; Menager, C; Marguet, D; Lenne, PF; Rougon, G; Matarazzo, V				Conchonaud, Fabien; Nicolas, Stephane; Amoureux, Marie-Claude; Menager, Celine; Marguet, Didier; Lenne, Pierre-Francois; Rougon, Genevieve; Matarazzo, Valery			Polysialylation increases lateral diffusion of neural cell adhesion molecule in the cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; LIPID RAFTS; CORRELATION SPECTROSCOPY; PRECURSOR CELLS; NCAM; ORGANIZATION; PLASTICITY; RECEPTOR; GDNF; CYTOSKELETON	Polysialic acid (PSA) is a polymer of N-acetylneuraminic acid residues added post-translationally to the membrane-bound neural cell adhesion molecule ( NCAM). The large excluded volume created by PSA polymer is thought to facilitate cell migration by decreasing cell adhesion. Here we used live cell imaging ( spot fluorescence recovery after photobleaching and fluorescence correlation spectroscopy) combined with biochemical approaches in an attempt to uncover a link between cell motility and the impact of polysialylation on NCAM dynamics. We show that PSA regulates specifically NCAM lateral diffusion and this is dependent on the integrity of the cytoskeleton. However, whereas the glial-derivative neurotrophic factor chemotactic effect is dependent on PSA, the molecular dynamics of PSANCAM is not directly affected by glial-derivative neurotrophic factor. These findings reveal a new intrinsic mechanism by which polysialylation regulates NCAM dynamics and thereby a biological function like cell migration.	IBDML, Parc Sci Luminy, F-13288 Marseille 9, France; Univ Aix Marseille 2, Inst Biol Dev Marseille Luminy, F-13288 Marseille, France; Univ Aix Marseille 2, Ctr Immunol Marseille Luminy, MOSAIC Grp, F-13288 Marseille, France; CNRS, UMR 6216, F-13288 Marseille, France; CNRS, UMR 6102, F-13288 Marseille, France; INSERM, UMR 631, F-13288 Marseille, France; Univ Aix Marseille III, Inst Fresnel, F-13397 Marseille, France; CNRS, UMR 6133, F-13397 Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Rougon, G (corresponding author), IBDML, Parc Sci Luminy, Case 907, F-13288 Marseille 9, France.	rougon@ibdm.univ-mrs.fr	Matarazzo, Valery/M-9040-2016; Marguet, Didier/B-9946-2008; Matarazzo, Valery/V-2359-2019; Marguet, Didier/AGO-5421-2022; ROUGON, Genevieve/G-2578-2013	Matarazzo, Valery/0000-0002-0833-203X; Matarazzo, Valery/0000-0002-0833-203X; Marguet, Didier/0000-0003-3198-5095; ROUGON, Genevieve/0000-0003-1316-8200; Lenne, Pierre-Francois/0000-0003-1066-7506				Doetsch F, 1997, J NEUROSCI, V17, P5046; Gambin Y, 2006, P NATL ACAD SCI USA, V103, P2098, DOI 10.1073/pnas.0511026103; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Hinsby AM, 2004, FRONT BIOSCI-LANDMRK, V9, P2227, DOI 10.2741/1393; Iwase T, 2005, J NEUROCHEM, V94, P1488, DOI 10.1111/j.1471-4159.2005.03290.x; Jacobson KA, 1997, BBA-BIOMEMBRANES, V1330, P138, DOI 10.1016/S0005-2736(97)00128-4; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Kiss JZ, 2001, REV NEUROSCIENCE, V12, P297; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Lenne PF, 2006, EMBO J, V25, P3245, DOI 10.1038/sj.emboj.7601214; Muller D, 2000, P NATL ACAD SCI USA, V97, P4315, DOI 10.1073/pnas.070022697; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Okabe S, 1999, NAT NEUROSCI, V2, P804, DOI 10.1038/12175; Paratcha G, 2006, MOL CELL NEUROSCI, V31, P505, DOI 10.1016/j.mcn.2005.11.007; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025; Povlsen GK, 2003, NEUROCHEM RES, V28, P127, DOI 10.1023/A:1021660531484; Rougon G, 2003, ANNU REV NEUROSCI, V26, P207, DOI 10.1146/annurev.neuro.26.041002.131014; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Saarma M, 2001, TRENDS NEUROSCI, V24, P427, DOI 10.1016/S0166-2236(00)01864-6; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Stephens DJ, 2003, SCIENCE, V300, P82, DOI 10.1126/science.1082160; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Thoumine O, 2005, BIOPHYS J, V89, pL40, DOI 10.1529/biophysj.105.071688; Torregrossa P, 2004, J BIOL CHEM, V279, P30707, DOI 10.1074/jbc.M403935200; TSUJI A, 1986, BIOCHEMISTRY-US, V25, P6133, DOI 10.1021/bi00368a045; Vutskits L, 2003, EUR J NEUROSCI, V17, P2119, DOI 10.1046/j.1460-9568.2003.02660.x; WANG C, 1994, J NEUROSCI, V14, P4446; Wawrezinieck L, 2005, BIOPHYS J, V89, P4029, DOI 10.1529/biophysj.105.067959; Wawrezinieck L, 2004, PROC SPIE, V5462, P92, DOI 10.1117/12.545014; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; YANG PF, 1994, J BIOL CHEM, V269, P23039; Zhang H, 2004, J CELL SCI, V117, P93, DOI 10.1242/jcs.00827	39	22	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26266	26274		10.1074/jbc.M608590200	http://dx.doi.org/10.1074/jbc.M608590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623676	hybrid			2022-12-25	WOS:000249239600031
J	Li, JH; Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Bloodworth, LM; Zhang, XH; Wess, J				Li, Jian Hua; Han, Sung-Jun; Hamdan, Fadi F.; Kim, Soo-Kyung; Jacobson, Kenneth A.; Bloodworth, Lanh M.; Zhang, Xiaohong; Wess, Juergen			Distinct structural changes in a g protein-coupled receptor caused by different classes of agonist ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA(2) ADRENERGIC-RECEPTOR; DISULFIDE CROSS-LINKING; CONFORMATIONAL-CHANGES; INVERSE AGONISM; CYTOPLASMIC END; MOLECULAR-BASIS; IN-SITU; SULFHYDRYL REACTIVITY; CONSTITUTIVE ACTIVITY	The activity of Gprotein-coupled receptors can be modulated by different classes of ligands, including agonists that promote receptor signaling and inverse agonists that reduce basal receptor activity. The conformational changes in receptor structure induced by different agonist ligands are not well understood at present. In this study, we employed an in situ disulfide crosslinking strategy to monitor ligand-induced conformational changes in a series of cysteine-substituted mutant M-3 muscarinic acetylcholine receptors. The observed disulfide cross-linking patterns indicated that muscarinic agonists trigger a separation of the N-terminal segment of the cytoplasmic tail ( helix 8) from the cytoplasmic end of transmembrane domain I. In contrast, inverse muscarinic agonists were found to increase the proximity between these two receptor regions. These findings provide a structural basis for the opposing biological effects of muscarinic agonists and inverse agonists. This study also provides the first piece of direct structural information as to how the conformations induced by these two functionally different classes of ligands differ at the molecular level. Given the high degree of structural homology found among most G protein-coupled receptors, our findings should be of broad general relevance.	NIDDK, Natl Inst Hlth, Bioorgan Chem Lab, Mol Signaling Sect, Bethesda, MD 20892 USA; NIDDK, Natl Inst Hlth, Mol Recognit Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Natl Inst Hlth, Bioorgan Chem Lab, Mol Signaling Sect, Bldg 8A,Rm B1A-05,8 Ctr Dr,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov	Han, Sung-Jun/B-9547-2012; Li, Jianhua/B-7671-2011; Jacobson, Kenneth Alan/A-1530-2009	Li, Jianhua/0000-0002-5744-3182; Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031129, ZIADK031129, ZIADK031126, Z01DK031126] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Goin JC, 2006, J BIOL CHEM, V281, P5416, DOI 10.1074/jbc.M507476200; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; Han SJ, 2005, J BIOL CHEM, V280, P24870, DOI 10.1074/jbc.M500379200; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; KOBILKA BK, 2006, BIOCHIM BIOPHYS ACTA, V768, P794; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Lim WK, 2001, BIOCHEM J, V354, P337, DOI 10.1042/0264-6021:3540337; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Nelson CP, 2006, J PHARMACOL EXP THER, V316, P279, DOI 10.1124/jpet.105.094383; Nikolaev VO, 2006, J BIOL CHEM, V281, P24506, DOI 10.1074/jbc.M603266200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Santos N. M. D., 2006, J BIOL CHEM, V281, P12896; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; Strange PG, 2002, TRENDS PHARMACOL SCI, V23, P89, DOI 10.1016/S0165-6147(02)01993-4; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Swift S, 2006, J BIOL CHEM, V281, P4109, DOI 10.1074/jbc.M509525200; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Ward SDC, 2006, BIOCHEMISTRY-US, V45, P676, DOI 10.1021/bi051503q; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	49	40	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26284	26293		10.1074/jbc.M704875200	http://dx.doi.org/10.1074/jbc.M704875200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623649	hybrid			2022-12-25	WOS:000249239600033
J	Liko, D; Slattery, MG; Heideman, W				Liko, Dritan; Slattery, Matthew G.; Heideman, Warren			Stb3 binds to ribosomal RNA processing element motifs that control transcriptional responses to growth in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL GENOMICS APPROACH; RPD3 HISTONE DEACETYLASE; GENE-EXPRESSION; STATIONARY-PHASE; PROTEIN GENES; RRB REGULON; YEAST; IDENTIFICATION; GLUCOSE; TOR	Transfer of quiescent Saccharomyces cerevisiae cells to fresh medium rapidly induces hundreds of genes needed for growth. A large subset of these genes is regulated via a DNA sequence motif known as the ribosomal RNA processing element (RRPE). However, no RRPE-binding proteins have been identified. We screened a panel of 6144 glutathione S-transferase-open reading frame fusions for RRPE-binding proteins and identified Stb3 as a specific RRPE-binding protein, both in vitro and in vivo. Chromatin immunoprecipitation experiments showed that glucose increases Stb3 binding to RRPE-containing promoters. Microarray experiments demonstrated that the loss of Stb3 inhibits the transcriptional response to fresh glucose, especially for genes with RRPE motifs. However, these experiments also showed that not all genes containing RRPEs were dependent on Stb3 for expression. Overall our data support a model in which Stb3 plays an important but not exclusive role in the transcriptional response to growth conditions.	Univ Wisconsin, Sch Pharm, Dept Pharmaceut Sci, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Dept Biomol Cherm, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Heideman, W (corresponding author), Univ Wisconsin, Sch Pharm, Dept Pharmaceut Sci, 777 Highland Ave, Madison, WI 53705 USA.	wheidema@wisc.edu	Liko, Dritan/A-3549-2011					Barbara KE, 2007, MOL GENET GENOMICS, V277, P171, DOI 10.1007/s00438-006-0182-0; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Fabrizio P, 2003, GENETICS, V163, P35; Fingerman I, 2003, EUKARYOT CELL, V2, P1061, DOI 10.1128/EC.2.5.1061-1068.2003; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; Hazbun TR, 2002, MOL CELL PROTEOMICS, V1, P538, DOI 10.1074/mcp.T200002-MCP200; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Humphrey EL, 2004, CHEM BIOL, V11, P295, DOI 10.1016/j.chembiol.2004.03.001; Johnston Leland H., 1992, Trends in Cell Biology, V2, P353, DOI 10.1016/0962-8924(92)90041-K; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jorgensen P, 2002, GENETICS, V162, P1091; KALKUM M, 2001, P 49 ASMS C MASS SPE; Kasten MM, 1997, MOL GEN GENET, V256, P376, DOI 10.1007/s004380050581; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li C., 2003, ANAL GENE EXPRESSION, P120; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; MAGER WH, 1990, BIOCHIM BIOPHYS ACTA, V1050, P351, DOI 10.1016/0167-4781(90)90193-6; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Martinez MJ, 2004, MOL BIOL CELL, V15, P5295, DOI 10.1091/mbc.E03-11-0856; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; Newcomb LL, 2002, MOL CELL BIOL, V22, P1607, DOI 10.1128/MCB.22.5.1607-1614.2002; Parviz F, 1998, J BACTERIOL, V180, P4508, DOI 10.1128/JB.180.17.4508-4515.1998; Phizicky EM, 2002, METHOD ENZYMOL, V350, P546; Pina B, 2003, MOL GENET GENOMICS, V268, P791, DOI 10.1007/s00438-002-0801-3; Radonjic M, 2005, MOL CELL, V18, P171, DOI 10.1016/j.molcel.2005.03.010; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Rudra D, 2005, EMBO J, V24, P533, DOI 10.1038/sj.emboj.7600553; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Schneper L, 2004, CURR OPIN MICROBIOL, V7, P624, DOI 10.1016/j.mib.2004.10.002; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Slattery MG, 2007, CELL CYCLE, V6, P1210, DOI 10.4161/cc.6.10.4257; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Tsang CK, 2003, EMBO J, V22, P6045, DOI 10.1093/emboj/cdg578; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; Wade C, 2001, MOL CELL BIOL, V21, P8638, DOI 10.1128/MCB.21.24.8638-8650.2001; Wade CH, 2006, YEAST, V23, P293, DOI 10.1002/yea.1353; Wade JT, 2004, NATURE, V432, P1054, DOI 10.1038/nature03175; Wang Y, 2004, PLOS BIOL, V2, P610, DOI 10.1371/journal.pbio.0020128; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7	46	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26623	10.1074/jbc.M704762200	http://dx.doi.org/10.1074/jbc.M704762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17616518	hybrid			2022-12-25	WOS:000249239600065
J	Stauff, DL; Torres, VJ; Skaar, EP				Stauff, Devin L.; Torres, Victor J.; Skaar, Eric P.			Signaling and DNA-binding activities of the staphylococcus aureus HssR-HssS two-component system required for heme sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-CHAIN-REACTION; GENE-EXPRESSION; REGULATORY SYSTEM; ESCHERICHIA-COLI; VIRULENCE DETERMINANTS; BACTERIAL CHEMOTAXIS; TRANSDUCTION SYSTEM; IDENTIFICATION; IRON; OPERON	For the important human pathogen Staphylococcus aureus, host heme is a vital source of nutrient iron during infection. Paradoxically, heme is also toxic at high concentrations and is capable of killing S. aureus. To maintain cellular heme homeo-stasis, S. aureus employs the coordinated actions of the heme sensing two-component system (HssRS) and the heme regulated transporter efflux pump ( HrtAB). HssRS-dependent expression of HrtAB results in the alleviation of heme toxicity and tempered staphylococcal virulence. Although genetic experiments have defined the role of HssRS in the heme-dependent activation of hrtAB, the mechanism of this activation is not known. Furthermore, the global effect of HssRS on S. aureus gene expression has not been evaluated. Herein, we combine multi-variable difference gel electrophoresis with mass spectrometry to identify the heme-induced cytoplasmic HssRS regulon. These experiments establish hrtAB as the major target of activation by HssRS in S. aureus. In addition, we show that signaling between the sensor histidine kinase HssS and the response regulator HssR is necessary for growth of S. aureus in high concentrations of heme. Finally, we show that a direct repeat DNA sequence within the hrtAB promoter is required for heme-induced, HssR-dependent expression driven by this promoter and that phosphorylated HssR binds to this direct repeat upon exposure of S. aureus to high concentrations of heme. Taken together, these data establish the mechanism for HssRS-dependent expression of HrtAB and, in turn, provide a functional understanding for how S. aureus avoids heme-mediated toxicity.	Vanderbilt Univ, Med Ctr, Dept Immunol & Microbiol, Nashville, TN 37232 USA	Vanderbilt University	Skaar, EP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Immunol & Microbiol, Nashville, TN 37232 USA.	eric.skaar@vanderbilt.edu		Torres, Victor/0000-0002-7126-0489	NHLBI NIH HHS [T32 HL069765] Funding Source: Medline; NIAID NIH HHS [AI071487, AI69233] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI069233, F32AI071487] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson KL, 2006, J BACTERIOL, V188, P6739, DOI 10.1128/JB.00609-06; Bae T, 2006, PLASMID, V55, P58, DOI 10.1016/j.plasmid.2005.05.005; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; Bronner S, 2004, FEMS MICROBIOL REV, V28, P183, DOI 10.1016/j.femsre.2003.09.003; Brunskill EW, 1996, J BACTERIOL, V178, P611, DOI 10.1128/jb.178.3.611-618.1996; BULLEN JJ, 1999, IRON INFECTION MOL P; Cheung AL, 2004, FEMS IMMUNOL MED MIC, V40, P1, DOI 10.1016/S0928-8244(03)00309-2; Clausen VA, 2003, J MOL MICROB BIOTECH, V5, P252, DOI 10.1159/000071077; DEISS A, 1983, SEMIN HEMATOL, V20, P81; Dubrac S, 2004, J BACTERIOL, V186, P1175, DOI 10.1128/JB.186.4.1175-1181.2004; DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95; Everse J, 1997, FREE RADICAL BIO MED, V22, P1075, DOI 10.1016/S0891-5849(96)00499-6; Fabret C, 1998, J BACTERIOL, V180, P6375; Fournier B, 2001, MOL MICROBIOL, V41, P247, DOI 10.1046/j.1365-2958.2001.02515.x; Friedman DB, 2006, PLOS PATHOG, V2, P777, DOI 10.1371/journal.ppat.0020087; Fuchs S, 2007, J BACTERIOL, V189, P4275, DOI 10.1128/JB.00081-07; Giraudo AT, 1997, ARCH MICROBIOL, V168, P53, DOI 10.1007/s002030050469; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Mascher T, 2006, MICROBIOL MOL BIOL R, V70, P910, DOI 10.1128/MMBR.00020-06; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MIZUNO T, 1982, J BIOL CHEM, V257, P13692; NAKASHIMA K, 1992, MOL MICROBIOL, V6, P1777, DOI 10.1111/j.1365-2958.1992.tb01350.x; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; RECSEI P, 1986, MOL GEN GENET, V202, P58, DOI 10.1007/BF00330517; Reniere ML, 2007, BIOMETALS, V20, P333, DOI 10.1007/s10534-006-9032-0; Richardson AR, 2006, MOL MICROBIOL, V61, P927, DOI 10.1111/j.1365-2958.2006.05290.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Skaar EP, 2004, MICROBES INFECT, V6, P390, DOI 10.1016/j.micinf.2003.12.008; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; Stojiljkovic I, 2001, EXPERT OPIN INV DRUG, V10, P309, DOI 10.1517/13543784.10.2.309; Stojiljkovic I, 1999, MOL MICROBIOL, V31, P429, DOI 10.1046/j.1365-2958.1999.01175.x; TAYLOR RK, 1981, J BACTERIOL, V147, P255, DOI 10.1128/JB.147.1.255-258.1981; Throup JP, 2001, BIOCHEMISTRY-US, V40, P10392, DOI 10.1021/bi0102959; Torres VJ, 2007, CELL HOST MICROBE, V1, P109, DOI 10.1016/j.chom.2007.03.001; Torres VJ, 2006, J BACTERIOL, V188, P8421, DOI 10.1128/JB.01335-06; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; Wardenburg JB, 2006, P NATL ACAD SCI USA, V103, P13831, DOI 10.1073/pnas.0603072103; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; Yarwood JM, 2001, J BACTERIOL, V183, P1113, DOI 10.1128/JB.183.4.1113-1123.2001	47	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26111	26121		10.1074/jbc.M703797200	http://dx.doi.org/10.1074/jbc.M703797200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17635909	hybrid			2022-12-25	WOS:000249239600014
J	He, YX; Liu, SW; Jing, WG; Lu, H; Cai, DM; Chin, DJ; Debnath, AK; Kirchhoff, F; Jiang, SB				He, Yuxian; Liu, Shuwen; Jing, Weiguo; Lu, Hong; Cai, Dongmei; Chin, Darin Jeekin; Debnath, Asim K.; Kirchhoff, Frank; Jiang, Shibo			Conserved residue Lys(574) in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ENVELOPE GLYCOPROTEIN; TRANSMEMBRANE PROTEIN GP41; PEPTIDE INHIBITOR; MEMBRANE-FUSION; TARGETING GP41; CORE STRUCTURE; INTERHELICAL INTERACTIONS; MONOCLONAL-ANTIBODY; MUTATIONAL ANALYSIS; ANTIVIRAL ACTIVITY	The fusion-active HIV-1 gp41 core structure is a stable six-helix bundle ( 6-HB) formed by its N- and C-terminal heptad-repeat sequences ( NHR and CHR). A highly conserved, deep hydrophobic cavity on the surface of the N- helical trimer is important for stability of the 6-HB and serves as an ideal target for developing anti-human immunodeficiency virus ( HIV) fusion inhibitors. We have recently identified several small molecule HIV-1 fusion inhibitors that bind to the gp41 cavity through hydrophobic and ionic interactions and block the gp41 6-HB formation. Molecular docking analysis reveals that these small molecules fit inside the hydrophobic cavity and interact with positively charged residue Lys(574) to form a conserved salt bridge. In this study, the functionality of Lys574 has been finely characterized by mutational analysis and biophysical approaches. We found that substitutions of Lys574 with non-conserved residues ( K574D, K574E, and K574V) could completely abolish virus infectivity. With a set of wildtype and mutant N36 peptides derived from the NHR sequence as a model, we demonstrated that non-conservative Lys574 substitutions severely impaired the stability and conformation of 6-HBs as detected by circular dichroism spectroscopy, native polyacrylamide gel electrophoresis, and enzyme-linked immunosorbent assay. The binding affinity of N36 mutants bearing non-conservative Lys574 substitutions to the peptide C34 derived from the CHR sequence dramatically decreased as measured by isothermal titration calorimetry. These substitutions also significantly reduced the potency of N- peptides to inhibit HIV-1 infection. Collectively, these data suggest that conserved Lys574 plays a critical role in 6-HB formation and HIV-1 infectivity, and may serve as an important target for designing anti-HIV drugs.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; So Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Guangdong, Peoples R China; Univ Ulm, Inst Virol, D-89081 Ulm, Germany	New York Blood Center; Southern Medical University - China; Ulm University	He, YX (corresponding author), 310 E 67th St, New York, NY 10021 USA.	yhe@nybloodcenter.org; sjiang@nybloodcenter.org	Jiang, Shibo/L-4500-2014; Kirchhoff, Frank/O-8367-2018	Jiang, Shibo/0000-0001-8283-7135; Kirchhoff, Frank/0000-0002-7052-2360; Liu, Shuwen/0000-0001-6346-5006	PHS HHS [R01 AZ46221] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chang DK, 1999, J BIOL CHEM, V274, P5299, DOI 10.1074/jbc.274.9.5299; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d; Dong XN, 2001, IMMUNOL LETT, V75, P215, DOI 10.1016/S0165-2478(00)00302-3; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Gallo SA, 2006, J BIOL CHEM, V281, P18787, DOI 10.1074/jbc.M602422200; He YX, 2003, VACCINE, V21, P4421, DOI 10.1016/S0264-410X(03)00451-1; Ji H, 1999, J VIROL, V73, P8578, DOI 10.1128/JVI.73.10.8578-8586.1999; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004; Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5; Jiang SB, 2000, BIOCHEM BIOPH RES CO, V270, P153, DOI 10.1006/bbrc.2000.2411; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Korazim O, 2006, J MOL BIOL, V364, P1103, DOI 10.1016/j.jmb.2006.08.091; Lalezari JP, 2003, AIDS, V17, P691, DOI 10.1097/00002030-200303280-00007; Liu J, 2002, J BIOL CHEM, V277, P12891, DOI 10.1074/jbc.M110315200; Liu SW, 2005, BBA-GEN SUBJECTS, V1723, P270, DOI 10.1016/j.bbagen.2005.02.012; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Liu SW, 2004, CURR PHARM DESIGN, V10, P1827, DOI 10.2174/1381612043384466; Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lu M, 1999, J VIROL, V73, P4433, DOI 10.1128/JVI.73.5.4433-4438.1999; Lu M, 2001, J VIROL, V75, P11146, DOI 10.1128/JVI.75.22.11146-11156.2001; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Mo HM, 2004, VIROLOGY, V329, P319, DOI 10.1016/j.virol.2004.08.025; Sackett K, 2006, J BIOL CHEM, V281, P21755, DOI 10.1074/jbc.M603135200; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; Vaillant A, 2006, ANTIMICROB AGENTS CH, V50, P1393, DOI 10.1128/AAC.50.4.1393-1401.2006; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; Weng YK, 2000, J VIROL, V74, P5368, DOI 10.1128/JVI.74.11.5368-5372.2000; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xu Y, 2006, J COMB CHEM, V8, P531, DOI 10.1021/cc0600167; Zhao Q, 2002, AIDS RES HUM RETROV, V18, P989, DOI 10.1089/08892220260235353	52	73	77	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25631	25639		10.1074/jbc.M703781200	http://dx.doi.org/10.1074/jbc.M703781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17616522	hybrid			2022-12-25	WOS:000249014100050
J	Chen, YF; Shakeel, SN; Bowers, J; Zhao, XC; Etheridge, N; Schaller, GE				Chen, Yi-Feng; Shakeel, Samina N.; Bowers, Julie; Zhao, Xue-Chu; Etheridge, Naomi; Schaller, G. Eric			Ligand-induced degradation of the ethylene receptor ETR2 through a proteasome-dependent pathway in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; HISTIDINE KINASE-ACTIVITY; SEEDLING-GROWTH-RESPONSE; RAF-LIKE KINASE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; MUTANT ARABIDOPSIS; ESCHERICHIA-COLI; MULTIGENE FAMILY; GENE FAMILY	Protein degradation plays an important role in modulating ethylene signal transduction in plants. Here we show that the ethylene receptor ETR2 is one such target for degradation and that its degradation is dependent upon perception of the signaling ligand ethylene. The ETR2 protein is initially induced by ethylene treatment, consistent with an increase in transcript levels. At ethylene concentrations above 1 mu l/liter, however, ETR2 protein levels subsequently decrease in a post-transcriptional fashion. Genetic and chemical approaches indicate that ethylene perception by the receptors initiates the reduction in ETR2 protein levels. The ethylene-induced decrease in ETR2 levels is not affected by cycloheximide, an inhibitor of protein biosynthesis, but is affected by proteasome inhibitors, indicating a role for the proteasome in ETR2 degradation. Ethylene-induced degradation still occurs in seedlings treated with brefeldin A, indicating that degradation of ETR2 does not require exit from its subcellular location at the endoplasmic reticulum. These data support a model in which ETR2 is degraded by a proteasome-dependent pathway in response to ethylene binding. Implications of this model for ethylene signaling are discussed.	Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	Dartmouth College; University System Of New Hampshire; University of New Hampshire	Schaller, GE (corresponding author), Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA.	george.e.schaller@dartmouth.edu	Etheridge, Naomi/C-6030-2009					Abeles F, 1992, ETHYLENE PLANT BIOL; Alonso JM, 1999, SCIENCE, V284, P2148, DOI 10.1126/science.284.5423.2148; [Anonymous], 2002, ARABIDOPSIS BOOK; Binder BM, 2004, PLANT PHYSIOL, V136, P2913, DOI 10.1104/pp.104.050369; Binder BM, 2004, PLANT PHYSIOL, V136, P2921, DOI 10.1104/pp.104.050393; Cancel JD, 2002, PLANT PHYSIOL, V129, P1557, DOI 10.1104/pp.003780; Chang C, 2001, BIOESSAYS, V23, P619, DOI 10.1002/bies.1087; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHANG C, 1995, P NATL ACAD SCI USA, V92, P4129, DOI 10.1073/pnas.92.10.4129; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Chen YF, 2002, J BIOL CHEM, V277, P19861, DOI 10.1074/jbc.M201286200; Clark KL, 1998, P NATL ACAD SCI USA, V95, P5401, DOI 10.1073/pnas.95.9.5401; Gagne JM, 2004, P NATL ACAD SCI USA, V101, P6803, DOI 10.1073/pnas.0401698101; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; Gao ZY, 2003, J BIOL CHEM, V278, P34725, DOI 10.1074/jbc.M305548200; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guo HW, 2003, CELL, V115, P667, DOI 10.1016/S0092-8674(03)00969-3; Hong BM, 1999, PLANT PHYSIOL, V119, P1165, DOI 10.1104/pp.119.4.1165; Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; Huang YF, 2003, PLANT J, V33, P221, DOI 10.1046/j.1365-313X.2003.01620.x; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee JH, 2006, BIOCHEM BIOPH RES CO, V350, P484, DOI 10.1016/j.bbrc.2006.09.074; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LORD JM, 1987, METHOD ENZYMOL, V148, P542; LUETHY MH, 1993, PLANT PHYSIOL, V101, P931, DOI 10.1104/pp.101.3.931; MAESHIMA M, 1992, PLANT PHYSIOL, V98, P1248, DOI 10.1104/pp.98.4.1248; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Moussatche P, 2004, J BIOL CHEM, V279, P48734, DOI 10.1074/jbc.M403100200; Nebenfuhr A, 1999, PLANT PHYSIOL, V121, P1127, DOI 10.1104/pp.121.4.1127; O'Malley RC, 2005, PLANT J, V41, P651, DOI 10.1111/j.1365-313X.2004.02331.X; Potuschak T, 2003, CELL, V115, P679, DOI 10.1016/S0092-8674(03)00968-1; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; SANDERS IO, 1991, ANN BOT-LONDON, V68, P97, DOI 10.1093/oxfordjournals.aob.a088242; Schaller GE, 1995, METHOD CELL BIOL, V50, P129, DOI 10.1016/S0091-679X(08)61027-4; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schaller GE, 2000, ADV BOT RES, V32, P109, DOI 10.1016/S0065-2296(00)32023-7; Shen YP, 2005, PLANT PHYSIOL, V139, P1234, DOI 10.1104/pp.105.067645; SISLER EC, 1991, PLANT HORMONE ETHYLE; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tieman DV, 2000, P NATL ACAD SCI USA, V97, P5663, DOI 10.1073/pnas.090550597; Wang KLC, 2004, NATURE, V428, P945, DOI 10.1038/nature02516; Wang WY, 2003, P NATL ACAD SCI USA, V100, P352, DOI 10.1073/pnas.0237085100; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WILEY HS, 1992, FUNDAMENTALS MED CEL; Yanagisawa S, 2003, NATURE, V425, P521, DOI 10.1038/nature01984; Zhao XC, 2002, PLANT PHYSIOL, V130, P1983, DOI 10.1104/pp.011635	51	108	118	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24752	24758		10.1074/jbc.M704419200	http://dx.doi.org/10.1074/jbc.M704419200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17595158	hybrid			2022-12-25	WOS:000248933000030
J	Sithu, SD; English, WR; Olson, P; Krubasik, D; Baker, AH; Murphy, G; D'Souza, SE				Sithu, Srinivas D.; English, William R.; Olson, Paul; Krubasik, Davia; Baker, Andrew H.; Murphy, Gillian; D'Souza, Stanley E.			Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE TRANSENDOTHELIAL MIGRATION; MATRIX-METALLOPROTEINASE; CELL-MIGRATION; TISSUE INHIBITOR; GELATINASE-A; ICAM-1; ACTIVATION; MT1-MMP; CLEAVAGE; SIGNALS	We examined the mechanism regulating intercellular cell adhesion molecule-1 ( ICAM-1)-dependent monocyte transendothelial migration. Monocyte migration through endothelial cells expressing ICAM- 1 alone was comparable to that of tumor necrosis factor- alpha- treated cells. Transmigration was reduced in ICAM- 1 lacking the cytoplasmic tail and in tyrosine to alanine substitutions at Tyr- 485 and Tyr- 474. Tissue inhibitors of matrix metalloproteinases ( TIMPs) - 2 and - 3 blocked transmigration, whereas TIMP- 1 was ineffective. This profile suggested a role for membrane-type matrix metalloproteinases ( MT-MMPs) in transmigration. Inhibitory antibodies and small interference RNA directed against MT1- MMP blocked transmigration, whereas overexpression of MT1- MMP in endothelial cells or monocytes promoted transmigration. MT1- MMP mediated the ectodomain cleavage of ICAM- 1 that was blocked by TIMP- 2 and - 3. Overexpression of MT1- MM Prescued function in ICAM-1Y485A, and to a lesser extent in the cytoplasmic tail-deleted ICAM- 1. In a binding assay, wild-type ICAM- 1 bound to purified MT1- MMP while ICAM- 1 mutants bound poorly. MT1- MMP co-localized with ICAM- 1 at distinct structures in endothelial cells. MT1- MMP localization with cells expressing ICAM- 1 mutations was reduced and diffused. These results indicate that the cytoplasmic tail of ICAM- 1 regulates leukocyte transmigration through MT1- MMP interaction.	Univ Louisville, Hlth Sci Ctr, Dept Physiol & Biophys, Louisville, KY 40292 USA; Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England; Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow G12 8TA, Lanark, Scotland	University of Louisville; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Glasgow	D'Souza, SE (corresponding author), Univ Louisville, Hlth Sci Ctr, Dept Physiol & Biophys, A-1115, Louisville, KY 40292 USA.	sedsou01@louisville.edu	Baker, Andy/AAO-5250-2021	Baker, Andy/0000-0003-1441-5576; English, William/0000-0003-3024-2441	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011860] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01ES011860] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson P, 1999, J IMMUNOL, V162, P2964; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bridges LC, 2005, CURR PHARM DESIGN, V11, P837, DOI 10.2174/1381612053381747; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; Faveeuw C, 2001, BLOOD, V98, P688, DOI 10.1182/blood.V98.3.688; Gardiner EE, 1999, J BIOL CHEM, V274, P11930, DOI 10.1074/jbc.274.17.11930; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holland J, 1997, J BIOL CHEM, V272, P9108; Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003; ISSEKUTZ TB, 1995, AGENT ACTION SUPPL, V46, P85; Johnson JL, 2006, CIRCULATION, V113, P2435, DOI 10.1161/CIRCULATIONAHA.106.613281; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Krieglstein CF, 2001, AM J HYPERTENS, V14, p44S, DOI 10.1016/S0895-7061(01)02069-6; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lessner SM, 2004, TRENDS CARDIOVAS MED, V14, P105, DOI 10.1016/j.tcm.2003.12.009; Manso AM, 2006, CARDIOVASC RES, V69, P574, DOI 10.1016/j.cardiores.2005.09.004; Matias-Roman S, 2005, BLOOD, V105, P3956, DOI 10.1182/blood-2004-06-2382; Nicklin SA, 2003, GENET ENG P, V25, P15; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pluskota E, 2000, EUR J BIOCHEM, V267, P4693, DOI 10.1046/j.1432-1327.2000.01520.x; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Sans E, 2001, J IMMUNOL, V166, P544, DOI 10.4049/jimmunol.166.1.544; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; SBARBA PD, 2002, BIOL CHEM, V383, P69; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shankavaram UT, 2001, J BIOL CHEM, V276, P19027, DOI 10.1074/jbc.M009562200; Stanton H, 1998, J CELL SCI, V111, P2789; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Suenaga N, 2005, ONCOGENE, V24, P859, DOI 10.1038/sj.onc.1208258; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Tsakadze NL, 2004, AM J PHYSIOL-CELL PH, V287, pC55, DOI 10.1152/ajpcell.00585.2003; Tsakadze NL, 2006, J BIOL CHEM, V281, P3157, DOI 10.1074/jbc.M510797200; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Yadav R, 2003, THROMB HAEMOSTASIS, V90, P598, DOI 10.1160/TH03-04-0220	43	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25010	25019		10.1074/jbc.M611273200	http://dx.doi.org/10.1074/jbc.M611273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17591781	hybrid			2022-12-25	WOS:000248933000057
J	Voss, OH; Batra, S; Kolattukudy, SJ; Gonzalez-Mejia, ME; Smith, JB; Doseff, AI				Voss, Oliver H.; Batra, Sanjay; Kolattukudy, Sunny J.; Gonzalez-Mejia, M. Elba; Smith, Jeffrey B.; Doseff, Andrea I.			Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CYTOCHROME-C; DIFFERENTIAL EXPRESSION; ALVEOLAR MACROPHAGE; MEDIATED APOPTOSIS; DYNAMIC CHANGES; HSP27; SURVIVAL; HSP70; ATHEROSCLEROSIS	Caspase- 3 is an essential executioner of apoptosis responsible for regulating many important cellular processes, among them the number of circulating monocytes, central players in the innate immune response. The activation of caspase- 3 requires its processing from an inactive precursor. Here we show that the small heat shock protein 27 ( Hsp27) associates with caspase- 3 and protein-protein interaction experiments in vivo and with purified proteins demonstrate a direct interaction between Hsp27 and the amino-terminal prodomain of caspase- 3. Using an in vitro caspase- 3 activation assay, our results further establish that the interaction of Hsp27 with the caspase- 3 prodomain inhibits the second proteolytic cleavage necessary for caspase- 3 activation, revealing a novel mechanism for the regulation of this effector caspase. Hsp27 expression in monocytes is constitutive. Consistent with a central role of Hsp27 in blocking caspase- 3 activation, Hsp27 down-regulation by double-stranded RNA interference induces apoptosis of macrophages, whereas Hsp27 overexpression increases the life span of monocytes by inhibiting apoptosis. Highlighting the importance of cell partitioning in the regulation of apoptosis, immunofluorescence, and subcellular fractionation studies revealed that whereas both caspase- 3 and Hsp27 are cytoplasmic in fresh monocytes ( i. e. not undergoing apoptosis), Hsp27 moves to the nucleus during apoptosis, a relocalization that can be blocked by promoting the differentiation of monocytes to macrophages or by inhibiting cell death. These results reveal a novel mechanism of caspase- 3 regulation and underscore a novel and fundamental role of Hsp27 in the regulation of monocyte life span.	Ohio State Univ, Div Pulm & Crit Care, Heart & Lung Res Inst 201, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Doseff, AI (corresponding author), Ohio State Univ, Div Pulm & Crit Care, Heart & Lung Res Inst 201, 473 W 12th Ave, Columbus, OH 43210 USA.	doseff.1@osu.edu	Doseff, Andrea/E-2991-2011; Gonzalez-Mejia, M. Elba/F-8739-2012	Gonzalez-Mejia, M. Elba/0000-0003-2569-1998; Batra, Sanjay/0000-0002-8980-3592	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075040] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL075040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 2002, SMALL HEAT SHOCK PRO, P185; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen L, 2003, MOL PHARMACOL, V64, P334, DOI 10.1124/mol.64.2.334; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Doseff AI, 2003, AM J RESP CELL MOL, V29, P367, DOI 10.1165/rcmb.2002-0158OC; Elpek GO, 2003, APMIS, V111, P523, DOI 10.1034/j.1600-0463.2003.1110411.x; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; Fahy RJ, 1999, J IMMUNOL, V163, P1755; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; HANCE AJ, 1985, J IMMUNOL, V134, P284; Hansen RK, 1999, BREAST CANCER RES TR, V56, P187; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Lang D, 2000, J LEUKOCYTE BIOL, V68, P729; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mahoney JA, 2000, HBK PRACT ANIM C BIO, P121; MANGAN DF, 1993, J PERIODONTOL, V64, P461; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; MEHLEN P, 1996, J BIOL CHEM, V271, P3395; Mese H, 2002, ONCOL REP, V9, P341; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Paul C, 2000, EXP GERONTOL, V35, P757, DOI 10.1016/S0531-5565(00)00150-9; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Rajavashisth T, 1998, J CLIN INVEST, V101, P2702, DOI 10.1172/JCI119891; Ross J., 2002, BIOL MACROPHAGE; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMAS ED, 1976, SCIENCE, V192, P1016, DOI 10.1126/science.775638; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Voss OH, 2005, J BIOL CHEM, V280, P17371, DOI 10.1074/jbc.M412449200; Zhang Jiyan, 2003, Hematol J, V4, P277, DOI 10.1038/sj.thj.6200252	41	127	132	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					25088	25099		10.1074/jbc.M701740200	http://dx.doi.org/10.1074/jbc.M701740200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17597071	hybrid			2022-12-25	WOS:000248933000064
J	Xu, ZM; Tavares-Sanchez, OL; Li, QZ; Fernando, J; Rodriguez, CM; Studer, EJ; Pandak, WM; Hylemon, PB; Gil, G				Xu, Zhumei; Tavares-Sanchez, Olga L.; Li, Quanzhong; Fernando, Josephine; Rodriguez, Carmen M.; Studer, Elaine J.; Pandak, William M.; Hylemon, Phillip B.; Gil, Gregorio			Activation of bile acid biosynthesis by the p38 mitogen-activated protein kinase (MAPK) - Hepatocyte nuclear factor-4 alpha phosphorylation by the p38 MAPK is required for cholesterol 7 alpha-hydroxylase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY RAT HEPATOCYTES; GROWTH-FACTOR RECEPTOR; TRANSCRIPTIONAL ACTIVITY; ALTERNATIVE PATHWAY; HETERODIMER PARTNER; GENE-EXPRESSION; DNA-BINDING; MECHANISM; CYP7A1; SUPPRESSION	Bile acids are required for intestinal absorption and biliary solubilization of cholesterol and lipids. In addition, bile acids play a crucial role in cholesterol homeostasis. One of the key enzymes in the bile acid biosynthetic pathways is cholesterol 7 alpha-hydroxylase/cytochrome P450 7 alpha-hydroxylase (7 alpha-hydroxylase), which is the rate-limiting and regulatory step of the "classic" pathway. Transcription of the 7 alpha-hydroxylase gene is highly regulated. Two nuclear receptors, hepatocyte nuclear factor 4 alpha (HNF-4 alpha) and alpha(1)-fetoprotein transcription factor, are required for both transcription and regulation by different physiological events. It has been shown that some mitogen-activated protein kinases, such as the c-Jun N-terminal kinase and the ERK, play important roles in the regulation of 7 alpha-hydroxylase transcription. In this study, we show evidence that the p38 kinase pathway plays an important role in 7 alpha-hydroxylase expression and hence in bile acid synthesis. Inhibition of p38 kinase activity in primary hepatocytes results in similar to 5-10-fold reduction of 7 alpha-hydroxylase mRNA. This suppression is mediated, at least in part, through HNF-4 alpha. Inhibition of p38 kinase activity diminishes HNF-4 alpha nuclear protein levels and its phosphorylation in vivo and in vitro, and it renders a less stable protein. Induction of the p38 kinase pathway by insulin results in an increase in HNF-4 alpha protein and a concomitant induction of 7 alpha-hydroxylase expression that is blocked by inhibiting the p38 pathway. These studies show a functional link between the p38 signaling pathway, HNF-4 alpha, and bile acid synthesis.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Gil, G (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biol, POB 980614, Richmond, VA 23298 USA.	ggil@vcu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065049, R01DK057543] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK057543, R01 DK057543-08, DK065049, R01 DK065049] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN E, 1988, EUR J CLIN INVEST, V18, P166, DOI 10.1111/j.1365-2362.1988.tb02408.x; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Datta S, 2006, J BIOL CHEM, V281, P807, DOI 10.1074/jbc.M511050200; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; Fang YW, 2004, HEPATOLOGY, V40, P961, DOI 10.1002/hep.20385; FOLCH J, 1957, J BIOL CHEM, V226, P497; Guo HT, 2007, J BIOCHEM, V141, P635, DOI 10.1093/jb/mvm066; Guo HT, 2006, BIOCHEM J, V394, P379, DOI 10.1042/BJ20051730; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Han SL, 2004, HEPATOLOGY, V39, P456, DOI 10.1002/hep.20043; Harrison EM, 2006, FEBS J, V273, P2345, DOI 10.1111/j.1742-4658.2006.05224.x; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; Inoue Y, 2006, J LIPID RES, V47, P215, DOI 10.1194/jlr.M500430-JLR200; Jahan A, 2005, AM J PHYSIOL-GASTR L, V288, pG685, DOI 10.1152/ajpgi.00207.2004; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Kubitz R, 2004, GASTROENTEROLOGY, V126, P541, DOI 10.1053/j.gastro.2003.11.003; Li TG, 2006, J BIOL CHEM, V281, P28745, DOI 10.1074/jbc.M605815200; Pandak WM, 2002, J BIOL CHEM, V277, P48158, DOI 10.1074/jbc.M205244200; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rao YP, 2002, HEPATOLOGY, V35, P307, DOI 10.1053/jhep.2002.31104; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; Stroup D, 2000, J LIPID RES, V41, P1; VILLANUEVA GR, 1990, J LAB CLIN MED, V115, P441; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208	36	33	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24607	24614		10.1074/jbc.M611481200	http://dx.doi.org/10.1074/jbc.M611481200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17603092	Green Accepted, hybrid			2022-12-25	WOS:000248933000015
J	Hughes, AL; Lee, CYS; Bien, CM; Espenshade, PJ				Hughes, Adam L.; Lee, Chih-Yung S.; Bien, Clara M.; Espenshade, Peter J.			4-methyl sterols regulate fission yeast SREBP-Scap under low oxygen and cell stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CHOLESTEROL HOMEOSTASIS; GENE-EXPRESSION; SENSING DOMAIN; INSIG; ACTIVATION; REDUCTASE; PATHWAYS; ER	In fission yeast, orthologs of mammalian SREBP and Scap, called Sre1 and Scp1, monitor oxygen-dependent sterol synthesis as a measure of cellular oxygen supply. Under low oxygen conditions, sterol synthesis is inhibited, and Sre1 cleavage is activated. However, the sterol signal for Sre1 activation is unknown. In this study, we characterized the sterol signal for Sre1 activation using a combination of Sre1 cleavage assays and gas chromatography sterol analysis. We find that Sre1 activation is regulated by levels of the 4-methyl sterols 24-methylene lanosterol and 4,4-dimethylfecosterol under conditions of low oxygen and cell stress. Both increases and decreases in the level of these ergosterol pathway intermediates induce Sre1 proteolysis in a Scp1-dependent manner. The SREBP ortholog in the pathogenic fungus Cryptococcus neoformans is also activated by high levels of 4-methyl sterols, suggesting that this signal for SREBP activation is conserved among unicellular eukaryotes. Finally, we provide evidence that the sterol-sensing domain of Scp1 is important for regulating Sre1 proteolysis. The conserved mutations Y247C, L264F, and D392N in Scp1 that render Scap insensitive to sterols cause constitutive Sre1 activation. These findings indicate that unlike Scap, fission yeast Scp1 responds to 4-methyl sterols and thus shares properties with mammalian HMG-CoA reductase, a sterol-sensing domain protein whose degradation is regulated by the 4-methyl sterol lanosterol.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Espenshade, PJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St,Physiol 107B, Baltimore, MD 21205 USA.	peter.espenshade@jhmi.edu		Hughes, Adam/0000-0002-7095-3793	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL077588, HL077588, R01 HL077588-04] Funding Source: Medline; NIGMS NIH HHS [GM007445, T32 GM007445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Chang YC, 2007, MOL MICROBIOL, V64, P614, DOI 10.1111/j.1365-2958.2007.05676.x; Espenshade PJ, 2006, J CELL SCI, V119, P973, DOI 10.1242/jcs02866; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Gurcel L, 2006, CELL, V126, P1135, DOI 10.1016/j.cell.2006.07.033; Harding HP, 2005, CELL METAB, V2, P361, DOI 10.1016/j.cmet.2005.11.005; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Hughes AL, 2007, CELL METAB, V5, P143, DOI 10.1016/j.cmet.2006.12.009; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; Lee JN, 2004, J BIOL CHEM, V279, P45257, DOI 10.1074/jbc.M408235200; Loewen CJR, 2002, CURR BIOL, V12, pR779, DOI 10.1016/S0960-9822(02)01292-7; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Rosenfeld E, 2003, YEAST, V20, P1115, DOI 10.1002/yea.1026; Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; WILKIN DJ, 1992, J BIOL CHEM, V267, P2831; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	25	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					24388	24396		10.1074/jbc.M701326200	http://dx.doi.org/10.1074/jbc.M701326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17595166	hybrid, Green Accepted			2022-12-25	WOS:000248686600065
J	Miller, MR; White, A; Wilson, K; Boots, M				Miller, Martin R.; White, Andrew; Wilson, Kenneth; Boots, Michael			The Population Dynamical Implications of Male-Biased Parasitism in Different Mating Systems	PLOS ONE			English	Article								Although there is growing evidence that males tend to suffer higher levels of parasitism than females, the implications of this for the population dynamics of the host population are not yet understood. Here we build on an established 'two-sex' model and investigate how increased susceptibility to infection in males affects the dynamics, under different mating systems. We investigate the effect of pathogenic disease at different case mortalities, under both monogamous and polygynous mating systems. If the case mortality is low, then male-biased parasitism appears similar to unbiased parasitism in terms of its effect on the population dynamics. At higher case mortalities, we identified significant differences between male-biased and unbiased parasitism. A host population may therefore be differentially affected by male-biased and unbiased parasitism. The dynamical outcome is likely to depend on a complex interaction between the host's mating system and demography, and the parasite virulence.	[Miller, Martin R.; Boots, Michael] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; [White, Andrew] Heriot Watt Univ, Dept Math, Edinburgh, Midlothian, Scotland; [White, Andrew] Heriot Watt Univ, Maxwell Inst Math Sci, Edinburgh, Midlothian, Scotland; [Wilson, Kenneth] Univ Lancaster, Dept Biol Sci, Lancaster Environm Ctr, Lancaster, England	University of Sheffield; Heriot Watt University; Heriot Watt University; University of Edinburgh; Lancaster University	Miller, MR (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.	m.r.miller@sheffield.ac.uk	Wilson, Kenneth/B-7452-2008	Wilson, Kenneth/0000-0001-5264-6522	Biotechnology and Biological Sciences Research Council; Natural Environment Research Council	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This study was supported by a studentship from the Biotechnology and Biological Sciences Research Council and a Natural Environment Research Council Advanced Postdoctoral Fellowship.	Allee W., 1938, SOCIAL LIFE ANIMALS; Allee W.C, 1931, ANIMAL AGGREGATION S; Allen K.R., 1980, CONSERVATION MANAGEM; ANDERSON RM, 1982, PARASITOLOGY, V85, P411, DOI 10.1017/S0031182000055360; ANDERSON RM, 1981, PHILOS T R SOC B, V291, P451, DOI 10.1098/rstb.1981.0005; BATEMAN AJ, 1948, HEREDITY, V2, P349, DOI 10.1038/hdy.1948.21; BERRYMAN AA, 1989, TRENDS ECOL EVOL, V4, P26, DOI 10.1016/0169-5347(89)90014-1; CASWELL H, 1986, AM NAT, V128, P707, DOI 10.1086/284598; Caswell H, 2000, MATRIX POPULATION MO, V2nd; Clutton-Brock T.H., 1991, EVOLUTION PARENTAL C, DOI DOI 10.104641420-9101.1992.5040719.X; Clutton-Brock T. H., 1988, REPROD SUCCESS; Clutton-Brock TH., 1982, RED DEER BEHAV ECOLO; CLUTTONBROCK TH, 1985, NATURE, V313, P131, DOI 10.1038/313131a0; Ferrari N, 2004, ECOL LETT, V7, P88, DOI 10.1046/j.1461-0248.2003.00552.x; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; HASSELL MP, 1976, J ANIM ECOL, V45, P471, DOI 10.2307/3886; HOUDE AE, 1992, BEHAV ECOL, V3, P346, DOI 10.1093/beheco/3.4.346; KAVALIERS M, 1995, P ROY SOC B-BIOL SCI, V261, P31, DOI 10.1098/rspb.1995.0113; Koella JC, 1999, J THEOR BIOL, V198, P461, DOI 10.1006/jtbi.1999.0925; Labuda M, 1997, VIROLOGY, V235, P138, DOI 10.1006/viro.1997.8622; Lindstrom J, 1998, P ROY SOC B-BIOL SCI, V265, P483, DOI 10.1098/rspb.1998.0320; Lipsitch M, 1997, TRENDS MICROBIOL, V5, P31, DOI 10.1016/S0966-842X(97)81772-6; Lockhart AB, 1996, BIOL REV, V71, P415, DOI 10.1111/j.1469-185X.1996.tb01281.x; Mackinnon MJ, 1999, EVOLUTION, V53, P689, DOI [10.2307/2640710, 10.1111/j.1558-5646.1999.tb05364.x]; MASSOT M, 1992, ECOLOGY, V73, P1742, DOI 10.2307/1940026; MAY RM, 1985, AM NAT, V125, P573, DOI 10.1086/284363; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, AM NAT, V110, P573, DOI 10.1086/283092; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; McCarthy MA, 1997, ECOL MODEL, V103, P99, DOI 10.1016/S0304-3800(97)00104-X; McCurdy DG, 1998, OIKOS, V82, P303, DOI 10.2307/3546970; Milner-Gulland EJ, 2003, NATURE, V422, P135, DOI 10.1038/422135a; Moore SL, 2002, SCIENCE, V297, P2015, DOI 10.1126/science.1074196; MORAN PAP, 1950, BIOMETRICS, V6, P250, DOI 10.2307/3001822; Muehlenbein MP, 2005, AM J HUM BIOL, V17, P527, DOI 10.1002/ajhb.20419; OHGUSHI T, 1995, RES POPUL ECOL, V37, P29, DOI 10.1007/BF02515758; Perkins SE, 2003, INT J PARASITOL, V33, P909, DOI 10.1016/S0020-7519(03)00128-0; Poulin R, 1996, AM NAT, V147, P287, DOI 10.1086/285851; PROMISLOW DEL, 1992, P ROY SOC B-BIOL SCI, V247, P203, DOI 10.1098/rspb.1992.0030; Regoes RR, 2000, EVOLUTION, V54, P64, DOI 10.1111/j.0014-3820.2000.tb00008.x; RICKER W. E., 1954, JOUR FISH RES BD CANADA, V11, P559; Roberts ML, 2004, ANIM BEHAV, V68, P227, DOI 10.1016/j.anbehav.2004.05.001; Rolff J, 2002, P ROY SOC B-BIOL SCI, V269, P867, DOI 10.1098/rspb.2002.1959; Rolff J, 2003, SCIENCE, V301, P472, DOI 10.1126/science.1080623; Schalk G, 1997, OIKOS, V78, P67, DOI 10.2307/3545801; Scheuring I, 1999, J THEOR BIOL, V199, P407, DOI 10.1006/jtbi.1999.0966; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; SHERMAN PW, 1984, ECOLOGY, V65, P1617, DOI 10.2307/1939140; Skorping A, 2004, TRENDS ECOL EVOL, V19, P219, DOI 10.1016/j.tree.2004.02.006; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; White A, 1996, AM NAT, V148, P220, DOI 10.1086/285921; Wilson K, 2003, SCIENCE, V300, p55B, DOI 10.1126/science.1081430; Wilson K., 2002, P6; Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338	56	16	16	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e624	10.1371/journal.pone.0000624	http://dx.doi.org/10.1371/journal.pone.0000624			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637840	gold, Green Published, Green Submitted, Green Accepted			2022-12-25	WOS:000207452100014
J	D'Avino, PP; Archambault, V; Przewloka, MR; Zhang, W; Lilley, KS; Laue, E; Glover, DM				D'Avino, Pier Paolo; Archambault, Vincent; Przewloka, Marcin R.; Zhang, Wei; Lilley, Kathryn S.; Laue, Ernest; Glover, David M.			Recruitment of Polo Kinase to the Spindle Midzone during Cytokinesis Requires the Feo/Klp3A Complex	PLOS ONE			English	Article								Background. Polo-like kinases control multiple events during cell division, including mitotic entry, centrosome organization, spindle formation, chromosome segregation and cytokinesis. Their roles during cytokinesis, however, are not well understood because the requirement of these kinases during early stages of mitosis complicates the study of their functions after anaphase onset. Methodology/Principal Findings. We used time-lapse microscopy to analyze the dynamics of Polo::GFP in Drosophila tissue culture cells during mitosis. After anaphase onset, Polo:: GFP concentrated at the spindle midzone, but also diffused along the entire length of the central spindle. Using RNA interference we demonstrate that the microtubule-associated proteins Feo and Klp3A are required for Polo recruitment to the spindle midzone, but not the kinesin Pavarotti as previously thought. Moreover, we show that Feo and Klp3A form a complex and that Polo co-localizes with both proteins during cytokinesis. Conclusion/Significance. Our results reveal that the Feo/Klp3A complex is necessary for Polo recruitment to the spindle midzone. A similar finding has also been recently reported in mammalian cells [ 1], suggesting that this basic mechanism has been conserved during evolution, albeit with some differences. Finally, since cleavage furrow formation and ingression are unaffected following feo RNAi, our data imply that Polo recruitment to the central spindle is not required for furrowing, but some other aspect of cytokinesis.	[D'Avino, Pier Paolo; Archambault, Vincent; Przewloka, Marcin R.; Glover, David M.] Univ Cambridge, Dept Genet, Canc Res UK Cell Cycle Genet Res Grp, Cambridge CB2 3EH, England; [Zhang, Wei; Lilley, Kathryn S.; Laue, Ernest] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge; University of Cambridge	D'Avino, PP (corresponding author), Univ Cambridge, Dept Genet, Canc Res UK Cell Cycle Genet Res Grp, Downing St, Cambridge CB2 3EH, England.	p.davino@gen.cam.ac.uk	Przewloka, Marcin R./AAA-5137-2020; Lilley, Kathryn/ABF-5787-2020; D'Avino, Pier Paolo/AAU-4577-2020	Przewloka, Marcin R./0000-0002-0329-9162; Lilley, Kathryn/0000-0003-0594-6543; Laue, Ernest/0000-0002-7476-4148; D'Avino, Pier Paolo/0000-0002-4773-6950; Glover, David/0000-0003-0956-0103	Cancer Research-UK; BBSRC; EMBO; HSFP; Biotechnology and Biological Sciences Research Council [BB/E011586/1] Funding Source: researchfish; Medical Research Council [G0501718] Funding Source: researchfish; BBSRC [BB/E011586/1] Funding Source: UKRI; MRC [G0501718] Funding Source: UKRI	Cancer Research-UK(Cancer Research UK); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EMBO(European Molecular Biology Organization (EMBO)); HSFP; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a Cancer Research-UK Programme Grant ( to DMG) and a BBSRC project grant ( to PPD, DMG, EL and KSL). VA held postdoctoral fellowships from EMBO and HSFP.	Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Brennan IM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000409; Burgess DR, 2005, TRENDS CELL BIOL, V15, P156, DOI 10.1016/j.tcb.2005.01.006; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Chen F, 2007, CURR BIOL, V17, P293, DOI 10.1016/j.cub.2007.01.068; D'Avino PP, 2006, J CELL SCI, V119, P4402, DOI 10.1242/jcs.03210; D'Avino PP, 2005, J CELL SCI, V118, P1549, DOI 10.1242/jcs.02335; D'Avino PP, 2004, J CELL BIOL, V166, P61, DOI 10.1083/jcb.200402157; Glover DM, 2005, ONCOGENE, V24, P230, DOI 10.1038/sj.onc.1208279; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Guse A, 2005, CURR BIOL, V15, P778, DOI 10.1016/j.cub.2005.03.041; Kurasawa Y, 2004, EMBO J, V23, P3237, DOI 10.1038/sj.emboj.7600347; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Logarinho E, 1998, J CELL SCI, V111, P2897; Minestrini G, 2002, J CELL SCI, V115, P725; Mishima M, 2004, NATURE, V430, P908, DOI 10.1038/nature02767; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Neef R, 2006, CURR BIOL, V16, P301, DOI 10.1016/j.cub.2005.12.030; Neef R, 2007, NAT CELL BIOL, V9, P436, DOI 10.1038/ncb1557; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Pearson J, 2006, EXP CELL RES, V312, P770, DOI 10.1016/j.yexcr.2005.11.031; Piekny A, 2005, TRENDS CELL BIOL, V15, P651, DOI 10.1016/j.tcb.2005.10.006; Powers J, 1998, CURR BIOL, V8, P1133, DOI 10.1016/S0960-9822(98)70470-1; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; SUNKEL CE, 1988, J CELL SCI, V89, P25; Verbrugghe KJC, 2004, CURR BIOL, V14, P1755, DOI 10.1016/j.cub.2004.09.055; Verni F, 2004, CURR BIOL, V14, P1569, DOI 10.1016/j.cub.2004.08.054; WILLIAMS BC, 1995, J CELL BIOL, V129, P709, DOI 10.1083/jcb.129.3.709; Yoshida S, 2006, SCIENCE, V313, P108, DOI 10.1126/science.1126747; Zhu CJ, 2005, P NATL ACAD SCI USA, V102, P343, DOI 10.1073/pnas.0408438102	36	41	41	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2007	2	6							e572	10.1371/journal.pone.0000572	http://dx.doi.org/10.1371/journal.pone.0000572			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GF	17593971	Green Accepted, Green Published, gold, Green Submitted			2022-12-25	WOS:000207451800016
J	Ehrhardt, H; Hacker, S; Wittmann, S; Maurer, M; Borkhardt, A; Toloczko, A; Debatin, KM; Fulda, S; Jeremias, I				Ehrhardt, H.; Haecker, S.; Wittmann, S.; Maurer, M.; Borkhardt, A.; Toloczko, A.; Debatin, K-M; Fulda, S.; Jeremias, I.			Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells	ONCOGENE			English	Article						caspase-8; p53; cytotoxic drugs; TRAIL; TRAIL-R1; TRAIL-R2	MUTANT P53; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; DEATH RECEPTORS; CANCER-CELLS; EXPRESSION; TRAIL; RESTORATION; THERAPY; PROLIFERATION	Apoptosis resistance is crucially involved in cancer development and progression, represents the leading cause for failure of anticancer therapy and is caused, for example, by downregulation of proapoptotic intracellular signaling molecules such as caspase-8. We found that the cytotoxic drugs methotrexate (MTX) and 5-fluorouracil (5-FU) were both able to sensitize resistant tumor cells for induction of apoptosis by p53-mediated upregulation of caspase-8. Increase in caspase-8 messenger RNA and protein expression disabled tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced proliferation and restored sensitivity toward TRAIL-induced apoptosis which was inhibited by transfection of p53 decoy oligonucleotides, p53 shRNA and caspase-8 shRNA. Upregulation of caspase-8 and sensitization toward TRAIL-induced apoptosis was found both in a broad panel of tumor cell lines with downregulated caspase-8 and in TRAIL-resistant primary tumor cells of children with acute leukemia. Taken together, we have identified caspase-8 as an important p53 target gene regulated by cytotoxic drugs. These findings highlight a new drug-induced modulation of physiological apoptosis pathways, which may be involved in successful anticancer therapy using MTX and 5-FU in leukemia and solid tumors over decades.	[Ehrhardt, H.; Wittmann, S.; Maurer, M.; Borkhardt, A.; Jeremias, I.] Univ Munich, Dr Von Haunerschen Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany; [Haecker, S.; Debatin, K-M; Fulda, S.] Klin Kinder & Jugendmed, Ulm, Germany; [Toloczko, A.; Jeremias, I.] GSF Res Ctr Environm & Hlth, Munich, Germany; [Ehrhardt, H.] Univ Munich, Dept Obstet & Gynecol, Div Neonatol, Munich, Germany	University of Munich; University of Munich	Jeremias, I (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Abt Genvektoren, Marchioninistr 25, D-81377 Munich, Germany.	I.Jeremias@lrz.uni-muenchen.de	Ehrhardt, Harald/L-9007-2018; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Jeremias, Irmela/Q-5934-2019; Jeremias, Irmela/C-6090-2015	Ehrhardt, Harald/0000-0003-4587-1734; Debatin, Klaus-Michael/0000-0002-8397-1886; Jeremias, Irmela/0000-0003-1773-7677; Fulda, Simone/0000-0002-0459-6417				Ashley DM, 2005, CANCER-AM CANCER SOC, V104, P1487, DOI 10.1002/cncr.21323; Baader E, 2005, CANCER RES, V65, P7888, DOI 10.1158/0008-5472.CAN-04-4278; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ehrhardt H, 2004, LEUKEMIA, V18, P1406, DOI 10.1038/sj.leu.2403406; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Gomez-Lazaro M, 2004, J PHYSIOL BIOCHEM, V60, P287, DOI 10.1007/BF03167075; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; MILNER J, 1987, ONCOGENE, V1, P453; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ohnishi T, 1999, INT J RADIAT BIOL, V75, P1095; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232	31	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					783	793		10.1038/sj.onc.1210666	http://dx.doi.org/10.1038/sj.onc.1210666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17637740				2022-12-25	WOS:000252884500007
J	Runeberg-Roos, P; Virtanen, H; Saarma, M				Runeberg-Roos, P.; Virtanen, H.; Saarma, M.			RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface	ONCOGENE			English	Article						RET; MEN 2B; precursor; downstream signalling; endoplasmic reticulum	ENDOCRINE NEOPLASIA TYPE-2; RET PROTOONCOGENE PRODUCTS; HIRSCHSPRUNGS-DISEASE; TYROSINE KINASE; THYROID-CELLS; ACTIVATION; MUTATIONS; MECHANISM; RECEPTOR; GDNF	MEN 2B ( multiple endocrine neoplasia type 2B) is an autosomal dominant cancer syndrome caused by an oncogenic form of the receptor tyrosine kinase REarranged during transfection (RET). The MEN 2B syndrome is associated with an abnormal autophosphorylation of the mutated receptor even without ligand-stimulation. Here, we characterize the activation of a RETMEN2B variant carrying the point mutation Met918Thr, and show that the 150 kDa precursor of RETMEN2B becomes phosphorylated already during synthesis in the endoplasmic reticulum (ER). At least three different tyrosine residues (Tyr905, Tyr1062, Tyr1096) of the RETMEN2B precursor are phosphorylated before the oncogenic receptor reaches the cell surface. We also demonstrate that the precursor of RETMEN2B interacts with both growth factor receptor-bound protein and Src homology 2 domain-containing already in the ER, and that this interaction is dependent on the kinase activity of RET. With the aid of two RET mutants (RETMEN2B/S32L and RETMEN2B/ F393L), which accumulate in the ER, we show that the oncogenic precursor of the receptor has the capacity to activate AKT, extracellular signal-regulated kinase and signal transducer and activator of transcription 3 from the ER. Taken together, our data demonstrate that the oncogenic precursor of RETMEN2B is phosphorylated, interacts with adapter proteins and induces downstream signalling from the ER.	[Runeberg-Roos, P.; Virtanen, H.; Saarma, M.] Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki	Runeberg-Roos, P (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9,POB 56, FIN-00014 Helsinki, Finland.	pia.runeberg@helsinki.fi						Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Cerchia L, 2003, BIOCHEM J, V372, P897, DOI 10.1042/BJ20021530; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; Pelet A, 1998, J CLIN INVEST, V101, P1415, DOI 10.1172/JCI375; Salvatore D, 2001, CANCER RES, V61, P1426; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; TAKAHASHI M, 1991, ONCOGENE, V6, P297; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; Virtanen H, 2005, BIOCHEM J, V387, P817, DOI 10.1042/BJ20041257	24	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7909	7915		10.1038/sj.onc.1210591	http://dx.doi.org/10.1038/sj.onc.1210591			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599050				2022-12-25	WOS:000252163500009
J	Chen, RR; Silva, EA; Yuen, WW; Brock, AA; Fischbach, C; Lin, AS; Guldberg, RE; Mooney, DJ				Chen, Ruth R.; Silva, Eduardo A.; Yuen, William W.; Brock, Andrea A.; Fischbach, Claudia; Lin, Angela S.; Guldberg, Robert E.; Mooney, David J.			Integrated approach to designing growth factor delivery systems	FASEB JOURNAL			English	Article						tissue engineering; in vitro models; angiogenesis	ANGIOGENESIS; VEGF; MIGRATION; RECEPTORS; VEGF(165); CELLS; ASSAY	Growth factors have been widely used in strategies to regenerate and repair diseased tissues, but current therapies that go directly from bench to bedside have had limited clinical success. We hypothesize that engineering successful therapies with recombinant proteins will often require specific quantitative information of the spatiotemporal role of the factors and the development of sophisticated delivery approaches that provide appropriate tissue exposures. This hypothesis was tested in the context of therapeutic angiogenesis. An in vitro model of angiogenesis was adapted to quantify the role of the concentration/ gradient of vascular endothelial growth factor [VEGF( 165)] on microvascular endothelial cells, and a delivery system was then designed, based on a mathematical model, to provide the desired profile in ischemic mice hindlimbs. This system significantly enhanced blood vessel formation, and perfusion and recovery from severe ischemia. This general approach may be broadly applicable to growth factor therapies.	Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; St Louis Univ, Dept Biochem Med, St Louis, MO 63103 USA; Sch Mech Engn, Georgia Inst Technol, Atlanta, GA 30332 USA	University of Michigan System; University of Michigan; Harvard University; Saint Louis University; University System of Georgia; Georgia Institute of Technology	Mooney, DJ (corresponding author), Harvard Univ, 319 Pierce Hall, Cambridge, MA 02138 USA.	mooneyd@deas.harvard.edu	Fischbach, Claudia/C-8550-2009; Silva, Eduardo A./M-2711-2015	Fischbach, Claudia/0000-0002-9368-0150; Silva, Eduardo A./0000-0003-3173-7622; Mooney, David/0000-0001-6299-1194	NHLBI NIH HHS [R01 HL-069957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069957] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen RR, 2003, PHARM RES-DORDR, V20, P1103, DOI 10.1023/A:1025034925152; Chen RR, 2007, MICROCIRCULATION, V14, P77, DOI 10.1080/10739680601131101; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Davenport A.P., 2005, RECEPTOR BINDING TEC, V2nd; Dietrich Franziska, 2006, Angiogenesis, V9, P111, DOI 10.1007/s10456-006-9037-x; Eichmann A, 2005, CURR OPIN NEUROBIOL, V15, P108, DOI 10.1016/j.conb.2005.01.008; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Harris LD, 1998, J BIOMED MATER RES, V42, P396, DOI 10.1002/(SICI)1097-4636(19981205)42:3<396::AID-JBM7>3.3.CO;2-P; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Peters MC, 2002, J BIOMED MATER RES, V60, P668, DOI 10.1002/jbm.10134; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Rosinberg Audrey, 2004, Expert Rev Cardiovasc Ther, V2, P271, DOI 10.1586/14779072.2.2.271; Ruhrberg C, 2003, BIOESSAYS, V25, P1052, DOI 10.1002/bies.10351; Russ J. C., 2002, IMAGE PROCESSING HDB, V4th, DOI DOI 10.1201/9781420040760; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Sun QH, 2005, PHARM RES-DORDR, V22, P1110, DOI 10.1007/s11095-005-5644-2; VAISMAN N, 1990, J BIOL CHEM, V265, P19461	24	110	128	1	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3896	3903		10.1096/fj.06-7873com	http://dx.doi.org/10.1096/fj.06-7873com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17644610	Green Submitted			2022-12-25	WOS:000251283500015
J	Goralski, KB; McCarthy, TC; Hanniman, EA; Zabel, BA; Butcher, EC; Parlee, SD; Muruganandan, S; Sinal, CJ				Goralski, Kerry B.; McCarthy, Tanya C.; Hanniman, Elyisha A.; Zabel, Brian A.; Butcher, Eugene C.; Parlee, Sebastian D.; Muruganandan, Shanmugam; Sinal, Christopher J.			Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACYLATION-STIMULATING PROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; NON-SHIVERING THERMOGENESIS; BROWN ADIPOSE-TISSUE; IN-VIVO; GENE-EXPRESSION; TNF-ALPHA; OBESITY; FAT	Obesity is an alarming primary health problem and is an independent risk factor for type 11 diabetes, cardiovascular diseases, and hypertension. Although the pathologic mechanisms linking obesity with these co-morbidities are most likely multifactorial, increasing evidence indicates that altered secretion of adipose-derived signaling molecules (adipokines; e.g. adiponectin., leptin, and tumor necrosis factor a) and local inflammatory responses are contributing factors. Chemerin (RARRES2 or TIG2) is a recently discovered chemoattractant protein that serves as a ligand for the G protein-coupled receptor CMKLR1 (ChemR23 or DEZ) and has a role in adaptive and innate immunity. Here we show an unexpected, high level expression of chemerin and its cognate receptor CMICLR1 in mouse and human adipocytes. Cultured 3T3-L1 adipocytes secrete chemerin protein, which triggers CMKLR1 signaling in adipocytes and other cell types and stimulates chemotaxis of CMKLR1-expressing cells. Adenoviral small hairpin RNA targeted knockdown of chemerin or CMKLR1 expression impairs differentiation of 3T3-L1 cells into adipocytes, reduces the expression of adipocyte genes involved in glucose and lipid homeostasis, and alters metabolic functions in mature adipocytes. We conclude that chemerin is a novel adipose-derived signaling molecule that regulates adipogenesis and adipocyte metabolism.	Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Coll Pharm, Dept Pharmacol, Halifax, NS B3H 3J5, Canada; Stanford Univ, Sch Med, Immunol Lab, Dept Pathol, Stanford, CA 94305 USA; Ctr Mol Biol & Med, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Dalhousie University; Dalhousie University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Sinal, CJ (corresponding author), Dalhousie Univ, Dept Pharmacol, Rm 5E ,Sir Charles Tupper Bldg,5850 Coll St, Halifax, NS B3H 4H7, Canada.	csinal@dal.ca	Muruganandan, Shanmugam/H-5673-2019	Sinal, Christopher/0000-0001-8301-3349; Shanmugam, Muruganandan/0000-0001-9552-2175; Goralski, Kerry/0000-0003-0040-5879	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059635, R01AI059635] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-59635] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Bullo M, 2005, AM J PHYSIOL-ENDOC M, V289, pE62, DOI 10.1152/ajpendo.00008.2005; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Carmen GY, 2006, CELL SIGNAL, V18, P401, DOI 10.1016/j.cellsig.2005.08.009; Cianflone K, 2005, CLIN ENDOCRINOL, V62, P567, DOI 10.1111/j.1365-2265.2005.02260.x; Cianflone K, 2003, BBA-BIOMEMBRANES, V1609, P127, DOI 10.1016/S0005-2736(02)00686-7; Cinti S, 2005, PROSTAG LEUKOTR ESS, V73, P9, DOI 10.1016/j.plefa.2005.04.010; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Diamond F., 2002, GROWTH GENET HORM, V18, P17; Eriksson P, 1998, DIABETOLOGIA, V41, P65, DOI 10.1007/s001250050868; Fajas L, 2003, ANN MED, V35, P79, DOI 10.1080/07853890310009999; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Goralski KB, 2006, DRUG METAB DISPOS, V34, P288, DOI 10.1124/dmd.105.007427; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143; HOGAN S, 1980, AM J PHYSIOL, V239, pE301; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hutley L, 2005, AM J MED SCI, V330, P280, DOI 10.1097/00000441-200512000-00005; JOHNSON PR, 1972, J LIPID RES, V13, P2; Kalant D, 2005, J BIOL CHEM, V280, P23936, DOI 10.1074/jbc.M406921200; KAWAKAMI M, 1989, J CELL PHYSIOL, V138, P1, DOI 10.1002/jcp.1041380102; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Klaus S, 2004, CURR DRUG TARGETS, V5, P241, DOI 10.2174/1389450043490523; Lagace DC, 2004, ENDOCRINOLOGY, V145, P5493, DOI 10.1210/en.2004-0877; LeaCurrie YR, 1997, INT J OBESITY, V21, P1058, DOI 10.1038/sj.ijo.0800516; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maachi M, 2004, INT J OBESITY, V28, P993, DOI 10.1038/sj.ijo.0802718; MAEEA N, 2002, NAT MED, V8, P731; Mallow H, 2000, HORM METAB RES, V32, P500, DOI 10.1055/s-2007-978676; Meder W, 2003, FEBS LETT, V555, P495, DOI 10.1016/S0014-5793(03)01312-7; Nagpal S, 1997, J INVEST DERMATOL, V109, P91, DOI 10.1111/1523-1747.ep12276660; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; Orlicky DJ, 2001, J LIPID RES, V42, P460; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Rosen ED, 2000, GENE DEV, V14, P1293; Roytblat L, 2000, OBES RES, V8, P673, DOI 10.1038/oby.2000.86; Saleh J, 1998, J LIPID RES, V39, P884; Saleh J, 1999, AM J PHYSIOL-ENDOC M, V276, pE815, DOI 10.1152/ajpendo.1999.276.5.E815; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seboek D, 2004, J CLIN ENDOCR METAB, V89, P4833, DOI 10.1210/jc.2004-0271; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tiraby C, 2003, TRENDS ENDOCRIN MET, V14, P439, DOI 10.1016/j.tem.2003.10.001; TRAYHURN P, 1978, PFLUG ARCH EUR J PHY, V373, P189, DOI 10.1007/BF00584859; TRAYHURN P, 1979, PFLUG ARCH EUR J PHY, V380, P227, DOI 10.1007/BF00582901; Wang MY, 2005, P NATL ACAD SCI USA, V102, P18011, DOI 10.1073/pnas.0509001102; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wittamer V, 2005, J IMMUNOL, V175, P487, DOI 10.4049/jimmunol.175.1.487; Wittamer V, 2004, J BIOL CHEM, V279, P9956, DOI 10.1074/jbc.M313016200; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zabel BA, 2005, J BIOL CHEM, V280, P34661, DOI 10.1074/jbc.M504868200; Zabel BA, 2006, EXP HEMATOL, V34, P1021, DOI 10.1016/j.exphem.2006.05.003; Zabel BA, 2006, EXP HEMATOL, V34, P1106, DOI 10.1016/j.exphem.2006.03.011	67	597	652	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					28175	28188		10.1074/jbc.M700793200	http://dx.doi.org/10.1074/jbc.M700793200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17635925	hybrid			2022-12-25	WOS:000249455600067
J	Kuhn, FJP; Knop, G; Luckhoff, A				Kuehn, Frank J. P.; Knop, Gabriel; Lueckhoff, Andreas			The transmembrane segment S6 determines cation versus anion selectivity of TRPM2 and TRPM8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL; ADP-RIBOSE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; VOLTAGE SENSOR; CELL-DEATH; P-LOOP; RECEPTOR; ACTIVATION; PERMEATION	TRPM2 and TRPM8, closely related members of the transient receptor potential (TRP) family, are cation channels activated by quite different mechanisms. Their transmembrane segments S5 and S6 are highly conserved. To identify common structures in S5 and S6 that govern interaction with the pore, we created a chimera in which the S5-pore-S6 region of TRPM8 was inserted into TRPM2, along with a lysine at each transition site. Currents through this chimera were induced by ADP-ribose (ADPR) in cooperation with Ca2+. In contrast to wild-type TRPM2 channels, currents through the chimera were carried by Cl-, as demonstrated in ion substitution experiments using the cation N-methyl-D-glucamine (NMDG) and the anion glutamate. Extracellular NMDG had no effects. The substitution of either intracellular or extracellular Cl- with glutamate shifted the reversal potential, decreased the current amplitude and induced a voltage-dependent block relieved by depolarization. The lysine in S6 was responsible for the anion selectivity; insertion of a lysine into corresponding sites within S6 of either TRPM2 or TRPM8 created anion channels that were activated by ADPR (TRPM2 11045K) or by cold temperatures (TRPM8 V976K). The positive charge of the lysine was decisive for the glutamate block because the mutant TRPM2 11045H displayed cation currents that were blocked at acidic but not alkaline intracellular pH values. We conclude that the distal part of S6 is crucial for the discrimination of charge. Because of the high homology of S6 in the whole TRP family, TRP channels.	Rhein Westfal TH Aachen, Fac Med, Inst Physiol, D-52057 Aachen, Germany	RWTH Aachen University	Kuhn, FJP (corresponding author), Carl von Ossietzky Univ Oldenburg, Dept Biol & Environm Sci, D-26111 Oldenburg, Germany.	fkuehn@physiology.rwth-aachen.de	Kuehn, Frank JP/H-5889-2018					Abeele FV, 2006, J BIOL CHEM, V281, P40174, DOI 10.1074/jbc.M605779200; Barry PH, 2005, IEEE T NANOBIOSCI, V4, P70, DOI 10.1109/TNB.2004.842497; Brauchi S, 2004, P NATL ACAD SCI USA, V101, P15494, DOI 10.1073/pnas.0406773101; Brauchi S, 2007, P NATL ACAD SCI USA, V104, P10246, DOI 10.1073/pnas.0703420104; ESTACION M, 2006, J PHYSL, V15, P359; FLOCKERZI V, 2006, TRANSIENT RECEPTOR P, P1; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Grubisha O, 2006, J BIOL CHEM, V281, P14057, DOI 10.1074/jbc.M513741200; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; HEINER I, 2006, BIOCHEM J, V371, P1045; Hille B., 1992, IONIC CHANNELS EXCIT, P337, DOI 10.1016/0014-5793(92)81020-M; Kaneko S, 2006, J PHARMACOL SCI, V101, P66, DOI 10.1254/jphs.FP0060128; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kraft R, 2006, BRIT J PHARMACOL, V148, P264, DOI 10.1038/sj.bjp.0706739; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; LU Z, 2005, J GEN PHYSIOL, V120, P663; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; MEI ZZ, 2006, AM J PHYSIOL, V291, P1022; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Nilius B, 2005, J BIOL CHEM, V280, P22899, DOI 10.1074/jbc.M501686200; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Qu W, 2006, J GEN PHYSIOL, V127, P375, DOI 10.1085/jgp.200509378; REID G, 2002, J PHYSL, V542, P595; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Tsavaler L, 2001, CANCER RES, V61, P3760; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Voets T, 2007, NAT CHEM BIOL, V3, P174, DOI 10.1038/nchembio862; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200; Zhang WY, 2006, AM J PHYSIOL-CELL PH, V290, pC1146, DOI 10.1152/ajpcell.00205.2005; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	46	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2007	282	38					27598	27609		10.1074/jbc.M702247200	http://dx.doi.org/10.1074/jbc.M702247200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	210KR	17604279	hybrid			2022-12-25	WOS:000249455600007
J	Saito, M; Hanson, PI; Schlesinger, P				Saito, Mitsuyoshi; Hanson, Phyllis I.; Schlesinger, Paul			Luminal chloride-dependent activation of endosome calcium channels - Patch clamp study of enlarged endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION CHANNEL; KIDNEY-DISEASE; FUSION; ENDOCYTOSIS; TRANSPORT; MEMBRANE; CA2+	Although Ca2+ release from early endosomes (EE) is important for the fusion of primary endosomes, the presence of an ion channel responsible for releasing calcium from the EE has not been shown. A recent proteomics study has identified the TRPV2 channel protein in EE, suggesting that transient receptor potential-like Ca2+ channels may be in endosomes. The submicron size of endosomes has made it difficult to study their ion channels in the past. We have overcome this problem by generating enlarged EE with the help of a hydrolysis-deficient SKD1/VPS4B mutant in HEK293 cells. Here we report the first patch clamp recording of a novel endosome calcium channel (ECC) in these enlarged EE. The ECC shows a similar pharmacology to that of the TRPV2 channel. In addition, the ECC has a unique chloride-dependent regulation; it is inhibited by the endosome luminal chloride with a K-50 of 82 mM.	Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Saito, M (corresponding author), Washington Univ, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	msaito@cellbiology.wustl.edu	Hanson, Phyllis/E-9420-2012; Schlesinger, Paul H/C-6049-2012					Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Clapham DE, 2005, PHARMACOL REV, V57, P427, DOI 10.1124/pr.57.4.6; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; FAT P, 1958, J PHYSIOL-LONDON, V142, P516; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; Gonzalez-Perrett S, 2002, J BIOL CHEM, V277, P24959, DOI 10.1074/jbc.M105084200; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Holroyd C, 1999, MOL BIOL CELL, V10, P3035, DOI 10.1091/mbc.10.9.3035; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Jentsch TJ, 2005, J CLIN INVEST, V115, P2039, DOI 10.1172/JCI25470; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Li M, 2006, J GEN PHYSIOL, V127, P525, DOI 10.1085/jgp.200609502; Lin Y, 2005, J BIOL CHEM, V280, P12799, DOI 10.1074/jbc.M413968200; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mills IG, 2001, J CELL SCI, V114, P1959; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Sonawane ND, 2003, J CELL BIOL, V160, P1129, DOI 10.1083/jcb.200211098; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; van de Graaf SFJ, 2006, MOL CELL BIOL, V26, P303, DOI 10.1128/MCB.26.1.303-312.2006; Wainszelbaum MJ, 2006, EXP CELL RES, V312, P2238, DOI 10.1016/j.yexcr.2006.03.025; Yan Q, 2004, J BIOL CHEM, V279, P18270, DOI 10.1074/jbc.M400093200	28	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					27327	27333		10.1074/jbc.M702557200	http://dx.doi.org/10.1074/jbc.M702557200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17609211	hybrid			2022-12-25	WOS:000249304900074
J	Shahi, P; Gulshan, K; Moye-Rowley, WS				Shahi, Puja; Gulshan, Kailash; Moye-Rowley, W. Scott			Negative transcriptional regulation of multidrug resistance gene expression by an Hsp70 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; BINDING-CASSETTE TRANSPORTER; NUCLEOTIDE EXCHANGE FACTOR; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL CRISTAE; MOLECULAR CHAPERONES; HEME ACTIVATION; PLASMA-MEMBRANE; ATP SYNTHASE; YEAST	One of the most common origins of multidrug resistance occurs via the overproduction of ATP-binding cassette ( ABC) transporter proteins. These ABC transporters then act as broad specificity drug pumps and efflux a wide range of toxic agents out of the cell. The yeast Saccharomyces cerevisiae exhibits multiple or pleiotropic drug resistance ( Pdr) often through the overproduction of a plasma membrane-localized ABC transporter protein called Pdr5p. Expression of the PDR5 gene is controlled by two zinc cluster-containing transcription factors called Pdr1p and Pdr3p. Cells that lack their mitochondrial genome ( rho(0) cells) strongly induce PDR5 transcription in a Pdr3p-dependent fashion. To identify proteins associated with Pdr3p that might act to regulate this factor, a tandem affinity purification ( TAP) moiety was fused to Pdr3p, and this recombinant protein was purified from yeast cells. The cytosolic Hsp70 chaperone Ssa1p co-purified with TAP-Pdr3p. Overexpression of Ssa1p repressed expression of PDR5 but had no effect on expression of other genes involved in the Pdr phenotype. This Ssa1p-mediated repression required the presence of Pdr3p and did not influence Pdr1p-dependent gene expression. Loss of the nucleotide exchange factor Fes1p mimicked Ssa1p-mediated repression of PDR5. Co-immunoprecipitation experiments indicated that Ssa1p was associated with Pdr3p but not Pdr1p in yeast cells. Finally, rho(0) cells had less Ssa1p bound to Pdr3p than rho(+) cells, consistent with Ssa1p-mediated repression of Pdr3p activity serving as a key regulatory step in control of multidrug resistance in yeast.	Univ Iowa, Dept Physiol & Mol Biophys, Iowa City, IA 52242 USA	University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Mol Biophys, 6-530 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.	scott-moyerowley@uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM 49825] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Craig E, 1995, COLD SPRING HARB SYM, V60, P441, DOI 10.1101/SQB.1995.060.01.049; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; Delahodde A, 2001, MOL MICROBIOL, V39, P304, DOI 10.1046/j.1365-2958.2001.02182.x; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Dragovic Z, 2006, EMBO J, V25, P2519, DOI 10.1038/sj.emboj.7601138; Duttagupta R, 2003, MOL CELL BIOL, V23, P2623, DOI 10.1128/MCB.23.8.2623-2632.2003; Eisenman HC, 2004, MOL MICROBIOL, V53, P335, DOI 10.1111/j.1365-2958.2004.04134.x; Ernst R, 2005, METHOD ENZYMOL, V400, P460, DOI 10.1016/S0076-6879(05)00026-1; Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hach A, 1999, MOL CELL BIOL, V19, P4324; Hallstrom TC, 2000, MOL MICROBIOL, V36, P402, DOI 10.1046/j.1365-2958.2000.01858.x; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; Hon T, 2005, GENETICS, V169, P1343, DOI 10.1534/genetics.104.037143; Hon T, 2001, MOL CELL BIOL, V21, P7923, DOI 10.1128/MCB.21.23.7923-7932.2001; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jones G, 2004, MOL CELL BIOL, V24, P3928, DOI 10.1128/MCB.24.9.3928-3937.2004; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KINTER M, 2000, WILEY INTERSCIENCE S, P1; Lan CG, 2004, J BIOL CHEM, V279, P27607, DOI 10.1074/jbc.M402777200; Lee HC, 2002, J BIOL CHEM, V277, P7430, DOI 10.1074/jbc.M106951200; Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Moye-Rowley WS, 2005, GENE, V354, P15, DOI 10.1016/j.gene.2005.03.019; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Pena MMO, 1998, MOL CELL BIOL, V18, P2514, DOI 10.1128/MCB.18.5.2514; Poch O, 1997, GENE, V184, P229, DOI 10.1016/S0378-1119(96)00602-6; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; Raviol H, 2006, EMBO J, V25, P2510, DOI 10.1038/sj.emboj.7601139; Ribeil JA, 2007, NATURE, V445, P102, DOI 10.1038/nature05378; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sanglard D, 2002, LANCET INFECT DIS, V2, P73, DOI 10.1016/S1473-3099(02)00181-0; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; Shaner L, 2006, BIOCHEMISTRY-US, V45, P15075, DOI 10.1021/bi061279k; Sherman F, 1979, METHODS YEAST GENETI; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; Simonics T, 2000, CURR GENET, V38, P248, DOI 10.1007/s002940000164; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; Zhang XT, 2001, J BIOL CHEM, V276, P47844, DOI 10.1074/jbc.M106285200; Zhang XT, 2005, J BIOL CHEM, V280, P2759, DOI 10.1074/jbc.M408333200	69	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2007	282	37					26822	26831		10.1074/jbc.M704772200	http://dx.doi.org/10.1074/jbc.M704772200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	208FJ	17636264	hybrid			2022-12-25	WOS:000249304900022
J	Forbes, A; Wadehra, M; Mareninov, S; Morales, S; Shimazaki, K; Gordon, LK; Braun, J				Forbes, Ashley; Wadehra, Madhuri; Mareninov, Sergei; Morales, Shawn; Shimazaki, Kaori; Gordon, Lynn K.; Braun, Jonathan			The tetraspan protein EMP2 regulates expression of caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL MEMBRANE PROTEIN-2; SURFACE EXPRESSION; TYROSINE PHOSPHORYLATION; TUMOR-SUPPRESSOR; ADIPOSE-CELLS; IN-VIVO; GENE; TRANSPORT; DEGRADATION; CHOLESTEROL	Caveolin-1 is the primary component of caveolae and functions in a variety of intracellular activities, including membrane trafficking and signal transduction. EMP2(epithelial membrane protein 2) is a tetraspan protein recently identified as a novel regulator of caveolin-1 expression. In this study, we analyzed the mechanism of EMP2-mediated caveolin-1 regulation. In NIH 3T3 cells and in the human retinal pigment epithelium cell line (ARPE-19), EMP2 regulates caveolin-1 transcription and more substantially its protein levels. EMP2-mediated down-regulation of caveolin-1 does not affect caveolin-1 translational efficiency, phosphorylation, or proteasome-mediated degradation. Analysis of caveolin-1 protein half-life indicates the EMP2-mediated loss of caveolin-1 occurs rapidly. Protease inhibition and laser confocal microscopy associates this fate with specific intracellular compartmentalization, including early lysosomal delivery. These findings elucidate a new mechanism of caveolin-1 regulation and define an additional role for EMP2 as a key regulator of cell membrane composition.	Greater Los Angeles Vet Affairs Healthcare Syst, Dept Surg, Los Angeles, CA 90099 USA; Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Ctr Hlth Sci 13 222, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Braun, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Ctr Hlth Sci 13 222, Los Angeles, CA 90095 USA.	jbraun@mednet.ucla.edu		Braun, Jonathan/0000-0003-1646-2974	NCI NIH HHS [CA16042, CA9120, P30 CA016042] Funding Source: Medline; NIAID NIH HHS [AI52031] Funding Source: Medline; NICHD NIH HHS [HD48540, R03 HD048540] Funding Source: Medline; NIGMS NIH HHS [GM7185] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD048540] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI052031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283; BenPorath I, 1996, GENE, V183, P69, DOI 10.1016/S0378-1119(96)00475-1; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Burmester JK, 2004, HUM HERED, V57, P172, DOI 10.1159/000081443; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Donohue TM, 2003, ALCOHOL RES HEALTH, V27, P317; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Evtimova V, 2003, TUMOR BIOL, V24, P189, DOI 10.1159/000074429; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Floyd ZE, 2002, J BIOL CHEM, V277, P4062, DOI 10.1074/jbc.M108473200; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Hino M, 2003, SURG TODAY, V33, P486, DOI 10.1007/s10595-002-2538-4; Hoiby T, 2004, EMBO J, V23, P3083, DOI 10.1038/sj.emboj.7600304; Hung G, 2002, GLIA, V38, P363, DOI 10.1002/glia.10077; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Li JS, 2005, J HISTOCHEM CYTOCHEM, V53, P885, DOI 10.1369/jhc.4A6546.2005; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Ni X, 2006, HISTOL HISTOPATHOL, V21, P899, DOI 10.14670/HH-21.899; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Peterson TE, 2003, ARTERIOSCL THROM VAS, V23, P1521, DOI 10.1161/01.ATV.0000081743.35125.05; Quest AFG, 2004, BIOCHEM CELL BIOL, V82, P129, DOI 10.1139/o03-071; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; van Dartel M, 2004, CANCER GENET CYTOGEN, V152, P113, DOI 10.1016/j.cancergencyto.2003.11.003; van Dartel M, 2004, CANCER GENET CYTOGEN, V152, P8, DOI 10.1016/j.cancergencyto.2003.09.024; van Dartel M, 2002, CANCER GENET CYTOGEN, V139, P91, DOI 10.1016/S0165-4608(02)00627-1; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wadehra M, 2005, DEV BIOL, V287, P336, DOI 10.1016/j.ydbio.2005.09.003; Wadehra M, 2004, MOL BIOL CELL, V15, P2073, DOI 10.1091/mbc.E03-07-0488; Wadehra M, 2003, CLIN IMMUNOL, V107, P129, DOI 10.1016/S1521-6616(03)00048-2; Wadehra M, 2002, J BIOL CHEM, V277, P41094, DOI 10.1074/jbc.M206868200; Wadehra M, 2006, CANCER-AM CANCER SOC, V107, P90, DOI 10.1002/cncr.21957; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang CX, 2001, BLOOD, V97, P3890, DOI 10.1182/blood.V97.12.3890; Wilson HL, 2004, J IMMUNOL, V173, P1202, DOI 10.4049/jimmunol.173.2.1202; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	59	32	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36							26542	10.1074/jbc.M702117200	http://dx.doi.org/10.1074/jbc.M702117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17609206	hybrid			2022-12-25	WOS:000249239600058
J	Sossey-Alaoui, K; Li, XR; Cowell, JK				Sossey-Alaoui, Khalid; Li, Xiurong; Cowell, John K.			c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; PROTEIN N-WASP; ACTIN POLYMERIZATION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FILOPODIUM FORMATION; SIGNALING COMPLEX; TYROSINE KINASES; FAMILY PROTEINS; ACTIVATION; LOCALIZATION	The activity of the Wiskott-Aldrich syndrome-related WAVE3 protein is critical for the regulation of the Arp2/3-dependent cytoskeleton organization downstream of Rac-GTPase. The Ableson (Abl) non-receptor tyrosine kinase is also involved in the remolding of actin cytoskeleton in response to extracellular stimuli. Here we show that platelet-derived growth factor stimulation of cultured cells results in WAVE3-Abl interaction and localization to the cell periphery. WAVE3-Abl interaction promotes the tyrosine phosphorylation of WAVE3 by Abl, and STI-571, a specific inhibitor of Abl kinase activity, abrogates the Abl-mediated phosphorylation of WAVE3. We have also shown that Abl targets and phosphorylates four tyrosine residues in WAVE3 and that the Abl-dependent phosphorylation of WAVE3 is critical for the stimulation of lamellipodia formation and cell migration. Our results show that the activation of WAVE3 to promote actin remodeling is enhanced by the c-Ablmediated tyrosine phosphorylation of WAVE3.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sossey-Alaoui, K (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	khalid.sossey-alaoui@roswellpark.org		Cowell, John/0000-0002-2079-5950	NCI NIH HHS [CA16056] Funding Source: Medline; NINDS NIH HHS [NS35791] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035791] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Cory GOC, 2002, NATURE, V418, P732, DOI 10.1038/418732a; Echarri A, 2004, MOL CELL BIOL, V24, P4979, DOI 10.1128/MCB.24.11.4979-4993.2004; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Kim Y, 2006, NATURE, V442, P814, DOI 10.1038/nature04976; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005; Leng Y, 2005, P NATL ACAD SCI USA, V102, P1098, DOI 10.1073/pnas.0409120102; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Park SJ, 2005, EMBO J, V24, P1557, DOI 10.1038/sj.emboj.7600586; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Schulte RJ, 2003, BIOCHEMISTRY-US, V42, P9424, DOI 10.1021/bi034519u; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2003, MAMM GENOME, V14, P314, DOI 10.1007/s00335-002-2247-7; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Stovold CF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-11; Stradal TEB, 2004, TRENDS CELL BIOL, V14, P303, DOI 10.1016/j.tcb.2004.04.007; Stuart JR, 2006, J BIOL CHEM, V281, P31290, DOI 10.1074/jbc.M602389200; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200; Yokoyama N, 2005, J BIOL CHEM, V280, P42219, DOI 10.1074/jbc.M506996200	36	68	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2007	282	36					26257	26265		10.1074/jbc.M701484200	http://dx.doi.org/10.1074/jbc.M701484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	207GM	17623672	hybrid			2022-12-25	WOS:000249239600030
J	Sano, M; Tokudome, S; Shimizu, N; Yoshikawa, N; Ogawa, C; Shirakawa, K; Endo, J; Katayama, T; Yuasa, S; Ieda, M; Makino, S; Hattori, F; Tanaka, H; Fukuda, K				Sano, Motoaki; Tokudome, Satori; Shimizu, Noriaki; Yoshikawa, Noritada; Ogawa, Chie; Shirakawa, Kousuke; Endo, Jin; Katayama, Takaharu; Yuasa, Shinsuke; Ieda, Masaki; Makino, Shinji; Hattori, Fumiyuki; Tanaka, Hirotoshi; Fukuda, Keiichi			Intramolecular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor gamma coactivator 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; MITOCHONDRIAL-FUNCTION; ENERGY-METABOLISM; HEART-FAILURE; PGC-1-ALPHA; DEGRADATION; UBIQUITIN; PGC-1; DISEASE; SUPPRESSION	Peroxisome proliferator- activated receptor gamma coactivator (PGC)-1 is a critical transcriptional regulator of energy metabolism. Here we found that PGC-1 alpha is a short lived and aggregation-prone protein. PGC-1 alpha localized throughout the nucleoplasm and was rapidly destroyed via the ubiquitin-proteasome pathway. Upon proteasome inhibition, PGC-1 alpha formed insoluble polyubiquitinated aggregates. Ubiquitination of PGC-1 alpha depended on the integrity of the C terminus-containing arginine-serine-rich domains and an RNA recognition motif. Interestingly, ectopically expressed C-terminal fragment of PGC-1 alpha was autonomously ubiquitinated and aggregated with promyelocytic leukemia protein. Cooperation of the N-terminal region containing two PEST-like motifs was required for prevention of aggregation and targeting of the polyubiquitinated PGC- 1 alpha for degradation. This region thereby negatively controlled the aggregation properties of the C-terminal region to regulate protein turnover and intranuclear compartmentalization of PGC-1 alpha. Exogenous expression of the PGC-1 alpha C-terminal fragment interfered with degradation of full-length PGC-1 alpha and enhanced its coactivation properties. We concluded that PGC-1 alpha function is critically regulated at multiple steps via intramolecular cooperation among several distinct structural domains of the protein.	Keio Univ, Sch Med, Dept Regenerta Med & Adv Cardiac Therapeut, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Div Cardiol, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Internal Med, Tokyo 1608582, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Rheumatol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Allergy Res Hosp, Tokyo 1088639, Japan	Keio University; Keio University; Keio University; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; University of Tokyo	Sano, M (corresponding author), Keio Univ, Sch Med, Dept Regenerta Med & Adv Cardiac Therapeut, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	msano@sc.itc.keio.ac.jp	Fukuda, Keiichi/L-3777-2013; Sano, Motoaki/L-3405-2013; Yuasa, Shinsuke/L-8310-2013	Yuasa, Shinsuke/0000-0001-5593-7552				Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Arany Z, 2006, P NATL ACAD SCI USA, V103, P10086, DOI 10.1073/pnas.0603615103; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Fu LW, 2005, MOL BIOL CELL, V16, P4905, DOI 10.1091/mbc.E05-01-0019; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Huss JM, 2005, J CLIN INVEST, V115, P547, DOI 10.1172/JCI200524405; Janer A, 2006, J CELL BIOL, V174, P65, DOI 10.1083/jcb.200511045; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Kodadek T, 2006, CELL, V127, P261, DOI 10.1016/j.cell.2006.10.002; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nalley K, 2006, NATURE, V442, P1054, DOI 10.1038/nature05067; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; RECHSTEINER M, 1989, RBC-CELL BIOL REV, V20, P235; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sano M, 2005, CELL METAB, V1, P216, DOI 10.1016/j.cmet.2005.03.009; Sano M, 2004, EMBO J, V23, P3559, DOI 10.1038/sj.emboj.7600351; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sano M, 2007, CELL METAB, V5, P129, DOI 10.1016/j.cmet.2007.01.003; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Spector DL, 2001, J CELL SCI, V114, P2891; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Sun QY, 2006, FRONT BIOSCI-LANDMRK, V11, P1137, DOI 10.2741/1868; Tavanez JP, 2005, RNA, V11, P752, DOI 10.1261/rna.7217105; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200	46	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25970	25980		10.1074/jbc.M703634200	http://dx.doi.org/10.1074/jbc.M703634200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17620342	hybrid			2022-12-25	WOS:000249014100082
J	Xie, Z; Gong, MC; Su, W; Turk, J; Guo, Z				Xie, Zhongwen; Gong, Ming C.; Su, Wen; Turk, John; Guo, Zhenheng			Group VIA phospholipase A(2) (iPLA(2)beta) participates in angiotensin II-induced transcriptional up-regulation of regulator of G-protein signaling-2 in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MESSENGER-RNA; DYNAMIC REGULATION; KINASE ACTIVATION; PANCREATIC-ISLETS; EXPRESS GROUP; A(2); RGS2; INHIBITION; MECHANISM	Rgs2 ( regulator of G-protein signaling-2)-deficient mice exhibit severe hypertension, and genetic variations of RGS2 occur in hypertensive patients. RGS2 mRNA up-regulation by angiotensin II (Ang II) in vascular smooth muscle cells (VSMC) is a potentially important negative feedback mechanism in blood pressure homeostasis, but how it occurs is unknown. Here we demonstrate that group VIA phospholipase A(2) (iPLA(2)beta) plays a pivotal role in Ang II-induced RGS2 mRNA up-regulation in VSMC by three independent approaches, including pharmacologic inhibition with a bromoenol lactone suicide substrate, suppression of iPLA2 beta expression with antisense oligonucleotides, and genetic deletion in iPLA(2)beta-null mice. Selective inhibition of iPLA(2)beta by each of these approaches abolishes Ang II-induced RGS2 mRNA up-regulation. Furthermore, using adenovirus-mediated gene transfer, we demonstrate that restoration of iPLA(2)beta-expression in iPLA(2)beta-null VSMC reconstitutes the ability of Ang II to up-regulate RGS2 mRNA expression. In contrast, Ang II-induced vasodilator-stimulated phosphoprotein phosphorylation and Ang II receptor expression are unaffected. Moreover, in wild-type but not iPLA(2)beta-null VSMC, Ang II stimulates iPLA(2) enzymatic activity significantly. Both arachidonic acid and lysophosphatidylcholine, products of iPLA(2)beta action, induce RGS2 mRNA up-regulation. Inhibition of lipoxygenases, particularly 15-lipoxygenase, and cyclooxygenases, but not cytochrome P450-dependent epoxygenases inhibits Ang II-or AA-induced RGS2 mRNA expression. Moreover, RGS2 protein expression is also up-regulated by Ang II, and this is attenuated by bromoenol lactone. Disruption of the Ang II/iPLA(2)beta/RGS2 feedback pathway in iPLA(2)beta-null cells potentiates Ang II-induced vasodilator-stimulated phosphoprotein and Akt phosphorylation in a time-dependent manner. Collectively, our results demonstrate that iPLA(2)beta participates in Ang II-induced transcriptional up-regulation of RGS2 in VSMC.	Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA; Washington Univ, Sch Med, Dept Med, Div Endocrinol, St Louis, MO 63110 USA	University of Kentucky; University of Kentucky; Washington University (WUSTL)	Guo, Z (corresponding author), 569 Wethington Bldg,900 S Limestone, Lexington, KY 40536 USA.	zguo2@uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082791, R01HL067284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, R37DK034388, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103422] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR000954-30, P41 RR000954] Funding Source: Medline; NHLBI NIH HHS [HL67284, R01 HL082791, R01 HL067284, HL082791] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-069003, P30 DK056341, P60 DK020579-269005, R37 DK034388-23, P30 DK056341-06, P60 DK020579, R37 DK034388, P30 DK056341-07] Funding Source: Medline; NIGMS NIH HHS [P41 GM103422] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiba S, 2004, BIOL PHARM BULL, V27, P1174, DOI 10.1248/bpb.27.1174; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Alzoghaibi MA, 2004, AM J PHYSIOL-GASTR L, V286, pG528, DOI 10.1152/ajpgi.00189.2003; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Beadling C, 1999, J IMMUNOL, V162, P2677; Burchett SA, 1999, J NEUROCHEM, V72, P1529, DOI 10.1046/j.1471-4159.1999.721529.x; Calo LA, 2004, J CLIN ENDOCR METAB, V89, P4153, DOI 10.1210/jc.2004-0498; Cho H, 2003, BIOCHEM J, V371, P973, DOI 10.1042/BJ20021769; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dronadula N, 2006, J LIPID RES, V47, P767, DOI 10.1194/jlr.M500369-JLR200; Dulin NO, 2001, J BIOL CHEM, V276, P20827, DOI 10.1074/jbc.C100195200; Eszlinger M, 2004, EUR J ENDOCRINOL, V151, P383, DOI 10.1530/eje.0.1510383; Fatima S, 2001, J PHARMACOL EXP THER, V298, P331; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; Freeman EJ, 1998, AM J PHYSIOL-CELL PH, V274, pC282, DOI 10.1152/ajpcell.1998.274.1.C282; Fuentes L, 2003, J BIOL CHEM, V278, P44683, DOI 10.1074/jbc.M307209200; Gan XHT, 2005, J PHARMACOL EXP THER, V312, P27, DOI 10.1124/jpet.104.073122; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; Guo ZH, 2003, J BIOL CHEM, V278, P1856, DOI 10.1074/jbc.M211075200; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Ingi T, 1998, J NEUROSCI, V18, P7178; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kalyankrishna S, 2003, J PHARMACOL EXP THER, V304, P761, DOI 10.1124/jpet.102.040949; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Kim JH, 2005, BIOCHEM PHARMACOL, V69, P1715, DOI 10.1016/j.bcp.2005.04.002; Kveberg L, 2005, IMMUNOLOGY, V115, P358, DOI 10.1111/j.1365-2567.2005.02174.x; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; Li YA, 2005, CARDIOVASC RES, V66, P503, DOI 10.1016/j.cardiores.2005.02.005; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Miles RR, 2000, ENDOCRINOLOGY, V141, P28, DOI 10.1210/en.141.1.28; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Pang HA, 2005, AM J PHYSIOL-CELL PH, V289, pC352, DOI 10.1152/ajpcell.00111.2005; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, ONCOGENE, V8, P2759; Reddy MA, 2002, J BIOL CHEM, V277, P9920, DOI 10.1074/jbc.M111305200; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Riddle EL, 2006, HYPERTENSION, V47, P415, DOI 10.1161/01.HYP.0000200714.81990.61; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Sakata Y, 2004, ARTERIOSCL THROM VAS, V24, P2069, DOI 10.1161/01.ATV.0000143936.77094.a4; Schwable J, 2005, BLOOD, V105, P2107, DOI 10.1182/blood-2004-03-0940; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Song L, 1999, J BIOL CHEM, V274, P29689, DOI 10.1074/jbc.274.42.29689; Sun XG, 2005, MOL PHARMACOL, V67, P631, DOI 10.1124/mol.104.007724; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Taymans JM, 2004, EUR J NEUROSCI, V19, P2249, DOI 10.1111/j.0953-816X.2004.03336.x; Touyz RM, 2003, CURR HYPERTENS REP, V5, P155, DOI 10.1007/s11906-003-0073-2; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V834, P23, DOI 10.1016/0005-2760(85)90172-9; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; Wilson LD, 2005, GENE EXPR PATTERNS, V5, P305, DOI 10.1016/j.modgep.2004.10.005; Xie ZW, 2006, CARDIOVASC RES, V69, P491, DOI 10.1016/j.cardiores.2005.11.002; Yaghini FA, 2007, J BIOL CHEM, V282, P16878, DOI 10.1074/jbc.M610494200; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248; Yang J, 2005, J HYPERTENS, V23, P1497, DOI 10.1097/01.hjh.0000174606.41651.ae; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200; Zmijewski JW, 2001, BBA-MOL CELL RES, V1541, P201, DOI 10.1016/S0167-4889(01)00144-6	72	40	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2007	282	35					25278	25289		10.1074/jbc.M611206200	http://dx.doi.org/10.1074/jbc.M611206200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	204AB	17613534	Green Accepted, hybrid			2022-12-25	WOS:000249014100013
J	Locasale, JW				Locasale, Jason W.			Computational Investigations into the Origins of Short-Term Biochemical Memory in T cell Activation	PLOS ONE			English	Article								Recent studies have reported that T cells can integrate signals between interrupted encounters with Antigen Presenting Cells (APCs) in such a way that the process of signal integration exhibits a form of memory. Here, we carry out a computational study using a simple mathematical model of T cell activation to investigate the ramifications of interrupted T cell-APC contacts on signal integration. We consider several mechanisms of how signal integration at these time scales may be achieved and conclude that feedback control of immediate early gene products (IEGs) appears to be a highly plausible mechanism that allows for effective signal integration and cytokine production from multiple exposures to APCs. Analysis of these computer simulations provides an experimental roadmap involving several testable predictions.	MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Locasale, JW (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	Locasale@MIT.edu	Locasale, Jason W/ABE-6505-2020	Locasale, Jason W/0000-0002-7766-3502	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Work was undertaken through the sponsorship of Professor Arup Chakraborty who was able to support the work with funds provided through an NIH director's pioneer award	Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; Daniels MA, 2006, NATURE, V444, P724, DOI 10.1038/nature05269; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Faroudi M, 2003, J IMMUNOL, V171, P1128, DOI 10.4049/jimmunol.171.3.1128; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Janeway C., 2004, IMMUNOBIOLOGY; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Li QJ, 2004, NAT IMMUNOL, V5, P791, DOI 10.1038/ni1095; MacKeigan JP, 2005, MOL CELL BIOL, V25, P4676, DOI 10.1128/MCB.25.11.4676-4682.2005; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Munitic I, 2005, J IMMUNOL, V174, P4010, DOI 10.4049/jimmunol.174.7.4010; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Reth M, 2004, NAT REV IMMUNOL, V4, P269, DOI 10.1038/nri1335; Rosette C, 2001, IMMUNITY, V15, P59, DOI 10.1016/S1074-7613(01)00173-X; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Schade AE, 2004, J IMMUNOL, V172, P5828, DOI 10.4049/jimmunol.172.10.5828; Sumen C, 2004, IMMUNITY, V21, P315, DOI 10.1016/S1074-7613(04)00237-7; van Kampen N.G., 2001, STOCHASTIC PROCESSES; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Wylie DC, 2007, P NATL ACAD SCI USA, V104, P5533, DOI 10.1073/pnas.0611482104; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272	27	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2007	2	7							e627	10.1371/journal.pone.0000627	http://dx.doi.org/10.1371/journal.pone.0000627			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GI	17637843	Green Published, Green Submitted, gold			2022-12-25	WOS:000207452100017
J	Delelis, O; Parissi, V; Leh, H; Mbemba, G; Petit, C; Sonigo, P; Deprez, E; Mouscadet, JF				Delelis, Olivier; Parissi, Vincent; Leh, Herve; Mbemba, Gladys; Petit, Caroline; Sonigo, Pierre; Deprez, Eric; Mouscadet, Jean-Francois			Efficient and Specific Internal Cleavage of a Retroviral Palindromic DNA Sequence by Tetrameric HIV-1 Integrase	PLOS ONE			English	Article								Background. HIV-1 integrase (IN) catalyses the retroviral integration process, removing two nucleotides from each long terminal repeat and inserting the processed viral DNA into the target DNA. It is widely assumed that the strand transfer step has no sequence specificity. However, recently, it has been reported by several groups that integration sites display a preference for palindromic sequences, suggesting that a symmetry in the target DNA may stabilise the tetrameric organisation of IN in the synaptic complex. Methodology/Principal Findings. We assessed the ability of several palindrome-containing sequences to organise tetrameric IN and investigated the ability of IN to catalyse DNA cleavage at internal positions. Only one palindromic sequence was successfully cleaved by IN. Interestingly, this symmetrical sequence corresponded to the 2-LTR junction of retroviral DNA circles-a palindrome similar but not identical to the consensus sequence found at integration sites. This reaction depended strictly on the cognate retroviral sequence of IN and required a full-length wild-type IN. Furthermore, the oligomeric state of IN responsible for this cleavage differed from that involved in the 39-processing reaction. Palindromic cleavage strictly required the tetrameric form, whereas 39-processing was efficiently catalysed by a dimer. Conclusions/Significance. Our findings suggest that the restriction-like cleavage of palindromic sequences may be a general physiological activity of retroviral INs and that IN tetramerisation is strongly favoured by DNA symmetry, either at the target site for the concerted integration or when the DNA contains the 2-LTR junction in the case of the palindromic internal cleavage.	[Delelis, Olivier; Leh, Herve; Mbemba, Gladys; Deprez, Eric; Mouscadet, Jean-Francois] Ecole Normale Super, CNRS, LBPA, UMR8113, Cachan, France; [Parissi, Vincent] Lab REGER, IFR Pathol Infect & Canc 66, Bordeaux, France; [Petit, Caroline; Sonigo, Pierre] Univ Paris 05, CNRS, Inst Cochin, Dept Malad Infect,INSERM,U567,UMR8104, F-75270 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Delelis, O (corresponding author), Ecole Normale Super, CNRS, LBPA, UMR8113, Cachan, France.	delelis@lbpa.ens-cachan.fr		Sonigo, Pierre/0000-0003-2686-1303	TrioH European [503480]; Centre National de la Recherche Scientifique; French National Agency	TrioH European; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); French National Agency(French National Research Agency (ANR))	This work was supported by grants from the TrioH European project (FP6 grant 503480), the Centre National de la Recherche Scientifique, and the French National Agency for Research against AIDS (ANRS).	Agapkina J, 2006, J BIOL CHEM, V281, P11530, DOI 10.1074/jbc.M512271200; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Delelis O, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-31; Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85; DUYK G, 1985, J VIROL, V56, P589, DOI 10.1128/JVI.56.2.589-599.1985; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241; Gerton JL, 1997, J BIOL CHEM, V272, P25809, DOI 10.1074/jbc.272.41.25809; Grandgenett DP, 2005, P NATL ACAD SCI USA, V102, P5903, DOI 10.1073/pnas.0502045102; GRANDGENETT DP, 1985, NUCLEIC ACIDS RES, V13, P6205, DOI 10.1093/nar/13.17.6205; Guiot E, 2006, J BIOL CHEM, V281, P22707, DOI 10.1074/jbc.M602198200; Holman AG, 2005, P NATL ACAD SCI USA, V102, P6103, DOI 10.1073/pnas.0501646102; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; Katzman M, 2000, VIRUS RES, V66, P87, DOI 10.1016/S0168-1702(99)00126-4; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; Kilzer JM, 2003, VIROLOGY, V314, P460, DOI 10.1016/S0042-6822(03)00455-0; Laboulais C, 2001, BIOPHYS J, V81, P473, DOI 10.1016/S0006-3495(01)75715-3; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; Lee I, 2001, J MOL BIOL, V314, P433, DOI 10.1006/jmbi.2001.5177; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Lewinski MK, 2006, PLOS PATHOG, V2, P611, DOI 10.1371/journal.ppat.0020060; Lewinski MK, 2005, ADV GENET, V55, P147, DOI 10.1016/S0065-2660(05)55005-3; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005; Li M, 2005, J BIOL CHEM, V280, P29334, DOI 10.1074/jbc.M505367200; Miles LR, 2005, J VIROL, V79, P6859, DOI 10.1128/JVI.79.11.6859-6867.2005; Neugebauerova S, 2000, J BIOMOL STRUCT DYN, V18, P73, DOI 10.1080/07391102.2000.10506648; OLSEN JC, 1990, J VIROL, V64, P5475, DOI 10.1128/JVI.64.11.5475-5484.1990; Serhan F, 2004, J VIROL, V78, P6190, DOI 10.1128/JVI.78.12.6190-6199.2004; Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005; Skinner LM, 2001, J BIOL CHEM, V276, P114, DOI 10.1074/jbc.M007032200; Smolov M, 2006, FEBS J, V273, P1137, DOI 10.1111/j.1742-4658.2006.05139.x; Svarovskaia ES, 2004, J VIROL, V78, P3210, DOI 10.1128/JVI.78.7.3210-3222.2004; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; Wu XL, 2005, J VIROL, V79, P5211, DOI 10.1128/JVI.79.8.5211-5214.2005	35	30	31	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e608	10.1371/journal.pone.0000608	http://dx.doi.org/10.1371/journal.pone.0000608			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622353	Green Submitted, Green Published, gold			2022-12-25	WOS:000207452000015
J	Shang, EH; Zhdanova, IV				Shang, Eva H.; Zhdanova, Irina V.			The Circadian System Is a Target and Modulator of Prenatal Cocaine Effects	PLOS ONE			English	Article							TRANSGENIC ZEBRAFISH; GENE-EXPRESSION; CLOCK; MELATONIN; NEURONS; CHILDREN	Background. Prenatal exposure to cocaine can be deleterious to embryonic brain development, but the results in humans remain controversial, the mechanisms involved are not well understood and effective therapies are yet to be designed. We hypothesize that some of the prenatal effects of cocaine might be related to dysregulation of physiological rhythms due to alterations in the integrating circadian clock function. Methodology and Principle Findings. Here we introduce a new high-throughput genetically well-characterized diurnal vertebrate model for studying the mechanisms of prenatal cocaine effects by demonstrating reduced viability and alterations in the pattern of neuronal development following repeated cocaine exposure in zebrafish embryos. This effect is associated with acute cocaine-induced changes in the expression of genes affecting growth (growth hormone, zGH) and neurotransmission (dopamine transporter, zDAT). Analysis of circadian gene expression, using quantitative real-time RT-PCR (QPCR), demonstrates that cocaine acutely and dose-dependently changes the expression of the circadian genes (zPer-3, zBmal-1) and genes encoding melatonin receptors (zMelR) that mediate the circadian message to the entire organism. Moreover, the effects of prenatal cocaine depend on the time of treatment, being more robust during the day, independent of whether the embryos are raised under the light-dark cycle or in constant light. The latter suggests involvement of the inherited circadian factors. The principal circadian hormone, melatonin, counteracts the effects of cocaine on neuronal development and gene expression, acting via specific melatonin receptors. Conclusions/Significance. These findings demonstrate that, in a diurnal vertebrate, prenatal cocaine can acutely dysregulate the expression of circadian genes and those affecting melatonin signaling, growth and neurotransmission, while repeated cocaine exposure can alter neuronal development. Daily variation in these effects of cocaine and their attenuation by melatonin suggest a potential prophylactic or therapeutic role for circadian factors in prenatal cocaine exposure.	[Shang, Eva H.; Zhdanova, Irina V.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA	Boston University	Zhdanova, IV (corresponding author), Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.	zhdanova@bu.edu		Zhdanova, Irina/0000-0002-8401-9571	National Institutes of Health [DA 1541801, MH 065528]; NIDA [DA-4-7733]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015418] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the National Institutes of Health grants, DA 1541801 and MH 065528, and NIDA contract DA-4-7733.	Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; Baas PW, 1997, CURR OPIN CELL BIOL, V9, P29, DOI 10.1016/S0955-0674(97)80148-2; Behnke M, 2006, J PEDIATR PSYCHOL, V31, P41, DOI 10.1093/jpepsy/jsj027; Cahill GM, 2002, CELL TISSUE RES, V309, P27, DOI 10.1007/s00441-002-0570-7; Danilova N, 2004, FASEB J, V18, P751, DOI 10.1096/fj.03-0544fje; Davis FC, 1997, J BIOL RHYTHM, V12, P498, DOI 10.1177/074873049701200603; Debruyne J, 2004, J NEUROGENET, V18, P403, DOI 10.1080/01677060490894540; Dekens MPS, 2003, CURR BIOL, V13, P2051, DOI 10.1016/j.cub.2003.10.022; Delaunay F, 2000, SCIENCE, V289, P297, DOI 10.1126/science.289.5477.297; DeLucia R, 1997, BRAZ J MED BIOL RES, V30, P637, DOI 10.1590/S0100-879X1997000500011; Dempsey DA, 1998, J ANAL TOXICOL, V22, P220, DOI 10.1093/jat/22.3.220; Friedman E, 1996, NEUROSCIENCE, V70, P739, DOI 10.1016/S0306-4522(96)83011-9; Gloster A, 1999, J COMP NEUROL, V405, P45, DOI 10.1002/(SICI)1096-9861(19990301)405:1<45::AID-CNE4>3.0.CO;2-M; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Goldman D, 2001, TRANSGENIC RES, V10, P21, DOI 10.1023/A:1008998832552; Gulati-Leekha A, 2006, DEV BIOL, V296, P29, DOI 10.1016/j.ydbio.2006.03.024; Guo S, 1999, NEURON, V24, P555, DOI 10.1016/S0896-6273(00)81112-5; Holzschuh J, 2001, MECH DEVELOP, V101, P237, DOI 10.1016/S0925-4773(01)00287-8; Hurd MW, 2002, J BIOL RHYTHM, V17, P307, DOI 10.1177/074873002129002618; Hurt H, 2005, NEUROTOXICOL TERATOL, V27, P203, DOI 10.1016/j.ntt.2004.10.006; Kaneko M, 2005, PLOS BIOL, V3, P313, DOI 10.1371/journal.pbio.0030034; Kennaway DJ, 2004, FRONT BIOSCI, V9, P56, DOI 10.2741/1200; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lin SN, 2001, J ANAL TOXICOL, V25, P497, DOI 10.1093/jat/25.7.497; Manev H, 2006, TRENDS PHARMACOL SCI, V27, P186, DOI 10.1016/j.tips.2006.02.003; McClung CA, 2005, P NATL ACAD SCI USA, V102, P9377, DOI 10.1073/pnas.0503584102; Mendelson JH, 1999, NEUROPSYCHOPHARMACOL, V21, P294, DOI 10.1016/S0893-133X(99)00020-2; Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104; Miller-Loncar C, 2005, NEUROTOXICOL TERATOL, V27, P213, DOI 10.1016/j.ntt.2004.10.007; NASSOGNE MC, 1995, P NATL ACAD SCI USA, V92, P11029, DOI 10.1073/pnas.92.24.11029; Niyomchai T, 2006, BRAIN RES BULL, V68, P310, DOI 10.1016/j.brainresbull.2005.09.001; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; *SAMHSA OFF APPL S, 2003, RES 2002 NAT SURV DR; Smale L, 2003, J BIOL RHYTHM, V18, P356, DOI 10.1177/0748730403256651; Thompson AM, 2005, NEUROPHARMACOLOGY, V49, P185, DOI 10.1016/j.neuropharm.2005.03.005; Vuilleumier R, 2006, ENDOCRINOLOGY, V147, P2273, DOI 10.1210/en.2005-1565; Zhdanova IV, 2005, SLEEP MED REV, V9, P51, DOI 10.1016/j.smrv.2004.04.003; Ziv L, 2005, J NEUROENDOCRINOL, V17, P314, DOI 10.1111/j.1365-2826.2005.01315.x	38	25	29	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2007	2	7							e587	10.1371/journal.pone.0000587	http://dx.doi.org/10.1371/journal.pone.0000587			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GH	17622340	Green Published, gold, Green Submitted			2022-12-25	WOS:000207452000002
J	Carlson, J; Kadie, C; Mallal, S; Heckerman, D				Carlson, Jonathan; Kadie, Carl; Mallal, Simon; Heckerman, David			Leveraging Hierarchical Population Structure in Discrete Association Studies	PLOS ONE			English	Article								Population structure can confound the identification of correlations in biological data. Such confounding has been recognized in multiple biological disciplines, resulting in a disparate collection of proposed solutions. We examine several methods that correct for confounding on discrete data with hierarchical population structure and identify two distinct confounding processes, which we call coevolution and conditional influence. We describe these processes in terms of generative models and show that these generative models can be used to correct for the confounding effects. Finally, we apply the models to three applications: identification of escape mutations in HIV-1 in response to specific HLA-mediated immune pressure, prediction of coevolving residues in an HIV-1 peptide, and a search for genotypes that are associated with bacterial resistance traits in Arabidopsis thaliana. We show that coevolution is a better description of confounding in some applications and conditional influence is better in others. That is, we show that no single method is best for addressing all forms of confounding. Analysis tools based on these models are available on the internet as both web based applications and downloadable source code at http://atom.research.microsoft.com/bio/phylod.aspx.	[Carlson, Jonathan; Heckerman, David] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA; [Carlson, Jonathan; Kadie, Carl] Microsoft Res, Machine Learning & Appl Stat Grp, Redmond, WA USA; [Mallal, Simon] Royal Perth Hosp, Ctr Clin Immunol & Biomed Stat, Perth, WA, Australia	University of Washington; University of Washington Seattle; Microsoft; Royal Perth Hospital; University of Western Australia	Heckerman, D (corresponding author), Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA.	heckerma@microsoft.com	Mallal, Simon Alexander/HDM-9561-2022	Mallal, Simon Alexander/0000-0002-7036-1309	Microsoft Research	Microsoft Research(Microsoft)	This work was funded by Microsoft Research. Microsoft Research had no role in any other aspect of this work.	Aranzana MJ, 2005, PLOS GENET, V1, P531, DOI 10.1371/journal.pgen.0010060; Auranen M, 2003, MOL PSYCHIATR, V8, P879, DOI 10.1038/sj.mp.4001299; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BHATTACHARYA T, SCIENCE IN PRESS; Bruno WJ, 1996, MOL BIOL EVOL, V13, P1368, DOI 10.1093/oxfordjournals.molbev.a025583; Buck MJ, 2005, MOL BIOL EVOL, V22, P1627, DOI 10.1093/molbev/msi157; Campbell CD, 2005, NAT GENET, V37, P868, DOI 10.1038/ng1607; CONAWAY MR, 1990, BIOMETRICS, V46, P317, DOI 10.2307/2531437; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Devlin B, 2001, THEOR POPUL BIOL, V60, P155, DOI 10.1006/tpbi.2001.1542; Evans DM, 2006, TRENDS GENET, V22, P350, DOI 10.1016/j.tig.2006.05.001; FELSENSTEIN, 1985, AM NATURALIST, V125; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Felsenstein J., 2004, INFERRING PHYLOGENIE, VVolume 2; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Fodor AA, 2004, PROTEINS, V56, P211, DOI 10.1002/prot.20098; Fossen T, 2005, J BIOL CHEM, V280, P42515, DOI 10.1074/jbc.M507375200; GOBEL U, 1994, PROTEINS, V18, P309, DOI 10.1002/prot.340180402; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Heckerman D, 1998, NATO ADV SCI I D-BEH, V89, P301; Helgason A, 2005, NAT GENET, V37, P90, DOI 10.1038/ng1492; HIRSCHHORN JN, 2005, NATURE REV GENETICS, V6, P108; KENNEDY BW, 1992, J ANIM SCI, V70, P2000, DOI 10.2527/1992.7072000x; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; KORBER BTM, 1993, P NATL ACAD SCI USA, V90, P7176, DOI 10.1073/pnas.90.15.7176; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; MADDISON DR, 1990, THESIS HARVARD U CAM; Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; NEHER E, 1994, P NATL ACAD SCI USA, V91, P98, DOI 10.1073/pnas.91.1.98; Noivirt O, 2005, PROTEIN ENG DES SEL, V18, P247, DOI 10.1093/protein/gzi029; Nordborg M, 2002, NAT GENET, V30, P190, DOI 10.1038/ng813; PAGEL M, 1994, P ROY SOC B-BIOL SCI, V255, P37, DOI 10.1098/rspb.1994.0006; Pollock DD, 1997, PROTEIN ENG, V10, P647, DOI 10.1093/protein/10.6.647; Pollock DD, 1999, J MOL BIOL, V287, P187, DOI 10.1006/jmbi.1998.2601; Press W. H., 1992, ART SCI COMPUTING; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Ridley M., 1983, EXPLANATION ORGANIC; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Satten GA, 2001, AM J HUM GENET, V68, P466, DOI 10.1086/318195; Setakis E, 2006, GENOME RES, V16, P290, DOI 10.1101/gr.4346306; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; TAYLOR WR, 1994, PROTEIN ENG, V7, P341, DOI 10.1093/protein/7.3.341; Thornsberry JM, 2001, NAT GENET, V28, P286, DOI 10.1038/90135; Voight BF, 2005, PLOS GENET, V1, P302, DOI 10.1371/journal.pgen.0010032; Wollenberg KR, 2000, P NATL ACAD SCI USA, V97, P3288, DOI 10.1073/pnas.070154797; Yu JM, 2006, NAT GENET, V38, P203, DOI 10.1038/ng1702	55	30	31	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2007	2	7							e591	10.1371/journal.pone.0000591	http://dx.doi.org/10.1371/journal.pone.0000591			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10GG	17611623	gold, Green Published			2022-12-25	WOS:000207451900008
